Cross_talk_ID	Regulated_Target	UNIPROT	Disease_ID	Disease_Name	Clinical status	Drug_name	Synonymous	Drug_CID	Drugbank_ID	TTD_DRUG_ID	Drug_Bank_ID	CT_Protential_ID
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT00012	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT00013	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT00059	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02075	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02098	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02099	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02100	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02193	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02194	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02195	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02196	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02197	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02198	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02199	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02200	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02202	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03070	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03092	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03192	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03201	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03213	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03214	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03250	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03251	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03252	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03482	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03483	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03484	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03485	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03486	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03487	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03488	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03489	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03490	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03536	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03537	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03538	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05003	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05006	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05008	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05037	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05038	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05039	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05040	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05041	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05042	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05043	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05044	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05045	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05046	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05047	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05052	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05053	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05054	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05057	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05066	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05067	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05068	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05069	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05085	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05111	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05112	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05113	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05114	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05119	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05120	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05121	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05126	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05136	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05137	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05156	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05158	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05159	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05227	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05228	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05264	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05273	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05305	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05306	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05311	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05314	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05315	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05316	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05317	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05354	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05355	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05361	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05363	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05462	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05463	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT02055	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03122	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03123	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03155	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03409	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03410	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03411	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03412	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03413	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03414	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03415	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03416	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03417	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03418	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03419	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03420	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03421	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03422	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03423	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03424	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03425	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03426	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03427	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03428	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03429	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT03430	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05060	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05079	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05080	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05494	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05504	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05532	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05533	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05534	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05535	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05547	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05548	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05559	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05568	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05575	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05588	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05611	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05612	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05630	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05639	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05640	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05655	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05656	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05663	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05673	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05695	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05711	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05726	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05743	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05747	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05756	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05757	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05761	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05762	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05889	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05899	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05900	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05901	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05944	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05945	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05948	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05949	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Approved	90Y-loaded resin microspheres	.	.	Approved	DGWE36	.	CTPDG000010
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Approved	Ferumoxides	AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric	6432052	Approved	D08QAC	DB06215	CTPDG000517
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Nofazinlimab	CS1003; EQ176	.	Phase 3	DX9GT7	.	CTPDG000868
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	Brivanib	"649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol"	11234052	Phase 3	D0HS5V	DB11958	CTPDG001186
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	JX-594	Pexastimogene devacirepvec	.	Phase 3	D0HB0V	.	CTPDG012361
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 3	ABH001	.	.	Phase 3	D05LPP	.	CTPDG001398
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2/3	MTC-DOX	MTC-doxorubicin	.	Phase 2/3	D0W9AI	.	CTPDG001529
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	KD018	.	.	Phase 2	D0NB9T	.	CTPDG002160
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Doxorubicin-eluting beads	DC Bead (TN)	.	Phase 2	D0M5CD	.	CTPDG002204
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	32-P BioSilicon	BrachySil	.	Phase 2	D0M1YS	.	CTPDG002211
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	[131I]-Metuximab	.	.	Phase 2	D0E5BW	.	CTPDG002427
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 2	CMC-001	"Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast"	.	Phase 2	D00WMJ	.	CTPDG003059
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	OBP-301	.	.	Phase 1/2	D0D8ZK	.	CTPDG003456
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	MBO7133	.	.	Phase 1/2	D0C3MW	.	CTPDG003462
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	NV-1020	.	.	Phase 1/2	D0B6EA	.	CTPDG003470
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1/2	DCVax-Liver	"Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics"	.	Phase 1/2	D00ESH	.	CTPDG003635
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SRF388	.	.	Phase 1	DLY89F	.	CTPDG003827
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ET140202	.	.	Phase 1	D4K2OF	.	CTPDG004113
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ADP-A2AFP	.	.	Phase 1	D31ORV	.	CTPDG004148
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	SM04755	.	.	Phase 1	D0P5XM	.	CTPDG004516
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	PI-166	.	.	Phase 1	D0J2YR	.	CTPDG004697
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	CRS-100	.	.	Phase 1	D0B4DL	.	CTPDG004920
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Autologous ET1402L1-CART cells	.	.	Phase 1	D09TGO	.	CTPDG004975
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	MRX34	.	.	Phase 1	D08SJY	.	CTPDG005032
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Phase 1	ALN-VSP	.	.	Phase 1	D08JMI	.	CTPDG005050
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 3	ADI	Arginine deiminase	46906074	Discontinued in Phase 3	D0O4EV	.	CTPDG006345
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	GN-1140	.	.	Discontinued in Phase 2	D0V4CL	.	CTPDG006419
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	OGT-719	OGS-719	9838997	Discontinued in Phase 2	D0C2CH	.	CTPDG006546
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Discontinued in Phase 2	AFP-Scan	.	.	Discontinued in Phase 2	D08CCC	.	CTPDG006587
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	SR1078	"1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2"	17980288	Preclinical	D9D6QN	.	CTPDG006997
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Preclinical	Occlusin	Occlusin 50 Injection; Occlusin 500 injection	.	Preclinical	D00INM	.	CTPDG007159
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Terminated	HRC-201	"Hemoglobin-imaging conjugate (HepSelect), Hemosol"	.	Terminated	D09ZCH	.	CTPDG007408
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	"1,2,3,4,5,6-hexabromocyclohexane"	"1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	Investigative	DLW69V	.	CTPDG007595
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	STP-322	"Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics"	.	Investigative	D0R8KF	.	CTPDG007904
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	AMB-8LK	"Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma"	.	Investigative	D0P2MD	.	CTPDG007984
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	MiR-34a mimics	MiR-34a mimics (liver cancer)	.	Investigative	D0M9TD	.	CTPDG008067
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	P53 fusion protein	P53 fusion protein (pancreatic/liver cancer)	.	Investigative	D06WLG	.	CTPDG008723
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	OP-05	"OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon"	.	Investigative	D02OIP	.	CTPDG009017
M6ACROT05969	.	.	M6ADIS0006	2C12: Liver cancer	Investigative	GR-DD1	"Cytotoxin (hepatic metastasis), ERYtech"	.	Investigative	D00QFV	.	CTPDG009163
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	Kevzara	.	Approved	D0Z8CQ	.	CTPDG000029
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulindac	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	1548887	Approved	D0Z5IU	DB00605	CTPDG000031
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Felbinac	"Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda"	3332	Approved	D0Y7EM	DB07477	CTPDG000057
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Salsalate	"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid"	5161	Approved	D0Y0JH	DB01399	CTPDG000063
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Fostamatinib	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]	11671467	Phase 3	D0V8HJ	DB12010	CTPDG000102
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Methotrexate	"Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	126941	Phase 3	D0SV8E	DB00563	CTPDG000144
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IPI-145	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;	50905713	Phase 3	D0RU0O	DB11952	CTPDG000166
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	Approved	D0R1RS	DB00328	CTPDG000188
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Inosine pranobex	Imunovir (TN)	135449284	Approved	D0Q2QU	.	CTPDG000206
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Citrofen	Citrofen (TN)	.	Approved	D0P6UK	.	CTPDG000218
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meclofenamate Sodium	.	4038	Approved	D0MN9K	.	CTPDG000266
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxaprozin	"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid"	4614	Approved	D0M9DC	DB00991	CTPDG000269
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Zinc salts	.	.	Approved	D0K8AA	.	CTPDG000300
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	Approved	D0K5KS	.	CTPDG000305
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Orthokine	Orthokine (TN)	.	Approved	D0J1PW	.	CTPDG000330
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	SK-1306X	Cararthron; Joins	.	Approved	D0IL0C	.	CTPDG000339
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	Approved	D0I6IB	DB00469	CTPDG000343
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	Approved	D0I5QX	.	CTPDG000345
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	Approved	D0G7FJ	DB00814	CTPDG000369
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Gold sodium thiomalate	Sodium aurothiomalate	22318	Approved	D0FH7C	DB09276	CTPDG000381
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Abatacept	Orencia (TN)	.	Approved	D0EW4L	.	CTPDG000397
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)"	9926791	Approved	D0EG1I	DB08895	CTPDG000400
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	OM-89	Subreum; UroVaxom; UroVaxon; OM-8980	.	Approved	D0E1VD	.	CTPDG000414
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rimexolone	"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)"	5311412	Approved	D0D2TN	DB00896	CTPDG000426
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	Approved	D0CA0P	.	CTPDG000432
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Alclofenac	"22131-79-9; Alclophenac; Prinalgin; Medifenac; Reufenac; Allopydin; Mervan; Alclofenacum; Alclofenaco; Zumaril; Neoston; Neosten; 2-(4-(Allyloxy)-3-chlorophenyl)acetic acid; [4-(Allyloxy)-3-chlorophenyl]acetic acid; Desinflam; Marvan Forte; 3-Chloro-4-(2-propenyloxy)benzeneacetic acid; (4-Allyloxy-3-chlorphenyl)essigsaeure; MY 101; Epinal; Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-; Alclofenacum [INN-Latin]; Alclofenaco [INN-Spanish]; UNII-M9CP5H21N8; W 7320; CHEBI:31183; EINECS 244-795-4"	30951	Approved	D0C6OQ	DB13167	CTPDG000435
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Careram	Iguratimod	124246	Approved	D0B8MZ	DB12233	CTPDG000450
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	Approved	D0A1PX	DB00712	CTPDG000472
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Nafcillin	"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	8982	Approved	D0A0JH	DB00607	CTPDG000473
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etofenamate	30544-47-9; Rheumon; Bayrogel; Rheumon gel; UNII-KZF0XM66JC; Etofenamatum [INN-Latin]; Etofenamato [INN-Spanish]; Bay d 1107; C18H18F3NO4; TVX 485; WHR 5020; EINECS 250-231-8; KZF0XM66JC; BRN 2953263; 2-(2-Hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate; 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate; WHR-5020; NCGC00016804-01; 2-(2-Hydroxyaethoxy)aethylester der flutenaminsaeure [German]; CAS-30544-47-9; 2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate	35375	Approved	D09YVX	DB08984	CTPDG000475
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	Approved	D09MGR	DB01628	CTPDG000489
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	Approved	D09FSG	.	CTPDG000501
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	Approved	D09BHB	DB00500	CTPDG000505
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)	.	Phase 2	D08WSY	.	CTPDG000511
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Leflunomide	"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide"	3899	Approved	D08ROP	DB01097	CTPDG000515
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Penicillamine	"D-Penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine"	5852	Approved	D08HZC	DB00859	CTPDG000523
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dimethyl Sulfoxide	Rimso-50	679	Approved	D08HVE	DB01093	CTPDG000524
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tocilizumab	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody	.	Approved	D08HPZ	.	CTPDG000526
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Benorilate	"5003-48-5; BENORYLATE; 4-acetamidophenyl 2-acetoxybenzoate; Benoral; Salipran; Benortan; Fenasprate; Fenasparate; Aspirin acetaminophen ester; Benorilato; Benorilato [Spanish]; p-Acetamidophenyl acetylsalicylate; Benorilatum [INN-Latin]; Benorilato [INN-Spanish]; UNII-W1QX9DV96G; p-N-Acetylaminophenylacetylsalicylate; TO 125; WIN 11450; 4'-(Acetamido)phenyl-2-acetoxybenzoate; 2-Acetoxy-4'-(acetamino)phenylbenzoate; CCRIS 1739; Benzoic acid, 2-(acetyloxy)-, 4-(acetylamino)phenyl ester; 4-Acetamidophenyl salicylate acet"	21102	Approved	D08GJO	DB13657	CTPDG000528
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Halopredone acetate	Haloart (TN)	91667	Approved	D08BDT	.	CTPDG000531
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Teriflunomide	.	54684141	Approved	D07QFP	DB08880	CTPDG009757
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Siponimod	BAF312	44599207	Phase 2	D07FKQ	DB12371	CTPDG000573
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxyphenbutazone	Tandearil	4641	Approved	D06ZPS	DB03585	CTPDG000587
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	FENBUFEN	"36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	Approved	D06LHG	DB08981	CTPDG000602
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexchlorpheniramine Maleate	Polaramine	5281070	Approved	D05ZGQ	DB09555	CTPDG000614
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Enbrel	.	.	Approved	D05LTY	.	CTPDG000635
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Fenoprofen	"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid"	3342	Approved	D03XYW	DB00573	CTPDG000689
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	Approved	D03RTS	DB00482	CTPDG000700
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sodium Succinate	"Disodium succinate; 150-90-3; Disodium butanedioate; Butanedioic acid, disodium salt; Succinic acid disodium salt; Soduxin; Jantaran sodny [Czech]; UNII-V8ZGC8ISR3; Succinic acid, disodium salt; FEMA No. 3277; CCRIS 3700; Sodium succinate dibasic; EINECS 205-778-7; V8ZGC8ISR3; Butanedioic acid, sodium salt (1:2); Succinic acid disodium salt anhydrous; Butanedioic acid disodium salt; sodium succinate (anhydrous); Jantaran sodny; Butanedioic acid disodium hexahydrate; Succinic acid, disodium salt, 99%, anhydrous"	9020	Approved	D03RCJ	.	CTPDG000703
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulfasalazine	599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Sulfasalizine	5339	Approved	D02ZTJ	DB00795	CTPDG000732
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	Kineret; Kineret (TN); Anakinra (USAN/INN)	.	Approved	D02DES	.	CTPDG000759
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Cyproheptadine	"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene"	2913	Approved	D00TLN	DB00434	CTPDG000802
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	Approved	D00HGB	DB04552	CTPDG000816
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Nipocalimab	.	.	Phase 2	DS69NO	.	CTPDG000882
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Nipocalimab?	.	.	Phase 3	DR5V8I	.	CTPDG000884
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	BI 695501	BI-695501)	.	Phase 3	D0Z4VX	.	CTPDG000966
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06410293	.	.	Phase 3	D0Y8TZ	.	CTPDG000976
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Flobufen	VUFB-16066; VUFB-17203	159476	Phase 3	D0X8VV	.	CTPDG000989
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	Phase 3	D0W2CX	DB12399	CTPDG001013
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP-2017	.	.	Phase 3	D0S7JN	.	CTPDG001055
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cartistem	"Stem cell therapy (cartilage disease/rheumatoid arthritis), Medipost"	.	Phase 3	D0OH5E	.	CTPDG001096
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IR-201	Seryl-glutaminyl-isoleucyl-valyl-asparaginyl-aspartyl-phenylalanyl-glutaminyl-lysyl-glycyl-aspartyl-isoleucyl-alanyl-glutamyl-glycyl-tyrosyl-serine	.	Phase 3	D0N3SA	.	CTPDG001116
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Esonarimod	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298	127998	Phase 3	D0MY7X	.	CTPDG001120
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CIPEMASTAT	"Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	Phase 3	D0MW3H	.	CTPDG001123
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Methylprednisolone	.	6741	Approved	D0LN1Z	DB00959	CTPDG001141
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	STI-002	.	.	Phase 3	D0I6UE	.	CTPDG001181
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MK-8808	.	.	Phase 1	D0GP8N	.	CTPDG001196
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 798	.	.	Phase 3	D0E8NJ	.	CTPDG001224
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06438179	.	.	Phase 3	D0D9HZ	.	CTPDG001236
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	.	44205240	Approved	D0D5FU	DB11817	CTPDG001241
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cilengitide	"188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)"	176873	Phase 3	D09ZXO	DB11890	CTPDG001287
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CEP-41750	.	.	Phase 3	D09WRG	.	CTPDG001291
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	.	.	Approved	D08SJT	.	CTPDG001320
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Andolast	"Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm"	65970	Phase 3	D08PGC	.	CTPDG001324
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Vanadate	"Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3"	516859	Phase 3	D08NCO	.	CTPDG001327
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	Phase 3	D08DGC	DB12193	CTPDG011311
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Spermidine	"Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, > =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0"	1102	Phase 3	D08BXT	DB03566	CTPDG001337
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Varespladib methyl	"A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera"	9886917	Phase 3	D07KFB	DB05737	CTPDG001360
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 501	.	.	Phase 3	D06FMO	.	CTPDG001379
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	.	.	Approved	D06CXL	.	CTPDG001384
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Atacicept	.	.	Phase 2	D04YWM	.	CTPDG001412
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Tenidap	.	60712	Phase 3	D02RQT	DB13481	CTPDG001457
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LY3090106	Tibulizumab	.	Phase 1	D09JVK	.	CTPDG001558
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2/3	VX-509	"Decernotinib; Adelatinib; 944842-54-0; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	Phase 2/3	D04QWQ	DB12566	CTPDG001571
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D03ZYQ	.	CTPDG001574
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	CreaVax-RA	"Autologous DC therapy (injectable, rheumatoid arthritis), CreaGene; Autologous dendritic cell therapy (injectable, rheumatoid arthritis), CreaGene"	.	Phase 2a	D0U9OD	.	CTPDG001585
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	RhuDex	.	.	Phase 2a	D0J0KT	.	CTPDG001586
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cevidoplenib	"(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone; 1703788-21-9; 3N3H8BX897; AKOS040748110; BDBM196772; Cevidoplenib; Cevidoplenib [INN]; Cevidoplenib [WHO-DD]; CHEMBL3921923; CS-0039259; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; EX-A5914; HY-109082; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; MS-28778; SCHEMBL16653204; UNII-3N3H8BX897; US9212178, 1; YCZUBLQESBVOSH-IBGZPJMESA-N"	91754477	Phase 2	DY57LN	.	CTPDG001609
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Dazodalibep	VIB4920	.	Phase 2	DPDI65	.	CTPDG001652
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Natrunix	.	.	Phase 2	DOVW19	.	CTPDG001657
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-5718	"1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 920036-34-6; A860172; AKOS022178093; AMY21637; CS-0048281; FT-0702852; GS-5718; MFCD13183727; OKKLWSNHFSFXEM-UHFFFAOYSA-N; PB26872; SCHEMBL3606964; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate"	57443610	Phase 2	DF1T2W	.	CTPDG001727
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Branebrutinib	"(S)-4-(3-(2-BUTYNOYLAMINO)PIPERIDIN-1-YL)-5-FLUORO-2,3-DIMETHYL-1H-INDOLE-7-CARBOXAMIDE; (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 1912445-55-6; 1H-Indole-7-carboxamide, 5-fluoro-2,3-dimethyl-4-((3S)-3-((1-oxo-2-butyn-1-yl)amino)-1-piperidinyl)-; 4-((3S)-3-(2-BUTYNOYLAMINO)-1-PIPERIDINYL)-5-FLUORO-2,3-DIMETHYL-1HINDOLE-7-CARBOXAMIDE; 4-((3S)-3-(2-Butynoylamino)-1-piperidinyl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-((3S)-3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 7LBRZUYSHU; AC-31535; AKOS037649047; BCP29496; BDBM164638; BDBM166759; BMS986195; BMS986195; BMS986195; BMS-986195; Branebrutinib; Branebrutinib (BMS-986195); Branebrutinib (USAN); BRANEBRUTINIB [INN]; Branebrutinib [USAN]; BRANEBRUTINIB [WHO-DD]; BS-16393; C20H23FN4O2; CHEMBL4297674; CS-0043577; D11478; DB15347; EN300-2007801; EX-A2720; Example 223 [US20160115126A1]; GTPL9869; HY-112161; MFCD31631584; NSC807627; NSC-807627; Q50825082; s8832; SCHEMBL17699728; UNII-7LBRZUYSHU; US9688629, 123; US9688629, 223; VJPPLCNBDLZIFG-ZDUSSCGKSA-N; WHO 11026"	121293929	Phase 2	DE3VU1	DB15347	CTPDG001734
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vobarilizumab	ALX-0061	.	Phase 2	D9J6XV	.	CTPDG001766
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IRL201805	.	.	Phase 2	D9EHD7	.	CTPDG001767
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KPL-404	.	.	Phase 2	D3NSU0	.	CTPDG001824
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FK-3311	"116686-15-8; FK 3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	Phase 2	D0Z9YW	.	CTPDG001858
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-783	"Rheumatoid arthritis therapy (oral), Takeda Pharmaceutical"	.	Phase 2	D0Z4OQ	.	CTPDG001864
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Piclamilast	"144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL"	154575	Phase 2	D0Z2FB	DB01791	CTPDG001866
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ADL-5859	PF-04856880	46931003	Phase 2	D0W9ZT	.	CTPDG001918
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SBI-087	PF-05230895	.	Phase 2	D0W9QG	.	CTPDG001920
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SB-705498	501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504	9910486	Phase 2	D0VJ5N	DB11883	CTPDG001948
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-817399	.	44537841	Phase 2	D0UX2V	DB14941	CTPDG001971
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CFZ533	.	.	Phase 2	D0SD6V	.	CTPDG002036
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PD-360324	"PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer"	.	Phase 2	D0S1UZ	.	CTPDG002048
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MGCD-290	"MG-1; MG-3290; Histone deacetylase inhibitors (cardiovascular diseases), MethylGene; Histone deacetylase inhibitors (diabetes), MethylGene; Histone deacetylase inhibitors (fungal infection), MethylGene; Histone deacetylase inhibitors (inflammation), MethylGene; HDAC inhibitors (non-oncology), MethylGene; Histone deacetylase inhibitors (non-oncology), MethylGene"	3035813	Phase 2	D0RF3F	.	CTPDG002061
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Prednisone/ dipyridamole	Synavive (TN)	5865	Phase 2	D0R4NR	DB00635	CTPDG002071
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	QAL964	.	.	Phase 2	D0QZ3P	.	CTPDG002077
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	M2951	"evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin"	71479709	Phase 2	D0QX8X	DB15170	CTPDG002078
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AK-106-001616	.	.	Phase 2	D0QH5K	.	CTPDG002079
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABT-122	.	.	Phase 2	D0OX5H	.	CTPDG002123
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Meninge ACYW	.	.	Phase 2	D0OQ5W	.	CTPDG002127
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-715	"P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda"	9952773	Phase 2	D0O6ZO	.	CTPDG002136
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MPC-300-IV	.	.	Phase 2	D0MM0N	.	CTPDG002186
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Anti-LT alpha	.	.	Phase 2	D0L1OC	.	CTPDG002241
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NNC-0151-0000-0000	"Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk"	.	Phase 2	D0J4PM	.	CTPDG002288
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-945429	.	.	Phase 2	D0J1KS	.	CTPDG002291
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ONO-4641	"Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono"	11502996	Phase 2	D0I2RB	.	CTPDG002320
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNT0-1959	.	.	Phase 2	D0HT2X	.	CTPDG002325
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	Phase 2	D0HG5M	DB13020	CTPDG002328
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FLUASTERONE	HE-2500; 16alpha-Fluoroandrost-5-en-17-one	133967	Phase 2	D0H9YO	DB06250	CTPDG002329
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-4059	"tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno"	54755438	Phase 2	D0H0KH	DB15227	CTPDG002346
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VVZ-149	VVZ-000149	.	Phase 2	D0G9OH	.	CTPDG002358
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MRC-375	"Tetracycline (enteric-coated oral tablet, rheumatoid arthritis), Molecular Research Center Inc"	.	Phase 2	D0F9NA	.	CTPDG002393
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AWD-12-281	"GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline"	6918428	Phase 2	D0F4TV	.	CTPDG002402
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	APX-001	"EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics"	44123754	Investigative	D0DL3W	DB15183	CTPDG002437
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SR-31747	SR-317417A	6439330	Phase 2	D0D4JI	DB05792	CTPDG002454
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BI 655064	.	.	Phase 2	D0C8NG	.	CTPDG002478
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK3196165	.	.	Phase 2	D0C7ZB	.	CTPDG002482
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK315234	Oncostatin M mAb	.	Phase 2	D0C4YQ	.	CTPDG002485
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GS-9876	"XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr"	118161062	Phase 1	D0BW6F	DB14770	CTPDG002497
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TZI-41078	"3,5-Di-tert-butyl-4-hydroxybenzophenone oxime"	.	Phase 2	D0B6VN	.	CTPDG002510
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNTO-6785	.	.	Phase 2	D0A7NZ	.	CTPDG002538
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AMG-714	.	.	Discontinued in Phase 1	D0A5EN	.	CTPDG002547
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	LX2931	.	135564845	Phase 2	D09ZWH	DB06297	CTPDG002552
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VAY736	.	.	Phase 2	D09SQM	.	CTPDG002563
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KB002/003	.	.	Phase 2	D09SJE	.	CTPDG002564
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-180575	"2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide"	9930560	Phase 2	D09OTU	.	CTPDG002571
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rabeximod	"Rob-803; B-220 analog (RA), OxyPharma; B-220 analog (rheumatoid arthritis), OxyPharma"	56841552	Phase 2	D09BDH	DB05772	CTPDG002587
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BIIB 023	.	.	Phase 2	D08YHB	.	CTPDG002598
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Baminercept	"BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec"	.	Phase 2	D08XVR	.	CTPDG002599
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-06823859	.	.	Phase 2	D08RDD	.	CTPDG002615
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MK-8457	.	53251506	Phase 2	D08PXL	.	CTPDG002620
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP323	"Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01"	23394557	Phase 2	D08MJO	.	CTPDG002628
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	.	9926791	Approved	D08ICX	DB08895	CTPDG002636
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-986142	"Unii-pjx9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide"	86582336	Phase 2	D08AOZ	DB15291	CTPDG002651
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8765	.	.	Phase 2	D07YNM	.	CTPDG002655
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AMG0714	HuMax-IL15	.	Phase 2	D07LCA	.	CTPDG002686
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Fosbretabulin	Zybrestat (TN)	5351387	Phase 2	D07JVO	DB12577	CTPDG002693
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rimacalib	SMP-114	9800765	Phase 2	D06PHH	DB12571	CTPDG002739
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Mavrilimumab	.	.	Phase 2	D06KCF	.	CTPDG002750
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CCX-354	CCX-354-C; GSK2941266	135565361	Phase 2	D05VTN	DB12963	CTPDG002783
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	[L/D]-aminopterin	.	.	Phase 2	D05QPC	.	CTPDG002790
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALX-0061	"Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx"	.	Phase 2	D05NIR	.	CTPDG002795
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Ozoralizumab	ATN-103	.	Phase 2	D05EPV	.	CTPDG002814
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	JNJ-38518168	.	23650961	Phase 2	D04VBF	DB12522	CTPDG002835
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	UCB-35440	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide	9894415	Phase 2	D04JIM	.	CTPDG002862
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Otilimab	.	.	Phase 3	D04GWO	.	CTPDG002865
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Pegsunercept	STNF-R1	.	Phase 2	D04GTA	.	CTPDG002866
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AD-452	RS(+)-mefloquine; (+)-erythro-mefloquine	.	Phase 2	D03YKQ	.	CTPDG002884
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-240612	"N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride"	44235958	Phase 2	D03UVL	.	CTPDG002897
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TOK-8801	"105963-46-0; Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide; Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; Tok 8801; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide; Imidazo(2,1-b)thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; AC1L3UYM; ACMC-20m9c6; SCHEMBL9774378; CTK4A4247; AKOS030604802"	122628	Phase 2	D03UIB	.	CTPDG002898
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D03RIX	.	CTPDG002908
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PG-760564	"Rheumatoid arthritis therapy, Procter & Gamble"	.	Phase 2	D03PBW	.	CTPDG002912
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Peresolimab	.	.	Phase 2	D02XFH	.	CTPDG002947
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-04171327	"Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317"	24872952	Phase 2	D01PLR	DB12198	CTPDG003019
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MANOALIDE	"UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975"	6437368	Phase 2	D00XQO	.	CTPDG003057
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cenplacel-L	PDA-001	.	Phase 2	D00UGX	.	CTPDG003062
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BT-016	Tregalizumab	.	Phase 2	D00PUT	.	CTPDG003072
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Xmab 5871	XmAb 5871 (TN)	.	Phase 1/2	D00NXT	.	CTPDG003076
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vidofludimus	717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644	9820008	Phase 2	D00LSI	DB15446	CTPDG003080
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	K-832	"10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9"	9844960	Phase 2	D00IUD	.	CTPDG003086
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	PRTX-100	Staphylococcal protein A	.	Phase 1/2	D0ZC6X	.	CTPDG003265
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Cx-611	"Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), Cellerix; Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), TiGenix"	.	Phase 1/2	D0T3HL	.	CTPDG003323
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	BIO-300	"Radioprotective therapy, Humanetics"	.	Phase 1/2	D0J2ES	.	CTPDG003405
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Chondrogen	Chondrogen (TN)	.	Phase 1/2	D09YVQ	.	CTPDG003481
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	.	3715	Approved	D06LFE	DB00328	CTPDG003540
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HM71224	"Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide"	56644522	Phase 1	DTF20P	.	CTPDG003715
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LABP-104	NIM-1324	.	Phase 1	DN2Z5C	.	CTPDG003811
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ORTD-1	.theta.-Defensin 1; 1-[3-[benzyl-tetrakis(3-guanidinopropyl)-[(1R)-1-hydroxyethyl]-isobutyl-isopropyl-[(1S)-1-methylpropyl]-octadecaoxo-[?]yl]propyl]guanidine; 251442-64-5; BDBM50236198; CHEMBL4073105; Cyclic-(GVCRCICTRGFCRCLCRR); DTXSID60179822; oRTD-1; RTD-1; theta-Defensin 1; theta-Defensin RTD-1	16130642	Phase 1	DH5F4M	.	CTPDG003897
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	JNJ-67484703	JNJ-4703	.	Phase 1	D4VLI7	.	CTPDG004107
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	IA-14069	.	.	Phase 1	D1ROU2	.	CTPDG004184
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BX-U001	.	.	Phase 1	D17OQM	.	CTPDG004201
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	KPE-06001	"Asthma/arthritis therapy, Kemin"	.	Phase 1	D0Z8PO	.	CTPDG004223
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	PF-05230905	ATN-192	.	Phase 1	D0Y0FZ	.	CTPDG004268
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RG6125	.	.	Phase 1	D0X8RS	.	CTPDG004281
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	TAK-020	.	.	Phase 1	D0VS3U	.	CTPDG004329
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AXS-06	.	.	Phase 1	D0VJ9X	.	CTPDG004331
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Aminoguanidine	"Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284"	2146	Discontinued in Phase 2	D0V0NL	DB05383	CTPDG004355
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	OPL-CCL2-LPM	"CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey"	.	Phase 1	D0U7PM	.	CTPDG004372
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVE1701	.	.	Phase 1	D0Q2BB	.	CTPDG004488
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVP-13358	"IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR"	9805635	Phase 1	D0P9YP	.	CTPDG004508
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Cadherin-11	SDP051	.	Phase 1	D0P5QB	.	CTPDG004517
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BF-389	"Biofor 389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029"	6439259	Phase 1	D0L6VH	.	CTPDG004624
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HMR-1031	"MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid"	9809368	Phase 1	D0L3DC	.	CTPDG004633
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VI7734	.	.	Phase 1	D0JC9K	.	CTPDG004677
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BMS-986104	"Unii-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-"	77050638	Phase 1	D0GG7L	DB15214	CTPDG004765
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AMAP-102	"5-HT antagonist (rheumatism), AnaMar"	.	Phase 1	D0G7BR	.	CTPDG004771
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Sc Veltuzumab	.	.	Phase 1	D0D8NG	.	CTPDG004853
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MORAb-022	"Antibody (inflammation/autoimmune disease), Morphotek"	.	Phase 1	D0B0VD	.	CTPDG004925
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ARG301	.	.	Phase 1	D09PJB	.	CTPDG004987
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SCH-900117	.	.	Phase 1	D08YWY	.	CTPDG005018
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	DWP-422	.	.	Phase 1	D08SXV	.	CTPDG005031
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VEL-0230	"NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar"	25102841	Phase 1	D07BIK	.	CTPDG005126
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Synthetic neutrophil inhibitor peptide	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide	71482	Phase 1	D07ANO	.	CTPDG005128
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RWJ-67657	215303-72-3; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	Phase 1	D06OZJ	.	CTPDG005150
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI4920	.	.	Phase 1	D06HNO	.	CTPDG005164
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RPI-78M	"Antiviral agent, Receptogen; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm"	.	Discontinued in Phase 1	D05FVK	.	CTPDG005210
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP2408	CTLA4-Ig fusion protein	.	Phase 1	D04OQU	.	CTPDG005246
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK3117391	.	53630042	Phase 1	D04KMQ	DB15440	CTPDG005255
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ABBV-257	.	.	Phase 1	D04DQO	.	CTPDG005266
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VGX-1027	"6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590"	10798271	Phase 1	D03QEB	.	CTPDG005296
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK-1827771	"IL-1 antagonist (antibody, rheumatoid arthritis), GSK"	.	Phase 1	D03FVR	.	CTPDG005318
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP5094	.	.	Phase 1	D03ACE	.	CTPDG005331
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	EVT 401	.	.	Phase 1	D01TLV	.	CTPDG005379
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SKI-O-703	.	.	Phase 1	D01IDW	.	CTPDG005409
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Clinical trial	AZ-4217	AZ4217; AZ 4217	57406537	Clinical trial	D00XKB	.	CTPDG005509
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Floctafenine	"23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline"	3360	Withdrawn from market	D0AK5R	DB08976	CTPDG006315
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Aurothioglucose	HMS3262I11; LP00685	454937	Withdrawn from market	D0A4BR	.	CTPDG006316
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Preregistration	Amiprilose	Therafectin; Amiprilose hydrochloride; KAP-690; SM-1213	121928	Discontinued in Preregistration	D07MEL	.	CTPDG006326
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	Nerelimomab	BAY-X-1351	.	Discontinued in Phase 3	D0VW2Z	.	CTPDG006333
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	M-5010	M-5011; T-3788; 2(R)-[4-(3-Methyl-2-thienyl)phenyl]propionic acid	12769847	Discontinued in Phase 3	D0RJ0J	.	CTPDG006340
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	BR3-Fc	.	.	Discontinued in Phase 2	D0YA0N	.	CTPDG006399
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	EFLETIRIZINE	Efletirizine < Rec INN; Ucb-28754; 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid	66003	Discontinued in Phase 2	D0XK4R	.	CTPDG006402
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IX207-887	.	6509858	Discontinued in Phase 2	D0X2PQ	.	CTPDG006407
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AMG 108	.	444499	Discontinued in Phase 2	D0W7VG	.	CTPDG006413
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HR325	.	66583751	Discontinued in Phase 2	D0SX4K	.	CTPDG006435
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	TA-383	"Cis-2-(4-Chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride; Cis-2-(4-Chlorophenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole hydrochloride"	131180	Discontinued in Phase 2	D0R2CM	.	CTPDG006447
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	Discontinued in Phase 2	D0Q9ZD	.	CTPDG006450
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SM-8849	"113759-19-6; 4-(1-(2-fluoro-4-biphenylyl)ethyl)-2-methylaminothiazole; 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole; ZTFDMDJGJVUYQE-UHFFFAOYSA-N; AC1L3Y3S; SCHEMBL5078854; 4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; (+)-2-methylamino-4-(1-(2-fluoro-4-biphenylyl)ethyl)thiazole; 4-[1-(3-fluoro-4-phenylphenyl)ethyl]-N-methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 4-(1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-N-methyl-"	124238	Discontinued in Phase 2	D0Q0AJ	.	CTPDG006455
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Zolimomab aritox	XomaZyme-CD5 Plus; XomaZyme-H65; XomaZyme-lym; OrthoZyme-CD5+; Xmmly-h65-rta; XomaZyme-H65-rta	.	Discontinued in Phase 2	D0O2QB	.	CTPDG006464
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CP-195543	"LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer"	9823886	Discontinued in Phase 2	D0MM2K	DB13053	CTPDG006475
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MLN3897	.	.	Discontinued in Phase 2	D0KF6X	.	CTPDG006490
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-5751	"AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid"	9867949	Discontinued in Phase 2	D0K0VH	.	CTPDG006494
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MP-435	"C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe"	.	Discontinued in Phase 2	D0H0ZU	.	CTPDG006510
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CPA-926	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one	9800054	Discontinued in Phase 2	D0G6PG	.	CTPDG006516
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SINOMENINE	"Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one"	5459308	Discontinued in Phase 2	D0F9WF	.	CTPDG006522
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Linetastine	"Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Molecule 26"	6439232	Discontinued in Phase 2	D0E8UV	.	CTPDG006530
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SC-106	AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid	492984	Discontinued in Phase 2	D0D3KY	.	CTPDG006539
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PRO-515	.	.	Discontinued in Phase 2	D09FEN	.	CTPDG006572
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GW-215864	GR-215864; GR-215864X; GW-215864X	56841560	Discontinued in Phase 2	D09AUP	.	CTPDG006573
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HSR-609	"FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate"	3081352	Discontinued in Phase 2	D08RZV	.	CTPDG006576
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AnergiX.RA	"AG-4263; RA-AnergiX; Antigen specific therapy (rheumatoid arthritis, AnergiX), Corixa/ Organon"	.	Discontinued in Phase 2	D07BEE	.	CTPDG006598
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GLPG-0259	"G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562"	44462738	Discontinued in Phase 2	D06NPB	DB15190	CTPDG006604
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NN8209	.	.	Discontinued in Phase 2	D05ILZ	.	CTPDG006618
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IDEC-151	Clenoliximab	.	Discontinued in Phase 2	D04ZLG	.	CTPDG006624
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	Discontinued in Phase 2	D04DUJ	.	CTPDG006634
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NPC-567	"Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-"	119343	Discontinued in Phase 2	D03ZBM	.	CTPDG006637
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	T-5224	AKOS003047196; T5224	23626877	Discontinued in Phase 2	D02LCL	.	CTPDG006652
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AD-121	"PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest"	.	Discontinued in Phase 1/2	D06YFO	.	CTPDG006694
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AME-527	.	.	Discontinued in Phase 1/2	D05RTF	.	CTPDG006696
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-4629991	"PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer"	.	Discontinued in Phase 1	D0N8AB	.	CTPDG006767
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	NN8210	.	.	Discontinued in Phase 1	D0MT7W	.	CTPDG006774
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	ARRY-614	"Pexmetinib; 945614-12-0; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	Discontinued in Phase 1	D0ML0L	.	CTPDG006775
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Oncolysin CD6	Anti-CD6-bR; Anti-T12-bR	.	Discontinued in Phase 1	D0L4SB	.	CTPDG006784
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Eltenac	BY-820; B-788-20	51717	Discontinued in Phase 1	D0JF6O	.	CTPDG006796
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RG-4934	"IL-17 huMAb (psoriatic arthritis), Roche"	.	Discontinued in Phase 1	D0J8JF	.	CTPDG006797
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AC-100	"Bicyclo[4.2.0]octa-1,3,5-trien-3-ylboronic acid; BENZOCYCLOBUTANE-4-BORONIC ACID; Boronic acid, bicyclo[4.2.0]octa-1,3,5-trien-3-yl-; SCHEMBL12759201; KS-00000SRU; MolPort-005-942-889; ZINC196051840; AKOS025146995; DS-8536; BC225113; AK164312; 1,2-Dihydrobenzocyclobutene-4-ylboranic acid; CS-0043999; J3.522.588I; 4-bbcb                                             benzocyclobutene-4-boronic acid"	11171056	Discontinued in Phase 1	D0J6PR	.	CTPDG006798
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Roquinimex	Linomide	54676478	Discontinued in Phase 1	D0G9ZW	DB11366	CTPDG006812
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	D-1367	"167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-"	15259989	Discontinued in Phase 1	D0E8MW	.	CTPDG006818
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AVE-9940	.	.	Discontinued in Phase 1	D08CQE	.	CTPDG006862
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	LY-231617	"2,6-Di-tert-butyl-4-(ethylaminomethyl)phenol hydrochloride"	3968	Discontinued in Phase 1	D05XYC	.	CTPDG006882
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	CI-972	.	135418360	Discontinued in Phase 1	D05UPB	.	CTPDG006883
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R1295	CHEMBL2146615	70329	Discontinued in Phase 1	D04XJM	.	CTPDG006893
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	KB-2683	.	129748	Discontinued in Phase 1	D03LXJ	.	CTPDG006908
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-6703	"P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca"	11373432	Discontinued in Phase 1	D03KWN	.	CTPDG006909
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SC-57666	CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	Discontinued in Phase 1	D02OHR	.	CTPDG006916
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	C-5997	"7709-58-2; 4-(Chloromethyl)thiazole hydrochloride; 4-(chloromethyl)-1,3-thiazole Hydrochloride; 4-(chloromethyl)thiazole hcl; 4-chloromethylthiazole hydrochloride; 4-chloromethylthiazole hcl; 4-(chloromethyl)thiazolehcl; C4H4ClNS.ClH; ACMC-1BBSC; chloromethylthiazole-4 hcl; AC1Q3BH9; AC1MC82W; SCHEMBL122926; 4-(Chloromethyl)thiazole, HCl; CTK6H6834; DTXSID60376874; NVTBASMQHFMANH-UHFFFAOYSA-N; MolPort-000-139-475; 4-(chloromethyl)thiazole HCl salt; ACT02312; KS-000004ND; ANW-36949; 4-chloromethyl thiazole hydrochloride"	2763289	Discontinued in Phase 1	D01CBV	.	CTPDG006932
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-755616	.	.	Discontinued in Phase 1	D00FGY	.	CTPDG006939
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	GP2015	.	.	Application submitted	D0K9SS	.	CTPDG006944
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	SR1555	"CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675"	71470549	Preclinical	DW5R6Y	.	CTPDG006962
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	MCP-1	.	.	Preclinical	D0V9ND	.	CTPDG007038
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NPC-17923	"147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-"	9824607	Terminated	D0Z3AK	.	CTPDG007165
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	TM-31	.	.	Terminated	D0Y9CC	.	CTPDG007170
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BCX-25	BCX-14	.	Terminated	D0V2ZJ	.	CTPDG007200
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BB-1433	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241	101708593	Terminated	D0V0RW	.	CTPDG007202
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	ZK-90695	.	.	Terminated	D0US3C	.	CTPDG007203
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RP-54745	"RP 54745; 135330-08-4; AC1L2PX8; SCHEMBL4362761; rp54745; CS-6750; 4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one; HY-101716; 4-chloro-5-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)dithiol-3-one; 3H-1,2-Dithiol-3-one, 4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-"	126203	Terminated	D0T0LO	.	CTPDG007223
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	Terminated	D0R5TT	.	CTPDG007238
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Seprilose	GW-80126	60818	Terminated	D0Q5ZN	.	CTPDG007243
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NOX-200	"2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478"	95438	Terminated	D0OX9Q	.	CTPDG007255
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SAN-18	.	.	Terminated	D0M8QG	.	CTPDG007278
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	CI-986	"CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate"	3037017	Terminated	D0L8RG	.	CTPDG007289
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-6942	"CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca"	.	Terminated	D0I9YI	.	CTPDG007324
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	3-DEAZAADENOSINE	"Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine"	23190	Terminated	D0I7TN	DB04546	CTPDG007326
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-28342	.	9882188	Terminated	D0H0IA	.	CTPDG007341
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AG-2024	.	.	Terminated	D0G2CL	.	CTPDG007350
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Ro-31-4724	CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	Terminated	D0EF7V	DB08482	CTPDG007361
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-33516	.	.	Terminated	D0DR3I	.	CTPDG007371
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	D-5410	CH-138; CH-263	.	Terminated	D09TRM	.	CTPDG007412
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SKF-104351	"111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole"	122656	Terminated	D09SCI	.	CTPDG007413
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RWJ-63556	.	9882374	Terminated	D08JKK	.	CTPDG007441
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	YM-26734	"YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1"	9853400	Terminated	D07OGR	.	CTPDG007458
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD5672	"CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide"	11614352	Terminated	D07GIB	.	CTPDG007463
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-16276-1	.	.	Terminated	D06MTM	.	CTPDG007476
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-111142	WF-2015A	9909502	Terminated	D06AKJ	.	CTPDG007482
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BW A4C	"BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide"	6438354	Terminated	D05WPQ	.	CTPDG007485
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-48989	"WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile"	132006	Terminated	D04YNI	.	CTPDG007505
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-133605	.	.	Terminated	D04SVB	.	CTPDG007508
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SR-26831	"SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate"	132270	Terminated	D03GII	.	CTPDG007535
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	GDC-0834	"1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz"	25234918	Terminated	D03FUO	.	CTPDG007536
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	Terminated	D01QRG	.	CTPDG007565
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	LY-221068	"LY 221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-"	6439333	Terminated	D01QAR	.	CTPDG007566
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	DPC-333	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide	9847838	Terminated	D01DVX	.	CTPDG007574
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	PXS-2076	"PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis"	.	Terminated	D01DTQ	.	CTPDG007575
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ODN-1411	.	.	Investigative	D5S7JL	.	CTPDG007609
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	Investigative	D0YK4L	.	CTPDG007651
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	Investigative	D0Y4ZI	.	CTPDG007665
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BFPT-16864	BFPT-6864; BRFD-104	.	Investigative	D0XP3A	.	CTPDG007695
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Arthromir	.	.	Investigative	D0WI1L	.	CTPDG007743
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	SPX-601	.	.	Investigative	D0VB2K	.	CTPDG007786
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-814	"Hsp60 peptide (juvenile idiopathic arthritis), CIGB"	.	Investigative	D0V5VA	.	CTPDG007796
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD40-XTEN	"CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0V3HC	.	CTPDG007800
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	X-071-NAB	"NATHMAB (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech; Natural/true human monoclonal antibody (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech"	.	Investigative	D0U2OQ	.	CTPDG007838
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TENOSAL	MR-Y134; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	Investigative	D0T3KZ	.	CTPDG007862
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DW-908	DW-0908	.	Investigative	D0R4NJ	.	CTPDG007910
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	Investigative	D0N8TM	.	CTPDG008032
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	MDDR 217769	"(E)-2-(4,6-Difluoroindan-1-ylidene)acetamide"	.	Investigative	D0N8JJ	.	CTPDG008033
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FKB327	.	.	Investigative	D0L8UQ	.	CTPDG008105
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DMARDs	"DMARDs (oral, rheumatoid arthritis); DMARDs (oral, rheumatoid arthritis), Abbott; Disease-modifying antirheumatic drugs (oral, rheumatoid arthritis), Abbott"	.	Investigative	D0L2BT	.	CTPDG008121
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TX-RAD	"RA1-TX; RA1-TX (ankylosing spondylitis), TxCell; RA1-TX (rheumatoid arthritis), TxCell; RA1-TX (psoriatic arthritis,inflammatory disease), TxCell"	.	Investigative	D0K8BO	.	CTPDG008134
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	UR-5269	"Rheumatoid arthritis therapy, UBE Industries"	.	Investigative	D0J7XN	.	CTPDG008168
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	AVX-002	.	.	Investigative	D0J4TX	.	CTPDG008173
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-125	"Synoviocyte inhibitor + glucocorticoid (arthritis), Xaragen"	.	Investigative	D0I9FQ	.	CTPDG008191
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DWJ-425	"DW-Ab2; MAb (RA), Daewoong; Monoclonal antibody (rheumatoid arthritis), Daewoong"	.	Investigative	D0I4MW	.	CTPDG008211
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	HL-1020	"Grape seed proanthocyanidin extract (rheumatoid arthritis), Hanlim"	.	Investigative	D0G8EI	.	CTPDG008263
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-120	"Synoviocyte inhibitor + DMARD (arthritis), Xaragen"	.	Investigative	D0G2GZ	.	CTPDG008276
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-115	"Synoviocyte inhibitor + NSAID (arthritis), Xaragen"	.	Investigative	D0F8BR	.	CTPDG008296
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CTLA-4-XTEN	"Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0EZ9C	.	CTPDG008324
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Nano-steroid	"Steroidal anti-inflammatory (slow release nanoparticle formulation), LTT Bio-Pharma; Steroids (sustained release nanoparticles), LTT Bio-Pharma/Cipra; Steroidal anti-inflammatory (rheumatoid arthritis/collagen disease), LTT Bio-Pharma"	.	Investigative	D0B9XM	.	CTPDG008440
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	YD-101	.	.	Investigative	D0B3KI	.	CTPDG008455
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	KI-0906	.	.	Investigative	D0A2RF	.	CTPDG008498
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FHT-401	"PTD-conjugated methotrexate (transdermal, rheumatoid arthritis), ForHumanTech/Hyundai"	.	Investigative	D0A0FI	.	CTPDG008502
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TCH-013	"NF-kB inhibitors (rheumatoid arthritis); NF-kB inhibitors (rheumatoid arthritis), TCH Pharmaceuticals"	76850167	Investigative	D09TVH	.	CTPDG008515
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD97 mab	"Anti-CD97 monoclonal antibody (rheumatoid arthritis); Anti-CD97 mAb (RA), Organon/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Organon/AMC; Anti-CD97 mAb (RA), Schering-Plough/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Merck & Co/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Schering-Plough/AMC"	.	Investigative	D09RGS	.	CTPDG008524
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-55	.	.	Investigative	D09NQD	.	CTPDG008534
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Dendritic cell-based immunotherapy	"Dendritic cell-based immunotherapy (rheumatoid arthritis); Dendritic cell-based immunotherapy (rheumatoid arthritis), Dendright; Dendritic cell-based immunotherapy (rheumatoid arthritis, injectable formulation), Dendright"	.	Investigative	D07OCM	.	CTPDG008673
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	RT-401	"BoNTA protein (topical, rhinitis), Revance"	.	Investigative	D07JPL	.	CTPDG008692
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	VVZ-138	VVZ-000138	.	Investigative	D07GFZ	.	CTPDG008699
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	IG-AI-025	.	.	Investigative	D06XXD	.	CTPDG008716
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CHR-4487	"Esterase-sensitive motif compounds (inflammatory disease); Esterase-sensitive motif compounds (inflammatory disease), Chroma Therapeutics"	.	Investigative	D06HWU	.	CTPDG008757
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ROSMARINIC ACID	"20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid"	5281792	Investigative	D05PTT	.	CTPDG008813
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CT-340	"TrkA kinase inhibitor (polyoxyethylene conjugated, LSE, arthritis, scarring, pain), Creabilis"	.	Investigative	D05KRS	.	CTPDG008827
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ADR58	.	.	Investigative	D04VCF	.	CTPDG008856
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CEL-2000	"T-cell modulating vaccine (LEAPS, rheumatoid arthritis), CEL-SCI"	.	Investigative	D03XSX	.	CTPDG008918
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FM-201	.	.	Investigative	D03TKI	.	CTPDG008933
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BMS-345541	"445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05"	9926054	Investigative	D00YTQ	.	CTPDG009140
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CAT-2200	"MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)"	.	Investigative	D00XNC	.	CTPDG009145
M6ACROT00016	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	OCT-SG815	"OPG secretagogues (osteoporosis/arthritis), Oscotec; Osteoprotegerin secretagogues (osteoporosis/arthritis), Oscotec; OPG secretagogues (osteoporosis/arthritis), KT&G; Osteoprotegerin secretagogues (osteoporosis/arthritis), KT&G"	.	Investigative	D00QOH	.	CTPDG009161
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	Kevzara	.	Approved	D0Z8CQ	.	CTPDG000029
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulindac	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	1548887	Approved	D0Z5IU	DB00605	CTPDG000031
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Felbinac	"Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda"	3332	Approved	D0Y7EM	DB07477	CTPDG000057
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Salsalate	"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid"	5161	Approved	D0Y0JH	DB01399	CTPDG000063
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Fostamatinib	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]	11671467	Phase 3	D0V8HJ	DB12010	CTPDG000102
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Methotrexate	"Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	126941	Phase 3	D0SV8E	DB00563	CTPDG000144
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IPI-145	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;	50905713	Phase 3	D0RU0O	DB11952	CTPDG000166
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	Approved	D0R1RS	DB00328	CTPDG000188
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Inosine pranobex	Imunovir (TN)	135449284	Approved	D0Q2QU	.	CTPDG000206
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Citrofen	Citrofen (TN)	.	Approved	D0P6UK	.	CTPDG000218
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meclofenamate Sodium	.	4038	Approved	D0MN9K	.	CTPDG000266
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxaprozin	"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid"	4614	Approved	D0M9DC	DB00991	CTPDG000269
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Zinc salts	.	.	Approved	D0K8AA	.	CTPDG000300
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	Approved	D0K5KS	.	CTPDG000305
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Orthokine	Orthokine (TN)	.	Approved	D0J1PW	.	CTPDG000330
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	SK-1306X	Cararthron; Joins	.	Approved	D0IL0C	.	CTPDG000339
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	Approved	D0I6IB	DB00469	CTPDG000343
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	Approved	D0I5QX	.	CTPDG000345
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	Approved	D0G7FJ	DB00814	CTPDG000369
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Gold sodium thiomalate	Sodium aurothiomalate	22318	Approved	D0FH7C	DB09276	CTPDG000381
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Abatacept	Orencia (TN)	.	Approved	D0EW4L	.	CTPDG000397
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)"	9926791	Approved	D0EG1I	DB08895	CTPDG000400
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	OM-89	Subreum; UroVaxom; UroVaxon; OM-8980	.	Approved	D0E1VD	.	CTPDG000414
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rimexolone	"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)"	5311412	Approved	D0D2TN	DB00896	CTPDG000426
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	Approved	D0CA0P	.	CTPDG000432
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Alclofenac	"22131-79-9; Alclophenac; Prinalgin; Medifenac; Reufenac; Allopydin; Mervan; Alclofenacum; Alclofenaco; Zumaril; Neoston; Neosten; 2-(4-(Allyloxy)-3-chlorophenyl)acetic acid; [4-(Allyloxy)-3-chlorophenyl]acetic acid; Desinflam; Marvan Forte; 3-Chloro-4-(2-propenyloxy)benzeneacetic acid; (4-Allyloxy-3-chlorphenyl)essigsaeure; MY 101; Epinal; Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-; Alclofenacum [INN-Latin]; Alclofenaco [INN-Spanish]; UNII-M9CP5H21N8; W 7320; CHEBI:31183; EINECS 244-795-4"	30951	Approved	D0C6OQ	DB13167	CTPDG000435
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Careram	Iguratimod	124246	Approved	D0B8MZ	DB12233	CTPDG000450
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	Approved	D0A1PX	DB00712	CTPDG000472
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Nafcillin	"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	8982	Approved	D0A0JH	DB00607	CTPDG000473
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etofenamate	30544-47-9; Rheumon; Bayrogel; Rheumon gel; UNII-KZF0XM66JC; Etofenamatum [INN-Latin]; Etofenamato [INN-Spanish]; Bay d 1107; C18H18F3NO4; TVX 485; WHR 5020; EINECS 250-231-8; KZF0XM66JC; BRN 2953263; 2-(2-Hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate; 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate; WHR-5020; NCGC00016804-01; 2-(2-Hydroxyaethoxy)aethylester der flutenaminsaeure [German]; CAS-30544-47-9; 2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate	35375	Approved	D09YVX	DB08984	CTPDG000475
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	Approved	D09MGR	DB01628	CTPDG000489
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	Approved	D09FSG	.	CTPDG000501
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	Approved	D09BHB	DB00500	CTPDG000505
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)	.	Phase 2	D08WSY	.	CTPDG000511
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Leflunomide	"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide"	3899	Approved	D08ROP	DB01097	CTPDG000515
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Penicillamine	"D-Penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine"	5852	Approved	D08HZC	DB00859	CTPDG000523
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dimethyl Sulfoxide	Rimso-50	679	Approved	D08HVE	DB01093	CTPDG000524
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tocilizumab	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody	.	Approved	D08HPZ	.	CTPDG000526
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Benorilate	"5003-48-5; BENORYLATE; 4-acetamidophenyl 2-acetoxybenzoate; Benoral; Salipran; Benortan; Fenasprate; Fenasparate; Aspirin acetaminophen ester; Benorilato; Benorilato [Spanish]; p-Acetamidophenyl acetylsalicylate; Benorilatum [INN-Latin]; Benorilato [INN-Spanish]; UNII-W1QX9DV96G; p-N-Acetylaminophenylacetylsalicylate; TO 125; WIN 11450; 4'-(Acetamido)phenyl-2-acetoxybenzoate; 2-Acetoxy-4'-(acetamino)phenylbenzoate; CCRIS 1739; Benzoic acid, 2-(acetyloxy)-, 4-(acetylamino)phenyl ester; 4-Acetamidophenyl salicylate acet"	21102	Approved	D08GJO	DB13657	CTPDG000528
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Halopredone acetate	Haloart (TN)	91667	Approved	D08BDT	.	CTPDG000531
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Teriflunomide	.	54684141	Approved	D07QFP	DB08880	CTPDG009757
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Siponimod	BAF312	44599207	Phase 2	D07FKQ	DB12371	CTPDG000573
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxyphenbutazone	Tandearil	4641	Approved	D06ZPS	DB03585	CTPDG000587
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	FENBUFEN	"36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	Approved	D06LHG	DB08981	CTPDG000602
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexchlorpheniramine Maleate	Polaramine	5281070	Approved	D05ZGQ	DB09555	CTPDG000614
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Enbrel	.	.	Approved	D05LTY	.	CTPDG000635
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Fenoprofen	"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid"	3342	Approved	D03XYW	DB00573	CTPDG000689
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	Approved	D03RTS	DB00482	CTPDG000700
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sodium Succinate	"Disodium succinate; 150-90-3; Disodium butanedioate; Butanedioic acid, disodium salt; Succinic acid disodium salt; Soduxin; Jantaran sodny [Czech]; UNII-V8ZGC8ISR3; Succinic acid, disodium salt; FEMA No. 3277; CCRIS 3700; Sodium succinate dibasic; EINECS 205-778-7; V8ZGC8ISR3; Butanedioic acid, sodium salt (1:2); Succinic acid disodium salt anhydrous; Butanedioic acid disodium salt; sodium succinate (anhydrous); Jantaran sodny; Butanedioic acid disodium hexahydrate; Succinic acid, disodium salt, 99%, anhydrous"	9020	Approved	D03RCJ	.	CTPDG000703
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulfasalazine	599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Sulfasalizine	5339	Approved	D02ZTJ	DB00795	CTPDG000732
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	Kineret; Kineret (TN); Anakinra (USAN/INN)	.	Approved	D02DES	.	CTPDG000759
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Cyproheptadine	"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene"	2913	Approved	D00TLN	DB00434	CTPDG000802
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	Approved	D00HGB	DB04552	CTPDG000816
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Nipocalimab	.	.	Phase 2	DS69NO	.	CTPDG000882
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Nipocalimab?	.	.	Phase 3	DR5V8I	.	CTPDG000884
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	BI 695501	BI-695501)	.	Phase 3	D0Z4VX	.	CTPDG000966
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06410293	.	.	Phase 3	D0Y8TZ	.	CTPDG000976
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Flobufen	VUFB-16066; VUFB-17203	159476	Phase 3	D0X8VV	.	CTPDG000989
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	Phase 3	D0W2CX	DB12399	CTPDG001013
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP-2017	.	.	Phase 3	D0S7JN	.	CTPDG001055
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cartistem	"Stem cell therapy (cartilage disease/rheumatoid arthritis), Medipost"	.	Phase 3	D0OH5E	.	CTPDG001096
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IR-201	Seryl-glutaminyl-isoleucyl-valyl-asparaginyl-aspartyl-phenylalanyl-glutaminyl-lysyl-glycyl-aspartyl-isoleucyl-alanyl-glutamyl-glycyl-tyrosyl-serine	.	Phase 3	D0N3SA	.	CTPDG001116
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Esonarimod	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298	127998	Phase 3	D0MY7X	.	CTPDG001120
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CIPEMASTAT	"Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	Phase 3	D0MW3H	.	CTPDG001123
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Methylprednisolone	.	6741	Approved	D0LN1Z	DB00959	CTPDG001141
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	STI-002	.	.	Phase 3	D0I6UE	.	CTPDG001181
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MK-8808	.	.	Phase 1	D0GP8N	.	CTPDG001196
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 798	.	.	Phase 3	D0E8NJ	.	CTPDG001224
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06438179	.	.	Phase 3	D0D9HZ	.	CTPDG001236
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	.	44205240	Approved	D0D5FU	DB11817	CTPDG001241
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cilengitide	"188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)"	176873	Phase 3	D09ZXO	DB11890	CTPDG001287
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CEP-41750	.	.	Phase 3	D09WRG	.	CTPDG001291
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	.	.	Approved	D08SJT	.	CTPDG001320
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Andolast	"Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm"	65970	Phase 3	D08PGC	.	CTPDG001324
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Vanadate	"Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3"	516859	Phase 3	D08NCO	.	CTPDG001327
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	Phase 3	D08DGC	DB12193	CTPDG011311
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Spermidine	"Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, &gt; =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0"	1102	Phase 3	D08BXT	DB03566	CTPDG001337
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Varespladib methyl	"A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera"	9886917	Phase 3	D07KFB	DB05737	CTPDG001360
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 501	.	.	Phase 3	D06FMO	.	CTPDG001379
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	.	.	Approved	D06CXL	.	CTPDG001384
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Atacicept	.	.	Phase 2	D04YWM	.	CTPDG001412
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Tenidap	.	60712	Phase 3	D02RQT	DB13481	CTPDG001457
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LY3090106	Tibulizumab	.	Phase 1	D09JVK	.	CTPDG001558
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2/3	VX-509	"Decernotinib; Adelatinib; 944842-54-0; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	Phase 2/3	D04QWQ	DB12566	CTPDG001571
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D03ZYQ	.	CTPDG001574
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	CreaVax-RA	"Autologous DC therapy (injectable, rheumatoid arthritis), CreaGene; Autologous dendritic cell therapy (injectable, rheumatoid arthritis), CreaGene"	.	Phase 2a	D0U9OD	.	CTPDG001585
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	RhuDex	.	.	Phase 2a	D0J0KT	.	CTPDG001586
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cevidoplenib	"(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone; 1703788-21-9; 3N3H8BX897; AKOS040748110; BDBM196772; Cevidoplenib; Cevidoplenib [INN]; Cevidoplenib [WHO-DD]; CHEMBL3921923; CS-0039259; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; EX-A5914; HY-109082; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; MS-28778; SCHEMBL16653204; UNII-3N3H8BX897; US9212178, 1; YCZUBLQESBVOSH-IBGZPJMESA-N"	91754477	Phase 2	DY57LN	.	CTPDG001609
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Dazodalibep	VIB4920	.	Phase 2	DPDI65	.	CTPDG001652
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Natrunix	.	.	Phase 2	DOVW19	.	CTPDG001657
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-5718	"1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 920036-34-6; A860172; AKOS022178093; AMY21637; CS-0048281; FT-0702852; GS-5718; MFCD13183727; OKKLWSNHFSFXEM-UHFFFAOYSA-N; PB26872; SCHEMBL3606964; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate"	57443610	Phase 2	DF1T2W	.	CTPDG001727
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Branebrutinib	"(S)-4-(3-(2-BUTYNOYLAMINO)PIPERIDIN-1-YL)-5-FLUORO-2,3-DIMETHYL-1H-INDOLE-7-CARBOXAMIDE; (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 1912445-55-6; 1H-Indole-7-carboxamide, 5-fluoro-2,3-dimethyl-4-((3S)-3-((1-oxo-2-butyn-1-yl)amino)-1-piperidinyl)-; 4-((3S)-3-(2-BUTYNOYLAMINO)-1-PIPERIDINYL)-5-FLUORO-2,3-DIMETHYL-1HINDOLE-7-CARBOXAMIDE; 4-((3S)-3-(2-Butynoylamino)-1-piperidinyl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-((3S)-3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 7LBRZUYSHU; AC-31535; AKOS037649047; BCP29496; BDBM164638; BDBM166759; BMS986195; BMS986195; BMS986195; BMS-986195; Branebrutinib; Branebrutinib (BMS-986195); Branebrutinib (USAN); BRANEBRUTINIB [INN]; Branebrutinib [USAN]; BRANEBRUTINIB [WHO-DD]; BS-16393; C20H23FN4O2; CHEMBL4297674; CS-0043577; D11478; DB15347; EN300-2007801; EX-A2720; Example 223 [US20160115126A1]; GTPL9869; HY-112161; MFCD31631584; NSC807627; NSC-807627; Q50825082; s8832; SCHEMBL17699728; UNII-7LBRZUYSHU; US9688629, 123; US9688629, 223; VJPPLCNBDLZIFG-ZDUSSCGKSA-N; WHO 11026"	121293929	Phase 2	DE3VU1	DB15347	CTPDG001734
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vobarilizumab	ALX-0061	.	Phase 2	D9J6XV	.	CTPDG001766
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IRL201805	.	.	Phase 2	D9EHD7	.	CTPDG001767
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KPL-404	.	.	Phase 2	D3NSU0	.	CTPDG001824
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FK-3311	"116686-15-8; FK 3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	Phase 2	D0Z9YW	.	CTPDG001858
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-783	"Rheumatoid arthritis therapy (oral), Takeda Pharmaceutical"	.	Phase 2	D0Z4OQ	.	CTPDG001864
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Piclamilast	"144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL"	154575	Phase 2	D0Z2FB	DB01791	CTPDG001866
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ADL-5859	PF-04856880	46931003	Phase 2	D0W9ZT	.	CTPDG001918
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SBI-087	PF-05230895	.	Phase 2	D0W9QG	.	CTPDG001920
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SB-705498	501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504	9910486	Phase 2	D0VJ5N	DB11883	CTPDG001948
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-817399	.	44537841	Phase 2	D0UX2V	DB14941	CTPDG001971
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CFZ533	.	.	Phase 2	D0SD6V	.	CTPDG002036
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PD-360324	"PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer"	.	Phase 2	D0S1UZ	.	CTPDG002048
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MGCD-290	"MG-1; MG-3290; Histone deacetylase inhibitors (cardiovascular diseases), MethylGene; Histone deacetylase inhibitors (diabetes), MethylGene; Histone deacetylase inhibitors (fungal infection), MethylGene; Histone deacetylase inhibitors (inflammation), MethylGene; HDAC inhibitors (non-oncology), MethylGene; Histone deacetylase inhibitors (non-oncology), MethylGene"	3035813	Phase 2	D0RF3F	.	CTPDG002061
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Prednisone/ dipyridamole	Synavive (TN)	5865	Phase 2	D0R4NR	DB00635	CTPDG002071
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	QAL964	.	.	Phase 2	D0QZ3P	.	CTPDG002077
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	M2951	"evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin"	71479709	Phase 2	D0QX8X	DB15170	CTPDG002078
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AK-106-001616	.	.	Phase 2	D0QH5K	.	CTPDG002079
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABT-122	.	.	Phase 2	D0OX5H	.	CTPDG002123
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Meninge ACYW	.	.	Phase 2	D0OQ5W	.	CTPDG002127
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-715	"P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda"	9952773	Phase 2	D0O6ZO	.	CTPDG002136
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MPC-300-IV	.	.	Phase 2	D0MM0N	.	CTPDG002186
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Anti-LT alpha	.	.	Phase 2	D0L1OC	.	CTPDG002241
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NNC-0151-0000-0000	"Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk"	.	Phase 2	D0J4PM	.	CTPDG002288
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-945429	.	.	Phase 2	D0J1KS	.	CTPDG002291
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ONO-4641	"Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono"	11502996	Phase 2	D0I2RB	.	CTPDG002320
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNT0-1959	.	.	Phase 2	D0HT2X	.	CTPDG002325
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	Phase 2	D0HG5M	DB13020	CTPDG002328
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FLUASTERONE	HE-2500; 16alpha-Fluoroandrost-5-en-17-one	133967	Phase 2	D0H9YO	DB06250	CTPDG002329
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-4059	"tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno"	54755438	Phase 2	D0H0KH	DB15227	CTPDG002346
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VVZ-149	VVZ-000149	.	Phase 2	D0G9OH	.	CTPDG002358
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MRC-375	"Tetracycline (enteric-coated oral tablet, rheumatoid arthritis), Molecular Research Center Inc"	.	Phase 2	D0F9NA	.	CTPDG002393
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AWD-12-281	"GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline"	6918428	Phase 2	D0F4TV	.	CTPDG002402
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	APX-001	"EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics"	44123754	Investigative	D0DL3W	DB15183	CTPDG002437
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SR-31747	SR-317417A	6439330	Phase 2	D0D4JI	DB05792	CTPDG002454
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BI 655064	.	.	Phase 2	D0C8NG	.	CTPDG002478
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK3196165	.	.	Phase 2	D0C7ZB	.	CTPDG002482
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK315234	Oncostatin M mAb	.	Phase 2	D0C4YQ	.	CTPDG002485
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GS-9876	"XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr"	118161062	Phase 1	D0BW6F	DB14770	CTPDG002497
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TZI-41078	"3,5-Di-tert-butyl-4-hydroxybenzophenone oxime"	.	Phase 2	D0B6VN	.	CTPDG002510
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNTO-6785	.	.	Phase 2	D0A7NZ	.	CTPDG002538
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AMG-714	.	.	Discontinued in Phase 1	D0A5EN	.	CTPDG002547
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	LX2931	.	135564845	Phase 2	D09ZWH	DB06297	CTPDG002552
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VAY736	.	.	Phase 2	D09SQM	.	CTPDG002563
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KB002/003	.	.	Phase 2	D09SJE	.	CTPDG002564
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-180575	"2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide"	9930560	Phase 2	D09OTU	.	CTPDG002571
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rabeximod	"Rob-803; B-220 analog (RA), OxyPharma; B-220 analog (rheumatoid arthritis), OxyPharma"	56841552	Phase 2	D09BDH	DB05772	CTPDG002587
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BIIB 023	.	.	Phase 2	D08YHB	.	CTPDG002598
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Baminercept	"BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec"	.	Phase 2	D08XVR	.	CTPDG002599
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-06823859	.	.	Phase 2	D08RDD	.	CTPDG002615
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MK-8457	.	53251506	Phase 2	D08PXL	.	CTPDG002620
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP323	"Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01"	23394557	Phase 2	D08MJO	.	CTPDG002628
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	.	9926791	Approved	D08ICX	DB08895	CTPDG002636
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-986142	"Unii-pjx9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide"	86582336	Phase 2	D08AOZ	DB15291	CTPDG002651
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8765	.	.	Phase 2	D07YNM	.	CTPDG002655
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AMG0714	HuMax-IL15	.	Phase 2	D07LCA	.	CTPDG002686
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Fosbretabulin	Zybrestat (TN)	5351387	Phase 2	D07JVO	DB12577	CTPDG002693
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rimacalib	SMP-114	9800765	Phase 2	D06PHH	DB12571	CTPDG002739
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Mavrilimumab	.	.	Phase 2	D06KCF	.	CTPDG002750
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CCX-354	CCX-354-C; GSK2941266	135565361	Phase 2	D05VTN	DB12963	CTPDG002783
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	[L/D]-aminopterin	.	.	Phase 2	D05QPC	.	CTPDG002790
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALX-0061	"Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx"	.	Phase 2	D05NIR	.	CTPDG002795
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Ozoralizumab	ATN-103	.	Phase 2	D05EPV	.	CTPDG002814
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	JNJ-38518168	.	23650961	Phase 2	D04VBF	DB12522	CTPDG002835
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	UCB-35440	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide	9894415	Phase 2	D04JIM	.	CTPDG002862
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Otilimab	.	.	Phase 3	D04GWO	.	CTPDG002865
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Pegsunercept	STNF-R1	.	Phase 2	D04GTA	.	CTPDG002866
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AD-452	RS(+)-mefloquine; (+)-erythro-mefloquine	.	Phase 2	D03YKQ	.	CTPDG002884
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-240612	"N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride"	44235958	Phase 2	D03UVL	.	CTPDG002897
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TOK-8801	"105963-46-0; Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide; Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; Tok 8801; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide; Imidazo(2,1-b)thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; AC1L3UYM; ACMC-20m9c6; SCHEMBL9774378; CTK4A4247; AKOS030604802"	122628	Phase 2	D03UIB	.	CTPDG002898
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D03RIX	.	CTPDG002908
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PG-760564	"Rheumatoid arthritis therapy, Procter & Gamble"	.	Phase 2	D03PBW	.	CTPDG002912
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Peresolimab	.	.	Phase 2	D02XFH	.	CTPDG002947
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-04171327	"Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317"	24872952	Phase 2	D01PLR	DB12198	CTPDG003019
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MANOALIDE	"UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975"	6437368	Phase 2	D00XQO	.	CTPDG003057
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cenplacel-L	PDA-001	.	Phase 2	D00UGX	.	CTPDG003062
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BT-016	Tregalizumab	.	Phase 2	D00PUT	.	CTPDG003072
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Xmab 5871	XmAb 5871 (TN)	.	Phase 1/2	D00NXT	.	CTPDG003076
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vidofludimus	717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644	9820008	Phase 2	D00LSI	DB15446	CTPDG003080
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	K-832	"10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9"	9844960	Phase 2	D00IUD	.	CTPDG003086
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	PRTX-100	Staphylococcal protein A	.	Phase 1/2	D0ZC6X	.	CTPDG003265
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Cx-611	"Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), Cellerix; Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), TiGenix"	.	Phase 1/2	D0T3HL	.	CTPDG003323
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	BIO-300	"Radioprotective therapy, Humanetics"	.	Phase 1/2	D0J2ES	.	CTPDG003405
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Chondrogen	Chondrogen (TN)	.	Phase 1/2	D09YVQ	.	CTPDG003481
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	.	3715	Approved	D06LFE	DB00328	CTPDG003540
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HM71224	"Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide"	56644522	Phase 1	DTF20P	.	CTPDG003715
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LABP-104	NIM-1324	.	Phase 1	DN2Z5C	.	CTPDG003811
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ORTD-1	.theta.-Defensin 1; 1-[3-[benzyl-tetrakis(3-guanidinopropyl)-[(1R)-1-hydroxyethyl]-isobutyl-isopropyl-[(1S)-1-methylpropyl]-octadecaoxo-[?]yl]propyl]guanidine; 251442-64-5; BDBM50236198; CHEMBL4073105; Cyclic-(GVCRCICTRGFCRCLCRR); DTXSID60179822; oRTD-1; RTD-1; theta-Defensin 1; theta-Defensin RTD-1	16130642	Phase 1	DH5F4M	.	CTPDG003897
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	JNJ-67484703	JNJ-4703	.	Phase 1	D4VLI7	.	CTPDG004107
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	IA-14069	.	.	Phase 1	D1ROU2	.	CTPDG004184
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BX-U001	.	.	Phase 1	D17OQM	.	CTPDG004201
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	KPE-06001	"Asthma/arthritis therapy, Kemin"	.	Phase 1	D0Z8PO	.	CTPDG004223
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	PF-05230905	ATN-192	.	Phase 1	D0Y0FZ	.	CTPDG004268
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RG6125	.	.	Phase 1	D0X8RS	.	CTPDG004281
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	TAK-020	.	.	Phase 1	D0VS3U	.	CTPDG004329
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AXS-06	.	.	Phase 1	D0VJ9X	.	CTPDG004331
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Aminoguanidine	"Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284"	2146	Discontinued in Phase 2	D0V0NL	DB05383	CTPDG004355
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	OPL-CCL2-LPM	"CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey"	.	Phase 1	D0U7PM	.	CTPDG004372
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVE1701	.	.	Phase 1	D0Q2BB	.	CTPDG004488
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVP-13358	"IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR"	9805635	Phase 1	D0P9YP	.	CTPDG004508
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Cadherin-11	SDP051	.	Phase 1	D0P5QB	.	CTPDG004517
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BF-389	"Biofor 389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029"	6439259	Phase 1	D0L6VH	.	CTPDG004624
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HMR-1031	"MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid"	9809368	Phase 1	D0L3DC	.	CTPDG004633
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VI7734	.	.	Phase 1	D0JC9K	.	CTPDG004677
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BMS-986104	"Unii-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-"	77050638	Phase 1	D0GG7L	DB15214	CTPDG004765
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AMAP-102	"5-HT antagonist (rheumatism), AnaMar"	.	Phase 1	D0G7BR	.	CTPDG004771
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Sc Veltuzumab	.	.	Phase 1	D0D8NG	.	CTPDG004853
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MORAb-022	"Antibody (inflammation/autoimmune disease), Morphotek"	.	Phase 1	D0B0VD	.	CTPDG004925
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ARG301	.	.	Phase 1	D09PJB	.	CTPDG004987
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SCH-900117	.	.	Phase 1	D08YWY	.	CTPDG005018
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	DWP-422	.	.	Phase 1	D08SXV	.	CTPDG005031
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VEL-0230	"NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar"	25102841	Phase 1	D07BIK	.	CTPDG005126
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Synthetic neutrophil inhibitor peptide	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide	71482	Phase 1	D07ANO	.	CTPDG005128
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RWJ-67657	215303-72-3; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	Phase 1	D06OZJ	.	CTPDG005150
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI4920	.	.	Phase 1	D06HNO	.	CTPDG005164
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RPI-78M	"Antiviral agent, Receptogen; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm"	.	Discontinued in Phase 1	D05FVK	.	CTPDG005210
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP2408	CTLA4-Ig fusion protein	.	Phase 1	D04OQU	.	CTPDG005246
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK3117391	.	53630042	Phase 1	D04KMQ	DB15440	CTPDG005255
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ABBV-257	.	.	Phase 1	D04DQO	.	CTPDG005266
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VGX-1027	"6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590"	10798271	Phase 1	D03QEB	.	CTPDG005296
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK-1827771	"IL-1 antagonist (antibody, rheumatoid arthritis), GSK"	.	Phase 1	D03FVR	.	CTPDG005318
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP5094	.	.	Phase 1	D03ACE	.	CTPDG005331
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	EVT 401	.	.	Phase 1	D01TLV	.	CTPDG005379
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SKI-O-703	.	.	Phase 1	D01IDW	.	CTPDG005409
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Clinical trial	AZ-4217	AZ4217; AZ 4217	57406537	Clinical trial	D00XKB	.	CTPDG005509
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Floctafenine	"23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline"	3360	Withdrawn from market	D0AK5R	DB08976	CTPDG006315
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Aurothioglucose	HMS3262I11; LP00685	454937	Withdrawn from market	D0A4BR	.	CTPDG006316
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Preregistration	Amiprilose	Therafectin; Amiprilose hydrochloride; KAP-690; SM-1213	121928	Discontinued in Preregistration	D07MEL	.	CTPDG006326
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	Nerelimomab	BAY-X-1351	.	Discontinued in Phase 3	D0VW2Z	.	CTPDG006333
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	M-5010	M-5011; T-3788; 2(R)-[4-(3-Methyl-2-thienyl)phenyl]propionic acid	12769847	Discontinued in Phase 3	D0RJ0J	.	CTPDG006340
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	BR3-Fc	.	.	Discontinued in Phase 2	D0YA0N	.	CTPDG006399
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	EFLETIRIZINE	Efletirizine < Rec INN; Ucb-28754; 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid	66003	Discontinued in Phase 2	D0XK4R	.	CTPDG006402
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IX207-887	.	6509858	Discontinued in Phase 2	D0X2PQ	.	CTPDG006407
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AMG 108	.	444499	Discontinued in Phase 2	D0W7VG	.	CTPDG006413
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HR325	.	66583751	Discontinued in Phase 2	D0SX4K	.	CTPDG006435
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	TA-383	"Cis-2-(4-Chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride; Cis-2-(4-Chlorophenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole hydrochloride"	131180	Discontinued in Phase 2	D0R2CM	.	CTPDG006447
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	Discontinued in Phase 2	D0Q9ZD	.	CTPDG006450
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SM-8849	"113759-19-6; 4-(1-(2-fluoro-4-biphenylyl)ethyl)-2-methylaminothiazole; 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole; ZTFDMDJGJVUYQE-UHFFFAOYSA-N; AC1L3Y3S; SCHEMBL5078854; 4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; (+)-2-methylamino-4-(1-(2-fluoro-4-biphenylyl)ethyl)thiazole; 4-[1-(3-fluoro-4-phenylphenyl)ethyl]-N-methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 4-(1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-N-methyl-"	124238	Discontinued in Phase 2	D0Q0AJ	.	CTPDG006455
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Zolimomab aritox	XomaZyme-CD5 Plus; XomaZyme-H65; XomaZyme-lym; OrthoZyme-CD5+; Xmmly-h65-rta; XomaZyme-H65-rta	.	Discontinued in Phase 2	D0O2QB	.	CTPDG006464
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CP-195543	"LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer"	9823886	Discontinued in Phase 2	D0MM2K	DB13053	CTPDG006475
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MLN3897	.	.	Discontinued in Phase 2	D0KF6X	.	CTPDG006490
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-5751	"AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid"	9867949	Discontinued in Phase 2	D0K0VH	.	CTPDG006494
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MP-435	"C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe"	.	Discontinued in Phase 2	D0H0ZU	.	CTPDG006510
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CPA-926	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one	9800054	Discontinued in Phase 2	D0G6PG	.	CTPDG006516
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SINOMENINE	"Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one"	5459308	Discontinued in Phase 2	D0F9WF	.	CTPDG006522
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Linetastine	"Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Molecule 26"	6439232	Discontinued in Phase 2	D0E8UV	.	CTPDG006530
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SC-106	AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid	492984	Discontinued in Phase 2	D0D3KY	.	CTPDG006539
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PRO-515	.	.	Discontinued in Phase 2	D09FEN	.	CTPDG006572
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GW-215864	GR-215864; GR-215864X; GW-215864X	56841560	Discontinued in Phase 2	D09AUP	.	CTPDG006573
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HSR-609	"FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate"	3081352	Discontinued in Phase 2	D08RZV	.	CTPDG006576
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AnergiX.RA	"AG-4263; RA-AnergiX; Antigen specific therapy (rheumatoid arthritis, AnergiX), Corixa/ Organon"	.	Discontinued in Phase 2	D07BEE	.	CTPDG006598
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GLPG-0259	"G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562"	44462738	Discontinued in Phase 2	D06NPB	DB15190	CTPDG006604
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NN8209	.	.	Discontinued in Phase 2	D05ILZ	.	CTPDG006618
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IDEC-151	Clenoliximab	.	Discontinued in Phase 2	D04ZLG	.	CTPDG006624
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	Discontinued in Phase 2	D04DUJ	.	CTPDG006634
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NPC-567	"Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-"	119343	Discontinued in Phase 2	D03ZBM	.	CTPDG006637
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	T-5224	AKOS003047196; T5224	23626877	Discontinued in Phase 2	D02LCL	.	CTPDG006652
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AD-121	"PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest"	.	Discontinued in Phase 1/2	D06YFO	.	CTPDG006694
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AME-527	.	.	Discontinued in Phase 1/2	D05RTF	.	CTPDG006696
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-4629991	"PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer"	.	Discontinued in Phase 1	D0N8AB	.	CTPDG006767
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	NN8210	.	.	Discontinued in Phase 1	D0MT7W	.	CTPDG006774
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	ARRY-614	"Pexmetinib; 945614-12-0; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	Discontinued in Phase 1	D0ML0L	.	CTPDG006775
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Oncolysin CD6	Anti-CD6-bR; Anti-T12-bR	.	Discontinued in Phase 1	D0L4SB	.	CTPDG006784
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Eltenac	BY-820; B-788-20	51717	Discontinued in Phase 1	D0JF6O	.	CTPDG006796
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RG-4934	"IL-17 huMAb (psoriatic arthritis), Roche"	.	Discontinued in Phase 1	D0J8JF	.	CTPDG006797
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AC-100	"Bicyclo[4.2.0]octa-1,3,5-trien-3-ylboronic acid; BENZOCYCLOBUTANE-4-BORONIC ACID; Boronic acid, bicyclo[4.2.0]octa-1,3,5-trien-3-yl-; SCHEMBL12759201; KS-00000SRU; MolPort-005-942-889; ZINC196051840; AKOS025146995; DS-8536; BC225113; AK164312; 1,2-Dihydrobenzocyclobutene-4-ylboranic acid; CS-0043999; J3.522.588I; 4-bbcb                                             benzocyclobutene-4-boronic acid"	11171056	Discontinued in Phase 1	D0J6PR	.	CTPDG006798
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Roquinimex	Linomide	54676478	Discontinued in Phase 1	D0G9ZW	DB11366	CTPDG006812
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	D-1367	"167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-"	15259989	Discontinued in Phase 1	D0E8MW	.	CTPDG006818
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AVE-9940	.	.	Discontinued in Phase 1	D08CQE	.	CTPDG006862
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	LY-231617	"2,6-Di-tert-butyl-4-(ethylaminomethyl)phenol hydrochloride"	3968	Discontinued in Phase 1	D05XYC	.	CTPDG006882
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	CI-972	.	135418360	Discontinued in Phase 1	D05UPB	.	CTPDG006883
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R1295	CHEMBL2146615	70329	Discontinued in Phase 1	D04XJM	.	CTPDG006893
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	KB-2683	.	129748	Discontinued in Phase 1	D03LXJ	.	CTPDG006908
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-6703	"P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca"	11373432	Discontinued in Phase 1	D03KWN	.	CTPDG006909
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SC-57666	CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	Discontinued in Phase 1	D02OHR	.	CTPDG006916
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	C-5997	"7709-58-2; 4-(Chloromethyl)thiazole hydrochloride; 4-(chloromethyl)-1,3-thiazole Hydrochloride; 4-(chloromethyl)thiazole hcl; 4-chloromethylthiazole hydrochloride; 4-chloromethylthiazole hcl; 4-(chloromethyl)thiazolehcl; C4H4ClNS.ClH; ACMC-1BBSC; chloromethylthiazole-4 hcl; AC1Q3BH9; AC1MC82W; SCHEMBL122926; 4-(Chloromethyl)thiazole, HCl; CTK6H6834; DTXSID60376874; NVTBASMQHFMANH-UHFFFAOYSA-N; MolPort-000-139-475; 4-(chloromethyl)thiazole HCl salt; ACT02312; KS-000004ND; ANW-36949; 4-chloromethyl thiazole hydrochloride"	2763289	Discontinued in Phase 1	D01CBV	.	CTPDG006932
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-755616	.	.	Discontinued in Phase 1	D00FGY	.	CTPDG006939
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	GP2015	.	.	Application submitted	D0K9SS	.	CTPDG006944
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	SR1555	"CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675"	71470549	Preclinical	DW5R6Y	.	CTPDG006962
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	MCP-1	.	.	Preclinical	D0V9ND	.	CTPDG007038
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NPC-17923	"147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-"	9824607	Terminated	D0Z3AK	.	CTPDG007165
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	TM-31	.	.	Terminated	D0Y9CC	.	CTPDG007170
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BCX-25	BCX-14	.	Terminated	D0V2ZJ	.	CTPDG007200
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BB-1433	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241	101708593	Terminated	D0V0RW	.	CTPDG007202
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	ZK-90695	.	.	Terminated	D0US3C	.	CTPDG007203
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RP-54745	"RP 54745; 135330-08-4; AC1L2PX8; SCHEMBL4362761; rp54745; CS-6750; 4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one; HY-101716; 4-chloro-5-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)dithiol-3-one; 3H-1,2-Dithiol-3-one, 4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-"	126203	Terminated	D0T0LO	.	CTPDG007223
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	Terminated	D0R5TT	.	CTPDG007238
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Seprilose	GW-80126	60818	Terminated	D0Q5ZN	.	CTPDG007243
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NOX-200	"2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478"	95438	Terminated	D0OX9Q	.	CTPDG007255
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SAN-18	.	.	Terminated	D0M8QG	.	CTPDG007278
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	CI-986	"CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate"	3037017	Terminated	D0L8RG	.	CTPDG007289
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-6942	"CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca"	.	Terminated	D0I9YI	.	CTPDG007324
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	3-DEAZAADENOSINE	"Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine"	23190	Terminated	D0I7TN	DB04546	CTPDG007326
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-28342	.	9882188	Terminated	D0H0IA	.	CTPDG007341
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AG-2024	.	.	Terminated	D0G2CL	.	CTPDG007350
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Ro-31-4724	CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	Terminated	D0EF7V	DB08482	CTPDG007361
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-33516	.	.	Terminated	D0DR3I	.	CTPDG007371
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	D-5410	CH-138; CH-263	.	Terminated	D09TRM	.	CTPDG007412
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SKF-104351	"111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole"	122656	Terminated	D09SCI	.	CTPDG007413
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RWJ-63556	.	9882374	Terminated	D08JKK	.	CTPDG007441
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	YM-26734	"YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1"	9853400	Terminated	D07OGR	.	CTPDG007458
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD5672	"CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide"	11614352	Terminated	D07GIB	.	CTPDG007463
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-16276-1	.	.	Terminated	D06MTM	.	CTPDG007476
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-111142	WF-2015A	9909502	Terminated	D06AKJ	.	CTPDG007482
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BW A4C	"BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide"	6438354	Terminated	D05WPQ	.	CTPDG007485
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-48989	"WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile"	132006	Terminated	D04YNI	.	CTPDG007505
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-133605	.	.	Terminated	D04SVB	.	CTPDG007508
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SR-26831	"SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate"	132270	Terminated	D03GII	.	CTPDG007535
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	GDC-0834	"1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz"	25234918	Terminated	D03FUO	.	CTPDG007536
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	Terminated	D01QRG	.	CTPDG007565
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	LY-221068	"LY 221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-"	6439333	Terminated	D01QAR	.	CTPDG007566
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	DPC-333	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide	9847838	Terminated	D01DVX	.	CTPDG007574
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	PXS-2076	"PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis"	.	Terminated	D01DTQ	.	CTPDG007575
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ODN-1411	.	.	Investigative	D5S7JL	.	CTPDG007609
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	Investigative	D0YK4L	.	CTPDG007651
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	Investigative	D0Y4ZI	.	CTPDG007665
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BFPT-16864	BFPT-6864; BRFD-104	.	Investigative	D0XP3A	.	CTPDG007695
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Arthromir	.	.	Investigative	D0WI1L	.	CTPDG007743
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	SPX-601	.	.	Investigative	D0VB2K	.	CTPDG007786
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-814	"Hsp60 peptide (juvenile idiopathic arthritis), CIGB"	.	Investigative	D0V5VA	.	CTPDG007796
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD40-XTEN	"CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0V3HC	.	CTPDG007800
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	X-071-NAB	"NATHMAB (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech; Natural/true human monoclonal antibody (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech"	.	Investigative	D0U2OQ	.	CTPDG007838
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TENOSAL	MR-Y134; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	Investigative	D0T3KZ	.	CTPDG007862
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DW-908	DW-0908	.	Investigative	D0R4NJ	.	CTPDG007910
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	Investigative	D0N8TM	.	CTPDG008032
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	MDDR 217769	"(E)-2-(4,6-Difluoroindan-1-ylidene)acetamide"	.	Investigative	D0N8JJ	.	CTPDG008033
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FKB327	.	.	Investigative	D0L8UQ	.	CTPDG008105
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DMARDs	"DMARDs (oral, rheumatoid arthritis); DMARDs (oral, rheumatoid arthritis), Abbott; Disease-modifying antirheumatic drugs (oral, rheumatoid arthritis), Abbott"	.	Investigative	D0L2BT	.	CTPDG008121
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TX-RAD	"RA1-TX; RA1-TX (ankylosing spondylitis), TxCell; RA1-TX (rheumatoid arthritis), TxCell; RA1-TX (psoriatic arthritis,inflammatory disease), TxCell"	.	Investigative	D0K8BO	.	CTPDG008134
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	UR-5269	"Rheumatoid arthritis therapy, UBE Industries"	.	Investigative	D0J7XN	.	CTPDG008168
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	AVX-002	.	.	Investigative	D0J4TX	.	CTPDG008173
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-125	"Synoviocyte inhibitor + glucocorticoid (arthritis), Xaragen"	.	Investigative	D0I9FQ	.	CTPDG008191
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DWJ-425	"DW-Ab2; MAb (RA), Daewoong; Monoclonal antibody (rheumatoid arthritis), Daewoong"	.	Investigative	D0I4MW	.	CTPDG008211
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	HL-1020	"Grape seed proanthocyanidin extract (rheumatoid arthritis), Hanlim"	.	Investigative	D0G8EI	.	CTPDG008263
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-120	"Synoviocyte inhibitor + DMARD (arthritis), Xaragen"	.	Investigative	D0G2GZ	.	CTPDG008276
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-115	"Synoviocyte inhibitor + NSAID (arthritis), Xaragen"	.	Investigative	D0F8BR	.	CTPDG008296
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CTLA-4-XTEN	"Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0EZ9C	.	CTPDG008324
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Nano-steroid	"Steroidal anti-inflammatory (slow release nanoparticle formulation), LTT Bio-Pharma; Steroids (sustained release nanoparticles), LTT Bio-Pharma/Cipra; Steroidal anti-inflammatory (rheumatoid arthritis/collagen disease), LTT Bio-Pharma"	.	Investigative	D0B9XM	.	CTPDG008440
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	YD-101	.	.	Investigative	D0B3KI	.	CTPDG008455
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	KI-0906	.	.	Investigative	D0A2RF	.	CTPDG008498
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FHT-401	"PTD-conjugated methotrexate (transdermal, rheumatoid arthritis), ForHumanTech/Hyundai"	.	Investigative	D0A0FI	.	CTPDG008502
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TCH-013	"NF-kB inhibitors (rheumatoid arthritis); NF-kB inhibitors (rheumatoid arthritis), TCH Pharmaceuticals"	76850167	Investigative	D09TVH	.	CTPDG008515
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD97 mab	"Anti-CD97 monoclonal antibody (rheumatoid arthritis); Anti-CD97 mAb (RA), Organon/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Organon/AMC; Anti-CD97 mAb (RA), Schering-Plough/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Merck & Co/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Schering-Plough/AMC"	.	Investigative	D09RGS	.	CTPDG008524
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-55	.	.	Investigative	D09NQD	.	CTPDG008534
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Dendritic cell-based immunotherapy	"Dendritic cell-based immunotherapy (rheumatoid arthritis); Dendritic cell-based immunotherapy (rheumatoid arthritis), Dendright; Dendritic cell-based immunotherapy (rheumatoid arthritis, injectable formulation), Dendright"	.	Investigative	D07OCM	.	CTPDG008673
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	RT-401	"BoNTA protein (topical, rhinitis), Revance"	.	Investigative	D07JPL	.	CTPDG008692
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	VVZ-138	VVZ-000138	.	Investigative	D07GFZ	.	CTPDG008699
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	IG-AI-025	.	.	Investigative	D06XXD	.	CTPDG008716
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CHR-4487	"Esterase-sensitive motif compounds (inflammatory disease); Esterase-sensitive motif compounds (inflammatory disease), Chroma Therapeutics"	.	Investigative	D06HWU	.	CTPDG008757
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ROSMARINIC ACID	"20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid"	5281792	Investigative	D05PTT	.	CTPDG008813
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CT-340	"TrkA kinase inhibitor (polyoxyethylene conjugated, LSE, arthritis, scarring, pain), Creabilis"	.	Investigative	D05KRS	.	CTPDG008827
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ADR58	.	.	Investigative	D04VCF	.	CTPDG008856
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CEL-2000	"T-cell modulating vaccine (LEAPS, rheumatoid arthritis), CEL-SCI"	.	Investigative	D03XSX	.	CTPDG008918
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FM-201	.	.	Investigative	D03TKI	.	CTPDG008933
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BMS-345541	"445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05"	9926054	Investigative	D00YTQ	.	CTPDG009140
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CAT-2200	"MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)"	.	Investigative	D00XNC	.	CTPDG009145
M6ACROT05221	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	OCT-SG815	"OPG secretagogues (osteoporosis/arthritis), Oscotec; Osteoprotegerin secretagogues (osteoporosis/arthritis), Oscotec; OPG secretagogues (osteoporosis/arthritis), KT&G; Osteoprotegerin secretagogues (osteoporosis/arthritis), KT&G"	.	Investigative	D00QOH	.	CTPDG009161
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	Kevzara	.	Approved	D0Z8CQ	.	CTPDG000029
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulindac	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	1548887	Approved	D0Z5IU	DB00605	CTPDG000031
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Felbinac	"Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda"	3332	Approved	D0Y7EM	DB07477	CTPDG000057
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Salsalate	"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid"	5161	Approved	D0Y0JH	DB01399	CTPDG000063
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Fostamatinib	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]	11671467	Phase 3	D0V8HJ	DB12010	CTPDG000102
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Methotrexate	"Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	126941	Phase 3	D0SV8E	DB00563	CTPDG000144
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IPI-145	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;	50905713	Phase 3	D0RU0O	DB11952	CTPDG000166
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	Approved	D0R1RS	DB00328	CTPDG000188
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Inosine pranobex	Imunovir (TN)	135449284	Approved	D0Q2QU	.	CTPDG000206
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Citrofen	Citrofen (TN)	.	Approved	D0P6UK	.	CTPDG000218
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meclofenamate Sodium	.	4038	Approved	D0MN9K	.	CTPDG000266
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxaprozin	"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid"	4614	Approved	D0M9DC	DB00991	CTPDG000269
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Zinc salts	.	.	Approved	D0K8AA	.	CTPDG000300
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	Approved	D0K5KS	.	CTPDG000305
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Orthokine	Orthokine (TN)	.	Approved	D0J1PW	.	CTPDG000330
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	SK-1306X	Cararthron; Joins	.	Approved	D0IL0C	.	CTPDG000339
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	Approved	D0I6IB	DB00469	CTPDG000343
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	Approved	D0I5QX	.	CTPDG000345
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	Approved	D0G7FJ	DB00814	CTPDG000369
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Gold sodium thiomalate	Sodium aurothiomalate	22318	Approved	D0FH7C	DB09276	CTPDG000381
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Abatacept	Orencia (TN)	.	Approved	D0EW4L	.	CTPDG000397
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)"	9926791	Approved	D0EG1I	DB08895	CTPDG000400
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	OM-89	Subreum; UroVaxom; UroVaxon; OM-8980	.	Approved	D0E1VD	.	CTPDG000414
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rimexolone	"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)"	5311412	Approved	D0D2TN	DB00896	CTPDG000426
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	Approved	D0CA0P	.	CTPDG000432
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Alclofenac	"22131-79-9; Alclophenac; Prinalgin; Medifenac; Reufenac; Allopydin; Mervan; Alclofenacum; Alclofenaco; Zumaril; Neoston; Neosten; 2-(4-(Allyloxy)-3-chlorophenyl)acetic acid; [4-(Allyloxy)-3-chlorophenyl]acetic acid; Desinflam; Marvan Forte; 3-Chloro-4-(2-propenyloxy)benzeneacetic acid; (4-Allyloxy-3-chlorphenyl)essigsaeure; MY 101; Epinal; Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-; Alclofenacum [INN-Latin]; Alclofenaco [INN-Spanish]; UNII-M9CP5H21N8; W 7320; CHEBI:31183; EINECS 244-795-4"	30951	Approved	D0C6OQ	DB13167	CTPDG000435
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Careram	Iguratimod	124246	Approved	D0B8MZ	DB12233	CTPDG000450
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	Approved	D0A1PX	DB00712	CTPDG000472
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Nafcillin	"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	8982	Approved	D0A0JH	DB00607	CTPDG000473
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etofenamate	30544-47-9; Rheumon; Bayrogel; Rheumon gel; UNII-KZF0XM66JC; Etofenamatum [INN-Latin]; Etofenamato [INN-Spanish]; Bay d 1107; C18H18F3NO4; TVX 485; WHR 5020; EINECS 250-231-8; KZF0XM66JC; BRN 2953263; 2-(2-Hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate; 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate; WHR-5020; NCGC00016804-01; 2-(2-Hydroxyaethoxy)aethylester der flutenaminsaeure [German]; CAS-30544-47-9; 2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate	35375	Approved	D09YVX	DB08984	CTPDG000475
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	Approved	D09MGR	DB01628	CTPDG000489
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	Approved	D09FSG	.	CTPDG000501
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	Approved	D09BHB	DB00500	CTPDG000505
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)	.	Phase 2	D08WSY	.	CTPDG000511
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Leflunomide	"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide"	3899	Approved	D08ROP	DB01097	CTPDG000515
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Penicillamine	"D-Penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine"	5852	Approved	D08HZC	DB00859	CTPDG000523
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dimethyl Sulfoxide	Rimso-50	679	Approved	D08HVE	DB01093	CTPDG000524
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tocilizumab	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody	.	Approved	D08HPZ	.	CTPDG000526
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Benorilate	"5003-48-5; BENORYLATE; 4-acetamidophenyl 2-acetoxybenzoate; Benoral; Salipran; Benortan; Fenasprate; Fenasparate; Aspirin acetaminophen ester; Benorilato; Benorilato [Spanish]; p-Acetamidophenyl acetylsalicylate; Benorilatum [INN-Latin]; Benorilato [INN-Spanish]; UNII-W1QX9DV96G; p-N-Acetylaminophenylacetylsalicylate; TO 125; WIN 11450; 4'-(Acetamido)phenyl-2-acetoxybenzoate; 2-Acetoxy-4'-(acetamino)phenylbenzoate; CCRIS 1739; Benzoic acid, 2-(acetyloxy)-, 4-(acetylamino)phenyl ester; 4-Acetamidophenyl salicylate acet"	21102	Approved	D08GJO	DB13657	CTPDG000528
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Halopredone acetate	Haloart (TN)	91667	Approved	D08BDT	.	CTPDG000531
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Teriflunomide	.	54684141	Approved	D07QFP	DB08880	CTPDG009757
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Siponimod	BAF312	44599207	Phase 2	D07FKQ	DB12371	CTPDG000573
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxyphenbutazone	Tandearil	4641	Approved	D06ZPS	DB03585	CTPDG000587
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	FENBUFEN	"36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	Approved	D06LHG	DB08981	CTPDG000602
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexchlorpheniramine Maleate	Polaramine	5281070	Approved	D05ZGQ	DB09555	CTPDG000614
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Enbrel	.	.	Approved	D05LTY	.	CTPDG000635
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Fenoprofen	"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid"	3342	Approved	D03XYW	DB00573	CTPDG000689
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	Approved	D03RTS	DB00482	CTPDG000700
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sodium Succinate	"Disodium succinate; 150-90-3; Disodium butanedioate; Butanedioic acid, disodium salt; Succinic acid disodium salt; Soduxin; Jantaran sodny [Czech]; UNII-V8ZGC8ISR3; Succinic acid, disodium salt; FEMA No. 3277; CCRIS 3700; Sodium succinate dibasic; EINECS 205-778-7; V8ZGC8ISR3; Butanedioic acid, sodium salt (1:2); Succinic acid disodium salt anhydrous; Butanedioic acid disodium salt; sodium succinate (anhydrous); Jantaran sodny; Butanedioic acid disodium hexahydrate; Succinic acid, disodium salt, 99%, anhydrous"	9020	Approved	D03RCJ	.	CTPDG000703
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulfasalazine	599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Sulfasalizine	5339	Approved	D02ZTJ	DB00795	CTPDG000732
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	Kineret; Kineret (TN); Anakinra (USAN/INN)	.	Approved	D02DES	.	CTPDG000759
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Cyproheptadine	"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene"	2913	Approved	D00TLN	DB00434	CTPDG000802
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	Approved	D00HGB	DB04552	CTPDG000816
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Nipocalimab	.	.	Phase 2	DS69NO	.	CTPDG000882
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Nipocalimab?	.	.	Phase 3	DR5V8I	.	CTPDG000884
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	BI 695501	BI-695501)	.	Phase 3	D0Z4VX	.	CTPDG000966
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06410293	.	.	Phase 3	D0Y8TZ	.	CTPDG000976
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Flobufen	VUFB-16066; VUFB-17203	159476	Phase 3	D0X8VV	.	CTPDG000989
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	Phase 3	D0W2CX	DB12399	CTPDG001013
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP-2017	.	.	Phase 3	D0S7JN	.	CTPDG001055
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cartistem	"Stem cell therapy (cartilage disease/rheumatoid arthritis), Medipost"	.	Phase 3	D0OH5E	.	CTPDG001096
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IR-201	Seryl-glutaminyl-isoleucyl-valyl-asparaginyl-aspartyl-phenylalanyl-glutaminyl-lysyl-glycyl-aspartyl-isoleucyl-alanyl-glutamyl-glycyl-tyrosyl-serine	.	Phase 3	D0N3SA	.	CTPDG001116
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Esonarimod	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298	127998	Phase 3	D0MY7X	.	CTPDG001120
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CIPEMASTAT	"Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	Phase 3	D0MW3H	.	CTPDG001123
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Methylprednisolone	.	6741	Approved	D0LN1Z	DB00959	CTPDG001141
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	STI-002	.	.	Phase 3	D0I6UE	.	CTPDG001181
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MK-8808	.	.	Phase 1	D0GP8N	.	CTPDG001196
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 798	.	.	Phase 3	D0E8NJ	.	CTPDG001224
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06438179	.	.	Phase 3	D0D9HZ	.	CTPDG001236
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	.	44205240	Approved	D0D5FU	DB11817	CTPDG001241
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cilengitide	"188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)"	176873	Phase 3	D09ZXO	DB11890	CTPDG001287
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CEP-41750	.	.	Phase 3	D09WRG	.	CTPDG001291
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	.	.	Approved	D08SJT	.	CTPDG001320
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Andolast	"Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm"	65970	Phase 3	D08PGC	.	CTPDG001324
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Vanadate	"Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3"	516859	Phase 3	D08NCO	.	CTPDG001327
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	Phase 3	D08DGC	DB12193	CTPDG011311
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Spermidine	"Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, &gt; =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0"	1102	Phase 3	D08BXT	DB03566	CTPDG001337
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Varespladib methyl	"A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera"	9886917	Phase 3	D07KFB	DB05737	CTPDG001360
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 501	.	.	Phase 3	D06FMO	.	CTPDG001379
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	.	.	Approved	D06CXL	.	CTPDG001384
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Atacicept	.	.	Phase 2	D04YWM	.	CTPDG001412
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Tenidap	.	60712	Phase 3	D02RQT	DB13481	CTPDG001457
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LY3090106	Tibulizumab	.	Phase 1	D09JVK	.	CTPDG001558
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2/3	VX-509	"Decernotinib; Adelatinib; 944842-54-0; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	Phase 2/3	D04QWQ	DB12566	CTPDG001571
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D03ZYQ	.	CTPDG001574
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	CreaVax-RA	"Autologous DC therapy (injectable, rheumatoid arthritis), CreaGene; Autologous dendritic cell therapy (injectable, rheumatoid arthritis), CreaGene"	.	Phase 2a	D0U9OD	.	CTPDG001585
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	RhuDex	.	.	Phase 2a	D0J0KT	.	CTPDG001586
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cevidoplenib	"(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone; 1703788-21-9; 3N3H8BX897; AKOS040748110; BDBM196772; Cevidoplenib; Cevidoplenib [INN]; Cevidoplenib [WHO-DD]; CHEMBL3921923; CS-0039259; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; EX-A5914; HY-109082; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; MS-28778; SCHEMBL16653204; UNII-3N3H8BX897; US9212178, 1; YCZUBLQESBVOSH-IBGZPJMESA-N"	91754477	Phase 2	DY57LN	.	CTPDG001609
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Dazodalibep	VIB4920	.	Phase 2	DPDI65	.	CTPDG001652
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Natrunix	.	.	Phase 2	DOVW19	.	CTPDG001657
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-5718	"1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 920036-34-6; A860172; AKOS022178093; AMY21637; CS-0048281; FT-0702852; GS-5718; MFCD13183727; OKKLWSNHFSFXEM-UHFFFAOYSA-N; PB26872; SCHEMBL3606964; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate"	57443610	Phase 2	DF1T2W	.	CTPDG001727
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Branebrutinib	"(S)-4-(3-(2-BUTYNOYLAMINO)PIPERIDIN-1-YL)-5-FLUORO-2,3-DIMETHYL-1H-INDOLE-7-CARBOXAMIDE; (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 1912445-55-6; 1H-Indole-7-carboxamide, 5-fluoro-2,3-dimethyl-4-((3S)-3-((1-oxo-2-butyn-1-yl)amino)-1-piperidinyl)-; 4-((3S)-3-(2-BUTYNOYLAMINO)-1-PIPERIDINYL)-5-FLUORO-2,3-DIMETHYL-1HINDOLE-7-CARBOXAMIDE; 4-((3S)-3-(2-Butynoylamino)-1-piperidinyl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-((3S)-3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 7LBRZUYSHU; AC-31535; AKOS037649047; BCP29496; BDBM164638; BDBM166759; BMS986195; BMS986195; BMS986195; BMS-986195; Branebrutinib; Branebrutinib (BMS-986195); Branebrutinib (USAN); BRANEBRUTINIB [INN]; Branebrutinib [USAN]; BRANEBRUTINIB [WHO-DD]; BS-16393; C20H23FN4O2; CHEMBL4297674; CS-0043577; D11478; DB15347; EN300-2007801; EX-A2720; Example 223 [US20160115126A1]; GTPL9869; HY-112161; MFCD31631584; NSC807627; NSC-807627; Q50825082; s8832; SCHEMBL17699728; UNII-7LBRZUYSHU; US9688629, 123; US9688629, 223; VJPPLCNBDLZIFG-ZDUSSCGKSA-N; WHO 11026"	121293929	Phase 2	DE3VU1	DB15347	CTPDG001734
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vobarilizumab	ALX-0061	.	Phase 2	D9J6XV	.	CTPDG001766
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IRL201805	.	.	Phase 2	D9EHD7	.	CTPDG001767
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KPL-404	.	.	Phase 2	D3NSU0	.	CTPDG001824
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FK-3311	"116686-15-8; FK 3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	Phase 2	D0Z9YW	.	CTPDG001858
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-783	"Rheumatoid arthritis therapy (oral), Takeda Pharmaceutical"	.	Phase 2	D0Z4OQ	.	CTPDG001864
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Piclamilast	"144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL"	154575	Phase 2	D0Z2FB	DB01791	CTPDG001866
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ADL-5859	PF-04856880	46931003	Phase 2	D0W9ZT	.	CTPDG001918
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SBI-087	PF-05230895	.	Phase 2	D0W9QG	.	CTPDG001920
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SB-705498	501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504	9910486	Phase 2	D0VJ5N	DB11883	CTPDG001948
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-817399	.	44537841	Phase 2	D0UX2V	DB14941	CTPDG001971
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CFZ533	.	.	Phase 2	D0SD6V	.	CTPDG002036
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PD-360324	"PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer"	.	Phase 2	D0S1UZ	.	CTPDG002048
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MGCD-290	"MG-1; MG-3290; Histone deacetylase inhibitors (cardiovascular diseases), MethylGene; Histone deacetylase inhibitors (diabetes), MethylGene; Histone deacetylase inhibitors (fungal infection), MethylGene; Histone deacetylase inhibitors (inflammation), MethylGene; HDAC inhibitors (non-oncology), MethylGene; Histone deacetylase inhibitors (non-oncology), MethylGene"	3035813	Phase 2	D0RF3F	.	CTPDG002061
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Prednisone/ dipyridamole	Synavive (TN)	5865	Phase 2	D0R4NR	DB00635	CTPDG002071
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	QAL964	.	.	Phase 2	D0QZ3P	.	CTPDG002077
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	M2951	"evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin"	71479709	Phase 2	D0QX8X	DB15170	CTPDG002078
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AK-106-001616	.	.	Phase 2	D0QH5K	.	CTPDG002079
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABT-122	.	.	Phase 2	D0OX5H	.	CTPDG002123
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Meninge ACYW	.	.	Phase 2	D0OQ5W	.	CTPDG002127
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-715	"P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda"	9952773	Phase 2	D0O6ZO	.	CTPDG002136
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MPC-300-IV	.	.	Phase 2	D0MM0N	.	CTPDG002186
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Anti-LT alpha	.	.	Phase 2	D0L1OC	.	CTPDG002241
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NNC-0151-0000-0000	"Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk"	.	Phase 2	D0J4PM	.	CTPDG002288
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-945429	.	.	Phase 2	D0J1KS	.	CTPDG002291
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ONO-4641	"Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono"	11502996	Phase 2	D0I2RB	.	CTPDG002320
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNT0-1959	.	.	Phase 2	D0HT2X	.	CTPDG002325
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	Phase 2	D0HG5M	DB13020	CTPDG002328
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FLUASTERONE	HE-2500; 16alpha-Fluoroandrost-5-en-17-one	133967	Phase 2	D0H9YO	DB06250	CTPDG002329
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-4059	"tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno"	54755438	Phase 2	D0H0KH	DB15227	CTPDG002346
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VVZ-149	VVZ-000149	.	Phase 2	D0G9OH	.	CTPDG002358
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MRC-375	"Tetracycline (enteric-coated oral tablet, rheumatoid arthritis), Molecular Research Center Inc"	.	Phase 2	D0F9NA	.	CTPDG002393
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AWD-12-281	"GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline"	6918428	Phase 2	D0F4TV	.	CTPDG002402
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	APX-001	"EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics"	44123754	Investigative	D0DL3W	DB15183	CTPDG002437
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SR-31747	SR-317417A	6439330	Phase 2	D0D4JI	DB05792	CTPDG002454
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BI 655064	.	.	Phase 2	D0C8NG	.	CTPDG002478
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK3196165	.	.	Phase 2	D0C7ZB	.	CTPDG002482
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK315234	Oncostatin M mAb	.	Phase 2	D0C4YQ	.	CTPDG002485
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GS-9876	"XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr"	118161062	Phase 1	D0BW6F	DB14770	CTPDG002497
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TZI-41078	"3,5-Di-tert-butyl-4-hydroxybenzophenone oxime"	.	Phase 2	D0B6VN	.	CTPDG002510
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNTO-6785	.	.	Phase 2	D0A7NZ	.	CTPDG002538
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AMG-714	.	.	Discontinued in Phase 1	D0A5EN	.	CTPDG002547
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	LX2931	.	135564845	Phase 2	D09ZWH	DB06297	CTPDG002552
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VAY736	.	.	Phase 2	D09SQM	.	CTPDG002563
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KB002/003	.	.	Phase 2	D09SJE	.	CTPDG002564
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-180575	"2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide"	9930560	Phase 2	D09OTU	.	CTPDG002571
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rabeximod	"Rob-803; B-220 analog (RA), OxyPharma; B-220 analog (rheumatoid arthritis), OxyPharma"	56841552	Phase 2	D09BDH	DB05772	CTPDG002587
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BIIB 023	.	.	Phase 2	D08YHB	.	CTPDG002598
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Baminercept	"BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec"	.	Phase 2	D08XVR	.	CTPDG002599
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-06823859	.	.	Phase 2	D08RDD	.	CTPDG002615
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MK-8457	.	53251506	Phase 2	D08PXL	.	CTPDG002620
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP323	"Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01"	23394557	Phase 2	D08MJO	.	CTPDG002628
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	.	9926791	Approved	D08ICX	DB08895	CTPDG002636
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-986142	"Unii-pjx9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide"	86582336	Phase 2	D08AOZ	DB15291	CTPDG002651
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8765	.	.	Phase 2	D07YNM	.	CTPDG002655
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AMG0714	HuMax-IL15	.	Phase 2	D07LCA	.	CTPDG002686
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Fosbretabulin	Zybrestat (TN)	5351387	Phase 2	D07JVO	DB12577	CTPDG002693
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rimacalib	SMP-114	9800765	Phase 2	D06PHH	DB12571	CTPDG002739
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Mavrilimumab	.	.	Phase 2	D06KCF	.	CTPDG002750
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CCX-354	CCX-354-C; GSK2941266	135565361	Phase 2	D05VTN	DB12963	CTPDG002783
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	[L/D]-aminopterin	.	.	Phase 2	D05QPC	.	CTPDG002790
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALX-0061	"Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx"	.	Phase 2	D05NIR	.	CTPDG002795
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Ozoralizumab	ATN-103	.	Phase 2	D05EPV	.	CTPDG002814
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	JNJ-38518168	.	23650961	Phase 2	D04VBF	DB12522	CTPDG002835
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	UCB-35440	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide	9894415	Phase 2	D04JIM	.	CTPDG002862
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Otilimab	.	.	Phase 3	D04GWO	.	CTPDG002865
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Pegsunercept	STNF-R1	.	Phase 2	D04GTA	.	CTPDG002866
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AD-452	RS(+)-mefloquine; (+)-erythro-mefloquine	.	Phase 2	D03YKQ	.	CTPDG002884
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-240612	"N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride"	44235958	Phase 2	D03UVL	.	CTPDG002897
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TOK-8801	"105963-46-0; Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide; Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; Tok 8801; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide; Imidazo(2,1-b)thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; AC1L3UYM; ACMC-20m9c6; SCHEMBL9774378; CTK4A4247; AKOS030604802"	122628	Phase 2	D03UIB	.	CTPDG002898
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D03RIX	.	CTPDG002908
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PG-760564	"Rheumatoid arthritis therapy, Procter & Gamble"	.	Phase 2	D03PBW	.	CTPDG002912
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Peresolimab	.	.	Phase 2	D02XFH	.	CTPDG002947
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-04171327	"Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317"	24872952	Phase 2	D01PLR	DB12198	CTPDG003019
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MANOALIDE	"UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975"	6437368	Phase 2	D00XQO	.	CTPDG003057
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cenplacel-L	PDA-001	.	Phase 2	D00UGX	.	CTPDG003062
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BT-016	Tregalizumab	.	Phase 2	D00PUT	.	CTPDG003072
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Xmab 5871	XmAb 5871 (TN)	.	Phase 1/2	D00NXT	.	CTPDG003076
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vidofludimus	717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644	9820008	Phase 2	D00LSI	DB15446	CTPDG003080
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	K-832	"10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9"	9844960	Phase 2	D00IUD	.	CTPDG003086
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	PRTX-100	Staphylococcal protein A	.	Phase 1/2	D0ZC6X	.	CTPDG003265
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Cx-611	"Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), Cellerix; Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), TiGenix"	.	Phase 1/2	D0T3HL	.	CTPDG003323
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	BIO-300	"Radioprotective therapy, Humanetics"	.	Phase 1/2	D0J2ES	.	CTPDG003405
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Chondrogen	Chondrogen (TN)	.	Phase 1/2	D09YVQ	.	CTPDG003481
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	.	3715	Approved	D06LFE	DB00328	CTPDG003540
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HM71224	"Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide"	56644522	Phase 1	DTF20P	.	CTPDG003715
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LABP-104	NIM-1324	.	Phase 1	DN2Z5C	.	CTPDG003811
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ORTD-1	.theta.-Defensin 1; 1-[3-[benzyl-tetrakis(3-guanidinopropyl)-[(1R)-1-hydroxyethyl]-isobutyl-isopropyl-[(1S)-1-methylpropyl]-octadecaoxo-[?]yl]propyl]guanidine; 251442-64-5; BDBM50236198; CHEMBL4073105; Cyclic-(GVCRCICTRGFCRCLCRR); DTXSID60179822; oRTD-1; RTD-1; theta-Defensin 1; theta-Defensin RTD-1	16130642	Phase 1	DH5F4M	.	CTPDG003897
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	JNJ-67484703	JNJ-4703	.	Phase 1	D4VLI7	.	CTPDG004107
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	IA-14069	.	.	Phase 1	D1ROU2	.	CTPDG004184
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BX-U001	.	.	Phase 1	D17OQM	.	CTPDG004201
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	KPE-06001	"Asthma/arthritis therapy, Kemin"	.	Phase 1	D0Z8PO	.	CTPDG004223
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	PF-05230905	ATN-192	.	Phase 1	D0Y0FZ	.	CTPDG004268
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RG6125	.	.	Phase 1	D0X8RS	.	CTPDG004281
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	TAK-020	.	.	Phase 1	D0VS3U	.	CTPDG004329
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AXS-06	.	.	Phase 1	D0VJ9X	.	CTPDG004331
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Aminoguanidine	"Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284"	2146	Discontinued in Phase 2	D0V0NL	DB05383	CTPDG004355
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	OPL-CCL2-LPM	"CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey"	.	Phase 1	D0U7PM	.	CTPDG004372
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVE1701	.	.	Phase 1	D0Q2BB	.	CTPDG004488
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVP-13358	"IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR"	9805635	Phase 1	D0P9YP	.	CTPDG004508
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Cadherin-11	SDP051	.	Phase 1	D0P5QB	.	CTPDG004517
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BF-389	"Biofor 389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029"	6439259	Phase 1	D0L6VH	.	CTPDG004624
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HMR-1031	"MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid"	9809368	Phase 1	D0L3DC	.	CTPDG004633
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VI7734	.	.	Phase 1	D0JC9K	.	CTPDG004677
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BMS-986104	"Unii-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-"	77050638	Phase 1	D0GG7L	DB15214	CTPDG004765
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AMAP-102	"5-HT antagonist (rheumatism), AnaMar"	.	Phase 1	D0G7BR	.	CTPDG004771
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Sc Veltuzumab	.	.	Phase 1	D0D8NG	.	CTPDG004853
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MORAb-022	"Antibody (inflammation/autoimmune disease), Morphotek"	.	Phase 1	D0B0VD	.	CTPDG004925
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ARG301	.	.	Phase 1	D09PJB	.	CTPDG004987
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SCH-900117	.	.	Phase 1	D08YWY	.	CTPDG005018
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	DWP-422	.	.	Phase 1	D08SXV	.	CTPDG005031
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VEL-0230	"NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar"	25102841	Phase 1	D07BIK	.	CTPDG005126
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Synthetic neutrophil inhibitor peptide	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide	71482	Phase 1	D07ANO	.	CTPDG005128
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RWJ-67657	215303-72-3; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	Phase 1	D06OZJ	.	CTPDG005150
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI4920	.	.	Phase 1	D06HNO	.	CTPDG005164
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RPI-78M	"Antiviral agent, Receptogen; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm"	.	Discontinued in Phase 1	D05FVK	.	CTPDG005210
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP2408	CTLA4-Ig fusion protein	.	Phase 1	D04OQU	.	CTPDG005246
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK3117391	.	53630042	Phase 1	D04KMQ	DB15440	CTPDG005255
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ABBV-257	.	.	Phase 1	D04DQO	.	CTPDG005266
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VGX-1027	"6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590"	10798271	Phase 1	D03QEB	.	CTPDG005296
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK-1827771	"IL-1 antagonist (antibody, rheumatoid arthritis), GSK"	.	Phase 1	D03FVR	.	CTPDG005318
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP5094	.	.	Phase 1	D03ACE	.	CTPDG005331
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	EVT 401	.	.	Phase 1	D01TLV	.	CTPDG005379
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SKI-O-703	.	.	Phase 1	D01IDW	.	CTPDG005409
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Clinical trial	AZ-4217	AZ4217; AZ 4217	57406537	Clinical trial	D00XKB	.	CTPDG005509
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Floctafenine	"23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline"	3360	Withdrawn from market	D0AK5R	DB08976	CTPDG006315
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Aurothioglucose	HMS3262I11; LP00685	454937	Withdrawn from market	D0A4BR	.	CTPDG006316
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Preregistration	Amiprilose	Therafectin; Amiprilose hydrochloride; KAP-690; SM-1213	121928	Discontinued in Preregistration	D07MEL	.	CTPDG006326
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	Nerelimomab	BAY-X-1351	.	Discontinued in Phase 3	D0VW2Z	.	CTPDG006333
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	M-5010	M-5011; T-3788; 2(R)-[4-(3-Methyl-2-thienyl)phenyl]propionic acid	12769847	Discontinued in Phase 3	D0RJ0J	.	CTPDG006340
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	BR3-Fc	.	.	Discontinued in Phase 2	D0YA0N	.	CTPDG006399
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	EFLETIRIZINE	Efletirizine < Rec INN; Ucb-28754; 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid	66003	Discontinued in Phase 2	D0XK4R	.	CTPDG006402
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IX207-887	.	6509858	Discontinued in Phase 2	D0X2PQ	.	CTPDG006407
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AMG 108	.	444499	Discontinued in Phase 2	D0W7VG	.	CTPDG006413
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HR325	.	66583751	Discontinued in Phase 2	D0SX4K	.	CTPDG006435
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	TA-383	"Cis-2-(4-Chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride; Cis-2-(4-Chlorophenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole hydrochloride"	131180	Discontinued in Phase 2	D0R2CM	.	CTPDG006447
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	Discontinued in Phase 2	D0Q9ZD	.	CTPDG006450
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SM-8849	"113759-19-6; 4-(1-(2-fluoro-4-biphenylyl)ethyl)-2-methylaminothiazole; 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole; ZTFDMDJGJVUYQE-UHFFFAOYSA-N; AC1L3Y3S; SCHEMBL5078854; 4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; (+)-2-methylamino-4-(1-(2-fluoro-4-biphenylyl)ethyl)thiazole; 4-[1-(3-fluoro-4-phenylphenyl)ethyl]-N-methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 4-(1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-N-methyl-"	124238	Discontinued in Phase 2	D0Q0AJ	.	CTPDG006455
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Zolimomab aritox	XomaZyme-CD5 Plus; XomaZyme-H65; XomaZyme-lym; OrthoZyme-CD5+; Xmmly-h65-rta; XomaZyme-H65-rta	.	Discontinued in Phase 2	D0O2QB	.	CTPDG006464
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CP-195543	"LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer"	9823886	Discontinued in Phase 2	D0MM2K	DB13053	CTPDG006475
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MLN3897	.	.	Discontinued in Phase 2	D0KF6X	.	CTPDG006490
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-5751	"AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid"	9867949	Discontinued in Phase 2	D0K0VH	.	CTPDG006494
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MP-435	"C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe"	.	Discontinued in Phase 2	D0H0ZU	.	CTPDG006510
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CPA-926	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one	9800054	Discontinued in Phase 2	D0G6PG	.	CTPDG006516
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SINOMENINE	"Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one"	5459308	Discontinued in Phase 2	D0F9WF	.	CTPDG006522
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Linetastine	"Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Molecule 26"	6439232	Discontinued in Phase 2	D0E8UV	.	CTPDG006530
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SC-106	AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid	492984	Discontinued in Phase 2	D0D3KY	.	CTPDG006539
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PRO-515	.	.	Discontinued in Phase 2	D09FEN	.	CTPDG006572
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GW-215864	GR-215864; GR-215864X; GW-215864X	56841560	Discontinued in Phase 2	D09AUP	.	CTPDG006573
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HSR-609	"FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate"	3081352	Discontinued in Phase 2	D08RZV	.	CTPDG006576
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AnergiX.RA	"AG-4263; RA-AnergiX; Antigen specific therapy (rheumatoid arthritis, AnergiX), Corixa/ Organon"	.	Discontinued in Phase 2	D07BEE	.	CTPDG006598
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GLPG-0259	"G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562"	44462738	Discontinued in Phase 2	D06NPB	DB15190	CTPDG006604
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NN8209	.	.	Discontinued in Phase 2	D05ILZ	.	CTPDG006618
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IDEC-151	Clenoliximab	.	Discontinued in Phase 2	D04ZLG	.	CTPDG006624
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	Discontinued in Phase 2	D04DUJ	.	CTPDG006634
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NPC-567	"Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-"	119343	Discontinued in Phase 2	D03ZBM	.	CTPDG006637
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	T-5224	AKOS003047196; T5224	23626877	Discontinued in Phase 2	D02LCL	.	CTPDG006652
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AD-121	"PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest"	.	Discontinued in Phase 1/2	D06YFO	.	CTPDG006694
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AME-527	.	.	Discontinued in Phase 1/2	D05RTF	.	CTPDG006696
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-4629991	"PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer"	.	Discontinued in Phase 1	D0N8AB	.	CTPDG006767
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	NN8210	.	.	Discontinued in Phase 1	D0MT7W	.	CTPDG006774
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	ARRY-614	"Pexmetinib; 945614-12-0; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	Discontinued in Phase 1	D0ML0L	.	CTPDG006775
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Oncolysin CD6	Anti-CD6-bR; Anti-T12-bR	.	Discontinued in Phase 1	D0L4SB	.	CTPDG006784
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Eltenac	BY-820; B-788-20	51717	Discontinued in Phase 1	D0JF6O	.	CTPDG006796
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RG-4934	"IL-17 huMAb (psoriatic arthritis), Roche"	.	Discontinued in Phase 1	D0J8JF	.	CTPDG006797
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AC-100	"Bicyclo[4.2.0]octa-1,3,5-trien-3-ylboronic acid; BENZOCYCLOBUTANE-4-BORONIC ACID; Boronic acid, bicyclo[4.2.0]octa-1,3,5-trien-3-yl-; SCHEMBL12759201; KS-00000SRU; MolPort-005-942-889; ZINC196051840; AKOS025146995; DS-8536; BC225113; AK164312; 1,2-Dihydrobenzocyclobutene-4-ylboranic acid; CS-0043999; J3.522.588I; 4-bbcb                                             benzocyclobutene-4-boronic acid"	11171056	Discontinued in Phase 1	D0J6PR	.	CTPDG006798
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Roquinimex	Linomide	54676478	Discontinued in Phase 1	D0G9ZW	DB11366	CTPDG006812
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	D-1367	"167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-"	15259989	Discontinued in Phase 1	D0E8MW	.	CTPDG006818
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AVE-9940	.	.	Discontinued in Phase 1	D08CQE	.	CTPDG006862
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	LY-231617	"2,6-Di-tert-butyl-4-(ethylaminomethyl)phenol hydrochloride"	3968	Discontinued in Phase 1	D05XYC	.	CTPDG006882
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	CI-972	.	135418360	Discontinued in Phase 1	D05UPB	.	CTPDG006883
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R1295	CHEMBL2146615	70329	Discontinued in Phase 1	D04XJM	.	CTPDG006893
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	KB-2683	.	129748	Discontinued in Phase 1	D03LXJ	.	CTPDG006908
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-6703	"P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca"	11373432	Discontinued in Phase 1	D03KWN	.	CTPDG006909
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SC-57666	CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	Discontinued in Phase 1	D02OHR	.	CTPDG006916
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	C-5997	"7709-58-2; 4-(Chloromethyl)thiazole hydrochloride; 4-(chloromethyl)-1,3-thiazole Hydrochloride; 4-(chloromethyl)thiazole hcl; 4-chloromethylthiazole hydrochloride; 4-chloromethylthiazole hcl; 4-(chloromethyl)thiazolehcl; C4H4ClNS.ClH; ACMC-1BBSC; chloromethylthiazole-4 hcl; AC1Q3BH9; AC1MC82W; SCHEMBL122926; 4-(Chloromethyl)thiazole, HCl; CTK6H6834; DTXSID60376874; NVTBASMQHFMANH-UHFFFAOYSA-N; MolPort-000-139-475; 4-(chloromethyl)thiazole HCl salt; ACT02312; KS-000004ND; ANW-36949; 4-chloromethyl thiazole hydrochloride"	2763289	Discontinued in Phase 1	D01CBV	.	CTPDG006932
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-755616	.	.	Discontinued in Phase 1	D00FGY	.	CTPDG006939
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	GP2015	.	.	Application submitted	D0K9SS	.	CTPDG006944
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	SR1555	"CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675"	71470549	Preclinical	DW5R6Y	.	CTPDG006962
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	MCP-1	.	.	Preclinical	D0V9ND	.	CTPDG007038
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NPC-17923	"147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-"	9824607	Terminated	D0Z3AK	.	CTPDG007165
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	TM-31	.	.	Terminated	D0Y9CC	.	CTPDG007170
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BCX-25	BCX-14	.	Terminated	D0V2ZJ	.	CTPDG007200
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BB-1433	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241	101708593	Terminated	D0V0RW	.	CTPDG007202
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	ZK-90695	.	.	Terminated	D0US3C	.	CTPDG007203
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RP-54745	"RP 54745; 135330-08-4; AC1L2PX8; SCHEMBL4362761; rp54745; CS-6750; 4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one; HY-101716; 4-chloro-5-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)dithiol-3-one; 3H-1,2-Dithiol-3-one, 4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-"	126203	Terminated	D0T0LO	.	CTPDG007223
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	Terminated	D0R5TT	.	CTPDG007238
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Seprilose	GW-80126	60818	Terminated	D0Q5ZN	.	CTPDG007243
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NOX-200	"2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478"	95438	Terminated	D0OX9Q	.	CTPDG007255
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SAN-18	.	.	Terminated	D0M8QG	.	CTPDG007278
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	CI-986	"CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate"	3037017	Terminated	D0L8RG	.	CTPDG007289
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-6942	"CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca"	.	Terminated	D0I9YI	.	CTPDG007324
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	3-DEAZAADENOSINE	"Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine"	23190	Terminated	D0I7TN	DB04546	CTPDG007326
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-28342	.	9882188	Terminated	D0H0IA	.	CTPDG007341
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AG-2024	.	.	Terminated	D0G2CL	.	CTPDG007350
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Ro-31-4724	CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	Terminated	D0EF7V	DB08482	CTPDG007361
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-33516	.	.	Terminated	D0DR3I	.	CTPDG007371
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	D-5410	CH-138; CH-263	.	Terminated	D09TRM	.	CTPDG007412
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SKF-104351	"111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole"	122656	Terminated	D09SCI	.	CTPDG007413
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RWJ-63556	.	9882374	Terminated	D08JKK	.	CTPDG007441
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	YM-26734	"YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1"	9853400	Terminated	D07OGR	.	CTPDG007458
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD5672	"CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide"	11614352	Terminated	D07GIB	.	CTPDG007463
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-16276-1	.	.	Terminated	D06MTM	.	CTPDG007476
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-111142	WF-2015A	9909502	Terminated	D06AKJ	.	CTPDG007482
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BW A4C	"BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide"	6438354	Terminated	D05WPQ	.	CTPDG007485
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-48989	"WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile"	132006	Terminated	D04YNI	.	CTPDG007505
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-133605	.	.	Terminated	D04SVB	.	CTPDG007508
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SR-26831	"SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate"	132270	Terminated	D03GII	.	CTPDG007535
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	GDC-0834	"1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz"	25234918	Terminated	D03FUO	.	CTPDG007536
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	Terminated	D01QRG	.	CTPDG007565
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	LY-221068	"LY 221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-"	6439333	Terminated	D01QAR	.	CTPDG007566
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	DPC-333	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide	9847838	Terminated	D01DVX	.	CTPDG007574
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	PXS-2076	"PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis"	.	Terminated	D01DTQ	.	CTPDG007575
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ODN-1411	.	.	Investigative	D5S7JL	.	CTPDG007609
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	Investigative	D0YK4L	.	CTPDG007651
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	Investigative	D0Y4ZI	.	CTPDG007665
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BFPT-16864	BFPT-6864; BRFD-104	.	Investigative	D0XP3A	.	CTPDG007695
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Arthromir	.	.	Investigative	D0WI1L	.	CTPDG007743
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	SPX-601	.	.	Investigative	D0VB2K	.	CTPDG007786
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-814	"Hsp60 peptide (juvenile idiopathic arthritis), CIGB"	.	Investigative	D0V5VA	.	CTPDG007796
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD40-XTEN	"CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0V3HC	.	CTPDG007800
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	X-071-NAB	"NATHMAB (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech; Natural/true human monoclonal antibody (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech"	.	Investigative	D0U2OQ	.	CTPDG007838
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TENOSAL	MR-Y134; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	Investigative	D0T3KZ	.	CTPDG007862
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DW-908	DW-0908	.	Investigative	D0R4NJ	.	CTPDG007910
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	Investigative	D0N8TM	.	CTPDG008032
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	MDDR 217769	"(E)-2-(4,6-Difluoroindan-1-ylidene)acetamide"	.	Investigative	D0N8JJ	.	CTPDG008033
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FKB327	.	.	Investigative	D0L8UQ	.	CTPDG008105
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DMARDs	"DMARDs (oral, rheumatoid arthritis); DMARDs (oral, rheumatoid arthritis), Abbott; Disease-modifying antirheumatic drugs (oral, rheumatoid arthritis), Abbott"	.	Investigative	D0L2BT	.	CTPDG008121
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TX-RAD	"RA1-TX; RA1-TX (ankylosing spondylitis), TxCell; RA1-TX (rheumatoid arthritis), TxCell; RA1-TX (psoriatic arthritis,inflammatory disease), TxCell"	.	Investigative	D0K8BO	.	CTPDG008134
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	UR-5269	"Rheumatoid arthritis therapy, UBE Industries"	.	Investigative	D0J7XN	.	CTPDG008168
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	AVX-002	.	.	Investigative	D0J4TX	.	CTPDG008173
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-125	"Synoviocyte inhibitor + glucocorticoid (arthritis), Xaragen"	.	Investigative	D0I9FQ	.	CTPDG008191
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DWJ-425	"DW-Ab2; MAb (RA), Daewoong; Monoclonal antibody (rheumatoid arthritis), Daewoong"	.	Investigative	D0I4MW	.	CTPDG008211
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	HL-1020	"Grape seed proanthocyanidin extract (rheumatoid arthritis), Hanlim"	.	Investigative	D0G8EI	.	CTPDG008263
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-120	"Synoviocyte inhibitor + DMARD (arthritis), Xaragen"	.	Investigative	D0G2GZ	.	CTPDG008276
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-115	"Synoviocyte inhibitor + NSAID (arthritis), Xaragen"	.	Investigative	D0F8BR	.	CTPDG008296
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CTLA-4-XTEN	"Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0EZ9C	.	CTPDG008324
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Nano-steroid	"Steroidal anti-inflammatory (slow release nanoparticle formulation), LTT Bio-Pharma; Steroids (sustained release nanoparticles), LTT Bio-Pharma/Cipra; Steroidal anti-inflammatory (rheumatoid arthritis/collagen disease), LTT Bio-Pharma"	.	Investigative	D0B9XM	.	CTPDG008440
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	YD-101	.	.	Investigative	D0B3KI	.	CTPDG008455
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	KI-0906	.	.	Investigative	D0A2RF	.	CTPDG008498
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FHT-401	"PTD-conjugated methotrexate (transdermal, rheumatoid arthritis), ForHumanTech/Hyundai"	.	Investigative	D0A0FI	.	CTPDG008502
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TCH-013	"NF-kB inhibitors (rheumatoid arthritis); NF-kB inhibitors (rheumatoid arthritis), TCH Pharmaceuticals"	76850167	Investigative	D09TVH	.	CTPDG008515
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD97 mab	"Anti-CD97 monoclonal antibody (rheumatoid arthritis); Anti-CD97 mAb (RA), Organon/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Organon/AMC; Anti-CD97 mAb (RA), Schering-Plough/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Merck & Co/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Schering-Plough/AMC"	.	Investigative	D09RGS	.	CTPDG008524
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-55	.	.	Investigative	D09NQD	.	CTPDG008534
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Dendritic cell-based immunotherapy	"Dendritic cell-based immunotherapy (rheumatoid arthritis); Dendritic cell-based immunotherapy (rheumatoid arthritis), Dendright; Dendritic cell-based immunotherapy (rheumatoid arthritis, injectable formulation), Dendright"	.	Investigative	D07OCM	.	CTPDG008673
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	RT-401	"BoNTA protein (topical, rhinitis), Revance"	.	Investigative	D07JPL	.	CTPDG008692
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	VVZ-138	VVZ-000138	.	Investigative	D07GFZ	.	CTPDG008699
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	IG-AI-025	.	.	Investigative	D06XXD	.	CTPDG008716
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CHR-4487	"Esterase-sensitive motif compounds (inflammatory disease); Esterase-sensitive motif compounds (inflammatory disease), Chroma Therapeutics"	.	Investigative	D06HWU	.	CTPDG008757
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ROSMARINIC ACID	"20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid"	5281792	Investigative	D05PTT	.	CTPDG008813
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CT-340	"TrkA kinase inhibitor (polyoxyethylene conjugated, LSE, arthritis, scarring, pain), Creabilis"	.	Investigative	D05KRS	.	CTPDG008827
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ADR58	.	.	Investigative	D04VCF	.	CTPDG008856
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CEL-2000	"T-cell modulating vaccine (LEAPS, rheumatoid arthritis), CEL-SCI"	.	Investigative	D03XSX	.	CTPDG008918
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FM-201	.	.	Investigative	D03TKI	.	CTPDG008933
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BMS-345541	"445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05"	9926054	Investigative	D00YTQ	.	CTPDG009140
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CAT-2200	"MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)"	.	Investigative	D00XNC	.	CTPDG009145
M6ACROT05368	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	OCT-SG815	"OPG secretagogues (osteoporosis/arthritis), Oscotec; Osteoprotegerin secretagogues (osteoporosis/arthritis), Oscotec; OPG secretagogues (osteoporosis/arthritis), KT&G; Osteoprotegerin secretagogues (osteoporosis/arthritis), KT&G"	.	Investigative	D00QOH	.	CTPDG009161
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	Kevzara	.	Approved	D0Z8CQ	.	CTPDG000029
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulindac	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	1548887	Approved	D0Z5IU	DB00605	CTPDG000031
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Felbinac	"Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda"	3332	Approved	D0Y7EM	DB07477	CTPDG000057
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Salsalate	"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid"	5161	Approved	D0Y0JH	DB01399	CTPDG000063
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Fostamatinib	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]	11671467	Phase 3	D0V8HJ	DB12010	CTPDG000102
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Methotrexate	"Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	126941	Phase 3	D0SV8E	DB00563	CTPDG000144
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IPI-145	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;	50905713	Phase 3	D0RU0O	DB11952	CTPDG000166
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	Approved	D0R1RS	DB00328	CTPDG000188
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Inosine pranobex	Imunovir (TN)	135449284	Approved	D0Q2QU	.	CTPDG000206
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Citrofen	Citrofen (TN)	.	Approved	D0P6UK	.	CTPDG000218
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meclofenamate Sodium	.	4038	Approved	D0MN9K	.	CTPDG000266
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxaprozin	"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid"	4614	Approved	D0M9DC	DB00991	CTPDG000269
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Zinc salts	.	.	Approved	D0K8AA	.	CTPDG000300
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	Approved	D0K5KS	.	CTPDG000305
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Orthokine	Orthokine (TN)	.	Approved	D0J1PW	.	CTPDG000330
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	SK-1306X	Cararthron; Joins	.	Approved	D0IL0C	.	CTPDG000339
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	Approved	D0I6IB	DB00469	CTPDG000343
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	Approved	D0I5QX	.	CTPDG000345
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	Approved	D0G7FJ	DB00814	CTPDG000369
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Gold sodium thiomalate	Sodium aurothiomalate	22318	Approved	D0FH7C	DB09276	CTPDG000381
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Abatacept	Orencia (TN)	.	Approved	D0EW4L	.	CTPDG000397
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)"	9926791	Approved	D0EG1I	DB08895	CTPDG000400
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	OM-89	Subreum; UroVaxom; UroVaxon; OM-8980	.	Approved	D0E1VD	.	CTPDG000414
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rimexolone	"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)"	5311412	Approved	D0D2TN	DB00896	CTPDG000426
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	Approved	D0CA0P	.	CTPDG000432
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Alclofenac	"22131-79-9; Alclophenac; Prinalgin; Medifenac; Reufenac; Allopydin; Mervan; Alclofenacum; Alclofenaco; Zumaril; Neoston; Neosten; 2-(4-(Allyloxy)-3-chlorophenyl)acetic acid; [4-(Allyloxy)-3-chlorophenyl]acetic acid; Desinflam; Marvan Forte; 3-Chloro-4-(2-propenyloxy)benzeneacetic acid; (4-Allyloxy-3-chlorphenyl)essigsaeure; MY 101; Epinal; Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-; Alclofenacum [INN-Latin]; Alclofenaco [INN-Spanish]; UNII-M9CP5H21N8; W 7320; CHEBI:31183; EINECS 244-795-4"	30951	Approved	D0C6OQ	DB13167	CTPDG000435
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Careram	Iguratimod	124246	Approved	D0B8MZ	DB12233	CTPDG000450
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	Approved	D0A1PX	DB00712	CTPDG000472
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Nafcillin	"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	8982	Approved	D0A0JH	DB00607	CTPDG000473
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etofenamate	30544-47-9; Rheumon; Bayrogel; Rheumon gel; UNII-KZF0XM66JC; Etofenamatum [INN-Latin]; Etofenamato [INN-Spanish]; Bay d 1107; C18H18F3NO4; TVX 485; WHR 5020; EINECS 250-231-8; KZF0XM66JC; BRN 2953263; 2-(2-Hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate; 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate; WHR-5020; NCGC00016804-01; 2-(2-Hydroxyaethoxy)aethylester der flutenaminsaeure [German]; CAS-30544-47-9; 2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate	35375	Approved	D09YVX	DB08984	CTPDG000475
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	Approved	D09MGR	DB01628	CTPDG000489
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	Approved	D09FSG	.	CTPDG000501
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	Approved	D09BHB	DB00500	CTPDG000505
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)	.	Phase 2	D08WSY	.	CTPDG000511
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Leflunomide	"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide"	3899	Approved	D08ROP	DB01097	CTPDG000515
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Penicillamine	"D-Penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine"	5852	Approved	D08HZC	DB00859	CTPDG000523
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dimethyl Sulfoxide	Rimso-50	679	Approved	D08HVE	DB01093	CTPDG000524
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tocilizumab	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody	.	Approved	D08HPZ	.	CTPDG000526
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Benorilate	"5003-48-5; BENORYLATE; 4-acetamidophenyl 2-acetoxybenzoate; Benoral; Salipran; Benortan; Fenasprate; Fenasparate; Aspirin acetaminophen ester; Benorilato; Benorilato [Spanish]; p-Acetamidophenyl acetylsalicylate; Benorilatum [INN-Latin]; Benorilato [INN-Spanish]; UNII-W1QX9DV96G; p-N-Acetylaminophenylacetylsalicylate; TO 125; WIN 11450; 4'-(Acetamido)phenyl-2-acetoxybenzoate; 2-Acetoxy-4'-(acetamino)phenylbenzoate; CCRIS 1739; Benzoic acid, 2-(acetyloxy)-, 4-(acetylamino)phenyl ester; 4-Acetamidophenyl salicylate acet"	21102	Approved	D08GJO	DB13657	CTPDG000528
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Halopredone acetate	Haloart (TN)	91667	Approved	D08BDT	.	CTPDG000531
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Teriflunomide	.	54684141	Approved	D07QFP	DB08880	CTPDG009757
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Siponimod	BAF312	44599207	Phase 2	D07FKQ	DB12371	CTPDG000573
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxyphenbutazone	Tandearil	4641	Approved	D06ZPS	DB03585	CTPDG000587
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	FENBUFEN	"36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	Approved	D06LHG	DB08981	CTPDG000602
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexchlorpheniramine Maleate	Polaramine	5281070	Approved	D05ZGQ	DB09555	CTPDG000614
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Enbrel	.	.	Approved	D05LTY	.	CTPDG000635
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Fenoprofen	"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid"	3342	Approved	D03XYW	DB00573	CTPDG000689
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	Approved	D03RTS	DB00482	CTPDG000700
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sodium Succinate	"Disodium succinate; 150-90-3; Disodium butanedioate; Butanedioic acid, disodium salt; Succinic acid disodium salt; Soduxin; Jantaran sodny [Czech]; UNII-V8ZGC8ISR3; Succinic acid, disodium salt; FEMA No. 3277; CCRIS 3700; Sodium succinate dibasic; EINECS 205-778-7; V8ZGC8ISR3; Butanedioic acid, sodium salt (1:2); Succinic acid disodium salt anhydrous; Butanedioic acid disodium salt; sodium succinate (anhydrous); Jantaran sodny; Butanedioic acid disodium hexahydrate; Succinic acid, disodium salt, 99%, anhydrous"	9020	Approved	D03RCJ	.	CTPDG000703
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulfasalazine	599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Sulfasalizine	5339	Approved	D02ZTJ	DB00795	CTPDG000732
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	Kineret; Kineret (TN); Anakinra (USAN/INN)	.	Approved	D02DES	.	CTPDG000759
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Cyproheptadine	"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene"	2913	Approved	D00TLN	DB00434	CTPDG000802
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	Approved	D00HGB	DB04552	CTPDG000816
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Nipocalimab	.	.	Phase 2	DS69NO	.	CTPDG000882
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Nipocalimab?	.	.	Phase 3	DR5V8I	.	CTPDG000884
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	BI 695501	BI-695501)	.	Phase 3	D0Z4VX	.	CTPDG000966
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06410293	.	.	Phase 3	D0Y8TZ	.	CTPDG000976
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Flobufen	VUFB-16066; VUFB-17203	159476	Phase 3	D0X8VV	.	CTPDG000989
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	Phase 3	D0W2CX	DB12399	CTPDG001013
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP-2017	.	.	Phase 3	D0S7JN	.	CTPDG001055
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cartistem	"Stem cell therapy (cartilage disease/rheumatoid arthritis), Medipost"	.	Phase 3	D0OH5E	.	CTPDG001096
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IR-201	Seryl-glutaminyl-isoleucyl-valyl-asparaginyl-aspartyl-phenylalanyl-glutaminyl-lysyl-glycyl-aspartyl-isoleucyl-alanyl-glutamyl-glycyl-tyrosyl-serine	.	Phase 3	D0N3SA	.	CTPDG001116
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Esonarimod	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298	127998	Phase 3	D0MY7X	.	CTPDG001120
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CIPEMASTAT	"Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	Phase 3	D0MW3H	.	CTPDG001123
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Methylprednisolone	.	6741	Approved	D0LN1Z	DB00959	CTPDG001141
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	STI-002	.	.	Phase 3	D0I6UE	.	CTPDG001181
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MK-8808	.	.	Phase 1	D0GP8N	.	CTPDG001196
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 798	.	.	Phase 3	D0E8NJ	.	CTPDG001224
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06438179	.	.	Phase 3	D0D9HZ	.	CTPDG001236
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	.	44205240	Approved	D0D5FU	DB11817	CTPDG001241
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cilengitide	"188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)"	176873	Phase 3	D09ZXO	DB11890	CTPDG001287
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CEP-41750	.	.	Phase 3	D09WRG	.	CTPDG001291
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	.	.	Approved	D08SJT	.	CTPDG001320
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Andolast	"Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm"	65970	Phase 3	D08PGC	.	CTPDG001324
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Vanadate	"Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3"	516859	Phase 3	D08NCO	.	CTPDG001327
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	Phase 3	D08DGC	DB12193	CTPDG011311
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Spermidine	"Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, &gt; =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0"	1102	Phase 3	D08BXT	DB03566	CTPDG001337
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Varespladib methyl	"A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera"	9886917	Phase 3	D07KFB	DB05737	CTPDG001360
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 501	.	.	Phase 3	D06FMO	.	CTPDG001379
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	.	.	Approved	D06CXL	.	CTPDG001384
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Atacicept	.	.	Phase 2	D04YWM	.	CTPDG001412
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Tenidap	.	60712	Phase 3	D02RQT	DB13481	CTPDG001457
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LY3090106	Tibulizumab	.	Phase 1	D09JVK	.	CTPDG001558
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2/3	VX-509	"Decernotinib; Adelatinib; 944842-54-0; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	Phase 2/3	D04QWQ	DB12566	CTPDG001571
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D03ZYQ	.	CTPDG001574
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	CreaVax-RA	"Autologous DC therapy (injectable, rheumatoid arthritis), CreaGene; Autologous dendritic cell therapy (injectable, rheumatoid arthritis), CreaGene"	.	Phase 2a	D0U9OD	.	CTPDG001585
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	RhuDex	.	.	Phase 2a	D0J0KT	.	CTPDG001586
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cevidoplenib	"(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone; 1703788-21-9; 3N3H8BX897; AKOS040748110; BDBM196772; Cevidoplenib; Cevidoplenib [INN]; Cevidoplenib [WHO-DD]; CHEMBL3921923; CS-0039259; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; EX-A5914; HY-109082; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; MS-28778; SCHEMBL16653204; UNII-3N3H8BX897; US9212178, 1; YCZUBLQESBVOSH-IBGZPJMESA-N"	91754477	Phase 2	DY57LN	.	CTPDG001609
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Dazodalibep	VIB4920	.	Phase 2	DPDI65	.	CTPDG001652
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Natrunix	.	.	Phase 2	DOVW19	.	CTPDG001657
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-5718	"1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 920036-34-6; A860172; AKOS022178093; AMY21637; CS-0048281; FT-0702852; GS-5718; MFCD13183727; OKKLWSNHFSFXEM-UHFFFAOYSA-N; PB26872; SCHEMBL3606964; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate"	57443610	Phase 2	DF1T2W	.	CTPDG001727
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Branebrutinib	"(S)-4-(3-(2-BUTYNOYLAMINO)PIPERIDIN-1-YL)-5-FLUORO-2,3-DIMETHYL-1H-INDOLE-7-CARBOXAMIDE; (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 1912445-55-6; 1H-Indole-7-carboxamide, 5-fluoro-2,3-dimethyl-4-((3S)-3-((1-oxo-2-butyn-1-yl)amino)-1-piperidinyl)-; 4-((3S)-3-(2-BUTYNOYLAMINO)-1-PIPERIDINYL)-5-FLUORO-2,3-DIMETHYL-1HINDOLE-7-CARBOXAMIDE; 4-((3S)-3-(2-Butynoylamino)-1-piperidinyl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-((3S)-3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 7LBRZUYSHU; AC-31535; AKOS037649047; BCP29496; BDBM164638; BDBM166759; BMS986195; BMS986195; BMS986195; BMS-986195; Branebrutinib; Branebrutinib (BMS-986195); Branebrutinib (USAN); BRANEBRUTINIB [INN]; Branebrutinib [USAN]; BRANEBRUTINIB [WHO-DD]; BS-16393; C20H23FN4O2; CHEMBL4297674; CS-0043577; D11478; DB15347; EN300-2007801; EX-A2720; Example 223 [US20160115126A1]; GTPL9869; HY-112161; MFCD31631584; NSC807627; NSC-807627; Q50825082; s8832; SCHEMBL17699728; UNII-7LBRZUYSHU; US9688629, 123; US9688629, 223; VJPPLCNBDLZIFG-ZDUSSCGKSA-N; WHO 11026"	121293929	Phase 2	DE3VU1	DB15347	CTPDG001734
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vobarilizumab	ALX-0061	.	Phase 2	D9J6XV	.	CTPDG001766
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IRL201805	.	.	Phase 2	D9EHD7	.	CTPDG001767
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KPL-404	.	.	Phase 2	D3NSU0	.	CTPDG001824
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FK-3311	"116686-15-8; FK 3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	Phase 2	D0Z9YW	.	CTPDG001858
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-783	"Rheumatoid arthritis therapy (oral), Takeda Pharmaceutical"	.	Phase 2	D0Z4OQ	.	CTPDG001864
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Piclamilast	"144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL"	154575	Phase 2	D0Z2FB	DB01791	CTPDG001866
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ADL-5859	PF-04856880	46931003	Phase 2	D0W9ZT	.	CTPDG001918
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SBI-087	PF-05230895	.	Phase 2	D0W9QG	.	CTPDG001920
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SB-705498	501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504	9910486	Phase 2	D0VJ5N	DB11883	CTPDG001948
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-817399	.	44537841	Phase 2	D0UX2V	DB14941	CTPDG001971
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CFZ533	.	.	Phase 2	D0SD6V	.	CTPDG002036
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PD-360324	"PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer"	.	Phase 2	D0S1UZ	.	CTPDG002048
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MGCD-290	"MG-1; MG-3290; Histone deacetylase inhibitors (cardiovascular diseases), MethylGene; Histone deacetylase inhibitors (diabetes), MethylGene; Histone deacetylase inhibitors (fungal infection), MethylGene; Histone deacetylase inhibitors (inflammation), MethylGene; HDAC inhibitors (non-oncology), MethylGene; Histone deacetylase inhibitors (non-oncology), MethylGene"	3035813	Phase 2	D0RF3F	.	CTPDG002061
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Prednisone/ dipyridamole	Synavive (TN)	5865	Phase 2	D0R4NR	DB00635	CTPDG002071
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	QAL964	.	.	Phase 2	D0QZ3P	.	CTPDG002077
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	M2951	"evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin"	71479709	Phase 2	D0QX8X	DB15170	CTPDG002078
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AK-106-001616	.	.	Phase 2	D0QH5K	.	CTPDG002079
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABT-122	.	.	Phase 2	D0OX5H	.	CTPDG002123
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Meninge ACYW	.	.	Phase 2	D0OQ5W	.	CTPDG002127
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-715	"P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda"	9952773	Phase 2	D0O6ZO	.	CTPDG002136
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MPC-300-IV	.	.	Phase 2	D0MM0N	.	CTPDG002186
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Anti-LT alpha	.	.	Phase 2	D0L1OC	.	CTPDG002241
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NNC-0151-0000-0000	"Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk"	.	Phase 2	D0J4PM	.	CTPDG002288
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-945429	.	.	Phase 2	D0J1KS	.	CTPDG002291
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ONO-4641	"Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono"	11502996	Phase 2	D0I2RB	.	CTPDG002320
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNT0-1959	.	.	Phase 2	D0HT2X	.	CTPDG002325
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	Phase 2	D0HG5M	DB13020	CTPDG002328
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FLUASTERONE	HE-2500; 16alpha-Fluoroandrost-5-en-17-one	133967	Phase 2	D0H9YO	DB06250	CTPDG002329
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-4059	"tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno"	54755438	Phase 2	D0H0KH	DB15227	CTPDG002346
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VVZ-149	VVZ-000149	.	Phase 2	D0G9OH	.	CTPDG002358
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MRC-375	"Tetracycline (enteric-coated oral tablet, rheumatoid arthritis), Molecular Research Center Inc"	.	Phase 2	D0F9NA	.	CTPDG002393
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AWD-12-281	"GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline"	6918428	Phase 2	D0F4TV	.	CTPDG002402
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	APX-001	"EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics"	44123754	Investigative	D0DL3W	DB15183	CTPDG002437
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SR-31747	SR-317417A	6439330	Phase 2	D0D4JI	DB05792	CTPDG002454
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BI 655064	.	.	Phase 2	D0C8NG	.	CTPDG002478
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK3196165	.	.	Phase 2	D0C7ZB	.	CTPDG002482
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK315234	Oncostatin M mAb	.	Phase 2	D0C4YQ	.	CTPDG002485
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GS-9876	"XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr"	118161062	Phase 1	D0BW6F	DB14770	CTPDG002497
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TZI-41078	"3,5-Di-tert-butyl-4-hydroxybenzophenone oxime"	.	Phase 2	D0B6VN	.	CTPDG002510
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNTO-6785	.	.	Phase 2	D0A7NZ	.	CTPDG002538
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AMG-714	.	.	Discontinued in Phase 1	D0A5EN	.	CTPDG002547
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	LX2931	.	135564845	Phase 2	D09ZWH	DB06297	CTPDG002552
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VAY736	.	.	Phase 2	D09SQM	.	CTPDG002563
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KB002/003	.	.	Phase 2	D09SJE	.	CTPDG002564
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-180575	"2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide"	9930560	Phase 2	D09OTU	.	CTPDG002571
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rabeximod	"Rob-803; B-220 analog (RA), OxyPharma; B-220 analog (rheumatoid arthritis), OxyPharma"	56841552	Phase 2	D09BDH	DB05772	CTPDG002587
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BIIB 023	.	.	Phase 2	D08YHB	.	CTPDG002598
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Baminercept	"BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec"	.	Phase 2	D08XVR	.	CTPDG002599
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-06823859	.	.	Phase 2	D08RDD	.	CTPDG002615
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MK-8457	.	53251506	Phase 2	D08PXL	.	CTPDG002620
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP323	"Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01"	23394557	Phase 2	D08MJO	.	CTPDG002628
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	.	9926791	Approved	D08ICX	DB08895	CTPDG002636
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-986142	"Unii-pjx9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide"	86582336	Phase 2	D08AOZ	DB15291	CTPDG002651
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8765	.	.	Phase 2	D07YNM	.	CTPDG002655
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AMG0714	HuMax-IL15	.	Phase 2	D07LCA	.	CTPDG002686
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Fosbretabulin	Zybrestat (TN)	5351387	Phase 2	D07JVO	DB12577	CTPDG002693
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rimacalib	SMP-114	9800765	Phase 2	D06PHH	DB12571	CTPDG002739
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Mavrilimumab	.	.	Phase 2	D06KCF	.	CTPDG002750
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CCX-354	CCX-354-C; GSK2941266	135565361	Phase 2	D05VTN	DB12963	CTPDG002783
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	[L/D]-aminopterin	.	.	Phase 2	D05QPC	.	CTPDG002790
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALX-0061	"Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx"	.	Phase 2	D05NIR	.	CTPDG002795
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Ozoralizumab	ATN-103	.	Phase 2	D05EPV	.	CTPDG002814
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	JNJ-38518168	.	23650961	Phase 2	D04VBF	DB12522	CTPDG002835
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	UCB-35440	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide	9894415	Phase 2	D04JIM	.	CTPDG002862
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Otilimab	.	.	Phase 3	D04GWO	.	CTPDG002865
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Pegsunercept	STNF-R1	.	Phase 2	D04GTA	.	CTPDG002866
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AD-452	RS(+)-mefloquine; (+)-erythro-mefloquine	.	Phase 2	D03YKQ	.	CTPDG002884
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-240612	"N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride"	44235958	Phase 2	D03UVL	.	CTPDG002897
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TOK-8801	"105963-46-0; Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide; Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; Tok 8801; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide; Imidazo(2,1-b)thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; AC1L3UYM; ACMC-20m9c6; SCHEMBL9774378; CTK4A4247; AKOS030604802"	122628	Phase 2	D03UIB	.	CTPDG002898
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D03RIX	.	CTPDG002908
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PG-760564	"Rheumatoid arthritis therapy, Procter & Gamble"	.	Phase 2	D03PBW	.	CTPDG002912
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Peresolimab	.	.	Phase 2	D02XFH	.	CTPDG002947
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-04171327	"Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317"	24872952	Phase 2	D01PLR	DB12198	CTPDG003019
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MANOALIDE	"UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975"	6437368	Phase 2	D00XQO	.	CTPDG003057
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cenplacel-L	PDA-001	.	Phase 2	D00UGX	.	CTPDG003062
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BT-016	Tregalizumab	.	Phase 2	D00PUT	.	CTPDG003072
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Xmab 5871	XmAb 5871 (TN)	.	Phase 1/2	D00NXT	.	CTPDG003076
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vidofludimus	717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644	9820008	Phase 2	D00LSI	DB15446	CTPDG003080
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	K-832	"10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9"	9844960	Phase 2	D00IUD	.	CTPDG003086
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	PRTX-100	Staphylococcal protein A	.	Phase 1/2	D0ZC6X	.	CTPDG003265
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Cx-611	"Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), Cellerix; Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), TiGenix"	.	Phase 1/2	D0T3HL	.	CTPDG003323
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	BIO-300	"Radioprotective therapy, Humanetics"	.	Phase 1/2	D0J2ES	.	CTPDG003405
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Chondrogen	Chondrogen (TN)	.	Phase 1/2	D09YVQ	.	CTPDG003481
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	.	3715	Approved	D06LFE	DB00328	CTPDG003540
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HM71224	"Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide"	56644522	Phase 1	DTF20P	.	CTPDG003715
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LABP-104	NIM-1324	.	Phase 1	DN2Z5C	.	CTPDG003811
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ORTD-1	.theta.-Defensin 1; 1-[3-[benzyl-tetrakis(3-guanidinopropyl)-[(1R)-1-hydroxyethyl]-isobutyl-isopropyl-[(1S)-1-methylpropyl]-octadecaoxo-[?]yl]propyl]guanidine; 251442-64-5; BDBM50236198; CHEMBL4073105; Cyclic-(GVCRCICTRGFCRCLCRR); DTXSID60179822; oRTD-1; RTD-1; theta-Defensin 1; theta-Defensin RTD-1	16130642	Phase 1	DH5F4M	.	CTPDG003897
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	JNJ-67484703	JNJ-4703	.	Phase 1	D4VLI7	.	CTPDG004107
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	IA-14069	.	.	Phase 1	D1ROU2	.	CTPDG004184
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BX-U001	.	.	Phase 1	D17OQM	.	CTPDG004201
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	KPE-06001	"Asthma/arthritis therapy, Kemin"	.	Phase 1	D0Z8PO	.	CTPDG004223
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	PF-05230905	ATN-192	.	Phase 1	D0Y0FZ	.	CTPDG004268
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RG6125	.	.	Phase 1	D0X8RS	.	CTPDG004281
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	TAK-020	.	.	Phase 1	D0VS3U	.	CTPDG004329
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AXS-06	.	.	Phase 1	D0VJ9X	.	CTPDG004331
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Aminoguanidine	"Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284"	2146	Discontinued in Phase 2	D0V0NL	DB05383	CTPDG004355
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	OPL-CCL2-LPM	"CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey"	.	Phase 1	D0U7PM	.	CTPDG004372
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVE1701	.	.	Phase 1	D0Q2BB	.	CTPDG004488
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVP-13358	"IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR"	9805635	Phase 1	D0P9YP	.	CTPDG004508
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Cadherin-11	SDP051	.	Phase 1	D0P5QB	.	CTPDG004517
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BF-389	"Biofor 389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029"	6439259	Phase 1	D0L6VH	.	CTPDG004624
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HMR-1031	"MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid"	9809368	Phase 1	D0L3DC	.	CTPDG004633
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VI7734	.	.	Phase 1	D0JC9K	.	CTPDG004677
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BMS-986104	"Unii-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-"	77050638	Phase 1	D0GG7L	DB15214	CTPDG004765
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AMAP-102	"5-HT antagonist (rheumatism), AnaMar"	.	Phase 1	D0G7BR	.	CTPDG004771
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Sc Veltuzumab	.	.	Phase 1	D0D8NG	.	CTPDG004853
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MORAb-022	"Antibody (inflammation/autoimmune disease), Morphotek"	.	Phase 1	D0B0VD	.	CTPDG004925
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ARG301	.	.	Phase 1	D09PJB	.	CTPDG004987
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SCH-900117	.	.	Phase 1	D08YWY	.	CTPDG005018
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	DWP-422	.	.	Phase 1	D08SXV	.	CTPDG005031
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VEL-0230	"NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar"	25102841	Phase 1	D07BIK	.	CTPDG005126
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Synthetic neutrophil inhibitor peptide	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide	71482	Phase 1	D07ANO	.	CTPDG005128
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RWJ-67657	215303-72-3; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	Phase 1	D06OZJ	.	CTPDG005150
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI4920	.	.	Phase 1	D06HNO	.	CTPDG005164
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RPI-78M	"Antiviral agent, Receptogen; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm"	.	Discontinued in Phase 1	D05FVK	.	CTPDG005210
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP2408	CTLA4-Ig fusion protein	.	Phase 1	D04OQU	.	CTPDG005246
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK3117391	.	53630042	Phase 1	D04KMQ	DB15440	CTPDG005255
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ABBV-257	.	.	Phase 1	D04DQO	.	CTPDG005266
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VGX-1027	"6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590"	10798271	Phase 1	D03QEB	.	CTPDG005296
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK-1827771	"IL-1 antagonist (antibody, rheumatoid arthritis), GSK"	.	Phase 1	D03FVR	.	CTPDG005318
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP5094	.	.	Phase 1	D03ACE	.	CTPDG005331
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	EVT 401	.	.	Phase 1	D01TLV	.	CTPDG005379
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SKI-O-703	.	.	Phase 1	D01IDW	.	CTPDG005409
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Clinical trial	AZ-4217	AZ4217; AZ 4217	57406537	Clinical trial	D00XKB	.	CTPDG005509
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Floctafenine	"23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline"	3360	Withdrawn from market	D0AK5R	DB08976	CTPDG006315
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Aurothioglucose	HMS3262I11; LP00685	454937	Withdrawn from market	D0A4BR	.	CTPDG006316
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Preregistration	Amiprilose	Therafectin; Amiprilose hydrochloride; KAP-690; SM-1213	121928	Discontinued in Preregistration	D07MEL	.	CTPDG006326
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	Nerelimomab	BAY-X-1351	.	Discontinued in Phase 3	D0VW2Z	.	CTPDG006333
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	M-5010	M-5011; T-3788; 2(R)-[4-(3-Methyl-2-thienyl)phenyl]propionic acid	12769847	Discontinued in Phase 3	D0RJ0J	.	CTPDG006340
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	BR3-Fc	.	.	Discontinued in Phase 2	D0YA0N	.	CTPDG006399
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	EFLETIRIZINE	Efletirizine < Rec INN; Ucb-28754; 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid	66003	Discontinued in Phase 2	D0XK4R	.	CTPDG006402
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IX207-887	.	6509858	Discontinued in Phase 2	D0X2PQ	.	CTPDG006407
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AMG 108	.	444499	Discontinued in Phase 2	D0W7VG	.	CTPDG006413
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HR325	.	66583751	Discontinued in Phase 2	D0SX4K	.	CTPDG006435
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	TA-383	"Cis-2-(4-Chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride; Cis-2-(4-Chlorophenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole hydrochloride"	131180	Discontinued in Phase 2	D0R2CM	.	CTPDG006447
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	Discontinued in Phase 2	D0Q9ZD	.	CTPDG006450
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SM-8849	"113759-19-6; 4-(1-(2-fluoro-4-biphenylyl)ethyl)-2-methylaminothiazole; 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole; ZTFDMDJGJVUYQE-UHFFFAOYSA-N; AC1L3Y3S; SCHEMBL5078854; 4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; (+)-2-methylamino-4-(1-(2-fluoro-4-biphenylyl)ethyl)thiazole; 4-[1-(3-fluoro-4-phenylphenyl)ethyl]-N-methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 4-(1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-N-methyl-"	124238	Discontinued in Phase 2	D0Q0AJ	.	CTPDG006455
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Zolimomab aritox	XomaZyme-CD5 Plus; XomaZyme-H65; XomaZyme-lym; OrthoZyme-CD5+; Xmmly-h65-rta; XomaZyme-H65-rta	.	Discontinued in Phase 2	D0O2QB	.	CTPDG006464
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CP-195543	"LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer"	9823886	Discontinued in Phase 2	D0MM2K	DB13053	CTPDG006475
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MLN3897	.	.	Discontinued in Phase 2	D0KF6X	.	CTPDG006490
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-5751	"AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid"	9867949	Discontinued in Phase 2	D0K0VH	.	CTPDG006494
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MP-435	"C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe"	.	Discontinued in Phase 2	D0H0ZU	.	CTPDG006510
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CPA-926	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one	9800054	Discontinued in Phase 2	D0G6PG	.	CTPDG006516
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SINOMENINE	"Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one"	5459308	Discontinued in Phase 2	D0F9WF	.	CTPDG006522
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Linetastine	"Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Molecule 26"	6439232	Discontinued in Phase 2	D0E8UV	.	CTPDG006530
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SC-106	AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid	492984	Discontinued in Phase 2	D0D3KY	.	CTPDG006539
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PRO-515	.	.	Discontinued in Phase 2	D09FEN	.	CTPDG006572
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GW-215864	GR-215864; GR-215864X; GW-215864X	56841560	Discontinued in Phase 2	D09AUP	.	CTPDG006573
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HSR-609	"FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate"	3081352	Discontinued in Phase 2	D08RZV	.	CTPDG006576
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AnergiX.RA	"AG-4263; RA-AnergiX; Antigen specific therapy (rheumatoid arthritis, AnergiX), Corixa/ Organon"	.	Discontinued in Phase 2	D07BEE	.	CTPDG006598
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GLPG-0259	"G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562"	44462738	Discontinued in Phase 2	D06NPB	DB15190	CTPDG006604
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NN8209	.	.	Discontinued in Phase 2	D05ILZ	.	CTPDG006618
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IDEC-151	Clenoliximab	.	Discontinued in Phase 2	D04ZLG	.	CTPDG006624
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	Discontinued in Phase 2	D04DUJ	.	CTPDG006634
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NPC-567	"Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-"	119343	Discontinued in Phase 2	D03ZBM	.	CTPDG006637
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	T-5224	AKOS003047196; T5224	23626877	Discontinued in Phase 2	D02LCL	.	CTPDG006652
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AD-121	"PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest"	.	Discontinued in Phase 1/2	D06YFO	.	CTPDG006694
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AME-527	.	.	Discontinued in Phase 1/2	D05RTF	.	CTPDG006696
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-4629991	"PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer"	.	Discontinued in Phase 1	D0N8AB	.	CTPDG006767
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	NN8210	.	.	Discontinued in Phase 1	D0MT7W	.	CTPDG006774
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	ARRY-614	"Pexmetinib; 945614-12-0; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	Discontinued in Phase 1	D0ML0L	.	CTPDG006775
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Oncolysin CD6	Anti-CD6-bR; Anti-T12-bR	.	Discontinued in Phase 1	D0L4SB	.	CTPDG006784
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Eltenac	BY-820; B-788-20	51717	Discontinued in Phase 1	D0JF6O	.	CTPDG006796
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RG-4934	"IL-17 huMAb (psoriatic arthritis), Roche"	.	Discontinued in Phase 1	D0J8JF	.	CTPDG006797
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AC-100	"Bicyclo[4.2.0]octa-1,3,5-trien-3-ylboronic acid; BENZOCYCLOBUTANE-4-BORONIC ACID; Boronic acid, bicyclo[4.2.0]octa-1,3,5-trien-3-yl-; SCHEMBL12759201; KS-00000SRU; MolPort-005-942-889; ZINC196051840; AKOS025146995; DS-8536; BC225113; AK164312; 1,2-Dihydrobenzocyclobutene-4-ylboranic acid; CS-0043999; J3.522.588I; 4-bbcb                                             benzocyclobutene-4-boronic acid"	11171056	Discontinued in Phase 1	D0J6PR	.	CTPDG006798
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Roquinimex	Linomide	54676478	Discontinued in Phase 1	D0G9ZW	DB11366	CTPDG006812
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	D-1367	"167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-"	15259989	Discontinued in Phase 1	D0E8MW	.	CTPDG006818
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AVE-9940	.	.	Discontinued in Phase 1	D08CQE	.	CTPDG006862
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	LY-231617	"2,6-Di-tert-butyl-4-(ethylaminomethyl)phenol hydrochloride"	3968	Discontinued in Phase 1	D05XYC	.	CTPDG006882
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	CI-972	.	135418360	Discontinued in Phase 1	D05UPB	.	CTPDG006883
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R1295	CHEMBL2146615	70329	Discontinued in Phase 1	D04XJM	.	CTPDG006893
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	KB-2683	.	129748	Discontinued in Phase 1	D03LXJ	.	CTPDG006908
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-6703	"P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca"	11373432	Discontinued in Phase 1	D03KWN	.	CTPDG006909
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SC-57666	CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	Discontinued in Phase 1	D02OHR	.	CTPDG006916
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	C-5997	"7709-58-2; 4-(Chloromethyl)thiazole hydrochloride; 4-(chloromethyl)-1,3-thiazole Hydrochloride; 4-(chloromethyl)thiazole hcl; 4-chloromethylthiazole hydrochloride; 4-chloromethylthiazole hcl; 4-(chloromethyl)thiazolehcl; C4H4ClNS.ClH; ACMC-1BBSC; chloromethylthiazole-4 hcl; AC1Q3BH9; AC1MC82W; SCHEMBL122926; 4-(Chloromethyl)thiazole, HCl; CTK6H6834; DTXSID60376874; NVTBASMQHFMANH-UHFFFAOYSA-N; MolPort-000-139-475; 4-(chloromethyl)thiazole HCl salt; ACT02312; KS-000004ND; ANW-36949; 4-chloromethyl thiazole hydrochloride"	2763289	Discontinued in Phase 1	D01CBV	.	CTPDG006932
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-755616	.	.	Discontinued in Phase 1	D00FGY	.	CTPDG006939
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	GP2015	.	.	Application submitted	D0K9SS	.	CTPDG006944
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	SR1555	"CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675"	71470549	Preclinical	DW5R6Y	.	CTPDG006962
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	MCP-1	.	.	Preclinical	D0V9ND	.	CTPDG007038
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NPC-17923	"147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-"	9824607	Terminated	D0Z3AK	.	CTPDG007165
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	TM-31	.	.	Terminated	D0Y9CC	.	CTPDG007170
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BCX-25	BCX-14	.	Terminated	D0V2ZJ	.	CTPDG007200
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BB-1433	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241	101708593	Terminated	D0V0RW	.	CTPDG007202
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	ZK-90695	.	.	Terminated	D0US3C	.	CTPDG007203
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RP-54745	"RP 54745; 135330-08-4; AC1L2PX8; SCHEMBL4362761; rp54745; CS-6750; 4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one; HY-101716; 4-chloro-5-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)dithiol-3-one; 3H-1,2-Dithiol-3-one, 4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-"	126203	Terminated	D0T0LO	.	CTPDG007223
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	Terminated	D0R5TT	.	CTPDG007238
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Seprilose	GW-80126	60818	Terminated	D0Q5ZN	.	CTPDG007243
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NOX-200	"2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478"	95438	Terminated	D0OX9Q	.	CTPDG007255
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SAN-18	.	.	Terminated	D0M8QG	.	CTPDG007278
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	CI-986	"CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate"	3037017	Terminated	D0L8RG	.	CTPDG007289
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-6942	"CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca"	.	Terminated	D0I9YI	.	CTPDG007324
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	3-DEAZAADENOSINE	"Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine"	23190	Terminated	D0I7TN	DB04546	CTPDG007326
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-28342	.	9882188	Terminated	D0H0IA	.	CTPDG007341
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AG-2024	.	.	Terminated	D0G2CL	.	CTPDG007350
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Ro-31-4724	CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	Terminated	D0EF7V	DB08482	CTPDG007361
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-33516	.	.	Terminated	D0DR3I	.	CTPDG007371
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	D-5410	CH-138; CH-263	.	Terminated	D09TRM	.	CTPDG007412
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SKF-104351	"111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole"	122656	Terminated	D09SCI	.	CTPDG007413
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RWJ-63556	.	9882374	Terminated	D08JKK	.	CTPDG007441
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	YM-26734	"YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1"	9853400	Terminated	D07OGR	.	CTPDG007458
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD5672	"CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide"	11614352	Terminated	D07GIB	.	CTPDG007463
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-16276-1	.	.	Terminated	D06MTM	.	CTPDG007476
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-111142	WF-2015A	9909502	Terminated	D06AKJ	.	CTPDG007482
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BW A4C	"BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide"	6438354	Terminated	D05WPQ	.	CTPDG007485
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-48989	"WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile"	132006	Terminated	D04YNI	.	CTPDG007505
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-133605	.	.	Terminated	D04SVB	.	CTPDG007508
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SR-26831	"SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate"	132270	Terminated	D03GII	.	CTPDG007535
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	GDC-0834	"1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz"	25234918	Terminated	D03FUO	.	CTPDG007536
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	Terminated	D01QRG	.	CTPDG007565
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	LY-221068	"LY 221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-"	6439333	Terminated	D01QAR	.	CTPDG007566
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	DPC-333	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide	9847838	Terminated	D01DVX	.	CTPDG007574
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	PXS-2076	"PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis"	.	Terminated	D01DTQ	.	CTPDG007575
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ODN-1411	.	.	Investigative	D5S7JL	.	CTPDG007609
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	Investigative	D0YK4L	.	CTPDG007651
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	Investigative	D0Y4ZI	.	CTPDG007665
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BFPT-16864	BFPT-6864; BRFD-104	.	Investigative	D0XP3A	.	CTPDG007695
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Arthromir	.	.	Investigative	D0WI1L	.	CTPDG007743
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	SPX-601	.	.	Investigative	D0VB2K	.	CTPDG007786
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-814	"Hsp60 peptide (juvenile idiopathic arthritis), CIGB"	.	Investigative	D0V5VA	.	CTPDG007796
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD40-XTEN	"CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0V3HC	.	CTPDG007800
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	X-071-NAB	"NATHMAB (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech; Natural/true human monoclonal antibody (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech"	.	Investigative	D0U2OQ	.	CTPDG007838
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TENOSAL	MR-Y134; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	Investigative	D0T3KZ	.	CTPDG007862
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DW-908	DW-0908	.	Investigative	D0R4NJ	.	CTPDG007910
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	Investigative	D0N8TM	.	CTPDG008032
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	MDDR 217769	"(E)-2-(4,6-Difluoroindan-1-ylidene)acetamide"	.	Investigative	D0N8JJ	.	CTPDG008033
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FKB327	.	.	Investigative	D0L8UQ	.	CTPDG008105
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DMARDs	"DMARDs (oral, rheumatoid arthritis); DMARDs (oral, rheumatoid arthritis), Abbott; Disease-modifying antirheumatic drugs (oral, rheumatoid arthritis), Abbott"	.	Investigative	D0L2BT	.	CTPDG008121
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TX-RAD	"RA1-TX; RA1-TX (ankylosing spondylitis), TxCell; RA1-TX (rheumatoid arthritis), TxCell; RA1-TX (psoriatic arthritis,inflammatory disease), TxCell"	.	Investigative	D0K8BO	.	CTPDG008134
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	UR-5269	"Rheumatoid arthritis therapy, UBE Industries"	.	Investigative	D0J7XN	.	CTPDG008168
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	AVX-002	.	.	Investigative	D0J4TX	.	CTPDG008173
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-125	"Synoviocyte inhibitor + glucocorticoid (arthritis), Xaragen"	.	Investigative	D0I9FQ	.	CTPDG008191
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DWJ-425	"DW-Ab2; MAb (RA), Daewoong; Monoclonal antibody (rheumatoid arthritis), Daewoong"	.	Investigative	D0I4MW	.	CTPDG008211
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	HL-1020	"Grape seed proanthocyanidin extract (rheumatoid arthritis), Hanlim"	.	Investigative	D0G8EI	.	CTPDG008263
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-120	"Synoviocyte inhibitor + DMARD (arthritis), Xaragen"	.	Investigative	D0G2GZ	.	CTPDG008276
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-115	"Synoviocyte inhibitor + NSAID (arthritis), Xaragen"	.	Investigative	D0F8BR	.	CTPDG008296
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CTLA-4-XTEN	"Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0EZ9C	.	CTPDG008324
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Nano-steroid	"Steroidal anti-inflammatory (slow release nanoparticle formulation), LTT Bio-Pharma; Steroids (sustained release nanoparticles), LTT Bio-Pharma/Cipra; Steroidal anti-inflammatory (rheumatoid arthritis/collagen disease), LTT Bio-Pharma"	.	Investigative	D0B9XM	.	CTPDG008440
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	YD-101	.	.	Investigative	D0B3KI	.	CTPDG008455
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	KI-0906	.	.	Investigative	D0A2RF	.	CTPDG008498
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FHT-401	"PTD-conjugated methotrexate (transdermal, rheumatoid arthritis), ForHumanTech/Hyundai"	.	Investigative	D0A0FI	.	CTPDG008502
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TCH-013	"NF-kB inhibitors (rheumatoid arthritis); NF-kB inhibitors (rheumatoid arthritis), TCH Pharmaceuticals"	76850167	Investigative	D09TVH	.	CTPDG008515
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD97 mab	"Anti-CD97 monoclonal antibody (rheumatoid arthritis); Anti-CD97 mAb (RA), Organon/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Organon/AMC; Anti-CD97 mAb (RA), Schering-Plough/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Merck & Co/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Schering-Plough/AMC"	.	Investigative	D09RGS	.	CTPDG008524
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-55	.	.	Investigative	D09NQD	.	CTPDG008534
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Dendritic cell-based immunotherapy	"Dendritic cell-based immunotherapy (rheumatoid arthritis); Dendritic cell-based immunotherapy (rheumatoid arthritis), Dendright; Dendritic cell-based immunotherapy (rheumatoid arthritis, injectable formulation), Dendright"	.	Investigative	D07OCM	.	CTPDG008673
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	RT-401	"BoNTA protein (topical, rhinitis), Revance"	.	Investigative	D07JPL	.	CTPDG008692
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	VVZ-138	VVZ-000138	.	Investigative	D07GFZ	.	CTPDG008699
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	IG-AI-025	.	.	Investigative	D06XXD	.	CTPDG008716
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CHR-4487	"Esterase-sensitive motif compounds (inflammatory disease); Esterase-sensitive motif compounds (inflammatory disease), Chroma Therapeutics"	.	Investigative	D06HWU	.	CTPDG008757
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ROSMARINIC ACID	"20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid"	5281792	Investigative	D05PTT	.	CTPDG008813
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CT-340	"TrkA kinase inhibitor (polyoxyethylene conjugated, LSE, arthritis, scarring, pain), Creabilis"	.	Investigative	D05KRS	.	CTPDG008827
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ADR58	.	.	Investigative	D04VCF	.	CTPDG008856
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CEL-2000	"T-cell modulating vaccine (LEAPS, rheumatoid arthritis), CEL-SCI"	.	Investigative	D03XSX	.	CTPDG008918
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FM-201	.	.	Investigative	D03TKI	.	CTPDG008933
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BMS-345541	"445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05"	9926054	Investigative	D00YTQ	.	CTPDG009140
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CAT-2200	"MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)"	.	Investigative	D00XNC	.	CTPDG009145
M6ACROT05369	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	OCT-SG815	"OPG secretagogues (osteoporosis/arthritis), Oscotec; Osteoprotegerin secretagogues (osteoporosis/arthritis), Oscotec; OPG secretagogues (osteoporosis/arthritis), KT&G; Osteoprotegerin secretagogues (osteoporosis/arthritis), KT&G"	.	Investigative	D00QOH	.	CTPDG009161
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	Kevzara	.	Approved	D0Z8CQ	.	CTPDG000029
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulindac	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	1548887	Approved	D0Z5IU	DB00605	CTPDG000031
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Felbinac	"Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda"	3332	Approved	D0Y7EM	DB07477	CTPDG000057
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Salsalate	"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid"	5161	Approved	D0Y0JH	DB01399	CTPDG000063
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Fostamatinib	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]	11671467	Phase 3	D0V8HJ	DB12010	CTPDG000102
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Methotrexate	"Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	126941	Phase 3	D0SV8E	DB00563	CTPDG000144
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IPI-145	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;	50905713	Phase 3	D0RU0O	DB11952	CTPDG000166
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	Approved	D0R1RS	DB00328	CTPDG000188
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Inosine pranobex	Imunovir (TN)	135449284	Approved	D0Q2QU	.	CTPDG000206
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Citrofen	Citrofen (TN)	.	Approved	D0P6UK	.	CTPDG000218
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meclofenamate Sodium	.	4038	Approved	D0MN9K	.	CTPDG000266
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxaprozin	"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid"	4614	Approved	D0M9DC	DB00991	CTPDG000269
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Zinc salts	.	.	Approved	D0K8AA	.	CTPDG000300
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	Approved	D0K5KS	.	CTPDG000305
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Orthokine	Orthokine (TN)	.	Approved	D0J1PW	.	CTPDG000330
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	SK-1306X	Cararthron; Joins	.	Approved	D0IL0C	.	CTPDG000339
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	Approved	D0I6IB	DB00469	CTPDG000343
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	Approved	D0I5QX	.	CTPDG000345
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	Approved	D0G7FJ	DB00814	CTPDG000369
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Gold sodium thiomalate	Sodium aurothiomalate	22318	Approved	D0FH7C	DB09276	CTPDG000381
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Abatacept	Orencia (TN)	.	Approved	D0EW4L	.	CTPDG000397
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)"	9926791	Approved	D0EG1I	DB08895	CTPDG000400
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	OM-89	Subreum; UroVaxom; UroVaxon; OM-8980	.	Approved	D0E1VD	.	CTPDG000414
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rimexolone	"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)"	5311412	Approved	D0D2TN	DB00896	CTPDG000426
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	Approved	D0CA0P	.	CTPDG000432
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Alclofenac	"22131-79-9; Alclophenac; Prinalgin; Medifenac; Reufenac; Allopydin; Mervan; Alclofenacum; Alclofenaco; Zumaril; Neoston; Neosten; 2-(4-(Allyloxy)-3-chlorophenyl)acetic acid; [4-(Allyloxy)-3-chlorophenyl]acetic acid; Desinflam; Marvan Forte; 3-Chloro-4-(2-propenyloxy)benzeneacetic acid; (4-Allyloxy-3-chlorphenyl)essigsaeure; MY 101; Epinal; Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-; Alclofenacum [INN-Latin]; Alclofenaco [INN-Spanish]; UNII-M9CP5H21N8; W 7320; CHEBI:31183; EINECS 244-795-4"	30951	Approved	D0C6OQ	DB13167	CTPDG000435
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Careram	Iguratimod	124246	Approved	D0B8MZ	DB12233	CTPDG000450
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	Approved	D0A1PX	DB00712	CTPDG000472
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Nafcillin	"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	8982	Approved	D0A0JH	DB00607	CTPDG000473
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etofenamate	30544-47-9; Rheumon; Bayrogel; Rheumon gel; UNII-KZF0XM66JC; Etofenamatum [INN-Latin]; Etofenamato [INN-Spanish]; Bay d 1107; C18H18F3NO4; TVX 485; WHR 5020; EINECS 250-231-8; KZF0XM66JC; BRN 2953263; 2-(2-Hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate; 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate; WHR-5020; NCGC00016804-01; 2-(2-Hydroxyaethoxy)aethylester der flutenaminsaeure [German]; CAS-30544-47-9; 2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate	35375	Approved	D09YVX	DB08984	CTPDG000475
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	Approved	D09MGR	DB01628	CTPDG000489
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	Approved	D09FSG	.	CTPDG000501
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	Approved	D09BHB	DB00500	CTPDG000505
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)	.	Phase 2	D08WSY	.	CTPDG000511
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Leflunomide	"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide"	3899	Approved	D08ROP	DB01097	CTPDG000515
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Penicillamine	"D-Penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine"	5852	Approved	D08HZC	DB00859	CTPDG000523
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dimethyl Sulfoxide	Rimso-50	679	Approved	D08HVE	DB01093	CTPDG000524
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tocilizumab	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody	.	Approved	D08HPZ	.	CTPDG000526
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Benorilate	"5003-48-5; BENORYLATE; 4-acetamidophenyl 2-acetoxybenzoate; Benoral; Salipran; Benortan; Fenasprate; Fenasparate; Aspirin acetaminophen ester; Benorilato; Benorilato [Spanish]; p-Acetamidophenyl acetylsalicylate; Benorilatum [INN-Latin]; Benorilato [INN-Spanish]; UNII-W1QX9DV96G; p-N-Acetylaminophenylacetylsalicylate; TO 125; WIN 11450; 4'-(Acetamido)phenyl-2-acetoxybenzoate; 2-Acetoxy-4'-(acetamino)phenylbenzoate; CCRIS 1739; Benzoic acid, 2-(acetyloxy)-, 4-(acetylamino)phenyl ester; 4-Acetamidophenyl salicylate acet"	21102	Approved	D08GJO	DB13657	CTPDG000528
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Halopredone acetate	Haloart (TN)	91667	Approved	D08BDT	.	CTPDG000531
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Teriflunomide	.	54684141	Approved	D07QFP	DB08880	CTPDG009757
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Siponimod	BAF312	44599207	Phase 2	D07FKQ	DB12371	CTPDG000573
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxyphenbutazone	Tandearil	4641	Approved	D06ZPS	DB03585	CTPDG000587
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	FENBUFEN	"36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	Approved	D06LHG	DB08981	CTPDG000602
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexchlorpheniramine Maleate	Polaramine	5281070	Approved	D05ZGQ	DB09555	CTPDG000614
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Enbrel	.	.	Approved	D05LTY	.	CTPDG000635
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Fenoprofen	"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid"	3342	Approved	D03XYW	DB00573	CTPDG000689
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	Approved	D03RTS	DB00482	CTPDG000700
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sodium Succinate	"Disodium succinate; 150-90-3; Disodium butanedioate; Butanedioic acid, disodium salt; Succinic acid disodium salt; Soduxin; Jantaran sodny [Czech]; UNII-V8ZGC8ISR3; Succinic acid, disodium salt; FEMA No. 3277; CCRIS 3700; Sodium succinate dibasic; EINECS 205-778-7; V8ZGC8ISR3; Butanedioic acid, sodium salt (1:2); Succinic acid disodium salt anhydrous; Butanedioic acid disodium salt; sodium succinate (anhydrous); Jantaran sodny; Butanedioic acid disodium hexahydrate; Succinic acid, disodium salt, 99%, anhydrous"	9020	Approved	D03RCJ	.	CTPDG000703
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulfasalazine	599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Sulfasalizine	5339	Approved	D02ZTJ	DB00795	CTPDG000732
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	Kineret; Kineret (TN); Anakinra (USAN/INN)	.	Approved	D02DES	.	CTPDG000759
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Cyproheptadine	"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene"	2913	Approved	D00TLN	DB00434	CTPDG000802
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	Approved	D00HGB	DB04552	CTPDG000816
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Nipocalimab	.	.	Phase 2	DS69NO	.	CTPDG000882
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Nipocalimab?	.	.	Phase 3	DR5V8I	.	CTPDG000884
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	BI 695501	BI-695501)	.	Phase 3	D0Z4VX	.	CTPDG000966
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06410293	.	.	Phase 3	D0Y8TZ	.	CTPDG000976
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Flobufen	VUFB-16066; VUFB-17203	159476	Phase 3	D0X8VV	.	CTPDG000989
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	Phase 3	D0W2CX	DB12399	CTPDG001013
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP-2017	.	.	Phase 3	D0S7JN	.	CTPDG001055
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cartistem	"Stem cell therapy (cartilage disease/rheumatoid arthritis), Medipost"	.	Phase 3	D0OH5E	.	CTPDG001096
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IR-201	Seryl-glutaminyl-isoleucyl-valyl-asparaginyl-aspartyl-phenylalanyl-glutaminyl-lysyl-glycyl-aspartyl-isoleucyl-alanyl-glutamyl-glycyl-tyrosyl-serine	.	Phase 3	D0N3SA	.	CTPDG001116
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Esonarimod	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298	127998	Phase 3	D0MY7X	.	CTPDG001120
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CIPEMASTAT	"Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	Phase 3	D0MW3H	.	CTPDG001123
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Methylprednisolone	.	6741	Approved	D0LN1Z	DB00959	CTPDG001141
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	STI-002	.	.	Phase 3	D0I6UE	.	CTPDG001181
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MK-8808	.	.	Phase 1	D0GP8N	.	CTPDG001196
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 798	.	.	Phase 3	D0E8NJ	.	CTPDG001224
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06438179	.	.	Phase 3	D0D9HZ	.	CTPDG001236
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	.	44205240	Approved	D0D5FU	DB11817	CTPDG001241
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cilengitide	"188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)"	176873	Phase 3	D09ZXO	DB11890	CTPDG001287
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CEP-41750	.	.	Phase 3	D09WRG	.	CTPDG001291
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	.	.	Approved	D08SJT	.	CTPDG001320
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Andolast	"Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm"	65970	Phase 3	D08PGC	.	CTPDG001324
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Vanadate	"Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3"	516859	Phase 3	D08NCO	.	CTPDG001327
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	Phase 3	D08DGC	DB12193	CTPDG011311
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Spermidine	"Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, &gt; =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0"	1102	Phase 3	D08BXT	DB03566	CTPDG001337
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Varespladib methyl	"A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera"	9886917	Phase 3	D07KFB	DB05737	CTPDG001360
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 501	.	.	Phase 3	D06FMO	.	CTPDG001379
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	.	.	Approved	D06CXL	.	CTPDG001384
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Atacicept	.	.	Phase 2	D04YWM	.	CTPDG001412
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Tenidap	.	60712	Phase 3	D02RQT	DB13481	CTPDG001457
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LY3090106	Tibulizumab	.	Phase 1	D09JVK	.	CTPDG001558
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2/3	VX-509	"Decernotinib; Adelatinib; 944842-54-0; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	Phase 2/3	D04QWQ	DB12566	CTPDG001571
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D03ZYQ	.	CTPDG001574
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	CreaVax-RA	"Autologous DC therapy (injectable, rheumatoid arthritis), CreaGene; Autologous dendritic cell therapy (injectable, rheumatoid arthritis), CreaGene"	.	Phase 2a	D0U9OD	.	CTPDG001585
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	RhuDex	.	.	Phase 2a	D0J0KT	.	CTPDG001586
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cevidoplenib	"(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone; 1703788-21-9; 3N3H8BX897; AKOS040748110; BDBM196772; Cevidoplenib; Cevidoplenib [INN]; Cevidoplenib [WHO-DD]; CHEMBL3921923; CS-0039259; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; EX-A5914; HY-109082; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; MS-28778; SCHEMBL16653204; UNII-3N3H8BX897; US9212178, 1; YCZUBLQESBVOSH-IBGZPJMESA-N"	91754477	Phase 2	DY57LN	.	CTPDG001609
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Dazodalibep	VIB4920	.	Phase 2	DPDI65	.	CTPDG001652
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Natrunix	.	.	Phase 2	DOVW19	.	CTPDG001657
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-5718	"1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 920036-34-6; A860172; AKOS022178093; AMY21637; CS-0048281; FT-0702852; GS-5718; MFCD13183727; OKKLWSNHFSFXEM-UHFFFAOYSA-N; PB26872; SCHEMBL3606964; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate"	57443610	Phase 2	DF1T2W	.	CTPDG001727
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Branebrutinib	"(S)-4-(3-(2-BUTYNOYLAMINO)PIPERIDIN-1-YL)-5-FLUORO-2,3-DIMETHYL-1H-INDOLE-7-CARBOXAMIDE; (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 1912445-55-6; 1H-Indole-7-carboxamide, 5-fluoro-2,3-dimethyl-4-((3S)-3-((1-oxo-2-butyn-1-yl)amino)-1-piperidinyl)-; 4-((3S)-3-(2-BUTYNOYLAMINO)-1-PIPERIDINYL)-5-FLUORO-2,3-DIMETHYL-1HINDOLE-7-CARBOXAMIDE; 4-((3S)-3-(2-Butynoylamino)-1-piperidinyl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-((3S)-3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 7LBRZUYSHU; AC-31535; AKOS037649047; BCP29496; BDBM164638; BDBM166759; BMS986195; BMS986195; BMS986195; BMS-986195; Branebrutinib; Branebrutinib (BMS-986195); Branebrutinib (USAN); BRANEBRUTINIB [INN]; Branebrutinib [USAN]; BRANEBRUTINIB [WHO-DD]; BS-16393; C20H23FN4O2; CHEMBL4297674; CS-0043577; D11478; DB15347; EN300-2007801; EX-A2720; Example 223 [US20160115126A1]; GTPL9869; HY-112161; MFCD31631584; NSC807627; NSC-807627; Q50825082; s8832; SCHEMBL17699728; UNII-7LBRZUYSHU; US9688629, 123; US9688629, 223; VJPPLCNBDLZIFG-ZDUSSCGKSA-N; WHO 11026"	121293929	Phase 2	DE3VU1	DB15347	CTPDG001734
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vobarilizumab	ALX-0061	.	Phase 2	D9J6XV	.	CTPDG001766
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IRL201805	.	.	Phase 2	D9EHD7	.	CTPDG001767
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KPL-404	.	.	Phase 2	D3NSU0	.	CTPDG001824
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FK-3311	"116686-15-8; FK 3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	Phase 2	D0Z9YW	.	CTPDG001858
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-783	"Rheumatoid arthritis therapy (oral), Takeda Pharmaceutical"	.	Phase 2	D0Z4OQ	.	CTPDG001864
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Piclamilast	"144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL"	154575	Phase 2	D0Z2FB	DB01791	CTPDG001866
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ADL-5859	PF-04856880	46931003	Phase 2	D0W9ZT	.	CTPDG001918
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SBI-087	PF-05230895	.	Phase 2	D0W9QG	.	CTPDG001920
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SB-705498	501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504	9910486	Phase 2	D0VJ5N	DB11883	CTPDG001948
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-817399	.	44537841	Phase 2	D0UX2V	DB14941	CTPDG001971
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CFZ533	.	.	Phase 2	D0SD6V	.	CTPDG002036
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PD-360324	"PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer"	.	Phase 2	D0S1UZ	.	CTPDG002048
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MGCD-290	"MG-1; MG-3290; Histone deacetylase inhibitors (cardiovascular diseases), MethylGene; Histone deacetylase inhibitors (diabetes), MethylGene; Histone deacetylase inhibitors (fungal infection), MethylGene; Histone deacetylase inhibitors (inflammation), MethylGene; HDAC inhibitors (non-oncology), MethylGene; Histone deacetylase inhibitors (non-oncology), MethylGene"	3035813	Phase 2	D0RF3F	.	CTPDG002061
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Prednisone/ dipyridamole	Synavive (TN)	5865	Phase 2	D0R4NR	DB00635	CTPDG002071
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	QAL964	.	.	Phase 2	D0QZ3P	.	CTPDG002077
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	M2951	"evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin"	71479709	Phase 2	D0QX8X	DB15170	CTPDG002078
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AK-106-001616	.	.	Phase 2	D0QH5K	.	CTPDG002079
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABT-122	.	.	Phase 2	D0OX5H	.	CTPDG002123
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Meninge ACYW	.	.	Phase 2	D0OQ5W	.	CTPDG002127
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-715	"P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda"	9952773	Phase 2	D0O6ZO	.	CTPDG002136
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MPC-300-IV	.	.	Phase 2	D0MM0N	.	CTPDG002186
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Anti-LT alpha	.	.	Phase 2	D0L1OC	.	CTPDG002241
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NNC-0151-0000-0000	"Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk"	.	Phase 2	D0J4PM	.	CTPDG002288
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-945429	.	.	Phase 2	D0J1KS	.	CTPDG002291
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ONO-4641	"Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono"	11502996	Phase 2	D0I2RB	.	CTPDG002320
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNT0-1959	.	.	Phase 2	D0HT2X	.	CTPDG002325
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	Phase 2	D0HG5M	DB13020	CTPDG002328
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FLUASTERONE	HE-2500; 16alpha-Fluoroandrost-5-en-17-one	133967	Phase 2	D0H9YO	DB06250	CTPDG002329
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-4059	"tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno"	54755438	Phase 2	D0H0KH	DB15227	CTPDG002346
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VVZ-149	VVZ-000149	.	Phase 2	D0G9OH	.	CTPDG002358
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MRC-375	"Tetracycline (enteric-coated oral tablet, rheumatoid arthritis), Molecular Research Center Inc"	.	Phase 2	D0F9NA	.	CTPDG002393
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AWD-12-281	"GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline"	6918428	Phase 2	D0F4TV	.	CTPDG002402
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	APX-001	"EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics"	44123754	Investigative	D0DL3W	DB15183	CTPDG002437
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SR-31747	SR-317417A	6439330	Phase 2	D0D4JI	DB05792	CTPDG002454
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BI 655064	.	.	Phase 2	D0C8NG	.	CTPDG002478
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK3196165	.	.	Phase 2	D0C7ZB	.	CTPDG002482
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK315234	Oncostatin M mAb	.	Phase 2	D0C4YQ	.	CTPDG002485
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GS-9876	"XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr"	118161062	Phase 1	D0BW6F	DB14770	CTPDG002497
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TZI-41078	"3,5-Di-tert-butyl-4-hydroxybenzophenone oxime"	.	Phase 2	D0B6VN	.	CTPDG002510
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNTO-6785	.	.	Phase 2	D0A7NZ	.	CTPDG002538
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AMG-714	.	.	Discontinued in Phase 1	D0A5EN	.	CTPDG002547
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	LX2931	.	135564845	Phase 2	D09ZWH	DB06297	CTPDG002552
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VAY736	.	.	Phase 2	D09SQM	.	CTPDG002563
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KB002/003	.	.	Phase 2	D09SJE	.	CTPDG002564
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-180575	"2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide"	9930560	Phase 2	D09OTU	.	CTPDG002571
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rabeximod	"Rob-803; B-220 analog (RA), OxyPharma; B-220 analog (rheumatoid arthritis), OxyPharma"	56841552	Phase 2	D09BDH	DB05772	CTPDG002587
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BIIB 023	.	.	Phase 2	D08YHB	.	CTPDG002598
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Baminercept	"BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec"	.	Phase 2	D08XVR	.	CTPDG002599
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-06823859	.	.	Phase 2	D08RDD	.	CTPDG002615
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MK-8457	.	53251506	Phase 2	D08PXL	.	CTPDG002620
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP323	"Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01"	23394557	Phase 2	D08MJO	.	CTPDG002628
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	.	9926791	Approved	D08ICX	DB08895	CTPDG002636
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-986142	"Unii-pjx9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide"	86582336	Phase 2	D08AOZ	DB15291	CTPDG002651
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8765	.	.	Phase 2	D07YNM	.	CTPDG002655
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AMG0714	HuMax-IL15	.	Phase 2	D07LCA	.	CTPDG002686
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Fosbretabulin	Zybrestat (TN)	5351387	Phase 2	D07JVO	DB12577	CTPDG002693
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rimacalib	SMP-114	9800765	Phase 2	D06PHH	DB12571	CTPDG002739
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Mavrilimumab	.	.	Phase 2	D06KCF	.	CTPDG002750
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CCX-354	CCX-354-C; GSK2941266	135565361	Phase 2	D05VTN	DB12963	CTPDG002783
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	[L/D]-aminopterin	.	.	Phase 2	D05QPC	.	CTPDG002790
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALX-0061	"Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx"	.	Phase 2	D05NIR	.	CTPDG002795
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Ozoralizumab	ATN-103	.	Phase 2	D05EPV	.	CTPDG002814
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	JNJ-38518168	.	23650961	Phase 2	D04VBF	DB12522	CTPDG002835
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	UCB-35440	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide	9894415	Phase 2	D04JIM	.	CTPDG002862
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Otilimab	.	.	Phase 3	D04GWO	.	CTPDG002865
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Pegsunercept	STNF-R1	.	Phase 2	D04GTA	.	CTPDG002866
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AD-452	RS(+)-mefloquine; (+)-erythro-mefloquine	.	Phase 2	D03YKQ	.	CTPDG002884
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-240612	"N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride"	44235958	Phase 2	D03UVL	.	CTPDG002897
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TOK-8801	"105963-46-0; Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide; Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; Tok 8801; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide; Imidazo(2,1-b)thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; AC1L3UYM; ACMC-20m9c6; SCHEMBL9774378; CTK4A4247; AKOS030604802"	122628	Phase 2	D03UIB	.	CTPDG002898
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D03RIX	.	CTPDG002908
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PG-760564	"Rheumatoid arthritis therapy, Procter & Gamble"	.	Phase 2	D03PBW	.	CTPDG002912
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Peresolimab	.	.	Phase 2	D02XFH	.	CTPDG002947
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-04171327	"Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317"	24872952	Phase 2	D01PLR	DB12198	CTPDG003019
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MANOALIDE	"UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975"	6437368	Phase 2	D00XQO	.	CTPDG003057
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cenplacel-L	PDA-001	.	Phase 2	D00UGX	.	CTPDG003062
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BT-016	Tregalizumab	.	Phase 2	D00PUT	.	CTPDG003072
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Xmab 5871	XmAb 5871 (TN)	.	Phase 1/2	D00NXT	.	CTPDG003076
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vidofludimus	717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644	9820008	Phase 2	D00LSI	DB15446	CTPDG003080
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	K-832	"10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9"	9844960	Phase 2	D00IUD	.	CTPDG003086
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	PRTX-100	Staphylococcal protein A	.	Phase 1/2	D0ZC6X	.	CTPDG003265
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Cx-611	"Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), Cellerix; Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), TiGenix"	.	Phase 1/2	D0T3HL	.	CTPDG003323
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	BIO-300	"Radioprotective therapy, Humanetics"	.	Phase 1/2	D0J2ES	.	CTPDG003405
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Chondrogen	Chondrogen (TN)	.	Phase 1/2	D09YVQ	.	CTPDG003481
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	.	3715	Approved	D06LFE	DB00328	CTPDG003540
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HM71224	"Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide"	56644522	Phase 1	DTF20P	.	CTPDG003715
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LABP-104	NIM-1324	.	Phase 1	DN2Z5C	.	CTPDG003811
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ORTD-1	.theta.-Defensin 1; 1-[3-[benzyl-tetrakis(3-guanidinopropyl)-[(1R)-1-hydroxyethyl]-isobutyl-isopropyl-[(1S)-1-methylpropyl]-octadecaoxo-[?]yl]propyl]guanidine; 251442-64-5; BDBM50236198; CHEMBL4073105; Cyclic-(GVCRCICTRGFCRCLCRR); DTXSID60179822; oRTD-1; RTD-1; theta-Defensin 1; theta-Defensin RTD-1	16130642	Phase 1	DH5F4M	.	CTPDG003897
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	JNJ-67484703	JNJ-4703	.	Phase 1	D4VLI7	.	CTPDG004107
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	IA-14069	.	.	Phase 1	D1ROU2	.	CTPDG004184
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BX-U001	.	.	Phase 1	D17OQM	.	CTPDG004201
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	KPE-06001	"Asthma/arthritis therapy, Kemin"	.	Phase 1	D0Z8PO	.	CTPDG004223
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	PF-05230905	ATN-192	.	Phase 1	D0Y0FZ	.	CTPDG004268
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RG6125	.	.	Phase 1	D0X8RS	.	CTPDG004281
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	TAK-020	.	.	Phase 1	D0VS3U	.	CTPDG004329
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AXS-06	.	.	Phase 1	D0VJ9X	.	CTPDG004331
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Aminoguanidine	"Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284"	2146	Discontinued in Phase 2	D0V0NL	DB05383	CTPDG004355
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	OPL-CCL2-LPM	"CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey"	.	Phase 1	D0U7PM	.	CTPDG004372
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVE1701	.	.	Phase 1	D0Q2BB	.	CTPDG004488
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVP-13358	"IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR"	9805635	Phase 1	D0P9YP	.	CTPDG004508
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Cadherin-11	SDP051	.	Phase 1	D0P5QB	.	CTPDG004517
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BF-389	"Biofor 389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029"	6439259	Phase 1	D0L6VH	.	CTPDG004624
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HMR-1031	"MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid"	9809368	Phase 1	D0L3DC	.	CTPDG004633
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VI7734	.	.	Phase 1	D0JC9K	.	CTPDG004677
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BMS-986104	"Unii-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-"	77050638	Phase 1	D0GG7L	DB15214	CTPDG004765
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AMAP-102	"5-HT antagonist (rheumatism), AnaMar"	.	Phase 1	D0G7BR	.	CTPDG004771
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Sc Veltuzumab	.	.	Phase 1	D0D8NG	.	CTPDG004853
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MORAb-022	"Antibody (inflammation/autoimmune disease), Morphotek"	.	Phase 1	D0B0VD	.	CTPDG004925
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ARG301	.	.	Phase 1	D09PJB	.	CTPDG004987
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SCH-900117	.	.	Phase 1	D08YWY	.	CTPDG005018
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	DWP-422	.	.	Phase 1	D08SXV	.	CTPDG005031
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VEL-0230	"NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar"	25102841	Phase 1	D07BIK	.	CTPDG005126
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Synthetic neutrophil inhibitor peptide	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide	71482	Phase 1	D07ANO	.	CTPDG005128
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RWJ-67657	215303-72-3; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	Phase 1	D06OZJ	.	CTPDG005150
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI4920	.	.	Phase 1	D06HNO	.	CTPDG005164
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RPI-78M	"Antiviral agent, Receptogen; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm"	.	Discontinued in Phase 1	D05FVK	.	CTPDG005210
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP2408	CTLA4-Ig fusion protein	.	Phase 1	D04OQU	.	CTPDG005246
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK3117391	.	53630042	Phase 1	D04KMQ	DB15440	CTPDG005255
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ABBV-257	.	.	Phase 1	D04DQO	.	CTPDG005266
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VGX-1027	"6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590"	10798271	Phase 1	D03QEB	.	CTPDG005296
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK-1827771	"IL-1 antagonist (antibody, rheumatoid arthritis), GSK"	.	Phase 1	D03FVR	.	CTPDG005318
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP5094	.	.	Phase 1	D03ACE	.	CTPDG005331
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	EVT 401	.	.	Phase 1	D01TLV	.	CTPDG005379
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SKI-O-703	.	.	Phase 1	D01IDW	.	CTPDG005409
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Clinical trial	AZ-4217	AZ4217; AZ 4217	57406537	Clinical trial	D00XKB	.	CTPDG005509
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Floctafenine	"23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline"	3360	Withdrawn from market	D0AK5R	DB08976	CTPDG006315
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Aurothioglucose	HMS3262I11; LP00685	454937	Withdrawn from market	D0A4BR	.	CTPDG006316
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Preregistration	Amiprilose	Therafectin; Amiprilose hydrochloride; KAP-690; SM-1213	121928	Discontinued in Preregistration	D07MEL	.	CTPDG006326
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	Nerelimomab	BAY-X-1351	.	Discontinued in Phase 3	D0VW2Z	.	CTPDG006333
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	M-5010	M-5011; T-3788; 2(R)-[4-(3-Methyl-2-thienyl)phenyl]propionic acid	12769847	Discontinued in Phase 3	D0RJ0J	.	CTPDG006340
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	BR3-Fc	.	.	Discontinued in Phase 2	D0YA0N	.	CTPDG006399
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	EFLETIRIZINE	Efletirizine < Rec INN; Ucb-28754; 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid	66003	Discontinued in Phase 2	D0XK4R	.	CTPDG006402
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IX207-887	.	6509858	Discontinued in Phase 2	D0X2PQ	.	CTPDG006407
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AMG 108	.	444499	Discontinued in Phase 2	D0W7VG	.	CTPDG006413
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HR325	.	66583751	Discontinued in Phase 2	D0SX4K	.	CTPDG006435
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	TA-383	"Cis-2-(4-Chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride; Cis-2-(4-Chlorophenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole hydrochloride"	131180	Discontinued in Phase 2	D0R2CM	.	CTPDG006447
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	Discontinued in Phase 2	D0Q9ZD	.	CTPDG006450
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SM-8849	"113759-19-6; 4-(1-(2-fluoro-4-biphenylyl)ethyl)-2-methylaminothiazole; 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole; ZTFDMDJGJVUYQE-UHFFFAOYSA-N; AC1L3Y3S; SCHEMBL5078854; 4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; (+)-2-methylamino-4-(1-(2-fluoro-4-biphenylyl)ethyl)thiazole; 4-[1-(3-fluoro-4-phenylphenyl)ethyl]-N-methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 4-(1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-N-methyl-"	124238	Discontinued in Phase 2	D0Q0AJ	.	CTPDG006455
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Zolimomab aritox	XomaZyme-CD5 Plus; XomaZyme-H65; XomaZyme-lym; OrthoZyme-CD5+; Xmmly-h65-rta; XomaZyme-H65-rta	.	Discontinued in Phase 2	D0O2QB	.	CTPDG006464
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CP-195543	"LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer"	9823886	Discontinued in Phase 2	D0MM2K	DB13053	CTPDG006475
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MLN3897	.	.	Discontinued in Phase 2	D0KF6X	.	CTPDG006490
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-5751	"AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid"	9867949	Discontinued in Phase 2	D0K0VH	.	CTPDG006494
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MP-435	"C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe"	.	Discontinued in Phase 2	D0H0ZU	.	CTPDG006510
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CPA-926	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one	9800054	Discontinued in Phase 2	D0G6PG	.	CTPDG006516
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SINOMENINE	"Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one"	5459308	Discontinued in Phase 2	D0F9WF	.	CTPDG006522
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Linetastine	"Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Molecule 26"	6439232	Discontinued in Phase 2	D0E8UV	.	CTPDG006530
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SC-106	AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid	492984	Discontinued in Phase 2	D0D3KY	.	CTPDG006539
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PRO-515	.	.	Discontinued in Phase 2	D09FEN	.	CTPDG006572
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GW-215864	GR-215864; GR-215864X; GW-215864X	56841560	Discontinued in Phase 2	D09AUP	.	CTPDG006573
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HSR-609	"FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate"	3081352	Discontinued in Phase 2	D08RZV	.	CTPDG006576
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AnergiX.RA	"AG-4263; RA-AnergiX; Antigen specific therapy (rheumatoid arthritis, AnergiX), Corixa/ Organon"	.	Discontinued in Phase 2	D07BEE	.	CTPDG006598
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GLPG-0259	"G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562"	44462738	Discontinued in Phase 2	D06NPB	DB15190	CTPDG006604
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NN8209	.	.	Discontinued in Phase 2	D05ILZ	.	CTPDG006618
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IDEC-151	Clenoliximab	.	Discontinued in Phase 2	D04ZLG	.	CTPDG006624
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	Discontinued in Phase 2	D04DUJ	.	CTPDG006634
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NPC-567	"Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-"	119343	Discontinued in Phase 2	D03ZBM	.	CTPDG006637
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	T-5224	AKOS003047196; T5224	23626877	Discontinued in Phase 2	D02LCL	.	CTPDG006652
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AD-121	"PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest"	.	Discontinued in Phase 1/2	D06YFO	.	CTPDG006694
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AME-527	.	.	Discontinued in Phase 1/2	D05RTF	.	CTPDG006696
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-4629991	"PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer"	.	Discontinued in Phase 1	D0N8AB	.	CTPDG006767
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	NN8210	.	.	Discontinued in Phase 1	D0MT7W	.	CTPDG006774
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	ARRY-614	"Pexmetinib; 945614-12-0; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	Discontinued in Phase 1	D0ML0L	.	CTPDG006775
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Oncolysin CD6	Anti-CD6-bR; Anti-T12-bR	.	Discontinued in Phase 1	D0L4SB	.	CTPDG006784
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Eltenac	BY-820; B-788-20	51717	Discontinued in Phase 1	D0JF6O	.	CTPDG006796
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RG-4934	"IL-17 huMAb (psoriatic arthritis), Roche"	.	Discontinued in Phase 1	D0J8JF	.	CTPDG006797
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AC-100	"Bicyclo[4.2.0]octa-1,3,5-trien-3-ylboronic acid; BENZOCYCLOBUTANE-4-BORONIC ACID; Boronic acid, bicyclo[4.2.0]octa-1,3,5-trien-3-yl-; SCHEMBL12759201; KS-00000SRU; MolPort-005-942-889; ZINC196051840; AKOS025146995; DS-8536; BC225113; AK164312; 1,2-Dihydrobenzocyclobutene-4-ylboranic acid; CS-0043999; J3.522.588I; 4-bbcb                                             benzocyclobutene-4-boronic acid"	11171056	Discontinued in Phase 1	D0J6PR	.	CTPDG006798
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Roquinimex	Linomide	54676478	Discontinued in Phase 1	D0G9ZW	DB11366	CTPDG006812
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	D-1367	"167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-"	15259989	Discontinued in Phase 1	D0E8MW	.	CTPDG006818
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AVE-9940	.	.	Discontinued in Phase 1	D08CQE	.	CTPDG006862
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	LY-231617	"2,6-Di-tert-butyl-4-(ethylaminomethyl)phenol hydrochloride"	3968	Discontinued in Phase 1	D05XYC	.	CTPDG006882
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	CI-972	.	135418360	Discontinued in Phase 1	D05UPB	.	CTPDG006883
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R1295	CHEMBL2146615	70329	Discontinued in Phase 1	D04XJM	.	CTPDG006893
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	KB-2683	.	129748	Discontinued in Phase 1	D03LXJ	.	CTPDG006908
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-6703	"P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca"	11373432	Discontinued in Phase 1	D03KWN	.	CTPDG006909
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SC-57666	CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	Discontinued in Phase 1	D02OHR	.	CTPDG006916
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	C-5997	"7709-58-2; 4-(Chloromethyl)thiazole hydrochloride; 4-(chloromethyl)-1,3-thiazole Hydrochloride; 4-(chloromethyl)thiazole hcl; 4-chloromethylthiazole hydrochloride; 4-chloromethylthiazole hcl; 4-(chloromethyl)thiazolehcl; C4H4ClNS.ClH; ACMC-1BBSC; chloromethylthiazole-4 hcl; AC1Q3BH9; AC1MC82W; SCHEMBL122926; 4-(Chloromethyl)thiazole, HCl; CTK6H6834; DTXSID60376874; NVTBASMQHFMANH-UHFFFAOYSA-N; MolPort-000-139-475; 4-(chloromethyl)thiazole HCl salt; ACT02312; KS-000004ND; ANW-36949; 4-chloromethyl thiazole hydrochloride"	2763289	Discontinued in Phase 1	D01CBV	.	CTPDG006932
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-755616	.	.	Discontinued in Phase 1	D00FGY	.	CTPDG006939
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	GP2015	.	.	Application submitted	D0K9SS	.	CTPDG006944
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	SR1555	"CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675"	71470549	Preclinical	DW5R6Y	.	CTPDG006962
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	MCP-1	.	.	Preclinical	D0V9ND	.	CTPDG007038
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NPC-17923	"147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-"	9824607	Terminated	D0Z3AK	.	CTPDG007165
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	TM-31	.	.	Terminated	D0Y9CC	.	CTPDG007170
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BCX-25	BCX-14	.	Terminated	D0V2ZJ	.	CTPDG007200
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BB-1433	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241	101708593	Terminated	D0V0RW	.	CTPDG007202
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	ZK-90695	.	.	Terminated	D0US3C	.	CTPDG007203
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RP-54745	"RP 54745; 135330-08-4; AC1L2PX8; SCHEMBL4362761; rp54745; CS-6750; 4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one; HY-101716; 4-chloro-5-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)dithiol-3-one; 3H-1,2-Dithiol-3-one, 4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-"	126203	Terminated	D0T0LO	.	CTPDG007223
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	Terminated	D0R5TT	.	CTPDG007238
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Seprilose	GW-80126	60818	Terminated	D0Q5ZN	.	CTPDG007243
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NOX-200	"2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478"	95438	Terminated	D0OX9Q	.	CTPDG007255
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SAN-18	.	.	Terminated	D0M8QG	.	CTPDG007278
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	CI-986	"CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate"	3037017	Terminated	D0L8RG	.	CTPDG007289
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-6942	"CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca"	.	Terminated	D0I9YI	.	CTPDG007324
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	3-DEAZAADENOSINE	"Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine"	23190	Terminated	D0I7TN	DB04546	CTPDG007326
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-28342	.	9882188	Terminated	D0H0IA	.	CTPDG007341
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AG-2024	.	.	Terminated	D0G2CL	.	CTPDG007350
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Ro-31-4724	CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	Terminated	D0EF7V	DB08482	CTPDG007361
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-33516	.	.	Terminated	D0DR3I	.	CTPDG007371
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	D-5410	CH-138; CH-263	.	Terminated	D09TRM	.	CTPDG007412
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SKF-104351	"111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole"	122656	Terminated	D09SCI	.	CTPDG007413
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RWJ-63556	.	9882374	Terminated	D08JKK	.	CTPDG007441
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	YM-26734	"YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1"	9853400	Terminated	D07OGR	.	CTPDG007458
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD5672	"CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide"	11614352	Terminated	D07GIB	.	CTPDG007463
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-16276-1	.	.	Terminated	D06MTM	.	CTPDG007476
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-111142	WF-2015A	9909502	Terminated	D06AKJ	.	CTPDG007482
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BW A4C	"BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide"	6438354	Terminated	D05WPQ	.	CTPDG007485
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-48989	"WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile"	132006	Terminated	D04YNI	.	CTPDG007505
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-133605	.	.	Terminated	D04SVB	.	CTPDG007508
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SR-26831	"SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate"	132270	Terminated	D03GII	.	CTPDG007535
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	GDC-0834	"1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz"	25234918	Terminated	D03FUO	.	CTPDG007536
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	Terminated	D01QRG	.	CTPDG007565
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	LY-221068	"LY 221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-"	6439333	Terminated	D01QAR	.	CTPDG007566
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	DPC-333	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide	9847838	Terminated	D01DVX	.	CTPDG007574
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	PXS-2076	"PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis"	.	Terminated	D01DTQ	.	CTPDG007575
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ODN-1411	.	.	Investigative	D5S7JL	.	CTPDG007609
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	Investigative	D0YK4L	.	CTPDG007651
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	Investigative	D0Y4ZI	.	CTPDG007665
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BFPT-16864	BFPT-6864; BRFD-104	.	Investigative	D0XP3A	.	CTPDG007695
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Arthromir	.	.	Investigative	D0WI1L	.	CTPDG007743
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	SPX-601	.	.	Investigative	D0VB2K	.	CTPDG007786
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-814	"Hsp60 peptide (juvenile idiopathic arthritis), CIGB"	.	Investigative	D0V5VA	.	CTPDG007796
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD40-XTEN	"CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0V3HC	.	CTPDG007800
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	X-071-NAB	"NATHMAB (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech; Natural/true human monoclonal antibody (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech"	.	Investigative	D0U2OQ	.	CTPDG007838
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TENOSAL	MR-Y134; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	Investigative	D0T3KZ	.	CTPDG007862
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DW-908	DW-0908	.	Investigative	D0R4NJ	.	CTPDG007910
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	Investigative	D0N8TM	.	CTPDG008032
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	MDDR 217769	"(E)-2-(4,6-Difluoroindan-1-ylidene)acetamide"	.	Investigative	D0N8JJ	.	CTPDG008033
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FKB327	.	.	Investigative	D0L8UQ	.	CTPDG008105
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DMARDs	"DMARDs (oral, rheumatoid arthritis); DMARDs (oral, rheumatoid arthritis), Abbott; Disease-modifying antirheumatic drugs (oral, rheumatoid arthritis), Abbott"	.	Investigative	D0L2BT	.	CTPDG008121
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TX-RAD	"RA1-TX; RA1-TX (ankylosing spondylitis), TxCell; RA1-TX (rheumatoid arthritis), TxCell; RA1-TX (psoriatic arthritis,inflammatory disease), TxCell"	.	Investigative	D0K8BO	.	CTPDG008134
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	UR-5269	"Rheumatoid arthritis therapy, UBE Industries"	.	Investigative	D0J7XN	.	CTPDG008168
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	AVX-002	.	.	Investigative	D0J4TX	.	CTPDG008173
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-125	"Synoviocyte inhibitor + glucocorticoid (arthritis), Xaragen"	.	Investigative	D0I9FQ	.	CTPDG008191
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DWJ-425	"DW-Ab2; MAb (RA), Daewoong; Monoclonal antibody (rheumatoid arthritis), Daewoong"	.	Investigative	D0I4MW	.	CTPDG008211
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	HL-1020	"Grape seed proanthocyanidin extract (rheumatoid arthritis), Hanlim"	.	Investigative	D0G8EI	.	CTPDG008263
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-120	"Synoviocyte inhibitor + DMARD (arthritis), Xaragen"	.	Investigative	D0G2GZ	.	CTPDG008276
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-115	"Synoviocyte inhibitor + NSAID (arthritis), Xaragen"	.	Investigative	D0F8BR	.	CTPDG008296
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CTLA-4-XTEN	"Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0EZ9C	.	CTPDG008324
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Nano-steroid	"Steroidal anti-inflammatory (slow release nanoparticle formulation), LTT Bio-Pharma; Steroids (sustained release nanoparticles), LTT Bio-Pharma/Cipra; Steroidal anti-inflammatory (rheumatoid arthritis/collagen disease), LTT Bio-Pharma"	.	Investigative	D0B9XM	.	CTPDG008440
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	YD-101	.	.	Investigative	D0B3KI	.	CTPDG008455
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	KI-0906	.	.	Investigative	D0A2RF	.	CTPDG008498
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FHT-401	"PTD-conjugated methotrexate (transdermal, rheumatoid arthritis), ForHumanTech/Hyundai"	.	Investigative	D0A0FI	.	CTPDG008502
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TCH-013	"NF-kB inhibitors (rheumatoid arthritis); NF-kB inhibitors (rheumatoid arthritis), TCH Pharmaceuticals"	76850167	Investigative	D09TVH	.	CTPDG008515
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD97 mab	"Anti-CD97 monoclonal antibody (rheumatoid arthritis); Anti-CD97 mAb (RA), Organon/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Organon/AMC; Anti-CD97 mAb (RA), Schering-Plough/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Merck & Co/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Schering-Plough/AMC"	.	Investigative	D09RGS	.	CTPDG008524
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-55	.	.	Investigative	D09NQD	.	CTPDG008534
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Dendritic cell-based immunotherapy	"Dendritic cell-based immunotherapy (rheumatoid arthritis); Dendritic cell-based immunotherapy (rheumatoid arthritis), Dendright; Dendritic cell-based immunotherapy (rheumatoid arthritis, injectable formulation), Dendright"	.	Investigative	D07OCM	.	CTPDG008673
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	RT-401	"BoNTA protein (topical, rhinitis), Revance"	.	Investigative	D07JPL	.	CTPDG008692
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	VVZ-138	VVZ-000138	.	Investigative	D07GFZ	.	CTPDG008699
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	IG-AI-025	.	.	Investigative	D06XXD	.	CTPDG008716
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CHR-4487	"Esterase-sensitive motif compounds (inflammatory disease); Esterase-sensitive motif compounds (inflammatory disease), Chroma Therapeutics"	.	Investigative	D06HWU	.	CTPDG008757
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ROSMARINIC ACID	"20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid"	5281792	Investigative	D05PTT	.	CTPDG008813
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CT-340	"TrkA kinase inhibitor (polyoxyethylene conjugated, LSE, arthritis, scarring, pain), Creabilis"	.	Investigative	D05KRS	.	CTPDG008827
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ADR58	.	.	Investigative	D04VCF	.	CTPDG008856
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CEL-2000	"T-cell modulating vaccine (LEAPS, rheumatoid arthritis), CEL-SCI"	.	Investigative	D03XSX	.	CTPDG008918
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FM-201	.	.	Investigative	D03TKI	.	CTPDG008933
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BMS-345541	"445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05"	9926054	Investigative	D00YTQ	.	CTPDG009140
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CAT-2200	"MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)"	.	Investigative	D00XNC	.	CTPDG009145
M6ACROT05370	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	OCT-SG815	"OPG secretagogues (osteoporosis/arthritis), Oscotec; Osteoprotegerin secretagogues (osteoporosis/arthritis), Oscotec; OPG secretagogues (osteoporosis/arthritis), KT&G; Osteoprotegerin secretagogues (osteoporosis/arthritis), KT&G"	.	Investigative	D00QOH	.	CTPDG009161
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	Kevzara	.	Approved	D0Z8CQ	.	CTPDG000029
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulindac	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	1548887	Approved	D0Z5IU	DB00605	CTPDG000031
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Felbinac	"Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda"	3332	Approved	D0Y7EM	DB07477	CTPDG000057
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Salsalate	"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid"	5161	Approved	D0Y0JH	DB01399	CTPDG000063
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Fostamatinib	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]	11671467	Phase 3	D0V8HJ	DB12010	CTPDG000102
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Methotrexate	"Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate"	126941	Phase 3	D0SV8E	DB00563	CTPDG000144
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IPI-145	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;	50905713	Phase 3	D0RU0O	DB11952	CTPDG000166
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	Approved	D0R1RS	DB00328	CTPDG000188
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Inosine pranobex	Imunovir (TN)	135449284	Approved	D0Q2QU	.	CTPDG000206
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Citrofen	Citrofen (TN)	.	Approved	D0P6UK	.	CTPDG000218
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meclofenamate Sodium	.	4038	Approved	D0MN9K	.	CTPDG000266
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxaprozin	"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid"	4614	Approved	D0M9DC	DB00991	CTPDG000269
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Zinc salts	.	.	Approved	D0K8AA	.	CTPDG000300
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	Approved	D0K5KS	.	CTPDG000305
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Orthokine	Orthokine (TN)	.	Approved	D0J1PW	.	CTPDG000330
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	SK-1306X	Cararthron; Joins	.	Approved	D0IL0C	.	CTPDG000339
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	Approved	D0I6IB	DB00469	CTPDG000343
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	Approved	D0I5QX	.	CTPDG000345
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	Approved	D0G7FJ	DB00814	CTPDG000369
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Gold sodium thiomalate	Sodium aurothiomalate	22318	Approved	D0FH7C	DB09276	CTPDG000381
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Abatacept	Orencia (TN)	.	Approved	D0EW4L	.	CTPDG000397
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)"	9926791	Approved	D0EG1I	DB08895	CTPDG000400
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	OM-89	Subreum; UroVaxom; UroVaxon; OM-8980	.	Approved	D0E1VD	.	CTPDG000414
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rimexolone	"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)"	5311412	Approved	D0D2TN	DB00896	CTPDG000426
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	Approved	D0CA0P	.	CTPDG000432
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Alclofenac	"22131-79-9; Alclophenac; Prinalgin; Medifenac; Reufenac; Allopydin; Mervan; Alclofenacum; Alclofenaco; Zumaril; Neoston; Neosten; 2-(4-(Allyloxy)-3-chlorophenyl)acetic acid; [4-(Allyloxy)-3-chlorophenyl]acetic acid; Desinflam; Marvan Forte; 3-Chloro-4-(2-propenyloxy)benzeneacetic acid; (4-Allyloxy-3-chlorphenyl)essigsaeure; MY 101; Epinal; Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)-; Alclofenacum [INN-Latin]; Alclofenaco [INN-Spanish]; UNII-M9CP5H21N8; W 7320; CHEBI:31183; EINECS 244-795-4"	30951	Approved	D0C6OQ	DB13167	CTPDG000435
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Careram	Iguratimod	124246	Approved	D0B8MZ	DB12233	CTPDG000450
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	Approved	D0A1PX	DB00712	CTPDG000472
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Nafcillin	"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid"	8982	Approved	D0A0JH	DB00607	CTPDG000473
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etofenamate	30544-47-9; Rheumon; Bayrogel; Rheumon gel; UNII-KZF0XM66JC; Etofenamatum [INN-Latin]; Etofenamato [INN-Spanish]; Bay d 1107; C18H18F3NO4; TVX 485; WHR 5020; EINECS 250-231-8; KZF0XM66JC; BRN 2953263; 2-(2-Hydroxyethoxy)ethyl 2-((3-(trifluoromethyl)phenyl)amino)benzoate; 2-(2-hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate; WHR-5020; NCGC00016804-01; 2-(2-Hydroxyaethoxy)aethylester der flutenaminsaeure [German]; CAS-30544-47-9; 2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate	35375	Approved	D09YVX	DB08984	CTPDG000475
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	Approved	D09MGR	DB01628	CTPDG000489
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	Approved	D09FSG	.	CTPDG000501
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	Approved	D09BHB	DB00500	CTPDG000505
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Denosumab	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)	.	Phase 2	D08WSY	.	CTPDG000511
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Leflunomide	"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide"	3899	Approved	D08ROP	DB01097	CTPDG000515
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Penicillamine	"D-Penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine"	5852	Approved	D08HZC	DB00859	CTPDG000523
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dimethyl Sulfoxide	Rimso-50	679	Approved	D08HVE	DB01093	CTPDG000524
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tocilizumab	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody	.	Approved	D08HPZ	.	CTPDG000526
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Benorilate	"5003-48-5; BENORYLATE; 4-acetamidophenyl 2-acetoxybenzoate; Benoral; Salipran; Benortan; Fenasprate; Fenasparate; Aspirin acetaminophen ester; Benorilato; Benorilato [Spanish]; p-Acetamidophenyl acetylsalicylate; Benorilatum [INN-Latin]; Benorilato [INN-Spanish]; UNII-W1QX9DV96G; p-N-Acetylaminophenylacetylsalicylate; TO 125; WIN 11450; 4'-(Acetamido)phenyl-2-acetoxybenzoate; 2-Acetoxy-4'-(acetamino)phenylbenzoate; CCRIS 1739; Benzoic acid, 2-(acetyloxy)-, 4-(acetylamino)phenyl ester; 4-Acetamidophenyl salicylate acet"	21102	Approved	D08GJO	DB13657	CTPDG000528
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Halopredone acetate	Haloart (TN)	91667	Approved	D08BDT	.	CTPDG000531
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Teriflunomide	.	54684141	Approved	D07QFP	DB08880	CTPDG009757
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Siponimod	BAF312	44599207	Phase 2	D07FKQ	DB12371	CTPDG000573
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Oxyphenbutazone	Tandearil	4641	Approved	D06ZPS	DB03585	CTPDG000587
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	FENBUFEN	"36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	Approved	D06LHG	DB08981	CTPDG000602
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Dexchlorpheniramine Maleate	Polaramine	5281070	Approved	D05ZGQ	DB09555	CTPDG000614
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Enbrel	.	.	Approved	D05LTY	.	CTPDG000635
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Fenoprofen	"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid"	3342	Approved	D03XYW	DB00573	CTPDG000689
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	Approved	D03RTS	DB00482	CTPDG000700
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sodium Succinate	"Disodium succinate; 150-90-3; Disodium butanedioate; Butanedioic acid, disodium salt; Succinic acid disodium salt; Soduxin; Jantaran sodny [Czech]; UNII-V8ZGC8ISR3; Succinic acid, disodium salt; FEMA No. 3277; CCRIS 3700; Sodium succinate dibasic; EINECS 205-778-7; V8ZGC8ISR3; Butanedioic acid, sodium salt (1:2); Succinic acid disodium salt anhydrous; Butanedioic acid disodium salt; sodium succinate (anhydrous); Jantaran sodny; Butanedioic acid disodium hexahydrate; Succinic acid, disodium salt, 99%, anhydrous"	9020	Approved	D03RCJ	.	CTPDG000703
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sulfasalazine	599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; Sulfasalizine	5339	Approved	D02ZTJ	DB00795	CTPDG000732
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	Kineret; Kineret (TN); Anakinra (USAN/INN)	.	Approved	D02DES	.	CTPDG000759
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Cyproheptadine	"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene"	2913	Approved	D00TLN	DB00434	CTPDG000802
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	Approved	D00HGB	DB04552	CTPDG000816
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Nipocalimab	.	.	Phase 2	DS69NO	.	CTPDG000882
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Nipocalimab?	.	.	Phase 3	DR5V8I	.	CTPDG000884
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	BI 695501	BI-695501)	.	Phase 3	D0Z4VX	.	CTPDG000966
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06410293	.	.	Phase 3	D0Y8TZ	.	CTPDG000976
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Flobufen	VUFB-16066; VUFB-17203	159476	Phase 3	D0X8VV	.	CTPDG000989
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	Phase 3	D0W2CX	DB12399	CTPDG001013
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP-2017	.	.	Phase 3	D0S7JN	.	CTPDG001055
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cartistem	"Stem cell therapy (cartilage disease/rheumatoid arthritis), Medipost"	.	Phase 3	D0OH5E	.	CTPDG001096
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	IR-201	Seryl-glutaminyl-isoleucyl-valyl-asparaginyl-aspartyl-phenylalanyl-glutaminyl-lysyl-glycyl-aspartyl-isoleucyl-alanyl-glutamyl-glycyl-tyrosyl-serine	.	Phase 3	D0N3SA	.	CTPDG001116
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Esonarimod	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298	127998	Phase 3	D0MY7X	.	CTPDG001120
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CIPEMASTAT	"Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	Phase 3	D0MW3H	.	CTPDG001123
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Methylprednisolone	.	6741	Approved	D0LN1Z	DB00959	CTPDG001141
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	STI-002	.	.	Phase 3	D0I6UE	.	CTPDG001181
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MK-8808	.	.	Phase 1	D0GP8N	.	CTPDG001196
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 798	.	.	Phase 3	D0E8NJ	.	CTPDG001224
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	PF-06438179	.	.	Phase 3	D0D9HZ	.	CTPDG001236
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Baricitinib	.	44205240	Approved	D0D5FU	DB11817	CTPDG001241
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Cilengitide	"188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)"	176873	Phase 3	D09ZXO	DB11890	CTPDG001287
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CEP-41750	.	.	Phase 3	D09WRG	.	CTPDG001291
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Sarilumab	.	.	Approved	D08SJT	.	CTPDG001320
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Andolast	"Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm"	65970	Phase 3	D08PGC	.	CTPDG001324
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Vanadate	"Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3"	516859	Phase 3	D08NCO	.	CTPDG001327
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	Phase 3	D08DGC	DB12193	CTPDG011311
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Spermidine	"Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, &gt; =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0"	1102	Phase 3	D08BXT	DB03566	CTPDG001337
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Varespladib methyl	"A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera"	9886917	Phase 3	D07KFB	DB05737	CTPDG001360
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ABP 501	.	.	Phase 3	D06FMO	.	CTPDG001379
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Anakinra	.	.	Approved	D06CXL	.	CTPDG001384
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Atacicept	.	.	Phase 2	D04YWM	.	CTPDG001412
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Tenidap	.	60712	Phase 3	D02RQT	DB13481	CTPDG001457
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LY3090106	Tibulizumab	.	Phase 1	D09JVK	.	CTPDG001558
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2/3	VX-509	"Decernotinib; Adelatinib; 944842-54-0; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	Phase 2/3	D04QWQ	DB12566	CTPDG001571
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Olokizumab	.	.	Phase 3	D03ZYQ	.	CTPDG001574
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	CreaVax-RA	"Autologous DC therapy (injectable, rheumatoid arthritis), CreaGene; Autologous dendritic cell therapy (injectable, rheumatoid arthritis), CreaGene"	.	Phase 2a	D0U9OD	.	CTPDG001585
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	RhuDex	.	.	Phase 2a	D0J0KT	.	CTPDG001586
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cevidoplenib	"(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone; 1703788-21-9; 3N3H8BX897; AKOS040748110; BDBM196772; Cevidoplenib; Cevidoplenib [INN]; Cevidoplenib [WHO-DD]; CHEMBL3921923; CS-0039259; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; EX-A5914; HY-109082; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; MS-28778; SCHEMBL16653204; UNII-3N3H8BX897; US9212178, 1; YCZUBLQESBVOSH-IBGZPJMESA-N"	91754477	Phase 2	DY57LN	.	CTPDG001609
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Dazodalibep	VIB4920	.	Phase 2	DPDI65	.	CTPDG001652
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Natrunix	.	.	Phase 2	DOVW19	.	CTPDG001657
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-5718	"1-BOC-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE; 1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLIC ACID, 3-IODO-, 1,1-DIMETHYLETHYLESTER; 1H-Pyrazolo[3,4-b]pyridine-1-carboxylicacid,3-iodo-,1,1-diMethylethylester; 920036-34-6; A860172; AKOS022178093; AMY21637; CS-0048281; FT-0702852; GS-5718; MFCD13183727; OKKLWSNHFSFXEM-UHFFFAOYSA-N; PB26872; SCHEMBL3606964; tert-Butyl 3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate; tert-butyl 3-iodopyrazolo[3,4-b]pyridine-1-carboxylate; tert-Butyl3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate"	57443610	Phase 2	DF1T2W	.	CTPDG001727
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Branebrutinib	"(S)-4-(3-(2-BUTYNOYLAMINO)PIPERIDIN-1-YL)-5-FLUORO-2,3-DIMETHYL-1H-INDOLE-7-CARBOXAMIDE; (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 1912445-55-6; 1H-Indole-7-carboxamide, 5-fluoro-2,3-dimethyl-4-((3S)-3-((1-oxo-2-butyn-1-yl)amino)-1-piperidinyl)-; 4-((3S)-3-(2-BUTYNOYLAMINO)-1-PIPERIDINYL)-5-FLUORO-2,3-DIMETHYL-1HINDOLE-7-CARBOXAMIDE; 4-((3S)-3-(2-Butynoylamino)-1-piperidinyl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-((3S)-3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; 7LBRZUYSHU; AC-31535; AKOS037649047; BCP29496; BDBM164638; BDBM166759; BMS986195; BMS986195; BMS986195; BMS-986195; Branebrutinib; Branebrutinib (BMS-986195); Branebrutinib (USAN); BRANEBRUTINIB [INN]; Branebrutinib [USAN]; BRANEBRUTINIB [WHO-DD]; BS-16393; C20H23FN4O2; CHEMBL4297674; CS-0043577; D11478; DB15347; EN300-2007801; EX-A2720; Example 223 [US20160115126A1]; GTPL9869; HY-112161; MFCD31631584; NSC807627; NSC-807627; Q50825082; s8832; SCHEMBL17699728; UNII-7LBRZUYSHU; US9688629, 123; US9688629, 223; VJPPLCNBDLZIFG-ZDUSSCGKSA-N; WHO 11026"	121293929	Phase 2	DE3VU1	DB15347	CTPDG001734
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vobarilizumab	ALX-0061	.	Phase 2	D9J6XV	.	CTPDG001766
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IRL201805	.	.	Phase 2	D9EHD7	.	CTPDG001767
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KPL-404	.	.	Phase 2	D3NSU0	.	CTPDG001824
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FK-3311	"116686-15-8; FK 3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	Phase 2	D0Z9YW	.	CTPDG001858
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-783	"Rheumatoid arthritis therapy (oral), Takeda Pharmaceutical"	.	Phase 2	D0Z4OQ	.	CTPDG001864
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Piclamilast	"144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL"	154575	Phase 2	D0Z2FB	DB01791	CTPDG001866
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ADL-5859	PF-04856880	46931003	Phase 2	D0W9ZT	.	CTPDG001918
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SBI-087	PF-05230895	.	Phase 2	D0W9QG	.	CTPDG001920
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SB-705498	501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504	9910486	Phase 2	D0VJ5N	DB11883	CTPDG001948
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-817399	.	44537841	Phase 2	D0UX2V	DB14941	CTPDG001971
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CFZ533	.	.	Phase 2	D0SD6V	.	CTPDG002036
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PD-360324	"PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer"	.	Phase 2	D0S1UZ	.	CTPDG002048
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MGCD-290	"MG-1; MG-3290; Histone deacetylase inhibitors (cardiovascular diseases), MethylGene; Histone deacetylase inhibitors (diabetes), MethylGene; Histone deacetylase inhibitors (fungal infection), MethylGene; Histone deacetylase inhibitors (inflammation), MethylGene; HDAC inhibitors (non-oncology), MethylGene; Histone deacetylase inhibitors (non-oncology), MethylGene"	3035813	Phase 2	D0RF3F	.	CTPDG002061
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Prednisone/ dipyridamole	Synavive (TN)	5865	Phase 2	D0R4NR	DB00635	CTPDG002071
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	QAL964	.	.	Phase 2	D0QZ3P	.	CTPDG002077
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	M2951	"evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin"	71479709	Phase 2	D0QX8X	DB15170	CTPDG002078
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AK-106-001616	.	.	Phase 2	D0QH5K	.	CTPDG002079
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ABT-122	.	.	Phase 2	D0OX5H	.	CTPDG002123
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Meninge ACYW	.	.	Phase 2	D0OQ5W	.	CTPDG002127
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TAK-715	"P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda"	9952773	Phase 2	D0O6ZO	.	CTPDG002136
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MPC-300-IV	.	.	Phase 2	D0MM0N	.	CTPDG002186
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Anti-LT alpha	.	.	Phase 2	D0L1OC	.	CTPDG002241
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NNC-0151-0000-0000	"Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk"	.	Phase 2	D0J4PM	.	CTPDG002288
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-945429	.	.	Phase 2	D0J1KS	.	CTPDG002291
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ONO-4641	"Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono"	11502996	Phase 2	D0I2RB	.	CTPDG002320
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNT0-1959	.	.	Phase 2	D0HT2X	.	CTPDG002325
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	Phase 2	D0HG5M	DB13020	CTPDG002328
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	FLUASTERONE	HE-2500; 16alpha-Fluoroandrost-5-en-17-one	133967	Phase 2	D0H9YO	DB06250	CTPDG002329
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GS-4059	"tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno"	54755438	Phase 2	D0H0KH	DB15227	CTPDG002346
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VVZ-149	VVZ-000149	.	Phase 2	D0G9OH	.	CTPDG002358
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MRC-375	"Tetracycline (enteric-coated oral tablet, rheumatoid arthritis), Molecular Research Center Inc"	.	Phase 2	D0F9NA	.	CTPDG002393
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AWD-12-281	"GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline"	6918428	Phase 2	D0F4TV	.	CTPDG002402
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	APX-001	"EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics"	44123754	Investigative	D0DL3W	DB15183	CTPDG002437
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SR-31747	SR-317417A	6439330	Phase 2	D0D4JI	DB05792	CTPDG002454
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BI 655064	.	.	Phase 2	D0C8NG	.	CTPDG002478
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK3196165	.	.	Phase 2	D0C7ZB	.	CTPDG002482
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK315234	Oncostatin M mAb	.	Phase 2	D0C4YQ	.	CTPDG002485
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GS-9876	"XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr"	118161062	Phase 1	D0BW6F	DB14770	CTPDG002497
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TZI-41078	"3,5-Di-tert-butyl-4-hydroxybenzophenone oxime"	.	Phase 2	D0B6VN	.	CTPDG002510
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CNTO-6785	.	.	Phase 2	D0A7NZ	.	CTPDG002538
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AMG-714	.	.	Discontinued in Phase 1	D0A5EN	.	CTPDG002547
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	LX2931	.	135564845	Phase 2	D09ZWH	DB06297	CTPDG002552
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VAY736	.	.	Phase 2	D09SQM	.	CTPDG002563
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	KB002/003	.	.	Phase 2	D09SJE	.	CTPDG002564
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-180575	"2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide"	9930560	Phase 2	D09OTU	.	CTPDG002571
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rabeximod	"Rob-803; B-220 analog (RA), OxyPharma; B-220 analog (rheumatoid arthritis), OxyPharma"	56841552	Phase 2	D09BDH	DB05772	CTPDG002587
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BIIB 023	.	.	Phase 2	D08YHB	.	CTPDG002598
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Baminercept	"BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec"	.	Phase 2	D08XVR	.	CTPDG002599
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-06823859	.	.	Phase 2	D08RDD	.	CTPDG002615
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MK-8457	.	53251506	Phase 2	D08PXL	.	CTPDG002620
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP323	"Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01"	23394557	Phase 2	D08MJO	.	CTPDG002628
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Tofacitinib	.	9926791	Approved	D08ICX	DB08895	CTPDG002636
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BMS-986142	"Unii-pjx9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide"	86582336	Phase 2	D08AOZ	DB15291	CTPDG002651
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8765	.	.	Phase 2	D07YNM	.	CTPDG002655
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AMG0714	HuMax-IL15	.	Phase 2	D07LCA	.	CTPDG002686
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Fosbretabulin	Zybrestat (TN)	5351387	Phase 2	D07JVO	DB12577	CTPDG002693
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Rimacalib	SMP-114	9800765	Phase 2	D06PHH	DB12571	CTPDG002739
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Mavrilimumab	.	.	Phase 2	D06KCF	.	CTPDG002750
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CCX-354	CCX-354-C; GSK2941266	135565361	Phase 2	D05VTN	DB12963	CTPDG002783
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	[L/D]-aminopterin	.	.	Phase 2	D05QPC	.	CTPDG002790
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	ALX-0061	"Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx"	.	Phase 2	D05NIR	.	CTPDG002795
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Ozoralizumab	ATN-103	.	Phase 2	D05EPV	.	CTPDG002814
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	JNJ-38518168	.	23650961	Phase 2	D04VBF	DB12522	CTPDG002835
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	UCB-35440	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide	9894415	Phase 2	D04JIM	.	CTPDG002862
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Otilimab	.	.	Phase 3	D04GWO	.	CTPDG002865
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Pegsunercept	STNF-R1	.	Phase 2	D04GTA	.	CTPDG002866
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	AD-452	RS(+)-mefloquine; (+)-erythro-mefloquine	.	Phase 2	D03YKQ	.	CTPDG002884
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	SSR-240612	"N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride"	44235958	Phase 2	D03UVL	.	CTPDG002897
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	TOK-8801	"105963-46-0; Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide; Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; Tok 8801; N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide; Imidazo(2,1-b)thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-; AC1L3UYM; ACMC-20m9c6; SCHEMBL9774378; CTK4A4247; AKOS030604802"	122628	Phase 2	D03UIB	.	CTPDG002898
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 3	Sirukumab	.	.	Phase 3	D03RIX	.	CTPDG002908
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PG-760564	"Rheumatoid arthritis therapy, Procter & Gamble"	.	Phase 2	D03PBW	.	CTPDG002912
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Peresolimab	.	.	Phase 2	D02XFH	.	CTPDG002947
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	PF-04171327	"Fosdagrocorat; UNII-HPI19004QS; 1044535-58-1; HPI19004QS; 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-;2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)-; Fosdagrocorat [USAN:INN]; PF 04171327; Fosdagrocorat (USAN/INN); SCHEMBL1707427; GTPL9649; US8901310, Example 2; CHEMBL3137316; BDBM140010; SB17317"	24872952	Phase 2	D01PLR	DB12198	CTPDG003019
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	MANOALIDE	"UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975"	6437368	Phase 2	D00XQO	.	CTPDG003057
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Cenplacel-L	PDA-001	.	Phase 2	D00UGX	.	CTPDG003062
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	BT-016	Tregalizumab	.	Phase 2	D00PUT	.	CTPDG003072
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Xmab 5871	XmAb 5871 (TN)	.	Phase 1/2	D00NXT	.	CTPDG003076
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	Vidofludimus	717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644	9820008	Phase 2	D00LSI	DB15446	CTPDG003080
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 2	K-832	"10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9"	9844960	Phase 2	D00IUD	.	CTPDG003086
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	PRTX-100	Staphylococcal protein A	.	Phase 1/2	D0ZC6X	.	CTPDG003265
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Cx-611	"Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), Cellerix; Allogeneic adipose-derived stem cell therapy (intravenous, rheumatoid arthritis), TiGenix"	.	Phase 1/2	D0T3HL	.	CTPDG003323
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	BIO-300	"Radioprotective therapy, Humanetics"	.	Phase 1/2	D0J2ES	.	CTPDG003405
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	Chondrogen	Chondrogen (TN)	.	Phase 1/2	D09YVQ	.	CTPDG003481
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Approved	Indomethacin	.	3715	Approved	D06LFE	DB00328	CTPDG003540
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HM71224	"Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide"	56644522	Phase 1	DTF20P	.	CTPDG003715
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	LABP-104	NIM-1324	.	Phase 1	DN2Z5C	.	CTPDG003811
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ORTD-1	.theta.-Defensin 1; 1-[3-[benzyl-tetrakis(3-guanidinopropyl)-[(1R)-1-hydroxyethyl]-isobutyl-isopropyl-[(1S)-1-methylpropyl]-octadecaoxo-[?]yl]propyl]guanidine; 251442-64-5; BDBM50236198; CHEMBL4073105; Cyclic-(GVCRCICTRGFCRCLCRR); DTXSID60179822; oRTD-1; RTD-1; theta-Defensin 1; theta-Defensin RTD-1	16130642	Phase 1	DH5F4M	.	CTPDG003897
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	JNJ-67484703	JNJ-4703	.	Phase 1	D4VLI7	.	CTPDG004107
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	IA-14069	.	.	Phase 1	D1ROU2	.	CTPDG004184
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BX-U001	.	.	Phase 1	D17OQM	.	CTPDG004201
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	KPE-06001	"Asthma/arthritis therapy, Kemin"	.	Phase 1	D0Z8PO	.	CTPDG004223
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	PF-05230905	ATN-192	.	Phase 1	D0Y0FZ	.	CTPDG004268
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RG6125	.	.	Phase 1	D0X8RS	.	CTPDG004281
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	TAK-020	.	.	Phase 1	D0VS3U	.	CTPDG004329
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AXS-06	.	.	Phase 1	D0VJ9X	.	CTPDG004331
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Aminoguanidine	"Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284"	2146	Discontinued in Phase 2	D0V0NL	DB05383	CTPDG004355
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	OPL-CCL2-LPM	"CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey"	.	Phase 1	D0U7PM	.	CTPDG004372
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVE1701	.	.	Phase 1	D0Q2BB	.	CTPDG004488
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AVP-13358	"IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR"	9805635	Phase 1	D0P9YP	.	CTPDG004508
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Cadherin-11	SDP051	.	Phase 1	D0P5QB	.	CTPDG004517
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BF-389	"Biofor 389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029"	6439259	Phase 1	D0L6VH	.	CTPDG004624
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	HMR-1031	"MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid"	9809368	Phase 1	D0L3DC	.	CTPDG004633
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VI7734	.	.	Phase 1	D0JC9K	.	CTPDG004677
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	BMS-986104	"Unii-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-"	77050638	Phase 1	D0GG7L	DB15214	CTPDG004765
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	AMAP-102	"5-HT antagonist (rheumatism), AnaMar"	.	Phase 1	D0G7BR	.	CTPDG004771
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Sc Veltuzumab	.	.	Phase 1	D0D8NG	.	CTPDG004853
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MORAb-022	"Antibody (inflammation/autoimmune disease), Morphotek"	.	Phase 1	D0B0VD	.	CTPDG004925
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ARG301	.	.	Phase 1	D09PJB	.	CTPDG004987
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SCH-900117	.	.	Phase 1	D08YWY	.	CTPDG005018
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	DWP-422	.	.	Phase 1	D08SXV	.	CTPDG005031
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VEL-0230	"NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar"	25102841	Phase 1	D07BIK	.	CTPDG005126
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	Synthetic neutrophil inhibitor peptide	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide	71482	Phase 1	D07ANO	.	CTPDG005128
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RWJ-67657	215303-72-3; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	Phase 1	D06OZJ	.	CTPDG005150
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	MEDI4920	.	.	Phase 1	D06HNO	.	CTPDG005164
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RPI-78M	"Antiviral agent, Receptogen; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm"	.	Discontinued in Phase 1	D05FVK	.	CTPDG005210
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP2408	CTLA4-Ig fusion protein	.	Phase 1	D04OQU	.	CTPDG005246
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK3117391	.	53630042	Phase 1	D04KMQ	DB15440	CTPDG005255
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ABBV-257	.	.	Phase 1	D04DQO	.	CTPDG005266
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	VGX-1027	"6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590"	10798271	Phase 1	D03QEB	.	CTPDG005296
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	GSK-1827771	"IL-1 antagonist (antibody, rheumatoid arthritis), GSK"	.	Phase 1	D03FVR	.	CTPDG005318
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	ASP5094	.	.	Phase 1	D03ACE	.	CTPDG005331
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	EVT 401	.	.	Phase 1	D01TLV	.	CTPDG005379
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Phase 1	SKI-O-703	.	.	Phase 1	D01IDW	.	CTPDG005409
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Clinical trial	AZ-4217	AZ4217; AZ 4217	57406537	Clinical trial	D00XKB	.	CTPDG005509
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Floctafenine	"23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline"	3360	Withdrawn from market	D0AK5R	DB08976	CTPDG006315
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Withdrawn from market	Aurothioglucose	HMS3262I11; LP00685	454937	Withdrawn from market	D0A4BR	.	CTPDG006316
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Preregistration	Amiprilose	Therafectin; Amiprilose hydrochloride; KAP-690; SM-1213	121928	Discontinued in Preregistration	D07MEL	.	CTPDG006326
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	Nerelimomab	BAY-X-1351	.	Discontinued in Phase 3	D0VW2Z	.	CTPDG006333
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 3	M-5010	M-5011; T-3788; 2(R)-[4-(3-Methyl-2-thienyl)phenyl]propionic acid	12769847	Discontinued in Phase 3	D0RJ0J	.	CTPDG006340
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	BR3-Fc	.	.	Discontinued in Phase 2	D0YA0N	.	CTPDG006399
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	EFLETIRIZINE	Efletirizine < Rec INN; Ucb-28754; 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid	66003	Discontinued in Phase 2	D0XK4R	.	CTPDG006402
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IX207-887	.	6509858	Discontinued in Phase 2	D0X2PQ	.	CTPDG006407
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AMG 108	.	444499	Discontinued in Phase 2	D0W7VG	.	CTPDG006413
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HR325	.	66583751	Discontinued in Phase 2	D0SX4K	.	CTPDG006435
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	TA-383	"Cis-2-(4-Chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride; Cis-2-(4-Chlorophenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole hydrochloride"	131180	Discontinued in Phase 2	D0R2CM	.	CTPDG006447
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	Discontinued in Phase 2	D0Q9ZD	.	CTPDG006450
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SM-8849	"113759-19-6; 4-(1-(2-fluoro-4-biphenylyl)ethyl)-2-methylaminothiazole; 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole; ZTFDMDJGJVUYQE-UHFFFAOYSA-N; AC1L3Y3S; SCHEMBL5078854; 4-(1-(2-Fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; (+)-2-methylamino-4-(1-(2-fluoro-4-biphenylyl)ethyl)thiazole; 4-[1-(3-fluoro-4-phenylphenyl)ethyl]-N-methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 4-(1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-N-methyl-"	124238	Discontinued in Phase 2	D0Q0AJ	.	CTPDG006455
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Zolimomab aritox	XomaZyme-CD5 Plus; XomaZyme-H65; XomaZyme-lym; OrthoZyme-CD5+; Xmmly-h65-rta; XomaZyme-H65-rta	.	Discontinued in Phase 2	D0O2QB	.	CTPDG006464
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CP-195543	"LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer"	9823886	Discontinued in Phase 2	D0MM2K	DB13053	CTPDG006475
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MLN3897	.	.	Discontinued in Phase 2	D0KF6X	.	CTPDG006490
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-5751	"AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid"	9867949	Discontinued in Phase 2	D0K0VH	.	CTPDG006494
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	MP-435	"C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe"	.	Discontinued in Phase 2	D0H0ZU	.	CTPDG006510
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CPA-926	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one	9800054	Discontinued in Phase 2	D0G6PG	.	CTPDG006516
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SINOMENINE	"Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one"	5459308	Discontinued in Phase 2	D0F9WF	.	CTPDG006522
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	Linetastine	"Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Molecule 26"	6439232	Discontinued in Phase 2	D0E8UV	.	CTPDG006530
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	SC-106	AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid	492984	Discontinued in Phase 2	D0D3KY	.	CTPDG006539
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PRO-515	.	.	Discontinued in Phase 2	D09FEN	.	CTPDG006572
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GW-215864	GR-215864; GR-215864X; GW-215864X	56841560	Discontinued in Phase 2	D09AUP	.	CTPDG006573
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	HSR-609	"FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate"	3081352	Discontinued in Phase 2	D08RZV	.	CTPDG006576
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	AnergiX.RA	"AG-4263; RA-AnergiX; Antigen specific therapy (rheumatoid arthritis, AnergiX), Corixa/ Organon"	.	Discontinued in Phase 2	D07BEE	.	CTPDG006598
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	GLPG-0259	"G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562"	44462738	Discontinued in Phase 2	D06NPB	DB15190	CTPDG006604
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NN8209	.	.	Discontinued in Phase 2	D05ILZ	.	CTPDG006618
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	IDEC-151	Clenoliximab	.	Discontinued in Phase 2	D04ZLG	.	CTPDG006624
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	Discontinued in Phase 2	D04DUJ	.	CTPDG006634
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	NPC-567	"Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-"	119343	Discontinued in Phase 2	D03ZBM	.	CTPDG006637
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 2	T-5224	AKOS003047196; T5224	23626877	Discontinued in Phase 2	D02LCL	.	CTPDG006652
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AD-121	"PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest"	.	Discontinued in Phase 1/2	D06YFO	.	CTPDG006694
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1/2	AME-527	.	.	Discontinued in Phase 1/2	D05RTF	.	CTPDG006696
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-4629991	"PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer"	.	Discontinued in Phase 1	D0N8AB	.	CTPDG006767
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	NN8210	.	.	Discontinued in Phase 1	D0MT7W	.	CTPDG006774
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	ARRY-614	"Pexmetinib; 945614-12-0; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	Discontinued in Phase 1	D0ML0L	.	CTPDG006775
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Oncolysin CD6	Anti-CD6-bR; Anti-T12-bR	.	Discontinued in Phase 1	D0L4SB	.	CTPDG006784
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Eltenac	BY-820; B-788-20	51717	Discontinued in Phase 1	D0JF6O	.	CTPDG006796
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	RG-4934	"IL-17 huMAb (psoriatic arthritis), Roche"	.	Discontinued in Phase 1	D0J8JF	.	CTPDG006797
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AC-100	"Bicyclo[4.2.0]octa-1,3,5-trien-3-ylboronic acid; BENZOCYCLOBUTANE-4-BORONIC ACID; Boronic acid, bicyclo[4.2.0]octa-1,3,5-trien-3-yl-; SCHEMBL12759201; KS-00000SRU; MolPort-005-942-889; ZINC196051840; AKOS025146995; DS-8536; BC225113; AK164312; 1,2-Dihydrobenzocyclobutene-4-ylboranic acid; CS-0043999; J3.522.588I; 4-bbcb                                             benzocyclobutene-4-boronic acid"	11171056	Discontinued in Phase 1	D0J6PR	.	CTPDG006798
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	Roquinimex	Linomide	54676478	Discontinued in Phase 1	D0G9ZW	DB11366	CTPDG006812
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	D-1367	"167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-"	15259989	Discontinued in Phase 1	D0E8MW	.	CTPDG006818
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AVE-9940	.	.	Discontinued in Phase 1	D08CQE	.	CTPDG006862
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	LY-231617	"2,6-Di-tert-butyl-4-(ethylaminomethyl)phenol hydrochloride"	3968	Discontinued in Phase 1	D05XYC	.	CTPDG006882
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	CI-972	.	135418360	Discontinued in Phase 1	D05UPB	.	CTPDG006883
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	R1295	CHEMBL2146615	70329	Discontinued in Phase 1	D04XJM	.	CTPDG006893
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	KB-2683	.	129748	Discontinued in Phase 1	D03LXJ	.	CTPDG006908
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	AZD-6703	"P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca"	11373432	Discontinued in Phase 1	D03KWN	.	CTPDG006909
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	SC-57666	CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	Discontinued in Phase 1	D02OHR	.	CTPDG006916
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	C-5997	"7709-58-2; 4-(Chloromethyl)thiazole hydrochloride; 4-(chloromethyl)-1,3-thiazole Hydrochloride; 4-(chloromethyl)thiazole hcl; 4-chloromethylthiazole hydrochloride; 4-chloromethylthiazole hcl; 4-(chloromethyl)thiazolehcl; C4H4ClNS.ClH; ACMC-1BBSC; chloromethylthiazole-4 hcl; AC1Q3BH9; AC1MC82W; SCHEMBL122926; 4-(Chloromethyl)thiazole, HCl; CTK6H6834; DTXSID60376874; NVTBASMQHFMANH-UHFFFAOYSA-N; MolPort-000-139-475; 4-(chloromethyl)thiazole HCl salt; ACT02312; KS-000004ND; ANW-36949; 4-chloromethyl thiazole hydrochloride"	2763289	Discontinued in Phase 1	D01CBV	.	CTPDG006932
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Discontinued in Phase 1	PF-755616	.	.	Discontinued in Phase 1	D00FGY	.	CTPDG006939
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Application submitted	GP2015	.	.	Application submitted	D0K9SS	.	CTPDG006944
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	SR1555	"CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675"	71470549	Preclinical	DW5R6Y	.	CTPDG006962
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	MCP-1	.	.	Preclinical	D0V9ND	.	CTPDG007038
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NPC-17923	"147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-"	9824607	Terminated	D0Z3AK	.	CTPDG007165
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	TM-31	.	.	Terminated	D0Y9CC	.	CTPDG007170
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BCX-25	BCX-14	.	Terminated	D0V2ZJ	.	CTPDG007200
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BB-1433	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241	101708593	Terminated	D0V0RW	.	CTPDG007202
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	ZK-90695	.	.	Terminated	D0US3C	.	CTPDG007203
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RP-54745	"RP 54745; 135330-08-4; AC1L2PX8; SCHEMBL4362761; rp54745; CS-6750; 4-Chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-3H-1,2-dithiol-3-one; HY-101716; 4-chloro-5-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)dithiol-3-one; 3H-1,2-Dithiol-3-one, 4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-"	126203	Terminated	D0T0LO	.	CTPDG007223
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	Terminated	D0R5TT	.	CTPDG007238
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Seprilose	GW-80126	60818	Terminated	D0Q5ZN	.	CTPDG007243
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	NOX-200	"2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478"	95438	Terminated	D0OX9Q	.	CTPDG007255
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SAN-18	.	.	Terminated	D0M8QG	.	CTPDG007278
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	CI-986	"CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate"	3037017	Terminated	D0L8RG	.	CTPDG007289
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-6942	"CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca"	.	Terminated	D0I9YI	.	CTPDG007324
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	3-DEAZAADENOSINE	"Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine"	23190	Terminated	D0I7TN	DB04546	CTPDG007326
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-28342	.	9882188	Terminated	D0H0IA	.	CTPDG007341
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AG-2024	.	.	Terminated	D0G2CL	.	CTPDG007350
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	Ro-31-4724	CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	Terminated	D0EF7V	DB08482	CTPDG007361
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-33516	.	.	Terminated	D0DR3I	.	CTPDG007371
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	D-5410	CH-138; CH-263	.	Terminated	D09TRM	.	CTPDG007412
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SKF-104351	"111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole"	122656	Terminated	D09SCI	.	CTPDG007413
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RWJ-63556	.	9882374	Terminated	D08JKK	.	CTPDG007441
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	YM-26734	"YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1"	9853400	Terminated	D07OGR	.	CTPDG007458
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD5672	"CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide"	11614352	Terminated	D07GIB	.	CTPDG007463
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	S-16276-1	.	.	Terminated	D06MTM	.	CTPDG007476
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-111142	WF-2015A	9909502	Terminated	D06AKJ	.	CTPDG007482
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	BW A4C	"BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide"	6438354	Terminated	D05WPQ	.	CTPDG007485
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	WY-48989	"WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile"	132006	Terminated	D04YNI	.	CTPDG007505
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	FR-133605	.	.	Terminated	D04SVB	.	CTPDG007508
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	SR-26831	"SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate"	132270	Terminated	D03GII	.	CTPDG007535
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	GDC-0834	"1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz"	25234918	Terminated	D03FUO	.	CTPDG007536
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	Terminated	D01QRG	.	CTPDG007565
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	LY-221068	"LY 221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-"	6439333	Terminated	D01QAR	.	CTPDG007566
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	DPC-333	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide	9847838	Terminated	D01DVX	.	CTPDG007574
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Terminated	PXS-2076	"PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis"	.	Terminated	D01DTQ	.	CTPDG007575
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ODN-1411	.	.	Investigative	D5S7JL	.	CTPDG007609
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	Investigative	D0YK4L	.	CTPDG007651
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	Investigative	D0Y4ZI	.	CTPDG007665
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BFPT-16864	BFPT-6864; BRFD-104	.	Investigative	D0XP3A	.	CTPDG007695
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Arthromir	.	.	Investigative	D0WI1L	.	CTPDG007743
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	SPX-601	.	.	Investigative	D0VB2K	.	CTPDG007786
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-814	"Hsp60 peptide (juvenile idiopathic arthritis), CIGB"	.	Investigative	D0V5VA	.	CTPDG007796
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD40-XTEN	"CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0V3HC	.	CTPDG007800
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	X-071-NAB	"NATHMAB (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech; Natural/true human monoclonal antibody (systemic lupus erythematosus/multiple myeloma/arthritis), XBiotech"	.	Investigative	D0U2OQ	.	CTPDG007838
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TENOSAL	MR-Y134; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	Investigative	D0T3KZ	.	CTPDG007862
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DW-908	DW-0908	.	Investigative	D0R4NJ	.	CTPDG007910
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	Investigative	D0N8TM	.	CTPDG008032
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	MDDR 217769	"(E)-2-(4,6-Difluoroindan-1-ylidene)acetamide"	.	Investigative	D0N8JJ	.	CTPDG008033
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FKB327	.	.	Investigative	D0L8UQ	.	CTPDG008105
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DMARDs	"DMARDs (oral, rheumatoid arthritis); DMARDs (oral, rheumatoid arthritis), Abbott; Disease-modifying antirheumatic drugs (oral, rheumatoid arthritis), Abbott"	.	Investigative	D0L2BT	.	CTPDG008121
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TX-RAD	"RA1-TX; RA1-TX (ankylosing spondylitis), TxCell; RA1-TX (rheumatoid arthritis), TxCell; RA1-TX (psoriatic arthritis,inflammatory disease), TxCell"	.	Investigative	D0K8BO	.	CTPDG008134
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	UR-5269	"Rheumatoid arthritis therapy, UBE Industries"	.	Investigative	D0J7XN	.	CTPDG008168
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	AVX-002	.	.	Investigative	D0J4TX	.	CTPDG008173
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-125	"Synoviocyte inhibitor + glucocorticoid (arthritis), Xaragen"	.	Investigative	D0I9FQ	.	CTPDG008191
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	DWJ-425	"DW-Ab2; MAb (RA), Daewoong; Monoclonal antibody (rheumatoid arthritis), Daewoong"	.	Investigative	D0I4MW	.	CTPDG008211
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	HL-1020	"Grape seed proanthocyanidin extract (rheumatoid arthritis), Hanlim"	.	Investigative	D0G8EI	.	CTPDG008263
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-120	"Synoviocyte inhibitor + DMARD (arthritis), Xaragen"	.	Investigative	D0G2GZ	.	CTPDG008276
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	XGP-115	"Synoviocyte inhibitor + NSAID (arthritis), Xaragen"	.	Investigative	D0F8BR	.	CTPDG008296
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CTLA-4-XTEN	"Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix"	.	Investigative	D0EZ9C	.	CTPDG008324
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Nano-steroid	"Steroidal anti-inflammatory (slow release nanoparticle formulation), LTT Bio-Pharma; Steroids (sustained release nanoparticles), LTT Bio-Pharma/Cipra; Steroidal anti-inflammatory (rheumatoid arthritis/collagen disease), LTT Bio-Pharma"	.	Investigative	D0B9XM	.	CTPDG008440
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	YD-101	.	.	Investigative	D0B3KI	.	CTPDG008455
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	KI-0906	.	.	Investigative	D0A2RF	.	CTPDG008498
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FHT-401	"PTD-conjugated methotrexate (transdermal, rheumatoid arthritis), ForHumanTech/Hyundai"	.	Investigative	D0A0FI	.	CTPDG008502
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	TCH-013	"NF-kB inhibitors (rheumatoid arthritis); NF-kB inhibitors (rheumatoid arthritis), TCH Pharmaceuticals"	76850167	Investigative	D09TVH	.	CTPDG008515
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Anti-CD97 mab	"Anti-CD97 monoclonal antibody (rheumatoid arthritis); Anti-CD97 mAb (RA), Organon/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Organon/AMC; Anti-CD97 mAb (RA), Schering-Plough/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Merck & Co/AMC; Anti-CD97 monoclonal antibody (rheumatoid arthritis), Schering-Plough/AMC"	.	Investigative	D09RGS	.	CTPDG008524
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CIGB-55	.	.	Investigative	D09NQD	.	CTPDG008534
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Dendritic cell-based immunotherapy	"Dendritic cell-based immunotherapy (rheumatoid arthritis); Dendritic cell-based immunotherapy (rheumatoid arthritis), Dendright; Dendritic cell-based immunotherapy (rheumatoid arthritis, injectable formulation), Dendright"	.	Investigative	D07OCM	.	CTPDG008673
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	RT-401	"BoNTA protein (topical, rhinitis), Revance"	.	Investigative	D07JPL	.	CTPDG008692
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	VVZ-138	VVZ-000138	.	Investigative	D07GFZ	.	CTPDG008699
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	IG-AI-025	.	.	Investigative	D06XXD	.	CTPDG008716
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CHR-4487	"Esterase-sensitive motif compounds (inflammatory disease); Esterase-sensitive motif compounds (inflammatory disease), Chroma Therapeutics"	.	Investigative	D06HWU	.	CTPDG008757
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ROSMARINIC ACID	"20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid"	5281792	Investigative	D05PTT	.	CTPDG008813
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CT-340	"TrkA kinase inhibitor (polyoxyethylene conjugated, LSE, arthritis, scarring, pain), Creabilis"	.	Investigative	D05KRS	.	CTPDG008827
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	ADR58	.	.	Investigative	D04VCF	.	CTPDG008856
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CEL-2000	"T-cell modulating vaccine (LEAPS, rheumatoid arthritis), CEL-SCI"	.	Investigative	D03XSX	.	CTPDG008918
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	FM-201	.	.	Investigative	D03TKI	.	CTPDG008933
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	BMS-345541	"445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05"	9926054	Investigative	D00YTQ	.	CTPDG009140
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	CAT-2200	"MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)"	.	Investigative	D00XNC	.	CTPDG009145
M6ACROT05371	.	.	M6ADIS0112	FA20: Rheumatoid arthritis	Investigative	OCT-SG815	"OPG secretagogues (osteoporosis/arthritis), Oscotec; Osteoprotegerin secretagogues (osteoporosis/arthritis), Oscotec; OPG secretagogues (osteoporosis/arthritis), KT&G; Osteoprotegerin secretagogues (osteoporosis/arthritis), KT&G"	.	Investigative	D00QOH	.	CTPDG009161
M6ACROT00050	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00050	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00050	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00050	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00050	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00050	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00051	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00051	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00051	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00051	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00051	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00051	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00052	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00052	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00052	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00052	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00052	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00052	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00053	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00053	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00053	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00053	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00053	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00053	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00054	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00054	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00054	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00054	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00054	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00054	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00055	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00055	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00055	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00055	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00055	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00055	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00056	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00056	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00056	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00056	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00056	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00056	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00057	.	.	M6ADIS0132	EE60: Keloid	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT00057	.	.	M6ADIS0132	EE60: Keloid	Phase 2	Remlarsen	.	.	Phase 2	DC7UF3	.	CTPDG001749
M6ACROT00057	.	.	M6ADIS0132	EE60: Keloid	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT00057	.	.	M6ADIS0132	EE60: Keloid	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT00057	.	.	M6ADIS0132	EE60: Keloid	Phase 1/2	STP705	.	.	Phase 1/2	D0E9XR	.	CTPDG002411
M6ACROT00057	.	.	M6ADIS0132	EE60: Keloid	Phase 2	MRG-201	.	.	Phase 2	D08WZQ	.	CTPDG002602
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT00058	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT00075	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05106	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05308	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05310	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05326	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05339	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05340	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05378	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05445	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05591	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05592	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05677	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05764	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05765	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05872	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05873	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05896	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	Approved	D0X7HM	.	CTPDG000068
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Catumaxomab	.	.	Phase 2	D0O5ER	.	CTPDG000246
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tisotumab vedotin	.	.	Phase 2	D0A4GQ	.	CTPDG000465
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	MVax	MVax (TN)	.	Approved	D09JNP	.	CTPDG000494
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Intedanib	"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate"	135423438	Phase 2	D09HNV	DB09079	CTPDG000496
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Fluzone QIV	Seasonal influenza vaccine (quadrivalent)	.	Approved	D09FHM	.	CTPDG000502
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Plicamycin	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01	163659	Approved	D06EPF	DB06810	CTPDG000606
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Trabectedin	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)	108150	Approved	D03RTK	DB05109	CTPDG000701
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Topotecan	"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin"	60700	Approved	D02PMO	DB01030	CTPDG000742
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Altretamine	"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine"	2123	Approved	D02LPF	DB00488	CTPDG000749
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	Approved	D01SHZ	DB12332	CTPDG000776
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Ofranergene obadenovec	VB-111	.	Phase 3	DU60ND	.	CTPDG000876
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Batiraxcept	AVB-S6-500	.	Phase 3	DDRX30	.	CTPDG000916
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RRx-001	"925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015"	15950826	Phase 2	D0X8TS	DB12060	CTPDG000990
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Picoplatin	"AMD 473; JM-473; ZD0473; (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-; Picoplatin [INN:BAN]; UNII-B5TAN0L720; ZD 0473; AC1L42P3; B5TAN0L720; DB04874; Amminedichloro(2-methylpyridine)platinium; AN-30599; LS-184068; J-011604; azane; 2-methylpyridine; dichloride"	177358	Phase 3	D0T7GV	DB04874	CTPDG001042
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Upifitamab rilsodotin	.	.	Phase 3	D0QFD2	.	CTPDG001076
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Rubraca rucaparib	.	.	Phase 3	D0NA8B	.	CTPDG001109
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	PM1183	.	.	Phase 3	D0K6AL	.	CTPDG001166
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Amonafide	Quinamed (TN)	50515	Phase 3	D0HR7P	DB05022	CTPDG001187
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Etirinotecan pegol	NKTR-102	56935717	Phase 2	D0H5IZ	.	CTPDG001191
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Opdivo + Yervoynivolumab + ipilimumab	.	.	Phase 1/2	D08TBK	.	CTPDG001319
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Epothilon	.	.	Phase 3	D07WPE	.	CTPDG001340
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Oregovomab	.	.	Phase 3	D07HUW	.	CTPDG001361
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Farletuzumab	.	.	Phase 3	D06XVN	.	CTPDG001371
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-8109	.	.	Phase 3	D02TJT	.	CTPDG001456
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	Karenitecin	Karenitecin (TN)	148202	Phase 3	D02CZK	DB05806	CTPDG001475
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	EC20	Technetium Tc-99m etarfolatide	135428923	Phase 3	D00BHL	.	CTPDG001509
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2/3	Abagovomab	.	.	Phase 2/3	D00KGB	.	CTPDG001581
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GEN-1	.	.	Phase 2	DRT2P7	.	CTPDG001641
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-100	.	.	Phase 2	DL76CW	.	CTPDG001687
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP0057	CRLX101	.	Phase 2	DGD93X	.	CTPDG001714
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TJ004309	.	.	Phase 2	DFYL50	.	CTPDG001719
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Maveropepimut-S	.	.	Phase 2	DFS8A7	.	CTPDG001723
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	SPL-108	.	.	Phase 2	D2C0DY	.	CTPDG001837
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Mirvetuximab soratansine	.	.	Phase 2	D0V9EX	.	CTPDG001954
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ovapuldencel-T	.	.	Phase 2	D0TR3Y	.	CTPDG002001
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MUC-1 cancer vaccine	CVac (TN)	.	Phase 2	D0T5ES	.	CTPDG002018
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EGEN-001	.	.	Phase 2	D0OS7K	.	CTPDG002124
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TPIV200	.	.	Phase 2	D0LB8Z	.	CTPDG002223
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BBI503	.	25190990	Phase 2	D0L9XF	DB14866	CTPDG002224
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OTL38	.	.	Phase 2	D0I9IL	.	CTPDG002298
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	NanoPac	.	.	Phase 2	D0FZ7Q	.	CTPDG002383
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Sagopilone	"ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione"	11284169	Phase 2	D0F6YW	DB12391	CTPDG002397
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	BGB-290	Pamiparib	135565554	Phase 2	D0D9IQ	DB14769	CTPDG002440
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Anetumab ravtansine	Mesothelin-ADC	.	Phase 2	D0CN9D	.	CTPDG002472
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ZW25	Zanidatamab	.	Phase 1	D0AJ9V	.	CTPDG002525
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CDX-1401	.	.	Phase 2	D09TCY	.	CTPDG002562
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CA4P	Fosbretabulin disodium; 168555-66-6; Combretastatin A4 disodium phosphate; CA4DP; Fosbretabulin (disodium); Zybrestat; UNII-702RHR475O; Combretastatin A4 Phosphate Disodium Salt; Fosbretabulin disodium [USAN]; 702RHR475O; Combretastatin A-4 phosphate; Fosbretabulin disodium (USAN); CHEMBL289351; Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium; AC1OCF9S; Fosbretabulin Disodium Salt; CA-4P; CA 4P; SCHEMBL321426; C18H19O8P.2Na; MolPort-006-823-175; ACT03122; 3559AH; s7204; AKOS027327946; BCP9000542; CS-1484; NSC-752293; Fosbr	100154	Phase 2	D09OKZ	DB05284	CTPDG002572
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Dendritic cell vaccine	"Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn"	.	Phase 2	D09NFW	.	CTPDG002573
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	LY2606368	prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013	46700756	Phase 2	D08UUL	DB12008	CTPDG002607
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Approved	Melphalan	.	460612	Approved	D06XES	DB01042	CTPDG002720
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MEDI-546	.	.	Phase 2	D06TME	.	CTPDG002731
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	RG-7599	"DNIB-0600A; Antibody-drug conjugate (NSCLC/ovarian cancer), Genentech"	.	Phase 2	D05YYP	.	CTPDG002774
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	EP-201	"Chissonox 201; Unox epoxide 201; Unox 201; Epoxide-201; EP 201; 141-37-7; CCRIS 279; NSC 61273; BRN 0246264; MLS002638023; CHEBI:82463; 3,4-epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexanecarboxylate; Epoxide 201; 6-Methyl-3,4-epoxycyclohexylmethyl 6-methyl-3,4-epoxycyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl-3',4'-epoxy-6'-methylcyclohexane carboxylate; 3,4-Epoxy-6-methylcyclohexylmethyl 3,4-epoxy-6-methylcyclohexanec"	61094	Phase 2	D05GYU	.	CTPDG002810
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	MK-1775	"955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	Phase 2	D02KKA	DB11740	CTPDG002972
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	CP-547632	"BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide"	9811611	Phase 2	D00YPR	DB12962	CTPDG003055
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	Motolimid	.	.	Phase 2	D00OYC	.	CTPDG003074
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN5668	.	.	Phase 1/2	DT1R9E	.	CTPDG003141
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	TC-510	.	.	Phase 1/2	DJA64B	.	CTPDG003173
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	XMT-1592	.	.	Phase 1/2	DDL79K	.	CTPDG003189
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GL-ONC1	olvimulogene nanivacirepvec	.	Phase 2	DA6OU0	.	CTPDG003206
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	LY2940680	1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]	49848070	Phase 1/2	D0W0SL	DB12550	CTPDG003293
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Her-2/neu vaccine	.	.	Phase 1/2	D0U3FP	.	CTPDG003307
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-302	.	.	Phase 1/2	D0T7MZ	.	CTPDG003320
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	DPX-survivac cancer vaccine	.	.	Phase 1/2	D0T2IF	.	CTPDG003324
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	REGN4018	.	.	Phase 1/2	D0LA9K	.	CTPDG003386
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	GALE-301 + GALE-302	.	.	Phase 1/2	D0IW4E	.	CTPDG003410
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	O-Vax	"AC vaccine (ovarian cancer), AVAX"	.	Phase 1/2	D09GRH	.	CTPDG003493
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	NT-501 CNTF	.	.	Phase 1/2	D07GWZ	.	CTPDG003527
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	IL-2/gene-modified lymphocytes	.	.	Phase 1/2	D01VWB	.	CTPDG003618
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Ovarian dendritic cell-based vaccine	.	.	Phase 1/2	D01EMD	.	CTPDG003622
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	BNT115	.	.	Phase 1	DT3OZ4	.	CTPDG003717
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MEDI3617	.	.	Phase 1	DP7J0Z	.	CTPDG003771
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	INKmune	.	.	Phase 1	DJ9H4F	.	CTPDG003865
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DeTIL-0255	.	.	Phase 1	DJ3QK6	.	CTPDG003871
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DS-6000	.	.	Phase 1	DISJ28	.	CTPDG003875
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MCY-M11	.	.	Phase 1	D8EIB7	.	CTPDG004018
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT1012	.	.	Phase 1	D7W6SO	.	CTPDG004029
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	mRNA-2416	mRNA-OX40L	.	Phase 1	D70SHJ	.	CTPDG004053
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	TG4050	.	.	Phase 1	D6CV1Q	.	CTPDG004069
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	GRN-300	.	.	Phase 1	D40NQW	.	CTPDG004125
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	ITIL-306	.	.	Phase 1	D3MGD9	.	CTPDG004135
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STRO-002	.	.	Phase 1	D10GPJ	.	CTPDG004206
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Ipafricept	.	.	Phase 1	D0Z6AM	.	CTPDG004228
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	IMT-1012 immunotherapeutic vaccine	.	.	Phase 1	D0Y9VC	.	CTPDG004251
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	STM 434	.	.	Phase 1	D0X6DC	.	CTPDG004284
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Withdrawn from market	Mibefradil	"Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	Withdrawn from market	D0W8XT	DB01388	CTPDG004310
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SC-003	.	.	Phase 1	D0SZ2G	.	CTPDG004417
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	KHK-2866	.	.	Phase 1	D0S4KJ	.	CTPDG004436
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PUMVC3-hIGFBP-2	"IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer); IGFBP-2 DNA plasmid vaccine (intradermal, ovarian cancer), Fred Hutchinson"	.	Phase 1	D0O9FH	.	CTPDG004542
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Prolanta	.	.	Phase 1	D0J1OG	.	CTPDG004699
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	JCAR020	.	.	Phase 1	D0I0FA	.	CTPDG004733
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Cantrixil	"UNII-5DVS457HEG; 5DVS457HEG; SCHEMBL19410294; TRX-E-002-1; cis-4-(p-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan; (+)-cis-4-(Para-hydroxyphenyl)-7,4-dihydroxy-3,5-dimethoxy-8-methylisoflavan; 1803036-93-2"	129851403	Phase 1	D0FL2K	.	CTPDG004795
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Hu-CART meso cells	.	.	Phase 1	D07YPB	.	CTPDG005074
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	PTC596	.	.	Phase 1	D07EKK	.	CTPDG005116
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	AE-O	"Ovarian vaccine, Generex"	.	Phase 1	D05MEP	.	CTPDG005197
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	E 7974	"26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872"	10127315	Phase 1	D05HBZ	.	CTPDG005207
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	DMUC-5754A	.	.	Phase 1	D04ZIZ	.	CTPDG005228
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	R1549	.	.	Discontinued in Phase 3	D0VE6X	.	CTPDG006334
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 3	IDM-1	Osidem	.	Discontinued in Phase 3	D02YWW	.	CTPDG006386
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	Discontinued in Phase 2	D0Q7FC	DB12222	CTPDG006453
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	AGS-8M4	"AGS-8 MAb, Agensys, AGS8M4, ASP-6183"	.	Discontinued in Phase 2	D05DBZ	.	CTPDG006620
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	Onyvax-O	.	.	Discontinued in Phase 1	D0XT5F	.	CTPDG006711
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7458	.	.	Discontinued in Phase 1	D0G9ZJ	.	CTPDG006813
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Preclinical	S-8184	.	.	Preclinical	D0X4UH	.	CTPDG007029
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Terminated	111In-OC-125 F(ab1/2)-DTPA	Indimacis 125; Indium-111-OC-125 F(ab1/2)-DTPA	.	Terminated	D07PMU	.	CTPDG007453
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HumaRAD-OV	HumaRAD88BV59; KSB-310	.	Investigative	D0Z1CQ	.	CTPDG007643
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FOLIGO 002	.	.	Investigative	D0Y6QX	.	CTPDG007659
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	HS-210	"HS-01; Endoplasmin modulator (ovary tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumorantigen secreting live cell vaccine (ovary tumor, HeatShock), Heat Biologics"	.	Investigative	D0XK6P	.	CTPDG007699
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	CGEN-991	"Anti-CGEN-991 antibody (ovarian cancer); CGEN-991 (ovarian cancer), Compugen; Anti-CGEN-991 antibody (ovarian cancer), Compugen"	.	Investigative	D0V1TV	.	CTPDG007805
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	FabOvar	"Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Advanced Accelerator Applications; Alpha-folate receptor-targeting I131-labeled mAb fragment (ip, ovarian carcinoma), Dompe"	.	Investigative	D0S6OY	.	CTPDG007884
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ALVAC-CEA/hB7.1	.	.	Investigative	D0Q2IV	.	CTPDG007961
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	MX-35	"Monoclonal antibody (ovarian cancer), Recepta"	.	Investigative	D0P6YL	.	CTPDG007978
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	"6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)"	CHEMBL1082330; BDBM50320180	46891330	Investigative	D0OQ5H	.	CTPDG007993
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	ET-006	.	.	Investigative	D0L3LO	.	CTPDG008117
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	AB-3D3	"AB-0447a; KAAG1-targeting mAb (ovarian cancer), Alethia; KAAG1-targeting monoclonal antibody (ovarian cancer), Alethia; Kidney associated antigen 1-targeting mAb (ovarian cancer), Alethia; Kidney associated antigen 1-targeting monoclonal antibody (ovarian cancer), Alethia; AB-0447-targeting monoclonal antibodies (cancer), Alethia"	.	Investigative	D0F6DF	.	CTPDG008300
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	RAP-701	"Small stabilized receptor active peptide (ovarian cancer), RAPID Pharmaceuticals"	.	Investigative	D0CO3O	.	CTPDG008395
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-folate receptor 1 humanized mab	Anti-folate receptor 1 humanized mAb (cancer)	.	Investigative	D09IVP	.	CTPDG008548
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Disorazol Z-LHRH conjugates	Disorazol Z-LHRH conjugates (ovarian cancer)	.	Investigative	D08LRU	.	CTPDG008610
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	Anti-CGEN-153 mab	"CGEN-153; Anti-CGEN-153 mAb (ovarian cancer); CGEN-153 (Ovarian cancer), Compugen; Anti-CGEN-153 mAb (ovarian cancer), Compugen"	.	Investigative	D08ENJ	.	CTPDG008631
M6ACROT05897	.	.	M6ADIS0066	2C73: Ovarian cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT00063	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT00064	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03038	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03039	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03072	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03221	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03293	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03294	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03295	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03296	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03297	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03298	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03299	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03300	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03301	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03302	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03303	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03304	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03305	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03315	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03316	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03317	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03318	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03319	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03320	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03321	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03322	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03323	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03324	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03325	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03326	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03539	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03540	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT03541	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05007	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05056	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05108	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05164	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05165	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05358	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05359	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05360	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05048	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05437	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05438	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05492	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05525	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05528	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05596	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05597	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05603	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05708	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05709	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05771	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05802	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05803	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05812	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05874	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05875	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05876	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05881	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05882	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05883	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05884	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05885	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05886	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05894	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Zinostatin stimalamer	Smancs (TN)	70682998	Approved	D0Z4PE	.	CTPDG000033
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Motexafin gadolinium	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)	158385	Approved	D05BJD	DB05428	CTPDG000650
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Lomustine	"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea"	3950	Approved	D04JPJ	DB01206	CTPDG000674
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Borocaptate sodium B 10	.	.	Approved	D03EOT	.	CTPDG000723
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Approved	DTI-015	"Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics"	2578	Approved	D01OXI	DB00262	CTPDG000779
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	INO-1001	"Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one"	6708742	Phase 3	D0ZY3E	.	CTPDG000955
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	GliAtak	GliAtak (TN)	.	Phase 3	D0T3JF	.	CTPDG001047
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	SOT-107	TransMID	.	Phase 3	D0QL4X	.	CTPDG001075
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	ICT-107	.	.	Phase 3	D0M1RD	.	CTPDG001134
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Cintredekin besudotox	.	.	Phase 3	D0G6RB	.	CTPDG001201
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Ovarian	"DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics"	.	Phase 3	D02XEI	.	CTPDG001452
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 3	DCVax-Brain	"Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics"	.	Phase 3	D02RED	.	CTPDG001458
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	TVI-Brain-1	.	.	Phase 2/3	D5A6JN	.	CTPDG001521
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Synthetic survivin peptide vaccine	.	.	Phase 2	DWZ02M	.	CTPDG001616
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	Fresolimumab	GC-1008	.	Phase 2	DB35WK	.	CTPDG001756
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DNX-2401	Tasadenoturev	.	Phase 2	D8SV9R	.	CTPDG001771
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	TVI-Brain-1 cancer vaccine	.	.	Phase 2	D0ZR6E	.	CTPDG001853
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PDT with Photofrin	.	.	Phase 2	D0XL1T	.	CTPDG001888
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	F18-ML-10	.	.	Phase 2	D0K9NJ	.	CTPDG002257
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	CLR1404-I-124	.	.	Phase 1/2	D06EWT	.	CTPDG002766
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	DM-CHOC-PEN	.	16126905	Phase 2	D02ZZU	DB15075	CTPDG002941
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	L-alanosine	SDX-102	135409347	Phase 2	D02ELS	DB05540	CTPDG002984
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	rhenium-186	"(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM"	161105	Phase 1	DB7W8H	.	CTPDG003969
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	IGV-001	.	.	Phase 1	D9PM2E	.	CTPDG003992
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DA-3607	"Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A"	.	Phase 1	D0V3ZX	.	CTPDG004350
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	DC/I540/KLH vaccine	"HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber"	.	Phase 1	D0RH3S	.	CTPDG004447
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	KX2-361	KX-02	11545920	Phase 1	D0RE4L	.	CTPDG004448
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	INdoximod + temozolomide	.	.	Phase 1	D0B8BY	.	CTPDG004914
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 3	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	Discontinued in Phase 3	D0N5AY	.	CTPDG006347
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Oncolysin S	N901-bR	.	Discontinued in Phase 2	D0H0VW	.	CTPDG006511
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 2	Labradimil	"Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide"	6918284	Discontinued in Phase 2	D0G0IZ	DB06549	CTPDG006519
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Discontinued in Phase 1	Brain tumor vaccine	"Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC"	.	Discontinued in Phase 1	D0JT1P	.	CTPDG006795
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	PCNU	NSC-95466	26328	Terminated	D0JI5G	.	CTPDG007308
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Terminated	NSD-551	"BK channel activator (cancer), NeuroSearch/TopoTarget"	.	Terminated	D03QTB	.	CTPDG007526
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	NV.XOD.09	.	.	Investigative	D02RDC	.	CTPDG009014
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	EDP-19	"SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx"	.	Investigative	D02JIF	.	CTPDG009021
M6ACROT05921	.	.	M6ADIS0001	2A00: Brain cancer	Investigative	MIQ-004	M-IQ-004	.	Investigative	D01KZV	.	CTPDG009101
M6ACROT00065	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT00065	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT00066	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT00066	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02101	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02101	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02102	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02102	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02103	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02103	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02203	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02203	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02204	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02204	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02205	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02205	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02206	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02206	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02207	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02207	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02208	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02208	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02209	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02209	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02210	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02210	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02211	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02211	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02212	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02212	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02213	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02213	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02214	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02214	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02215	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02215	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02216	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02216	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02217	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02217	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02218	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02218	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02219	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02219	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02220	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02220	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02221	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02221	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02222	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02222	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02223	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02223	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02224	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02224	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02225	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02225	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02226	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02226	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02227	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02227	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02228	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02228	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02229	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02229	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02230	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02230	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02231	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02231	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02232	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02232	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02233	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02233	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02234	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02234	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02235	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02235	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02236	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02236	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02237	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02237	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02238	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02238	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02239	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02239	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02240	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02240	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02241	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02241	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02242	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02242	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02243	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02243	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02244	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02244	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02245	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02245	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02246	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02246	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02247	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02247	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02248	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02248	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02249	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02249	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02250	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02250	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02251	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02251	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02252	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02252	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02253	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02253	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02254	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02254	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02255	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02255	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02256	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02256	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02257	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02257	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02258	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02258	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02259	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02259	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02260	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02260	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02261	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02261	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02262	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02262	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02263	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02263	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02264	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02264	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02265	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02265	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02266	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02266	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02267	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02267	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02268	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02268	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02269	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02269	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02270	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02270	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02271	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02271	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02272	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02272	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02273	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02273	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02274	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02274	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05036	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05036	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05074	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05074	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05075	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05075	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05076	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05076	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05077	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05077	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05093	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05093	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05094	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05094	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05129	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05129	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05130	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05130	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05131	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05131	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05132	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05132	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05133	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05133	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05134	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05134	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05135	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05135	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05138	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05138	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05139	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05139	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05140	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05140	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05141	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05141	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05142	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05142	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05143	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05143	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05144	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05144	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05145	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05145	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05146	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05146	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05147	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05147	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05197	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05197	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05218	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05218	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05219	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05219	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05225	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05225	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05284	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05284	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05285	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05285	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05286	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05286	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05289	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05289	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05291	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05291	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05307	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05307	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05322	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05322	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05351	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05351	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05352	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05352	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05353	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05353	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05362	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05362	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05366	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05366	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05375	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05375	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05403	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05403	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05468	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05468	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05471	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05471	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT02054	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02054	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05383	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05383	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05384	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05384	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05385	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05385	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05386	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05386	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05387	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05387	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05388	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05388	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05389	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05389	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05390	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05390	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05391	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05391	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05392	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05392	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05393	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05393	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05394	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05394	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05431	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05431	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05510	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05510	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05546	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05546	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05565	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05565	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05579	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05579	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05608	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05608	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05610	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05610	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05613	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05613	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05679	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05679	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05702	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05702	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05877	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05877	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05931	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05931	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05956	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05956	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05957	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05957	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05976	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05976	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05977	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05977	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05978	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05978	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05979	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05979	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05980	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05980	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05981	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05981	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05993	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05993	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT05994	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05994	.	.	M6ADIS0065	2C60: Breast cancer	Approved	Everolimus	.	6442177	Approved	D09ZSC	DB01590	CTPDG008503
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT00072	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT02111	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT02112	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03046	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03190	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03191	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03208	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03228	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03634	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03635	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03636	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03637	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03638	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03639	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03640	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03641	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03642	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03643	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03644	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03645	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03646	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03647	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03648	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03649	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03650	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03651	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03652	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03653	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03654	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03655	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03656	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03657	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03658	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03659	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03660	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03661	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03662	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03663	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03664	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03665	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03666	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03667	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05002	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05051	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05065	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05107	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05117	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05122	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05208	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05209	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05216	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05217	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05230	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05287	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05288	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05293	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05309	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05312	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05313	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05323	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05324	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05325	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05350	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05395	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05401	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05402	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT02074	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT02106	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT02107	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03131	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03157	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03469	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03470	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03471	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03472	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03494	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03495	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03496	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03497	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03498	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03499	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03500	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03501	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT03502	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05212	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05499	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05522	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05582	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05598	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05599	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05614	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05645	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05662	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05698	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05825	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05869	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05923	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05941	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05961	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05962	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05982	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT05983	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT06019	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT06020	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT06021	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT06022	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Leniolisib	"1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ"	57495353	Approved	DGO2C1	.	CTPDG000014
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Ramucirumab	LY3009806	.	Approved	D09HVD	.	CTPDG000495
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Tucatinib	"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE"	51039094	Approved	D09GRX	DB11652	CTPDG009878
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Antacids	.	.	Approved	D06AJL	.	CTPDG000611
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	Approved	D04WFL	.	CTPDG009877
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Carbamazepine	"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals"	2554	Phase 3	D04MSM	DB00564	CTPDG000665
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Margetuximab	.	.	Approved	D01YYP	.	CTPDG009876
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GRANITE	"Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-"	11784975	Phase 3	DKF9I3	.	CTPDG000899
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	ABP 980	.	.	Phase 3	D0WZ0X	.	CTPDG001002
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	S-1	"Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)"	163872	Phase 3	D0S8LJ	.	CTPDG001054
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Lonsurf	.	.	Phase 3	D0PM0Y	.	CTPDG001090
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Edotecarin	"ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9808998	Phase 3	D0I1DW	DB04882	CTPDG001185
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	G17DT	Gastrimmune; Insegia	.	Phase 3	D0G8ZQ	.	CTPDG001198
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Nelipepimut S	E75	9941306	Phase 3	D0F8UV	.	CTPDG009882
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Rivoceranib	.	.	Phase 3	D0D7BX	.	CTPDG001239
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	OS-440	"CNS modulator (spasticity), Osmotica"	.	Phase 3	D09OHH	.	CTPDG001299
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Oraxol	.	.	Phase 3	D04UWU	.	CTPDG001415
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	"ICI 118,551"	"Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO"	3682	Phase 3	D04DJS	.	CTPDG001428
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	GSK1292263	.	24996872	Phase 2	D0S4II	DB12627	CTPDG002044
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	MM-111	.	.	Phase 2	D0Q2KM	.	CTPDG002097
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed	"ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,"	135430970	Phase 2	D0I9GR	DB06163	CTPDG002300
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	DS-8201	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-	10671	Phase 1	D0E8IQ	.	CTPDG002418
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	BAY-57-9352	Telatinib; Bay 57-9352	9808844	Phase 2	D07NOI	DB15393	CTPDG002682
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Bemarituzumab	.	.	Phase 2	D05ISO	.	CTPDG002804
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	Plevitrexed (R)-isomer	YW3548	213022	Phase 2	D04FYZ	.	CTPDG002868
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CT-041	.	.	Phase 1/2	DJ6AW5	.	CTPDG003175
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D0C9MJ	.	CTPDG003458
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1/2	PAT-SC1	"SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab"	.	Phase 1/2	D00UOQ	.	CTPDG003627
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	ASP2138	.	.	Phase 1	DTQL30	.	CTPDG003712
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	SAR443216	.	.	Phase 1	DL6F3E	.	CTPDG003835
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 199	.	.	Phase 1	DEP3Z8	.	CTPDG003930
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AMG 910	.	.	Phase 1	DEDP81	.	CTPDG003931
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	HER2-specific CAR T cell	.	.	Phase 1	D0YF6K	.	CTPDG004248
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	XR-5944	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942	439035	Phase 1	D0Q5TH	DB06364	CTPDG004482
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	A168	.	.	Phase 1	D0L9PU	.	CTPDG004618
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Minnelide 001	.	.	Phase 1	D05UFJ	.	CTPDG005185
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	CAR-T cells targeting EpCAM	.	.	Phase 1	D01TNK	.	CTPDG005378
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Clinical trial	EPCAM-targeted CAR-T cells	.	.	Clinical trial	D0T8DD	.	CTPDG005488
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	TOPIXANTRONE HYDROCHLORIDE	"SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride"	6918273	Discontinued in Phase 2	D06DWQ	.	CTPDG006607
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 2	BBR-3438	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438	3038512	Discontinued in Phase 2	D01VPR	.	CTPDG006658
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Application submitted	Kanjinti	.	.	Application submitted	D0CW3U	.	CTPDG006946
M6ACROT06023	.	.	M6ADIS0057	2B72: Gastric cancer	Investigative	Anti-CD9 mab	"ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University"	.	Investigative	D09BPT	.	CTPDG008570
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT00073	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT00074	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05174	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05175	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05266	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05381	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05382	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05514	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05529	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05530	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05531	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05536	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05567	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05581	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05583	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05922	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05958	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05959	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Enfortumab vedotin	Padcev	.	Phase 3	DAG87H	.	CTPDG000017
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Halaven	"Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent"	17755248	Phase 1/2	D0XQ5X	.	CTPDG000066
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Erdafitinib	"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino"	67462786	Approved	D0NW0T	DB12147	CTPDG000252
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Hexyl aminolevulinate	Hexvix (TN)	6433082	Approved	D0AY9Q	.	CTPDG000457
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	BCG vaccine	"OncoTice; TiceBCG; BCG vaccine, Organon"	.	Approved	D0A8LZ	.	CTPDG000460
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicineum	Oportuzumab monatox	.	Phase 3	DRP4Q9	.	CTPDG000883
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Sasanlimab	PF-06801591	.	Phase 3	DP2Z0X	.	CTPDG000889
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	CG0070	"CG-5757; Oncolytic virus therapy, Cell Genesys; Oncolytic virus therapy, Cold Genesys"	.	Phase 3	D7EZ0H	.	CTPDG000929
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Nadofaragene firadenovec	.	.	Phase 3	D0X4TK	.	CTPDG000995
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Oportuzumab monatox	.	.	Phase 3	D0OF1R	.	CTPDG001097
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Apaziquone	"EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin"	5813717	Phase 3	D0FP0R	DB12593	CTPDG001206
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	EN3488	.	.	Phase 3	D09KHE	.	CTPDG001306
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Ramucirumab	.	.	Phase 3	D01QWT	.	CTPDG001482
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 3	Vicinium	.	.	Phase 3	D00RTC	.	CTPDG001495
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ICP-192	.	.	Phase 2	DZM65T	.	CTPDG001597
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Inodiftagene vixteplasmid	BC-819	.	Phase 2	DE2V3Y	.	CTPDG001736
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CPX-POM	.	.	Phase 2	D7K3FB	.	CTPDG001779
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CV-301	.	.	Phase 2	D0W8FE	.	CTPDG001922
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	INO-5401	.	.	Phase 2	D0P2ME	.	CTPDG002117
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	NC-6004	.	.	Phase 2	D0FG2Z	.	CTPDG002387
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesigenurtacel-L	.	.	Phase 2	D0E8QE	.	CTPDG002413
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	BAY1163877	Rogaratinib	71611869	Phase 2	D0E8PR	DB15078	CTPDG002414
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	OGX-427	.	71710946	Phase 2	D0AX1N	.	CTPDG002521
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	VesiGel	.	.	Phase 2	D08LYZ	.	CTPDG002629
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Instiladrin	.	.	Phase 2	D07CNY	.	CTPDG002708
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	CDX-1307	"BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics"	.	Phase 2	D04REV	.	CTPDG002847
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	MV-NIS	"MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc"	.	Phase 1	D01IJJ	.	CTPDG003034
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-PSMA	.	.	Phase 1/2	D0VI8T	.	CTPDG003295
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	Lx-TB-PstS1	Lx-Bladder	.	Phase 1/2	D0H7LN	.	CTPDG003424
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	4SCAR-FRa	.	.	Phase 1/2	D09NUH	.	CTPDG003489
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1/2	ABY-025	.	.	Phase 1/2	D08KCJ	.	CTPDG003509
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	TAR-200	.	.	Phase 1	D0WM3D	.	CTPDG004302
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	ASG-15ME	.	.	Phase 1	D0UM4S	.	CTPDG004361
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 2	Vesimune	.	.	Phase 2	D0S0ZQ	.	CTPDG004440
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Neo-Urinary Conduit	.	.	Phase 1	D0B6LP	.	CTPDG004916
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	FPA144	.	.	Phase 1	D06NND	.	CTPDG005152
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	Ad-IFN-alpha	"Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI"	.	Phase 1	D03QWG	.	CTPDG005295
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Phase 1	LNK-754	"LNK 754; 439153-64-7; OSI 754; CP 609754; CP-609,754; DTXSID60195986; 2(1H)-Quinolinone, 6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-ethynylphenyl)-1-methyl-"	46208720	Phase 1	D03BXU	DB12640	CTPDG005324
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	example 7 [US8664233]	"SCHEMBL977927; GTPL8283; HFGHRUCCKVYFKL-UHFFFAOYSA-N; SB19793; 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indole; 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole"	24990553	Clinical trial	D0Y9FX	.	CTPDG005481
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Clinical trial	(S)-DRF-1042	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT	91623363	Clinical trial	D0M8KY	.	CTPDG005498
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 3	Keyhole limpet hemocyanin	.	.	Discontinued in Phase 3	D07UQR	.	CTPDG006374
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2/3	IDM-2	"Bexidem; MAK anticancer agents (2), Immuno-Designed Molecules/IDM Pharma"	.	Discontinued in Phase 2/3	D0YW4R	.	CTPDG006394
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 2	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	Discontinued in Phase 2	D0U9LL	.	CTPDG006424
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Discontinued in Phase 1/2	S-288310	"Peptide vaccine (bladder cancer), OncoTherapy Science; Peptide vaccine (bladder cancer), Shionogi"	.	Discontinued in Phase 1/2	D0Z2KU	.	CTPDG006682
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Application submitted	Capzola	.	.	Application submitted	D0VO7K	.	CTPDG006941
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	MINAMESTANE	"FCE-24928; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	Terminated	D0FS9K	.	CTPDG007352
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Terminated	CG-8840	CV-884	.	Terminated	D02GJE	.	CTPDG007555
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ET-009	.	.	Investigative	D0XT3G	.	CTPDG007690
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-6989	.	.	Investigative	D0V9BX	.	CTPDG007788
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SL-601	.	.	Investigative	D0QI1O	.	CTPDG007931
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	ASC-JMZ1	.	.	Investigative	D0O0II	.	CTPDG008021
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-3633	.	.	Investigative	D0A5KO	.	CTPDG008489
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	CEL-011	.	.	Investigative	D09TSX	.	CTPDG008516
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Debio-1141	"PLK-1 targeting UsiRNA (liposomal, cancer), Marina; PLK1-targeting UsiRNA (liposomal, cancer), MDRNA; PLK-1 targeting UsiRNA (liposomal, bladder cancer), Marina/Debiopharm"	.	Investigative	D09OLR	.	CTPDG008532
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TD-1770	.	.	Investigative	D08VWJ	.	CTPDG008580
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	Chitosan/IL-12	"Chitosan/IL-12 immunotherapy (intravesical, cancer), National Cancer Institute"	.	Investigative	D08UZA	.	CTPDG008586
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BAMLET	"BAMLET (liquid formulation, bladder cancer); BAMLET instillation (bladder cancer), NatImmune; BAMLET (liquid formulation, bladder cancer), NatImmune; Bovine alpha-lactalbumin-lipid complex (liquid formulation, bladder cancer), NatImmune"	.	Investigative	D07FCA	.	CTPDG008701
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	TMX-202	TMX-20X	.	Investigative	D05TCC	.	CTPDG008798
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	AP-300	.	.	Investigative	D03KIK	.	CTPDG008964
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	BC-821	"IGF2-DTA; Diphtheria toxin A conjugated insulin-like growth factor 2 (cancer), BioCancell"	.	Investigative	D03IQK	.	CTPDG008968
M6ACROT05960	.	.	M6ADIS0070	2C94: Bladder cancer	Investigative	OGX-427 + Paclitaxel	.	91866823	Investigative	D00ZBZ	.	CTPDG009138
M6ACROT02001	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT02001	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02001	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02001	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02001	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02002	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT02002	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02002	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02002	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02002	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02003	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT02003	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02003	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02003	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02003	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02004	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT02004	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02004	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02004	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02004	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02005	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT02005	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02005	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02005	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02005	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT03159	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT03159	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT03159	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT03159	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT03159	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT03079	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT03079	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT03079	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT03079	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT03079	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT05650	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Clinical Trial	KB174	.	.	Clinical Trial	DDNL40	.	CTPDG005480
M6ACROT05650	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT05650	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT05650	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT05650	.	.	M6ADIS0017	DB93: Hepatic fibrosis/cirrhosis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02014	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT02015	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT02016	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT02017	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT02018	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03073	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03327	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03328	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03329	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03330	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03331	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT03332	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05078	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05102	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05265	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05294	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05297	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05343	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05344	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05427	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05428	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05571	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05572	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05587	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05623	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05674	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05693	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05744	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05832	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05918	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05964	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05965	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05966	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT05967	.	.	M6ADIS0068	2C82: Prostate cancer	Phase 1	CC-94676	.	.	Phase 1	DNY63Z	.	CTPDG003796
M6ACROT02025	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT02025	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT02025	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT02026	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT02026	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT02026	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT03005	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT03005	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT03005	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT03006	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT03006	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT03006	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT03160	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT03160	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT03160	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT03161	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT03161	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT03161	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT03503	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT03503	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT03503	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05329	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05329	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05329	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05330	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05330	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05330	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT03238	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT03238	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT03238	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05557	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05557	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05557	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05970	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05970	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05970	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05971	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05971	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05971	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05972	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05972	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05972	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05973	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05973	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05973	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT05974	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 3	Rexlemestrocel-L	MPC-150-M	.	Phase 3	DHV2L8	.	CTPDG000904
M6ACROT05974	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	CybroCell	.	.	Phase 1/2	DS6C1Y	.	CTPDG003144
M6ACROT05974	.	.	M6ADIS0168	FA80: Intervertebral disc degeneration	Phase 1/2	IDCT	rebonuputemcel	.	Phase 1/2	DK65RJ	.	CTPDG003171
M6ACROT02027	.	.	M6ADIS0077	3C0Z: Hematological disorders	Approved	Lmw heparin	Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)	25244225	Approved	D08PSU	.	CTPDG000518
M6ACROT02027	.	.	M6ADIS0077	3C0Z: Hematological disorders	Phase 1	CK0801	.	.	Phase 1	DX8QZ3	.	CTPDG003665
M6ACROT02027	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	HemoTech	"Blood substitute (hematological disease), HemoBiotech; Bovine hemoglobin + adenosine 5'-triphosphate + o-adenosine + reduced glutathione (hemotological disease), HemoBiotech"	.	Investigative	D0BA8H	.	CTPDG008439
M6ACROT02027	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	PN-951	.	.	Investigative	D06WLY	.	CTPDG008722
M6ACROT02027	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	Hematological disease agents	"Hematological disease agents, Tartis; SM-27"	486047	Investigative	D03BPU	.	CTPDG008986
M6ACROT02028	.	.	M6ADIS0077	3C0Z: Hematological disorders	Approved	Lmw heparin	Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)	25244225	Approved	D08PSU	.	CTPDG000518
M6ACROT02028	.	.	M6ADIS0077	3C0Z: Hematological disorders	Phase 1	CK0801	.	.	Phase 1	DX8QZ3	.	CTPDG003665
M6ACROT02028	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	HemoTech	"Blood substitute (hematological disease), HemoBiotech; Bovine hemoglobin + adenosine 5'-triphosphate + o-adenosine + reduced glutathione (hemotological disease), HemoBiotech"	.	Investigative	D0BA8H	.	CTPDG008439
M6ACROT02028	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	PN-951	.	.	Investigative	D06WLY	.	CTPDG008722
M6ACROT02028	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	Hematological disease agents	"Hematological disease agents, Tartis; SM-27"	486047	Investigative	D03BPU	.	CTPDG008986
M6ACROT02029	.	.	M6ADIS0077	3C0Z: Hematological disorders	Approved	Lmw heparin	Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)	25244225	Approved	D08PSU	.	CTPDG000518
M6ACROT02029	.	.	M6ADIS0077	3C0Z: Hematological disorders	Phase 1	CK0801	.	.	Phase 1	DX8QZ3	.	CTPDG003665
M6ACROT02029	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	HemoTech	"Blood substitute (hematological disease), HemoBiotech; Bovine hemoglobin + adenosine 5'-triphosphate + o-adenosine + reduced glutathione (hemotological disease), HemoBiotech"	.	Investigative	D0BA8H	.	CTPDG008439
M6ACROT02029	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	PN-951	.	.	Investigative	D06WLY	.	CTPDG008722
M6ACROT02029	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	Hematological disease agents	"Hematological disease agents, Tartis; SM-27"	486047	Investigative	D03BPU	.	CTPDG008986
M6ACROT02097	.	.	M6ADIS0077	3C0Z: Hematological disorders	Approved	Lmw heparin	Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)	25244225	Approved	D08PSU	.	CTPDG000518
M6ACROT02097	.	.	M6ADIS0077	3C0Z: Hematological disorders	Phase 1	CK0801	.	.	Phase 1	DX8QZ3	.	CTPDG003665
M6ACROT02097	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	HemoTech	"Blood substitute (hematological disease), HemoBiotech; Bovine hemoglobin + adenosine 5'-triphosphate + o-adenosine + reduced glutathione (hemotological disease), HemoBiotech"	.	Investigative	D0BA8H	.	CTPDG008439
M6ACROT02097	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	PN-951	.	.	Investigative	D06WLY	.	CTPDG008722
M6ACROT02097	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	Hematological disease agents	"Hematological disease agents, Tartis; SM-27"	486047	Investigative	D03BPU	.	CTPDG008986
M6ACROT05527	.	.	M6ADIS0077	3C0Z: Hematological disorders	Approved	Lmw heparin	Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)	25244225	Approved	D08PSU	.	CTPDG000518
M6ACROT05527	.	.	M6ADIS0077	3C0Z: Hematological disorders	Phase 1	CK0801	.	.	Phase 1	DX8QZ3	.	CTPDG003665
M6ACROT05527	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	HemoTech	"Blood substitute (hematological disease), HemoBiotech; Bovine hemoglobin + adenosine 5'-triphosphate + o-adenosine + reduced glutathione (hemotological disease), HemoBiotech"	.	Investigative	D0BA8H	.	CTPDG008439
M6ACROT05527	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	PN-951	.	.	Investigative	D06WLY	.	CTPDG008722
M6ACROT05527	.	.	M6ADIS0077	3C0Z: Hematological disorders	Investigative	Hematological disease agents	"Hematological disease agents, Tartis; SM-27"	486047	Investigative	D03BPU	.	CTPDG008986
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02030	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02031	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02032	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02033	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02116	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02117	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02118	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02119	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02120	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02121	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02122	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02123	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02124	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02125	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02126	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02127	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02128	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02129	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02130	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02131	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT02133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03080	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03083	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03084	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03132	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03133	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03198	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03199	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03473	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03474	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03475	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03476	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03477	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03478	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03479	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT03480	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05004	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05201	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05214	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05281	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05318	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05319	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05377	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05379	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05469	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05081	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05376	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05526	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05543	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05563	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05564	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05574	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05625	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05634	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05672	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05686	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05689	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05699	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05700	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05735	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05736	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05775	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05776	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05863	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05864	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05865	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05866	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05867	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05868	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT05950	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT06041	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Trimethadione	"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]"	5576	Approved	D0U4VT	DB00347	CTPDG000123
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Uridine triacetate	PN401	20058	Approved	D0OL7F	DB09144	CTPDG000232
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Bentiromide	Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so	6957673	Approved	D0L0SW	DB00522	CTPDG000292
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Olaparib	"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one"	23725625	Approved	D0J9HW	DB09074	CTPDG000323
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Streptozocin	"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose"	29327	Approved	D0I8RR	DB00428	CTPDG000340
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Plazomicin	"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,"	42613186	Phase 3	D0E6BB	DB12615	CTPDG000408
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Coenzyme Q10	"CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen"	5281915	Phase 2	D01ZUA	DB09270	CTPDG000852
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Aglatimagene besadenovec	.	.	Phase 1/2	DE8H1W	.	CTPDG000913
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zolbetuximab	IMAB362	.	Phase 3	D4HQ1F	.	CTPDG000939
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfomide	.	.	Phase 3	D0W7PQ	.	CTPDG001009
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Yttrium (90Y) clivatuzumab tetraxetan	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4	.	Phase 3	D0V2KR	.	CTPDG001022
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Y-90 Clivatuzumab	.	.	Phase 3	D0T8AI	.	CTPDG001041
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Civacir	.	.	Phase 3	D0P9UP	.	CTPDG001092
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	GV1001	.	.	Phase 3	D0N0QC	.	CTPDG001119
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Glufosfamide	"Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol"	123628	Phase 3	D0L9IA	DB06177	CTPDG001144
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pamrevlumab	.	.	Phase 3	D09TJJ	.	CTPDG001296
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	GRASPA	"L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech"	.	Phase 1	D09JKS	.	CTPDG001309
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Pancreas algenpantucel-L	HyperAcute (TN)	.	Phase 3	D08PBQ	.	CTPDG001326
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	MM-398	.	91809656	Phase 3	D07HOH	.	CTPDG001363
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	ANX-510	.	135400185	Phase 3	D01YKI	.	CTPDG001476
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 3	Algenpantucel-L	HyperAcute pancreas (TN)	.	Phase 3	D00HSK	.	CTPDG001502
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2/3	SM-88	.	3125	Phase 2/3	D03ZDX	.	CTPDG001575
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT141	.	.	Phase 2	DFZ19J	.	CTPDG001718
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BNT321	MVT-5873	.	Phase 2	D7AOL8	.	CTPDG001782
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BPM 31510	.	.	Phase 2	D4MZR2	.	CTPDG001815
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GC4711	"UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,"	131634674	Phase 2	D3P8JK	.	CTPDG001823
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CYTO-401	.	.	Phase 2	D2Q5XO	.	CTPDG001833
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Zenocutuzumab	.	.	Phase 2	D1J4CI	.	CTPDG001846
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	.	.	Phase 2	D0VG7I	.	CTPDG001949
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MENK	IRT-101	.	Phase 2	D0TN1J	.	CTPDG002002
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TL-118	"Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma"	.	Phase 2	D0T9OC	.	CTPDG002007
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	NPC-1C	Ensituximab	.	Phase 2	D0T2FC	.	CTPDG002025
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Necuparanib	.	.	Phase 2	D0S3CX	.	CTPDG002045
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CCX872	.	.	Phase 2	D0Q3PB	.	CTPDG002095
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GC4419	"Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-"	71587734	Phase 1/2	D0PV9N	.	CTPDG002106
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Istiratumab	.	.	Phase 2	D0P4ZR	.	CTPDG002116
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000	.	.	Phase 2	D0N4SF	.	CTPDG002173
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	OCV-101	OTS-11101	.	Phase 2	D0LX8Z	.	CTPDG002215
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ensitiximab	.	.	Phase 2	D0KL4T	.	CTPDG002250
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BC-819	.	.	Phase 2	D0K0KQ	.	CTPDG002272
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	IRT-102	.	42785	Phase 2	D0J5UK	.	CTPDG002286
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LE-DT	Liposomal docetaxel	.	Phase 2	D0J2NX	.	CTPDG002289
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Demcizumab	.	.	Phase 2	D0GJ7N	.	CTPDG002354
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Anti-PSCA mab	.	.	Phase 2	D0G7ZT	.	CTPDG002362
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	ARQ 761	.	.	Phase 2	D0DR0P	.	CTPDG002435
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Reolysinpelareorep	.	.	Phase 2	D0CW2N	.	CTPDG002465
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PBI-05204	.	11541511	Phase 2	D0A4YK	DB12843	CTPDG002548
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PCI-27483	.	135425273	Phase 2	D09TFL	DB13000	CTPDG002560
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CP-613	.	.	Phase 2	D07FXF	.	CTPDG002702
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	CART 19	.	.	Preclinical	D06TKR	.	CTPDG002732
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	VT-122	.	.	Phase 1	D05VKS	.	CTPDG002784
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PEGPH20	.	.	Phase 2	D05INV	.	CTPDG002805
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tigatuzumab	.	.	Phase 2	D03LTO	.	CTPDG002920
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207	.	.	Phase 2	D02WSB	.	CTPDG002948
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CAP1-6D	"Modified CEA peptide (pancreatic cancer), University of Chicago"	396060	Phase 2	D02UKX	.	CTPDG002952
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Ocaperidone	"Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019"	71351	Phase 2	D01FQR	DB06229	CTPDG003044
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	Encapsulated live cells converting ifosfamide	.	.	Phase 2	D01DLT	.	CTPDG003048
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	LY2603618	Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea	11955855	Phase 2	D00NZL	DB11662	CTPDG003075
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GB1275	.	.	Phase 1/2	DZ5K6F	.	CTPDG003119
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ABTL0812	"(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ"	21158511	Phase 1/2	DMBQ10	.	CTPDG003162
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GP-2250	.	.	Phase 1/2	DARV32	.	CTPDG003202
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	GSK3145095	"1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)"	118557502	Phase 1/2	D0Z7BX	.	CTPDG003267
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	ETBX-011 cancer vaccine	.	.	Phase 1/2	D0U1WU	.	CTPDG003308
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BPX-601	.	.	Phase 1/2	D0TY6U	.	CTPDG003313
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	NANT	.	.	Phase 1/2	D0T4GG	.	CTPDG003322
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	BrevaRex	BrevaRex MAb; monoclonal antibody	.	Phase 1/2	D0M5JC	.	CTPDG003378
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	DCVax-Pancreas	"Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics"	.	Phase 1/2	D0L7LT	.	CTPDG003388
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	PEGylated hyaluronidase (human recombinant)	"PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme"	.	Phase 1/2	D0L5IA	.	CTPDG003389
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T cells targeting mesothelin	.	.	Phase 1/2	D0KC2S	.	CTPDG003393
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-Mesothelin CAR-T cells	.	.	Phase 1/2	D0BE6M	.	CTPDG003467
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 CAR T Cells	.	.	Phase 1/2	D08WII	.	CTPDG003500
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-HER2 CAR-T	.	.	Phase 1/2	D08QZH	.	CTPDG003503
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-MUC1 AR20.5	.	.	Phase 1/2	D07YGQ	.	CTPDG003519
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	AR20.5	.	.	Phase 1/2	D07PCZ	.	CTPDG003523
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LOAd703	.	.	Phase 1/2	D03ZIP	.	CTPDG003581
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	Anti-mesothelin CAR transduced PBL	.	.	Phase 1/2	D00YXG	.	CTPDG003625
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	M9241	NHS-IL12	.	Phase 1	DO8W9E	.	CTPDG003785
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	NBF-006	.	.	Phase 1	D8UZ5R	.	CTPDG004009
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AB680	"AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH"	130205852	Phase 1	D7CE6N	.	CTPDG004045
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	STAT400	.	.	Phase 1	D75WVO	.	CTPDG004048
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CEND-1	"iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide"	134611625	Phase 1	D5WU7B	.	CTPDG004079
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HuCART-meso cells	.	.	Phase 1	D0ZF9J	.	CTPDG004218
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	OCV-105	"Cancer vaccine (pancreas), Otsuka/OncoTherapy"	.	Phase 1	D0X9YB	.	CTPDG004279
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SBP-101	diethyl dihydroxyhomospermine	.	Phase 1	D0VE9F	.	CTPDG004335
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	RG7882	.	.	Phase 1	D0V7QW	.	CTPDG004343
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso-19 T cells	.	.	Phase 1	D0V5DD	.	CTPDG004348
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MOv19-BBz CAR T cells	.	.	Phase 1	D0T7CR	.	CTPDG004403
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 AR20.5 mab	.	.	Phase 1	D0S3AE	.	CTPDG004437
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA-CAR T	.	.	Phase 1	D0S1QN	.	CTPDG004438
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-5873	.	.	Phase 1	D0Q5QV	.	CTPDG004483
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CART-meso cells	.	.	Phase 1	D0P2GA	.	CTPDG004526
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-20/19-T Cells	.	.	Phase 1	D0NU9L	.	CTPDG004562
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CARTmeso/19	.	.	Phase 1	D0MD8S	.	CTPDG004593
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting Mesothelin	.	.	Phase 1	D0L7OJ	.	CTPDG004622
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting CEA	.	.	Phase 1	D0L6HU	.	CTPDG004626
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine	"HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)"	.	Phase 1	D0K6UQ	.	CTPDG004653
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MORAb-066	"Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek"	.	Phase 1	D0H8PX	.	CTPDG004745
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-MUC1 mab	.	.	Phase 1	D0H2CF	.	CTPDG004756
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	CRS-207 + GVAX	.	.	Phase 2	D0EY1Y	.	CTPDG004816
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	.	.	Phase 1	D0EB0Y	.	CTPDG004826
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Meso-CART	.	.	Phase 1	D0D2LE	.	CTPDG004868
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	ASG-5ME	.	.	Phase 1	D0BC6M	.	CTPDG004908
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CD133-CAR vector-transduced T cells	.	.	Phase 1	D09HRH	.	CTPDG005002
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	IRX4204	"220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid"	9863341	Phase 1	D09DJC	DB11806	CTPDG005009
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	AbGn-107	.	.	Phase 1	D08GZE	.	CTPDG005055
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1/2	LMB-100	.	.	Phase 1/2	D07RDQ	.	CTPDG005087
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting HER2	.	.	Phase 1	D06XWD	.	CTPDG005132
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting MUCI	.	.	Phase 1	D06URX	.	CTPDG005138
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	SEL-403	.	.	Phase 1	D03ZLN	.	CTPDG005274
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	CAR-T Cells targeting PSCA	.	.	Phase 1	D02MYI	.	CTPDG005352
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D00KDQ	.	CTPDG005459
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 1	MVT-1075	.	.	Phase 1	D00IFQ	.	CTPDG005464
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CAR-CLD18 T cell	.	.	Clinical trial	D06CWZ	.	CTPDG005506
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Clinical trial	CART-meso cells	.	.	Clinical trial	D04WZL	.	CTPDG005508
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Patented	PMID28460551-Compound-1	.	25190990	Patented	D0IH3I	DB14866	CTPDG005853
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 3	Larotaxel	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881	6918260	Discontinued in Phase 3	D0J0RV	DB12984	CTPDG006353
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Apricoxib	TG01	9820073	Discontinued in Phase 2	D0S7IZ	DB12378	CTPDG006437
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Lintitript	"SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid"	122077	Discontinued in Phase 2	D01ZXW	DB04867	CTPDG006656
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	Merbarone	NSC-336628	4990817	Discontinued in Phase 2	D00VZF	.	CTPDG006670
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 2	LY293111	"Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny"	177941	Discontinued in Phase 2	D00GNK	DB12850	CTPDG006674
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	Discontinued in Phase 1	D0R7ID	.	CTPDG006751
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Discontinued in Phase 1	RG7600	.	.	Discontinued in Phase 1	D04TYP	.	CTPDG006895
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	IC261	IC-261; IC 261	5288600	Preclinical	D0UN8H	DB03083	CTPDG007041
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Terminated	IPH-4201	"MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM"	.	Terminated	D0F6HW	.	CTPDG007355
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	MesoTarg	.	.	Investigative	D0W5KO	.	CTPDG007763
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	PAT-PM-1	"PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys"	.	Investigative	D0U9YV	.	CTPDG007818
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	OP-04	"OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon"	.	Investigative	D0S0DY	.	CTPDG007896
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	GS-326	GS-326C	3041004	Investigative	D0LI3A	.	CTPDG008097
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Phase 2	PX-12	.	219104	Phase 2	D0FT8G	DB05448	CTPDG008286
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Prodigiosin	.	135455579	Investigative	D06YEE	.	CTPDG008714
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Pbi-shPDX-1 LP	.	.	Investigative	D02FAI	.	CTPDG009032
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	Gastrin 17C diphtheria toxoid conjugate	Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)	.	Investigative	D01PNR	.	CTPDG009084
M6ACROT06042	.	.	M6ADIS0061	2C10: Pancreatic cancer	Investigative	HS-P1	"HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics"	71537	Investigative	D00JKJ	.	CTPDG009181
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02043	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02058	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02059	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02060	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02061	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02062	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02063	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02064	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02065	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02066	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02067	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02068	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02069	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02141	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02142	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02143	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02145	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02146	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02147	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02148	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02149	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02150	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02151	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02152	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02153	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02154	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02155	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02156	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02158	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02159	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02160	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02161	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02162	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02163	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02164	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02165	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02166	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02167	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02168	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02169	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02171	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02172	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02173	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02174	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02175	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02176	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02177	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02178	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02179	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02180	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02181	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02182	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02184	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02185	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02186	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02187	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02188	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02189	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02190	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02191	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02192	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03042	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03064	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03128	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03156	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03307	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03308	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03309	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03465	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03466	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03467	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03468	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03493	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05020	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05032	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05033	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05034	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05035	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05109	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05115	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05157	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05190	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05223	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05224	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05235	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05236	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05237	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05238	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05239	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05240	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05241	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05242	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05243	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05244	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05245	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05246	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05247	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05248	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05249	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05250	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05251	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05252	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05253	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05254	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05255	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05256	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05257	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05258	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05259	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05260	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05261	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05262	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05271	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05272	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05301	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05327	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05365	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05367	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05404	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05405	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05406	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05407	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05408	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05409	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05413	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05453	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02034	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02035	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02036	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02037	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02038	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02039	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02134	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02135	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02136	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02137	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02138	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02139	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT02140	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03107	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03108	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03109	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03110	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03147	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03158	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03377	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03378	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03379	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03380	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03381	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03382	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03383	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03384	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03385	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03386	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03387	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03388	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03389	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03390	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03391	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03392	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03393	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03394	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03395	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03396	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03397	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03398	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03399	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03400	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03401	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT03402	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05283	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05335	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05419	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05490	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05493	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05498	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05511	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05523	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05524	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05544	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05545	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05549	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05550	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05551	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05576	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05577	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05578	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05585	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05586	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05605	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05609	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05617	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05618	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05620	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05631	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05633	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05646	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05648	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05649	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05676	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05692	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05712	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05728	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05750	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05758	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05759	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05767	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05770	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05773	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05774	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05785	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05795	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05796	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05797	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05798	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05799	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05800	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05826	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05854	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05855	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05856	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05857	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05890	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05902	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05903	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05904	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05905	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05906	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05907	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05908	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05909	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05910	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05911	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05912	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05913	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05914	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05915	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sacituzumab govitecan	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6	91668186	Approved	D8LAE2	.	CTPDG013135
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Repotrectinib	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778	135565923	Approved	D05NFR	.	CTPDG000629
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	MYL-1402O	bevacizumab biosimilar	.	Phase 3	DYH3Q6	.	CTPDG000864
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	AB154	Domvanalimab	.	Phase 3	DT1FS0	.	CTPDG000877
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Datopotamab deruxtecan	.	.	Phase 3	DP41HV	.	CTPDG000888
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	TRS003	.	.	Phase 3	D2KVG4	.	CTPDG000947
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	Tusamitamab ravtansine	SAR408701	.	Phase 3	D2D6NJ	.	CTPDG000948
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 3	RG6058	Tiragolumab	.	Phase 3	D0L4VD	.	CTPDG001147
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	GSK4069889	TSR-022	.	Phase 2	DZW53X	.	CTPDG001593
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	SGN-LIV1A	Ladiratuzumab Vedotin	.	Phase 2	DS6B1L	.	CTPDG001637
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	BNT116	.	.	Phase 2	DR39GZ	.	CTPDG001643
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AZD7789	.	.	Phase 2	DNI7E3	.	CTPDG001663
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	L-DOS47	.	.	Phase 1/2	DN3Z5D	.	CTPDG001668
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	NC318	.	.	Phase 2	D9UZ5Q	.	CTPDG001763
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Vorolanib	"UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"	59215954	Phase 2	D8AG3S	DB15247	CTPDG001773
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Xofigo	.	.	Phase 2	D6B7FP	.	CTPDG001791
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	AB-106	DS6051b; GTPL11198; AB106	154699459	Phase 2	D2KV8B	.	CTPDG001834
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 2	RO-5126766	"VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche"	16719221	Phase 2	D0M6BD	DB15254	CTPDG002198
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	TC-210	.	.	Phase 1/2	DX6O9V	.	CTPDG003133
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	MRx0518	.	.	Phase 1/2	DP4J2K	.	CTPDG003154
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	BGB-A425	.	.	Phase 1/2	D7UIZ1	.	CTPDG003222
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	Rilvegostomig	AZD2936	.	Phase 1/2	D4RMC9	.	CTPDG003244
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1/2	IK-007	grapiprant	.	Phase 1/2	D1KES8	.	CTPDG003258
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ENV-105	Carotuximab	.	Phase 1	DQ8K3R	.	CTPDG003754
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	AMG 160	.	.	Phase 1	DOY4E6	.	CTPDG003777
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	MEDI5752	.	.	Phase 1	D7L1MP	.	CTPDG004039
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-06936308	.	.	Phase 1	D2LUK7	.	CTPDG004161
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	GEM3PSCA	.	.	Phase 1	D1L7DE	.	CTPDG004190
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Approved	Gemcitabine	.	60750	Approved	D0AJ3K	DB00441	CTPDG007098
M6ACROT05916	.	.	M6ADIS0007	2C25: Lung cancer	Investigative	SMI-4a	"438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione"	1361334	Investigative	DAJ3D2	.	CTPDG007606
M6ACROT02053	.	.	M6ADIS0038	GB60: Acute kidney failure	Phase 3	BQ788	"(2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752"	16759603	Phase 3	D08IXA	.	CTPDG001334
M6ACROT02053	.	.	M6ADIS0038	GB60: Acute kidney failure	Phase 2	EA-230	"503844-09-5; (2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-methylbutanoic acid; L-Valine, L-alanyl-L-glutaminylglycyl-; DTXSID80436085"	10133920	Phase 2	DL51QK	.	CTPDG001690
M6ACROT02053	.	.	M6ADIS0038	GB60: Acute kidney failure	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT02053	.	.	M6ADIS0038	GB60: Acute kidney failure	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Carbocisteine	"Carbocysteine; Siroxyl; Carbocisteine, Sopar"	193653	Approved	D0X5SI	DB04339	CTPDG000069
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Aclidinium	UNII-K17VY42F6C; K17VY42F6C; CHEBI:65346; 727649-81-2; CHEMBL551466; (3R)-3-[2-hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide; SCHEMBL72141; GTPL7449; SCHEMBL15096073; CHEMBL1194325; DTXSID00223070; ZINC30691727; BDBM50296331; DB08897; AJ-84146; AB01565828_02; 1-(3-Phenoxypropyl)-3alpha-[hydroxybis(2-thienyl)acetyloxy]-1-azoniabicyclo[2.2.2]octane	11434515	Approved	D0VP1V	DB08897	CTPDG000095
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Tiotropium	"186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide"	5487427	Approved	D0P1WA	DB01409	CTPDG000223
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Fluorometholone	"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione"	9878	Approved	D0P0HT	DB00324	CTPDG000227
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Bamifylline	Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride	16229	Approved	D0O7SP	DB13203	CTPDG000239
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Maraviroc	"376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc"	3002977	Phase 3	D0NR6S	DB04835	CTPDG000258
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Glycopyrrolate	"596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide"	11693	Approved	D0M0AM	.	CTPDG000278
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Salmeterol	"Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol"	5152	Approved	D0L5YV	DB00938	CTPDG000287
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Vilanterol	"503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair"	10184665	Approved	D0L0GM	DB09082	CTPDG000293
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	MK-08887A	DULERA	71301227	Approved	D0K3WO	.	CTPDG000312
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Revefenacin	UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7	11753673	Approved	D0K1ST	DB11855	CTPDG000314
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Prasterone	"Dehydroepiandrosterone; DHEA; 53-43-0; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone"	5881	Approved	D0K0EK	DB01708	CTPDG000316
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Meprednisone	Betapar	5284587	Approved	D0I5DS	DB09383	CTPDG000347
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Theophylline	"Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione"	2153	Approved	D0F8RA	DB00277	CTPDG000383
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Almitrine	"Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine"	33887	Approved	D0D9NA	DB01430	CTPDG000420
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Arformoterol	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate	3083544	Approved	D0D1DI	DB01274	CTPDG000428
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Incruse Ellipta	"Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2"	11519069	Approved	D09ZOQ	.	CTPDG000474
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	LAS-34273	"Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide"	11519741	Approved	D07KHH	.	CTPDG000564
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Bitolterol	Tornalate	35330	Approved	D06RUL	DB00901	CTPDG000593
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Olodaterol	BI-1744	11504295	Approved	D04UTT	DB09080	CTPDG000659
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Symbicort	"(22R)-Budesonide; UNII-2HI1006KPH; 51333-22-3; 51372-29-3; 2HI1006KPH; DSSTox_CID_202; DSSTox_RID_75430; DSSTox_GSID_20202; (1~{s},2~{s},4~{r},6~{r},8~{s},9~{s},11~{s},12~{s},13~{r})-9,13-Dimethyl-11-Oxidanyl-8-(2-Oxidanylethanoyl)-6-Propyl-5,7-Dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-Dien-16-One; R-Budesonide; Budesonide-22R; NCGC00016862-01; EINECS 257-161-7; CAS-51333-22-3; BUDESONIDE (11beta,16alpha(R)); SCHEMBL4095; AC1L22VC; CHEMBL2110662"	40000	Approved	D04QNO	.	CTPDG000662
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Indacaterol	"312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone"	6918554	Approved	D03DJL	DB05039	CTPDG000726
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Benralizumab	.	.	Approved	D02PIO	.	CTPDG000744
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Anoro	Umeclidinium + vilanterol	.	Approved	D02CKO	.	CTPDG000762
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Pregabalin	"Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer"	5486971	Approved	D00WUF	DB00230	CTPDG000797
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Relvar/Breo	Vilanterol + fluticasone furoate	71306415	Approved	D00WMK	.	CTPDG000798
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Umeclidinium	.	11519070	Approved	D00SLY	DB09076	CTPDG000805
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 4	Aclidinium/formoterol	"(S,S)-Formoterol; CHEBI:63081; (S,S)-N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formaldehyde; NCGC00025167-01; 67346-48-9; Tocris-1448; AC1MHY5S; ZINC856"	3034756	Phase 4	D0Q1IT	.	CTPDG000845
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 4	Ozagrel	"Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika"	5282440	Phase 4	D0C7AA	DB12017	CTPDG013845
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 4	Levosalbutamol/ipratropium	"8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-; 3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane (3-endo,8-syn)-"	43232	Phase 4	D06PTA	.	CTPDG000850
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Itepekimab	.	.	Phase 3	DPT90B	.	CTPDG000886
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	MEDI3506	Tozorakimab	.	Phase 3	DOTF14	.	CTPDG000890
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Astegolimab	MSTT1041A; RG6149	.	Phase 3	DBAL18	.	CTPDG000919
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	SAR440340	Itepekimab	.	Phase 3	D8U1EX	.	CTPDG000926
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Olodaterol/tiotropium bromide	"136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0"	5487426	Phase 3	D0Z7AB	.	CTPDG000962
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	PT005	Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005	6917983	Phase 3	D0YS2W	.	CTPDG000972
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Tozorakimab	.	.	Phase 3	D0YFN1	.	CTPDG000973
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	GSK642444	"threo isoleucyl thiazolidide, 1; BDBM17299"	23647689	Phase 3	D0T6TW	.	CTPDG001043
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Arofylline	"Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione"	166553	Phase 3	D0T0NG	.	CTPDG001049
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	PT003	.	.	Phase 3	D0S1KP	.	CTPDG001060
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	PT001 GP	.	.	Phase 3	D0Q7QA	.	CTPDG001081
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	QVA-149	Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol	11564052	Phase 3	D0Q5AT	.	CTPDG001084
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Darotropium + 642444	.	25195533	Phase 3	D0H0UB	.	CTPDG001194
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	QMF149	"Indacaterol, mometasone furoate"	.	Phase 3	D0E0XL	.	CTPDG001229
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	SUN-101	.	.	Phase 3	D04RNN	.	CTPDG001417
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Bococizumab	.	.	Phase 3	D03DJT	.	CTPDG001448
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Mitiperstat	"1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1933460-19-5; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; Azd 4831; AZD 4831 [WHO-DD]; AZD4831; AZD-4831; AZD-4831 [WHO-DD]; BDBM312172; BHKKSKOHRFHHIN-MRVPVSSYSA-N; CHEMBL5095218; compound 16 [PMID: 36005476]; CS-0376445; EX-A7129; GLXC-26157; GTPL12154; HY-145581; Mitiperstat; Mitiperstat [INN]; MITIPERSTAT [USAN]; S6GYK3X4QQ; SCHEMBL17782047; UNII-S6GYK3X4QQ; US9616063, 3"	121362450	Phase 2	D87IQS	.	CTPDG001519
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2b	OrM3	.	.	Phase 2b	D06CVO	.	CTPDG001584
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	CSJ117	Ecleralimab	.	Phase 2	DU6O4B	.	CTPDG001628
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD8871	"1435519-06-4; 2-THIOPHENEACETIC ACID, .ALPHA.-HYDROXY-.ALPHA.-2-THIENYL-, TRANS-4-((3-(5-((((2R)-2-(1,2-DIHYDRO-8-HYDROXY-2-OXO-5-QUINOLINYL)-2-HYDROXYETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)METHYLAMINO)CYCLOHEXYL ESTER; 2-Thiopheneacetic acid, alpha-hydroxy-alpha-2-thienyl-, trans-4-((3-(5-((((2R)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl)amino)methyl)-1H-benzotriazol-1-yl)propyl)methylamino)cyclohexyl ester; AKOS040750679; Azd 8871; AZD 8871 [WHO-DD]; AZD8871; AZD-8871; BDBM50528210; CHEMBL4297483; CS-0079218; EX-A7799; HY-120802; LAS191351; LAS-191351; Navafenterol; NAVAFENTEROL [INN]; Navafenterol [USAN]; SCHEMBL16429536; SCHEMBL22766780; TRANS-4-((3-(5-((((2R)-2-HYDROXY-2-(8-HYDROXY-2-OXO-1,2-DIHYDRO-5- QUINOLINYL)ETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)(METHYL)AMINO)CYCLOHEXYL HYDROXY(DI-2-THIENYL)ACETATE; U29GY32XJ4; UNII-U29GY32XJ4; WHO 11100"	71558565	Phase 2	DM63YS	.	CTPDG001678
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	YPL-001	.	.	Phase 2	DGT7B6	.	CTPDG001711
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	DS102	.	.	Phase 2	DGL7Z2	.	CTPDG001713
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	QBW251	"(S)-3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide; 1334546-77-8; 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-((2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-; 2-pyridinecarboxamide, 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-2-pyridinecarboxamide; 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide; AKOS040759841; AMB0BO0WFH; BDBM297402; CHEMBL4650318; compound 33 [PMID: 34028270]; CS-0116371; DTXSID601336884; GTPL11547; HY-109177; Icenticaftor; Icenticaftor [INN]; Icenticaftor [USAN:INN]; Icenticaftor [USAN]; MS-25717; Qbw251; QBW-251; SCHEMBL2372751; UNII-AMB0BO0WFH; US10117858, Example 5; WHO 11246"	58442344	Phase 2	DFV1I4	.	CTPDG001721
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SelK2	.	.	Phase 2	DFTV08	.	CTPDG001722
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSP 304	.	.	Phase 2	D6AZ5H	.	CTPDG001792
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD7594	.	67041274	Phase 2	D0X9YP	.	CTPDG001890
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TA-2005	Carmoterol hydrochloride; CHF 4226.01; 8-Hydroxy-5-((1R)-1-hydroxy-2-(N-(1R)-2-(p-methoxyphenyl)isopropylamino)ethyl)carbostyril HCl; 8-Hydroxy-5-(1-hydroxy-2-(N-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one hydrochloride; 8-hydroxy-5-[(1r)-1-hydroxy-2-{[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]quinolin-2(1h)-one hydrochloride(1:1)	63951	Phase 2	D0VU2M	.	CTPDG001944
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Interferon-alpha lozenge	Veldona (TN)	.	Phase 2	D0U7SU	.	CTPDG001984
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Tetomilast	"145739-56-6; 6-(2-(3,4-Diethoxyphenyl)thiazol-4-yl)picolinic acid; OPC-6535; UNII-S6RXB5KF56; S6RXB5KF56; 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-6-pyridyl)thiazole; 2-Pyridinecarboxylicacid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-; 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid; Tetomilast [INN]; 6-(2-(3,4-Diethoxyphenyl)-1,3-thiazol-4-yl)pyridine-2-carboxylic acid; OPC 6535; ACMC-1BW9F; AC1MHG07; SCHEMBL436663; GTPL9877; CHEMBL332750; CTK0H7037; OPC6535; DTXSID00163149"	3025803	Phase 2	D0T6IM	DB05298	CTPDG002012
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TPI-1020	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate	.	Phase 2	D0T5TU	.	CTPDG002016
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Vasoactive intestinal peptide	"CCRIS 7231; Vasoactive intestinal polypeptide; Vasointestinal Peptide; Vasoactive intestinal peptide, synthetic porcine; SCHEMBL3041046; GTPL1152; VIP (Vasoactive Intestinal Peptide); LS-174653; VIP"	53314964	Phase 2	D0T4TN	.	CTPDG002019
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD1981	"802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603"	11292191	Phase 2	D0T4SG	DB11946	CTPDG002020
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SB-656933	Elubrixin; UNII-MW2AIJ8USP; MW2AIJ8USP; SB-656933-AAF; 688763-64-6; CHEMBL2178579; Elubrixin [USAN:INN]; SB656933; elubirixin; Elubrixin (USAN); SCHEMBL1562280; GTPL8499; DTXSID60218962; BDBM50398333; DB12135; SB 656933; D10332	10479502	Phase 2	D0SN7I	DB12135	CTPDG002029
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK1325756	Danirixin; 954126-98-8; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea	24780598	Phase 2	D0R7XD	DB11922	CTPDG002066
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	Igmesine	Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen	6438340	Phase 1	D0N5LJ	.	CTPDG002169
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PF-489791	"UNII-2S27T3DSZ3; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide"	11465695	Phase 2	D0M9FQ	DB11736	CTPDG002189
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	BCT-197	BCT-197-A2201	11338127	Phase 2	D0M6PA	DB15448	CTPDG002197
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	ONO-6126	21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709	9864321	Phase 2	D0M5BS	.	CTPDG002205
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-2115	"Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca"	.	Phase 2	D0L9CD	.	CTPDG002225
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	EP-101	"106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409"	7832	Phase 2	D0KX9B	.	CTPDG002243
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PH-797804	"586379-66-0; PH797804; PH 797804; 3-(3-Bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide; UNII-SI09I1V827; UNII-GEL7GRJ3R6; GEL7GRJ3R6; CHEMBL1088751; CHEBI:82715; SI09I1V827; 3-{3-Bromo-4-[(2,4-Difluorobenzyl)oxy]-6-Methyl-2-Oxopyridin-1(2h)-Yl}-N,4-Dimethylbenzamide; PHA-797804; 1358027-80-1; 3-Bromo-4-((2,4-difluorobenzyl)oxy)-1-(5-((methylamino)carbonyl)-2-methylphenyl)-6-methylpyridin-2(1H)-one; 3hll; KCAJXIDMCNPGHZ-UHFFFAOYSA-N"	22049997	Phase 2	D0K2ZF	DB07941	CTPDG002270
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	LAS 100977	LABA	11962616	Phase 2	D0J1AV	DB12100	CTPDG002292
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PF-3635659	PF-03635659	16065403	Phase 2	D0I5XU	DB12408	CTPDG002311
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Lancovutide	"Duramycin; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio"	86289378	Phase 2	D0H8XB	.	CTPDG002332
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PS-938285	.	.	Phase 2	D0H8GW	.	CTPDG002333
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK961081	"CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate"	10372836	Phase 2	D0GP8P	DB12526	CTPDG002350
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Haemophilus recombinant vaccine	.	.	Phase 2	D0GM8E	.	CTPDG002353
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Carmoterol	"147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1"	63952	Phase 2	D0G0RT	.	CTPDG002381
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	LIRIMILAST	"Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester"	6433118	Phase 2	D0F5IY	.	CTPDG002400
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-2423	"CCR2b antagonist (pain, COPD), AstraZeneca"	46213922	Phase 2	D0E5NY	.	CTPDG002425
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	UK-432097	"Adenosine A2a agonist (asthma), Pfizer"	9833519	Phase 2	D0D5VJ	DB12691	CTPDG002450
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD9056	"AZD-9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide"	10161381	Phase 2	D0CS2C	DB12594	CTPDG002467
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	BIO-11006	.	.	Phase 2	D0C3XD	.	CTPDG002487
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PF-03715455	UNII-0TJ631J0KP; 1056164-52-3; 0TJ631J0KP; CHEMBL1938400; PF-3715455; 2yis; SCHEMBL981777; GTPL8179; DTXSID70147214; BDBM50361467; SB16724; DB12138	11714580	Phase 2	D0A1WN	DB12138	CTPDG002551
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	IC-485	.	23724885	Phase 2	D09USN	.	CTPDG002557
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TOFIMILAST	"CP-325366; Tofimilast < Prop INN; 9-Cyclopentyl-7-ethyl-3-(2-thienyl)-5,6-dihydro-9H-pyrazolo[3,4-c][1,2,4]triazolo[4,3-a]pyridine"	9896267	Phase 2	D09TFB	DB11681	CTPDG002561
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	ODSH	"Cardiac ischemia reperfusion injury therapy, ParinGenix; ODSH (iv); PGX-100; PGX-200; ODSH (inhaled formulation), ParinGenix; ODSH (iv), ParinGenix; 2-O, 3-O desulfated heparin (inhaled), ParinGenix; 2-O, 3-O heparin (intravenous formulation), ParinGenix"	.	Phase 2	D09AWM	.	CTPDG002592
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-8683	.	.	Phase 2	D08WSG	.	CTPDG002603
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AER-002	"Aerolytic; Bikunin; Pulmolytic; Bikunin, Aerovance; Bikunin, Bayer"	.	Phase 2	D07YRV	.	CTPDG002654
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	QBM076	.	.	Phase 2	D06SCQ	.	CTPDG002733
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK233705	.	.	Phase 2	D05KXJ	.	CTPDG002800
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-9164	IDDBCP239717	44517831	Phase 2	D05GNW	DB12115	CTPDG002811
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	QAX-028	"Bronchodilatory agent (inhaled, COPD), Novartis"	.	Phase 2	D04XVE	.	CTPDG002827
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD7624	.	25143624	Phase 2	D04SPJ	.	CTPDG002845
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	THRX-198321	"Beta 2 adrenoreceptor agonist/muscarinic receptor antagonist (asthma), Theravance"	.	Phase 2	D04GRB	.	CTPDG002867
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TRN-157	"LAMA antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals; Long acting muscarinic M3 antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals"	.	Phase 2	D02TXV	.	CTPDG002955
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD9668	"Alvelestat; 848141-11-7; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide"	46861623	Phase 2	D02PHE	DB11863	CTPDG002964
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SB-265610	"SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, &gt; J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be"	9841667	Phase 2	D02JXG	.	CTPDG002974
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AQX-1125	"AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox"	76965484	Phase 2	D02HDG	DB13012	CTPDG002979
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	JNJ-10311795	"CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid"	10146470	Phase 2	D01YIO	.	CTPDG003000
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SCH-527123	"Navarixin; 473727-83-2; Sch527123; SCH 527123; (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide; MK-7123; CHEMBL216981; (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide; SCHEMBL184744; GTPL8497; KS-00001CQK; CTK8B8735; MolPort-023-331-228; BDBM50200880; MK7123; ANW-61143; ZINC100033051; AKOS016003539; CS-0609; NCGC00390675-01; HY-10198; AX8217127; TC-149888; W-5650; SCH 527123,CAS:473727-83-2; PF-00547659"	9865554	Phase 2	D00QKI	.	CTPDG003070
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	O-desulfated heparin	Intravenous	.	Phase 2	D00AKQ	.	CTPDG003110
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1/2	Zofin	.	.	Phase 1/2	D9XJ0U	.	CTPDG003211
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	CCI 15106	.	.	Phase 1	DSM39E	.	CTPDG003722
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	PUR1800	.	.	Phase 1	DG2EK3	.	CTPDG003910
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	BI 1323495	.	.	Phase 1	D8PO7Y	.	CTPDG004011
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	GSK3923868	.	.	Phase 1	D5KX2H	.	CTPDG004090
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	CHF 5407	.	.	Phase 1	D0V0JQ	.	CTPDG004356
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD-9819	"Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca"	24890141	Phase 1	D0U0AU	.	CTPDG004392
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	RG-7103	"R-7103; RO-5024118; VPAC2 agonist (COPD), Roche"	90871060	Phase 1	D0S7UQ	.	CTPDG004430
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD4721	.	.	Phase 1	D0Q0RK	.	CTPDG004490
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	Ronomilast	"ELB-353; PDE4 inhibitor, BioTie; PDE4 inhibitor, elbion; AWD-12-353"	9803446	Phase 1	D0O8JW	.	CTPDG004546
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD-5122	.	.	Phase 1	D0N3QF	.	CTPDG004584
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	Dexpirronium	"Anticholinergic compound (COPD), Meda"	.	Phase 1	D0L3CQ	.	CTPDG004634
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	MEDI7814	.	.	Phase 1	D0H0ZV	.	CTPDG004757
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD-2551	.	.	Phase 1	D0E4GE	.	CTPDG004832
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	BI-137882	.	.	Phase 1	D0B7TM	.	CTPDG004915
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	GSK2256294	GSK-2256294	59448236	Phase 1	D0A8KQ	.	CTPDG004939
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	PUR0200	.	.	Phase 1	D09ZRB	.	CTPDG004954
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	MEDI-2338	.	.	Phase 1	D05UCW	.	CTPDG005186
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	QAK-423	.	.	Phase 1	D02PYM	.	CTPDG005346
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	POL-6014	"Serine protease inhibitors (inhaled, PEM, asthma/COPD), Polyphor"	.	Investigative	D01OGV	.	CTPDG005395
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Preregistration	Telenzepine	"Telenzepine [INN]; Telenzepinum [Latin]; Telenzepino [Spanish]; 80880-90-6; UNII-0990EG3K10; 0990EG3K10; NCGC00015987-05; DSSTox_RID_80752; DSSTox_CID_25209; 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one; DSSTox_GSID_45209; 4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10H-thieno(3,4-b)(1,5)benzodiazepin-10-one; Telenzepine hydrochloride; Telenzepine dihydrochloide; C19H22N4O2S; Telenzepino; Telenzepinum; Telenzepine dihydrochloride hydrate; BY-802; [3H](+)telenzepine"	5387	Discontinued in Preregistration	D0FX4J	.	CTPDG006324
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Preregistration	Levcromakalim	"Lemakalim; Cromakalim; (-)-Cromakalim; 94535-50-9; Levcromakelim; BRL 38227; BRL-38227; UNII-RW7PN4BLDJ; RW7PN4BLDJ; CHEMBL100; BRN 3622889; MLS000069770; CHEBI:6436; Cromakalime [French]; Cromakalimum [Latin]; Cromakalim, (3S-trans)-Isomer; SMR000058880; (3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile; DSSTox_RID_81051; DSSTox_CID_25677; DSSTox_GSID_45677; 94470-67-4; Cromakalimum; Cromakalime; BRL-34915; BRL 34915; 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-o"	93504	Discontinued in Preregistration	D08DKA	.	CTPDG006325
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 3	Sibenadet	"UNII-N32934RHGW; 154189-40-9; CHEMBL82663; N32934RHGW; Sibenadet [INN:BAN]; AC1L4DOB; SCHEMBL48983; DTXSID50165552; AR-C 68397XX; ZINC36268680; ARC-68397; BDBM50128690; AR-C 68397; 4-Hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-2(3H)-one; SB-07499; 2(3H)-Benzothiazolone, 4-hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-; FT-0674579; L001485; 4-Hydroxy-7-{2-[2-(3-phenethyloxy-propane-1-sulfonyl)-ethylamino]-ethyl}-3H-benzothiazol-2-one"	183812	Discontinued in Phase 3	D0C5PA	.	CTPDG006363
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 3	Cilomilast	"Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid"	151170	Discontinued in Phase 3	D02EMR	DB03849	CTPDG006389
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Rispenzepine	Nuvenzepine; DF-545	129505	Discontinued in Phase 2	D0XE5L	.	CTPDG006403
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	CDP840	"Cdp-840; Cdp 840; CHEMBL32442; 4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; (R)-4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; 4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine; Pyridine, 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)-, (R)-; 162542-90-7; AC1L2SW5; SCHEMBL84490; 4-[2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-ethyl]-pyridine; GTPL9330; UTUUPXBCDMQYRR-HSZRJFAPSA-N; ZINC599006; PDSP2_001272; BDBM50064858; PDSP1_001288"	127928	Discontinued in Phase 2	D0UG4T	.	CTPDG006423
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	CE-1037	"SPWHS19WTL; UNII-SPWHS19WTL; CHEMBL56605; Mdl 201404YA; Mdl 201,404YA; CE 1037; 150493-09-7; ce1037; SCHEMBL8974527; BDBM50058491; Bis(4-(2'-(carboxy-2'-methylpropylsulfonyl)phenyl)2,2'-(1,4-phenylene))diisobutyrate; 3-{4-[2-(4-{1-[4-(2-Carboxy-2-methyl-propane-1-sulfonyl)-phenoxycarbonyl]-1-methyl-ethyl}-phenyl)-2-methyl-propionyloxy]-benzenesulfonyl}-2,2-dimethyl-propionic acid(CE-1037)"	131801066	Discontinued in Phase 2	D0T5GT	.	CTPDG006430
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	MLN-977	"CHEMBL73148; CMI977; LDP-977; SCHEMBL16932371; LDP 977; CMI 977; HY-U00260; BDBM50144621; CS-7474; 175212-04-1; UNII-VNR0T3Q498 component YANONWCPCKIWEC-CABCVRRESA-N; N-(4-{(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydrofuran-2-yl}but-3-ynyl)-N-hydroxyurea; Urea, N-(4-((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydro-2-furanyl)-3-butyn-1-yl)-N-hydroxy-"	9905233	Discontinued in Phase 2	D0P1TZ	DB05431	CTPDG006460
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	GSK-159797	Milveterol hydrochloride; UNII-1D1MD355SJ; 1D1MD355SJ; 804518-03-4; Milveterol hydrochloride [USAN]; Milveterol hydrochloride (USAN); GSK159797C; Milveterol HCl; SCHEMBL2014099; CHEMBL2107356; DTXSID50230335; QQPHRRSYJMOQOC-DKIIUIKKSA-N; D08945; N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; 2-5A-anti-hTR	11225217	Discontinued in Phase 2	D0N8MQ	.	CTPDG006468
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Filaminast	Way-pda-641; UNII-CDD69JC61J; 141184-34-1; CDD69JC61J; (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONE O-(AMINOCARBONYL)OXIME; FIL; Filaminast [USAN:INN]; Filaminast (USAN/INN); SCHEMBL73844; SCHEMBL73843; CHEMBL590754; BDBM14771; 1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethanone-(E)-O-(aminocarbonyl)oxime; DB02660; D04185; 3'-(Cyclopentyloxy)-4'-methoxyacetophenone (E)-O-carbamoyloxime; [1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino] carbamate; (E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino	9578243	Discontinued in Phase 2	D0H9KW	DB02660	CTPDG006505
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	BRL-55834	"Brl 55834; 131899-25-7; brl55834; SCHEMBL6369898; AC1L2Z70; DTXSID80157243; 3,4-Dihydro-2,2-dimethyl-4-(oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol; 2-Piperidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(pentafluoroethyl)-2H-1-benzopyran-4-yl)-, (3S-trans)-"	131442	Discontinued in Phase 2	D0GT4N	.	CTPDG006513
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	WC-3027	"SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG"	.	Discontinued in Phase 2	D0G2CQ	.	CTPDG006518
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	AZD1236	"(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)"	24751752	Discontinued in Phase 2	D0E5YG	DB11961	CTPDG006533
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	PF-610355	"PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer"	11505444	Discontinued in Phase 2	D0AQ3H	DB11871	CTPDG006558
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	AZD-5423	"1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-"	24825740	Discontinued in Phase 2	D09UFV	DB12280	CTPDG006566
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	EPI-12323	.	.	Discontinued in Phase 2	D07EIJ	.	CTPDG006597
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Tolafentrine	BY-4070	65990	Discontinued in Phase 2	D05YAS	.	CTPDG006610
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Milveterol+Fluticasone	"S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; 90566-53-3; S-(fluoromethyl) (6a,8x,11b,16a,17a)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate; AC1Q68ZV; AC1L1Y1V; AN-15808; s-(fluoromethyl)(6; A,8; I,11"	62924	Discontinued in Phase 2	D04MOF	.	CTPDG006628
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	CS-003	.	9831640	Discontinued in Phase 2	D03ZKE	.	CTPDG006636
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Darotropium	.	25195533	Discontinued in Phase 2	D03STA	.	CTPDG006641
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	KCO-912	.	.	Discontinued in Phase 2	D03NDI	.	CTPDG006644
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	AZD4818	18-HYDROXYASCOMYCIN; AC1L9IBR; SCHEMBL14434002	.	Discontinued in Phase 2	D00PFW	.	CTPDG006672
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD5904	"UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-"	10264211	Discontinued in Phase 1	D0Y3LJ	.	CTPDG006709
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-6553	"Neutrophil elastase inhibitor (oral, COPD), AstraZeneca/Quintiles"	.	Discontinued in Phase 1	D0X7WK	.	CTPDG006713
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	ZD-0892	"CHEMBL55210; SCHEMBL7363455; CTK4D4091; BDBM50058391; HY-19254; 171964-73-1; CS-0014993; L-Prolinamide,N-(4-methoxybenzoyl)-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-; (S)-1-[(S)-2-(4-Methoxy-benzoylamino)-3-methyl-butyryl]-pyrrolidine-2-carboxylic acid"	9892148	Discontinued in Phase 1	D0WY9H	.	CTPDG006719
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-4407	ZD-4407	.	Discontinued in Phase 1	D0P3CF	.	CTPDG006759
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	QAN-747	.	.	Discontinued in Phase 1	D0L3VA	.	CTPDG006786
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	Revatropate	"UK-112166; UK-112,166; UK-112166-04; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate"	9690123	Discontinued in Phase 1	D09LMX	.	CTPDG006849
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD8075	.	.	Discontinued in Phase 1	D06XSG	.	CTPDG006873
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AE-3763	.	9807572	Discontinued in Phase 1	D06DET	.	CTPDG006881
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	FR167653	"HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818"	135484078	Discontinued in Phase 1	D05QMG	.	CTPDG006886
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	SB-332235	"1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea"	9887803	Discontinued in Phase 1	D03PDY	.	CTPDG006905
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD5985	.	9811072	Discontinued in Phase 1	D01RVS	.	CTPDG006919
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	Rilmakalim	Hoe-234	65966	Discontinued in Phase 1	D01KHX	.	CTPDG006925
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	SCH-351591	"SCH 351591; UNII-G6EF7V146S; CHEMBL250546; G6EF7V146S; CHEBI:77774; N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide; 444659-43-2; N-(3,5-dichloro-1-oxidopyridin-4-yl)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide; SCH351591; SCHEMBL157018; DTXSID8044125; NOCAS_44125; BDBM50219270; D 4396; 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide; 5-Quinolinecarboxamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-     ("	9802841	Discontinued in Phase 1	D01FXD	.	CTPDG006930
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-3342	.	.	Discontinued in Phase 1	D01CAJ	.	CTPDG006933
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Preclinical	RS-504393	"300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463"	9953769	Preclinical	D0X4SI	.	CTPDG007030
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Preclinical	AZD-7928	.	.	Preclinical	D0KJ0U	.	CTPDG007068
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Preclinical	GW-3333	"SMZPWUUYPYYHIV-HNJRGHQBSA-N; GW3333; CHEMBL514958; UNII-54J77T5T74; 54J77T5T74; 212609-68-2; AC1Q5NWC; AC1L50QR; BIDD:PXR0031; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; SCHEMBL2875070; BDBM50247805; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide; Gw 3333; 5-carboxymethylthio-3-(3'-chlorophenyl)-1,2,4-oxadiazol"	216470	Preclinical	D03ESO	.	CTPDG007144
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AR-C-89855	AR-C68164AA; AR-C68475AA; AR-C69457AA; AR-C89855AA	10206844	Terminated	D0F6AB	.	CTPDG007356
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	ZARDAVERINE	101975-10-4; Zardaverina; Zardaverinum; Zardaverine [INN]; Zardaverinum [INN-Latin]; UNII-TQ358GWH6Y; Zardaverina [INN-Spanish]; 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE; C12H10F2N2O3; 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone; TQ358GWH6Y; CHEMBL313842; CHEBI:46548; 6-[4-(difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one; HJMQDJPMQIHLPB-UHFFFAOYSA-N; 6-(4-Difluoromethoxy-3-methoxyphenyl)-3(2H)-pyridazinone; NCGC00016106-04	5723	Terminated	D0F0CS	DB02918	CTPDG007359
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	SSR-69071	SSR 69071; 344930-95-6; SSR69071; DSSTox_RID_82301; DSSTox_CID_27368; DSSTox_GSID_47368; MLS006010264; SCHEMBL4295477; CHEMBL1354892; DTXSID1047368; CTK8E8740; CHEBI:93283; MolPort-023-276-460; HMS3269M07; ZINC1490807; Tox21_300247; AKOS024457139; NCGC00254231-01; NCGC00167751-02; NCGC00167751-01; NCGC00167751-03; SMR001822512; RT-015782; LS-191133; FT-0724044; CAS-344930-95-6; J-019626; BRD-K72895815-001-01-4	9872438	Terminated	D0B3MV	.	CTPDG007395
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AZD-2914	.	.	Terminated	D0A4VI	.	CTPDG007404
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	NIK-616	.	.	Terminated	D07UHY	.	CTPDG007449
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AD-313	.	.	Terminated	D01KWB	.	CTPDG007570
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	ML-03	"Cystic fibrosis therapy, Milkhaus; HP-3; Respiratory therapeutics, Milkhaus"	.	Terminated	D00GDN	.	CTPDG007587
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PUP-1	MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen	.	Investigative	D0Y0BZ	.	CTPDG007684
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	OT-010	"OT-010 (inhaled dry powder, asthma/COPD); OT-010 (inhaled dry powder, asthma/COPD), Oriel Therapeutics; OT-010 (inhaled dry powder, asthma/COPD), Sandoz"	.	Investigative	D0XM6L	.	CTPDG007697
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	TRN-101	"Dual ROCK1/ROCK2 inhibitor (inhalant, COPD), Theron Pharmaceuticals; Dual Rho kinase 1/ Rho kinase2 inhibitor (inhalant, COPD), Theron Pharmaceuticals"	.	Investigative	D0X8UW	.	CTPDG007706
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PD-3766	"RAC GTPase inhibitor (COPD), P2D Biosciences; Ras related C3 botulinum substrate guanosine triphosphatase inhibitor (COPD), P2D Biosciences"	.	Investigative	D0X3QL	.	CTPDG007727
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	EP-102	.	.	Investigative	D0QM3Q	.	CTPDG007929
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	RBx-343E48F0	.	.	Investigative	D0OY7A	.	CTPDG007990
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ZP-003	.	.	Investigative	D0M6XE	.	CTPDG008075
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	CHF-5480	"PDE 4 inhibitors (COPD/asthma); PDE 4 inhibitors (COPD/asthma), Chiesi"	.	Investigative	D0K9PS	.	CTPDG008130
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ADC-7828	"Neutrophil elastase inhibitors (inhaled, CF/COPD); Neutrophil elastase inhibitor (inhaled, cystic fibrosis/chronic obstructive pulmonary disease), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Pulmagen"	.	Investigative	D0K2MT	.	CTPDG008147
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	SOM-0525	.	.	Investigative	D0I9RB	.	CTPDG008189
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	MBS-103	"Bismuth thiol based antibacterial agent (inhaled, pulmonary tuberculosis), Microbion; Bismuth thiol based agent (inhalant, pulmonary tuberculosis/cystic fibrosis/lung infection/COPD/pneumonia), Microbion"	.	Investigative	D0I5IS	.	CTPDG008206
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ADS-0101	"ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta"	.	Investigative	D0G9XS	.	CTPDG008257
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	DX-2300	"Kallikrein-1 inhibitors (asthma); Kallikrein-1 inhibitors (asthma), Dyax"	.	Investigative	D0F4FV	.	CTPDG008311
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	YPL-1101	.	.	Investigative	D0C9LE	.	CTPDG008400
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	J-104135	"UNII-6137X5QNJF; 6137X5QNJF; J-104871; SCHEMBL15207668; SCHEMBL15207665; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-pentenyl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-penten-1-yl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 191088-19-4; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-(((2-(1,3-benzodioxol-5-yl)-5-(2-benzoxa"	9962301	Investigative	D0BP7C	.	CTPDG008437
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	SOM-1033	.	.	Investigative	D0AX0V	.	CTPDG008466
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PF-613322	"Beta 2 adrenoceptor agonists (COPD); UK-503590; Beta 2 adrenoceptor agonists (COPD),Pfizer"	.	Investigative	D08GZX	.	CTPDG008626
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	MDT-011	.	.	Investigative	D04OPS	.	CTPDG008872
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ZP-013	.	.	Investigative	D04OBS	.	CTPDG008877
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PYM-60001	TRPV1-modulators	.	Investigative	D03QUJ	.	CTPDG008950
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	AMA-237	"AMA-63; ROCK inhibitors (COPD); ROCK inhibitors (COPD), Amakem"	.	Investigative	D02RYE	.	CTPDG009012
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	CDP-146	"CT-8730; MAPK antagonists, Celltech; NG-1054; P38 MAP kinase inhibitor, Celltech; P38 kinase inhibitor, Celltech"	.	Investigative	D01RSK	.	CTPDG009075
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	X-072-NAB	"NATHMAB (COPD), XBiotech"	.	Investigative	D01HOT	.	CTPDG009108
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	MMP-408	"MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth"	.	Investigative	D00NPE	.	CTPDG009174
M6ACROT02070	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	UR-5908	"COPD therapy, UBE Industries"	.	Investigative	D00JBM	.	CTPDG009185
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Carbocisteine	"Carbocysteine; Siroxyl; Carbocisteine, Sopar"	193653	Approved	D0X5SI	DB04339	CTPDG000069
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Aclidinium	UNII-K17VY42F6C; K17VY42F6C; CHEBI:65346; 727649-81-2; CHEMBL551466; (3R)-3-[2-hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide; SCHEMBL72141; GTPL7449; SCHEMBL15096073; CHEMBL1194325; DTXSID00223070; ZINC30691727; BDBM50296331; DB08897; AJ-84146; AB01565828_02; 1-(3-Phenoxypropyl)-3alpha-[hydroxybis(2-thienyl)acetyloxy]-1-azoniabicyclo[2.2.2]octane	11434515	Approved	D0VP1V	DB08897	CTPDG000095
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Tiotropium	"186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide"	5487427	Approved	D0P1WA	DB01409	CTPDG000223
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Fluorometholone	"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione"	9878	Approved	D0P0HT	DB00324	CTPDG000227
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Bamifylline	Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride	16229	Approved	D0O7SP	DB13203	CTPDG000239
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Maraviroc	"376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc"	3002977	Phase 3	D0NR6S	DB04835	CTPDG000258
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Glycopyrrolate	"596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide"	11693	Approved	D0M0AM	.	CTPDG000278
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Salmeterol	"Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol"	5152	Approved	D0L5YV	DB00938	CTPDG000287
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Vilanterol	"503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair"	10184665	Approved	D0L0GM	DB09082	CTPDG000293
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	MK-08887A	DULERA	71301227	Approved	D0K3WO	.	CTPDG000312
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Revefenacin	UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7	11753673	Approved	D0K1ST	DB11855	CTPDG000314
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Prasterone	"Dehydroepiandrosterone; DHEA; 53-43-0; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone"	5881	Approved	D0K0EK	DB01708	CTPDG000316
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Meprednisone	Betapar	5284587	Approved	D0I5DS	DB09383	CTPDG000347
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Theophylline	"Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione"	2153	Approved	D0F8RA	DB00277	CTPDG000383
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Almitrine	"Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine"	33887	Approved	D0D9NA	DB01430	CTPDG000420
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Arformoterol	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate	3083544	Approved	D0D1DI	DB01274	CTPDG000428
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Incruse Ellipta	"Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2"	11519069	Approved	D09ZOQ	.	CTPDG000474
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	LAS-34273	"Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide"	11519741	Approved	D07KHH	.	CTPDG000564
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Bitolterol	Tornalate	35330	Approved	D06RUL	DB00901	CTPDG000593
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Olodaterol	BI-1744	11504295	Approved	D04UTT	DB09080	CTPDG000659
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Symbicort	"(22R)-Budesonide; UNII-2HI1006KPH; 51333-22-3; 51372-29-3; 2HI1006KPH; DSSTox_CID_202; DSSTox_RID_75430; DSSTox_GSID_20202; (1~{s},2~{s},4~{r},6~{r},8~{s},9~{s},11~{s},12~{s},13~{r})-9,13-Dimethyl-11-Oxidanyl-8-(2-Oxidanylethanoyl)-6-Propyl-5,7-Dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-Dien-16-One; R-Budesonide; Budesonide-22R; NCGC00016862-01; EINECS 257-161-7; CAS-51333-22-3; BUDESONIDE (11beta,16alpha(R)); SCHEMBL4095; AC1L22VC; CHEMBL2110662"	40000	Approved	D04QNO	.	CTPDG000662
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Indacaterol	"312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone"	6918554	Approved	D03DJL	DB05039	CTPDG000726
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Benralizumab	.	.	Approved	D02PIO	.	CTPDG000744
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Anoro	Umeclidinium + vilanterol	.	Approved	D02CKO	.	CTPDG000762
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Pregabalin	"Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer"	5486971	Approved	D00WUF	DB00230	CTPDG000797
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Relvar/Breo	Vilanterol + fluticasone furoate	71306415	Approved	D00WMK	.	CTPDG000798
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Approved	Umeclidinium	.	11519070	Approved	D00SLY	DB09076	CTPDG000805
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 4	Aclidinium/formoterol	"(S,S)-Formoterol; CHEBI:63081; (S,S)-N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formaldehyde; NCGC00025167-01; 67346-48-9; Tocris-1448; AC1MHY5S; ZINC856"	3034756	Phase 4	D0Q1IT	.	CTPDG000845
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 4	Ozagrel	"Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika"	5282440	Phase 4	D0C7AA	DB12017	CTPDG013845
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 4	Levosalbutamol/ipratropium	"8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-; 3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane (3-endo,8-syn)-"	43232	Phase 4	D06PTA	.	CTPDG000850
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Itepekimab	.	.	Phase 3	DPT90B	.	CTPDG000886
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	MEDI3506	Tozorakimab	.	Phase 3	DOTF14	.	CTPDG000890
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Astegolimab	MSTT1041A; RG6149	.	Phase 3	DBAL18	.	CTPDG000919
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	SAR440340	Itepekimab	.	Phase 3	D8U1EX	.	CTPDG000926
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Olodaterol/tiotropium bromide	"136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0"	5487426	Phase 3	D0Z7AB	.	CTPDG000962
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	PT005	Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005	6917983	Phase 3	D0YS2W	.	CTPDG000972
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Tozorakimab	.	.	Phase 3	D0YFN1	.	CTPDG000973
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	GSK642444	"threo isoleucyl thiazolidide, 1; BDBM17299"	23647689	Phase 3	D0T6TW	.	CTPDG001043
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Arofylline	"Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione"	166553	Phase 3	D0T0NG	.	CTPDG001049
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	PT003	.	.	Phase 3	D0S1KP	.	CTPDG001060
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	PT001 GP	.	.	Phase 3	D0Q7QA	.	CTPDG001081
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	QVA-149	Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol	11564052	Phase 3	D0Q5AT	.	CTPDG001084
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Darotropium + 642444	.	25195533	Phase 3	D0H0UB	.	CTPDG001194
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	QMF149	"Indacaterol, mometasone furoate"	.	Phase 3	D0E0XL	.	CTPDG001229
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	SUN-101	.	.	Phase 3	D04RNN	.	CTPDG001417
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 3	Bococizumab	.	.	Phase 3	D03DJT	.	CTPDG001448
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Mitiperstat	"1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1933460-19-5; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; Azd 4831; AZD 4831 [WHO-DD]; AZD4831; AZD-4831; AZD-4831 [WHO-DD]; BDBM312172; BHKKSKOHRFHHIN-MRVPVSSYSA-N; CHEMBL5095218; compound 16 [PMID: 36005476]; CS-0376445; EX-A7129; GLXC-26157; GTPL12154; HY-145581; Mitiperstat; Mitiperstat [INN]; MITIPERSTAT [USAN]; S6GYK3X4QQ; SCHEMBL17782047; UNII-S6GYK3X4QQ; US9616063, 3"	121362450	Phase 2	D87IQS	.	CTPDG001519
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2b	OrM3	.	.	Phase 2b	D06CVO	.	CTPDG001584
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	CSJ117	Ecleralimab	.	Phase 2	DU6O4B	.	CTPDG001628
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD8871	"1435519-06-4; 2-THIOPHENEACETIC ACID, .ALPHA.-HYDROXY-.ALPHA.-2-THIENYL-, TRANS-4-((3-(5-((((2R)-2-(1,2-DIHYDRO-8-HYDROXY-2-OXO-5-QUINOLINYL)-2-HYDROXYETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)METHYLAMINO)CYCLOHEXYL ESTER; 2-Thiopheneacetic acid, alpha-hydroxy-alpha-2-thienyl-, trans-4-((3-(5-((((2R)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl)amino)methyl)-1H-benzotriazol-1-yl)propyl)methylamino)cyclohexyl ester; AKOS040750679; Azd 8871; AZD 8871 [WHO-DD]; AZD8871; AZD-8871; BDBM50528210; CHEMBL4297483; CS-0079218; EX-A7799; HY-120802; LAS191351; LAS-191351; Navafenterol; NAVAFENTEROL [INN]; Navafenterol [USAN]; SCHEMBL16429536; SCHEMBL22766780; TRANS-4-((3-(5-((((2R)-2-HYDROXY-2-(8-HYDROXY-2-OXO-1,2-DIHYDRO-5- QUINOLINYL)ETHYL)AMINO)METHYL)-1H-BENZOTRIAZOL-1-YL)PROPYL)(METHYL)AMINO)CYCLOHEXYL HYDROXY(DI-2-THIENYL)ACETATE; U29GY32XJ4; UNII-U29GY32XJ4; WHO 11100"	71558565	Phase 2	DM63YS	.	CTPDG001678
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	YPL-001	.	.	Phase 2	DGT7B6	.	CTPDG001711
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	DS102	.	.	Phase 2	DGL7Z2	.	CTPDG001713
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	QBW251	"(S)-3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide; 1334546-77-8; 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-((2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-; 2-pyridinecarboxamide, 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-2-pyridinecarboxamide; 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide; AKOS040759841; AMB0BO0WFH; BDBM297402; CHEMBL4650318; compound 33 [PMID: 34028270]; CS-0116371; DTXSID601336884; GTPL11547; HY-109177; Icenticaftor; Icenticaftor [INN]; Icenticaftor [USAN:INN]; Icenticaftor [USAN]; MS-25717; Qbw251; QBW-251; SCHEMBL2372751; UNII-AMB0BO0WFH; US10117858, Example 5; WHO 11246"	58442344	Phase 2	DFV1I4	.	CTPDG001721
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SelK2	.	.	Phase 2	DFTV08	.	CTPDG001722
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSP 304	.	.	Phase 2	D6AZ5H	.	CTPDG001792
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD7594	.	67041274	Phase 2	D0X9YP	.	CTPDG001890
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TA-2005	Carmoterol hydrochloride; CHF 4226.01; 8-Hydroxy-5-((1R)-1-hydroxy-2-(N-(1R)-2-(p-methoxyphenyl)isopropylamino)ethyl)carbostyril HCl; 8-Hydroxy-5-(1-hydroxy-2-(N-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one hydrochloride; 8-hydroxy-5-[(1r)-1-hydroxy-2-{[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]quinolin-2(1h)-one hydrochloride(1:1)	63951	Phase 2	D0VU2M	.	CTPDG001944
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Interferon-alpha lozenge	Veldona (TN)	.	Phase 2	D0U7SU	.	CTPDG001984
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Tetomilast	"145739-56-6; 6-(2-(3,4-Diethoxyphenyl)thiazol-4-yl)picolinic acid; OPC-6535; UNII-S6RXB5KF56; S6RXB5KF56; 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-6-pyridyl)thiazole; 2-Pyridinecarboxylicacid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-; 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid; Tetomilast [INN]; 6-(2-(3,4-Diethoxyphenyl)-1,3-thiazol-4-yl)pyridine-2-carboxylic acid; OPC 6535; ACMC-1BW9F; AC1MHG07; SCHEMBL436663; GTPL9877; CHEMBL332750; CTK0H7037; OPC6535; DTXSID00163149"	3025803	Phase 2	D0T6IM	DB05298	CTPDG002012
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TPI-1020	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate	.	Phase 2	D0T5TU	.	CTPDG002016
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Vasoactive intestinal peptide	"CCRIS 7231; Vasoactive intestinal polypeptide; Vasointestinal Peptide; Vasoactive intestinal peptide, synthetic porcine; SCHEMBL3041046; GTPL1152; VIP (Vasoactive Intestinal Peptide); LS-174653; VIP"	53314964	Phase 2	D0T4TN	.	CTPDG002019
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD1981	"802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603"	11292191	Phase 2	D0T4SG	DB11946	CTPDG002020
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SB-656933	Elubrixin; UNII-MW2AIJ8USP; MW2AIJ8USP; SB-656933-AAF; 688763-64-6; CHEMBL2178579; Elubrixin [USAN:INN]; SB656933; elubirixin; Elubrixin (USAN); SCHEMBL1562280; GTPL8499; DTXSID60218962; BDBM50398333; DB12135; SB 656933; D10332	10479502	Phase 2	D0SN7I	DB12135	CTPDG002029
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK1325756	Danirixin; 954126-98-8; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea	24780598	Phase 2	D0R7XD	DB11922	CTPDG002066
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	Igmesine	Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen	6438340	Phase 1	D0N5LJ	.	CTPDG002169
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PF-489791	"UNII-2S27T3DSZ3; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide"	11465695	Phase 2	D0M9FQ	DB11736	CTPDG002189
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	BCT-197	BCT-197-A2201	11338127	Phase 2	D0M6PA	DB15448	CTPDG002197
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	ONO-6126	21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709	9864321	Phase 2	D0M5BS	.	CTPDG002205
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-2115	"Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca"	.	Phase 2	D0L9CD	.	CTPDG002225
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	EP-101	"106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409"	7832	Phase 2	D0KX9B	.	CTPDG002243
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PH-797804	"586379-66-0; PH797804; PH 797804; 3-(3-Bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide; UNII-SI09I1V827; UNII-GEL7GRJ3R6; GEL7GRJ3R6; CHEMBL1088751; CHEBI:82715; SI09I1V827; 3-{3-Bromo-4-[(2,4-Difluorobenzyl)oxy]-6-Methyl-2-Oxopyridin-1(2h)-Yl}-N,4-Dimethylbenzamide; PHA-797804; 1358027-80-1; 3-Bromo-4-((2,4-difluorobenzyl)oxy)-1-(5-((methylamino)carbonyl)-2-methylphenyl)-6-methylpyridin-2(1H)-one; 3hll; KCAJXIDMCNPGHZ-UHFFFAOYSA-N"	22049997	Phase 2	D0K2ZF	DB07941	CTPDG002270
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	LAS 100977	LABA	11962616	Phase 2	D0J1AV	DB12100	CTPDG002292
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PF-3635659	PF-03635659	16065403	Phase 2	D0I5XU	DB12408	CTPDG002311
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Lancovutide	"Duramycin; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio"	86289378	Phase 2	D0H8XB	.	CTPDG002332
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PS-938285	.	.	Phase 2	D0H8GW	.	CTPDG002333
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK961081	"CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate"	10372836	Phase 2	D0GP8P	DB12526	CTPDG002350
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Haemophilus recombinant vaccine	.	.	Phase 2	D0GM8E	.	CTPDG002353
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	Carmoterol	"147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1"	63952	Phase 2	D0G0RT	.	CTPDG002381
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	LIRIMILAST	"Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester"	6433118	Phase 2	D0F5IY	.	CTPDG002400
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-2423	"CCR2b antagonist (pain, COPD), AstraZeneca"	46213922	Phase 2	D0E5NY	.	CTPDG002425
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	UK-432097	"Adenosine A2a agonist (asthma), Pfizer"	9833519	Phase 2	D0D5VJ	DB12691	CTPDG002450
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD9056	"AZD-9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide"	10161381	Phase 2	D0CS2C	DB12594	CTPDG002467
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	BIO-11006	.	.	Phase 2	D0C3XD	.	CTPDG002487
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	PF-03715455	UNII-0TJ631J0KP; 1056164-52-3; 0TJ631J0KP; CHEMBL1938400; PF-3715455; 2yis; SCHEMBL981777; GTPL8179; DTXSID70147214; BDBM50361467; SB16724; DB12138	11714580	Phase 2	D0A1WN	DB12138	CTPDG002551
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	IC-485	.	23724885	Phase 2	D09USN	.	CTPDG002557
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TOFIMILAST	"CP-325366; Tofimilast < Prop INN; 9-Cyclopentyl-7-ethyl-3-(2-thienyl)-5,6-dihydro-9H-pyrazolo[3,4-c][1,2,4]triazolo[4,3-a]pyridine"	9896267	Phase 2	D09TFB	DB11681	CTPDG002561
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	ODSH	"Cardiac ischemia reperfusion injury therapy, ParinGenix; ODSH (iv); PGX-100; PGX-200; ODSH (inhaled formulation), ParinGenix; ODSH (iv), ParinGenix; 2-O, 3-O desulfated heparin (inhaled), ParinGenix; 2-O, 3-O heparin (intravenous formulation), ParinGenix"	.	Phase 2	D09AWM	.	CTPDG002592
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-8683	.	.	Phase 2	D08WSG	.	CTPDG002603
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AER-002	"Aerolytic; Bikunin; Pulmolytic; Bikunin, Aerovance; Bikunin, Bayer"	.	Phase 2	D07YRV	.	CTPDG002654
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	QBM076	.	.	Phase 2	D06SCQ	.	CTPDG002733
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK233705	.	.	Phase 2	D05KXJ	.	CTPDG002800
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD-9164	IDDBCP239717	44517831	Phase 2	D05GNW	DB12115	CTPDG002811
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	QAX-028	"Bronchodilatory agent (inhaled, COPD), Novartis"	.	Phase 2	D04XVE	.	CTPDG002827
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD7624	.	25143624	Phase 2	D04SPJ	.	CTPDG002845
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	THRX-198321	"Beta 2 adrenoreceptor agonist/muscarinic receptor antagonist (asthma), Theravance"	.	Phase 2	D04GRB	.	CTPDG002867
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	TRN-157	"LAMA antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals; Long acting muscarinic M3 antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals"	.	Phase 2	D02TXV	.	CTPDG002955
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AZD9668	"Alvelestat; 848141-11-7; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide"	46861623	Phase 2	D02PHE	DB11863	CTPDG002964
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SB-265610	"SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, &gt; J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be"	9841667	Phase 2	D02JXG	.	CTPDG002974
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	AQX-1125	"AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox"	76965484	Phase 2	D02HDG	DB13012	CTPDG002979
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	JNJ-10311795	"CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid"	10146470	Phase 2	D01YIO	.	CTPDG003000
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	SCH-527123	"Navarixin; 473727-83-2; Sch527123; SCH 527123; (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide; MK-7123; CHEMBL216981; (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide; SCHEMBL184744; GTPL8497; KS-00001CQK; CTK8B8735; MolPort-023-331-228; BDBM50200880; MK7123; ANW-61143; ZINC100033051; AKOS016003539; CS-0609; NCGC00390675-01; HY-10198; AX8217127; TC-149888; W-5650; SCH 527123,CAS:473727-83-2; PF-00547659"	9865554	Phase 2	D00QKI	.	CTPDG003070
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 2	O-desulfated heparin	Intravenous	.	Phase 2	D00AKQ	.	CTPDG003110
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1/2	Zofin	.	.	Phase 1/2	D9XJ0U	.	CTPDG003211
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	CCI 15106	.	.	Phase 1	DSM39E	.	CTPDG003722
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	PUR1800	.	.	Phase 1	DG2EK3	.	CTPDG003910
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	BI 1323495	.	.	Phase 1	D8PO7Y	.	CTPDG004011
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	GSK3923868	.	.	Phase 1	D5KX2H	.	CTPDG004090
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	CHF 5407	.	.	Phase 1	D0V0JQ	.	CTPDG004356
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD-9819	"Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca"	24890141	Phase 1	D0U0AU	.	CTPDG004392
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	RG-7103	"R-7103; RO-5024118; VPAC2 agonist (COPD), Roche"	90871060	Phase 1	D0S7UQ	.	CTPDG004430
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD4721	.	.	Phase 1	D0Q0RK	.	CTPDG004490
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	Ronomilast	"ELB-353; PDE4 inhibitor, BioTie; PDE4 inhibitor, elbion; AWD-12-353"	9803446	Phase 1	D0O8JW	.	CTPDG004546
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD-5122	.	.	Phase 1	D0N3QF	.	CTPDG004584
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	Dexpirronium	"Anticholinergic compound (COPD), Meda"	.	Phase 1	D0L3CQ	.	CTPDG004634
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	MEDI7814	.	.	Phase 1	D0H0ZV	.	CTPDG004757
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	AZD-2551	.	.	Phase 1	D0E4GE	.	CTPDG004832
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	BI-137882	.	.	Phase 1	D0B7TM	.	CTPDG004915
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	GSK2256294	GSK-2256294	59448236	Phase 1	D0A8KQ	.	CTPDG004939
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	PUR0200	.	.	Phase 1	D09ZRB	.	CTPDG004954
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	MEDI-2338	.	.	Phase 1	D05UCW	.	CTPDG005186
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Phase 1	QAK-423	.	.	Phase 1	D02PYM	.	CTPDG005346
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	POL-6014	"Serine protease inhibitors (inhaled, PEM, asthma/COPD), Polyphor"	.	Investigative	D01OGV	.	CTPDG005395
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Preregistration	Telenzepine	"Telenzepine [INN]; Telenzepinum [Latin]; Telenzepino [Spanish]; 80880-90-6; UNII-0990EG3K10; 0990EG3K10; NCGC00015987-05; DSSTox_RID_80752; DSSTox_CID_25209; 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one; DSSTox_GSID_45209; 4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10H-thieno(3,4-b)(1,5)benzodiazepin-10-one; Telenzepine hydrochloride; Telenzepine dihydrochloide; C19H22N4O2S; Telenzepino; Telenzepinum; Telenzepine dihydrochloride hydrate; BY-802; [3H](+)telenzepine"	5387	Discontinued in Preregistration	D0FX4J	.	CTPDG006324
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Preregistration	Levcromakalim	"Lemakalim; Cromakalim; (-)-Cromakalim; 94535-50-9; Levcromakelim; BRL 38227; BRL-38227; UNII-RW7PN4BLDJ; RW7PN4BLDJ; CHEMBL100; BRN 3622889; MLS000069770; CHEBI:6436; Cromakalime [French]; Cromakalimum [Latin]; Cromakalim, (3S-trans)-Isomer; SMR000058880; (3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile; DSSTox_RID_81051; DSSTox_CID_25677; DSSTox_GSID_45677; 94470-67-4; Cromakalimum; Cromakalime; BRL-34915; BRL 34915; 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-o"	93504	Discontinued in Preregistration	D08DKA	.	CTPDG006325
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 3	Sibenadet	"UNII-N32934RHGW; 154189-40-9; CHEMBL82663; N32934RHGW; Sibenadet [INN:BAN]; AC1L4DOB; SCHEMBL48983; DTXSID50165552; AR-C 68397XX; ZINC36268680; ARC-68397; BDBM50128690; AR-C 68397; 4-Hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-2(3H)-one; SB-07499; 2(3H)-Benzothiazolone, 4-hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-; FT-0674579; L001485; 4-Hydroxy-7-{2-[2-(3-phenethyloxy-propane-1-sulfonyl)-ethylamino]-ethyl}-3H-benzothiazol-2-one"	183812	Discontinued in Phase 3	D0C5PA	.	CTPDG006363
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 3	Cilomilast	"Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid"	151170	Discontinued in Phase 3	D02EMR	DB03849	CTPDG006389
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Rispenzepine	Nuvenzepine; DF-545	129505	Discontinued in Phase 2	D0XE5L	.	CTPDG006403
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	CDP840	"Cdp-840; Cdp 840; CHEMBL32442; 4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; (R)-4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; 4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine; Pyridine, 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)-, (R)-; 162542-90-7; AC1L2SW5; SCHEMBL84490; 4-[2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-ethyl]-pyridine; GTPL9330; UTUUPXBCDMQYRR-HSZRJFAPSA-N; ZINC599006; PDSP2_001272; BDBM50064858; PDSP1_001288"	127928	Discontinued in Phase 2	D0UG4T	.	CTPDG006423
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	CE-1037	"SPWHS19WTL; UNII-SPWHS19WTL; CHEMBL56605; Mdl 201404YA; Mdl 201,404YA; CE 1037; 150493-09-7; ce1037; SCHEMBL8974527; BDBM50058491; Bis(4-(2'-(carboxy-2'-methylpropylsulfonyl)phenyl)2,2'-(1,4-phenylene))diisobutyrate; 3-{4-[2-(4-{1-[4-(2-Carboxy-2-methyl-propane-1-sulfonyl)-phenoxycarbonyl]-1-methyl-ethyl}-phenyl)-2-methyl-propionyloxy]-benzenesulfonyl}-2,2-dimethyl-propionic acid(CE-1037)"	131801066	Discontinued in Phase 2	D0T5GT	.	CTPDG006430
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	MLN-977	"CHEMBL73148; CMI977; LDP-977; SCHEMBL16932371; LDP 977; CMI 977; HY-U00260; BDBM50144621; CS-7474; 175212-04-1; UNII-VNR0T3Q498 component YANONWCPCKIWEC-CABCVRRESA-N; N-(4-{(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydrofuran-2-yl}but-3-ynyl)-N-hydroxyurea; Urea, N-(4-((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydro-2-furanyl)-3-butyn-1-yl)-N-hydroxy-"	9905233	Discontinued in Phase 2	D0P1TZ	DB05431	CTPDG006460
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	GSK-159797	Milveterol hydrochloride; UNII-1D1MD355SJ; 1D1MD355SJ; 804518-03-4; Milveterol hydrochloride [USAN]; Milveterol hydrochloride (USAN); GSK159797C; Milveterol HCl; SCHEMBL2014099; CHEMBL2107356; DTXSID50230335; QQPHRRSYJMOQOC-DKIIUIKKSA-N; D08945; N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; 2-5A-anti-hTR	11225217	Discontinued in Phase 2	D0N8MQ	.	CTPDG006468
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Filaminast	Way-pda-641; UNII-CDD69JC61J; 141184-34-1; CDD69JC61J; (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONE O-(AMINOCARBONYL)OXIME; FIL; Filaminast [USAN:INN]; Filaminast (USAN/INN); SCHEMBL73844; SCHEMBL73843; CHEMBL590754; BDBM14771; 1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethanone-(E)-O-(aminocarbonyl)oxime; DB02660; D04185; 3'-(Cyclopentyloxy)-4'-methoxyacetophenone (E)-O-carbamoyloxime; [1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino] carbamate; (E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino	9578243	Discontinued in Phase 2	D0H9KW	DB02660	CTPDG006505
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	BRL-55834	"Brl 55834; 131899-25-7; brl55834; SCHEMBL6369898; AC1L2Z70; DTXSID80157243; 3,4-Dihydro-2,2-dimethyl-4-(oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol; 2-Piperidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(pentafluoroethyl)-2H-1-benzopyran-4-yl)-, (3S-trans)-"	131442	Discontinued in Phase 2	D0GT4N	.	CTPDG006513
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	WC-3027	"SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG"	.	Discontinued in Phase 2	D0G2CQ	.	CTPDG006518
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	AZD1236	"(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)"	24751752	Discontinued in Phase 2	D0E5YG	DB11961	CTPDG006533
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	PF-610355	"PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer"	11505444	Discontinued in Phase 2	D0AQ3H	DB11871	CTPDG006558
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	AZD-5423	"1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-"	24825740	Discontinued in Phase 2	D09UFV	DB12280	CTPDG006566
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	EPI-12323	.	.	Discontinued in Phase 2	D07EIJ	.	CTPDG006597
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Tolafentrine	BY-4070	65990	Discontinued in Phase 2	D05YAS	.	CTPDG006610
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Milveterol+Fluticasone	"S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; 90566-53-3; S-(fluoromethyl) (6a,8x,11b,16a,17a)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate; AC1Q68ZV; AC1L1Y1V; AN-15808; s-(fluoromethyl)(6; A,8; I,11"	62924	Discontinued in Phase 2	D04MOF	.	CTPDG006628
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	CS-003	.	9831640	Discontinued in Phase 2	D03ZKE	.	CTPDG006636
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	Darotropium	.	25195533	Discontinued in Phase 2	D03STA	.	CTPDG006641
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	KCO-912	.	.	Discontinued in Phase 2	D03NDI	.	CTPDG006644
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 2	AZD4818	18-HYDROXYASCOMYCIN; AC1L9IBR; SCHEMBL14434002	.	Discontinued in Phase 2	D00PFW	.	CTPDG006672
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD5904	"UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-"	10264211	Discontinued in Phase 1	D0Y3LJ	.	CTPDG006709
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-6553	"Neutrophil elastase inhibitor (oral, COPD), AstraZeneca/Quintiles"	.	Discontinued in Phase 1	D0X7WK	.	CTPDG006713
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	ZD-0892	"CHEMBL55210; SCHEMBL7363455; CTK4D4091; BDBM50058391; HY-19254; 171964-73-1; CS-0014993; L-Prolinamide,N-(4-methoxybenzoyl)-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-; (S)-1-[(S)-2-(4-Methoxy-benzoylamino)-3-methyl-butyryl]-pyrrolidine-2-carboxylic acid"	9892148	Discontinued in Phase 1	D0WY9H	.	CTPDG006719
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-7140	.	.	Discontinued in Phase 1	D0TN3D	.	CTPDG006737
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-4407	ZD-4407	.	Discontinued in Phase 1	D0P3CF	.	CTPDG006759
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	QAN-747	.	.	Discontinued in Phase 1	D0L3VA	.	CTPDG006786
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	Revatropate	"UK-112166; UK-112,166; UK-112166-04; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate"	9690123	Discontinued in Phase 1	D09LMX	.	CTPDG006849
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-2315	ZD-2315	.	Discontinued in Phase 1	D08GKD	.	CTPDG006860
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-8309	.	.	Discontinued in Phase 1	D07TTI	.	CTPDG006863
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD8075	.	.	Discontinued in Phase 1	D06XSG	.	CTPDG006873
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD8566	.	.	Discontinued in Phase 1	D06EMW	.	CTPDG006880
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AE-3763	.	9807572	Discontinued in Phase 1	D06DET	.	CTPDG006881
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	FR167653	"HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818"	135484078	Discontinued in Phase 1	D05QMG	.	CTPDG006886
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	SB-332235	"1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea"	9887803	Discontinued in Phase 1	D03PDY	.	CTPDG006905
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD5985	.	9811072	Discontinued in Phase 1	D01RVS	.	CTPDG006919
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	Rilmakalim	Hoe-234	65966	Discontinued in Phase 1	D01KHX	.	CTPDG006925
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	SCH-351591	"SCH 351591; UNII-G6EF7V146S; CHEMBL250546; G6EF7V146S; CHEBI:77774; N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide; 444659-43-2; N-(3,5-dichloro-1-oxidopyridin-4-yl)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide; SCH351591; SCHEMBL157018; DTXSID8044125; NOCAS_44125; BDBM50219270; D 4396; 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide; 5-Quinolinecarboxamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-     ("	9802841	Discontinued in Phase 1	D01FXD	.	CTPDG006930
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Discontinued in Phase 1	AZD-3342	.	.	Discontinued in Phase 1	D01CAJ	.	CTPDG006933
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Preclinical	RS-504393	"300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463"	9953769	Preclinical	D0X4SI	.	CTPDG007030
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Preclinical	AZD-7928	.	.	Preclinical	D0KJ0U	.	CTPDG007068
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Preclinical	GW-3333	"SMZPWUUYPYYHIV-HNJRGHQBSA-N; GW3333; CHEMBL514958; UNII-54J77T5T74; 54J77T5T74; 212609-68-2; AC1Q5NWC; AC1L50QR; BIDD:PXR0031; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; SCHEMBL2875070; BDBM50247805; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide; Gw 3333; 5-carboxymethylthio-3-(3'-chlorophenyl)-1,2,4-oxadiazol"	216470	Preclinical	D03ESO	.	CTPDG007144
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AZD-0902	.	.	Terminated	D0F7LE	.	CTPDG007354
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AR-C-89855	AR-C68164AA; AR-C68475AA; AR-C69457AA; AR-C89855AA	10206844	Terminated	D0F6AB	.	CTPDG007356
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	ZARDAVERINE	101975-10-4; Zardaverina; Zardaverinum; Zardaverine [INN]; Zardaverinum [INN-Latin]; UNII-TQ358GWH6Y; Zardaverina [INN-Spanish]; 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE; C12H10F2N2O3; 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone; TQ358GWH6Y; CHEMBL313842; CHEBI:46548; 6-[4-(difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one; HJMQDJPMQIHLPB-UHFFFAOYSA-N; 6-(4-Difluoromethoxy-3-methoxyphenyl)-3(2H)-pyridazinone; NCGC00016106-04	5723	Terminated	D0F0CS	DB02918	CTPDG007359
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	SSR-69071	SSR 69071; 344930-95-6; SSR69071; DSSTox_RID_82301; DSSTox_CID_27368; DSSTox_GSID_47368; MLS006010264; SCHEMBL4295477; CHEMBL1354892; DTXSID1047368; CTK8E8740; CHEBI:93283; MolPort-023-276-460; HMS3269M07; ZINC1490807; Tox21_300247; AKOS024457139; NCGC00254231-01; NCGC00167751-02; NCGC00167751-01; NCGC00167751-03; SMR001822512; RT-015782; LS-191133; FT-0724044; CAS-344930-95-6; J-019626; BRD-K72895815-001-01-4	9872438	Terminated	D0B3MV	.	CTPDG007395
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AZD-2914	.	.	Terminated	D0A4VI	.	CTPDG007404
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	NIK-616	.	.	Terminated	D07UHY	.	CTPDG007449
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AZD-0275	.	.	Terminated	D03DYB	.	CTPDG007538
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	AD-313	.	.	Terminated	D01KWB	.	CTPDG007570
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Terminated	ML-03	"Cystic fibrosis therapy, Milkhaus; HP-3; Respiratory therapeutics, Milkhaus"	.	Terminated	D00GDN	.	CTPDG007587
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PUP-1	MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen	.	Investigative	D0Y0BZ	.	CTPDG007684
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	OT-010	"OT-010 (inhaled dry powder, asthma/COPD); OT-010 (inhaled dry powder, asthma/COPD), Oriel Therapeutics; OT-010 (inhaled dry powder, asthma/COPD), Sandoz"	.	Investigative	D0XM6L	.	CTPDG007697
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	TRN-101	"Dual ROCK1/ROCK2 inhibitor (inhalant, COPD), Theron Pharmaceuticals; Dual Rho kinase 1/ Rho kinase2 inhibitor (inhalant, COPD), Theron Pharmaceuticals"	.	Investigative	D0X8UW	.	CTPDG007706
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PD-3766	"RAC GTPase inhibitor (COPD), P2D Biosciences; Ras related C3 botulinum substrate guanosine triphosphatase inhibitor (COPD), P2D Biosciences"	.	Investigative	D0X3QL	.	CTPDG007727
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	EP-102	.	.	Investigative	D0QM3Q	.	CTPDG007929
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	RBx-343E48F0	.	.	Investigative	D0OY7A	.	CTPDG007990
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ZP-003	.	.	Investigative	D0M6XE	.	CTPDG008075
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	CHF-5480	"PDE 4 inhibitors (COPD/asthma); PDE 4 inhibitors (COPD/asthma), Chiesi"	.	Investigative	D0K9PS	.	CTPDG008130
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ADC-7828	"Neutrophil elastase inhibitors (inhaled, CF/COPD); Neutrophil elastase inhibitor (inhaled, cystic fibrosis/chronic obstructive pulmonary disease), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Pulmagen"	.	Investigative	D0K2MT	.	CTPDG008147
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	SOM-0525	.	.	Investigative	D0I9RB	.	CTPDG008189
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	MBS-103	"Bismuth thiol based antibacterial agent (inhaled, pulmonary tuberculosis), Microbion; Bismuth thiol based agent (inhalant, pulmonary tuberculosis/cystic fibrosis/lung infection/COPD/pneumonia), Microbion"	.	Investigative	D0I5IS	.	CTPDG008206
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ADS-0101	"ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta"	.	Investigative	D0G9XS	.	CTPDG008257
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	DX-2300	"Kallikrein-1 inhibitors (asthma); Kallikrein-1 inhibitors (asthma), Dyax"	.	Investigative	D0F4FV	.	CTPDG008311
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	YPL-1101	.	.	Investigative	D0C9LE	.	CTPDG008400
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	J-104135	"UNII-6137X5QNJF; 6137X5QNJF; J-104871; SCHEMBL15207668; SCHEMBL15207665; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-pentenyl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-penten-1-yl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 191088-19-4; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-(((2-(1,3-benzodioxol-5-yl)-5-(2-benzoxa"	9962301	Investigative	D0BP7C	.	CTPDG008437
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	SOM-1033	.	.	Investigative	D0AX0V	.	CTPDG008466
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PF-613322	"Beta 2 adrenoceptor agonists (COPD); UK-503590; Beta 2 adrenoceptor agonists (COPD),Pfizer"	.	Investigative	D08GZX	.	CTPDG008626
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	MDT-011	.	.	Investigative	D04OPS	.	CTPDG008872
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	ZP-013	.	.	Investigative	D04OBS	.	CTPDG008877
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	PYM-60001	TRPV1-modulators	.	Investigative	D03QUJ	.	CTPDG008950
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	AMA-237	"AMA-63; ROCK inhibitors (COPD); ROCK inhibitors (COPD), Amakem"	.	Investigative	D02RYE	.	CTPDG009012
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	CDP-146	"CT-8730; MAPK antagonists, Celltech; NG-1054; P38 MAP kinase inhibitor, Celltech; P38 kinase inhibitor, Celltech"	.	Investigative	D01RSK	.	CTPDG009075
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	X-072-NAB	"NATHMAB (COPD), XBiotech"	.	Investigative	D01HOT	.	CTPDG009108
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	MMP-408	"MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth"	.	Investigative	D00NPE	.	CTPDG009174
M6ACROT02071	.	.	M6ADIS0268	CA22: Chronic obstructive pulmonary disease	Investigative	UR-5908	"COPD therapy, UBE Industries"	.	Investigative	D00JBM	.	CTPDG009185
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT02073	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05025	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05099	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05105	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05263	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05434	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT03206	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT03207	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05690	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05727	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	PEG-bHb-CO	"Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals"	.	Phase 2	D0A6LT	.	CTPDG001555
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	DM199	.	.	Phase 2	DS70MP	.	CTPDG001635
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BIIB131	"(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007"	50898407	Phase 2	DEV2G0	.	CTPDG001728
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	BMS-986177	"Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2"	118277544	Phase 2	DB6XD8	.	CTPDG001754
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 2	SonoLysis Prolyse	.	.	Phase 2	D08JGE	.	CTPDG002633
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Phase 1/2	ACT017	.	.	Phase 1/2	DPG5T9	.	CTPDG003153
M6ACROT05821	.	.	M6ADIS0091	8B11: Acute ischemic stroke	Patented	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	PMID27998201-Compound-16	1720818	Patented	D0UX4J	.	CTPDG005605
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rivastigmine	Rivastigmine (transdermal patch)	77991	Approved	D0WY5Q	DB00989	CTPDG000074
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Propentofylline propionate	Hextol (TN)	4938	Approved	D0UU9Y	DB06479	CTPDG000111
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Dihydroergotoxine	"Ergotamine, dihydro, methanesulfonate (salt)"	6420006	Approved	D0SP3D	.	CTPDG000148
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Galantamine	"GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol"	9651	Approved	D0R9VR	DB00674	CTPDG000171
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Eicosapentaenoic acid/docosa-hexaenoic acid	"Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN)"	445580	Approved	D0Q5XX	DB03756	CTPDG012556
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Donepezil	"Donepezil (transdermal patch, Alzheimer's disease)"	3152	Approved	D0NS6H	DB00843	CTPDG000257
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved in China	GV-971	.	.	Approved in China	D0FS5O	.	CTPDG000380
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Tacrine	"Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine"	1935	Approved	D0E6YQ	DB00382	CTPDG000406
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Lemborexant	E2006	56944144	Phase 2	D0A7ZK	DB11951	CTPDG000461
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Pexidartinib	PLX-3397	25151352	Approved	D09TAB	DB12978	CTPDG013033
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-florbetaben	.	.	Approved	D07TRF	.	CTPDG000548
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Colostrinin	Colostrinin (TN)	.	Approved	D07NPH	.	CTPDG000558
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Huperzine A	"Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680"	854026	Approved	D06XWB	DB04864	CTPDG000589
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Lecanemab	.	.	Approved	D06XVR	.	CTPDG000590
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-flutemetamol	.	.	Approved	D06XOT	.	CTPDG000591
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Ergoloid mesylate	Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)	592735	Approved	D02IQY	.	CTPDG000752
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Immune globulin	.	.	Approved	D01OWB	.	CTPDG000780
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Memantine	"Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest"	4054	Approved	D01JEU	DB01043	CTPDG000790
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Aducanumab	.	.	Approved	D00RRU	.	CTPDG000806
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nirogacestat	"Nirogacestat; 1290543-63-3; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01"	46224413	Phase 2	D00GPQ	DB12005	CTPDG000817
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 4	18F-AV-1451	Tau imaging agent)	70957463	Phase 4	D0F4CG	DB14914	CTPDG000847
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NE3107	.	.	Phase 3	D9I6QG	.	CTPDG000924
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Guanfacine	"(2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride; 29110-47-2; 30OMY4G3MK; A902647; A918619; AB01563079_01; AKOS030255657; AKOS030526130; BCP09647; BDBM81984; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; BPBio1_000415; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; BSPBio_000377; C02AC02; C07037; CAS_29110-47-2; CAS-29110-48-3; CCG-204609; CHEBI:5558; CHEMBL862; D08031; DB01018; DTXCID7026944; DTXSID9046944; EINECS 249-442-8; EN300-243924; Estulic; Estulic (Salt/Mix); Estulic (TN); FT-0669067; FT-0669068; GTPL522; Guanfacina; Guanfacina (INN-Spanish); Guanfacina [INN-Spanish]; GUANFACINE; Guanfacine (INN); Guanfacine [INN:BAN]; GUANFACINE [INN]; GUANFACINE [MI]; GUANFACINE [VANDF]; GUANFACINE [WHO-DD]; Guanfacine HCl; Guanfacine hydrochloride (Salt/Mix); Guanfacinum; Guanfacinum (INN-Latin); Guanfacinum [INN-Latin]; HY-17416A; J-017394; L000286; L013430; LON 798 (Salt/Mix); Lopac0_000519; Lopac-G-1043; MRF-0000019; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; N-amidino-2-(2,6-dichlorophenyl)acetamide; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-05; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; NSC 759121; NSC_3519; NSC-759121; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Q5613599; RASPBERRYKETONEGLUCOSIDE; SCHEMBL35094; SDCCGSBI-0050502.P002; SPBio_002298; Tenex (Salt/Mix); Tocris-1030; UNII-30OMY4G3MK"	3519	Phase 3	D8NY3J	DB01018	CTPDG000928
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	BPDO-1603	.	.	Phase 3	D71LNO	.	CTPDG000931
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AXS-05	.	.	Phase 2/3	D3PD8C	.	CTPDG000941
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Remternetug	LY3372993	.	Phase 3	D34FRG	.	CTPDG000944
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Donanemab	.	.	Phase 3	D2ZP0A	.	CTPDG000945
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AR1001	"(-)-methylbenzylamine; (+)-2-Methylbutylp-aminocinnamate; 103-67-3; 7KN7F4X49E; AI3-26793; AKOS000119094; AR1001; Benzenemethanamine, N-methyl-; benzyl methyl amine; benzyl methylamine; Benzyl(methyl)amine; BENZYLAMINE, N-METHYL; Benzylamine, N-methyl-; Benzylmethylamine; benzyl-methylamine; Benzyl-methyl-amine; Benzylmethyl-d3-amine; BRD-K44558320-003-01-7; CHEMBL1338; CS-W007426; DTXSID9048439; EC 203-133-4; EINECS 203-133-4; EN300-18191; F2190-0316; FT-0631560; HNMeBzl; HY-W007426; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H; KBio2_001842; KBio2_004410; KBio2_006978; KBioGR_002247; KBioSS_001842; M0164; methyl benzylamine; Methyl(phenylmethyl)amine; methyl-benzyl amine; Methylbenzylamine; Methylbenzylamine, N-; methylbezylamine; MFCD00008289; MLS004773900; N-(Phenylmethyl)methylamine; N-benzyl methyl amine; N-benzyl methylamine; N-benzylmethanamine; N-benzyl-methyl amine; N-Benzylmethylamine; N-benzyl-methylamine; N-Benzylmethylamine, 97%; N-Benzyl-N-methylamine; N-benzyl-N-methyl-amine; NCGC00166047-01; N-methyl benzyl amine; N-methyl benzylamine; N-methyl -benzylamine; N-Methyl(phenyl)methanamine; N-methyl-1-phenylmethanamine; N-methyl-1-phenyl-methanamine; N-methylbenzenemethanamine; N-methyl-benzenemethanamine; N-methylbenzyl amine; N-methyl-benzyl amine; N-METHYLBENZYLAMINE; N-methyl-benzylamine; N-methyl-N-(phenylmethyl)amine; N-methyl-N-benzyl amine; N-methyl-N-benzylamine; N-Methy-N-benzylamine; NSC 8059; NSC8059; NSC-8059; omega-Methylaminotoluene; Q23978278; Racemic methylbenzyl amine; SCHEMBL2271; SDCCGMLS-0066901.P001; SMR000112361; Spectrum_001362; Spectrum4_001764; Spectrum5_000347; STR02536; UNII-7KN7F4X49E; W-108843; Z57327124"	7669	Phase 3	D1OM8E	.	CTPDG000951
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	GV-971	sodium oligomannate	.	Phase 3	D1KR3N	.	CTPDG000952
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AVP-786	.	25052519	Phase 3	D0Z6IB	.	CTPDG000965
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NI-101	"BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec"	.	Phase 3	D0Z2GF	.	CTPDG000968
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Lanabecestat	"1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane"	67979346	Phase 3	D0Y0EP	DB14814	CTPDG000986
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SB-742457	GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline	11256720	Phase 3	D0R9HI	DB12680	CTPDG001066
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Crenezumab	MABT5102A; RG7412	.	Phase 3	D0R7EQ	.	CTPDG001069
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	verubecestat	example 25 (US8940748)	51352361	Phase 3	D0R4KK	DB12285	CTPDG001070
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Gantenerumab	RG1450	.	Phase 3	D0Q7YZ	.	CTPDG001078
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	PF-4494700	"PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer"	11180124	Phase 3	D0MW7B	DB12689	CTPDG001122
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SI-657	"AC1L9R2T; 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid"	453618	Phase 3	D0E9SZ	.	CTPDG001222
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	EVP-6124	"Encenicline; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626"	46196517	Phase 3	D0D3TX	DB11726	CTPDG001246
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ALZT-OP1	ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen	.	Phase 3	D0CH6B	.	CTPDG001252
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	MIM-D3	"TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen"	9808372	Phase 3	D0C2OR	DB12441	CTPDG001261
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LCS 16	.	.	Phase 3	D0A4DP	.	CTPDG001278
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Bapineuzumab	"AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan"	.	Phase 3	D0A1MX	.	CTPDG001282
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tirapazamine	TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075	135413511	Phase 3	D09XQU	DB04858	CTPDG001290
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AV 133	.	.	Phase 3	D09NAF	.	CTPDG001302
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tramiprosate	"Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS"	1646	Phase 3	D09DLP	DB06527	CTPDG001314
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	E-2609	"Beta secretase inhibitor (Alzheimer's disease), Eisai"	57827330	Phase 3	D08MHD	DB15391	CTPDG001329
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	(-)-Phenserine	"CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate"	192706	Phase 3	D07CIN	DB04892	CTPDG001369
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ARC029	"Nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino"	4494	Phase 3	D06GRK	DB06712	CTPDG001378
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Eltoprazine	"Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company"	65853	Phase 2	D06FKC	DB12883	CTPDG001380
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	INM-176	"WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn"	.	Phase 3	D05UXU	.	CTPDG001390
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Xaliproden	"Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine"	128919	Phase 3	D02OJC	DB06393	CTPDG001464
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tamibarotene	"Tamibarotene (oral, Alzheimer's disease)"	108143	Phase 3	D02GTY	DB04942	CTPDG001471
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Immune globulin + albumin	.	.	Phase 3	D00KLP	.	CTPDG001501
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Solanezumab	.	.	Phase 3	D00CZT	.	CTPDG001504
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD106	.	.	Phase 2/3	DF3UN2	.	CTPDG001516
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Icosapent ethyl	"(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 6GC8A4PAYH; 73310-10-8; 86227-47-6; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound; AB01563352_01; AC-33765; AKOS025295847; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; AMR 101; AMR101; AMR-101; BS-48985; CCG-213714; CHEBI:80366; CHEBI:84883; CHEMBL2095209; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; cis-Eicosapentaenoic acid ethyl ester; CS-5304; D01892; DB08887; DTXSID601018686; E0442; E0853; E-EPA; Eicosapentaenoic acid (ethyl ester); Eicosapentaenoic acid ethyl ester; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; Eicosapentaenoic acid, ethyl ester; Eicosapentaenoicacidethylester; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EN300-25951782; EPA ethyl ester; Epadel; Epadel S; Epadel S (TN); EPA-E; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; ethyl eicosapentaenoate; Ethyl eicosapentaenoic acid; Ethyl EPA; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Ethyl icosapent; ethyl icosapentaenoate; ethyl icosapentate; Ethyl icosapentate (JP17); Ethyl icosapentate [JAN]; Ethyl icosapentate, JAN; ethyl-eicosapentaenoic acid; ethyl-EPA; GTPL7441; HMS2094K19; HY-B0747; ICOSAPENT ETHYL; Icosapent ethyl (USAN); ICOSAPENT ETHYL [ORANGE BOOK]; Icosapent ethyl [USAN]; ICOSAPENT ETHYL [VANDF]; Icosapent ethyl ester; LMFA07010877; MFCD00673476; MND 21; NSC 759597; NSC759597; NSC-759597; Pharmakon1600-01300030; Q5404453; s6466; SBI-0206684.P002; SCHEMBL123305; SR-05000002595; SR-05000002595-1; Timnodonic acid ethyl ester; UNII-6GC8A4PAYH; Vascepa; Vascepa (TN); Vazkepa"	9831415	Phase 2/3	DF29AZ	DB08887	CTPDG001517
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Fosgonimeton	"2093305-05-4; AKOS040757261; ATH-1017; ATH-1017 FREE ACID; CHEMBL5095419; CS-0204081; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate; Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN:INN]; Fosgonimeton [USAN]; H91OA9858J; HY-132814; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; NDX-1017; NDX-1017 FREE ACID; UNII-H91OA9858J; WHO 11782"	156596375	Phase 2/3	DDBY18	.	CTPDG001518
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Ginkgo biloba	.	.	Phase 2/3	D6S9AH	.	CTPDG001520
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Atuzaginstat	"2211981-76-7; Atuzaginstat; Atuzaginstat [INN]; AtuzaginstatCOR388; BDBM453275; CHEMBL5095230; COR388; COR-388; Cyclopentanecarboxamide, N-((1S)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-; DGN7ROZ8EN; EX-A6081; N-((3S)-7-Amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide; N-[(3S)-7-amino-2-oxo-1-(2,3,6-trifluorophenoxy)heptan-3-yl]cyclopentanecarboxamide; SCHEMBL19972758; UNII-DGN7ROZ8EN; US10730826, Compound 1a-non-racemic; US10730826, Compound 1a-racemic"	134347893	Phase 2/3	D58BFC	.	CTPDG001522
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	JNJ-54861911	.	68254185	Phase 2/3	D0T2FP	DB15307	CTPDG001532
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Plasminogen	.	.	Phase 2/3	D0S4YT	.	CTPDG001533
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD-106	"Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis"	.	Phase 2/3	D0I3VT	.	CTPDG001544
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AMG520	CNP520	.	Phase 2/3	D0H4YD	.	CTPDG001545
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	SI-614	Modified Hyaluronate	.	Phase 2/3	D08QGE	.	CTPDG001559
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AZD3293	CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099	57404290	Phase 2/3	D01AYX	.	CTPDG001580
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABvac40	.	.	Phase 2	DZQI76	.	CTPDG001594
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AL002	.	.	Phase 2	DYT9B4	.	CTPDG001604
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MLC901	NeuroAiD	.	Phase 2	DYB14S	.	CTPDG001607
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-916	.	.	Phase 2	DY6DS3	.	CTPDG001608
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TB006	.	.	Phase 2	DW7J9D	.	CTPDG001619
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3372689	"2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; CS-0433932; EX-A6549; GLXC-25705; GTPL11953; HY-144681; LY3372689; LY-3372689; MS-26295; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide; SCHEMBL20421995; U0SGP6ZX2V; UNII-U0SGP6ZX2V"	135260636	Phase 2	DVY0C6	.	CTPDG001621
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MP-101	.	.	Phase 2	DSK7I5	.	CTPDG001634
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DHP1401	.	.	Phase 2	DS4CL2	.	CTPDG001638
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CY6463	"2201048-82-8; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; AKOS040757400; CS-0376702; CY6463; CY-6463; EX-A7620; GTKNNCQKFKGSHR-UHFFFAOYSA-N; H7KEN3O8AI; HY-145607; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; IW-6463; MS-25746; SCHEMBL19922804; UNII-H7KEN3O8AI; Zagociguat; Zagociguat [INN]; ZAGOCIGUAT [USAN]"	134304734	Phase 2	DO37EF	.	CTPDG001660
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ID1201	.	.	Phase 2	DM95PZ	.	CTPDG001677
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Benfotiamine	"(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid; 22457-89-2; 22457-89-2 (free acid); 775256-41-2; AC-8280; AKOS015920320; Benfotamine; Benfotiamina; benfotiamine; Benfotiamine (JAN/INN); Benfotiaminum; Benphothiamine; Benzoylthiamine monophosphate; Betivina; Biotamin (TN); BPBio1_000757; BSPBio_000687; CAS-22457-89-2; CCG-220654; CHEBI:41039; CHEMBL4303665; D01255; DB11748; DTXCID1025433; DTXSID3045433; EN300-21694383; HMS1570C09; HMS2097C09; HMS3714C09; MFCD00057343; N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; NCGC00016764-01; NCGC00016764-04; NCGC00179477-01; Prestwick_68; Prestwick2_000654; Prestwick3_000654; S-(2-(N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl)benzothioa; S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; s-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; S-Benzoylthiamine-O-monophosphate; SCHEMBL188070; SCHEMBL19184708; SR-01000872627; SR-01000872627-1; SR-01000872627-2; Tox21_110597; Tox21_110597_1"	3032771	Phase 2	DL7CK2	DB11748	CTPDG001686
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAGE-718	.	.	Phase 2	DI54FM	.	CTPDG001703
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	APH-1105	.	.	Phase 2	DH6G1L	.	CTPDG001708
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuplazid	"Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,  ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate"	11672491	Phase 2	DDI6B0	.	CTPDG001741
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-1942	.	.	Phase 2	DDAH09	.	CTPDG001742
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	"(1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate; 2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-; 2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-; 37O2X55Y9E; 83314-01-6; BDBM50258529; BMY-45618; BRN 4349157; BRYOSTATIN; Bryostatin 1; Bryostatin 1 - CAS 83314-01-6; BRYOSTATIN 1 [MI]; BRYOSTATIN 1 [WHO-DD]; Bryostatin 1, >=99%, solid; Bryostatin-1; CHEBI:88353; CHEMBL449158; CS-0025440; DTXSID8046876; HY-105231; MFCD00893832; MJQUEDHRCUIRLF-TVIXENOKSA-N; NSC 339555; NSC-339555; Q27095907; SCHEMBL182960; UNII-37O2X55Y9E"	5280757	Phase 2	DD8L0V	.	CTPDG001743
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AADvac-1	.	.	Phase 2	DA1L7V	.	CTPDG001761
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NLY01	.	.	Phase 2	D7A5LO	.	CTPDG001783
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD-35	"1531586-58-9; 6'-(2-(1-(Pyridin-2-ylmethyl)piperidin-4-yl)ethyl)spiro[cyClopropane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-7'(6'H)-one; AD-35; BDBM231544; CHEMBL3949886; GLXC-15057; IND-120499; SCHEMBL15598869; starbld0021420; US9346818, I-29; US9346818, I-33; US9346818, I-35"	72707125	Phase 2	D67DST	.	CTPDG001793
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RPh201	.	.	Phase 2	D3YT8E	.	CTPDG001820
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Trontinemab	RG6102	.	Phase 2	D3XP8N	.	CTPDG001821
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI-287	"849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546"	11564168	Phase 1	D3X2TH	.	CTPDG001822
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MW150	"1628502-91-9; 3GF; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; AKOS040758765; BDBM50537600; CHEMBL4129018; CIIVUDIZZJLXCN-UHFFFAOYSA-N; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; compound 8 [PMID: 25676389]; CS-0069509; EPZ68T461K; EX-A3206A; GTPL10524; HY-120111; MS-26255; MW 150; MW01-18-150SRM; MW150; MW-150; NSC785340; NSC-785340; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; Q27453797; SCHEMBL16061104; UNII-EPZ68T461K"	86270361	Phase 2	D38LQO	.	CTPDG001827
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NP001	.	.	Phase 1	D1LU7W	.	CTPDG001845
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuedexta	.	.	Phase 2	D0ZR4W	.	CTPDG001854
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SUVN-502	"SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven"	10073773	Phase 2	D0Z0GX	DB06140	CTPDG001870
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	S-38093	"S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier"	11380684	Phase 2	D0XW6Y	.	CTPDG001883
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3202626	.	.	Phase 2	D0XD5N	.	CTPDG001889
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AN-1792	Betabloc; AIP-001	15176	Phase 2	D0X4ZL	.	CTPDG001899
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BI-409306	.	135908617	Phase 2	D0W7UN	.	CTPDG001924
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Methanesulfonyl fluoride	"Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)"	11207	Phase 2	D0W3BA	DB13058	CTPDG001935
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NIC5-15	"D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336"	164619	Phase 2	D0W0NU	DB12969	CTPDG001941
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAM-531	"PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer"	16071605	Phase 2	D0V4ZQ	DB12229	CTPDG001961
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	Phase 2	D0V3CK	.	CTPDG001968
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK933776A	.	.	Phase 2	D0T6KV	.	CTPDG002011
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3002813	.	.	Phase 2	D0SD7G	.	CTPDG002035
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD02 vaccine	.	.	Phase 2	D0S1BF	.	CTPDG002050
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2027	.	.	Phase 1	D0S0FD	.	CTPDG002054
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TTP-448	.	.	Phase 2	D0PU9C	.	CTPDG002107
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CPC-201	.	.	Phase 2	D0PN4D	.	CTPDG002111
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UE-2343	.	.	Phase 2	D0OE5S	.	CTPDG002131
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVP-0962	.	.	Phase 2	D0OB4R	.	CTPDG002132
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	R-phenserine	Posiphen (TN)	11249342	Phase 2	D0O5GK	DB15317	CTPDG002141
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FK-962	"FK-960 analog, Fujisawa"	56842107	Phase 2	D0O3TC	.	CTPDG002143
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAR-110894	SAR-110894D	.	Phase 2	D0O0EX	.	CTPDG002150
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UB-311	.	.	Phase 2	D0NR6T	.	CTPDG002156
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-288	"UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4"	24743471	Phase 2	D0N8QK	DB15192	CTPDG002162
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Oleoyl-estrone	"Anti-obesity hormone-based therapy, Manhattan"	6918373	Phase 2	D0N5CW	DB04870	CTPDG002171
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CERE-110	.	.	Phase 2	D0MP1M	.	CTPDG002184
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HSRx-888	.	.	Phase 2	D0LO2G	.	CTPDG002217
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN 322	.	.	Phase 1	D0L8IO	.	CTPDG002228
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nefiracetam	Motiva (TN)	71157	Phase 2	D0KD5P	DB13082	CTPDG002254
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JOT106	.	.	Phase 2	D0K4JI	.	CTPDG002268
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BPN14770	KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide	90111638	Phase 2	D0IZ8X	.	CTPDG002296
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-5213	.	53342708	Phase 2	D0I6ZO	.	CTPDG002308
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-8E12	C2N-8E12	.	Phase 2	D0H7KQ	.	CTPDG002337
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LymPro	.	.	Phase 2	D0H1YZ	.	CTPDG002341
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AQW-051	669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane	50914822	Phase 2	D0H1AY	.	CTPDG002345
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-717	"CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex"	3323368	Preclinical	D0G3AR	DB05047	CTPDG002374
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-05212377	SAM-760	.	Phase 2	D0G1YA	.	CTPDG002378
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CT1812	Elayta	118278088	Phase 2	D0FX8N	.	CTPDG002384
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY2886721	"1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475"	49837968	Phase 2	D0F8GK	DB12547	CTPDG002396
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CSTC1	"BAC; D-Bacillosamine; Bacillosamine; D-Bac; 2,4-Diamino-2,4,6-Trideoxy-D-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucose; 2,4-Diamino-2,4,6-Trideoxy-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranoside; 2,4-Diamino-2,4,6-Trideoxy-D-Gluc"	54029194	Phase 2	D0ED6O	.	CTPDG002410
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T-817MA	"Edonerpic maleate; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:"	11338749	Phase 2	D0E8HA	.	CTPDG002419
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	KPAX002	.	.	Phase 2	D0E7WH	.	CTPDG002420
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	Bryostatin 1; 83314-01-6	5280757	Phase 2	D0E6AH	.	CTPDG002423
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MIQ-001	"M-IQ 001; Fatty acid metabolism inhibitor (Alzheimer's disease), Meta-IQ"	.	Phase 2	D0E1SV	.	CTPDG002434
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Basmisanil	"1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha"	57336276	Phase 2	D0CH7C	DB11877	CTPDG002474
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ladostigil	"Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326"	208907	Phase 2	D0C3UC	.	CTPDG002488
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NDD-094	NDD-094A; SDZ-NDD-094	.	Phase 2	D0B7LZ	.	CTPDG002508
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ponezumab	"Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219"	.	Phase 2	D0B5EB	.	CTPDG002513
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORM-12741	"Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion"	71301276	Phase 2	D0B3ZF	DB12057	CTPDG002515
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-4447943	BCP16255	135564558	Phase 2	D0A9IY	DB11953	CTPDG002535
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DCB-AD1	.	.	Phase 2	D09BCL	.	CTPDG002589
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-126	.	24987875	Phase 2	D08XOY	.	CTPDG002601
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD4694	.	71306407	Phase 2	D08VDM	.	CTPDG002606
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK239512	"720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K"	9976892	Phase 2	D07YGH	DB15120	CTPDG002657
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ALZ-801	.	25008296	Phase 2	D07VAI	.	CTPDG002666
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SYN-120	.	.	Phase 2	D07RQR	.	CTPDG002673
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VI-1121	.	.	Phase 2	D07KGR	.	CTPDG002691
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI 287	"FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-"	118797983	Phase 1	D07IOT	.	CTPDG002697
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ST-101	"ST 101 [French]; 7-Chloro-1,3-dihydro-5-phenyl-1-trimethylgermyl-2H-1,4-benzodiazepin-2-one; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2 [French]; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylgermyl-; AC1O4GHW; ST 101; LS-34275; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2"	10220323	Phase 2	D07CJN	DB12621	CTPDG002709
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVT302	.	.	Phase 2	D06PHS	.	CTPDG002738
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RP5063	.	.	Phase 1	D05XEA	.	CTPDG002780
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-384	UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide	11670435	Phase 2	D05WCI	DB12501	CTPDG002781
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PRX-3140	.	.	Phase 2	D05BWH	.	CTPDG002818
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Myo-inositol	"Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite"	892	Phase 2	D03SHD	DB03106	CTPDG002906
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CHF-5074	"CHF 5074; CHF5074; 749269-83-8; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261"	9996409	Phase 2	D03MFQ	.	CTPDG002919
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FRM-0962	.	.	Phase 2	D02XKK	.	CTPDG002946
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-7622	"M1 receptor modulator; 1227923-29-6; MK7622; MK 7622; 3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one; SCHEMBL2399084; EX-A804; JUVQLZBJFOGEEO-GOTSBHOMSA-N; BCP27739; ZINC95930184; AKOS028113668; DB12897; CS-5442; HY-15618; Benzo(H)quinazolin-4(3H)-one, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methyl-3-pyridinyl)methyl)-; AS-35236; KB-145903; J-690076; UNII-57R7D1Q49R component JUVQLZBJFOGEEO-GOTSBHOMSA-N"	46207733	Phase 2	D02WFN	DB12897	CTPDG002950
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG1577	.	.	Phase 2	D02PSS	.	CTPDG002962
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BMS-708163	Avagacestat	46883536	Phase 2	D02JOH	DB11893	CTPDG002976
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-0752	"471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635"	9803433	Phase 2	D02HNG	DB12852	CTPDG002978
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GM-602	"Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid"	9875671	Phase 2	D02DEH	.	CTPDG002988
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HF-0220	"Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming"	9836181	Phase 2	D02AOD	DB06622	CTPDG002994
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mibampator	"LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly"	9889366	Phase 2	D01WBD	DB12717	CTPDG003005
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AVN 101	.	.	Phase 2	D01NDF	.	CTPDG003024
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Coluracetam	"BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells"	214346	Phase 2	D01MHI	.	CTPDG003025
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-1446	"TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca"	96568204	Phase 2	D01MAU	.	CTPDG003026
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AUS-131	.	91469	Phase 2	D01HXA	DB11674	CTPDG003039
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	TD-8954	"UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate"	11961293	Phase 1/2	D01HVZ	DB12725	CTPDG003041
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vanutide cridificar	ACC-001	.	Phase 2	D01FBP	.	CTPDG003045
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Neu-P11	"Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819"	24815904	Phase 2	D00CVJ	DB12288	CTPDG003102
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ICA-17043	"Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215"	216327	Phase 2	D00BUR	DB06280	CTPDG003105
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MIB-626	.	.	Phase 1/2	DN0A1J	.	CTPDG003160
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	Xanamem	"(5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone; 1346013-80-6; compound 4 [PMID: 28012176]; GLXC-26582; GTPL12037; SCHEMBL23207782; SCHEMBL23798797; starbld0030988; UE2343; UE-2343; Xanamem"	137530063	Phase 1/2	DJMK69	.	CTPDG003172
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VGH-AD1	.	.	Phase 1/2	DIM79Y	.	CTPDG003177
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	GB301	.	.	Phase 1/2	DBU2J7	.	CTPDG003200
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	"N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide"	18604758	Phase 1/2	D82DMK	.	CTPDG003221
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LX1001	AAVrh.10hAPOE2	.	Phase 1/2	D6UEI3	.	CTPDG003230
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VAC20121	ACI-35	.	Phase 1/2	D3C0LO	.	CTPDG003247
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AL 001	Latozinemab	.	Phase 1/2	D2A6QI	.	CTPDG003251
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AstroStem	.	.	Phase 1/2	D0VD9X	.	CTPDG003296
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	EB-101	"Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals"	.	Phase 1/2	D0TU1E	.	CTPDG011346
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	IONIS-MAPTRx	.	.	Phase 1/2	D0RK4B	.	CTPDG003331
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	ACI-24	"Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune"	.	Phase 1/2	D0R6UR	.	CTPDG003339
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	RVX-208	.	24871506	Phase 1/2	D0N7WW	.	CTPDG003366
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VLP norovirus bivalent vaccine	"VLP norovirus bivalent vaccine (intranasal, norovirus-induced gastroenteritis)"	.	Phase 1/2	D0J3DC	.	CTPDG003404
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	APH-0703	.	.	Phase 1/2	D09QVU	.	CTPDG003487
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	.	.	Phase 1/2	D02XJJ	.	CTPDG003601
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIIB080	.	.	Phase 1/2	D02TWR	.	CTPDG003604
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIL010t	.	.	Phase 1/2	D02AIZ	.	CTPDG003615
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	"1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione"	73441910	Phase 1	DZ76PB	.	CTPDG003647
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD101	"(2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone; (2,4-Dimethylpyridin-3-yl)(4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{3-methyl-4-[1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone; 306293-36-7; AD101; BDBM50104946; CHEMBL113436; DTKUANPECHGGBY-UNMCSNQZSA-N; PD084304; Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2S)-; SCHEMBL4453513"	464036	Phase 1	DYS52Z	.	CTPDG003652
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	IGCAD1	.	.	Phase 1	DWNR12	.	CTPDG003674
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN-322	"1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475"	135905417	Phase 1	DWD06K	.	CTPDG003675
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	J147	"(E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; 1146963-51-0; 1807913-16-1; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; A894156; AC-35232; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; AKOS024458485; AS-16718; CCG-268030; CHEBI:192601; CHEMBL2387144; CS-3688; DB13957; DTXSID501045787; EX-A2235; HMS3886O17; HY-13779; HYMZAYGFKNNHDN-SSDVNMTOSA-N; j147; J-147; MFCD25976644; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; s5269; SCHEMBL12995834; SCHEMBL21294999; UNII-Z41H3C5BT9; Z41H3C5BT9"	25229652	Phase 1	DW4O2J	DB13957	CTPDG003676
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG6289	.	.	Phase 1	DUV3B0	.	CTPDG003698
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASN51	.	.	Phase 1	DS70NZ	.	CTPDG003728
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2511	.	.	Phase 1	DRT09Y	.	CTPDG003737
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SHR-1707	.	.	Phase 1	DPYA76	.	CTPDG003763
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APH-1104	.	.	Phase 1	DNH51Q	.	CTPDG003800
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL919	TAK-920	.	Phase 1	DN48GC	.	CTPDG003808
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NTRX-07	MDA7	.	Phase 1	DK3WQ5	.	CTPDG003852
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAV-hTERT	.	.	Phase 1	DI9X5U	.	CTPDG003881
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL104	.	.	Phase 1	DHD2S9	.	CTPDG003895
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL747	.	.	Phase 1	DGH83L	.	CTPDG003903
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	REM0046127	.	.	Phase 1	DF21MW	.	CTPDG003924
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACU193	.	.	Phase 1	DCP0I8	.	CTPDG003951
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protollin	.	.	Phase 1	DC0DU9	.	CTPDG003960
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	.	.	Phase 1	DB7V3D	.	CTPDG003970
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ALN-APP	.	.	Phase 1	D8W0NQ	.	CTPDG004008
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-4334	.	.	Phase 1	D7PGM4	.	CTPDG004033
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NNI-362	.	.	Phase 1	D6KWF3	.	CTPDG004060
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR588	.	.	Phase 1	D62XNL	.	CTPDG004074
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AL003	.	.	Phase 1	D5QKY2	.	CTPDG004088
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3372993	.	.	Phase 1	D4YD7V	.	CTPDG004104
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MER5101	.	.	Phase 1	D4JPV8	.	CTPDG004117
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	"(4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; 1375752-78-5; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; 3I1803DK5Z; AKOS040756698; BDBM50536712; BMS984923; BMS-984923; CHEMBL4571075; CS-0087012; HY-122559; SCHEMBL4541143; UNII-3I1803DK5Z"	69084898	Phase 1	D34YLZ	.	CTPDG004146
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB113	.	.	Phase 1	D2KV0F	.	CTPDG004163
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-6-Me-BTA-1	Carbon-11-6-Me-BTA-1; 11C-BTA-1	.	Phase 1	D0ZX2D	.	CTPDG004207
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-104	.	.	Phase 1	D0ZW2I	.	CTPDG004210
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	V950 vaccine	.	.	Phase 1	D0Z2HG	.	CTPDG004232
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06751979	"ZLZUHACSRMOLLV-RAALSFIWSA-N; 1818339-66-0; UNII-1Y0Y126GUG; 1Y0Y126GUG; US9315520, Example 1; CHEMBL3952064; US9315520, Example 2; US9315520, Comparator 1; SCHEMBL17162186; BDBM223395; HY-112157; CS-0043501; US9315520, 1; N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide; N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carb"	118435360	Phase 1	D0Y5NA	DB15105	CTPDG004257
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-932481	.	91844660	Phase 1	D0XI4P	.	CTPDG004275
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-354	.	.	Phase 1	D0X9HF	.	CTPDG004280
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Affitope AD-01	"AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS"	.	Phase 1	D0X2UK	.	CTPDG004290
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-212	.	.	Phase 1	D0X1XK	.	CTPDG004293
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR-388	.	.	Phase 1	D0WS4E	.	CTPDG004298
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB076	.	.	Phase 1	D0WL5T	.	CTPDG004303
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-250	.	.	Phase 1	D0WI9W	.	CTPDG004305
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACI-35	.	.	Phase 1	D0W9LS	.	CTPDG004309
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-241027	.	.	Phase 1	D0V9HL	.	CTPDG004340
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD03 vaccine	.	.	Phase 1	D0V3EQ	.	CTPDG004351
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-AZD-2184	"AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184"	.	Phase 1	D0V0VI	.	CTPDG004354
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSI-136	"WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth"	11358855	Phase 1	D0U6FT	DB12819	CTPDG004374
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	18F-FEDAA-1106	"ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer"	.	Phase 1	D0U1US	.	CTPDG004382
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	.	.	Phase 1	D0TQ4Y	.	CTPDG004394
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BCI-632	"LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,"	9886034	Phase 1	D0T3DG	.	CTPDG004411
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ARC031	.	.	Phase 1	D0T0NL	.	CTPDG004413
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-103+RVT-104	.	.	Phase 1	D0S1KR	.	CTPDG004439
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Exebryl-1	Exebryl-1 (TN)	.	Phase 1	D0RD1Z	.	CTPDG004450
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAu mAb	.	.	Phase 1	D0R6WL	.	CTPDG004459
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BAY-1006578	"Diagnostic PET imaging agent (Alzheimer's disease), Bayer"	.	Phase 1	D0O9HG	.	CTPDG004540
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG7129	.	53241828	Phase 1	D0O8UB	.	CTPDG004543
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SAR228810	.	.	Phase 1	D0N9JB	.	CTPDG004573
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GRF6019	.	.	Phase 1	D0N8QR	.	CTPDG004576
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-168	"Alzheimer's diagnostic, IND; 123I-SPECT diagnostic (Alzheimer's disease), IND"	.	Phase 1	D0N3UQ	.	CTPDG004583
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY-2811376	"LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,"	44251605	Phase 1	D0N1BF	DB13065	CTPDG004586
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-330	.	.	Phase 1	D0MU7N	.	CTPDG004589
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SUVN-D4010	"DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole"	71508291	Phase 1	D0M9RI	.	CTPDG004596
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Mesenchymal stem cell therapy	.	.	Phase 1	D0M6AR	.	CTPDG004600
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2184	.	.	Phase 1	D0M0UB	.	CTPDG004608
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP-0777	.	.	Phase 1	D0L1UH	.	CTPDG004640
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NPT088	.	.	Phase 1	D0KN7Y	.	CTPDG004647
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Aleplasinin	"PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth"	10224267	Phase 1	D0JI2E	DB12635	CTPDG004674
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1841	.	.	Phase 1	D0J9PS	.	CTPDG004681
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E-2212	.	46854987	Phase 1	D0I1OS	.	CTPDG004731
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TTP-4000	"Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech"	.	Phase 1	D0I0YS	.	CTPDG004732
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANVS301	Bisnormcerysine	.	Phase 1	D0HRC9	.	CTPDG004738
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2012	870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N	11560787	Phase 1	D0F0JJ	DB05171	CTPDG004815
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NGP 555	"WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine"	46853593	Phase 1	D0EV5O	.	CTPDG004818
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AV-965	.	.	Phase 1	D0EH0C	.	CTPDG004824
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2647544	GSK-2647544	.	Phase 1	D0E6KN	.	CTPDG004830
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NDX-1017	.	.	Phase 1	D0E3CX	.	CTPDG004833
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GC021109	.	.	Phase 1	D0D4HO	.	CTPDG004863
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NsG-0202	"ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene"	.	Phase 1	D0D0GH	.	CTPDG004872
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SGC-1061	.	.	Phase 1	D0B3HP	.	CTPDG004921
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NBXT-001+Nobilis inhalation device	.	.	Phase 1	D0AY8D	.	CTPDG004928
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF20513	.	.	Phase 1	D0A9PD	.	CTPDG004933
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Begacestat	GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953	11269353	Phase 1	D09ZVC	DB12263	CTPDG004953
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	BCI-838	.	.	Discontinued in Phase 1	D09WZU	.	CTPDG004961
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-3328	UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073	44555286	Phase 1	D09PYZ	.	CTPDG004984
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JES-9501	DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride	.	Phase 1	D09MEV	.	CTPDG004992
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAK-071	WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5	92042879	Phase 1	D09BBA	.	CTPDG005012
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANAVEX 2-73	.	46932299	Phase 1	D09AOO	.	CTPDG005014
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SPI-014	"SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals"	46221695	Phase 1	D08XKL	.	CTPDG005020
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	HPP-854	.	.	Phase 1	D08TVI	.	CTPDG005028
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JNJ-63733657	.	.	Phase 1	D07PFU	.	CTPDG005091
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DWP-09031	DWJ-301	.	Phase 1	D06KWU	.	CTPDG005157
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2995	.	.	Phase 1	D06JPY	.	CTPDG005158
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Palomid-529	"P-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma"	.	Phase 1	D06JCO	.	CTPDG005159
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protexia	"RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene"	.	Phase 1	D06FGJ	.	CTPDG005166
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	FGLL	"NCAM mimetics (Alzheimer's disease), Enkam"	.	Phase 1	D06EXI	.	CTPDG005167
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Posiphen R-phenserine	.	.	Phase 1	D05VAE	.	CTPDG005184
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Anti-N3pG-Abeta antibody	.	.	Phase 1	D05ORO	.	CTPDG005192
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CTS-21166	.	.	Phase 1	D04VZS	.	CTPDG005234
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MCD-386	"CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion"	.	Phase 1	D04SIU	.	CTPDG005240
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD-3839	"GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D"	46202416	Phase 1	D04OSA	DB12368	CTPDG005245
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1814	.	.	Phase 1	D04AZT	.	CTPDG005269
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-957	.	.	Phase 1	D03NLQ	.	CTPDG005302
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	XEL 001HP	.	.	Phase 1	D03CCY	.	CTPDG005321
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-05251749	.	.	Phase 1	D03AGK	.	CTPDG005330
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-04995274	"UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, &gt; 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol"	53354764	Phase 1	D02YKI	DB12675	CTPDG005332
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAB-003/PF-05236812	.	.	Phase 1	D01ZSP	.	CTPDG005370
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2981710	.	.	Phase 1	D01YDH	.	CTPDG005373
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP3662	.	44598960	Phase 1	D00UEC	.	CTPDG005437
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAD-2004	"927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID"	16042343	Phase 1	D00MBY	.	CTPDG005453
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	Phase 1	D00EHX	DB12899	CTPDG005470
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	"methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate"	"MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate"	2314952	Clinical trial	D0R7EA	.	CTPDG005492
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	bimatoprost (free acid form)	17-phenyl-omega-trinor-PGF2alpha	5283081	Clinical trial	D08QWQ	.	CTPDG005504
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	JNJ-479655	"1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, &gt; Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide"	66553218	Clinical trial	D07QTG	.	CTPDG005505
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	alpha-ketothiazole analogue 36	"GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide"	16098914	Clinical trial	D05TKW	.	CTPDG005507
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-22	.	19910	Patented	D0KG9M	DB01422	CTPDG005806
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-20	.	.	Patented	D0I9VU	.	CTPDG005858
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-2	.	.	Patented	D0E2AF	.	CTPDG005956
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 2	PMID29324067-Compound-53	.	Patented	D0DW5P	.	CTPDG005961
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID29334795-Compound-22	.	.	Patented	D0B2NV	.	CTPDG006029
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-19	.	.	Patented	D09UJB	.	CTPDG006053
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Thiadiazolyl carboxamide derivative 1	PMID28270010-Compound-Figure18-1	71263688	Patented	D06STX	.	CTPDG006137
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 1	PMID29324067-Compound-43	.	Patented	D05RJG	.	CTPDG006162
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-18	.	.	Patented	D04NCC	.	CTPDG006193
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	Zanapezil	TAK-147	198752	Discontinued in Phase 3	D0AM8W	DB04859	CTPDG006368
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	PF-1913539	"Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261"	176408	Discontinued in Phase 3	D07ESH	.	CTPDG006376
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AZD0328	"AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]"	9794392	Discontinued in Phase 2	D0Q9RR	DB12145	CTPDG006451
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	S-18986	"S 18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine"	637863	Discontinued in Phase 2	D0M0HJ	.	CTPDG006484
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AVN 397	.	.	Discontinued in Phase 2	D0J7EP	.	CTPDG006497
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	DPC-543	.	.	Discontinued in Phase 2	D0I4PL	.	CTPDG006502
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	NGD-97-1	"CP-457,920"	.	Discontinued in Phase 2	D0FN6D	.	CTPDG006521
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	IPENOXAZONE	"MLV-6976; NC-1200; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one"	65882	Discontinued in Phase 2	D0B4EV	.	CTPDG006554
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Ispronicline	RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine	9824145	Discontinued in Phase 2	D0AB4Q	.	CTPDG006559
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	ABT-418	"Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398"	119380	Discontinued in Phase 2	D09ADT	.	CTPDG006574
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Talsaclidine fumarate	"Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane"	6918244	Discontinued in Phase 2	D06ODM	.	CTPDG006603
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Affitope AD-02	"Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals"	.	Discontinued in Phase 2	D06BVT	.	CTPDG006608
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	SIB-1553A	"191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride"	5310968	Discontinued in Phase 2	D00ECO	.	CTPDG006677
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	VP-025	"Inflammation therapeutics, Vasogen; VP-015"	.	Discontinued in Phase 1	D0Y8IS	.	CTPDG006707
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TRx-0037	.	.	Discontinued in Phase 1	D0S9XR	.	CTPDG006743
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	EVT-301	"MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche"	.	Discontinued in Phase 1	D0P1WB	.	CTPDG006760
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	PF-05236812	AAB-003	.	Discontinued in Phase 1	D0K3SV	.	CTPDG006792
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	C-9138	.	.	Discontinued in Phase 1	D0K0XW	.	CTPDG006794
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	SL-25.1188	.	.	Discontinued in Phase 1	D0E3JL	.	CTPDG006819
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	GR-253035	.	.	Discontinued in Phase 1	D0C2HF	.	CTPDG006828
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TAK-065	"Neuroregeneration enhancer (oral, Alzheimers/Parkinsons disease), Takeda"	.	Discontinued in Phase 1	D0A2XD	.	CTPDG006837
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	NP-61	"Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira"	.	Discontinued in Phase 1	D04UKJ	.	CTPDG006894
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	ACC-002	.	.	Phase 0	D0YM4F	.	CTPDG006951
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	INP102	.	.	Phase 0	D0P7BA	.	CTPDG006952
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	AAB-002	.	.	Phase 0	D01QLM	.	CTPDG006954
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	TPT-43	.	.	Preclinical	D0YH9A	.	CTPDG007021
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-1501	"AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals"	.	Preclinical	D0XM3S	.	CTPDG007024
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SPH-1285	"Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359"	.	Preclinical	D0V7FG	.	CTPDG007039
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	ANAVEX 1-41	.	10446473	Preclinical	D0T0UC	.	CTPDG007053
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	VER-155008	"Heat shock protein 70 inhibitor (cancer), Vernalis; Hsp 70 inhibitor (cancer), Vernalis"	25195348	Preclinical	D0H0AU	.	CTPDG007083
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Pepticlere	"DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech"	.	Preclinical	D0G7LP	.	CTPDG007086
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SCH-1359113	"SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough"	23627211	Preclinical	D0E3SX	.	CTPDG007089
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	humanin	formyl humanin	16131438	Preclinical	D09TXO	.	CTPDG007101
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CDD-0199-J	.	.	Preclinical	D09MQQ	.	CTPDG007103
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Alvameline	Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M	178030	Terminated	D0X8MZ	.	CTPDG007181
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Ro-46-5934	.	.	Terminated	D0TK0W	.	CTPDG007215
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	IDRA-21	IDRA-21 analogs; IDRA-5	3688	Terminated	D0S0VZ	.	CTPDG007229
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-99	"Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	132712	Terminated	D0R1VL	.	CTPDG007239
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS-66252	.	9803861	Terminated	D0Q7SO	.	CTPDG007242
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-93426	"ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-"	115210	Terminated	D0P3IE	.	CTPDG007252
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-427	.	.	Terminated	D0O7DN	.	CTPDG007262
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	EHT-1864	"EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit"	9938202	Terminated	D0M9ER	.	CTPDG007276
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CI-1002	PD-142676	9838284	Terminated	D0M2GI	.	CTPDG007282
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BU-4514N	"BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one"	54704416	Terminated	D0L8TN	.	CTPDG007287
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	DNP-004089	"BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo"	.	Terminated	D0K3WN	.	CTPDG007302
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF-8615	.	.	Terminated	D0K0XG	.	CTPDG007305
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-152558	.	.	Terminated	D0J4GQ	.	CTPDG007314
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-649	.	9905818	Terminated	D0G7HO	.	CTPDG007347
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MDL-28170	MDL-2170	72430	Terminated	D0G5ZE	.	CTPDG007348
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-377	.	9860852	Terminated	D0EP5O	.	CTPDG007360
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	R-1315	.	.	Terminated	D0CX2J	.	CTPDG007380
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	L-698544	"7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ"	10220180	Terminated	D0AZ5V	.	CTPDG007398
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GYKI-52466	"102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2"	3538	Terminated	D0A9VO	.	CTPDG007402
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Nerve growth factor	"Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia"	.	Terminated	D0A0MJ	.	CTPDG007406
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-3796	.	.	Terminated	D09IUG	.	CTPDG007420
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NNC-90-0270	"Nicotinic ACh agonists, Novo Nordisk"	.	Terminated	D09GRB	.	CTPDG007422
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-14413	"Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre"	.	Terminated	D08VJI	.	CTPDG007432
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-4001	.	.	Terminated	D08TCU	.	CTPDG007433
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Milacemide	Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S	53569	Terminated	D07OLO	.	CTPDG007457
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sch-57790	CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294	9867750	Terminated	D07IZF	.	CTPDG007461
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF268	"MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet"	5288799	Terminated	D06ZAM	DB04021	CTPDG007467
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Z-4105	"119737-52-9; Butanoic acid, 4-(((3-methyl-5-isoxazolyl)carbonyl)amino)-; Butanoic acid,4-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-; ACMC-20cew8; AC1Q5P7F; SCHEMBL195378; AC1L4P39; CTK4B1474; 4-[(3-methyl-1,2-oxazole-5-carbonyl)amino]butanoic acid; DTXSID50152568; 4-{[(3-methyl-1,2-oxazol-5-yl)carbonyl]amino}butanoic acid"	189689	Terminated	D06PAW	.	CTPDG007475
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RU-33965	"RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-"	129696	Terminated	D05IVZ	.	CTPDG007496
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS 86	"RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl  -D-galactopyranoside; 2-Nitrophenyl; A-D-galactopyranoside"	87934	Terminated	D05HKB	.	CTPDG007497
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-121196	"FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-"	131688	Terminated	D05EKM	.	CTPDG007500
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	AZD-2858	AZD2858; 486424-20-8; AZD 2858; CHEMBL2177161; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide; 3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide; GSK-3 inhibition; 3-amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL8478; SCHEMBL3327702; C21H23N7O3S; EX-A707; AOB6850; MolPort-035-395-808	10138980	Terminated	D04WZK	.	CTPDG007507
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-431	"Clipsin inhibitor, Cephalon"	.	Terminated	D04RDT	.	CTPDG007509
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NP-7557	"Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech"	.	Terminated	D03DFY	.	CTPDG007539
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-2016	GT 2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653	9839975	Terminated	D02YXQ	.	CTPDG007540
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	A-72055	.	.	Terminated	D02VHE	.	CTPDG007544
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ABS-301	"ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS"	.	Terminated	D02UQU	.	CTPDG007545
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-91296	"ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester"	123700	Terminated	D02UIE	.	CTPDG007546
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-140	"Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	10030021	Terminated	D02JNY	.	CTPDG007550
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Bifemelane	Alnert; Celeport; E-0687; MCI-2016; SON-216	2377	Terminated	D02CGY	DB13550	CTPDG007557
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sibopirdine	"DuP-921; EXP-9121; EXP-921; 5H-Cyclopenta[2,1-b:3,4-b']dipyridine, 5,5-bis(4-pyridinylmethyl)-, monohydrate"	195376	Terminated	D01LRH	.	CTPDG007569
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Tenilsetam	CAS-997	65649	Terminated	D00JNL	.	CTPDG007586
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AD-0802	"Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic"	.	Investigative	D0Y9ES	.	CTPDG007656
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	VK-11	"Imaging agent (Alzheimer's disease), Prana"	.	Investigative	D0Y4TQ	.	CTPDG007666
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZD-6319	"Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca"	.	Investigative	D0X2NB	.	CTPDG007732
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PD-2015	"PD-2016; TNF alpha inhibitors (Alzheimers disease); TNF alpha inhibitors (Alzheimers disease), P2D Bioscience"	.	Investigative	D0WO8I	.	CTPDG007740
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CBNU-06	.	.	Investigative	D0WA3T	.	CTPDG007746
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RAP-310	"Small stabilized receptor active peptide (Alzheimers disease), RAPID Pharmaceuticals"	.	Investigative	D0W9OW	.	CTPDG007748
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tideglusib	.	11313622	Phase 2	D0W5WZ	DB12129	CTPDG007762
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DWJ-209	.	.	Investigative	D0W5CI	.	CTPDG007764
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EVP-4473	.	.	Investigative	D0VE4O	.	CTPDG007780
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ReN-004	"Stem cell therapy (neurological disorders), ReNeuron"	.	Investigative	D0UO6M	.	CTPDG007813
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-901	.	.	Investigative	D0T6FY	.	CTPDG007853
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR APLs	NAChR APLs (Alzheimer's disease)	.	Investigative	D0T5ZM	.	CTPDG007855
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	COG-248	"Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease); Neuroprotectant (Alzheimers/Parkinsons disease), Cognosci; Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease), Cognosci"	.	Investigative	D0S2QP	.	CTPDG007894
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ELND-007	"ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan"	53308121	Investigative	D0Q6ZQ	.	CTPDG007946
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	BAN-2203	"Beta amyloid modulator (Alzheimer's disease), BioArctic"	.	Investigative	D0Q5VC	.	CTPDG007953
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Turmeric extracts	"HSS-808; HSS-818; HSS-838; HSS-848; HSS-888; Turmeric extracts (Alzheimer's disease); Turmeric extracts (Alzheimer's disease), HerbalScience"	.	Investigative	D0Q2XN	.	CTPDG007960
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Ginkgo biloba extract	"YY-1224; YY-1824; Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease); Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease), Yuyu Inc"	.	Investigative	D0OB9V	.	CTPDG008000
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SX-AZD1	.	.	Investigative	D0N6EL	.	CTPDG008040
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AIKb2	.	.	Investigative	D0N0SC	.	CTPDG008055
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR alpha 7 APLs	NAChR alpha 7 APLs (Alzheimer's disease)	.	Investigative	D0M7MH	.	CTPDG008070
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	11A1	.	.	Investigative	D0K4WW	.	CTPDG008142
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Gamma-secretase modulators	"Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche"	24781184	Investigative	D0J5SD	.	CTPDG008172
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	MCD-386/glycopyrrolate	"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,"	3494	Investigative	D0IL1B	DB00986	CTPDG008185
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	HL-026	.	.	Investigative	D0IC8P	.	CTPDG008187
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ESN-XX	.	.	Investigative	D0I3OX	.	CTPDG008215
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ETN-001	.	.	Investigative	D0I0ZY	.	CTPDG008222
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DBT-1339	"DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech"	.	Investigative	D0HK7G	.	CTPDG008227
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GRL-11097	"Memapsin 2 inhibitors (Alzheimers); Memapsin 2 inhibitors (Alzheimers), Purdue University/Astellas"	.	Investigative	D0H2VN	.	CTPDG008244
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KNX-Monoclonal204	"KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis"	.	Investigative	D0G4AE	.	CTPDG008271
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KMS-88009	"KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical"	.	Investigative	D0F5UO	.	CTPDG008302
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NGN-9079	"Alzheimer's disease therapy, NeuroGeneration"	.	Investigative	D0F5IS	.	CTPDG008306
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PNB-04	"Alzheimer's disease therapy, PharmaNeuroBoost"	.	Investigative	D0EW4M	.	CTPDG008325
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	IMD-4482	"IMD-4690; PAI-1 inhibitor (oral, Alzheimers disease), IMMD; Plasminogen activator inhibitor-1 inhibitor (oral, Alzheimers disease), Institute of Medicinal Molecular Design"	.	Investigative	D0EW2D	.	CTPDG008326
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Abloid	"Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics"	.	Investigative	D0E5CX	.	CTPDG008345
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Memex	Nicotinomide adenine dinucleotide (NADH)	.	Investigative	D0E0OI	.	CTPDG008353
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-0235-J	.	.	Investigative	D0D7KR	.	CTPDG008371
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-103	"NP-060103; NP-60103; Glycogen synthase kinase-3 inhibitor (Alzheimer's disease), Neuropharma"	.	Investigative	D0D6WF	.	CTPDG008374
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Leptin	Leptin (Alzheimer's disease)	.	Investigative	D0C6TL	.	CTPDG008408
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SP-08	SP-008	.	Investigative	D0C4WY	.	CTPDG008411
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SPI-017	"SPI-017 (oral, Alzheimer's disease)"	.	Investigative	D0C1TT	.	CTPDG008423
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RECALL-VAX	"RV-01; RV-02; Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease); Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease), Intellect Neuroscience"	.	Investigative	D0B4AH	.	CTPDG008454
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CWF-0804	.	.	Investigative	D09NEL	.	CTPDG008535
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACU-0101979	"HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co"	.	Investigative	D09MRY	.	CTPDG008536
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Cystatin C	Cystatin C (Alzheimer's disease)	.	Investigative	D09HVY	.	CTPDG008553
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EDN-OL1	"Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn"	.	Investigative	D07ZDG	.	CTPDG008644
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ADepVac	"DNA vaccine (Alzheimer's disease), University of California Irvine; DNA vaccine (TriGrid electroporation, Alzheimers), Ichor/UCI/IMM"	.	Investigative	D07ZBO	.	CTPDG008646
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Anticalin	Anticalin (Alzheimer's disease)	.	Investigative	D07YAC	.	CTPDG008650
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-518	"AMPA glutamate receptor agonist (Alzheimer's disease), AC Immune"	.	Investigative	D07KMI	.	CTPDG008690
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEN-1500	"SEN-1576; Beta-amyloid aggregation inhibitors (Alzheimer's disease); Beta-amyloid aggregation inhibitors (Alzheimer's disease), Senexis"	54589394	Investigative	D07JKA	.	CTPDG008693
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARN-2966	"ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences"	14936865	Investigative	D07DNV	.	CTPDG008707
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZ-AAV9	"Alzheimers disease gene therapy, RegenX Biosciences; Adeno-associated virus vector-9 based gene therapy (injectable,AD), RegenX Biosciences"	.	Investigative	D06UUE	.	CTPDG008732
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-636	"Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune"	.	Investigative	D06MBR	.	CTPDG008752
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	TKP-1001	"Amyloid-beta modulator (Alzheimer's disease), EUSA Pharma; Amyloid-beta modulator (Alzheimer's disease), Talisker Pharma; Amyloid-beta synthesis modulator (Alzheimer's disease), The Open University"	.	Investigative	D06LRQ	.	CTPDG008753
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-17	"NP-21; NPM-01; NPM-05 series; NPM-05B1; NPM-05B2; Alpha-secreatse activators (oral, Alzheimer's disease), Noscira"	.	Investigative	D05NIO	.	CTPDG008822
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ANA-5	.	.	Investigative	D04ZTA	.	CTPDG008850
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NXD-9062	.	.	Investigative	D04UQS	.	CTPDG008858
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3186	.	.	Investigative	D04TZK	.	CTPDG008860
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	A-887755	.	.	Investigative	D04TPS	.	CTPDG008861
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARC-069	"Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals"	.	Investigative	D04QXW	.	CTPDG008864
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NNI-AD	"NNI-251; NNI-362; NNI-C; NNI-X01; AD therapy (oral), Neuronascent"	.	Investigative	D04OUP	.	CTPDG008871
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZP-2006	"Amyloid precursor protein modulator (AD), AlzProtect/INSERM/University of Lille II"	87057554	Investigative	D04MHP	.	CTPDG008882
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AC-4402	"GABAA receptor inverse agonist (Alzheimer's disease), Dainippon Sumitomo Pharma"	3084937	Investigative	D03TDE	.	CTPDG008935
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GT 1061	.	53483797	Investigative	D03IHA	.	CTPDG008969
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3248	.	.	Investigative	D01ZFM	.	CTPDG009049
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	UC-1011	"UC-2021; UC-2025; GABA A receptor antagonists (Alzheimer's disease); GABA A receptor antagonists (Alzheimer's disease), Umecrine; 3beta-20beta-dihydroxy-5alpha-pregnane; 3beta-20beta-dihydroxy-5alpha-pregnane (Alzheimer's disease), Umecrine"	.	Investigative	D01YGY	.	CTPDG009051
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	F-18 T808	.	.	Investigative	D01SXE	.	CTPDG009066
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-501	.	.	Investigative	D01QNJ	.	CTPDG009082
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Haw-AD-14	.	.	Investigative	D01LBD	.	CTPDG009100
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-190	.	.	Investigative	D01GBV	.	CTPDG009117
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	123I-DRM-106	"DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd"	49801966	Investigative	D01GAZ	.	CTPDG009118
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PN-403	.	.	Investigative	D01FTK	.	CTPDG009120
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Mimovax	"MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS"	.	Investigative	D01BJK	.	CTPDG009132
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEL-103	.	.	Investigative	D00YJD	.	CTPDG009144
M6ACROT02076	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Molecule 22	"MARK3 inhibitors (Alzheimer's disease); MARK3 inhibitors (Alzheimer's disease), Merck & Co"	.	Investigative	D00HDH	.	CTPDG009188
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rivastigmine	Rivastigmine (transdermal patch)	77991	Approved	D0WY5Q	DB00989	CTPDG000074
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Propentofylline propionate	Hextol (TN)	4938	Approved	D0UU9Y	DB06479	CTPDG000111
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Dihydroergotoxine	"Ergotamine, dihydro, methanesulfonate (salt)"	6420006	Approved	D0SP3D	.	CTPDG000148
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Galantamine	"GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol"	9651	Approved	D0R9VR	DB00674	CTPDG000171
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Eicosapentaenoic acid/docosa-hexaenoic acid	"Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN)"	445580	Approved	D0Q5XX	DB03756	CTPDG012556
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Donepezil	"Donepezil (transdermal patch, Alzheimer's disease)"	3152	Approved	D0NS6H	DB00843	CTPDG000257
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved in China	GV-971	.	.	Approved in China	D0FS5O	.	CTPDG000380
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Tacrine	"Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine"	1935	Approved	D0E6YQ	DB00382	CTPDG000406
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Lemborexant	E2006	56944144	Phase 2	D0A7ZK	DB11951	CTPDG000461
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Pexidartinib	PLX-3397	25151352	Approved	D09TAB	DB12978	CTPDG013033
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-florbetaben	.	.	Approved	D07TRF	.	CTPDG000548
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Colostrinin	Colostrinin (TN)	.	Approved	D07NPH	.	CTPDG000558
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Huperzine A	"Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680"	854026	Approved	D06XWB	DB04864	CTPDG000589
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Lecanemab	.	.	Approved	D06XVR	.	CTPDG000590
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-flutemetamol	.	.	Approved	D06XOT	.	CTPDG000591
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Ergoloid mesylate	Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)	592735	Approved	D02IQY	.	CTPDG000752
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Immune globulin	.	.	Approved	D01OWB	.	CTPDG000780
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Memantine	"Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest"	4054	Approved	D01JEU	DB01043	CTPDG000790
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Aducanumab	.	.	Approved	D00RRU	.	CTPDG000806
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nirogacestat	"Nirogacestat; 1290543-63-3; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01"	46224413	Phase 2	D00GPQ	DB12005	CTPDG000817
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 4	18F-AV-1451	Tau imaging agent)	70957463	Phase 4	D0F4CG	DB14914	CTPDG000847
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NE3107	.	.	Phase 3	D9I6QG	.	CTPDG000924
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Guanfacine	"(2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride; 29110-47-2; 30OMY4G3MK; A902647; A918619; AB01563079_01; AKOS030255657; AKOS030526130; BCP09647; BDBM81984; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; BPBio1_000415; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; BSPBio_000377; C02AC02; C07037; CAS_29110-47-2; CAS-29110-48-3; CCG-204609; CHEBI:5558; CHEMBL862; D08031; DB01018; DTXCID7026944; DTXSID9046944; EINECS 249-442-8; EN300-243924; Estulic; Estulic (Salt/Mix); Estulic (TN); FT-0669067; FT-0669068; GTPL522; Guanfacina; Guanfacina (INN-Spanish); Guanfacina [INN-Spanish]; GUANFACINE; Guanfacine (INN); Guanfacine [INN:BAN]; GUANFACINE [INN]; GUANFACINE [MI]; GUANFACINE [VANDF]; GUANFACINE [WHO-DD]; Guanfacine HCl; Guanfacine hydrochloride (Salt/Mix); Guanfacinum; Guanfacinum (INN-Latin); Guanfacinum [INN-Latin]; HY-17416A; J-017394; L000286; L013430; LON 798 (Salt/Mix); Lopac0_000519; Lopac-G-1043; MRF-0000019; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; N-amidino-2-(2,6-dichlorophenyl)acetamide; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-05; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; NSC 759121; NSC_3519; NSC-759121; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Q5613599; RASPBERRYKETONEGLUCOSIDE; SCHEMBL35094; SDCCGSBI-0050502.P002; SPBio_002298; Tenex (Salt/Mix); Tocris-1030; UNII-30OMY4G3MK"	3519	Phase 3	D8NY3J	DB01018	CTPDG000928
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	BPDO-1603	.	.	Phase 3	D71LNO	.	CTPDG000931
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AXS-05	.	.	Phase 2/3	D3PD8C	.	CTPDG000941
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Remternetug	LY3372993	.	Phase 3	D34FRG	.	CTPDG000944
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Donanemab	.	.	Phase 3	D2ZP0A	.	CTPDG000945
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AR1001	"(-)-methylbenzylamine; (+)-2-Methylbutylp-aminocinnamate; 103-67-3; 7KN7F4X49E; AI3-26793; AKOS000119094; AR1001; Benzenemethanamine, N-methyl-; benzyl methyl amine; benzyl methylamine; Benzyl(methyl)amine; BENZYLAMINE, N-METHYL; Benzylamine, N-methyl-; Benzylmethylamine; benzyl-methylamine; Benzyl-methyl-amine; Benzylmethyl-d3-amine; BRD-K44558320-003-01-7; CHEMBL1338; CS-W007426; DTXSID9048439; EC 203-133-4; EINECS 203-133-4; EN300-18191; F2190-0316; FT-0631560; HNMeBzl; HY-W007426; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H; KBio2_001842; KBio2_004410; KBio2_006978; KBioGR_002247; KBioSS_001842; M0164; methyl benzylamine; Methyl(phenylmethyl)amine; methyl-benzyl amine; Methylbenzylamine; Methylbenzylamine, N-; methylbezylamine; MFCD00008289; MLS004773900; N-(Phenylmethyl)methylamine; N-benzyl methyl amine; N-benzyl methylamine; N-benzylmethanamine; N-benzyl-methyl amine; N-Benzylmethylamine; N-benzyl-methylamine; N-Benzylmethylamine, 97%; N-Benzyl-N-methylamine; N-benzyl-N-methyl-amine; NCGC00166047-01; N-methyl benzyl amine; N-methyl benzylamine; N-methyl -benzylamine; N-Methyl(phenyl)methanamine; N-methyl-1-phenylmethanamine; N-methyl-1-phenyl-methanamine; N-methylbenzenemethanamine; N-methyl-benzenemethanamine; N-methylbenzyl amine; N-methyl-benzyl amine; N-METHYLBENZYLAMINE; N-methyl-benzylamine; N-methyl-N-(phenylmethyl)amine; N-methyl-N-benzyl amine; N-methyl-N-benzylamine; N-Methy-N-benzylamine; NSC 8059; NSC8059; NSC-8059; omega-Methylaminotoluene; Q23978278; Racemic methylbenzyl amine; SCHEMBL2271; SDCCGMLS-0066901.P001; SMR000112361; Spectrum_001362; Spectrum4_001764; Spectrum5_000347; STR02536; UNII-7KN7F4X49E; W-108843; Z57327124"	7669	Phase 3	D1OM8E	.	CTPDG000951
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	GV-971	sodium oligomannate	.	Phase 3	D1KR3N	.	CTPDG000952
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AVP-786	.	25052519	Phase 3	D0Z6IB	.	CTPDG000965
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NI-101	"BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec"	.	Phase 3	D0Z2GF	.	CTPDG000968
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Lanabecestat	"1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane"	67979346	Phase 3	D0Y0EP	DB14814	CTPDG000986
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SB-742457	GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline	11256720	Phase 3	D0R9HI	DB12680	CTPDG001066
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Crenezumab	MABT5102A; RG7412	.	Phase 3	D0R7EQ	.	CTPDG001069
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	verubecestat	example 25 (US8940748)	51352361	Phase 3	D0R4KK	DB12285	CTPDG001070
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Gantenerumab	RG1450	.	Phase 3	D0Q7YZ	.	CTPDG001078
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	PF-4494700	"PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer"	11180124	Phase 3	D0MW7B	DB12689	CTPDG001122
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SI-657	"AC1L9R2T; 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid"	453618	Phase 3	D0E9SZ	.	CTPDG001222
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	EVP-6124	"Encenicline; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626"	46196517	Phase 3	D0D3TX	DB11726	CTPDG001246
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ALZT-OP1	ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen	.	Phase 3	D0CH6B	.	CTPDG001252
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	MIM-D3	"TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen"	9808372	Phase 3	D0C2OR	DB12441	CTPDG001261
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LCS 16	.	.	Phase 3	D0A4DP	.	CTPDG001278
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Bapineuzumab	"AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan"	.	Phase 3	D0A1MX	.	CTPDG001282
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tirapazamine	TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075	135413511	Phase 3	D09XQU	DB04858	CTPDG001290
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AV 133	.	.	Phase 3	D09NAF	.	CTPDG001302
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tramiprosate	"Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS"	1646	Phase 3	D09DLP	DB06527	CTPDG001314
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	E-2609	"Beta secretase inhibitor (Alzheimer's disease), Eisai"	57827330	Phase 3	D08MHD	DB15391	CTPDG001329
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	(-)-Phenserine	"CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate"	192706	Phase 3	D07CIN	DB04892	CTPDG001369
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ARC029	"Nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino"	4494	Phase 3	D06GRK	DB06712	CTPDG001378
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Eltoprazine	"Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company"	65853	Phase 2	D06FKC	DB12883	CTPDG001380
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	INM-176	"WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn"	.	Phase 3	D05UXU	.	CTPDG001390
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Xaliproden	"Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine"	128919	Phase 3	D02OJC	DB06393	CTPDG001464
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tamibarotene	"Tamibarotene (oral, Alzheimer's disease)"	108143	Phase 3	D02GTY	DB04942	CTPDG001471
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Immune globulin + albumin	.	.	Phase 3	D00KLP	.	CTPDG001501
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Solanezumab	.	.	Phase 3	D00CZT	.	CTPDG001504
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD106	.	.	Phase 2/3	DF3UN2	.	CTPDG001516
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Icosapent ethyl	"(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 6GC8A4PAYH; 73310-10-8; 86227-47-6; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound; AB01563352_01; AC-33765; AKOS025295847; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; AMR 101; AMR101; AMR-101; BS-48985; CCG-213714; CHEBI:80366; CHEBI:84883; CHEMBL2095209; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; cis-Eicosapentaenoic acid ethyl ester; CS-5304; D01892; DB08887; DTXSID601018686; E0442; E0853; E-EPA; Eicosapentaenoic acid (ethyl ester); Eicosapentaenoic acid ethyl ester; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; Eicosapentaenoic acid, ethyl ester; Eicosapentaenoicacidethylester; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EN300-25951782; EPA ethyl ester; Epadel; Epadel S; Epadel S (TN); EPA-E; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; ethyl eicosapentaenoate; Ethyl eicosapentaenoic acid; Ethyl EPA; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Ethyl icosapent; ethyl icosapentaenoate; ethyl icosapentate; Ethyl icosapentate (JP17); Ethyl icosapentate [JAN]; Ethyl icosapentate, JAN; ethyl-eicosapentaenoic acid; ethyl-EPA; GTPL7441; HMS2094K19; HY-B0747; ICOSAPENT ETHYL; Icosapent ethyl (USAN); ICOSAPENT ETHYL [ORANGE BOOK]; Icosapent ethyl [USAN]; ICOSAPENT ETHYL [VANDF]; Icosapent ethyl ester; LMFA07010877; MFCD00673476; MND 21; NSC 759597; NSC759597; NSC-759597; Pharmakon1600-01300030; Q5404453; s6466; SBI-0206684.P002; SCHEMBL123305; SR-05000002595; SR-05000002595-1; Timnodonic acid ethyl ester; UNII-6GC8A4PAYH; Vascepa; Vascepa (TN); Vazkepa"	9831415	Phase 2/3	DF29AZ	DB08887	CTPDG001517
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Fosgonimeton	"2093305-05-4; AKOS040757261; ATH-1017; ATH-1017 FREE ACID; CHEMBL5095419; CS-0204081; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate; Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN:INN]; Fosgonimeton [USAN]; H91OA9858J; HY-132814; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; NDX-1017; NDX-1017 FREE ACID; UNII-H91OA9858J; WHO 11782"	156596375	Phase 2/3	DDBY18	.	CTPDG001518
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Ginkgo biloba	.	.	Phase 2/3	D6S9AH	.	CTPDG001520
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Atuzaginstat	"2211981-76-7; Atuzaginstat; Atuzaginstat [INN]; AtuzaginstatCOR388; BDBM453275; CHEMBL5095230; COR388; COR-388; Cyclopentanecarboxamide, N-((1S)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-; DGN7ROZ8EN; EX-A6081; N-((3S)-7-Amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide; N-[(3S)-7-amino-2-oxo-1-(2,3,6-trifluorophenoxy)heptan-3-yl]cyclopentanecarboxamide; SCHEMBL19972758; UNII-DGN7ROZ8EN; US10730826, Compound 1a-non-racemic; US10730826, Compound 1a-racemic"	134347893	Phase 2/3	D58BFC	.	CTPDG001522
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	JNJ-54861911	.	68254185	Phase 2/3	D0T2FP	DB15307	CTPDG001532
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Plasminogen	.	.	Phase 2/3	D0S4YT	.	CTPDG001533
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD-106	"Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis"	.	Phase 2/3	D0I3VT	.	CTPDG001544
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AMG520	CNP520	.	Phase 2/3	D0H4YD	.	CTPDG001545
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	SI-614	Modified Hyaluronate	.	Phase 2/3	D08QGE	.	CTPDG001559
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AZD3293	CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099	57404290	Phase 2/3	D01AYX	.	CTPDG001580
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABvac40	.	.	Phase 2	DZQI76	.	CTPDG001594
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AL002	.	.	Phase 2	DYT9B4	.	CTPDG001604
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MLC901	NeuroAiD	.	Phase 2	DYB14S	.	CTPDG001607
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-916	.	.	Phase 2	DY6DS3	.	CTPDG001608
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TB006	.	.	Phase 2	DW7J9D	.	CTPDG001619
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3372689	"2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; CS-0433932; EX-A6549; GLXC-25705; GTPL11953; HY-144681; LY3372689; LY-3372689; MS-26295; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide; SCHEMBL20421995; U0SGP6ZX2V; UNII-U0SGP6ZX2V"	135260636	Phase 2	DVY0C6	.	CTPDG001621
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MP-101	.	.	Phase 2	DSK7I5	.	CTPDG001634
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DHP1401	.	.	Phase 2	DS4CL2	.	CTPDG001638
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CY6463	"2201048-82-8; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; AKOS040757400; CS-0376702; CY6463; CY-6463; EX-A7620; GTKNNCQKFKGSHR-UHFFFAOYSA-N; H7KEN3O8AI; HY-145607; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; IW-6463; MS-25746; SCHEMBL19922804; UNII-H7KEN3O8AI; Zagociguat; Zagociguat [INN]; ZAGOCIGUAT [USAN]"	134304734	Phase 2	DO37EF	.	CTPDG001660
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ID1201	.	.	Phase 2	DM95PZ	.	CTPDG001677
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Benfotiamine	"(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid; 22457-89-2; 22457-89-2 (free acid); 775256-41-2; AC-8280; AKOS015920320; Benfotamine; Benfotiamina; benfotiamine; Benfotiamine (JAN/INN); Benfotiaminum; Benphothiamine; Benzoylthiamine monophosphate; Betivina; Biotamin (TN); BPBio1_000757; BSPBio_000687; CAS-22457-89-2; CCG-220654; CHEBI:41039; CHEMBL4303665; D01255; DB11748; DTXCID1025433; DTXSID3045433; EN300-21694383; HMS1570C09; HMS2097C09; HMS3714C09; MFCD00057343; N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; NCGC00016764-01; NCGC00016764-04; NCGC00179477-01; Prestwick_68; Prestwick2_000654; Prestwick3_000654; S-(2-(N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl)benzothioa; S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; s-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; S-Benzoylthiamine-O-monophosphate; SCHEMBL188070; SCHEMBL19184708; SR-01000872627; SR-01000872627-1; SR-01000872627-2; Tox21_110597; Tox21_110597_1"	3032771	Phase 2	DL7CK2	DB11748	CTPDG001686
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAGE-718	.	.	Phase 2	DI54FM	.	CTPDG001703
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	APH-1105	.	.	Phase 2	DH6G1L	.	CTPDG001708
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuplazid	"Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,  ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate"	11672491	Phase 2	DDI6B0	.	CTPDG001741
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-1942	.	.	Phase 2	DDAH09	.	CTPDG001742
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	"(1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate; 2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-; 2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-; 37O2X55Y9E; 83314-01-6; BDBM50258529; BMY-45618; BRN 4349157; BRYOSTATIN; Bryostatin 1; Bryostatin 1 - CAS 83314-01-6; BRYOSTATIN 1 [MI]; BRYOSTATIN 1 [WHO-DD]; Bryostatin 1, >=99%, solid; Bryostatin-1; CHEBI:88353; CHEMBL449158; CS-0025440; DTXSID8046876; HY-105231; MFCD00893832; MJQUEDHRCUIRLF-TVIXENOKSA-N; NSC 339555; NSC-339555; Q27095907; SCHEMBL182960; UNII-37O2X55Y9E"	5280757	Phase 2	DD8L0V	.	CTPDG001743
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AADvac-1	.	.	Phase 2	DA1L7V	.	CTPDG001761
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NLY01	.	.	Phase 2	D7A5LO	.	CTPDG001783
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD-35	"1531586-58-9; 6'-(2-(1-(Pyridin-2-ylmethyl)piperidin-4-yl)ethyl)spiro[cyClopropane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-7'(6'H)-one; AD-35; BDBM231544; CHEMBL3949886; GLXC-15057; IND-120499; SCHEMBL15598869; starbld0021420; US9346818, I-29; US9346818, I-33; US9346818, I-35"	72707125	Phase 2	D67DST	.	CTPDG001793
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RPh201	.	.	Phase 2	D3YT8E	.	CTPDG001820
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Trontinemab	RG6102	.	Phase 2	D3XP8N	.	CTPDG001821
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI-287	"849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546"	11564168	Phase 1	D3X2TH	.	CTPDG001822
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MW150	"1628502-91-9; 3GF; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; AKOS040758765; BDBM50537600; CHEMBL4129018; CIIVUDIZZJLXCN-UHFFFAOYSA-N; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; compound 8 [PMID: 25676389]; CS-0069509; EPZ68T461K; EX-A3206A; GTPL10524; HY-120111; MS-26255; MW 150; MW01-18-150SRM; MW150; MW-150; NSC785340; NSC-785340; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; Q27453797; SCHEMBL16061104; UNII-EPZ68T461K"	86270361	Phase 2	D38LQO	.	CTPDG001827
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NP001	.	.	Phase 1	D1LU7W	.	CTPDG001845
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuedexta	.	.	Phase 2	D0ZR4W	.	CTPDG001854
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SUVN-502	"SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven"	10073773	Phase 2	D0Z0GX	DB06140	CTPDG001870
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	S-38093	"S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier"	11380684	Phase 2	D0XW6Y	.	CTPDG001883
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3202626	.	.	Phase 2	D0XD5N	.	CTPDG001889
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AN-1792	Betabloc; AIP-001	15176	Phase 2	D0X4ZL	.	CTPDG001899
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BI-409306	.	135908617	Phase 2	D0W7UN	.	CTPDG001924
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Methanesulfonyl fluoride	"Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)"	11207	Phase 2	D0W3BA	DB13058	CTPDG001935
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NIC5-15	"D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336"	164619	Phase 2	D0W0NU	DB12969	CTPDG001941
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAM-531	"PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer"	16071605	Phase 2	D0V4ZQ	DB12229	CTPDG001961
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	Phase 2	D0V3CK	.	CTPDG001968
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK933776A	.	.	Phase 2	D0T6KV	.	CTPDG002011
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3002813	.	.	Phase 2	D0SD7G	.	CTPDG002035
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD02 vaccine	.	.	Phase 2	D0S1BF	.	CTPDG002050
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2027	.	.	Phase 1	D0S0FD	.	CTPDG002054
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TTP-448	.	.	Phase 2	D0PU9C	.	CTPDG002107
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CPC-201	.	.	Phase 2	D0PN4D	.	CTPDG002111
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UE-2343	.	.	Phase 2	D0OE5S	.	CTPDG002131
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVP-0962	.	.	Phase 2	D0OB4R	.	CTPDG002132
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	R-phenserine	Posiphen (TN)	11249342	Phase 2	D0O5GK	DB15317	CTPDG002141
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FK-962	"FK-960 analog, Fujisawa"	56842107	Phase 2	D0O3TC	.	CTPDG002143
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAR-110894	SAR-110894D	.	Phase 2	D0O0EX	.	CTPDG002150
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UB-311	.	.	Phase 2	D0NR6T	.	CTPDG002156
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-288	"UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4"	24743471	Phase 2	D0N8QK	DB15192	CTPDG002162
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Oleoyl-estrone	"Anti-obesity hormone-based therapy, Manhattan"	6918373	Phase 2	D0N5CW	DB04870	CTPDG002171
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CERE-110	.	.	Phase 2	D0MP1M	.	CTPDG002184
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HSRx-888	.	.	Phase 2	D0LO2G	.	CTPDG002217
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN 322	.	.	Phase 1	D0L8IO	.	CTPDG002228
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nefiracetam	Motiva (TN)	71157	Phase 2	D0KD5P	DB13082	CTPDG002254
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JOT106	.	.	Phase 2	D0K4JI	.	CTPDG002268
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BPN14770	KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide	90111638	Phase 2	D0IZ8X	.	CTPDG002296
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-5213	.	53342708	Phase 2	D0I6ZO	.	CTPDG002308
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-8E12	C2N-8E12	.	Phase 2	D0H7KQ	.	CTPDG002337
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LymPro	.	.	Phase 2	D0H1YZ	.	CTPDG002341
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AQW-051	669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane	50914822	Phase 2	D0H1AY	.	CTPDG002345
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-717	"CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex"	3323368	Preclinical	D0G3AR	DB05047	CTPDG002374
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-05212377	SAM-760	.	Phase 2	D0G1YA	.	CTPDG002378
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CT1812	Elayta	118278088	Phase 2	D0FX8N	.	CTPDG002384
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY2886721	"1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475"	49837968	Phase 2	D0F8GK	DB12547	CTPDG002396
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CSTC1	"BAC; D-Bacillosamine; Bacillosamine; D-Bac; 2,4-Diamino-2,4,6-Trideoxy-D-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucose; 2,4-Diamino-2,4,6-Trideoxy-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranoside; 2,4-Diamino-2,4,6-Trideoxy-D-Gluc"	54029194	Phase 2	D0ED6O	.	CTPDG002410
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T-817MA	"Edonerpic maleate; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:"	11338749	Phase 2	D0E8HA	.	CTPDG002419
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	KPAX002	.	.	Phase 2	D0E7WH	.	CTPDG002420
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	Bryostatin 1; 83314-01-6	5280757	Phase 2	D0E6AH	.	CTPDG002423
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MIQ-001	"M-IQ 001; Fatty acid metabolism inhibitor (Alzheimer's disease), Meta-IQ"	.	Phase 2	D0E1SV	.	CTPDG002434
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Basmisanil	"1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha"	57336276	Phase 2	D0CH7C	DB11877	CTPDG002474
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ladostigil	"Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326"	208907	Phase 2	D0C3UC	.	CTPDG002488
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NDD-094	NDD-094A; SDZ-NDD-094	.	Phase 2	D0B7LZ	.	CTPDG002508
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ponezumab	"Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219"	.	Phase 2	D0B5EB	.	CTPDG002513
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORM-12741	"Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion"	71301276	Phase 2	D0B3ZF	DB12057	CTPDG002515
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-4447943	BCP16255	135564558	Phase 2	D0A9IY	DB11953	CTPDG002535
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DCB-AD1	.	.	Phase 2	D09BCL	.	CTPDG002589
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-126	.	24987875	Phase 2	D08XOY	.	CTPDG002601
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD4694	.	71306407	Phase 2	D08VDM	.	CTPDG002606
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK239512	"720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K"	9976892	Phase 2	D07YGH	DB15120	CTPDG002657
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ALZ-801	.	25008296	Phase 2	D07VAI	.	CTPDG002666
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SYN-120	.	.	Phase 2	D07RQR	.	CTPDG002673
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VI-1121	.	.	Phase 2	D07KGR	.	CTPDG002691
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI 287	"FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-"	118797983	Phase 1	D07IOT	.	CTPDG002697
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ST-101	"ST 101 [French]; 7-Chloro-1,3-dihydro-5-phenyl-1-trimethylgermyl-2H-1,4-benzodiazepin-2-one; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2 [French]; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylgermyl-; AC1O4GHW; ST 101; LS-34275; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2"	10220323	Phase 2	D07CJN	DB12621	CTPDG002709
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVT302	.	.	Phase 2	D06PHS	.	CTPDG002738
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RP5063	.	.	Phase 1	D05XEA	.	CTPDG002780
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-384	UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide	11670435	Phase 2	D05WCI	DB12501	CTPDG002781
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PRX-3140	.	.	Phase 2	D05BWH	.	CTPDG002818
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Myo-inositol	"Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite"	892	Phase 2	D03SHD	DB03106	CTPDG002906
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CHF-5074	"CHF 5074; CHF5074; 749269-83-8; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261"	9996409	Phase 2	D03MFQ	.	CTPDG002919
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FRM-0962	.	.	Phase 2	D02XKK	.	CTPDG002946
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-7622	"M1 receptor modulator; 1227923-29-6; MK7622; MK 7622; 3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one; SCHEMBL2399084; EX-A804; JUVQLZBJFOGEEO-GOTSBHOMSA-N; BCP27739; ZINC95930184; AKOS028113668; DB12897; CS-5442; HY-15618; Benzo(H)quinazolin-4(3H)-one, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methyl-3-pyridinyl)methyl)-; AS-35236; KB-145903; J-690076; UNII-57R7D1Q49R component JUVQLZBJFOGEEO-GOTSBHOMSA-N"	46207733	Phase 2	D02WFN	DB12897	CTPDG002950
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG1577	.	.	Phase 2	D02PSS	.	CTPDG002962
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BMS-708163	Avagacestat	46883536	Phase 2	D02JOH	DB11893	CTPDG002976
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-0752	"471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635"	9803433	Phase 2	D02HNG	DB12852	CTPDG002978
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GM-602	"Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid"	9875671	Phase 2	D02DEH	.	CTPDG002988
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HF-0220	"Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming"	9836181	Phase 2	D02AOD	DB06622	CTPDG002994
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mibampator	"LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly"	9889366	Phase 2	D01WBD	DB12717	CTPDG003005
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AVN 101	.	.	Phase 2	D01NDF	.	CTPDG003024
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Coluracetam	"BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells"	214346	Phase 2	D01MHI	.	CTPDG003025
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-1446	"TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca"	96568204	Phase 2	D01MAU	.	CTPDG003026
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AUS-131	.	91469	Phase 2	D01HXA	DB11674	CTPDG003039
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	TD-8954	"UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate"	11961293	Phase 1/2	D01HVZ	DB12725	CTPDG003041
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vanutide cridificar	ACC-001	.	Phase 2	D01FBP	.	CTPDG003045
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Neu-P11	"Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819"	24815904	Phase 2	D00CVJ	DB12288	CTPDG003102
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ICA-17043	"Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215"	216327	Phase 2	D00BUR	DB06280	CTPDG003105
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MIB-626	.	.	Phase 1/2	DN0A1J	.	CTPDG003160
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	Xanamem	"(5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone; 1346013-80-6; compound 4 [PMID: 28012176]; GLXC-26582; GTPL12037; SCHEMBL23207782; SCHEMBL23798797; starbld0030988; UE2343; UE-2343; Xanamem"	137530063	Phase 1/2	DJMK69	.	CTPDG003172
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VGH-AD1	.	.	Phase 1/2	DIM79Y	.	CTPDG003177
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	GB301	.	.	Phase 1/2	DBU2J7	.	CTPDG003200
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	"N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide"	18604758	Phase 1/2	D82DMK	.	CTPDG003221
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LX1001	AAVrh.10hAPOE2	.	Phase 1/2	D6UEI3	.	CTPDG003230
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VAC20121	ACI-35	.	Phase 1/2	D3C0LO	.	CTPDG003247
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AL 001	Latozinemab	.	Phase 1/2	D2A6QI	.	CTPDG003251
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AstroStem	.	.	Phase 1/2	D0VD9X	.	CTPDG003296
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	EB-101	"Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals"	.	Phase 1/2	D0TU1E	.	CTPDG011346
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	IONIS-MAPTRx	.	.	Phase 1/2	D0RK4B	.	CTPDG003331
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	ACI-24	"Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune"	.	Phase 1/2	D0R6UR	.	CTPDG003339
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	RVX-208	.	24871506	Phase 1/2	D0N7WW	.	CTPDG003366
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VLP norovirus bivalent vaccine	"VLP norovirus bivalent vaccine (intranasal, norovirus-induced gastroenteritis)"	.	Phase 1/2	D0J3DC	.	CTPDG003404
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	APH-0703	.	.	Phase 1/2	D09QVU	.	CTPDG003487
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	.	.	Phase 1/2	D02XJJ	.	CTPDG003601
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIIB080	.	.	Phase 1/2	D02TWR	.	CTPDG003604
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIL010t	.	.	Phase 1/2	D02AIZ	.	CTPDG003615
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	"1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione"	73441910	Phase 1	DZ76PB	.	CTPDG003647
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD101	"(2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone; (2,4-Dimethylpyridin-3-yl)(4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{3-methyl-4-[1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone; 306293-36-7; AD101; BDBM50104946; CHEMBL113436; DTKUANPECHGGBY-UNMCSNQZSA-N; PD084304; Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2S)-; SCHEMBL4453513"	464036	Phase 1	DYS52Z	.	CTPDG003652
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	IGCAD1	.	.	Phase 1	DWNR12	.	CTPDG003674
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN-322	"1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475"	135905417	Phase 1	DWD06K	.	CTPDG003675
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	J147	"(E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; 1146963-51-0; 1807913-16-1; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; A894156; AC-35232; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; AKOS024458485; AS-16718; CCG-268030; CHEBI:192601; CHEMBL2387144; CS-3688; DB13957; DTXSID501045787; EX-A2235; HMS3886O17; HY-13779; HYMZAYGFKNNHDN-SSDVNMTOSA-N; j147; J-147; MFCD25976644; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; s5269; SCHEMBL12995834; SCHEMBL21294999; UNII-Z41H3C5BT9; Z41H3C5BT9"	25229652	Phase 1	DW4O2J	DB13957	CTPDG003676
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG6289	.	.	Phase 1	DUV3B0	.	CTPDG003698
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASN51	.	.	Phase 1	DS70NZ	.	CTPDG003728
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2511	.	.	Phase 1	DRT09Y	.	CTPDG003737
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SHR-1707	.	.	Phase 1	DPYA76	.	CTPDG003763
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APH-1104	.	.	Phase 1	DNH51Q	.	CTPDG003800
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL919	TAK-920	.	Phase 1	DN48GC	.	CTPDG003808
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NTRX-07	MDA7	.	Phase 1	DK3WQ5	.	CTPDG003852
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAV-hTERT	.	.	Phase 1	DI9X5U	.	CTPDG003881
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL104	.	.	Phase 1	DHD2S9	.	CTPDG003895
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL747	.	.	Phase 1	DGH83L	.	CTPDG003903
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	REM0046127	.	.	Phase 1	DF21MW	.	CTPDG003924
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACU193	.	.	Phase 1	DCP0I8	.	CTPDG003951
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protollin	.	.	Phase 1	DC0DU9	.	CTPDG003960
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	.	.	Phase 1	DB7V3D	.	CTPDG003970
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ALN-APP	.	.	Phase 1	D8W0NQ	.	CTPDG004008
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-4334	.	.	Phase 1	D7PGM4	.	CTPDG004033
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NNI-362	.	.	Phase 1	D6KWF3	.	CTPDG004060
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR588	.	.	Phase 1	D62XNL	.	CTPDG004074
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AL003	.	.	Phase 1	D5QKY2	.	CTPDG004088
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3372993	.	.	Phase 1	D4YD7V	.	CTPDG004104
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MER5101	.	.	Phase 1	D4JPV8	.	CTPDG004117
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	"(4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; 1375752-78-5; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; 3I1803DK5Z; AKOS040756698; BDBM50536712; BMS984923; BMS-984923; CHEMBL4571075; CS-0087012; HY-122559; SCHEMBL4541143; UNII-3I1803DK5Z"	69084898	Phase 1	D34YLZ	.	CTPDG004146
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB113	.	.	Phase 1	D2KV0F	.	CTPDG004163
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-6-Me-BTA-1	Carbon-11-6-Me-BTA-1; 11C-BTA-1	.	Phase 1	D0ZX2D	.	CTPDG004207
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-104	.	.	Phase 1	D0ZW2I	.	CTPDG004210
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	V950 vaccine	.	.	Phase 1	D0Z2HG	.	CTPDG004232
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06751979	"ZLZUHACSRMOLLV-RAALSFIWSA-N; 1818339-66-0; UNII-1Y0Y126GUG; 1Y0Y126GUG; US9315520, Example 1; CHEMBL3952064; US9315520, Example 2; US9315520, Comparator 1; SCHEMBL17162186; BDBM223395; HY-112157; CS-0043501; US9315520, 1; N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide; N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carb"	118435360	Phase 1	D0Y5NA	DB15105	CTPDG004257
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-932481	.	91844660	Phase 1	D0XI4P	.	CTPDG004275
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-354	.	.	Phase 1	D0X9HF	.	CTPDG004280
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Affitope AD-01	"AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS"	.	Phase 1	D0X2UK	.	CTPDG004290
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-212	.	.	Phase 1	D0X1XK	.	CTPDG004293
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR-388	.	.	Phase 1	D0WS4E	.	CTPDG004298
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB076	.	.	Phase 1	D0WL5T	.	CTPDG004303
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-250	.	.	Phase 1	D0WI9W	.	CTPDG004305
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACI-35	.	.	Phase 1	D0W9LS	.	CTPDG004309
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-241027	.	.	Phase 1	D0V9HL	.	CTPDG004340
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD03 vaccine	.	.	Phase 1	D0V3EQ	.	CTPDG004351
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-AZD-2184	"AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184"	.	Phase 1	D0V0VI	.	CTPDG004354
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSI-136	"WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth"	11358855	Phase 1	D0U6FT	DB12819	CTPDG004374
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	18F-FEDAA-1106	"ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer"	.	Phase 1	D0U1US	.	CTPDG004382
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	.	.	Phase 1	D0TQ4Y	.	CTPDG004394
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BCI-632	"LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,"	9886034	Phase 1	D0T3DG	.	CTPDG004411
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ARC031	.	.	Phase 1	D0T0NL	.	CTPDG004413
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-103+RVT-104	.	.	Phase 1	D0S1KR	.	CTPDG004439
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Exebryl-1	Exebryl-1 (TN)	.	Phase 1	D0RD1Z	.	CTPDG004450
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAu mAb	.	.	Phase 1	D0R6WL	.	CTPDG004459
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BAY-1006578	"Diagnostic PET imaging agent (Alzheimer's disease), Bayer"	.	Phase 1	D0O9HG	.	CTPDG004540
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG7129	.	53241828	Phase 1	D0O8UB	.	CTPDG004543
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SAR228810	.	.	Phase 1	D0N9JB	.	CTPDG004573
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GRF6019	.	.	Phase 1	D0N8QR	.	CTPDG004576
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-168	"Alzheimer's diagnostic, IND; 123I-SPECT diagnostic (Alzheimer's disease), IND"	.	Phase 1	D0N3UQ	.	CTPDG004583
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY-2811376	"LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,"	44251605	Phase 1	D0N1BF	DB13065	CTPDG004586
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-330	.	.	Phase 1	D0MU7N	.	CTPDG004589
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SUVN-D4010	"DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole"	71508291	Phase 1	D0M9RI	.	CTPDG004596
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Mesenchymal stem cell therapy	.	.	Phase 1	D0M6AR	.	CTPDG004600
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2184	.	.	Phase 1	D0M0UB	.	CTPDG004608
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP-0777	.	.	Phase 1	D0L1UH	.	CTPDG004640
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NPT088	.	.	Phase 1	D0KN7Y	.	CTPDG004647
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Aleplasinin	"PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth"	10224267	Phase 1	D0JI2E	DB12635	CTPDG004674
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1841	.	.	Phase 1	D0J9PS	.	CTPDG004681
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E-2212	.	46854987	Phase 1	D0I1OS	.	CTPDG004731
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TTP-4000	"Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech"	.	Phase 1	D0I0YS	.	CTPDG004732
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANVS301	Bisnormcerysine	.	Phase 1	D0HRC9	.	CTPDG004738
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2012	870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N	11560787	Phase 1	D0F0JJ	DB05171	CTPDG004815
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NGP 555	"WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine"	46853593	Phase 1	D0EV5O	.	CTPDG004818
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AV-965	.	.	Phase 1	D0EH0C	.	CTPDG004824
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2647544	GSK-2647544	.	Phase 1	D0E6KN	.	CTPDG004830
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NDX-1017	.	.	Phase 1	D0E3CX	.	CTPDG004833
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GC021109	.	.	Phase 1	D0D4HO	.	CTPDG004863
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NsG-0202	"ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene"	.	Phase 1	D0D0GH	.	CTPDG004872
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SGC-1061	.	.	Phase 1	D0B3HP	.	CTPDG004921
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NBXT-001+Nobilis inhalation device	.	.	Phase 1	D0AY8D	.	CTPDG004928
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF20513	.	.	Phase 1	D0A9PD	.	CTPDG004933
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Begacestat	GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953	11269353	Phase 1	D09ZVC	DB12263	CTPDG004953
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	BCI-838	.	.	Discontinued in Phase 1	D09WZU	.	CTPDG004961
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-3328	UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073	44555286	Phase 1	D09PYZ	.	CTPDG004984
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JES-9501	DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride	.	Phase 1	D09MEV	.	CTPDG004992
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAK-071	WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5	92042879	Phase 1	D09BBA	.	CTPDG005012
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANAVEX 2-73	.	46932299	Phase 1	D09AOO	.	CTPDG005014
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SPI-014	"SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals"	46221695	Phase 1	D08XKL	.	CTPDG005020
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	HPP-854	.	.	Phase 1	D08TVI	.	CTPDG005028
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JNJ-63733657	.	.	Phase 1	D07PFU	.	CTPDG005091
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DWP-09031	DWJ-301	.	Phase 1	D06KWU	.	CTPDG005157
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2995	.	.	Phase 1	D06JPY	.	CTPDG005158
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Palomid-529	"P-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma"	.	Phase 1	D06JCO	.	CTPDG005159
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protexia	"RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene"	.	Phase 1	D06FGJ	.	CTPDG005166
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	FGLL	"NCAM mimetics (Alzheimer's disease), Enkam"	.	Phase 1	D06EXI	.	CTPDG005167
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Posiphen R-phenserine	.	.	Phase 1	D05VAE	.	CTPDG005184
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Anti-N3pG-Abeta antibody	.	.	Phase 1	D05ORO	.	CTPDG005192
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CTS-21166	.	.	Phase 1	D04VZS	.	CTPDG005234
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MCD-386	"CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion"	.	Phase 1	D04SIU	.	CTPDG005240
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD-3839	"GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D"	46202416	Phase 1	D04OSA	DB12368	CTPDG005245
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1814	.	.	Phase 1	D04AZT	.	CTPDG005269
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-957	.	.	Phase 1	D03NLQ	.	CTPDG005302
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	XEL 001HP	.	.	Phase 1	D03CCY	.	CTPDG005321
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-05251749	.	.	Phase 1	D03AGK	.	CTPDG005330
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-04995274	"UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, &gt; 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol"	53354764	Phase 1	D02YKI	DB12675	CTPDG005332
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAB-003/PF-05236812	.	.	Phase 1	D01ZSP	.	CTPDG005370
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2981710	.	.	Phase 1	D01YDH	.	CTPDG005373
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP3662	.	44598960	Phase 1	D00UEC	.	CTPDG005437
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAD-2004	"927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID"	16042343	Phase 1	D00MBY	.	CTPDG005453
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	Phase 1	D00EHX	DB12899	CTPDG005470
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	"methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate"	"MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate"	2314952	Clinical trial	D0R7EA	.	CTPDG005492
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	bimatoprost (free acid form)	17-phenyl-omega-trinor-PGF2alpha	5283081	Clinical trial	D08QWQ	.	CTPDG005504
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	JNJ-479655	"1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, &gt; Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide"	66553218	Clinical trial	D07QTG	.	CTPDG005505
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	alpha-ketothiazole analogue 36	"GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide"	16098914	Clinical trial	D05TKW	.	CTPDG005507
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-22	.	19910	Patented	D0KG9M	DB01422	CTPDG005806
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-20	.	.	Patented	D0I9VU	.	CTPDG005858
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-2	.	.	Patented	D0E2AF	.	CTPDG005956
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 2	PMID29324067-Compound-53	.	Patented	D0DW5P	.	CTPDG005961
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID29334795-Compound-22	.	.	Patented	D0B2NV	.	CTPDG006029
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-19	.	.	Patented	D09UJB	.	CTPDG006053
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Thiadiazolyl carboxamide derivative 1	PMID28270010-Compound-Figure18-1	71263688	Patented	D06STX	.	CTPDG006137
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 1	PMID29324067-Compound-43	.	Patented	D05RJG	.	CTPDG006162
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-18	.	.	Patented	D04NCC	.	CTPDG006193
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	Zanapezil	TAK-147	198752	Discontinued in Phase 3	D0AM8W	DB04859	CTPDG006368
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	PF-1913539	"Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261"	176408	Discontinued in Phase 3	D07ESH	.	CTPDG006376
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AZD0328	"AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]"	9794392	Discontinued in Phase 2	D0Q9RR	DB12145	CTPDG006451
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	S-18986	"S 18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine"	637863	Discontinued in Phase 2	D0M0HJ	.	CTPDG006484
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AVN 397	.	.	Discontinued in Phase 2	D0J7EP	.	CTPDG006497
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	DPC-543	.	.	Discontinued in Phase 2	D0I4PL	.	CTPDG006502
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	NGD-97-1	"CP-457,920"	.	Discontinued in Phase 2	D0FN6D	.	CTPDG006521
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	IPENOXAZONE	"MLV-6976; NC-1200; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one"	65882	Discontinued in Phase 2	D0B4EV	.	CTPDG006554
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Ispronicline	RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine	9824145	Discontinued in Phase 2	D0AB4Q	.	CTPDG006559
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	ABT-418	"Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398"	119380	Discontinued in Phase 2	D09ADT	.	CTPDG006574
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Talsaclidine fumarate	"Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane"	6918244	Discontinued in Phase 2	D06ODM	.	CTPDG006603
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Affitope AD-02	"Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals"	.	Discontinued in Phase 2	D06BVT	.	CTPDG006608
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	SIB-1553A	"191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride"	5310968	Discontinued in Phase 2	D00ECO	.	CTPDG006677
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	VP-025	"Inflammation therapeutics, Vasogen; VP-015"	.	Discontinued in Phase 1	D0Y8IS	.	CTPDG006707
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TRx-0037	.	.	Discontinued in Phase 1	D0S9XR	.	CTPDG006743
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	EVT-301	"MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche"	.	Discontinued in Phase 1	D0P1WB	.	CTPDG006760
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	PF-05236812	AAB-003	.	Discontinued in Phase 1	D0K3SV	.	CTPDG006792
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	C-9138	.	.	Discontinued in Phase 1	D0K0XW	.	CTPDG006794
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	SL-25.1188	.	.	Discontinued in Phase 1	D0E3JL	.	CTPDG006819
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	GR-253035	.	.	Discontinued in Phase 1	D0C2HF	.	CTPDG006828
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TAK-065	"Neuroregeneration enhancer (oral, Alzheimers/Parkinsons disease), Takeda"	.	Discontinued in Phase 1	D0A2XD	.	CTPDG006837
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	NP-61	"Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira"	.	Discontinued in Phase 1	D04UKJ	.	CTPDG006894
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	ACC-002	.	.	Phase 0	D0YM4F	.	CTPDG006951
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	INP102	.	.	Phase 0	D0P7BA	.	CTPDG006952
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	AAB-002	.	.	Phase 0	D01QLM	.	CTPDG006954
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	TPT-43	.	.	Preclinical	D0YH9A	.	CTPDG007021
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-1501	"AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals"	.	Preclinical	D0XM3S	.	CTPDG007024
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SPH-1285	"Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359"	.	Preclinical	D0V7FG	.	CTPDG007039
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	ANAVEX 1-41	.	10446473	Preclinical	D0T0UC	.	CTPDG007053
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	VER-155008	"Heat shock protein 70 inhibitor (cancer), Vernalis; Hsp 70 inhibitor (cancer), Vernalis"	25195348	Preclinical	D0H0AU	.	CTPDG007083
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Pepticlere	"DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech"	.	Preclinical	D0G7LP	.	CTPDG007086
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SCH-1359113	"SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough"	23627211	Preclinical	D0E3SX	.	CTPDG007089
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	humanin	formyl humanin	16131438	Preclinical	D09TXO	.	CTPDG007101
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CDD-0199-J	.	.	Preclinical	D09MQQ	.	CTPDG007103
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Alvameline	Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M	178030	Terminated	D0X8MZ	.	CTPDG007181
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Ro-46-5934	.	.	Terminated	D0TK0W	.	CTPDG007215
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	IDRA-21	IDRA-21 analogs; IDRA-5	3688	Terminated	D0S0VZ	.	CTPDG007229
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-99	"Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	132712	Terminated	D0R1VL	.	CTPDG007239
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS-66252	.	9803861	Terminated	D0Q7SO	.	CTPDG007242
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-93426	"ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-"	115210	Terminated	D0P3IE	.	CTPDG007252
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-427	.	.	Terminated	D0O7DN	.	CTPDG007262
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	EHT-1864	"EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit"	9938202	Terminated	D0M9ER	.	CTPDG007276
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CI-1002	PD-142676	9838284	Terminated	D0M2GI	.	CTPDG007282
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BU-4514N	"BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one"	54704416	Terminated	D0L8TN	.	CTPDG007287
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	DNP-004089	"BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo"	.	Terminated	D0K3WN	.	CTPDG007302
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF-8615	.	.	Terminated	D0K0XG	.	CTPDG007305
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-152558	.	.	Terminated	D0J4GQ	.	CTPDG007314
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-649	.	9905818	Terminated	D0G7HO	.	CTPDG007347
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MDL-28170	MDL-2170	72430	Terminated	D0G5ZE	.	CTPDG007348
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-377	.	9860852	Terminated	D0EP5O	.	CTPDG007360
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	R-1315	.	.	Terminated	D0CX2J	.	CTPDG007380
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	L-698544	"7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ"	10220180	Terminated	D0AZ5V	.	CTPDG007398
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GYKI-52466	"102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2"	3538	Terminated	D0A9VO	.	CTPDG007402
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Nerve growth factor	"Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia"	.	Terminated	D0A0MJ	.	CTPDG007406
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-3796	.	.	Terminated	D09IUG	.	CTPDG007420
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NNC-90-0270	"Nicotinic ACh agonists, Novo Nordisk"	.	Terminated	D09GRB	.	CTPDG007422
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-14413	"Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre"	.	Terminated	D08VJI	.	CTPDG007432
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-4001	.	.	Terminated	D08TCU	.	CTPDG007433
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Milacemide	Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S	53569	Terminated	D07OLO	.	CTPDG007457
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sch-57790	CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294	9867750	Terminated	D07IZF	.	CTPDG007461
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF268	"MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet"	5288799	Terminated	D06ZAM	DB04021	CTPDG007467
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Z-4105	"119737-52-9; Butanoic acid, 4-(((3-methyl-5-isoxazolyl)carbonyl)amino)-; Butanoic acid,4-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-; ACMC-20cew8; AC1Q5P7F; SCHEMBL195378; AC1L4P39; CTK4B1474; 4-[(3-methyl-1,2-oxazole-5-carbonyl)amino]butanoic acid; DTXSID50152568; 4-{[(3-methyl-1,2-oxazol-5-yl)carbonyl]amino}butanoic acid"	189689	Terminated	D06PAW	.	CTPDG007475
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RU-33965	"RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-"	129696	Terminated	D05IVZ	.	CTPDG007496
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS 86	"RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl  -D-galactopyranoside; 2-Nitrophenyl; A-D-galactopyranoside"	87934	Terminated	D05HKB	.	CTPDG007497
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-121196	"FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-"	131688	Terminated	D05EKM	.	CTPDG007500
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	AZD-2858	AZD2858; 486424-20-8; AZD 2858; CHEMBL2177161; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide; 3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide; GSK-3 inhibition; 3-amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL8478; SCHEMBL3327702; C21H23N7O3S; EX-A707; AOB6850; MolPort-035-395-808	10138980	Terminated	D04WZK	.	CTPDG007507
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-431	"Clipsin inhibitor, Cephalon"	.	Terminated	D04RDT	.	CTPDG007509
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NP-7557	"Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech"	.	Terminated	D03DFY	.	CTPDG007539
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-2016	GT 2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653	9839975	Terminated	D02YXQ	.	CTPDG007540
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	A-72055	.	.	Terminated	D02VHE	.	CTPDG007544
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ABS-301	"ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS"	.	Terminated	D02UQU	.	CTPDG007545
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-91296	"ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester"	123700	Terminated	D02UIE	.	CTPDG007546
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-140	"Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	10030021	Terminated	D02JNY	.	CTPDG007550
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Bifemelane	Alnert; Celeport; E-0687; MCI-2016; SON-216	2377	Terminated	D02CGY	DB13550	CTPDG007557
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sibopirdine	"DuP-921; EXP-9121; EXP-921; 5H-Cyclopenta[2,1-b:3,4-b']dipyridine, 5,5-bis(4-pyridinylmethyl)-, monohydrate"	195376	Terminated	D01LRH	.	CTPDG007569
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Tenilsetam	CAS-997	65649	Terminated	D00JNL	.	CTPDG007586
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AD-0802	"Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic"	.	Investigative	D0Y9ES	.	CTPDG007656
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	VK-11	"Imaging agent (Alzheimer's disease), Prana"	.	Investigative	D0Y4TQ	.	CTPDG007666
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZD-6319	"Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca"	.	Investigative	D0X2NB	.	CTPDG007732
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PD-2015	"PD-2016; TNF alpha inhibitors (Alzheimers disease); TNF alpha inhibitors (Alzheimers disease), P2D Bioscience"	.	Investigative	D0WO8I	.	CTPDG007740
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CBNU-06	.	.	Investigative	D0WA3T	.	CTPDG007746
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RAP-310	"Small stabilized receptor active peptide (Alzheimers disease), RAPID Pharmaceuticals"	.	Investigative	D0W9OW	.	CTPDG007748
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tideglusib	.	11313622	Phase 2	D0W5WZ	DB12129	CTPDG007762
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DWJ-209	.	.	Investigative	D0W5CI	.	CTPDG007764
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EVP-4473	.	.	Investigative	D0VE4O	.	CTPDG007780
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ReN-004	"Stem cell therapy (neurological disorders), ReNeuron"	.	Investigative	D0UO6M	.	CTPDG007813
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-901	.	.	Investigative	D0T6FY	.	CTPDG007853
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR APLs	NAChR APLs (Alzheimer's disease)	.	Investigative	D0T5ZM	.	CTPDG007855
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	COG-248	"Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease); Neuroprotectant (Alzheimers/Parkinsons disease), Cognosci; Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease), Cognosci"	.	Investigative	D0S2QP	.	CTPDG007894
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ELND-007	"ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan"	53308121	Investigative	D0Q6ZQ	.	CTPDG007946
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	BAN-2203	"Beta amyloid modulator (Alzheimer's disease), BioArctic"	.	Investigative	D0Q5VC	.	CTPDG007953
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Turmeric extracts	"HSS-808; HSS-818; HSS-838; HSS-848; HSS-888; Turmeric extracts (Alzheimer's disease); Turmeric extracts (Alzheimer's disease), HerbalScience"	.	Investigative	D0Q2XN	.	CTPDG007960
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Ginkgo biloba extract	"YY-1224; YY-1824; Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease); Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease), Yuyu Inc"	.	Investigative	D0OB9V	.	CTPDG008000
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SX-AZD1	.	.	Investigative	D0N6EL	.	CTPDG008040
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AIKb2	.	.	Investigative	D0N0SC	.	CTPDG008055
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR alpha 7 APLs	NAChR alpha 7 APLs (Alzheimer's disease)	.	Investigative	D0M7MH	.	CTPDG008070
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	11A1	.	.	Investigative	D0K4WW	.	CTPDG008142
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Gamma-secretase modulators	"Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche"	24781184	Investigative	D0J5SD	.	CTPDG008172
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	MCD-386/glycopyrrolate	"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,"	3494	Investigative	D0IL1B	DB00986	CTPDG008185
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	HL-026	.	.	Investigative	D0IC8P	.	CTPDG008187
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ESN-XX	.	.	Investigative	D0I3OX	.	CTPDG008215
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ETN-001	.	.	Investigative	D0I0ZY	.	CTPDG008222
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DBT-1339	"DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech"	.	Investigative	D0HK7G	.	CTPDG008227
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GRL-11097	"Memapsin 2 inhibitors (Alzheimers); Memapsin 2 inhibitors (Alzheimers), Purdue University/Astellas"	.	Investigative	D0H2VN	.	CTPDG008244
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KNX-Monoclonal204	"KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis"	.	Investigative	D0G4AE	.	CTPDG008271
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KMS-88009	"KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical"	.	Investigative	D0F5UO	.	CTPDG008302
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NGN-9079	"Alzheimer's disease therapy, NeuroGeneration"	.	Investigative	D0F5IS	.	CTPDG008306
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PNB-04	"Alzheimer's disease therapy, PharmaNeuroBoost"	.	Investigative	D0EW4M	.	CTPDG008325
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	IMD-4482	"IMD-4690; PAI-1 inhibitor (oral, Alzheimers disease), IMMD; Plasminogen activator inhibitor-1 inhibitor (oral, Alzheimers disease), Institute of Medicinal Molecular Design"	.	Investigative	D0EW2D	.	CTPDG008326
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Abloid	"Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics"	.	Investigative	D0E5CX	.	CTPDG008345
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Memex	Nicotinomide adenine dinucleotide (NADH)	.	Investigative	D0E0OI	.	CTPDG008353
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-0235-J	.	.	Investigative	D0D7KR	.	CTPDG008371
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-103	"NP-060103; NP-60103; Glycogen synthase kinase-3 inhibitor (Alzheimer's disease), Neuropharma"	.	Investigative	D0D6WF	.	CTPDG008374
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Leptin	Leptin (Alzheimer's disease)	.	Investigative	D0C6TL	.	CTPDG008408
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SP-08	SP-008	.	Investigative	D0C4WY	.	CTPDG008411
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SPI-017	"SPI-017 (oral, Alzheimer's disease)"	.	Investigative	D0C1TT	.	CTPDG008423
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RECALL-VAX	"RV-01; RV-02; Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease); Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease), Intellect Neuroscience"	.	Investigative	D0B4AH	.	CTPDG008454
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CWF-0804	.	.	Investigative	D09NEL	.	CTPDG008535
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACU-0101979	"HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co"	.	Investigative	D09MRY	.	CTPDG008536
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Cystatin C	Cystatin C (Alzheimer's disease)	.	Investigative	D09HVY	.	CTPDG008553
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EDN-OL1	"Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn"	.	Investigative	D07ZDG	.	CTPDG008644
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ADepVac	"DNA vaccine (Alzheimer's disease), University of California Irvine; DNA vaccine (TriGrid electroporation, Alzheimers), Ichor/UCI/IMM"	.	Investigative	D07ZBO	.	CTPDG008646
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Anticalin	Anticalin (Alzheimer's disease)	.	Investigative	D07YAC	.	CTPDG008650
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-518	"AMPA glutamate receptor agonist (Alzheimer's disease), AC Immune"	.	Investigative	D07KMI	.	CTPDG008690
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEN-1500	"SEN-1576; Beta-amyloid aggregation inhibitors (Alzheimer's disease); Beta-amyloid aggregation inhibitors (Alzheimer's disease), Senexis"	54589394	Investigative	D07JKA	.	CTPDG008693
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARN-2966	"ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences"	14936865	Investigative	D07DNV	.	CTPDG008707
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZ-AAV9	"Alzheimers disease gene therapy, RegenX Biosciences; Adeno-associated virus vector-9 based gene therapy (injectable,AD), RegenX Biosciences"	.	Investigative	D06UUE	.	CTPDG008732
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-636	"Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune"	.	Investigative	D06MBR	.	CTPDG008752
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	TKP-1001	"Amyloid-beta modulator (Alzheimer's disease), EUSA Pharma; Amyloid-beta modulator (Alzheimer's disease), Talisker Pharma; Amyloid-beta synthesis modulator (Alzheimer's disease), The Open University"	.	Investigative	D06LRQ	.	CTPDG008753
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-17	"NP-21; NPM-01; NPM-05 series; NPM-05B1; NPM-05B2; Alpha-secreatse activators (oral, Alzheimer's disease), Noscira"	.	Investigative	D05NIO	.	CTPDG008822
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ANA-5	.	.	Investigative	D04ZTA	.	CTPDG008850
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NXD-9062	.	.	Investigative	D04UQS	.	CTPDG008858
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3186	.	.	Investigative	D04TZK	.	CTPDG008860
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	A-887755	.	.	Investigative	D04TPS	.	CTPDG008861
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARC-069	"Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals"	.	Investigative	D04QXW	.	CTPDG008864
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NNI-AD	"NNI-251; NNI-362; NNI-C; NNI-X01; AD therapy (oral), Neuronascent"	.	Investigative	D04OUP	.	CTPDG008871
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZP-2006	"Amyloid precursor protein modulator (AD), AlzProtect/INSERM/University of Lille II"	87057554	Investigative	D04MHP	.	CTPDG008882
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AC-4402	"GABAA receptor inverse agonist (Alzheimer's disease), Dainippon Sumitomo Pharma"	3084937	Investigative	D03TDE	.	CTPDG008935
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GT 1061	.	53483797	Investigative	D03IHA	.	CTPDG008969
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3248	.	.	Investigative	D01ZFM	.	CTPDG009049
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	UC-1011	"UC-2021; UC-2025; GABA A receptor antagonists (Alzheimer's disease); GABA A receptor antagonists (Alzheimer's disease), Umecrine; 3beta-20beta-dihydroxy-5alpha-pregnane; 3beta-20beta-dihydroxy-5alpha-pregnane (Alzheimer's disease), Umecrine"	.	Investigative	D01YGY	.	CTPDG009051
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	F-18 T808	.	.	Investigative	D01SXE	.	CTPDG009066
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-501	.	.	Investigative	D01QNJ	.	CTPDG009082
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Haw-AD-14	.	.	Investigative	D01LBD	.	CTPDG009100
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-190	.	.	Investigative	D01GBV	.	CTPDG009117
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	123I-DRM-106	"DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd"	49801966	Investigative	D01GAZ	.	CTPDG009118
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PN-403	.	.	Investigative	D01FTK	.	CTPDG009120
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Mimovax	"MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS"	.	Investigative	D01BJK	.	CTPDG009132
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEL-103	.	.	Investigative	D00YJD	.	CTPDG009144
M6ACROT02077	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Molecule 22	"MARK3 inhibitors (Alzheimer's disease); MARK3 inhibitors (Alzheimer's disease), Merck & Co"	.	Investigative	D00HDH	.	CTPDG009188
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rivastigmine	Rivastigmine (transdermal patch)	77991	Approved	D0WY5Q	DB00989	CTPDG000074
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Propentofylline propionate	Hextol (TN)	4938	Approved	D0UU9Y	DB06479	CTPDG000111
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Dihydroergotoxine	"Ergotamine, dihydro, methanesulfonate (salt)"	6420006	Approved	D0SP3D	.	CTPDG000148
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Galantamine	"GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol"	9651	Approved	D0R9VR	DB00674	CTPDG000171
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Eicosapentaenoic acid/docosa-hexaenoic acid	"Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN)"	445580	Approved	D0Q5XX	DB03756	CTPDG012556
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Donepezil	"Donepezil (transdermal patch, Alzheimer's disease)"	3152	Approved	D0NS6H	DB00843	CTPDG000257
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved in China	GV-971	.	.	Approved in China	D0FS5O	.	CTPDG000380
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Tacrine	"Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine"	1935	Approved	D0E6YQ	DB00382	CTPDG000406
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Lemborexant	E2006	56944144	Phase 2	D0A7ZK	DB11951	CTPDG000461
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Pexidartinib	PLX-3397	25151352	Approved	D09TAB	DB12978	CTPDG013033
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-florbetaben	.	.	Approved	D07TRF	.	CTPDG000548
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Colostrinin	Colostrinin (TN)	.	Approved	D07NPH	.	CTPDG000558
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Huperzine A	"Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680"	854026	Approved	D06XWB	DB04864	CTPDG000589
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Lecanemab	.	.	Approved	D06XVR	.	CTPDG000590
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-flutemetamol	.	.	Approved	D06XOT	.	CTPDG000591
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Ergoloid mesylate	Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)	592735	Approved	D02IQY	.	CTPDG000752
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Immune globulin	.	.	Approved	D01OWB	.	CTPDG000780
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Memantine	"Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest"	4054	Approved	D01JEU	DB01043	CTPDG000790
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Aducanumab	.	.	Approved	D00RRU	.	CTPDG000806
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nirogacestat	"Nirogacestat; 1290543-63-3; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01"	46224413	Phase 2	D00GPQ	DB12005	CTPDG000817
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 4	18F-AV-1451	Tau imaging agent)	70957463	Phase 4	D0F4CG	DB14914	CTPDG000847
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NE3107	.	.	Phase 3	D9I6QG	.	CTPDG000924
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Guanfacine	"(2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride; 29110-47-2; 30OMY4G3MK; A902647; A918619; AB01563079_01; AKOS030255657; AKOS030526130; BCP09647; BDBM81984; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; BPBio1_000415; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; BSPBio_000377; C02AC02; C07037; CAS_29110-47-2; CAS-29110-48-3; CCG-204609; CHEBI:5558; CHEMBL862; D08031; DB01018; DTXCID7026944; DTXSID9046944; EINECS 249-442-8; EN300-243924; Estulic; Estulic (Salt/Mix); Estulic (TN); FT-0669067; FT-0669068; GTPL522; Guanfacina; Guanfacina (INN-Spanish); Guanfacina [INN-Spanish]; GUANFACINE; Guanfacine (INN); Guanfacine [INN:BAN]; GUANFACINE [INN]; GUANFACINE [MI]; GUANFACINE [VANDF]; GUANFACINE [WHO-DD]; Guanfacine HCl; Guanfacine hydrochloride (Salt/Mix); Guanfacinum; Guanfacinum (INN-Latin); Guanfacinum [INN-Latin]; HY-17416A; J-017394; L000286; L013430; LON 798 (Salt/Mix); Lopac0_000519; Lopac-G-1043; MRF-0000019; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; N-amidino-2-(2,6-dichlorophenyl)acetamide; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-05; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; NSC 759121; NSC_3519; NSC-759121; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Q5613599; RASPBERRYKETONEGLUCOSIDE; SCHEMBL35094; SDCCGSBI-0050502.P002; SPBio_002298; Tenex (Salt/Mix); Tocris-1030; UNII-30OMY4G3MK"	3519	Phase 3	D8NY3J	DB01018	CTPDG000928
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	BPDO-1603	.	.	Phase 3	D71LNO	.	CTPDG000931
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AXS-05	.	.	Phase 2/3	D3PD8C	.	CTPDG000941
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Remternetug	LY3372993	.	Phase 3	D34FRG	.	CTPDG000944
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Donanemab	.	.	Phase 3	D2ZP0A	.	CTPDG000945
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AR1001	"(-)-methylbenzylamine; (+)-2-Methylbutylp-aminocinnamate; 103-67-3; 7KN7F4X49E; AI3-26793; AKOS000119094; AR1001; Benzenemethanamine, N-methyl-; benzyl methyl amine; benzyl methylamine; Benzyl(methyl)amine; BENZYLAMINE, N-METHYL; Benzylamine, N-methyl-; Benzylmethylamine; benzyl-methylamine; Benzyl-methyl-amine; Benzylmethyl-d3-amine; BRD-K44558320-003-01-7; CHEMBL1338; CS-W007426; DTXSID9048439; EC 203-133-4; EINECS 203-133-4; EN300-18191; F2190-0316; FT-0631560; HNMeBzl; HY-W007426; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H; KBio2_001842; KBio2_004410; KBio2_006978; KBioGR_002247; KBioSS_001842; M0164; methyl benzylamine; Methyl(phenylmethyl)amine; methyl-benzyl amine; Methylbenzylamine; Methylbenzylamine, N-; methylbezylamine; MFCD00008289; MLS004773900; N-(Phenylmethyl)methylamine; N-benzyl methyl amine; N-benzyl methylamine; N-benzylmethanamine; N-benzyl-methyl amine; N-Benzylmethylamine; N-benzyl-methylamine; N-Benzylmethylamine, 97%; N-Benzyl-N-methylamine; N-benzyl-N-methyl-amine; NCGC00166047-01; N-methyl benzyl amine; N-methyl benzylamine; N-methyl -benzylamine; N-Methyl(phenyl)methanamine; N-methyl-1-phenylmethanamine; N-methyl-1-phenyl-methanamine; N-methylbenzenemethanamine; N-methyl-benzenemethanamine; N-methylbenzyl amine; N-methyl-benzyl amine; N-METHYLBENZYLAMINE; N-methyl-benzylamine; N-methyl-N-(phenylmethyl)amine; N-methyl-N-benzyl amine; N-methyl-N-benzylamine; N-Methy-N-benzylamine; NSC 8059; NSC8059; NSC-8059; omega-Methylaminotoluene; Q23978278; Racemic methylbenzyl amine; SCHEMBL2271; SDCCGMLS-0066901.P001; SMR000112361; Spectrum_001362; Spectrum4_001764; Spectrum5_000347; STR02536; UNII-7KN7F4X49E; W-108843; Z57327124"	7669	Phase 3	D1OM8E	.	CTPDG000951
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	GV-971	sodium oligomannate	.	Phase 3	D1KR3N	.	CTPDG000952
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AVP-786	.	25052519	Phase 3	D0Z6IB	.	CTPDG000965
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NI-101	"BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec"	.	Phase 3	D0Z2GF	.	CTPDG000968
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Lanabecestat	"1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane"	67979346	Phase 3	D0Y0EP	DB14814	CTPDG000986
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SB-742457	GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline	11256720	Phase 3	D0R9HI	DB12680	CTPDG001066
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Crenezumab	MABT5102A; RG7412	.	Phase 3	D0R7EQ	.	CTPDG001069
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	verubecestat	example 25 (US8940748)	51352361	Phase 3	D0R4KK	DB12285	CTPDG001070
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Gantenerumab	RG1450	.	Phase 3	D0Q7YZ	.	CTPDG001078
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	PF-4494700	"PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer"	11180124	Phase 3	D0MW7B	DB12689	CTPDG001122
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SI-657	"AC1L9R2T; 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid"	453618	Phase 3	D0E9SZ	.	CTPDG001222
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	EVP-6124	"Encenicline; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626"	46196517	Phase 3	D0D3TX	DB11726	CTPDG001246
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ALZT-OP1	ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen	.	Phase 3	D0CH6B	.	CTPDG001252
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	MIM-D3	"TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen"	9808372	Phase 3	D0C2OR	DB12441	CTPDG001261
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LCS 16	.	.	Phase 3	D0A4DP	.	CTPDG001278
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Bapineuzumab	"AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan"	.	Phase 3	D0A1MX	.	CTPDG001282
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tirapazamine	TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075	135413511	Phase 3	D09XQU	DB04858	CTPDG001290
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AV 133	.	.	Phase 3	D09NAF	.	CTPDG001302
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tramiprosate	"Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS"	1646	Phase 3	D09DLP	DB06527	CTPDG001314
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	E-2609	"Beta secretase inhibitor (Alzheimer's disease), Eisai"	57827330	Phase 3	D08MHD	DB15391	CTPDG001329
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	(-)-Phenserine	"CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate"	192706	Phase 3	D07CIN	DB04892	CTPDG001369
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ARC029	"Nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino"	4494	Phase 3	D06GRK	DB06712	CTPDG001378
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Eltoprazine	"Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company"	65853	Phase 2	D06FKC	DB12883	CTPDG001380
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	INM-176	"WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn"	.	Phase 3	D05UXU	.	CTPDG001390
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Xaliproden	"Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine"	128919	Phase 3	D02OJC	DB06393	CTPDG001464
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tamibarotene	"Tamibarotene (oral, Alzheimer's disease)"	108143	Phase 3	D02GTY	DB04942	CTPDG001471
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Immune globulin + albumin	.	.	Phase 3	D00KLP	.	CTPDG001501
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Solanezumab	.	.	Phase 3	D00CZT	.	CTPDG001504
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD106	.	.	Phase 2/3	DF3UN2	.	CTPDG001516
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Icosapent ethyl	"(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 6GC8A4PAYH; 73310-10-8; 86227-47-6; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound; AB01563352_01; AC-33765; AKOS025295847; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; AMR 101; AMR101; AMR-101; BS-48985; CCG-213714; CHEBI:80366; CHEBI:84883; CHEMBL2095209; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; cis-Eicosapentaenoic acid ethyl ester; CS-5304; D01892; DB08887; DTXSID601018686; E0442; E0853; E-EPA; Eicosapentaenoic acid (ethyl ester); Eicosapentaenoic acid ethyl ester; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; Eicosapentaenoic acid, ethyl ester; Eicosapentaenoicacidethylester; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EN300-25951782; EPA ethyl ester; Epadel; Epadel S; Epadel S (TN); EPA-E; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; ethyl eicosapentaenoate; Ethyl eicosapentaenoic acid; Ethyl EPA; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Ethyl icosapent; ethyl icosapentaenoate; ethyl icosapentate; Ethyl icosapentate (JP17); Ethyl icosapentate [JAN]; Ethyl icosapentate, JAN; ethyl-eicosapentaenoic acid; ethyl-EPA; GTPL7441; HMS2094K19; HY-B0747; ICOSAPENT ETHYL; Icosapent ethyl (USAN); ICOSAPENT ETHYL [ORANGE BOOK]; Icosapent ethyl [USAN]; ICOSAPENT ETHYL [VANDF]; Icosapent ethyl ester; LMFA07010877; MFCD00673476; MND 21; NSC 759597; NSC759597; NSC-759597; Pharmakon1600-01300030; Q5404453; s6466; SBI-0206684.P002; SCHEMBL123305; SR-05000002595; SR-05000002595-1; Timnodonic acid ethyl ester; UNII-6GC8A4PAYH; Vascepa; Vascepa (TN); Vazkepa"	9831415	Phase 2/3	DF29AZ	DB08887	CTPDG001517
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Fosgonimeton	"2093305-05-4; AKOS040757261; ATH-1017; ATH-1017 FREE ACID; CHEMBL5095419; CS-0204081; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate; Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN:INN]; Fosgonimeton [USAN]; H91OA9858J; HY-132814; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; NDX-1017; NDX-1017 FREE ACID; UNII-H91OA9858J; WHO 11782"	156596375	Phase 2/3	DDBY18	.	CTPDG001518
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Ginkgo biloba	.	.	Phase 2/3	D6S9AH	.	CTPDG001520
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Atuzaginstat	"2211981-76-7; Atuzaginstat; Atuzaginstat [INN]; AtuzaginstatCOR388; BDBM453275; CHEMBL5095230; COR388; COR-388; Cyclopentanecarboxamide, N-((1S)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-; DGN7ROZ8EN; EX-A6081; N-((3S)-7-Amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide; N-[(3S)-7-amino-2-oxo-1-(2,3,6-trifluorophenoxy)heptan-3-yl]cyclopentanecarboxamide; SCHEMBL19972758; UNII-DGN7ROZ8EN; US10730826, Compound 1a-non-racemic; US10730826, Compound 1a-racemic"	134347893	Phase 2/3	D58BFC	.	CTPDG001522
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	JNJ-54861911	.	68254185	Phase 2/3	D0T2FP	DB15307	CTPDG001532
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Plasminogen	.	.	Phase 2/3	D0S4YT	.	CTPDG001533
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD-106	"Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis"	.	Phase 2/3	D0I3VT	.	CTPDG001544
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AMG520	CNP520	.	Phase 2/3	D0H4YD	.	CTPDG001545
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	SI-614	Modified Hyaluronate	.	Phase 2/3	D08QGE	.	CTPDG001559
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AZD3293	CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099	57404290	Phase 2/3	D01AYX	.	CTPDG001580
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABvac40	.	.	Phase 2	DZQI76	.	CTPDG001594
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AL002	.	.	Phase 2	DYT9B4	.	CTPDG001604
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MLC901	NeuroAiD	.	Phase 2	DYB14S	.	CTPDG001607
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-916	.	.	Phase 2	DY6DS3	.	CTPDG001608
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TB006	.	.	Phase 2	DW7J9D	.	CTPDG001619
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3372689	"2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; CS-0433932; EX-A6549; GLXC-25705; GTPL11953; HY-144681; LY3372689; LY-3372689; MS-26295; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide; SCHEMBL20421995; U0SGP6ZX2V; UNII-U0SGP6ZX2V"	135260636	Phase 2	DVY0C6	.	CTPDG001621
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MP-101	.	.	Phase 2	DSK7I5	.	CTPDG001634
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DHP1401	.	.	Phase 2	DS4CL2	.	CTPDG001638
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CY6463	"2201048-82-8; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; AKOS040757400; CS-0376702; CY6463; CY-6463; EX-A7620; GTKNNCQKFKGSHR-UHFFFAOYSA-N; H7KEN3O8AI; HY-145607; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; IW-6463; MS-25746; SCHEMBL19922804; UNII-H7KEN3O8AI; Zagociguat; Zagociguat [INN]; ZAGOCIGUAT [USAN]"	134304734	Phase 2	DO37EF	.	CTPDG001660
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ID1201	.	.	Phase 2	DM95PZ	.	CTPDG001677
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Benfotiamine	"(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid; 22457-89-2; 22457-89-2 (free acid); 775256-41-2; AC-8280; AKOS015920320; Benfotamine; Benfotiamina; benfotiamine; Benfotiamine (JAN/INN); Benfotiaminum; Benphothiamine; Benzoylthiamine monophosphate; Betivina; Biotamin (TN); BPBio1_000757; BSPBio_000687; CAS-22457-89-2; CCG-220654; CHEBI:41039; CHEMBL4303665; D01255; DB11748; DTXCID1025433; DTXSID3045433; EN300-21694383; HMS1570C09; HMS2097C09; HMS3714C09; MFCD00057343; N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; NCGC00016764-01; NCGC00016764-04; NCGC00179477-01; Prestwick_68; Prestwick2_000654; Prestwick3_000654; S-(2-(N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl)benzothioa; S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; s-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; S-Benzoylthiamine-O-monophosphate; SCHEMBL188070; SCHEMBL19184708; SR-01000872627; SR-01000872627-1; SR-01000872627-2; Tox21_110597; Tox21_110597_1"	3032771	Phase 2	DL7CK2	DB11748	CTPDG001686
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAGE-718	.	.	Phase 2	DI54FM	.	CTPDG001703
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	APH-1105	.	.	Phase 2	DH6G1L	.	CTPDG001708
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuplazid	"Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,  ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate"	11672491	Phase 2	DDI6B0	.	CTPDG001741
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-1942	.	.	Phase 2	DDAH09	.	CTPDG001742
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	"(1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate; 2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-; 2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-; 37O2X55Y9E; 83314-01-6; BDBM50258529; BMY-45618; BRN 4349157; BRYOSTATIN; Bryostatin 1; Bryostatin 1 - CAS 83314-01-6; BRYOSTATIN 1 [MI]; BRYOSTATIN 1 [WHO-DD]; Bryostatin 1, >=99%, solid; Bryostatin-1; CHEBI:88353; CHEMBL449158; CS-0025440; DTXSID8046876; HY-105231; MFCD00893832; MJQUEDHRCUIRLF-TVIXENOKSA-N; NSC 339555; NSC-339555; Q27095907; SCHEMBL182960; UNII-37O2X55Y9E"	5280757	Phase 2	DD8L0V	.	CTPDG001743
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AADvac-1	.	.	Phase 2	DA1L7V	.	CTPDG001761
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NLY01	.	.	Phase 2	D7A5LO	.	CTPDG001783
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD-35	"1531586-58-9; 6'-(2-(1-(Pyridin-2-ylmethyl)piperidin-4-yl)ethyl)spiro[cyClopropane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-7'(6'H)-one; AD-35; BDBM231544; CHEMBL3949886; GLXC-15057; IND-120499; SCHEMBL15598869; starbld0021420; US9346818, I-29; US9346818, I-33; US9346818, I-35"	72707125	Phase 2	D67DST	.	CTPDG001793
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RPh201	.	.	Phase 2	D3YT8E	.	CTPDG001820
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Trontinemab	RG6102	.	Phase 2	D3XP8N	.	CTPDG001821
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI-287	"849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546"	11564168	Phase 1	D3X2TH	.	CTPDG001822
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MW150	"1628502-91-9; 3GF; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; AKOS040758765; BDBM50537600; CHEMBL4129018; CIIVUDIZZJLXCN-UHFFFAOYSA-N; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; compound 8 [PMID: 25676389]; CS-0069509; EPZ68T461K; EX-A3206A; GTPL10524; HY-120111; MS-26255; MW 150; MW01-18-150SRM; MW150; MW-150; NSC785340; NSC-785340; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; Q27453797; SCHEMBL16061104; UNII-EPZ68T461K"	86270361	Phase 2	D38LQO	.	CTPDG001827
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NP001	.	.	Phase 1	D1LU7W	.	CTPDG001845
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuedexta	.	.	Phase 2	D0ZR4W	.	CTPDG001854
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SUVN-502	"SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven"	10073773	Phase 2	D0Z0GX	DB06140	CTPDG001870
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	S-38093	"S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier"	11380684	Phase 2	D0XW6Y	.	CTPDG001883
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3202626	.	.	Phase 2	D0XD5N	.	CTPDG001889
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AN-1792	Betabloc; AIP-001	15176	Phase 2	D0X4ZL	.	CTPDG001899
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BI-409306	.	135908617	Phase 2	D0W7UN	.	CTPDG001924
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Methanesulfonyl fluoride	"Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)"	11207	Phase 2	D0W3BA	DB13058	CTPDG001935
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NIC5-15	"D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336"	164619	Phase 2	D0W0NU	DB12969	CTPDG001941
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAM-531	"PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer"	16071605	Phase 2	D0V4ZQ	DB12229	CTPDG001961
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	Phase 2	D0V3CK	.	CTPDG001968
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK933776A	.	.	Phase 2	D0T6KV	.	CTPDG002011
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3002813	.	.	Phase 2	D0SD7G	.	CTPDG002035
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD02 vaccine	.	.	Phase 2	D0S1BF	.	CTPDG002050
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2027	.	.	Phase 1	D0S0FD	.	CTPDG002054
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TTP-448	.	.	Phase 2	D0PU9C	.	CTPDG002107
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CPC-201	.	.	Phase 2	D0PN4D	.	CTPDG002111
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UE-2343	.	.	Phase 2	D0OE5S	.	CTPDG002131
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVP-0962	.	.	Phase 2	D0OB4R	.	CTPDG002132
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	R-phenserine	Posiphen (TN)	11249342	Phase 2	D0O5GK	DB15317	CTPDG002141
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FK-962	"FK-960 analog, Fujisawa"	56842107	Phase 2	D0O3TC	.	CTPDG002143
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAR-110894	SAR-110894D	.	Phase 2	D0O0EX	.	CTPDG002150
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UB-311	.	.	Phase 2	D0NR6T	.	CTPDG002156
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-288	"UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4"	24743471	Phase 2	D0N8QK	DB15192	CTPDG002162
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Oleoyl-estrone	"Anti-obesity hormone-based therapy, Manhattan"	6918373	Phase 2	D0N5CW	DB04870	CTPDG002171
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CERE-110	.	.	Phase 2	D0MP1M	.	CTPDG002184
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HSRx-888	.	.	Phase 2	D0LO2G	.	CTPDG002217
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN 322	.	.	Phase 1	D0L8IO	.	CTPDG002228
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nefiracetam	Motiva (TN)	71157	Phase 2	D0KD5P	DB13082	CTPDG002254
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JOT106	.	.	Phase 2	D0K4JI	.	CTPDG002268
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BPN14770	KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide	90111638	Phase 2	D0IZ8X	.	CTPDG002296
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-5213	.	53342708	Phase 2	D0I6ZO	.	CTPDG002308
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-8E12	C2N-8E12	.	Phase 2	D0H7KQ	.	CTPDG002337
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LymPro	.	.	Phase 2	D0H1YZ	.	CTPDG002341
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AQW-051	669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane	50914822	Phase 2	D0H1AY	.	CTPDG002345
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-717	"CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex"	3323368	Preclinical	D0G3AR	DB05047	CTPDG002374
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-05212377	SAM-760	.	Phase 2	D0G1YA	.	CTPDG002378
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CT1812	Elayta	118278088	Phase 2	D0FX8N	.	CTPDG002384
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY2886721	"1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475"	49837968	Phase 2	D0F8GK	DB12547	CTPDG002396
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CSTC1	"BAC; D-Bacillosamine; Bacillosamine; D-Bac; 2,4-Diamino-2,4,6-Trideoxy-D-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucose; 2,4-Diamino-2,4,6-Trideoxy-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranoside; 2,4-Diamino-2,4,6-Trideoxy-D-Gluc"	54029194	Phase 2	D0ED6O	.	CTPDG002410
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T-817MA	"Edonerpic maleate; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:"	11338749	Phase 2	D0E8HA	.	CTPDG002419
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	KPAX002	.	.	Phase 2	D0E7WH	.	CTPDG002420
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	Bryostatin 1; 83314-01-6	5280757	Phase 2	D0E6AH	.	CTPDG002423
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MIQ-001	"M-IQ 001; Fatty acid metabolism inhibitor (Alzheimer's disease), Meta-IQ"	.	Phase 2	D0E1SV	.	CTPDG002434
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Basmisanil	"1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha"	57336276	Phase 2	D0CH7C	DB11877	CTPDG002474
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ladostigil	"Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326"	208907	Phase 2	D0C3UC	.	CTPDG002488
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NDD-094	NDD-094A; SDZ-NDD-094	.	Phase 2	D0B7LZ	.	CTPDG002508
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ponezumab	"Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219"	.	Phase 2	D0B5EB	.	CTPDG002513
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORM-12741	"Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion"	71301276	Phase 2	D0B3ZF	DB12057	CTPDG002515
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-4447943	BCP16255	135564558	Phase 2	D0A9IY	DB11953	CTPDG002535
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DCB-AD1	.	.	Phase 2	D09BCL	.	CTPDG002589
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-126	.	24987875	Phase 2	D08XOY	.	CTPDG002601
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD4694	.	71306407	Phase 2	D08VDM	.	CTPDG002606
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK239512	"720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K"	9976892	Phase 2	D07YGH	DB15120	CTPDG002657
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ALZ-801	.	25008296	Phase 2	D07VAI	.	CTPDG002666
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SYN-120	.	.	Phase 2	D07RQR	.	CTPDG002673
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VI-1121	.	.	Phase 2	D07KGR	.	CTPDG002691
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI 287	"FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-"	118797983	Phase 1	D07IOT	.	CTPDG002697
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ST-101	"ST 101 [French]; 7-Chloro-1,3-dihydro-5-phenyl-1-trimethylgermyl-2H-1,4-benzodiazepin-2-one; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2 [French]; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylgermyl-; AC1O4GHW; ST 101; LS-34275; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2"	10220323	Phase 2	D07CJN	DB12621	CTPDG002709
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVT302	.	.	Phase 2	D06PHS	.	CTPDG002738
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RP5063	.	.	Phase 1	D05XEA	.	CTPDG002780
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-384	UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide	11670435	Phase 2	D05WCI	DB12501	CTPDG002781
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PRX-3140	.	.	Phase 2	D05BWH	.	CTPDG002818
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Myo-inositol	"Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite"	892	Phase 2	D03SHD	DB03106	CTPDG002906
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CHF-5074	"CHF 5074; CHF5074; 749269-83-8; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261"	9996409	Phase 2	D03MFQ	.	CTPDG002919
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FRM-0962	.	.	Phase 2	D02XKK	.	CTPDG002946
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-7622	"M1 receptor modulator; 1227923-29-6; MK7622; MK 7622; 3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one; SCHEMBL2399084; EX-A804; JUVQLZBJFOGEEO-GOTSBHOMSA-N; BCP27739; ZINC95930184; AKOS028113668; DB12897; CS-5442; HY-15618; Benzo(H)quinazolin-4(3H)-one, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methyl-3-pyridinyl)methyl)-; AS-35236; KB-145903; J-690076; UNII-57R7D1Q49R component JUVQLZBJFOGEEO-GOTSBHOMSA-N"	46207733	Phase 2	D02WFN	DB12897	CTPDG002950
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG1577	.	.	Phase 2	D02PSS	.	CTPDG002962
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BMS-708163	Avagacestat	46883536	Phase 2	D02JOH	DB11893	CTPDG002976
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-0752	"471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635"	9803433	Phase 2	D02HNG	DB12852	CTPDG002978
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GM-602	"Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid"	9875671	Phase 2	D02DEH	.	CTPDG002988
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HF-0220	"Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming"	9836181	Phase 2	D02AOD	DB06622	CTPDG002994
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mibampator	"LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly"	9889366	Phase 2	D01WBD	DB12717	CTPDG003005
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AVN 101	.	.	Phase 2	D01NDF	.	CTPDG003024
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Coluracetam	"BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells"	214346	Phase 2	D01MHI	.	CTPDG003025
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-1446	"TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca"	96568204	Phase 2	D01MAU	.	CTPDG003026
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AUS-131	.	91469	Phase 2	D01HXA	DB11674	CTPDG003039
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	TD-8954	"UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate"	11961293	Phase 1/2	D01HVZ	DB12725	CTPDG003041
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vanutide cridificar	ACC-001	.	Phase 2	D01FBP	.	CTPDG003045
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Neu-P11	"Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819"	24815904	Phase 2	D00CVJ	DB12288	CTPDG003102
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ICA-17043	"Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215"	216327	Phase 2	D00BUR	DB06280	CTPDG003105
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MIB-626	.	.	Phase 1/2	DN0A1J	.	CTPDG003160
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	Xanamem	"(5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone; 1346013-80-6; compound 4 [PMID: 28012176]; GLXC-26582; GTPL12037; SCHEMBL23207782; SCHEMBL23798797; starbld0030988; UE2343; UE-2343; Xanamem"	137530063	Phase 1/2	DJMK69	.	CTPDG003172
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VGH-AD1	.	.	Phase 1/2	DIM79Y	.	CTPDG003177
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	GB301	.	.	Phase 1/2	DBU2J7	.	CTPDG003200
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	"N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide"	18604758	Phase 1/2	D82DMK	.	CTPDG003221
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LX1001	AAVrh.10hAPOE2	.	Phase 1/2	D6UEI3	.	CTPDG003230
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VAC20121	ACI-35	.	Phase 1/2	D3C0LO	.	CTPDG003247
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AL 001	Latozinemab	.	Phase 1/2	D2A6QI	.	CTPDG003251
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AstroStem	.	.	Phase 1/2	D0VD9X	.	CTPDG003296
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	EB-101	"Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals"	.	Phase 1/2	D0TU1E	.	CTPDG011346
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	IONIS-MAPTRx	.	.	Phase 1/2	D0RK4B	.	CTPDG003331
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	ACI-24	"Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune"	.	Phase 1/2	D0R6UR	.	CTPDG003339
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	RVX-208	.	24871506	Phase 1/2	D0N7WW	.	CTPDG003366
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VLP norovirus bivalent vaccine	"VLP norovirus bivalent vaccine (intranasal, norovirus-induced gastroenteritis)"	.	Phase 1/2	D0J3DC	.	CTPDG003404
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	APH-0703	.	.	Phase 1/2	D09QVU	.	CTPDG003487
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	.	.	Phase 1/2	D02XJJ	.	CTPDG003601
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIIB080	.	.	Phase 1/2	D02TWR	.	CTPDG003604
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIL010t	.	.	Phase 1/2	D02AIZ	.	CTPDG003615
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	"1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione"	73441910	Phase 1	DZ76PB	.	CTPDG003647
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD101	"(2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone; (2,4-Dimethylpyridin-3-yl)(4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{3-methyl-4-[1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone; 306293-36-7; AD101; BDBM50104946; CHEMBL113436; DTKUANPECHGGBY-UNMCSNQZSA-N; PD084304; Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2S)-; SCHEMBL4453513"	464036	Phase 1	DYS52Z	.	CTPDG003652
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	IGCAD1	.	.	Phase 1	DWNR12	.	CTPDG003674
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN-322	"1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475"	135905417	Phase 1	DWD06K	.	CTPDG003675
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	J147	"(E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; 1146963-51-0; 1807913-16-1; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; A894156; AC-35232; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; AKOS024458485; AS-16718; CCG-268030; CHEBI:192601; CHEMBL2387144; CS-3688; DB13957; DTXSID501045787; EX-A2235; HMS3886O17; HY-13779; HYMZAYGFKNNHDN-SSDVNMTOSA-N; j147; J-147; MFCD25976644; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; s5269; SCHEMBL12995834; SCHEMBL21294999; UNII-Z41H3C5BT9; Z41H3C5BT9"	25229652	Phase 1	DW4O2J	DB13957	CTPDG003676
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG6289	.	.	Phase 1	DUV3B0	.	CTPDG003698
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASN51	.	.	Phase 1	DS70NZ	.	CTPDG003728
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2511	.	.	Phase 1	DRT09Y	.	CTPDG003737
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SHR-1707	.	.	Phase 1	DPYA76	.	CTPDG003763
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APH-1104	.	.	Phase 1	DNH51Q	.	CTPDG003800
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL919	TAK-920	.	Phase 1	DN48GC	.	CTPDG003808
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NTRX-07	MDA7	.	Phase 1	DK3WQ5	.	CTPDG003852
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAV-hTERT	.	.	Phase 1	DI9X5U	.	CTPDG003881
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL104	.	.	Phase 1	DHD2S9	.	CTPDG003895
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL747	.	.	Phase 1	DGH83L	.	CTPDG003903
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	REM0046127	.	.	Phase 1	DF21MW	.	CTPDG003924
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACU193	.	.	Phase 1	DCP0I8	.	CTPDG003951
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protollin	.	.	Phase 1	DC0DU9	.	CTPDG003960
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	.	.	Phase 1	DB7V3D	.	CTPDG003970
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ALN-APP	.	.	Phase 1	D8W0NQ	.	CTPDG004008
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-4334	.	.	Phase 1	D7PGM4	.	CTPDG004033
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NNI-362	.	.	Phase 1	D6KWF3	.	CTPDG004060
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR588	.	.	Phase 1	D62XNL	.	CTPDG004074
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AL003	.	.	Phase 1	D5QKY2	.	CTPDG004088
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3372993	.	.	Phase 1	D4YD7V	.	CTPDG004104
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MER5101	.	.	Phase 1	D4JPV8	.	CTPDG004117
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	"(4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; 1375752-78-5; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; 3I1803DK5Z; AKOS040756698; BDBM50536712; BMS984923; BMS-984923; CHEMBL4571075; CS-0087012; HY-122559; SCHEMBL4541143; UNII-3I1803DK5Z"	69084898	Phase 1	D34YLZ	.	CTPDG004146
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB113	.	.	Phase 1	D2KV0F	.	CTPDG004163
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-6-Me-BTA-1	Carbon-11-6-Me-BTA-1; 11C-BTA-1	.	Phase 1	D0ZX2D	.	CTPDG004207
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-104	.	.	Phase 1	D0ZW2I	.	CTPDG004210
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	V950 vaccine	.	.	Phase 1	D0Z2HG	.	CTPDG004232
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06751979	"ZLZUHACSRMOLLV-RAALSFIWSA-N; 1818339-66-0; UNII-1Y0Y126GUG; 1Y0Y126GUG; US9315520, Example 1; CHEMBL3952064; US9315520, Example 2; US9315520, Comparator 1; SCHEMBL17162186; BDBM223395; HY-112157; CS-0043501; US9315520, 1; N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide; N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carb"	118435360	Phase 1	D0Y5NA	DB15105	CTPDG004257
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-932481	.	91844660	Phase 1	D0XI4P	.	CTPDG004275
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-354	.	.	Phase 1	D0X9HF	.	CTPDG004280
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Affitope AD-01	"AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS"	.	Phase 1	D0X2UK	.	CTPDG004290
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-212	.	.	Phase 1	D0X1XK	.	CTPDG004293
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR-388	.	.	Phase 1	D0WS4E	.	CTPDG004298
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB076	.	.	Phase 1	D0WL5T	.	CTPDG004303
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-250	.	.	Phase 1	D0WI9W	.	CTPDG004305
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACI-35	.	.	Phase 1	D0W9LS	.	CTPDG004309
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-241027	.	.	Phase 1	D0V9HL	.	CTPDG004340
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD03 vaccine	.	.	Phase 1	D0V3EQ	.	CTPDG004351
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-AZD-2184	"AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184"	.	Phase 1	D0V0VI	.	CTPDG004354
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSI-136	"WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth"	11358855	Phase 1	D0U6FT	DB12819	CTPDG004374
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	18F-FEDAA-1106	"ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer"	.	Phase 1	D0U1US	.	CTPDG004382
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	.	.	Phase 1	D0TQ4Y	.	CTPDG004394
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BCI-632	"LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,"	9886034	Phase 1	D0T3DG	.	CTPDG004411
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ARC031	.	.	Phase 1	D0T0NL	.	CTPDG004413
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-103+RVT-104	.	.	Phase 1	D0S1KR	.	CTPDG004439
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Exebryl-1	Exebryl-1 (TN)	.	Phase 1	D0RD1Z	.	CTPDG004450
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAu mAb	.	.	Phase 1	D0R6WL	.	CTPDG004459
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BAY-1006578	"Diagnostic PET imaging agent (Alzheimer's disease), Bayer"	.	Phase 1	D0O9HG	.	CTPDG004540
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG7129	.	53241828	Phase 1	D0O8UB	.	CTPDG004543
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SAR228810	.	.	Phase 1	D0N9JB	.	CTPDG004573
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GRF6019	.	.	Phase 1	D0N8QR	.	CTPDG004576
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-168	"Alzheimer's diagnostic, IND; 123I-SPECT diagnostic (Alzheimer's disease), IND"	.	Phase 1	D0N3UQ	.	CTPDG004583
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY-2811376	"LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,"	44251605	Phase 1	D0N1BF	DB13065	CTPDG004586
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-330	.	.	Phase 1	D0MU7N	.	CTPDG004589
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SUVN-D4010	"DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole"	71508291	Phase 1	D0M9RI	.	CTPDG004596
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Mesenchymal stem cell therapy	.	.	Phase 1	D0M6AR	.	CTPDG004600
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2184	.	.	Phase 1	D0M0UB	.	CTPDG004608
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP-0777	.	.	Phase 1	D0L1UH	.	CTPDG004640
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NPT088	.	.	Phase 1	D0KN7Y	.	CTPDG004647
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Aleplasinin	"PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth"	10224267	Phase 1	D0JI2E	DB12635	CTPDG004674
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1841	.	.	Phase 1	D0J9PS	.	CTPDG004681
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E-2212	.	46854987	Phase 1	D0I1OS	.	CTPDG004731
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TTP-4000	"Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech"	.	Phase 1	D0I0YS	.	CTPDG004732
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANVS301	Bisnormcerysine	.	Phase 1	D0HRC9	.	CTPDG004738
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2012	870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N	11560787	Phase 1	D0F0JJ	DB05171	CTPDG004815
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NGP 555	"WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine"	46853593	Phase 1	D0EV5O	.	CTPDG004818
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AV-965	.	.	Phase 1	D0EH0C	.	CTPDG004824
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2647544	GSK-2647544	.	Phase 1	D0E6KN	.	CTPDG004830
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NDX-1017	.	.	Phase 1	D0E3CX	.	CTPDG004833
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GC021109	.	.	Phase 1	D0D4HO	.	CTPDG004863
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NsG-0202	"ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene"	.	Phase 1	D0D0GH	.	CTPDG004872
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SGC-1061	.	.	Phase 1	D0B3HP	.	CTPDG004921
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NBXT-001+Nobilis inhalation device	.	.	Phase 1	D0AY8D	.	CTPDG004928
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF20513	.	.	Phase 1	D0A9PD	.	CTPDG004933
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Begacestat	GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953	11269353	Phase 1	D09ZVC	DB12263	CTPDG004953
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	BCI-838	.	.	Discontinued in Phase 1	D09WZU	.	CTPDG004961
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-3328	UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073	44555286	Phase 1	D09PYZ	.	CTPDG004984
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JES-9501	DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride	.	Phase 1	D09MEV	.	CTPDG004992
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAK-071	WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5	92042879	Phase 1	D09BBA	.	CTPDG005012
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANAVEX 2-73	.	46932299	Phase 1	D09AOO	.	CTPDG005014
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SPI-014	"SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals"	46221695	Phase 1	D08XKL	.	CTPDG005020
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	HPP-854	.	.	Phase 1	D08TVI	.	CTPDG005028
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JNJ-63733657	.	.	Phase 1	D07PFU	.	CTPDG005091
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DWP-09031	DWJ-301	.	Phase 1	D06KWU	.	CTPDG005157
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2995	.	.	Phase 1	D06JPY	.	CTPDG005158
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Palomid-529	"P-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma"	.	Phase 1	D06JCO	.	CTPDG005159
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protexia	"RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene"	.	Phase 1	D06FGJ	.	CTPDG005166
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	FGLL	"NCAM mimetics (Alzheimer's disease), Enkam"	.	Phase 1	D06EXI	.	CTPDG005167
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Posiphen R-phenserine	.	.	Phase 1	D05VAE	.	CTPDG005184
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Anti-N3pG-Abeta antibody	.	.	Phase 1	D05ORO	.	CTPDG005192
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CTS-21166	.	.	Phase 1	D04VZS	.	CTPDG005234
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MCD-386	"CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion"	.	Phase 1	D04SIU	.	CTPDG005240
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD-3839	"GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D"	46202416	Phase 1	D04OSA	DB12368	CTPDG005245
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1814	.	.	Phase 1	D04AZT	.	CTPDG005269
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-957	.	.	Phase 1	D03NLQ	.	CTPDG005302
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	XEL 001HP	.	.	Phase 1	D03CCY	.	CTPDG005321
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-05251749	.	.	Phase 1	D03AGK	.	CTPDG005330
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-04995274	"UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, &gt; 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol"	53354764	Phase 1	D02YKI	DB12675	CTPDG005332
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAB-003/PF-05236812	.	.	Phase 1	D01ZSP	.	CTPDG005370
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2981710	.	.	Phase 1	D01YDH	.	CTPDG005373
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP3662	.	44598960	Phase 1	D00UEC	.	CTPDG005437
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAD-2004	"927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID"	16042343	Phase 1	D00MBY	.	CTPDG005453
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	Phase 1	D00EHX	DB12899	CTPDG005470
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	"methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate"	"MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate"	2314952	Clinical trial	D0R7EA	.	CTPDG005492
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	bimatoprost (free acid form)	17-phenyl-omega-trinor-PGF2alpha	5283081	Clinical trial	D08QWQ	.	CTPDG005504
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	JNJ-479655	"1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, &gt; Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide"	66553218	Clinical trial	D07QTG	.	CTPDG005505
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	alpha-ketothiazole analogue 36	"GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide"	16098914	Clinical trial	D05TKW	.	CTPDG005507
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-22	.	19910	Patented	D0KG9M	DB01422	CTPDG005806
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-20	.	.	Patented	D0I9VU	.	CTPDG005858
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-2	.	.	Patented	D0E2AF	.	CTPDG005956
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 2	PMID29324067-Compound-53	.	Patented	D0DW5P	.	CTPDG005961
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID29334795-Compound-22	.	.	Patented	D0B2NV	.	CTPDG006029
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-19	.	.	Patented	D09UJB	.	CTPDG006053
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Thiadiazolyl carboxamide derivative 1	PMID28270010-Compound-Figure18-1	71263688	Patented	D06STX	.	CTPDG006137
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 1	PMID29324067-Compound-43	.	Patented	D05RJG	.	CTPDG006162
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-18	.	.	Patented	D04NCC	.	CTPDG006193
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	Zanapezil	TAK-147	198752	Discontinued in Phase 3	D0AM8W	DB04859	CTPDG006368
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	PF-1913539	"Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261"	176408	Discontinued in Phase 3	D07ESH	.	CTPDG006376
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AZD0328	"AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]"	9794392	Discontinued in Phase 2	D0Q9RR	DB12145	CTPDG006451
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	S-18986	"S 18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine"	637863	Discontinued in Phase 2	D0M0HJ	.	CTPDG006484
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AVN 397	.	.	Discontinued in Phase 2	D0J7EP	.	CTPDG006497
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	DPC-543	.	.	Discontinued in Phase 2	D0I4PL	.	CTPDG006502
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	NGD-97-1	"CP-457,920"	.	Discontinued in Phase 2	D0FN6D	.	CTPDG006521
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	IPENOXAZONE	"MLV-6976; NC-1200; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one"	65882	Discontinued in Phase 2	D0B4EV	.	CTPDG006554
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Ispronicline	RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine	9824145	Discontinued in Phase 2	D0AB4Q	.	CTPDG006559
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	ABT-418	"Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398"	119380	Discontinued in Phase 2	D09ADT	.	CTPDG006574
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Talsaclidine fumarate	"Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane"	6918244	Discontinued in Phase 2	D06ODM	.	CTPDG006603
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Affitope AD-02	"Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals"	.	Discontinued in Phase 2	D06BVT	.	CTPDG006608
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	SIB-1553A	"191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride"	5310968	Discontinued in Phase 2	D00ECO	.	CTPDG006677
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	VP-025	"Inflammation therapeutics, Vasogen; VP-015"	.	Discontinued in Phase 1	D0Y8IS	.	CTPDG006707
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TRx-0037	.	.	Discontinued in Phase 1	D0S9XR	.	CTPDG006743
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	EVT-301	"MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche"	.	Discontinued in Phase 1	D0P1WB	.	CTPDG006760
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	PF-05236812	AAB-003	.	Discontinued in Phase 1	D0K3SV	.	CTPDG006792
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	C-9138	.	.	Discontinued in Phase 1	D0K0XW	.	CTPDG006794
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	SL-25.1188	.	.	Discontinued in Phase 1	D0E3JL	.	CTPDG006819
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	GR-253035	.	.	Discontinued in Phase 1	D0C2HF	.	CTPDG006828
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TAK-065	"Neuroregeneration enhancer (oral, Alzheimers/Parkinsons disease), Takeda"	.	Discontinued in Phase 1	D0A2XD	.	CTPDG006837
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	NP-61	"Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira"	.	Discontinued in Phase 1	D04UKJ	.	CTPDG006894
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	ACC-002	.	.	Phase 0	D0YM4F	.	CTPDG006951
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	INP102	.	.	Phase 0	D0P7BA	.	CTPDG006952
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	AAB-002	.	.	Phase 0	D01QLM	.	CTPDG006954
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	TPT-43	.	.	Preclinical	D0YH9A	.	CTPDG007021
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-1501	"AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals"	.	Preclinical	D0XM3S	.	CTPDG007024
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SPH-1285	"Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359"	.	Preclinical	D0V7FG	.	CTPDG007039
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	ANAVEX 1-41	.	10446473	Preclinical	D0T0UC	.	CTPDG007053
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	VER-155008	"Heat shock protein 70 inhibitor (cancer), Vernalis; Hsp 70 inhibitor (cancer), Vernalis"	25195348	Preclinical	D0H0AU	.	CTPDG007083
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Pepticlere	"DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech"	.	Preclinical	D0G7LP	.	CTPDG007086
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SCH-1359113	"SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough"	23627211	Preclinical	D0E3SX	.	CTPDG007089
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	humanin	formyl humanin	16131438	Preclinical	D09TXO	.	CTPDG007101
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CDD-0199-J	.	.	Preclinical	D09MQQ	.	CTPDG007103
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Alvameline	Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M	178030	Terminated	D0X8MZ	.	CTPDG007181
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Ro-46-5934	.	.	Terminated	D0TK0W	.	CTPDG007215
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	IDRA-21	IDRA-21 analogs; IDRA-5	3688	Terminated	D0S0VZ	.	CTPDG007229
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-99	"Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	132712	Terminated	D0R1VL	.	CTPDG007239
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS-66252	.	9803861	Terminated	D0Q7SO	.	CTPDG007242
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-93426	"ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-"	115210	Terminated	D0P3IE	.	CTPDG007252
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-427	.	.	Terminated	D0O7DN	.	CTPDG007262
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	EHT-1864	"EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit"	9938202	Terminated	D0M9ER	.	CTPDG007276
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CI-1002	PD-142676	9838284	Terminated	D0M2GI	.	CTPDG007282
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BU-4514N	"BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one"	54704416	Terminated	D0L8TN	.	CTPDG007287
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	DNP-004089	"BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo"	.	Terminated	D0K3WN	.	CTPDG007302
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF-8615	.	.	Terminated	D0K0XG	.	CTPDG007305
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-152558	.	.	Terminated	D0J4GQ	.	CTPDG007314
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-649	.	9905818	Terminated	D0G7HO	.	CTPDG007347
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MDL-28170	MDL-2170	72430	Terminated	D0G5ZE	.	CTPDG007348
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-377	.	9860852	Terminated	D0EP5O	.	CTPDG007360
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	R-1315	.	.	Terminated	D0CX2J	.	CTPDG007380
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	L-698544	"7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ"	10220180	Terminated	D0AZ5V	.	CTPDG007398
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GYKI-52466	"102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2"	3538	Terminated	D0A9VO	.	CTPDG007402
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Nerve growth factor	"Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia"	.	Terminated	D0A0MJ	.	CTPDG007406
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-3796	.	.	Terminated	D09IUG	.	CTPDG007420
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NNC-90-0270	"Nicotinic ACh agonists, Novo Nordisk"	.	Terminated	D09GRB	.	CTPDG007422
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-14413	"Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre"	.	Terminated	D08VJI	.	CTPDG007432
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-4001	.	.	Terminated	D08TCU	.	CTPDG007433
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Milacemide	Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S	53569	Terminated	D07OLO	.	CTPDG007457
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sch-57790	CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294	9867750	Terminated	D07IZF	.	CTPDG007461
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF268	"MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet"	5288799	Terminated	D06ZAM	DB04021	CTPDG007467
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Z-4105	"119737-52-9; Butanoic acid, 4-(((3-methyl-5-isoxazolyl)carbonyl)amino)-; Butanoic acid,4-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-; ACMC-20cew8; AC1Q5P7F; SCHEMBL195378; AC1L4P39; CTK4B1474; 4-[(3-methyl-1,2-oxazole-5-carbonyl)amino]butanoic acid; DTXSID50152568; 4-{[(3-methyl-1,2-oxazol-5-yl)carbonyl]amino}butanoic acid"	189689	Terminated	D06PAW	.	CTPDG007475
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RU-33965	"RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-"	129696	Terminated	D05IVZ	.	CTPDG007496
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS 86	"RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl  -D-galactopyranoside; 2-Nitrophenyl; A-D-galactopyranoside"	87934	Terminated	D05HKB	.	CTPDG007497
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-121196	"FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-"	131688	Terminated	D05EKM	.	CTPDG007500
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	AZD-2858	AZD2858; 486424-20-8; AZD 2858; CHEMBL2177161; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide; 3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide; GSK-3 inhibition; 3-amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL8478; SCHEMBL3327702; C21H23N7O3S; EX-A707; AOB6850; MolPort-035-395-808	10138980	Terminated	D04WZK	.	CTPDG007507
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-431	"Clipsin inhibitor, Cephalon"	.	Terminated	D04RDT	.	CTPDG007509
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NP-7557	"Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech"	.	Terminated	D03DFY	.	CTPDG007539
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-2016	GT 2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653	9839975	Terminated	D02YXQ	.	CTPDG007540
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	A-72055	.	.	Terminated	D02VHE	.	CTPDG007544
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ABS-301	"ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS"	.	Terminated	D02UQU	.	CTPDG007545
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-91296	"ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester"	123700	Terminated	D02UIE	.	CTPDG007546
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-140	"Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	10030021	Terminated	D02JNY	.	CTPDG007550
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Bifemelane	Alnert; Celeport; E-0687; MCI-2016; SON-216	2377	Terminated	D02CGY	DB13550	CTPDG007557
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sibopirdine	"DuP-921; EXP-9121; EXP-921; 5H-Cyclopenta[2,1-b:3,4-b']dipyridine, 5,5-bis(4-pyridinylmethyl)-, monohydrate"	195376	Terminated	D01LRH	.	CTPDG007569
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Tenilsetam	CAS-997	65649	Terminated	D00JNL	.	CTPDG007586
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AD-0802	"Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic"	.	Investigative	D0Y9ES	.	CTPDG007656
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	VK-11	"Imaging agent (Alzheimer's disease), Prana"	.	Investigative	D0Y4TQ	.	CTPDG007666
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZD-6319	"Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca"	.	Investigative	D0X2NB	.	CTPDG007732
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PD-2015	"PD-2016; TNF alpha inhibitors (Alzheimers disease); TNF alpha inhibitors (Alzheimers disease), P2D Bioscience"	.	Investigative	D0WO8I	.	CTPDG007740
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CBNU-06	.	.	Investigative	D0WA3T	.	CTPDG007746
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RAP-310	"Small stabilized receptor active peptide (Alzheimers disease), RAPID Pharmaceuticals"	.	Investigative	D0W9OW	.	CTPDG007748
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tideglusib	.	11313622	Phase 2	D0W5WZ	DB12129	CTPDG007762
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DWJ-209	.	.	Investigative	D0W5CI	.	CTPDG007764
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EVP-4473	.	.	Investigative	D0VE4O	.	CTPDG007780
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ReN-004	"Stem cell therapy (neurological disorders), ReNeuron"	.	Investigative	D0UO6M	.	CTPDG007813
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-901	.	.	Investigative	D0T6FY	.	CTPDG007853
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR APLs	NAChR APLs (Alzheimer's disease)	.	Investigative	D0T5ZM	.	CTPDG007855
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	COG-248	"Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease); Neuroprotectant (Alzheimers/Parkinsons disease), Cognosci; Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease), Cognosci"	.	Investigative	D0S2QP	.	CTPDG007894
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ELND-007	"ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan"	53308121	Investigative	D0Q6ZQ	.	CTPDG007946
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	BAN-2203	"Beta amyloid modulator (Alzheimer's disease), BioArctic"	.	Investigative	D0Q5VC	.	CTPDG007953
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Turmeric extracts	"HSS-808; HSS-818; HSS-838; HSS-848; HSS-888; Turmeric extracts (Alzheimer's disease); Turmeric extracts (Alzheimer's disease), HerbalScience"	.	Investigative	D0Q2XN	.	CTPDG007960
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Ginkgo biloba extract	"YY-1224; YY-1824; Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease); Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease), Yuyu Inc"	.	Investigative	D0OB9V	.	CTPDG008000
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SX-AZD1	.	.	Investigative	D0N6EL	.	CTPDG008040
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AIKb2	.	.	Investigative	D0N0SC	.	CTPDG008055
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR alpha 7 APLs	NAChR alpha 7 APLs (Alzheimer's disease)	.	Investigative	D0M7MH	.	CTPDG008070
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	11A1	.	.	Investigative	D0K4WW	.	CTPDG008142
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Gamma-secretase modulators	"Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche"	24781184	Investigative	D0J5SD	.	CTPDG008172
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	MCD-386/glycopyrrolate	"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,"	3494	Investigative	D0IL1B	DB00986	CTPDG008185
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	HL-026	.	.	Investigative	D0IC8P	.	CTPDG008187
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ESN-XX	.	.	Investigative	D0I3OX	.	CTPDG008215
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ETN-001	.	.	Investigative	D0I0ZY	.	CTPDG008222
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DBT-1339	"DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech"	.	Investigative	D0HK7G	.	CTPDG008227
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GRL-11097	"Memapsin 2 inhibitors (Alzheimers); Memapsin 2 inhibitors (Alzheimers), Purdue University/Astellas"	.	Investigative	D0H2VN	.	CTPDG008244
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KNX-Monoclonal204	"KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis"	.	Investigative	D0G4AE	.	CTPDG008271
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KMS-88009	"KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical"	.	Investigative	D0F5UO	.	CTPDG008302
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NGN-9079	"Alzheimer's disease therapy, NeuroGeneration"	.	Investigative	D0F5IS	.	CTPDG008306
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PNB-04	"Alzheimer's disease therapy, PharmaNeuroBoost"	.	Investigative	D0EW4M	.	CTPDG008325
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	IMD-4482	"IMD-4690; PAI-1 inhibitor (oral, Alzheimers disease), IMMD; Plasminogen activator inhibitor-1 inhibitor (oral, Alzheimers disease), Institute of Medicinal Molecular Design"	.	Investigative	D0EW2D	.	CTPDG008326
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Abloid	"Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics"	.	Investigative	D0E5CX	.	CTPDG008345
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Memex	Nicotinomide adenine dinucleotide (NADH)	.	Investigative	D0E0OI	.	CTPDG008353
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-0235-J	.	.	Investigative	D0D7KR	.	CTPDG008371
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-103	"NP-060103; NP-60103; Glycogen synthase kinase-3 inhibitor (Alzheimer's disease), Neuropharma"	.	Investigative	D0D6WF	.	CTPDG008374
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Leptin	Leptin (Alzheimer's disease)	.	Investigative	D0C6TL	.	CTPDG008408
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SP-08	SP-008	.	Investigative	D0C4WY	.	CTPDG008411
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SPI-017	"SPI-017 (oral, Alzheimer's disease)"	.	Investigative	D0C1TT	.	CTPDG008423
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RECALL-VAX	"RV-01; RV-02; Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease); Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease), Intellect Neuroscience"	.	Investigative	D0B4AH	.	CTPDG008454
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CWF-0804	.	.	Investigative	D09NEL	.	CTPDG008535
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACU-0101979	"HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co"	.	Investigative	D09MRY	.	CTPDG008536
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Cystatin C	Cystatin C (Alzheimer's disease)	.	Investigative	D09HVY	.	CTPDG008553
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EDN-OL1	"Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn"	.	Investigative	D07ZDG	.	CTPDG008644
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ADepVac	"DNA vaccine (Alzheimer's disease), University of California Irvine; DNA vaccine (TriGrid electroporation, Alzheimers), Ichor/UCI/IMM"	.	Investigative	D07ZBO	.	CTPDG008646
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Anticalin	Anticalin (Alzheimer's disease)	.	Investigative	D07YAC	.	CTPDG008650
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-518	"AMPA glutamate receptor agonist (Alzheimer's disease), AC Immune"	.	Investigative	D07KMI	.	CTPDG008690
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEN-1500	"SEN-1576; Beta-amyloid aggregation inhibitors (Alzheimer's disease); Beta-amyloid aggregation inhibitors (Alzheimer's disease), Senexis"	54589394	Investigative	D07JKA	.	CTPDG008693
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARN-2966	"ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences"	14936865	Investigative	D07DNV	.	CTPDG008707
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZ-AAV9	"Alzheimers disease gene therapy, RegenX Biosciences; Adeno-associated virus vector-9 based gene therapy (injectable,AD), RegenX Biosciences"	.	Investigative	D06UUE	.	CTPDG008732
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-636	"Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune"	.	Investigative	D06MBR	.	CTPDG008752
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	TKP-1001	"Amyloid-beta modulator (Alzheimer's disease), EUSA Pharma; Amyloid-beta modulator (Alzheimer's disease), Talisker Pharma; Amyloid-beta synthesis modulator (Alzheimer's disease), The Open University"	.	Investigative	D06LRQ	.	CTPDG008753
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-17	"NP-21; NPM-01; NPM-05 series; NPM-05B1; NPM-05B2; Alpha-secreatse activators (oral, Alzheimer's disease), Noscira"	.	Investigative	D05NIO	.	CTPDG008822
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ANA-5	.	.	Investigative	D04ZTA	.	CTPDG008850
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NXD-9062	.	.	Investigative	D04UQS	.	CTPDG008858
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3186	.	.	Investigative	D04TZK	.	CTPDG008860
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	A-887755	.	.	Investigative	D04TPS	.	CTPDG008861
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARC-069	"Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals"	.	Investigative	D04QXW	.	CTPDG008864
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NNI-AD	"NNI-251; NNI-362; NNI-C; NNI-X01; AD therapy (oral), Neuronascent"	.	Investigative	D04OUP	.	CTPDG008871
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZP-2006	"Amyloid precursor protein modulator (AD), AlzProtect/INSERM/University of Lille II"	87057554	Investigative	D04MHP	.	CTPDG008882
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AC-4402	"GABAA receptor inverse agonist (Alzheimer's disease), Dainippon Sumitomo Pharma"	3084937	Investigative	D03TDE	.	CTPDG008935
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GT 1061	.	53483797	Investigative	D03IHA	.	CTPDG008969
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3248	.	.	Investigative	D01ZFM	.	CTPDG009049
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	UC-1011	"UC-2021; UC-2025; GABA A receptor antagonists (Alzheimer's disease); GABA A receptor antagonists (Alzheimer's disease), Umecrine; 3beta-20beta-dihydroxy-5alpha-pregnane; 3beta-20beta-dihydroxy-5alpha-pregnane (Alzheimer's disease), Umecrine"	.	Investigative	D01YGY	.	CTPDG009051
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	F-18 T808	.	.	Investigative	D01SXE	.	CTPDG009066
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-501	.	.	Investigative	D01QNJ	.	CTPDG009082
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Haw-AD-14	.	.	Investigative	D01LBD	.	CTPDG009100
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-190	.	.	Investigative	D01GBV	.	CTPDG009117
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	123I-DRM-106	"DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd"	49801966	Investigative	D01GAZ	.	CTPDG009118
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PN-403	.	.	Investigative	D01FTK	.	CTPDG009120
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Mimovax	"MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS"	.	Investigative	D01BJK	.	CTPDG009132
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEL-103	.	.	Investigative	D00YJD	.	CTPDG009144
M6ACROT03177	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Molecule 22	"MARK3 inhibitors (Alzheimer's disease); MARK3 inhibitors (Alzheimer's disease), Merck & Co"	.	Investigative	D00HDH	.	CTPDG009188
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rivastigmine	Rivastigmine (transdermal patch)	77991	Approved	D0WY5Q	DB00989	CTPDG000074
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Propentofylline propionate	Hextol (TN)	4938	Approved	D0UU9Y	DB06479	CTPDG000111
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Dihydroergotoxine	"Ergotamine, dihydro, methanesulfonate (salt)"	6420006	Approved	D0SP3D	.	CTPDG000148
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Galantamine	"GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol"	9651	Approved	D0R9VR	DB00674	CTPDG000171
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Eicosapentaenoic acid/docosa-hexaenoic acid	"Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN)"	445580	Approved	D0Q5XX	DB03756	CTPDG012556
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Donepezil	"Donepezil (transdermal patch, Alzheimer's disease)"	3152	Approved	D0NS6H	DB00843	CTPDG000257
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved in China	GV-971	.	.	Approved in China	D0FS5O	.	CTPDG000380
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Tacrine	"Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine"	1935	Approved	D0E6YQ	DB00382	CTPDG000406
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Lemborexant	E2006	56944144	Phase 2	D0A7ZK	DB11951	CTPDG000461
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Pexidartinib	PLX-3397	25151352	Approved	D09TAB	DB12978	CTPDG013033
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-florbetaben	.	.	Approved	D07TRF	.	CTPDG000548
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Colostrinin	Colostrinin (TN)	.	Approved	D07NPH	.	CTPDG000558
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Huperzine A	"Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680"	854026	Approved	D06XWB	DB04864	CTPDG000589
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Lecanemab	.	.	Approved	D06XVR	.	CTPDG000590
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-flutemetamol	.	.	Approved	D06XOT	.	CTPDG000591
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Ergoloid mesylate	Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)	592735	Approved	D02IQY	.	CTPDG000752
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Immune globulin	.	.	Approved	D01OWB	.	CTPDG000780
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Memantine	"Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest"	4054	Approved	D01JEU	DB01043	CTPDG000790
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Aducanumab	.	.	Approved	D00RRU	.	CTPDG000806
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nirogacestat	"Nirogacestat; 1290543-63-3; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01"	46224413	Phase 2	D00GPQ	DB12005	CTPDG000817
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 4	18F-AV-1451	Tau imaging agent)	70957463	Phase 4	D0F4CG	DB14914	CTPDG000847
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NE3107	.	.	Phase 3	D9I6QG	.	CTPDG000924
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Guanfacine	"(2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride; 29110-47-2; 30OMY4G3MK; A902647; A918619; AB01563079_01; AKOS030255657; AKOS030526130; BCP09647; BDBM81984; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; BPBio1_000415; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; BSPBio_000377; C02AC02; C07037; CAS_29110-47-2; CAS-29110-48-3; CCG-204609; CHEBI:5558; CHEMBL862; D08031; DB01018; DTXCID7026944; DTXSID9046944; EINECS 249-442-8; EN300-243924; Estulic; Estulic (Salt/Mix); Estulic (TN); FT-0669067; FT-0669068; GTPL522; Guanfacina; Guanfacina (INN-Spanish); Guanfacina [INN-Spanish]; GUANFACINE; Guanfacine (INN); Guanfacine [INN:BAN]; GUANFACINE [INN]; GUANFACINE [MI]; GUANFACINE [VANDF]; GUANFACINE [WHO-DD]; Guanfacine HCl; Guanfacine hydrochloride (Salt/Mix); Guanfacinum; Guanfacinum (INN-Latin); Guanfacinum [INN-Latin]; HY-17416A; J-017394; L000286; L013430; LON 798 (Salt/Mix); Lopac0_000519; Lopac-G-1043; MRF-0000019; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; N-amidino-2-(2,6-dichlorophenyl)acetamide; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-05; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; NSC 759121; NSC_3519; NSC-759121; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Q5613599; RASPBERRYKETONEGLUCOSIDE; SCHEMBL35094; SDCCGSBI-0050502.P002; SPBio_002298; Tenex (Salt/Mix); Tocris-1030; UNII-30OMY4G3MK"	3519	Phase 3	D8NY3J	DB01018	CTPDG000928
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	BPDO-1603	.	.	Phase 3	D71LNO	.	CTPDG000931
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AXS-05	.	.	Phase 2/3	D3PD8C	.	CTPDG000941
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Remternetug	LY3372993	.	Phase 3	D34FRG	.	CTPDG000944
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Donanemab	.	.	Phase 3	D2ZP0A	.	CTPDG000945
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AR1001	"(-)-methylbenzylamine; (+)-2-Methylbutylp-aminocinnamate; 103-67-3; 7KN7F4X49E; AI3-26793; AKOS000119094; AR1001; Benzenemethanamine, N-methyl-; benzyl methyl amine; benzyl methylamine; Benzyl(methyl)amine; BENZYLAMINE, N-METHYL; Benzylamine, N-methyl-; Benzylmethylamine; benzyl-methylamine; Benzyl-methyl-amine; Benzylmethyl-d3-amine; BRD-K44558320-003-01-7; CHEMBL1338; CS-W007426; DTXSID9048439; EC 203-133-4; EINECS 203-133-4; EN300-18191; F2190-0316; FT-0631560; HNMeBzl; HY-W007426; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H; KBio2_001842; KBio2_004410; KBio2_006978; KBioGR_002247; KBioSS_001842; M0164; methyl benzylamine; Methyl(phenylmethyl)amine; methyl-benzyl amine; Methylbenzylamine; Methylbenzylamine, N-; methylbezylamine; MFCD00008289; MLS004773900; N-(Phenylmethyl)methylamine; N-benzyl methyl amine; N-benzyl methylamine; N-benzylmethanamine; N-benzyl-methyl amine; N-Benzylmethylamine; N-benzyl-methylamine; N-Benzylmethylamine, 97%; N-Benzyl-N-methylamine; N-benzyl-N-methyl-amine; NCGC00166047-01; N-methyl benzyl amine; N-methyl benzylamine; N-methyl -benzylamine; N-Methyl(phenyl)methanamine; N-methyl-1-phenylmethanamine; N-methyl-1-phenyl-methanamine; N-methylbenzenemethanamine; N-methyl-benzenemethanamine; N-methylbenzyl amine; N-methyl-benzyl amine; N-METHYLBENZYLAMINE; N-methyl-benzylamine; N-methyl-N-(phenylmethyl)amine; N-methyl-N-benzyl amine; N-methyl-N-benzylamine; N-Methy-N-benzylamine; NSC 8059; NSC8059; NSC-8059; omega-Methylaminotoluene; Q23978278; Racemic methylbenzyl amine; SCHEMBL2271; SDCCGMLS-0066901.P001; SMR000112361; Spectrum_001362; Spectrum4_001764; Spectrum5_000347; STR02536; UNII-7KN7F4X49E; W-108843; Z57327124"	7669	Phase 3	D1OM8E	.	CTPDG000951
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	GV-971	sodium oligomannate	.	Phase 3	D1KR3N	.	CTPDG000952
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AVP-786	.	25052519	Phase 3	D0Z6IB	.	CTPDG000965
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NI-101	"BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec"	.	Phase 3	D0Z2GF	.	CTPDG000968
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Lanabecestat	"1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane"	67979346	Phase 3	D0Y0EP	DB14814	CTPDG000986
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SB-742457	GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline	11256720	Phase 3	D0R9HI	DB12680	CTPDG001066
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Crenezumab	MABT5102A; RG7412	.	Phase 3	D0R7EQ	.	CTPDG001069
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	verubecestat	example 25 (US8940748)	51352361	Phase 3	D0R4KK	DB12285	CTPDG001070
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Gantenerumab	RG1450	.	Phase 3	D0Q7YZ	.	CTPDG001078
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	PF-4494700	"PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer"	11180124	Phase 3	D0MW7B	DB12689	CTPDG001122
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SI-657	"AC1L9R2T; 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid"	453618	Phase 3	D0E9SZ	.	CTPDG001222
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	EVP-6124	"Encenicline; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626"	46196517	Phase 3	D0D3TX	DB11726	CTPDG001246
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ALZT-OP1	ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen	.	Phase 3	D0CH6B	.	CTPDG001252
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	MIM-D3	"TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen"	9808372	Phase 3	D0C2OR	DB12441	CTPDG001261
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LCS 16	.	.	Phase 3	D0A4DP	.	CTPDG001278
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Bapineuzumab	"AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan"	.	Phase 3	D0A1MX	.	CTPDG001282
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tirapazamine	TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075	135413511	Phase 3	D09XQU	DB04858	CTPDG001290
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AV 133	.	.	Phase 3	D09NAF	.	CTPDG001302
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tramiprosate	"Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS"	1646	Phase 3	D09DLP	DB06527	CTPDG001314
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	E-2609	"Beta secretase inhibitor (Alzheimer's disease), Eisai"	57827330	Phase 3	D08MHD	DB15391	CTPDG001329
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	(-)-Phenserine	"CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate"	192706	Phase 3	D07CIN	DB04892	CTPDG001369
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ARC029	"Nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino"	4494	Phase 3	D06GRK	DB06712	CTPDG001378
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Eltoprazine	"Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company"	65853	Phase 2	D06FKC	DB12883	CTPDG001380
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	INM-176	"WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn"	.	Phase 3	D05UXU	.	CTPDG001390
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Xaliproden	"Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine"	128919	Phase 3	D02OJC	DB06393	CTPDG001464
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tamibarotene	"Tamibarotene (oral, Alzheimer's disease)"	108143	Phase 3	D02GTY	DB04942	CTPDG001471
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Immune globulin + albumin	.	.	Phase 3	D00KLP	.	CTPDG001501
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Solanezumab	.	.	Phase 3	D00CZT	.	CTPDG001504
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD106	.	.	Phase 2/3	DF3UN2	.	CTPDG001516
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Icosapent ethyl	"(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 6GC8A4PAYH; 73310-10-8; 86227-47-6; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound; AB01563352_01; AC-33765; AKOS025295847; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; AMR 101; AMR101; AMR-101; BS-48985; CCG-213714; CHEBI:80366; CHEBI:84883; CHEMBL2095209; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; cis-Eicosapentaenoic acid ethyl ester; CS-5304; D01892; DB08887; DTXSID601018686; E0442; E0853; E-EPA; Eicosapentaenoic acid (ethyl ester); Eicosapentaenoic acid ethyl ester; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; Eicosapentaenoic acid, ethyl ester; Eicosapentaenoicacidethylester; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EN300-25951782; EPA ethyl ester; Epadel; Epadel S; Epadel S (TN); EPA-E; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; ethyl eicosapentaenoate; Ethyl eicosapentaenoic acid; Ethyl EPA; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Ethyl icosapent; ethyl icosapentaenoate; ethyl icosapentate; Ethyl icosapentate (JP17); Ethyl icosapentate [JAN]; Ethyl icosapentate, JAN; ethyl-eicosapentaenoic acid; ethyl-EPA; GTPL7441; HMS2094K19; HY-B0747; ICOSAPENT ETHYL; Icosapent ethyl (USAN); ICOSAPENT ETHYL [ORANGE BOOK]; Icosapent ethyl [USAN]; ICOSAPENT ETHYL [VANDF]; Icosapent ethyl ester; LMFA07010877; MFCD00673476; MND 21; NSC 759597; NSC759597; NSC-759597; Pharmakon1600-01300030; Q5404453; s6466; SBI-0206684.P002; SCHEMBL123305; SR-05000002595; SR-05000002595-1; Timnodonic acid ethyl ester; UNII-6GC8A4PAYH; Vascepa; Vascepa (TN); Vazkepa"	9831415	Phase 2/3	DF29AZ	DB08887	CTPDG001517
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Fosgonimeton	"2093305-05-4; AKOS040757261; ATH-1017; ATH-1017 FREE ACID; CHEMBL5095419; CS-0204081; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate; Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN:INN]; Fosgonimeton [USAN]; H91OA9858J; HY-132814; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; NDX-1017; NDX-1017 FREE ACID; UNII-H91OA9858J; WHO 11782"	156596375	Phase 2/3	DDBY18	.	CTPDG001518
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Ginkgo biloba	.	.	Phase 2/3	D6S9AH	.	CTPDG001520
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Atuzaginstat	"2211981-76-7; Atuzaginstat; Atuzaginstat [INN]; AtuzaginstatCOR388; BDBM453275; CHEMBL5095230; COR388; COR-388; Cyclopentanecarboxamide, N-((1S)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-; DGN7ROZ8EN; EX-A6081; N-((3S)-7-Amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide; N-[(3S)-7-amino-2-oxo-1-(2,3,6-trifluorophenoxy)heptan-3-yl]cyclopentanecarboxamide; SCHEMBL19972758; UNII-DGN7ROZ8EN; US10730826, Compound 1a-non-racemic; US10730826, Compound 1a-racemic"	134347893	Phase 2/3	D58BFC	.	CTPDG001522
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	JNJ-54861911	.	68254185	Phase 2/3	D0T2FP	DB15307	CTPDG001532
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Plasminogen	.	.	Phase 2/3	D0S4YT	.	CTPDG001533
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD-106	"Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis"	.	Phase 2/3	D0I3VT	.	CTPDG001544
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AMG520	CNP520	.	Phase 2/3	D0H4YD	.	CTPDG001545
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	SI-614	Modified Hyaluronate	.	Phase 2/3	D08QGE	.	CTPDG001559
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AZD3293	CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099	57404290	Phase 2/3	D01AYX	.	CTPDG001580
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABvac40	.	.	Phase 2	DZQI76	.	CTPDG001594
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AL002	.	.	Phase 2	DYT9B4	.	CTPDG001604
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MLC901	NeuroAiD	.	Phase 2	DYB14S	.	CTPDG001607
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-916	.	.	Phase 2	DY6DS3	.	CTPDG001608
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TB006	.	.	Phase 2	DW7J9D	.	CTPDG001619
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3372689	"2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; CS-0433932; EX-A6549; GLXC-25705; GTPL11953; HY-144681; LY3372689; LY-3372689; MS-26295; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide; SCHEMBL20421995; U0SGP6ZX2V; UNII-U0SGP6ZX2V"	135260636	Phase 2	DVY0C6	.	CTPDG001621
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MP-101	.	.	Phase 2	DSK7I5	.	CTPDG001634
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DHP1401	.	.	Phase 2	DS4CL2	.	CTPDG001638
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CY6463	"2201048-82-8; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; AKOS040757400; CS-0376702; CY6463; CY-6463; EX-A7620; GTKNNCQKFKGSHR-UHFFFAOYSA-N; H7KEN3O8AI; HY-145607; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; IW-6463; MS-25746; SCHEMBL19922804; UNII-H7KEN3O8AI; Zagociguat; Zagociguat [INN]; ZAGOCIGUAT [USAN]"	134304734	Phase 2	DO37EF	.	CTPDG001660
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ID1201	.	.	Phase 2	DM95PZ	.	CTPDG001677
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Benfotiamine	"(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid; 22457-89-2; 22457-89-2 (free acid); 775256-41-2; AC-8280; AKOS015920320; Benfotamine; Benfotiamina; benfotiamine; Benfotiamine (JAN/INN); Benfotiaminum; Benphothiamine; Benzoylthiamine monophosphate; Betivina; Biotamin (TN); BPBio1_000757; BSPBio_000687; CAS-22457-89-2; CCG-220654; CHEBI:41039; CHEMBL4303665; D01255; DB11748; DTXCID1025433; DTXSID3045433; EN300-21694383; HMS1570C09; HMS2097C09; HMS3714C09; MFCD00057343; N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; NCGC00016764-01; NCGC00016764-04; NCGC00179477-01; Prestwick_68; Prestwick2_000654; Prestwick3_000654; S-(2-(N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl)benzothioa; S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; s-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; S-Benzoylthiamine-O-monophosphate; SCHEMBL188070; SCHEMBL19184708; SR-01000872627; SR-01000872627-1; SR-01000872627-2; Tox21_110597; Tox21_110597_1"	3032771	Phase 2	DL7CK2	DB11748	CTPDG001686
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAGE-718	.	.	Phase 2	DI54FM	.	CTPDG001703
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	APH-1105	.	.	Phase 2	DH6G1L	.	CTPDG001708
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuplazid	"Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,  ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate"	11672491	Phase 2	DDI6B0	.	CTPDG001741
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-1942	.	.	Phase 2	DDAH09	.	CTPDG001742
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	"(1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate; 2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-; 2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-; 37O2X55Y9E; 83314-01-6; BDBM50258529; BMY-45618; BRN 4349157; BRYOSTATIN; Bryostatin 1; Bryostatin 1 - CAS 83314-01-6; BRYOSTATIN 1 [MI]; BRYOSTATIN 1 [WHO-DD]; Bryostatin 1, >=99%, solid; Bryostatin-1; CHEBI:88353; CHEMBL449158; CS-0025440; DTXSID8046876; HY-105231; MFCD00893832; MJQUEDHRCUIRLF-TVIXENOKSA-N; NSC 339555; NSC-339555; Q27095907; SCHEMBL182960; UNII-37O2X55Y9E"	5280757	Phase 2	DD8L0V	.	CTPDG001743
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AADvac-1	.	.	Phase 2	DA1L7V	.	CTPDG001761
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NLY01	.	.	Phase 2	D7A5LO	.	CTPDG001783
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD-35	"1531586-58-9; 6'-(2-(1-(Pyridin-2-ylmethyl)piperidin-4-yl)ethyl)spiro[cyClopropane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-7'(6'H)-one; AD-35; BDBM231544; CHEMBL3949886; GLXC-15057; IND-120499; SCHEMBL15598869; starbld0021420; US9346818, I-29; US9346818, I-33; US9346818, I-35"	72707125	Phase 2	D67DST	.	CTPDG001793
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RPh201	.	.	Phase 2	D3YT8E	.	CTPDG001820
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Trontinemab	RG6102	.	Phase 2	D3XP8N	.	CTPDG001821
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI-287	"849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546"	11564168	Phase 1	D3X2TH	.	CTPDG001822
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MW150	"1628502-91-9; 3GF; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; AKOS040758765; BDBM50537600; CHEMBL4129018; CIIVUDIZZJLXCN-UHFFFAOYSA-N; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; compound 8 [PMID: 25676389]; CS-0069509; EPZ68T461K; EX-A3206A; GTPL10524; HY-120111; MS-26255; MW 150; MW01-18-150SRM; MW150; MW-150; NSC785340; NSC-785340; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; Q27453797; SCHEMBL16061104; UNII-EPZ68T461K"	86270361	Phase 2	D38LQO	.	CTPDG001827
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NP001	.	.	Phase 1	D1LU7W	.	CTPDG001845
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuedexta	.	.	Phase 2	D0ZR4W	.	CTPDG001854
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SUVN-502	"SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven"	10073773	Phase 2	D0Z0GX	DB06140	CTPDG001870
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	S-38093	"S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier"	11380684	Phase 2	D0XW6Y	.	CTPDG001883
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3202626	.	.	Phase 2	D0XD5N	.	CTPDG001889
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AN-1792	Betabloc; AIP-001	15176	Phase 2	D0X4ZL	.	CTPDG001899
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BI-409306	.	135908617	Phase 2	D0W7UN	.	CTPDG001924
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Methanesulfonyl fluoride	"Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)"	11207	Phase 2	D0W3BA	DB13058	CTPDG001935
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NIC5-15	"D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336"	164619	Phase 2	D0W0NU	DB12969	CTPDG001941
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAM-531	"PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer"	16071605	Phase 2	D0V4ZQ	DB12229	CTPDG001961
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	Phase 2	D0V3CK	.	CTPDG001968
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK933776A	.	.	Phase 2	D0T6KV	.	CTPDG002011
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3002813	.	.	Phase 2	D0SD7G	.	CTPDG002035
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD02 vaccine	.	.	Phase 2	D0S1BF	.	CTPDG002050
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2027	.	.	Phase 1	D0S0FD	.	CTPDG002054
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TTP-448	.	.	Phase 2	D0PU9C	.	CTPDG002107
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CPC-201	.	.	Phase 2	D0PN4D	.	CTPDG002111
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UE-2343	.	.	Phase 2	D0OE5S	.	CTPDG002131
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVP-0962	.	.	Phase 2	D0OB4R	.	CTPDG002132
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	R-phenserine	Posiphen (TN)	11249342	Phase 2	D0O5GK	DB15317	CTPDG002141
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FK-962	"FK-960 analog, Fujisawa"	56842107	Phase 2	D0O3TC	.	CTPDG002143
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAR-110894	SAR-110894D	.	Phase 2	D0O0EX	.	CTPDG002150
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UB-311	.	.	Phase 2	D0NR6T	.	CTPDG002156
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-288	"UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4"	24743471	Phase 2	D0N8QK	DB15192	CTPDG002162
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Oleoyl-estrone	"Anti-obesity hormone-based therapy, Manhattan"	6918373	Phase 2	D0N5CW	DB04870	CTPDG002171
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CERE-110	.	.	Phase 2	D0MP1M	.	CTPDG002184
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HSRx-888	.	.	Phase 2	D0LO2G	.	CTPDG002217
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN 322	.	.	Phase 1	D0L8IO	.	CTPDG002228
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nefiracetam	Motiva (TN)	71157	Phase 2	D0KD5P	DB13082	CTPDG002254
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JOT106	.	.	Phase 2	D0K4JI	.	CTPDG002268
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BPN14770	KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide	90111638	Phase 2	D0IZ8X	.	CTPDG002296
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-5213	.	53342708	Phase 2	D0I6ZO	.	CTPDG002308
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-8E12	C2N-8E12	.	Phase 2	D0H7KQ	.	CTPDG002337
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LymPro	.	.	Phase 2	D0H1YZ	.	CTPDG002341
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AQW-051	669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane	50914822	Phase 2	D0H1AY	.	CTPDG002345
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-717	"CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex"	3323368	Preclinical	D0G3AR	DB05047	CTPDG002374
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-05212377	SAM-760	.	Phase 2	D0G1YA	.	CTPDG002378
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CT1812	Elayta	118278088	Phase 2	D0FX8N	.	CTPDG002384
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY2886721	"1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475"	49837968	Phase 2	D0F8GK	DB12547	CTPDG002396
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CSTC1	"BAC; D-Bacillosamine; Bacillosamine; D-Bac; 2,4-Diamino-2,4,6-Trideoxy-D-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucose; 2,4-Diamino-2,4,6-Trideoxy-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranoside; 2,4-Diamino-2,4,6-Trideoxy-D-Gluc"	54029194	Phase 2	D0ED6O	.	CTPDG002410
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T-817MA	"Edonerpic maleate; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:"	11338749	Phase 2	D0E8HA	.	CTPDG002419
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	KPAX002	.	.	Phase 2	D0E7WH	.	CTPDG002420
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	Bryostatin 1; 83314-01-6	5280757	Phase 2	D0E6AH	.	CTPDG002423
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MIQ-001	"M-IQ 001; Fatty acid metabolism inhibitor (Alzheimer's disease), Meta-IQ"	.	Phase 2	D0E1SV	.	CTPDG002434
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Basmisanil	"1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha"	57336276	Phase 2	D0CH7C	DB11877	CTPDG002474
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ladostigil	"Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326"	208907	Phase 2	D0C3UC	.	CTPDG002488
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NDD-094	NDD-094A; SDZ-NDD-094	.	Phase 2	D0B7LZ	.	CTPDG002508
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ponezumab	"Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219"	.	Phase 2	D0B5EB	.	CTPDG002513
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORM-12741	"Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion"	71301276	Phase 2	D0B3ZF	DB12057	CTPDG002515
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-4447943	BCP16255	135564558	Phase 2	D0A9IY	DB11953	CTPDG002535
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DCB-AD1	.	.	Phase 2	D09BCL	.	CTPDG002589
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-126	.	24987875	Phase 2	D08XOY	.	CTPDG002601
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD4694	.	71306407	Phase 2	D08VDM	.	CTPDG002606
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK239512	"720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K"	9976892	Phase 2	D07YGH	DB15120	CTPDG002657
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ALZ-801	.	25008296	Phase 2	D07VAI	.	CTPDG002666
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SYN-120	.	.	Phase 2	D07RQR	.	CTPDG002673
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VI-1121	.	.	Phase 2	D07KGR	.	CTPDG002691
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI 287	"FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-"	118797983	Phase 1	D07IOT	.	CTPDG002697
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ST-101	"ST 101 [French]; 7-Chloro-1,3-dihydro-5-phenyl-1-trimethylgermyl-2H-1,4-benzodiazepin-2-one; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2 [French]; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylgermyl-; AC1O4GHW; ST 101; LS-34275; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2"	10220323	Phase 2	D07CJN	DB12621	CTPDG002709
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVT302	.	.	Phase 2	D06PHS	.	CTPDG002738
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RP5063	.	.	Phase 1	D05XEA	.	CTPDG002780
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-384	UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide	11670435	Phase 2	D05WCI	DB12501	CTPDG002781
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PRX-3140	.	.	Phase 2	D05BWH	.	CTPDG002818
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Myo-inositol	"Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite"	892	Phase 2	D03SHD	DB03106	CTPDG002906
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CHF-5074	"CHF 5074; CHF5074; 749269-83-8; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261"	9996409	Phase 2	D03MFQ	.	CTPDG002919
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FRM-0962	.	.	Phase 2	D02XKK	.	CTPDG002946
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-7622	"M1 receptor modulator; 1227923-29-6; MK7622; MK 7622; 3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one; SCHEMBL2399084; EX-A804; JUVQLZBJFOGEEO-GOTSBHOMSA-N; BCP27739; ZINC95930184; AKOS028113668; DB12897; CS-5442; HY-15618; Benzo(H)quinazolin-4(3H)-one, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methyl-3-pyridinyl)methyl)-; AS-35236; KB-145903; J-690076; UNII-57R7D1Q49R component JUVQLZBJFOGEEO-GOTSBHOMSA-N"	46207733	Phase 2	D02WFN	DB12897	CTPDG002950
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG1577	.	.	Phase 2	D02PSS	.	CTPDG002962
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BMS-708163	Avagacestat	46883536	Phase 2	D02JOH	DB11893	CTPDG002976
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-0752	"471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635"	9803433	Phase 2	D02HNG	DB12852	CTPDG002978
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GM-602	"Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid"	9875671	Phase 2	D02DEH	.	CTPDG002988
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HF-0220	"Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming"	9836181	Phase 2	D02AOD	DB06622	CTPDG002994
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mibampator	"LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly"	9889366	Phase 2	D01WBD	DB12717	CTPDG003005
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AVN 101	.	.	Phase 2	D01NDF	.	CTPDG003024
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Coluracetam	"BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells"	214346	Phase 2	D01MHI	.	CTPDG003025
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-1446	"TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca"	96568204	Phase 2	D01MAU	.	CTPDG003026
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AUS-131	.	91469	Phase 2	D01HXA	DB11674	CTPDG003039
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	TD-8954	"UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate"	11961293	Phase 1/2	D01HVZ	DB12725	CTPDG003041
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vanutide cridificar	ACC-001	.	Phase 2	D01FBP	.	CTPDG003045
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Neu-P11	"Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819"	24815904	Phase 2	D00CVJ	DB12288	CTPDG003102
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ICA-17043	"Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215"	216327	Phase 2	D00BUR	DB06280	CTPDG003105
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MIB-626	.	.	Phase 1/2	DN0A1J	.	CTPDG003160
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	Xanamem	"(5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone; 1346013-80-6; compound 4 [PMID: 28012176]; GLXC-26582; GTPL12037; SCHEMBL23207782; SCHEMBL23798797; starbld0030988; UE2343; UE-2343; Xanamem"	137530063	Phase 1/2	DJMK69	.	CTPDG003172
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VGH-AD1	.	.	Phase 1/2	DIM79Y	.	CTPDG003177
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	GB301	.	.	Phase 1/2	DBU2J7	.	CTPDG003200
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	"N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide"	18604758	Phase 1/2	D82DMK	.	CTPDG003221
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LX1001	AAVrh.10hAPOE2	.	Phase 1/2	D6UEI3	.	CTPDG003230
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VAC20121	ACI-35	.	Phase 1/2	D3C0LO	.	CTPDG003247
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AL 001	Latozinemab	.	Phase 1/2	D2A6QI	.	CTPDG003251
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AstroStem	.	.	Phase 1/2	D0VD9X	.	CTPDG003296
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	EB-101	"Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals"	.	Phase 1/2	D0TU1E	.	CTPDG011346
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	IONIS-MAPTRx	.	.	Phase 1/2	D0RK4B	.	CTPDG003331
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	ACI-24	"Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune"	.	Phase 1/2	D0R6UR	.	CTPDG003339
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	RVX-208	.	24871506	Phase 1/2	D0N7WW	.	CTPDG003366
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VLP norovirus bivalent vaccine	"VLP norovirus bivalent vaccine (intranasal, norovirus-induced gastroenteritis)"	.	Phase 1/2	D0J3DC	.	CTPDG003404
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	APH-0703	.	.	Phase 1/2	D09QVU	.	CTPDG003487
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	.	.	Phase 1/2	D02XJJ	.	CTPDG003601
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIIB080	.	.	Phase 1/2	D02TWR	.	CTPDG003604
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIL010t	.	.	Phase 1/2	D02AIZ	.	CTPDG003615
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	"1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione"	73441910	Phase 1	DZ76PB	.	CTPDG003647
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD101	"(2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone; (2,4-Dimethylpyridin-3-yl)(4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{3-methyl-4-[1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone; 306293-36-7; AD101; BDBM50104946; CHEMBL113436; DTKUANPECHGGBY-UNMCSNQZSA-N; PD084304; Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2S)-; SCHEMBL4453513"	464036	Phase 1	DYS52Z	.	CTPDG003652
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	IGCAD1	.	.	Phase 1	DWNR12	.	CTPDG003674
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN-322	"1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475"	135905417	Phase 1	DWD06K	.	CTPDG003675
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	J147	"(E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; 1146963-51-0; 1807913-16-1; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; A894156; AC-35232; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; AKOS024458485; AS-16718; CCG-268030; CHEBI:192601; CHEMBL2387144; CS-3688; DB13957; DTXSID501045787; EX-A2235; HMS3886O17; HY-13779; HYMZAYGFKNNHDN-SSDVNMTOSA-N; j147; J-147; MFCD25976644; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; s5269; SCHEMBL12995834; SCHEMBL21294999; UNII-Z41H3C5BT9; Z41H3C5BT9"	25229652	Phase 1	DW4O2J	DB13957	CTPDG003676
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG6289	.	.	Phase 1	DUV3B0	.	CTPDG003698
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASN51	.	.	Phase 1	DS70NZ	.	CTPDG003728
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2511	.	.	Phase 1	DRT09Y	.	CTPDG003737
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SHR-1707	.	.	Phase 1	DPYA76	.	CTPDG003763
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APH-1104	.	.	Phase 1	DNH51Q	.	CTPDG003800
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL919	TAK-920	.	Phase 1	DN48GC	.	CTPDG003808
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NTRX-07	MDA7	.	Phase 1	DK3WQ5	.	CTPDG003852
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAV-hTERT	.	.	Phase 1	DI9X5U	.	CTPDG003881
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL104	.	.	Phase 1	DHD2S9	.	CTPDG003895
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL747	.	.	Phase 1	DGH83L	.	CTPDG003903
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	REM0046127	.	.	Phase 1	DF21MW	.	CTPDG003924
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACU193	.	.	Phase 1	DCP0I8	.	CTPDG003951
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protollin	.	.	Phase 1	DC0DU9	.	CTPDG003960
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	.	.	Phase 1	DB7V3D	.	CTPDG003970
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ALN-APP	.	.	Phase 1	D8W0NQ	.	CTPDG004008
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-4334	.	.	Phase 1	D7PGM4	.	CTPDG004033
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NNI-362	.	.	Phase 1	D6KWF3	.	CTPDG004060
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR588	.	.	Phase 1	D62XNL	.	CTPDG004074
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AL003	.	.	Phase 1	D5QKY2	.	CTPDG004088
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3372993	.	.	Phase 1	D4YD7V	.	CTPDG004104
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MER5101	.	.	Phase 1	D4JPV8	.	CTPDG004117
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	"(4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; 1375752-78-5; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; 3I1803DK5Z; AKOS040756698; BDBM50536712; BMS984923; BMS-984923; CHEMBL4571075; CS-0087012; HY-122559; SCHEMBL4541143; UNII-3I1803DK5Z"	69084898	Phase 1	D34YLZ	.	CTPDG004146
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB113	.	.	Phase 1	D2KV0F	.	CTPDG004163
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-6-Me-BTA-1	Carbon-11-6-Me-BTA-1; 11C-BTA-1	.	Phase 1	D0ZX2D	.	CTPDG004207
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-104	.	.	Phase 1	D0ZW2I	.	CTPDG004210
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	V950 vaccine	.	.	Phase 1	D0Z2HG	.	CTPDG004232
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06751979	"ZLZUHACSRMOLLV-RAALSFIWSA-N; 1818339-66-0; UNII-1Y0Y126GUG; 1Y0Y126GUG; US9315520, Example 1; CHEMBL3952064; US9315520, Example 2; US9315520, Comparator 1; SCHEMBL17162186; BDBM223395; HY-112157; CS-0043501; US9315520, 1; N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide; N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carb"	118435360	Phase 1	D0Y5NA	DB15105	CTPDG004257
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-932481	.	91844660	Phase 1	D0XI4P	.	CTPDG004275
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-354	.	.	Phase 1	D0X9HF	.	CTPDG004280
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Affitope AD-01	"AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS"	.	Phase 1	D0X2UK	.	CTPDG004290
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-212	.	.	Phase 1	D0X1XK	.	CTPDG004293
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR-388	.	.	Phase 1	D0WS4E	.	CTPDG004298
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB076	.	.	Phase 1	D0WL5T	.	CTPDG004303
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-250	.	.	Phase 1	D0WI9W	.	CTPDG004305
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACI-35	.	.	Phase 1	D0W9LS	.	CTPDG004309
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-241027	.	.	Phase 1	D0V9HL	.	CTPDG004340
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD03 vaccine	.	.	Phase 1	D0V3EQ	.	CTPDG004351
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-AZD-2184	"AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184"	.	Phase 1	D0V0VI	.	CTPDG004354
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSI-136	"WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth"	11358855	Phase 1	D0U6FT	DB12819	CTPDG004374
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	18F-FEDAA-1106	"ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer"	.	Phase 1	D0U1US	.	CTPDG004382
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	.	.	Phase 1	D0TQ4Y	.	CTPDG004394
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BCI-632	"LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,"	9886034	Phase 1	D0T3DG	.	CTPDG004411
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ARC031	.	.	Phase 1	D0T0NL	.	CTPDG004413
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-103+RVT-104	.	.	Phase 1	D0S1KR	.	CTPDG004439
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Exebryl-1	Exebryl-1 (TN)	.	Phase 1	D0RD1Z	.	CTPDG004450
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAu mAb	.	.	Phase 1	D0R6WL	.	CTPDG004459
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BAY-1006578	"Diagnostic PET imaging agent (Alzheimer's disease), Bayer"	.	Phase 1	D0O9HG	.	CTPDG004540
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG7129	.	53241828	Phase 1	D0O8UB	.	CTPDG004543
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SAR228810	.	.	Phase 1	D0N9JB	.	CTPDG004573
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GRF6019	.	.	Phase 1	D0N8QR	.	CTPDG004576
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-168	"Alzheimer's diagnostic, IND; 123I-SPECT diagnostic (Alzheimer's disease), IND"	.	Phase 1	D0N3UQ	.	CTPDG004583
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY-2811376	"LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,"	44251605	Phase 1	D0N1BF	DB13065	CTPDG004586
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-330	.	.	Phase 1	D0MU7N	.	CTPDG004589
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SUVN-D4010	"DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole"	71508291	Phase 1	D0M9RI	.	CTPDG004596
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Mesenchymal stem cell therapy	.	.	Phase 1	D0M6AR	.	CTPDG004600
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2184	.	.	Phase 1	D0M0UB	.	CTPDG004608
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP-0777	.	.	Phase 1	D0L1UH	.	CTPDG004640
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NPT088	.	.	Phase 1	D0KN7Y	.	CTPDG004647
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Aleplasinin	"PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth"	10224267	Phase 1	D0JI2E	DB12635	CTPDG004674
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1841	.	.	Phase 1	D0J9PS	.	CTPDG004681
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E-2212	.	46854987	Phase 1	D0I1OS	.	CTPDG004731
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TTP-4000	"Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech"	.	Phase 1	D0I0YS	.	CTPDG004732
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANVS301	Bisnormcerysine	.	Phase 1	D0HRC9	.	CTPDG004738
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2012	870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N	11560787	Phase 1	D0F0JJ	DB05171	CTPDG004815
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NGP 555	"WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine"	46853593	Phase 1	D0EV5O	.	CTPDG004818
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AV-965	.	.	Phase 1	D0EH0C	.	CTPDG004824
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2647544	GSK-2647544	.	Phase 1	D0E6KN	.	CTPDG004830
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NDX-1017	.	.	Phase 1	D0E3CX	.	CTPDG004833
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GC021109	.	.	Phase 1	D0D4HO	.	CTPDG004863
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NsG-0202	"ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene"	.	Phase 1	D0D0GH	.	CTPDG004872
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SGC-1061	.	.	Phase 1	D0B3HP	.	CTPDG004921
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NBXT-001+Nobilis inhalation device	.	.	Phase 1	D0AY8D	.	CTPDG004928
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF20513	.	.	Phase 1	D0A9PD	.	CTPDG004933
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Begacestat	GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953	11269353	Phase 1	D09ZVC	DB12263	CTPDG004953
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	BCI-838	.	.	Discontinued in Phase 1	D09WZU	.	CTPDG004961
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-3328	UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073	44555286	Phase 1	D09PYZ	.	CTPDG004984
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JES-9501	DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride	.	Phase 1	D09MEV	.	CTPDG004992
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAK-071	WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5	92042879	Phase 1	D09BBA	.	CTPDG005012
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANAVEX 2-73	.	46932299	Phase 1	D09AOO	.	CTPDG005014
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SPI-014	"SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals"	46221695	Phase 1	D08XKL	.	CTPDG005020
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	HPP-854	.	.	Phase 1	D08TVI	.	CTPDG005028
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JNJ-63733657	.	.	Phase 1	D07PFU	.	CTPDG005091
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DWP-09031	DWJ-301	.	Phase 1	D06KWU	.	CTPDG005157
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2995	.	.	Phase 1	D06JPY	.	CTPDG005158
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Palomid-529	"P-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma"	.	Phase 1	D06JCO	.	CTPDG005159
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protexia	"RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene"	.	Phase 1	D06FGJ	.	CTPDG005166
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	FGLL	"NCAM mimetics (Alzheimer's disease), Enkam"	.	Phase 1	D06EXI	.	CTPDG005167
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Posiphen R-phenserine	.	.	Phase 1	D05VAE	.	CTPDG005184
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Anti-N3pG-Abeta antibody	.	.	Phase 1	D05ORO	.	CTPDG005192
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CTS-21166	.	.	Phase 1	D04VZS	.	CTPDG005234
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MCD-386	"CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion"	.	Phase 1	D04SIU	.	CTPDG005240
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD-3839	"GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D"	46202416	Phase 1	D04OSA	DB12368	CTPDG005245
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1814	.	.	Phase 1	D04AZT	.	CTPDG005269
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-957	.	.	Phase 1	D03NLQ	.	CTPDG005302
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	XEL 001HP	.	.	Phase 1	D03CCY	.	CTPDG005321
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-05251749	.	.	Phase 1	D03AGK	.	CTPDG005330
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-04995274	"UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, &gt; 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol"	53354764	Phase 1	D02YKI	DB12675	CTPDG005332
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAB-003/PF-05236812	.	.	Phase 1	D01ZSP	.	CTPDG005370
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2981710	.	.	Phase 1	D01YDH	.	CTPDG005373
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP3662	.	44598960	Phase 1	D00UEC	.	CTPDG005437
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAD-2004	"927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID"	16042343	Phase 1	D00MBY	.	CTPDG005453
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	Phase 1	D00EHX	DB12899	CTPDG005470
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	"methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate"	"MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate"	2314952	Clinical trial	D0R7EA	.	CTPDG005492
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	bimatoprost (free acid form)	17-phenyl-omega-trinor-PGF2alpha	5283081	Clinical trial	D08QWQ	.	CTPDG005504
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	JNJ-479655	"1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, &gt; Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide"	66553218	Clinical trial	D07QTG	.	CTPDG005505
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	alpha-ketothiazole analogue 36	"GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide"	16098914	Clinical trial	D05TKW	.	CTPDG005507
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-22	.	19910	Patented	D0KG9M	DB01422	CTPDG005806
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-20	.	.	Patented	D0I9VU	.	CTPDG005858
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-2	.	.	Patented	D0E2AF	.	CTPDG005956
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 2	PMID29324067-Compound-53	.	Patented	D0DW5P	.	CTPDG005961
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID29334795-Compound-22	.	.	Patented	D0B2NV	.	CTPDG006029
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-19	.	.	Patented	D09UJB	.	CTPDG006053
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Thiadiazolyl carboxamide derivative 1	PMID28270010-Compound-Figure18-1	71263688	Patented	D06STX	.	CTPDG006137
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 1	PMID29324067-Compound-43	.	Patented	D05RJG	.	CTPDG006162
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-18	.	.	Patented	D04NCC	.	CTPDG006193
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	Zanapezil	TAK-147	198752	Discontinued in Phase 3	D0AM8W	DB04859	CTPDG006368
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	PF-1913539	"Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261"	176408	Discontinued in Phase 3	D07ESH	.	CTPDG006376
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AZD0328	"AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]"	9794392	Discontinued in Phase 2	D0Q9RR	DB12145	CTPDG006451
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	S-18986	"S 18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine"	637863	Discontinued in Phase 2	D0M0HJ	.	CTPDG006484
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AVN 397	.	.	Discontinued in Phase 2	D0J7EP	.	CTPDG006497
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	DPC-543	.	.	Discontinued in Phase 2	D0I4PL	.	CTPDG006502
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	NGD-97-1	"CP-457,920"	.	Discontinued in Phase 2	D0FN6D	.	CTPDG006521
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	IPENOXAZONE	"MLV-6976; NC-1200; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one"	65882	Discontinued in Phase 2	D0B4EV	.	CTPDG006554
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Ispronicline	RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine	9824145	Discontinued in Phase 2	D0AB4Q	.	CTPDG006559
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	ABT-418	"Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398"	119380	Discontinued in Phase 2	D09ADT	.	CTPDG006574
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Talsaclidine fumarate	"Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane"	6918244	Discontinued in Phase 2	D06ODM	.	CTPDG006603
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Affitope AD-02	"Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals"	.	Discontinued in Phase 2	D06BVT	.	CTPDG006608
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	SIB-1553A	"191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride"	5310968	Discontinued in Phase 2	D00ECO	.	CTPDG006677
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	VP-025	"Inflammation therapeutics, Vasogen; VP-015"	.	Discontinued in Phase 1	D0Y8IS	.	CTPDG006707
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TRx-0037	.	.	Discontinued in Phase 1	D0S9XR	.	CTPDG006743
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	EVT-301	"MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche"	.	Discontinued in Phase 1	D0P1WB	.	CTPDG006760
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	PF-05236812	AAB-003	.	Discontinued in Phase 1	D0K3SV	.	CTPDG006792
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	C-9138	.	.	Discontinued in Phase 1	D0K0XW	.	CTPDG006794
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	SL-25.1188	.	.	Discontinued in Phase 1	D0E3JL	.	CTPDG006819
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	GR-253035	.	.	Discontinued in Phase 1	D0C2HF	.	CTPDG006828
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TAK-065	"Neuroregeneration enhancer (oral, Alzheimers/Parkinsons disease), Takeda"	.	Discontinued in Phase 1	D0A2XD	.	CTPDG006837
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	NP-61	"Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira"	.	Discontinued in Phase 1	D04UKJ	.	CTPDG006894
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	ACC-002	.	.	Phase 0	D0YM4F	.	CTPDG006951
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	INP102	.	.	Phase 0	D0P7BA	.	CTPDG006952
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	AAB-002	.	.	Phase 0	D01QLM	.	CTPDG006954
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	TPT-43	.	.	Preclinical	D0YH9A	.	CTPDG007021
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-1501	"AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals"	.	Preclinical	D0XM3S	.	CTPDG007024
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SPH-1285	"Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359"	.	Preclinical	D0V7FG	.	CTPDG007039
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	ANAVEX 1-41	.	10446473	Preclinical	D0T0UC	.	CTPDG007053
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	VER-155008	"Heat shock protein 70 inhibitor (cancer), Vernalis; Hsp 70 inhibitor (cancer), Vernalis"	25195348	Preclinical	D0H0AU	.	CTPDG007083
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Pepticlere	"DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech"	.	Preclinical	D0G7LP	.	CTPDG007086
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SCH-1359113	"SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough"	23627211	Preclinical	D0E3SX	.	CTPDG007089
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	humanin	formyl humanin	16131438	Preclinical	D09TXO	.	CTPDG007101
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CDD-0199-J	.	.	Preclinical	D09MQQ	.	CTPDG007103
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Alvameline	Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M	178030	Terminated	D0X8MZ	.	CTPDG007181
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Ro-46-5934	.	.	Terminated	D0TK0W	.	CTPDG007215
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	IDRA-21	IDRA-21 analogs; IDRA-5	3688	Terminated	D0S0VZ	.	CTPDG007229
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-99	"Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	132712	Terminated	D0R1VL	.	CTPDG007239
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS-66252	.	9803861	Terminated	D0Q7SO	.	CTPDG007242
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-93426	"ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-"	115210	Terminated	D0P3IE	.	CTPDG007252
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-427	.	.	Terminated	D0O7DN	.	CTPDG007262
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	EHT-1864	"EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit"	9938202	Terminated	D0M9ER	.	CTPDG007276
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CI-1002	PD-142676	9838284	Terminated	D0M2GI	.	CTPDG007282
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BU-4514N	"BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one"	54704416	Terminated	D0L8TN	.	CTPDG007287
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	DNP-004089	"BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo"	.	Terminated	D0K3WN	.	CTPDG007302
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF-8615	.	.	Terminated	D0K0XG	.	CTPDG007305
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-152558	.	.	Terminated	D0J4GQ	.	CTPDG007314
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-649	.	9905818	Terminated	D0G7HO	.	CTPDG007347
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MDL-28170	MDL-2170	72430	Terminated	D0G5ZE	.	CTPDG007348
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-377	.	9860852	Terminated	D0EP5O	.	CTPDG007360
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	R-1315	.	.	Terminated	D0CX2J	.	CTPDG007380
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	L-698544	"7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ"	10220180	Terminated	D0AZ5V	.	CTPDG007398
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GYKI-52466	"102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2"	3538	Terminated	D0A9VO	.	CTPDG007402
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Nerve growth factor	"Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia"	.	Terminated	D0A0MJ	.	CTPDG007406
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-3796	.	.	Terminated	D09IUG	.	CTPDG007420
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NNC-90-0270	"Nicotinic ACh agonists, Novo Nordisk"	.	Terminated	D09GRB	.	CTPDG007422
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-14413	"Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre"	.	Terminated	D08VJI	.	CTPDG007432
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-4001	.	.	Terminated	D08TCU	.	CTPDG007433
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Milacemide	Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S	53569	Terminated	D07OLO	.	CTPDG007457
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sch-57790	CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294	9867750	Terminated	D07IZF	.	CTPDG007461
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF268	"MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet"	5288799	Terminated	D06ZAM	DB04021	CTPDG007467
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Z-4105	"119737-52-9; Butanoic acid, 4-(((3-methyl-5-isoxazolyl)carbonyl)amino)-; Butanoic acid,4-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-; ACMC-20cew8; AC1Q5P7F; SCHEMBL195378; AC1L4P39; CTK4B1474; 4-[(3-methyl-1,2-oxazole-5-carbonyl)amino]butanoic acid; DTXSID50152568; 4-{[(3-methyl-1,2-oxazol-5-yl)carbonyl]amino}butanoic acid"	189689	Terminated	D06PAW	.	CTPDG007475
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RU-33965	"RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-"	129696	Terminated	D05IVZ	.	CTPDG007496
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS 86	"RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl  -D-galactopyranoside; 2-Nitrophenyl; A-D-galactopyranoside"	87934	Terminated	D05HKB	.	CTPDG007497
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-121196	"FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-"	131688	Terminated	D05EKM	.	CTPDG007500
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	AZD-2858	AZD2858; 486424-20-8; AZD 2858; CHEMBL2177161; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide; 3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide; GSK-3 inhibition; 3-amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL8478; SCHEMBL3327702; C21H23N7O3S; EX-A707; AOB6850; MolPort-035-395-808	10138980	Terminated	D04WZK	.	CTPDG007507
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-431	"Clipsin inhibitor, Cephalon"	.	Terminated	D04RDT	.	CTPDG007509
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NP-7557	"Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech"	.	Terminated	D03DFY	.	CTPDG007539
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-2016	GT 2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653	9839975	Terminated	D02YXQ	.	CTPDG007540
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	A-72055	.	.	Terminated	D02VHE	.	CTPDG007544
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ABS-301	"ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS"	.	Terminated	D02UQU	.	CTPDG007545
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-91296	"ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester"	123700	Terminated	D02UIE	.	CTPDG007546
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-140	"Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	10030021	Terminated	D02JNY	.	CTPDG007550
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Bifemelane	Alnert; Celeport; E-0687; MCI-2016; SON-216	2377	Terminated	D02CGY	DB13550	CTPDG007557
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sibopirdine	"DuP-921; EXP-9121; EXP-921; 5H-Cyclopenta[2,1-b:3,4-b']dipyridine, 5,5-bis(4-pyridinylmethyl)-, monohydrate"	195376	Terminated	D01LRH	.	CTPDG007569
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Tenilsetam	CAS-997	65649	Terminated	D00JNL	.	CTPDG007586
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AD-0802	"Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic"	.	Investigative	D0Y9ES	.	CTPDG007656
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	VK-11	"Imaging agent (Alzheimer's disease), Prana"	.	Investigative	D0Y4TQ	.	CTPDG007666
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZD-6319	"Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca"	.	Investigative	D0X2NB	.	CTPDG007732
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PD-2015	"PD-2016; TNF alpha inhibitors (Alzheimers disease); TNF alpha inhibitors (Alzheimers disease), P2D Bioscience"	.	Investigative	D0WO8I	.	CTPDG007740
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CBNU-06	.	.	Investigative	D0WA3T	.	CTPDG007746
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RAP-310	"Small stabilized receptor active peptide (Alzheimers disease), RAPID Pharmaceuticals"	.	Investigative	D0W9OW	.	CTPDG007748
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tideglusib	.	11313622	Phase 2	D0W5WZ	DB12129	CTPDG007762
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DWJ-209	.	.	Investigative	D0W5CI	.	CTPDG007764
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EVP-4473	.	.	Investigative	D0VE4O	.	CTPDG007780
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ReN-004	"Stem cell therapy (neurological disorders), ReNeuron"	.	Investigative	D0UO6M	.	CTPDG007813
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-901	.	.	Investigative	D0T6FY	.	CTPDG007853
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR APLs	NAChR APLs (Alzheimer's disease)	.	Investigative	D0T5ZM	.	CTPDG007855
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	COG-248	"Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease); Neuroprotectant (Alzheimers/Parkinsons disease), Cognosci; Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease), Cognosci"	.	Investigative	D0S2QP	.	CTPDG007894
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ELND-007	"ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan"	53308121	Investigative	D0Q6ZQ	.	CTPDG007946
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	BAN-2203	"Beta amyloid modulator (Alzheimer's disease), BioArctic"	.	Investigative	D0Q5VC	.	CTPDG007953
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Turmeric extracts	"HSS-808; HSS-818; HSS-838; HSS-848; HSS-888; Turmeric extracts (Alzheimer's disease); Turmeric extracts (Alzheimer's disease), HerbalScience"	.	Investigative	D0Q2XN	.	CTPDG007960
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Ginkgo biloba extract	"YY-1224; YY-1824; Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease); Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease), Yuyu Inc"	.	Investigative	D0OB9V	.	CTPDG008000
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SX-AZD1	.	.	Investigative	D0N6EL	.	CTPDG008040
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AIKb2	.	.	Investigative	D0N0SC	.	CTPDG008055
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR alpha 7 APLs	NAChR alpha 7 APLs (Alzheimer's disease)	.	Investigative	D0M7MH	.	CTPDG008070
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	11A1	.	.	Investigative	D0K4WW	.	CTPDG008142
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Gamma-secretase modulators	"Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche"	24781184	Investigative	D0J5SD	.	CTPDG008172
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	MCD-386/glycopyrrolate	"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,"	3494	Investigative	D0IL1B	DB00986	CTPDG008185
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	HL-026	.	.	Investigative	D0IC8P	.	CTPDG008187
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ESN-XX	.	.	Investigative	D0I3OX	.	CTPDG008215
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ETN-001	.	.	Investigative	D0I0ZY	.	CTPDG008222
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DBT-1339	"DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech"	.	Investigative	D0HK7G	.	CTPDG008227
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GRL-11097	"Memapsin 2 inhibitors (Alzheimers); Memapsin 2 inhibitors (Alzheimers), Purdue University/Astellas"	.	Investigative	D0H2VN	.	CTPDG008244
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KNX-Monoclonal204	"KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis"	.	Investigative	D0G4AE	.	CTPDG008271
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KMS-88009	"KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical"	.	Investigative	D0F5UO	.	CTPDG008302
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NGN-9079	"Alzheimer's disease therapy, NeuroGeneration"	.	Investigative	D0F5IS	.	CTPDG008306
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PNB-04	"Alzheimer's disease therapy, PharmaNeuroBoost"	.	Investigative	D0EW4M	.	CTPDG008325
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	IMD-4482	"IMD-4690; PAI-1 inhibitor (oral, Alzheimers disease), IMMD; Plasminogen activator inhibitor-1 inhibitor (oral, Alzheimers disease), Institute of Medicinal Molecular Design"	.	Investigative	D0EW2D	.	CTPDG008326
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Abloid	"Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics"	.	Investigative	D0E5CX	.	CTPDG008345
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Memex	Nicotinomide adenine dinucleotide (NADH)	.	Investigative	D0E0OI	.	CTPDG008353
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-0235-J	.	.	Investigative	D0D7KR	.	CTPDG008371
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-103	"NP-060103; NP-60103; Glycogen synthase kinase-3 inhibitor (Alzheimer's disease), Neuropharma"	.	Investigative	D0D6WF	.	CTPDG008374
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Leptin	Leptin (Alzheimer's disease)	.	Investigative	D0C6TL	.	CTPDG008408
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SP-08	SP-008	.	Investigative	D0C4WY	.	CTPDG008411
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SPI-017	"SPI-017 (oral, Alzheimer's disease)"	.	Investigative	D0C1TT	.	CTPDG008423
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RECALL-VAX	"RV-01; RV-02; Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease); Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease), Intellect Neuroscience"	.	Investigative	D0B4AH	.	CTPDG008454
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CWF-0804	.	.	Investigative	D09NEL	.	CTPDG008535
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACU-0101979	"HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co"	.	Investigative	D09MRY	.	CTPDG008536
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Cystatin C	Cystatin C (Alzheimer's disease)	.	Investigative	D09HVY	.	CTPDG008553
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EDN-OL1	"Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn"	.	Investigative	D07ZDG	.	CTPDG008644
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ADepVac	"DNA vaccine (Alzheimer's disease), University of California Irvine; DNA vaccine (TriGrid electroporation, Alzheimers), Ichor/UCI/IMM"	.	Investigative	D07ZBO	.	CTPDG008646
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Anticalin	Anticalin (Alzheimer's disease)	.	Investigative	D07YAC	.	CTPDG008650
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-518	"AMPA glutamate receptor agonist (Alzheimer's disease), AC Immune"	.	Investigative	D07KMI	.	CTPDG008690
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEN-1500	"SEN-1576; Beta-amyloid aggregation inhibitors (Alzheimer's disease); Beta-amyloid aggregation inhibitors (Alzheimer's disease), Senexis"	54589394	Investigative	D07JKA	.	CTPDG008693
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARN-2966	"ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences"	14936865	Investigative	D07DNV	.	CTPDG008707
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZ-AAV9	"Alzheimers disease gene therapy, RegenX Biosciences; Adeno-associated virus vector-9 based gene therapy (injectable,AD), RegenX Biosciences"	.	Investigative	D06UUE	.	CTPDG008732
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-636	"Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune"	.	Investigative	D06MBR	.	CTPDG008752
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	TKP-1001	"Amyloid-beta modulator (Alzheimer's disease), EUSA Pharma; Amyloid-beta modulator (Alzheimer's disease), Talisker Pharma; Amyloid-beta synthesis modulator (Alzheimer's disease), The Open University"	.	Investigative	D06LRQ	.	CTPDG008753
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-17	"NP-21; NPM-01; NPM-05 series; NPM-05B1; NPM-05B2; Alpha-secreatse activators (oral, Alzheimer's disease), Noscira"	.	Investigative	D05NIO	.	CTPDG008822
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ANA-5	.	.	Investigative	D04ZTA	.	CTPDG008850
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NXD-9062	.	.	Investigative	D04UQS	.	CTPDG008858
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3186	.	.	Investigative	D04TZK	.	CTPDG008860
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	A-887755	.	.	Investigative	D04TPS	.	CTPDG008861
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARC-069	"Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals"	.	Investigative	D04QXW	.	CTPDG008864
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NNI-AD	"NNI-251; NNI-362; NNI-C; NNI-X01; AD therapy (oral), Neuronascent"	.	Investigative	D04OUP	.	CTPDG008871
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZP-2006	"Amyloid precursor protein modulator (AD), AlzProtect/INSERM/University of Lille II"	87057554	Investigative	D04MHP	.	CTPDG008882
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AC-4402	"GABAA receptor inverse agonist (Alzheimer's disease), Dainippon Sumitomo Pharma"	3084937	Investigative	D03TDE	.	CTPDG008935
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GT 1061	.	53483797	Investigative	D03IHA	.	CTPDG008969
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3248	.	.	Investigative	D01ZFM	.	CTPDG009049
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	UC-1011	"UC-2021; UC-2025; GABA A receptor antagonists (Alzheimer's disease); GABA A receptor antagonists (Alzheimer's disease), Umecrine; 3beta-20beta-dihydroxy-5alpha-pregnane; 3beta-20beta-dihydroxy-5alpha-pregnane (Alzheimer's disease), Umecrine"	.	Investigative	D01YGY	.	CTPDG009051
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	F-18 T808	.	.	Investigative	D01SXE	.	CTPDG009066
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-501	.	.	Investigative	D01QNJ	.	CTPDG009082
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Haw-AD-14	.	.	Investigative	D01LBD	.	CTPDG009100
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-190	.	.	Investigative	D01GBV	.	CTPDG009117
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	123I-DRM-106	"DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd"	49801966	Investigative	D01GAZ	.	CTPDG009118
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PN-403	.	.	Investigative	D01FTK	.	CTPDG009120
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Mimovax	"MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS"	.	Investigative	D01BJK	.	CTPDG009132
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEL-103	.	.	Investigative	D00YJD	.	CTPDG009144
M6ACROT03530	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Molecule 22	"MARK3 inhibitors (Alzheimer's disease); MARK3 inhibitors (Alzheimer's disease), Merck & Co"	.	Investigative	D00HDH	.	CTPDG009188
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rivastigmine	Rivastigmine (transdermal patch)	77991	Approved	D0WY5Q	DB00989	CTPDG000074
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Propentofylline propionate	Hextol (TN)	4938	Approved	D0UU9Y	DB06479	CTPDG000111
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Dihydroergotoxine	"Ergotamine, dihydro, methanesulfonate (salt)"	6420006	Approved	D0SP3D	.	CTPDG000148
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Galantamine	"GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol"	9651	Approved	D0R9VR	DB00674	CTPDG000171
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Eicosapentaenoic acid/docosa-hexaenoic acid	"Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN)"	445580	Approved	D0Q5XX	DB03756	CTPDG012556
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Donepezil	"Donepezil (transdermal patch, Alzheimer's disease)"	3152	Approved	D0NS6H	DB00843	CTPDG000257
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved in China	GV-971	.	.	Approved in China	D0FS5O	.	CTPDG000380
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Tacrine	"Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine"	1935	Approved	D0E6YQ	DB00382	CTPDG000406
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Lemborexant	E2006	56944144	Phase 2	D0A7ZK	DB11951	CTPDG000461
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Pexidartinib	PLX-3397	25151352	Approved	D09TAB	DB12978	CTPDG013033
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-florbetaben	.	.	Approved	D07TRF	.	CTPDG000548
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Colostrinin	Colostrinin (TN)	.	Approved	D07NPH	.	CTPDG000558
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Huperzine A	"Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680"	854026	Approved	D06XWB	DB04864	CTPDG000589
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Lecanemab	.	.	Approved	D06XVR	.	CTPDG000590
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	F18-flutemetamol	.	.	Approved	D06XOT	.	CTPDG000591
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Ergoloid mesylate	Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)	592735	Approved	D02IQY	.	CTPDG000752
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Immune globulin	.	.	Approved	D01OWB	.	CTPDG000780
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Memantine	"Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest"	4054	Approved	D01JEU	DB01043	CTPDG000790
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Approved	Aducanumab	.	.	Approved	D00RRU	.	CTPDG000806
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nirogacestat	"Nirogacestat; 1290543-63-3; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01"	46224413	Phase 2	D00GPQ	DB12005	CTPDG000817
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 4	18F-AV-1451	Tau imaging agent)	70957463	Phase 4	D0F4CG	DB14914	CTPDG000847
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NE3107	.	.	Phase 3	D9I6QG	.	CTPDG000924
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Guanfacine	"(2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride; 29110-47-2; 30OMY4G3MK; A902647; A918619; AB01563079_01; AKOS030255657; AKOS030526130; BCP09647; BDBM81984; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; BPBio1_000415; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; BSPBio_000377; C02AC02; C07037; CAS_29110-47-2; CAS-29110-48-3; CCG-204609; CHEBI:5558; CHEMBL862; D08031; DB01018; DTXCID7026944; DTXSID9046944; EINECS 249-442-8; EN300-243924; Estulic; Estulic (Salt/Mix); Estulic (TN); FT-0669067; FT-0669068; GTPL522; Guanfacina; Guanfacina (INN-Spanish); Guanfacina [INN-Spanish]; GUANFACINE; Guanfacine (INN); Guanfacine [INN:BAN]; GUANFACINE [INN]; GUANFACINE [MI]; GUANFACINE [VANDF]; GUANFACINE [WHO-DD]; Guanfacine HCl; Guanfacine hydrochloride (Salt/Mix); Guanfacinum; Guanfacinum (INN-Latin); Guanfacinum [INN-Latin]; HY-17416A; J-017394; L000286; L013430; LON 798 (Salt/Mix); Lopac0_000519; Lopac-G-1043; MRF-0000019; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; N-amidino-2-(2,6-dichlorophenyl)acetamide; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-05; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; NSC 759121; NSC_3519; NSC-759121; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Q5613599; RASPBERRYKETONEGLUCOSIDE; SCHEMBL35094; SDCCGSBI-0050502.P002; SPBio_002298; Tenex (Salt/Mix); Tocris-1030; UNII-30OMY4G3MK"	3519	Phase 3	D8NY3J	DB01018	CTPDG000928
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	BPDO-1603	.	.	Phase 3	D71LNO	.	CTPDG000931
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AXS-05	.	.	Phase 2/3	D3PD8C	.	CTPDG000941
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Remternetug	LY3372993	.	Phase 3	D34FRG	.	CTPDG000944
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Donanemab	.	.	Phase 3	D2ZP0A	.	CTPDG000945
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AR1001	"(-)-methylbenzylamine; (+)-2-Methylbutylp-aminocinnamate; 103-67-3; 7KN7F4X49E; AI3-26793; AKOS000119094; AR1001; Benzenemethanamine, N-methyl-; benzyl methyl amine; benzyl methylamine; Benzyl(methyl)amine; BENZYLAMINE, N-METHYL; Benzylamine, N-methyl-; Benzylmethylamine; benzyl-methylamine; Benzyl-methyl-amine; Benzylmethyl-d3-amine; BRD-K44558320-003-01-7; CHEMBL1338; CS-W007426; DTXSID9048439; EC 203-133-4; EINECS 203-133-4; EN300-18191; F2190-0316; FT-0631560; HNMeBzl; HY-W007426; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H; KBio2_001842; KBio2_004410; KBio2_006978; KBioGR_002247; KBioSS_001842; M0164; methyl benzylamine; Methyl(phenylmethyl)amine; methyl-benzyl amine; Methylbenzylamine; Methylbenzylamine, N-; methylbezylamine; MFCD00008289; MLS004773900; N-(Phenylmethyl)methylamine; N-benzyl methyl amine; N-benzyl methylamine; N-benzylmethanamine; N-benzyl-methyl amine; N-Benzylmethylamine; N-benzyl-methylamine; N-Benzylmethylamine, 97%; N-Benzyl-N-methylamine; N-benzyl-N-methyl-amine; NCGC00166047-01; N-methyl benzyl amine; N-methyl benzylamine; N-methyl -benzylamine; N-Methyl(phenyl)methanamine; N-methyl-1-phenylmethanamine; N-methyl-1-phenyl-methanamine; N-methylbenzenemethanamine; N-methyl-benzenemethanamine; N-methylbenzyl amine; N-methyl-benzyl amine; N-METHYLBENZYLAMINE; N-methyl-benzylamine; N-methyl-N-(phenylmethyl)amine; N-methyl-N-benzyl amine; N-methyl-N-benzylamine; N-Methy-N-benzylamine; NSC 8059; NSC8059; NSC-8059; omega-Methylaminotoluene; Q23978278; Racemic methylbenzyl amine; SCHEMBL2271; SDCCGMLS-0066901.P001; SMR000112361; Spectrum_001362; Spectrum4_001764; Spectrum5_000347; STR02536; UNII-7KN7F4X49E; W-108843; Z57327124"	7669	Phase 3	D1OM8E	.	CTPDG000951
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	GV-971	sodium oligomannate	.	Phase 3	D1KR3N	.	CTPDG000952
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AVP-786	.	25052519	Phase 3	D0Z6IB	.	CTPDG000965
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	NI-101	"BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec"	.	Phase 3	D0Z2GF	.	CTPDG000968
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AC-1204	"isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA"	12311031	Phase 3	D0Y1RN	.	CTPDG000984
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Lanabecestat	"1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane"	67979346	Phase 3	D0Y0EP	DB14814	CTPDG000986
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SB-742457	GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline	11256720	Phase 3	D0R9HI	DB12680	CTPDG001066
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Crenezumab	MABT5102A; RG7412	.	Phase 3	D0R7EQ	.	CTPDG001069
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	verubecestat	example 25 (US8940748)	51352361	Phase 3	D0R4KK	DB12285	CTPDG001070
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Gantenerumab	RG1450	.	Phase 3	D0Q7YZ	.	CTPDG001078
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	PF-4494700	"PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer"	11180124	Phase 3	D0MW7B	DB12689	CTPDG001122
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	acelarin	NUC-1031	11169170	Phase 2	D0M1IN	DB15057	CTPDG001135
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	SI-657	"AC1L9R2T; 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid"	453618	Phase 3	D0E9SZ	.	CTPDG001222
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	EVP-6124	"Encenicline; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626"	46196517	Phase 3	D0D3TX	DB11726	CTPDG001246
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ALZT-OP1	ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen	.	Phase 3	D0CH6B	.	CTPDG001252
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	MIM-D3	"TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen"	9808372	Phase 3	D0C2OR	DB12441	CTPDG001261
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LCS 16	.	.	Phase 3	D0A4DP	.	CTPDG001278
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Bapineuzumab	"AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan"	.	Phase 3	D0A1MX	.	CTPDG001282
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tirapazamine	TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075	135413511	Phase 3	D09XQU	DB04858	CTPDG001290
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	AV 133	.	.	Phase 3	D09NAF	.	CTPDG001302
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tramiprosate	"Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS"	1646	Phase 3	D09DLP	DB06527	CTPDG001314
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	E-2609	"Beta secretase inhibitor (Alzheimer's disease), Eisai"	57827330	Phase 3	D08MHD	DB15391	CTPDG001329
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	(-)-Phenserine	"CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate"	192706	Phase 3	D07CIN	DB04892	CTPDG001369
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	ARC029	"Nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino"	4494	Phase 3	D06GRK	DB06712	CTPDG001378
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Eltoprazine	"Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company"	65853	Phase 2	D06FKC	DB12883	CTPDG001380
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	INM-176	"WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn"	.	Phase 3	D05UXU	.	CTPDG001390
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Xaliproden	"Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine"	128919	Phase 3	D02OJC	DB06393	CTPDG001464
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Tamibarotene	"Tamibarotene (oral, Alzheimer's disease)"	108143	Phase 3	D02GTY	DB04942	CTPDG001471
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Immune globulin + albumin	.	.	Phase 3	D00KLP	.	CTPDG001501
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 3	Solanezumab	.	.	Phase 3	D00CZT	.	CTPDG001504
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD106	.	.	Phase 2/3	DF3UN2	.	CTPDG001516
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Icosapent ethyl	"(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 6GC8A4PAYH; 73310-10-8; 86227-47-6; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound; AB01563352_01; AC-33765; AKOS025295847; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; AMR 101; AMR101; AMR-101; BS-48985; CCG-213714; CHEBI:80366; CHEBI:84883; CHEMBL2095209; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; cis-Eicosapentaenoic acid ethyl ester; CS-5304; D01892; DB08887; DTXSID601018686; E0442; E0853; E-EPA; Eicosapentaenoic acid (ethyl ester); Eicosapentaenoic acid ethyl ester; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; Eicosapentaenoic acid, ethyl ester; Eicosapentaenoicacidethylester; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EN300-25951782; EPA ethyl ester; Epadel; Epadel S; Epadel S (TN); EPA-E; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; ethyl eicosapentaenoate; Ethyl eicosapentaenoic acid; Ethyl EPA; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Ethyl icosapent; ethyl icosapentaenoate; ethyl icosapentate; Ethyl icosapentate (JP17); Ethyl icosapentate [JAN]; Ethyl icosapentate, JAN; ethyl-eicosapentaenoic acid; ethyl-EPA; GTPL7441; HMS2094K19; HY-B0747; ICOSAPENT ETHYL; Icosapent ethyl (USAN); ICOSAPENT ETHYL [ORANGE BOOK]; Icosapent ethyl [USAN]; ICOSAPENT ETHYL [VANDF]; Icosapent ethyl ester; LMFA07010877; MFCD00673476; MND 21; NSC 759597; NSC759597; NSC-759597; Pharmakon1600-01300030; Q5404453; s6466; SBI-0206684.P002; SCHEMBL123305; SR-05000002595; SR-05000002595-1; Timnodonic acid ethyl ester; UNII-6GC8A4PAYH; Vascepa; Vascepa (TN); Vazkepa"	9831415	Phase 2/3	DF29AZ	DB08887	CTPDG001517
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Fosgonimeton	"2093305-05-4; AKOS040757261; ATH-1017; ATH-1017 FREE ACID; CHEMBL5095419; CS-0204081; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate; Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN:INN]; Fosgonimeton [USAN]; H91OA9858J; HY-132814; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; NDX-1017; NDX-1017 FREE ACID; UNII-H91OA9858J; WHO 11782"	156596375	Phase 2/3	DDBY18	.	CTPDG001518
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Ginkgo biloba	.	.	Phase 2/3	D6S9AH	.	CTPDG001520
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Atuzaginstat	"2211981-76-7; Atuzaginstat; Atuzaginstat [INN]; AtuzaginstatCOR388; BDBM453275; CHEMBL5095230; COR388; COR-388; Cyclopentanecarboxamide, N-((1S)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-; DGN7ROZ8EN; EX-A6081; N-((3S)-7-Amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide; N-[(3S)-7-amino-2-oxo-1-(2,3,6-trifluorophenoxy)heptan-3-yl]cyclopentanecarboxamide; SCHEMBL19972758; UNII-DGN7ROZ8EN; US10730826, Compound 1a-non-racemic; US10730826, Compound 1a-racemic"	134347893	Phase 2/3	D58BFC	.	CTPDG001522
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	JNJ-54861911	.	68254185	Phase 2/3	D0T2FP	DB15307	CTPDG001532
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	Plasminogen	.	.	Phase 2/3	D0S4YT	.	CTPDG001533
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	CAD-106	"Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis"	.	Phase 2/3	D0I3VT	.	CTPDG001544
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AMG520	CNP520	.	Phase 2/3	D0H4YD	.	CTPDG001545
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	SI-614	Modified Hyaluronate	.	Phase 2/3	D08QGE	.	CTPDG001559
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2/3	AZD3293	CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099	57404290	Phase 2/3	D01AYX	.	CTPDG001580
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABvac40	.	.	Phase 2	DZQI76	.	CTPDG001594
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AL002	.	.	Phase 2	DYT9B4	.	CTPDG001604
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MLC901	NeuroAiD	.	Phase 2	DYB14S	.	CTPDG001607
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-916	.	.	Phase 2	DY6DS3	.	CTPDG001608
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TB006	.	.	Phase 2	DW7J9D	.	CTPDG001619
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3372689	"2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; CS-0433932; EX-A6549; GLXC-25705; GTPL11953; HY-144681; LY3372689; LY-3372689; MS-26295; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide; SCHEMBL20421995; U0SGP6ZX2V; UNII-U0SGP6ZX2V"	135260636	Phase 2	DVY0C6	.	CTPDG001621
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MP-101	.	.	Phase 2	DSK7I5	.	CTPDG001634
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DHP1401	.	.	Phase 2	DS4CL2	.	CTPDG001638
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CY6463	"2201048-82-8; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; AKOS040757400; CS-0376702; CY6463; CY-6463; EX-A7620; GTKNNCQKFKGSHR-UHFFFAOYSA-N; H7KEN3O8AI; HY-145607; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; IW-6463; MS-25746; SCHEMBL19922804; UNII-H7KEN3O8AI; Zagociguat; Zagociguat [INN]; ZAGOCIGUAT [USAN]"	134304734	Phase 2	DO37EF	.	CTPDG001660
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ID1201	.	.	Phase 2	DM95PZ	.	CTPDG001677
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Benfotiamine	"(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid; 22457-89-2; 22457-89-2 (free acid); 775256-41-2; AC-8280; AKOS015920320; Benfotamine; Benfotiamina; benfotiamine; Benfotiamine (JAN/INN); Benfotiaminum; Benphothiamine; Benzoylthiamine monophosphate; Betivina; Biotamin (TN); BPBio1_000757; BSPBio_000687; CAS-22457-89-2; CCG-220654; CHEBI:41039; CHEMBL4303665; D01255; DB11748; DTXCID1025433; DTXSID3045433; EN300-21694383; HMS1570C09; HMS2097C09; HMS3714C09; MFCD00057343; N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; NCGC00016764-01; NCGC00016764-04; NCGC00179477-01; Prestwick_68; Prestwick2_000654; Prestwick3_000654; S-(2-(N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl)benzothioa; S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; s-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; S-Benzoylthiamine-O-monophosphate; SCHEMBL188070; SCHEMBL19184708; SR-01000872627; SR-01000872627-1; SR-01000872627-2; Tox21_110597; Tox21_110597_1"	3032771	Phase 2	DL7CK2	DB11748	CTPDG001686
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAGE-718	.	.	Phase 2	DI54FM	.	CTPDG001703
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	APH-1105	.	.	Phase 2	DH6G1L	.	CTPDG001708
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuplazid	"Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,  ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate"	11672491	Phase 2	DDI6B0	.	CTPDG001741
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-1942	.	.	Phase 2	DDAH09	.	CTPDG001742
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	"(1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate; 2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-; 2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-; 37O2X55Y9E; 83314-01-6; BDBM50258529; BMY-45618; BRN 4349157; BRYOSTATIN; Bryostatin 1; Bryostatin 1 - CAS 83314-01-6; BRYOSTATIN 1 [MI]; BRYOSTATIN 1 [WHO-DD]; Bryostatin 1, >=99%, solid; Bryostatin-1; CHEBI:88353; CHEMBL449158; CS-0025440; DTXSID8046876; HY-105231; MFCD00893832; MJQUEDHRCUIRLF-TVIXENOKSA-N; NSC 339555; NSC-339555; Q27095907; SCHEMBL182960; UNII-37O2X55Y9E"	5280757	Phase 2	DD8L0V	.	CTPDG001743
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AADvac-1	.	.	Phase 2	DA1L7V	.	CTPDG001761
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NLY01	.	.	Phase 2	D7A5LO	.	CTPDG001783
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD-35	"1531586-58-9; 6'-(2-(1-(Pyridin-2-ylmethyl)piperidin-4-yl)ethyl)spiro[cyClopropane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-7'(6'H)-one; AD-35; BDBM231544; CHEMBL3949886; GLXC-15057; IND-120499; SCHEMBL15598869; starbld0021420; US9346818, I-29; US9346818, I-33; US9346818, I-35"	72707125	Phase 2	D67DST	.	CTPDG001793
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RPh201	.	.	Phase 2	D3YT8E	.	CTPDG001820
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Trontinemab	RG6102	.	Phase 2	D3XP8N	.	CTPDG001821
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI-287	"849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546"	11564168	Phase 1	D3X2TH	.	CTPDG001822
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MW150	"1628502-91-9; 3GF; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; AKOS040758765; BDBM50537600; CHEMBL4129018; CIIVUDIZZJLXCN-UHFFFAOYSA-N; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; compound 8 [PMID: 25676389]; CS-0069509; EPZ68T461K; EX-A3206A; GTPL10524; HY-120111; MS-26255; MW 150; MW01-18-150SRM; MW150; MW-150; NSC785340; NSC-785340; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; Q27453797; SCHEMBL16061104; UNII-EPZ68T461K"	86270361	Phase 2	D38LQO	.	CTPDG001827
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NP001	.	.	Phase 1	D1LU7W	.	CTPDG001845
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nuedexta	.	.	Phase 2	D0ZR4W	.	CTPDG001854
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SUVN-502	"SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven"	10073773	Phase 2	D0Z0GX	DB06140	CTPDG001870
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	S-38093	"S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier"	11380684	Phase 2	D0XW6Y	.	CTPDG001883
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3202626	.	.	Phase 2	D0XD5N	.	CTPDG001889
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AN-1792	Betabloc; AIP-001	15176	Phase 2	D0X4ZL	.	CTPDG001899
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BI-409306	.	135908617	Phase 2	D0W7UN	.	CTPDG001924
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Methanesulfonyl fluoride	"Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)"	11207	Phase 2	D0W3BA	DB13058	CTPDG001935
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NIC5-15	"D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336"	164619	Phase 2	D0W0NU	DB12969	CTPDG001941
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAM-531	"PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer"	16071605	Phase 2	D0V4ZQ	DB12229	CTPDG001961
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	Phase 2	D0V3CK	.	CTPDG001968
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK933776A	.	.	Phase 2	D0T6KV	.	CTPDG002011
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY3002813	.	.	Phase 2	D0SD7G	.	CTPDG002035
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AD02 vaccine	.	.	Phase 2	D0S1BF	.	CTPDG002050
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2027	.	.	Phase 1	D0S0FD	.	CTPDG002054
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	TTP-448	.	.	Phase 2	D0PU9C	.	CTPDG002107
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CPC-201	.	.	Phase 2	D0PN4D	.	CTPDG002111
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UE-2343	.	.	Phase 2	D0OE5S	.	CTPDG002131
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVP-0962	.	.	Phase 2	D0OB4R	.	CTPDG002132
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	R-phenserine	Posiphen (TN)	11249342	Phase 2	D0O5GK	DB15317	CTPDG002141
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FK-962	"FK-960 analog, Fujisawa"	56842107	Phase 2	D0O3TC	.	CTPDG002143
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SAR-110894	SAR-110894D	.	Phase 2	D0O0EX	.	CTPDG002150
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	UB-311	.	.	Phase 2	D0NR6T	.	CTPDG002156
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-288	"UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4"	24743471	Phase 2	D0N8QK	DB15192	CTPDG002162
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Oleoyl-estrone	"Anti-obesity hormone-based therapy, Manhattan"	6918373	Phase 2	D0N5CW	DB04870	CTPDG002171
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CERE-110	.	.	Phase 2	D0MP1M	.	CTPDG002184
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HSRx-888	.	.	Phase 2	D0LO2G	.	CTPDG002217
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN 322	.	.	Phase 1	D0L8IO	.	CTPDG002228
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Nefiracetam	Motiva (TN)	71157	Phase 2	D0KD5P	DB13082	CTPDG002254
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	JOT106	.	.	Phase 2	D0K4JI	.	CTPDG002268
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BPN14770	KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide	90111638	Phase 2	D0IZ8X	.	CTPDG002296
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-5213	.	53342708	Phase 2	D0I6ZO	.	CTPDG002308
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABBV-8E12	C2N-8E12	.	Phase 2	D0H7KQ	.	CTPDG002337
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LymPro	.	.	Phase 2	D0H1YZ	.	CTPDG002341
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AQW-051	669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane	50914822	Phase 2	D0H1AY	.	CTPDG002345
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-717	"CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex"	3323368	Preclinical	D0G3AR	DB05047	CTPDG002374
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-05212377	SAM-760	.	Phase 2	D0G1YA	.	CTPDG002378
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CT1812	Elayta	118278088	Phase 2	D0FX8N	.	CTPDG002384
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	LY2886721	"1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475"	49837968	Phase 2	D0F8GK	DB12547	CTPDG002396
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CSTC1	"BAC; D-Bacillosamine; Bacillosamine; D-Bac; 2,4-Diamino-2,4,6-Trideoxy-D-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucose; 2,4-Diamino-2,4,6-Trideoxy-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranoside; 2,4-Diamino-2,4,6-Trideoxy-D-Gluc"	54029194	Phase 2	D0ED6O	.	CTPDG002410
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	T-817MA	"Edonerpic maleate; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:"	11338749	Phase 2	D0E8HA	.	CTPDG002419
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	KPAX002	.	.	Phase 2	D0E7WH	.	CTPDG002420
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Bryostatin-1	Bryostatin 1; 83314-01-6	5280757	Phase 2	D0E6AH	.	CTPDG002423
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MIQ-001	"M-IQ 001; Fatty acid metabolism inhibitor (Alzheimer's disease), Meta-IQ"	.	Phase 2	D0E1SV	.	CTPDG002434
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Basmisanil	"1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha"	57336276	Phase 2	D0CH7C	DB11877	CTPDG002474
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ladostigil	"Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326"	208907	Phase 2	D0C3UC	.	CTPDG002488
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	NDD-094	NDD-094A; SDZ-NDD-094	.	Phase 2	D0B7LZ	.	CTPDG002508
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Ponezumab	"Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219"	.	Phase 2	D0B5EB	.	CTPDG002513
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ORM-12741	"Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion"	71301276	Phase 2	D0B3ZF	DB12057	CTPDG002515
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PF-4447943	BCP16255	135564558	Phase 2	D0A9IY	DB11953	CTPDG002535
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DCB-AD1	.	.	Phase 2	D09BCL	.	CTPDG002589
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-126	.	24987875	Phase 2	D08XOY	.	CTPDG002601
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD4694	.	71306407	Phase 2	D08VDM	.	CTPDG002606
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GSK239512	"720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K"	9976892	Phase 2	D07YGH	DB15120	CTPDG002657
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ALZ-801	.	25008296	Phase 2	D07VAI	.	CTPDG002666
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	SYN-120	.	.	Phase 2	D07RQR	.	CTPDG002673
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VI-1121	.	.	Phase 2	D07KGR	.	CTPDG002691
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TPI 287	"FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-"	118797983	Phase 1	D07IOT	.	CTPDG002697
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ST-101	"ST 101 [French]; 7-Chloro-1,3-dihydro-5-phenyl-1-trimethylgermyl-2H-1,4-benzodiazepin-2-one; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2 [French]; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylgermyl-; AC1O4GHW; ST 101; LS-34275; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2"	10220323	Phase 2	D07CJN	DB12621	CTPDG002709
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	EVT302	.	.	Phase 2	D06PHS	.	CTPDG002738
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RP5063	.	.	Phase 1	D05XEA	.	CTPDG002780
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ABT-384	UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide	11670435	Phase 2	D05WCI	DB12501	CTPDG002781
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PRX-3140	.	.	Phase 2	D05BWH	.	CTPDG002818
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Myo-inositol	"Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite"	892	Phase 2	D03SHD	DB03106	CTPDG002906
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	CHF-5074	"CHF 5074; CHF5074; 749269-83-8; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261"	9996409	Phase 2	D03MFQ	.	CTPDG002919
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	FRM-0962	.	.	Phase 2	D02XKK	.	CTPDG002946
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-7622	"M1 receptor modulator; 1227923-29-6; MK7622; MK 7622; 3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one; SCHEMBL2399084; EX-A804; JUVQLZBJFOGEEO-GOTSBHOMSA-N; BCP27739; ZINC95930184; AKOS028113668; DB12897; CS-5442; HY-15618; Benzo(H)quinazolin-4(3H)-one, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methyl-3-pyridinyl)methyl)-; AS-35236; KB-145903; J-690076; UNII-57R7D1Q49R component JUVQLZBJFOGEEO-GOTSBHOMSA-N"	46207733	Phase 2	D02WFN	DB12897	CTPDG002950
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG1577	.	.	Phase 2	D02PSS	.	CTPDG002962
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	BMS-708163	Avagacestat	46883536	Phase 2	D02JOH	DB11893	CTPDG002976
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	MK-0752	"471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635"	9803433	Phase 2	D02HNG	DB12852	CTPDG002978
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	GM-602	"Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid"	9875671	Phase 2	D02DEH	.	CTPDG002988
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	HF-0220	"Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming"	9836181	Phase 2	D02AOD	DB06622	CTPDG002994
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mibampator	"LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly"	9889366	Phase 2	D01WBD	DB12717	CTPDG003005
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AVN 101	.	.	Phase 2	D01NDF	.	CTPDG003024
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Coluracetam	"BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells"	214346	Phase 2	D01MHI	.	CTPDG003025
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AZD-1446	"TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca"	96568204	Phase 2	D01MAU	.	CTPDG003026
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	AUS-131	.	91469	Phase 2	D01HXA	DB11674	CTPDG003039
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	TD-8954	"UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate"	11961293	Phase 1/2	D01HVZ	DB12725	CTPDG003041
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Vanutide cridificar	ACC-001	.	Phase 2	D01FBP	.	CTPDG003045
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Neu-P11	"Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819"	24815904	Phase 2	D00CVJ	DB12288	CTPDG003102
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	ICA-17043	"Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215"	216327	Phase 2	D00BUR	DB06280	CTPDG003105
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MIB-626	.	.	Phase 1/2	DN0A1J	.	CTPDG003160
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	Xanamem	"(5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone; 1346013-80-6; compound 4 [PMID: 28012176]; GLXC-26582; GTPL12037; SCHEMBL23207782; SCHEMBL23798797; starbld0030988; UE2343; UE-2343; Xanamem"	137530063	Phase 1/2	DJMK69	.	CTPDG003172
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VGH-AD1	.	.	Phase 1/2	DIM79Y	.	CTPDG003177
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	GB301	.	.	Phase 1/2	DBU2J7	.	CTPDG003200
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	"N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide"	18604758	Phase 1/2	D82DMK	.	CTPDG003221
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LX1001	AAVrh.10hAPOE2	.	Phase 1/2	D6UEI3	.	CTPDG003230
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VAC20121	ACI-35	.	Phase 1/2	D3C0LO	.	CTPDG003247
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AL 001	Latozinemab	.	Phase 1/2	D2A6QI	.	CTPDG003251
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	AstroStem	.	.	Phase 1/2	D0VD9X	.	CTPDG003296
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	EB-101	"Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals"	.	Phase 1/2	D0TU1E	.	CTPDG011346
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	IONIS-MAPTRx	.	.	Phase 1/2	D0RK4B	.	CTPDG003331
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	ACI-24	"Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune"	.	Phase 1/2	D0R6UR	.	CTPDG003339
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	RVX-208	.	24871506	Phase 1/2	D0N7WW	.	CTPDG003366
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	VLP norovirus bivalent vaccine	"VLP norovirus bivalent vaccine (intranasal, norovirus-induced gastroenteritis)"	.	Phase 1/2	D0J3DC	.	CTPDG003404
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	APH-0703	.	.	Phase 1/2	D09QVU	.	CTPDG003487
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	LM11A-31	.	.	Phase 1/2	D02XJJ	.	CTPDG003601
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIIB080	.	.	Phase 1/2	D02TWR	.	CTPDG003604
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	BIL010t	.	.	Phase 1/2	D02AIZ	.	CTPDG003615
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	"1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione"	73441910	Phase 1	DZ76PB	.	CTPDG003647
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD101	"(2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone; (2,4-Dimethylpyridin-3-yl)(4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{3-methyl-4-[1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone; 306293-36-7; AD101; BDBM50104946; CHEMBL113436; DTKUANPECHGGBY-UNMCSNQZSA-N; PD084304; Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2S)-; SCHEMBL4453513"	464036	Phase 1	DYS52Z	.	CTPDG003652
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	IGCAD1	.	.	Phase 1	DWNR12	.	CTPDG003674
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AVN-322	"1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475"	135905417	Phase 1	DWD06K	.	CTPDG003675
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	J147	"(E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; 1146963-51-0; 1807913-16-1; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; A894156; AC-35232; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; AKOS024458485; AS-16718; CCG-268030; CHEBI:192601; CHEMBL2387144; CS-3688; DB13957; DTXSID501045787; EX-A2235; HMS3886O17; HY-13779; HYMZAYGFKNNHDN-SSDVNMTOSA-N; j147; J-147; MFCD25976644; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; s5269; SCHEMBL12995834; SCHEMBL21294999; UNII-Z41H3C5BT9; Z41H3C5BT9"	25229652	Phase 1	DW4O2J	DB13957	CTPDG003676
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG6289	.	.	Phase 1	DUV3B0	.	CTPDG003698
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASN51	.	.	Phase 1	DS70NZ	.	CTPDG003728
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2511	.	.	Phase 1	DRT09Y	.	CTPDG003737
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SHR-1707	.	.	Phase 1	DPYA76	.	CTPDG003763
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	APH-1104	.	.	Phase 1	DNH51Q	.	CTPDG003800
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL919	TAK-920	.	Phase 1	DN48GC	.	CTPDG003808
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NTRX-07	MDA7	.	Phase 1	DK3WQ5	.	CTPDG003852
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAV-hTERT	.	.	Phase 1	DI9X5U	.	CTPDG003881
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL104	.	.	Phase 1	DHD2S9	.	CTPDG003895
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DNL747	.	.	Phase 1	DGH83L	.	CTPDG003903
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	REM0046127	.	.	Phase 1	DF21MW	.	CTPDG003924
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACU193	.	.	Phase 1	DCP0I8	.	CTPDG003951
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protollin	.	.	Phase 1	DC0DU9	.	CTPDG003960
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	.	.	Phase 1	DB7V3D	.	CTPDG003970
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ALN-APP	.	.	Phase 1	D8W0NQ	.	CTPDG004008
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-4334	.	.	Phase 1	D7PGM4	.	CTPDG004033
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NNI-362	.	.	Phase 1	D6KWF3	.	CTPDG004060
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR588	.	.	Phase 1	D62XNL	.	CTPDG004074
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AL003	.	.	Phase 1	D5QKY2	.	CTPDG004088
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3372993	.	.	Phase 1	D4YD7V	.	CTPDG004104
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MER5101	.	.	Phase 1	D4JPV8	.	CTPDG004117
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-984923	"(4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; 1375752-78-5; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; 3I1803DK5Z; AKOS040756698; BDBM50536712; BMS984923; BMS-984923; CHEMBL4571075; CS-0087012; HY-122559; SCHEMBL4541143; UNII-3I1803DK5Z"	69084898	Phase 1	D34YLZ	.	CTPDG004146
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB113	.	.	Phase 1	D2KV0F	.	CTPDG004163
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-6-Me-BTA-1	Carbon-11-6-Me-BTA-1; 11C-BTA-1	.	Phase 1	D0ZX2D	.	CTPDG004207
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-104	.	.	Phase 1	D0ZW2I	.	CTPDG004210
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	V950 vaccine	.	.	Phase 1	D0Z2HG	.	CTPDG004232
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06751979	"ZLZUHACSRMOLLV-RAALSFIWSA-N; 1818339-66-0; UNII-1Y0Y126GUG; 1Y0Y126GUG; US9315520, Example 1; CHEMBL3952064; US9315520, Example 2; US9315520, Comparator 1; SCHEMBL17162186; BDBM223395; HY-112157; CS-0043501; US9315520, 1; N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide; N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carb"	118435360	Phase 1	D0Y5NA	DB15105	CTPDG004257
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-932481	.	91844660	Phase 1	D0XI4P	.	CTPDG004275
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-354	.	.	Phase 1	D0X9HF	.	CTPDG004280
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Affitope AD-01	"AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS"	.	Phase 1	D0X2UK	.	CTPDG004290
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-212	.	.	Phase 1	D0X1XK	.	CTPDG004293
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	COR-388	.	.	Phase 1	D0WS4E	.	CTPDG004298
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BIIB076	.	.	Phase 1	D0WL5T	.	CTPDG004303
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CPC-250	.	.	Phase 1	D0WI9W	.	CTPDG004305
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ACI-35	.	.	Phase 1	D0W9LS	.	CTPDG004309
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BMS-241027	.	.	Phase 1	D0V9HL	.	CTPDG004340
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AD03 vaccine	.	.	Phase 1	D0V3EQ	.	CTPDG004351
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	11C-AZD-2184	"AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184"	.	Phase 1	D0V0VI	.	CTPDG004354
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSI-136	"WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth"	11358855	Phase 1	D0U6FT	DB12819	CTPDG004374
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	18F-FEDAA-1106	"ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer"	.	Phase 1	D0U1US	.	CTPDG004382
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-06648671	.	.	Phase 1	D0TQ4Y	.	CTPDG004394
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BCI-632	"LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,"	9886034	Phase 1	D0T3DG	.	CTPDG004411
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ARC031	.	.	Phase 1	D0T0NL	.	CTPDG004413
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RVT-103+RVT-104	.	.	Phase 1	D0S1KR	.	CTPDG004439
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Exebryl-1	Exebryl-1 (TN)	.	Phase 1	D0RD1Z	.	CTPDG004450
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAu mAb	.	.	Phase 1	D0R6WL	.	CTPDG004459
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	BAY-1006578	"Diagnostic PET imaging agent (Alzheimer's disease), Bayer"	.	Phase 1	D0O9HG	.	CTPDG004540
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	RG7129	.	53241828	Phase 1	D0O8UB	.	CTPDG004543
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SAR228810	.	.	Phase 1	D0N9JB	.	CTPDG004573
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GRF6019	.	.	Phase 1	D0N8QR	.	CTPDG004576
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-168	"Alzheimer's diagnostic, IND; 123I-SPECT diagnostic (Alzheimer's disease), IND"	.	Phase 1	D0N3UQ	.	CTPDG004583
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY-2811376	"LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,"	44251605	Phase 1	D0N1BF	DB13065	CTPDG004586
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	123I-MNI-330	.	.	Phase 1	D0MU7N	.	CTPDG004589
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SUVN-D4010	"DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole"	71508291	Phase 1	D0M9RI	.	CTPDG004596
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Mesenchymal stem cell therapy	.	.	Phase 1	D0M6AR	.	CTPDG004600
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2184	.	.	Phase 1	D0M0UB	.	CTPDG004608
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP-0777	.	.	Phase 1	D0L1UH	.	CTPDG004640
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NPT088	.	.	Phase 1	D0KN7Y	.	CTPDG004647
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Aleplasinin	"PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth"	10224267	Phase 1	D0JI2E	DB12635	CTPDG004674
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1841	.	.	Phase 1	D0J9PS	.	CTPDG004681
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E-2212	.	46854987	Phase 1	D0I1OS	.	CTPDG004731
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TTP-4000	"Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech"	.	Phase 1	D0I0YS	.	CTPDG004732
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANVS301	Bisnormcerysine	.	Phase 1	D0HRC9	.	CTPDG004738
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	E2012	870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N	11560787	Phase 1	D0F0JJ	DB05171	CTPDG004815
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NGP 555	"WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine"	46853593	Phase 1	D0EV5O	.	CTPDG004818
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AV-965	.	.	Phase 1	D0EH0C	.	CTPDG004824
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2647544	GSK-2647544	.	Phase 1	D0E6KN	.	CTPDG004830
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NDX-1017	.	.	Phase 1	D0E3CX	.	CTPDG004833
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GC021109	.	.	Phase 1	D0D4HO	.	CTPDG004863
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NsG-0202	"ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene"	.	Phase 1	D0D0GH	.	CTPDG004872
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SGC-1061	.	.	Phase 1	D0B3HP	.	CTPDG004921
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	NBXT-001+Nobilis inhalation device	.	.	Phase 1	D0AY8D	.	CTPDG004928
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Lu AF20513	.	.	Phase 1	D0A9PD	.	CTPDG004933
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Begacestat	GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953	11269353	Phase 1	D09ZVC	DB12263	CTPDG004953
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	BCI-838	.	.	Discontinued in Phase 1	D09WZU	.	CTPDG004961
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MK-3328	UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073	44555286	Phase 1	D09PYZ	.	CTPDG004984
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JES-9501	DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride	.	Phase 1	D09MEV	.	CTPDG004992
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TAK-071	WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5	92042879	Phase 1	D09BBA	.	CTPDG005012
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ANAVEX 2-73	.	46932299	Phase 1	D09AOO	.	CTPDG005014
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SPI-014	"SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals"	46221695	Phase 1	D08XKL	.	CTPDG005020
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	HPP-854	.	.	Phase 1	D08TVI	.	CTPDG005028
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	JNJ-63733657	.	.	Phase 1	D07PFU	.	CTPDG005091
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	SOR-C13	.	121596688	Phase 1	D06UWF	DB15366	CTPDG005136
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	DWP-09031	DWJ-301	.	Phase 1	D06KWU	.	CTPDG005157
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD2995	.	.	Phase 1	D06JPY	.	CTPDG005158
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Palomid-529	"P-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma"	.	Phase 1	D06JCO	.	CTPDG005159
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Protexia	"RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene"	.	Phase 1	D06FGJ	.	CTPDG005166
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	FGLL	"NCAM mimetics (Alzheimer's disease), Enkam"	.	Phase 1	D06EXI	.	CTPDG005167
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Posiphen R-phenserine	.	.	Phase 1	D05VAE	.	CTPDG005184
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	Anti-N3pG-Abeta antibody	.	.	Phase 1	D05ORO	.	CTPDG005192
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	CTS-21166	.	.	Phase 1	D04VZS	.	CTPDG005234
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MCD-386	"CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion"	.	Phase 1	D04SIU	.	CTPDG005240
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AZD-3839	"GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D"	46202416	Phase 1	D04OSA	DB12368	CTPDG005245
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	MEDI1814	.	.	Phase 1	D04AZT	.	CTPDG005269
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ABT-957	.	.	Phase 1	D03NLQ	.	CTPDG005302
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	XEL 001HP	.	.	Phase 1	D03CCY	.	CTPDG005321
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-05251749	.	.	Phase 1	D03AGK	.	CTPDG005330
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	PF-04995274	"UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, &gt; 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol"	53354764	Phase 1	D02YKI	DB12675	CTPDG005332
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAB-003/PF-05236812	.	.	Phase 1	D01ZSP	.	CTPDG005370
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	GSK2981710	.	.	Phase 1	D01YDH	.	CTPDG005373
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	ASP3662	.	44598960	Phase 1	D00UEC	.	CTPDG005437
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	AAD-2004	"927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID"	16042343	Phase 1	D00MBY	.	CTPDG005453
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 1	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	Phase 1	D00EHX	DB12899	CTPDG005470
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	"methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate"	"MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate"	2314952	Clinical trial	D0R7EA	.	CTPDG005492
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	bimatoprost (free acid form)	17-phenyl-omega-trinor-PGF2alpha	5283081	Clinical trial	D08QWQ	.	CTPDG005504
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	JNJ-479655	"1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, &gt; Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide"	66553218	Clinical trial	D07QTG	.	CTPDG005505
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Clinical trial	alpha-ketothiazole analogue 36	"GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide"	16098914	Clinical trial	D05TKW	.	CTPDG005507
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-22	.	19910	Patented	D0KG9M	DB01422	CTPDG005806
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-20	.	.	Patented	D0I9VU	.	CTPDG005858
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID27998201-Compound-2	.	.	Patented	D0E2AF	.	CTPDG005956
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 2	PMID29324067-Compound-53	.	Patented	D0DW5P	.	CTPDG005961
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID29334795-Compound-22	.	.	Patented	D0B2NV	.	CTPDG006029
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-19	.	.	Patented	D09UJB	.	CTPDG006053
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Thiadiazolyl carboxamide derivative 1	PMID28270010-Compound-Figure18-1	71263688	Patented	D06STX	.	CTPDG006137
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	Schiff base compound 1	PMID29324067-Compound-43	.	Patented	D05RJG	.	CTPDG006162
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Patented	PMID28350212-Compound-18	.	.	Patented	D04NCC	.	CTPDG006193
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	Zanapezil	TAK-147	198752	Discontinued in Phase 3	D0AM8W	DB04859	CTPDG006368
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 3	PF-1913539	"Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261"	176408	Discontinued in Phase 3	D07ESH	.	CTPDG006376
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AZD0328	"AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]"	9794392	Discontinued in Phase 2	D0Q9RR	DB12145	CTPDG006451
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	S-18986	"S 18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine"	637863	Discontinued in Phase 2	D0M0HJ	.	CTPDG006484
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	AVN 397	.	.	Discontinued in Phase 2	D0J7EP	.	CTPDG006497
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	DPC-543	.	.	Discontinued in Phase 2	D0I4PL	.	CTPDG006502
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	NGD-97-1	"CP-457,920"	.	Discontinued in Phase 2	D0FN6D	.	CTPDG006521
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	IPENOXAZONE	"MLV-6976; NC-1200; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one"	65882	Discontinued in Phase 2	D0B4EV	.	CTPDG006554
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Ispronicline	RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine	9824145	Discontinued in Phase 2	D0AB4Q	.	CTPDG006559
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	ABT-418	"Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398"	119380	Discontinued in Phase 2	D09ADT	.	CTPDG006574
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Talsaclidine fumarate	"Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane"	6918244	Discontinued in Phase 2	D06ODM	.	CTPDG006603
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	Affitope AD-02	"Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals"	.	Discontinued in Phase 2	D06BVT	.	CTPDG006608
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 2	SIB-1553A	"191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride"	5310968	Discontinued in Phase 2	D00ECO	.	CTPDG006677
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	VP-025	"Inflammation therapeutics, Vasogen; VP-015"	.	Discontinued in Phase 1	D0Y8IS	.	CTPDG006707
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TRx-0037	.	.	Discontinued in Phase 1	D0S9XR	.	CTPDG006743
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	EVT-301	"MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche"	.	Discontinued in Phase 1	D0P1WB	.	CTPDG006760
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	PF-05236812	AAB-003	.	Discontinued in Phase 1	D0K3SV	.	CTPDG006792
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	C-9138	.	.	Discontinued in Phase 1	D0K0XW	.	CTPDG006794
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	SL-25.1188	.	.	Discontinued in Phase 1	D0E3JL	.	CTPDG006819
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	GR-253035	.	.	Discontinued in Phase 1	D0C2HF	.	CTPDG006828
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	TAK-065	"Neuroregeneration enhancer (oral, Alzheimers/Parkinsons disease), Takeda"	.	Discontinued in Phase 1	D0A2XD	.	CTPDG006837
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Discontinued in Phase 1	NP-61	"Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira"	.	Discontinued in Phase 1	D04UKJ	.	CTPDG006894
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	ACC-002	.	.	Phase 0	D0YM4F	.	CTPDG006951
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	INP102	.	.	Phase 0	D0P7BA	.	CTPDG006952
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 0	AAB-002	.	.	Phase 0	D01QLM	.	CTPDG006954
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	TPT-43	.	.	Preclinical	D0YH9A	.	CTPDG007021
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CX-1501	"AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals"	.	Preclinical	D0XM3S	.	CTPDG007024
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SPH-1285	"Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359"	.	Preclinical	D0V7FG	.	CTPDG007039
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	ANAVEX 1-41	.	10446473	Preclinical	D0T0UC	.	CTPDG007053
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	VER-155008	"Heat shock protein 70 inhibitor (cancer), Vernalis; Hsp 70 inhibitor (cancer), Vernalis"	25195348	Preclinical	D0H0AU	.	CTPDG007083
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	Pepticlere	"DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech"	.	Preclinical	D0G7LP	.	CTPDG007086
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	SCH-1359113	"SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough"	23627211	Preclinical	D0E3SX	.	CTPDG007089
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	humanin	formyl humanin	16131438	Preclinical	D09TXO	.	CTPDG007101
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Preclinical	CDD-0199-J	.	.	Preclinical	D09MQQ	.	CTPDG007103
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Alvameline	Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M	178030	Terminated	D0X8MZ	.	CTPDG007181
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Ro-46-5934	.	.	Terminated	D0TK0W	.	CTPDG007215
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	IDRA-21	IDRA-21 analogs; IDRA-5	3688	Terminated	D0S0VZ	.	CTPDG007229
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-99	"Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	132712	Terminated	D0R1VL	.	CTPDG007239
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS-66252	.	9803861	Terminated	D0Q7SO	.	CTPDG007242
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-93426	"ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-"	115210	Terminated	D0P3IE	.	CTPDG007252
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-427	.	.	Terminated	D0O7DN	.	CTPDG007262
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	EHT-1864	"EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit"	9938202	Terminated	D0M9ER	.	CTPDG007276
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CI-1002	PD-142676	9838284	Terminated	D0M2GI	.	CTPDG007282
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BU-4514N	"BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one"	54704416	Terminated	D0L8TN	.	CTPDG007287
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	DNP-004089	"BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo"	.	Terminated	D0K3WN	.	CTPDG007302
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF-8615	.	.	Terminated	D0K0XG	.	CTPDG007305
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-152558	.	.	Terminated	D0J4GQ	.	CTPDG007314
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-649	.	9905818	Terminated	D0G7HO	.	CTPDG007347
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MDL-28170	MDL-2170	72430	Terminated	D0G5ZE	.	CTPDG007348
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NS-377	.	9860852	Terminated	D0EP5O	.	CTPDG007360
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	R-1315	.	.	Terminated	D0CX2J	.	CTPDG007380
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	L-698544	"7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ"	10220180	Terminated	D0AZ5V	.	CTPDG007398
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GYKI-52466	"102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2"	3538	Terminated	D0A9VO	.	CTPDG007402
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Nerve growth factor	"Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia"	.	Terminated	D0A0MJ	.	CTPDG007406
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-3796	.	.	Terminated	D09IUG	.	CTPDG007420
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NNC-90-0270	"Nicotinic ACh agonists, Novo Nordisk"	.	Terminated	D09GRB	.	CTPDG007422
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	F-14413	"Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre"	.	Terminated	D08VJI	.	CTPDG007432
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-4001	.	.	Terminated	D08TCU	.	CTPDG007433
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Milacemide	Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S	53569	Terminated	D07OLO	.	CTPDG007457
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sch-57790	CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294	9867750	Terminated	D07IZF	.	CTPDG007461
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	MF268	"MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet"	5288799	Terminated	D06ZAM	DB04021	CTPDG007467
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Z-4105	"119737-52-9; Butanoic acid, 4-(((3-methyl-5-isoxazolyl)carbonyl)amino)-; Butanoic acid,4-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-; ACMC-20cew8; AC1Q5P7F; SCHEMBL195378; AC1L4P39; CTK4B1474; 4-[(3-methyl-1,2-oxazole-5-carbonyl)amino]butanoic acid; DTXSID50152568; 4-{[(3-methyl-1,2-oxazol-5-yl)carbonyl]amino}butanoic acid"	189689	Terminated	D06PAW	.	CTPDG007475
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RU-33965	"RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-"	129696	Terminated	D05IVZ	.	CTPDG007496
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	RS 86	"RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl  -D-galactopyranoside; 2-Nitrophenyl; A-D-galactopyranoside"	87934	Terminated	D05HKB	.	CTPDG007497
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	FR-121196	"FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-"	131688	Terminated	D05EKM	.	CTPDG007500
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	AZD-2858	AZD2858; 486424-20-8; AZD 2858; CHEMBL2177161; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide; 3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide; GSK-3 inhibition; 3-amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL8478; SCHEMBL3327702; C21H23N7O3S; EX-A707; AOB6850; MolPort-035-395-808	10138980	Terminated	D04WZK	.	CTPDG007507
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	CEP-431	"Clipsin inhibitor, Cephalon"	.	Terminated	D04RDT	.	CTPDG007509
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	NP-7557	"Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech"	.	Terminated	D03DFY	.	CTPDG007539
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	GT-2016	GT 2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653	9839975	Terminated	D02YXQ	.	CTPDG007540
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	A-72055	.	.	Terminated	D02VHE	.	CTPDG007544
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ABS-301	"ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS"	.	Terminated	D02UQU	.	CTPDG007545
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	ZK-91296	"ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester"	123700	Terminated	D02UIE	.	CTPDG007546
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	BIBN-140	"Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-"	10030021	Terminated	D02JNY	.	CTPDG007550
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Bifemelane	Alnert; Celeport; E-0687; MCI-2016; SON-216	2377	Terminated	D02CGY	DB13550	CTPDG007557
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Sibopirdine	"DuP-921; EXP-9121; EXP-921; 5H-Cyclopenta[2,1-b:3,4-b']dipyridine, 5,5-bis(4-pyridinylmethyl)-, monohydrate"	195376	Terminated	D01LRH	.	CTPDG007569
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Terminated	Tenilsetam	CAS-997	65649	Terminated	D00JNL	.	CTPDG007586
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AD-0802	"Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic"	.	Investigative	D0Y9ES	.	CTPDG007656
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	VK-11	"Imaging agent (Alzheimer's disease), Prana"	.	Investigative	D0Y4TQ	.	CTPDG007666
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZD-6319	"Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca"	.	Investigative	D0X2NB	.	CTPDG007732
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PD-2015	"PD-2016; TNF alpha inhibitors (Alzheimers disease); TNF alpha inhibitors (Alzheimers disease), P2D Bioscience"	.	Investigative	D0WO8I	.	CTPDG007740
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CBNU-06	.	.	Investigative	D0WA3T	.	CTPDG007746
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RAP-310	"Small stabilized receptor active peptide (Alzheimers disease), RAPID Pharmaceuticals"	.	Investigative	D0W9OW	.	CTPDG007748
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Phase 2	Tideglusib	.	11313622	Phase 2	D0W5WZ	DB12129	CTPDG007762
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DWJ-209	.	.	Investigative	D0W5CI	.	CTPDG007764
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EVP-4473	.	.	Investigative	D0VE4O	.	CTPDG007780
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ReN-004	"Stem cell therapy (neurological disorders), ReNeuron"	.	Investigative	D0UO6M	.	CTPDG007813
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-901	.	.	Investigative	D0T6FY	.	CTPDG007853
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR APLs	NAChR APLs (Alzheimer's disease)	.	Investigative	D0T5ZM	.	CTPDG007855
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	COG-248	"Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease); Neuroprotectant (Alzheimers/Parkinsons disease), Cognosci; Apolipoprotein E agonist series (Alzheimer's/Parkinsons disease), Cognosci"	.	Investigative	D0S2QP	.	CTPDG007894
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ELND-007	"ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan"	53308121	Investigative	D0Q6ZQ	.	CTPDG007946
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	BAN-2203	"Beta amyloid modulator (Alzheimer's disease), BioArctic"	.	Investigative	D0Q5VC	.	CTPDG007953
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Turmeric extracts	"HSS-808; HSS-818; HSS-838; HSS-848; HSS-888; Turmeric extracts (Alzheimer's disease); Turmeric extracts (Alzheimer's disease), HerbalScience"	.	Investigative	D0Q2XN	.	CTPDG007960
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Ginkgo biloba extract	"YY-1224; YY-1824; Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease); Ginkgo biloba extract (Parkinson's disease/Alzheimer's disease), Yuyu Inc"	.	Investigative	D0OB9V	.	CTPDG008000
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SX-AZD1	.	.	Investigative	D0N6EL	.	CTPDG008040
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AIKb2	.	.	Investigative	D0N0SC	.	CTPDG008055
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NAChR alpha 7 APLs	NAChR alpha 7 APLs (Alzheimer's disease)	.	Investigative	D0M7MH	.	CTPDG008070
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	11A1	.	.	Investigative	D0K4WW	.	CTPDG008142
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Gamma-secretase modulators	"Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche"	24781184	Investigative	D0J5SD	.	CTPDG008172
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	MCD-386/glycopyrrolate	"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,"	3494	Investigative	D0IL1B	DB00986	CTPDG008185
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	HL-026	.	.	Investigative	D0IC8P	.	CTPDG008187
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ESN-XX	.	.	Investigative	D0I3OX	.	CTPDG008215
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ETN-001	.	.	Investigative	D0I0ZY	.	CTPDG008222
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	DBT-1339	"DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech"	.	Investigative	D0HK7G	.	CTPDG008227
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GRL-11097	"Memapsin 2 inhibitors (Alzheimers); Memapsin 2 inhibitors (Alzheimers), Purdue University/Astellas"	.	Investigative	D0H2VN	.	CTPDG008244
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KNX-Monoclonal204	"KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis"	.	Investigative	D0G4AE	.	CTPDG008271
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KMS-88009	"KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical"	.	Investigative	D0F5UO	.	CTPDG008302
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NGN-9079	"Alzheimer's disease therapy, NeuroGeneration"	.	Investigative	D0F5IS	.	CTPDG008306
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PNB-04	"Alzheimer's disease therapy, PharmaNeuroBoost"	.	Investigative	D0EW4M	.	CTPDG008325
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	IMD-4482	"IMD-4690; PAI-1 inhibitor (oral, Alzheimers disease), IMMD; Plasminogen activator inhibitor-1 inhibitor (oral, Alzheimers disease), Institute of Medicinal Molecular Design"	.	Investigative	D0EW2D	.	CTPDG008326
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Abloid	"Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics"	.	Investigative	D0E5CX	.	CTPDG008345
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Memex	Nicotinomide adenine dinucleotide (NADH)	.	Investigative	D0E0OI	.	CTPDG008353
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-0235-J	.	.	Investigative	D0D7KR	.	CTPDG008371
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-103	"NP-060103; NP-60103; Glycogen synthase kinase-3 inhibitor (Alzheimer's disease), Neuropharma"	.	Investigative	D0D6WF	.	CTPDG008374
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Leptin	Leptin (Alzheimer's disease)	.	Investigative	D0C6TL	.	CTPDG008408
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SP-08	SP-008	.	Investigative	D0C4WY	.	CTPDG008411
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SPI-017	"SPI-017 (oral, Alzheimer's disease)"	.	Investigative	D0C1TT	.	CTPDG008423
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	RECALL-VAX	"RV-01; RV-02; Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease); Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease), Intellect Neuroscience"	.	Investigative	D0B4AH	.	CTPDG008454
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CWF-0804	.	.	Investigative	D09NEL	.	CTPDG008535
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACU-0101979	"HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co"	.	Investigative	D09MRY	.	CTPDG008536
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Cystatin C	Cystatin C (Alzheimer's disease)	.	Investigative	D09HVY	.	CTPDG008553
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	EDN-OL1	"Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn"	.	Investigative	D07ZDG	.	CTPDG008644
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ADepVac	"DNA vaccine (Alzheimer's disease), University of California Irvine; DNA vaccine (TriGrid electroporation, Alzheimers), Ichor/UCI/IMM"	.	Investigative	D07ZBO	.	CTPDG008646
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Anticalin	Anticalin (Alzheimer's disease)	.	Investigative	D07YAC	.	CTPDG008650
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-518	"AMPA glutamate receptor agonist (Alzheimer's disease), AC Immune"	.	Investigative	D07KMI	.	CTPDG008690
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEN-1500	"SEN-1576; Beta-amyloid aggregation inhibitors (Alzheimer's disease); Beta-amyloid aggregation inhibitors (Alzheimer's disease), Senexis"	54589394	Investigative	D07JKA	.	CTPDG008693
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARN-2966	"ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences"	14936865	Investigative	D07DNV	.	CTPDG008707
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZ-AAV9	"Alzheimers disease gene therapy, RegenX Biosciences; Adeno-associated virus vector-9 based gene therapy (injectable,AD), RegenX Biosciences"	.	Investigative	D06UUE	.	CTPDG008732
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ACI-636	"Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune"	.	Investigative	D06MBR	.	CTPDG008752
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	TKP-1001	"Amyloid-beta modulator (Alzheimer's disease), EUSA Pharma; Amyloid-beta modulator (Alzheimer's disease), Talisker Pharma; Amyloid-beta synthesis modulator (Alzheimer's disease), The Open University"	.	Investigative	D06LRQ	.	CTPDG008753
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NP-17	"NP-21; NPM-01; NPM-05 series; NPM-05B1; NPM-05B2; Alpha-secreatse activators (oral, Alzheimer's disease), Noscira"	.	Investigative	D05NIO	.	CTPDG008822
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ANA-5	.	.	Investigative	D04ZTA	.	CTPDG008850
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NXD-9062	.	.	Investigative	D04UQS	.	CTPDG008858
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3186	.	.	Investigative	D04TZK	.	CTPDG008860
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	A-887755	.	.	Investigative	D04TPS	.	CTPDG008861
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	ARC-069	"Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals"	.	Investigative	D04QXW	.	CTPDG008864
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	NNI-AD	"NNI-251; NNI-362; NNI-C; NNI-X01; AD therapy (oral), Neuronascent"	.	Investigative	D04OUP	.	CTPDG008871
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AZP-2006	"Amyloid precursor protein modulator (AD), AlzProtect/INSERM/University of Lille II"	87057554	Investigative	D04MHP	.	CTPDG008882
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	AC-4402	"GABAA receptor inverse agonist (Alzheimer's disease), Dainippon Sumitomo Pharma"	3084937	Investigative	D03TDE	.	CTPDG008935
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	GT 1061	.	53483797	Investigative	D03IHA	.	CTPDG008969
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	LNK-3248	.	.	Investigative	D01ZFM	.	CTPDG009049
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	UC-1011	"UC-2021; UC-2025; GABA A receptor antagonists (Alzheimer's disease); GABA A receptor antagonists (Alzheimer's disease), Umecrine; 3beta-20beta-dihydroxy-5alpha-pregnane; 3beta-20beta-dihydroxy-5alpha-pregnane (Alzheimer's disease), Umecrine"	.	Investigative	D01YGY	.	CTPDG009051
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	F-18 T808	.	.	Investigative	D01SXE	.	CTPDG009066
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	KD-501	.	.	Investigative	D01QNJ	.	CTPDG009082
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Haw-AD-14	.	.	Investigative	D01LBD	.	CTPDG009100
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	CDD-190	.	.	Investigative	D01GBV	.	CTPDG009117
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	123I-DRM-106	"DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd"	49801966	Investigative	D01GAZ	.	CTPDG009118
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	PN-403	.	.	Investigative	D01FTK	.	CTPDG009120
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Mimovax	"MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS"	.	Investigative	D01BJK	.	CTPDG009132
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	SEL-103	.	.	Investigative	D00YJD	.	CTPDG009144
M6ACROT03531	.	.	M6ADIS0089	8A20: Alzheimer disease	Investigative	Molecule 22	"MARK3 inhibitors (Alzheimer's disease); MARK3 inhibitors (Alzheimer's disease), Merck & Co"	.	Investigative	D00HDH	.	CTPDG009188
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Morphine	Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr	5288826	Approved	D0WE3O	DB00295	CTPDG000078
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Ketoprofen	"Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid"	3825	Approved	D0W9WF	DB01009	CTPDG000080
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Strontium Chloride Sr-89	Metastron	5388879	Approved	D0R6HN	DB09498	CTPDG000179
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Withdrawn from market	Alpha 1-PI	Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine	3689	Withdrawn from market	D0I0DL	DB08954	CTPDG000356
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Fentanyl	"Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	3345	Approved	D0E1WI	DB00813	CTPDG011520
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Phenylbutazone	"Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione"	4781	Approved	D07VHR	DB00812	CTPDG000546
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Samarium Sm-153 Lexidronam Pentasodium	.	9810246	Approved	D04YHR	DB09509	CTPDG000653
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Hydromorphone	"Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug"	5284570	Approved	D04JHN	DB00327	CTPDG011532
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Ethanol	"Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA"	702	Approved	D00AMQ	DB00898	CTPDG000831
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Mirogabalin	"1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303"	59509752	Phase 3	D07VFD	DB11825	CTPDG000836
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 4	Dihydrocodeine	"Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine"	5284543	Phase 4	D0T6RC	DB01551	CTPDG000843
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Preregistration	GSK2696273	.	.	Preregistration	D0F4QV	.	CTPDG000856
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Egalet-002	.	.	Phase 3	D0R8FL	.	CTPDG001068
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Fulranumab	.	.	Phase 3	D0O1GS	.	CTPDG001105
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Nabiximols	Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02	44148067	Phase 3	D0C5CE	.	CTPDG001256
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Tanezumab	.	.	Phase 3	D00BVS	.	CTPDG001506
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	CR-845	"Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring"	.	Phase 2	D08NJE	.	CTPDG001560
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	LY3556050	"(1R,5S,6R)-N-{2-methyl-1-[(3-methylpyridin-2-yl)oxy]propan-2-yl}-3-azabicyclo[3.1.0]hexane-6-carboxamide; 1638588-92-7; AT36106; BDBM311911; EN300-1700347; LY3556050; SCHEMBL16252692; US10166214, Example 47; Z3071648657"	86294067	Phase 2	DXE53Z	.	CTPDG001614
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	A277	.	.	Phase 2	DDQH94	.	CTPDG001740
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	LY3526318	.	.	Phase 2	D40GBC	.	CTPDG001819
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	V120083	S120083	.	Phase 2	D0X3JK	.	CTPDG001902
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	XEN-2174	.	.	Phase 2	D0U2XU	.	CTPDG001994
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Flupirtine	"56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami"	53276	Phase 2	D0SD9V	DB06623	CTPDG002034
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	ABT-652	.	.	Phase 2	D0S5BV	.	CTPDG002042
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	PF-05089771	"Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer"	46840946	Phase 2	D0O7QA	DB14856	CTPDG002135
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	EB-001	.	.	Phase 2	D0O1VU	.	CTPDG002145
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Omnitram	.	.	Phase 2	D0KZ3Q	.	CTPDG002242
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	NP-2 gene therapy	.	.	Phase 2	D06ZQL	.	CTPDG002712
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	PF-06372865	.	76287260	Phase 2	D06TQR	.	CTPDG002730
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Resiniferatoxin	"Reciniferatoxin; UNII-A5O6P1UL4I; A5O6P1UL4I; 57444-62-9; RTX; [3H]resiniferatoxin; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); CHEMBL448382; resinferatoxin; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; Resiniferatoxin(RTX); CHEMBL17976"	5702546	Phase 1	D05XJW	DB06515	CTPDG002779
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	REL-1015	.	.	Phase 2	D03RYJ	.	CTPDG002907
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Neramexane	"Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine"	6433106	Phase 2	D01KMR	DB04926	CTPDG003032
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1/2	COL-195	.	.	Phase 1/2	D0XB8Y	.	CTPDG003283
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	REL-1028	.	.	Phase 1	D0XD0N	.	CTPDG004278
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	CNTX-0290	.	.	Phase 1	D0U0CF	.	CTPDG004390
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Egalet-004	.	.	Phase 1	D0R9WD	.	CTPDG004454
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	TRV734	.	.	Phase 1	D0OK6F	.	CTPDG004534
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	CA-011	"2-Amino-4-(p-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-1,3-thiazol-2-amine; 2-Amino-4-(4-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-2-thiazolamine; 2-Thiazolamine, 4-(4-nitrophenyl)-; 4-(4-nitrophenyl)thiazol-2-amine; THIAZOLE, 2-AMINO-4-(p-NITROPHENYL)-; 4-(4-Nitrophenyl)thiazol-2-ylamine; 2-amino-4-(4'-nitrophenyl)-1,3-thiazole; RIKJWJIWXCUKQV-UHFFFAOYSA-N; BRN 0200321; 4-(4-Nitro-phenyl)-thiazol-2-ylamine; AI3-62320; 4-(4-nitrophenyl)-1,3-thiazole-2-ylamine; DSSTox_CID_65; AC1L27WX; Cambridge id 5156331; DSSTox_RID_"	16420	Phase 1	D0KK9D	.	CTPDG004648
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	PF-06305591	.	71666749	Phase 1	D0K9IF	DB12106	CTPDG004651
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	OX-27	.	.	Phase 1	D0J9GR	.	CTPDG004682
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	DWJ-208	.	.	Phase 1	D0G0ER	.	CTPDG004783
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	JNJ-39439335	Mavatrep; 956274-94-5; UNII-F197218T99; F197218T99; Mavatrep [USAN:INN]; Mavatrep (USAN); JNJ 39439335; SCHEMBL1796599; SCHEMBL1797450; CHEMBL2364618; Mavatrep(JNJ-39439335); DTXSID90241905; BCP23936; EX-A2266; ZINC43175494; BDBM50086717; AKOS030527038; DB12875; CS-4591; SB17026; trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol; BC600772; HY-16935; B5930; J3.561.747G; D10370	17751090	Phase 1	D0EM4S	DB12875	CTPDG004821
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	ABT-110	"Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics"	.	Phase 1	D03APM	.	CTPDG005329
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Debio 0827	.	16123252	Phase 1	D02HUY	.	CTPDG005358
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	GDC0310	"RG6029; FCTMRPTVPHVTTN-UHFFFAOYSA-N; SCHEMBL16770884; BDBM71258; BCP25347; US9694002, 346; 1788066-71-6"	118120526	Phase 1	D01FZZ	.	CTPDG005415
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	PF614	.	.	Phase 1	D00SBU	.	CTPDG005443
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	ABT-102	"3-(1H-indazol-4-yl)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea"	11256560	Phase 1	D00CMV	.	CTPDG005473
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-68	.	23628075	Patented	D0ZZ8F	.	CTPDG005511
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-152	.	44548476	Patented	D0ZS3E	.	CTPDG005514
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-96	.	.	Patented	D0ZQ2W	.	CTPDG005516
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-105	.	25027804	Patented	D0ZP2C	.	CTPDG005517
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-18	.	25265637	Patented	D0ZM8H	.	CTPDG005519
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015143654Example29	.	Patented	D0ZE6H	.	CTPDG005522
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-107	.	51349201	Patented	D0ZE1M	.	CTPDG005524
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-144	.	67412556	Patented	D0Z5HH	.	CTPDG005531
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-160	.	.	Patented	D0Z4QQ	.	CTPDG005533
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-151	.	68324656	Patented	D0YU9B	.	CTPDG005541
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-21	.	.	Patented	D0YR4E	.	CTPDG005542
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014078408Example26	.	.	Patented	D0YN0I	.	CTPDG005544
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-67	.	23628014	Patented	D0YM1M	.	CTPDG005545
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-64	.	.	Patented	D0Y9ST	.	CTPDG005548
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-100	.	71480662	Patented	D0Y1SI	.	CTPDG005550
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013009582Example76	.	.	Patented	D0Y0XJ	.	CTPDG005552
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-161	.	.	Patented	D0XX8R	.	CTPDG005555
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpyrrolidine ether derivative 1	PMID28270021-Compound-WO2016020784Example11	.	Patented	D0X4LA	.	CTPDG005566
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-39	.	57335613	Patented	D0X1OO	.	CTPDG005567
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 3	PMID28270021-Compound-WO2015092610Example164	.	Patented	D0X1LP	.	CTPDG005568
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-120	.	53477386	Patented	D0WX4W	.	CTPDG005569
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-132	.	66908117	Patented	D0WT1W	.	CTPDG005574
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-91	.	.	Patented	D0WJ8R	.	CTPDG005580
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Imidazo pyridine derivative 1	PMID28270021-Compound-WO2015200341Example96	.	Patented	D0WI7N	.	CTPDG005581
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-33	.	71611619	Patented	D0W4AA	.	CTPDG005583
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example12	.	.	Patented	D0VD5J	.	CTPDG005592
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[1,5-a]pyridine derivative 2"	PMID28270021-Compound-WO2013088257Example240	.	Patented	D0V9ZJ	.	CTPDG005597
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-89	.	.	Patented	D0V9RM	.	CTPDG005598
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-36	.	71611910	Patented	D0V3PI	.	CTPDG005602
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Tri-substituted urea derivative 1	PMID28270021-Compound-WO2013176970Example1	.	Patented	D0UQ2G	.	CTPDG005607
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 5	PMID28270021-Compound-WO2015148344Example152	.	Patented	D0UN4M	.	CTPDG005608
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-83	.	11720246	Patented	D0UE9K	.	CTPDG005611
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-45	.	70816331	Patented	D0U8YZ	.	CTPDG005615
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example11	.	.	Patented	D0U5XI	.	CTPDG005618
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-125	.	53475699	Patented	D0U5ON	.	CTPDG005619
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-54	.	70816505	Patented	D0U5CQ	.	CTPDG005621
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrido[3,2-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012125668Example27	.	Patented	D0U3RD	.	CTPDG005624
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-38	.	87087836	Patented	D0TZ2W	.	CTPDG005626
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015148350Example36	.	Patented	D0T4CF	.	CTPDG005640
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 109	.	.	Patented	D0T0HM	.	CTPDG005644
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-16	.	46191563	Patented	D0SD4G	.	CTPDG005651
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012137089cE-245677	.	Patented	D0S0II	.	CTPDG005658
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrido[3,2-d]pyrimidine derivative 2"	PMID28270021-Compound-WO2012125668Example12	.	Patented	D0RR8O	.	CTPDG005662
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[4,3-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053965Example3	.	Patented	D0RK6W	.	CTPDG005664
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-139	.	.	Patented	D0RC7L	.	CTPDG005670
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-32	.	.	Patented	D0R9RP	.	CTPDG005672
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-14	.	60202428	Patented	D0R8GA	.	CTPDG005674
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-106	.	51349065	Patented	D0R2VB	.	CTPDG005681
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-122	.	53476470	Patented	D0R2QV	.	CTPDG005682
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014129431Example8-1	.	.	Patented	D0QT8L	.	CTPDG005690
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-81	.	11706654	Patented	D0QP4N	.	CTPDG005692
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 201	.	.	Patented	D0PY0G	.	CTPDG005704
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-112	.	70652314	Patented	D0PT0U	.	CTPDG005705
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-129	.	.	Patented	D0PJ8O	.	CTPDG005707
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-43	.	.	Patented	D0P9KJ	.	CTPDG005710
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 1"	PMID28270021-Compound-WO2008063888P-0171	.	Patented	D0P8SR	.	CTPDG005711
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-49	.	71238636	Patented	D0P5SB	.	CTPDG005716
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-57	.	71537379	Patented	D0P0MR	.	CTPDG005722
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-8	.	66549082	Patented	D0ON4M	.	CTPDG005728
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-75	.	11598064	Patented	D0OC6A	.	CTPDG005730
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-53	.	70816499	Patented	D0OA1P	.	CTPDG005731
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-63	.	71534837	Patented	D0O9GI	.	CTPDG005732
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1"	PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)	.	Patented	D0O8SX	.	CTPDG005733
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-6	.	66549275	Patented	D0O7IQ	.	CTPDG005736
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-92	.	.	Patented	D0O6VU	.	CTPDG005737
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-136	.	58387639	Patented	D0O3TG	.	CTPDG005740
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-86	.	56949431	Patented	D0O0UG	.	CTPDG005741
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 3	PMID28270021-Compound-WO2015148354Example41	.	Patented	D0O0GZ	.	CTPDG005742
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-157	.	52949700	Patented	D0NV2M	.	CTPDG005743
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-19	.	25263543	Patented	D0NM3D	.	CTPDG005744
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-142	.	58387658	Patented	D0NH2M	.	CTPDG005747
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-35	.	.	Patented	D0NB5M	.	CTPDG005749
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-7	.	66551085	Patented	D0N9FJ	.	CTPDG005751
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 7	PMID28270021-Compound-WO2015148373Example36	.	Patented	D0N6NG	.	CTPDG005753
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-24	.	.	Patented	D0N2UQ	.	CTPDG005760
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-156	.	24783142	Patented	D0N0TF	.	CTPDG005764
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-146	.	59730981	Patented	D0N0QN	.	CTPDG005765
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Triazolo[4,3-b]pyridazine derivative 2"	PMID28270021-Compound-WO2012125667Example24	.	Patented	D0MZ7K	.	CTPDG005767
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-109	.	11187857	Patented	D0MY3K	.	CTPDG005769
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-47	.	88995251	Patented	D0MU3S	.	CTPDG005771
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-29	.	71599906	Patented	D0M4WY	.	CTPDG005784
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example112	.	.	Patented	D0LK8E	.	CTPDG005792
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-162	.	.	Patented	D0LA0Q	.	CTPDG005794
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-137	.	.	Patented	D0KM0W	.	CTPDG005805
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-98	.	71480662	Patented	D0KF3A	.	CTPDG005808
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 5	PMID28270021-Compound-WO2015148373Example104	.	Patented	D0KC8X	.	CTPDG005811
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-1	.	68313317	Patented	D0KB2Z	.	CTPDG005812
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 495	.	.	Patented	D0K6IM	.	CTPDG005818
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-46	.	.	Patented	D0K4SZ	.	CTPDG005820
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-148	.	59731038	Patented	D0K3KM	.	CTPDG005821
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-155	.	24782891	Patented	D0K3KE	.	CTPDG005822
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-141	.	53402973	Patented	D0K0ZI	.	CTPDG005826
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-62	.	71506872	Patented	D0JX4I	.	CTPDG005828
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-147	.	59731029	Patented	D0JT8B	.	CTPDG005830
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-22	.	.	Patented	D0JK2N	.	CTPDG005833
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-31	.	.	Patented	D0JC8L	.	CTPDG005834
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-59	.	71539690	Patented	D0J9CS	.	CTPDG005836
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 103	.	.	Patented	D0J4CA	.	CTPDG005843
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-52	.	70816169	Patented	D0IU1H	.	CTPDG005845
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-94	.	.	Patented	D0IT4N	.	CTPDG005846
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-27	.	71599827	Patented	D0IR7H	.	CTPDG005848
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-9	.	66549271	Patented	D0IP5E	.	CTPDG005849
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-48	.	.	Patented	D0IN5E	.	CTPDG005851
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-102	.	.	Patented	D0IK1S	.	CTPDG005852
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 4	PMID28270021-Compound-WO2015148354Example99	.	Patented	D0I9FU	.	CTPDG005859
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-159	.	.	Patented	D0I3ZW	.	CTPDG005864
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013161919Example85-117	.	.	Patented	D0I2OO	.	CTPDG005866
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-20	.	.	Patented	D0HS1D	.	CTPDG005873
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 1	PMID28270021-Compound-WO2015148354Example21(R or S)	.	Patented	D0HF1A	.	CTPDG005877
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-11	.	66549650	Patented	D0HE7X	.	CTPDG005879
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-72	.	11582721	Patented	D0H6CX	.	CTPDG005886
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-80	.	11656215	Patented	D0H4TR	.	CTPDG005889
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015143654Example41	.	Patented	D0H3ZG	.	CTPDG005891
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-4	.	66551282	Patented	D0GZ4G	.	CTPDG005898
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-66	.	23627957	Patented	D0GV5G	.	CTPDG005903
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-143	.	.	Patented	D0G6IQ	.	CTPDG005913
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-55	.	56836246	Patented	D0G3UV	.	CTPDG005914
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 481	.	.	Patented	D0FL8A	.	CTPDG005922
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 2	PMID28270021-Compound-WO2015148354Example33(R or S)	.	Patented	D0F8BF	.	CTPDG005930
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-65	.	71238361	Patented	D0F5NQ	.	CTPDG005932
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-15	.	25263680	Patented	D0F4YX	.	CTPDG005933
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-30	.	71598766	Patented	D0F4DI	.	CTPDG005935
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-101	.	71609207	Patented	D0F3HP	.	CTPDG005936
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 803	.	.	Patented	D0F2BF	.	CTPDG005937
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-26	.	71599484	Patented	D0EV3G	.	CTPDG005942
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-118	.	53386424	Patented	D0EH2T	.	CTPDG005948
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 4	PMID28270021-Compound-WO2015143654Example62	.	Patented	D0EC4Z	.	CTPDG005949
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-82	.	.	Patented	D0EC3Z	.	CTPDG005950
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-69	.	23628077	Patented	D0E8UP	.	CTPDG005954
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-110	.	.	Patented	D0E0SA	.	CTPDG005958
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 8	PMID28270021-Compound-WO2015148373Example41(S)	.	Patented	D0DY5R	.	CTPDG005959
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-124	.	53476472	Patented	D0DT7M	.	CTPDG005962
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[3,2-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053968Example5	.	Patented	D0DQ5G	.	CTPDG005963
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[1,5-a]pyridine derivative 1"	PMID28270021-Compound-WO2013088256Example59	.	Patented	D0DN3Q	.	CTPDG005966
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-130	.	.	Patented	D0DI1R	.	CTPDG005970
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-42	.	70816270	Patented	D0DE5K	.	CTPDG005973
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-78	.	.	Patented	D0DE5I	.	CTPDG005974
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-74	.	11676921	Patented	D0DC4O	.	CTPDG005976
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-108	.	51349341	Patented	D0D4NX	.	CTPDG005986
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-115	.	88875843	Patented	D0D2CF	.	CTPDG005989
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015148350Example81	.	Patented	D0CY3U	.	CTPDG005992
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-76	.	11532887	Patented	D0CX4C	.	CTPDG005993
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-138	.	.	Patented	D0CR0H	.	CTPDG005997
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Tri-substituted urea derivative 2	PMID28270021-Compound-WO2013176970Example2	.	Patented	D0CG8N	.	CTPDG006004
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-87	.	56961050	Patented	D0C9FN	.	CTPDG006008
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-12	.	66549652	Patented	D0C8ZZ	.	CTPDG006009
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-114	.	89556774	Patented	D0C5NT	.	CTPDG006012
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-(phenylpyrazolyl)benzamide derivative 1	PMID28270021-Compound-WO2013132376Example157	.	Patented	D0C3RK	.	CTPDG006014
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-10	.	66551086	Patented	D0C1MZ	.	CTPDG006015
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example80	.	.	Patented	D0BO1H	.	CTPDG006019
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-77	.	11562798	Patented	D0B4NI	.	CTPDG006026
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-51	.	57335038	Patented	D0B0WJ	.	CTPDG006032
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-153	.	88937082	Patented	D0AQ3U	.	CTPDG006035
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-113	.	70652315	Patented	D0A8LU	.	CTPDG006042
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-25	.	71599909	Patented	D0A3XC	.	CTPDG006045
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-34	.	71611907	Patented	D0A0YI	.	CTPDG006049
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-40	.	66644325	Patented	D09ZWU	.	CTPDG006050
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-128	.	24758063	Patented	D09SMA	.	CTPDG006055
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-79	.	11677423	Patented	D09QXC	.	CTPDG006057
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-84	.	11613881	Patented	D08ZBB	.	CTPDG006070
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-111	.	.	Patented	D08YAL	.	CTPDG006072
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-135	.	58387673	Patented	D08UEC	.	CTPDG006077
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-13	.	66549649	Patented	D08ICT	.	CTPDG006083
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example71	.	.	Patented	D08CZY	.	CTPDG006086
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-123	.	53476471	Patented	D08CLA	.	CTPDG006087
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpyrrolidine ether derivative 2	PMID28270021-Compound-WO2016020784Example12	.	Patented	D08BIH	.	CTPDG006090
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-134	.	11674039	Patented	D07XZR	.	CTPDG006094
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-119	.	53477385	Patented	D07XVL	.	CTPDG006095
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015143654Example60	.	Patented	D07VFQ	.	CTPDG006097
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-131	.	25094155	Patented	D07RYM	.	CTPDG006100
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-127	.	24759759	Patented	D07MNI	.	CTPDG006112
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 811	.	.	Patented	D07KVL	.	CTPDG006113
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-17	.	.	Patented	D07JNJ	.	CTPDG006115
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-117	.	.	Patented	D07FWF	.	CTPDG006121
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-50	.	71237925	Patented	D07FIY	.	CTPDG006123
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-56	.	71238385	Patented	D07EGF	.	CTPDG006124
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-41	.	66644203	Patented	D07EAV	.	CTPDG006125
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 6	PMID28270021-Compound-WO2015148373Example111	.	Patented	D07CPL	.	CTPDG006126
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-85	.	11671115	Patented	D07BZW	.	CTPDG006127
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 9	PMID28270021-Compound-WO2015148373Example42(R)	.	Patented	D07AJO	.	CTPDG006129
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID27998201-Compound-12	.	.	Patented	D06XCD	.	CTPDG006131
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-3	.	66549466	Patented	D06VYF	.	CTPDG006134
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-37	.	49802515	Patented	D06JHW	.	CTPDG006147
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 2"	PMID28270021-Compound-WO2008063888P-0180	.	Patented	D06GOT	.	CTPDG006149
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-90	.	.	Patented	D05ZWR	.	CTPDG006154
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-28	.	71580510	Patented	D05SWL	.	CTPDG006160
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-116	.	88875796	Patented	D05SMP	.	CTPDG006161
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-99	.	71498842	Patented	D05RBF	.	CTPDG006163
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 7	PMID28270021-Compound-WO2015148344Example96	.	Patented	D05MRY	.	CTPDG006168
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014078408Example1	.	.	Patented	D05AQT	.	CTPDG006179
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-154	.	88937150	Patented	D04TIU	.	CTPDG006185
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 2	PMID28270021-Compound-WO2015092610Example114	.	Patented	D04RXX	.	CTPDG006186
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 6	PMID28270021-Compound-WO2015148344Example59	.	Patented	D04JCD	.	CTPDG006197
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-93	.	.	Patented	D04HCS	.	CTPDG006198
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 6	PMID28270021-Compound-WO2015092610Example9	.	Patented	D04GCC	.	CTPDG006201
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-44	.	70816274	Patented	D04FRL	.	CTPDG006202
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015148350Example76	.	Patented	D04BRW	.	CTPDG006207
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-97	.	.	Patented	D03ZOZ	.	CTPDG006210
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-71	.	23628017	Patented	D03YFL	.	CTPDG006211
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-145	.	67412506	Patented	D03VXP	.	CTPDG006218
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-88	.	.	Patented	D03SHM	.	CTPDG006221
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-61	.	.	Patented	D03QAW	.	CTPDG006223
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-73	.	11532940	Patented	D03FSF	.	CTPDG006233
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-70	.	58416270	Patented	D03EEA	.	CTPDG006235
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 5	PMID28270021-Compound-WO2015092610Example3	.	Patented	D03BAY	.	CTPDG006238
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013009582Example16	.	.	Patented	D02ZQN	.	CTPDG006241
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-23	.	.	Patented	D02QJE	.	CTPDG006251
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 7	PMID28270021-Compound-WO2016009296Example15	.	Patented	D02OLJ	.	CTPDG006252
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-5	.	.	Patented	D02OAH	.	CTPDG006254
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-140	.	23585453	Patented	D02JQB	.	CTPDG006258
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 3"	PMID28270021-Compound-WO2010129570P-2061	.	Patented	D02IBX	.	CTPDG006259
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014152663 701	.	.	Patented	D02ETU	.	CTPDG006261
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-126	.	53475700	Patented	D02EKO	.	CTPDG006262
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-104	.	25104368	Patented	D01RUK	.	CTPDG006268
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-58	.	.	Patented	D01PLJ	.	CTPDG006271
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-103	.	.	Patented	D01LGQ	.	CTPDG006276
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-158	.	16742146	Patented	D01HED	.	CTPDG006279
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-133	.	25094231	Patented	D01GEK	.	CTPDG006280
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-150	.	68324561	Patented	D01DNH	.	CTPDG006281
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-2	.	66549276	Patented	D00YXA	.	CTPDG006287
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 1	PMID28270021-Compound-WO2015092610Example113	.	Patented	D00XXZ	.	CTPDG006288
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-60	.	.	Patented	D00QEZ	.	CTPDG006299
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-149	.	.	Patented	D00OLY	.	CTPDG006301
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-95	.	.	Patented	D00ODY	.	CTPDG006302
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-121	.	53477387	Patented	D00KTN	.	CTPDG006306
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 4	PMID28270021-Compound-WO2015092610Example2	.	Patented	D00FJH	.	CTPDG006308
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example82	.	.	Patented	D00EUL	.	CTPDG006309
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 3	Propiram fumarate	Algeril; Diramax; Dirame; Diramine; Diratab; Propiram; FBA-4503	6433584	Discontinued in Phase 3	D08LIF	.	CTPDG006373
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 1	AMG-517	AMG 517; BD-0082	16007367	Discontinued in Phase 1	D0L5XI	.	CTPDG006783
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 1	BL-1827	.	.	Discontinued in Phase 1	D06MXY	.	CTPDG006876
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	SequestOx	Oxycodone / naltrexone; Naltrexone / oxycodone; Troxyca Er; Oxycodone hydrochloride / naltrexone hydrochloride; Naltrexone hydrochloride / oxycodone hydrochloride; Naltrexone hydrochloride and oxycodone hydrochloride; ALO-02; Naltrexone hydrochloride mixture with oxycodone hydrochloride; 850636-71-4; Oxycodone hydrochloride and naltrexone hydrochloride	90479726	Application submitted	D0FU5Y	.	CTPDG006945
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	Remoxy ER	.	.	Application submitted	D0B7VH	.	CTPDG006947
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	Oxycodone hydrochloride	oxycodone ER	5462350	Application submitted	D07WPQ	.	CTPDG006949
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	DBO-17	.	10042211	Terminated	D0XH1H	.	CTPDG007179
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	DBO-11	166374-49-8; Naxifylline (USAN/INN)	23724971	Terminated	D0PE1A	.	CTPDG007250
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	ACEA-1328	.	9816093	Terminated	D0O4JH	.	CTPDG007264
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	RO-25-6981	"Ro 25-6981; CHEMBL305195; ro25-6981; 169274-78-6; 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol; 4-((1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol; QEM; Tocris-1594; AC1O7H0A; Lopac0_001082; ZINC7042; SCHEMBL6159263; CHEBI:92897; HMS3268G13; EX-A1825; PDSP2_000361; BDBM50080029; CS-2011; CCG-205159; NCGC00025226-01; NCGC00025226-03; NCGC00025226-02; HY-13993; (AR,BS)-ALPHA-(4-HYDROXYPHENYL)-BETA-METHYL-4-(PHENYLMETHYL)-1-PIPERIDINEPROPANOL MALEATE; BRD-K51541829-001-01-3"	6604887	Terminated	D0K0DB	.	CTPDG007307
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Investigative	THA-901	TH-901	.	Investigative	D06MEC	.	CTPDG008750
M6ACROT02094	.	.	M6ADIS0024	MG30: Chronic pain	Investigative	SP-SAP	"NK1-saporin conjugate, Advanced Targeting Systems; Neurokinin NK1-saporin conjugate, ATS; SP-SAP, APT; SP-SAP, Advanced Pain Therapeutics; SP-SAP, Advanced Targeting Systems; Substance P-saporin conjugate, ATS; Substance P-saporin conjugate, Advanced Targeting Systems"	.	Investigative	D04LHG	.	CTPDG008884
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Morphine	Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr	5288826	Approved	D0WE3O	DB00295	CTPDG000078
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Ketoprofen	"Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid"	3825	Approved	D0W9WF	DB01009	CTPDG000080
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Strontium Chloride Sr-89	Metastron	5388879	Approved	D0R6HN	DB09498	CTPDG000179
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Withdrawn from market	Alpha 1-PI	Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine	3689	Withdrawn from market	D0I0DL	DB08954	CTPDG000356
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Fentanyl	"Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	3345	Approved	D0E1WI	DB00813	CTPDG011520
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Phenylbutazone	"Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione"	4781	Approved	D07VHR	DB00812	CTPDG000546
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Samarium Sm-153 Lexidronam Pentasodium	.	9810246	Approved	D04YHR	DB09509	CTPDG000653
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Hydromorphone	"Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug"	5284570	Approved	D04JHN	DB00327	CTPDG011532
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Ethanol	"Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA"	702	Approved	D00AMQ	DB00898	CTPDG000831
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Mirogabalin	"1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303"	59509752	Phase 3	D07VFD	DB11825	CTPDG000836
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 4	Dihydrocodeine	"Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine"	5284543	Phase 4	D0T6RC	DB01551	CTPDG000843
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Preregistration	GSK2696273	.	.	Preregistration	D0F4QV	.	CTPDG000856
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Egalet-002	.	.	Phase 3	D0R8FL	.	CTPDG001068
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Fulranumab	.	.	Phase 3	D0O1GS	.	CTPDG001105
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Nabiximols	Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02	44148067	Phase 3	D0C5CE	.	CTPDG001256
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Tanezumab	.	.	Phase 3	D00BVS	.	CTPDG001506
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	CR-845	"Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring"	.	Phase 2	D08NJE	.	CTPDG001560
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	LY3556050	"(1R,5S,6R)-N-{2-methyl-1-[(3-methylpyridin-2-yl)oxy]propan-2-yl}-3-azabicyclo[3.1.0]hexane-6-carboxamide; 1638588-92-7; AT36106; BDBM311911; EN300-1700347; LY3556050; SCHEMBL16252692; US10166214, Example 47; Z3071648657"	86294067	Phase 2	DXE53Z	.	CTPDG001614
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	A277	.	.	Phase 2	DDQH94	.	CTPDG001740
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	LY3526318	.	.	Phase 2	D40GBC	.	CTPDG001819
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	V120083	S120083	.	Phase 2	D0X3JK	.	CTPDG001902
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	XEN-2174	.	.	Phase 2	D0U2XU	.	CTPDG001994
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Flupirtine	"56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami"	53276	Phase 2	D0SD9V	DB06623	CTPDG002034
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	ABT-652	.	.	Phase 2	D0S5BV	.	CTPDG002042
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	PF-05089771	"Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer"	46840946	Phase 2	D0O7QA	DB14856	CTPDG002135
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	EB-001	.	.	Phase 2	D0O1VU	.	CTPDG002145
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Omnitram	.	.	Phase 2	D0KZ3Q	.	CTPDG002242
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	NP-2 gene therapy	.	.	Phase 2	D06ZQL	.	CTPDG002712
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	PF-06372865	.	76287260	Phase 2	D06TQR	.	CTPDG002730
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Resiniferatoxin	"Reciniferatoxin; UNII-A5O6P1UL4I; A5O6P1UL4I; 57444-62-9; RTX; [3H]resiniferatoxin; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); CHEMBL448382; resinferatoxin; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; Resiniferatoxin(RTX); CHEMBL17976"	5702546	Phase 1	D05XJW	DB06515	CTPDG002779
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	REL-1015	.	.	Phase 2	D03RYJ	.	CTPDG002907
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Neramexane	"Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine"	6433106	Phase 2	D01KMR	DB04926	CTPDG003032
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1/2	COL-195	.	.	Phase 1/2	D0XB8Y	.	CTPDG003283
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	REL-1028	.	.	Phase 1	D0XD0N	.	CTPDG004278
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	CNTX-0290	.	.	Phase 1	D0U0CF	.	CTPDG004390
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Egalet-004	.	.	Phase 1	D0R9WD	.	CTPDG004454
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	TRV734	.	.	Phase 1	D0OK6F	.	CTPDG004534
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	CA-011	"2-Amino-4-(p-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-1,3-thiazol-2-amine; 2-Amino-4-(4-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-2-thiazolamine; 2-Thiazolamine, 4-(4-nitrophenyl)-; 4-(4-nitrophenyl)thiazol-2-amine; THIAZOLE, 2-AMINO-4-(p-NITROPHENYL)-; 4-(4-Nitrophenyl)thiazol-2-ylamine; 2-amino-4-(4'-nitrophenyl)-1,3-thiazole; RIKJWJIWXCUKQV-UHFFFAOYSA-N; BRN 0200321; 4-(4-Nitro-phenyl)-thiazol-2-ylamine; AI3-62320; 4-(4-nitrophenyl)-1,3-thiazole-2-ylamine; DSSTox_CID_65; AC1L27WX; Cambridge id 5156331; DSSTox_RID_"	16420	Phase 1	D0KK9D	.	CTPDG004648
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	PF-06305591	.	71666749	Phase 1	D0K9IF	DB12106	CTPDG004651
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	OX-27	.	.	Phase 1	D0J9GR	.	CTPDG004682
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	DWJ-208	.	.	Phase 1	D0G0ER	.	CTPDG004783
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	JNJ-39439335	Mavatrep; 956274-94-5; UNII-F197218T99; F197218T99; Mavatrep [USAN:INN]; Mavatrep (USAN); JNJ 39439335; SCHEMBL1796599; SCHEMBL1797450; CHEMBL2364618; Mavatrep(JNJ-39439335); DTXSID90241905; BCP23936; EX-A2266; ZINC43175494; BDBM50086717; AKOS030527038; DB12875; CS-4591; SB17026; trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol; BC600772; HY-16935; B5930; J3.561.747G; D10370	17751090	Phase 1	D0EM4S	DB12875	CTPDG004821
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	ABT-110	"Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics"	.	Phase 1	D03APM	.	CTPDG005329
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Debio 0827	.	16123252	Phase 1	D02HUY	.	CTPDG005358
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	GDC0310	"RG6029; FCTMRPTVPHVTTN-UHFFFAOYSA-N; SCHEMBL16770884; BDBM71258; BCP25347; US9694002, 346; 1788066-71-6"	118120526	Phase 1	D01FZZ	.	CTPDG005415
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	PF614	.	.	Phase 1	D00SBU	.	CTPDG005443
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	ABT-102	"3-(1H-indazol-4-yl)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea"	11256560	Phase 1	D00CMV	.	CTPDG005473
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-68	.	23628075	Patented	D0ZZ8F	.	CTPDG005511
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-152	.	44548476	Patented	D0ZS3E	.	CTPDG005514
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-96	.	.	Patented	D0ZQ2W	.	CTPDG005516
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-105	.	25027804	Patented	D0ZP2C	.	CTPDG005517
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-18	.	25265637	Patented	D0ZM8H	.	CTPDG005519
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015143654Example29	.	Patented	D0ZE6H	.	CTPDG005522
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-107	.	51349201	Patented	D0ZE1M	.	CTPDG005524
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-144	.	67412556	Patented	D0Z5HH	.	CTPDG005531
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-160	.	.	Patented	D0Z4QQ	.	CTPDG005533
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-151	.	68324656	Patented	D0YU9B	.	CTPDG005541
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-21	.	.	Patented	D0YR4E	.	CTPDG005542
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014078408Example26	.	.	Patented	D0YN0I	.	CTPDG005544
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-67	.	23628014	Patented	D0YM1M	.	CTPDG005545
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-64	.	.	Patented	D0Y9ST	.	CTPDG005548
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-100	.	71480662	Patented	D0Y1SI	.	CTPDG005550
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013009582Example76	.	.	Patented	D0Y0XJ	.	CTPDG005552
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-161	.	.	Patented	D0XX8R	.	CTPDG005555
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpyrrolidine ether derivative 1	PMID28270021-Compound-WO2016020784Example11	.	Patented	D0X4LA	.	CTPDG005566
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-39	.	57335613	Patented	D0X1OO	.	CTPDG005567
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 3	PMID28270021-Compound-WO2015092610Example164	.	Patented	D0X1LP	.	CTPDG005568
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-120	.	53477386	Patented	D0WX4W	.	CTPDG005569
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-132	.	66908117	Patented	D0WT1W	.	CTPDG005574
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-91	.	.	Patented	D0WJ8R	.	CTPDG005580
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Imidazo pyridine derivative 1	PMID28270021-Compound-WO2015200341Example96	.	Patented	D0WI7N	.	CTPDG005581
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-33	.	71611619	Patented	D0W4AA	.	CTPDG005583
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example12	.	.	Patented	D0VD5J	.	CTPDG005592
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[1,5-a]pyridine derivative 2"	PMID28270021-Compound-WO2013088257Example240	.	Patented	D0V9ZJ	.	CTPDG005597
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-89	.	.	Patented	D0V9RM	.	CTPDG005598
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-36	.	71611910	Patented	D0V3PI	.	CTPDG005602
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Tri-substituted urea derivative 1	PMID28270021-Compound-WO2013176970Example1	.	Patented	D0UQ2G	.	CTPDG005607
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 5	PMID28270021-Compound-WO2015148344Example152	.	Patented	D0UN4M	.	CTPDG005608
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-83	.	11720246	Patented	D0UE9K	.	CTPDG005611
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-45	.	70816331	Patented	D0U8YZ	.	CTPDG005615
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example11	.	.	Patented	D0U5XI	.	CTPDG005618
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-125	.	53475699	Patented	D0U5ON	.	CTPDG005619
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-54	.	70816505	Patented	D0U5CQ	.	CTPDG005621
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrido[3,2-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012125668Example27	.	Patented	D0U3RD	.	CTPDG005624
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-38	.	87087836	Patented	D0TZ2W	.	CTPDG005626
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015148350Example36	.	Patented	D0T4CF	.	CTPDG005640
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 109	.	.	Patented	D0T0HM	.	CTPDG005644
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-16	.	46191563	Patented	D0SD4G	.	CTPDG005651
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012137089cE-245677	.	Patented	D0S0II	.	CTPDG005658
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrido[3,2-d]pyrimidine derivative 2"	PMID28270021-Compound-WO2012125668Example12	.	Patented	D0RR8O	.	CTPDG005662
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[4,3-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053965Example3	.	Patented	D0RK6W	.	CTPDG005664
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-139	.	.	Patented	D0RC7L	.	CTPDG005670
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-32	.	.	Patented	D0R9RP	.	CTPDG005672
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-14	.	60202428	Patented	D0R8GA	.	CTPDG005674
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-106	.	51349065	Patented	D0R2VB	.	CTPDG005681
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-122	.	53476470	Patented	D0R2QV	.	CTPDG005682
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014129431Example8-1	.	.	Patented	D0QT8L	.	CTPDG005690
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-81	.	11706654	Patented	D0QP4N	.	CTPDG005692
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 201	.	.	Patented	D0PY0G	.	CTPDG005704
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-112	.	70652314	Patented	D0PT0U	.	CTPDG005705
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-129	.	.	Patented	D0PJ8O	.	CTPDG005707
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-43	.	.	Patented	D0P9KJ	.	CTPDG005710
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 1"	PMID28270021-Compound-WO2008063888P-0171	.	Patented	D0P8SR	.	CTPDG005711
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-49	.	71238636	Patented	D0P5SB	.	CTPDG005716
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-57	.	71537379	Patented	D0P0MR	.	CTPDG005722
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-8	.	66549082	Patented	D0ON4M	.	CTPDG005728
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-75	.	11598064	Patented	D0OC6A	.	CTPDG005730
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-53	.	70816499	Patented	D0OA1P	.	CTPDG005731
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-63	.	71534837	Patented	D0O9GI	.	CTPDG005732
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1"	PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)	.	Patented	D0O8SX	.	CTPDG005733
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-6	.	66549275	Patented	D0O7IQ	.	CTPDG005736
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-92	.	.	Patented	D0O6VU	.	CTPDG005737
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-136	.	58387639	Patented	D0O3TG	.	CTPDG005740
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-86	.	56949431	Patented	D0O0UG	.	CTPDG005741
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 3	PMID28270021-Compound-WO2015148354Example41	.	Patented	D0O0GZ	.	CTPDG005742
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-157	.	52949700	Patented	D0NV2M	.	CTPDG005743
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-19	.	25263543	Patented	D0NM3D	.	CTPDG005744
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-142	.	58387658	Patented	D0NH2M	.	CTPDG005747
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-35	.	.	Patented	D0NB5M	.	CTPDG005749
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-7	.	66551085	Patented	D0N9FJ	.	CTPDG005751
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 7	PMID28270021-Compound-WO2015148373Example36	.	Patented	D0N6NG	.	CTPDG005753
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-24	.	.	Patented	D0N2UQ	.	CTPDG005760
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-156	.	24783142	Patented	D0N0TF	.	CTPDG005764
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-146	.	59730981	Patented	D0N0QN	.	CTPDG005765
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Triazolo[4,3-b]pyridazine derivative 2"	PMID28270021-Compound-WO2012125667Example24	.	Patented	D0MZ7K	.	CTPDG005767
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-109	.	11187857	Patented	D0MY3K	.	CTPDG005769
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-47	.	88995251	Patented	D0MU3S	.	CTPDG005771
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-29	.	71599906	Patented	D0M4WY	.	CTPDG005784
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example112	.	.	Patented	D0LK8E	.	CTPDG005792
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-162	.	.	Patented	D0LA0Q	.	CTPDG005794
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-137	.	.	Patented	D0KM0W	.	CTPDG005805
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-98	.	71480662	Patented	D0KF3A	.	CTPDG005808
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 5	PMID28270021-Compound-WO2015148373Example104	.	Patented	D0KC8X	.	CTPDG005811
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-1	.	68313317	Patented	D0KB2Z	.	CTPDG005812
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 495	.	.	Patented	D0K6IM	.	CTPDG005818
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-46	.	.	Patented	D0K4SZ	.	CTPDG005820
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-148	.	59731038	Patented	D0K3KM	.	CTPDG005821
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-155	.	24782891	Patented	D0K3KE	.	CTPDG005822
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-141	.	53402973	Patented	D0K0ZI	.	CTPDG005826
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-62	.	71506872	Patented	D0JX4I	.	CTPDG005828
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-147	.	59731029	Patented	D0JT8B	.	CTPDG005830
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-22	.	.	Patented	D0JK2N	.	CTPDG005833
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-31	.	.	Patented	D0JC8L	.	CTPDG005834
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-59	.	71539690	Patented	D0J9CS	.	CTPDG005836
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 103	.	.	Patented	D0J4CA	.	CTPDG005843
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-52	.	70816169	Patented	D0IU1H	.	CTPDG005845
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-94	.	.	Patented	D0IT4N	.	CTPDG005846
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-27	.	71599827	Patented	D0IR7H	.	CTPDG005848
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-9	.	66549271	Patented	D0IP5E	.	CTPDG005849
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-48	.	.	Patented	D0IN5E	.	CTPDG005851
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-102	.	.	Patented	D0IK1S	.	CTPDG005852
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 4	PMID28270021-Compound-WO2015148354Example99	.	Patented	D0I9FU	.	CTPDG005859
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-159	.	.	Patented	D0I3ZW	.	CTPDG005864
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013161919Example85-117	.	.	Patented	D0I2OO	.	CTPDG005866
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-20	.	.	Patented	D0HS1D	.	CTPDG005873
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 1	PMID28270021-Compound-WO2015148354Example21(R or S)	.	Patented	D0HF1A	.	CTPDG005877
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-11	.	66549650	Patented	D0HE7X	.	CTPDG005879
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-72	.	11582721	Patented	D0H6CX	.	CTPDG005886
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-80	.	11656215	Patented	D0H4TR	.	CTPDG005889
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015143654Example41	.	Patented	D0H3ZG	.	CTPDG005891
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-4	.	66551282	Patented	D0GZ4G	.	CTPDG005898
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-66	.	23627957	Patented	D0GV5G	.	CTPDG005903
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-143	.	.	Patented	D0G6IQ	.	CTPDG005913
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-55	.	56836246	Patented	D0G3UV	.	CTPDG005914
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 481	.	.	Patented	D0FL8A	.	CTPDG005922
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 2	PMID28270021-Compound-WO2015148354Example33(R or S)	.	Patented	D0F8BF	.	CTPDG005930
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-65	.	71238361	Patented	D0F5NQ	.	CTPDG005932
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-15	.	25263680	Patented	D0F4YX	.	CTPDG005933
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-30	.	71598766	Patented	D0F4DI	.	CTPDG005935
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-101	.	71609207	Patented	D0F3HP	.	CTPDG005936
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 803	.	.	Patented	D0F2BF	.	CTPDG005937
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-26	.	71599484	Patented	D0EV3G	.	CTPDG005942
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-118	.	53386424	Patented	D0EH2T	.	CTPDG005948
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 4	PMID28270021-Compound-WO2015143654Example62	.	Patented	D0EC4Z	.	CTPDG005949
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-82	.	.	Patented	D0EC3Z	.	CTPDG005950
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-69	.	23628077	Patented	D0E8UP	.	CTPDG005954
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-110	.	.	Patented	D0E0SA	.	CTPDG005958
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 8	PMID28270021-Compound-WO2015148373Example41(S)	.	Patented	D0DY5R	.	CTPDG005959
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-124	.	53476472	Patented	D0DT7M	.	CTPDG005962
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[3,2-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053968Example5	.	Patented	D0DQ5G	.	CTPDG005963
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[1,5-a]pyridine derivative 1"	PMID28270021-Compound-WO2013088256Example59	.	Patented	D0DN3Q	.	CTPDG005966
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-130	.	.	Patented	D0DI1R	.	CTPDG005970
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-42	.	70816270	Patented	D0DE5K	.	CTPDG005973
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-78	.	.	Patented	D0DE5I	.	CTPDG005974
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-74	.	11676921	Patented	D0DC4O	.	CTPDG005976
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-108	.	51349341	Patented	D0D4NX	.	CTPDG005986
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-115	.	88875843	Patented	D0D2CF	.	CTPDG005989
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015148350Example81	.	Patented	D0CY3U	.	CTPDG005992
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-76	.	11532887	Patented	D0CX4C	.	CTPDG005993
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-138	.	.	Patented	D0CR0H	.	CTPDG005997
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Tri-substituted urea derivative 2	PMID28270021-Compound-WO2013176970Example2	.	Patented	D0CG8N	.	CTPDG006004
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-87	.	56961050	Patented	D0C9FN	.	CTPDG006008
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-12	.	66549652	Patented	D0C8ZZ	.	CTPDG006009
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-114	.	89556774	Patented	D0C5NT	.	CTPDG006012
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-(phenylpyrazolyl)benzamide derivative 1	PMID28270021-Compound-WO2013132376Example157	.	Patented	D0C3RK	.	CTPDG006014
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-10	.	66551086	Patented	D0C1MZ	.	CTPDG006015
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example80	.	.	Patented	D0BO1H	.	CTPDG006019
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-77	.	11562798	Patented	D0B4NI	.	CTPDG006026
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-51	.	57335038	Patented	D0B0WJ	.	CTPDG006032
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-153	.	88937082	Patented	D0AQ3U	.	CTPDG006035
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-113	.	70652315	Patented	D0A8LU	.	CTPDG006042
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-25	.	71599909	Patented	D0A3XC	.	CTPDG006045
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-34	.	71611907	Patented	D0A0YI	.	CTPDG006049
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-40	.	66644325	Patented	D09ZWU	.	CTPDG006050
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-128	.	24758063	Patented	D09SMA	.	CTPDG006055
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-79	.	11677423	Patented	D09QXC	.	CTPDG006057
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-84	.	11613881	Patented	D08ZBB	.	CTPDG006070
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-111	.	.	Patented	D08YAL	.	CTPDG006072
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-135	.	58387673	Patented	D08UEC	.	CTPDG006077
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-13	.	66549649	Patented	D08ICT	.	CTPDG006083
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example71	.	.	Patented	D08CZY	.	CTPDG006086
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-123	.	53476471	Patented	D08CLA	.	CTPDG006087
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpyrrolidine ether derivative 2	PMID28270021-Compound-WO2016020784Example12	.	Patented	D08BIH	.	CTPDG006090
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-134	.	11674039	Patented	D07XZR	.	CTPDG006094
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-119	.	53477385	Patented	D07XVL	.	CTPDG006095
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015143654Example60	.	Patented	D07VFQ	.	CTPDG006097
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-131	.	25094155	Patented	D07RYM	.	CTPDG006100
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-127	.	24759759	Patented	D07MNI	.	CTPDG006112
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 811	.	.	Patented	D07KVL	.	CTPDG006113
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-17	.	.	Patented	D07JNJ	.	CTPDG006115
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-117	.	.	Patented	D07FWF	.	CTPDG006121
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-50	.	71237925	Patented	D07FIY	.	CTPDG006123
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-56	.	71238385	Patented	D07EGF	.	CTPDG006124
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-41	.	66644203	Patented	D07EAV	.	CTPDG006125
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 6	PMID28270021-Compound-WO2015148373Example111	.	Patented	D07CPL	.	CTPDG006126
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-85	.	11671115	Patented	D07BZW	.	CTPDG006127
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 9	PMID28270021-Compound-WO2015148373Example42(R)	.	Patented	D07AJO	.	CTPDG006129
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID27998201-Compound-12	.	.	Patented	D06XCD	.	CTPDG006131
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-3	.	66549466	Patented	D06VYF	.	CTPDG006134
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-37	.	49802515	Patented	D06JHW	.	CTPDG006147
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 2"	PMID28270021-Compound-WO2008063888P-0180	.	Patented	D06GOT	.	CTPDG006149
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-90	.	.	Patented	D05ZWR	.	CTPDG006154
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-28	.	71580510	Patented	D05SWL	.	CTPDG006160
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-116	.	88875796	Patented	D05SMP	.	CTPDG006161
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-99	.	71498842	Patented	D05RBF	.	CTPDG006163
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 7	PMID28270021-Compound-WO2015148344Example96	.	Patented	D05MRY	.	CTPDG006168
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014078408Example1	.	.	Patented	D05AQT	.	CTPDG006179
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-154	.	88937150	Patented	D04TIU	.	CTPDG006185
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 2	PMID28270021-Compound-WO2015092610Example114	.	Patented	D04RXX	.	CTPDG006186
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 6	PMID28270021-Compound-WO2015148344Example59	.	Patented	D04JCD	.	CTPDG006197
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-93	.	.	Patented	D04HCS	.	CTPDG006198
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 6	PMID28270021-Compound-WO2015092610Example9	.	Patented	D04GCC	.	CTPDG006201
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-44	.	70816274	Patented	D04FRL	.	CTPDG006202
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015148350Example76	.	Patented	D04BRW	.	CTPDG006207
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-97	.	.	Patented	D03ZOZ	.	CTPDG006210
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-71	.	23628017	Patented	D03YFL	.	CTPDG006211
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-145	.	67412506	Patented	D03VXP	.	CTPDG006218
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-88	.	.	Patented	D03SHM	.	CTPDG006221
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-61	.	.	Patented	D03QAW	.	CTPDG006223
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-73	.	11532940	Patented	D03FSF	.	CTPDG006233
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-70	.	58416270	Patented	D03EEA	.	CTPDG006235
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 5	PMID28270021-Compound-WO2015092610Example3	.	Patented	D03BAY	.	CTPDG006238
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013009582Example16	.	.	Patented	D02ZQN	.	CTPDG006241
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-23	.	.	Patented	D02QJE	.	CTPDG006251
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 7	PMID28270021-Compound-WO2016009296Example15	.	Patented	D02OLJ	.	CTPDG006252
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-5	.	.	Patented	D02OAH	.	CTPDG006254
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-140	.	23585453	Patented	D02JQB	.	CTPDG006258
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 3"	PMID28270021-Compound-WO2010129570P-2061	.	Patented	D02IBX	.	CTPDG006259
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014152663 701	.	.	Patented	D02ETU	.	CTPDG006261
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-126	.	53475700	Patented	D02EKO	.	CTPDG006262
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-104	.	25104368	Patented	D01RUK	.	CTPDG006268
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-58	.	.	Patented	D01PLJ	.	CTPDG006271
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-103	.	.	Patented	D01LGQ	.	CTPDG006276
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-158	.	16742146	Patented	D01HED	.	CTPDG006279
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-133	.	25094231	Patented	D01GEK	.	CTPDG006280
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-150	.	68324561	Patented	D01DNH	.	CTPDG006281
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-2	.	66549276	Patented	D00YXA	.	CTPDG006287
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 1	PMID28270021-Compound-WO2015092610Example113	.	Patented	D00XXZ	.	CTPDG006288
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-60	.	.	Patented	D00QEZ	.	CTPDG006299
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-149	.	.	Patented	D00OLY	.	CTPDG006301
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-95	.	.	Patented	D00ODY	.	CTPDG006302
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-121	.	53477387	Patented	D00KTN	.	CTPDG006306
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 4	PMID28270021-Compound-WO2015092610Example2	.	Patented	D00FJH	.	CTPDG006308
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example82	.	.	Patented	D00EUL	.	CTPDG006309
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 3	Propiram fumarate	Algeril; Diramax; Dirame; Diramine; Diratab; Propiram; FBA-4503	6433584	Discontinued in Phase 3	D08LIF	.	CTPDG006373
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 1	AMG-517	AMG 517; BD-0082	16007367	Discontinued in Phase 1	D0L5XI	.	CTPDG006783
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 1	BL-1827	.	.	Discontinued in Phase 1	D06MXY	.	CTPDG006876
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	SequestOx	Oxycodone / naltrexone; Naltrexone / oxycodone; Troxyca Er; Oxycodone hydrochloride / naltrexone hydrochloride; Naltrexone hydrochloride / oxycodone hydrochloride; Naltrexone hydrochloride and oxycodone hydrochloride; ALO-02; Naltrexone hydrochloride mixture with oxycodone hydrochloride; 850636-71-4; Oxycodone hydrochloride and naltrexone hydrochloride	90479726	Application submitted	D0FU5Y	.	CTPDG006945
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	Remoxy ER	.	.	Application submitted	D0B7VH	.	CTPDG006947
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	Oxycodone hydrochloride	oxycodone ER	5462350	Application submitted	D07WPQ	.	CTPDG006949
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	DBO-17	.	10042211	Terminated	D0XH1H	.	CTPDG007179
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	DBO-11	166374-49-8; Naxifylline (USAN/INN)	23724971	Terminated	D0PE1A	.	CTPDG007250
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	ACEA-1328	.	9816093	Terminated	D0O4JH	.	CTPDG007264
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	RO-25-6981	"Ro 25-6981; CHEMBL305195; ro25-6981; 169274-78-6; 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol; 4-((1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol; QEM; Tocris-1594; AC1O7H0A; Lopac0_001082; ZINC7042; SCHEMBL6159263; CHEBI:92897; HMS3268G13; EX-A1825; PDSP2_000361; BDBM50080029; CS-2011; CCG-205159; NCGC00025226-01; NCGC00025226-03; NCGC00025226-02; HY-13993; (AR,BS)-ALPHA-(4-HYDROXYPHENYL)-BETA-METHYL-4-(PHENYLMETHYL)-1-PIPERIDINEPROPANOL MALEATE; BRD-K51541829-001-01-3"	6604887	Terminated	D0K0DB	.	CTPDG007307
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Investigative	THA-901	TH-901	.	Investigative	D06MEC	.	CTPDG008750
M6ACROT02095	.	.	M6ADIS0024	MG30: Chronic pain	Investigative	SP-SAP	"NK1-saporin conjugate, Advanced Targeting Systems; Neurokinin NK1-saporin conjugate, ATS; SP-SAP, APT; SP-SAP, Advanced Pain Therapeutics; SP-SAP, Advanced Targeting Systems; Substance P-saporin conjugate, ATS; Substance P-saporin conjugate, Advanced Targeting Systems"	.	Investigative	D04LHG	.	CTPDG008884
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Morphine	Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr	5288826	Approved	D0WE3O	DB00295	CTPDG000078
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Ketoprofen	"Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid"	3825	Approved	D0W9WF	DB01009	CTPDG000080
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Strontium Chloride Sr-89	Metastron	5388879	Approved	D0R6HN	DB09498	CTPDG000179
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Withdrawn from market	Alpha 1-PI	Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine	3689	Withdrawn from market	D0I0DL	DB08954	CTPDG000356
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Fentanyl	"Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	3345	Approved	D0E1WI	DB00813	CTPDG011520
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Phenylbutazone	"Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione"	4781	Approved	D07VHR	DB00812	CTPDG000546
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Samarium Sm-153 Lexidronam Pentasodium	.	9810246	Approved	D04YHR	DB09509	CTPDG000653
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Hydromorphone	"Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug"	5284570	Approved	D04JHN	DB00327	CTPDG011532
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Approved	Ethanol	"Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA"	702	Approved	D00AMQ	DB00898	CTPDG000831
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Mirogabalin	"1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303"	59509752	Phase 3	D07VFD	DB11825	CTPDG000836
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 4	Dihydrocodeine	"Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine"	5284543	Phase 4	D0T6RC	DB01551	CTPDG000843
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Preregistration	GSK2696273	.	.	Preregistration	D0F4QV	.	CTPDG000856
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Egalet-002	.	.	Phase 3	D0R8FL	.	CTPDG001068
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Fulranumab	.	.	Phase 3	D0O1GS	.	CTPDG001105
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Nabiximols	Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02	44148067	Phase 3	D0C5CE	.	CTPDG001256
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 3	Tanezumab	.	.	Phase 3	D00BVS	.	CTPDG001506
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	CR-845	"Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring"	.	Phase 2	D08NJE	.	CTPDG001560
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	LY3556050	"(1R,5S,6R)-N-{2-methyl-1-[(3-methylpyridin-2-yl)oxy]propan-2-yl}-3-azabicyclo[3.1.0]hexane-6-carboxamide; 1638588-92-7; AT36106; BDBM311911; EN300-1700347; LY3556050; SCHEMBL16252692; US10166214, Example 47; Z3071648657"	86294067	Phase 2	DXE53Z	.	CTPDG001614
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	A277	.	.	Phase 2	DDQH94	.	CTPDG001740
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	LY3526318	.	.	Phase 2	D40GBC	.	CTPDG001819
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	V120083	S120083	.	Phase 2	D0X3JK	.	CTPDG001902
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	XEN-2174	.	.	Phase 2	D0U2XU	.	CTPDG001994
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Flupirtine	"56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami"	53276	Phase 2	D0SD9V	DB06623	CTPDG002034
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	ABT-652	.	.	Phase 2	D0S5BV	.	CTPDG002042
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	PF-05089771	"Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer"	46840946	Phase 2	D0O7QA	DB14856	CTPDG002135
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	EB-001	.	.	Phase 2	D0O1VU	.	CTPDG002145
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Omnitram	.	.	Phase 2	D0KZ3Q	.	CTPDG002242
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	NP-2 gene therapy	.	.	Phase 2	D06ZQL	.	CTPDG002712
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	PF-06372865	.	76287260	Phase 2	D06TQR	.	CTPDG002730
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Resiniferatoxin	"Reciniferatoxin; UNII-A5O6P1UL4I; A5O6P1UL4I; 57444-62-9; RTX; [3H]resiniferatoxin; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); CHEMBL448382; resinferatoxin; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; Resiniferatoxin(RTX); CHEMBL17976"	5702546	Phase 1	D05XJW	DB06515	CTPDG002779
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	REL-1015	.	.	Phase 2	D03RYJ	.	CTPDG002907
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 2	Neramexane	"Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine"	6433106	Phase 2	D01KMR	DB04926	CTPDG003032
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1/2	COL-195	.	.	Phase 1/2	D0XB8Y	.	CTPDG003283
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	REL-1028	.	.	Phase 1	D0XD0N	.	CTPDG004278
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	CNTX-0290	.	.	Phase 1	D0U0CF	.	CTPDG004390
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Egalet-004	.	.	Phase 1	D0R9WD	.	CTPDG004454
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	TRV734	.	.	Phase 1	D0OK6F	.	CTPDG004534
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	CA-011	"2-Amino-4-(p-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-1,3-thiazol-2-amine; 2-Amino-4-(4-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-2-thiazolamine; 2-Thiazolamine, 4-(4-nitrophenyl)-; 4-(4-nitrophenyl)thiazol-2-amine; THIAZOLE, 2-AMINO-4-(p-NITROPHENYL)-; 4-(4-Nitrophenyl)thiazol-2-ylamine; 2-amino-4-(4'-nitrophenyl)-1,3-thiazole; RIKJWJIWXCUKQV-UHFFFAOYSA-N; BRN 0200321; 4-(4-Nitro-phenyl)-thiazol-2-ylamine; AI3-62320; 4-(4-nitrophenyl)-1,3-thiazole-2-ylamine; DSSTox_CID_65; AC1L27WX; Cambridge id 5156331; DSSTox_RID_"	16420	Phase 1	D0KK9D	.	CTPDG004648
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	PF-06305591	.	71666749	Phase 1	D0K9IF	DB12106	CTPDG004651
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	OX-27	.	.	Phase 1	D0J9GR	.	CTPDG004682
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	DWJ-208	.	.	Phase 1	D0G0ER	.	CTPDG004783
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	JNJ-39439335	Mavatrep; 956274-94-5; UNII-F197218T99; F197218T99; Mavatrep [USAN:INN]; Mavatrep (USAN); JNJ 39439335; SCHEMBL1796599; SCHEMBL1797450; CHEMBL2364618; Mavatrep(JNJ-39439335); DTXSID90241905; BCP23936; EX-A2266; ZINC43175494; BDBM50086717; AKOS030527038; DB12875; CS-4591; SB17026; trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol; BC600772; HY-16935; B5930; J3.561.747G; D10370	17751090	Phase 1	D0EM4S	DB12875	CTPDG004821
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	ABT-110	"Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics"	.	Phase 1	D03APM	.	CTPDG005329
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	Debio 0827	.	16123252	Phase 1	D02HUY	.	CTPDG005358
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	GDC0310	"RG6029; FCTMRPTVPHVTTN-UHFFFAOYSA-N; SCHEMBL16770884; BDBM71258; BCP25347; US9694002, 346; 1788066-71-6"	118120526	Phase 1	D01FZZ	.	CTPDG005415
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	PF614	.	.	Phase 1	D00SBU	.	CTPDG005443
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Phase 1	ABT-102	"3-(1H-indazol-4-yl)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea"	11256560	Phase 1	D00CMV	.	CTPDG005473
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-68	.	23628075	Patented	D0ZZ8F	.	CTPDG005511
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-152	.	44548476	Patented	D0ZS3E	.	CTPDG005514
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-96	.	.	Patented	D0ZQ2W	.	CTPDG005516
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-105	.	25027804	Patented	D0ZP2C	.	CTPDG005517
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-18	.	25265637	Patented	D0ZM8H	.	CTPDG005519
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015143654Example29	.	Patented	D0ZE6H	.	CTPDG005522
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-107	.	51349201	Patented	D0ZE1M	.	CTPDG005524
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-144	.	67412556	Patented	D0Z5HH	.	CTPDG005531
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-160	.	.	Patented	D0Z4QQ	.	CTPDG005533
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-151	.	68324656	Patented	D0YU9B	.	CTPDG005541
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-21	.	.	Patented	D0YR4E	.	CTPDG005542
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014078408Example26	.	.	Patented	D0YN0I	.	CTPDG005544
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-67	.	23628014	Patented	D0YM1M	.	CTPDG005545
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-64	.	.	Patented	D0Y9ST	.	CTPDG005548
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-100	.	71480662	Patented	D0Y1SI	.	CTPDG005550
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013009582Example76	.	.	Patented	D0Y0XJ	.	CTPDG005552
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-161	.	.	Patented	D0XX8R	.	CTPDG005555
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpyrrolidine ether derivative 1	PMID28270021-Compound-WO2016020784Example11	.	Patented	D0X4LA	.	CTPDG005566
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-39	.	57335613	Patented	D0X1OO	.	CTPDG005567
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 3	PMID28270021-Compound-WO2015092610Example164	.	Patented	D0X1LP	.	CTPDG005568
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-120	.	53477386	Patented	D0WX4W	.	CTPDG005569
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-132	.	66908117	Patented	D0WT1W	.	CTPDG005574
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-91	.	.	Patented	D0WJ8R	.	CTPDG005580
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Imidazo pyridine derivative 1	PMID28270021-Compound-WO2015200341Example96	.	Patented	D0WI7N	.	CTPDG005581
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-33	.	71611619	Patented	D0W4AA	.	CTPDG005583
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example12	.	.	Patented	D0VD5J	.	CTPDG005592
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[1,5-a]pyridine derivative 2"	PMID28270021-Compound-WO2013088257Example240	.	Patented	D0V9ZJ	.	CTPDG005597
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-89	.	.	Patented	D0V9RM	.	CTPDG005598
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-36	.	71611910	Patented	D0V3PI	.	CTPDG005602
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Tri-substituted urea derivative 1	PMID28270021-Compound-WO2013176970Example1	.	Patented	D0UQ2G	.	CTPDG005607
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 5	PMID28270021-Compound-WO2015148344Example152	.	Patented	D0UN4M	.	CTPDG005608
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-83	.	11720246	Patented	D0UE9K	.	CTPDG005611
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-45	.	70816331	Patented	D0U8YZ	.	CTPDG005615
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example11	.	.	Patented	D0U5XI	.	CTPDG005618
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-125	.	53475699	Patented	D0U5ON	.	CTPDG005619
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-54	.	70816505	Patented	D0U5CQ	.	CTPDG005621
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrido[3,2-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012125668Example27	.	Patented	D0U3RD	.	CTPDG005624
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-38	.	87087836	Patented	D0TZ2W	.	CTPDG005626
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015148350Example36	.	Patented	D0T4CF	.	CTPDG005640
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 109	.	.	Patented	D0T0HM	.	CTPDG005644
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-16	.	46191563	Patented	D0SD4G	.	CTPDG005651
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012137089cE-245677	.	Patented	D0S0II	.	CTPDG005658
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrido[3,2-d]pyrimidine derivative 2"	PMID28270021-Compound-WO2012125668Example12	.	Patented	D0RR8O	.	CTPDG005662
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[4,3-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053965Example3	.	Patented	D0RK6W	.	CTPDG005664
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-139	.	.	Patented	D0RC7L	.	CTPDG005670
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-32	.	.	Patented	D0R9RP	.	CTPDG005672
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-14	.	60202428	Patented	D0R8GA	.	CTPDG005674
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-106	.	51349065	Patented	D0R2VB	.	CTPDG005681
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-122	.	53476470	Patented	D0R2QV	.	CTPDG005682
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014129431Example8-1	.	.	Patented	D0QT8L	.	CTPDG005690
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-81	.	11706654	Patented	D0QP4N	.	CTPDG005692
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 201	.	.	Patented	D0PY0G	.	CTPDG005704
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-112	.	70652314	Patented	D0PT0U	.	CTPDG005705
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-129	.	.	Patented	D0PJ8O	.	CTPDG005707
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-43	.	.	Patented	D0P9KJ	.	CTPDG005710
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 1"	PMID28270021-Compound-WO2008063888P-0171	.	Patented	D0P8SR	.	CTPDG005711
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-49	.	71238636	Patented	D0P5SB	.	CTPDG005716
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-57	.	71537379	Patented	D0P0MR	.	CTPDG005722
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-8	.	66549082	Patented	D0ON4M	.	CTPDG005728
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-75	.	11598064	Patented	D0OC6A	.	CTPDG005730
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-53	.	70816499	Patented	D0OA1P	.	CTPDG005731
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-63	.	71534837	Patented	D0O9GI	.	CTPDG005732
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1"	PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)	.	Patented	D0O8SX	.	CTPDG005733
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-6	.	66549275	Patented	D0O7IQ	.	CTPDG005736
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-92	.	.	Patented	D0O6VU	.	CTPDG005737
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-136	.	58387639	Patented	D0O3TG	.	CTPDG005740
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-86	.	56949431	Patented	D0O0UG	.	CTPDG005741
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 3	PMID28270021-Compound-WO2015148354Example41	.	Patented	D0O0GZ	.	CTPDG005742
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-157	.	52949700	Patented	D0NV2M	.	CTPDG005743
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-19	.	25263543	Patented	D0NM3D	.	CTPDG005744
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-142	.	58387658	Patented	D0NH2M	.	CTPDG005747
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-35	.	.	Patented	D0NB5M	.	CTPDG005749
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-7	.	66551085	Patented	D0N9FJ	.	CTPDG005751
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 7	PMID28270021-Compound-WO2015148373Example36	.	Patented	D0N6NG	.	CTPDG005753
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-24	.	.	Patented	D0N2UQ	.	CTPDG005760
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-156	.	24783142	Patented	D0N0TF	.	CTPDG005764
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-146	.	59730981	Patented	D0N0QN	.	CTPDG005765
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Triazolo[4,3-b]pyridazine derivative 2"	PMID28270021-Compound-WO2012125667Example24	.	Patented	D0MZ7K	.	CTPDG005767
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-109	.	11187857	Patented	D0MY3K	.	CTPDG005769
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-47	.	88995251	Patented	D0MU3S	.	CTPDG005771
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-29	.	71599906	Patented	D0M4WY	.	CTPDG005784
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example112	.	.	Patented	D0LK8E	.	CTPDG005792
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-162	.	.	Patented	D0LA0Q	.	CTPDG005794
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-137	.	.	Patented	D0KM0W	.	CTPDG005805
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-98	.	71480662	Patented	D0KF3A	.	CTPDG005808
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 5	PMID28270021-Compound-WO2015148373Example104	.	Patented	D0KC8X	.	CTPDG005811
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-1	.	68313317	Patented	D0KB2Z	.	CTPDG005812
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 495	.	.	Patented	D0K6IM	.	CTPDG005818
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-46	.	.	Patented	D0K4SZ	.	CTPDG005820
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-148	.	59731038	Patented	D0K3KM	.	CTPDG005821
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-155	.	24782891	Patented	D0K3KE	.	CTPDG005822
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-141	.	53402973	Patented	D0K0ZI	.	CTPDG005826
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-62	.	71506872	Patented	D0JX4I	.	CTPDG005828
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-147	.	59731029	Patented	D0JT8B	.	CTPDG005830
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-22	.	.	Patented	D0JK2N	.	CTPDG005833
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-31	.	.	Patented	D0JC8L	.	CTPDG005834
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-59	.	71539690	Patented	D0J9CS	.	CTPDG005836
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 103	.	.	Patented	D0J4CA	.	CTPDG005843
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-52	.	70816169	Patented	D0IU1H	.	CTPDG005845
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-94	.	.	Patented	D0IT4N	.	CTPDG005846
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-27	.	71599827	Patented	D0IR7H	.	CTPDG005848
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-9	.	66549271	Patented	D0IP5E	.	CTPDG005849
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-48	.	.	Patented	D0IN5E	.	CTPDG005851
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-102	.	.	Patented	D0IK1S	.	CTPDG005852
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 4	PMID28270021-Compound-WO2015148354Example99	.	Patented	D0I9FU	.	CTPDG005859
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-159	.	.	Patented	D0I3ZW	.	CTPDG005864
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013161919Example85-117	.	.	Patented	D0I2OO	.	CTPDG005866
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-20	.	.	Patented	D0HS1D	.	CTPDG005873
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 1	PMID28270021-Compound-WO2015148354Example21(R or S)	.	Patented	D0HF1A	.	CTPDG005877
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-11	.	66549650	Patented	D0HE7X	.	CTPDG005879
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-72	.	11582721	Patented	D0H6CX	.	CTPDG005886
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-80	.	11656215	Patented	D0H4TR	.	CTPDG005889
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015143654Example41	.	Patented	D0H3ZG	.	CTPDG005891
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-4	.	66551282	Patented	D0GZ4G	.	CTPDG005898
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-66	.	23627957	Patented	D0GV5G	.	CTPDG005903
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-143	.	.	Patented	D0G6IQ	.	CTPDG005913
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-55	.	56836246	Patented	D0G3UV	.	CTPDG005914
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 481	.	.	Patented	D0FL8A	.	CTPDG005922
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 2	PMID28270021-Compound-WO2015148354Example33(R or S)	.	Patented	D0F8BF	.	CTPDG005930
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-65	.	71238361	Patented	D0F5NQ	.	CTPDG005932
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-15	.	25263680	Patented	D0F4YX	.	CTPDG005933
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-30	.	71598766	Patented	D0F4DI	.	CTPDG005935
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-101	.	71609207	Patented	D0F3HP	.	CTPDG005936
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 803	.	.	Patented	D0F2BF	.	CTPDG005937
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-26	.	71599484	Patented	D0EV3G	.	CTPDG005942
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-118	.	53386424	Patented	D0EH2T	.	CTPDG005948
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 4	PMID28270021-Compound-WO2015143654Example62	.	Patented	D0EC4Z	.	CTPDG005949
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-82	.	.	Patented	D0EC3Z	.	CTPDG005950
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-69	.	23628077	Patented	D0E8UP	.	CTPDG005954
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-110	.	.	Patented	D0E0SA	.	CTPDG005958
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 8	PMID28270021-Compound-WO2015148373Example41(S)	.	Patented	D0DY5R	.	CTPDG005959
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-124	.	53476472	Patented	D0DT7M	.	CTPDG005962
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[3,2-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053968Example5	.	Patented	D0DQ5G	.	CTPDG005963
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrazolo[1,5-a]pyridine derivative 1"	PMID28270021-Compound-WO2013088256Example59	.	Patented	D0DN3Q	.	CTPDG005966
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-130	.	.	Patented	D0DI1R	.	CTPDG005970
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-42	.	70816270	Patented	D0DE5K	.	CTPDG005973
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-78	.	.	Patented	D0DE5I	.	CTPDG005974
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-74	.	11676921	Patented	D0DC4O	.	CTPDG005976
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-108	.	51349341	Patented	D0D4NX	.	CTPDG005986
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-115	.	88875843	Patented	D0D2CF	.	CTPDG005989
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015148350Example81	.	Patented	D0CY3U	.	CTPDG005992
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-76	.	11532887	Patented	D0CX4C	.	CTPDG005993
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-138	.	.	Patented	D0CR0H	.	CTPDG005997
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Tri-substituted urea derivative 2	PMID28270021-Compound-WO2013176970Example2	.	Patented	D0CG8N	.	CTPDG006004
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-87	.	56961050	Patented	D0C9FN	.	CTPDG006008
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-12	.	66549652	Patented	D0C8ZZ	.	CTPDG006009
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-114	.	89556774	Patented	D0C5NT	.	CTPDG006012
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-(phenylpyrazolyl)benzamide derivative 1	PMID28270021-Compound-WO2013132376Example157	.	Patented	D0C3RK	.	CTPDG006014
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-10	.	66551086	Patented	D0C1MZ	.	CTPDG006015
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example80	.	.	Patented	D0BO1H	.	CTPDG006019
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-77	.	11562798	Patented	D0B4NI	.	CTPDG006026
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-51	.	57335038	Patented	D0B0WJ	.	CTPDG006032
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-153	.	88937082	Patented	D0AQ3U	.	CTPDG006035
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-113	.	70652315	Patented	D0A8LU	.	CTPDG006042
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-25	.	71599909	Patented	D0A3XC	.	CTPDG006045
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-34	.	71611907	Patented	D0A0YI	.	CTPDG006049
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-40	.	66644325	Patented	D09ZWU	.	CTPDG006050
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-128	.	24758063	Patented	D09SMA	.	CTPDG006055
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-79	.	11677423	Patented	D09QXC	.	CTPDG006057
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-84	.	11613881	Patented	D08ZBB	.	CTPDG006070
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-111	.	.	Patented	D08YAL	.	CTPDG006072
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-135	.	58387673	Patented	D08UEC	.	CTPDG006077
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-13	.	66549649	Patented	D08ICT	.	CTPDG006083
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example71	.	.	Patented	D08CZY	.	CTPDG006086
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-123	.	53476471	Patented	D08CLA	.	CTPDG006087
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpyrrolidine ether derivative 2	PMID28270021-Compound-WO2016020784Example12	.	Patented	D08BIH	.	CTPDG006090
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-134	.	11674039	Patented	D07XZR	.	CTPDG006094
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-119	.	53477385	Patented	D07XVL	.	CTPDG006095
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015143654Example60	.	Patented	D07VFQ	.	CTPDG006097
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-131	.	25094155	Patented	D07RYM	.	CTPDG006100
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-127	.	24759759	Patented	D07MNI	.	CTPDG006112
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2010077680 811	.	.	Patented	D07KVL	.	CTPDG006113
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-17	.	.	Patented	D07JNJ	.	CTPDG006115
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-117	.	.	Patented	D07FWF	.	CTPDG006121
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-50	.	71237925	Patented	D07FIY	.	CTPDG006123
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-56	.	71238385	Patented	D07EGF	.	CTPDG006124
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-41	.	66644203	Patented	D07EAV	.	CTPDG006125
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 6	PMID28270021-Compound-WO2015148373Example111	.	Patented	D07CPL	.	CTPDG006126
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-85	.	11671115	Patented	D07BZW	.	CTPDG006127
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Bicyclic heteroaryl benzamide derivative 9	PMID28270021-Compound-WO2015148373Example42(R)	.	Patented	D07AJO	.	CTPDG006129
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID27998201-Compound-12	.	.	Patented	D06XCD	.	CTPDG006131
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-3	.	66549466	Patented	D06VYF	.	CTPDG006134
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-37	.	49802515	Patented	D06JHW	.	CTPDG006147
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 2"	PMID28270021-Compound-WO2008063888P-0180	.	Patented	D06GOT	.	CTPDG006149
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-90	.	.	Patented	D05ZWR	.	CTPDG006154
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-28	.	71580510	Patented	D05SWL	.	CTPDG006160
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-116	.	88875796	Patented	D05SMP	.	CTPDG006161
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-99	.	71498842	Patented	D05RBF	.	CTPDG006163
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 7	PMID28270021-Compound-WO2015148344Example96	.	Patented	D05MRY	.	CTPDG006168
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014078408Example1	.	.	Patented	D05AQT	.	CTPDG006179
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-154	.	88937150	Patented	D04TIU	.	CTPDG006185
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 2	PMID28270021-Compound-WO2015092610Example114	.	Patented	D04RXX	.	CTPDG006186
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Six-membered heterocyclic benzamide derivative 6	PMID28270021-Compound-WO2015148344Example59	.	Patented	D04JCD	.	CTPDG006197
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-93	.	.	Patented	D04HCS	.	CTPDG006198
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 6	PMID28270021-Compound-WO2015092610Example9	.	Patented	D04GCC	.	CTPDG006201
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-44	.	70816274	Patented	D04FRL	.	CTPDG006202
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	Five membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015148350Example76	.	Patented	D04BRW	.	CTPDG006207
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-97	.	.	Patented	D03ZOZ	.	CTPDG006210
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-71	.	23628017	Patented	D03YFL	.	CTPDG006211
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-145	.	67412506	Patented	D03VXP	.	CTPDG006218
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-88	.	.	Patented	D03SHM	.	CTPDG006221
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-61	.	.	Patented	D03QAW	.	CTPDG006223
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-73	.	11532940	Patented	D03FSF	.	CTPDG006233
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-70	.	58416270	Patented	D03EEA	.	CTPDG006235
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 5	PMID28270021-Compound-WO2015092610Example3	.	Patented	D03BAY	.	CTPDG006238
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2013009582Example16	.	.	Patented	D02ZQN	.	CTPDG006241
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-23	.	.	Patented	D02QJE	.	CTPDG006251
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 7	PMID28270021-Compound-WO2016009296Example15	.	Patented	D02OLJ	.	CTPDG006252
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-5	.	.	Patented	D02OAH	.	CTPDG006254
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-140	.	23585453	Patented	D02JQB	.	CTPDG006258
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	"Pyrrolo[2,3-b]pyridine derivative 3"	PMID28270021-Compound-WO2010129570P-2061	.	Patented	D02IBX	.	CTPDG006259
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2014152663 701	.	.	Patented	D02ETU	.	CTPDG006261
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-126	.	53475700	Patented	D02EKO	.	CTPDG006262
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-104	.	25104368	Patented	D01RUK	.	CTPDG006268
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-58	.	.	Patented	D01PLJ	.	CTPDG006271
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-103	.	.	Patented	D01LGQ	.	CTPDG006276
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-158	.	16742146	Patented	D01HED	.	CTPDG006279
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-133	.	25094231	Patented	D01GEK	.	CTPDG006280
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-150	.	68324561	Patented	D01DNH	.	CTPDG006281
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-2	.	66549276	Patented	D00YXA	.	CTPDG006287
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 1	PMID28270021-Compound-WO2015092610Example113	.	Patented	D00XXZ	.	CTPDG006288
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-60	.	.	Patented	D00QEZ	.	CTPDG006299
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-149	.	.	Patented	D00OLY	.	CTPDG006301
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-95	.	.	Patented	D00ODY	.	CTPDG006302
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID25666693-Compound-121	.	53477387	Patented	D00KTN	.	CTPDG006306
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	N-acylpiperidine ether derivative 4	PMID28270021-Compound-WO2015092610Example2	.	Patented	D00FJH	.	CTPDG006308
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Patented	PMID28270021-Compound-WO2016054807Example82	.	.	Patented	D00EUL	.	CTPDG006309
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 3	Propiram fumarate	Algeril; Diramax; Dirame; Diramine; Diratab; Propiram; FBA-4503	6433584	Discontinued in Phase 3	D08LIF	.	CTPDG006373
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 1	AMG-517	AMG 517; BD-0082	16007367	Discontinued in Phase 1	D0L5XI	.	CTPDG006783
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Discontinued in Phase 1	BL-1827	.	.	Discontinued in Phase 1	D06MXY	.	CTPDG006876
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	SequestOx	Oxycodone / naltrexone; Naltrexone / oxycodone; Troxyca Er; Oxycodone hydrochloride / naltrexone hydrochloride; Naltrexone hydrochloride / oxycodone hydrochloride; Naltrexone hydrochloride and oxycodone hydrochloride; ALO-02; Naltrexone hydrochloride mixture with oxycodone hydrochloride; 850636-71-4; Oxycodone hydrochloride and naltrexone hydrochloride	90479726	Application submitted	D0FU5Y	.	CTPDG006945
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	Remoxy ER	.	.	Application submitted	D0B7VH	.	CTPDG006947
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Application submitted	Oxycodone hydrochloride	oxycodone ER	5462350	Application submitted	D07WPQ	.	CTPDG006949
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	DBO-17	.	10042211	Terminated	D0XH1H	.	CTPDG007179
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	DBO-11	166374-49-8; Naxifylline (USAN/INN)	23724971	Terminated	D0PE1A	.	CTPDG007250
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	ACEA-1328	.	9816093	Terminated	D0O4JH	.	CTPDG007264
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Terminated	RO-25-6981	"Ro 25-6981; CHEMBL305195; ro25-6981; 169274-78-6; 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol; 4-((1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol; QEM; Tocris-1594; AC1O7H0A; Lopac0_001082; ZINC7042; SCHEMBL6159263; CHEBI:92897; HMS3268G13; EX-A1825; PDSP2_000361; BDBM50080029; CS-2011; CCG-205159; NCGC00025226-01; NCGC00025226-03; NCGC00025226-02; HY-13993; (AR,BS)-ALPHA-(4-HYDROXYPHENYL)-BETA-METHYL-4-(PHENYLMETHYL)-1-PIPERIDINEPROPANOL MALEATE; BRD-K51541829-001-01-3"	6604887	Terminated	D0K0DB	.	CTPDG007307
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Investigative	THA-901	TH-901	.	Investigative	D06MEC	.	CTPDG008750
M6ACROT05411	.	.	M6ADIS0024	MG30: Chronic pain	Investigative	SP-SAP	"NK1-saporin conjugate, Advanced Targeting Systems; Neurokinin NK1-saporin conjugate, ATS; SP-SAP, APT; SP-SAP, Advanced Pain Therapeutics; SP-SAP, Advanced Targeting Systems; Substance P-saporin conjugate, ATS; Substance P-saporin conjugate, Advanced Targeting Systems"	.	Investigative	D04LHG	.	CTPDG008884
M6ACROT02109	.	.	M6ADIS0326	2D80: Liver metastases	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT02109	.	.	M6ADIS0326	2D80: Liver metastases	Phase 2	Codrituzumab	.	.	Phase 2	D0P0BY	.	CTPDG002120
M6ACROT02109	.	.	M6ADIS0326	2D80: Liver metastases	Phase 1	DNX-2440	.	.	Phase 1	D28VIO	.	CTPDG004173
M6ACROT02109	.	.	M6ADIS0326	2D80: Liver metastases	Phase 1	Anti-CEA CAR-T therapy	.	.	Phase 1	D0OP1L	.	CTPDG004533
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03020	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03021	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03022	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03023	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03024	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03115	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03181	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03202	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03203	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03256	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03257	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03258	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03259	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03260	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03261	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03262	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03263	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03264	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03265	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03266	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03267	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03268	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03269	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03270	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03271	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03272	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03273	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03274	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT03275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05103	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05127	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05172	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05290	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05292	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05321	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05833	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05834	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT02104	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT02275	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05668	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05681	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05682	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05924	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05925	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05926	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05927	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05928	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05932	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05933	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05934	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05935	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05936	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05937	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05938	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ENASIDENIB MESYLATE	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541	90480031	Approved	D0WH4P	.	CTPDG000077
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	ARN-509	Arn-509 (AR inhibitor)	24872560	Approved	D0S7LG	DB11901	CTPDG000150
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Bestatin	"Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid"	72172	Approved	D0RA5Q	DB03424	CTPDG000170
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Tagraxofusp	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor	.	Approved	D0R7NI	.	CTPDG000175
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Uracil mustard	"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol"	6194	Approved	D0J9UN	DB00791	CTPDG000322
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Olutasidenib	"NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1"	118955396	Approved	D07VYP	.	CTPDG000543
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	Approved	D07NVU	DB06595	CTPDG000557
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Quizartinib	Quizartinib	24889392	Approved	D07KYT	DB12874	CTPDG000563
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	Approved	D07DCG	DB14568	CTPDG000583
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gemtuzumab ozogamicin	Mylotarg (TN)	.	Approved	D06EWO	.	CTPDG000605
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Thioguanine	"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)"	2723601	Approved	D02ZXM	DB00352	CTPDG000731
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Daunorubicin	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	Approved	D01XWG	DB00694	CTPDG000768
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Idarubicin	"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin"	42890	Approved	D01XDL	DB01177	CTPDG000770
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Approved	Aclarubicin	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A	451415	Approved	D01UBX	DB11617	CTPDG000772
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Magrolimab	GS-4721	.	Phase 3	DN5CM6	.	CTPDG000894
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DSP-7888	.	.	Phase 2	DE5L6B	.	CTPDG000914
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	131I-labelled aCD45	.	.	Phase 3	DC8EN0	.	CTPDG000918
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	ATIR101	.	.	Phase 3	D6O2PN	.	CTPDG000933
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B CD45	.	.	Phase 3	D0Z0MI	.	CTPDG000970
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Tasisulam	"Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly"	10160238	Phase 3	D0X0KM	DB11941	CTPDG001001
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Vadastuximab talirine	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5	122706909	Phase 3	D0W2BF	.	CTPDG001014
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Peginterferon lambda-1a	"BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb"	.	Phase 3	D0T6IN	.	CTPDG001044
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPX-351	"Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"	11422859	Phase 3	D0SB1B	.	CTPDG001053
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	BYM338	.	.	Phase 2/3	D0S5FF	.	CTPDG001056
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elacytarabine	Elacyt (TN)	6438895	Phase 3	D0PY5D	DB05494	CTPDG001089
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Pracinostat	"929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-"	49855250	Phase 3	D0L2UQ	DB05223	CTPDG001152
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	DFP-10917	.	119184	Phase 3	D0KE1F	DB11667	CTPDG001157
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AG-881	"Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop"	117817422	Phase 1	D0K9PC	.	CTPDG001162
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	AG-221	AG-221 (IDH2 inhibitor)	89683805	Phase 1/2	D0K7FT	DB13874	CTPDG001165
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Rydaptmidostaurin	.	.	Phase 3	D0H6BS	.	CTPDG001190
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Sapacitabine	CYC682	153970	Phase 3	D0D4RF	DB06365	CTPDG001243
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	VAL-083	"Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6"	15942827	Phase 1/2	D0A1IL	DB12873	CTPDG001283
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Iomab-B	Iomab-B (TN)	.	Phase 3	D08BBL	.	CTPDG001338
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PEG arginine deiminase	ADI-PEG 20	.	Phase 1	D07UAS	.	CTPDG001342
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Zarnestra	"JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE"	159324	Phase 3	D07NPS	DB04960	CTPDG001358
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Elesclomol	"488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum"	300471	Phase 3	D05IRV	DB05719	CTPDG001402
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	PR1 peptide antigen vaccine	"PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company"	.	Phase 3	D03GHV	.	CTPDG001447
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	SNS-595	"Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid"	9952884	Phase 3	D00NVM	DB11999	CTPDG001496
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 3	Volasertib	"755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	Phase 3	D00BYM	DB12062	CTPDG001505
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	Rivo-cel	BPX-501	.	Phase 2/3	D4OU6H	.	CTPDG001524
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CLL1 CAR-T Cell	.	.	Phase 2/3	D0RF4J	.	CTPDG001535
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2/3	CD123/CLL1 CAR-T Cells	.	.	Phase 2/3	D04GGG	.	CTPDG001572
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K-NK002	CSTD-002-NK	.	Phase 2	DTU7W2	.	CTPDG001632
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Dilanubicel	NLA101	.	Phase 2	DS01GZ	.	CTPDG001639
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BST-236	"Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine"	135390942	Phase 2	DGN26L	.	CTPDG001712
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Zelenoleucel	.	.	Phase 2	D4T8JV	.	CTPDG001813
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CX-01	.	.	Phase 2	D0ZI4L	.	CTPDG001856
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flotetuzumab	.	.	Phase 2	D0YA1B	.	CTPDG001875
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LY2523355	Litronesib	25167017	Phase 2	D0W9SL	DB11861	CTPDG001919
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Prexigebersen	"Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4"	123132008	Phase 2	D0W3GR	.	CTPDG001933
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	Phase 2	D0RG8Z	.	CTPDG002060
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Inecalcitol oral	"Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics"	6915835	Phase 2	D0R8IE	DB04796	CTPDG002065
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Eryaspase	.	.	Phase 2	D0P0SD	.	CTPDG002119
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALXN6000	Samalizumab	.	Phase 2	D0OY9L	.	CTPDG002121
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BI 2536	"BI2536, BI 2536"	11364421	Phase 2	D0O0LQ	.	CTPDG002148
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MK8242	.	.	Phase 2	D0NT6P	.	CTPDG002151
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia DNA vaccine	.	.	Phase 2	D0N6UA	.	CTPDG002167
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Anti-CD45 mAb 131I-BC8	.	.	Phase 2	D0N4NH	.	CTPDG002174
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BREQUINAR	"96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum"	57030	Phase 1/2	D0N3XT	DB03523	CTPDG002175
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Leukemia cancer vaccine	.	.	Phase 2	D0M0OT	.	CTPDG002214
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ADCT-301	camidanlumab tesirine	.	Phase 1	D0LL1N	.	CTPDG002218
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Flavopiridol	"FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one"	5287969	Phase 2	D0LF1U	DB03496	CTPDG002222
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IRX-2	.	.	Phase 2	D0KS6F	.	CTPDG002247
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lirilumab	.	.	Phase 2	D0I7PU	.	CTPDG002304
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GRNVAC1	.	.	Phase 2	D0I6RI	.	CTPDG002309
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	.	.	Phase 1	D0H7BF	.	CTPDG002338
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GS-9973	"Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385"	59473233	Phase 2	D0G9AW	DB12121	CTPDG002361
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	CHR-2797	"Tosedostat; Tosedostat, CHR2797, CHR-2797"	15547703	Phase 2	D0F2JS	DB11781	CTPDG002404
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	HTERT RNA vaccine	.	.	Phase 2	D0CQ1X	.	CTPDG002470
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	MB-102	"Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0"	53389120	Phase 2	D0C3JB	.	CTPDG002491
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	phorbol 12-myristate 13-acetate	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate	27924	Phase 2	D09DHT	.	CTPDG002582
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AEB1102	.	.	Phase 1	D08WQU	.	CTPDG002604
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	BP1001	.	.	Phase 2	D08IVF	.	CTPDG002635
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AS-101	Ossirene; Tellaxium trichloride glycol; IVX-Q-101	11260998	Phase 2	D08EAI	.	CTPDG002645
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	GO-203-2c	.	.	Phase 2	D07OAD	.	CTPDG002680
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Talacotuzumab	JNJ 473; JNJ 56022473; TAL	.	Phase 2	D07MGC	.	CTPDG002685
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AST-VAC1	.	.	Phase 2	D07KAB	.	CTPDG002692
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Lomab B	BCS-I-131 construct	.	Phase 2	D07CQW	.	CTPDG002707
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Fipamezole	"150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole"	213041	Phase 2	D05LGX	DB06585	CTPDG002799
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PR104	"851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5-     dinitro-N-(2-(phosphonooxy)ethyl)-"	11455973	Phase 2	D05CFG	DB05968	CTPDG002816
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BI-836858	.	.	Phase 1/2	D04MGW	.	CTPDG002856
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	K562/GM-CSF	"GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins"	.	Phase 2	D03PRC	.	CTPDG002911
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	PCM-075	Onvansertib	49792852	Phase 2	D03HUX	DB15110	CTPDG002927
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	Actimab-A	.	.	Phase 2	D03HSA	.	CTPDG002929
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	Phase 2	D02MLO	.	CTPDG002971
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	AZD-4877	"Anticancer therapeutic (solid tumors), AstraZeneca"	10368812	Phase 2	D02AAO	DB11671	CTPDG002996
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 2	IPH-2102	.	.	Phase 2	D00RYU	.	CTPDG003068
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ASP7517	.	.	Phase 1/2	DYM1J4	.	CTPDG003123
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CG-806	"1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-"	66981446	Phase 1/2	DT3BA1	.	CTPDG003140
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	KO-539	"UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6"	138497449	Phase 1/2	DS4JE8	.	CTPDG003146
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SAR440234	.	.	Phase 1/2	DL1FG3	.	CTPDG003168
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HM43239	.	.	Phase 1/2	DI1VM3	.	CTPDG003178
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Annamycin	"92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903"	115212	Phase 1/2	DCT2Q3	DB06420	CTPDG003192
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10101	"1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-"	90052320	Phase 1/2	D28HJI	.	CTPDG003252
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL-24	"Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita"	.	Phase 1/2	D0X8ID	.	CTPDG003285
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SEL24	MEN1703	.	Phase 1/2	D0V2ZC	.	CTPDG003298
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD38-specific gene-engineered T cells	.	.	Phase 1/2	D0UJ3C	.	CTPDG003301
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	HuM-195-Ac-225	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab	.	Phase 1/2	D0TV6H	.	CTPDG003314
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	NEXI-001	.	.	Phase 1/2	D0SZT3	.	CTPDG003325
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	MG7-CART	.	.	Phase 1/2	D0Q5GK	.	CTPDG003346
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CART-123 cells	.	.	Phase 1/2	D0N6PE	.	CTPDG003368
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OXi4503	"Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt"	6918545	Phase 1/2	D0N4HQ	.	CTPDG003370
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CIK-CAR.CD19	.	.	Phase 1/2	D0M2XK	.	CTPDG003381
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RhH1.3	"Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec"	.	Phase 1/2	D0K6UG	.	CTPDG003395
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	JTCR016	.	.	Phase 1/2	D0J6AJ	.	CTPDG003402
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Muc1-specific gene-engineered T cells	.	.	Phase 1/2	D0IQ3E	.	CTPDG003412
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	Lintuzumab Ac-225	Actimab-A (TN)	.	Phase 1/2	D0HV7A	.	CTPDG003420
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD33-specific gene-engineered T cells	.	.	Phase 1/2	D0G9MY	.	CTPDG003429
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD19 specific CAR T cells	.	.	Phase 1/2	D0FR3J	.	CTPDG003435
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	EPZ-5676	"pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine"	57345410	Phase 1/2	D0C6GK	DB12920	CTPDG003461
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BSK01	.	.	Phase 1/2	D0AZ1N	.	CTPDG003473
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CNDO-109	.	.	Phase 1/2	D0A0CY	.	CTPDG003479
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	DT388IL-3	.	.	Phase 1/2	D08MKR	.	CTPDG003506
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	BPX-501	.	.	Phase 1/2	D06LYI	.	CTPDG003538
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	RTX-240	.	.	Phase 1/2	D05ZBV	.	CTPDG003548
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	G0-203-2c	.	.	Phase 1/2	D04WHM	.	CTPDG003558
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD123-specific gene-engineered T cells	.	.	Phase 1/2	D04MLR	.	CTPDG003568
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CD56-specific gene-engineered T cells	.	.	Phase 1/2	D03HML	.	CTPDG003595
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	FF-10501-01	.	.	Phase 1/2	D02BVW	.	CTPDG003612
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	SGN-CD33A	.	.	Phase 1/2	D01KKI	.	CTPDG003620
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1/2	CLL1-specific gene-engineered T cells	.	.	Phase 1/2	D00QWK	.	CTPDG003628
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLT030	.	.	Phase 1	DW01LJ	.	CTPDG003681
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT500	.	.	Phase 1	DSYM73	.	CTPDG003719
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	225Ac-labelled aCD33	.	.	Phase 1	DSI4G9	.	CTPDG003723
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PRGN-3006	.	.	Phase 1	DR0L8A	.	CTPDG003747
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GEM333	.	.	Phase 1	DQD1T2	.	CTPDG003751
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKX101	.	.	Phase 1	DOBZ63	.	CTPDG003783
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 673	.	.	Phase 1	DNS2P1	.	CTPDG003797
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR443579	.	.	Phase 1	DMKG40	.	CTPDG003819
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IO-202	.	.	Phase 1	DM9GO4	.	CTPDG003821
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	Phase 1	DK26FL	.	CTPDG003854
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SKI-G-801	.	.	Phase 1	DIA08F	.	CTPDG003880
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG6007	.	.	Phase 1	DHWF68	.	CTPDG003891
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CB-5339	.	.	Phase 1	DFC0V4	.	CTPDG003917
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR445419	.	.	Phase 1	DCQ6L4	.	CTPDG003950
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AB-110	.	.	Phase 1	DC6LS1	.	CTPDG003956
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	H3B-8800	"(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017"	92135969	Phase 1	DB5O1U	DB14017	CTPDG003972
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123-CD33 Ccar	.	.	Phase 1	DB4C5H	.	CTPDG003974
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-63709178	.	.	Phase 1	D9TG4H	.	CTPDG003988
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	JNJ-67571244	.	.	Phase 1	D9OZ3B	.	CTPDG003993
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 427	.	.	Phase 1	D91CMX	.	CTPDG004005
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 330	.	.	Phase 1	D8AOC1	.	CTPDG004019
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-184	.	.	Phase 1	D7QHV6	.	CTPDG004032
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	MIK665	"1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5"	118157243	Phase 1	D7LC8N	.	CTPDG004037
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SEA-CD70	.	.	Phase 1	D6H9TE	.	CTPDG004063
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CLL1-CD33 cCART cell therapy	.	.	Phase 1	D5T9GZ	.	CTPDG004084
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KITE-222	.	.	Phase 1	D4UQ2B	.	CTPDG004108
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CYAD-02	.	.	Phase 1	D2Z7EL	.	CTPDG004149
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GDX012	.	.	Phase 1	D2V9RQ	.	CTPDG004153
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	APVO436	.	.	Phase 1	D2GY5C	.	CTPDG004167
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LAM-003	.	.	Phase 1	D20IMG	.	CTPDG004176
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMGN779	.	.	Phase 1	D0ZR1Z	.	CTPDG004212
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BPX-701	.	.	Phase 1	D0ZA1K	.	CTPDG004222
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	UCART123	.	.	Phase 1	D0Z7QK	.	CTPDG004226
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FF-10101-01	.	.	Phase 1	D0YQ9I	.	CTPDG004242
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-56 cells	.	.	Phase 1	D0YH5L	.	CTPDG004247
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	LC-1	"Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix"	.	Phase 1	D0V5AL	.	CTPDG004349
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART123 cells	.	.	Phase 1	D0R5NU	.	CTPDG004460
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 cells	.	.	Phase 1	D0QR2K	.	CTPDG004469
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-33 cells	.	.	Phase 1	D0P6YN	.	CTPDG004514
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BI-811283	.	.	Phase 1	D0P5IZ	.	CTPDG004520
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	INNO-305	.	.	Phase 1	D0P2ZY	.	CTPDG004525
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-34 cells	.	.	Phase 1	D0NY1Y	.	CTPDG004558
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMV564	.	.	Phase 1	D0LP7U	.	CTPDG004611
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SAR-103168	.	.	Phase 1	D0LO5N	.	CTPDG004612
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	DCLL9718S	.	.	Phase 1	D0K6JZ	.	CTPDG004658
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	.	.	Phase 1	D0JX7M	.	CTPDG004668
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CSL-362	"CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3"	.	Phase 1	D0JF9Z	.	CTPDG004675
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	XmAb14045	.	.	Phase 1	D0I4BK	.	CTPDG004726
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SY-1425	.	.	Phase 1	D0HY3D	.	CTPDG004736
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS62P1	AGS-62P1	.	Phase 1	D0H3ND	.	CTPDG004753
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-117 cells	.	.	Phase 1	D0E0SH	.	CTPDG004840
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-Muc1 cells	.	.	Phase 1	D0DJ8S	.	CTPDG004848
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	BAY1436032	"RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid"	118310260	Phase 1	D0C6RM	.	CTPDG004883
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CD33-CAR-T Cell	.	.	Phase 1	D0C4GN	.	CTPDG004888
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-123 cells	.	.	Phase 1	D0AW4T	.	CTPDG004929
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	FATE-NK100	.	.	Phase 1	D0A9GE	.	CTPDG004935
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CC-90009	.	.	Phase 1	D09WIR	.	CTPDG004963
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	NKR-2 CAR-T Cells	.	.	Phase 1	D08YHE	.	CTPDG005019
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CEA CAR-T cells	.	.	Phase 1	D08UVN	.	CTPDG005025
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	OTSSP167	OTSSP 167; OTSSP-167; AMX10201	135398499	Phase 1	D08FIX	.	CTPDG005056
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IMC-EB10	Anti-Flt-3 Mab	.	Phase 1	D07ZNF	.	CTPDG005072
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	Phase 1	D07TWK	DB14636	CTPDG005082
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	CART-38 cells	.	.	Phase 1	D06OES	.	CTPDG005151
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	Phase 1	D02JEW	.	CTPDG005355
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	SGN-CD123A	.	.	Phase 1	D01BRD	.	CTPDG005423
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	IM23	.	.	Phase 1	D00HAN	.	CTPDG005466
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	Anti-CD33	.	.	Phase 1	D00DIB	.	CTPDG005472
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 1	KW-2449	"Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo"	11427553	Phase 1	D00ABO	.	CTPDG005478
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	Valspodar	.	5281884	Discontinued in Phase 3	D09TGX	DB11869	CTPDG006369
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	Lintuzumab Bi-213	Bismab-A (TN)	.	Discontinued in Phase 1/2	D0S1LE	.	CTPDG006686
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	HuM-195-Bi-213	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195	.	Discontinued in Phase 1/2	D0IJ1D	.	CTPDG006688
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Discontinued in Phase 1/2	CER-227185	"TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis"	.	Discontinued in Phase 1/2	D01CEQ	.	CTPDG006701
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Phase 0	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	.	.	Phase 0	D0H8UT	.	CTPDG006953
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	ATA2321	.	.	Preclinical	DI2X8V	.	CTPDG006983
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	2-D08	"144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE"	22507438	Preclinical	D4UFT5	.	CTPDG007007
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD117	.	.	Preclinical	D0TS2B	.	CTPDG007049
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD123	.	.	Preclinical	D0N4VG	.	CTPDG007060
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting Mucl	.	.	Preclinical	D0JW9E	.	CTPDG007072
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD33	.	.	Preclinical	D0JT0U	.	CTPDG007073
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD34	.	.	Preclinical	D08ABX	.	CTPDG007116
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Preclinical	CAR-T cells targeting CD133	.	.	Preclinical	D04JSI	.	CTPDG007138
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Terminated	CEP-4186	"CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma"	.	Terminated	D0T9SJ	.	CTPDG007218
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	BI 7273	"BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221"	118796358	Investigative	DVZ6M1	.	CTPDG007592
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	CG-1255	"CG-1552; Histone deacetylase inhibitors, CircaGen"	.	Investigative	D0J3QN	.	CTPDG008174
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AC-501	.	.	Investigative	D0E1UY	.	CTPDG008350
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	AKN-028	"Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska"	44177328	Investigative	D0D0TQ	DB12746	CTPDG008388
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	VLIM-88	.	.	Investigative	D0B1TN	.	CTPDG008457
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Anti-CD44 mab	"Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma"	.	Investigative	D0A9JA	.	CTPDG008479
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	SB-559457	.	.	Investigative	D09WOY	.	CTPDG008508
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	COTI-001	"COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies"	.	Investigative	D04BXH	.	CTPDG008911
M6ACROT05939	.	.	M6ADIS0046	2A60: Acute myeloid leukaemia	Investigative	Rebelex	"Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals"	.	Investigative	D01UJS	.	CTPDG009061
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03036	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03037	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03085	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03100	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03101	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03102	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03103	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03124	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03125	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03126	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03222	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03223	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03276	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03277	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03278	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03279	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03280	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03281	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03282	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03283	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03284	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03285	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03286	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03287	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03288	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03289	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03290	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03291	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03292	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03333	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03334	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03335	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03336	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03337	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03338	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03339	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03340	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03341	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03342	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03343	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03344	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03345	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03346	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03347	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03348	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03349	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03350	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03351	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03352	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03355	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03356	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03357	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03358	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03359	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03360	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03361	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03362	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03363	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03364	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03365	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03366	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03367	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03368	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03369	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03431	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03432	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03433	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03434	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03435	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03436	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03437	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03438	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03439	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03440	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03441	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03442	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03443	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03444	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03445	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03446	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03447	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03448	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03449	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03450	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03451	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03452	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03453	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03454	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03455	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03456	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03457	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03458	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03459	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03460	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03461	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03462	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03463	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03464	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03542	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03543	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03544	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03545	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03546	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03547	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03548	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03549	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03550	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03551	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03552	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03553	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03554	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03555	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03556	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03557	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03558	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03559	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03560	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03561	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03562	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03563	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03564	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03565	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03566	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03567	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03568	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03569	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03570	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03571	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03572	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03573	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03574	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03575	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03576	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03577	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03578	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03579	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03580	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03581	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03582	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03583	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03584	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03585	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03586	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03587	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03588	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03589	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03590	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03591	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03592	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03593	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03594	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03595	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03596	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03597	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03598	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03599	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03600	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03601	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03602	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03603	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03604	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03605	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03606	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03607	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03608	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03609	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03610	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03611	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03612	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03613	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03614	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03615	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03616	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03617	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03618	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03619	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03620	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03621	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03622	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03623	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03624	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03625	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03626	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03627	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03628	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03629	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03630	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT03631	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05009	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05026	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05027	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05055	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05070	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05071	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05098	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05100	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05101	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05171	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05181	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05182	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05183	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05192	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05198	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05199	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05200	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05211	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05220	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05222	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05267	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05268	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05269	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05270	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05274	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05276	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05277	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05278	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05295	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05296	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05302	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05320	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05372	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05397	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05400	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05460	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05461	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05470	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT02056	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT02057	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05215	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05410	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05420	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05421	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05444	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05488	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05517	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05537	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05538	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05566	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05615	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05641	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05670	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05683	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05684	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05701	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05716	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05731	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05763	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05766	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05850	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05853	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05898	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05920	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05929	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT05975	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT06043	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT06044	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Retifanlimab	INCMGA0012; Retifanlimab	.	Approved	D0PG5O	.	CTPDG012784
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	Approved	D09GDD	DB08896	CTPDG000500
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 3	CPI-613	"95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874"	24770514	Phase 3	D07NVI	DB12109	CTPDG001355
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Approved	Bevacizumab	.	.	Approved	D0FX3U	.	CTPDG001546
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2/3	AlloStim	AlloStim (TN)	.	Phase 2/3	D0B3CC	.	CTPDG001551
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	CV301	.	.	Phase 2	D9LT5G	.	CTPDG001765
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Efatutazone	"Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione"	9832447	Phase 2	D0Y8NZ	DB11894	CTPDG001876
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	LOR-2040	.	.	Phase 2	D0I7NG	.	CTPDG002306
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	PEG-SN38	EZN-2208	59443782	Phase 2	D05UFP	.	CTPDG002786
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	MEGF0444A	.	.	Phase 2	D01LES	.	CTPDG003030
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	Encapsulated cell therapy	.	.	Phase 1/2	D0XY8C	.	CTPDG003279
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1/2	AB928	.	135242184	Phase 1/2	D04UBI	.	CTPDG003561
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	MGD007	.	.	Phase 1	D00PEN	.	CTPDG003629
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Terminated	Nimesulide	"51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	Terminated	D0C0JT	DB04743	CTPDG007390
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Phase 2	Saracatinib	.	10302451	Phase 2	D05YTN	DB11805	CTPDG008778
M6ACROT06045	.	.	M6ADIS0059	2B91: Colorectal cancer	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT03040	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT03041	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT03253	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT03254	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05347	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05348	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05349	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05466	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05467	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05417	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05418	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05496	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05497	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05589	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05644	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Approved	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Approved	D0U5HU	.	CTPDG000121
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Naxitamab	.	.	Phase 2	D0HI5D	.	CTPDG000358
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Hu3F8 mAb	.	.	Phase 2	D0R4UA	.	CTPDG002070
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 2	Saracatinib	"H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine"	10302451	Phase 2	D0M0XB	DB11805	CTPDG002213
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1/2	AU101	.	.	Phase 1/2	D0T9JW	.	CTPDG003318
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	[153Sm]CycloSam	.	.	Phase 1	D8W1DJ	.	CTPDG004007
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	GD2 T cells	.	.	Phase 1	D0QB7N	.	CTPDG004475
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Phase 1	Anti-GD2-CAR engineered T cells	.	.	Phase 1	D09DND	.	CTPDG005008
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Discontinued in Phase 2	Robatumumab	.	.	Discontinued in Phase 2	D0X9RN	.	CTPDG006404
M6ACROT05822	.	.	M6ADIS0051	2B51: Osteosarcoma	Investigative	DG-8	"DH-9; PPAR gamma agonists (osteosarcoma/ADPKD); PPAR gamma agonists (osteosarcoma/ADPKD), Chinese Academy of Sciences"	.	Investigative	D0L3VC	.	CTPDG008116
M6ACROT03047	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03048	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03049	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03050	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03051	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03052	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03053	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03054	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03233	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03234	.	.	M6ADIS0072	2D0Y: Melanoma of uvea 	Phase 3	Hepzato	.	.	Phase 3	DFB62M	.	CTPDG000910
M6ACROT03062	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT03062	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03062	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05010	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05010	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05010	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05177	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05177	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05177	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05178	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05178	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05178	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05179	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05179	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05179	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05341	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05341	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05341	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05425	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05425	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05425	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05426	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05426	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05426	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03116	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT03116	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03116	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05624	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05624	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05624	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05737	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Approved	OraTest	.	.	Approved	D00DCY	.	CTPDG000828
M6ACROT05737	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05737	.	.	M6ADIS0055	2B6E: Head and neck squamous carcinoma	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03063	.	.	M6ADIS0398	6C43: Disorders due to use of opioids	Approved	Lofexidine	"Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole"	30668	Approved	D0K0MW	DB04948	CTPDG000315
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT03065	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT03186	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT03310	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05396	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT03152	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT03153	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05601	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05602	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05627	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05703	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05740	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05741	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05891	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05892	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05893	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05943	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved	Lotilaner	.	.	Approved	DV87CQ	.	CTPDG000002
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Tabelecleucel	Tab-cel	.	Phase 2	DY4Q6M	.	CTPDG000865
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	MLN4924	"Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn"	16720766	Phase 1	D0ZD2M	DB11759	CTPDG000959
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	TT10	EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3	134827875	Phase 3	D0NS3O	.	CTPDG001106
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	MK-2206	"1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	Phase 2	D0W3RW	.	CTPDG001929
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 2	Epstein-barr virus-specific immunotherapy	Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)	.	Phase 2	D03XEY	.	CTPDG002891
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1/2	LMP1-CAR-T cells	.	.	Phase 1/2	D0RJ2V	.	CTPDG003332
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Phase 1	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	Phase 1	D0HI1K	.	CTPDG014299
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	PD173074	.	1401	Investigative	D0VF6E	.	CTPDG007779
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ad5f35-LMPd1-2-transduced autologous dendritic cells	"AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI"	.	Investigative	D0Q8PF	.	CTPDG007941
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	THZ1	HY-80013	73602827	Investigative	D0LO5B	.	CTPDG008091
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	SAIT301	.	.	Investigative	D07QNH	.	CTPDG008666
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	HITOPK-032	"HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J"	1936439	Investigative	D06DPJ	.	CTPDG008769
M6ACROT05947	.	.	M6ADIS0054	2B6B: Nasopharyngeal carcinoma	Investigative	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	Investigative	D05WDM	.	CTPDG008784
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Talquetamab	.	.	Approved	DXR1A6	.	CTPDG000001
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Belantamab mafodotin	.	.	Approved	D52NZX	.	CTPDG000024
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elranatamab	PF-06863135	.	Approved	D3KO5Y	.	CTPDG000027
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Metadoxine	"MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra"	115198	Approved	D0YH0N	.	CTPDG000042
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Ixazomib	.	25183872	Approved	D0Y2SW	DB09570	CTPDG000061
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide"	5426	Approved	D0U7GK	DB01041	CTPDG000117
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Bortezomib	"179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate"	387447	Approved	D0SH3I	DB00188	CTPDG000149
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Daratumumab	.	.	Approved	D0RV4P	.	CTPDG000165
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Lenalidomide	"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)"	216326	Approved	D0Q5NX	DB00480	CTPDG000204
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Isatuximab	.	.	Approved	D0JB2J	.	CTPDG000320
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elotuzumab	BMS-901608	.	Approved	D05DZR	.	CTPDG000645
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Idecabtagene vicleucel	Bb2121	.	Approved	D03NPI	.	CTPDG000707
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Cerivastatin	"Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins"	446156	Approved	D03KIA	DB00439	CTPDG009748
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Teclistamab	.	.	Approved	D03AFF	.	CTPDG000730
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Futibatinib	.	71621331	Phase 1/2	D01ZLU	DB15149	CTPDG000765
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Romiplostim	.	5329098	Approved	D01PZD	DB06436	CTPDG009981
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	MLN9708	.	49867936	Approved	D01MML	.	CTPDG000784
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Carfilzomib	868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide	11556711	Approved	D00UVA	DB08889	CTPDG000801
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan	"Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine"	460612	Approved	D00FGO	DB01042	CTPDG000824
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ciltacabtagene autoleucel	JNJ-68284528	.	Phase 3	DXV06E	.	CTPDG000867
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	ABC294640	915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8	15604015	Phase 3	D0X6BX	DB12764	CTPDG000992
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Tabalumab	LY2127399	.	Phase 3	D0U6UK	.	CTPDG001035
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Marizomib	"salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1"	11347535	Phase 1	D0N0RN	DB11762	CTPDG001118
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Plitidepsin	Aplidin (TN)	9812534	Phase 3	D07QJK	DB04977	CTPDG001348
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	T89	"2-Propanone, 1-(5-nitro-2H-tetrazol-2-yl)-; 131394-19-9; 1-(5-nitro-1,2,3,4-tetraazol-2-yl)acetone; ZERO/000247; AC1LOTQU; ACMC-20mu2z; 2-acetonyl-5-nitrotetrazole; CTK0C0970; DTXSID40361521; MolPort-001-904-996; ZINC1084291; STK760073; SBB000169; AKOS000558886; MCULE-5436124308; 1-(5-nitrotetrazol-2-yl)propan-2-one; 2-(2-Oxopropyl)-5-nitro-2H-tetrazole; ST026974; ST023819; BAS 01313849; 1-(5-Nitro-tetrazol-2-yl)-propan-2-one; EU-0085349; 1-(5-nitro-2H-tetrazol-2-yl)propan-2-one; SR-01000523987; SR-01000523987-1"	1270252	Phase 3	D05QUL	.	CTPDG001394
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Imetelstat	Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448	71587831	Phase 2	D04XEQ	.	CTPDG001570
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CLR 131	.	.	Phase 1	DNCA54	.	CTPDG001665
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-11	.	.	Phase 2	DN28SH	.	CTPDG001671
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	RAPA-201	.	.	Phase 2	DL7J8B	.	CTPDG001685
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BHQ880	"BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis"	.	Phase 2	D62FLA	.	CTPDG001796
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INCB00928	.	.	Phase 2	D50OLM	.	CTPDG001809
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-08	.	.	Phase 2	D0Z6AR	.	CTPDG001863
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2857916	.	.	Phase 2	D0YV0N	.	CTPDG001872
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Delanzomib	"((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-"	24800541	Phase 2	D0VO0T	DB11956	CTPDG001947
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Myeloma cancer vaccine	.	.	Phase 2	D0U0NS	.	CTPDG001998
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CJM112	.	.	Phase 2	D0T5TN	.	CTPDG012295
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 3	Tanespimycin	"CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374"	6505803	Discontinued in Phase 3	D0SC2J	DB05134	CTPDG002037
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CLR-131	.	.	Phase 2	D0RX6F	.	CTPDG002055
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CDX-301	.	.	Phase 2	D0Q8CV	.	CTPDG002084
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	SurVaxM	.	.	Phase 2	D0KQ8W	.	CTPDG013956
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCAR-B38M CAR-T Cell	.	.	Phase 2	D0K1AK	.	CTPDG002271
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CART-19 cells	.	.	Phase 2	D0I0NJ	.	CTPDG002324
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCL161	.	24737642	Phase 2	D09MIN	DB12085	CTPDG002575
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	mab 1-7F9	.	.	Phase 2	D08XPN	.	CTPDG002600
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	JNJ 63723283	.	.	Phase 2	D08UGS	.	CTPDG002611
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GL-0817	"912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER"	122706930	Phase 2	D08DUF	.	CTPDG002647
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Selinexor	.	71481097	Approved	D07KVV	DB11942	CTPDG002689
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	.	5426	Approved	D07ISX	DB01041	CTPDG002696
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Bb2121	.	.	Phase 2	D07CUR	.	CTPDG002706
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	PVX-410	.	.	Phase 2	D06DUS	.	CTPDG002768
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Rocilinostat	1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010	53340666	Phase 2	D05KED	DB12376	CTPDG002802
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	NVP-AUY922	"Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide"	135539077	Phase 2	D05BYA	.	CTPDG002817
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ARRY-520	"Filanesib; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04"	44224257	Phase 2	D04VWJ	DB06040	CTPDG002833
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BT-062	.	.	Phase 2	D04PUI	.	CTPDG002849
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Captisol-enabled Melphalan	.	.	Phase 2	D04LXB	.	CTPDG002857
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	IPH-2101	.	.	Phase 2	D04IXD	.	CTPDG002863
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GVAX	.	.	Phase 2	D03OSE	.	CTPDG002913
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Oprozomib	.	25067547	Phase 1	D02BLD	DB11991	CTPDG002992
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-220	AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266	67335295	Phase 1	D01XVX	DB12101	CTPDG003001
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ygalo	.	.	Phase 2	D01CBE	.	CTPDG003051
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Indatuximab ravtansine	.	.	Phase 2	D00CQI	.	CTPDG003104
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5459	.	.	Phase 1/2	DY9G1D	.	CTPDG003125
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5458	.	.	Phase 1/2	DR7Q5N	.	CTPDG003147
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ISB 1342	GBR1342	.	Phase 1/2	DE0L6O	.	CTPDG003184
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	PBCAR269A	.	.	Phase 1/2	D7LU8R	.	CTPDG003223
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NEXI-002	.	.	Phase 1/2	D6EI9F	.	CTPDG003232
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Tinostamustine	"1236199-60-2; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide; AKOS030526024; BCP20331; BDBM50569838; BE170657; CHEMBL3989941; CS-6484; D11182; DB15147; E76854; EDO-S 101; EDO-S101; EDO-S-101; EX-A1322; HY-101780; Minomustine; MS-27198; S8769; SB19172; SCHEMBL7915449; starbld0018955; Tinostamustine; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; Tinostamustine [USAN]; TINOSTAMUSTINE [WHO-DD]; Tinostamustine(EDO-S101); UNII-29DKI2H2NY"	46836227	Phase 1/2	D39TVC	DB15147	CTPDG003248
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Modakafusp alfa	TAK-573	.	Phase 1/2	D1B3VP	.	CTPDG003260
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Milatuzumab-doxorubicin conjugate	.	.	Phase 1/2	D0Y6BO	.	CTPDG003275
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0Y4MA	.	CTPDG003276
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD30	.	.	Phase 1/2	D0UA0U	.	CTPDG003302
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD56 CAR T cells	.	.	Phase 1/2	D0U1GP	.	CTPDG003309
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD22	.	.	Phase 1/2	D0PD4C	.	CTPDG003352
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-CD38 CAR-T cells	.	.	Phase 1/2	D0OO1S	.	CTPDG003360
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	MOR-202	"Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys"	.	Phase 1/2	D0O4IN	.	CTPDG003364
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BIW-8962	.	.	Phase 1/2	D0N6TD	.	CTPDG003367
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA CAR-T cells	.	.	Phase 1/2	D0MK7H	.	CTPDG003374
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0M3RI	.	CTPDG003379
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CC-92480	CELMoD	.	Phase 1/2	D0HT4Y	.	CTPDG003421
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 and BCMA CAR-T Cells	.	.	Phase 1/2	D0G0PI	.	CTPDG003434
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JCARH125	.	.	Phase 1/2	D0EQ6D	.	CTPDG003442
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CLL1	.	.	Phase 1/2	D0DO8E	.	CTPDG003452
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BION-1301	.	.	Phase 1/2	D0DJ2H	.	CTPDG003453
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting BCMA	.	.	Phase 1/2	D0D4ZN	.	CTPDG003457
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AUTO2	.	.	Phase 1/2	D0B8UW	.	CTPDG003469
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-19/BCMA	.	.	Phase 1/2	D0AC9S	.	CTPDG003476
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 CAR T cells	.	.	Phase 1/2	D09UFZ	.	CTPDG003484
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	P-BCMA-101	.	.	Phase 1/2	D09JKN	.	CTPDG003492
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JCAR017	.	.	Phase 1	D08BPS	.	CTPDG003516
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA-CAR-transduced T cells	.	.	Phase 1/2	D07QIQ	.	CTPDG003521
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JNJ-68284528	.	.	Phase 1/2	D07PJS	.	CTPDG003522
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AR-42	935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571	6918848	Phase 1/2	D07KDI	DB12707	CTPDG003525
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	LGH-447	.	44814409	Phase 1/2	D07EHV	DB14943	CTPDG003529
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD138 CAR T cells	.	.	Phase 1/2	D05CTQ	.	CTPDG003555
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ImMucin	"MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical"	.	Phase 1/2	D04UFI	.	CTPDG003560
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-BCMA cells	.	.	Phase 1/2	D04PIU	.	CTPDG003566
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD19	.	.	Phase 1/2	D04JHH	.	CTPDG003572
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR-T	.	.	Phase 1/2	D02JNC	.	CTPDG003607
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR T cells	.	.	Phase 1/2	D01CUC	.	CTPDG003624
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-98633	.	.	Phase 1	DX6J8M	.	CTPDG003667
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CS1 cCAR	.	.	Phase 1	DX1LD3	.	CTPDG003671
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TNB-383B	.	.	Phase 1	DW1H9O	.	CTPDG003679
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	131I-labelled CLR1404	.	.	Phase 1	DVR84A	.	CTPDG003686
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GPRC5D CAR-T cell therapy	.	.	Phase 1	DV9M0Y	.	CTPDG003691
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 420	.	.	Phase 1	DUZ0F7	.	CTPDG003697
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CD19 cCAR	.	.	Phase 1	DTR05Z	.	CTPDG003711
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CD38 CAR-T	.	.	Phase 1	DSWZ60	.	CTPDG003720
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6538	.	.	Phase 1	DS86KN	.	CTPDG003727
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	UCARTCS1	.	.	Phase 1	DS6W8Z	.	CTPDG003729
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MB-104	.	.	Phase 1	DRU0M6	.	CTPDG003736
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-79635322	JNJ-5322	.	Phase 1	DRFS19	.	CTPDG003742
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-93269	BCMA TCE	.	Phase 1	DOQ13X	.	CTPDG003779
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 424	.	.	Phase 1	DLY65X	.	CTPDG003828
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	225Ac-labelled aCD38	.	.	Phase 1	DK1PA2	.	CTPDG003855
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-99712	.	.	Phase 1	DH5BX2	.	CTPDG003898
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MEDI2228	.	.	Phase 1	DG80IS	.	CTPDG003907
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 701	.	.	Phase 1	DF43EH	.	CTPDG003923
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KP1237	BHV-1100	.	Phase 1	DECJ17	.	CTPDG003932
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CTX120	.	.	Phase 1	DE49RW	.	CTPDG003938
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6296	AFM-26	.	Phase 1	DC3Y7O	.	CTPDG003958
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	WVT078	.	.	Phase 1	D81YIK	.	CTPDG004024
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	M3258	"LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid"	138319683	Phase 1	D7X8AQ	.	CTPDG004027
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6234	.	.	Phase 1	D6RT9L	.	CTPDG004056
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells	.	.	Phase 1	D6N8UJ	.	CTPDG004059
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PHE885	.	.	Phase 1	D67ZDJ	.	CTPDG004071
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-467	.	.	Phase 1	D63QIY	.	CTPDG004073
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ALLO-715	.	.	Phase 1	D5YN8U	.	CTPDG004078
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TTI-622	.	.	Phase 1	D5FCP1	.	CTPDG004093
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SEA-BCMA	.	.	Phase 1	D4QZ3O	.	CTPDG004110
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FOR46	.	.	Phase 1	D48ZBO	.	CTPDG004122
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-ddBCMA	.	.	Phase 1	D3T7NY	.	CTPDG004127
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-169	.	.	Phase 1	D2HE9I	.	CTPDG004166
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CT053	.	.	Phase 1	D1WOX4	.	CTPDG004181
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RO6870810	"JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-"	54670351	Phase 1	D15ZUR	DB15151	CTPDG004203
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	HPN217	.	.	Phase 1	D12DYT	.	CTPDG004204
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-573	.	.	Phase 1	D0ZDP2	.	CTPDG004220
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PT-112	.	.	Phase 1	D0YJ5F	.	CTPDG004245
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cell therapy	.	.	Phase 1	D0Y7LV	.	CTPDG004254
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Actimab-M	"Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1"	167045	Phase 1	D0XE4W	.	CTPDG004276
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0W7AB	.	CTPDG004315
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-FGFR3	.	.	Phase 1	D0V0BO	.	CTPDG004357
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19/BCMA CAR-T cells	.	.	Phase 1	D0U7WY	.	CTPDG004371
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MTV273	.	.	Phase 1	D0U4KJ	.	CTPDG004376
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0U2PU	.	CTPDG004380
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA nanobody CAR-T cells	.	.	Phase 1	D0T9CE	.	CTPDG004401
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART and huCART19	.	.	Phase 1	D0T8RV	.	CTPDG004402
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD48A	.	.	Phase 1	D0S5CY	.	CTPDG004435
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART	.	.	Phase 1	D0RD0D	.	CTPDG004451
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CART Cells	.	.	Phase 1	D0RA7L	.	CTPDG004452
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	Phase 1	D0Q6SF	.	CTPDG004480
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cell therapy	.	.	Phase 1	D0O7XA	.	CTPDG004547
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-115	CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389	58298318	Phase 1	D0O1IM	DB12740	CTPDG004555
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	P-BCMA-101 CAR-T cells	.	.	Phase 1	D0NK6K	.	CTPDG004567
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CAR-T Cells	.	.	Phase 1	D0NG3T	.	CTPDG004568
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06688992	.	.	Phase 1	D0JB9C	.	CTPDG004678
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	DFRF4539A	.	.	Phase 1	D0J9YS	.	CTPDG004679
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	C-CAR088	.	.	Phase 1	D0J7OU	.	CTPDG004685
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	LCAR-B4822M CAR-T Cell	.	.	Phase 1	D0I1PF	.	CTPDG004730
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Natural killer cell therapy	"Killer cell therapy; Natural killer cell therapy (autologous, multiple myeloma)"	.	Phase 1	D0H6FY	.	CTPDG004749
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VLX1570	SCKXBVLYWLLALY-ZSIIYVIPSA-N; VLX-1570; 1431280-51-1; BCP18900	71523377	Phase 1	D0G7IF	.	CTPDG004770
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	STRO-001	.	.	Phase 1	D0E7FC	.	CTPDG004828
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-64407564	.	.	Phase 1	D0DA4B	.	CTPDG004852
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KITE-585	.	.	Phase 1	D0C8QA	.	CTPDG004880
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-838	.	.	Phase 1	D0BB2V	.	CTPDG004909
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR-T cells targeting BCMA	.	.	Phase 1	D0B2WU	.	CTPDG004923
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR138 T Cells	.	.	Phase 1	D09ZDY	.	CTPDG004955
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD352A	.	.	Phase 1	D09RUO	.	CTPDG004980
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CB-5083	.	73051434	Phase 1	D08OOJ	.	CTPDG005039
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cells	.	.	Phase 1	D07HJS	.	CTPDG005109
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	IM21 CART	.	.	Phase 1	D05XNF	.	CTPDG005178
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cells	.	.	Phase 1	D05WET	.	CTPDG005182
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ATA520	.	.	Phase 1	D05MVX	.	CTPDG005196
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GRN163	.	56603713	Phase 1	D04HDZ	.	CTPDG005258
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GBR 1342	.	.	Phase 1	D04GAG	.	CTPDG005260
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ACTR-BCMA	ACTR087 + SEA-BCMA	.	Phase 1	D03XFH	.	CTPDG005281
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-122	"1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995"	24967599	Phase 1	D03QZJ	DB14857	CTPDG005294
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19 CART Cells	.	.	Phase 1	D02NFE	.	CTPDG005350
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BFCR4350A	RG6160	.	Phase 1	D02HFN	.	CTPDG005359
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-BCMA	.	.	Phase 1	D01YZF	.	CTPDG005372
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Citarinostat	ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942	53340426	Phase 1	D01WKZ	DB15449	CTPDG005375
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells + IL-2	.	.	Phase 1	D01PXH	.	CTPDG005391
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06863135	.	.	Phase 1	D01JSI	.	CTPDG005405
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 224	.	.	Phase 1	D01EXG	.	CTPDG005420
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-19 T cells	.	.	Phase 1	D00YUQ	.	CTPDG005428
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Bb21217	.	.	Phase 1	D00OXP	.	CTPDG005447
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD138	.	.	Clinical trial	D0T6NG	.	CTPDG005489
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-BCMA T cell	.	.	Clinical trial	D0PF1A	.	CTPDG005494
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-UCART	.	.	Clinical trial	D0N8NT	.	CTPDG005496
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting BCMA	.	.	Clinical trial	D0LP1L	.	CTPDG005499
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-CART	.	.	Clinical trial	D09ZGK	.	CTPDG005503
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	RG7598	.	.	Discontinued in Phase 1	D0S3BR	.	CTPDG006747
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	AS602868	"Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin"	9820526	Discontinued in Phase 1	D01OLO	.	CTPDG006922
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	UCART-CLL1	.	.	Preclinical	DIW58H	.	CTPDG006982
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	211At-labelled aLAT-1	.	.	Preclinical	D2J4YT	.	CTPDG007016
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	P-BCMA-ALL01	.	.	Preclinical	D01SNU	.	CTPDG007151
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	zoxazolamine	"61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%"	6103	Terminated	D0N0LB	.	CTPDG007274
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	AG490	"(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665"	5328779	Terminated	D0GZ7B	.	CTPDG007342
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	GNE-652	"PIM kinase inhibitor (multiple myeloma), Genentech"	.	Investigative	D0U2OS	.	CTPDG007837
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CCX-721	"CCR1 antagonist (myeloma), ChemoCentryx"	.	Investigative	D0P8HU	.	CTPDG007976
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	JB-1	JB1	25150849	Investigative	D0O0RY	.	CTPDG008020
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BIBF100	.	.	Investigative	D0N1RE	.	CTPDG008046
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BAY11-7082	bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile	5353431	Investigative	D0L2XO	.	CTPDG008118
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	UCL-67022	"HDAC inhibitor (multiple myeloma), ST Barts/UCL"	.	Investigative	D0L0LR	.	CTPDG008125
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	AbGn-150	Antibody-150	.	Investigative	D0I6UN	.	CTPDG008201
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	ACHP	.	135465539	Investigative	D0F0VD	.	CTPDG008322
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	SU5402	215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid	5289418	Investigative	D0A4XJ	DB08577	CTPDG008492
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TP-110	"Tyropeptin A derivatives, Microbial Chemistry Research Foundation; Proteasome inhibitors (cancer), Microbial Chemistry Research Foundation"	11592579	Investigative	D0A4VW	.	CTPDG008493
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TMPyP4	"TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin"	135398505	Investigative	D08UZL	.	CTPDG008585
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Sant7	"beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide"	128225	Investigative	D07VQW	.	CTPDG008655
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	PS-1145	"431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide"	9949093	Investigative	D07MQC	.	CTPDG008683
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	FM-101	.	.	Investigative	D07CIX	.	CTPDG008710
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	NVP-ADW742	"475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	Investigative	D06NMZ	.	CTPDG008744
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CGEN-928	"Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment); Anti-TM21 polyclonal antibody (multiple myeloma treatment), Compugen; CGEN-928 (multiple myeloma treatment), Compugen; Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment), Compugen"	.	Investigative	D04VUM	.	CTPDG008854
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Tubacin	"537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166"	6675804	Investigative	D04KQF	.	CTPDG008886
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Anti-HM1.24	.	.	Investigative	D01LZB	.	CTPDG009095
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Telomestatin	YVSQVYZBDXIXCC-UHFFFAOYSA-N; AC1L9EVW; CHEMBL443683; CHEBI:29689; Telomestatin (TMS); gm95; SureCN10025441; SCHEMBL10025441; CHEBI:601758; BDBM213233; DCL000983	443590	Investigative	D01GEO	.	CTPDG009116
M6ACROT03066	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Talquetamab	.	.	Approved	DXR1A6	.	CTPDG000001
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Belantamab mafodotin	.	.	Approved	D52NZX	.	CTPDG000024
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elranatamab	PF-06863135	.	Approved	D3KO5Y	.	CTPDG000027
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Metadoxine	"MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra"	115198	Approved	D0YH0N	.	CTPDG000042
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Ixazomib	.	25183872	Approved	D0Y2SW	DB09570	CTPDG000061
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide"	5426	Approved	D0U7GK	DB01041	CTPDG000117
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Bortezomib	"179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate"	387447	Approved	D0SH3I	DB00188	CTPDG000149
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Daratumumab	.	.	Approved	D0RV4P	.	CTPDG000165
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Lenalidomide	"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)"	216326	Approved	D0Q5NX	DB00480	CTPDG000204
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Isatuximab	.	.	Approved	D0JB2J	.	CTPDG000320
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elotuzumab	BMS-901608	.	Approved	D05DZR	.	CTPDG000645
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Idecabtagene vicleucel	Bb2121	.	Approved	D03NPI	.	CTPDG000707
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Cerivastatin	"Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins"	446156	Approved	D03KIA	DB00439	CTPDG009748
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Teclistamab	.	.	Approved	D03AFF	.	CTPDG000730
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Futibatinib	.	71621331	Phase 1/2	D01ZLU	DB15149	CTPDG000765
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Romiplostim	.	5329098	Approved	D01PZD	DB06436	CTPDG009981
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	MLN9708	.	49867936	Approved	D01MML	.	CTPDG000784
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Carfilzomib	868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide	11556711	Approved	D00UVA	DB08889	CTPDG000801
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan	"Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine"	460612	Approved	D00FGO	DB01042	CTPDG000824
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ciltacabtagene autoleucel	JNJ-68284528	.	Phase 3	DXV06E	.	CTPDG000867
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	ABC294640	915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8	15604015	Phase 3	D0X6BX	DB12764	CTPDG000992
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Tabalumab	LY2127399	.	Phase 3	D0U6UK	.	CTPDG001035
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Marizomib	"salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1"	11347535	Phase 1	D0N0RN	DB11762	CTPDG001118
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Plitidepsin	Aplidin (TN)	9812534	Phase 3	D07QJK	DB04977	CTPDG001348
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	T89	"2-Propanone, 1-(5-nitro-2H-tetrazol-2-yl)-; 131394-19-9; 1-(5-nitro-1,2,3,4-tetraazol-2-yl)acetone; ZERO/000247; AC1LOTQU; ACMC-20mu2z; 2-acetonyl-5-nitrotetrazole; CTK0C0970; DTXSID40361521; MolPort-001-904-996; ZINC1084291; STK760073; SBB000169; AKOS000558886; MCULE-5436124308; 1-(5-nitrotetrazol-2-yl)propan-2-one; 2-(2-Oxopropyl)-5-nitro-2H-tetrazole; ST026974; ST023819; BAS 01313849; 1-(5-Nitro-tetrazol-2-yl)-propan-2-one; EU-0085349; 1-(5-nitro-2H-tetrazol-2-yl)propan-2-one; SR-01000523987; SR-01000523987-1"	1270252	Phase 3	D05QUL	.	CTPDG001394
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Imetelstat	Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448	71587831	Phase 2	D04XEQ	.	CTPDG001570
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CLR 131	.	.	Phase 1	DNCA54	.	CTPDG001665
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-11	.	.	Phase 2	DN28SH	.	CTPDG001671
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	RAPA-201	.	.	Phase 2	DL7J8B	.	CTPDG001685
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BHQ880	"BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis"	.	Phase 2	D62FLA	.	CTPDG001796
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INCB00928	.	.	Phase 2	D50OLM	.	CTPDG001809
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-08	.	.	Phase 2	D0Z6AR	.	CTPDG001863
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2857916	.	.	Phase 2	D0YV0N	.	CTPDG001872
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Delanzomib	"((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-"	24800541	Phase 2	D0VO0T	DB11956	CTPDG001947
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Myeloma cancer vaccine	.	.	Phase 2	D0U0NS	.	CTPDG001998
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CJM112	.	.	Phase 2	D0T5TN	.	CTPDG012295
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 3	Tanespimycin	"CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374"	6505803	Discontinued in Phase 3	D0SC2J	DB05134	CTPDG002037
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CLR-131	.	.	Phase 2	D0RX6F	.	CTPDG002055
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CDX-301	.	.	Phase 2	D0Q8CV	.	CTPDG002084
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	SurVaxM	.	.	Phase 2	D0KQ8W	.	CTPDG013956
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCAR-B38M CAR-T Cell	.	.	Phase 2	D0K1AK	.	CTPDG002271
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CART-19 cells	.	.	Phase 2	D0I0NJ	.	CTPDG002324
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCL161	.	24737642	Phase 2	D09MIN	DB12085	CTPDG002575
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	mab 1-7F9	.	.	Phase 2	D08XPN	.	CTPDG002600
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	JNJ 63723283	.	.	Phase 2	D08UGS	.	CTPDG002611
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GL-0817	"912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER"	122706930	Phase 2	D08DUF	.	CTPDG002647
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Selinexor	.	71481097	Approved	D07KVV	DB11942	CTPDG002689
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	.	5426	Approved	D07ISX	DB01041	CTPDG002696
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Bb2121	.	.	Phase 2	D07CUR	.	CTPDG002706
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	PVX-410	.	.	Phase 2	D06DUS	.	CTPDG002768
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Rocilinostat	1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010	53340666	Phase 2	D05KED	DB12376	CTPDG002802
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	NVP-AUY922	"Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide"	135539077	Phase 2	D05BYA	.	CTPDG002817
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ARRY-520	"Filanesib; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04"	44224257	Phase 2	D04VWJ	DB06040	CTPDG002833
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BT-062	.	.	Phase 2	D04PUI	.	CTPDG002849
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Captisol-enabled Melphalan	.	.	Phase 2	D04LXB	.	CTPDG002857
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	IPH-2101	.	.	Phase 2	D04IXD	.	CTPDG002863
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GVAX	.	.	Phase 2	D03OSE	.	CTPDG002913
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Oprozomib	.	25067547	Phase 1	D02BLD	DB11991	CTPDG002992
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-220	AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266	67335295	Phase 1	D01XVX	DB12101	CTPDG003001
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ygalo	.	.	Phase 2	D01CBE	.	CTPDG003051
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Indatuximab ravtansine	.	.	Phase 2	D00CQI	.	CTPDG003104
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5459	.	.	Phase 1/2	DY9G1D	.	CTPDG003125
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5458	.	.	Phase 1/2	DR7Q5N	.	CTPDG003147
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ISB 1342	GBR1342	.	Phase 1/2	DE0L6O	.	CTPDG003184
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	PBCAR269A	.	.	Phase 1/2	D7LU8R	.	CTPDG003223
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NEXI-002	.	.	Phase 1/2	D6EI9F	.	CTPDG003232
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Tinostamustine	"1236199-60-2; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide; AKOS030526024; BCP20331; BDBM50569838; BE170657; CHEMBL3989941; CS-6484; D11182; DB15147; E76854; EDO-S 101; EDO-S101; EDO-S-101; EX-A1322; HY-101780; Minomustine; MS-27198; S8769; SB19172; SCHEMBL7915449; starbld0018955; Tinostamustine; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; Tinostamustine [USAN]; TINOSTAMUSTINE [WHO-DD]; Tinostamustine(EDO-S101); UNII-29DKI2H2NY"	46836227	Phase 1/2	D39TVC	DB15147	CTPDG003248
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Modakafusp alfa	TAK-573	.	Phase 1/2	D1B3VP	.	CTPDG003260
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Milatuzumab-doxorubicin conjugate	.	.	Phase 1/2	D0Y6BO	.	CTPDG003275
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0Y4MA	.	CTPDG003276
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD30	.	.	Phase 1/2	D0UA0U	.	CTPDG003302
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD56 CAR T cells	.	.	Phase 1/2	D0U1GP	.	CTPDG003309
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD22	.	.	Phase 1/2	D0PD4C	.	CTPDG003352
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-CD38 CAR-T cells	.	.	Phase 1/2	D0OO1S	.	CTPDG003360
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	MOR-202	"Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys"	.	Phase 1/2	D0O4IN	.	CTPDG003364
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BIW-8962	.	.	Phase 1/2	D0N6TD	.	CTPDG003367
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA CAR-T cells	.	.	Phase 1/2	D0MK7H	.	CTPDG003374
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0M3RI	.	CTPDG003379
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CC-92480	CELMoD	.	Phase 1/2	D0HT4Y	.	CTPDG003421
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 and BCMA CAR-T Cells	.	.	Phase 1/2	D0G0PI	.	CTPDG003434
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JCARH125	.	.	Phase 1/2	D0EQ6D	.	CTPDG003442
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CLL1	.	.	Phase 1/2	D0DO8E	.	CTPDG003452
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BION-1301	.	.	Phase 1/2	D0DJ2H	.	CTPDG003453
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting BCMA	.	.	Phase 1/2	D0D4ZN	.	CTPDG003457
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AUTO2	.	.	Phase 1/2	D0B8UW	.	CTPDG003469
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-19/BCMA	.	.	Phase 1/2	D0AC9S	.	CTPDG003476
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 CAR T cells	.	.	Phase 1/2	D09UFZ	.	CTPDG003484
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	P-BCMA-101	.	.	Phase 1/2	D09JKN	.	CTPDG003492
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JCAR017	.	.	Phase 1	D08BPS	.	CTPDG003516
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA-CAR-transduced T cells	.	.	Phase 1/2	D07QIQ	.	CTPDG003521
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JNJ-68284528	.	.	Phase 1/2	D07PJS	.	CTPDG003522
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AR-42	935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571	6918848	Phase 1/2	D07KDI	DB12707	CTPDG003525
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	LGH-447	.	44814409	Phase 1/2	D07EHV	DB14943	CTPDG003529
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD138 CAR T cells	.	.	Phase 1/2	D05CTQ	.	CTPDG003555
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ImMucin	"MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical"	.	Phase 1/2	D04UFI	.	CTPDG003560
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-BCMA cells	.	.	Phase 1/2	D04PIU	.	CTPDG003566
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD19	.	.	Phase 1/2	D04JHH	.	CTPDG003572
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR-T	.	.	Phase 1/2	D02JNC	.	CTPDG003607
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR T cells	.	.	Phase 1/2	D01CUC	.	CTPDG003624
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-98633	.	.	Phase 1	DX6J8M	.	CTPDG003667
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CS1 cCAR	.	.	Phase 1	DX1LD3	.	CTPDG003671
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TNB-383B	.	.	Phase 1	DW1H9O	.	CTPDG003679
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	131I-labelled CLR1404	.	.	Phase 1	DVR84A	.	CTPDG003686
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GPRC5D CAR-T cell therapy	.	.	Phase 1	DV9M0Y	.	CTPDG003691
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 420	.	.	Phase 1	DUZ0F7	.	CTPDG003697
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CD19 cCAR	.	.	Phase 1	DTR05Z	.	CTPDG003711
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CD38 CAR-T	.	.	Phase 1	DSWZ60	.	CTPDG003720
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6538	.	.	Phase 1	DS86KN	.	CTPDG003727
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	UCARTCS1	.	.	Phase 1	DS6W8Z	.	CTPDG003729
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MB-104	.	.	Phase 1	DRU0M6	.	CTPDG003736
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-79635322	JNJ-5322	.	Phase 1	DRFS19	.	CTPDG003742
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-93269	BCMA TCE	.	Phase 1	DOQ13X	.	CTPDG003779
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 424	.	.	Phase 1	DLY65X	.	CTPDG003828
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	225Ac-labelled aCD38	.	.	Phase 1	DK1PA2	.	CTPDG003855
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-99712	.	.	Phase 1	DH5BX2	.	CTPDG003898
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MEDI2228	.	.	Phase 1	DG80IS	.	CTPDG003907
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 701	.	.	Phase 1	DF43EH	.	CTPDG003923
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KP1237	BHV-1100	.	Phase 1	DECJ17	.	CTPDG003932
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CTX120	.	.	Phase 1	DE49RW	.	CTPDG003938
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6296	AFM-26	.	Phase 1	DC3Y7O	.	CTPDG003958
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	WVT078	.	.	Phase 1	D81YIK	.	CTPDG004024
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	M3258	"LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid"	138319683	Phase 1	D7X8AQ	.	CTPDG004027
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6234	.	.	Phase 1	D6RT9L	.	CTPDG004056
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells	.	.	Phase 1	D6N8UJ	.	CTPDG004059
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PHE885	.	.	Phase 1	D67ZDJ	.	CTPDG004071
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-467	.	.	Phase 1	D63QIY	.	CTPDG004073
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ALLO-715	.	.	Phase 1	D5YN8U	.	CTPDG004078
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TTI-622	.	.	Phase 1	D5FCP1	.	CTPDG004093
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SEA-BCMA	.	.	Phase 1	D4QZ3O	.	CTPDG004110
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FOR46	.	.	Phase 1	D48ZBO	.	CTPDG004122
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-ddBCMA	.	.	Phase 1	D3T7NY	.	CTPDG004127
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-169	.	.	Phase 1	D2HE9I	.	CTPDG004166
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CT053	.	.	Phase 1	D1WOX4	.	CTPDG004181
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RO6870810	"JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-"	54670351	Phase 1	D15ZUR	DB15151	CTPDG004203
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	HPN217	.	.	Phase 1	D12DYT	.	CTPDG004204
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-573	.	.	Phase 1	D0ZDP2	.	CTPDG004220
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PT-112	.	.	Phase 1	D0YJ5F	.	CTPDG004245
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cell therapy	.	.	Phase 1	D0Y7LV	.	CTPDG004254
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Actimab-M	"Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1"	167045	Phase 1	D0XE4W	.	CTPDG004276
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0W7AB	.	CTPDG004315
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-FGFR3	.	.	Phase 1	D0V0BO	.	CTPDG004357
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19/BCMA CAR-T cells	.	.	Phase 1	D0U7WY	.	CTPDG004371
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MTV273	.	.	Phase 1	D0U4KJ	.	CTPDG004376
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0U2PU	.	CTPDG004380
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA nanobody CAR-T cells	.	.	Phase 1	D0T9CE	.	CTPDG004401
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART and huCART19	.	.	Phase 1	D0T8RV	.	CTPDG004402
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD48A	.	.	Phase 1	D0S5CY	.	CTPDG004435
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART	.	.	Phase 1	D0RD0D	.	CTPDG004451
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CART Cells	.	.	Phase 1	D0RA7L	.	CTPDG004452
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	Phase 1	D0Q6SF	.	CTPDG004480
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cell therapy	.	.	Phase 1	D0O7XA	.	CTPDG004547
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-115	CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389	58298318	Phase 1	D0O1IM	DB12740	CTPDG004555
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	P-BCMA-101 CAR-T cells	.	.	Phase 1	D0NK6K	.	CTPDG004567
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CAR-T Cells	.	.	Phase 1	D0NG3T	.	CTPDG004568
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06688992	.	.	Phase 1	D0JB9C	.	CTPDG004678
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	DFRF4539A	.	.	Phase 1	D0J9YS	.	CTPDG004679
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	C-CAR088	.	.	Phase 1	D0J7OU	.	CTPDG004685
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	LCAR-B4822M CAR-T Cell	.	.	Phase 1	D0I1PF	.	CTPDG004730
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Natural killer cell therapy	"Killer cell therapy; Natural killer cell therapy (autologous, multiple myeloma)"	.	Phase 1	D0H6FY	.	CTPDG004749
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VLX1570	SCKXBVLYWLLALY-ZSIIYVIPSA-N; VLX-1570; 1431280-51-1; BCP18900	71523377	Phase 1	D0G7IF	.	CTPDG004770
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	STRO-001	.	.	Phase 1	D0E7FC	.	CTPDG004828
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-64407564	.	.	Phase 1	D0DA4B	.	CTPDG004852
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KITE-585	.	.	Phase 1	D0C8QA	.	CTPDG004880
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-838	.	.	Phase 1	D0BB2V	.	CTPDG004909
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR-T cells targeting BCMA	.	.	Phase 1	D0B2WU	.	CTPDG004923
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR138 T Cells	.	.	Phase 1	D09ZDY	.	CTPDG004955
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD352A	.	.	Phase 1	D09RUO	.	CTPDG004980
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CB-5083	.	73051434	Phase 1	D08OOJ	.	CTPDG005039
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cells	.	.	Phase 1	D07HJS	.	CTPDG005109
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	IM21 CART	.	.	Phase 1	D05XNF	.	CTPDG005178
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cells	.	.	Phase 1	D05WET	.	CTPDG005182
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ATA520	.	.	Phase 1	D05MVX	.	CTPDG005196
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GRN163	.	56603713	Phase 1	D04HDZ	.	CTPDG005258
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GBR 1342	.	.	Phase 1	D04GAG	.	CTPDG005260
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ACTR-BCMA	ACTR087 + SEA-BCMA	.	Phase 1	D03XFH	.	CTPDG005281
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-122	"1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995"	24967599	Phase 1	D03QZJ	DB14857	CTPDG005294
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19 CART Cells	.	.	Phase 1	D02NFE	.	CTPDG005350
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BFCR4350A	RG6160	.	Phase 1	D02HFN	.	CTPDG005359
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-BCMA	.	.	Phase 1	D01YZF	.	CTPDG005372
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Citarinostat	ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942	53340426	Phase 1	D01WKZ	DB15449	CTPDG005375
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells + IL-2	.	.	Phase 1	D01PXH	.	CTPDG005391
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06863135	.	.	Phase 1	D01JSI	.	CTPDG005405
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 224	.	.	Phase 1	D01EXG	.	CTPDG005420
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-19 T cells	.	.	Phase 1	D00YUQ	.	CTPDG005428
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Bb21217	.	.	Phase 1	D00OXP	.	CTPDG005447
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD138	.	.	Clinical trial	D0T6NG	.	CTPDG005489
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-BCMA T cell	.	.	Clinical trial	D0PF1A	.	CTPDG005494
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-UCART	.	.	Clinical trial	D0N8NT	.	CTPDG005496
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting BCMA	.	.	Clinical trial	D0LP1L	.	CTPDG005499
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-CART	.	.	Clinical trial	D09ZGK	.	CTPDG005503
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	RG7598	.	.	Discontinued in Phase 1	D0S3BR	.	CTPDG006747
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	AS602868	"Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin"	9820526	Discontinued in Phase 1	D01OLO	.	CTPDG006922
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	UCART-CLL1	.	.	Preclinical	DIW58H	.	CTPDG006982
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	211At-labelled aLAT-1	.	.	Preclinical	D2J4YT	.	CTPDG007016
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	P-BCMA-ALL01	.	.	Preclinical	D01SNU	.	CTPDG007151
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	zoxazolamine	"61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%"	6103	Terminated	D0N0LB	.	CTPDG007274
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	AG490	"(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665"	5328779	Terminated	D0GZ7B	.	CTPDG007342
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	GNE-652	"PIM kinase inhibitor (multiple myeloma), Genentech"	.	Investigative	D0U2OS	.	CTPDG007837
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CCX-721	"CCR1 antagonist (myeloma), ChemoCentryx"	.	Investigative	D0P8HU	.	CTPDG007976
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	JB-1	JB1	25150849	Investigative	D0O0RY	.	CTPDG008020
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BIBF100	.	.	Investigative	D0N1RE	.	CTPDG008046
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BAY11-7082	bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile	5353431	Investigative	D0L2XO	.	CTPDG008118
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	UCL-67022	"HDAC inhibitor (multiple myeloma), ST Barts/UCL"	.	Investigative	D0L0LR	.	CTPDG008125
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	AbGn-150	Antibody-150	.	Investigative	D0I6UN	.	CTPDG008201
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	ACHP	.	135465539	Investigative	D0F0VD	.	CTPDG008322
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	SU5402	215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid	5289418	Investigative	D0A4XJ	DB08577	CTPDG008492
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TP-110	"Tyropeptin A derivatives, Microbial Chemistry Research Foundation; Proteasome inhibitors (cancer), Microbial Chemistry Research Foundation"	11592579	Investigative	D0A4VW	.	CTPDG008493
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TMPyP4	"TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin"	135398505	Investigative	D08UZL	.	CTPDG008585
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Sant7	"beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide"	128225	Investigative	D07VQW	.	CTPDG008655
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	PS-1145	"431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide"	9949093	Investigative	D07MQC	.	CTPDG008683
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	FM-101	.	.	Investigative	D07CIX	.	CTPDG008710
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	NVP-ADW742	"475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	Investigative	D06NMZ	.	CTPDG008744
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CGEN-928	"Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment); Anti-TM21 polyclonal antibody (multiple myeloma treatment), Compugen; CGEN-928 (multiple myeloma treatment), Compugen; Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment), Compugen"	.	Investigative	D04VUM	.	CTPDG008854
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Tubacin	"537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166"	6675804	Investigative	D04KQF	.	CTPDG008886
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Anti-HM1.24	.	.	Investigative	D01LZB	.	CTPDG009095
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Telomestatin	YVSQVYZBDXIXCC-UHFFFAOYSA-N; AC1L9EVW; CHEMBL443683; CHEBI:29689; Telomestatin (TMS); gm95; SureCN10025441; SCHEMBL10025441; CHEBI:601758; BDBM213233; DCL000983	443590	Investigative	D01GEO	.	CTPDG009116
M6ACROT05604	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Talquetamab	.	.	Approved	DXR1A6	.	CTPDG000001
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Belantamab mafodotin	.	.	Approved	D52NZX	.	CTPDG000024
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elranatamab	PF-06863135	.	Approved	D3KO5Y	.	CTPDG000027
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Metadoxine	"MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra"	115198	Approved	D0YH0N	.	CTPDG000042
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Ixazomib	.	25183872	Approved	D0Y2SW	DB09570	CTPDG000061
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide"	5426	Approved	D0U7GK	DB01041	CTPDG000117
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Bortezomib	"179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate"	387447	Approved	D0SH3I	DB00188	CTPDG000149
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Daratumumab	.	.	Approved	D0RV4P	.	CTPDG000165
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Lenalidomide	"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)"	216326	Approved	D0Q5NX	DB00480	CTPDG000204
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Isatuximab	.	.	Approved	D0JB2J	.	CTPDG000320
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elotuzumab	BMS-901608	.	Approved	D05DZR	.	CTPDG000645
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Idecabtagene vicleucel	Bb2121	.	Approved	D03NPI	.	CTPDG000707
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Cerivastatin	"Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins"	446156	Approved	D03KIA	DB00439	CTPDG009748
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Teclistamab	.	.	Approved	D03AFF	.	CTPDG000730
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Futibatinib	.	71621331	Phase 1/2	D01ZLU	DB15149	CTPDG000765
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Romiplostim	.	5329098	Approved	D01PZD	DB06436	CTPDG009981
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	MLN9708	.	49867936	Approved	D01MML	.	CTPDG000784
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Carfilzomib	868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide	11556711	Approved	D00UVA	DB08889	CTPDG000801
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan	"Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine"	460612	Approved	D00FGO	DB01042	CTPDG000824
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ciltacabtagene autoleucel	JNJ-68284528	.	Phase 3	DXV06E	.	CTPDG000867
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	ABC294640	915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8	15604015	Phase 3	D0X6BX	DB12764	CTPDG000992
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Tabalumab	LY2127399	.	Phase 3	D0U6UK	.	CTPDG001035
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Marizomib	"salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1"	11347535	Phase 1	D0N0RN	DB11762	CTPDG001118
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Plitidepsin	Aplidin (TN)	9812534	Phase 3	D07QJK	DB04977	CTPDG001348
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	T89	"2-Propanone, 1-(5-nitro-2H-tetrazol-2-yl)-; 131394-19-9; 1-(5-nitro-1,2,3,4-tetraazol-2-yl)acetone; ZERO/000247; AC1LOTQU; ACMC-20mu2z; 2-acetonyl-5-nitrotetrazole; CTK0C0970; DTXSID40361521; MolPort-001-904-996; ZINC1084291; STK760073; SBB000169; AKOS000558886; MCULE-5436124308; 1-(5-nitrotetrazol-2-yl)propan-2-one; 2-(2-Oxopropyl)-5-nitro-2H-tetrazole; ST026974; ST023819; BAS 01313849; 1-(5-Nitro-tetrazol-2-yl)-propan-2-one; EU-0085349; 1-(5-nitro-2H-tetrazol-2-yl)propan-2-one; SR-01000523987; SR-01000523987-1"	1270252	Phase 3	D05QUL	.	CTPDG001394
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Imetelstat	Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448	71587831	Phase 2	D04XEQ	.	CTPDG001570
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CLR 131	.	.	Phase 1	DNCA54	.	CTPDG001665
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-11	.	.	Phase 2	DN28SH	.	CTPDG001671
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	RAPA-201	.	.	Phase 2	DL7J8B	.	CTPDG001685
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BHQ880	"BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis"	.	Phase 2	D62FLA	.	CTPDG001796
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INCB00928	.	.	Phase 2	D50OLM	.	CTPDG001809
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-08	.	.	Phase 2	D0Z6AR	.	CTPDG001863
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2857916	.	.	Phase 2	D0YV0N	.	CTPDG001872
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Delanzomib	"((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-"	24800541	Phase 2	D0VO0T	DB11956	CTPDG001947
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Myeloma cancer vaccine	.	.	Phase 2	D0U0NS	.	CTPDG001998
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CJM112	.	.	Phase 2	D0T5TN	.	CTPDG012295
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 3	Tanespimycin	"CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374"	6505803	Discontinued in Phase 3	D0SC2J	DB05134	CTPDG002037
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CLR-131	.	.	Phase 2	D0RX6F	.	CTPDG002055
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CDX-301	.	.	Phase 2	D0Q8CV	.	CTPDG002084
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	SurVaxM	.	.	Phase 2	D0KQ8W	.	CTPDG013956
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCAR-B38M CAR-T Cell	.	.	Phase 2	D0K1AK	.	CTPDG002271
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CART-19 cells	.	.	Phase 2	D0I0NJ	.	CTPDG002324
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCL161	.	24737642	Phase 2	D09MIN	DB12085	CTPDG002575
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	mab 1-7F9	.	.	Phase 2	D08XPN	.	CTPDG002600
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	JNJ 63723283	.	.	Phase 2	D08UGS	.	CTPDG002611
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GL-0817	"912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER"	122706930	Phase 2	D08DUF	.	CTPDG002647
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Selinexor	.	71481097	Approved	D07KVV	DB11942	CTPDG002689
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	.	5426	Approved	D07ISX	DB01041	CTPDG002696
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Bb2121	.	.	Phase 2	D07CUR	.	CTPDG002706
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	PVX-410	.	.	Phase 2	D06DUS	.	CTPDG002768
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Rocilinostat	1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010	53340666	Phase 2	D05KED	DB12376	CTPDG002802
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	NVP-AUY922	"Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide"	135539077	Phase 2	D05BYA	.	CTPDG002817
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ARRY-520	"Filanesib; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04"	44224257	Phase 2	D04VWJ	DB06040	CTPDG002833
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BT-062	.	.	Phase 2	D04PUI	.	CTPDG002849
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Captisol-enabled Melphalan	.	.	Phase 2	D04LXB	.	CTPDG002857
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	IPH-2101	.	.	Phase 2	D04IXD	.	CTPDG002863
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GVAX	.	.	Phase 2	D03OSE	.	CTPDG002913
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Oprozomib	.	25067547	Phase 1	D02BLD	DB11991	CTPDG002992
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-220	AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266	67335295	Phase 1	D01XVX	DB12101	CTPDG003001
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ygalo	.	.	Phase 2	D01CBE	.	CTPDG003051
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Indatuximab ravtansine	.	.	Phase 2	D00CQI	.	CTPDG003104
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5459	.	.	Phase 1/2	DY9G1D	.	CTPDG003125
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5458	.	.	Phase 1/2	DR7Q5N	.	CTPDG003147
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ISB 1342	GBR1342	.	Phase 1/2	DE0L6O	.	CTPDG003184
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	PBCAR269A	.	.	Phase 1/2	D7LU8R	.	CTPDG003223
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NEXI-002	.	.	Phase 1/2	D6EI9F	.	CTPDG003232
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Tinostamustine	"1236199-60-2; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide; AKOS030526024; BCP20331; BDBM50569838; BE170657; CHEMBL3989941; CS-6484; D11182; DB15147; E76854; EDO-S 101; EDO-S101; EDO-S-101; EX-A1322; HY-101780; Minomustine; MS-27198; S8769; SB19172; SCHEMBL7915449; starbld0018955; Tinostamustine; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; Tinostamustine [USAN]; TINOSTAMUSTINE [WHO-DD]; Tinostamustine(EDO-S101); UNII-29DKI2H2NY"	46836227	Phase 1/2	D39TVC	DB15147	CTPDG003248
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Modakafusp alfa	TAK-573	.	Phase 1/2	D1B3VP	.	CTPDG003260
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Milatuzumab-doxorubicin conjugate	.	.	Phase 1/2	D0Y6BO	.	CTPDG003275
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0Y4MA	.	CTPDG003276
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD30	.	.	Phase 1/2	D0UA0U	.	CTPDG003302
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD56 CAR T cells	.	.	Phase 1/2	D0U1GP	.	CTPDG003309
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD22	.	.	Phase 1/2	D0PD4C	.	CTPDG003352
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-CD38 CAR-T cells	.	.	Phase 1/2	D0OO1S	.	CTPDG003360
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	MOR-202	"Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys"	.	Phase 1/2	D0O4IN	.	CTPDG003364
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BIW-8962	.	.	Phase 1/2	D0N6TD	.	CTPDG003367
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA CAR-T cells	.	.	Phase 1/2	D0MK7H	.	CTPDG003374
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0M3RI	.	CTPDG003379
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CC-92480	CELMoD	.	Phase 1/2	D0HT4Y	.	CTPDG003421
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 and BCMA CAR-T Cells	.	.	Phase 1/2	D0G0PI	.	CTPDG003434
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JCARH125	.	.	Phase 1/2	D0EQ6D	.	CTPDG003442
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CLL1	.	.	Phase 1/2	D0DO8E	.	CTPDG003452
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BION-1301	.	.	Phase 1/2	D0DJ2H	.	CTPDG003453
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting BCMA	.	.	Phase 1/2	D0D4ZN	.	CTPDG003457
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AUTO2	.	.	Phase 1/2	D0B8UW	.	CTPDG003469
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-19/BCMA	.	.	Phase 1/2	D0AC9S	.	CTPDG003476
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 CAR T cells	.	.	Phase 1/2	D09UFZ	.	CTPDG003484
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	P-BCMA-101	.	.	Phase 1/2	D09JKN	.	CTPDG003492
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JCAR017	.	.	Phase 1	D08BPS	.	CTPDG003516
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA-CAR-transduced T cells	.	.	Phase 1/2	D07QIQ	.	CTPDG003521
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JNJ-68284528	.	.	Phase 1/2	D07PJS	.	CTPDG003522
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AR-42	935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571	6918848	Phase 1/2	D07KDI	DB12707	CTPDG003525
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	LGH-447	.	44814409	Phase 1/2	D07EHV	DB14943	CTPDG003529
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD138 CAR T cells	.	.	Phase 1/2	D05CTQ	.	CTPDG003555
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ImMucin	"MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical"	.	Phase 1/2	D04UFI	.	CTPDG003560
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-BCMA cells	.	.	Phase 1/2	D04PIU	.	CTPDG003566
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD19	.	.	Phase 1/2	D04JHH	.	CTPDG003572
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR-T	.	.	Phase 1/2	D02JNC	.	CTPDG003607
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR T cells	.	.	Phase 1/2	D01CUC	.	CTPDG003624
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-98633	.	.	Phase 1	DX6J8M	.	CTPDG003667
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CS1 cCAR	.	.	Phase 1	DX1LD3	.	CTPDG003671
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TNB-383B	.	.	Phase 1	DW1H9O	.	CTPDG003679
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	131I-labelled CLR1404	.	.	Phase 1	DVR84A	.	CTPDG003686
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GPRC5D CAR-T cell therapy	.	.	Phase 1	DV9M0Y	.	CTPDG003691
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 420	.	.	Phase 1	DUZ0F7	.	CTPDG003697
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CD19 cCAR	.	.	Phase 1	DTR05Z	.	CTPDG003711
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CD38 CAR-T	.	.	Phase 1	DSWZ60	.	CTPDG003720
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6538	.	.	Phase 1	DS86KN	.	CTPDG003727
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	UCARTCS1	.	.	Phase 1	DS6W8Z	.	CTPDG003729
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MB-104	.	.	Phase 1	DRU0M6	.	CTPDG003736
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-79635322	JNJ-5322	.	Phase 1	DRFS19	.	CTPDG003742
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-93269	BCMA TCE	.	Phase 1	DOQ13X	.	CTPDG003779
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 424	.	.	Phase 1	DLY65X	.	CTPDG003828
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	225Ac-labelled aCD38	.	.	Phase 1	DK1PA2	.	CTPDG003855
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-99712	.	.	Phase 1	DH5BX2	.	CTPDG003898
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MEDI2228	.	.	Phase 1	DG80IS	.	CTPDG003907
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 701	.	.	Phase 1	DF43EH	.	CTPDG003923
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KP1237	BHV-1100	.	Phase 1	DECJ17	.	CTPDG003932
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CTX120	.	.	Phase 1	DE49RW	.	CTPDG003938
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6296	AFM-26	.	Phase 1	DC3Y7O	.	CTPDG003958
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	WVT078	.	.	Phase 1	D81YIK	.	CTPDG004024
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	M3258	"LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid"	138319683	Phase 1	D7X8AQ	.	CTPDG004027
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6234	.	.	Phase 1	D6RT9L	.	CTPDG004056
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells	.	.	Phase 1	D6N8UJ	.	CTPDG004059
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PHE885	.	.	Phase 1	D67ZDJ	.	CTPDG004071
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-467	.	.	Phase 1	D63QIY	.	CTPDG004073
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ALLO-715	.	.	Phase 1	D5YN8U	.	CTPDG004078
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TTI-622	.	.	Phase 1	D5FCP1	.	CTPDG004093
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SEA-BCMA	.	.	Phase 1	D4QZ3O	.	CTPDG004110
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FOR46	.	.	Phase 1	D48ZBO	.	CTPDG004122
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-ddBCMA	.	.	Phase 1	D3T7NY	.	CTPDG004127
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-169	.	.	Phase 1	D2HE9I	.	CTPDG004166
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CT053	.	.	Phase 1	D1WOX4	.	CTPDG004181
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RO6870810	"JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-"	54670351	Phase 1	D15ZUR	DB15151	CTPDG004203
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	HPN217	.	.	Phase 1	D12DYT	.	CTPDG004204
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-573	.	.	Phase 1	D0ZDP2	.	CTPDG004220
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PT-112	.	.	Phase 1	D0YJ5F	.	CTPDG004245
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cell therapy	.	.	Phase 1	D0Y7LV	.	CTPDG004254
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Actimab-M	"Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1"	167045	Phase 1	D0XE4W	.	CTPDG004276
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0W7AB	.	CTPDG004315
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-FGFR3	.	.	Phase 1	D0V0BO	.	CTPDG004357
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19/BCMA CAR-T cells	.	.	Phase 1	D0U7WY	.	CTPDG004371
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MTV273	.	.	Phase 1	D0U4KJ	.	CTPDG004376
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0U2PU	.	CTPDG004380
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA nanobody CAR-T cells	.	.	Phase 1	D0T9CE	.	CTPDG004401
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART and huCART19	.	.	Phase 1	D0T8RV	.	CTPDG004402
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD48A	.	.	Phase 1	D0S5CY	.	CTPDG004435
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART	.	.	Phase 1	D0RD0D	.	CTPDG004451
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CART Cells	.	.	Phase 1	D0RA7L	.	CTPDG004452
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	Phase 1	D0Q6SF	.	CTPDG004480
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cell therapy	.	.	Phase 1	D0O7XA	.	CTPDG004547
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-115	CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389	58298318	Phase 1	D0O1IM	DB12740	CTPDG004555
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	P-BCMA-101 CAR-T cells	.	.	Phase 1	D0NK6K	.	CTPDG004567
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CAR-T Cells	.	.	Phase 1	D0NG3T	.	CTPDG004568
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06688992	.	.	Phase 1	D0JB9C	.	CTPDG004678
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	DFRF4539A	.	.	Phase 1	D0J9YS	.	CTPDG004679
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	C-CAR088	.	.	Phase 1	D0J7OU	.	CTPDG004685
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	LCAR-B4822M CAR-T Cell	.	.	Phase 1	D0I1PF	.	CTPDG004730
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Natural killer cell therapy	"Killer cell therapy; Natural killer cell therapy (autologous, multiple myeloma)"	.	Phase 1	D0H6FY	.	CTPDG004749
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VLX1570	SCKXBVLYWLLALY-ZSIIYVIPSA-N; VLX-1570; 1431280-51-1; BCP18900	71523377	Phase 1	D0G7IF	.	CTPDG004770
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	STRO-001	.	.	Phase 1	D0E7FC	.	CTPDG004828
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-64407564	.	.	Phase 1	D0DA4B	.	CTPDG004852
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KITE-585	.	.	Phase 1	D0C8QA	.	CTPDG004880
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-838	.	.	Phase 1	D0BB2V	.	CTPDG004909
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR-T cells targeting BCMA	.	.	Phase 1	D0B2WU	.	CTPDG004923
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR138 T Cells	.	.	Phase 1	D09ZDY	.	CTPDG004955
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD352A	.	.	Phase 1	D09RUO	.	CTPDG004980
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CB-5083	.	73051434	Phase 1	D08OOJ	.	CTPDG005039
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cells	.	.	Phase 1	D07HJS	.	CTPDG005109
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	IM21 CART	.	.	Phase 1	D05XNF	.	CTPDG005178
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cells	.	.	Phase 1	D05WET	.	CTPDG005182
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ATA520	.	.	Phase 1	D05MVX	.	CTPDG005196
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GRN163	.	56603713	Phase 1	D04HDZ	.	CTPDG005258
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GBR 1342	.	.	Phase 1	D04GAG	.	CTPDG005260
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ACTR-BCMA	ACTR087 + SEA-BCMA	.	Phase 1	D03XFH	.	CTPDG005281
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-122	"1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995"	24967599	Phase 1	D03QZJ	DB14857	CTPDG005294
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19 CART Cells	.	.	Phase 1	D02NFE	.	CTPDG005350
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BFCR4350A	RG6160	.	Phase 1	D02HFN	.	CTPDG005359
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-BCMA	.	.	Phase 1	D01YZF	.	CTPDG005372
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Citarinostat	ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942	53340426	Phase 1	D01WKZ	DB15449	CTPDG005375
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells + IL-2	.	.	Phase 1	D01PXH	.	CTPDG005391
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06863135	.	.	Phase 1	D01JSI	.	CTPDG005405
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 224	.	.	Phase 1	D01EXG	.	CTPDG005420
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-19 T cells	.	.	Phase 1	D00YUQ	.	CTPDG005428
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Bb21217	.	.	Phase 1	D00OXP	.	CTPDG005447
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD138	.	.	Clinical trial	D0T6NG	.	CTPDG005489
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-BCMA T cell	.	.	Clinical trial	D0PF1A	.	CTPDG005494
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-UCART	.	.	Clinical trial	D0N8NT	.	CTPDG005496
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting BCMA	.	.	Clinical trial	D0LP1L	.	CTPDG005499
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-CART	.	.	Clinical trial	D09ZGK	.	CTPDG005503
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	RG7598	.	.	Discontinued in Phase 1	D0S3BR	.	CTPDG006747
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	AS602868	"Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin"	9820526	Discontinued in Phase 1	D01OLO	.	CTPDG006922
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	UCART-CLL1	.	.	Preclinical	DIW58H	.	CTPDG006982
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	211At-labelled aLAT-1	.	.	Preclinical	D2J4YT	.	CTPDG007016
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	P-BCMA-ALL01	.	.	Preclinical	D01SNU	.	CTPDG007151
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	zoxazolamine	"61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%"	6103	Terminated	D0N0LB	.	CTPDG007274
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	AG490	"(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665"	5328779	Terminated	D0GZ7B	.	CTPDG007342
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	GNE-652	"PIM kinase inhibitor (multiple myeloma), Genentech"	.	Investigative	D0U2OS	.	CTPDG007837
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CCX-721	"CCR1 antagonist (myeloma), ChemoCentryx"	.	Investigative	D0P8HU	.	CTPDG007976
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	JB-1	JB1	25150849	Investigative	D0O0RY	.	CTPDG008020
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BIBF100	.	.	Investigative	D0N1RE	.	CTPDG008046
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BAY11-7082	bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile	5353431	Investigative	D0L2XO	.	CTPDG008118
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	UCL-67022	"HDAC inhibitor (multiple myeloma), ST Barts/UCL"	.	Investigative	D0L0LR	.	CTPDG008125
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	AbGn-150	Antibody-150	.	Investigative	D0I6UN	.	CTPDG008201
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	ACHP	.	135465539	Investigative	D0F0VD	.	CTPDG008322
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	SU5402	215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid	5289418	Investigative	D0A4XJ	DB08577	CTPDG008492
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TP-110	"Tyropeptin A derivatives, Microbial Chemistry Research Foundation; Proteasome inhibitors (cancer), Microbial Chemistry Research Foundation"	11592579	Investigative	D0A4VW	.	CTPDG008493
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TMPyP4	"TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin"	135398505	Investigative	D08UZL	.	CTPDG008585
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Sant7	"beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide"	128225	Investigative	D07VQW	.	CTPDG008655
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	PS-1145	"431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide"	9949093	Investigative	D07MQC	.	CTPDG008683
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	FM-101	.	.	Investigative	D07CIX	.	CTPDG008710
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	NVP-ADW742	"475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	Investigative	D06NMZ	.	CTPDG008744
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CGEN-928	"Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment); Anti-TM21 polyclonal antibody (multiple myeloma treatment), Compugen; CGEN-928 (multiple myeloma treatment), Compugen; Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment), Compugen"	.	Investigative	D04VUM	.	CTPDG008854
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Tubacin	"537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166"	6675804	Investigative	D04KQF	.	CTPDG008886
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Anti-HM1.24	.	.	Investigative	D01LZB	.	CTPDG009095
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Telomestatin	YVSQVYZBDXIXCC-UHFFFAOYSA-N; AC1L9EVW; CHEMBL443683; CHEBI:29689; Telomestatin (TMS); gm95; SureCN10025441; SCHEMBL10025441; CHEBI:601758; BDBM213233; DCL000983	443590	Investigative	D01GEO	.	CTPDG009116
M6ACROT05733	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Talquetamab	.	.	Approved	DXR1A6	.	CTPDG000001
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Belantamab mafodotin	.	.	Approved	D52NZX	.	CTPDG000024
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elranatamab	PF-06863135	.	Approved	D3KO5Y	.	CTPDG000027
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Metadoxine	"MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra"	115198	Approved	D0YH0N	.	CTPDG000042
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Ixazomib	.	25183872	Approved	D0Y2SW	DB09570	CTPDG000061
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide"	5426	Approved	D0U7GK	DB01041	CTPDG000117
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Bortezomib	"179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate"	387447	Approved	D0SH3I	DB00188	CTPDG000149
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Daratumumab	.	.	Approved	D0RV4P	.	CTPDG000165
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Lenalidomide	"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)"	216326	Approved	D0Q5NX	DB00480	CTPDG000204
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Isatuximab	.	.	Approved	D0JB2J	.	CTPDG000320
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Elotuzumab	BMS-901608	.	Approved	D05DZR	.	CTPDG000645
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Idecabtagene vicleucel	Bb2121	.	Approved	D03NPI	.	CTPDG000707
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Cerivastatin	"Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins"	446156	Approved	D03KIA	DB00439	CTPDG009748
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Teclistamab	.	.	Approved	D03AFF	.	CTPDG000730
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Futibatinib	.	71621331	Phase 1/2	D01ZLU	DB15149	CTPDG000765
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Romiplostim	.	5329098	Approved	D01PZD	DB06436	CTPDG009981
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	MLN9708	.	49867936	Approved	D01MML	.	CTPDG000784
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan flufenamide	"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides"	9935639	Approved	D01HPY	.	CTPDG000792
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Carfilzomib	868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide	11556711	Approved	D00UVA	DB08889	CTPDG000801
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Melphalan	"Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine"	460612	Approved	D00FGO	DB01042	CTPDG000824
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ciltacabtagene autoleucel	JNJ-68284528	.	Phase 3	DXV06E	.	CTPDG000867
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	ABC294640	915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8	15604015	Phase 3	D0X6BX	DB12764	CTPDG000992
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Tabalumab	LY2127399	.	Phase 3	D0U6UK	.	CTPDG001035
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Marizomib	"salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1"	11347535	Phase 1	D0N0RN	DB11762	CTPDG001118
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Galinpepimut-S	.	.	Phase 3	D0M9OO	.	CTPDG001128
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Pelareorep	.	.	Phase 2	D0BF8Y	.	CTPDG001264
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Plitidepsin	Aplidin (TN)	9812534	Phase 3	D07QJK	DB04977	CTPDG001348
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	T89	"2-Propanone, 1-(5-nitro-2H-tetrazol-2-yl)-; 131394-19-9; 1-(5-nitro-1,2,3,4-tetraazol-2-yl)acetone; ZERO/000247; AC1LOTQU; ACMC-20mu2z; 2-acetonyl-5-nitrotetrazole; CTK0C0970; DTXSID40361521; MolPort-001-904-996; ZINC1084291; STK760073; SBB000169; AKOS000558886; MCULE-5436124308; 1-(5-nitrotetrazol-2-yl)propan-2-one; 2-(2-Oxopropyl)-5-nitro-2H-tetrazole; ST026974; ST023819; BAS 01313849; 1-(5-Nitro-tetrazol-2-yl)-propan-2-one; EU-0085349; 1-(5-nitro-2H-tetrazol-2-yl)propan-2-one; SR-01000523987; SR-01000523987-1"	1270252	Phase 3	D05QUL	.	CTPDG001394
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	GMI-1271	Uproleselan	71600085	Phase 3	D03PWD	DB14829	CTPDG001438
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Imetelstat	Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448	71587831	Phase 2	D04XEQ	.	CTPDG001570
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CLR 131	.	.	Phase 1	DNCA54	.	CTPDG001665
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-11	.	.	Phase 2	DN28SH	.	CTPDG001671
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	RAPA-201	.	.	Phase 2	DL7J8B	.	CTPDG001685
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BHQ880	"BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis"	.	Phase 2	D62FLA	.	CTPDG001796
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INCB00928	.	.	Phase 2	D50OLM	.	CTPDG001809
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Descartes-08	.	.	Phase 2	D0Z6AR	.	CTPDG001863
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2857916	.	.	Phase 2	D0YV0N	.	CTPDG001872
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Delanzomib	"((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-"	24800541	Phase 2	D0VO0T	DB11956	CTPDG001947
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Myeloma cancer vaccine	.	.	Phase 2	D0U0NS	.	CTPDG001998
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CJM112	.	.	Phase 2	D0T5TN	.	CTPDG012295
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 3	Tanespimycin	"CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374"	6505803	Discontinued in Phase 3	D0SC2J	DB05134	CTPDG002037
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CLR-131	.	.	Phase 2	D0RX6F	.	CTPDG002055
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CDX-301	.	.	Phase 2	D0Q8CV	.	CTPDG002084
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	SurVaxM	.	.	Phase 2	D0KQ8W	.	CTPDG013956
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCAR-B38M CAR-T Cell	.	.	Phase 2	D0K1AK	.	CTPDG002271
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	CART-19 cells	.	.	Phase 2	D0I0NJ	.	CTPDG002324
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ALT-803	"IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience"	.	Phase 2	D0FD7H	.	CTPDG002389
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	LCL161	.	24737642	Phase 2	D09MIN	DB12085	CTPDG002575
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	mab 1-7F9	.	.	Phase 2	D08XPN	.	CTPDG002600
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	JNJ 63723283	.	.	Phase 2	D08UGS	.	CTPDG002611
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GL-0817	"912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER"	122706930	Phase 2	D08DUF	.	CTPDG002647
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Selinexor	.	71481097	Approved	D07KVV	DB11942	CTPDG002689
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Approved	Thalidomide	.	5426	Approved	D07ISX	DB01041	CTPDG002696
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Bb2121	.	.	Phase 2	D07CUR	.	CTPDG002706
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	PVX-410	.	.	Phase 2	D06DUS	.	CTPDG002768
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Rocilinostat	1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010	53340666	Phase 2	D05KED	DB12376	CTPDG002802
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	NVP-AUY922	"Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide"	135539077	Phase 2	D05BYA	.	CTPDG002817
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	ARRY-520	"Filanesib; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04"	44224257	Phase 2	D04VWJ	DB06040	CTPDG002833
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	BT-062	.	.	Phase 2	D04PUI	.	CTPDG002849
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Captisol-enabled Melphalan	.	.	Phase 2	D04LXB	.	CTPDG002857
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	IPH-2101	.	.	Phase 2	D04IXD	.	CTPDG002863
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Darinaparsin	ZIO-101	11683005	Phase 2	D03ZME	DB06179	CTPDG002882
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ficlatuzumab	AV-299	.	Phase 2	D03UBW	.	CTPDG002899
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GVAX	.	.	Phase 2	D03OSE	.	CTPDG002913
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Oprozomib	.	25067547	Phase 1	D02BLD	DB11991	CTPDG002992
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-220	AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266	67335295	Phase 1	D01XVX	DB12101	CTPDG003001
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Ygalo	.	.	Phase 2	D01CBE	.	CTPDG003051
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 2	Indatuximab ravtansine	.	.	Phase 2	D00CQI	.	CTPDG003104
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5459	.	.	Phase 1/2	DY9G1D	.	CTPDG003125
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	REGN5458	.	.	Phase 1/2	DR7Q5N	.	CTPDG003147
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ISB 1342	GBR1342	.	Phase 1/2	DE0L6O	.	CTPDG003184
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	PBCAR269A	.	.	Phase 1/2	D7LU8R	.	CTPDG003223
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NEXI-002	.	.	Phase 1/2	D6EI9F	.	CTPDG003232
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Tinostamustine	"1236199-60-2; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide; AKOS030526024; BCP20331; BDBM50569838; BE170657; CHEMBL3989941; CS-6484; D11182; DB15147; E76854; EDO-S 101; EDO-S101; EDO-S-101; EX-A1322; HY-101780; Minomustine; MS-27198; S8769; SB19172; SCHEMBL7915449; starbld0018955; Tinostamustine; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; Tinostamustine [USAN]; TINOSTAMUSTINE [WHO-DD]; Tinostamustine(EDO-S101); UNII-29DKI2H2NY"	46836227	Phase 1/2	D39TVC	DB15147	CTPDG003248
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Modakafusp alfa	TAK-573	.	Phase 1/2	D1B3VP	.	CTPDG003260
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	SL-401	.	.	Phase 1/2	D0Z2ZY	.	CTPDG003268
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Milatuzumab-doxorubicin conjugate	.	.	Phase 1/2	D0Y6BO	.	CTPDG003275
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0Y4MA	.	CTPDG003276
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD30	.	.	Phase 1/2	D0UA0U	.	CTPDG003302
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD56 CAR T cells	.	.	Phase 1/2	D0U1GP	.	CTPDG003309
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD22	.	.	Phase 1/2	D0PD4C	.	CTPDG003352
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-CD38 CAR-T cells	.	.	Phase 1/2	D0OO1S	.	CTPDG003360
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	MOR-202	"Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys"	.	Phase 1/2	D0O4IN	.	CTPDG003364
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BIW-8962	.	.	Phase 1/2	D0N6TD	.	CTPDG003367
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA CAR-T cells	.	.	Phase 1/2	D0MK7H	.	CTPDG003374
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-138 cells	.	.	Phase 1/2	D0M3RI	.	CTPDG003379
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CC-92480	CELMoD	.	Phase 1/2	D0HT4Y	.	CTPDG003421
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 and BCMA CAR-T Cells	.	.	Phase 1/2	D0G0PI	.	CTPDG003434
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JCARH125	.	.	Phase 1/2	D0EQ6D	.	CTPDG003442
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CLL1	.	.	Phase 1/2	D0DO8E	.	CTPDG003452
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BION-1301	.	.	Phase 1/2	D0DJ2H	.	CTPDG003453
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting BCMA	.	.	Phase 1/2	D0D4ZN	.	CTPDG003457
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AUTO2	.	.	Phase 1/2	D0B8UW	.	CTPDG003469
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-19/BCMA	.	.	Phase 1/2	D0AC9S	.	CTPDG003476
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD38 CAR T cells	.	.	Phase 1/2	D09UFZ	.	CTPDG003484
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	P-BCMA-101	.	.	Phase 1/2	D09JKN	.	CTPDG003492
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JCAR017	.	.	Phase 1	D08BPS	.	CTPDG003516
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	Anti-BCMA-CAR-transduced T cells	.	.	Phase 1/2	D07QIQ	.	CTPDG003521
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	JNJ-68284528	.	.	Phase 1/2	D07PJS	.	CTPDG003522
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	AR-42	935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571	6918848	Phase 1/2	D07KDI	DB12707	CTPDG003525
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	LGH-447	.	44814409	Phase 1/2	D07EHV	DB14943	CTPDG003529
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CWP232291	.	.	Phase 1/2	D07AYI	.	CTPDG003530
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CD138 CAR T cells	.	.	Phase 1/2	D05CTQ	.	CTPDG003555
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	ImMucin	"MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical"	.	Phase 1/2	D04UFI	.	CTPDG003560
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CART-BCMA cells	.	.	Phase 1/2	D04PIU	.	CTPDG003566
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	CAR-T cells targeting CD19	.	.	Phase 1/2	D04JHH	.	CTPDG003572
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR-T	.	.	Phase 1/2	D02JNC	.	CTPDG003607
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1/2	BCMA CAR T cells	.	.	Phase 1/2	D01CUC	.	CTPDG003624
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-98633	.	.	Phase 1	DX6J8M	.	CTPDG003667
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CS1 cCAR	.	.	Phase 1	DX1LD3	.	CTPDG003671
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TNB-383B	.	.	Phase 1	DW1H9O	.	CTPDG003679
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	131I-labelled CLR1404	.	.	Phase 1	DVR84A	.	CTPDG003686
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GPRC5D CAR-T cell therapy	.	.	Phase 1	DV9M0Y	.	CTPDG003691
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 420	.	.	Phase 1	DUZ0F7	.	CTPDG003697
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA-CD19 cCAR	.	.	Phase 1	DTR05Z	.	CTPDG003711
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CD38 CAR-T	.	.	Phase 1	DSWZ60	.	CTPDG003720
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6538	.	.	Phase 1	DS86KN	.	CTPDG003727
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	UCARTCS1	.	.	Phase 1	DS6W8Z	.	CTPDG003729
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MB-104	.	.	Phase 1	DRU0M6	.	CTPDG003736
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-79635322	JNJ-5322	.	Phase 1	DRFS19	.	CTPDG003742
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-93269	BCMA TCE	.	Phase 1	DOQ13X	.	CTPDG003779
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 424	.	.	Phase 1	DLY65X	.	CTPDG003828
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	225Ac-labelled aCD38	.	.	Phase 1	DK1PA2	.	CTPDG003855
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-99712	.	.	Phase 1	DH5BX2	.	CTPDG003898
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MEDI2228	.	.	Phase 1	DG80IS	.	CTPDG003907
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 701	.	.	Phase 1	DF43EH	.	CTPDG003923
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KP1237	BHV-1100	.	Phase 1	DECJ17	.	CTPDG003932
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CTX120	.	.	Phase 1	DE49RW	.	CTPDG003938
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6296	AFM-26	.	Phase 1	DC3Y7O	.	CTPDG003958
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	WVT078	.	.	Phase 1	D81YIK	.	CTPDG004024
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	M3258	"LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid"	138319683	Phase 1	D7X8AQ	.	CTPDG004027
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FT538	.	.	Phase 1	D79JZU	.	CTPDG004047
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RG6234	.	.	Phase 1	D6RT9L	.	CTPDG004056
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells	.	.	Phase 1	D6N8UJ	.	CTPDG004059
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PHE885	.	.	Phase 1	D67ZDJ	.	CTPDG004071
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-467	.	.	Phase 1	D63QIY	.	CTPDG004073
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ALLO-715	.	.	Phase 1	D5YN8U	.	CTPDG004078
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TTI-622	.	.	Phase 1	D5FCP1	.	CTPDG004093
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SEA-BCMA	.	.	Phase 1	D4QZ3O	.	CTPDG004110
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	FOR46	.	.	Phase 1	D48ZBO	.	CTPDG004122
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-ddBCMA	.	.	Phase 1	D3T7NY	.	CTPDG004127
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-169	.	.	Phase 1	D2HE9I	.	CTPDG004166
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CT053	.	.	Phase 1	D1WOX4	.	CTPDG004181
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	RO6870810	"JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-"	54670351	Phase 1	D15ZUR	DB15151	CTPDG004203
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	HPN217	.	.	Phase 1	D12DYT	.	CTPDG004204
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	TAK-573	.	.	Phase 1	D0ZDP2	.	CTPDG004220
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PT-112	.	.	Phase 1	D0YJ5F	.	CTPDG004245
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cell therapy	.	.	Phase 1	D0Y7LV	.	CTPDG004254
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Actimab-M	"Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1"	167045	Phase 1	D0XE4W	.	CTPDG004276
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0W7AB	.	CTPDG004315
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BB-MPI-03	.	.	Phase 1	D0W1TL	.	CTPDG004323
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-FGFR3	.	.	Phase 1	D0V0BO	.	CTPDG004357
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19/BCMA CAR-T cells	.	.	Phase 1	D0U7WY	.	CTPDG004371
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	MTV273	.	.	Phase 1	D0U4KJ	.	CTPDG004376
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR T cells	.	.	Phase 1	D0U2PU	.	CTPDG004380
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA nanobody CAR-T cells	.	.	Phase 1	D0T9CE	.	CTPDG004401
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART and huCART19	.	.	Phase 1	D0T8RV	.	CTPDG004402
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD48A	.	.	Phase 1	D0S5CY	.	CTPDG004435
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CART	.	.	Phase 1	D0RD0D	.	CTPDG004451
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CART Cells	.	.	Phase 1	D0RA7L	.	CTPDG004452
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	Phase 1	D0Q6SF	.	CTPDG004480
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cell therapy	.	.	Phase 1	D0O7XA	.	CTPDG004547
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-115	CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389	58298318	Phase 1	D0O1IM	DB12740	CTPDG004555
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	P-BCMA-101 CAR-T cells	.	.	Phase 1	D0NK6K	.	CTPDG004567
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BCMA CAR-T Cells	.	.	Phase 1	D0NG3T	.	CTPDG004568
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CM-CS1 T-cell	.	.	Phase 1	D0NC9M	.	CTPDG004571
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Mivebresib	"ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815"	71600087	Phase 1	D0M2TS	.	CTPDG004607
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06688992	.	.	Phase 1	D0JB9C	.	CTPDG004678
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	DFRF4539A	.	.	Phase 1	D0J9YS	.	CTPDG004679
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	C-CAR088	.	.	Phase 1	D0J7OU	.	CTPDG004685
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 176	"JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-"	118910268	Phase 1	D0I5DP	.	CTPDG004722
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	LCAR-B4822M CAR-T Cell	.	.	Phase 1	D0I1PF	.	CTPDG004730
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Natural killer cell therapy	"Killer cell therapy; Natural killer cell therapy (autologous, multiple myeloma)"	.	Phase 1	D0H6FY	.	CTPDG004749
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	VLX1570	SCKXBVLYWLLALY-ZSIIYVIPSA-N; VLX-1570; 1431280-51-1; BCP18900	71523377	Phase 1	D0G7IF	.	CTPDG004770
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	STRO-001	.	.	Phase 1	D0E7FC	.	CTPDG004828
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	JNJ-64407564	.	.	Phase 1	D0DA4B	.	CTPDG004852
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	KITE-585	.	.	Phase 1	D0C8QA	.	CTPDG004880
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ABBV-838	.	.	Phase 1	D0BB2V	.	CTPDG004909
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR-T cells targeting BCMA	.	.	Phase 1	D0B2WU	.	CTPDG004923
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CAR138 T Cells	.	.	Phase 1	D09ZDY	.	CTPDG004955
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	SGN-CD352A	.	.	Phase 1	D09RUO	.	CTPDG004980
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CB-5083	.	73051434	Phase 1	D08OOJ	.	CTPDG005039
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-BCMA CAR-T cells	.	.	Phase 1	D07HJS	.	CTPDG005109
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	IM21 CART	.	.	Phase 1	D05XNF	.	CTPDG005178
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD38 CAR-T cells	.	.	Phase 1	D05WET	.	CTPDG005182
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ATA520	.	.	Phase 1	D05MVX	.	CTPDG005196
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GRN163	.	56603713	Phase 1	D04HDZ	.	CTPDG005258
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	GBR 1342	.	.	Phase 1	D04GAG	.	CTPDG005260
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	ACTR-BCMA	ACTR087 + SEA-BCMA	.	Phase 1	D03XFH	.	CTPDG005281
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CC-122	"1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995"	24967599	Phase 1	D03QZJ	DB14857	CTPDG005294
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PNK-007	.	.	Phase 1	D03IRG	.	CTPDG005311
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Anti-CD19 CART Cells	.	.	Phase 1	D02NFE	.	CTPDG005350
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	BFCR4350A	RG6160	.	Phase 1	D02HFN	.	CTPDG005359
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-BCMA	.	.	Phase 1	D01YZF	.	CTPDG005372
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Citarinostat	ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942	53340426	Phase 1	D01WKZ	DB15449	CTPDG005375
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	NAM-NK cells + IL-2	.	.	Phase 1	D01PXH	.	CTPDG005391
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	PF-06863135	.	.	Phase 1	D01JSI	.	CTPDG005405
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	AMG 224	.	.	Phase 1	D01EXG	.	CTPDG005420
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	CART-19 T cells	.	.	Phase 1	D00YUQ	.	CTPDG005428
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Phase 1	Bb21217	.	.	Phase 1	D00OXP	.	CTPDG005447
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD56	.	.	Clinical trial	D0V6WW	.	CTPDG005483
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD38	.	.	Clinical trial	D0V6WU	.	CTPDG005485
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting CD138	.	.	Clinical trial	D0T6NG	.	CTPDG005489
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-BCMA T cell	.	.	Clinical trial	D0PF1A	.	CTPDG005494
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-UCART	.	.	Clinical trial	D0N8NT	.	CTPDG005496
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	CAR-T cells targeting BCMA	.	.	Clinical trial	D0LP1L	.	CTPDG005499
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Clinical trial	BCMA-CART	.	.	Clinical trial	D09ZGK	.	CTPDG005503
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	RG7598	.	.	Discontinued in Phase 1	D0S3BR	.	CTPDG006747
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Discontinued in Phase 1	AS602868	"Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin"	9820526	Discontinued in Phase 1	D01OLO	.	CTPDG006922
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	UCART-CLL1	.	.	Preclinical	DIW58H	.	CTPDG006982
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	211At-labelled aLAT-1	.	.	Preclinical	D2J4YT	.	CTPDG007016
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Preclinical	P-BCMA-ALL01	.	.	Preclinical	D01SNU	.	CTPDG007151
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	zoxazolamine	"61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%"	6103	Terminated	D0N0LB	.	CTPDG007274
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Terminated	AG490	"(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665"	5328779	Terminated	D0GZ7B	.	CTPDG007342
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	GNE-652	"PIM kinase inhibitor (multiple myeloma), Genentech"	.	Investigative	D0U2OS	.	CTPDG007837
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CCX-721	"CCR1 antagonist (myeloma), ChemoCentryx"	.	Investigative	D0P8HU	.	CTPDG007976
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	JB-1	JB1	25150849	Investigative	D0O0RY	.	CTPDG008020
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BIBF100	.	.	Investigative	D0N1RE	.	CTPDG008046
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	BAY11-7082	bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile	5353431	Investigative	D0L2XO	.	CTPDG008118
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	UCL-67022	"HDAC inhibitor (multiple myeloma), ST Barts/UCL"	.	Investigative	D0L0LR	.	CTPDG008125
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	AbGn-150	Antibody-150	.	Investigative	D0I6UN	.	CTPDG008201
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	ACHP	.	135465539	Investigative	D0F0VD	.	CTPDG008322
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	SU5402	215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid	5289418	Investigative	D0A4XJ	DB08577	CTPDG008492
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TP-110	"Tyropeptin A derivatives, Microbial Chemistry Research Foundation; Proteasome inhibitors (cancer), Microbial Chemistry Research Foundation"	11592579	Investigative	D0A4VW	.	CTPDG008493
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	TMPyP4	"TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin"	135398505	Investigative	D08UZL	.	CTPDG008585
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Sant7	"beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide"	128225	Investigative	D07VQW	.	CTPDG008655
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	PS-1145	"431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide"	9949093	Investigative	D07MQC	.	CTPDG008683
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	FM-101	.	.	Investigative	D07CIX	.	CTPDG008710
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	NVP-ADW742	"475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	Investigative	D06NMZ	.	CTPDG008744
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	CGEN-928	"Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment); Anti-TM21 polyclonal antibody (multiple myeloma treatment), Compugen; CGEN-928 (multiple myeloma treatment), Compugen; Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment), Compugen"	.	Investigative	D04VUM	.	CTPDG008854
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Tubacin	"537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166"	6675804	Investigative	D04KQF	.	CTPDG008886
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Anti-HM1.24	.	.	Investigative	D01LZB	.	CTPDG009095
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	Telomestatin	YVSQVYZBDXIXCC-UHFFFAOYSA-N; AC1L9EVW; CHEMBL443683; CHEBI:29689; Telomestatin (TMS); gm95; SureCN10025441; SCHEMBL10025441; CHEBI:601758; BDBM213233; DCL000983	443590	Investigative	D01GEO	.	CTPDG009116
M6ACROT05888	.	.	M6ADIS0048	2A83: Multiple myeloma	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT03071	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2/3	MyoCell	MyoCell (TN)	.	Phase 2/3	D0O7CO	.	CTPDG001540
M6ACROT03071	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2	Diannexin	.	.	Phase 2	D07FQL	.	CTPDG002703
M6ACROT03071	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03071	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	ED1	"ethylenediamine scaffold, 10; BDBM31426; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid"	25181318	Investigative	D0G1SN	.	CTPDG008278
M6ACROT03071	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	ED45	.	.	Investigative	D01NJE	.	CTPDG009091
M6ACROT03071	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	DD7	.	.	Investigative	D00QBV	.	CTPDG009165
M6ACROT05154	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2/3	MyoCell	MyoCell (TN)	.	Phase 2/3	D0O7CO	.	CTPDG001540
M6ACROT05154	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2	Diannexin	.	.	Phase 2	D07FQL	.	CTPDG002703
M6ACROT05154	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT05154	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	ED1	"ethylenediamine scaffold, 10; BDBM31426; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid"	25181318	Investigative	D0G1SN	.	CTPDG008278
M6ACROT05154	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	ED45	.	.	Investigative	D01NJE	.	CTPDG009091
M6ACROT05154	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	DD7	.	.	Investigative	D00QBV	.	CTPDG009165
M6ACROT05626	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2/3	MyoCell	MyoCell (TN)	.	Phase 2/3	D0O7CO	.	CTPDG001540
M6ACROT05626	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2	Diannexin	.	.	Phase 2	D07FQL	.	CTPDG002703
M6ACROT05626	.	.	M6ADIS0159	NB31: Injury of heart	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT05626	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	ED1	"ethylenediamine scaffold, 10; BDBM31426; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid"	25181318	Investigative	D0G1SN	.	CTPDG008278
M6ACROT05626	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	ED45	.	.	Investigative	D01NJE	.	CTPDG009091
M6ACROT05626	.	.	M6ADIS0159	NB31: Injury of heart	Investigative	DD7	.	.	Investigative	D00QBV	.	CTPDG009165
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT03077	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT03078	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT03134	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT03135	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT03164	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT03481	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT02110	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT02276	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT05838	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT05839	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT05840	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT05841	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT05842	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Epeleuton	"(S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 15(S)-HEPE-EE; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER; 1667760-39-5; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; AKOS040748327; CHEMBL5095178; Epeleuton; Epeleuton [INN]; FA9BPX1T6V; UNII-FA9BPX1T6V"	133082733	Phase 2	DV8F9L	.	CTPDG001626
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	IMM-124E	.	.	Phase 2	DMN03O	.	CTPDG001673
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Vupanorsen	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx	.	Phase 2	DDU2Y0	.	CTPDG001739
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ZED1227	"(2E,6S)-7-((1-(2-((2-Ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester; (2E,6S)-7-[[1-[2-[(2-Ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoic Acid Methyl Ester; 1542132-88-6; 2-Heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2E,6S)-; 2-Heptenoic acid, 7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-, methyl ester, (2E,6S)-; AKOS040742843; BDBM50245478; CHEMBL4081588; CS-0015432; EX-A7845R; GLUTAMINASE; GTPL12802; HY-19359; Methyl (2E,6S)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1H-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoate; Methyl (2E,6S)-7-[[1-[2-[(2-ethylbutyl)amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]amino]-6-[[(1-methyl-1H-imidazol-5-yl)carbonyl]amino]-7-oxo-2-heptenoate; Methyl (E,6S)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate; methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(3-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate; methyl (S,E)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate; MS-29784; SCHEMBL16735736; SCHEMBL16751074; T4SR539YKF; TAK-227; UNII-T4SR539YKF; ZED1227; ZED-1227"	72950407	Phase 2	DB2V8K	.	CTPDG001757
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	PXL-770	.	.	Phase 2	D67AKN	.	CTPDG001794
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	ASP9831	.	.	Phase 2	D5ON9Z	.	CTPDG001803
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Phase 1	RG-125	AZD4076	.	Phase 1	D0U0SD	.	CTPDG004388
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Preclinical	KD-3020	.	.	Preclinical	D06GFG	.	CTPDG007126
M6ACROT05843	.	.	M6ADIS0107	DB92: Non-alcoholic fatty liver disease	Investigative	RIPA-56	"1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956"	121439991	Investigative	DF5C2I	.	CTPDG007602
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Elagolix sodium	Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336	24785956	Approved	D0VG7Y	.	CTPDG000097
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Histrelin	Supprelin (TN)	25077993	Approved	D0O7DG	.	CTPDG000240
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Relugolix	"737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917"	10348973	Phase 3	D0F2WP	DB11853	CTPDG000389
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Naproxen	22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex	156391	Approved	D0DJ1B	DB00788	CTPDG012555
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Nafarelin	"Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)"	25077405	Approved	D08WYM	DB00666	CTPDG000510
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Oestradiol valerate and dienogest	"Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)"	68861	Approved	D04CBI	DB09123	CTPDG000681
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	TZTX-001	Teverelix LA; TX 12-001-HR	.	Phase 3	D0IC7A	.	CTPDG001179
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Nestorone	"Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux"	108059	Phase 3	D02HUB	DB14583	CTPDG001469
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Telapristone	"Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11"	20761503	Phase 2	D0U8AS	.	CTPDG001982
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2	.	.	Phase 2	D0I3RN	.	CTPDG002317
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BAY 98-7196	.	.	Phase 2	D0E7VY	.	CTPDG002421
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	KLH-2109	.	16656889	Phase 2	D08FKH	.	CTPDG002642
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Vilaprisan	"UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-"	50915138	Phase 2	D07YGK	DB11971	CTPDG002656
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2001	"Steroid sulfatase inhibitor (endometriosis), PregLem"	6918339	Phase 2	D04ZND	DB06597	CTPDG002823
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BGS-649	.	.	Phase 2	D02XMD	.	CTPDG002945
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	ASP-1707	.	.	Phase 2	D02ROU	.	CTPDG002959
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1817080	Eliapixant	.	Phase 1	DF0PI8	.	CTPDG003925
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	Alfa-interferon	.	.	Phase 1	D0SX9C	.	CTPDG004419
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-4418948	"PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer"	25114442	Phase 1	D0S5EF	DB12024	CTPDG004434
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY-1817080	.	.	Phase 1	D0NF1D	.	CTPDG004570
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-2413873	PF-02413873	16662425	Phase 1	D0K2HA	.	CTPDG004664
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1026153	.	.	Phase 1	D0FJ0W	.	CTPDG004796
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Patented	PMID27215781-Compound-28	.	.	Patented	D03YAA	.	CTPDG006212
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	Asoprisnil	"J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one"	9577221	Discontinued in Phase 3	D0W5RL	DB06680	CTPDG006332
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	FP-1096	.	.	Discontinued in Phase 3	D0K8MQ	.	CTPDG006351
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	ASP-0265	.	.	Terminated	D0J3PS	.	CTPDG007318
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	NS398	"ns-398; 123653-11-2; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942"	4553	Terminated	D09BKE	DB14060	CTPDG007427
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	LHRH	SCHEMBL7378993	36523	Investigative	D0V6KF	DB00644	CTPDG007793
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	PF-02367982	CHEMBL1083754; BDBM50318934	11964844	Investigative	D0H2MF	.	CTPDG008245
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	Recombinant human CC10	"Claragen-WH; Recombinant human CC10 (intravaginal, endometriosis/infertility); Recombinant human CC10 (intravaginal, endometriosis/infertility), Clarassance; Uteroglobin (intravaginal, endometriosis/infertility), Clarassance"	.	Investigative	D05RZJ	.	CTPDG008804
M6ACROT03081	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	DXL-1215	"Monoclonal antibody (endometriosis), InNexus"	.	Investigative	D01UBV	.	CTPDG009063
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Elagolix sodium	Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336	24785956	Approved	D0VG7Y	.	CTPDG000097
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Histrelin	Supprelin (TN)	25077993	Approved	D0O7DG	.	CTPDG000240
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Relugolix	"737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917"	10348973	Phase 3	D0F2WP	DB11853	CTPDG000389
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Naproxen	22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex	156391	Approved	D0DJ1B	DB00788	CTPDG012555
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Nafarelin	"Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)"	25077405	Approved	D08WYM	DB00666	CTPDG000510
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Oestradiol valerate and dienogest	"Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)"	68861	Approved	D04CBI	DB09123	CTPDG000681
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	TZTX-001	Teverelix LA; TX 12-001-HR	.	Phase 3	D0IC7A	.	CTPDG001179
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Nestorone	"Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux"	108059	Phase 3	D02HUB	DB14583	CTPDG001469
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Telapristone	"Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11"	20761503	Phase 2	D0U8AS	.	CTPDG001982
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2	.	.	Phase 2	D0I3RN	.	CTPDG002317
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BAY 98-7196	.	.	Phase 2	D0E7VY	.	CTPDG002421
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	KLH-2109	.	16656889	Phase 2	D08FKH	.	CTPDG002642
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Vilaprisan	"UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-"	50915138	Phase 2	D07YGK	DB11971	CTPDG002656
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2001	"Steroid sulfatase inhibitor (endometriosis), PregLem"	6918339	Phase 2	D04ZND	DB06597	CTPDG002823
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BGS-649	.	.	Phase 2	D02XMD	.	CTPDG002945
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	ASP-1707	.	.	Phase 2	D02ROU	.	CTPDG002959
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1817080	Eliapixant	.	Phase 1	DF0PI8	.	CTPDG003925
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	Alfa-interferon	.	.	Phase 1	D0SX9C	.	CTPDG004419
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-4418948	"PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer"	25114442	Phase 1	D0S5EF	DB12024	CTPDG004434
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY-1817080	.	.	Phase 1	D0NF1D	.	CTPDG004570
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-2413873	PF-02413873	16662425	Phase 1	D0K2HA	.	CTPDG004664
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1026153	.	.	Phase 1	D0FJ0W	.	CTPDG004796
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Patented	PMID27215781-Compound-28	.	.	Patented	D03YAA	.	CTPDG006212
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	Asoprisnil	"J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one"	9577221	Discontinued in Phase 3	D0W5RL	DB06680	CTPDG006332
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	FP-1096	.	.	Discontinued in Phase 3	D0K8MQ	.	CTPDG006351
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	ASP-0265	.	.	Terminated	D0J3PS	.	CTPDG007318
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	NS398	"ns-398; 123653-11-2; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942"	4553	Terminated	D09BKE	DB14060	CTPDG007427
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	LHRH	SCHEMBL7378993	36523	Investigative	D0V6KF	DB00644	CTPDG007793
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	PF-02367982	CHEMBL1083754; BDBM50318934	11964844	Investigative	D0H2MF	.	CTPDG008245
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	Recombinant human CC10	"Claragen-WH; Recombinant human CC10 (intravaginal, endometriosis/infertility); Recombinant human CC10 (intravaginal, endometriosis/infertility), Clarassance; Uteroglobin (intravaginal, endometriosis/infertility), Clarassance"	.	Investigative	D05RZJ	.	CTPDG008804
M6ACROT03082	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	DXL-1215	"Monoclonal antibody (endometriosis), InNexus"	.	Investigative	D01UBV	.	CTPDG009063
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Elagolix sodium	Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336	24785956	Approved	D0VG7Y	.	CTPDG000097
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Histrelin	Supprelin (TN)	25077993	Approved	D0O7DG	.	CTPDG000240
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Relugolix	"737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917"	10348973	Phase 3	D0F2WP	DB11853	CTPDG000389
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Naproxen	22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex	156391	Approved	D0DJ1B	DB00788	CTPDG012555
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Nafarelin	"Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)"	25077405	Approved	D08WYM	DB00666	CTPDG000510
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Oestradiol valerate and dienogest	"Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)"	68861	Approved	D04CBI	DB09123	CTPDG000681
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	TZTX-001	Teverelix LA; TX 12-001-HR	.	Phase 3	D0IC7A	.	CTPDG001179
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Nestorone	"Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux"	108059	Phase 3	D02HUB	DB14583	CTPDG001469
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Telapristone	"Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11"	20761503	Phase 2	D0U8AS	.	CTPDG001982
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2	.	.	Phase 2	D0I3RN	.	CTPDG002317
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BAY 98-7196	.	.	Phase 2	D0E7VY	.	CTPDG002421
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	KLH-2109	.	16656889	Phase 2	D08FKH	.	CTPDG002642
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Vilaprisan	"UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-"	50915138	Phase 2	D07YGK	DB11971	CTPDG002656
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2001	"Steroid sulfatase inhibitor (endometriosis), PregLem"	6918339	Phase 2	D04ZND	DB06597	CTPDG002823
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BGS-649	.	.	Phase 2	D02XMD	.	CTPDG002945
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	ASP-1707	.	.	Phase 2	D02ROU	.	CTPDG002959
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1817080	Eliapixant	.	Phase 1	DF0PI8	.	CTPDG003925
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	Alfa-interferon	.	.	Phase 1	D0SX9C	.	CTPDG004419
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-4418948	"PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer"	25114442	Phase 1	D0S5EF	DB12024	CTPDG004434
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY-1817080	.	.	Phase 1	D0NF1D	.	CTPDG004570
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-2413873	PF-02413873	16662425	Phase 1	D0K2HA	.	CTPDG004664
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1026153	.	.	Phase 1	D0FJ0W	.	CTPDG004796
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Patented	PMID27215781-Compound-28	.	.	Patented	D03YAA	.	CTPDG006212
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	Asoprisnil	"J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one"	9577221	Discontinued in Phase 3	D0W5RL	DB06680	CTPDG006332
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	FP-1096	.	.	Discontinued in Phase 3	D0K8MQ	.	CTPDG006351
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	ASP-0265	.	.	Terminated	D0J3PS	.	CTPDG007318
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	NS398	"ns-398; 123653-11-2; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942"	4553	Terminated	D09BKE	DB14060	CTPDG007427
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	LHRH	SCHEMBL7378993	36523	Investigative	D0V6KF	DB00644	CTPDG007793
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	PF-02367982	CHEMBL1083754; BDBM50318934	11964844	Investigative	D0H2MF	.	CTPDG008245
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	Recombinant human CC10	"Claragen-WH; Recombinant human CC10 (intravaginal, endometriosis/infertility); Recombinant human CC10 (intravaginal, endometriosis/infertility), Clarassance; Uteroglobin (intravaginal, endometriosis/infertility), Clarassance"	.	Investigative	D05RZJ	.	CTPDG008804
M6ACROT05304	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	DXL-1215	"Monoclonal antibody (endometriosis), InNexus"	.	Investigative	D01UBV	.	CTPDG009063
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Elagolix sodium	Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336	24785956	Approved	D0VG7Y	.	CTPDG000097
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Histrelin	Supprelin (TN)	25077993	Approved	D0O7DG	.	CTPDG000240
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Relugolix	"737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917"	10348973	Phase 3	D0F2WP	DB11853	CTPDG000389
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Naproxen	22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex	156391	Approved	D0DJ1B	DB00788	CTPDG012555
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Nafarelin	"Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)"	25077405	Approved	D08WYM	DB00666	CTPDG000510
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Approved	Oestradiol valerate and dienogest	"Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)"	68861	Approved	D04CBI	DB09123	CTPDG000681
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	TZTX-001	Teverelix LA; TX 12-001-HR	.	Phase 3	D0IC7A	.	CTPDG001179
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 3	Nestorone	"Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux"	108059	Phase 3	D02HUB	DB14583	CTPDG001469
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Telapristone	"Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11"	20761503	Phase 2	D0U8AS	.	CTPDG001982
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	F-8-IL-10 fusion protein	"Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen"	.	Phase 2	D0T4KG	.	CTPDG002021
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2	.	.	Phase 2	D0I3RN	.	CTPDG002317
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BAY 98-7196	.	.	Phase 2	D0E7VY	.	CTPDG002421
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	KLH-2109	.	16656889	Phase 2	D08FKH	.	CTPDG002642
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	Vilaprisan	"UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-"	50915138	Phase 2	D07YGK	DB11971	CTPDG002656
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	PGL-2001	"Steroid sulfatase inhibitor (endometriosis), PregLem"	6918339	Phase 2	D04ZND	DB06597	CTPDG002823
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	BGS-649	.	.	Phase 2	D02XMD	.	CTPDG002945
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 2	ASP-1707	.	.	Phase 2	D02ROU	.	CTPDG002959
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1817080	Eliapixant	.	Phase 1	DF0PI8	.	CTPDG003925
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	Alfa-interferon	.	.	Phase 1	D0SX9C	.	CTPDG004419
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-4418948	"PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer"	25114442	Phase 1	D0S5EF	DB12024	CTPDG004434
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY-1817080	.	.	Phase 1	D0NF1D	.	CTPDG004570
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	PF-2413873	PF-02413873	16662425	Phase 1	D0K2HA	.	CTPDG004664
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Phase 1	BAY 1026153	.	.	Phase 1	D0FJ0W	.	CTPDG004796
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Patented	PMID27215781-Compound-28	.	.	Patented	D03YAA	.	CTPDG006212
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	Asoprisnil	"J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one"	9577221	Discontinued in Phase 3	D0W5RL	DB06680	CTPDG006332
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Discontinued in Phase 3	FP-1096	.	.	Discontinued in Phase 3	D0K8MQ	.	CTPDG006351
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	ASP-0265	.	.	Terminated	D0J3PS	.	CTPDG007318
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Terminated	NS398	"ns-398; 123653-11-2; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942"	4553	Terminated	D09BKE	DB14060	CTPDG007427
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	LHRH	SCHEMBL7378993	36523	Investigative	D0V6KF	DB00644	CTPDG007793
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	PF-02367982	CHEMBL1083754; BDBM50318934	11964844	Investigative	D0H2MF	.	CTPDG008245
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	Recombinant human CC10	"Claragen-WH; Recombinant human CC10 (intravaginal, endometriosis/infertility); Recombinant human CC10 (intravaginal, endometriosis/infertility), Clarassance; Uteroglobin (intravaginal, endometriosis/infertility), Clarassance"	.	Investigative	D05RZJ	.	CTPDG008804
M6ACROT05595	.	.	M6ADIS0144	GA10: Endometriosis	Investigative	DXL-1215	"Monoclonal antibody (endometriosis), InNexus"	.	Investigative	D01UBV	.	CTPDG009063
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT03086	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT03087	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT03215	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT05118	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT05432	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT05768	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Phase 2	SHP607	.	.	Phase 2	D0R1JO	.	CTPDG002075
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	RST-001	"ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense"	.	Phase 1/2	D0RM6A	.	CTPDG003330
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Phase 1/2	ReN-003	"Stem cell therapy (retinal diseases), ReNeuron"	.	Phase 1/2	D03OVN	.	CTPDG003587
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Preclinical	SIR-1076	"Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics"	.	Preclinical	D06RVY	.	CTPDG007123
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	CytoRet	"Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO"	.	Investigative	D0V4YT	.	CTPDG007798
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	LPO-1010CSR	.	.	Investigative	D0MH8K	.	CTPDG008064
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-113	.	.	Investigative	D0I2AD	.	CTPDG008218
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	SF-106	.	.	Investigative	D07DRO	.	CTPDG008706
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	"Gene therapy, retinopathy,"	Gene therapy (retinopathy)	.	Investigative	D04ENF	.	CTPDG008904
M6ACROT05895	.	.	M6ADIS0015	9B71: Retinopathy	Investigative	Superoxide dismutase mimetics	"INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek"	.	Investigative	D03KRF	.	CTPDG008963
M6ACROT03088	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT03088	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT03088	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT03089	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT03089	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT03089	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT03090	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT03090	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT03090	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT03091	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT03091	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT03091	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT05125	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT05125	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT05125	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT05844	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT05844	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT05844	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT05845	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT05845	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT05845	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT05846	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT05846	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT05846	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT05847	.	.	M6ADIS0142	BC43: Cardiomyopathy	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT05847	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 3	ALN-TTRsc	SAR438714	.	Phase 3	D0E9AF	.	CTPDG001223
M6ACROT05847	.	.	M6ADIS0142	BC43: Cardiomyopathy	Phase 1	PB1046	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera	.	Phase 1	D0G9JQ	.	CTPDG002359
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03095	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03209	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03210	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03211	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03212	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03353	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03354	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05128	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05184	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05185	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05186	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05187	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT03255	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05424	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Finerenone	"UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho"	60150535	Approved	D0NV5O	.	CTPDG000254
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Doxercalciferol	"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)"	5281107	Approved	D0G5CF	DB06410	CTPDG000374
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferumoxytol	"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4"	14789	Approved	D06CTM	.	CTPDG000610
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Approved	Ferric citrate	"Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx"	61300	Approved	D04CJL	DB09162	CTPDG000680
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 3	REACT	.	.	Phase 3	D2QVG7	.	CTPDG000946
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2/3	US-APR2020	.	.	Phase 2/3	D3YKX2	.	CTPDG001525
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	ALLN-346	.	.	Phase 2	DG31WX	.	CTPDG001716
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Runcaciguat	"(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7"	134440946	Phase 2	D2RG4D	.	CTPDG001830
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	GCS-100	.	.	Phase 2	D0JW0V	.	CTPDG002274
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	Neo-Kidney Augment	.	.	Phase 2	D06XFV	.	CTPDG002718
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	LY-2623091	"Chronic renal disease therapy, Eli Lilly"	42636651	Phase 2	D05RZE	DB15367	CTPDG002788
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 2	AZD1772//RDX5791	.	.	Phase 2	D04AIB	.	CTPDG002881
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1/2	LY3016859	TGF-alpha.epiregulin mAb	.	Phase 1/2	D08EIK	.	CTPDG003515
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05930	.	.	M6ADIS0117	GB61: Chronic kidney disease	Phase 1	MEDI8367	.	.	Phase 1	D37AYZ	.	CTPDG004145
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT03111	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT03112	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT03113	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT03114	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05169	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05170	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05501	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05629	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05678	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05806	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05824	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05848	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05849	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Thyrotropin Alfa	.	.	Approved	D0H4TQ	.	CTPDG000361
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Approved	Selpercatinib	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636	134823904	Approved	D01KOA	.	CTPDG000785
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	QGE-031	.	.	Phase 2	D0J7CH	.	CTPDG001172
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 2	GI-6207	.	.	Phase 2	D0L7VC	.	CTPDG002231
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	CYTO-403	.	.	Phase 1	DB2R5Y	.	CTPDG003975
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Phase 1	Demogastrin	"Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2"	.	Phase 1	D0QJ6L	.	CTPDG004472
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	Recombinant TSH superagonists	"Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen"	.	Investigative	D0U2DY	.	CTPDG007840
M6ACROT05963	.	.	M6ADIS0073	2D10: Thyroid Cancer	Investigative	ITRI-305	"RET tyrosine kinase inhibitors, Industrial Technology Research Institute"	.	Investigative	D0N5TB	.	CTPDG008041
M6ACROT03129	.	.	M6ADIS0161	8E43: Pain disorders	Phase 2	FMX104	.	.	Phase 2	D0Z8EA	.	CTPDG001859
M6ACROT03130	.	.	M6ADIS0161	8E43: Pain disorders	Phase 2	FMX104	.	.	Phase 2	D0Z8EA	.	CTPDG001859
M6ACROT03231	.	.	M6ADIS0161	8E43: Pain disorders	Phase 2	FMX104	.	.	Phase 2	D0Z8EA	.	CTPDG001859
M6ACROT03232	.	.	M6ADIS0161	8E43: Pain disorders	Phase 2	FMX104	.	.	Phase 2	D0Z8EA	.	CTPDG001859
M6ACROT05558	.	.	M6ADIS0161	8E43: Pain disorders	Phase 2	FMX104	.	.	Phase 2	D0Z8EA	.	CTPDG001859
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT03173	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT03174	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT03175	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT03176	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT03196	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT03197	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05229	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05298	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05299	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05300	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05454	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05539	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05540	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Tivozanib	ASP4130/AV-951	9911830	Approved	D0W7JZ	DB11800	CTPDG000087
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Belzutifan	MK-6482	117947097	Approved	D0NU8J	.	CTPDG013127
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Reniale	"Autologous renal tumor cell vaccine (renal cell carcinoma), LipoNova"	.	Approved	D0N7KV	.	CTPDG000262
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pazopanib HCl	Votrient (TN)	11525740	Approved	D0F0ZY	.	CTPDG000393
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	CreaVax-RCC	"Autologous DC vaccines (renal cell carcinoma), CreaGene; Autologous dendritic cell vaccines (renal cell carcinoma), CreaGene"	.	Approved	D06KPV	.	CTPDG000603
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Aldesleukin	Proleukin (TN)	.	Approved	D05PUD	.	CTPDG000626
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Sifalimumab	"Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"	.	Approved	D05NDR	.	CTPDG000631
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BOL-303259-X	"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb"	11156438	Phase 3	D05LQX	DB11660	CTPDG000636
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Axitinib	"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)"	6450551	Approved	D01ZRI	DB06626	CTPDG000764
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	BLA submitted	Human coagulation factor X	.	.	BLA submitted	D07JEW	.	CTPDG000860
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Trebananib	.	.	Phase 3	D9NL3R	.	CTPDG000921
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Vitespen	Oncophage (TN)	.	Phase 3	D0UK2Z	.	CTPDG001032
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Nivolumab + ipilimumab	.	.	Phase 3	D0N5GV	.	CTPDG001112
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Rocapuldencel-T	.	.	Phase 3	D0J0GR	.	CTPDG001175
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	AM0010	.	.	Phase 3	D03MYX	.	CTPDG001441
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	IMA-901	"TUMAP vaccine (RCC), immatics; Tumor-associoated peptide vaccine (renal cell carcinoma), immatics"	.	Phase 3	D02UNP	.	CTPDG001455
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TRC105	.	.	Phase 2	D00YQI	.	CTPDG001492
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CMN-001	.	.	Phase 2	DVQ1F5	.	CTPDG001623
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-16C3F	.	.	Phase 2	D0XT5Q	.	CTPDG001885
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV-Kidney-1	.	.	Phase 2	D0WZ0E	.	CTPDG001909
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	IMO-2055	.	.	Phase 2	D0W6HO	.	CTPDG001926
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Anti-LAG3	.	.	Phase 2	D0T7OI	.	CTPDG002010
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	AGS-003	.	.	Phase 2	D0Q5OC	.	CTPDG002089
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ispinesib	"SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide"	6851740	Phase 2	D0PW4N	DB06188	CTPDG002105
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Ilixadencel	.	.	Phase 2	D0PR4O	.	CTPDG002109
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CRLX101	.	184196	Phase 2	D0ND9T	.	CTPDG002159
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	FolateImmune	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5	135564966	Phase 2	D0N8JG	DB12559	CTPDG002163
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Varlilumab	.	.	Phase 2	D0KV3M	.	CTPDG002245
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TVI-Kidney-1	.	.	Phase 2	D0JH5K	.	CTPDG002278
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Girentuximab I-124	Redectane (TN)	.	Phase 2	D0BH7Z	.	CTPDG002501
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Autologous renal cell carcinoma vaccine	.	.	Phase 2	D08FKD	.	CTPDG002643
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	Human interleukin-2	"Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice"	.	Phase 2	D04OJM	.	CTPDG002852
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	CB-839	.	71577426	Phase 2	D01PBW	DB15232	CTPDG003021
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	ATN-161	"PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan"	9960285	Phase 2	D00QVT	.	CTPDG003069
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 2	TV1-Kidney-1	.	.	Phase 2	D00HMZ	.	CTPDG003089
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-38 (targeting ROR2)	.	.	Phase 1/2	D0RA9C	.	CTPDG003334
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CCT301-59 (targeting ROR2)	.	.	Phase 1/2	D0C2PH	.	CTPDG003463
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	CDX-014	.	.	Phase 1/2	D09WXY	.	CTPDG003482
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1/2	IL-2 XL	"IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel"	.	Phase 1/2	D08XFA	.	CTPDG003497
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	ARO-HIF2	.	.	Phase 1	DE8V1R	.	CTPDG003934
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AGS-16 mab	AGS-16M18	.	Phase 1	D0X7MY	.	CTPDG004282
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Biomed 101	"SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390"	114999	Discontinued in Phase 1	D0S0WN	.	CTPDG004442
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	AMG 172	.	.	Phase 1	D0NC1Q	.	CTPDG004572
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Anti-hCD70 CAR transduced PBL	.	.	Phase 1	D0JO9M	.	CTPDG004670
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	Veglin	.	.	Phase 1	D0G6GB	.	CTPDG004772
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Phase 1	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine	RCC-26 tumor cell vaccine; IL-7/CD80-expressing allogeneic RCC-26 tumorcell vaccine (renal cell carcinoma)	.	Phase 1	D04HWK	.	CTPDG005256
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Discontinued in Phase 1	Vorsetuzumab mafodotin	.	.	Discontinued in Phase 1	D08WTE	.	CTPDG006858
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	BCL-004	.	.	Investigative	D09KTE	.	CTPDG008543
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GM-CAIX	"GM-CSF/cancer antigen chimeric protein (renal cancer), Kite"	.	Investigative	D07OQJ	.	CTPDG008671
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	GS-168	GS-168A	.	Investigative	D05YWN	.	CTPDG008777
M6ACROT05590	.	.	M6ADIS0010	2C90: Renal cell carcinoma	Investigative	STF-62247	"Renal cell carcinoma therapy, Stanford University"	704473	Investigative	D01CIN	.	CTPDG009127
M6ACROT03187	.	.	M6ADIS0397	CA05: Acute laryngitis or tracheitis	Phase 1	MMI-0100	"Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix"	.	Phase 1	D0S7NS	.	CTPDG004431
M6ACROT03187	.	.	M6ADIS0397	CA05: Acute laryngitis or tracheitis	Terminated	SU5614	"SU 5614; SU-5614; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone"	6536806	Terminated	D01MIP	.	CTPDG007567
M6ACROT03188	.	.	M6ADIS0397	CA05: Acute laryngitis or tracheitis	Phase 1	MMI-0100	"Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix"	.	Phase 1	D0S7NS	.	CTPDG004431
M6ACROT03188	.	.	M6ADIS0397	CA05: Acute laryngitis or tracheitis	Terminated	SU5614	"SU 5614; SU-5614; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone"	6536806	Terminated	D01MIP	.	CTPDG007567
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Phase 4	AEN-100	"Nobeldin; Nobelzin; Wilzin; NPC-02; Wilson's disease therapeutics, Nobel Pharma; Zinc acetate (Wilson's disease); Zinc acetate (Wilson's disease), Nobel Pharma/Orphan Europe/Teva; Zinc acetate (gastroretentive/ sustained-release/ tablet, amyotrophic lateral sclerosis), Adeona Pharmaceuticals"	.	Phase 4	D0Y5LR	.	CTPDG000841
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Phase 3	Creatine ALS-08	"Creatine; ALS-02; ALS-05; ALS-08; HD-02; PD-02; PD-04; PD-06; Creatine (ALS), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; PD-01, Avicena; AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena"	586	Phase 3	D01WZG	DB00148	CTPDG001478
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Phase 2	NT-KO-003	ATH-012; NT-K0-003	.	Phase 2	D0Q0TI	.	CTPDG002099
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Phase 1	CC-100	"Fendosal; 53597-27-6; 5-(4,5-Dihydro-2-phenyl-3H-benz[e]indol-3-yl)salicylic acid; Alnovin; Fendosalum; HP 129; Fendosalum [INN-Latin]; UNII-9Z709558TZ; P 71-0129; C25H19NO3; NSC 351522; BRN 1665211; 2-hydroxy-5-(2-phenyl-4,5-dihydrobenzo[e]indol-3-yl)benzoic acid; 2-Hydroxy-5-(2-phenyl-4,5-dihydro-3H-benzo[e]indol-3-yl)benzoic acid; 3-(3-Carboxy-4-hydroxyphenyl)-2-phenyl-4,5-dihydro-3H-benz(e)indole; 5-(4,5-Dihydro-2-phenyl-3H-benz(e)indol-3-yl)-2-hydroxybenzoic acid; NSC351522; HP-129; 9Z709558TZ"	40821	Phase 1	D0UU1E	.	CTPDG004359
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Phase 1	ISIS-SOD1	.	.	Phase 1	D05BYO	.	CTPDG005222
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Phase 1	RG-7010	"R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche"	.	Phase 1	D03WNN	.	CTPDG005284
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Discontinued in Phase 2	ORG-9273	"1-[(2beta,3alpha,5alpha,16beta,17beta)-17-Acetoxy-3-hydroxy-2-morpholinoandrostan-16-yl]-1-methylpiperidinium bromide; 17beta-Acetoxy-3alpha-hydroxy-16beta-(1-methylhexahydropyridinio-1-yl)-2beta-morpholino-5alpha-androstane bromide"	131901	Discontinued in Phase 2	D0C2HR	.	CTPDG006545
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Discontinued in Phase 1	ANQ-9040	"3alpha-Acetoxy-3beta-(hexahydroazepinomethyl)-17a,17a-dimethyl-17-homo-17a-azonia-5alpha-androstane benzenesulfonate"	9939141	Discontinued in Phase 1	D0N1DQ	.	CTPDG006771
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Preclinical	Celastrol	"Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid"	122724	Preclinical	D0I9XH	.	CTPDG007077
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Terminated	PLD-180	.	.	Terminated	D0T9ZG	.	CTPDG007217
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Terminated	AX-205	.	.	Terminated	D0D8ZU	.	CTPDG007375
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0111	.	.	Investigative	D0Z8UJ	.	CTPDG007623
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0020	.	.	Investigative	D0Z1HA	.	CTPDG007641
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0046	.	.	Investigative	D0Z0JA	.	CTPDG007645
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	Stem cell-derived astrocytes	Stem cell-derived astrocytes (ALS)	.	Investigative	D0Y3XF	.	CTPDG007667
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0113	.	.	Investigative	D0XR6I	.	CTPDG007693
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0098	.	.	Investigative	D0X6DK	.	CTPDG007715
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	Cis-tetracosenoyl sulfatide	"Cis-tetracosenoyl sulfatide (amyotrophic lateral sclerosis); Cis-tetracosenoyl sulfatide (amyotrophic lateral sclerosis), Glycoregimmune"	5459361	Investigative	D0X4FY	DB04661	CTPDG007724
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0115	.	.	Investigative	D0WT8Z	.	CTPDG007739
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0043	.	.	Investigative	D0W7NV	.	CTPDG007757
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0107	"Gene therapy (SOD1 gene inhibitor), ALS Therapy Development Foundation"	.	Investigative	D0W7DP	.	CTPDG007759
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	NNZ-4945	"Nerve regeneration program, Neuren/Metabolic Pharmaceuticals; Neurodegenerative disease peptides, Neuren/Metabolic Pharmaceuticals; Neuronal regeneration peptides (amyotrophic lateral sclerosis), CuroNZ; Neuronal regeneration peptides (motor neuron disease), CuroNZ; Neuronal regeneration peptides, Neuren/Calzada"	.	Investigative	D0VO5V	.	CTPDG007777
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	NT-FV-007	.	.	Investigative	D0U3DE	.	CTPDG007835
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0103	.	.	Investigative	D0TY1U	.	CTPDG007843
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0114	.	.	Investigative	D0T5JG	.	CTPDG007856
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	SCLERON	"Motoneuron degeneration blocker (amyotrophic lateral sclerosis), Lascco"	.	Investigative	D0SI1Z	.	CTPDG007877
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0047	.	.	Investigative	D0SD8V	.	CTPDG007879
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0033	"Gene therapy program (NGF receptor agonist); TDI-0034; TDI-0035; TDI-0036; TDI-0038; TDI-0041; Gene therapy program (NGF receptor agonist), ALS Therapy Development Foundation"	.	Investigative	D0Q8ZP	.	CTPDG007937
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	GEM-ALS	"Amyotrophic lateral sclerosis therapy (conjugated protein), Gemac"	.	Investigative	D0PS2X	.	CTPDG007969
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0042	.	.	Investigative	D0PH0U	.	CTPDG007972
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	NsG-33	Meteorin	.	Investigative	D0M0JR	.	CTPDG008087
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0066	.	.	Investigative	D0LX4K	.	CTPDG008088
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	ETN-002	.	.	Investigative	D0LR4M	.	CTPDG008090
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0010	.	.	Investigative	D0J2NI	.	CTPDG008177
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0105	.	.	Investigative	D0H2LJ	.	CTPDG008246
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0029	.	.	Investigative	D0GD6J	.	CTPDG008256
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0049	.	.	Investigative	D0FZ9N	.	CTPDG008284
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0068	.	.	Investigative	D0FK6A	.	CTPDG008290
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	AAV-IGF	"AAV-IGF (amyotrophic lateral sclerosis); AAV1-IGF-1; AAV-IGF (amyotrophic lateral sclerosis), Genzyme"	.	Investigative	D0E9DP	.	CTPDG008332
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0048	.	.	Investigative	D0E2EN	.	CTPDG008347
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0099	.	.	Investigative	D0C4UU	.	CTPDG008412
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0074	.	.	Investigative	D0C3RP	.	CTPDG008414
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0060	.	.	Investigative	D0BT4P	.	CTPDG008434
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0087	.	.	Investigative	D09MPN	.	CTPDG008538
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0026	.	.	Investigative	D09LVK	.	CTPDG008541
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0090	.	.	Investigative	D09DHL	.	CTPDG008562
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0039	.	.	Investigative	D09BSI	.	CTPDG008569
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0053	.	.	Investigative	D07TWZ	.	CTPDG008661
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0018	.	.	Investigative	D07TIX	.	CTPDG008662
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0032	.	.	Investigative	D07MUT	.	CTPDG008680
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0067	.	.	Investigative	D07IYC	.	CTPDG008695
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	CERE-135	"CERE-130; Insulin like growth factor-1 gene therapy, Ceregene; IGF-1 gene therapy (ALS), Ceregene; IGF-1 gene therapy (amyotrophic lateral sclerosis), Ceregene; AAV-IGF-1 gene therapy (ALS), Ceregene"	.	Investigative	D06XPX	.	CTPDG008717
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0028	ALS-TDI-00846	.	Investigative	D06VPT	.	CTPDG008728
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0094	.	.	Investigative	D06EYQ	.	CTPDG008762
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	ORG-9453	1-[3alpha-Acetoxy-17beta-butyryloxy-2beta-(piperidin-1-yl)-5alpha-androstan-16beta-yl]-1-methylpiperidinium bromide	.	Investigative	D06BHK	.	CTPDG008771
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0025	.	.	Investigative	D05YRG	.	CTPDG008779
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0079	"Superoxide dismutase-1 (SOD1) gene modulator (amyotrophic lateral sclerosis), ALS Therapy Development Foundation"	.	Investigative	D05SCQ	.	CTPDG008803
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	RTA-801	.	.	Investigative	D05GQV	.	CTPDG008838
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0055	.	.	Investigative	D05DZJ	.	CTPDG008842
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0054	.	.	Investigative	D04TPF	.	CTPDG008862
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0059	.	.	Investigative	D04LRQ	.	CTPDG008883
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0102	.	.	Investigative	D03JRL	.	CTPDG008966
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0106	.	.	Investigative	D02XUE	.	CTPDG008995
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0015	.	.	Investigative	D02TTP	.	CTPDG009003
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0050	.	.	Investigative	D02REO	.	CTPDG009013
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	MGN-8107	"MiR-206 targeted therapeutic (amyotrophic lateral sclerosis), miRagen Therapeutics"	.	Investigative	D02DZI	.	CTPDG009035
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0065	.	.	Investigative	D01PFX	.	CTPDG009085
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0057	"Gene therapy (cellular stress), ALS Therapy Development Foundation"	.	Investigative	D00SNY	.	CTPDG009157
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	ALS-AAV9	"Amyotrophic lateral sclerosis gene therapy, RegenX Biosciences; Adeno-associated virus vector-9 based gene therapy (injectable, ALS), RegenX Bioscience"	.	Investigative	D00PGA	.	CTPDG009169
M6ACROT03189	.	.	M6ADIS0135	8B60: Motor neuron disease	Investigative	TDI-0051	.	.	Investigative	D00HNQ	.	CTPDG009186
M6ACROT03204	.	.	M6ADIS0182	9A96: Uveitis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT03205	.	.	M6ADIS0182	9A96: Uveitis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05851	.	.	M6ADIS0182	9A96: Uveitis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05852	.	.	M6ADIS0182	9A96: Uveitis	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT03311	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT03312	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT03313	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT03314	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT05226	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT05600	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Reteplase	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)	.	Approved	D0T1UJ	.	CTPDG000141
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	M-enoxaparin	M-enoxaparin (angina)	.	Approved	D0P2EX	.	CTPDG000221
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Anistreplase	.	.	Approved	D0K4DI	.	CTPDG000311
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Ridogrel	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid	5362391	Approved	D0E3BH	DB01207	CTPDG000411
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tisokinase	Plasvata (TN)	.	Approved	D0E0ST	.	CTPDG000416
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Tirofiban	"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"	60947	Approved	D0BN9X	DB00775	CTPDG000447
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Approved	Prasugrel	Effient (TN)	6918456	Approved	D07IRF	DB06209	CTPDG000567
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Entresto	"Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi"	71449007	Phase 3	D0KQ8X	.	CTPDG001154
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	MultiStem	MultiStem (TN)	.	Phase 2	D0D7GS	.	CTPDG001238
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Bendavia	Elamipretide	11764719	Phase 2	D07TDV	DB11981	CTPDG001345
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	Dalcetrapib	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate	6918540	Phase 3	D05SSC	DB12181	CTPDG001392
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 3	REG1	.	86278323	Phase 3	D05ALP	DB06293	CTPDG001409
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RGN-352	Thymosin Beta 4 (injectable)	.	Phase 2	DU04SO	.	CTPDG001629
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CSL 112	.	.	Phase 2	DQY14Z	.	CTPDG001644
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MEDI6012	RhLCAT; ACP-501	.	Phase 1	D0T5YB	.	CTPDG002015
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	TF0023	.	.	Phase 2	D0PX0N	.	CTPDG002104
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	E5555	Atopaxar	10459564	Phase 2	D0PU8T	DB12046	CTPDG002108
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	VT-111a	.	.	Phase 2	D0O2XW	.	CTPDG002144
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	RO-4905417	.	.	Phase 2	D0M7VE	.	CTPDG002192
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Aliskiren/valsartan	Valturna (TN)	23231644	Phase 2	D0LH4J	.	CTPDG002221
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	M118	Adomiparin	21156139	Phase 2	D07XJJ	.	CTPDG002661
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	Ischemic tolerant allogeneic mesenchymal stem cell therapy	.	.	Phase 2	D06ZCP	.	CTPDG002713
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 2	CER-001	.	.	Phase 2	D03AKH	.	CTPDG002940
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1/2	KAI-9803	"DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d"	56843747	Phase 1/2	D0O6HP	.	CTPDG003362
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	PF-06282999	.	71571306	Phase 1	D09DXX	DB11683	CTPDG005007
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	REC-01	.	.	Phase 1	D03JWU	.	CTPDG005309
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 1	"Mesenchymal stem cell therapy, ischemic-tolerant stem cells"	.	.	Phase 1	D01GQO	.	CTPDG005413
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 3	Darexaban maleate	"UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate"	49843900	Discontinued in Phase 3	D07OGZ	.	CTPDG006375
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Phase 4	Streptokinase	.	.	Phase 4	D04NCK	.	CTPDG006381
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Discontinued in Phase 2	RG1512	P-selectin huMAb	.	Discontinued in Phase 2	D03AUN	.	CTPDG006647
M6ACROT06027	.	.	M6ADIS0097	BA41: Acute myocardial infarction	Investigative	LA-8045	LA-816	.	Investigative	D0W3JA	.	CTPDG007768
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05021	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05022	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05110	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05116	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05163	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05202	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05414	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05415	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT02008	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT02009	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03106	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03371	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03372	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03373	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03374	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03375	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03376	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05506	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05507	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05508	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05509	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05518	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05519	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05573	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05622	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05635	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05748	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06003	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06004	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06005	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06006	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06007	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06008	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06009	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06010	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06011	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Claudiximab	"IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed"	.	Phase 3	D0B3ZC	.	CTPDG001268
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Golnerminogene pradenovac	TNFerade (TN)	.	Phase 3	D03QBT	.	CTPDG001437
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	Pegamotecan	"Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon"	11297617	Phase 2	D0D4CX	.	CTPDG002455
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 3	Opdivo + Yervoy	.	.	Phase 3	D02VYE	.	CTPDG002951
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-NY-ESO-1 CAR-T cells	.	.	Phase 1/2	D0LJ2S	.	CTPDG003385
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	Anti-MUC1 CAR-T cells	.	.	Phase 1/2	D09KWN	.	CTPDG003491
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1/2	CAR-T Cells targeting EpCAM	.	.	Phase 1/2	D08QYW	.	CTPDG003504
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Phase 1	PCA062	.	.	Phase 1	D09WSR	.	CTPDG004962
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Clinical trial	Cellspan esophageal implant	.	.	Clinical trial	D0SW1D	.	CTPDG005490
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT06012	.	.	M6ADIS0056	2B70: Esophageal cancer	Discontinued in Phase 1	Ramorelix	Hoe-013	25077455	Discontinued in Phase 1	D0S6AQ	.	CTPDG006744
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Alkavervir	.	.	Approved	D0Y2MC	.	CTPDG000062
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Phenoxybenzamine	Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A	4768	Approved	D0X2DK	DB00925	CTPDG000072
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Ethacrynate Sodium	.	23668825	Approved	D0W5UV	.	CTPDG000089
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Mecamylamine	"Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane"	4032	Approved	D0V8HA	DB00657	CTPDG000103
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Nicardipine	"Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	4474	Approved	D0T0KA	DB00622	CTPDG000143
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Guanabenz	"GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine"	5702063	Approved	D0L4HY	.	CTPDG000288
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Benzthiazide	"Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	2343	Approved	D0L2MX	DB00562	CTPDG000290
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Mephentermine	"Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane"	3677	Approved	D0G1OZ	DB01365	CTPDG000378
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Olmesartan medoxomil	"Benevas; Benicar; Olmetec; Olvance; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Sankyo Brand of Olmesartan Medoxomil; Cs 866; Benicar (TN); Berlin-Chemie Brand of Olmesartan Medoxomil; CS-866; CS-866DM; CS-866RN; DE-092; KS-1182; Olmetec (TN); Benicar, Olmetec,Olmesartan; Olmesartan medoxomil (JAN/USAN); (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester"	130881	Approved	D07UBG	.	CTPDG000547
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Ethacrynic acid	"Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid"	3278	Approved	D06TNL	DB00903	CTPDG000592
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Timolol	"Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol"	33624	Approved	D05UVD	DB00373	CTPDG000618
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Nadolol	"Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol"	39147	Approved	D05SHK	DB01203	CTPDG000621
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Seractide Acetate	Acthar Gel-synthetic	16132296	Approved	D04WOM	.	CTPDG000657
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Bendroflumethiazide	"Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide"	2315	Approved	D02PAH	DB00436	CTPDG000746
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Pinacidil	"Pinacidilum; P 1134; S 1230; P-154; Pinacidil (anhydrous); Pinacidilum [INN-Latin]; S-1230; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; (+-)-Pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N""-(1,2,2-trimethylpropyl)guanidine; (R,S)-Pinacidil; (inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate"	4826	Approved	D02KMO	DB06762	CTPDG000750
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Approved	Veratrum Viride Root	Vertavis	.	Approved	D01XCL	.	CTPDG000771
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 3	Cilnidipine	"Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	5282138	Phase 3	D0N3SR	DB09232	CTPDG001115
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 3	Alilusem	M-12285; M-17000; M-17055; MD-31	6338015	Phase 3	D05ZHA	.	CTPDG001386
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 2	ACT-280778	.	.	Phase 2	D0J8EC	.	CTPDG002281
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 1/2	RMJH-111b	"Trimagnesium dicitrate; MAGNESIUM CITRATE; 3344-18-1; Trimagnesium citrate; UNII-RHO26O1T9V; magnesium dicitrate; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (2:3); 7779-25-1; RHO26O1T9V; Magnesium citrate, Mg3(C6H5O7)2; trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate; Trimagnesiumdicitrat; MAGNESIUMCITRATE; NSC-83517; Magnesium citrate (VAN); Magnesium citrate [USP]; Magnesium citrate (3:2); Trimagnesiumdicitrate; EINECS 222-093-9; Tectlol (TN); NSC 83517; Tri Magnesium Citrate; EC 222-093-9; Magnesium citrate (JAN/USP); C12H10Mg3O14; CHEMBL3989480; CHEBI:131391; DTXSID601015151; AKOS028109620; DB11110; H259; DB-048405; Citric acid, magnesium salt (2:3) (8CI); FT-0628080; FT-0628081; D03265; Q4177438; magnesium 2-hydroxypropane-1,2,3-tricarboxylate (3/2); 1,2,3-Propanetricarboxylic acid, hydroxy-, magnesium salt (2:3); 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (2:3) (9CI); Citric acid, magnesium salt (2:3),  Citric acid, magnesium salt (2:3) (8CI),  EINECS 222-093-9,  LS-121081,  MAGNESIUM CITRATE,  Magnesium citrate (3:2),  Magnesium citrate, Mg3(C6H5O7)2,  Magnesium; MAGNESIUM CITRATE,  Magnesium citrate (3:2),  Magnesium citrate, Mg3(C6H5O7)2,  Magnesium citrate [USAN],  Magnesium citrate (VAN),  NSC 83517,  Trimagnesiumdicitrat,  Trimagnesium dicitrate"	6099959	Phase 1/2	DC72LG	DB11110	CTPDG003194
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 1/2	RMJH-111b	.	.	Phase 1/2	D0JK2R	.	CTPDG003399
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 1	SKF-105494	.	9963434	Phase 1	D0N6ZP	.	CTPDG004577
M6ACROT05072	.	.	M6ADIS0274	BA00: DOX-induced cardiotoxicity	Phase 1	MK-8266	.	.	Phase 1	D01JKV	.	CTPDG005406
M6ACROT05086	.	.	M6ADIS0100	BC45: Cardiomegaly	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT02042	.	.	M6ADIS0100	BC45: Cardiomegaly	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT05495	.	.	M6ADIS0100	BC45: Cardiomegaly	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT05561	.	.	M6ADIS0100	BC45: Cardiomegaly	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT05562	.	.	M6ADIS0100	BC45: Cardiomegaly	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Tezepelumab	.	.	Approved	DMOF95	.	CTPDG000007
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Procaterol	"Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one"	4916	Approved	D0Z1WA	.	CTPDG000036
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Mometasone furoate/ formoterol fumarate	Dulera (TN)	441336	Approved	D0XW2H	DB14512	CTPDG000065
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Fluprednisolone	Alphadrol	5876	Approved	D0V9DZ	DB09378	CTPDG000100
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Pirbuterol	"Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol"	4845	Approved	D0SS4P	DB01291	CTPDG000146
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Formoterol/budesonide	"Formoterol-budesonide mixt; Budesonide-formoterol mixt; 150693-37-1; Budesonide mixture with formoterol; Formoterol / budesonide; Symbicort Inhalation Aerosol; Budesonide/formoterol combination; Budesonide and formoterol fumarate dihydrate; DTXSID80872449; Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-,     (11beta,16alpha)-, mixt with (R*,R*)-(+-)-N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide; Budesonide, Formoterol"	56841116	Approved	D0P2AG	.	CTPDG000222
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Lodoxamide	Lodoxamide ethyl; Lodoxamide trometamol; Lodoxamide tromethamine; U-42585; U-42585E; U-42718	44564	Approved	D0OG3K	DB06794	CTPDG000233
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Reslizumab	.	.	Approved	D0O8KX	.	CTPDG000236
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Repirinast	MY-1250; MY-5116; MY-6116	5050	Approved	D0O6KE	.	CTPDG000243
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Terbutaline	"Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol"	5403	Approved	D0M8RC	DB00871	CTPDG000270
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Ephedrine	"Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin"	9294	Approved	D0LG8E	DB01364	CTPDG000282
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	"Krypton, Kr-81m"	Mpi Krypton 81m Generator	66380	Approved	D0KL9X	DB09443	CTPDG000295
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Ciclesonide	"Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate"	6918155	Approved	D0K7HU	DB01410	CTPDG000304
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Salbutamol	"Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol"	2083	Approved	D0K5CB	DB01001	CTPDG000309
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Theobromine	"83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332"	5429	Approved	D0I0DS	DB01412	CTPDG000355
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Colforsin daropate hci	Adehl (TN); Adele (TN)	444028	Approved	D0H2MO	.	CTPDG000364
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Khellin	82-02-0; Visammin; Methafrone; Amicardine; Coronin; Medekellin; Ammivisnagen; Corafurone; Amikellin; Viscardan; Benecardin; Gynokhellan; Ammipuran; Kelourin; Rykellin; Interkhellin; Interkellin; Visammimix; Khellinorm; Khellanals; Khellamine; Kalangin; Deltoside; Ammispasmin; Visnagalin; Khelangin; Kelincor; Kelicorin; Norkel; Kelamin; Simeskellina; Khelloyd; Khelfren; Visnagen; Vasokellina; Kellosal; Mefurina; Lynamine; Khelisem; Kelicor; Chellin; Amiptan; Kellin; Ammivin; Keloid; Kellina; Eskel; Cardio-khellin; Ammi-khellin; Bi-Kellina	3828	Approved	D0G4KG	.	CTPDG000375
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	GW642444	"Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester"	21880659	Approved	D0FG6M	.	CTPDG000382
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Oxitropium bromide	Oxivent (TN)	6917865	Approved	D0D4IH	.	CTPDG000423
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Arformoterol	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate	3083544	Approved	D0D1DI	DB01274	CTPDG000428
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Ximelegatran	"Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide"	448042	Terminated	D0B5LF	DB08756	CTPDG000455
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	VR506	.	.	Approved	D09NTM	.	CTPDG000487
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Zileuton	"Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea"	60490	Approved	D09JUG	DB00744	CTPDG000493
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Enprofylline	"Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione"	1676	Approved	D09AMZ	DB00824	CTPDG000506
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Pranlukast	Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide	4887	Approved	D08QIP	DB01411	CTPDG000516
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Chymotrypsin	Alpha Chymar; Catarase; Zolyse	.	Approved	D08NAB	.	CTPDG000521
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Isoetharine	"Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol"	3762	Approved	D08HUC	DB00221	CTPDG000525
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Bambuterol	"Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)"	54766	Approved	D07XYV	DB01408	CTPDG000540
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Doxofylline	Ansimar (TN)	50942	Approved	D07NCN	DB09273	CTPDG000561
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Beclomethasone	"Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone"	20469	Approved	D07DVK	.	CTPDG000579
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	VR632	.	.	Approved	D07BXQ	.	CTPDG000584
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Bitolterol	Tornalate	35330	Approved	D06RUL	DB00901	CTPDG000593
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Cinalukast	"Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid"	6436135	Approved	D06PEB	DB00587	CTPDG000595
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Cromoglicate	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)	2882	Approved	D06NSS	DB01003	CTPDG000598
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Zafirlukast	"Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide"	5717	Approved	D05DVP	DB00549	CTPDG000646
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Brodalumab	AMG 827	.	Approved	D05CEO	.	CTPDG012293
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Fenoterol	"Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol"	3343	Approved	D04XEG	DB01288	CTPDG000655
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Methacholine Chloride	"Methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium"	6114	Approved	D04MWJ	.	CTPDG000664
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Formoterol	"Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate"	3410	Approved	D04KJO	DB00983	CTPDG000669
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Aminophylline	Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)	9433	Approved	D03TYI	DB01223	CTPDG000695
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Rimiterol	"Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI)"	36283	Approved	D03NOS	.	CTPDG000708
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Mepolizumab	"Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid"	.	Approved	D03MTN	.	CTPDG000710
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	CNTO-1959	Guselkumab	.	Phase 3	D03HSN	.	CTPDG000720
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Indacaterol	"312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone"	6918554	Approved	D03DJL	DB05039	CTPDG000726
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Levalbuterol	"Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol"	123600	Approved	D02ZJI	DB13139	CTPDG000733
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Metaproterenol Sulfate	"Metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol"	441333	Approved	D02UFG	.	CTPDG000737
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Ritlecitinib	"CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one"	118115473	Approved	D02TUL	DB14924	CTPDG011203
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Dyphylline	"Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline"	3182	Approved	D02PWM	DB00651	CTPDG000741
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Hydriodic acid iodine-125	Hydriodic acid; Iodine-125	24841	Approved	D02PJA	.	CTPDG000743
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Benralizumab	.	.	Approved	D02PIO	.	CTPDG000744
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Omalizumab	Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)	.	Approved	D02GEC	.	CTPDG000755
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Protokylol Hydrochloride	Ventaire	8699	Approved	D02FCQ	.	CTPDG000757
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Iodinated glycerol	"Organidin; Iodopropylidene glycerol; Glycerol, Iodinated; 5634-39-9; C6H11IO3; CCRIS 2378; 2-(1-IODOETHYL)-1,3-DIOXOLANE-4-METHANOL; HSDB 4185; Glycerol, iodinated [USAN:BAN]; NCI-C55469; EINECS 227-079-6; 1,3-Dioxolane-4-methanol, 2-(1-iodoethyl)-; 2-(1-Iodoethyl)-1,3-dioxolan-4-ylmethanol; [2-(1-iodoethyl)-1,3-dioxolan-4-yl]methanol; Iodinated Glycerol B; 1,3-Dioxolane-4-methanol, 2-(iodoethyl)-; Glycyrrhiza; (2-(1-Iodoethyl)-1,3-dioxolan-4-yl)methanol; iodoglycerin; Glycerol, Iondinated; SCHEMBL19693"	21852	Approved	D01JQJ	.	CTPDG000787
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	VR315	.	.	Approved	D01CHI	.	CTPDG000794
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Montelukast	Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid	5281040	Approved	D00QET	DB00471	CTPDG000808
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	NDA filed	RELVARTM or BREOTM ELLIPTATM	.	.	NDA filed	D09RJA	.	CTPDG000854
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	IND submitted	A378	.	.	IND submitted	DX8M3T	.	CTPDG000861
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Depemokimab	GSK3511294	.	Phase 3	DS9J7L	.	CTPDG000881
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	GSK3511294	depemokimab	.	Phase 3	DP8AS7	.	CTPDG000887
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Fevipiprant	"872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY"	23582412	Phase 3	DH7F9S	DB12011	CTPDG000905
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Astegolimab	MSTT1041A; RG6149	.	Phase 3	DBAL18	.	CTPDG000919
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SAR440340	Itepekimab	.	Phase 3	D8U1EX	.	CTPDG000926
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	D-5519	.	.	Phase 3	D0W8CW	.	CTPDG001008
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Setipiprant	ACT-129968	49843471	Phase 3	D0SP5V	DB12562	CTPDG001050
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	GMI-1070	"GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics"	44232546	Phase 3	D0N4EO	DB12778	CTPDG001114
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Pumactant	"Zofac; AP-0016; Pumactant, Britannia; Pumactant, airPharma; Pumactant, Britannia/airPharma"	.	Phase 3	D0L3VU	.	CTPDG001148
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Vinanterol/fluticasone furoate	Relovair (TN)	.	Phase 3	D0E5VO	.	CTPDG001225
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	ISRAPAFANT	"Y-24180; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine"	119175	Phase 3	D0D4ZM	.	CTPDG001242
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Quinotolast	Aslock; Quinotalast; FK-021; FR-71021	65871	Phase 3	D09YDO	.	CTPDG001288
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	E004	.	68423	Phase 3	D08UVZ	.	CTPDG001318
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	ABT-761	Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea	3086671	Phase 3	D08PXR	DB12758	CTPDG001323
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Approved	Ciclesonide	.	6918155	Approved	D07YLV	DB01410	CTPDG001339
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	QAW-039	.	.	Phase 3	D06XDI	.	CTPDG001372
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SOTB07	.	.	Phase 3	D06VFP	.	CTPDG001374
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	MDI-P	"CHEMBL595840; 60986-80-3; 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one; 3,6-Diphenyl-5-methylisoxazolo[4,5-c]pyridin-4(5H)-one; 3,6-DIPHENYL-5-METHYLISOXAZOLO(4,5-C)PYRIDIN-4(5H)-ONE; AC1Q3XQS; AC1Q3XQT; AC1N5X7T; MLS002153017; SCHEMBL3663640; GTPL6218; CTK5B2529; cid_4250909; DTXSID10401226; LCNDUGHNYMJGIW-UHFFFAOYSA-N; HMS2206G07; 5-methyl-3,6-diphenyl-isoxazolo[4,5-c]pyridine-4(5H)-one; ZINC394853; HMS3358C19; BDBM50305859; AKOS024323421; MCULE-8467817198; SMR001229079; FT-0714059"	3057996	Phase 3	D06ICW	DB06112	CTPDG001377
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	VR647	.	.	Phase 3	D01SPW	.	CTPDG001481
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Fluticasone furoate/ fluticasone propionate	.	9854489	Phase 3	D01IWJ	DB08906	CTPDG001486
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Bavituximab	.	.	Phase 2	D00UAE	.	CTPDG001494
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2/3	Darbufelone	PD-136095	6444826	Phase 2/3	D0AL8T	.	CTPDG001553
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2/3	CEP1347	AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403	9917013	Phase 2/3	D03QLG	.	CTPDG001576
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2a	Aerovant	.	.	Phase 2a	D0BW3P	.	CTPDG001588
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD1402	Elarekibep	.	Phase 2	DZGI51	.	CTPDG001598
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CSJ117	Ecleralimab	.	Phase 2	DU6O4B	.	CTPDG001628
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD8154	"1H-Isoindol-1-one, 2-((1S)-1-cyclopropylethyl)-2,3-dihydro-5-(4-methyl-2-((6-(2-oxo-1-pyrrolidinyl)-2-pyridinyl)amino)-5-thiazolyl)-7-(methylsulfonyl)-; 2-[(1S)-1-cyclopropylethyl]-5-[4-methyl-2-[[6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-3H-isoindol-1-one; 2215022-45-8; AKOS040757410; Azd 8154; AZD 8154 [WHO-DD]; AZD8154; AZD-8154; AZD-8154 [WHO-DD]; BDBM50512861; CHEMBL4558527; CS-0371158; EX-A5133; Example 1 [WO2018055040A1]; GTPL11204; HY-115870; J5M3TCK9Y9; MS-30088; SCHEMBL22204109; UNII-J5M3TCK9Y9"	141754136	Phase 2	DQ62LM	.	CTPDG001649
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RG6341	.	.	Phase 1	DLI53W	.	CTPDG001683
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GB001	.	.	Phase 2	DKP0T7	.	CTPDG001692
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SelK2	.	.	Phase 2	DFTV08	.	CTPDG001722
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK3772847	.	.	Phase 2	DCSZ97	.	CTPDG001747
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AVTX-002	quisovalimab	.	Phase 2	DBU4N1	.	CTPDG001753
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RPT193	"(1R,3r)-3-((R)-3-(1-(5-Chloro-4-(((R)-1-(2,4-dichlorophenyl)ethyl)amino)-6-methylpyrimidin-2-yl)azetidin-3-yl)piperidin-1-yl)-1-methylcyclobutane-1-carboxylic acid; 2366152-15-8; 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methylpyrimidin-2-yl]azetidin-3-yl]piperidin-1-yl]-1-methylcyclobutane-1-carboxylic acid; CS-0610200; Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-; example 37 [WO2019147862A1]; GLXC-26793; GTPL12893; HY-148074; MS-30263; Q0M1LOC2MM; RPT193; RPT193; RPT-193; SCHEMBL21193871; SCHEMBL21207415; Zelnecirnon; Zelnecirnon; zelnecirnon [INN]"	139344142	Phase 2	D5SDZ0	.	CTPDG001801
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MTPS9579A	RG6173	.	Phase 2	D4NF0L	.	CTPDG001814
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TD-8236	.	.	Phase 2	D2KTG5	.	CTPDG001835
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AMG 853	"VIDUPIPRANT; 1169483-24-2; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238"	42641863	Phase 2	D0YB2Y	DB12272	CTPDG001874
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Iralukast	CGP-45715A	6913104	Phase 2	D0X9LK	.	CTPDG001892
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PL-3994	.	121488161	Phase 2	D0X8QO	.	CTPDG001894
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	QBX258	.	.	Phase 2	D0X8OW	.	CTPDG001895
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Revamilast	"GRC-4039; PDE 4 inhibitor (inflammation), Glenmark; Phosphodiesterase 4 inhibitor (inflammation), Glenmark; Revamilast (inflammation), Glenmark"	11546664	Phase 2	D0X0PW	DB11838	CTPDG001907
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-54903	.	.	Phase 2	D0W8DA	.	CTPDG001923
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-54903 + olodaterol	.	.	Phase 2	D0W0YI	.	CTPDG001938
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CROMOGLYCATE LISETIL HYDROCHLORIDE	Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556	196639	Phase 2	D0VZ9S	.	CTPDG001942
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ONO-6950	.	46830962	Phase 2	D0U5YM	.	CTPDG001989
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK679586	.	.	Phase 2	D0T3QR	.	CTPDG002023
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PIRODOMAST	"Sch-37224; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one"	54680204	Phase 2	D0S2UR	.	CTPDG002046
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AP-761	BI-671800	45270144	Phase 2	D0RL4X	DB12524	CTPDG002057
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	OX-914	.	.	Phase 2	D0RJ1W	.	CTPDG002058
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	HI-1640V	.	.	Phase 2	D0R6VH	.	CTPDG002067
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PNU-142731A	"9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride"	9846800	Phase 2	D0Q9IY	.	CTPDG002082
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Tipelukast	"Asthma therapy, MediciNova; KCA-757; MN-001"	9893228	Phase 2	D0Q7UG	DB12435	CTPDG002086
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BIO-1211	"BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-"	9961766	Phase 2	D0Q5LF	.	CTPDG002090
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LM-1507.NA	MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt	.	Phase 2	D0OG6N	.	CTPDG002130
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Altrakincept	.	.	Phase 2	D0O5KH	.	CTPDG002140
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BT-061	.	.	Phase 2	D0NQ0V	.	CTPDG002157
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Pascolizumab	"SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs"	.	Phase 2	D0NO1L	.	CTPDG002158
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RNS-60	.	.	Phase 2	D0N9AD	.	CTPDG002161
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MK-1029	.	.	Phase 2	D0N4ZX	.	CTPDG002172
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ABT-308	.	.	Phase 1	D0N3WN	.	CTPDG002176
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Montelukast/mometasone	MK-0476C	4248	Phase 2	D0M5HV	.	CTPDG002202
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	JNJ-39758979	.	24994634	Phase 2	D0M4UZ	.	CTPDG002206
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Oglemilast	"GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark"	11387409	Phase 2	D0L8KJ	DB12375	CTPDG002227
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD-3199	.	16035068	Phase 2	D0L6LD	.	CTPDG002233
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-4191834	PF-04191834	24986635	Phase 2	D0L5XG	DB11645	CTPDG002234
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TA-270	.	54710630	Phase 2	D0L4SL	.	CTPDG002237
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	E-6700	.	9843006	Phase 2	D0K9UK	.	CTPDG002256
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	IPL-512602	"BLX-LSAID; IPL-576 series; OX-LSAID; Lead LSAID (asthma), Biolipox; Lead LSAID (asthma), Orexo; Lead LSAID (asthma), Inflazyme/Aventis; Lead LSAID (asthma), Inflazyme/sanofi-aventis"	.	Phase 2	D0I8CK	.	CTPDG002303
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BAY-X-7195	"UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid"	6442328	Phase 2	D0GY0O	.	CTPDG002348
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anti-IL-5 Receptor mab	.	.	Phase 2	D0G9EI	.	CTPDG002360
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TC-6987	.	44511587	Phase 2	D0G4GA	DB14854	CTPDG002373
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEDI-528	.	.	Phase 2	D0FI5C	.	CTPDG002386
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	KB-003	"KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios"	.	Phase 2	D0F0ZK	.	CTPDG002407
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	JNJ-40929837	.	57910975	Phase 2	D0ER9I	.	CTPDG002408
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD-5069	"CXCR2 inhibitor (COPD), Astrazeneca"	56645576	Phase 2	D0E6SX	.	CTPDG002422
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TJ-9	.	.	Phase 2	D0CR1I	.	CTPDG002469
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-BT	"Blomia tropicalis allergen immunotherapy (sublingual, asthma), National Biopreparations Center"	.	Phase 2	D0BS7T	.	CTPDG002498
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AIM-102	.	10126114	Phase 2	D0B7QU	.	CTPDG002506
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Rambazole	"Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole  pound&gt; SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510"	9799888	Phase 2	D0AA6Z	DB13083	CTPDG002532
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	WY-50295-tromethamine	WY-50295T; Wy-49232	10435196	Phase 2	D0A7JH	.	CTPDG002540
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RV-568	.	45109868	Phase 2	D0A5HC	.	CTPDG002546
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	N6022	1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206	44623946	Phase 2	D09LPV	DB12206	CTPDG002576
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZX-100	.	.	Phase 2	D09IGR	.	CTPDG002579
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CYT003	.	.	Phase 2	D09CEJ	.	CTPDG002583
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Ontazolast	"UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-"	71458	Phase 2	D08ZKJ	.	CTPDG002596
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ASM-024	.	117587641	Phase 2	D08NYZ	.	CTPDG002625
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PRO-98498	"HAE-1; Asthma therapy (subcutaneous), Genentech"	.	Phase 2	D07TYJ	.	CTPDG002669
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	KP-496	.	.	Phase 2	D07JKY	.	CTPDG002694
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK2269557	.	49784002	Phase 2	D06GUA	.	CTPDG002760
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	THR-18	.	86291591	Phase 2	D05ZDJ	.	CTPDG002773
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LEO 124249	"delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile"	50914062	Phase 2	D05UGH	.	CTPDG002785
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GW274150	"GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid"	9797017	Phase 2	D05QJT	DB12237	CTPDG002791
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Masilukast	D-3523; MCC-847; ZD-3523	204056	Phase 2	D05BHF	.	CTPDG002819
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	R411	.	61516	Phase 2	D04YJN	.	CTPDG002824
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Tepoxalin	"103475-41-8; Orf-20485; ORF 20485; Tepoxaline; Tepoxalina; Tepoxalinum [Latin]; Tepoxaline [French]; Tepoxalina [Spanish]; RWJ 20485; Tepoxalin [USAN:INN]; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; UNII-TZ4OX61974; C20H20ClN3O3; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-; CHEMBL316040; CHEBI:76277; TZ4OX61974; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; RWJ-20485; SIL-4R"	59757	Phase 2	D04WMR	DB11466	CTPDG002831
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-144807	.	.	Phase 2	D04UME	.	CTPDG002837
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK2245035	GSK-2245035	44623937	Phase 2	D04PAU	.	CTPDG002850
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AMG 157	.	.	Phase 2	D04FWP	.	CTPDG002869
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anti-M1 prime	.	.	Phase 2	D04CWS	.	CTPDG002877
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ONO-AE1-437	"16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1"	9824353	Phase 2	D03YAS	.	CTPDG002886
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-DP	"Dermatophagoides pteronyssinus allergen immunotherapy (subcutaneous, asthma), National Biopreparations Center"	.	Phase 2	D03UBI	.	CTPDG002901
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AHCQ	.	.	Phase 2	D03MZU	.	CTPDG002917
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anrukinzumab	"Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer"	.	Phase 2	D03ING	.	CTPDG002926
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	WIN-901	.	.	Phase 2	D03GXU	.	CTPDG002930
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Noberastine	Flamizole; R-64947; R-72075	60531	Phase 2	D03DRR	.	CTPDG002934
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TPI ASM8	.	.	Phase 2	D02RPP	.	CTPDG002958
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SB-265610	"SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, &gt; J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be"	9841667	Phase 2	D02JXG	.	CTPDG002974
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ZY-15106	MgNAAGA; NAAGAMg; Rhinaaxia; N-Acetylaspartyl-glutamic acid magnesium salt	71120	Phase 2	D02GTN	.	CTPDG002980
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GPD-1116	.	9841417	Phase 2	D01XFZ	.	CTPDG003003
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CTP-543	.	.	Phase 2	D01UAU	.	CTPDG003011
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEMP1972A	RG7449	.	Phase 2	D01LSB	.	CTPDG003028
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LCB-2183	.	135418284	Phase 2	D01KNY	.	CTPDG003031
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Flezelastine	D-18024	60432	Phase 2	D00NVO	.	CTPDG003077
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SR-2640	"SR 2640; SR 2640 Hydrochloride; 105350-26-3; CHEMBL18132; SR2640; Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]-; QMPB; Benzoic acid, 2-((3-(2-quinolinylmethoxy)phenyl)amino)-; SR-01000076219; Tocris-1804; Lopac-S-7690; AC1L2TN9; Lopac0_001079; 2-(3-(2-Quinolylmethoxy)phenylamino)benzoic acid; MLS002153402; cid_128355; GTPL3329; SCHEMBL9119607; CTK8F0698; CHEBI:104023; HMS3263G20; HMS2236C03; ZINC596951; HMS3373N15; Tox21_501079; BDBM50006798; AKOS030239522; LP01079; CCG-205156; NCGC00015965-02; NCGC00015965-04"	128355	Phase 2	D00MHP	.	CTPDG003079
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PEGylated pitrakinra	"Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance"	.	Phase 2	D00KQN	.	CTPDG003083
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Gallopamil	"16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; GSK 796406"	1234	Phase 2	D00ERV	DB12923	CTPDG003096
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ETX-9101	.	.	Phase 2	D00EGN	.	CTPDG003098
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEDI9929	.	.	Phase 2	D00CTZ	.	CTPDG003103
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1/2	MRx-4DP0004	.	.	Phase 1/2	DR5GC8	.	CTPDG003149
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1/2	Sodium pyruvate	"113-24-6; Pyruvic acid sodium salt; sodium 2-oxopropanoate; Pyruvic acid, sodium salt; Propanoic acid, 2-oxo-, sodium salt; Sodium alpha-ketopropionate; 2-Oxopropanoic acid sodium salt; UNII-POD38AIF08; POD38AIF08; CHEBI:50144; Natriumpyruvat; alpha-Ketopropionic acid sodium salt; MFCD00002586; Propanoic acid, 2-oxo-, sodium salt (1:1); S-6005; Pyruvic acid, sodium salt, 99+%; Pyruvate Sodium; Natrum pyruvicum; CHEMBL181886; sodiumpyruvate; Guna-flam; Guna-hypertension; EINECS 204-024-4; pyruvic acid na-salt; N-115; Sodium pyruvate (inhaled); Reactive oxygen species antagonist (inhaled), EmphyCorp; Sodium pyruvate (inhaled), EmphyCorp"	23662274	Phase 1/2	D02ECG	.	CTPDG003609
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GDC-0214	"1831144-46-7; AKOS040759985; BDBM232517; CHEMBL3964801; EX-A6434; GDC0214; GDC-0214; GTPL12318; iJak-381; N-(3-(5-Chloro-2-(difluoromethoxy)phenyl)-1-(2-(4-((2-cyanoethyl)(methyl)amino)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide; RG6151; RG-6151; SCHEMBL17271636; US9346815, 63"	118522534	Phase 1	DZ2RH6	.	CTPDG003649
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD8630	.	.	Phase 1	DYC40H	.	CTPDG003657
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD4604	"(2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-; 2241039-81-4; AKOS040733485; AT39356; AZD4604; AZD-4604; BDBM488779; CHEMBL4447181; CS-0101485; EX-A5343; example 35 [WO2018134213A1]; GTPL11716; HY-126294; JAC34RRR7S; JAK1-IN-7; londamocitinib; MS-30607; SCHEMBL20399395; UNII-JAC34RRR7S; US10961228, Example 35"	135240395	Phase 1	DX72LV	.	CTPDG003666
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ADL 018	Omalizumab biosimilar	.	Phase 1	DV3E9U	.	CTPDG003696
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	KN-002	.	.	Phase 1	DI19BZ	.	CTPDG003887
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK2292767	"1254036-66-2; 4M4E8NZ73C; AC-32649; AKOS032945160; BCP24323; BDBM50521218; C24H28N6O5S; CCG-269791; CHEMBL4434674; compound 2 [PMID: 30532965]; compound 3 [PMID: 26301626]; CS-0003832; EX-A994; GSK2292767; GSK-2292767; GTPL10633; HY-15280; Methanesulfonamide, N-(5-(4-(5-(((2R,6S)-2,6-dimethyl-4-morpholinyl)methyl)-2-oxazolyl)-1H-indazol-6-yl)-2-methoxy-3-pyridinyl)-, rel-; Methanesulfonamide, N-[5-[4-[5-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]-, rel-; MFCD22572737; N-(5-(4-(5-(((2R,6S)-2,6-Dimethylmorpholino)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide; n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide; N-[5-[4-[5-[[(2S,6R)-2,6-Dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; N-{5-[4-(5-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-methoxypyridin-3-yl}methanesulfonamide; PI3Kdelta inhibitor GS2292767; Q27464135; rel-N-[5-[4-[5-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]methanesulfonamide; s7938; SCHEMBL173490; UNII-4M4E8NZ73C"	49783923	Phase 1	DDE6F1	.	CTPDG003945
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SAR443765	.	.	Phase 1	D9TW0X	.	CTPDG003987
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AMG 104	.	.	Phase 1	D94LRF	.	CTPDG004002
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ARO-RAGE	.	.	Phase 1	D8JN6C	.	CTPDG004015
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	UPB-101	.	.	Phase 1	D7EJI9	.	CTPDG004043
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BI 894416	.	.	Phase 1	D7CI9P	.	CTPDG004044
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD0449	.	.	Phase 1	D63WFO	.	CTPDG004072
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CSL311	.	.	Phase 1	D3Q0FU	.	CTPDG004130
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BI 443651	.	.	Phase 1	D3D9CL	.	CTPDG004141
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ARO-MUC5AC	.	.	Phase 1	D17DXO	.	CTPDG004202
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RO-5271983	.	.	Phase 1	D0WP4E	.	CTPDG004299
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AM-211	"UNII-SZB129M7SZ; 1175526-27-8; SZB129M7SZ; CHEMBL2181753; AM211; [1,1'-Biphenyl]-3-acetic acid, 2'-[[ethyl[[(phenylmethyl)amino]carbonyl]amino]methyl]-6-methoxy-4'-(trifluoromethyl)-; SCHEMBL138450; DTXSID80151807; OPXIRFWNLBDKQB-UHFFFAOYSA-N; BDBM50397640; SB17010; HY-13213; CS-0003178; [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid"	44158492	Phase 1	D0U1HN	.	CTPDG004386
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SAR-21609	"TLR9 agonist (asthma/viral respiratory tract infection), sanofi-aventis"	.	Phase 1	D0R8RO	.	CTPDG004456
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SB-436811	"CHEMBL366221; 346729-66-6; Benzamide,3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-3-pyrrolidinyl]-; SCHEMBL6949936; GTPL2164; ZINC3964101; BDBM50240963; KB-74923; 3,4-Dichloro-N-{(S)-1-[4-(3-dimethylamino-propoxy)-benzyl]-pyrrolidin-3-yl}-benzamide; (S)-3,4-dichloro-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)benzamide; (S)-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)-3,4-dichlorobenzamide"	9846574	Phase 1	D0PQ8T	.	CTPDG004499
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	OPK-0018	.	.	Phase 1	D0O8SB	.	CTPDG004544
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	MEDI4212	.	.	Phase 1	D0O5CV	.	CTPDG004549
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	IMA-026	.	.	Phase 1	D0NY5Y	.	CTPDG004557
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AI-128	.	.	Phase 1	D0N6WX	.	CTPDG004578
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	PF-06444752	.	.	Phase 1	D0K2HU	.	CTPDG004663
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	Xmab-7195	"IgE inhibitor (asthma/allergy), Xencor"	.	Phase 1	D0JQ4S	.	CTPDG004669
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CNTO-3157	.	.	Phase 1	D0I9WR	.	CTPDG004714
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CVT-6883	"752222-83-6; GS-6201; UNII-67CKV7X08G; CHEMBL260933; 67CKV7X08G; CVT 6883; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione; Kinome_3621; SCHEMBL238694; GTPL5615; CVT6883; AOB4675; MolPort-035-765-814; CTV-6883; ZINC29055563; BDBM50236738; AKOS024458311; API0004749; 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione"	11270783	Phase 1	D0G4CF	DB05936	CTPDG004777
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	FP-025	.	.	Phase 1	D0F470	.	CTPDG004807
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BM-212	"BM212; UNII-U9HSU4GZWL; 146204-42-4; U9HSU4GZWL; 1-{[1,5-Bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl}-4-methylpiperazine; 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine; BM 212; AC1L9VRH; CHEMBL321077; SCHEMBL1452627; BCP24821; ZINC22445591; AKOS032944899; CS-5953; Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-; HY-100725"	456926	Phase 1	D0D4VH	.	CTPDG004859
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CI-959	"UNII-1A8130P4IY; CI 959; CI 159; 104795-68-8; 1A8130P4IY; Benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-, monosodium salt; DSSTox_RID_82225; DSSTox_CID_27268; DSSTox_GSID_47268; DTXSID8047268; CHEMBL3183386; Tox21_300435; NCGC00254320-01; LS-41129"	13961743	Phase 1	D07TAS	.	CTPDG005084
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AMG 282	.	.	Phase 1	D07GDR	.	CTPDG005110
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	PF-06413367	.	.	Phase 1	D05BYJ	.	CTPDG005223
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK1440115	"UNII-GCT6G5G3C7; GCT6G5G3C7; GSK 1440115; SCHEMBL2957737; 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; (1,1'-Biphenyl)-4-carboxylic acid, 4'-((1R)-1-((2-(6,7-dichloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)acetyl)methylamino)-2-(4-morpholinyl)ethyl)-"	24760693	Phase 1	D04LWT	.	CTPDG005253
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	Laevo-Bambuterol	R-Bambuterol; R-bambuterol hydrochloride	.	Phase 1	D03INQ	.	CTPDG005313
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	INO-4885	"FP-15; INO-1080; Peroxynitrite decomposition catalyst, Inotek; WW-85; Reactive oxygen species inhibitor (contrast induced nephropathy), Inotek"	.	Phase 1	D02SME	.	CTPDG005343
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD1419	.	.	Phase 1	D02AWQ	.	CTPDG005365
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SDZ-MKS-492	MKS-492	163931	Phase 1	D02ADC	.	CTPDG005369
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-DS	"Dermatophagoides siboney allergen immunotherapy (subcutaneous, asthma), National Biopreparations Center"	.	Phase 2	D01PCB	.	CTPDG005394
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CNT0-3157	.	.	Phase 1	D01ILP	.	CTPDG005407
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK-2239633	.	46861584	Phase 1	D00XBC	.	CTPDG005433
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GRC-6211	"Oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid; GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly"	138393987	Phase 1	D00MAN	.	CTPDG005454
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Preregistration	Clinprost	"Arteon; Isocarbacyclin methyl ester; TEI-9090; TTC-909; Clinprost (liposomal), Taisho; Clinprost (liposomal), Teijin"	6436040	Discontinued in Preregistration	D0X8DU	.	CTPDG006319
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Fosfructose	"Cordox; Fosfructose trisodium; CPC-111; FDP, Questcor; Fructose-1,6-diphosphate; Fructose-1,6-diphosphate, Questcor"	.	Discontinued in Phase 3	D0Z5SR	.	CTPDG006327
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	DG031	"Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148"	123723	Discontinued in Phase 3	D0S6VB	.	CTPDG006337
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Broxaterol	Summair; Z-1170	71149	Discontinued in Phase 3	D0OR2S	.	CTPDG006343
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Lenercept	"Tenefuse; RsTNFR-IgG1; Ro-45-2081; TNF receptor-Ig, Roche; TNFR-IgG1 fusion protein, Roche"	.	Discontinued in Phase 3	D0H6CA	.	CTPDG006356
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	BN 50730	"Rocepafant; UNII-4KGX1STY2N; BN-50730; 4KGX1STY2N; 132579-32-9; BN50730; 132418-36-1; 6-(2-Chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 4H-Pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-; Rocepafant [INN]; LAU8080; LAU-8080; LAU 8080; AC1MHWNG; C27H25ClN6OS; SCHEMBL1065775; CHEMBL2105298; ZINC1481916; LS-172840"	3033963	Discontinued in Phase 3	D0G2RE	.	CTPDG006359
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Ablukast	Ablukast sodium; RO-23-3544	57109	Discontinued in Phase 3	D09DIG	.	CTPDG006372
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	FOROPAFANT	"SR-27417; 2-[N-[2-(Dimethylamino)ethyl]-N-(3-pyridylmethyl)amino]-4-(2,4,6-triisopropylphenyl)thiazole"	119368	Discontinued in Phase 3	D05YUK	.	CTPDG006380
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Ataprost	ONO-41483; OP-41483	6436122	Discontinued in Phase 3	D00LWS	.	CTPDG006393
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Bamaquimast	"L-0042; N-Methylcarbamic acid 3-(2-oxo-1-propyl-1,2-dihydroquinoxalin-3-yl)propyl ester;3-[3-(Methylcarbamoyloxy)propyl]-1-propylquinoxalin-2(1H)-one"	184838	Discontinued in Phase 2	D0ZC7P	.	CTPDG006395
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK159802	.	.	Discontinued in Phase 2	D0YL3E	.	CTPDG006398
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	TIBENELAST	"LY-186655 (sodium salt); 5,6-Diethoxybenzothiophene-2-carboxylic acid"	59913	Discontinued in Phase 2	D0X1EX	.	CTPDG006409
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-613	.	9800584	Discontinued in Phase 2	D0W8QV	.	CTPDG006412
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Pumafentrine	Pumafentrin; BY-343; BYK-33043	3052763	Discontinued in Phase 2	D0V7IS	.	CTPDG006417
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Nolpitantium besilate	SR-140333; SR-140333B	3047794	Discontinued in Phase 2	D0UT3F	.	CTPDG006421
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	BUTIXOCORT	"JO-1717; 11beta,17-Dihydroxy-21-mercaptopregn-4-ene-3,20-dione 17-butyrate; 17-Butanoyloxy-11beta-hydroxy-21-mercaptopregn-4-ene-3,20-dione"	189904	Discontinued in Phase 2	D0UO2N	.	CTPDG006422
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	LY-223982	CGS-23131; LY-223980; LY-255253; SKF-107324	6444688	Discontinued in Phase 2	D0U9JL	.	CTPDG006425
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK256066	GSK-256066	9827968	Discontinued in Phase 2	D0U7PS	DB12137	CTPDG006427
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SC-45662	"CHEMBL84566; UNII-TPG7IO601I component ADVNUIUADIXWMI-QWHCGFSZSA-N; 2-[[(1S,2R)-2-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylpropyl]oxy]acetic acid"	5487420	Discontinued in Phase 2	D0U5EU	.	CTPDG006428
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	E-6123	"E 6123; 131614-02-3; BRN 4280434; E- 6123; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (S)-; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-; AC1MHYY4; CHEMBL114014; DTXSID20157146; API0009208; HY-10164; LS-134356"	3035214	Discontinued in Phase 2	D0R0EV	.	CTPDG006448
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	EPI-2010	.	.	Discontinued in Phase 2	D0QH0B	.	CTPDG006449
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SRP 299	.	.	Discontinued in Phase 2	D0Q1KN	.	CTPDG006454
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Valategrast	"220847-86-9; Valategrast (R411); UNII-06DM4KX7JG; 06DM4KX7JG; Valategrast [INN]; SCHEMBL480224; CHEMBL2107792; ZINC72190226; KB-81423; 2-(Diethylamino)ethyl N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzamido)-L-phenylalaninate"	11563636	Discontinued in Phase 2	D0PW0G	.	CTPDG006456
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	APC-366	"UNII-TGP1HP0WBC; TGP1HP0WBC; APC 366; 178925-65-0; apc366; N-(1-Hydroxy-2-naphthoyl)-L-arginyl-L-prolinamide hydrochloride; APC-366 hydrochloride; AC1L42OQ; SCHEMBL15659721; APC-366-C; APC-366-A; APC-366-R; L-Prolinamide, N2-((1-hydroxy-2-naphthalenyl)carbonyl)-L-arginyl-, monohydrochloride; (2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide hydrochloride"	177339	Discontinued in Phase 2	D0N9WB	.	CTPDG006467
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GW-766994	"CCR3 antagonists, GSK; CCR3 antagonists, GlaxoSmithKline; Chemokine receptor 3 antagonist, GlaxoSmithKline; GW-633647; GW-633647X; GW-701877; GW-701897; GW-701897X; GW-782415X; SB-297006; SB-328437"	10218765	Discontinued in Phase 2	D0N2FI	.	CTPDG006472
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	LTB 019	.	9959759	Discontinued in Phase 2	D0N0PU	.	CTPDG006473
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	WAY-123641	.	.	Discontinued in Phase 2	D0MF3C	.	CTPDG006477
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	MK-591	"Quiflapon; Quiflapon [INN]; L 686708; MK 0591; MK 591; L-686708; MK-0591; L-686,708; 3-(1-(4-chlorobenzyl-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl))-2,2-dimethyl propanoic acid; 3-(tert-Butylthio)-1-(p-chlorobenzyl)-alpha,alpha-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-(tert-butylthio)-1-(p-chlorobenzyl)-a,a-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid"	23672584	Discontinued in Phase 2	D0M0QX	.	CTPDG006483
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CI-949	"CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid"	159563	Discontinued in Phase 2	D0KV4Z	.	CTPDG006489
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Imitrodast	Logran; CS-518; RS-5186	65922	Discontinued in Phase 2	D0K4UW	.	CTPDG006491
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	MK-886	"118414-82-7; MK 886; MK886; 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid; UNII-080626SQ8C; QAOAOVKBIIKRNL-UHFFFAOYSA-N; L-663,536; CHEMBL29097; CHEBI:75390; L 663536; MK-886 (L-663,536); 080626SQ8C; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid; 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]; L-663536; SMR000466278"	3651377	Discontinued in Phase 2	D0K2ER	.	CTPDG006493
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Picumeterol	Levopicumeterol; Picumeterol fumarate; GX 63411; GR-114297; GR-114297A; GR-114297X; GR-63411	131251	Discontinued in Phase 2	D0GP4R	.	CTPDG006514
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Sulukast	LY-170680	6436123	Discontinued in Phase 2	D0G8UG	.	CTPDG006515
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AR-D-111421	.	.	Discontinued in Phase 2	D0F6JI	.	CTPDG006524
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	DS-4574	"DS 4574; 118314-35-5; 6-(2-Cyclohexylethyl)-(1,3,4)thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one; (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one, 6-(2-cyclohexylethyl)-; [1,3,4]Thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one,6-(2-cyclohexylethyl)-; AC1L4LXR; ACMC-20c9t1; AC1Q6E9S; SCHEMBL156066; CTK4B0638; DTXSID80152096; AKOS030534249; 6-(2-cyclohexylethyl)[1,3,4]thiadiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(2h)-one; LS-150402"	159491	Discontinued in Phase 2	D0F4IG	.	CTPDG006526
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Nafagrel	Nafagrel hydrochloride; DP-1904; SR-96325	65851	Discontinued in Phase 2	D0DT2P	.	CTPDG006537
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AS-35	"AS 35; 108427-72-1; 9-((4-Acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; C21H20N6O4; 4H-Pyrido[1,2-a]pyrimidin-4-one,9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)-; 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-; RVRGDCZGEKSIRW-UHFFFAOYSA-N; ACMC-20mbio; as35; AC1L2WU8; SCHEMBL159227; CTK4A6033; DTXSID90148546; CS-7624; LS-134160; HY-101946; L003846"	130135	Discontinued in Phase 2	D0B6EU	.	CTPDG006553
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	RPR-106541	.	9846880	Discontinued in Phase 2	D09UGP	.	CTPDG006565
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AZD-3778	"CHEMBL2158814; SCHEMBL5418656; GTPL7679; AZD3778; QVLZVRFIGXNZMN-UHFFFAOYSA-N; AZD 3778; BDBM50394155; N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide"	11753159	Discontinued in Phase 2	D09RGW	.	CTPDG006568
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	V-11294A	"Rolipram derivatives, Napp"	135430158	Discontinued in Phase 2	D08SNX	.	CTPDG006575
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Corus 1030	Inhaled Lidocaine	.	Discontinued in Phase 2	D08FZT	.	CTPDG006584
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	R-343	"R-921303; Syk tyrosine kinase inhibitor (allergic asthma), Rigel/Pfizer"	10344820	Discontinued in Phase 2	D08DBE	.	CTPDG006585
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	ZD-2138	"Ici D2138; 140841-32-3; UNII-B6G6OX1ZH5; B6G6OX1ZH5; CHEMBL20403; 2(1H)-Quinolinone,6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-; Ici-D2138; 6-((3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinolin-2(1H)-one; ZD 2138; ACMC-20mzth; AC1L30RD; zd2138; 6-((3-Fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinol-2-one; SCHEMBL1083603; CTK4C2357; DTXSID90161477; BDBM50000829; AKOS025404954; ACN-048395"	132306	Discontinued in Phase 2	D07HBI	.	CTPDG006593
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK2190914	.	.	Discontinued in Phase 2	D07ATG	.	CTPDG006600
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	IVL745	"F387KG9Ith; UNII-F387KG9ITH; XRP 1745A; IVL 745; SCHEMBL6136116; DTXSID9043930; NOCAS_43930; IVL-745; 229627-58-1; beta-Alanine, N-((3-methoxy-4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)glycyl-N-((3,4-dimethoxyphenyl)methyl)-"	9830010	Discontinued in Phase 2	D06NOR	.	CTPDG006605
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Isbufylline	TE/06	65681	Discontinued in Phase 2	D05VAA	.	CTPDG006612
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK2190915	"1093403-33-8; sirtuin modulator; SRT 2104; SRT2104 (GSK2245840); SRT2104; SRT-2104; UNII-4521NR0J09; 4521NR0J09; 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-; C26H24N6O2S2; 4-Methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide; 4-methyl-n-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide"	44473151	Discontinued in Phase 2	D05MCS	DB06346	CTPDG006615
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	ACREOZAST	"TYB-2285; N,N'-(2-Chloro-5-cyano-1,3-phenylene)bis[2-(acetyloxy)acetamide]; 3,5-Bis(2-acetoxyacetamido)-4-chlorobenzonitrile"	129991	Discontinued in Phase 2	D04VJH	.	CTPDG006626
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-011	.	.	Discontinued in Phase 2	D04HHW	.	CTPDG006632
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	KW-4490	.	9883436	Discontinued in Phase 2	D03ZVD	.	CTPDG006635
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Tetrazolast meglumine	Tetrazolast; Tetrazolast meglumine salt monohydrate; MDL-26024; MDL-26024GO	9825038	Discontinued in Phase 2	D03PHU	.	CTPDG006643
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Mequitamium iodide	LG-30435	72028	Discontinued in Phase 2	D02YBP	.	CTPDG006648
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Milveterol	UNII-LGY1VQ9622; LGY1VQ9622; 652990-07-3; Milveterol [INN]; SCHEMBL265694; CHEMBL1940832; DTXSID30215640; BMKINZUHKYLSKI-DQEYMECFSA-N; BDBM50419652	9892481	Discontinued in Phase 2	D02KMG	.	CTPDG006653
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-224	FR-115224	6437864	Discontinued in Phase 2	D02FIJ	.	CTPDG006654
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CGRP	"Calcitonin gene related peptide; LAB CGRP; CGRP (inhaled, asthma); CGRP (inhaled, asthma), Akela Pharma; Calcitonin gene-related peptide (inhaled, asthma), LAB International"	44134599	Discontinued in Phase 2	D01SPI	.	CTPDG006660
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CJ-13610	"CJ 13610; CJ-13,610"	9821945	Discontinued in Phase 2	D01DAD	.	CTPDG006665
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	E-6080	"E 6080; 120164-49-0; E6080; AC1L2UXT; SCHEMBL3053845; DTXSID10152706; 6-Hydroxy-2-(4-sulfamoylbenzylamine)-4,5,7-trimethylbenzothiazole hcl; 6-hydroxy-2-(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride; Benzenesulfonamide, 4-(((6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino)methyl)-, monohydrochloride; 4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide hydrochloride"	129064	Discontinued in Phase 2	D00HFD	.	CTPDG006673
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CI-1018	"UNII-Y4O6325SYW; Y4O6325SYW; CHEMBL111925; DSSTox_CID_27248; DSSTox_RID_82208; DSSTox_GSID_47248; SCHEMBL185627; CAS-NOCAS_47248; DTXSID0047248; NOCAS_47248; Tox21_300203; BDBM50217550; NCGC00254191-01; NCGC00247925-01; 179024-48-7; PD-168787; (+)-CI-1018; CI-1018, (+)-; UNII-05127JZ9KQ component KYFWUBJMTHVBIF-QFIPXVFZSA-N; 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; 4-Pyridinecarboxamide, N-((3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrol"	9865514	Discontinued in Phase 2	D00DBE	.	CTPDG006678
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SK&F-S-106203	SK&F-106203; (S)-beta-[(2-Carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid; 3(S)-[2-(Carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propionic acid	3035514	Discontinued in Phase 2	D00AKY	.	CTPDG006681
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	AVE-5883	.	.	Discontinued in Phase 1/2	D0Y4GJ	.	CTPDG006683
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	NCX 950	.	.	Discontinued in Phase 1/2	D0X5ES	.	CTPDG006684
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	Vepalimomab	"Vapantix; VAP-1 MAb (1), BioTie Therapies"	.	Discontinued in Phase 1/2	D01MQH	.	CTPDG006700
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RO7040547	BITS7201A; RG7990	.	Discontinued in Phase 1	DFU4B0	.	CTPDG006702
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	PF-3526299	.	.	Discontinued in Phase 1	D0Y2XQ	.	CTPDG006710
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	IPLl576092	"IPL 576,092"	.	Discontinued in Phase 1	D0X2YI	.	CTPDG006717
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SB-281832	.	.	Discontinued in Phase 1	D0W3AX	.	CTPDG006721
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SDZ-PCO-400	PCO-400	129348	Discontinued in Phase 1	D0U8IJ	.	CTPDG006732
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	F-11105	.	.	Discontinued in Phase 1	D0O2EB	.	CTPDG006763
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SMART anti-E/P selectin	"HuEP5C7; Bispecific anti-E/P selectin, PDL; SMART anti-E/P selectin, PDL; SMART anti-E/P selectin, Protein Design Labs; Anti-E/P selectin (humanized), PDL"	.	Discontinued in Phase 1	D0L3XV	.	CTPDG006785
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	NIP-520	NIP-502	.	Discontinued in Phase 1	D0J4WW	.	CTPDG006799
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	ABT-080	"VML-530; 4,4-Bis[4-(quinolin-2-ylmethoxy)phenyl]pentanoic acid sodium salt"	.	Discontinued in Phase 1	D0GB3A	.	CTPDG006811
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	YM-976	"4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one"	6604918	Discontinued in Phase 1	D0C7JT	.	CTPDG006826
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RG-7152	5-[3-[3-(2-Quinolinylmethoxy)phenoxy]propyl]-1H-tetrazole	129968	Discontinued in Phase 1	D0B7KF	.	CTPDG006831
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	HSR-6071	PTPC; 6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazine-2-carboxamide	159466	Discontinued in Phase 1	D09ZPX	.	CTPDG006840
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	AZD-1744	"Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca"	.	Discontinued in Phase 1	D09UXP	.	CTPDG006843
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	AMG 317	.	.	Discontinued in Phase 1	D09MKQ	.	CTPDG006848
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	PF-05212372	"PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth"	.	Discontinued in Phase 1	D08YFD	.	CTPDG006857
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	GR-63799X	"(-)-[1(R)-[1alpha(Z),2beta(R*),3alpha]-7-[3-Hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]-4-heptenoic acid 4-(benzoylamino)phenyl ester; (Z)-4,5-Didehydro-13-oxa-16-phenoxy-13,14-dihydro-17,18,19,20-tetranor-PGE1 4-(benzoylamino)phenyl ester; 119906-28-4"	6439068	Discontinued in Phase 1	D07RVP	.	CTPDG006865
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RWJ-56423	"CHEMBL256892; CHEMBL124571; (2S,4R)-1-ACETYL-N-[(1S)-4-[(AMINOIMINOMETHYL)AMINO]-1-(2-BENZOTHIAZOLYLCARBONYL)BUTYL]-4-HYDROXY-2-PYRROLIDINECARBOXAMIDE; (2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide; AC1NR9Y0; SCHEMBL4314345; GTPL9333; VXDAVYUFYPFGDX-SNPRPXQTSA-N; BDBM50228764; BDBM50131977; DB02812; (2S)-6; (4R)-1-acetyl-N-[(1S)-1-(1,3-benzothiazol-2-ylcarbonyl)-4-carbamimidamidobutyl]-4-hydroxy-L-prolinamide"	5287596	Discontinued in Phase 1	D05QMJ	DB02812	CTPDG006885
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	ABN-912	"Anti-CD46 mAb, Novartis; Anti-MCP1 monoclonal antibody, Novartis"	.	Discontinued in Phase 1	D04MYO	.	CTPDG006898
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	CGP-13774	.	.	Discontinued in Phase 1	D04FRB	.	CTPDG006901
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	NZ-107	4-Bromo-5-(3-ethoxy-4-methoxybenzylamino)pyridazin-3(2H)-one	129496	Discontinued in Phase 1	D02ANJ	.	CTPDG006917
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	TR-14531	IDDB25065	.	Discontinued in Phase 1	D01VSK	.	CTPDG006918
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RG-7185	"CRTH2 antagonist (asthma), Roche"	.	Discontinued in Phase 1	D01NGT	.	CTPDG006923
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	BM-113	1-[2-(Benzhydryloxy)ethyl]piperidine-4-acetic acid ethyl ester	72941791	Discontinued in Phase 1	D01GIF	.	CTPDG006928
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	GW-250495	GR-250495; GR-250495X; GW-250495X	.	Discontinued in Phase 1	D01EDO	.	CTPDG006931
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SMP-028	.	11949660	Discontinued in Phase 1	D00WWU	.	CTPDG006935
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Preclinical	YM-355179	GTPL793; SCHEMBL3808393	11556309	Preclinical	D0Y6TI	.	CTPDG007022
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Preclinical	AZD-1678	"CCR4 antagonist (asthma), AstraZeneca"	23585443	Preclinical	D0E2QN	.	CTPDG007090
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Preclinical	LAS-101057	"LAS-38096; Adenosine A2b receptor antagonists (inflammation), Almirall"	11716665	Preclinical	D08ECB	.	CTPDG007114
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Preclinical	YM-344031	.	56603737	Preclinical	D04EIL	.	CTPDG007139
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Preclinical	IMO-2134	.	.	Preclinical	D02ZWR	.	CTPDG007146
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	FPL-55712	"40786-08-1; 7-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-carboxy late, sodium salt; CHEMBL267976; 7-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]- 4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid sodium salt; 4H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy)-4-oxo-8-propyl-, monosodium salt; fpl55712; SCHEMBL1890293; AOB5208; ZDEVPOBNLIVGFA-UHFFFAOYSA-M; MFCD00068619; LS-186693; FT-0639668; FPL-55712, &gt"	23662025	Terminated	D0ZE5V	.	CTPDG007164
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-255283	GTPL3351; MolPort-009-018-745; HMS3649C08; ZINC27644044; SR-01000946596; SR-01000946596-1	122023	Terminated	D0Y2IH	.	CTPDG007175
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	A-78773	"141579-67-1; A 78773; CHEMBL59598; N-Hydroxy-N-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea; N-(3-(5-(4-Fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxyurea; 1-{4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl}-1-hydroxyurea; 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea; Urea,N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propyn-1-yl]-N-hydroxy-; CCRIS 8531"	71460	Terminated	D0X9KE	.	CTPDG007180
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	SKF-96231	.	135529458	Terminated	D0W8OH	.	CTPDG007187
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	BAY-44-3428	APC-1167	.	Terminated	D0W7DD	.	CTPDG007188
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	KA-398	"Scopinast; Scopinast, Wilmar Schwabe"	.	Terminated	D0VZ8S	.	CTPDG007193
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Fenspiride hydrochloride	KSP-193	68626	Terminated	D0V8KI	.	CTPDG007196
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	SM 11044	"142784-65-4; SM-11044; DTXSID90162181; AC1L3144; 3-(3,4-Dihydroxyphenyl)-N-(3-(4-fluorophenyl)propyl)serine pyrrolidine amide hydrobromide; Pyrrolidine, 1-(3-(3,4-dihydroxyphenyl)-2-((3-(4-fluorophenyl)propyl)amino)-3-hydroxy-1-oxopropyl)-, monohydrobromide, (R-(R*,S*))-; (2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one hydrobromide"	132507	Terminated	D0V4FK	.	CTPDG007197
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	BI-L-357	BI-L-226	6440014	Terminated	D0U6AL	.	CTPDG007208
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	FR-113680	"FR 113680; 126088-92-4; Ac-Thr-trp(cho)-phe-N-mebzl; AC1L2Y4S; DTXSID70155076; fr113680; N(alpha)-(N(alpha)-(N(alpha)-Acetylthreonyl)-N(1)-formyltryptophyl)-N-methyl-N-(phenylmethyl)phenylalaninamide; L-Phenylalaninamide, N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-"	130848	Terminated	D0T6MU	.	CTPDG007220
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	MEN-11149	.	101940285	Terminated	D0T4IQ	.	CTPDG007221
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	KF-17625	"KF17625; KF 17625; BRN 4874703; CHEMBL95509; 139339-02-9; 5-Phenyl-1H-imidazo(4,5-c)(1,8)naphthyridin-4(5H)-one; 1,5-Dihydro-5-phenyl-4H-imidazo(4,5-c)(1,8)naphthyridin-4-one; 4H-Imidazo(4,5-c)(1,8)naphthyridin-4-one, 1,5-dihydro-5-phenyl-; AC1L2QF6; SCHEMBL2457079; DTXSID10161015; NDDBRRFHXNPOLY-UHFFFAOYSA-N; BDBM50230286; ZINC13731342; LS-80025; LS-80024; 5-phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4-one; 5-Phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-one; 5-Phenyl-3H-Imidazo[4,5-c][1,8]Naphthyridin-4(5H) -One"	126487	Terminated	D0SI4C	.	CTPDG007224
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Tomelukast	LY-171883	3969	Terminated	D0S8YL	.	CTPDG007226
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	MX2/120	"155006-67-0; BRN 7252641; 7-(2,2-Dimethylpropyl)-1-methylxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-7-(2,2-dimethylpropyl)-1-methyl-; 3,7-Dihydro-7-(2,2-dimethylpropyl)-1-methyl-1H-purine-2,6-dione; AC1MINF6; SCHEMBL3843737; 7-(2,2-dimethylpropyl)-1-methyl-3H-purine-2,6-dione; CTK4C8491; DTXSID90165793; 1-Methyl-7-(2,2-dimethylpropyl)xanthine; LS-126951"	3074068	Terminated	D0RM5W	.	CTPDG007234
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8308	.	.	Terminated	D0R7UK	.	CTPDG007235
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8328	.	.	Terminated	D0Q7WW	.	CTPDG007241
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	OT-4003	IDDB10966	.	Terminated	D0PL5F	.	CTPDG007247
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Org-9935	Org-935	131100	Terminated	D0PB6P	.	CTPDG007251
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	MOL-218	"MOL-254; MOL-268; MOL-294; NFkB inhibitors, Molecumetics"	.	Terminated	D0P1YO	.	CTPDG007253
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-210073	LY210073; 148291-65-0; CHEMBL49210; LY 210073; SCHEMBL9148299; AC1O515S; BDBM50045092; HY-U00263; AKOS030562935; CS-7479; L005236; 5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid; 7-Carboxy-3-[[(E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]-9-oxo-9H-xanthene-4-propanoic acid; (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid; 7-Carboxy-3-((6-(methoxyphenyl)-5(E)-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid	6450158	Terminated	D0OP7B	.	CTPDG007258
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	SC-53228	"SC 53228; CHEMBL419948; 153633-01-3; AC1L4BTY; SCHEMBL1447495; DTXSID40165384; BDBM50037390; 3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid; 3-{(S)-7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-, (S)-"	204058	Terminated	D0NK8D	.	CTPDG007270
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	BAY-17-1998	BAY-35-8535	.	Terminated	D0L7ZX	.	CTPDG007290
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	A-79175	CHEMBL90552; UNII-25B75ID70W; 25B75ID70W; AC1L43J2; ZINC5333; SCHEMBL6438420; BDBM50369068; 141579-87-5; 1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea	178577	Terminated	D0L1IH	.	CTPDG007295
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	FK-355	"NK1 antagonists, Fujisawa"	.	Terminated	D0KD4U	.	CTPDG007299
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	ICI-198615	"Cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate; Ici 198615; 104448-53-5; CHEMBL22033; Ici-198,615; ZM 198615; ZM-198,615; cyclopentyl N-[1-({4-[(benzenesulfonyl)carbamoyl]-2-methoxyphenyl}methyl)-1H-indazol-6-yl]carbamate; [3H]ICI198615; [3H]-ICI198615; [3H]ICI-198615; [3H]ICI-198,615; AC1L3GQZ; (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester; GTPL3414; GTPL3358; SCHEMBL9806720; DTXSID80146490; BDBM50009075; PDSP1_000520; PDSP2_000518; ICI198615"	115219	Terminated	D0J7UI	.	CTPDG007310
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	SDZ-ISQ-844	"143526-87-8; Sdz isq 844; SDZ ISQ-844; SCHEMBL7298437; AC1L317P; CTK4C3695; 3-Isoquinolinemethanol,1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (3S)-; AKOS030566039; 6,7-Dimethoxy-1-(3,4-dimethoxyphenyl)-3-hydroxymethyl-3,4-dihydroisoquinoline; (S)-1-(3,5-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (S)-"	132565	Terminated	D0J5UC	.	CTPDG007312
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	ON-579	"141286-14-8; ON 579; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid; Acetic acid,2-[4-[[2-[[(4-chlorophenyl)sulfonyl]amino]ethyl]thio]-2,6-difluorophenoxy]-; ACMC-20cvej; AC1Q6UCK; AC1L4U4O; {4-[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)sulfanyl]-2,6-difluorophenoxy}acetic acid; CHEMBL312763; SCHEMBL2925987; CTK4C2555; DTXSID70161657; AKOS030574939; 4-(2-(4-Chlorophenylsulfonylamino)-ethylthio)-2,6-difluorophenoxyacetic acid; KB-227077"	192308	Terminated	D0J5QW	.	CTPDG007313
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-648051	"4-Apsob; L 648051; UNII-0LGZ40MB45; 0LGZ40MB45; 91541-18-3; 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid; 4-(4-{[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl}phenyl)-4-oxobutanoic acid; Benzenebutanoic acid, 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxo-; AC1Q5VP2; AC1L3TT7; SCHEMBL157166; CHEMBL282253; CTK8D5118; DTXSID50238619; ZAKKEARLDPTRLX-UHFFFAOYSA-N; AKOS030530731; LS-186850; LS-187510"	122010	Terminated	D0J4EG	.	CTPDG007315
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZD-7944	"CHEMBL339767; ZD7944; SCHEMBL7501969; BDBM50409575; (R)-3-((S)-1-(3,4-dichlorophenyl)-3-(4-(2-((S)-methylsulfinyl)phenyl)piperidin-1-yl)propyl)-2-ethylisoindolin-1-one"	44351946	Terminated	D0J3QU	.	CTPDG007317
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	AZD-2098	.	10308720	Terminated	D0J1FL	.	CTPDG007321
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	BW B70C	"BWB70C; BW-B 70C; 134470-38-5; BW-B70C; CHEMBL86676; CHEBI:75307; (E)-N-(3-(3-(4-Fluorophenoxy)phenyl)-1-(R,S)-methylprop-2-enyl)-N-hydroxyurea; 70C; N-[3-[3-4(-Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea; N-(3-(3-(4-Fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxyurea; Urea, N-(3-(3-(4-fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxy-; C17H17FN2O3; SR-01000075717; (e)-N-{3-[3-(4-fluorophenoxy)phenyl]-1-(r,s)-methylprop-2-enyl}-N-hydroxyurea; Lopac0_000202; BSPBio_001512; SCHEMBL2681955"	5353454	Terminated	D0HJ1Y	.	CTPDG007334
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	CP-0597	.	9833644	Terminated	D0H5PD	.	CTPDG007336
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Selenotifen	BN-52256	.	Terminated	D0FQ4M	.	CTPDG007353
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	443C81	BW 443C; BW-443C81	101630908	Terminated	D0E8SE	.	CTPDG007363
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZT-386	.	.	Terminated	D0E8JL	.	CTPDG007364
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	EFIPLADIB	"381683-94-9; UNII-S97YUG2A91; S97YUG2A91; CHEMBL272342; PLA-902; Efipladib [USAN:INN]; Efipladib (USAN); 4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid; SCHEMBL1500831; HIZOPJQOPKRKFM-UHFFFAOYSA-N; ZINC85536943; BDBM50226792; D06674; 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid"	9853499	Terminated	D0E1WY	.	CTPDG007369
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZM-230487	"ZM 230487; 155944-23-3; CHEMBL459236; Ici 230487; ICI-230487; AC1L31ZC; 1-Ethyl-6-((3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-2-quinolone; SCHEMBL6008852; CTK4C8893; DTXSID70165998; zm230487; ZINC1484223; BDBM50250926; 1-Ethyl-6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-2(1H)-quinolinone; KB-276139; 1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one"	132998	Terminated	D0D8MD	.	CTPDG007376
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-290154	.	.	Terminated	D0D0XX	.	CTPDG007379
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	BU-4601A	BU-4601B; BU-4601C	192421	Terminated	D0C9RZ	.	CTPDG007382
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	R zileuton	.	.	Terminated	D0C5HV	.	CTPDG007387
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8225	"UR 8225; 149455-36-7; 5,6-Dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-2-naphthalenecarbonitrile; 1,2-Dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile; 2-Naphthalenecarbonitrile, 5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; 2-Naphthalenecarbonitrile,5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; ACMC-20n5pl; AC1L560X; SCHEMBL6369766; CHEMBL303682; CTK4C6217; DTXSID60164273; LS-94452"	198778	Terminated	D0B7ND	.	CTPDG007392
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	AVE0675	.	.	Terminated	D0B6WN	.	CTPDG007393
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-670596	"121083-05-4; L-670,596; L 670596; 2-(6,8-Difluoro-9-(4-(methylsulfonyl)benzyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid; (-)-6-8-DIFLUORO-2,3,4,9-TETRAHYDRO-9-[[4-(METHYLSULFONYL)PHENYL]METHYL]-1H-CARBAZOLE-1-ACETIC ACID; AC1L2VGU; SCHEMBL3044967; CHEBI:91930; CTK8F0755; MolPort-003-983-606; HMS3268M18; BCP28232; BN0288; AKOS022180202; RT-013483; FT-0757831; SR-01000597550; L002392; C-35484; SR-01000597550-1; J-004444; BRD-A85472596-001-01-4"	129360	Terminated	D0AN1Y	.	CTPDG007399
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	MCI-826	"(E)-2,2-Diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid; (E)-2,2-Diethyl-N-[3-[2-(4-isopropylthiazol-2-yl)vinyl]phenyl]succinamic acid"	6439428	Terminated	D0AB7G	.	CTPDG007401
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	MDL-43291	"Mdl 43291; Mdl 43,291; AC1MI0EN; ((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; (4aalpha,7Z,8beta,8abeta)-((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; Acetic acid, ((octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)-, (4aalpha,7Z,8beta,8abeta)-; 2-[[(2Z,4aS,8S,8aS)-2-(2-oxotetradecan-7-ylidene)-3,4,4a,5,6,7,8,8a-octahydrochromen-8-yl]sulfanyl]acetic acid"	14430182	Terminated	D09ZVR	.	CTPDG007407
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	XR-12890	"MRP1 inhibitor, Xenova; Multidrug resisitance protein inhibitor, Xenova"	.	Terminated	D09XYU	.	CTPDG007410
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	CGS-13080	"PIRMAGREL; Pirmagrelum [Latin]; Pirmgrel; Pirmagrel [USAN:INN]; UNII-9J5H2VA91V; CGS 13080; 85691-74-3; CHEMBL48092; 9J5H2VA91V; Imidazo(1,5-a)pyridine-5-hexanoic acid; Pirmagrelum; Imidazo[1,5-a]pyridine-5-hexanoic acid; Pirmagrel (USAN/INN); AC1L1IZ7; SCHEMBL636018; DTXSID80234982; LIFOFTJHFFTNRV-UHFFFAOYSA-N; ZINC2021333; BDBM50025953; imidazol(1,5-a)pyridine-5-hexanoic acid; LS-177888; 6-imidazo[1,5-a]pyridin-5-ylhexanoic acid; 5-(5-carboxypentyl)imidazo[1,5-a]pyridine; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine"	55390	Terminated	D09QRO	.	CTPDG007414
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	RG-14893	"RG 14893; 141835-49-6; CHEMBL328712; 2-Naphthalenecarboxylicacid, 4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-; ACMC-20n0x5; AC1L30VP; SCHEMBL1894401; rg14893; CTK0H7370; DTXSID30161835; BDBM50001609; 4-(2-(Methyl(2-phenylethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; 4-(2-(Methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; L006851; 8-Benzyloxy-4-[(methyl-phenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid"	132379	Terminated	D09LQP	.	CTPDG007416
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Epocarbazolin-A	Epocarbazolin-B	192365	Terminated	D09JYF	.	CTPDG007419
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	NS-1619	"153587-01-0; NS 1619; 1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one; NS1619; CHEMBL384903; 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one; CHEBI:34879; 1-(2'-Hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone; 1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2h-benzimidazol-2-one; 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one"	4552	Terminated	D09BVL	.	CTPDG007425
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	U-78517F	Troloxamine; U-78517; U-78517G; U-78518F; U-83836E	107656	Terminated	D09BRE	.	CTPDG007426
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	GCC-AP0341	AP-0341	3074943	Terminated	D08MVK	.	CTPDG007438
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	RP-58802B	Imoxiterol; 88578-07-8; Imoxiterolum; Imoxiterol [INN]; Imoxiterolum [Latin]; AC1L23PZ; SCHEMBL249468; CHEMBL2104918; RP 58802B; CS-6651; 2-(3-(1-Benzimidazolyl)-1-methylpropylamino)-1-(4-hydroxy-3-methoxyphenyl)ethanol; RP-58802; HY-101585; L007875; alpha-(((3-(1-Benzimidazolyl)-1-methylpropyl)amino)methyl)vanillyl alcohol	65665	Terminated	D08HDD	.	CTPDG007442
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	WIN-64821	Q-20547A	158365	Terminated	D07PLK	.	CTPDG007454
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Sulotroban	BM-13177; SKF-95587	51550	Terminated	D07JSK	.	CTPDG007460
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Ro 20-1724	"4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 29925-17-5; 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one; ro-20-1724; Ro 201724; CHEMBL18701; 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-; RO-201724; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-, (+-)-; 4-(3-butoxy-4-methoxy-benzyl)imidazolidin-2-one; 34185-37-0; 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; SR-01000075647; keratan sulfate I; Keratan sulphate I; Naphthoquinone analogs"	5087	Terminated	D07FHZ	.	CTPDG007464
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZD-7717	ICI D7717	.	Terminated	D06YOD	.	CTPDG007468
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Isomazole	Isosulmazole; Isomazole fumarate; Isomazole hydrochloride; EMD-41064; EMD-47200; EMD-50250; EMD-52750; LY-175326	55690	Terminated	D05VLN	.	CTPDG007486
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	PLR-8	PLR-2224	.	Terminated	D05SXL	.	CTPDG007489
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	LF-801	.	.	Terminated	D05QTO	.	CTPDG007492
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-745337	"Thioflosulide; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337"	9799453	Terminated	D05EYG	.	CTPDG007499
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	CV 6209	"CHEMBL274420; CV6209; GTPL1852; AC1L32P4; SCHEMBL8538219; CHEMBL1180101; PDSP1_000728; PDSP1_000727; PDSP2_000718; PDSP2_000717; BDBM50005232; 2-(2-Acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacosan-1-yl)-1-ethylpyridinium; 2-{[Acetyl-(2-methoxy-3-octadecylcarbamoyloxy-propoxycarbonyl)-amino]-methyl}-1-ethyl-pyridinium; [2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate"	107756	Terminated	D05CEK	.	CTPDG007502
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	VZ-564	"VZ 564; 147495-99-6; 1-hydroxy-1-[(6-methoxy-3,4-dihydronaphthalen-2-yl)methyl]urea; Urea,N-[(3,4-dihydro-6-methoxy-2-naphthalenyl)methyl]-N-hydroxy-; VZ564; ACMC-20cs2n; AC1Q5JDP; AC1L4U8C; SCHEMBL9448945; CTK4C5429; N-Hydroxy-N-(6-methoxy-3,4-dihydro-2-naphthylmethyl)urea; DTXSID80163728; Urea, 1-hydroxy-1-(6-methoxy-3,4-dihydro-2-naphthylmethyl)-"	192375	Terminated	D04ZCL	.	CTPDG007504
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	MEN-10627	"MEN10627; 157351-81-0; AC1NSKCE; GTPL3901; cyc(2beta-5beta)(Met-Asp-Trp-Phe-Dap-Leu); (1R,4S,7S,10R,13R,16S)-13-(1H-indol-3-ylmethyl)-4-(2-methylpropyl)-7-(2-methylsulfanylethyl)-16-(phenylmethyl)-3,6,9,12,15,18,20-heptazabicyclo[8.8.4]docosane-2,5,8,11,14,17,21-heptone"	10327792	Terminated	D04RCG	.	CTPDG007510
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	RP-66153	"RP 66153; CHEMBL108415; 142422-79-5; AC1L30YM; SCHEMBL4355829; DTXSID80162034; 2,2-Dimethyl-7-(3-(3-phenylpropyl)-2-thienyl)heptanoic acid; BDBM50001162; 2-Thiopheneheptanoic acid, alpha,alpha-dimethyl-3-(3-phenylpropyl); 2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid; 2,2-Dimethyl-7-[3-(3-phenyl-propyl)-thiophen-2-yl]-heptanoic acid"	132425	Terminated	D04JJE	.	CTPDG007514
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	KC-11404	.	.	Terminated	D04APY	.	CTPDG007520
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	TAK-225	"2,2-Diethyl-3-(7-methyl[1,2,4]triazolo[1,5-b]pyridazin-6-yloxy)propanesulfonamide"	3073784	Terminated	D03WYV	.	CTPDG007522
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	NPC-17731	"Bradykinin antagonists, Scios; NPC-16731; NPC-17761; NPC-18521; NPC-18688; NPC-18884"	3081308	Terminated	D03WMY	.	CTPDG007523
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Midaglizole	"Midaglizole hydrochloride; DG 5218; DG-5128; Pyridine, 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]-, monohydrochloride"	68864	Terminated	D02XMM	.	CTPDG007542
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	BABIM	"Bis(5-amidino-2-benzimidazolyl)methane; 74733-75-8; CHEMBL99951; 1H-Benzimidazole-5-carboximidamide, 2,2'-methylenebis-; 1xug; 1c1v; AC1L1DKB; SCHEMBL65730; AC1Q1U90; CTK5E0415; BDBM16127; DTXSID60225717; AIDS007118; ZINC3871731; AKOS028112598; Bis(5-amidino-1H-benzimidazole-2-yl)methane; 1H-Benzimidazole-6-carboximidamide,2,2'-methylenebis-; 2,2 -methanediylbis(1H-benzimidazole-6-carboximidamide); 2-[(5-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-1H-benzimidazole-5-carboxamidine"	2387	Terminated	D02INZ	.	CTPDG007553
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	KF-15570	"KF 15570; BRN 4872911; 4H-Imidazo(4,5-c)quinolin-4-one, 1,5-dihydro-5-butyl-1-methyl-; 133305-92-7; 5-Butyl-1-methyl-1,5-dihydro-1H-imidazo(4,5-c)quinolin-4(5H)-one; AC1MIPZT; SCHEMBL9215327; CHEMBL434802; DTXSID80158053; CVLGNWUGFVTZRC-UHFFFAOYSA-N; ZINC1548061; LS-80514; 5-butyl-1-methylimidazo[4,5-c]quinolin-4-one; 5-butyl-1-methyl-1h-imidazo[4,5-c]quinolin-4(5h)-one; 5-n-Butyl-1-methyl-1H,5H-imidazo[4,5-c]quinolin-4-one"	3077017	Terminated	D01YGF	.	CTPDG007558
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	GW-3600	"Phosphodiesterase 4 inhibitor, Glaxo"	9842576	Terminated	D01QUF	.	CTPDG007564
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	KC-11425	.	.	Terminated	D01LXG	.	CTPDG007568
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	LM-1376	.	9891157	Terminated	D00YOW	.	CTPDG007578
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	Sch-45752	"Cephalochromin; MLS000876993; CHEMBL463175; NSC627953; NSC201419; 25908-26-3; SMR000440611; cefalochromin; 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one; Sch 45752; AC1Q6DTF; AC1L4N2K; SCHEMBL1111561; MEGxm0_000312; cid_160115; ACon0_000585; ACon1_000126; MolPort-001-739-590; HMS2270H11; BDBM50269745; NSC-201419; NSC-627953; MCULE-6609850631; NCGC00180856-01; SR-01000758207; SR-01000758207-2"	160115	Terminated	D00MEV	.	CTPDG007582
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Terminated	EP-012637	"Ciclosporin analogs, Enanta; Cyclosporin A analogs, Enanta; Cyclosporine analogs, Enanta; EP-1269; EP-314; EP-861; Immunosuppressant program, Enanta"	.	Terminated	D00JZX	.	CTPDG007585
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	IDR-1002	.	.	Investigative	DD3MB0	.	CTPDG007603
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	Vagonixen	.	.	Investigative	D0XS3T	.	CTPDG007692
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	RS-1748	.	46220480	Investigative	D0XH2N	.	CTPDG007700
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	BFPT-12603	BFPT-2603	.	Investigative	D0WW7U	.	CTPDG007738
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	LPCN-1056	LPCN-1052	.	Investigative	D0U8GH	.	CTPDG007821
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	AEOL-11207	"AEOL-11203; AEOL-11216; Catalytic antioxidants, Aeolus; Catalytic antioxidants, Incara"	42609706	Investigative	D0U4PG	.	CTPDG007830
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	GATA-3-specific DNAzyme	"GATA-3-specific DNAzyme (asthma); GATA-3-specific DNAzyme (asthma), Philipps-Universitat Marburg/sterna biologicals; Gd21 GATA-3-specific DNAzyme (asthma), Philipps-Universitat Marburg/sterna biologicals"	.	Investigative	D0R3NR	.	CTPDG007912
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	BW-858C	.	.	Investigative	D0R2MQ	.	CTPDG007919
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	PXS-4159	"Membrane copper amine oxidase modulators (asthma), Pharmaxis; SSAO/VAP-1 inhibitors (asthma), Pharmaxis"	.	Investigative	D0R0FU	.	CTPDG007923
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	IW-1221	"CRTH2 inhibitor (asthma), Ironwood"	.	Investigative	D0Q0GY	.	CTPDG007966
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	N-6060	"N-6338; N-6371; N-6446; N-6463; N-6501; N-6537; N-6603; S-nitrosoglutathione reductase inhibitors, N30"	.	Investigative	D0P5LX	.	CTPDG007981
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	SP-003	"SP-003, PhytoPharmacon; Euphorbia hirta-derived anti-inflammatory (oral, asthma), PhytoPharmacon"	.	Investigative	D0O8WM	.	CTPDG008002
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	NPT-CLN	"Calcineurin inhibitors (asthma), Biotica; NPT-CLN series (inhaled, asthma); NPT-CLN series (inhaled, asthma), Biotica"	.	Investigative	D0N9WY	.	CTPDG008029
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	Sulochrin	"519-57-3; UNII-8NA53C271Z; CHEBI:16159; 8NA53C271Z; Methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxybenzoate; Benzoic acid, 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxy-, methyl ester; Sulochrin_120096; AC1Q5ZJI; AC1L4NQS; MLS000863634; SCHEMBL233392; CHEMBL61133; MEGxm0_000192; CTK1H2445; ACon0_000926; ACon1_000208; DTXSID80199860; MolPort-001-739-420; YJRLSCDUYLRBIZ-UHFFFAOYSA-N; HMS2268H19; ZINC895263; MFCD07370145; ACM519573; Sulochrin, &gt; AKOS030615357; MCULE-7066877679"	160505	Investigative	D0N5SW	.	CTPDG008042
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	LMS-611	"LMS-611 (inhalant), Lamellar Biomedical; LMS-611 (oral), Lamellar Biomedical"	.	Investigative	D0JS7E	.	CTPDG008155
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	AG-NCA805	.	.	Investigative	D0I7YR	.	CTPDG008198
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	ER-23006	.	.	Investigative	D0G6RK	.	CTPDG008265
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	Anti-TSLP mab	Anti-TSLP mAb (asthma)	.	Investigative	D0F7RU	.	CTPDG008297
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	APX-E	"AXP-A0; AXP-D; CCR3 antagonists (asthma); CCR3 antagonists (asthma), Axikin"	.	Investigative	D0D5XV	.	CTPDG008375
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	L-873724	"UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	Investigative	D0D0LD	.	CTPDG008390
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	MAR--99	BRN 5609020	127154	Investigative	D0C7LA	.	CTPDG008406
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	DW-403	.	.	Investigative	D0A5CZ	.	CTPDG008490
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	UR-60427	"Histamine H4 inverse agonist (asthma), Palau Pharma"	.	Investigative	D09HUF	.	CTPDG008555
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	HMPL-342	"HM-A42; I-kappa beta kinase inhibitor (asthma/COPD/autoimmune diseases), Hutchison Medipharma"	.	Investigative	D09DEU	.	CTPDG008564
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	OT-121	"OT-121 (inhaled dry powder, asthma); OT-121 (inhaled dry powder, asthma), Oriel Therapeutics; OT-121 (inhaled dry powder, asthma),Sandoz"	.	Investigative	D08QUC	.	CTPDG008599
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	VALERGENT-BT	"VALERGEN-BT (subcutaneous); Blomia tropicalis allergen immunotherapy (sc, asthma), National Biopreparations Center"	.	Investigative	D08AXM	.	CTPDG008640
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	AIM-101	"AIM-101 (Neutropel, asthma/COPD), AIM Therapeutics"	.	Investigative	D06DPQ	.	CTPDG008768
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	CH-3697	.	.	Investigative	D05YEL	.	CTPDG008780
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	MER-2101	"Epitope-driven vaccine + MAS-1 adjuvant (asthma), Mercia"	.	Investigative	D05RPT	.	CTPDG008806
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	BCP-1081	"Non-steroidal anti-inflammatory agent (asthma), BioCure Pharma; Non-steroidal anti-inflammatory agent (asthma), InflammoGen"	.	Investigative	D05AAQ	.	CTPDG008847
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	DS-AH-14	.	19801656	Investigative	D04ZSZ	.	CTPDG008851
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	ASOBAMAST	Asobamast < Rec INN; Z-1819; N-[4-(3-Methylisoxazol-5-yl)thiazol-2-yl]oxamic acid 2-ethoxyethyl ester	72033	Investigative	D04LBJ	.	CTPDG008885
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	FHT-CT4	"CTLA4-PTD fusion protein (inflammation), Forhumantech"	.	Investigative	D04ALI	.	CTPDG008915
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	HD-101	"Antibody (asthma/autoimmune disease), Dreampharma"	.	Investigative	D03MSN	.	CTPDG008959
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	Recombinant anti-IgE Fabs	"Recombinant anti-IgE Fabs (asthma/immunological diseases); Anti-immunoglobulin E antibodies (asthma/immunological disease), Glycobia; Recombinant anti-IgE Fabs (asthma/immunological diseases), Glycobia; Recombinant anti-immunoglobulin E antigen binding fragments (asthma/immunological diseases), Glycobia"	.	Investigative	D03JXN	.	CTPDG008965
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	VBP	"VBP series (muscular dystrophy/asthma); VBP series (muscular dystrophy/asthma), Validus Biopharma; Non-hormonal steroids (spinal muscular atrophy/amyotropic lateral sclerosis/Duchenne dystrophy/asthma), Validus Biopharma"	6604912	Investigative	D02SJN	.	CTPDG009009
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	GSK-172981	"GSK-256471; SB-218795; SB-235375; SB-244487; SB-400238; SB-414240; SK-797230; NK-2 antagonists, GSK; NK-3 antagonists, GlaxoSmithKline; NK-3 antagonists, SB"	25195091	Investigative	D02CCA	.	CTPDG009043
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	ATL-844	"N-(4-Cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; MRS 1754; 264622-58-4; MRS-1754; MRS1754; CHEMBL273807; N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide; [3H]MRS1754; [3H]-MRS1754; NCGC00015689-01; Lopac-M-6316; Lopac0_000729; GTPL453; GTPL449; MLS002153324; SCHEMBL1222380; AC1O7G54; CTK8E7916; CHEBI:93269; AOB5542; DTXSID80424967; MolPort-023-276-567; HMS3373J21; HMS3268F13; HMS2230A06; ZINC4475274; BDBM50086170; AKOS027427086; AKOS024457276; EX-3306; ATL-618; ATL-GW-22; ATL-GW-8; A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil; A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics; A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data"	6603931	Investigative	D01QYQ	.	CTPDG009078
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	TA-106	"FAb antibody fragment (inflammation), Taligen Therapeutics; Anti-factor B FAb (inflammation), Alexion"	.	Investigative	D01ODC	.	CTPDG009089
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	HL-028	.	.	Investigative	D01BJS	.	CTPDG009131
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	PRS-060	"IL-4 alpha receptor inhibitor (Anticalin, asthma), Pieris; IL-4R alpha inhibitor (Anticalin, asthma), Pieris"	.	Investigative	D01BEX	.	CTPDG009134
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	KI-0905	.	.	Investigative	D00UHK	.	CTPDG009153
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	RV-1088	.	.	Investigative	D00PGF	.	CTPDG009168
M6ACROT05095	.	.	M6ADIS0164	CA23: Asthma	Investigative	CWF-0710	.	.	Investigative	D00ONE	.	CTPDG009171
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Tezepelumab	.	.	Approved	DMOF95	.	CTPDG000007
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Procaterol	"Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one"	4916	Approved	D0Z1WA	.	CTPDG000036
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Mometasone furoate/ formoterol fumarate	Dulera (TN)	441336	Approved	D0XW2H	DB14512	CTPDG000065
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Fluprednisolone	Alphadrol	5876	Approved	D0V9DZ	DB09378	CTPDG000100
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Pirbuterol	"Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol"	4845	Approved	D0SS4P	DB01291	CTPDG000146
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Formoterol/budesonide	"Formoterol-budesonide mixt; Budesonide-formoterol mixt; 150693-37-1; Budesonide mixture with formoterol; Formoterol / budesonide; Symbicort Inhalation Aerosol; Budesonide/formoterol combination; Budesonide and formoterol fumarate dihydrate; DTXSID80872449; Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-,     (11beta,16alpha)-, mixt with (R*,R*)-(+-)-N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide; Budesonide, Formoterol"	56841116	Approved	D0P2AG	.	CTPDG000222
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Lodoxamide	Lodoxamide ethyl; Lodoxamide trometamol; Lodoxamide tromethamine; U-42585; U-42585E; U-42718	44564	Approved	D0OG3K	DB06794	CTPDG000233
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Reslizumab	.	.	Approved	D0O8KX	.	CTPDG000236
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Repirinast	MY-1250; MY-5116; MY-6116	5050	Approved	D0O6KE	.	CTPDG000243
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Terbutaline	"Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol"	5403	Approved	D0M8RC	DB00871	CTPDG000270
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Ephedrine	"Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin"	9294	Approved	D0LG8E	DB01364	CTPDG000282
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	"Krypton, Kr-81m"	Mpi Krypton 81m Generator	66380	Approved	D0KL9X	DB09443	CTPDG000295
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Ciclesonide	"Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate"	6918155	Approved	D0K7HU	DB01410	CTPDG000304
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Salbutamol	"Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol"	2083	Approved	D0K5CB	DB01001	CTPDG000309
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Theobromine	"83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332"	5429	Approved	D0I0DS	DB01412	CTPDG000355
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Colforsin daropate hci	Adehl (TN); Adele (TN)	444028	Approved	D0H2MO	.	CTPDG000364
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Khellin	82-02-0; Visammin; Methafrone; Amicardine; Coronin; Medekellin; Ammivisnagen; Corafurone; Amikellin; Viscardan; Benecardin; Gynokhellan; Ammipuran; Kelourin; Rykellin; Interkhellin; Interkellin; Visammimix; Khellinorm; Khellanals; Khellamine; Kalangin; Deltoside; Ammispasmin; Visnagalin; Khelangin; Kelincor; Kelicorin; Norkel; Kelamin; Simeskellina; Khelloyd; Khelfren; Visnagen; Vasokellina; Kellosal; Mefurina; Lynamine; Khelisem; Kelicor; Chellin; Amiptan; Kellin; Ammivin; Keloid; Kellina; Eskel; Cardio-khellin; Ammi-khellin; Bi-Kellina	3828	Approved	D0G4KG	.	CTPDG000375
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	GW642444	"Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester"	21880659	Approved	D0FG6M	.	CTPDG000382
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Oxitropium bromide	Oxivent (TN)	6917865	Approved	D0D4IH	.	CTPDG000423
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Arformoterol	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate	3083544	Approved	D0D1DI	DB01274	CTPDG000428
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Ximelegatran	"Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide"	448042	Terminated	D0B5LF	DB08756	CTPDG000455
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	VR506	.	.	Approved	D09NTM	.	CTPDG000487
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Zileuton	"Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea"	60490	Approved	D09JUG	DB00744	CTPDG000493
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Enprofylline	"Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione"	1676	Approved	D09AMZ	DB00824	CTPDG000506
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Pranlukast	Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide	4887	Approved	D08QIP	DB01411	CTPDG000516
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Chymotrypsin	Alpha Chymar; Catarase; Zolyse	.	Approved	D08NAB	.	CTPDG000521
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Isoetharine	"Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol"	3762	Approved	D08HUC	DB00221	CTPDG000525
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Bambuterol	"Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)"	54766	Approved	D07XYV	DB01408	CTPDG000540
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Doxofylline	Ansimar (TN)	50942	Approved	D07NCN	DB09273	CTPDG000561
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Beclomethasone	"Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone"	20469	Approved	D07DVK	.	CTPDG000579
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	VR632	.	.	Approved	D07BXQ	.	CTPDG000584
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Bitolterol	Tornalate	35330	Approved	D06RUL	DB00901	CTPDG000593
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Cinalukast	"Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid"	6436135	Approved	D06PEB	DB00587	CTPDG000595
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Cromoglicate	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)	2882	Approved	D06NSS	DB01003	CTPDG000598
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Zafirlukast	"Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide"	5717	Approved	D05DVP	DB00549	CTPDG000646
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Brodalumab	AMG 827	.	Approved	D05CEO	.	CTPDG012293
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Fenoterol	"Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol"	3343	Approved	D04XEG	DB01288	CTPDG000655
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Methacholine Chloride	"Methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium"	6114	Approved	D04MWJ	.	CTPDG000664
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Formoterol	"Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate"	3410	Approved	D04KJO	DB00983	CTPDG000669
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Aminophylline	Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)	9433	Approved	D03TYI	DB01223	CTPDG000695
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Rimiterol	"Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI)"	36283	Approved	D03NOS	.	CTPDG000708
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Mepolizumab	"Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid"	.	Approved	D03MTN	.	CTPDG000710
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	CNTO-1959	Guselkumab	.	Phase 3	D03HSN	.	CTPDG000720
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Indacaterol	"312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone"	6918554	Approved	D03DJL	DB05039	CTPDG000726
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Levalbuterol	"Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol"	123600	Approved	D02ZJI	DB13139	CTPDG000733
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Metaproterenol Sulfate	"Metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol"	441333	Approved	D02UFG	.	CTPDG000737
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Ritlecitinib	"CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one"	118115473	Approved	D02TUL	DB14924	CTPDG011203
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Dyphylline	"Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline"	3182	Approved	D02PWM	DB00651	CTPDG000741
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Hydriodic acid iodine-125	Hydriodic acid; Iodine-125	24841	Approved	D02PJA	.	CTPDG000743
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Benralizumab	.	.	Approved	D02PIO	.	CTPDG000744
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Omalizumab	Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)	.	Approved	D02GEC	.	CTPDG000755
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Protokylol Hydrochloride	Ventaire	8699	Approved	D02FCQ	.	CTPDG000757
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Iodinated glycerol	"Organidin; Iodopropylidene glycerol; Glycerol, Iodinated; 5634-39-9; C6H11IO3; CCRIS 2378; 2-(1-IODOETHYL)-1,3-DIOXOLANE-4-METHANOL; HSDB 4185; Glycerol, iodinated [USAN:BAN]; NCI-C55469; EINECS 227-079-6; 1,3-Dioxolane-4-methanol, 2-(1-iodoethyl)-; 2-(1-Iodoethyl)-1,3-dioxolan-4-ylmethanol; [2-(1-iodoethyl)-1,3-dioxolan-4-yl]methanol; Iodinated Glycerol B; 1,3-Dioxolane-4-methanol, 2-(iodoethyl)-; Glycyrrhiza; (2-(1-Iodoethyl)-1,3-dioxolan-4-yl)methanol; iodoglycerin; Glycerol, Iondinated; SCHEMBL19693"	21852	Approved	D01JQJ	.	CTPDG000787
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	VR315	.	.	Approved	D01CHI	.	CTPDG000794
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Montelukast	Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid	5281040	Approved	D00QET	DB00471	CTPDG000808
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	NDA filed	RELVARTM or BREOTM ELLIPTATM	.	.	NDA filed	D09RJA	.	CTPDG000854
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	IND submitted	A378	.	.	IND submitted	DX8M3T	.	CTPDG000861
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Depemokimab	GSK3511294	.	Phase 3	DS9J7L	.	CTPDG000881
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	GSK3511294	depemokimab	.	Phase 3	DP8AS7	.	CTPDG000887
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Fevipiprant	"872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY"	23582412	Phase 3	DH7F9S	DB12011	CTPDG000905
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Astegolimab	MSTT1041A; RG6149	.	Phase 3	DBAL18	.	CTPDG000919
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SAR440340	Itepekimab	.	Phase 3	D8U1EX	.	CTPDG000926
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	D-5519	.	.	Phase 3	D0W8CW	.	CTPDG001008
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Setipiprant	ACT-129968	49843471	Phase 3	D0SP5V	DB12562	CTPDG001050
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	GMI-1070	"GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics"	44232546	Phase 3	D0N4EO	DB12778	CTPDG001114
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Pumactant	"Zofac; AP-0016; Pumactant, Britannia; Pumactant, airPharma; Pumactant, Britannia/airPharma"	.	Phase 3	D0L3VU	.	CTPDG001148
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Vinanterol/fluticasone furoate	Relovair (TN)	.	Phase 3	D0E5VO	.	CTPDG001225
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	ISRAPAFANT	"Y-24180; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine"	119175	Phase 3	D0D4ZM	.	CTPDG001242
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Quinotolast	Aslock; Quinotalast; FK-021; FR-71021	65871	Phase 3	D09YDO	.	CTPDG001288
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	E004	.	68423	Phase 3	D08UVZ	.	CTPDG001318
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	ABT-761	Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea	3086671	Phase 3	D08PXR	DB12758	CTPDG001323
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Approved	Ciclesonide	.	6918155	Approved	D07YLV	DB01410	CTPDG001339
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	QAW-039	.	.	Phase 3	D06XDI	.	CTPDG001372
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SOTB07	.	.	Phase 3	D06VFP	.	CTPDG001374
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	MDI-P	"CHEMBL595840; 60986-80-3; 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one; 3,6-Diphenyl-5-methylisoxazolo[4,5-c]pyridin-4(5H)-one; 3,6-DIPHENYL-5-METHYLISOXAZOLO(4,5-C)PYRIDIN-4(5H)-ONE; AC1Q3XQS; AC1Q3XQT; AC1N5X7T; MLS002153017; SCHEMBL3663640; GTPL6218; CTK5B2529; cid_4250909; DTXSID10401226; LCNDUGHNYMJGIW-UHFFFAOYSA-N; HMS2206G07; 5-methyl-3,6-diphenyl-isoxazolo[4,5-c]pyridine-4(5H)-one; ZINC394853; HMS3358C19; BDBM50305859; AKOS024323421; MCULE-8467817198; SMR001229079; FT-0714059"	3057996	Phase 3	D06ICW	DB06112	CTPDG001377
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	VR647	.	.	Phase 3	D01SPW	.	CTPDG001481
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Fluticasone furoate/ fluticasone propionate	.	9854489	Phase 3	D01IWJ	DB08906	CTPDG001486
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Bavituximab	.	.	Phase 2	D00UAE	.	CTPDG001494
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2/3	Darbufelone	PD-136095	6444826	Phase 2/3	D0AL8T	.	CTPDG001553
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2/3	CEP1347	AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403	9917013	Phase 2/3	D03QLG	.	CTPDG001576
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2a	Aerovant	.	.	Phase 2a	D0BW3P	.	CTPDG001588
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD1402	Elarekibep	.	Phase 2	DZGI51	.	CTPDG001598
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CSJ117	Ecleralimab	.	Phase 2	DU6O4B	.	CTPDG001628
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD8154	"1H-Isoindol-1-one, 2-((1S)-1-cyclopropylethyl)-2,3-dihydro-5-(4-methyl-2-((6-(2-oxo-1-pyrrolidinyl)-2-pyridinyl)amino)-5-thiazolyl)-7-(methylsulfonyl)-; 2-[(1S)-1-cyclopropylethyl]-5-[4-methyl-2-[[6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-3H-isoindol-1-one; 2215022-45-8; AKOS040757410; Azd 8154; AZD 8154 [WHO-DD]; AZD8154; AZD-8154; AZD-8154 [WHO-DD]; BDBM50512861; CHEMBL4558527; CS-0371158; EX-A5133; Example 1 [WO2018055040A1]; GTPL11204; HY-115870; J5M3TCK9Y9; MS-30088; SCHEMBL22204109; UNII-J5M3TCK9Y9"	141754136	Phase 2	DQ62LM	.	CTPDG001649
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RG6341	.	.	Phase 1	DLI53W	.	CTPDG001683
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GB001	.	.	Phase 2	DKP0T7	.	CTPDG001692
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SelK2	.	.	Phase 2	DFTV08	.	CTPDG001722
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK3772847	.	.	Phase 2	DCSZ97	.	CTPDG001747
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AVTX-002	quisovalimab	.	Phase 2	DBU4N1	.	CTPDG001753
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RPT193	"(1R,3r)-3-((R)-3-(1-(5-Chloro-4-(((R)-1-(2,4-dichlorophenyl)ethyl)amino)-6-methylpyrimidin-2-yl)azetidin-3-yl)piperidin-1-yl)-1-methylcyclobutane-1-carboxylic acid; 2366152-15-8; 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methylpyrimidin-2-yl]azetidin-3-yl]piperidin-1-yl]-1-methylcyclobutane-1-carboxylic acid; CS-0610200; Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-; example 37 [WO2019147862A1]; GLXC-26793; GTPL12893; HY-148074; MS-30263; Q0M1LOC2MM; RPT193; RPT193; RPT-193; SCHEMBL21193871; SCHEMBL21207415; Zelnecirnon; Zelnecirnon; zelnecirnon [INN]"	139344142	Phase 2	D5SDZ0	.	CTPDG001801
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MTPS9579A	RG6173	.	Phase 2	D4NF0L	.	CTPDG001814
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TD-8236	.	.	Phase 2	D2KTG5	.	CTPDG001835
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AMG 853	"VIDUPIPRANT; 1169483-24-2; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238"	42641863	Phase 2	D0YB2Y	DB12272	CTPDG001874
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Iralukast	CGP-45715A	6913104	Phase 2	D0X9LK	.	CTPDG001892
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PL-3994	.	121488161	Phase 2	D0X8QO	.	CTPDG001894
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	QBX258	.	.	Phase 2	D0X8OW	.	CTPDG001895
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Revamilast	"GRC-4039; PDE 4 inhibitor (inflammation), Glenmark; Phosphodiesterase 4 inhibitor (inflammation), Glenmark; Revamilast (inflammation), Glenmark"	11546664	Phase 2	D0X0PW	DB11838	CTPDG001907
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-54903	.	.	Phase 2	D0W8DA	.	CTPDG001923
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-54903 + olodaterol	.	.	Phase 2	D0W0YI	.	CTPDG001938
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CROMOGLYCATE LISETIL HYDROCHLORIDE	Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556	196639	Phase 2	D0VZ9S	.	CTPDG001942
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ONO-6950	.	46830962	Phase 2	D0U5YM	.	CTPDG001989
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK679586	.	.	Phase 2	D0T3QR	.	CTPDG002023
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PIRODOMAST	"Sch-37224; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one"	54680204	Phase 2	D0S2UR	.	CTPDG002046
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AP-761	BI-671800	45270144	Phase 2	D0RL4X	DB12524	CTPDG002057
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	OX-914	.	.	Phase 2	D0RJ1W	.	CTPDG002058
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	HI-1640V	.	.	Phase 2	D0R6VH	.	CTPDG002067
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PNU-142731A	"9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride"	9846800	Phase 2	D0Q9IY	.	CTPDG002082
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Tipelukast	"Asthma therapy, MediciNova; KCA-757; MN-001"	9893228	Phase 2	D0Q7UG	DB12435	CTPDG002086
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BIO-1211	"BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-"	9961766	Phase 2	D0Q5LF	.	CTPDG002090
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LM-1507.NA	MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt	.	Phase 2	D0OG6N	.	CTPDG002130
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Altrakincept	.	.	Phase 2	D0O5KH	.	CTPDG002140
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BT-061	.	.	Phase 2	D0NQ0V	.	CTPDG002157
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Pascolizumab	"SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs"	.	Phase 2	D0NO1L	.	CTPDG002158
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RNS-60	.	.	Phase 2	D0N9AD	.	CTPDG002161
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MK-1029	.	.	Phase 2	D0N4ZX	.	CTPDG002172
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ABT-308	.	.	Phase 1	D0N3WN	.	CTPDG002176
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Montelukast/mometasone	MK-0476C	4248	Phase 2	D0M5HV	.	CTPDG002202
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	JNJ-39758979	.	24994634	Phase 2	D0M4UZ	.	CTPDG002206
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Oglemilast	"GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark"	11387409	Phase 2	D0L8KJ	DB12375	CTPDG002227
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD-3199	.	16035068	Phase 2	D0L6LD	.	CTPDG002233
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-4191834	PF-04191834	24986635	Phase 2	D0L5XG	DB11645	CTPDG002234
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TA-270	.	54710630	Phase 2	D0L4SL	.	CTPDG002237
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	E-6700	.	9843006	Phase 2	D0K9UK	.	CTPDG002256
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	IPL-512602	"BLX-LSAID; IPL-576 series; OX-LSAID; Lead LSAID (asthma), Biolipox; Lead LSAID (asthma), Orexo; Lead LSAID (asthma), Inflazyme/Aventis; Lead LSAID (asthma), Inflazyme/sanofi-aventis"	.	Phase 2	D0I8CK	.	CTPDG002303
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BAY-X-7195	"UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid"	6442328	Phase 2	D0GY0O	.	CTPDG002348
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anti-IL-5 Receptor mab	.	.	Phase 2	D0G9EI	.	CTPDG002360
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TC-6987	.	44511587	Phase 2	D0G4GA	DB14854	CTPDG002373
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEDI-528	.	.	Phase 2	D0FI5C	.	CTPDG002386
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	KB-003	"KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios"	.	Phase 2	D0F0ZK	.	CTPDG002407
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	JNJ-40929837	.	57910975	Phase 2	D0ER9I	.	CTPDG002408
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD-5069	"CXCR2 inhibitor (COPD), Astrazeneca"	56645576	Phase 2	D0E6SX	.	CTPDG002422
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TJ-9	.	.	Phase 2	D0CR1I	.	CTPDG002469
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-BT	"Blomia tropicalis allergen immunotherapy (sublingual, asthma), National Biopreparations Center"	.	Phase 2	D0BS7T	.	CTPDG002498
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AIM-102	.	10126114	Phase 2	D0B7QU	.	CTPDG002506
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Rambazole	"Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole  pound&gt; SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510"	9799888	Phase 2	D0AA6Z	DB13083	CTPDG002532
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	WY-50295-tromethamine	WY-50295T; Wy-49232	10435196	Phase 2	D0A7JH	.	CTPDG002540
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RV-568	.	45109868	Phase 2	D0A5HC	.	CTPDG002546
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	N6022	1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206	44623946	Phase 2	D09LPV	DB12206	CTPDG002576
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZX-100	.	.	Phase 2	D09IGR	.	CTPDG002579
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CYT003	.	.	Phase 2	D09CEJ	.	CTPDG002583
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Ontazolast	"UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-"	71458	Phase 2	D08ZKJ	.	CTPDG002596
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ASM-024	.	117587641	Phase 2	D08NYZ	.	CTPDG002625
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PRO-98498	"HAE-1; Asthma therapy (subcutaneous), Genentech"	.	Phase 2	D07TYJ	.	CTPDG002669
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	KP-496	.	.	Phase 2	D07JKY	.	CTPDG002694
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK2269557	.	49784002	Phase 2	D06GUA	.	CTPDG002760
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	THR-18	.	86291591	Phase 2	D05ZDJ	.	CTPDG002773
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LEO 124249	"delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile"	50914062	Phase 2	D05UGH	.	CTPDG002785
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GW274150	"GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid"	9797017	Phase 2	D05QJT	DB12237	CTPDG002791
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Masilukast	D-3523; MCC-847; ZD-3523	204056	Phase 2	D05BHF	.	CTPDG002819
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	R411	.	61516	Phase 2	D04YJN	.	CTPDG002824
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Tepoxalin	"103475-41-8; Orf-20485; ORF 20485; Tepoxaline; Tepoxalina; Tepoxalinum [Latin]; Tepoxaline [French]; Tepoxalina [Spanish]; RWJ 20485; Tepoxalin [USAN:INN]; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; UNII-TZ4OX61974; C20H20ClN3O3; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-; CHEMBL316040; CHEBI:76277; TZ4OX61974; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; RWJ-20485; SIL-4R"	59757	Phase 2	D04WMR	DB11466	CTPDG002831
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-144807	.	.	Phase 2	D04UME	.	CTPDG002837
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK2245035	GSK-2245035	44623937	Phase 2	D04PAU	.	CTPDG002850
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AMG 157	.	.	Phase 2	D04FWP	.	CTPDG002869
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anti-M1 prime	.	.	Phase 2	D04CWS	.	CTPDG002877
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ONO-AE1-437	"16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1"	9824353	Phase 2	D03YAS	.	CTPDG002886
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-DP	"Dermatophagoides pteronyssinus allergen immunotherapy (subcutaneous, asthma), National Biopreparations Center"	.	Phase 2	D03UBI	.	CTPDG002901
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AHCQ	.	.	Phase 2	D03MZU	.	CTPDG002917
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anrukinzumab	"Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer"	.	Phase 2	D03ING	.	CTPDG002926
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	WIN-901	.	.	Phase 2	D03GXU	.	CTPDG002930
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Noberastine	Flamizole; R-64947; R-72075	60531	Phase 2	D03DRR	.	CTPDG002934
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TPI ASM8	.	.	Phase 2	D02RPP	.	CTPDG002958
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SB-265610	"SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, &gt; J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be"	9841667	Phase 2	D02JXG	.	CTPDG002974
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ZY-15106	MgNAAGA; NAAGAMg; Rhinaaxia; N-Acetylaspartyl-glutamic acid magnesium salt	71120	Phase 2	D02GTN	.	CTPDG002980
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GPD-1116	.	9841417	Phase 2	D01XFZ	.	CTPDG003003
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CTP-543	.	.	Phase 2	D01UAU	.	CTPDG003011
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEMP1972A	RG7449	.	Phase 2	D01LSB	.	CTPDG003028
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LCB-2183	.	135418284	Phase 2	D01KNY	.	CTPDG003031
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Flezelastine	D-18024	60432	Phase 2	D00NVO	.	CTPDG003077
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SR-2640	"SR 2640; SR 2640 Hydrochloride; 105350-26-3; CHEMBL18132; SR2640; Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]-; QMPB; Benzoic acid, 2-((3-(2-quinolinylmethoxy)phenyl)amino)-; SR-01000076219; Tocris-1804; Lopac-S-7690; AC1L2TN9; Lopac0_001079; 2-(3-(2-Quinolylmethoxy)phenylamino)benzoic acid; MLS002153402; cid_128355; GTPL3329; SCHEMBL9119607; CTK8F0698; CHEBI:104023; HMS3263G20; HMS2236C03; ZINC596951; HMS3373N15; Tox21_501079; BDBM50006798; AKOS030239522; LP01079; CCG-205156; NCGC00015965-02; NCGC00015965-04"	128355	Phase 2	D00MHP	.	CTPDG003079
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PEGylated pitrakinra	"Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance"	.	Phase 2	D00KQN	.	CTPDG003083
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Gallopamil	"16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; GSK 796406"	1234	Phase 2	D00ERV	DB12923	CTPDG003096
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ETX-9101	.	.	Phase 2	D00EGN	.	CTPDG003098
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEDI9929	.	.	Phase 2	D00CTZ	.	CTPDG003103
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1/2	MRx-4DP0004	.	.	Phase 1/2	DR5GC8	.	CTPDG003149
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1/2	Sodium pyruvate	"113-24-6; Pyruvic acid sodium salt; sodium 2-oxopropanoate; Pyruvic acid, sodium salt; Propanoic acid, 2-oxo-, sodium salt; Sodium alpha-ketopropionate; 2-Oxopropanoic acid sodium salt; UNII-POD38AIF08; POD38AIF08; CHEBI:50144; Natriumpyruvat; alpha-Ketopropionic acid sodium salt; MFCD00002586; Propanoic acid, 2-oxo-, sodium salt (1:1); S-6005; Pyruvic acid, sodium salt, 99+%; Pyruvate Sodium; Natrum pyruvicum; CHEMBL181886; sodiumpyruvate; Guna-flam; Guna-hypertension; EINECS 204-024-4; pyruvic acid na-salt; N-115; Sodium pyruvate (inhaled); Reactive oxygen species antagonist (inhaled), EmphyCorp; Sodium pyruvate (inhaled), EmphyCorp"	23662274	Phase 1/2	D02ECG	.	CTPDG003609
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GDC-0214	"1831144-46-7; AKOS040759985; BDBM232517; CHEMBL3964801; EX-A6434; GDC0214; GDC-0214; GTPL12318; iJak-381; N-(3-(5-Chloro-2-(difluoromethoxy)phenyl)-1-(2-(4-((2-cyanoethyl)(methyl)amino)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide; RG6151; RG-6151; SCHEMBL17271636; US9346815, 63"	118522534	Phase 1	DZ2RH6	.	CTPDG003649
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD8630	.	.	Phase 1	DYC40H	.	CTPDG003657
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD4604	"(2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-; 2241039-81-4; AKOS040733485; AT39356; AZD4604; AZD-4604; BDBM488779; CHEMBL4447181; CS-0101485; EX-A5343; example 35 [WO2018134213A1]; GTPL11716; HY-126294; JAC34RRR7S; JAK1-IN-7; londamocitinib; MS-30607; SCHEMBL20399395; UNII-JAC34RRR7S; US10961228, Example 35"	135240395	Phase 1	DX72LV	.	CTPDG003666
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ADL 018	Omalizumab biosimilar	.	Phase 1	DV3E9U	.	CTPDG003696
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	KN-002	.	.	Phase 1	DI19BZ	.	CTPDG003887
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK2292767	"1254036-66-2; 4M4E8NZ73C; AC-32649; AKOS032945160; BCP24323; BDBM50521218; C24H28N6O5S; CCG-269791; CHEMBL4434674; compound 2 [PMID: 30532965]; compound 3 [PMID: 26301626]; CS-0003832; EX-A994; GSK2292767; GSK-2292767; GTPL10633; HY-15280; Methanesulfonamide, N-(5-(4-(5-(((2R,6S)-2,6-dimethyl-4-morpholinyl)methyl)-2-oxazolyl)-1H-indazol-6-yl)-2-methoxy-3-pyridinyl)-, rel-; Methanesulfonamide, N-[5-[4-[5-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]-, rel-; MFCD22572737; N-(5-(4-(5-(((2R,6S)-2,6-Dimethylmorpholino)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide; n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide; N-[5-[4-[5-[[(2S,6R)-2,6-Dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; N-{5-[4-(5-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-methoxypyridin-3-yl}methanesulfonamide; PI3Kdelta inhibitor GS2292767; Q27464135; rel-N-[5-[4-[5-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]methanesulfonamide; s7938; SCHEMBL173490; UNII-4M4E8NZ73C"	49783923	Phase 1	DDE6F1	.	CTPDG003945
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SAR443765	.	.	Phase 1	D9TW0X	.	CTPDG003987
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AMG 104	.	.	Phase 1	D94LRF	.	CTPDG004002
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ARO-RAGE	.	.	Phase 1	D8JN6C	.	CTPDG004015
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	UPB-101	.	.	Phase 1	D7EJI9	.	CTPDG004043
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BI 894416	.	.	Phase 1	D7CI9P	.	CTPDG004044
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD0449	.	.	Phase 1	D63WFO	.	CTPDG004072
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CSL311	.	.	Phase 1	D3Q0FU	.	CTPDG004130
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BI 443651	.	.	Phase 1	D3D9CL	.	CTPDG004141
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ARO-MUC5AC	.	.	Phase 1	D17DXO	.	CTPDG004202
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RO-5271983	.	.	Phase 1	D0WP4E	.	CTPDG004299
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AM-211	"UNII-SZB129M7SZ; 1175526-27-8; SZB129M7SZ; CHEMBL2181753; AM211; [1,1'-Biphenyl]-3-acetic acid, 2'-[[ethyl[[(phenylmethyl)amino]carbonyl]amino]methyl]-6-methoxy-4'-(trifluoromethyl)-; SCHEMBL138450; DTXSID80151807; OPXIRFWNLBDKQB-UHFFFAOYSA-N; BDBM50397640; SB17010; HY-13213; CS-0003178; [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid"	44158492	Phase 1	D0U1HN	.	CTPDG004386
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SAR-21609	"TLR9 agonist (asthma/viral respiratory tract infection), sanofi-aventis"	.	Phase 1	D0R8RO	.	CTPDG004456
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SB-436811	"CHEMBL366221; 346729-66-6; Benzamide,3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-3-pyrrolidinyl]-; SCHEMBL6949936; GTPL2164; ZINC3964101; BDBM50240963; KB-74923; 3,4-Dichloro-N-{(S)-1-[4-(3-dimethylamino-propoxy)-benzyl]-pyrrolidin-3-yl}-benzamide; (S)-3,4-dichloro-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)benzamide; (S)-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)-3,4-dichlorobenzamide"	9846574	Phase 1	D0PQ8T	.	CTPDG004499
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	OPK-0018	.	.	Phase 1	D0O8SB	.	CTPDG004544
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	MEDI4212	.	.	Phase 1	D0O5CV	.	CTPDG004549
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	IMA-026	.	.	Phase 1	D0NY5Y	.	CTPDG004557
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AI-128	.	.	Phase 1	D0N6WX	.	CTPDG004578
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	PF-06444752	.	.	Phase 1	D0K2HU	.	CTPDG004663
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	Xmab-7195	"IgE inhibitor (asthma/allergy), Xencor"	.	Phase 1	D0JQ4S	.	CTPDG004669
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CNTO-3157	.	.	Phase 1	D0I9WR	.	CTPDG004714
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CVT-6883	"752222-83-6; GS-6201; UNII-67CKV7X08G; CHEMBL260933; 67CKV7X08G; CVT 6883; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione; Kinome_3621; SCHEMBL238694; GTPL5615; CVT6883; AOB4675; MolPort-035-765-814; CTV-6883; ZINC29055563; BDBM50236738; AKOS024458311; API0004749; 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione"	11270783	Phase 1	D0G4CF	DB05936	CTPDG004777
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	FP-025	.	.	Phase 1	D0F470	.	CTPDG004807
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BM-212	"BM212; UNII-U9HSU4GZWL; 146204-42-4; U9HSU4GZWL; 1-{[1,5-Bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl}-4-methylpiperazine; 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine; BM 212; AC1L9VRH; CHEMBL321077; SCHEMBL1452627; BCP24821; ZINC22445591; AKOS032944899; CS-5953; Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-; HY-100725"	456926	Phase 1	D0D4VH	.	CTPDG004859
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CI-959	"UNII-1A8130P4IY; CI 959; CI 159; 104795-68-8; 1A8130P4IY; Benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-, monosodium salt; DSSTox_RID_82225; DSSTox_CID_27268; DSSTox_GSID_47268; DTXSID8047268; CHEMBL3183386; Tox21_300435; NCGC00254320-01; LS-41129"	13961743	Phase 1	D07TAS	.	CTPDG005084
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AMG 282	.	.	Phase 1	D07GDR	.	CTPDG005110
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	PF-06413367	.	.	Phase 1	D05BYJ	.	CTPDG005223
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK1440115	"UNII-GCT6G5G3C7; GCT6G5G3C7; GSK 1440115; SCHEMBL2957737; 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; (1,1'-Biphenyl)-4-carboxylic acid, 4'-((1R)-1-((2-(6,7-dichloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)acetyl)methylamino)-2-(4-morpholinyl)ethyl)-"	24760693	Phase 1	D04LWT	.	CTPDG005253
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	Laevo-Bambuterol	R-Bambuterol; R-bambuterol hydrochloride	.	Phase 1	D03INQ	.	CTPDG005313
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	INO-4885	"FP-15; INO-1080; Peroxynitrite decomposition catalyst, Inotek; WW-85; Reactive oxygen species inhibitor (contrast induced nephropathy), Inotek"	.	Phase 1	D02SME	.	CTPDG005343
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD1419	.	.	Phase 1	D02AWQ	.	CTPDG005365
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SDZ-MKS-492	MKS-492	163931	Phase 1	D02ADC	.	CTPDG005369
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-DS	"Dermatophagoides siboney allergen immunotherapy (subcutaneous, asthma), National Biopreparations Center"	.	Phase 2	D01PCB	.	CTPDG005394
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CNT0-3157	.	.	Phase 1	D01ILP	.	CTPDG005407
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK-2239633	.	46861584	Phase 1	D00XBC	.	CTPDG005433
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GRC-6211	"Oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid; GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly"	138393987	Phase 1	D00MAN	.	CTPDG005454
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Preregistration	Clinprost	"Arteon; Isocarbacyclin methyl ester; TEI-9090; TTC-909; Clinprost (liposomal), Taisho; Clinprost (liposomal), Teijin"	6436040	Discontinued in Preregistration	D0X8DU	.	CTPDG006319
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Fosfructose	"Cordox; Fosfructose trisodium; CPC-111; FDP, Questcor; Fructose-1,6-diphosphate; Fructose-1,6-diphosphate, Questcor"	.	Discontinued in Phase 3	D0Z5SR	.	CTPDG006327
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	DG031	"Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148"	123723	Discontinued in Phase 3	D0S6VB	.	CTPDG006337
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Broxaterol	Summair; Z-1170	71149	Discontinued in Phase 3	D0OR2S	.	CTPDG006343
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Lenercept	"Tenefuse; RsTNFR-IgG1; Ro-45-2081; TNF receptor-Ig, Roche; TNFR-IgG1 fusion protein, Roche"	.	Discontinued in Phase 3	D0H6CA	.	CTPDG006356
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	BN 50730	"Rocepafant; UNII-4KGX1STY2N; BN-50730; 4KGX1STY2N; 132579-32-9; BN50730; 132418-36-1; 6-(2-Chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 4H-Pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-; Rocepafant [INN]; LAU8080; LAU-8080; LAU 8080; AC1MHWNG; C27H25ClN6OS; SCHEMBL1065775; CHEMBL2105298; ZINC1481916; LS-172840"	3033963	Discontinued in Phase 3	D0G2RE	.	CTPDG006359
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Ablukast	Ablukast sodium; RO-23-3544	57109	Discontinued in Phase 3	D09DIG	.	CTPDG006372
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	FOROPAFANT	"SR-27417; 2-[N-[2-(Dimethylamino)ethyl]-N-(3-pyridylmethyl)amino]-4-(2,4,6-triisopropylphenyl)thiazole"	119368	Discontinued in Phase 3	D05YUK	.	CTPDG006380
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Ataprost	ONO-41483; OP-41483	6436122	Discontinued in Phase 3	D00LWS	.	CTPDG006393
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Bamaquimast	"L-0042; N-Methylcarbamic acid 3-(2-oxo-1-propyl-1,2-dihydroquinoxalin-3-yl)propyl ester;3-[3-(Methylcarbamoyloxy)propyl]-1-propylquinoxalin-2(1H)-one"	184838	Discontinued in Phase 2	D0ZC7P	.	CTPDG006395
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK159802	.	.	Discontinued in Phase 2	D0YL3E	.	CTPDG006398
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	TIBENELAST	"LY-186655 (sodium salt); 5,6-Diethoxybenzothiophene-2-carboxylic acid"	59913	Discontinued in Phase 2	D0X1EX	.	CTPDG006409
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-613	.	9800584	Discontinued in Phase 2	D0W8QV	.	CTPDG006412
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Pumafentrine	Pumafentrin; BY-343; BYK-33043	3052763	Discontinued in Phase 2	D0V7IS	.	CTPDG006417
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Nolpitantium besilate	SR-140333; SR-140333B	3047794	Discontinued in Phase 2	D0UT3F	.	CTPDG006421
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	BUTIXOCORT	"JO-1717; 11beta,17-Dihydroxy-21-mercaptopregn-4-ene-3,20-dione 17-butyrate; 17-Butanoyloxy-11beta-hydroxy-21-mercaptopregn-4-ene-3,20-dione"	189904	Discontinued in Phase 2	D0UO2N	.	CTPDG006422
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	LY-223982	CGS-23131; LY-223980; LY-255253; SKF-107324	6444688	Discontinued in Phase 2	D0U9JL	.	CTPDG006425
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK256066	GSK-256066	9827968	Discontinued in Phase 2	D0U7PS	DB12137	CTPDG006427
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SC-45662	"CHEMBL84566; UNII-TPG7IO601I component ADVNUIUADIXWMI-QWHCGFSZSA-N; 2-[[(1S,2R)-2-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylpropyl]oxy]acetic acid"	5487420	Discontinued in Phase 2	D0U5EU	.	CTPDG006428
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	E-6123	"E 6123; 131614-02-3; BRN 4280434; E- 6123; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (S)-; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-; AC1MHYY4; CHEMBL114014; DTXSID20157146; API0009208; HY-10164; LS-134356"	3035214	Discontinued in Phase 2	D0R0EV	.	CTPDG006448
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	EPI-2010	.	.	Discontinued in Phase 2	D0QH0B	.	CTPDG006449
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SRP 299	.	.	Discontinued in Phase 2	D0Q1KN	.	CTPDG006454
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Valategrast	"220847-86-9; Valategrast (R411); UNII-06DM4KX7JG; 06DM4KX7JG; Valategrast [INN]; SCHEMBL480224; CHEMBL2107792; ZINC72190226; KB-81423; 2-(Diethylamino)ethyl N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzamido)-L-phenylalaninate"	11563636	Discontinued in Phase 2	D0PW0G	.	CTPDG006456
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	APC-366	"UNII-TGP1HP0WBC; TGP1HP0WBC; APC 366; 178925-65-0; apc366; N-(1-Hydroxy-2-naphthoyl)-L-arginyl-L-prolinamide hydrochloride; APC-366 hydrochloride; AC1L42OQ; SCHEMBL15659721; APC-366-C; APC-366-A; APC-366-R; L-Prolinamide, N2-((1-hydroxy-2-naphthalenyl)carbonyl)-L-arginyl-, monohydrochloride; (2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide hydrochloride"	177339	Discontinued in Phase 2	D0N9WB	.	CTPDG006467
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GW-766994	"CCR3 antagonists, GSK; CCR3 antagonists, GlaxoSmithKline; Chemokine receptor 3 antagonist, GlaxoSmithKline; GW-633647; GW-633647X; GW-701877; GW-701897; GW-701897X; GW-782415X; SB-297006; SB-328437"	10218765	Discontinued in Phase 2	D0N2FI	.	CTPDG006472
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	LTB 019	.	9959759	Discontinued in Phase 2	D0N0PU	.	CTPDG006473
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	WAY-123641	.	.	Discontinued in Phase 2	D0MF3C	.	CTPDG006477
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	MK-591	"Quiflapon; Quiflapon [INN]; L 686708; MK 0591; MK 591; L-686708; MK-0591; L-686,708; 3-(1-(4-chlorobenzyl-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl))-2,2-dimethyl propanoic acid; 3-(tert-Butylthio)-1-(p-chlorobenzyl)-alpha,alpha-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-(tert-butylthio)-1-(p-chlorobenzyl)-a,a-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid"	23672584	Discontinued in Phase 2	D0M0QX	.	CTPDG006483
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CI-949	"CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid"	159563	Discontinued in Phase 2	D0KV4Z	.	CTPDG006489
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Imitrodast	Logran; CS-518; RS-5186	65922	Discontinued in Phase 2	D0K4UW	.	CTPDG006491
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	MK-886	"118414-82-7; MK 886; MK886; 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid; UNII-080626SQ8C; QAOAOVKBIIKRNL-UHFFFAOYSA-N; L-663,536; CHEMBL29097; CHEBI:75390; L 663536; MK-886 (L-663,536); 080626SQ8C; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid; 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]; L-663536; SMR000466278"	3651377	Discontinued in Phase 2	D0K2ER	.	CTPDG006493
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Picumeterol	Levopicumeterol; Picumeterol fumarate; GX 63411; GR-114297; GR-114297A; GR-114297X; GR-63411	131251	Discontinued in Phase 2	D0GP4R	.	CTPDG006514
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Sulukast	LY-170680	6436123	Discontinued in Phase 2	D0G8UG	.	CTPDG006515
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AR-D-111421	.	.	Discontinued in Phase 2	D0F6JI	.	CTPDG006524
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	DS-4574	"DS 4574; 118314-35-5; 6-(2-Cyclohexylethyl)-(1,3,4)thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one; (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one, 6-(2-cyclohexylethyl)-; [1,3,4]Thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one,6-(2-cyclohexylethyl)-; AC1L4LXR; ACMC-20c9t1; AC1Q6E9S; SCHEMBL156066; CTK4B0638; DTXSID80152096; AKOS030534249; 6-(2-cyclohexylethyl)[1,3,4]thiadiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(2h)-one; LS-150402"	159491	Discontinued in Phase 2	D0F4IG	.	CTPDG006526
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Nafagrel	Nafagrel hydrochloride; DP-1904; SR-96325	65851	Discontinued in Phase 2	D0DT2P	.	CTPDG006537
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AS-35	"AS 35; 108427-72-1; 9-((4-Acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; C21H20N6O4; 4H-Pyrido[1,2-a]pyrimidin-4-one,9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)-; 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-; RVRGDCZGEKSIRW-UHFFFAOYSA-N; ACMC-20mbio; as35; AC1L2WU8; SCHEMBL159227; CTK4A6033; DTXSID90148546; CS-7624; LS-134160; HY-101946; L003846"	130135	Discontinued in Phase 2	D0B6EU	.	CTPDG006553
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	RPR-106541	.	9846880	Discontinued in Phase 2	D09UGP	.	CTPDG006565
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AZD-3778	"CHEMBL2158814; SCHEMBL5418656; GTPL7679; AZD3778; QVLZVRFIGXNZMN-UHFFFAOYSA-N; AZD 3778; BDBM50394155; N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide"	11753159	Discontinued in Phase 2	D09RGW	.	CTPDG006568
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	V-11294A	"Rolipram derivatives, Napp"	135430158	Discontinued in Phase 2	D08SNX	.	CTPDG006575
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Corus 1030	Inhaled Lidocaine	.	Discontinued in Phase 2	D08FZT	.	CTPDG006584
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	R-343	"R-921303; Syk tyrosine kinase inhibitor (allergic asthma), Rigel/Pfizer"	10344820	Discontinued in Phase 2	D08DBE	.	CTPDG006585
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	ZD-2138	"Ici D2138; 140841-32-3; UNII-B6G6OX1ZH5; B6G6OX1ZH5; CHEMBL20403; 2(1H)-Quinolinone,6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-; Ici-D2138; 6-((3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinolin-2(1H)-one; ZD 2138; ACMC-20mzth; AC1L30RD; zd2138; 6-((3-Fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinol-2-one; SCHEMBL1083603; CTK4C2357; DTXSID90161477; BDBM50000829; AKOS025404954; ACN-048395"	132306	Discontinued in Phase 2	D07HBI	.	CTPDG006593
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK2190914	.	.	Discontinued in Phase 2	D07ATG	.	CTPDG006600
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	IVL745	"F387KG9Ith; UNII-F387KG9ITH; XRP 1745A; IVL 745; SCHEMBL6136116; DTXSID9043930; NOCAS_43930; IVL-745; 229627-58-1; beta-Alanine, N-((3-methoxy-4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)glycyl-N-((3,4-dimethoxyphenyl)methyl)-"	9830010	Discontinued in Phase 2	D06NOR	.	CTPDG006605
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Isbufylline	TE/06	65681	Discontinued in Phase 2	D05VAA	.	CTPDG006612
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK2190915	"1093403-33-8; sirtuin modulator; SRT 2104; SRT2104 (GSK2245840); SRT2104; SRT-2104; UNII-4521NR0J09; 4521NR0J09; 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-; C26H24N6O2S2; 4-Methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide; 4-methyl-n-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide"	44473151	Discontinued in Phase 2	D05MCS	DB06346	CTPDG006615
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	ACREOZAST	"TYB-2285; N,N'-(2-Chloro-5-cyano-1,3-phenylene)bis[2-(acetyloxy)acetamide]; 3,5-Bis(2-acetoxyacetamido)-4-chlorobenzonitrile"	129991	Discontinued in Phase 2	D04VJH	.	CTPDG006626
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-011	.	.	Discontinued in Phase 2	D04HHW	.	CTPDG006632
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	KW-4490	.	9883436	Discontinued in Phase 2	D03ZVD	.	CTPDG006635
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Tetrazolast meglumine	Tetrazolast; Tetrazolast meglumine salt monohydrate; MDL-26024; MDL-26024GO	9825038	Discontinued in Phase 2	D03PHU	.	CTPDG006643
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Mequitamium iodide	LG-30435	72028	Discontinued in Phase 2	D02YBP	.	CTPDG006648
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Milveterol	UNII-LGY1VQ9622; LGY1VQ9622; 652990-07-3; Milveterol [INN]; SCHEMBL265694; CHEMBL1940832; DTXSID30215640; BMKINZUHKYLSKI-DQEYMECFSA-N; BDBM50419652	9892481	Discontinued in Phase 2	D02KMG	.	CTPDG006653
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-224	FR-115224	6437864	Discontinued in Phase 2	D02FIJ	.	CTPDG006654
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CGRP	"Calcitonin gene related peptide; LAB CGRP; CGRP (inhaled, asthma); CGRP (inhaled, asthma), Akela Pharma; Calcitonin gene-related peptide (inhaled, asthma), LAB International"	44134599	Discontinued in Phase 2	D01SPI	.	CTPDG006660
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CJ-13610	"CJ 13610; CJ-13,610"	9821945	Discontinued in Phase 2	D01DAD	.	CTPDG006665
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	E-6080	"E 6080; 120164-49-0; E6080; AC1L2UXT; SCHEMBL3053845; DTXSID10152706; 6-Hydroxy-2-(4-sulfamoylbenzylamine)-4,5,7-trimethylbenzothiazole hcl; 6-hydroxy-2-(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride; Benzenesulfonamide, 4-(((6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino)methyl)-, monohydrochloride; 4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide hydrochloride"	129064	Discontinued in Phase 2	D00HFD	.	CTPDG006673
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CI-1018	"UNII-Y4O6325SYW; Y4O6325SYW; CHEMBL111925; DSSTox_CID_27248; DSSTox_RID_82208; DSSTox_GSID_47248; SCHEMBL185627; CAS-NOCAS_47248; DTXSID0047248; NOCAS_47248; Tox21_300203; BDBM50217550; NCGC00254191-01; NCGC00247925-01; 179024-48-7; PD-168787; (+)-CI-1018; CI-1018, (+)-; UNII-05127JZ9KQ component KYFWUBJMTHVBIF-QFIPXVFZSA-N; 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; 4-Pyridinecarboxamide, N-((3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrol"	9865514	Discontinued in Phase 2	D00DBE	.	CTPDG006678
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SK&F-S-106203	SK&F-106203; (S)-beta-[(2-Carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid; 3(S)-[2-(Carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propionic acid	3035514	Discontinued in Phase 2	D00AKY	.	CTPDG006681
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	AVE-5883	.	.	Discontinued in Phase 1/2	D0Y4GJ	.	CTPDG006683
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	NCX 950	.	.	Discontinued in Phase 1/2	D0X5ES	.	CTPDG006684
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	Vepalimomab	"Vapantix; VAP-1 MAb (1), BioTie Therapies"	.	Discontinued in Phase 1/2	D01MQH	.	CTPDG006700
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RO7040547	BITS7201A; RG7990	.	Discontinued in Phase 1	DFU4B0	.	CTPDG006702
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	PF-3526299	.	.	Discontinued in Phase 1	D0Y2XQ	.	CTPDG006710
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	IPLl576092	"IPL 576,092"	.	Discontinued in Phase 1	D0X2YI	.	CTPDG006717
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SB-281832	.	.	Discontinued in Phase 1	D0W3AX	.	CTPDG006721
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SDZ-PCO-400	PCO-400	129348	Discontinued in Phase 1	D0U8IJ	.	CTPDG006732
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	F-11105	.	.	Discontinued in Phase 1	D0O2EB	.	CTPDG006763
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SMART anti-E/P selectin	"HuEP5C7; Bispecific anti-E/P selectin, PDL; SMART anti-E/P selectin, PDL; SMART anti-E/P selectin, Protein Design Labs; Anti-E/P selectin (humanized), PDL"	.	Discontinued in Phase 1	D0L3XV	.	CTPDG006785
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	NIP-520	NIP-502	.	Discontinued in Phase 1	D0J4WW	.	CTPDG006799
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	ABT-080	"VML-530; 4,4-Bis[4-(quinolin-2-ylmethoxy)phenyl]pentanoic acid sodium salt"	.	Discontinued in Phase 1	D0GB3A	.	CTPDG006811
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	YM-976	"4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one"	6604918	Discontinued in Phase 1	D0C7JT	.	CTPDG006826
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RG-7152	5-[3-[3-(2-Quinolinylmethoxy)phenoxy]propyl]-1H-tetrazole	129968	Discontinued in Phase 1	D0B7KF	.	CTPDG006831
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	HSR-6071	PTPC; 6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazine-2-carboxamide	159466	Discontinued in Phase 1	D09ZPX	.	CTPDG006840
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	AZD-1744	"Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca"	.	Discontinued in Phase 1	D09UXP	.	CTPDG006843
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	AMG 317	.	.	Discontinued in Phase 1	D09MKQ	.	CTPDG006848
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	PF-05212372	"PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth"	.	Discontinued in Phase 1	D08YFD	.	CTPDG006857
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	GR-63799X	"(-)-[1(R)-[1alpha(Z),2beta(R*),3alpha]-7-[3-Hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]-4-heptenoic acid 4-(benzoylamino)phenyl ester; (Z)-4,5-Didehydro-13-oxa-16-phenoxy-13,14-dihydro-17,18,19,20-tetranor-PGE1 4-(benzoylamino)phenyl ester; 119906-28-4"	6439068	Discontinued in Phase 1	D07RVP	.	CTPDG006865
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RWJ-56423	"CHEMBL256892; CHEMBL124571; (2S,4R)-1-ACETYL-N-[(1S)-4-[(AMINOIMINOMETHYL)AMINO]-1-(2-BENZOTHIAZOLYLCARBONYL)BUTYL]-4-HYDROXY-2-PYRROLIDINECARBOXAMIDE; (2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide; AC1NR9Y0; SCHEMBL4314345; GTPL9333; VXDAVYUFYPFGDX-SNPRPXQTSA-N; BDBM50228764; BDBM50131977; DB02812; (2S)-6; (4R)-1-acetyl-N-[(1S)-1-(1,3-benzothiazol-2-ylcarbonyl)-4-carbamimidamidobutyl]-4-hydroxy-L-prolinamide"	5287596	Discontinued in Phase 1	D05QMJ	DB02812	CTPDG006885
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	ABN-912	"Anti-CD46 mAb, Novartis; Anti-MCP1 monoclonal antibody, Novartis"	.	Discontinued in Phase 1	D04MYO	.	CTPDG006898
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	CGP-13774	.	.	Discontinued in Phase 1	D04FRB	.	CTPDG006901
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	NZ-107	4-Bromo-5-(3-ethoxy-4-methoxybenzylamino)pyridazin-3(2H)-one	129496	Discontinued in Phase 1	D02ANJ	.	CTPDG006917
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	TR-14531	IDDB25065	.	Discontinued in Phase 1	D01VSK	.	CTPDG006918
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RG-7185	"CRTH2 antagonist (asthma), Roche"	.	Discontinued in Phase 1	D01NGT	.	CTPDG006923
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	BM-113	1-[2-(Benzhydryloxy)ethyl]piperidine-4-acetic acid ethyl ester	72941791	Discontinued in Phase 1	D01GIF	.	CTPDG006928
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	GW-250495	GR-250495; GR-250495X; GW-250495X	.	Discontinued in Phase 1	D01EDO	.	CTPDG006931
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SMP-028	.	11949660	Discontinued in Phase 1	D00WWU	.	CTPDG006935
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Preclinical	YM-355179	GTPL793; SCHEMBL3808393	11556309	Preclinical	D0Y6TI	.	CTPDG007022
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Preclinical	AZD-1678	"CCR4 antagonist (asthma), AstraZeneca"	23585443	Preclinical	D0E2QN	.	CTPDG007090
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Preclinical	LAS-101057	"LAS-38096; Adenosine A2b receptor antagonists (inflammation), Almirall"	11716665	Preclinical	D08ECB	.	CTPDG007114
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Preclinical	YM-344031	.	56603737	Preclinical	D04EIL	.	CTPDG007139
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Preclinical	IMO-2134	.	.	Preclinical	D02ZWR	.	CTPDG007146
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	FPL-55712	"40786-08-1; 7-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-carboxy late, sodium salt; CHEMBL267976; 7-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]- 4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid sodium salt; 4H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy)-4-oxo-8-propyl-, monosodium salt; fpl55712; SCHEMBL1890293; AOB5208; ZDEVPOBNLIVGFA-UHFFFAOYSA-M; MFCD00068619; LS-186693; FT-0639668; FPL-55712, &gt"	23662025	Terminated	D0ZE5V	.	CTPDG007164
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-255283	GTPL3351; MolPort-009-018-745; HMS3649C08; ZINC27644044; SR-01000946596; SR-01000946596-1	122023	Terminated	D0Y2IH	.	CTPDG007175
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	A-78773	"141579-67-1; A 78773; CHEMBL59598; N-Hydroxy-N-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea; N-(3-(5-(4-Fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxyurea; 1-{4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl}-1-hydroxyurea; 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea; Urea,N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propyn-1-yl]-N-hydroxy-; CCRIS 8531"	71460	Terminated	D0X9KE	.	CTPDG007180
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	SKF-96231	.	135529458	Terminated	D0W8OH	.	CTPDG007187
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	BAY-44-3428	APC-1167	.	Terminated	D0W7DD	.	CTPDG007188
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	KA-398	"Scopinast; Scopinast, Wilmar Schwabe"	.	Terminated	D0VZ8S	.	CTPDG007193
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Fenspiride hydrochloride	KSP-193	68626	Terminated	D0V8KI	.	CTPDG007196
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	SM 11044	"142784-65-4; SM-11044; DTXSID90162181; AC1L3144; 3-(3,4-Dihydroxyphenyl)-N-(3-(4-fluorophenyl)propyl)serine pyrrolidine amide hydrobromide; Pyrrolidine, 1-(3-(3,4-dihydroxyphenyl)-2-((3-(4-fluorophenyl)propyl)amino)-3-hydroxy-1-oxopropyl)-, monohydrobromide, (R-(R*,S*))-; (2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one hydrobromide"	132507	Terminated	D0V4FK	.	CTPDG007197
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	BI-L-357	BI-L-226	6440014	Terminated	D0U6AL	.	CTPDG007208
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	FR-113680	"FR 113680; 126088-92-4; Ac-Thr-trp(cho)-phe-N-mebzl; AC1L2Y4S; DTXSID70155076; fr113680; N(alpha)-(N(alpha)-(N(alpha)-Acetylthreonyl)-N(1)-formyltryptophyl)-N-methyl-N-(phenylmethyl)phenylalaninamide; L-Phenylalaninamide, N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-"	130848	Terminated	D0T6MU	.	CTPDG007220
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	MEN-11149	.	101940285	Terminated	D0T4IQ	.	CTPDG007221
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	KF-17625	"KF17625; KF 17625; BRN 4874703; CHEMBL95509; 139339-02-9; 5-Phenyl-1H-imidazo(4,5-c)(1,8)naphthyridin-4(5H)-one; 1,5-Dihydro-5-phenyl-4H-imidazo(4,5-c)(1,8)naphthyridin-4-one; 4H-Imidazo(4,5-c)(1,8)naphthyridin-4-one, 1,5-dihydro-5-phenyl-; AC1L2QF6; SCHEMBL2457079; DTXSID10161015; NDDBRRFHXNPOLY-UHFFFAOYSA-N; BDBM50230286; ZINC13731342; LS-80025; LS-80024; 5-phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4-one; 5-Phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-one; 5-Phenyl-3H-Imidazo[4,5-c][1,8]Naphthyridin-4(5H) -One"	126487	Terminated	D0SI4C	.	CTPDG007224
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Tomelukast	LY-171883	3969	Terminated	D0S8YL	.	CTPDG007226
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	MX2/120	"155006-67-0; BRN 7252641; 7-(2,2-Dimethylpropyl)-1-methylxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-7-(2,2-dimethylpropyl)-1-methyl-; 3,7-Dihydro-7-(2,2-dimethylpropyl)-1-methyl-1H-purine-2,6-dione; AC1MINF6; SCHEMBL3843737; 7-(2,2-dimethylpropyl)-1-methyl-3H-purine-2,6-dione; CTK4C8491; DTXSID90165793; 1-Methyl-7-(2,2-dimethylpropyl)xanthine; LS-126951"	3074068	Terminated	D0RM5W	.	CTPDG007234
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8308	.	.	Terminated	D0R7UK	.	CTPDG007235
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8328	.	.	Terminated	D0Q7WW	.	CTPDG007241
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	OT-4003	IDDB10966	.	Terminated	D0PL5F	.	CTPDG007247
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Org-9935	Org-935	131100	Terminated	D0PB6P	.	CTPDG007251
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	MOL-218	"MOL-254; MOL-268; MOL-294; NFkB inhibitors, Molecumetics"	.	Terminated	D0P1YO	.	CTPDG007253
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-210073	LY210073; 148291-65-0; CHEMBL49210; LY 210073; SCHEMBL9148299; AC1O515S; BDBM50045092; HY-U00263; AKOS030562935; CS-7479; L005236; 5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid; 7-Carboxy-3-[[(E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]-9-oxo-9H-xanthene-4-propanoic acid; (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid; 7-Carboxy-3-((6-(methoxyphenyl)-5(E)-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid	6450158	Terminated	D0OP7B	.	CTPDG007258
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	SC-53228	"SC 53228; CHEMBL419948; 153633-01-3; AC1L4BTY; SCHEMBL1447495; DTXSID40165384; BDBM50037390; 3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid; 3-{(S)-7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-, (S)-"	204058	Terminated	D0NK8D	.	CTPDG007270
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	BAY-17-1998	BAY-35-8535	.	Terminated	D0L7ZX	.	CTPDG007290
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	A-79175	CHEMBL90552; UNII-25B75ID70W; 25B75ID70W; AC1L43J2; ZINC5333; SCHEMBL6438420; BDBM50369068; 141579-87-5; 1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea	178577	Terminated	D0L1IH	.	CTPDG007295
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	FK-355	"NK1 antagonists, Fujisawa"	.	Terminated	D0KD4U	.	CTPDG007299
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	ICI-198615	"Cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate; Ici 198615; 104448-53-5; CHEMBL22033; Ici-198,615; ZM 198615; ZM-198,615; cyclopentyl N-[1-({4-[(benzenesulfonyl)carbamoyl]-2-methoxyphenyl}methyl)-1H-indazol-6-yl]carbamate; [3H]ICI198615; [3H]-ICI198615; [3H]ICI-198615; [3H]ICI-198,615; AC1L3GQZ; (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester; GTPL3414; GTPL3358; SCHEMBL9806720; DTXSID80146490; BDBM50009075; PDSP1_000520; PDSP2_000518; ICI198615"	115219	Terminated	D0J7UI	.	CTPDG007310
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	SDZ-ISQ-844	"143526-87-8; Sdz isq 844; SDZ ISQ-844; SCHEMBL7298437; AC1L317P; CTK4C3695; 3-Isoquinolinemethanol,1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (3S)-; AKOS030566039; 6,7-Dimethoxy-1-(3,4-dimethoxyphenyl)-3-hydroxymethyl-3,4-dihydroisoquinoline; (S)-1-(3,5-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (S)-"	132565	Terminated	D0J5UC	.	CTPDG007312
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	ON-579	"141286-14-8; ON 579; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid; Acetic acid,2-[4-[[2-[[(4-chlorophenyl)sulfonyl]amino]ethyl]thio]-2,6-difluorophenoxy]-; ACMC-20cvej; AC1Q6UCK; AC1L4U4O; {4-[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)sulfanyl]-2,6-difluorophenoxy}acetic acid; CHEMBL312763; SCHEMBL2925987; CTK4C2555; DTXSID70161657; AKOS030574939; 4-(2-(4-Chlorophenylsulfonylamino)-ethylthio)-2,6-difluorophenoxyacetic acid; KB-227077"	192308	Terminated	D0J5QW	.	CTPDG007313
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-648051	"4-Apsob; L 648051; UNII-0LGZ40MB45; 0LGZ40MB45; 91541-18-3; 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid; 4-(4-{[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl}phenyl)-4-oxobutanoic acid; Benzenebutanoic acid, 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxo-; AC1Q5VP2; AC1L3TT7; SCHEMBL157166; CHEMBL282253; CTK8D5118; DTXSID50238619; ZAKKEARLDPTRLX-UHFFFAOYSA-N; AKOS030530731; LS-186850; LS-187510"	122010	Terminated	D0J4EG	.	CTPDG007315
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZD-7944	"CHEMBL339767; ZD7944; SCHEMBL7501969; BDBM50409575; (R)-3-((S)-1-(3,4-dichlorophenyl)-3-(4-(2-((S)-methylsulfinyl)phenyl)piperidin-1-yl)propyl)-2-ethylisoindolin-1-one"	44351946	Terminated	D0J3QU	.	CTPDG007317
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	AZD-2098	.	10308720	Terminated	D0J1FL	.	CTPDG007321
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	BW B70C	"BWB70C; BW-B 70C; 134470-38-5; BW-B70C; CHEMBL86676; CHEBI:75307; (E)-N-(3-(3-(4-Fluorophenoxy)phenyl)-1-(R,S)-methylprop-2-enyl)-N-hydroxyurea; 70C; N-[3-[3-4(-Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea; N-(3-(3-(4-Fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxyurea; Urea, N-(3-(3-(4-fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxy-; C17H17FN2O3; SR-01000075717; (e)-N-{3-[3-(4-fluorophenoxy)phenyl]-1-(r,s)-methylprop-2-enyl}-N-hydroxyurea; Lopac0_000202; BSPBio_001512; SCHEMBL2681955"	5353454	Terminated	D0HJ1Y	.	CTPDG007334
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	CP-0597	.	9833644	Terminated	D0H5PD	.	CTPDG007336
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Selenotifen	BN-52256	.	Terminated	D0FQ4M	.	CTPDG007353
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	443C81	BW 443C; BW-443C81	101630908	Terminated	D0E8SE	.	CTPDG007363
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZT-386	.	.	Terminated	D0E8JL	.	CTPDG007364
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	EFIPLADIB	"381683-94-9; UNII-S97YUG2A91; S97YUG2A91; CHEMBL272342; PLA-902; Efipladib [USAN:INN]; Efipladib (USAN); 4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid; SCHEMBL1500831; HIZOPJQOPKRKFM-UHFFFAOYSA-N; ZINC85536943; BDBM50226792; D06674; 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid"	9853499	Terminated	D0E1WY	.	CTPDG007369
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZM-230487	"ZM 230487; 155944-23-3; CHEMBL459236; Ici 230487; ICI-230487; AC1L31ZC; 1-Ethyl-6-((3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-2-quinolone; SCHEMBL6008852; CTK4C8893; DTXSID70165998; zm230487; ZINC1484223; BDBM50250926; 1-Ethyl-6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-2(1H)-quinolinone; KB-276139; 1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one"	132998	Terminated	D0D8MD	.	CTPDG007376
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-290154	.	.	Terminated	D0D0XX	.	CTPDG007379
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	BU-4601A	BU-4601B; BU-4601C	192421	Terminated	D0C9RZ	.	CTPDG007382
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	R zileuton	.	.	Terminated	D0C5HV	.	CTPDG007387
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8225	"UR 8225; 149455-36-7; 5,6-Dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-2-naphthalenecarbonitrile; 1,2-Dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile; 2-Naphthalenecarbonitrile, 5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; 2-Naphthalenecarbonitrile,5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; ACMC-20n5pl; AC1L560X; SCHEMBL6369766; CHEMBL303682; CTK4C6217; DTXSID60164273; LS-94452"	198778	Terminated	D0B7ND	.	CTPDG007392
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	AVE0675	.	.	Terminated	D0B6WN	.	CTPDG007393
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-670596	"121083-05-4; L-670,596; L 670596; 2-(6,8-Difluoro-9-(4-(methylsulfonyl)benzyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid; (-)-6-8-DIFLUORO-2,3,4,9-TETRAHYDRO-9-[[4-(METHYLSULFONYL)PHENYL]METHYL]-1H-CARBAZOLE-1-ACETIC ACID; AC1L2VGU; SCHEMBL3044967; CHEBI:91930; CTK8F0755; MolPort-003-983-606; HMS3268M18; BCP28232; BN0288; AKOS022180202; RT-013483; FT-0757831; SR-01000597550; L002392; C-35484; SR-01000597550-1; J-004444; BRD-A85472596-001-01-4"	129360	Terminated	D0AN1Y	.	CTPDG007399
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	MCI-826	"(E)-2,2-Diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid; (E)-2,2-Diethyl-N-[3-[2-(4-isopropylthiazol-2-yl)vinyl]phenyl]succinamic acid"	6439428	Terminated	D0AB7G	.	CTPDG007401
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	MDL-43291	"Mdl 43291; Mdl 43,291; AC1MI0EN; ((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; (4aalpha,7Z,8beta,8abeta)-((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; Acetic acid, ((octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)-, (4aalpha,7Z,8beta,8abeta)-; 2-[[(2Z,4aS,8S,8aS)-2-(2-oxotetradecan-7-ylidene)-3,4,4a,5,6,7,8,8a-octahydrochromen-8-yl]sulfanyl]acetic acid"	14430182	Terminated	D09ZVR	.	CTPDG007407
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	XR-12890	"MRP1 inhibitor, Xenova; Multidrug resisitance protein inhibitor, Xenova"	.	Terminated	D09XYU	.	CTPDG007410
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	CGS-13080	"PIRMAGREL; Pirmagrelum [Latin]; Pirmgrel; Pirmagrel [USAN:INN]; UNII-9J5H2VA91V; CGS 13080; 85691-74-3; CHEMBL48092; 9J5H2VA91V; Imidazo(1,5-a)pyridine-5-hexanoic acid; Pirmagrelum; Imidazo[1,5-a]pyridine-5-hexanoic acid; Pirmagrel (USAN/INN); AC1L1IZ7; SCHEMBL636018; DTXSID80234982; LIFOFTJHFFTNRV-UHFFFAOYSA-N; ZINC2021333; BDBM50025953; imidazol(1,5-a)pyridine-5-hexanoic acid; LS-177888; 6-imidazo[1,5-a]pyridin-5-ylhexanoic acid; 5-(5-carboxypentyl)imidazo[1,5-a]pyridine; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine"	55390	Terminated	D09QRO	.	CTPDG007414
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	RG-14893	"RG 14893; 141835-49-6; CHEMBL328712; 2-Naphthalenecarboxylicacid, 4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-; ACMC-20n0x5; AC1L30VP; SCHEMBL1894401; rg14893; CTK0H7370; DTXSID30161835; BDBM50001609; 4-(2-(Methyl(2-phenylethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; 4-(2-(Methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; L006851; 8-Benzyloxy-4-[(methyl-phenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid"	132379	Terminated	D09LQP	.	CTPDG007416
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Epocarbazolin-A	Epocarbazolin-B	192365	Terminated	D09JYF	.	CTPDG007419
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	NS-1619	"153587-01-0; NS 1619; 1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one; NS1619; CHEMBL384903; 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one; CHEBI:34879; 1-(2'-Hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone; 1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2h-benzimidazol-2-one; 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one"	4552	Terminated	D09BVL	.	CTPDG007425
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	U-78517F	Troloxamine; U-78517; U-78517G; U-78518F; U-83836E	107656	Terminated	D09BRE	.	CTPDG007426
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	GCC-AP0341	AP-0341	3074943	Terminated	D08MVK	.	CTPDG007438
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	RP-58802B	Imoxiterol; 88578-07-8; Imoxiterolum; Imoxiterol [INN]; Imoxiterolum [Latin]; AC1L23PZ; SCHEMBL249468; CHEMBL2104918; RP 58802B; CS-6651; 2-(3-(1-Benzimidazolyl)-1-methylpropylamino)-1-(4-hydroxy-3-methoxyphenyl)ethanol; RP-58802; HY-101585; L007875; alpha-(((3-(1-Benzimidazolyl)-1-methylpropyl)amino)methyl)vanillyl alcohol	65665	Terminated	D08HDD	.	CTPDG007442
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	WIN-64821	Q-20547A	158365	Terminated	D07PLK	.	CTPDG007454
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Sulotroban	BM-13177; SKF-95587	51550	Terminated	D07JSK	.	CTPDG007460
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Ro 20-1724	"4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 29925-17-5; 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one; ro-20-1724; Ro 201724; CHEMBL18701; 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-; RO-201724; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-, (+-)-; 4-(3-butoxy-4-methoxy-benzyl)imidazolidin-2-one; 34185-37-0; 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; SR-01000075647; keratan sulfate I; Keratan sulphate I; Naphthoquinone analogs"	5087	Terminated	D07FHZ	.	CTPDG007464
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZD-7717	ICI D7717	.	Terminated	D06YOD	.	CTPDG007468
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Isomazole	Isosulmazole; Isomazole fumarate; Isomazole hydrochloride; EMD-41064; EMD-47200; EMD-50250; EMD-52750; LY-175326	55690	Terminated	D05VLN	.	CTPDG007486
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	PLR-8	PLR-2224	.	Terminated	D05SXL	.	CTPDG007489
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	LF-801	.	.	Terminated	D05QTO	.	CTPDG007492
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-745337	"Thioflosulide; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337"	9799453	Terminated	D05EYG	.	CTPDG007499
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	CV 6209	"CHEMBL274420; CV6209; GTPL1852; AC1L32P4; SCHEMBL8538219; CHEMBL1180101; PDSP1_000728; PDSP1_000727; PDSP2_000718; PDSP2_000717; BDBM50005232; 2-(2-Acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacosan-1-yl)-1-ethylpyridinium; 2-{[Acetyl-(2-methoxy-3-octadecylcarbamoyloxy-propoxycarbonyl)-amino]-methyl}-1-ethyl-pyridinium; [2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate"	107756	Terminated	D05CEK	.	CTPDG007502
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	VZ-564	"VZ 564; 147495-99-6; 1-hydroxy-1-[(6-methoxy-3,4-dihydronaphthalen-2-yl)methyl]urea; Urea,N-[(3,4-dihydro-6-methoxy-2-naphthalenyl)methyl]-N-hydroxy-; VZ564; ACMC-20cs2n; AC1Q5JDP; AC1L4U8C; SCHEMBL9448945; CTK4C5429; N-Hydroxy-N-(6-methoxy-3,4-dihydro-2-naphthylmethyl)urea; DTXSID80163728; Urea, 1-hydroxy-1-(6-methoxy-3,4-dihydro-2-naphthylmethyl)-"	192375	Terminated	D04ZCL	.	CTPDG007504
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	MEN-10627	"MEN10627; 157351-81-0; AC1NSKCE; GTPL3901; cyc(2beta-5beta)(Met-Asp-Trp-Phe-Dap-Leu); (1R,4S,7S,10R,13R,16S)-13-(1H-indol-3-ylmethyl)-4-(2-methylpropyl)-7-(2-methylsulfanylethyl)-16-(phenylmethyl)-3,6,9,12,15,18,20-heptazabicyclo[8.8.4]docosane-2,5,8,11,14,17,21-heptone"	10327792	Terminated	D04RCG	.	CTPDG007510
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	RP-66153	"RP 66153; CHEMBL108415; 142422-79-5; AC1L30YM; SCHEMBL4355829; DTXSID80162034; 2,2-Dimethyl-7-(3-(3-phenylpropyl)-2-thienyl)heptanoic acid; BDBM50001162; 2-Thiopheneheptanoic acid, alpha,alpha-dimethyl-3-(3-phenylpropyl); 2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid; 2,2-Dimethyl-7-[3-(3-phenyl-propyl)-thiophen-2-yl]-heptanoic acid"	132425	Terminated	D04JJE	.	CTPDG007514
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	KC-11404	.	.	Terminated	D04APY	.	CTPDG007520
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	TAK-225	"2,2-Diethyl-3-(7-methyl[1,2,4]triazolo[1,5-b]pyridazin-6-yloxy)propanesulfonamide"	3073784	Terminated	D03WYV	.	CTPDG007522
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	NPC-17731	"Bradykinin antagonists, Scios; NPC-16731; NPC-17761; NPC-18521; NPC-18688; NPC-18884"	3081308	Terminated	D03WMY	.	CTPDG007523
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Midaglizole	"Midaglizole hydrochloride; DG 5218; DG-5128; Pyridine, 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]-, monohydrochloride"	68864	Terminated	D02XMM	.	CTPDG007542
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	BABIM	"Bis(5-amidino-2-benzimidazolyl)methane; 74733-75-8; CHEMBL99951; 1H-Benzimidazole-5-carboximidamide, 2,2'-methylenebis-; 1xug; 1c1v; AC1L1DKB; SCHEMBL65730; AC1Q1U90; CTK5E0415; BDBM16127; DTXSID60225717; AIDS007118; ZINC3871731; AKOS028112598; Bis(5-amidino-1H-benzimidazole-2-yl)methane; 1H-Benzimidazole-6-carboximidamide,2,2'-methylenebis-; 2,2 -methanediylbis(1H-benzimidazole-6-carboximidamide); 2-[(5-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-1H-benzimidazole-5-carboxamidine"	2387	Terminated	D02INZ	.	CTPDG007553
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	KF-15570	"KF 15570; BRN 4872911; 4H-Imidazo(4,5-c)quinolin-4-one, 1,5-dihydro-5-butyl-1-methyl-; 133305-92-7; 5-Butyl-1-methyl-1,5-dihydro-1H-imidazo(4,5-c)quinolin-4(5H)-one; AC1MIPZT; SCHEMBL9215327; CHEMBL434802; DTXSID80158053; CVLGNWUGFVTZRC-UHFFFAOYSA-N; ZINC1548061; LS-80514; 5-butyl-1-methylimidazo[4,5-c]quinolin-4-one; 5-butyl-1-methyl-1h-imidazo[4,5-c]quinolin-4(5h)-one; 5-n-Butyl-1-methyl-1H,5H-imidazo[4,5-c]quinolin-4-one"	3077017	Terminated	D01YGF	.	CTPDG007558
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	GW-3600	"Phosphodiesterase 4 inhibitor, Glaxo"	9842576	Terminated	D01QUF	.	CTPDG007564
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	KC-11425	.	.	Terminated	D01LXG	.	CTPDG007568
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	LM-1376	.	9891157	Terminated	D00YOW	.	CTPDG007578
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	Sch-45752	"Cephalochromin; MLS000876993; CHEMBL463175; NSC627953; NSC201419; 25908-26-3; SMR000440611; cefalochromin; 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one; Sch 45752; AC1Q6DTF; AC1L4N2K; SCHEMBL1111561; MEGxm0_000312; cid_160115; ACon0_000585; ACon1_000126; MolPort-001-739-590; HMS2270H11; BDBM50269745; NSC-201419; NSC-627953; MCULE-6609850631; NCGC00180856-01; SR-01000758207; SR-01000758207-2"	160115	Terminated	D00MEV	.	CTPDG007582
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Terminated	EP-012637	"Ciclosporin analogs, Enanta; Cyclosporin A analogs, Enanta; Cyclosporine analogs, Enanta; EP-1269; EP-314; EP-861; Immunosuppressant program, Enanta"	.	Terminated	D00JZX	.	CTPDG007585
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	IDR-1002	.	.	Investigative	DD3MB0	.	CTPDG007603
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	Vagonixen	.	.	Investigative	D0XS3T	.	CTPDG007692
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	RS-1748	.	46220480	Investigative	D0XH2N	.	CTPDG007700
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	BFPT-12603	BFPT-2603	.	Investigative	D0WW7U	.	CTPDG007738
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	LPCN-1056	LPCN-1052	.	Investigative	D0U8GH	.	CTPDG007821
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	AEOL-11207	"AEOL-11203; AEOL-11216; Catalytic antioxidants, Aeolus; Catalytic antioxidants, Incara"	42609706	Investigative	D0U4PG	.	CTPDG007830
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	GATA-3-specific DNAzyme	"GATA-3-specific DNAzyme (asthma); GATA-3-specific DNAzyme (asthma), Philipps-Universitat Marburg/sterna biologicals; Gd21 GATA-3-specific DNAzyme (asthma), Philipps-Universitat Marburg/sterna biologicals"	.	Investigative	D0R3NR	.	CTPDG007912
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	BW-858C	.	.	Investigative	D0R2MQ	.	CTPDG007919
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	PXS-4159	"Membrane copper amine oxidase modulators (asthma), Pharmaxis; SSAO/VAP-1 inhibitors (asthma), Pharmaxis"	.	Investigative	D0R0FU	.	CTPDG007923
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	IW-1221	"CRTH2 inhibitor (asthma), Ironwood"	.	Investigative	D0Q0GY	.	CTPDG007966
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	N-6060	"N-6338; N-6371; N-6446; N-6463; N-6501; N-6537; N-6603; S-nitrosoglutathione reductase inhibitors, N30"	.	Investigative	D0P5LX	.	CTPDG007981
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	SP-003	"SP-003, PhytoPharmacon; Euphorbia hirta-derived anti-inflammatory (oral, asthma), PhytoPharmacon"	.	Investigative	D0O8WM	.	CTPDG008002
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	NPT-CLN	"Calcineurin inhibitors (asthma), Biotica; NPT-CLN series (inhaled, asthma); NPT-CLN series (inhaled, asthma), Biotica"	.	Investigative	D0N9WY	.	CTPDG008029
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	Sulochrin	"519-57-3; UNII-8NA53C271Z; CHEBI:16159; 8NA53C271Z; Methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxybenzoate; Benzoic acid, 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxy-, methyl ester; Sulochrin_120096; AC1Q5ZJI; AC1L4NQS; MLS000863634; SCHEMBL233392; CHEMBL61133; MEGxm0_000192; CTK1H2445; ACon0_000926; ACon1_000208; DTXSID80199860; MolPort-001-739-420; YJRLSCDUYLRBIZ-UHFFFAOYSA-N; HMS2268H19; ZINC895263; MFCD07370145; ACM519573; Sulochrin, &gt; AKOS030615357; MCULE-7066877679"	160505	Investigative	D0N5SW	.	CTPDG008042
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	LMS-611	"LMS-611 (inhalant), Lamellar Biomedical; LMS-611 (oral), Lamellar Biomedical"	.	Investigative	D0JS7E	.	CTPDG008155
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	AG-NCA805	.	.	Investigative	D0I7YR	.	CTPDG008198
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	ER-23006	.	.	Investigative	D0G6RK	.	CTPDG008265
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	Anti-TSLP mab	Anti-TSLP mAb (asthma)	.	Investigative	D0F7RU	.	CTPDG008297
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	APX-E	"AXP-A0; AXP-D; CCR3 antagonists (asthma); CCR3 antagonists (asthma), Axikin"	.	Investigative	D0D5XV	.	CTPDG008375
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	L-873724	"UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	Investigative	D0D0LD	.	CTPDG008390
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	MAR--99	BRN 5609020	127154	Investigative	D0C7LA	.	CTPDG008406
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	DW-403	.	.	Investigative	D0A5CZ	.	CTPDG008490
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	UR-60427	"Histamine H4 inverse agonist (asthma), Palau Pharma"	.	Investigative	D09HUF	.	CTPDG008555
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	HMPL-342	"HM-A42; I-kappa beta kinase inhibitor (asthma/COPD/autoimmune diseases), Hutchison Medipharma"	.	Investigative	D09DEU	.	CTPDG008564
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	OT-121	"OT-121 (inhaled dry powder, asthma); OT-121 (inhaled dry powder, asthma), Oriel Therapeutics; OT-121 (inhaled dry powder, asthma),Sandoz"	.	Investigative	D08QUC	.	CTPDG008599
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	VALERGENT-BT	"VALERGEN-BT (subcutaneous); Blomia tropicalis allergen immunotherapy (sc, asthma), National Biopreparations Center"	.	Investigative	D08AXM	.	CTPDG008640
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	AIM-101	"AIM-101 (Neutropel, asthma/COPD), AIM Therapeutics"	.	Investigative	D06DPQ	.	CTPDG008768
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	CH-3697	.	.	Investigative	D05YEL	.	CTPDG008780
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	MER-2101	"Epitope-driven vaccine + MAS-1 adjuvant (asthma), Mercia"	.	Investigative	D05RPT	.	CTPDG008806
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	BCP-1081	"Non-steroidal anti-inflammatory agent (asthma), BioCure Pharma; Non-steroidal anti-inflammatory agent (asthma), InflammoGen"	.	Investigative	D05AAQ	.	CTPDG008847
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	DS-AH-14	.	19801656	Investigative	D04ZSZ	.	CTPDG008851
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	ASOBAMAST	Asobamast < Rec INN; Z-1819; N-[4-(3-Methylisoxazol-5-yl)thiazol-2-yl]oxamic acid 2-ethoxyethyl ester	72033	Investigative	D04LBJ	.	CTPDG008885
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	FHT-CT4	"CTLA4-PTD fusion protein (inflammation), Forhumantech"	.	Investigative	D04ALI	.	CTPDG008915
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	HD-101	"Antibody (asthma/autoimmune disease), Dreampharma"	.	Investigative	D03MSN	.	CTPDG008959
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	Recombinant anti-IgE Fabs	"Recombinant anti-IgE Fabs (asthma/immunological diseases); Anti-immunoglobulin E antibodies (asthma/immunological disease), Glycobia; Recombinant anti-IgE Fabs (asthma/immunological diseases), Glycobia; Recombinant anti-immunoglobulin E antigen binding fragments (asthma/immunological diseases), Glycobia"	.	Investigative	D03JXN	.	CTPDG008965
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	VBP	"VBP series (muscular dystrophy/asthma); VBP series (muscular dystrophy/asthma), Validus Biopharma; Non-hormonal steroids (spinal muscular atrophy/amyotropic lateral sclerosis/Duchenne dystrophy/asthma), Validus Biopharma"	6604912	Investigative	D02SJN	.	CTPDG009009
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	GSK-172981	"GSK-256471; SB-218795; SB-235375; SB-244487; SB-400238; SB-414240; SK-797230; NK-2 antagonists, GSK; NK-3 antagonists, GlaxoSmithKline; NK-3 antagonists, SB"	25195091	Investigative	D02CCA	.	CTPDG009043
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	ATL-844	"N-(4-Cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; MRS 1754; 264622-58-4; MRS-1754; MRS1754; CHEMBL273807; N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide; [3H]MRS1754; [3H]-MRS1754; NCGC00015689-01; Lopac-M-6316; Lopac0_000729; GTPL453; GTPL449; MLS002153324; SCHEMBL1222380; AC1O7G54; CTK8E7916; CHEBI:93269; AOB5542; DTXSID80424967; MolPort-023-276-567; HMS3373J21; HMS3268F13; HMS2230A06; ZINC4475274; BDBM50086170; AKOS027427086; AKOS024457276; EX-3306; ATL-618; ATL-GW-22; ATL-GW-8; A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil; A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics; A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data"	6603931	Investigative	D01QYQ	.	CTPDG009078
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	TA-106	"FAb antibody fragment (inflammation), Taligen Therapeutics; Anti-factor B FAb (inflammation), Alexion"	.	Investigative	D01ODC	.	CTPDG009089
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	HL-028	.	.	Investigative	D01BJS	.	CTPDG009131
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	PRS-060	"IL-4 alpha receptor inhibitor (Anticalin, asthma), Pieris; IL-4R alpha inhibitor (Anticalin, asthma), Pieris"	.	Investigative	D01BEX	.	CTPDG009134
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	KI-0905	.	.	Investigative	D00UHK	.	CTPDG009153
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	RV-1088	.	.	Investigative	D00PGF	.	CTPDG009168
M6ACROT05096	.	.	M6ADIS0164	CA23: Asthma	Investigative	CWF-0710	.	.	Investigative	D00ONE	.	CTPDG009171
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Tezepelumab	.	.	Approved	DMOF95	.	CTPDG000007
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Procaterol	"Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one"	4916	Approved	D0Z1WA	.	CTPDG000036
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Mometasone furoate/ formoterol fumarate	Dulera (TN)	441336	Approved	D0XW2H	DB14512	CTPDG000065
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Fluprednisolone	Alphadrol	5876	Approved	D0V9DZ	DB09378	CTPDG000100
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Pirbuterol	"Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol"	4845	Approved	D0SS4P	DB01291	CTPDG000146
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Infliximab	Remicade (TN)	.	Approved	D0PG5G	.	CTPDG011309
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Formoterol/budesonide	"Formoterol-budesonide mixt; Budesonide-formoterol mixt; 150693-37-1; Budesonide mixture with formoterol; Formoterol / budesonide; Symbicort Inhalation Aerosol; Budesonide/formoterol combination; Budesonide and formoterol fumarate dihydrate; DTXSID80872449; Pregna-1,4-diene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-,     (11beta,16alpha)-, mixt with (R*,R*)-(+-)-N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide; Budesonide, Formoterol"	56841116	Approved	D0P2AG	.	CTPDG000222
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Lodoxamide	Lodoxamide ethyl; Lodoxamide trometamol; Lodoxamide tromethamine; U-42585; U-42585E; U-42718	44564	Approved	D0OG3K	DB06794	CTPDG000233
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Reslizumab	.	.	Approved	D0O8KX	.	CTPDG000236
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Repirinast	MY-1250; MY-5116; MY-6116	5050	Approved	D0O6KE	.	CTPDG000243
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Terbutaline	"Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol"	5403	Approved	D0M8RC	DB00871	CTPDG000270
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Ephedrine	"Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin"	9294	Approved	D0LG8E	DB01364	CTPDG000282
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	"Krypton, Kr-81m"	Mpi Krypton 81m Generator	66380	Approved	D0KL9X	DB09443	CTPDG000295
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Ciclesonide	"Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate"	6918155	Approved	D0K7HU	DB01410	CTPDG000304
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Salbutamol	"Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol"	2083	Approved	D0K5CB	DB01001	CTPDG000309
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Theobromine	"83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332"	5429	Approved	D0I0DS	DB01412	CTPDG000355
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Colforsin daropate hci	Adehl (TN); Adele (TN)	444028	Approved	D0H2MO	.	CTPDG000364
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Khellin	82-02-0; Visammin; Methafrone; Amicardine; Coronin; Medekellin; Ammivisnagen; Corafurone; Amikellin; Viscardan; Benecardin; Gynokhellan; Ammipuran; Kelourin; Rykellin; Interkhellin; Interkellin; Visammimix; Khellinorm; Khellanals; Khellamine; Kalangin; Deltoside; Ammispasmin; Visnagalin; Khelangin; Kelincor; Kelicorin; Norkel; Kelamin; Simeskellina; Khelloyd; Khelfren; Visnagen; Vasokellina; Kellosal; Mefurina; Lynamine; Khelisem; Kelicor; Chellin; Amiptan; Kellin; Ammivin; Keloid; Kellina; Eskel; Cardio-khellin; Ammi-khellin; Bi-Kellina	3828	Approved	D0G4KG	.	CTPDG000375
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	GW642444	"Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester"	21880659	Approved	D0FG6M	.	CTPDG000382
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Oxitropium bromide	Oxivent (TN)	6917865	Approved	D0D4IH	.	CTPDG000423
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Arformoterol	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate	3083544	Approved	D0D1DI	DB01274	CTPDG000428
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Ximelegatran	"Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide"	448042	Terminated	D0B5LF	DB08756	CTPDG000455
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	VR506	.	.	Approved	D09NTM	.	CTPDG000487
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Zileuton	"Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea"	60490	Approved	D09JUG	DB00744	CTPDG000493
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Enprofylline	"Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione"	1676	Approved	D09AMZ	DB00824	CTPDG000506
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Pranlukast	Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide	4887	Approved	D08QIP	DB01411	CTPDG000516
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Chymotrypsin	Alpha Chymar; Catarase; Zolyse	.	Approved	D08NAB	.	CTPDG000521
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Isoetharine	"Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol"	3762	Approved	D08HUC	DB00221	CTPDG000525
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Bambuterol	"Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)"	54766	Approved	D07XYV	DB01408	CTPDG000540
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Doxofylline	Ansimar (TN)	50942	Approved	D07NCN	DB09273	CTPDG000561
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Beclomethasone	"Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone"	20469	Approved	D07DVK	.	CTPDG000579
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	VR632	.	.	Approved	D07BXQ	.	CTPDG000584
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Bitolterol	Tornalate	35330	Approved	D06RUL	DB00901	CTPDG000593
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Cinalukast	"Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid"	6436135	Approved	D06PEB	DB00587	CTPDG000595
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Cromoglicate	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)	2882	Approved	D06NSS	DB01003	CTPDG000598
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Zafirlukast	"Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide"	5717	Approved	D05DVP	DB00549	CTPDG000646
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Brodalumab	AMG 827	.	Approved	D05CEO	.	CTPDG012293
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Fenoterol	"Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol"	3343	Approved	D04XEG	DB01288	CTPDG000655
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Methacholine Chloride	"Methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium"	6114	Approved	D04MWJ	.	CTPDG000664
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Formoterol	"Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate"	3410	Approved	D04KJO	DB00983	CTPDG000669
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Aminophylline	Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)	9433	Approved	D03TYI	DB01223	CTPDG000695
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Rimiterol	"Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI)"	36283	Approved	D03NOS	.	CTPDG000708
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Mepolizumab	"Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid"	.	Approved	D03MTN	.	CTPDG000710
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	CNTO-1959	Guselkumab	.	Phase 3	D03HSN	.	CTPDG000720
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Indacaterol	"312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone"	6918554	Approved	D03DJL	DB05039	CTPDG000726
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Levalbuterol	"Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol"	123600	Approved	D02ZJI	DB13139	CTPDG000733
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Metaproterenol Sulfate	"Metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol"	441333	Approved	D02UFG	.	CTPDG000737
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Ritlecitinib	"CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one"	118115473	Approved	D02TUL	DB14924	CTPDG011203
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Dyphylline	"Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline"	3182	Approved	D02PWM	DB00651	CTPDG000741
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Hydriodic acid iodine-125	Hydriodic acid; Iodine-125	24841	Approved	D02PJA	.	CTPDG000743
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Benralizumab	.	.	Approved	D02PIO	.	CTPDG000744
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Omalizumab	Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)	.	Approved	D02GEC	.	CTPDG000755
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Protokylol Hydrochloride	Ventaire	8699	Approved	D02FCQ	.	CTPDG000757
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Iodinated glycerol	"Organidin; Iodopropylidene glycerol; Glycerol, Iodinated; 5634-39-9; C6H11IO3; CCRIS 2378; 2-(1-IODOETHYL)-1,3-DIOXOLANE-4-METHANOL; HSDB 4185; Glycerol, iodinated [USAN:BAN]; NCI-C55469; EINECS 227-079-6; 1,3-Dioxolane-4-methanol, 2-(1-iodoethyl)-; 2-(1-Iodoethyl)-1,3-dioxolan-4-ylmethanol; [2-(1-iodoethyl)-1,3-dioxolan-4-yl]methanol; Iodinated Glycerol B; 1,3-Dioxolane-4-methanol, 2-(iodoethyl)-; Glycyrrhiza; (2-(1-Iodoethyl)-1,3-dioxolan-4-yl)methanol; iodoglycerin; Glycerol, Iondinated; SCHEMBL19693"	21852	Approved	D01JQJ	.	CTPDG000787
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	VR315	.	.	Approved	D01CHI	.	CTPDG000794
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Montelukast	Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid	5281040	Approved	D00QET	DB00471	CTPDG000808
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	NDA filed	RELVARTM or BREOTM ELLIPTATM	.	.	NDA filed	D09RJA	.	CTPDG000854
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	IND submitted	A378	.	.	IND submitted	DX8M3T	.	CTPDG000861
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Depemokimab	GSK3511294	.	Phase 3	DS9J7L	.	CTPDG000881
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	GSK3511294	depemokimab	.	Phase 3	DP8AS7	.	CTPDG000887
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Fevipiprant	"872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY"	23582412	Phase 3	DH7F9S	DB12011	CTPDG000905
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Astegolimab	MSTT1041A; RG6149	.	Phase 3	DBAL18	.	CTPDG000919
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SAR440340	Itepekimab	.	Phase 3	D8U1EX	.	CTPDG000926
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	D-5519	.	.	Phase 3	D0W8CW	.	CTPDG001008
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Setipiprant	ACT-129968	49843471	Phase 3	D0SP5V	DB12562	CTPDG001050
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	GMI-1070	"GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics"	44232546	Phase 3	D0N4EO	DB12778	CTPDG001114
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Pumactant	"Zofac; AP-0016; Pumactant, Britannia; Pumactant, airPharma; Pumactant, Britannia/airPharma"	.	Phase 3	D0L3VU	.	CTPDG001148
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	Phase 3	D0K8NR	.	CTPDG011047
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Vinanterol/fluticasone furoate	Relovair (TN)	.	Phase 3	D0E5VO	.	CTPDG001225
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	ISRAPAFANT	"Y-24180; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine"	119175	Phase 3	D0D4ZM	.	CTPDG001242
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Quinotolast	Aslock; Quinotalast; FK-021; FR-71021	65871	Phase 3	D09YDO	.	CTPDG001288
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	E004	.	68423	Phase 3	D08UVZ	.	CTPDG001318
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	ABT-761	Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea	3086671	Phase 3	D08PXR	DB12758	CTPDG001323
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Approved	Ciclesonide	.	6918155	Approved	D07YLV	DB01410	CTPDG001339
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	QAW-039	.	.	Phase 3	D06XDI	.	CTPDG001372
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	SOTB07	.	.	Phase 3	D06VFP	.	CTPDG001374
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	MDI-P	"CHEMBL595840; 60986-80-3; 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one; 3,6-Diphenyl-5-methylisoxazolo[4,5-c]pyridin-4(5H)-one; 3,6-DIPHENYL-5-METHYLISOXAZOLO(4,5-C)PYRIDIN-4(5H)-ONE; AC1Q3XQS; AC1Q3XQT; AC1N5X7T; MLS002153017; SCHEMBL3663640; GTPL6218; CTK5B2529; cid_4250909; DTXSID10401226; LCNDUGHNYMJGIW-UHFFFAOYSA-N; HMS2206G07; 5-methyl-3,6-diphenyl-isoxazolo[4,5-c]pyridine-4(5H)-one; ZINC394853; HMS3358C19; BDBM50305859; AKOS024323421; MCULE-8467817198; SMR001229079; FT-0714059"	3057996	Phase 3	D06ICW	DB06112	CTPDG001377
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	VR647	.	.	Phase 3	D01SPW	.	CTPDG001481
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 3	Fluticasone furoate/ fluticasone propionate	.	9854489	Phase 3	D01IWJ	DB08906	CTPDG001486
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Bavituximab	.	.	Phase 2	D00UAE	.	CTPDG001494
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2/3	Darbufelone	PD-136095	6444826	Phase 2/3	D0AL8T	.	CTPDG001553
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2/3	CEP1347	AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403	9917013	Phase 2/3	D03QLG	.	CTPDG001576
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2a	Aerovant	.	.	Phase 2a	D0BW3P	.	CTPDG001588
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD1402	Elarekibep	.	Phase 2	DZGI51	.	CTPDG001598
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CSJ117	Ecleralimab	.	Phase 2	DU6O4B	.	CTPDG001628
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD8154	"1H-Isoindol-1-one, 2-((1S)-1-cyclopropylethyl)-2,3-dihydro-5-(4-methyl-2-((6-(2-oxo-1-pyrrolidinyl)-2-pyridinyl)amino)-5-thiazolyl)-7-(methylsulfonyl)-; 2-[(1S)-1-cyclopropylethyl]-5-[4-methyl-2-[[6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-3H-isoindol-1-one; 2215022-45-8; AKOS040757410; Azd 8154; AZD 8154 [WHO-DD]; AZD8154; AZD-8154; AZD-8154 [WHO-DD]; BDBM50512861; CHEMBL4558527; CS-0371158; EX-A5133; Example 1 [WO2018055040A1]; GTPL11204; HY-115870; J5M3TCK9Y9; MS-30088; SCHEMBL22204109; UNII-J5M3TCK9Y9"	141754136	Phase 2	DQ62LM	.	CTPDG001649
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RG6341	.	.	Phase 1	DLI53W	.	CTPDG001683
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GB001	.	.	Phase 2	DKP0T7	.	CTPDG001692
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SelK2	.	.	Phase 2	DFTV08	.	CTPDG001722
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK3772847	.	.	Phase 2	DCSZ97	.	CTPDG001747
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AVTX-002	quisovalimab	.	Phase 2	DBU4N1	.	CTPDG001753
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RPT193	"(1R,3r)-3-((R)-3-(1-(5-Chloro-4-(((R)-1-(2,4-dichlorophenyl)ethyl)amino)-6-methylpyrimidin-2-yl)azetidin-3-yl)piperidin-1-yl)-1-methylcyclobutane-1-carboxylic acid; 2366152-15-8; 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methylpyrimidin-2-yl]azetidin-3-yl]piperidin-1-yl]-1-methylcyclobutane-1-carboxylic acid; CS-0610200; Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-; example 37 [WO2019147862A1]; GLXC-26793; GTPL12893; HY-148074; MS-30263; Q0M1LOC2MM; RPT193; RPT193; RPT-193; SCHEMBL21193871; SCHEMBL21207415; Zelnecirnon; Zelnecirnon; zelnecirnon [INN]"	139344142	Phase 2	D5SDZ0	.	CTPDG001801
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MTPS9579A	RG6173	.	Phase 2	D4NF0L	.	CTPDG001814
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TD-8236	.	.	Phase 2	D2KTG5	.	CTPDG001835
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AMG 853	"VIDUPIPRANT; 1169483-24-2; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238"	42641863	Phase 2	D0YB2Y	DB12272	CTPDG001874
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Iralukast	CGP-45715A	6913104	Phase 2	D0X9LK	.	CTPDG001892
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PL-3994	.	121488161	Phase 2	D0X8QO	.	CTPDG001894
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	QBX258	.	.	Phase 2	D0X8OW	.	CTPDG001895
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Revamilast	"GRC-4039; PDE 4 inhibitor (inflammation), Glenmark; Phosphodiesterase 4 inhibitor (inflammation), Glenmark; Revamilast (inflammation), Glenmark"	11546664	Phase 2	D0X0PW	DB11838	CTPDG001907
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-54903	.	.	Phase 2	D0W8DA	.	CTPDG001923
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-54903 + olodaterol	.	.	Phase 2	D0W0YI	.	CTPDG001938
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CROMOGLYCATE LISETIL HYDROCHLORIDE	Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556	196639	Phase 2	D0VZ9S	.	CTPDG001942
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ONO-6950	.	46830962	Phase 2	D0U5YM	.	CTPDG001989
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK679586	.	.	Phase 2	D0T3QR	.	CTPDG002023
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PIRODOMAST	"Sch-37224; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one"	54680204	Phase 2	D0S2UR	.	CTPDG002046
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AP-761	BI-671800	45270144	Phase 2	D0RL4X	DB12524	CTPDG002057
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	OX-914	.	.	Phase 2	D0RJ1W	.	CTPDG002058
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	HI-1640V	.	.	Phase 2	D0R6VH	.	CTPDG002067
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PNU-142731A	"9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride"	9846800	Phase 2	D0Q9IY	.	CTPDG002082
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Tipelukast	"Asthma therapy, MediciNova; KCA-757; MN-001"	9893228	Phase 2	D0Q7UG	DB12435	CTPDG002086
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BIO-1211	"BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-"	9961766	Phase 2	D0Q5LF	.	CTPDG002090
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LM-1507.NA	MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt	.	Phase 2	D0OG6N	.	CTPDG002130
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Altrakincept	.	.	Phase 2	D0O5KH	.	CTPDG002140
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BT-061	.	.	Phase 2	D0NQ0V	.	CTPDG002157
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Pascolizumab	"SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs"	.	Phase 2	D0NO1L	.	CTPDG002158
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RNS-60	.	.	Phase 2	D0N9AD	.	CTPDG002161
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MK-1029	.	.	Phase 2	D0N4ZX	.	CTPDG002172
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ABT-308	.	.	Phase 1	D0N3WN	.	CTPDG002176
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Montelukast/mometasone	MK-0476C	4248	Phase 2	D0M5HV	.	CTPDG002202
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	JNJ-39758979	.	24994634	Phase 2	D0M4UZ	.	CTPDG002206
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Oglemilast	"GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark"	11387409	Phase 2	D0L8KJ	DB12375	CTPDG002227
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD-3199	.	16035068	Phase 2	D0L6LD	.	CTPDG002233
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-4191834	PF-04191834	24986635	Phase 2	D0L5XG	DB11645	CTPDG002234
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TA-270	.	54710630	Phase 2	D0L4SL	.	CTPDG002237
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	E-6700	.	9843006	Phase 2	D0K9UK	.	CTPDG002256
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	IPL-512602	"BLX-LSAID; IPL-576 series; OX-LSAID; Lead LSAID (asthma), Biolipox; Lead LSAID (asthma), Orexo; Lead LSAID (asthma), Inflazyme/Aventis; Lead LSAID (asthma), Inflazyme/sanofi-aventis"	.	Phase 2	D0I8CK	.	CTPDG002303
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BAY-X-7195	"UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid"	6442328	Phase 2	D0GY0O	.	CTPDG002348
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anti-IL-5 Receptor mab	.	.	Phase 2	D0G9EI	.	CTPDG002360
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TC-6987	.	44511587	Phase 2	D0G4GA	DB14854	CTPDG002373
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEDI-528	.	.	Phase 2	D0FI5C	.	CTPDG002386
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	KB-003	"KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios"	.	Phase 2	D0F0ZK	.	CTPDG002407
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	JNJ-40929837	.	57910975	Phase 2	D0ER9I	.	CTPDG002408
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZD-5069	"CXCR2 inhibitor (COPD), Astrazeneca"	56645576	Phase 2	D0E6SX	.	CTPDG002422
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TJ-9	.	.	Phase 2	D0CR1I	.	CTPDG002469
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-BT	"Blomia tropicalis allergen immunotherapy (sublingual, asthma), National Biopreparations Center"	.	Phase 2	D0BS7T	.	CTPDG002498
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AIM-102	.	10126114	Phase 2	D0B7QU	.	CTPDG002506
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Rambazole	"Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole  pound&gt; SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510"	9799888	Phase 2	D0AA6Z	DB13083	CTPDG002532
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	WY-50295-tromethamine	WY-50295T; Wy-49232	10435196	Phase 2	D0A7JH	.	CTPDG002540
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	RV-568	.	45109868	Phase 2	D0A5HC	.	CTPDG002546
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	N6022	1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206	44623946	Phase 2	D09LPV	DB12206	CTPDG002576
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AZX-100	.	.	Phase 2	D09IGR	.	CTPDG002579
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CYT003	.	.	Phase 2	D09CEJ	.	CTPDG002583
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Ontazolast	"UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-"	71458	Phase 2	D08ZKJ	.	CTPDG002596
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ASM-024	.	117587641	Phase 2	D08NYZ	.	CTPDG002625
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PRO-98498	"HAE-1; Asthma therapy (subcutaneous), Genentech"	.	Phase 2	D07TYJ	.	CTPDG002669
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	KP-496	.	.	Phase 2	D07JKY	.	CTPDG002694
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK2269557	.	49784002	Phase 2	D06GUA	.	CTPDG002760
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	THR-18	.	86291591	Phase 2	D05ZDJ	.	CTPDG002773
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LEO 124249	"delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile"	50914062	Phase 2	D05UGH	.	CTPDG002785
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GW274150	"GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid"	9797017	Phase 2	D05QJT	DB12237	CTPDG002791
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Masilukast	D-3523; MCC-847; ZD-3523	204056	Phase 2	D05BHF	.	CTPDG002819
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	R411	.	61516	Phase 2	D04YJN	.	CTPDG002824
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Tepoxalin	"103475-41-8; Orf-20485; ORF 20485; Tepoxaline; Tepoxalina; Tepoxalinum [Latin]; Tepoxaline [French]; Tepoxalina [Spanish]; RWJ 20485; Tepoxalin [USAN:INN]; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; UNII-TZ4OX61974; C20H20ClN3O3; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-; CHEMBL316040; CHEBI:76277; TZ4OX61974; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; RWJ-20485; SIL-4R"	59757	Phase 2	D04WMR	DB11466	CTPDG002831
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	BI-144807	.	.	Phase 2	D04UME	.	CTPDG002837
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GSK2245035	GSK-2245035	44623937	Phase 2	D04PAU	.	CTPDG002850
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AMG 157	.	.	Phase 2	D04FWP	.	CTPDG002869
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anti-M1 prime	.	.	Phase 2	D04CWS	.	CTPDG002877
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ONO-AE1-437	"16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1"	9824353	Phase 2	D03YAS	.	CTPDG002886
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-DP	"Dermatophagoides pteronyssinus allergen immunotherapy (subcutaneous, asthma), National Biopreparations Center"	.	Phase 2	D03UBI	.	CTPDG002901
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	AHCQ	.	.	Phase 2	D03MZU	.	CTPDG002917
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Anrukinzumab	"Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer"	.	Phase 2	D03ING	.	CTPDG002926
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	WIN-901	.	.	Phase 2	D03GXU	.	CTPDG002930
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Noberastine	Flamizole; R-64947; R-72075	60531	Phase 2	D03DRR	.	CTPDG002934
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	TPI ASM8	.	.	Phase 2	D02RPP	.	CTPDG002958
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SB-265610	"SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, &gt; J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be"	9841667	Phase 2	D02JXG	.	CTPDG002974
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ZY-15106	MgNAAGA; NAAGAMg; Rhinaaxia; N-Acetylaspartyl-glutamic acid magnesium salt	71120	Phase 2	D02GTN	.	CTPDG002980
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	GPD-1116	.	9841417	Phase 2	D01XFZ	.	CTPDG003003
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	CTP-543	.	.	Phase 2	D01UAU	.	CTPDG003011
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEMP1972A	RG7449	.	Phase 2	D01LSB	.	CTPDG003028
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	LCB-2183	.	135418284	Phase 2	D01KNY	.	CTPDG003031
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Flezelastine	D-18024	60432	Phase 2	D00NVO	.	CTPDG003077
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	SR-2640	"SR 2640; SR 2640 Hydrochloride; 105350-26-3; CHEMBL18132; SR2640; Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]-; QMPB; Benzoic acid, 2-((3-(2-quinolinylmethoxy)phenyl)amino)-; SR-01000076219; Tocris-1804; Lopac-S-7690; AC1L2TN9; Lopac0_001079; 2-(3-(2-Quinolylmethoxy)phenylamino)benzoic acid; MLS002153402; cid_128355; GTPL3329; SCHEMBL9119607; CTK8F0698; CHEBI:104023; HMS3263G20; HMS2236C03; ZINC596951; HMS3373N15; Tox21_501079; BDBM50006798; AKOS030239522; LP01079; CCG-205156; NCGC00015965-02; NCGC00015965-04"	128355	Phase 2	D00MHP	.	CTPDG003079
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	PEGylated pitrakinra	"Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance"	.	Phase 2	D00KQN	.	CTPDG003083
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	Gallopamil	"16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; GSK 796406"	1234	Phase 2	D00ERV	DB12923	CTPDG003096
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	ETX-9101	.	.	Phase 2	D00EGN	.	CTPDG003098
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	MEDI9929	.	.	Phase 2	D00CTZ	.	CTPDG003103
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1/2	MRx-4DP0004	.	.	Phase 1/2	DR5GC8	.	CTPDG003149
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1/2	Sodium pyruvate	"113-24-6; Pyruvic acid sodium salt; sodium 2-oxopropanoate; Pyruvic acid, sodium salt; Propanoic acid, 2-oxo-, sodium salt; Sodium alpha-ketopropionate; 2-Oxopropanoic acid sodium salt; UNII-POD38AIF08; POD38AIF08; CHEBI:50144; Natriumpyruvat; alpha-Ketopropionic acid sodium salt; MFCD00002586; Propanoic acid, 2-oxo-, sodium salt (1:1); S-6005; Pyruvic acid, sodium salt, 99+%; Pyruvate Sodium; Natrum pyruvicum; CHEMBL181886; sodiumpyruvate; Guna-flam; Guna-hypertension; EINECS 204-024-4; pyruvic acid na-salt; N-115; Sodium pyruvate (inhaled); Reactive oxygen species antagonist (inhaled), EmphyCorp; Sodium pyruvate (inhaled), EmphyCorp"	23662274	Phase 1/2	D02ECG	.	CTPDG003609
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GDC-0214	"1831144-46-7; AKOS040759985; BDBM232517; CHEMBL3964801; EX-A6434; GDC0214; GDC-0214; GTPL12318; iJak-381; N-(3-(5-Chloro-2-(difluoromethoxy)phenyl)-1-(2-(4-((2-cyanoethyl)(methyl)amino)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide; RG6151; RG-6151; SCHEMBL17271636; US9346815, 63"	118522534	Phase 1	DZ2RH6	.	CTPDG003649
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD8630	.	.	Phase 1	DYC40H	.	CTPDG003657
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD4604	"(2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-; 2241039-81-4; AKOS040733485; AT39356; AZD4604; AZD-4604; BDBM488779; CHEMBL4447181; CS-0101485; EX-A5343; example 35 [WO2018134213A1]; GTPL11716; HY-126294; JAC34RRR7S; JAK1-IN-7; londamocitinib; MS-30607; SCHEMBL20399395; UNII-JAC34RRR7S; US10961228, Example 35"	135240395	Phase 1	DX72LV	.	CTPDG003666
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ADL 018	Omalizumab biosimilar	.	Phase 1	DV3E9U	.	CTPDG003696
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	KN-002	.	.	Phase 1	DI19BZ	.	CTPDG003887
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK2292767	"1254036-66-2; 4M4E8NZ73C; AC-32649; AKOS032945160; BCP24323; BDBM50521218; C24H28N6O5S; CCG-269791; CHEMBL4434674; compound 2 [PMID: 30532965]; compound 3 [PMID: 26301626]; CS-0003832; EX-A994; GSK2292767; GSK-2292767; GTPL10633; HY-15280; Methanesulfonamide, N-(5-(4-(5-(((2R,6S)-2,6-dimethyl-4-morpholinyl)methyl)-2-oxazolyl)-1H-indazol-6-yl)-2-methoxy-3-pyridinyl)-, rel-; Methanesulfonamide, N-[5-[4-[5-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]-, rel-; MFCD22572737; N-(5-(4-(5-(((2R,6S)-2,6-Dimethylmorpholino)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide; n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide; N-[5-[4-[5-[[(2S,6R)-2,6-Dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; N-{5-[4-(5-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-methoxypyridin-3-yl}methanesulfonamide; PI3Kdelta inhibitor GS2292767; Q27464135; rel-N-[5-[4-[5-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]methanesulfonamide; s7938; SCHEMBL173490; UNII-4M4E8NZ73C"	49783923	Phase 1	DDE6F1	.	CTPDG003945
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SAR443765	.	.	Phase 1	D9TW0X	.	CTPDG003987
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AMG 104	.	.	Phase 1	D94LRF	.	CTPDG004002
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ARO-RAGE	.	.	Phase 1	D8JN6C	.	CTPDG004015
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	UPB-101	.	.	Phase 1	D7EJI9	.	CTPDG004043
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BI 894416	.	.	Phase 1	D7CI9P	.	CTPDG004044
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD0449	.	.	Phase 1	D63WFO	.	CTPDG004072
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CSL311	.	.	Phase 1	D3Q0FU	.	CTPDG004130
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BI 443651	.	.	Phase 1	D3D9CL	.	CTPDG004141
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	ARO-MUC5AC	.	.	Phase 1	D17DXO	.	CTPDG004202
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RO-5271983	.	.	Phase 1	D0WP4E	.	CTPDG004299
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AM-211	"UNII-SZB129M7SZ; 1175526-27-8; SZB129M7SZ; CHEMBL2181753; AM211; [1,1'-Biphenyl]-3-acetic acid, 2'-[[ethyl[[(phenylmethyl)amino]carbonyl]amino]methyl]-6-methoxy-4'-(trifluoromethyl)-; SCHEMBL138450; DTXSID80151807; OPXIRFWNLBDKQB-UHFFFAOYSA-N; BDBM50397640; SB17010; HY-13213; CS-0003178; [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid"	44158492	Phase 1	D0U1HN	.	CTPDG004386
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SAR-21609	"TLR9 agonist (asthma/viral respiratory tract infection), sanofi-aventis"	.	Phase 1	D0R8RO	.	CTPDG004456
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SB-436811	"CHEMBL366221; 346729-66-6; Benzamide,3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-3-pyrrolidinyl]-; SCHEMBL6949936; GTPL2164; ZINC3964101; BDBM50240963; KB-74923; 3,4-Dichloro-N-{(S)-1-[4-(3-dimethylamino-propoxy)-benzyl]-pyrrolidin-3-yl}-benzamide; (S)-3,4-dichloro-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)benzamide; (S)-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)-3,4-dichlorobenzamide"	9846574	Phase 1	D0PQ8T	.	CTPDG004499
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	OPK-0018	.	.	Phase 1	D0O8SB	.	CTPDG004544
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	MEDI4212	.	.	Phase 1	D0O5CV	.	CTPDG004549
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	IMA-026	.	.	Phase 1	D0NY5Y	.	CTPDG004557
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AI-128	.	.	Phase 1	D0N6WX	.	CTPDG004578
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	PF-06444752	.	.	Phase 1	D0K2HU	.	CTPDG004663
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	Xmab-7195	"IgE inhibitor (asthma/allergy), Xencor"	.	Phase 1	D0JQ4S	.	CTPDG004669
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CNTO-3157	.	.	Phase 1	D0I9WR	.	CTPDG004714
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CVT-6883	"752222-83-6; GS-6201; UNII-67CKV7X08G; CHEMBL260933; 67CKV7X08G; CVT 6883; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione; Kinome_3621; SCHEMBL238694; GTPL5615; CVT6883; AOB4675; MolPort-035-765-814; CTV-6883; ZINC29055563; BDBM50236738; AKOS024458311; API0004749; 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione"	11270783	Phase 1	D0G4CF	DB05936	CTPDG004777
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	FP-025	.	.	Phase 1	D0F470	.	CTPDG004807
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	BM-212	"BM212; UNII-U9HSU4GZWL; 146204-42-4; U9HSU4GZWL; 1-{[1,5-Bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl}-4-methylpiperazine; 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine; BM 212; AC1L9VRH; CHEMBL321077; SCHEMBL1452627; BCP24821; ZINC22445591; AKOS032944899; CS-5953; Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-; HY-100725"	456926	Phase 1	D0D4VH	.	CTPDG004859
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CI-959	"UNII-1A8130P4IY; CI 959; CI 159; 104795-68-8; 1A8130P4IY; Benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-, monosodium salt; DSSTox_RID_82225; DSSTox_CID_27268; DSSTox_GSID_47268; DTXSID8047268; CHEMBL3183386; Tox21_300435; NCGC00254320-01; LS-41129"	13961743	Phase 1	D07TAS	.	CTPDG005084
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AMG 282	.	.	Phase 1	D07GDR	.	CTPDG005110
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	RX-10001	.	10473088	Phase 1	D05ECQ	DB13105	CTPDG005217
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	PF-06413367	.	.	Phase 1	D05BYJ	.	CTPDG005223
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK1440115	"UNII-GCT6G5G3C7; GCT6G5G3C7; GSK 1440115; SCHEMBL2957737; 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; (1,1'-Biphenyl)-4-carboxylic acid, 4'-((1R)-1-((2-(6,7-dichloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)acetyl)methylamino)-2-(4-morpholinyl)ethyl)-"	24760693	Phase 1	D04LWT	.	CTPDG005253
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	Laevo-Bambuterol	R-Bambuterol; R-bambuterol hydrochloride	.	Phase 1	D03INQ	.	CTPDG005313
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	INO-4885	"FP-15; INO-1080; Peroxynitrite decomposition catalyst, Inotek; WW-85; Reactive oxygen species inhibitor (contrast induced nephropathy), Inotek"	.	Phase 1	D02SME	.	CTPDG005343
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	AZD1419	.	.	Phase 1	D02AWQ	.	CTPDG005365
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	SDZ-MKS-492	MKS-492	163931	Phase 1	D02ADC	.	CTPDG005369
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 2	VALERGEN-DS	"Dermatophagoides siboney allergen immunotherapy (subcutaneous, asthma), National Biopreparations Center"	.	Phase 2	D01PCB	.	CTPDG005394
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	CNT0-3157	.	.	Phase 1	D01ILP	.	CTPDG005407
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GSK-2239633	.	46861584	Phase 1	D00XBC	.	CTPDG005433
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Phase 1	GRC-6211	"Oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid; GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly"	138393987	Phase 1	D00MAN	.	CTPDG005454
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Preregistration	Clinprost	"Arteon; Isocarbacyclin methyl ester; TEI-9090; TTC-909; Clinprost (liposomal), Taisho; Clinprost (liposomal), Teijin"	6436040	Discontinued in Preregistration	D0X8DU	.	CTPDG006319
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Fosfructose	"Cordox; Fosfructose trisodium; CPC-111; FDP, Questcor; Fructose-1,6-diphosphate; Fructose-1,6-diphosphate, Questcor"	.	Discontinued in Phase 3	D0Z5SR	.	CTPDG006327
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	DG031	"Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148"	123723	Discontinued in Phase 3	D0S6VB	.	CTPDG006337
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Broxaterol	Summair; Z-1170	71149	Discontinued in Phase 3	D0OR2S	.	CTPDG006343
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Lenercept	"Tenefuse; RsTNFR-IgG1; Ro-45-2081; TNF receptor-Ig, Roche; TNFR-IgG1 fusion protein, Roche"	.	Discontinued in Phase 3	D0H6CA	.	CTPDG006356
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	BN 50730	"Rocepafant; UNII-4KGX1STY2N; BN-50730; 4KGX1STY2N; 132579-32-9; BN50730; 132418-36-1; 6-(2-Chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 4H-Pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-; Rocepafant [INN]; LAU8080; LAU-8080; LAU 8080; AC1MHWNG; C27H25ClN6OS; SCHEMBL1065775; CHEMBL2105298; ZINC1481916; LS-172840"	3033963	Discontinued in Phase 3	D0G2RE	.	CTPDG006359
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Ablukast	Ablukast sodium; RO-23-3544	57109	Discontinued in Phase 3	D09DIG	.	CTPDG006372
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	FOROPAFANT	"SR-27417; 2-[N-[2-(Dimethylamino)ethyl]-N-(3-pyridylmethyl)amino]-4-(2,4,6-triisopropylphenyl)thiazole"	119368	Discontinued in Phase 3	D05YUK	.	CTPDG006380
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 3	Ataprost	ONO-41483; OP-41483	6436122	Discontinued in Phase 3	D00LWS	.	CTPDG006393
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Bamaquimast	"L-0042; N-Methylcarbamic acid 3-(2-oxo-1-propyl-1,2-dihydroquinoxalin-3-yl)propyl ester;3-[3-(Methylcarbamoyloxy)propyl]-1-propylquinoxalin-2(1H)-one"	184838	Discontinued in Phase 2	D0ZC7P	.	CTPDG006395
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK159802	.	.	Discontinued in Phase 2	D0YL3E	.	CTPDG006398
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	TIBENELAST	"LY-186655 (sodium salt); 5,6-Diethoxybenzothiophene-2-carboxylic acid"	59913	Discontinued in Phase 2	D0X1EX	.	CTPDG006409
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-613	.	9800584	Discontinued in Phase 2	D0W8QV	.	CTPDG006412
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Pumafentrine	Pumafentrin; BY-343; BYK-33043	3052763	Discontinued in Phase 2	D0V7IS	.	CTPDG006417
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Nolpitantium besilate	SR-140333; SR-140333B	3047794	Discontinued in Phase 2	D0UT3F	.	CTPDG006421
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	BUTIXOCORT	"JO-1717; 11beta,17-Dihydroxy-21-mercaptopregn-4-ene-3,20-dione 17-butyrate; 17-Butanoyloxy-11beta-hydroxy-21-mercaptopregn-4-ene-3,20-dione"	189904	Discontinued in Phase 2	D0UO2N	.	CTPDG006422
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	LY-223982	CGS-23131; LY-223980; LY-255253; SKF-107324	6444688	Discontinued in Phase 2	D0U9JL	.	CTPDG006425
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK256066	GSK-256066	9827968	Discontinued in Phase 2	D0U7PS	DB12137	CTPDG006427
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SC-45662	"CHEMBL84566; UNII-TPG7IO601I component ADVNUIUADIXWMI-QWHCGFSZSA-N; 2-[[(1S,2R)-2-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylpropyl]oxy]acetic acid"	5487420	Discontinued in Phase 2	D0U5EU	.	CTPDG006428
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	E-6123	"E 6123; 131614-02-3; BRN 4280434; E- 6123; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (S)-; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-; AC1MHYY4; CHEMBL114014; DTXSID20157146; API0009208; HY-10164; LS-134356"	3035214	Discontinued in Phase 2	D0R0EV	.	CTPDG006448
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	EPI-2010	.	.	Discontinued in Phase 2	D0QH0B	.	CTPDG006449
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SRP 299	.	.	Discontinued in Phase 2	D0Q1KN	.	CTPDG006454
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Valategrast	"220847-86-9; Valategrast (R411); UNII-06DM4KX7JG; 06DM4KX7JG; Valategrast [INN]; SCHEMBL480224; CHEMBL2107792; ZINC72190226; KB-81423; 2-(Diethylamino)ethyl N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzamido)-L-phenylalaninate"	11563636	Discontinued in Phase 2	D0PW0G	.	CTPDG006456
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	APC-366	"UNII-TGP1HP0WBC; TGP1HP0WBC; APC 366; 178925-65-0; apc366; N-(1-Hydroxy-2-naphthoyl)-L-arginyl-L-prolinamide hydrochloride; APC-366 hydrochloride; AC1L42OQ; SCHEMBL15659721; APC-366-C; APC-366-A; APC-366-R; L-Prolinamide, N2-((1-hydroxy-2-naphthalenyl)carbonyl)-L-arginyl-, monohydrochloride; (2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide hydrochloride"	177339	Discontinued in Phase 2	D0N9WB	.	CTPDG006467
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GW-766994	"CCR3 antagonists, GSK; CCR3 antagonists, GlaxoSmithKline; Chemokine receptor 3 antagonist, GlaxoSmithKline; GW-633647; GW-633647X; GW-701877; GW-701897; GW-701897X; GW-782415X; SB-297006; SB-328437"	10218765	Discontinued in Phase 2	D0N2FI	.	CTPDG006472
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	LTB 019	.	9959759	Discontinued in Phase 2	D0N0PU	.	CTPDG006473
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	WAY-123641	.	.	Discontinued in Phase 2	D0MF3C	.	CTPDG006477
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	MK-591	"Quiflapon; Quiflapon [INN]; L 686708; MK 0591; MK 591; L-686708; MK-0591; L-686,708; 3-(1-(4-chlorobenzyl-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl))-2,2-dimethyl propanoic acid; 3-(tert-Butylthio)-1-(p-chlorobenzyl)-alpha,alpha-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-(tert-butylthio)-1-(p-chlorobenzyl)-a,a-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid"	23672584	Discontinued in Phase 2	D0M0QX	.	CTPDG006483
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CI-949	"CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid"	159563	Discontinued in Phase 2	D0KV4Z	.	CTPDG006489
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Imitrodast	Logran; CS-518; RS-5186	65922	Discontinued in Phase 2	D0K4UW	.	CTPDG006491
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	MK-886	"118414-82-7; MK 886; MK886; 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid; UNII-080626SQ8C; QAOAOVKBIIKRNL-UHFFFAOYSA-N; L-663,536; CHEMBL29097; CHEBI:75390; L 663536; MK-886 (L-663,536); 080626SQ8C; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid; 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]; L-663536; SMR000466278"	3651377	Discontinued in Phase 2	D0K2ER	.	CTPDG006493
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Picumeterol	Levopicumeterol; Picumeterol fumarate; GX 63411; GR-114297; GR-114297A; GR-114297X; GR-63411	131251	Discontinued in Phase 2	D0GP4R	.	CTPDG006514
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Sulukast	LY-170680	6436123	Discontinued in Phase 2	D0G8UG	.	CTPDG006515
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AR-D-111421	.	.	Discontinued in Phase 2	D0F6JI	.	CTPDG006524
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	DS-4574	"DS 4574; 118314-35-5; 6-(2-Cyclohexylethyl)-(1,3,4)thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one; (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one, 6-(2-cyclohexylethyl)-; [1,3,4]Thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one,6-(2-cyclohexylethyl)-; AC1L4LXR; ACMC-20c9t1; AC1Q6E9S; SCHEMBL156066; CTK4B0638; DTXSID80152096; AKOS030534249; 6-(2-cyclohexylethyl)[1,3,4]thiadiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(2h)-one; LS-150402"	159491	Discontinued in Phase 2	D0F4IG	.	CTPDG006526
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Nafagrel	Nafagrel hydrochloride; DP-1904; SR-96325	65851	Discontinued in Phase 2	D0DT2P	.	CTPDG006537
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AS-35	"AS 35; 108427-72-1; 9-((4-Acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; C21H20N6O4; 4H-Pyrido[1,2-a]pyrimidin-4-one,9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)-; 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-; RVRGDCZGEKSIRW-UHFFFAOYSA-N; ACMC-20mbio; as35; AC1L2WU8; SCHEMBL159227; CTK4A6033; DTXSID90148546; CS-7624; LS-134160; HY-101946; L003846"	130135	Discontinued in Phase 2	D0B6EU	.	CTPDG006553
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	RPR-106541	.	9846880	Discontinued in Phase 2	D09UGP	.	CTPDG006565
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	AZD-3778	"CHEMBL2158814; SCHEMBL5418656; GTPL7679; AZD3778; QVLZVRFIGXNZMN-UHFFFAOYSA-N; AZD 3778; BDBM50394155; N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide"	11753159	Discontinued in Phase 2	D09RGW	.	CTPDG006568
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	V-11294A	"Rolipram derivatives, Napp"	135430158	Discontinued in Phase 2	D08SNX	.	CTPDG006575
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Corus 1030	Inhaled Lidocaine	.	Discontinued in Phase 2	D08FZT	.	CTPDG006584
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	R-343	"R-921303; Syk tyrosine kinase inhibitor (allergic asthma), Rigel/Pfizer"	10344820	Discontinued in Phase 2	D08DBE	.	CTPDG006585
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	ZD-2138	"Ici D2138; 140841-32-3; UNII-B6G6OX1ZH5; B6G6OX1ZH5; CHEMBL20403; 2(1H)-Quinolinone,6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-; Ici-D2138; 6-((3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinolin-2(1H)-one; ZD 2138; ACMC-20mzth; AC1L30RD; zd2138; 6-((3-Fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinol-2-one; SCHEMBL1083603; CTK4C2357; DTXSID90161477; BDBM50000829; AKOS025404954; ACN-048395"	132306	Discontinued in Phase 2	D07HBI	.	CTPDG006593
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK2190914	.	.	Discontinued in Phase 2	D07ATG	.	CTPDG006600
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	IVL745	"F387KG9Ith; UNII-F387KG9ITH; XRP 1745A; IVL 745; SCHEMBL6136116; DTXSID9043930; NOCAS_43930; IVL-745; 229627-58-1; beta-Alanine, N-((3-methoxy-4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)glycyl-N-((3,4-dimethoxyphenyl)methyl)-"	9830010	Discontinued in Phase 2	D06NOR	.	CTPDG006605
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Isbufylline	TE/06	65681	Discontinued in Phase 2	D05VAA	.	CTPDG006612
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK2190915	"1093403-33-8; sirtuin modulator; SRT 2104; SRT2104 (GSK2245840); SRT2104; SRT-2104; UNII-4521NR0J09; 4521NR0J09; 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-; C26H24N6O2S2; 4-Methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide; 4-methyl-n-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide"	44473151	Discontinued in Phase 2	D05MCS	DB06346	CTPDG006615
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	ACREOZAST	"TYB-2285; N,N'-(2-Chloro-5-cyano-1,3-phenylene)bis[2-(acetyloxy)acetamide]; 3,5-Bis(2-acetoxyacetamido)-4-chlorobenzonitrile"	129991	Discontinued in Phase 2	D04VJH	.	CTPDG006626
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-011	.	.	Discontinued in Phase 2	D04HHW	.	CTPDG006632
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	KW-4490	.	9883436	Discontinued in Phase 2	D03ZVD	.	CTPDG006635
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Tetrazolast meglumine	Tetrazolast; Tetrazolast meglumine salt monohydrate; MDL-26024; MDL-26024GO	9825038	Discontinued in Phase 2	D03PHU	.	CTPDG006643
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Mequitamium iodide	LG-30435	72028	Discontinued in Phase 2	D02YBP	.	CTPDG006648
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	Milveterol	UNII-LGY1VQ9622; LGY1VQ9622; 652990-07-3; Milveterol [INN]; SCHEMBL265694; CHEMBL1940832; DTXSID30215640; BMKINZUHKYLSKI-DQEYMECFSA-N; BDBM50419652	9892481	Discontinued in Phase 2	D02KMG	.	CTPDG006653
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	FK-224	FR-115224	6437864	Discontinued in Phase 2	D02FIJ	.	CTPDG006654
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CGRP	"Calcitonin gene related peptide; LAB CGRP; CGRP (inhaled, asthma); CGRP (inhaled, asthma), Akela Pharma; Calcitonin gene-related peptide (inhaled, asthma), LAB International"	44134599	Discontinued in Phase 2	D01SPI	.	CTPDG006660
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CJ-13610	"CJ 13610; CJ-13,610"	9821945	Discontinued in Phase 2	D01DAD	.	CTPDG006665
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	E-6080	"E 6080; 120164-49-0; E6080; AC1L2UXT; SCHEMBL3053845; DTXSID10152706; 6-Hydroxy-2-(4-sulfamoylbenzylamine)-4,5,7-trimethylbenzothiazole hcl; 6-hydroxy-2-(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride; Benzenesulfonamide, 4-(((6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino)methyl)-, monohydrochloride; 4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide hydrochloride"	129064	Discontinued in Phase 2	D00HFD	.	CTPDG006673
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	CI-1018	"UNII-Y4O6325SYW; Y4O6325SYW; CHEMBL111925; DSSTox_CID_27248; DSSTox_RID_82208; DSSTox_GSID_47248; SCHEMBL185627; CAS-NOCAS_47248; DTXSID0047248; NOCAS_47248; Tox21_300203; BDBM50217550; NCGC00254191-01; NCGC00247925-01; 179024-48-7; PD-168787; (+)-CI-1018; CI-1018, (+)-; UNII-05127JZ9KQ component KYFWUBJMTHVBIF-QFIPXVFZSA-N; 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; 4-Pyridinecarboxamide, N-((3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrol"	9865514	Discontinued in Phase 2	D00DBE	.	CTPDG006678
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 2	SK&F-S-106203	SK&F-106203; (S)-beta-[(2-Carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid; 3(S)-[2-(Carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propionic acid	3035514	Discontinued in Phase 2	D00AKY	.	CTPDG006681
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	AVE-5883	.	.	Discontinued in Phase 1/2	D0Y4GJ	.	CTPDG006683
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	NCX 950	.	.	Discontinued in Phase 1/2	D0X5ES	.	CTPDG006684
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1/2	Vepalimomab	"Vapantix; VAP-1 MAb (1), BioTie Therapies"	.	Discontinued in Phase 1/2	D01MQH	.	CTPDG006700
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RO7040547	BITS7201A; RG7990	.	Discontinued in Phase 1	DFU4B0	.	CTPDG006702
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	PF-3526299	.	.	Discontinued in Phase 1	D0Y2XQ	.	CTPDG006710
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	IPLl576092	"IPL 576,092"	.	Discontinued in Phase 1	D0X2YI	.	CTPDG006717
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SB-281832	.	.	Discontinued in Phase 1	D0W3AX	.	CTPDG006721
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SDZ-PCO-400	PCO-400	129348	Discontinued in Phase 1	D0U8IJ	.	CTPDG006732
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	F-11105	.	.	Discontinued in Phase 1	D0O2EB	.	CTPDG006763
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SMART anti-E/P selectin	"HuEP5C7; Bispecific anti-E/P selectin, PDL; SMART anti-E/P selectin, PDL; SMART anti-E/P selectin, Protein Design Labs; Anti-E/P selectin (humanized), PDL"	.	Discontinued in Phase 1	D0L3XV	.	CTPDG006785
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	NIP-520	NIP-502	.	Discontinued in Phase 1	D0J4WW	.	CTPDG006799
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	ABT-080	"VML-530; 4,4-Bis[4-(quinolin-2-ylmethoxy)phenyl]pentanoic acid sodium salt"	.	Discontinued in Phase 1	D0GB3A	.	CTPDG006811
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	YM-976	"4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one"	6604918	Discontinued in Phase 1	D0C7JT	.	CTPDG006826
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RG-7152	5-[3-[3-(2-Quinolinylmethoxy)phenoxy]propyl]-1H-tetrazole	129968	Discontinued in Phase 1	D0B7KF	.	CTPDG006831
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	HSR-6071	PTPC; 6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazine-2-carboxamide	159466	Discontinued in Phase 1	D09ZPX	.	CTPDG006840
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	AZD-1744	"Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca"	.	Discontinued in Phase 1	D09UXP	.	CTPDG006843
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	AMG 317	.	.	Discontinued in Phase 1	D09MKQ	.	CTPDG006848
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	PF-05212372	"PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth"	.	Discontinued in Phase 1	D08YFD	.	CTPDG006857
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	GR-63799X	"(-)-[1(R)-[1alpha(Z),2beta(R*),3alpha]-7-[3-Hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]-4-heptenoic acid 4-(benzoylamino)phenyl ester; (Z)-4,5-Didehydro-13-oxa-16-phenoxy-13,14-dihydro-17,18,19,20-tetranor-PGE1 4-(benzoylamino)phenyl ester; 119906-28-4"	6439068	Discontinued in Phase 1	D07RVP	.	CTPDG006865
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RWJ-56423	"CHEMBL256892; CHEMBL124571; (2S,4R)-1-ACETYL-N-[(1S)-4-[(AMINOIMINOMETHYL)AMINO]-1-(2-BENZOTHIAZOLYLCARBONYL)BUTYL]-4-HYDROXY-2-PYRROLIDINECARBOXAMIDE; (2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide; AC1NR9Y0; SCHEMBL4314345; GTPL9333; VXDAVYUFYPFGDX-SNPRPXQTSA-N; BDBM50228764; BDBM50131977; DB02812; (2S)-6; (4R)-1-acetyl-N-[(1S)-1-(1,3-benzothiazol-2-ylcarbonyl)-4-carbamimidamidobutyl]-4-hydroxy-L-prolinamide"	5287596	Discontinued in Phase 1	D05QMJ	DB02812	CTPDG006885
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	ABN-912	"Anti-CD46 mAb, Novartis; Anti-MCP1 monoclonal antibody, Novartis"	.	Discontinued in Phase 1	D04MYO	.	CTPDG006898
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	CGP-13774	.	.	Discontinued in Phase 1	D04FRB	.	CTPDG006901
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	NZ-107	4-Bromo-5-(3-ethoxy-4-methoxybenzylamino)pyridazin-3(2H)-one	129496	Discontinued in Phase 1	D02ANJ	.	CTPDG006917
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	TR-14531	IDDB25065	.	Discontinued in Phase 1	D01VSK	.	CTPDG006918
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	RG-7185	"CRTH2 antagonist (asthma), Roche"	.	Discontinued in Phase 1	D01NGT	.	CTPDG006923
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	BM-113	1-[2-(Benzhydryloxy)ethyl]piperidine-4-acetic acid ethyl ester	72941791	Discontinued in Phase 1	D01GIF	.	CTPDG006928
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	GW-250495	GR-250495; GR-250495X; GW-250495X	.	Discontinued in Phase 1	D01EDO	.	CTPDG006931
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Discontinued in Phase 1	SMP-028	.	11949660	Discontinued in Phase 1	D00WWU	.	CTPDG006935
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Preclinical	YM-355179	GTPL793; SCHEMBL3808393	11556309	Preclinical	D0Y6TI	.	CTPDG007022
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Preclinical	AZD-1678	"CCR4 antagonist (asthma), AstraZeneca"	23585443	Preclinical	D0E2QN	.	CTPDG007090
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Preclinical	LAS-101057	"LAS-38096; Adenosine A2b receptor antagonists (inflammation), Almirall"	11716665	Preclinical	D08ECB	.	CTPDG007114
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Preclinical	YM-344031	.	56603737	Preclinical	D04EIL	.	CTPDG007139
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Preclinical	IMO-2134	.	.	Preclinical	D02ZWR	.	CTPDG007146
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	FPL-55712	"40786-08-1; 7-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-carboxy late, sodium salt; CHEMBL267976; 7-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]- 4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid sodium salt; 4H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy)-4-oxo-8-propyl-, monosodium salt; fpl55712; SCHEMBL1890293; AOB5208; ZDEVPOBNLIVGFA-UHFFFAOYSA-M; MFCD00068619; LS-186693; FT-0639668; FPL-55712, &gt"	23662025	Terminated	D0ZE5V	.	CTPDG007164
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-255283	GTPL3351; MolPort-009-018-745; HMS3649C08; ZINC27644044; SR-01000946596; SR-01000946596-1	122023	Terminated	D0Y2IH	.	CTPDG007175
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	A-78773	"141579-67-1; A 78773; CHEMBL59598; N-Hydroxy-N-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea; N-(3-(5-(4-Fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxyurea; 1-{4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl}-1-hydroxyurea; 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea; Urea,N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propyn-1-yl]-N-hydroxy-; CCRIS 8531"	71460	Terminated	D0X9KE	.	CTPDG007180
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	SKF-96231	.	135529458	Terminated	D0W8OH	.	CTPDG007187
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	BAY-44-3428	APC-1167	.	Terminated	D0W7DD	.	CTPDG007188
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	KA-398	"Scopinast; Scopinast, Wilmar Schwabe"	.	Terminated	D0VZ8S	.	CTPDG007193
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Fenspiride hydrochloride	KSP-193	68626	Terminated	D0V8KI	.	CTPDG007196
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	SM 11044	"142784-65-4; SM-11044; DTXSID90162181; AC1L3144; 3-(3,4-Dihydroxyphenyl)-N-(3-(4-fluorophenyl)propyl)serine pyrrolidine amide hydrobromide; Pyrrolidine, 1-(3-(3,4-dihydroxyphenyl)-2-((3-(4-fluorophenyl)propyl)amino)-3-hydroxy-1-oxopropyl)-, monohydrobromide, (R-(R*,S*))-; (2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one hydrobromide"	132507	Terminated	D0V4FK	.	CTPDG007197
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	BI-L-357	BI-L-226	6440014	Terminated	D0U6AL	.	CTPDG007208
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	FR-113680	"FR 113680; 126088-92-4; Ac-Thr-trp(cho)-phe-N-mebzl; AC1L2Y4S; DTXSID70155076; fr113680; N(alpha)-(N(alpha)-(N(alpha)-Acetylthreonyl)-N(1)-formyltryptophyl)-N-methyl-N-(phenylmethyl)phenylalaninamide; L-Phenylalaninamide, N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-"	130848	Terminated	D0T6MU	.	CTPDG007220
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	MEN-11149	.	101940285	Terminated	D0T4IQ	.	CTPDG007221
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	KF-17625	"KF17625; KF 17625; BRN 4874703; CHEMBL95509; 139339-02-9; 5-Phenyl-1H-imidazo(4,5-c)(1,8)naphthyridin-4(5H)-one; 1,5-Dihydro-5-phenyl-4H-imidazo(4,5-c)(1,8)naphthyridin-4-one; 4H-Imidazo(4,5-c)(1,8)naphthyridin-4-one, 1,5-dihydro-5-phenyl-; AC1L2QF6; SCHEMBL2457079; DTXSID10161015; NDDBRRFHXNPOLY-UHFFFAOYSA-N; BDBM50230286; ZINC13731342; LS-80025; LS-80024; 5-phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4-one; 5-Phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-one; 5-Phenyl-3H-Imidazo[4,5-c][1,8]Naphthyridin-4(5H) -One"	126487	Terminated	D0SI4C	.	CTPDG007224
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Tomelukast	LY-171883	3969	Terminated	D0S8YL	.	CTPDG007226
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	MX2/120	"155006-67-0; BRN 7252641; 7-(2,2-Dimethylpropyl)-1-methylxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-7-(2,2-dimethylpropyl)-1-methyl-; 3,7-Dihydro-7-(2,2-dimethylpropyl)-1-methyl-1H-purine-2,6-dione; AC1MINF6; SCHEMBL3843737; 7-(2,2-dimethylpropyl)-1-methyl-3H-purine-2,6-dione; CTK4C8491; DTXSID90165793; 1-Methyl-7-(2,2-dimethylpropyl)xanthine; LS-126951"	3074068	Terminated	D0RM5W	.	CTPDG007234
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8308	.	.	Terminated	D0R7UK	.	CTPDG007235
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8328	.	.	Terminated	D0Q7WW	.	CTPDG007241
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	OT-4003	IDDB10966	.	Terminated	D0PL5F	.	CTPDG007247
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Org-9935	Org-935	131100	Terminated	D0PB6P	.	CTPDG007251
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	MOL-218	"MOL-254; MOL-268; MOL-294; NFkB inhibitors, Molecumetics"	.	Terminated	D0P1YO	.	CTPDG007253
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-210073	LY210073; 148291-65-0; CHEMBL49210; LY 210073; SCHEMBL9148299; AC1O515S; BDBM50045092; HY-U00263; AKOS030562935; CS-7479; L005236; 5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid; 7-Carboxy-3-[[(E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]-9-oxo-9H-xanthene-4-propanoic acid; (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid; 7-Carboxy-3-((6-(methoxyphenyl)-5(E)-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid	6450158	Terminated	D0OP7B	.	CTPDG007258
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	SC-53228	"SC 53228; CHEMBL419948; 153633-01-3; AC1L4BTY; SCHEMBL1447495; DTXSID40165384; BDBM50037390; 3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid; 3-{(S)-7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-, (S)-"	204058	Terminated	D0NK8D	.	CTPDG007270
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	BAY-17-1998	BAY-35-8535	.	Terminated	D0L7ZX	.	CTPDG007290
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	A-79175	CHEMBL90552; UNII-25B75ID70W; 25B75ID70W; AC1L43J2; ZINC5333; SCHEMBL6438420; BDBM50369068; 141579-87-5; 1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea	178577	Terminated	D0L1IH	.	CTPDG007295
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	FK-355	"NK1 antagonists, Fujisawa"	.	Terminated	D0KD4U	.	CTPDG007299
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	ICI-198615	"Cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate; Ici 198615; 104448-53-5; CHEMBL22033; Ici-198,615; ZM 198615; ZM-198,615; cyclopentyl N-[1-({4-[(benzenesulfonyl)carbamoyl]-2-methoxyphenyl}methyl)-1H-indazol-6-yl]carbamate; [3H]ICI198615; [3H]-ICI198615; [3H]ICI-198615; [3H]ICI-198,615; AC1L3GQZ; (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester; GTPL3414; GTPL3358; SCHEMBL9806720; DTXSID80146490; BDBM50009075; PDSP1_000520; PDSP2_000518; ICI198615"	115219	Terminated	D0J7UI	.	CTPDG007310
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	SDZ-ISQ-844	"143526-87-8; Sdz isq 844; SDZ ISQ-844; SCHEMBL7298437; AC1L317P; CTK4C3695; 3-Isoquinolinemethanol,1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (3S)-; AKOS030566039; 6,7-Dimethoxy-1-(3,4-dimethoxyphenyl)-3-hydroxymethyl-3,4-dihydroisoquinoline; (S)-1-(3,5-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (S)-"	132565	Terminated	D0J5UC	.	CTPDG007312
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	ON-579	"141286-14-8; ON 579; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid; Acetic acid,2-[4-[[2-[[(4-chlorophenyl)sulfonyl]amino]ethyl]thio]-2,6-difluorophenoxy]-; ACMC-20cvej; AC1Q6UCK; AC1L4U4O; {4-[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)sulfanyl]-2,6-difluorophenoxy}acetic acid; CHEMBL312763; SCHEMBL2925987; CTK4C2555; DTXSID70161657; AKOS030574939; 4-(2-(4-Chlorophenylsulfonylamino)-ethylthio)-2,6-difluorophenoxyacetic acid; KB-227077"	192308	Terminated	D0J5QW	.	CTPDG007313
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-648051	"4-Apsob; L 648051; UNII-0LGZ40MB45; 0LGZ40MB45; 91541-18-3; 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid; 4-(4-{[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl}phenyl)-4-oxobutanoic acid; Benzenebutanoic acid, 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxo-; AC1Q5VP2; AC1L3TT7; SCHEMBL157166; CHEMBL282253; CTK8D5118; DTXSID50238619; ZAKKEARLDPTRLX-UHFFFAOYSA-N; AKOS030530731; LS-186850; LS-187510"	122010	Terminated	D0J4EG	.	CTPDG007315
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZD-7944	"CHEMBL339767; ZD7944; SCHEMBL7501969; BDBM50409575; (R)-3-((S)-1-(3,4-dichlorophenyl)-3-(4-(2-((S)-methylsulfinyl)phenyl)piperidin-1-yl)propyl)-2-ethylisoindolin-1-one"	44351946	Terminated	D0J3QU	.	CTPDG007317
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	AZD-2098	.	10308720	Terminated	D0J1FL	.	CTPDG007321
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	BW B70C	"BWB70C; BW-B 70C; 134470-38-5; BW-B70C; CHEMBL86676; CHEBI:75307; (E)-N-(3-(3-(4-Fluorophenoxy)phenyl)-1-(R,S)-methylprop-2-enyl)-N-hydroxyurea; 70C; N-[3-[3-4(-Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea; N-(3-(3-(4-Fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxyurea; Urea, N-(3-(3-(4-fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxy-; C17H17FN2O3; SR-01000075717; (e)-N-{3-[3-(4-fluorophenoxy)phenyl]-1-(r,s)-methylprop-2-enyl}-N-hydroxyurea; Lopac0_000202; BSPBio_001512; SCHEMBL2681955"	5353454	Terminated	D0HJ1Y	.	CTPDG007334
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	CP-0597	.	9833644	Terminated	D0H5PD	.	CTPDG007336
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Selenotifen	BN-52256	.	Terminated	D0FQ4M	.	CTPDG007353
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	443C81	BW 443C; BW-443C81	101630908	Terminated	D0E8SE	.	CTPDG007363
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZT-386	.	.	Terminated	D0E8JL	.	CTPDG007364
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	EFIPLADIB	"381683-94-9; UNII-S97YUG2A91; S97YUG2A91; CHEMBL272342; PLA-902; Efipladib [USAN:INN]; Efipladib (USAN); 4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid; SCHEMBL1500831; HIZOPJQOPKRKFM-UHFFFAOYSA-N; ZINC85536943; BDBM50226792; D06674; 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid"	9853499	Terminated	D0E1WY	.	CTPDG007369
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZM-230487	"ZM 230487; 155944-23-3; CHEMBL459236; Ici 230487; ICI-230487; AC1L31ZC; 1-Ethyl-6-((3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-2-quinolone; SCHEMBL6008852; CTK4C8893; DTXSID70165998; zm230487; ZINC1484223; BDBM50250926; 1-Ethyl-6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-2(1H)-quinolinone; KB-276139; 1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one"	132998	Terminated	D0D8MD	.	CTPDG007376
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	LY-290154	.	.	Terminated	D0D0XX	.	CTPDG007379
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	BU-4601A	BU-4601B; BU-4601C	192421	Terminated	D0C9RZ	.	CTPDG007382
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	R zileuton	.	.	Terminated	D0C5HV	.	CTPDG007387
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	UR-8225	"UR 8225; 149455-36-7; 5,6-Dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-2-naphthalenecarbonitrile; 1,2-Dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile; 2-Naphthalenecarbonitrile, 5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; 2-Naphthalenecarbonitrile,5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; ACMC-20n5pl; AC1L560X; SCHEMBL6369766; CHEMBL303682; CTK4C6217; DTXSID60164273; LS-94452"	198778	Terminated	D0B7ND	.	CTPDG007392
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	AVE0675	.	.	Terminated	D0B6WN	.	CTPDG007393
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-670596	"121083-05-4; L-670,596; L 670596; 2-(6,8-Difluoro-9-(4-(methylsulfonyl)benzyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid; (-)-6-8-DIFLUORO-2,3,4,9-TETRAHYDRO-9-[[4-(METHYLSULFONYL)PHENYL]METHYL]-1H-CARBAZOLE-1-ACETIC ACID; AC1L2VGU; SCHEMBL3044967; CHEBI:91930; CTK8F0755; MolPort-003-983-606; HMS3268M18; BCP28232; BN0288; AKOS022180202; RT-013483; FT-0757831; SR-01000597550; L002392; C-35484; SR-01000597550-1; J-004444; BRD-A85472596-001-01-4"	129360	Terminated	D0AN1Y	.	CTPDG007399
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	MCI-826	"(E)-2,2-Diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid; (E)-2,2-Diethyl-N-[3-[2-(4-isopropylthiazol-2-yl)vinyl]phenyl]succinamic acid"	6439428	Terminated	D0AB7G	.	CTPDG007401
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	MDL-43291	"Mdl 43291; Mdl 43,291; AC1MI0EN; ((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; (4aalpha,7Z,8beta,8abeta)-((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; Acetic acid, ((octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)-, (4aalpha,7Z,8beta,8abeta)-; 2-[[(2Z,4aS,8S,8aS)-2-(2-oxotetradecan-7-ylidene)-3,4,4a,5,6,7,8,8a-octahydrochromen-8-yl]sulfanyl]acetic acid"	14430182	Terminated	D09ZVR	.	CTPDG007407
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	XR-12890	"MRP1 inhibitor, Xenova; Multidrug resisitance protein inhibitor, Xenova"	.	Terminated	D09XYU	.	CTPDG007410
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	CGS-13080	"PIRMAGREL; Pirmagrelum [Latin]; Pirmgrel; Pirmagrel [USAN:INN]; UNII-9J5H2VA91V; CGS 13080; 85691-74-3; CHEMBL48092; 9J5H2VA91V; Imidazo(1,5-a)pyridine-5-hexanoic acid; Pirmagrelum; Imidazo[1,5-a]pyridine-5-hexanoic acid; Pirmagrel (USAN/INN); AC1L1IZ7; SCHEMBL636018; DTXSID80234982; LIFOFTJHFFTNRV-UHFFFAOYSA-N; ZINC2021333; BDBM50025953; imidazol(1,5-a)pyridine-5-hexanoic acid; LS-177888; 6-imidazo[1,5-a]pyridin-5-ylhexanoic acid; 5-(5-carboxypentyl)imidazo[1,5-a]pyridine; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine"	55390	Terminated	D09QRO	.	CTPDG007414
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	RG-14893	"RG 14893; 141835-49-6; CHEMBL328712; 2-Naphthalenecarboxylicacid, 4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-; ACMC-20n0x5; AC1L30VP; SCHEMBL1894401; rg14893; CTK0H7370; DTXSID30161835; BDBM50001609; 4-(2-(Methyl(2-phenylethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; 4-(2-(Methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; L006851; 8-Benzyloxy-4-[(methyl-phenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid"	132379	Terminated	D09LQP	.	CTPDG007416
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Epocarbazolin-A	Epocarbazolin-B	192365	Terminated	D09JYF	.	CTPDG007419
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	NS-1619	"153587-01-0; NS 1619; 1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one; NS1619; CHEMBL384903; 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one; CHEBI:34879; 1-(2'-Hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone; 1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2h-benzimidazol-2-one; 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one"	4552	Terminated	D09BVL	.	CTPDG007425
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	U-78517F	Troloxamine; U-78517; U-78517G; U-78518F; U-83836E	107656	Terminated	D09BRE	.	CTPDG007426
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	GCC-AP0341	AP-0341	3074943	Terminated	D08MVK	.	CTPDG007438
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	RP-58802B	Imoxiterol; 88578-07-8; Imoxiterolum; Imoxiterol [INN]; Imoxiterolum [Latin]; AC1L23PZ; SCHEMBL249468; CHEMBL2104918; RP 58802B; CS-6651; 2-(3-(1-Benzimidazolyl)-1-methylpropylamino)-1-(4-hydroxy-3-methoxyphenyl)ethanol; RP-58802; HY-101585; L007875; alpha-(((3-(1-Benzimidazolyl)-1-methylpropyl)amino)methyl)vanillyl alcohol	65665	Terminated	D08HDD	.	CTPDG007442
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	WIN-64821	Q-20547A	158365	Terminated	D07PLK	.	CTPDG007454
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Sulotroban	BM-13177; SKF-95587	51550	Terminated	D07JSK	.	CTPDG007460
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Ro 20-1724	"4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 29925-17-5; 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one; ro-20-1724; Ro 201724; CHEMBL18701; 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-; RO-201724; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-, (+-)-; 4-(3-butoxy-4-methoxy-benzyl)imidazolidin-2-one; 34185-37-0; 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; SR-01000075647; keratan sulfate I; Keratan sulphate I; Naphthoquinone analogs"	5087	Terminated	D07FHZ	.	CTPDG007464
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	ZD-7717	ICI D7717	.	Terminated	D06YOD	.	CTPDG007468
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Isomazole	Isosulmazole; Isomazole fumarate; Isomazole hydrochloride; EMD-41064; EMD-47200; EMD-50250; EMD-52750; LY-175326	55690	Terminated	D05VLN	.	CTPDG007486
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	PLR-8	PLR-2224	.	Terminated	D05SXL	.	CTPDG007489
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	LF-801	.	.	Terminated	D05QTO	.	CTPDG007492
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	L-745337	"Thioflosulide; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337"	9799453	Terminated	D05EYG	.	CTPDG007499
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	CV 6209	"CHEMBL274420; CV6209; GTPL1852; AC1L32P4; SCHEMBL8538219; CHEMBL1180101; PDSP1_000728; PDSP1_000727; PDSP2_000718; PDSP2_000717; BDBM50005232; 2-(2-Acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacosan-1-yl)-1-ethylpyridinium; 2-{[Acetyl-(2-methoxy-3-octadecylcarbamoyloxy-propoxycarbonyl)-amino]-methyl}-1-ethyl-pyridinium; [2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate"	107756	Terminated	D05CEK	.	CTPDG007502
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	VZ-564	"VZ 564; 147495-99-6; 1-hydroxy-1-[(6-methoxy-3,4-dihydronaphthalen-2-yl)methyl]urea; Urea,N-[(3,4-dihydro-6-methoxy-2-naphthalenyl)methyl]-N-hydroxy-; VZ564; ACMC-20cs2n; AC1Q5JDP; AC1L4U8C; SCHEMBL9448945; CTK4C5429; N-Hydroxy-N-(6-methoxy-3,4-dihydro-2-naphthylmethyl)urea; DTXSID80163728; Urea, 1-hydroxy-1-(6-methoxy-3,4-dihydro-2-naphthylmethyl)-"	192375	Terminated	D04ZCL	.	CTPDG007504
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	MEN-10627	"MEN10627; 157351-81-0; AC1NSKCE; GTPL3901; cyc(2beta-5beta)(Met-Asp-Trp-Phe-Dap-Leu); (1R,4S,7S,10R,13R,16S)-13-(1H-indol-3-ylmethyl)-4-(2-methylpropyl)-7-(2-methylsulfanylethyl)-16-(phenylmethyl)-3,6,9,12,15,18,20-heptazabicyclo[8.8.4]docosane-2,5,8,11,14,17,21-heptone"	10327792	Terminated	D04RCG	.	CTPDG007510
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	RP-66153	"RP 66153; CHEMBL108415; 142422-79-5; AC1L30YM; SCHEMBL4355829; DTXSID80162034; 2,2-Dimethyl-7-(3-(3-phenylpropyl)-2-thienyl)heptanoic acid; BDBM50001162; 2-Thiopheneheptanoic acid, alpha,alpha-dimethyl-3-(3-phenylpropyl); 2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid; 2,2-Dimethyl-7-[3-(3-phenyl-propyl)-thiophen-2-yl]-heptanoic acid"	132425	Terminated	D04JJE	.	CTPDG007514
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	KC-11404	.	.	Terminated	D04APY	.	CTPDG007520
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	TAK-225	"2,2-Diethyl-3-(7-methyl[1,2,4]triazolo[1,5-b]pyridazin-6-yloxy)propanesulfonamide"	3073784	Terminated	D03WYV	.	CTPDG007522
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	NPC-17731	"Bradykinin antagonists, Scios; NPC-16731; NPC-17761; NPC-18521; NPC-18688; NPC-18884"	3081308	Terminated	D03WMY	.	CTPDG007523
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Midaglizole	"Midaglizole hydrochloride; DG 5218; DG-5128; Pyridine, 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]-, monohydrochloride"	68864	Terminated	D02XMM	.	CTPDG007542
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	BABIM	"Bis(5-amidino-2-benzimidazolyl)methane; 74733-75-8; CHEMBL99951; 1H-Benzimidazole-5-carboximidamide, 2,2'-methylenebis-; 1xug; 1c1v; AC1L1DKB; SCHEMBL65730; AC1Q1U90; CTK5E0415; BDBM16127; DTXSID60225717; AIDS007118; ZINC3871731; AKOS028112598; Bis(5-amidino-1H-benzimidazole-2-yl)methane; 1H-Benzimidazole-6-carboximidamide,2,2'-methylenebis-; 2,2 -methanediylbis(1H-benzimidazole-6-carboximidamide); 2-[(5-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-1H-benzimidazole-5-carboxamidine"	2387	Terminated	D02INZ	.	CTPDG007553
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	KF-15570	"KF 15570; BRN 4872911; 4H-Imidazo(4,5-c)quinolin-4-one, 1,5-dihydro-5-butyl-1-methyl-; 133305-92-7; 5-Butyl-1-methyl-1,5-dihydro-1H-imidazo(4,5-c)quinolin-4(5H)-one; AC1MIPZT; SCHEMBL9215327; CHEMBL434802; DTXSID80158053; CVLGNWUGFVTZRC-UHFFFAOYSA-N; ZINC1548061; LS-80514; 5-butyl-1-methylimidazo[4,5-c]quinolin-4-one; 5-butyl-1-methyl-1h-imidazo[4,5-c]quinolin-4(5h)-one; 5-n-Butyl-1-methyl-1H,5H-imidazo[4,5-c]quinolin-4-one"	3077017	Terminated	D01YGF	.	CTPDG007558
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	GW-3600	"Phosphodiesterase 4 inhibitor, Glaxo"	9842576	Terminated	D01QUF	.	CTPDG007564
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	KC-11425	.	.	Terminated	D01LXG	.	CTPDG007568
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	LM-1376	.	9891157	Terminated	D00YOW	.	CTPDG007578
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	Sch-45752	"Cephalochromin; MLS000876993; CHEMBL463175; NSC627953; NSC201419; 25908-26-3; SMR000440611; cefalochromin; 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one; Sch 45752; AC1Q6DTF; AC1L4N2K; SCHEMBL1111561; MEGxm0_000312; cid_160115; ACon0_000585; ACon1_000126; MolPort-001-739-590; HMS2270H11; BDBM50269745; NSC-201419; NSC-627953; MCULE-6609850631; NCGC00180856-01; SR-01000758207; SR-01000758207-2"	160115	Terminated	D00MEV	.	CTPDG007582
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Terminated	EP-012637	"Ciclosporin analogs, Enanta; Cyclosporin A analogs, Enanta; Cyclosporine analogs, Enanta; EP-1269; EP-314; EP-861; Immunosuppressant program, Enanta"	.	Terminated	D00JZX	.	CTPDG007585
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	IDR-1002	.	.	Investigative	DD3MB0	.	CTPDG007603
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	Vagonixen	.	.	Investigative	D0XS3T	.	CTPDG007692
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	RS-1748	.	46220480	Investigative	D0XH2N	.	CTPDG007700
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	BFPT-12603	BFPT-2603	.	Investigative	D0WW7U	.	CTPDG007738
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	LPCN-1056	LPCN-1052	.	Investigative	D0U8GH	.	CTPDG007821
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	AEOL-11207	"AEOL-11203; AEOL-11216; Catalytic antioxidants, Aeolus; Catalytic antioxidants, Incara"	42609706	Investigative	D0U4PG	.	CTPDG007830
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	GATA-3-specific DNAzyme	"GATA-3-specific DNAzyme (asthma); GATA-3-specific DNAzyme (asthma), Philipps-Universitat Marburg/sterna biologicals; Gd21 GATA-3-specific DNAzyme (asthma), Philipps-Universitat Marburg/sterna biologicals"	.	Investigative	D0R3NR	.	CTPDG007912
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	BW-858C	.	.	Investigative	D0R2MQ	.	CTPDG007919
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	PXS-4159	"Membrane copper amine oxidase modulators (asthma), Pharmaxis; SSAO/VAP-1 inhibitors (asthma), Pharmaxis"	.	Investigative	D0R0FU	.	CTPDG007923
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	IW-1221	"CRTH2 inhibitor (asthma), Ironwood"	.	Investigative	D0Q0GY	.	CTPDG007966
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	N-6060	"N-6338; N-6371; N-6446; N-6463; N-6501; N-6537; N-6603; S-nitrosoglutathione reductase inhibitors, N30"	.	Investigative	D0P5LX	.	CTPDG007981
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	SP-003	"SP-003, PhytoPharmacon; Euphorbia hirta-derived anti-inflammatory (oral, asthma), PhytoPharmacon"	.	Investigative	D0O8WM	.	CTPDG008002
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	NPT-CLN	"Calcineurin inhibitors (asthma), Biotica; NPT-CLN series (inhaled, asthma); NPT-CLN series (inhaled, asthma), Biotica"	.	Investigative	D0N9WY	.	CTPDG008029
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	Sulochrin	"519-57-3; UNII-8NA53C271Z; CHEBI:16159; 8NA53C271Z; Methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxybenzoate; Benzoic acid, 2-(2,6-dihydroxy-4-methylbenzoyl)-5-hydroxy-3-methoxy-, methyl ester; Sulochrin_120096; AC1Q5ZJI; AC1L4NQS; MLS000863634; SCHEMBL233392; CHEMBL61133; MEGxm0_000192; CTK1H2445; ACon0_000926; ACon1_000208; DTXSID80199860; MolPort-001-739-420; YJRLSCDUYLRBIZ-UHFFFAOYSA-N; HMS2268H19; ZINC895263; MFCD07370145; ACM519573; Sulochrin, &gt; AKOS030615357; MCULE-7066877679"	160505	Investigative	D0N5SW	.	CTPDG008042
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	LMS-611	"LMS-611 (inhalant), Lamellar Biomedical; LMS-611 (oral), Lamellar Biomedical"	.	Investigative	D0JS7E	.	CTPDG008155
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	AG-NCA805	.	.	Investigative	D0I7YR	.	CTPDG008198
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	ER-23006	.	.	Investigative	D0G6RK	.	CTPDG008265
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	Anti-TSLP mab	Anti-TSLP mAb (asthma)	.	Investigative	D0F7RU	.	CTPDG008297
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	APX-E	"AXP-A0; AXP-D; CCR3 antagonists (asthma); CCR3 antagonists (asthma), Axikin"	.	Investigative	D0D5XV	.	CTPDG008375
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	L-873724	"UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	Investigative	D0D0LD	.	CTPDG008390
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	MAR--99	BRN 5609020	127154	Investigative	D0C7LA	.	CTPDG008406
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	DW-403	.	.	Investigative	D0A5CZ	.	CTPDG008490
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	UR-60427	"Histamine H4 inverse agonist (asthma), Palau Pharma"	.	Investigative	D09HUF	.	CTPDG008555
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	HMPL-342	"HM-A42; I-kappa beta kinase inhibitor (asthma/COPD/autoimmune diseases), Hutchison Medipharma"	.	Investigative	D09DEU	.	CTPDG008564
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	OT-121	"OT-121 (inhaled dry powder, asthma); OT-121 (inhaled dry powder, asthma), Oriel Therapeutics; OT-121 (inhaled dry powder, asthma),Sandoz"	.	Investigative	D08QUC	.	CTPDG008599
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	VALERGENT-BT	"VALERGEN-BT (subcutaneous); Blomia tropicalis allergen immunotherapy (sc, asthma), National Biopreparations Center"	.	Investigative	D08AXM	.	CTPDG008640
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	AIM-101	"AIM-101 (Neutropel, asthma/COPD), AIM Therapeutics"	.	Investigative	D06DPQ	.	CTPDG008768
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	CH-3697	.	.	Investigative	D05YEL	.	CTPDG008780
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	MER-2101	"Epitope-driven vaccine + MAS-1 adjuvant (asthma), Mercia"	.	Investigative	D05RPT	.	CTPDG008806
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	BCP-1081	"Non-steroidal anti-inflammatory agent (asthma), BioCure Pharma; Non-steroidal anti-inflammatory agent (asthma), InflammoGen"	.	Investigative	D05AAQ	.	CTPDG008847
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	DS-AH-14	.	19801656	Investigative	D04ZSZ	.	CTPDG008851
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	ASOBAMAST	Asobamast < Rec INN; Z-1819; N-[4-(3-Methylisoxazol-5-yl)thiazol-2-yl]oxamic acid 2-ethoxyethyl ester	72033	Investigative	D04LBJ	.	CTPDG008885
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	FHT-CT4	"CTLA4-PTD fusion protein (inflammation), Forhumantech"	.	Investigative	D04ALI	.	CTPDG008915
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	HD-101	"Antibody (asthma/autoimmune disease), Dreampharma"	.	Investigative	D03MSN	.	CTPDG008959
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	Recombinant anti-IgE Fabs	"Recombinant anti-IgE Fabs (asthma/immunological diseases); Anti-immunoglobulin E antibodies (asthma/immunological disease), Glycobia; Recombinant anti-IgE Fabs (asthma/immunological diseases), Glycobia; Recombinant anti-immunoglobulin E antigen binding fragments (asthma/immunological diseases), Glycobia"	.	Investigative	D03JXN	.	CTPDG008965
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	VBP	"VBP series (muscular dystrophy/asthma); VBP series (muscular dystrophy/asthma), Validus Biopharma; Non-hormonal steroids (spinal muscular atrophy/amyotropic lateral sclerosis/Duchenne dystrophy/asthma), Validus Biopharma"	6604912	Investigative	D02SJN	.	CTPDG009009
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	GSK-172981	"GSK-256471; SB-218795; SB-235375; SB-244487; SB-400238; SB-414240; SK-797230; NK-2 antagonists, GSK; NK-3 antagonists, GlaxoSmithKline; NK-3 antagonists, SB"	25195091	Investigative	D02CCA	.	CTPDG009043
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	ATL-844	"N-(4-Cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; MRS 1754; 264622-58-4; MRS-1754; MRS1754; CHEMBL273807; N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide; [3H]MRS1754; [3H]-MRS1754; NCGC00015689-01; Lopac-M-6316; Lopac0_000729; GTPL453; GTPL449; MLS002153324; SCHEMBL1222380; AC1O7G54; CTK8E7916; CHEBI:93269; AOB5542; DTXSID80424967; MolPort-023-276-567; HMS3373J21; HMS3268F13; HMS2230A06; ZINC4475274; BDBM50086170; AKOS027427086; AKOS024457276; EX-3306; ATL-618; ATL-GW-22; ATL-GW-8; A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil; A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics; A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data"	6603931	Investigative	D01QYQ	.	CTPDG009078
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	TA-106	"FAb antibody fragment (inflammation), Taligen Therapeutics; Anti-factor B FAb (inflammation), Alexion"	.	Investigative	D01ODC	.	CTPDG009089
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	HL-028	.	.	Investigative	D01BJS	.	CTPDG009131
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	PRS-060	"IL-4 alpha receptor inhibitor (Anticalin, asthma), Pieris; IL-4R alpha inhibitor (Anticalin, asthma), Pieris"	.	Investigative	D01BEX	.	CTPDG009134
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	KI-0905	.	.	Investigative	D00UHK	.	CTPDG009153
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	RV-1088	.	.	Investigative	D00PGF	.	CTPDG009168
M6ACROT05760	.	.	M6ADIS0164	CA23: Asthma	Investigative	CWF-0710	.	.	Investigative	D00ONE	.	CTPDG009171
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	Pexiganan	"UNII-TVF29Q70Q1; TVF29Q70Q1; Pexiganan [INN]; 147664-63-9; SCHEMBL476400; CHEMBL1275802; Glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phenylalanylglycyl-L-lysyl-L-alanyl-L-phenylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysinamide; Magainin I, 7-L-lysine-8-L-lysine-10-L-lysine-18-L-lysine-19-de-L-glutamic acid-21-L-leucine-23-L-lysinamide; L-Lysinamide, glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lys"	16132253	Approved	D0Y9GM	.	CTPDG000047
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	CT-102	.	.	Approved	D0U5SC	.	CTPDG000119
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	Doxycycline	"Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline"	54671203	Phase 2	D0S0LZ	DB00254	CTPDG000161
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	Nemonoxacin	"378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid"	11993740	Phase 3	D0P0RX	DB06600	CTPDG000226
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	Alprostadil	"Prostaglandin E1; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil"	5280723	Approved	D0I4DQ	DB00770	CTPDG000348
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1	Daprodustat	"Daprodustat; 960539-70-2; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874"	91617630	Phase 1	D0F6JC	DB11682	CTPDG000386
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	Prezatide copper acetate	Iamin gel (TN)	3086626	Approved	D0C3LP	.	CTPDG000445
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	Apligraf	Graftskin	.	Approved	D07XCG	.	CTPDG000541
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	Donaperminogene seltoplasmid	VM202	.	Phase 3	D9CI7V	.	CTPDG000925
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	ALLO-ASC-DFU	.	.	Phase 3	D5JVD6	.	CTPDG000935
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	Granexin	.	.	Phase 3	D4MO2K	.	CTPDG000938
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	White blood cell therapy	.	.	Phase 3	D0Q9TB	.	CTPDG001077
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	ICX-PRO	"Cyzact; ProtoDerm; ICXP-007; Allogeneic human dermal fibroblasts (wound healing), Healthpoint; Allogeneic human dermal fibroblasts (wound healing), Intercytex"	.	Phase 3	D0O1UT	.	CTPDG001104
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	CureXcell	.	.	Phase 3	D0N1YG	.	CTPDG001117
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	INL-002	.	.	Phase 3	D0K4GW	.	CTPDG001167
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	Talactoferrin	Talactoferrin (topical)	.	Phase 3	D0IM6O	.	CTPDG001177
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	VM-202	.	.	Phase 3	D0D4OS	.	CTPDG001245
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	Ch14.18 mab	.	.	Phase 3	D07VKT	.	CTPDG001341
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	PDGF-BB	"PDGF-BB (BioChaperone technology, diabetic foot ulcer/venous ulcers/burns)"	.	Phase 3	D04BVN	.	CTPDG001429
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	DSC-127	"aclerastide; UNII-YYD6UT8T47; YYD6UT8T47; Aclerastide [INN]; Norleu3-a(1-7); Asp-arg-nle-tyr-ile-his-pro; DSC127; USB-001; 227803-63-6; 1-7-Angiotensin II, 3-L-norleucine-5-L-isoleucine"	9811551	Phase 3	D01TEA	DB12631	CTPDG001480
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 3	Granexin gel	alphaCT1	.	Phase 3	D01NWV	.	CTPDG001483
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	Dermacyn	.	.	Phase 2	D0VW0A	.	CTPDG001943
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	MBN-101	.	.	Phase 2	D0UC5G	.	CTPDG001976
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	ACT-1	.	.	Phase 2	D0Q4WG	.	CTPDG002091
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	CVBT-141B	.	.	Phase 2	D0Q3ER	.	CTPDG002096
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	IL22-Fc	.	.	Phase 2	D0Q1RN	.	CTPDG002098
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	HO/03/03	"PKC modulator (topical peptide, DU/VU/PU), HealOr"	.	Phase 2	D0O3XU	.	CTPDG002142
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	RG7880	.	.	Phase 2	D0G5BL	.	CTPDG002367
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	GAM-501	"Excellarate; Diabetic ulcer product, Selective Genetics; AdPDGF-B/GAM; Adenoviral gene therapy (PDGF-B), Selective Genetics; PDGF-B adenoviral gene therapy (collagen gel, diabetic foot ulcer), Tissue Repair Company"	.	Phase 2	D0A6WA	.	CTPDG002541
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	Nexagon	.	.	Phase 2	D09BIX	.	CTPDG002586
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	MRE-0094	SCHEMBL13010610; MRE 0094	9910098	Phase 2	D06MIQ	DB12443	CTPDG002745
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	CVBT-141B topical	.	.	Phase 2	D06HMO	.	CTPDG002757
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	PDA-002	.	.	Phase 2	D04PVE	.	CTPDG002848
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 2	DCB-WH1	"PAF4 + S1 (wound healing), Development Centre for Biotechnology; PAF4 + S1 (wound healing), Microbio"	.	Phase 2	D03VLG	.	CTPDG002894
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1/2	Galnobax	.	.	Phase 1/2	D0P5FA	.	CTPDG003354
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1/2	Nu-3	.	.	Phase 1/2	D0LP2P	.	CTPDG003383
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1/2	ATG002	.	.	Phase 1/2	D0E7MA	.	CTPDG003445
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1/2	Nu-3	"Topical Nubiotics (bacterial infection), Lakewood Amedex"	10279357	Phase 1/2	D03JDA	.	CTPDG003593
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1	ExpressGraft	.	.	Phase 1	D5H2SZ	.	CTPDG004092
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1	BRX-005	"Arimoclomol maleate; BRX-220; Bimoclomol derivatives, Biorex"	6421776	Phase 1	D09VWI	DB05444	CTPDG004965
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Phase 1	WPP-201	.	.	Phase 1	D07XEV	.	CTPDG005077
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Discontinued in Phase 2	Telbermin	Telbermin (USAN/INN)	.	Discontinued in Phase 2	D07HAD	.	CTPDG006594
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Discontinued in Phase 2	Rusalatide acetate	Chrysalin; TP508; Chrysalin (gel); TP-508; TP508 (gel); TRAP-508	44149697	Discontinued in Phase 2	D01FEC	.	CTPDG006664
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Terminated	PLR-15	.	.	Terminated	D0S2KX	.	CTPDG007227
M6ACROT05097	.	.	M6ADIS0340	BD54: Diabetic foot ulcers	Investigative	PDGF gene therapy	"UNII-54FF09J702; 54FF09J702; Ancriviroc besylate; SCH-351125 Besylate; 565428-86-6; (1,4'-Bipiperidine)-4-methanimine, alpha-(4-bromophenyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-N-ethoxy-4'-methyl-, (alphaZ)-, benzenesulfonate"	9875058	Investigative	D08NYO	.	CTPDG008605
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Teriparatide	Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN)	16133850	Discontinued in Phase 2	D0YA2L	.	CTPDG000044
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Ponesimod	"854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-"	11363176	Phase 2	D0Y4SI	DB12016	CTPDG000059
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Spesolimab	.	.	Approved	D0W9YW	.	CTPDG000079
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Deucravacitinib	.	134821691	Approved	D0S1XX	.	CTPDG013037
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Dithranol	"Anthralin; Micanol; Dithranol cream (Crystalip); Dithranol cream (Crystalip), Bioglan"	2202	Approved	D0QO7H	DB11157	CTPDG000197
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Ciclosporin	"Cyclosporine A; CSA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin"	24883466	Approved	D0O3YF	.	CTPDG000247
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Xp-828l	Dermylex (TN)	.	Approved	D0N1NE	.	CTPDG000265
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	Voclosporin	"Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Voclosporin [USAN]; R 1524; Trans-ISA 247; TrkA-IgG"	6918486	Phase 3	D0L9HX	DB11693	CTPDG000284
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Verteporfin	Visudyne (TN)	11980904	Approved	D0I3XG	.	CTPDG000349
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Mirikizumab	.	.	Approved	D0E7QB	.	CTPDG000404
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Tazarotene	"Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester"	5381	Approved	D0BM5G	DB00799	CTPDG000448
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	Ustekinumab	"6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN)"	.	Phase 3	D0A2UV	.	CTPDG000469
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Azaribine	"Triazure; Triacetyl-6-azauridine; Azaribinum; Azaribina; 2169-64-4; 6-Azaribine; TA-Azur; Azaribin; 2',3',5'-Tri-O-acetyl-6-azauridine; 6-Azauridine triacetate; 6-Azauridin-triacetat; 6-Azauridine 2',3',5'-triacetate; Azaribinum [INN-Latin]; 6-AzUR-TA; Azaribina [INN-Spanish]; 2',3',5'-Triacetyl-6-azauridine; CB-304; UNII-K1U80DO9EB; 6-Azauracilribosid-triacetat; K1U80DO9EB; Azaribine [USAN:INN:BAN]; MLS000069488; EINECS 218-515-6; Azauridine triacetate; 2-beta-D-Ribofuranosyl-as-triazine-3,5(2H,4H)-dione 2',3',5'-triace"	16574	Approved	D09SIK	.	CTPDG000482
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Ammoniated mercury	"White precipitate; Mercuric chloride, ammoniated; Mercury ammoniated; Ammoniated mercuric chloride; Mercury, ammoniated; Aminomercury chloride; Aminomercuric chloride; Hydrargyrum ammoniatum; Mercury amine chloride; MERCURIC AMMONIUM CHLORIDE; White mercuric precipitate; White mercury precipitated; Quecksilber(II)-amid-chlorid; Hydrargyrum precipitatum album; Hydrargyrum praecipitatum album; UNII-JD546Z56F0; Mercury(II) chloride ammonobasic; Mercury, ammonobasic (HgNH2Cl); HSDB 1175; JD546Z56F0; EINECS 233-3"	3032553	Approved	D08YPZ	DB13344	CTPDG000509
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Tacalcitol	Bonalfa (TN)	5283734	Approved	D08SVH	DB13689	CTPDG000512
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Methoxsalen	"Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one"	4114	Approved	D08SKH	DB00553	CTPDG000513
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Brodalumab	AMG 827	.	Approved	D05CEO	.	CTPDG012293
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Coal tar	.	.	Approved	D03YET	.	CTPDG000688
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Efalizumab	Raptiva; Raptiva (TN); Efalizumab (USAN/INN)	.	Approved	D03SGR	.	CTPDG000698
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Calcipotriol	"Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3"	5288783	Approved	D01QUS	DB02300	CTPDG000777
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 4	NPS-31807	"PP-05; TNF alpha modulator (inflammation), Piramal Life Sciences; TNF alpha modulator (inflammation), NPIL Research & Development"	.	Phase 4	D0S0ST	.	CTPDG000844
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 4	LEO 80185	Taclonex	9832804	Phase 4	D0FW2A	.	CTPDG000846
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	ARQ-151	.	.	Phase 3	DST04F	.	CTPDG000879
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	E-0116	.	.	Phase 3	D0V8GT	.	CTPDG001017
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	5-methoxypsoralen	5-MOP	2355	Phase 3	D0QR5G	DB12216	CTPDG001072
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	MK-3222	.	.	Phase 3	D0P1ME	.	CTPDG001095
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Serlopitant	"VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one"	23653789	Phase 2	D0CB2B	DB12973	CTPDG001254
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	M-518101	.	.	Phase 3	D0A8KX	.	CTPDG001276
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	Fumaric acid	"Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)"	444972	Phase 3	D03GOO	DB01677	CTPDG001446
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	JNJ-77242113	JNJ-2113	.	Phase 2	DY2GF8	.	CTPDG001610
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	PF-07038124	"(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4"	148293990	Phase 2	D81WBS	.	CTPDG001775
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	IR502	Zorcell	.	Phase 2	D0Z1CZ	.	CTPDG001869
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	VTP-43742	.	118282339	Phase 2	D0VB4X	.	CTPDG001952
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Bertilimumab	CAT-213; ICo-008	.	Phase 2	D0V9LY	.	CTPDG001953
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LEO 90100	.	.	Phase 2	D0V5VR	.	CTPDG001958
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	LEO-32731	LP0058	54765967	Phase 1	D0U9WS	.	CTPDG001977
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Ascrolimus	A-86281; ABT-281; ZK-248258	9919023	Phase 2	D0SL8J	.	CTPDG002032
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BMS-582949	"623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446"	10409068	Phase 2	D0Q0AP	DB12696	CTPDG002102
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BT-061	.	.	Phase 2	D0NQ0V	.	CTPDG002157
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	VB-201	.	45138527	Phase 2	D0N2IE	DB15259	CTPDG002178
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	MK-0873	"MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co"	9919680	Phase 2	D0M7CB	DB13029	CTPDG002195
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	PH-10	"Rose Bengal sodium salt; Bengal Rose B sodium salt; CI Acid red 94; NCGC00159508-02; disodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate; DSSTox_CID_2814; AC1L1NH9; AC1MC45U; DSSTox_RID_76740; DSSTox_GSID_22814; DTXSID4022814; CHEMBL2359093; CTK8G2989; Rose bengal, Dye content 95 %; UWBXIFCTIZXXLS-UHFFFAOYSA-L; Tox21_111727; MFCD00005043; GT2559; AKOS015902615; AKOS024319604; MCULE-2782240614; CAS-632-69-9; Tetrachlorotetraiodofluorescein disodium salt; ST50411638; F000"	32343	Phase 2	D0L1VF	.	CTPDG002240
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	ANB-019	.	.	Phase 2	D0G4JC	.	CTPDG002371
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	IP10 C8	IP10C8	.	Phase 2	D0E3HY	.	CTPDG002428
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BMS-986020	"GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl"	49792850	Phase 1	D0D6ZW	DB14948	CTPDG002447
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	CMI-392	"LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea"	6918268	Phase 2	D0D5ZV	.	CTPDG002449
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Santalum album	.	.	Phase 2	D0C8KP	.	CTPDG002480
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	CT 327	.	.	Phase 2	D0B7OY	.	CTPDG002507
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Rambazole	"Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole  pound&gt; SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510"	9799888	Phase 2	D0AA6Z	DB13083	CTPDG002532
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Siplizumab	Siplizumab (USAN/INN)	.	Discontinued in Phase 2	D0A7NB	.	CTPDG002539
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	IMO-3100	.	.	Phase 2	D08OXU	.	CTPDG002623
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LLL-3348	"Desoris; LL-3348; Herbal anti-inflammatory (psoriasis), Lupin"	.	Phase 2	D08HGR	.	CTPDG002638
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Elisidepsin	"Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar"	9855343	Phase 2	D08GIM	.	CTPDG002640
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Santalum	.	.	Phase 2	D06OVF	.	CTPDG002740
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Apo805K1	.	76318569	Phase 2	D06HQM	.	CTPDG002756
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BTT-1023	"SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie"	.	Phase 2	D06GUG	.	CTPDG002759
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BFH-772	NVP-BFH-772	24756034	Phase 2	D04OTY	.	CTPDG002851
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LL-4218	Desoside-P	.	Phase 2	D04MYS	.	CTPDG002855
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 3	BIM23A760	"Lonapalene; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene"	56237	Discontinued in Phase 3	D04FNQ	.	CTPDG002870
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	Phase 2	D03VPJ	.	CTPDG002893
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	DPS-102	"Non-steroidal anti-inflammatory (topical dermatological, scalp psoriasis), DermiPsor"	.	Phase 2	D02TYV	.	CTPDG002954
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LEO 22811	.	.	Phase 2	D01FZX	.	CTPDG003043
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	E6201	novel MEK inhibitors	10172827	Phase 2	D01CNB	DB11687	CTPDG003049
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Fezakinumab	"Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)"	.	Phase 2	D01AIN	.	CTPDG003052
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	NN-8226	"NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk"	.	Phase 2	D00LGA	.	CTPDG003081
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Lunacalcipol	"CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma"	10672195	Phase 2	D00DYK	.	CTPDG003099
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1b/2a	Dalazatide	Dalazatide [INN]; UNII-6U0259J807; 1081110-69-1; o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide; 6U0259J807	86278334	Phase 1b/2a	D0OK4O	.	CTPDG003112
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1b/2a	Debio-0824	"Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One"	.	Phase 1b/2a	D01XEO	.	CTPDG003113
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1/2a	COVA322	.	.	Phase 1/2a	D00BPH	.	CTPDG003114
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1/2	AS-210	"Psoraxine; AS-1001; AS-1002; AS-200; Psoriasis immunotherapy, Astralis/SkyePharma"	.	Phase 1/2	D0U8QC	.	CTPDG003303
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	JNJ-1459	.	.	Phase 1	DZ46KV	.	CTPDG003648
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	XCUR17	.	.	Phase 1	D0ZL5J	.	CTPDG004216
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	CM2489	.	.	Phase 1	D0W3JH	.	CTPDG004321
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	EDP1066	.	.	Phase 1	D0UD1J	.	CTPDG004365
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BAY1834845	.	.	Phase 1	D0QQ7I	.	CTPDG004470
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	LEO-27989	.	.	Phase 1	D0QJ2K	.	CTPDG004473
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	SNA-125	.	.	Phase 1	D0Q0IM	.	CTPDG004493
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	CC-90006	.	.	Phase 1	D0L5ZH	.	CTPDG004627
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	PRX003	.	.	Phase 1	D0L0DA	.	CTPDG004643
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	JNJ-3534	.	.	Phase 1	D0K9YJ	.	CTPDG004650
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BBI-6000	.	.	Phase 1	D0FY4J	.	CTPDG004785
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	PF-06263276	.	135567296	Phase 1	D0DK5X	.	CTPDG004847
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ALX-0761	.	.	Phase 1	D0B5UH	.	CTPDG004917
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ILV-095	"PF-05212368, WAY-264095"	.	Phase 1	D0A9GI	.	CTPDG004934
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ARN-6039	BOS172767	.	Phase 1	D0A0ZW	.	CTPDG004952
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	LY3316531	.	.	Phase 1	D08FIB	.	CTPDG005057
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	SAFINGOL	"Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol"	3058739	Phase 1	D07CAQ	DB11924	CTPDG005124
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BCT-194	.	.	Phase 1	D06CSK	.	CTPDG005173
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	SB414	.	.	Phase 1	D02UYM	.	CTPDG005335
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	AST-005	.	.	Phase 1	D02PTI	.	CTPDG005347
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Patented	VX-148	SCHEMBL12343182; BDBM248095; VX-148 (3)	56603796	Patented	D00RJA	.	CTPDG006297
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 3	IRX-4310	"AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310; RARa antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics; Retinoic acid receptor alpha antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics"	.	Discontinued in Phase 3	D0T0LE	.	CTPDG006336
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 3	Etarotene	Ro-15-1570; Ro-15-1570/000	6435463	Discontinued in Phase 3	D0FQ6O	.	CTPDG006360
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	VTP-201227	.	.	Discontinued in Phase 2	D0X6XF	.	CTPDG006405
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	IC-747	"LFA-1 antagonists, ICOS/Biogen"	.	Discontinued in Phase 2	D0W7GH	.	CTPDG006414
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	CRx-191	.	.	Discontinued in Phase 2	D0VA2I	.	CTPDG006416
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	LAS-37779	.	.	Discontinued in Phase 2	D0V2CN	.	CTPDG006420
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	TU-2100	.	4342838	Discontinued in Phase 2	D0P3TF	.	CTPDG006459
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	ASF-1075	.	.	Discontinued in Phase 2	D0KY4O	.	CTPDG006487
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	BMS-587101	BMS-688521	11635371	Discontinued in Phase 2	D0GT8W	.	CTPDG006512
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	R-68151	"1-Ethyl-3-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-5,5-dimethyl-2-thioxo-imidazolidin-4-one; 5-Lipoxygenase-In-1; R 68151; CHEMBL85599; 138331-04-1; AC1L30HG; SCHEMBL13696698; DTXSID10160583; BDBM50006793; HY-U00308; CS-7300; (1-Ethyl-3(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-dimethyl)-2-thioxo-4-imidazolidinone; 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one; M55551"	132150	Discontinued in Phase 2	D0G5GJ	.	CTPDG006517
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	T487	"AC1MVK5U; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methyl-ethanamine; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methylethanamine"	12896	Discontinued in Phase 2	D0E6DI	.	CTPDG006532
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	SDZ-LAP-977	SDZ-281-977	9818362	Discontinued in Phase 2	D0D5CJ	.	CTPDG006538
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	VML-262	"Marigold compound (topical, psoriasis), University of Strathclyde; VAN-10-4 (topical, psoriasis), University of Strathclyde/Vanguard Medica"	.	Discontinued in Phase 2	D0CC1Y	.	CTPDG006541
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	SB-201993	"UNII-4TWC061LPM; 4TWC061LPM; CHEMBL422598; SB 201993; AC1O5KJ7; SCHEMBL1893839; SCHEMBL1893835; sb201993; BDBM50037385; (E)-3-((((6-(2-Carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid; L009321; 3-[[6-[(E)-3-hydroxy-3-oxoprop-1-enyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid; 3-{6-((E)-2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid; Benzoic acid, 3-((((6-(2-carboxyethenyl)-5-((8-(4-m"	6435820	Discontinued in Phase 2	D0B6JV	.	CTPDG006552
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	PVAC	"DDMV, Corixa/ Genesis/ Zenyaku Kogyo; Delipidated, deglycolipidated Mycobacterium vaccae, Corixa/ Genesis/ Zenyaku Kogyo"	.	Discontinued in Phase 2	D0B1NA	.	CTPDG006556
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Tisocalcitate	"SH-597; ZK-156942; Calcitriol analog (topical formulation), Schering AG"	9913924	Discontinued in Phase 2	D07BDY	.	CTPDG006599
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	BAL-2299	"Cyclohexanediol, Basilea"	.	Discontinued in Phase 2	D07AIE	.	CTPDG006601
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Atocalcitol	KH-1650	6445225	Discontinued in Phase 2	D06SBK	.	CTPDG006602
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	FPL-64170	.	.	Discontinued in Phase 2	D04QVN	.	CTPDG006627
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	BIRT 2584	"QSNSVPRLHYSSQG-AMXDTQDGSA-N; UNII-24P4O1J71F; 24P4O1J71F; SCHEMBL4017930; BIRT-2584; (S)-2-[(R)-7-(3,5-Dichloro-phenyl)-5-methyl-6-oxo-5-(4-trifluoromethoxy-benzyl)-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide; 688756-00-5"	10348691	Discontinued in Phase 2	D01WQO	.	CTPDG006657
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	SB 235699	"4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-"	9797240	Discontinued in Phase 1	D0W0AM	.	CTPDG006724
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	ALS-00T2-0501	"TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences"	.	Discontinued in Phase 1	D05NUT	.	CTPDG006887
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	CCX-832	"ChemR2 receptor antagonist (inflammation), ChemoCentryx/GlaxoSmithKline"	.	Discontinued in Phase 1	D04HZX	.	CTPDG006899
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Application submitted	CLS008	.	.	Application submitted	D0A6SD	.	CTPDG006948
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	DYV024	.	.	Preclinical	DPW1K9	.	CTPDG006974
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	VCB102	.	.	Preclinical	DG07UD	.	CTPDG006986
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	RAP-160	.	.	Preclinical	D05VOP	.	CTPDG007130
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	ATL-1101	.	.	Preclinical	D01QKD	.	CTPDG007152
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	Hu Dreg 55	SMART Anti-L-Selectin	.	Terminated	D0Z0HS	.	CTPDG007166
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	DB-200	"DB-200 series (topical, psoriasis); CPT-1 inhibitor (topical, psoriasis), DARA; DB-200 series (topical, psoriasis), DARA BioSciences"	.	Terminated	D0SG0N	.	CTPDG007225
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	MOR-102	"MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys"	.	Terminated	D0M8JF	.	CTPDG007279
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	YP-008	"RPL-228; Cyclopentenone prostaglandin mimetic (PGM) (topical, psoriasis), York Pharma; Natural-defence-prostanoid mimetic (topical, psoriasis), York Pharma"	.	Terminated	D0L8TL	.	CTPDG007288
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	CRA-028129	.	.	Terminated	D0K0IW	.	CTPDG007306
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	SB-209247	"Ticolubant; LTB4 antagonist, SB"	6441619	Terminated	D0G7SP	.	CTPDG007346
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	AD-177	.	.	Terminated	D03JMN	.	CTPDG007531
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	R348	.	68254	Terminated	D01XEQ	.	CTPDG007559
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	FM-301	.	.	Investigative	D0U5SU	.	CTPDG007825
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	AZ-17	.	.	Investigative	D0K0CK	.	CTPDG008153
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	Hairpin RNA	"Hairpin RNA (psoriasis); Hairpin RNA (psoriasis), SomaGenics; ShRNA (psoriasis), SomaGenics"	.	Investigative	D0IY2B	.	CTPDG008182
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	KM-133	.	71605071	Investigative	D0IC6D	DB12187	CTPDG008188
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	PU-2049	N-[2-(5-Methoxyindol-3-yl)ethyl]-10-undecenamide; 5-Methoxy-N-(10-undecenoyl)tryptamine	.	Investigative	D0I8QF	.	CTPDG008194
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	ASB-16165	"PDE7 inhibitor (topical, psoriasis), Asubio"	25255436	Investigative	D0C3ET	.	CTPDG008417
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	Amphiregulin targeting human mabs	Amphiregulin targeting human mAbs (psoriasis)	.	Investigative	D0B1CJ	.	CTPDG008461
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	GSK-2263167	"S1P1 agonists (psoriasis), GlaxoSmithKline; Sphingosine 1 phosphate-1 agonists (psoriasis); Sphingosine 1 phosphate-1 agonists (psoriasis), GlaxoSmithKline"	.	Investigative	D08UDB	.	CTPDG008589
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	DPS-151	.	.	Investigative	D08UAT	.	CTPDG008590
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	LPD-1050	.	.	Investigative	D08EQQ	.	CTPDG008630
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	DM-512	.	.	Investigative	D06TAR	.	CTPDG008734
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	KIN-4050	"ERK inhibitor (topical, psoriasis), Kinentia; MAP kinase inhibitor (topical, psoriasis), Kinentia"	.	Investigative	D06MTH	.	CTPDG008749
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	BL-7020	"Recombinant IGFBP (intradermal, psoriasis), BioLineRx"	.	Investigative	D04FHY	.	CTPDG008900
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	X-083-NAB	"NATHMAB (psoriasis/Crohns disease/type 1 diabetes), XBiotech; Unspecified cytokine receptor antagonist (human monoclonal antibody, psoriasis/Crohns disease/type 1 diabetes), XBiotech"	.	Investigative	D04ASA	.	CTPDG008914
M6ACROT05123	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	LEO-90110	.	.	Investigative	D01ATS	.	CTPDG009135
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Teriparatide	Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN)	16133850	Discontinued in Phase 2	D0YA2L	.	CTPDG000044
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Ponesimod	"854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-"	11363176	Phase 2	D0Y4SI	DB12016	CTPDG000059
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Spesolimab	.	.	Approved	D0W9YW	.	CTPDG000079
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved (orphan drug)	Lestaurtinib	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)	126565	Approved (orphan drug)	D0V9WF	DB06469	CTPDG000098
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Belumosudil	.	11950170	Approved	D0U5UC	.	CTPDG012918
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Deucravacitinib	.	134821691	Approved	D0S1XX	.	CTPDG013037
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Dithranol	"Anthralin; Micanol; Dithranol cream (Crystalip); Dithranol cream (Crystalip), Bioglan"	2202	Approved	D0QO7H	DB11157	CTPDG000197
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Ciclosporin	"Cyclosporine A; CSA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin"	24883466	Approved	D0O3YF	.	CTPDG000247
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Xp-828l	Dermylex (TN)	.	Approved	D0N1NE	.	CTPDG000265
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	Voclosporin	"Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Voclosporin [USAN]; R 1524; Trans-ISA 247; TrkA-IgG"	6918486	Phase 3	D0L9HX	DB11693	CTPDG000284
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Verteporfin	Visudyne (TN)	11980904	Approved	D0I3XG	.	CTPDG000349
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Mirikizumab	.	.	Approved	D0E7QB	.	CTPDG000404
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Tazarotene	"Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester"	5381	Approved	D0BM5G	DB00799	CTPDG000448
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	Ustekinumab	"6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN)"	.	Phase 3	D0A2UV	.	CTPDG000469
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Azaribine	"Triazure; Triacetyl-6-azauridine; Azaribinum; Azaribina; 2169-64-4; 6-Azaribine; TA-Azur; Azaribin; 2',3',5'-Tri-O-acetyl-6-azauridine; 6-Azauridine triacetate; 6-Azauridin-triacetat; 6-Azauridine 2',3',5'-triacetate; Azaribinum [INN-Latin]; 6-AzUR-TA; Azaribina [INN-Spanish]; 2',3',5'-Triacetyl-6-azauridine; CB-304; UNII-K1U80DO9EB; 6-Azauracilribosid-triacetat; K1U80DO9EB; Azaribine [USAN:INN:BAN]; MLS000069488; EINECS 218-515-6; Azauridine triacetate; 2-beta-D-Ribofuranosyl-as-triazine-3,5(2H,4H)-dione 2',3',5'-triace"	16574	Approved	D09SIK	.	CTPDG000482
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Ammoniated mercury	"White precipitate; Mercuric chloride, ammoniated; Mercury ammoniated; Ammoniated mercuric chloride; Mercury, ammoniated; Aminomercury chloride; Aminomercuric chloride; Hydrargyrum ammoniatum; Mercury amine chloride; MERCURIC AMMONIUM CHLORIDE; White mercuric precipitate; White mercury precipitated; Quecksilber(II)-amid-chlorid; Hydrargyrum precipitatum album; Hydrargyrum praecipitatum album; UNII-JD546Z56F0; Mercury(II) chloride ammonobasic; Mercury, ammonobasic (HgNH2Cl); HSDB 1175; JD546Z56F0; EINECS 233-3"	3032553	Approved	D08YPZ	DB13344	CTPDG000509
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Tacalcitol	Bonalfa (TN)	5283734	Approved	D08SVH	DB13689	CTPDG000512
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Methoxsalen	"Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one"	4114	Approved	D08SKH	DB00553	CTPDG000513
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Valrubicin	"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester"	454216	Approved	D07IPB	DB00385	CTPDG000568
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Brodalumab	AMG 827	.	Approved	D05CEO	.	CTPDG012293
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Coal tar	.	.	Approved	D03YET	.	CTPDG000688
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Efalizumab	Raptiva; Raptiva (TN); Efalizumab (USAN/INN)	.	Approved	D03SGR	.	CTPDG000698
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Approved	Calcipotriol	"Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3"	5288783	Approved	D01QUS	DB02300	CTPDG000777
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 4	NPS-31807	"PP-05; TNF alpha modulator (inflammation), Piramal Life Sciences; TNF alpha modulator (inflammation), NPIL Research & Development"	.	Phase 4	D0S0ST	.	CTPDG000844
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 4	LEO 80185	Taclonex	9832804	Phase 4	D0FW2A	.	CTPDG000846
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	ARQ-151	.	.	Phase 3	DST04F	.	CTPDG000879
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	IB-MECA	152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide	123683	Phase 3	D0Y6ZK	DB05511	CTPDG000977
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	E-0116	.	.	Phase 3	D0V8GT	.	CTPDG001017
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	5-methoxypsoralen	5-MOP	2355	Phase 3	D0QR5G	DB12216	CTPDG001072
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	RAVAX	.	.	Phase 3	D0Q4GL	.	CTPDG001087
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	MK-3222	.	.	Phase 3	D0P1ME	.	CTPDG001095
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Serlopitant	"VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one"	23653789	Phase 2	D0CB2B	DB12973	CTPDG001254
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	M-518101	.	.	Phase 3	D0A8KX	.	CTPDG001276
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 3	Fumaric acid	"Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)"	444972	Phase 3	D03GOO	DB01677	CTPDG001446
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	JNJ-77242113	JNJ-2113	.	Phase 2	DY2GF8	.	CTPDG001610
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	PF-07038124	"(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4"	148293990	Phase 2	D81WBS	.	CTPDG001775
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	IR502	Zorcell	.	Phase 2	D0Z1CZ	.	CTPDG001869
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	VTP-43742	.	118282339	Phase 2	D0VB4X	.	CTPDG001952
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Bertilimumab	CAT-213; ICo-008	.	Phase 2	D0V9LY	.	CTPDG001953
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LEO 90100	.	.	Phase 2	D0V5VR	.	CTPDG001958
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	LEO-32731	LP0058	54765967	Phase 1	D0U9WS	.	CTPDG001977
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Ascrolimus	A-86281; ABT-281; ZK-248258	9919023	Phase 2	D0SL8J	.	CTPDG002032
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BMS-582949	"623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446"	10409068	Phase 2	D0Q0AP	DB12696	CTPDG002102
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BT-061	.	.	Phase 2	D0NQ0V	.	CTPDG002157
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	VB-201	.	45138527	Phase 2	D0N2IE	DB15259	CTPDG002178
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	MK-0873	"MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co"	9919680	Phase 2	D0M7CB	DB13029	CTPDG002195
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	GSK2982772	"LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr"	77108121	Phase 1	D0LQ3L	.	CTPDG002216
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	PH-10	"Rose Bengal sodium salt; Bengal Rose B sodium salt; CI Acid red 94; NCGC00159508-02; disodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate; DSSTox_CID_2814; AC1L1NH9; AC1MC45U; DSSTox_RID_76740; DSSTox_GSID_22814; DTXSID4022814; CHEMBL2359093; CTK8G2989; Rose bengal, Dye content 95 %; UWBXIFCTIZXXLS-UHFFFAOYSA-L; Tox21_111727; MFCD00005043; GT2559; AKOS015902615; AKOS024319604; MCULE-2782240614; CAS-632-69-9; Tetrachlorotetraiodofluorescein disodium salt; ST50411638; F000"	32343	Phase 2	D0L1VF	.	CTPDG002240
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	ANB-019	.	.	Phase 2	D0G4JC	.	CTPDG002371
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	IP10 C8	IP10C8	.	Phase 2	D0E3HY	.	CTPDG002428
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BMS-986020	"GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl"	49792850	Phase 1	D0D6ZW	DB14948	CTPDG002447
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	CMI-392	"LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea"	6918268	Phase 2	D0D5ZV	.	CTPDG002449
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Santalum album	.	.	Phase 2	D0C8KP	.	CTPDG002480
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	CT 327	.	.	Phase 2	D0B7OY	.	CTPDG002507
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Rambazole	"Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole  pound&gt; SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510"	9799888	Phase 2	D0AA6Z	DB13083	CTPDG002532
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Siplizumab	Siplizumab (USAN/INN)	.	Discontinued in Phase 2	D0A7NB	.	CTPDG002539
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	IMO-3100	.	.	Phase 2	D08OXU	.	CTPDG002623
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LLL-3348	"Desoris; LL-3348; Herbal anti-inflammatory (psoriasis), Lupin"	.	Phase 2	D08HGR	.	CTPDG002638
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Elisidepsin	"Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar"	9855343	Phase 2	D08GIM	.	CTPDG002640
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Santalum	.	.	Phase 2	D06OVF	.	CTPDG002740
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Apo805K1	.	76318569	Phase 2	D06HQM	.	CTPDG002756
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BTT-1023	"SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie"	.	Phase 2	D06GUG	.	CTPDG002759
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	BFH-772	NVP-BFH-772	24756034	Phase 2	D04OTY	.	CTPDG002851
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LL-4218	Desoside-P	.	Phase 2	D04MYS	.	CTPDG002855
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 3	BIM23A760	"Lonapalene; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene"	56237	Discontinued in Phase 3	D04FNQ	.	CTPDG002870
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	Phase 2	D03VPJ	.	CTPDG002893
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	DPS-102	"Non-steroidal anti-inflammatory (topical dermatological, scalp psoriasis), DermiPsor"	.	Phase 2	D02TYV	.	CTPDG002954
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	LEO 22811	.	.	Phase 2	D01FZX	.	CTPDG003043
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	E6201	novel MEK inhibitors	10172827	Phase 2	D01CNB	DB11687	CTPDG003049
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Fezakinumab	"Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)"	.	Phase 2	D01AIN	.	CTPDG003052
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	NN-8226	"NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk"	.	Phase 2	D00LGA	.	CTPDG003081
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 2	Lunacalcipol	"CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma"	10672195	Phase 2	D00DYK	.	CTPDG003099
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1b/2a	Dalazatide	Dalazatide [INN]; UNII-6U0259J807; 1081110-69-1; o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide; 6U0259J807	86278334	Phase 1b/2a	D0OK4O	.	CTPDG003112
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1b/2a	Debio-0824	"Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One"	.	Phase 1b/2a	D01XEO	.	CTPDG003113
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1/2a	COVA322	.	.	Phase 1/2a	D00BPH	.	CTPDG003114
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1/2	AS-210	"Psoraxine; AS-1001; AS-1002; AS-200; Psoriasis immunotherapy, Astralis/SkyePharma"	.	Phase 1/2	D0U8QC	.	CTPDG003303
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1/2	ART621	.	.	Phase 1/2	D08KCK	.	CTPDG003508
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	JNJ-1459	.	.	Phase 1	DZ46KV	.	CTPDG003648
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	XCUR17	.	.	Phase 1	D0ZL5J	.	CTPDG004216
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	CM2489	.	.	Phase 1	D0W3JH	.	CTPDG004321
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	EDP1066	.	.	Phase 1	D0UD1J	.	CTPDG004365
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BAY1834845	.	.	Phase 1	D0QQ7I	.	CTPDG004470
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	LEO-27989	.	.	Phase 1	D0QJ2K	.	CTPDG004473
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	SNA-125	.	.	Phase 1	D0Q0IM	.	CTPDG004493
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	CC-90006	.	.	Phase 1	D0L5ZH	.	CTPDG004627
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	PRX003	.	.	Phase 1	D0L0DA	.	CTPDG004643
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	JNJ-3534	.	.	Phase 1	D0K9YJ	.	CTPDG004650
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BBI-6000	.	.	Phase 1	D0FY4J	.	CTPDG004785
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	PF-06263276	.	135567296	Phase 1	D0DK5X	.	CTPDG004847
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ALX-0761	.	.	Phase 1	D0B5UH	.	CTPDG004917
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ILV-095	"PF-05212368, WAY-264095"	.	Phase 1	D0A9GI	.	CTPDG004934
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	ARN-6039	BOS172767	.	Phase 1	D0A0ZW	.	CTPDG004952
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	LY3316531	.	.	Phase 1	D08FIB	.	CTPDG005057
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	SAFINGOL	"Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol"	3058739	Phase 1	D07CAQ	DB11924	CTPDG005124
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	BCT-194	.	.	Phase 1	D06CSK	.	CTPDG005173
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	SB414	.	.	Phase 1	D02UYM	.	CTPDG005335
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Phase 1	AST-005	.	.	Phase 1	D02PTI	.	CTPDG005347
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Patented	Quinazoline derivative 12	PMID26936077-Compound-23	60163336	Patented	D0EC3H	.	CTPDG005951
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Patented	Quinazoline derivative 10	PMID26936077-Compound-21	6737869	Patented	D0CM5P	.	CTPDG006001
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Patented	Quinazoline derivative 11	PMID26936077-Compound-22	60163203	Patented	D08ZEM	.	CTPDG006069
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Patented	VX-148	SCHEMBL12343182; BDBM248095; VX-148 (3)	56603796	Patented	D00RJA	.	CTPDG006297
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 3	IRX-4310	"AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310; RARa antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics; Retinoic acid receptor alpha antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics"	.	Discontinued in Phase 3	D0T0LE	.	CTPDG006336
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 3	Etarotene	Ro-15-1570; Ro-15-1570/000	6435463	Discontinued in Phase 3	D0FQ6O	.	CTPDG006360
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	KC706	.	.	Discontinued in Phase 2	D0Y2HH	.	CTPDG006400
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	VTP-201227	.	.	Discontinued in Phase 2	D0X6XF	.	CTPDG006405
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	IC-747	"LFA-1 antagonists, ICOS/Biogen"	.	Discontinued in Phase 2	D0W7GH	.	CTPDG006414
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	CRx-191	.	.	Discontinued in Phase 2	D0VA2I	.	CTPDG006416
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	LAS-37779	.	.	Discontinued in Phase 2	D0V2CN	.	CTPDG006420
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	TU-2100	.	4342838	Discontinued in Phase 2	D0P3TF	.	CTPDG006459
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	ASF-1075	.	.	Discontinued in Phase 2	D0KY4O	.	CTPDG006487
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	BMS-587101	BMS-688521	11635371	Discontinued in Phase 2	D0GT8W	.	CTPDG006512
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	R-68151	"1-Ethyl-3-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-5,5-dimethyl-2-thioxo-imidazolidin-4-one; 5-Lipoxygenase-In-1; R 68151; CHEMBL85599; 138331-04-1; AC1L30HG; SCHEMBL13696698; DTXSID10160583; BDBM50006793; HY-U00308; CS-7300; (1-Ethyl-3(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-dimethyl)-2-thioxo-4-imidazolidinone; 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one; M55551"	132150	Discontinued in Phase 2	D0G5GJ	.	CTPDG006517
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	T487	"AC1MVK5U; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methyl-ethanamine; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methylethanamine"	12896	Discontinued in Phase 2	D0E6DI	.	CTPDG006532
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	SDZ-LAP-977	SDZ-281-977	9818362	Discontinued in Phase 2	D0D5CJ	.	CTPDG006538
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	VML-262	"Marigold compound (topical, psoriasis), University of Strathclyde; VAN-10-4 (topical, psoriasis), University of Strathclyde/Vanguard Medica"	.	Discontinued in Phase 2	D0CC1Y	.	CTPDG006541
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	SB-201993	"UNII-4TWC061LPM; 4TWC061LPM; CHEMBL422598; SB 201993; AC1O5KJ7; SCHEMBL1893839; SCHEMBL1893835; sb201993; BDBM50037385; (E)-3-((((6-(2-Carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid; L009321; 3-[[6-[(E)-3-hydroxy-3-oxoprop-1-enyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid; 3-{6-((E)-2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid; Benzoic acid, 3-((((6-(2-carboxyethenyl)-5-((8-(4-m"	6435820	Discontinued in Phase 2	D0B6JV	.	CTPDG006552
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	PVAC	"DDMV, Corixa/ Genesis/ Zenyaku Kogyo; Delipidated, deglycolipidated Mycobacterium vaccae, Corixa/ Genesis/ Zenyaku Kogyo"	.	Discontinued in Phase 2	D0B1NA	.	CTPDG006556
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Tisocalcitate	"SH-597; ZK-156942; Calcitriol analog (topical formulation), Schering AG"	9913924	Discontinued in Phase 2	D07BDY	.	CTPDG006599
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	BAL-2299	"Cyclohexanediol, Basilea"	.	Discontinued in Phase 2	D07AIE	.	CTPDG006601
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	Atocalcitol	KH-1650	6445225	Discontinued in Phase 2	D06SBK	.	CTPDG006602
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	FPL-64170	.	.	Discontinued in Phase 2	D04QVN	.	CTPDG006627
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 2	BIRT 2584	"QSNSVPRLHYSSQG-AMXDTQDGSA-N; UNII-24P4O1J71F; 24P4O1J71F; SCHEMBL4017930; BIRT-2584; (S)-2-[(R)-7-(3,5-Dichloro-phenyl)-5-methyl-6-oxo-5-(4-trifluoromethoxy-benzyl)-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide; 688756-00-5"	10348691	Discontinued in Phase 2	D01WQO	.	CTPDG006657
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	SB 235699	"4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-"	9797240	Discontinued in Phase 1	D0W0AM	.	CTPDG006724
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	ALS-00T2-0501	"TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences"	.	Discontinued in Phase 1	D05NUT	.	CTPDG006887
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Discontinued in Phase 1	CCX-832	"ChemR2 receptor antagonist (inflammation), ChemoCentryx/GlaxoSmithKline"	.	Discontinued in Phase 1	D04HZX	.	CTPDG006899
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Application submitted	CLS008	.	.	Application submitted	D0A6SD	.	CTPDG006948
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	DYV024	.	.	Preclinical	DPW1K9	.	CTPDG006974
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	VCB102	.	.	Preclinical	DG07UD	.	CTPDG006986
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	RAP-160	.	.	Preclinical	D05VOP	.	CTPDG007130
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Preclinical	ATL-1101	.	.	Preclinical	D01QKD	.	CTPDG007152
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	Hu Dreg 55	SMART Anti-L-Selectin	.	Terminated	D0Z0HS	.	CTPDG007166
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	DB-200	"DB-200 series (topical, psoriasis); CPT-1 inhibitor (topical, psoriasis), DARA; DB-200 series (topical, psoriasis), DARA BioSciences"	.	Terminated	D0SG0N	.	CTPDG007225
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	MOR-102	"MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys"	.	Terminated	D0M8JF	.	CTPDG007279
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	YP-008	"RPL-228; Cyclopentenone prostaglandin mimetic (PGM) (topical, psoriasis), York Pharma; Natural-defence-prostanoid mimetic (topical, psoriasis), York Pharma"	.	Terminated	D0L8TL	.	CTPDG007288
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	CRA-028129	.	.	Terminated	D0K0IW	.	CTPDG007306
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	SB-209247	"Ticolubant; LTB4 antagonist, SB"	6441619	Terminated	D0G7SP	.	CTPDG007346
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	AD-177	.	.	Terminated	D03JMN	.	CTPDG007531
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Terminated	R348	.	68254	Terminated	D01XEQ	.	CTPDG007559
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	FM-301	.	.	Investigative	D0U5SU	.	CTPDG007825
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	AZ-17	.	.	Investigative	D0K0CK	.	CTPDG008153
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	Hairpin RNA	"Hairpin RNA (psoriasis); Hairpin RNA (psoriasis), SomaGenics; ShRNA (psoriasis), SomaGenics"	.	Investigative	D0IY2B	.	CTPDG008182
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	KM-133	.	71605071	Investigative	D0IC6D	DB12187	CTPDG008188
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	PU-2049	N-[2-(5-Methoxyindol-3-yl)ethyl]-10-undecenamide; 5-Methoxy-N-(10-undecenoyl)tryptamine	.	Investigative	D0I8QF	.	CTPDG008194
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	ASB-16165	"PDE7 inhibitor (topical, psoriasis), Asubio"	25255436	Investigative	D0C3ET	.	CTPDG008417
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	Amphiregulin targeting human mabs	Amphiregulin targeting human mAbs (psoriasis)	.	Investigative	D0B1CJ	.	CTPDG008461
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	GSK-2263167	"S1P1 agonists (psoriasis), GlaxoSmithKline; Sphingosine 1 phosphate-1 agonists (psoriasis); Sphingosine 1 phosphate-1 agonists (psoriasis), GlaxoSmithKline"	.	Investigative	D08UDB	.	CTPDG008589
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	DPS-151	.	.	Investigative	D08UAT	.	CTPDG008590
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	LPD-1050	.	.	Investigative	D08EQQ	.	CTPDG008630
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	DM-512	.	.	Investigative	D06TAR	.	CTPDG008734
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	KIN-4050	"ERK inhibitor (topical, psoriasis), Kinentia; MAP kinase inhibitor (topical, psoriasis), Kinentia"	.	Investigative	D06MTH	.	CTPDG008749
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	Ankinara	.	.	Investigative	D05TZJ	.	CTPDG008795
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	BL-7020	"Recombinant IGFBP (intradermal, psoriasis), BioLineRx"	.	Investigative	D04FHY	.	CTPDG008900
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	X-083-NAB	"NATHMAB (psoriasis/Crohns disease/type 1 diabetes), XBiotech; Unspecified cytokine receptor antagonist (human monoclonal antibody, psoriasis/Crohns disease/type 1 diabetes), XBiotech"	.	Investigative	D04ASA	.	CTPDG008914
M6ACROT05560	.	.	M6ADIS0172	EA90: Psoriasis	Investigative	LEO-90110	.	.	Investigative	D01ATS	.	CTPDG009135
M6ACROT05180	.	.	M6ADIS0361	JA00: Abortion	Approved	Carboprost Tromethamine	"Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine"	5281074	Approved	D07PCI	.	CTPDG000555
M6ACROT05180	.	.	M6ADIS0361	JA00: Abortion	Approved	Dinoprost Tromethamine	"Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt"	5282415	Approved	D04RGA	DB01160	CTPDG000661
M6ACROT05180	.	.	M6ADIS0361	JA00: Abortion	Phase 2	GLPG0974	compound 99 [PMID 25380412]	57520598	Phase 2	D0TA4A	DB15406	CTPDG002006
M6ACROT05180	.	.	M6ADIS0361	JA00: Abortion	Investigative	Epostane	"Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-"	6917713	Investigative	D09SWM	.	CTPDG008521
M6ACROT05823	.	.	M6ADIS0361	JA00: Abortion	Approved	Carboprost Tromethamine	"Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine"	5281074	Approved	D07PCI	.	CTPDG000555
M6ACROT05823	.	.	M6ADIS0361	JA00: Abortion	Approved	Dinoprost Tromethamine	"Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt"	5282415	Approved	D04RGA	DB01160	CTPDG000661
M6ACROT05823	.	.	M6ADIS0361	JA00: Abortion	Phase 2	GLPG0974	compound 99 [PMID 25380412]	57520598	Phase 2	D0TA4A	DB15406	CTPDG002006
M6ACROT05823	.	.	M6ADIS0361	JA00: Abortion	Investigative	Epostane	"Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-"	6917713	Investigative	D09SWM	.	CTPDG008521
M6ACROT05830	.	.	M6ADIS0361	JA00: Abortion	Approved	Carboprost Tromethamine	"Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine"	5281074	Approved	D07PCI	.	CTPDG000555
M6ACROT05830	.	.	M6ADIS0361	JA00: Abortion	Approved	Dinoprost Tromethamine	"Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt"	5282415	Approved	D04RGA	DB01160	CTPDG000661
M6ACROT05830	.	.	M6ADIS0361	JA00: Abortion	Phase 2	GLPG0974	compound 99 [PMID 25380412]	57520598	Phase 2	D0TA4A	DB15406	CTPDG002006
M6ACROT05830	.	.	M6ADIS0361	JA00: Abortion	Investigative	Epostane	"Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-"	6917713	Investigative	D09SWM	.	CTPDG008521
M6ACROT05831	.	.	M6ADIS0361	JA00: Abortion	Approved	Carboprost Tromethamine	"Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine"	5281074	Approved	D07PCI	.	CTPDG000555
M6ACROT05831	.	.	M6ADIS0361	JA00: Abortion	Approved	Dinoprost Tromethamine	"Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt"	5282415	Approved	D04RGA	DB01160	CTPDG000661
M6ACROT05831	.	.	M6ADIS0361	JA00: Abortion	Phase 2	GLPG0974	compound 99 [PMID 25380412]	57520598	Phase 2	D0TA4A	DB15406	CTPDG002006
M6ACROT05831	.	.	M6ADIS0361	JA00: Abortion	Investigative	Epostane	"Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-"	6917713	Investigative	D09SWM	.	CTPDG008521
M6ACROT05951	.	.	M6ADIS0361	JA00: Abortion	Approved	Carboprost Tromethamine	"Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine"	5281074	Approved	D07PCI	.	CTPDG000555
M6ACROT05951	.	.	M6ADIS0361	JA00: Abortion	Approved	Dinoprost Tromethamine	"Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt"	5282415	Approved	D04RGA	DB01160	CTPDG000661
M6ACROT05951	.	.	M6ADIS0361	JA00: Abortion	Phase 2	GLPG0974	compound 99 [PMID 25380412]	57520598	Phase 2	D0TA4A	DB15406	CTPDG002006
M6ACROT05951	.	.	M6ADIS0361	JA00: Abortion	Investigative	Epostane	"Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-"	6917713	Investigative	D09SWM	.	CTPDG008521
M6ACROT05952	.	.	M6ADIS0361	JA00: Abortion	Approved	Carboprost Tromethamine	"Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine"	5281074	Approved	D07PCI	.	CTPDG000555
M6ACROT05952	.	.	M6ADIS0361	JA00: Abortion	Approved	Dinoprost Tromethamine	"Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt"	5282415	Approved	D04RGA	DB01160	CTPDG000661
M6ACROT05952	.	.	M6ADIS0361	JA00: Abortion	Phase 2	GLPG0974	compound 99 [PMID 25380412]	57520598	Phase 2	D0TA4A	DB15406	CTPDG002006
M6ACROT05952	.	.	M6ADIS0361	JA00: Abortion	Investigative	Epostane	"Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-"	6917713	Investigative	D09SWM	.	CTPDG008521
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Pimecrolimus	Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin	6509979	Approved	D0Z4UN	DB00337	CTPDG000032
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	cortisone	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone	222786	Approved	D0IX6I	DB14681	CTPDG000332
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Cromolyn sodium	"Altoderm; Cromolyn sodium (topical, atopic dermatitis); Cromolyn sodium (topical, atopic dermatitis), Manhattan Pharmaceuticals"	27503	Approved	D0G7IY	.	CTPDG000368
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	crisaborole	Crisaborole ointment 2%; PF-06930164	44591583	Approved	D08NWF	DB05219	CTPDG000520
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Abrocitinib	.	78323835	Approved	D05PCM	DB14973	CTPDG000627
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Desonide	"Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide"	5311066	Approved	D02JNM	DB01260	CTPDG000751
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Anapsos	"Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC"	.	Approved	D00OGX	.	CTPDG000810
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	ARQ-151	.	.	Phase 3	DST04F	.	CTPDG000879
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	IDP-124	.	.	Phase 3	D0XU3D	.	CTPDG000987
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	LY-686017	"NK1 antagonist (anxiety/alcoholism), Eli Lilly"	9916461	Phase 3	D0N8UY	DB12580	CTPDG001110
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Omiganan	"CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea"	16131445	Phase 2	D0JW7D	DB06610	CTPDG001169
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Nemolizumab	.	.	Phase 3	D0B2IR	.	CTPDG001271
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MABp1	.	.	Phase 2	D09AYM	.	CTPDG001317
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Dupixent	.	.	Phase 3	D05GZB	.	CTPDG001404
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Rocatinlimab	AMG 451 / KHK4083	.	Phase 3	D03AKW	.	CTPDG001449
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SAR 444727	"(2E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; (alphaE,3R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (alphaE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; 1581714-49-9; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; AKOS040756908; atuzabrutinib; Atuzabrutinib [INN]; ATUZABRUTINIB [USAN]; BDBM197260; BDBM50589191; CHEMBL4114766; compound 11 [PMID: 35302767]; CS-0204055; GTPL11666; HY-132808; PRN473; PRN-473; SAR444727; SAR-444727; SCHEMBL15515897; SCHEMBL15516108; UNII-YZ68ZB8LWA; US9090621, 125A; YZ68ZB8LWA"	73438222	Phase 2	DS6V8H	.	CTPDG001636
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	UCB1381	.	.	Phase 2	DN9K2Y	.	CTPDG001666
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q301	"Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid"	7010608	Phase 2	DES36M	.	CTPDG001729
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DMT210	.	.	Phase 2	DB5YU0	.	CTPDG001755
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-07038124	"(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4"	148293990	Phase 2	D81WBS	.	CTPDG001775
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	Phase 2	D6N5UC	.	CTPDG001788
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Zabedosertib	"1931994-81-8; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; AKOS040755617; BAY 1834845; BAY1834845; BAY-1834845; BDBM395297; CS-0198831; D96922; EX-A5143; GTPL11415; HY-139374; MFCD32900903; MS-28697; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide; N1GRK350ZM; OQAMEEFUUFJZRS-UHFFFAOYSA-N; SB74225; SCHEMBL17785221; SY323200; UNII-N1GRK350ZM; US10308634, Example 12; Zabedosertib; Zabedosertib [INN]"	121364961	Phase 2	D5XVM6	.	CTPDG001798
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	E6005	"Lotamilast; 947620-48-6; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7"	24864553	Phase 2	D0TT4H	DB12776	CTPDG002000
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	K-201	"DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519"	9868902	Phase 2	D0MT1Q	.	CTPDG002182
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	JNJ-26113100	"Dermatitis agent (oral), Alza"	.	Phase 2	D0K9KN	.	CTPDG002259
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SRD-441	"Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics"	.	Phase 2	D0J6ZA	.	CTPDG002284
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	S-777469	.	57331749	Phase 2	D0J6KZ	.	CTPDG002285
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PMX-53	"YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam"	6918468	Phase 2	D0G2XE	.	CTPDG002376
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	NCX 1022	.	.	Phase 2	D0E8YH	.	CTPDG002412
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ALX-101	"Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy"	89792952	Phase 2	D0CT5O	.	CTPDG002466
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	.	.	Phase 2	D0CG0K	.	CTPDG002475
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	Phase 2	D0BI3N	DB15499	CTPDG002499
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ASB17061	.	.	Phase 2	D0B1OH	.	CTPDG002518
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q-301	.	.	Phase 2	D09QMX	.	CTPDG002567
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PAC-14028	.	56649347	Phase 2	D09BDE	DB12428	CTPDG002588
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MM36	CHEMBL225555	57855696	Phase 2	D09ALR	DB14987	CTPDG002593
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BRT-FC-83C	"Dermatological agent (topical, atopic dermatitis), Biomed Research & Technologies"	.	Phase 2	D08YJN	.	CTPDG002597
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ADX-914	.	.	Phase 2	D08GVP	.	CTPDG002639
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	HL-009	"Adenosylcobamide; Adenosylcobalamin (vitamin B12) (nanoliposome, allergy), HanAll"	.	Phase 2	D07PFG	.	CTPDG002679
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DPK-060	"DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen"	.	Phase 2	D06XMW	.	CTPDG002716
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Santalum	.	.	Phase 2	D06OVF	.	CTPDG002740
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TS-022	"Prostaglandin derivative (topical, dermatitis), Taisho"	16049813	Phase 2	D06GNF	.	CTPDG002761
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BMX-010	"UNII-BN93L2NT5I; BN93L2NT5I; Manganese(III)meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride; Manganese(4+), chloro((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-ethylpyridiniumato))(2-))-, tetrachloride, (sp-5-12)-; 219818-60-7"	10033875	Phase 2	D06FER	.	CTPDG002765
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ANB-020	etokimab	.	Phase 2	D05TSG	.	CTPDG002787
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PRO22	.	.	Phase 2	D05MJS	.	CTPDG002797
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LEO-29102	.	66829720	Phase 2	D04XVJ	.	CTPDG002826
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LAS-41004	"Anti-inflammatory (psoriasis/atopic dermatitis), Almirall"	.	Phase 2	D04TJL	.	CTPDG002840
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cis-urocanic acid	"ProtoCure; ProtoCure (emulsion, atopic dermatitis), Biocis Pharma; Anti-inflammatory (topical emulsion, dermatological disease), BioCis; ProtoCure (emulsion, atopic dermatitis/psoriasis), Biocis Pharma; ProtoCure (emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-urocanic acid (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma"	1549103	Phase 2	D04CQV	.	CTPDG002878
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	Phase 2	D03VPJ	.	CTPDG002893
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GBR 830	.	.	Phase 2	D03DUI	.	CTPDG002933
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TA-7906	"T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl"	.	Phase 2	D02POH	.	CTPDG002963
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	VTB-38543	.	.	Phase 2	D01XMC	.	CTPDG003002
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN-2898	"PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor"	24806574	Phase 2	D00JED	.	CTPDG003084
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	KP-413	.	.	Phase 1/2	D0I3HI	.	CTPDG003417
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	REGN-846	RENG-846; SAR-302352; SAR-302532	.	Phase 1/2	D06DBJ	.	CTPDG003543
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	ZPL521	.	.	Phase 1/2	D02XBN	.	CTPDG003602
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07295324	.	.	Phase 1	DXVA93	.	CTPDG003662
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07242813	.	.	Phase 1	DUJ16L	.	CTPDG003701
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07275315	.	.	Phase 1	DIWU14	.	CTPDG003874
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	STMC-103H	.	.	Phase 1	D89XBL	.	CTPDG004020
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	UCB9741	.	.	Phase 1	D62JOV	.	CTPDG004076
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07264660	.	.	Phase 1	D1LP4B	.	CTPDG004189
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-06817024	.	.	Phase 1	D0W6YR	.	CTPDG004316
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	EDP1066	.	.	Phase 1	D0UD1J	.	CTPDG004365
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SNA-125	.	.	Phase 1	D0Q0IM	.	CTPDG004493
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SAR444656	.	.	Phase 1	D0CW9M	.	CTPDG004875
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	KPL-716	.	.	Phase 1	D09KEW	.	CTPDG004996
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SB414	.	.	Phase 1	D02UYM	.	CTPDG005335
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Piperazine derivative 5	PMID26936077-Compound-16	53244427	Patented	D0LT5Y	.	CTPDG005790
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 3	P-1	Zemaphyte; Zemaphyte (P1)	200882	Discontinued in Phase 3	D03HVN	.	CTPDG006385
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	GW842470X	.	.	Discontinued in Phase 2	D0F3BY	.	CTPDG006527
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	Dermolastin	.	188403	Discontinued in Phase 2	D0B9EH	.	CTPDG006551
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 1	CD-581	"1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol"	.	Discontinued in Phase 1	D0F5NB	.	CTPDG006816
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RESP-6000	.	.	Investigative	D0ZE3S	.	CTPDG007619
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	J-555Y	.	.	Investigative	D0U3TE	.	CTPDG007833
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-01113	.	.	Investigative	D0S4PZ	.	CTPDG007891
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	PBI-1308	"PBI-1308 (dermatological, dermatological diseases); PBI-1308 (dermatological, dermatological diseases), Darier/ProMetic"	.	Investigative	D0RB2H	.	CTPDG007900
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DPS-201	.	.	Investigative	D0GV0H	.	CTPDG008254
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RTU-1096	.	.	Investigative	D0F8KR	.	CTPDG008294
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	KF-66490	"K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin"	281833	Investigative	D0E5VP	.	CTPDG008343
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	MLR-1130	"Non-steroidal antiinflammatory (topical, atopic dermatitis), Melior"	.	Investigative	D0DA3D	.	CTPDG008362
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	AP-1189	"AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma"	.	Investigative	D09QPE	.	CTPDG008527
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DM-107	"MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis"	.	Investigative	D03OMK	.	CTPDG008954
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-05141	.	.	Investigative	D03DOW	.	CTPDG008980
M6ACROT05275	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	C-0333158	.	.	Investigative	D02YRX	.	CTPDG008993
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Pimecrolimus	Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin	6509979	Approved	D0Z4UN	DB00337	CTPDG000032
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	cortisone	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone	222786	Approved	D0IX6I	DB14681	CTPDG000332
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Cromolyn sodium	"Altoderm; Cromolyn sodium (topical, atopic dermatitis); Cromolyn sodium (topical, atopic dermatitis), Manhattan Pharmaceuticals"	27503	Approved	D0G7IY	.	CTPDG000368
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	crisaborole	Crisaborole ointment 2%; PF-06930164	44591583	Approved	D08NWF	DB05219	CTPDG000520
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Abrocitinib	.	78323835	Approved	D05PCM	DB14973	CTPDG000627
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Desonide	"Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide"	5311066	Approved	D02JNM	DB01260	CTPDG000751
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Anapsos	"Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC"	.	Approved	D00OGX	.	CTPDG000810
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	ARQ-151	.	.	Phase 3	DST04F	.	CTPDG000879
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	IDP-124	.	.	Phase 3	D0XU3D	.	CTPDG000987
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	LY-686017	"NK1 antagonist (anxiety/alcoholism), Eli Lilly"	9916461	Phase 3	D0N8UY	DB12580	CTPDG001110
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Omiganan	"CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea"	16131445	Phase 2	D0JW7D	DB06610	CTPDG001169
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Nemolizumab	.	.	Phase 3	D0B2IR	.	CTPDG001271
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MABp1	.	.	Phase 2	D09AYM	.	CTPDG001317
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Dupixent	.	.	Phase 3	D05GZB	.	CTPDG001404
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Rocatinlimab	AMG 451 / KHK4083	.	Phase 3	D03AKW	.	CTPDG001449
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SAR 444727	"(2E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; (alphaE,3R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (alphaE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; 1581714-49-9; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; AKOS040756908; atuzabrutinib; Atuzabrutinib [INN]; ATUZABRUTINIB [USAN]; BDBM197260; BDBM50589191; CHEMBL4114766; compound 11 [PMID: 35302767]; CS-0204055; GTPL11666; HY-132808; PRN473; PRN-473; SAR444727; SAR-444727; SCHEMBL15515897; SCHEMBL15516108; UNII-YZ68ZB8LWA; US9090621, 125A; YZ68ZB8LWA"	73438222	Phase 2	DS6V8H	.	CTPDG001636
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	UCB1381	.	.	Phase 2	DN9K2Y	.	CTPDG001666
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q301	"Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid"	7010608	Phase 2	DES36M	.	CTPDG001729
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DMT210	.	.	Phase 2	DB5YU0	.	CTPDG001755
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-07038124	"(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4"	148293990	Phase 2	D81WBS	.	CTPDG001775
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	Phase 2	D6N5UC	.	CTPDG001788
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Zabedosertib	"1931994-81-8; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; AKOS040755617; BAY 1834845; BAY1834845; BAY-1834845; BDBM395297; CS-0198831; D96922; EX-A5143; GTPL11415; HY-139374; MFCD32900903; MS-28697; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide; N1GRK350ZM; OQAMEEFUUFJZRS-UHFFFAOYSA-N; SB74225; SCHEMBL17785221; SY323200; UNII-N1GRK350ZM; US10308634, Example 12; Zabedosertib; Zabedosertib [INN]"	121364961	Phase 2	D5XVM6	.	CTPDG001798
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	E6005	"Lotamilast; 947620-48-6; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7"	24864553	Phase 2	D0TT4H	DB12776	CTPDG002000
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	K-201	"DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519"	9868902	Phase 2	D0MT1Q	.	CTPDG002182
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	JNJ-26113100	"Dermatitis agent (oral), Alza"	.	Phase 2	D0K9KN	.	CTPDG002259
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SRD-441	"Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics"	.	Phase 2	D0J6ZA	.	CTPDG002284
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	S-777469	.	57331749	Phase 2	D0J6KZ	.	CTPDG002285
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PMX-53	"YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam"	6918468	Phase 2	D0G2XE	.	CTPDG002376
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	NCX 1022	.	.	Phase 2	D0E8YH	.	CTPDG002412
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ALX-101	"Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy"	89792952	Phase 2	D0CT5O	.	CTPDG002466
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	.	.	Phase 2	D0CG0K	.	CTPDG002475
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	Phase 2	D0BI3N	DB15499	CTPDG002499
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ASB17061	.	.	Phase 2	D0B1OH	.	CTPDG002518
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q-301	.	.	Phase 2	D09QMX	.	CTPDG002567
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PAC-14028	.	56649347	Phase 2	D09BDE	DB12428	CTPDG002588
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MM36	CHEMBL225555	57855696	Phase 2	D09ALR	DB14987	CTPDG002593
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BRT-FC-83C	"Dermatological agent (topical, atopic dermatitis), Biomed Research & Technologies"	.	Phase 2	D08YJN	.	CTPDG002597
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ADX-914	.	.	Phase 2	D08GVP	.	CTPDG002639
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	HL-009	"Adenosylcobamide; Adenosylcobalamin (vitamin B12) (nanoliposome, allergy), HanAll"	.	Phase 2	D07PFG	.	CTPDG002679
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DPK-060	"DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen"	.	Phase 2	D06XMW	.	CTPDG002716
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Santalum	.	.	Phase 2	D06OVF	.	CTPDG002740
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TS-022	"Prostaglandin derivative (topical, dermatitis), Taisho"	16049813	Phase 2	D06GNF	.	CTPDG002761
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BMX-010	"UNII-BN93L2NT5I; BN93L2NT5I; Manganese(III)meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride; Manganese(4+), chloro((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-ethylpyridiniumato))(2-))-, tetrachloride, (sp-5-12)-; 219818-60-7"	10033875	Phase 2	D06FER	.	CTPDG002765
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ANB-020	etokimab	.	Phase 2	D05TSG	.	CTPDG002787
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PRO22	.	.	Phase 2	D05MJS	.	CTPDG002797
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LEO-29102	.	66829720	Phase 2	D04XVJ	.	CTPDG002826
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LAS-41004	"Anti-inflammatory (psoriasis/atopic dermatitis), Almirall"	.	Phase 2	D04TJL	.	CTPDG002840
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cis-urocanic acid	"ProtoCure; ProtoCure (emulsion, atopic dermatitis), Biocis Pharma; Anti-inflammatory (topical emulsion, dermatological disease), BioCis; ProtoCure (emulsion, atopic dermatitis/psoriasis), Biocis Pharma; ProtoCure (emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-urocanic acid (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma"	1549103	Phase 2	D04CQV	.	CTPDG002878
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	Phase 2	D03VPJ	.	CTPDG002893
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GBR 830	.	.	Phase 2	D03DUI	.	CTPDG002933
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TA-7906	"T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl"	.	Phase 2	D02POH	.	CTPDG002963
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	VTB-38543	.	.	Phase 2	D01XMC	.	CTPDG003002
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN-2898	"PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor"	24806574	Phase 2	D00JED	.	CTPDG003084
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	KP-413	.	.	Phase 1/2	D0I3HI	.	CTPDG003417
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	REGN-846	RENG-846; SAR-302352; SAR-302532	.	Phase 1/2	D06DBJ	.	CTPDG003543
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	ZPL521	.	.	Phase 1/2	D02XBN	.	CTPDG003602
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07295324	.	.	Phase 1	DXVA93	.	CTPDG003662
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07242813	.	.	Phase 1	DUJ16L	.	CTPDG003701
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07275315	.	.	Phase 1	DIWU14	.	CTPDG003874
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	STMC-103H	.	.	Phase 1	D89XBL	.	CTPDG004020
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	UCB9741	.	.	Phase 1	D62JOV	.	CTPDG004076
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07264660	.	.	Phase 1	D1LP4B	.	CTPDG004189
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-06817024	.	.	Phase 1	D0W6YR	.	CTPDG004316
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	EDP1066	.	.	Phase 1	D0UD1J	.	CTPDG004365
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SNA-125	.	.	Phase 1	D0Q0IM	.	CTPDG004493
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SAR444656	.	.	Phase 1	D0CW9M	.	CTPDG004875
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	KPL-716	.	.	Phase 1	D09KEW	.	CTPDG004996
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SB414	.	.	Phase 1	D02UYM	.	CTPDG005335
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Piperazine derivative 5	PMID26936077-Compound-16	53244427	Patented	D0LT5Y	.	CTPDG005790
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 3	P-1	Zemaphyte; Zemaphyte (P1)	200882	Discontinued in Phase 3	D03HVN	.	CTPDG006385
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	GW842470X	.	.	Discontinued in Phase 2	D0F3BY	.	CTPDG006527
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	Dermolastin	.	188403	Discontinued in Phase 2	D0B9EH	.	CTPDG006551
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 1	CD-581	"1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol"	.	Discontinued in Phase 1	D0F5NB	.	CTPDG006816
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RESP-6000	.	.	Investigative	D0ZE3S	.	CTPDG007619
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	J-555Y	.	.	Investigative	D0U3TE	.	CTPDG007833
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-01113	.	.	Investigative	D0S4PZ	.	CTPDG007891
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	PBI-1308	"PBI-1308 (dermatological, dermatological diseases); PBI-1308 (dermatological, dermatological diseases), Darier/ProMetic"	.	Investigative	D0RB2H	.	CTPDG007900
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DPS-201	.	.	Investigative	D0GV0H	.	CTPDG008254
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RTU-1096	.	.	Investigative	D0F8KR	.	CTPDG008294
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	KF-66490	"K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin"	281833	Investigative	D0E5VP	.	CTPDG008343
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	MLR-1130	"Non-steroidal antiinflammatory (topical, atopic dermatitis), Melior"	.	Investigative	D0DA3D	.	CTPDG008362
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	AP-1189	"AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma"	.	Investigative	D09QPE	.	CTPDG008527
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DM-107	"MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis"	.	Investigative	D03OMK	.	CTPDG008954
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-05141	.	.	Investigative	D03DOW	.	CTPDG008980
M6ACROT05637	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	C-0333158	.	.	Investigative	D02YRX	.	CTPDG008993
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Pimecrolimus	Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin	6509979	Approved	D0Z4UN	DB00337	CTPDG000032
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	cortisone	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone	222786	Approved	D0IX6I	DB14681	CTPDG000332
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Cromolyn sodium	"Altoderm; Cromolyn sodium (topical, atopic dermatitis); Cromolyn sodium (topical, atopic dermatitis), Manhattan Pharmaceuticals"	27503	Approved	D0G7IY	.	CTPDG000368
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	crisaborole	Crisaborole ointment 2%; PF-06930164	44591583	Approved	D08NWF	DB05219	CTPDG000520
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Abrocitinib	.	78323835	Approved	D05PCM	DB14973	CTPDG000627
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Desonide	"Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide"	5311066	Approved	D02JNM	DB01260	CTPDG000751
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Anapsos	"Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC"	.	Approved	D00OGX	.	CTPDG000810
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	ARQ-151	.	.	Phase 3	DST04F	.	CTPDG000879
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	IDP-124	.	.	Phase 3	D0XU3D	.	CTPDG000987
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	LY-686017	"NK1 antagonist (anxiety/alcoholism), Eli Lilly"	9916461	Phase 3	D0N8UY	DB12580	CTPDG001110
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Omiganan	"CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea"	16131445	Phase 2	D0JW7D	DB06610	CTPDG001169
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Nemolizumab	.	.	Phase 3	D0B2IR	.	CTPDG001271
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MABp1	.	.	Phase 2	D09AYM	.	CTPDG001317
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Dupixent	.	.	Phase 3	D05GZB	.	CTPDG001404
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Rocatinlimab	AMG 451 / KHK4083	.	Phase 3	D03AKW	.	CTPDG001449
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SAR 444727	"(2E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; (alphaE,3R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (alphaE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; 1581714-49-9; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; AKOS040756908; atuzabrutinib; Atuzabrutinib [INN]; ATUZABRUTINIB [USAN]; BDBM197260; BDBM50589191; CHEMBL4114766; compound 11 [PMID: 35302767]; CS-0204055; GTPL11666; HY-132808; PRN473; PRN-473; SAR444727; SAR-444727; SCHEMBL15515897; SCHEMBL15516108; UNII-YZ68ZB8LWA; US9090621, 125A; YZ68ZB8LWA"	73438222	Phase 2	DS6V8H	.	CTPDG001636
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	UCB1381	.	.	Phase 2	DN9K2Y	.	CTPDG001666
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q301	"Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid"	7010608	Phase 2	DES36M	.	CTPDG001729
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DMT210	.	.	Phase 2	DB5YU0	.	CTPDG001755
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-07038124	"(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4"	148293990	Phase 2	D81WBS	.	CTPDG001775
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	Phase 2	D6N5UC	.	CTPDG001788
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Zabedosertib	"1931994-81-8; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; AKOS040755617; BAY 1834845; BAY1834845; BAY-1834845; BDBM395297; CS-0198831; D96922; EX-A5143; GTPL11415; HY-139374; MFCD32900903; MS-28697; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide; N1GRK350ZM; OQAMEEFUUFJZRS-UHFFFAOYSA-N; SB74225; SCHEMBL17785221; SY323200; UNII-N1GRK350ZM; US10308634, Example 12; Zabedosertib; Zabedosertib [INN]"	121364961	Phase 2	D5XVM6	.	CTPDG001798
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	E6005	"Lotamilast; 947620-48-6; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7"	24864553	Phase 2	D0TT4H	DB12776	CTPDG002000
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	K-201	"DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519"	9868902	Phase 2	D0MT1Q	.	CTPDG002182
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	JNJ-26113100	"Dermatitis agent (oral), Alza"	.	Phase 2	D0K9KN	.	CTPDG002259
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SRD-441	"Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics"	.	Phase 2	D0J6ZA	.	CTPDG002284
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	S-777469	.	57331749	Phase 2	D0J6KZ	.	CTPDG002285
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PMX-53	"YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam"	6918468	Phase 2	D0G2XE	.	CTPDG002376
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	NCX 1022	.	.	Phase 2	D0E8YH	.	CTPDG002412
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ALX-101	"Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy"	89792952	Phase 2	D0CT5O	.	CTPDG002466
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	.	.	Phase 2	D0CG0K	.	CTPDG002475
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	Phase 2	D0BI3N	DB15499	CTPDG002499
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ASB17061	.	.	Phase 2	D0B1OH	.	CTPDG002518
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q-301	.	.	Phase 2	D09QMX	.	CTPDG002567
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PAC-14028	.	56649347	Phase 2	D09BDE	DB12428	CTPDG002588
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MM36	CHEMBL225555	57855696	Phase 2	D09ALR	DB14987	CTPDG002593
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BRT-FC-83C	"Dermatological agent (topical, atopic dermatitis), Biomed Research & Technologies"	.	Phase 2	D08YJN	.	CTPDG002597
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ADX-914	.	.	Phase 2	D08GVP	.	CTPDG002639
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	HL-009	"Adenosylcobamide; Adenosylcobalamin (vitamin B12) (nanoliposome, allergy), HanAll"	.	Phase 2	D07PFG	.	CTPDG002679
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DPK-060	"DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen"	.	Phase 2	D06XMW	.	CTPDG002716
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Santalum	.	.	Phase 2	D06OVF	.	CTPDG002740
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TS-022	"Prostaglandin derivative (topical, dermatitis), Taisho"	16049813	Phase 2	D06GNF	.	CTPDG002761
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BMX-010	"UNII-BN93L2NT5I; BN93L2NT5I; Manganese(III)meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride; Manganese(4+), chloro((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-ethylpyridiniumato))(2-))-, tetrachloride, (sp-5-12)-; 219818-60-7"	10033875	Phase 2	D06FER	.	CTPDG002765
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ANB-020	etokimab	.	Phase 2	D05TSG	.	CTPDG002787
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PRO22	.	.	Phase 2	D05MJS	.	CTPDG002797
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LEO-29102	.	66829720	Phase 2	D04XVJ	.	CTPDG002826
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LAS-41004	"Anti-inflammatory (psoriasis/atopic dermatitis), Almirall"	.	Phase 2	D04TJL	.	CTPDG002840
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cis-urocanic acid	"ProtoCure; ProtoCure (emulsion, atopic dermatitis), Biocis Pharma; Anti-inflammatory (topical emulsion, dermatological disease), BioCis; ProtoCure (emulsion, atopic dermatitis/psoriasis), Biocis Pharma; ProtoCure (emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-urocanic acid (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma"	1549103	Phase 2	D04CQV	.	CTPDG002878
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	Phase 2	D03VPJ	.	CTPDG002893
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GBR 830	.	.	Phase 2	D03DUI	.	CTPDG002933
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TA-7906	"T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl"	.	Phase 2	D02POH	.	CTPDG002963
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	VTB-38543	.	.	Phase 2	D01XMC	.	CTPDG003002
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN-2898	"PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor"	24806574	Phase 2	D00JED	.	CTPDG003084
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	KP-413	.	.	Phase 1/2	D0I3HI	.	CTPDG003417
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	REGN-846	RENG-846; SAR-302352; SAR-302532	.	Phase 1/2	D06DBJ	.	CTPDG003543
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	ZPL521	.	.	Phase 1/2	D02XBN	.	CTPDG003602
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07295324	.	.	Phase 1	DXVA93	.	CTPDG003662
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07242813	.	.	Phase 1	DUJ16L	.	CTPDG003701
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07275315	.	.	Phase 1	DIWU14	.	CTPDG003874
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	STMC-103H	.	.	Phase 1	D89XBL	.	CTPDG004020
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	UCB9741	.	.	Phase 1	D62JOV	.	CTPDG004076
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07264660	.	.	Phase 1	D1LP4B	.	CTPDG004189
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-06817024	.	.	Phase 1	D0W6YR	.	CTPDG004316
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	EDP1066	.	.	Phase 1	D0UD1J	.	CTPDG004365
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SNA-125	.	.	Phase 1	D0Q0IM	.	CTPDG004493
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SAR444656	.	.	Phase 1	D0CW9M	.	CTPDG004875
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	KPL-716	.	.	Phase 1	D09KEW	.	CTPDG004996
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SB414	.	.	Phase 1	D02UYM	.	CTPDG005335
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Piperazine derivative 5	PMID26936077-Compound-16	53244427	Patented	D0LT5Y	.	CTPDG005790
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 3	P-1	Zemaphyte; Zemaphyte (P1)	200882	Discontinued in Phase 3	D03HVN	.	CTPDG006385
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	GW842470X	.	.	Discontinued in Phase 2	D0F3BY	.	CTPDG006527
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	Dermolastin	.	188403	Discontinued in Phase 2	D0B9EH	.	CTPDG006551
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 1	CD-581	"1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol"	.	Discontinued in Phase 1	D0F5NB	.	CTPDG006816
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RESP-6000	.	.	Investigative	D0ZE3S	.	CTPDG007619
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	J-555Y	.	.	Investigative	D0U3TE	.	CTPDG007833
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-01113	.	.	Investigative	D0S4PZ	.	CTPDG007891
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	PBI-1308	"PBI-1308 (dermatological, dermatological diseases); PBI-1308 (dermatological, dermatological diseases), Darier/ProMetic"	.	Investigative	D0RB2H	.	CTPDG007900
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DPS-201	.	.	Investigative	D0GV0H	.	CTPDG008254
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RTU-1096	.	.	Investigative	D0F8KR	.	CTPDG008294
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	KF-66490	"K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin"	281833	Investigative	D0E5VP	.	CTPDG008343
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	MLR-1130	"Non-steroidal antiinflammatory (topical, atopic dermatitis), Melior"	.	Investigative	D0DA3D	.	CTPDG008362
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	AP-1189	"AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma"	.	Investigative	D09QPE	.	CTPDG008527
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DM-107	"MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis"	.	Investigative	D03OMK	.	CTPDG008954
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-05141	.	.	Investigative	D03DOW	.	CTPDG008980
M6ACROT05638	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	C-0333158	.	.	Investigative	D02YRX	.	CTPDG008993
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Pimecrolimus	Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin	6509979	Approved	D0Z4UN	DB00337	CTPDG000032
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Roflumilast	"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast"	449193	Approved	D0R4UW	DB01656	CTPDG000180
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Secukinumab	.	.	Phase 2	D0Q0OD	.	CTPDG000209
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	cortisone	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone	222786	Approved	D0IX6I	DB14681	CTPDG000332
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tralokinumab	"CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca"	.	Approved	D0I1ZY	.	CTPDG000351
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Cromolyn sodium	"Altoderm; Cromolyn sodium (topical, atopic dermatitis); Cromolyn sodium (topical, atopic dermatitis), Manhattan Pharmaceuticals"	27503	Approved	D0G7IY	.	CTPDG000368
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	crisaborole	Crisaborole ointment 2%; PF-06930164	44591583	Approved	D08NWF	DB05219	CTPDG000520
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Dupilumab	"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis"	.	Approved	D07FUP	.	CTPDG000571
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Abrocitinib	.	78323835	Approved	D05PCM	DB14973	CTPDG000627
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Desonide	"Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide"	5311066	Approved	D02JNM	DB01260	CTPDG000751
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Approved	Anapsos	"Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC"	.	Approved	D00OGX	.	CTPDG000810
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	ARQ-151	.	.	Phase 3	DST04F	.	CTPDG000879
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	CBP-201	.	.	Phase 3	DF7Y9S	.	CTPDG000911
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	IDP-124	.	.	Phase 3	D0XU3D	.	CTPDG000987
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Lebrikizumab	RG3637	.	Phase 3	D0SM8S	.	CTPDG001051
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	SAR231893	.	.	Phase 3	D0O9UN	.	CTPDG001099
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	LY-686017	"NK1 antagonist (anxiety/alcoholism), Eli Lilly"	9916461	Phase 3	D0N8UY	DB12580	CTPDG001110
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Omiganan	"CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea"	16131445	Phase 2	D0JW7D	DB06610	CTPDG001169
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Nemolizumab	.	.	Phase 3	D0B2IR	.	CTPDG001271
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MABp1	.	.	Phase 2	D09AYM	.	CTPDG001317
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Dupixent	.	.	Phase 3	D05GZB	.	CTPDG001404
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 3	Rocatinlimab	AMG 451 / KHK4083	.	Phase 3	D03AKW	.	CTPDG001449
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2a	Bimosiamose	TBC 1269; TBC-1269	9811353	Phase 2a	D02AUB	DB06197	CTPDG001591
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SAR 444727	"(2E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; (alphaE,3R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (alphaE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; 1581714-49-9; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; AKOS040756908; atuzabrutinib; Atuzabrutinib [INN]; ATUZABRUTINIB [USAN]; BDBM197260; BDBM50589191; CHEMBL4114766; compound 11 [PMID: 35302767]; CS-0204055; GTPL11666; HY-132808; PRN473; PRN-473; SAR444727; SAR-444727; SCHEMBL15515897; SCHEMBL15516108; UNII-YZ68ZB8LWA; US9090621, 125A; YZ68ZB8LWA"	73438222	Phase 2	DS6V8H	.	CTPDG001636
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	UCB1381	.	.	Phase 2	DN9K2Y	.	CTPDG001666
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Amlitelimab	.	.	Phase 2	DN2OL8	.	CTPDG001670
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q301	"Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid"	7010608	Phase 2	DES36M	.	CTPDG001729
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DMT210	.	.	Phase 2	DB5YU0	.	CTPDG001755
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-07038124	"(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4"	148293990	Phase 2	D81WBS	.	CTPDG001775
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	Phase 2	D6N5UC	.	CTPDG001788
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Zabedosertib	"1931994-81-8; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; AKOS040755617; BAY 1834845; BAY1834845; BAY-1834845; BDBM395297; CS-0198831; D96922; EX-A5143; GTPL11415; HY-139374; MFCD32900903; MS-28697; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide; N1GRK350ZM; OQAMEEFUUFJZRS-UHFFFAOYSA-N; SB74225; SCHEMBL17785221; SY323200; UNII-N1GRK350ZM; US10308634, Example 12; Zabedosertib; Zabedosertib [INN]"	121364961	Phase 2	D5XVM6	.	CTPDG001798
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	E6005	"Lotamilast; 947620-48-6; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7"	24864553	Phase 2	D0TT4H	DB12776	CTPDG002000
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	K-201	"DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519"	9868902	Phase 2	D0MT1Q	.	CTPDG002182
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	JNJ-26113100	"Dermatitis agent (oral), Alza"	.	Phase 2	D0K9KN	.	CTPDG002259
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	SRD-441	"Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics"	.	Phase 2	D0J6ZA	.	CTPDG002284
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	S-777469	.	57331749	Phase 2	D0J6KZ	.	CTPDG002285
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PMX-53	"YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam"	6918468	Phase 2	D0G2XE	.	CTPDG002376
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	NCX 1022	.	.	Phase 2	D0E8YH	.	CTPDG002412
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ALX-101	"Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy"	89792952	Phase 2	D0CT5O	.	CTPDG002466
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ATI-502	.	.	Phase 2	D0CG0K	.	CTPDG002475
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	Phase 2	D0BI3N	DB15499	CTPDG002499
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ASB17061	.	.	Phase 2	D0B1OH	.	CTPDG002518
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Q-301	.	.	Phase 2	D09QMX	.	CTPDG002567
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PAC-14028	.	56649347	Phase 2	D09BDE	DB12428	CTPDG002588
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	MM36	CHEMBL225555	57855696	Phase 2	D09ALR	DB14987	CTPDG002593
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BRT-FC-83C	"Dermatological agent (topical, atopic dermatitis), Biomed Research & Technologies"	.	Phase 2	D08YJN	.	CTPDG002597
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ADX-914	.	.	Phase 2	D08GVP	.	CTPDG002639
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	HL-009	"Adenosylcobamide; Adenosylcobalamin (vitamin B12) (nanoliposome, allergy), HanAll"	.	Phase 2	D07PFG	.	CTPDG002679
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	DPK-060	"DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen"	.	Phase 2	D06XMW	.	CTPDG002716
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Santalum	.	.	Phase 2	D06OVF	.	CTPDG002740
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TS-022	"Prostaglandin derivative (topical, dermatitis), Taisho"	16049813	Phase 2	D06GNF	.	CTPDG002761
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	BMX-010	"UNII-BN93L2NT5I; BN93L2NT5I; Manganese(III)meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride; Manganese(4+), chloro((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-ethylpyridiniumato))(2-))-, tetrachloride, (sp-5-12)-; 219818-60-7"	10033875	Phase 2	D06FER	.	CTPDG002765
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	ANB-020	etokimab	.	Phase 2	D05TSG	.	CTPDG002787
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PRO22	.	.	Phase 2	D05MJS	.	CTPDG002797
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LEO-29102	.	66829720	Phase 2	D04XVJ	.	CTPDG002826
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	LAS-41004	"Anti-inflammatory (psoriasis/atopic dermatitis), Almirall"	.	Phase 2	D04TJL	.	CTPDG002840
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	Cis-urocanic acid	"ProtoCure; ProtoCure (emulsion, atopic dermatitis), Biocis Pharma; Anti-inflammatory (topical emulsion, dermatological disease), BioCis; ProtoCure (emulsion, atopic dermatitis/psoriasis), Biocis Pharma; ProtoCure (emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-urocanic acid (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma"	1549103	Phase 2	D04CQV	.	CTPDG002878
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	Phase 2	D03VPJ	.	CTPDG002893
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	GBR 830	.	.	Phase 2	D03DUI	.	CTPDG002933
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	TA-7906	"T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl"	.	Phase 2	D02POH	.	CTPDG002963
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	PF-3893787	PF-03893787; PF-3826719	24745335	Phase 2	D02DTQ	DB15027	CTPDG002986
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	VTB-38543	.	.	Phase 2	D01XMC	.	CTPDG003002
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 2	AN-2898	"PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor"	24806574	Phase 2	D00JED	.	CTPDG003084
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	KP-413	.	.	Phase 1/2	D0I3HI	.	CTPDG003417
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	REGN-846	RENG-846; SAR-302352; SAR-302532	.	Phase 1/2	D06DBJ	.	CTPDG003543
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1/2	ZPL521	.	.	Phase 1/2	D02XBN	.	CTPDG003602
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07295324	.	.	Phase 1	DXVA93	.	CTPDG003662
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07242813	.	.	Phase 1	DUJ16L	.	CTPDG003701
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07275315	.	.	Phase 1	DIWU14	.	CTPDG003874
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	STMC-103H	.	.	Phase 1	D89XBL	.	CTPDG004020
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	UCB9741	.	.	Phase 1	D62JOV	.	CTPDG004076
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-07264660	.	.	Phase 1	D1LP4B	.	CTPDG004189
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	PF-06817024	.	.	Phase 1	D0W6YR	.	CTPDG004316
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	EDP1066	.	.	Phase 1	D0UD1J	.	CTPDG004365
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SNA-125	.	.	Phase 1	D0Q0IM	.	CTPDG004493
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SAR444656	.	.	Phase 1	D0CW9M	.	CTPDG004875
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	KPL-716	.	.	Phase 1	D09KEW	.	CTPDG004996
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Phase 1	SB414	.	.	Phase 1	D02UYM	.	CTPDG005335
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Patented	Piperazine derivative 5	PMID26936077-Compound-16	53244427	Patented	D0LT5Y	.	CTPDG005790
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 3	P-1	Zemaphyte; Zemaphyte (P1)	200882	Discontinued in Phase 3	D03HVN	.	CTPDG006385
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	AVAC	.	.	Discontinued in Phase 2	D0L8WA	.	CTPDG006485
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	GW842470X	.	.	Discontinued in Phase 2	D0F3BY	.	CTPDG006527
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 2	Dermolastin	.	188403	Discontinued in Phase 2	D0B9EH	.	CTPDG006551
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Discontinued in Phase 1	CD-581	"1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol"	.	Discontinued in Phase 1	D0F5NB	.	CTPDG006816
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RESP-6000	.	.	Investigative	D0ZE3S	.	CTPDG007619
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	J-555Y	.	.	Investigative	D0U3TE	.	CTPDG007833
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-01113	.	.	Investigative	D0S4PZ	.	CTPDG007891
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	PBI-1308	"PBI-1308 (dermatological, dermatological diseases); PBI-1308 (dermatological, dermatological diseases), Darier/ProMetic"	.	Investigative	D0RB2H	.	CTPDG007900
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DPS-201	.	.	Investigative	D0GV0H	.	CTPDG008254
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	RTU-1096	.	.	Investigative	D0F8KR	.	CTPDG008294
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	KF-66490	"K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin"	281833	Investigative	D0E5VP	.	CTPDG008343
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	MLR-1130	"Non-steroidal antiinflammatory (topical, atopic dermatitis), Melior"	.	Investigative	D0DA3D	.	CTPDG008362
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	AP-1189	"AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma"	.	Investigative	D09QPE	.	CTPDG008527
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	DM-107	"MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis"	.	Investigative	D03OMK	.	CTPDG008954
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	SWT-05141	.	.	Investigative	D03DOW	.	CTPDG008980
M6ACROT06028	.	.	M6ADIS0137	EA80: Atopic eczema	Investigative	C-0333158	.	.	Investigative	D02YRX	.	CTPDG008993
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Approved	Promegestone	Surgestone (TN)	36709	Approved	D0F2AK	DB13602	CTPDG000391
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Approved	Echovist	ZK-44012; SH-U-454	6036	Approved	D0A7GX	.	CTPDG000462
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Discontinued in Phase 2	PEN-203	"Papirines; Papilloma therapy, Pentose"	.	Discontinued in Phase 2	D0S7EQ	.	CTPDG006438
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Discontinued in Phase 1	SIM-916	"Womens health therapeutics, ArQule/Wyeth; Rheumatoid arthritis therapeutics (1), ArQule/Wyeth"	.	Discontinued in Phase 1	D0W7ZN	.	CTPDG006720
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Investigative	ZO-Y49	.	.	Investigative	D06VTL	.	CTPDG008727
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Investigative	AXP-107-16	.	.	Investigative	D05VWK	.	CTPDG008786
M6ACROT05279	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Investigative	GSK-008A	"Progesterone receptor agonists (gynecological disorder); Progesterone receptor agonists (gynecological disorder), GSK"	.	Investigative	D02WQR	.	CTPDG008997
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Approved	Promegestone	Surgestone (TN)	36709	Approved	D0F2AK	DB13602	CTPDG000391
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Approved	Echovist	ZK-44012; SH-U-454	6036	Approved	D0A7GX	.	CTPDG000462
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Discontinued in Phase 2	PEN-203	"Papirines; Papilloma therapy, Pentose"	.	Discontinued in Phase 2	D0S7EQ	.	CTPDG006438
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Discontinued in Phase 1	SIM-916	"Womens health therapeutics, ArQule/Wyeth; Rheumatoid arthritis therapeutics (1), ArQule/Wyeth"	.	Discontinued in Phase 1	D0W7ZN	.	CTPDG006720
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Investigative	ZO-Y49	.	.	Investigative	D06VTL	.	CTPDG008727
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Investigative	AXP-107-16	.	.	Investigative	D05VWK	.	CTPDG008786
M6ACROT05280	.	.	M6ADIS0394	GA6Z: Diseases of the female genital system	Investigative	GSK-008A	"Progesterone receptor agonists (gynecological disorder); Progesterone receptor agonists (gynecological disorder), GSK"	.	Investigative	D02WQR	.	CTPDG008997
M6ACROT05303	.	.	M6ADIS0093	8D43: Neurological disorders due to toxicity	Approved	Charybdotoxin	"ChTX; CTX Toxin; Quinquestriatus Toxin; Charybdotoxin (reduced); Toxin, CTX; Toxin, Quinquestriatus"	56842037	Approved	D0U5OB	.	CTPDG000120
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Glofitamab	Glofitamab	.	Approved	DKF7G0	.	CTPDG000008
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Epcoritamab	.	.	Approved	DB4M9J	.	CTPDG000016
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Loncastuximab tesirine	.	.	Approved	D8L5PA	.	CTPDG000022
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Pozelimab	REGN3918	.	Approved	D4XBR9	.	CTPDG000025
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Ocrelizumab	Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)	.	Approved	D0YV4F	.	CTPDG000037
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Tafasitamab	Xmab 5574/MOR208	.	Approved	D0R3PY	.	CTPDG000185
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	Umbralisib	RP5264; TGR-1202	72950888	Phase 2/3	D0O8SJ	DB14989	CTPDG000235
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Lisocabtagene maraleucel	JCAR017	.	Approved	D0M4WU	.	CTPDG000273
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	Blinatumomab	AMG 103; Blincyto	.	Phase 2/3	D0K4RK	.	CTPDG000310
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Axicabtagene ciloleucel	.	.	Approved	D0DK5R	.	CTPDG000417
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Polatuzumab vedotin	.	.	Approved	D05QOL	.	CTPDG000624
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	ICP-022	"Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide"	91667513	Phase 2	DUTJ12	.	CTPDG000873
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Pixantrone	Pixuvri (TN)	134019	Phase 3	D0Q4OW	DB06193	CTPDG001085
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Adcetris	.	.	Phase 3	D0F4IM	.	CTPDG001218
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Telcyta canfosfamide	.	.	Phase 3	D06BGO	.	CTPDG001385
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	VR876	.	.	Phase 3	D04EVE	.	CTPDG001427
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	Zilovertamab vedotin	MK-2140	.	Phase 2/3	D3YJZ7	.	CTPDG001526
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	MOR-208	"XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor"	.	Phase 2/3	D02CYL	.	CTPDG001579
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	MT-3724	.	.	Phase 2	DZNH43	.	CTPDG001595
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Plamotamab	XmAb 13676	.	Phase 2	DLM8G6	.	CTPDG001681
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	DPX Survivac	.	.	Phase 2	D5T3OY	.	CTPDG001800
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Naratuximab emtansine	DEBIO 1562	.	Phase 2	D2R0UM	.	CTPDG001831
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	CD20 CAR T cells	.	.	Phase 2	D0Y3HP	.	CTPDG001880
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Baltaleucel-T	.	.	Phase 2	D0WK1M	.	CTPDG001915
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	SGN-CD19A	Denintuzumab mafodotin	86278355	Phase 2	D0UT5A	.	CTPDG001973
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	DCDS-4501A	.	.	Phase 2	D0PA1B	.	CTPDG002113
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Cobomarsen	MRG-106	.	Phase 1	D0P9XM	.	CTPDG002114
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	CD19 CAR T cells	.	.	Phase 2	D0L5HM	.	CTPDG002236
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	CTL019	.	.	Phase 2	D0I0UM	.	CTPDG002323
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CART-19	.	.	Phase 1	D0G4IW	.	CTPDG002372
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	BI-836826	.	.	Phase 2	D09WKM	.	CTPDG002555
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	INCB50465	.	.	Phase 2	D07RHP	.	CTPDG002674
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	TAK-659	.	53252276	Phase 2	D06KTJ	.	CTPDG002748
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	DEBIO 1562	MGN529	.	Phase 2	D04SQO	.	CTPDG002844
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Denintuzumab mafodotin	.	.	Phase 2	D01QMK	.	CTPDG003017
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Coltuximab ravtansine	.	.	Phase 2	D00UNK	.	CTPDG003061
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	GEN3013	.	.	Phase 1/2	D9OMQ3	.	CTPDG003213
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	ALLO-501A	.	.	Phase 1/2	D1HID7	.	CTPDG003259
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	CD19 CAR T Cells	.	.	Phase 1/2	D0Z8GD	.	CTPDG003266
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD20-CAR vector-transduced autologous T cells	.	.	Phase 1/2	D0V6VD	.	CTPDG003297
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	MAK683	"XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663"	121412508	Phase 1/2	D0UO0C	.	CTPDG003299
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	JCAR014	.	.	Phase 1	D0U0BN	.	CTPDG003312
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD20 CAR-T cells	.	.	Phase 1/2	D0MA4O	.	CTPDG003376
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	PCAR-019	.	.	Phase 1/2	D0M0CO	.	CTPDG003382
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD19-CAR PBL	.	.	Phase 1/2	D0J3DN	.	CTPDG003403
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	KTE-C19 CAR	.	.	Phase 1/2	D0G5WV	.	CTPDG003431
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	SNS01-T	.	.	Phase 1/2	D0F8SW	.	CTPDG003437
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	CD19.CAR-T cells	.	.	Phase 1/2	D0EH1J	.	CTPDG003443
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CUDC-907	"1339928-25-4; Fimepinostat; CUDC 907; UNII-3S9RX35S5X; CUDC907; 3S9RX35S5X; CHEMBL3622533; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; Fimepinostat [USAN]; PI3K/HDAC Inhibitor centn; MLS006010994; SCHEMBL1284705; GTPL8952; KS-00000TDO; EX-A742; AOB6775; DTXSID90712307; MolPort-023-293-550; JOWXJLIFIIOYMS-UHFFFAOYSA-N; HMS3656H04; BCP06870; s2759; BDBM50188961; 2341AH; ZINC73488511; ABP001045; AKOS026750340; SB16569; CUDC-907 (PI3K/HDAC Inhibi"	54575456	Phase 1	D0E6UZ	DB11891	CTPDG003446
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Betalutin	.	131704322	Phase 1	D0B9XW	DB12227	CTPDG003468
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD19/22-CAR vector-transduced T cells	.	.	Phase 1/2	D08JTI	.	CTPDG003510
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	JCAR017	.	.	Phase 1	D08BPS	.	CTPDG003516
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD19 CAR-T cells	.	.	Phase 1/2	D05LIH	.	CTPDG003553
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Clinical trial	Anti-CD19-CAR vector-transduced T cells	.	.	Clinical trial	D03UNT	.	CTPDG003585
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	AUTO3	.	.	Phase 1/2	D02ONA	.	CTPDG003605
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1b	Vmab + Y-90 Emab	.	.	Phase 1b	D0Q6IF	.	CTPDG003638
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Iomab-ACT	.	.	Phase 1	DZ7OC3	.	CTPDG003646
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CD19t-haNK	.	.	Phase 1	DV3ZI0	.	CTPDG003693
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	KITE-363	.	.	Phase 1	DI6BK9	.	CTPDG003884
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	AMG 562	.	.	Phase 1	D2PFY3	.	CTPDG004157
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Veltuzumab/epratuzumab Y-90	.	.	Phase 1	D0V0YA	.	CTPDG004353
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	LIlotomab satetraxetan	.	.	Phase 1	D0S9EK	.	CTPDG004428
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Retroviral vector-transduced autologous T cells to express CD22-specific CARs	.	.	Phase 1	D0PO0L	.	CTPDG004501
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	YTB323	.	.	Phase 1	D0MWS2	.	CTPDG004588
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	ASP3026	"1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; MGGBYMDAPCCKCT-UHFFFAOYSA-N; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; QCR-144; EX-A140; DTXSID90149038; AOB6601; MolPort-028-720-342; BCP06436; 2229AH; ZINC68120928; s8054"	25134326	Phase 1	D09GEK	DB12729	CTPDG005005
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	ME-401	.	.	Phase 1	D08WLY	.	CTPDG005024
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Human CD19 targeted T Cells	.	.	Phase 1	D08LLB	.	CTPDG005043
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CC-122	"1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995"	24967599	Phase 1	D03QZJ	DB14857	CTPDG005294
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Clinical trial	Anti-CD19/20-CAR vector-transduced T cells	.	.	Clinical trial	D0NL9N	.	CTPDG005495
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Discontinued in Phase 2	DCDT-2980S	.	.	Discontinued in Phase 2	D0EI1U	.	CTPDG006529
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Discontinued in Phase 1/2	IM0-8400	.	.	Discontinued in Phase 1/2	D0H4XV	.	CTPDG006689
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Terminated	Dacetuzumab	SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789	.	Terminated	D0PU8Z	.	CTPDG007245
M6ACROT05328	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Glofitamab	Glofitamab	.	Approved	DKF7G0	.	CTPDG000008
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Epcoritamab	.	.	Approved	DB4M9J	.	CTPDG000016
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Loncastuximab tesirine	.	.	Approved	D8L5PA	.	CTPDG000022
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Pozelimab	REGN3918	.	Approved	D4XBR9	.	CTPDG000025
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Ocrelizumab	Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)	.	Approved	D0YV4F	.	CTPDG000037
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Ofatumumab	Arzerra (TN)	.	Phase 3	D0Y8ZN	.	CTPDG000049
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Tafasitamab	Xmab 5574/MOR208	.	Approved	D0R3PY	.	CTPDG000185
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	Umbralisib	RP5264; TGR-1202	72950888	Phase 2/3	D0O8SJ	DB14989	CTPDG000235
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Lisocabtagene maraleucel	JCAR017	.	Approved	D0M4WU	.	CTPDG000273
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	Blinatumomab	AMG 103; Blincyto	.	Phase 2/3	D0K4RK	.	CTPDG000310
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Application submitted	Tisagenlecleucel	Tisagenlecleucel-T	.	Application submitted	D0IM6T	.	CTPDG000337
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Axicabtagene ciloleucel	.	.	Approved	D0DK5R	.	CTPDG000417
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Ibrutinib	PCI-32765; Ibrutinib (BTK inhibitor)	24821094	Phase 3	D09KTS	DB09053	CTPDG000491
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Polatuzumab vedotin	.	.	Approved	D05QOL	.	CTPDG000624
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	ICP-022	"Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide"	91667513	Phase 2	DUTJ12	.	CTPDG000873
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Application submitted	BI-695500	Rituximab biosimilar	.	Application submitted	D0X3HV	.	CTPDG001000
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Abexinostat	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide	11749858	Phase 3	D0V0SL	DB12565	CTPDG001026
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Pixantrone	Pixuvri (TN)	134019	Phase 3	D0Q4OW	DB06193	CTPDG001085
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Adcetris	.	.	Phase 3	D0F4IM	.	CTPDG001218
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	GP2013	.	.	Phase 3	D07CPM	.	CTPDG001367
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Telcyta canfosfamide	.	.	Phase 3	D06BGO	.	CTPDG001385
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	VR876	.	.	Phase 3	D04EVE	.	CTPDG001427
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	Zilovertamab vedotin	MK-2140	.	Phase 2/3	D3YJZ7	.	CTPDG001526
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2/3	MOR-208	"XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor"	.	Phase 2/3	D02CYL	.	CTPDG001579
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	MT-3724	.	.	Phase 2	DZNH43	.	CTPDG001595
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Plamotamab	XmAb 13676	.	Phase 2	DLM8G6	.	CTPDG001681
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	DPX Survivac	.	.	Phase 2	D5T3OY	.	CTPDG001800
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Naratuximab emtansine	DEBIO 1562	.	Phase 2	D2R0UM	.	CTPDG001831
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	CD20 CAR T cells	.	.	Phase 2	D0Y3HP	.	CTPDG001880
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Baltaleucel-T	.	.	Phase 2	D0WK1M	.	CTPDG001915
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	SGN-CD19A	Denintuzumab mafodotin	86278355	Phase 2	D0UT5A	.	CTPDG001973
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	DCDS-4501A	.	.	Phase 2	D0PA1B	.	CTPDG002113
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Cobomarsen	MRG-106	.	Phase 1	D0P9XM	.	CTPDG002114
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	CD19 CAR T cells	.	.	Phase 2	D0L5HM	.	CTPDG002236
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	IMO-8400	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M	119058029	Phase 2	D0I0XF	.	CTPDG002321
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	CTL019	.	.	Phase 2	D0I0UM	.	CTPDG002323
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CART-19	.	.	Phase 1	D0G4IW	.	CTPDG002372
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	BI-836826	.	.	Phase 2	D09WKM	.	CTPDG002555
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	INCB50465	.	.	Phase 2	D07RHP	.	CTPDG002674
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	TAK-659	.	53252276	Phase 2	D06KTJ	.	CTPDG002748
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	DEBIO 1562	MGN529	.	Phase 2	D04SQO	.	CTPDG002844
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Denintuzumab mafodotin	.	.	Phase 2	D01QMK	.	CTPDG003017
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	Coltuximab ravtansine	.	.	Phase 2	D00UNK	.	CTPDG003061
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	GEN3013	.	.	Phase 1/2	D9OMQ3	.	CTPDG003213
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	ALLO-501A	.	.	Phase 1/2	D1HID7	.	CTPDG003259
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	CD19 CAR T Cells	.	.	Phase 1/2	D0Z8GD	.	CTPDG003266
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD20-CAR vector-transduced autologous T cells	.	.	Phase 1/2	D0V6VD	.	CTPDG003297
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	MAK683	"XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663"	121412508	Phase 1/2	D0UO0C	.	CTPDG003299
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	JCAR014	.	.	Phase 1	D0U0BN	.	CTPDG003312
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD20 CAR-T cells	.	.	Phase 1/2	D0MA4O	.	CTPDG003376
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	PCAR-019	.	.	Phase 1/2	D0M0CO	.	CTPDG003382
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD19-CAR PBL	.	.	Phase 1/2	D0J3DN	.	CTPDG003403
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	KTE-C19 CAR	.	.	Phase 1/2	D0G5WV	.	CTPDG003431
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	SNS01-T	.	.	Phase 1/2	D0F8SW	.	CTPDG003437
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	CD19.CAR-T cells	.	.	Phase 1/2	D0EH1J	.	CTPDG003443
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CUDC-907	"1339928-25-4; Fimepinostat; CUDC 907; UNII-3S9RX35S5X; CUDC907; 3S9RX35S5X; CHEMBL3622533; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; Fimepinostat [USAN]; PI3K/HDAC Inhibitor centn; MLS006010994; SCHEMBL1284705; GTPL8952; KS-00000TDO; EX-A742; AOB6775; DTXSID90712307; MolPort-023-293-550; JOWXJLIFIIOYMS-UHFFFAOYSA-N; HMS3656H04; BCP06870; s2759; BDBM50188961; 2341AH; ZINC73488511; ABP001045; AKOS026750340; SB16569; CUDC-907 (PI3K/HDAC Inhibi"	54575456	Phase 1	D0E6UZ	DB11891	CTPDG003446
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Betalutin	.	131704322	Phase 1	D0B9XW	DB12227	CTPDG003468
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD19/22-CAR vector-transduced T cells	.	.	Phase 1/2	D08JTI	.	CTPDG003510
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	JCAR017	.	.	Phase 1	D08BPS	.	CTPDG003516
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	Anti-CD19 CAR-T cells	.	.	Phase 1/2	D05LIH	.	CTPDG003553
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Clinical trial	Anti-CD19-CAR vector-transduced T cells	.	.	Clinical trial	D03UNT	.	CTPDG003585
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1/2	AUTO3	.	.	Phase 1/2	D02ONA	.	CTPDG003605
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1b	Vmab + Y-90 Emab	.	.	Phase 1b	D0Q6IF	.	CTPDG003638
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Iomab-ACT	.	.	Phase 1	DZ7OC3	.	CTPDG003646
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CD19t-haNK	.	.	Phase 1	DV3ZI0	.	CTPDG003693
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	KITE-363	.	.	Phase 1	DI6BK9	.	CTPDG003884
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	AMG 562	.	.	Phase 1	D2PFY3	.	CTPDG004157
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Veltuzumab/epratuzumab Y-90	.	.	Phase 1	D0V0YA	.	CTPDG004353
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	LIlotomab satetraxetan	.	.	Phase 1	D0S9EK	.	CTPDG004428
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Retroviral vector-transduced autologous T cells to express CD22-specific CARs	.	.	Phase 1	D0PO0L	.	CTPDG004501
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	YTB323	.	.	Phase 1	D0MWS2	.	CTPDG004588
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	ASP3026	"1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; MGGBYMDAPCCKCT-UHFFFAOYSA-N; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; QCR-144; EX-A140; DTXSID90149038; AOB6601; MolPort-028-720-342; BCP06436; 2229AH; ZINC68120928; s8054"	25134326	Phase 1	D09GEK	DB12729	CTPDG005005
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	ME-401	.	.	Phase 1	D08WLY	.	CTPDG005024
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	Human CD19 targeted T Cells	.	.	Phase 1	D08LLB	.	CTPDG005043
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Phase 1	CC-122	"1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995"	24967599	Phase 1	D03QZJ	DB14857	CTPDG005294
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Clinical trial	Anti-CD19/20-CAR vector-transduced T cells	.	.	Clinical trial	D0NL9N	.	CTPDG005495
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Discontinued in Phase 2	DCDT-2980S	.	.	Discontinued in Phase 2	D0EI1U	.	CTPDG006529
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Discontinued in Phase 1/2	IM0-8400	.	.	Discontinued in Phase 1/2	D0H4XV	.	CTPDG006689
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Terminated	Dacetuzumab	SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789	.	Terminated	D0PU8Z	.	CTPDG007245
M6ACROT05836	.	.	M6ADIS0177	2A81: Diffuse large B-cell lymphomas	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	FP-1039	"FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences"	.	Phase 2	D0U2DO	.	CTPDG001995
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	XBIO-101	"sodium cridanimod; cridanimod; 38609-97-1; 9-Oxo-10(9H)-acridineacetic acid; 10-Carboxymethyl-9-acridanone; N-(Carboxymethyl)acridone; (9-oxoacridin-10(9H)-yl)acetic acid; 10(9H)-ACRIDINEACETIC ACID, 9-OXO-; Cridanimod [INN]; 2-(9-oxoacridin-10(9H)-yl)acetic acid; (9-Oxo-9H-acridin-10-yl)-acetic acid; UNII-X91E9EME19; 10-Carboxymeth-9-acridanone; Cycloferon; BRN 0227508; 9-Oxo-10-acridanacetic acid; X91E9EME19; C15H11NO3; Cridanimod (INN); 2-(9-oxoacridin-10-yl)acetic acid; 10(9H)-Acridineaceticacid, 9-oxo-; (9-Oxo-10(9H)-acrid"	38072	Phase 2	D0OS6P	DB13674	CTPDG002125
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Virexxa	.	.	Phase 2	D0J0EM	.	CTPDG002295
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	Folate binding protein-E39	.	.	Phase 1/2	D0OT3L	.	CTPDG003359
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Discontinued in Phase 1	GSK1059615	KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060	23582824	Discontinued in Phase 1	D0L0ZC	DB11962	CTPDG006787
M6ACROT05336	.	.	M6ADIS0067	2C76: Endometrial cancer	Terminated	RU-46556	.	.	Terminated	D0N4PC	.	CTPDG007273
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	FP-1039	"FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences"	.	Phase 2	D0U2DO	.	CTPDG001995
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	XBIO-101	"sodium cridanimod; cridanimod; 38609-97-1; 9-Oxo-10(9H)-acridineacetic acid; 10-Carboxymethyl-9-acridanone; N-(Carboxymethyl)acridone; (9-oxoacridin-10(9H)-yl)acetic acid; 10(9H)-ACRIDINEACETIC ACID, 9-OXO-; Cridanimod [INN]; 2-(9-oxoacridin-10(9H)-yl)acetic acid; (9-Oxo-9H-acridin-10-yl)-acetic acid; UNII-X91E9EME19; 10-Carboxymeth-9-acridanone; Cycloferon; BRN 0227508; 9-Oxo-10-acridanacetic acid; X91E9EME19; C15H11NO3; Cridanimod (INN); 2-(9-oxoacridin-10-yl)acetic acid; 10(9H)-Acridineaceticacid, 9-oxo-; (9-Oxo-10(9H)-acrid"	38072	Phase 2	D0OS6P	DB13674	CTPDG002125
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Virexxa	.	.	Phase 2	D0J0EM	.	CTPDG002295
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	Folate binding protein-E39	.	.	Phase 1/2	D0OT3L	.	CTPDG003359
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Discontinued in Phase 1	GSK1059615	KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060	23582824	Discontinued in Phase 1	D0L0ZC	DB11962	CTPDG006787
M6ACROT05337	.	.	M6ADIS0067	2C76: Endometrial cancer	Terminated	RU-46556	.	.	Terminated	D0N4PC	.	CTPDG007273
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	FP-1039	"FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences"	.	Phase 2	D0U2DO	.	CTPDG001995
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	XBIO-101	"sodium cridanimod; cridanimod; 38609-97-1; 9-Oxo-10(9H)-acridineacetic acid; 10-Carboxymethyl-9-acridanone; N-(Carboxymethyl)acridone; (9-oxoacridin-10(9H)-yl)acetic acid; 10(9H)-ACRIDINEACETIC ACID, 9-OXO-; Cridanimod [INN]; 2-(9-oxoacridin-10(9H)-yl)acetic acid; (9-Oxo-9H-acridin-10-yl)-acetic acid; UNII-X91E9EME19; 10-Carboxymeth-9-acridanone; Cycloferon; BRN 0227508; 9-Oxo-10-acridanacetic acid; X91E9EME19; C15H11NO3; Cridanimod (INN); 2-(9-oxoacridin-10-yl)acetic acid; 10(9H)-Acridineaceticacid, 9-oxo-; (9-Oxo-10(9H)-acrid"	38072	Phase 2	D0OS6P	DB13674	CTPDG002125
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Virexxa	.	.	Phase 2	D0J0EM	.	CTPDG002295
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	Folate binding protein-E39	.	.	Phase 1/2	D0OT3L	.	CTPDG003359
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Discontinued in Phase 1	GSK1059615	KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060	23582824	Discontinued in Phase 1	D0L0ZC	DB11962	CTPDG006787
M6ACROT05483	.	.	M6ADIS0067	2C76: Endometrial cancer	Terminated	RU-46556	.	.	Terminated	D0N4PC	.	CTPDG007273
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Dostarlimab	.	.	Approved	DGQU43	.	CTPDG000011
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	Lurbinectedin	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B	57327016	Phase 3	D0V6OA	DB12674	CTPDG000105
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Approved	Mirvetuximab soravtansine	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489	91810695	Approved	D0RP2W	.	CTPDG000168
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	AL3818	"Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-"	25017411	Phase 1/2	D0G2CG	DB11885	CTPDG001202
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	DKN-01	.	.	Phase 2	DMF73Z	.	CTPDG001674
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	FP-1039	"FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences"	.	Phase 2	D0U2DO	.	CTPDG001995
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	XBIO-101	"sodium cridanimod; cridanimod; 38609-97-1; 9-Oxo-10(9H)-acridineacetic acid; 10-Carboxymethyl-9-acridanone; N-(Carboxymethyl)acridone; (9-oxoacridin-10(9H)-yl)acetic acid; 10(9H)-ACRIDINEACETIC ACID, 9-OXO-; Cridanimod [INN]; 2-(9-oxoacridin-10(9H)-yl)acetic acid; (9-Oxo-9H-acridin-10-yl)-acetic acid; UNII-X91E9EME19; 10-Carboxymeth-9-acridanone; Cycloferon; BRN 0227508; 9-Oxo-10-acridanacetic acid; X91E9EME19; C15H11NO3; Cridanimod (INN); 2-(9-oxoacridin-10-yl)acetic acid; 10(9H)-Acridineaceticacid, 9-oxo-; (9-Oxo-10(9H)-acrid"	38072	Phase 2	D0OS6P	DB13674	CTPDG002125
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Folate binding protein vaccine	.	.	Phase 2	D0M7YU	.	CTPDG002191
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	Virexxa	.	.	Phase 2	D0J0EM	.	CTPDG002295
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	ONC201	"Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid"	73777259	Phase 2	D07XQS	DB14844	CTPDG002658
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1/2	Folate binding protein-E39	.	.	Phase 1/2	D0OT3L	.	CTPDG003359
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 2	GALE-301	.	.	Phase 2	D02DEZ	.	CTPDG003610
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Phase 1	Anti-meso-CAR vector transduced T cells	.	.	Phase 1	D0G4GY	.	CTPDG004776
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Discontinued in Phase 1	GSK1059615	KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060	23582824	Discontinued in Phase 1	D0L0ZC	DB11962	CTPDG006787
M6ACROT05665	.	.	M6ADIS0067	2C76: Endometrial cancer	Terminated	RU-46556	.	.	Terminated	D0N4PC	.	CTPDG007273
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Approved	Digitoxin	"Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]"	441207	Approved	D0M3QP	DB01396	CTPDG000275
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Approved	Celacade	Celacade (TN)	.	Approved	D0K5CX	.	CTPDG000308
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Approved	Deslanoside	"Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide"	28620	Approved	D07TGN	DB01078	CTPDG000550
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Approved	Digoxin	"20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin"	2724385	Approved	D02OZE	DB00390	CTPDG000747
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 3	Recombinant human neuregulin-1 beta	.	.	Phase 3	D0O5KY	.	CTPDG001102
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 3	Satavaptan	.	158348	Phase 3	D0L9NX	DB14923	CTPDG001143
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	Neucardin	"Human neuregulin-1 recombinant peptide fragment (injectable, heart failure/cardiomyopathy), Zensun; RhNRG-1 (injectable, heartfailure/cardiomyopathy), Zensun"	.	Phase 2	D00ZPR	.	CTPDG001491
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Application submitted	Subcutaneous furosemide	.	.	Application submitted	D0MM5P	.	CTPDG001543
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2/3	C-Cure	"Autologous stem cell/cardiopoietic cell therapy (C-Cath, chronic heart failure), Mayo/Cardio3"	.	Phase 2/3	D09VKP	.	CTPDG001556
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	RT-400	JNJ-39588146	.	Phase 2	DYSA16	.	CTPDG001605
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	Cinaciguat	329773-35-5; BAY 58-2667; BAY582667; UNII-59K0Y58UAD; BAY-58-2667; 59K0Y58UAD; 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid; Cinaciguat [INN:JAN]; cinaciguatum; Z90; Cinaciguat (JAN/INN); SCHEMBL249267; GTPL5168; CHEMBL1236936; QCR-279; Cinaciguat (BAY 58-2667); MolPort-039-139-611; CHEBI:142433; ZINC3934935; BCP07942; 3550AH; AKOS026750293; AN-1845; CS-1169; HY-14181; KB-40005; AB0095741; D07577; W-5794	9808022	Phase 2	D0ZT0G	.	CTPDG001852
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	Neladenoson bialanate	"UNII-IV690462VZ; IV690462VZ; 1239309-58-0; Neladenoson dalanate; Neladenoson dalanate [INN]; Neladenoson bialanate [INN]; SCHEMBL7904070; AKOS032946515; DB13138; L-Alanine, L-alanyl-, 2-(4-(2-(((2-(4-chlorophenyl)-4-thiazolyl)methyl)thio)-3,5-dicyano-6-(1-pyrrolidinyl)-4-pyridinyl)phenoxy)ethyl ester; 2-(4-(2-(((2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate"	56848985	Phase 2	D0UD1Y	DB13138	CTPDG001975
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	CLR325	.	.	Phase 2	D0R1UE	.	CTPDG002074
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	Mesenchymal stem cell therapy	.	.	Phase 2	D0H7TS	.	CTPDG002336
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	CLP-1001	"Cross-linked polyelectrolyte polymer (renal disease), Sorbent Therapeutics"	.	Phase 2	D0D1ZS	.	CTPDG002457
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	BMS-986231	"N-Hydroxy-5-methylfuran-2-sulfonamide; Cimlanod; Cimlanod [USAN]; UNII-2US4FK1EPV; 2US4FK1EPV; SCHEMBL15878610; LIXKIXWSKOENAB-UHFFFAOYSA-N; ZINC145617689; 2-Furansulfonamide, N-hydroxy-5-methyl-; 1620330-72-4"	76685198	Phase 2	D0AG8L	DB14983	CTPDG002526
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	CXL-1020	.	52939580	Phase 2	D0AD4D	DB15326	CTPDG002530
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	SLV 306	"Daglutril; SLV-306; SLV306; UNII-KKV299446X; 182821-27-8; KKV299446X; ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid; Daglutril [INN]; 2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 1H-1-Benzazepine-1-acetic acid, 3-(((1-(2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,S*))-"	3038505	Phase 2	D01HDP	DB05796	CTPDG003042
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 2	Tonapofylline	"Bg 9928; 340021-17-2; BG-9928; UNII-83VNU4U44T; BG9928; CHEMBL386974; CHEMBL414157; 83VNU4U44T; 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[222]octanyl]propanoic acid; bicyclo[222]octane-1-propanoic acid, 4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)-; 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[222]oct-1-yl]-propionic acid; Bicyclo(222)octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; Tonapofylline [USAN:INN]"	216466	Phase 2	D00SUK	DB12569	CTPDG003066
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 1	mRNA-0184	.	.	Phase 1	DKWS78	.	CTPDG003839
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 1	LY3461767	.	.	Phase 1	DJX7I5	.	CTPDG003859
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 1	JTT-861	.	.	Phase 1	D52MXY	.	CTPDG004101
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 1	ANX-042	"BNP sliced variant (heart failure), Anexon; B-type natriuretic peptide spliced variant (heart failure), Anexon"	.	Phase 1	D0SZ5G	.	CTPDG004416
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Phase 1	BMS-986224	.	.	Phase 1	D0IG7W	.	CTPDG004710
M6ACROT05373	.	.	M6ADIS0243	BD1Z: Heart failure	Preclinical	NOX-F37	.	.	Preclinical	D09KAK	.	CTPDG007106
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Diatrizoate	Diatrizoate sodium	2140	Approved	D0T9DT	DB00271	CTPDG000133
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 3	Voclosporin	"Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Voclosporin [USAN]; R 1524; Trans-ISA 247; TrkA-IgG"	6918486	Phase 3	D0L9HX	DB11693	CTPDG000284
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Mesna	"Mesnex; Mexan; Mitexan; Uromitexan; Mesna, Shionogi; S-7878; 2-mercaptoethane sulfonate"	23662354	Approved	D0C3YQ	.	CTPDG000444
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Phloroglucinol	"108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; Phloroglucinol anhydrous; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 157"	359	Approved	D07EXH	DB12944	CTPDG000575
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Aminohippurate sodium	"p-Aminohippurate sodium; Sodium p-aminohippurate; 94-16-6; Sodium 4-aminohippurate; Natrium 4-aminohippurat; Aminohippuric acid Sodium salt; Sodium para-Aminohippurate; Ammohippurate sodium; Monosodium p-aminohippurate; Amino-hippurate-sodium; p-Aminohippuric acid sodium salt; UNII-SUO3KVS1O9; Paraaminohippurate Injection; 4-Aminohippursaeure, natriumsalz; N-(4-Aminobenzoyl)glycine monosodium salt; EINECS 202-309-8; SUO3KVS1O9; Aminohippurate sodium [USP]; CHEBI:31204; Glycine, N-(4-aminobenzoyl)-, monosodium salt; HIPPURIC AC"	443971	Approved	D06OAV	.	CTPDG000597
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Iodamide	Meglumine iodamide	3723	Approved	D06LHU	DB08948	CTPDG000601
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Iopentol	"Imagopaque; 89797-00-2; Iopentolum [Latin]; UNII-7D6XWX076T; 7D6XWX076T; CPD. 5411; N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxy-3-methoxypropyl)acetamido)-2,4,6-triiodoisophthalamide; 1,3-Benzenedicarboxamide, 5-(acetyl(2-hydroxy-3-methoxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-; Iopentolum; Iopentol [USAN:BAN:INN]; Iopentol [USAN:INN:BAN]; N,N'-bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxy-3-methoxypropyl)acetamido]-2,4,6-triiodoisophthalamide; Iopentol (USAN/INN); AC1L1K8R; SCHEMBL24471"	56016	Approved	D05MIL	DB13861	CTPDG000633
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 2	Tenapanor	"1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506"	71587953	Phase 2	D04TQO	DB11761	CTPDG000660
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 3	Cinacalcet	Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine	156419	Phase 3	D03YGR	DB01012	CTPDG000687
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Approved	Icodextrin	Extraneal	3517	Approved	D02YCH	DB00629	CTPDG000734
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 4	BMP-7 bone morphogenetic protein	"BMP-2; BMP-7; Vascular calcification therapeutics, Johnson & Johnson; BMP-7 (kidney disease), Curis; BMP-7 (kidney disease), Stryker; Bone morphogenetic protein (BioChaperone technology, bone repair), Adocia; Bone morphogenetic protein (BioChaperone technology, degenerative disc disease/spinal fusion),Adocia; Bone morphogenic protein modulators (renal osteodystrophy/ vascular calcification), Johnson & Johnson; BMP-based therapeutics (renal osteodystrophy/ vascular calcification), Johnson & Johnson; BMP-based therapeutics (renal osteodystrophy/ vascular calcification), Ortho Biotech/Centocor"	.	Phase 4	D05LCN	.	CTPDG000851
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Preregistration	CTAP101	.	.	Preregistration	D03EWD	.	CTPDG000857
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 3	FG-4592	"808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid"	11256664	Phase 3	D03YKE	DB04847	CTPDG001431
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 2	62Cu-ETS	"Copper-62-labeled PET renal perfusion imaging agent, Proportional Technologies; 62Cu-labeled PET renal perfusion imaging agent, Proportional Technologies"	.	Phase 2	D0X1XA	.	CTPDG001905
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 2	FG-2216	.	6914666	Phase 2	D0N6CS	DB08687	CTPDG002168
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 2	HD-003	"NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki"	.	Phase 2	D07ZMQ	.	CTPDG002653
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Discontinued in Phase 2	NCX-4016	"Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate"	119032	Discontinued in Phase 2	D05OQX	DB12445	CTPDG002794
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 1/2	KD020	.	.	Phase 1/2	D0S7AW	.	CTPDG003328
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 1	ION532	AZD2373	.	Phase 1	DR07FQ	.	CTPDG003748
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 1	LEO-27847	"Renal system agent (kidney disease), LEO Pharma"	.	Phase 1	D0B0OA	.	CTPDG004926
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Phase 1	PT-201	.	.	Phase 1	D08KDU	.	CTPDG005047
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Discontinued in Phase 2	TAK-802	.	9888392	Discontinued in Phase 2	D03GAX	.	CTPDG006646
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Discontinued in Phase 1	RG7641	.	.	Discontinued in Phase 1	D09LEB	.	CTPDG006850
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Discontinued in Phase 1	ASP-0306	.	.	Discontinued in Phase 1	D05AQP	.	CTPDG006890
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Terminated	A-68828	"A 68828; L-Cysteinamide, L-arginyl-L-cysteinyl-3-cyclohexyl-L-alanylglycylglycyl-L-arginyl-L-isoleucyl-L-alpha-aspartyl-L-arginyl-L-isoleucyl-L-phenylalanyl-L-arginyl-, cyclic(2-13)-disulfide"	25079032	Terminated	D02NFA	.	CTPDG007547
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	CT-100	"CT-100, CisThera; PAI-1 modulator (humanized antibody, kidney disease), CisThera; Plasminogen activator inhibitor-1 modulator (humanized antibody, kidney disease), CisThera"	12015870	Investigative	D0X7LY	.	CTPDG007710
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	ZAMI-633	.	.	Investigative	D0S6NH	.	CTPDG007886
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	INDUS-815B	"INDUS-815B (kidney disease); INDUS-815B (kidney disease), Indus Biotech; Protein kinase D-2 modulator (kidney disease),Indus Biotech"	.	Investigative	D0O8FN	.	CTPDG008004
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	XEL-005OP	.	.	Investigative	D08NUS	.	CTPDG008606
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	ETR-001	.	.	Investigative	D05TLQ	.	CTPDG008796
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	Recombinant human CFH protein	"Recombinant human CFH protein (AMD/renal disease); Recombinant human CFH protein (AMD/renal disease), Optherion; Recombinant human complement factor H protein (AMD/renal disease), Optherion"	.	Investigative	D05GPN	.	CTPDG008839
M6ACROT05380	.	.	M6ADIS0119	GC2Z: Diseases of the urinary system	Investigative	AA-204	"BMP agonist (chronic kidney disease), Thrasos Therapeutics"	.	Investigative	D04JCT	.	CTPDG008889
M6ACROT05422	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 3	Milademetan	"(3'R,4'S,5'R)-N-((3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-indole)-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyloxan-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide; 1398568-47-2; 2,6-Anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide; AKOS040733738; BDBM50467678; CHEMBL4292264; CS-0021065; DB15257; DS3032; DS-3032; DS3032b; DS-3032B; EX-A6155; GTPL12941; HY-101266; L-Erythro-hexonamide, 2,6-anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-; L-erythro-Hexonamide, 2,6-anhydro-5-[[[(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-[3H]indol]-5'-yl]carbonyl]amino]-3,4,5-trideoxy-; MDM2 inhibitor DS-3032; Milademetan; MILADEMETAN [INN]; MILADEMETAN [USAN]; MILADEMETAN [WHO-DD]; MS-30758; NSC800893; NSC-800893; Q27896170; R3I80TLN7S; RAIN-32; RYAYYVTWKAOAJF-QISPRATLSA-N; SCHEMBL12527208; UNII-R3I80TLN7S; YFC56847"	73297272	Phase 3	DGB7W9	DB15257	CTPDG000906
M6ACROT05422	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05422	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05422	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 1	PF-07220060	.	.	Phase 1	DZJ3D5	.	CTPDG003644
M6ACROT05422	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT05423	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 3	Milademetan	"(3'R,4'S,5'R)-N-((3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-indole)-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyloxan-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide; 1398568-47-2; 2,6-Anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide; AKOS040733738; BDBM50467678; CHEMBL4292264; CS-0021065; DB15257; DS3032; DS-3032; DS3032b; DS-3032B; EX-A6155; GTPL12941; HY-101266; L-Erythro-hexonamide, 2,6-anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-; L-erythro-Hexonamide, 2,6-anhydro-5-[[[(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-[3H]indol]-5'-yl]carbonyl]amino]-3,4,5-trideoxy-; MDM2 inhibitor DS-3032; Milademetan; MILADEMETAN [INN]; MILADEMETAN [USAN]; MILADEMETAN [WHO-DD]; MS-30758; NSC800893; NSC-800893; Q27896170; R3I80TLN7S; RAIN-32; RYAYYVTWKAOAJF-QISPRATLSA-N; SCHEMBL12527208; UNII-R3I80TLN7S; YFC56847"	73297272	Phase 3	DGB7W9	DB15257	CTPDG000906
M6ACROT05423	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 3	Selinexor	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F	71481097	Phase 3	D00LNW	DB11942	CTPDG001499
M6ACROT05423	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05423	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 1	PF-07220060	.	.	Phase 1	DZJ3D5	.	CTPDG003644
M6ACROT05423	.	.	M6ADIS0052	2B59: Liposarcoma	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT05430	.	.	M6ADIS0026	ND56: Unspecific body region injury	Discontinued in Phase 2	ONO-4819	Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734	9803828	Discontinued in Phase 2	D0O4XW	.	CTPDG006463
M6ACROT05446	.	.	M6ADIS0026	ND56: Unspecific body region injury	Discontinued in Phase 2	ONO-4819	Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734	9803828	Discontinued in Phase 2	D0O4XW	.	CTPDG006463
M6ACROT05447	.	.	M6ADIS0026	ND56: Unspecific body region injury	Discontinued in Phase 2	ONO-4819	Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734	9803828	Discontinued in Phase 2	D0O4XW	.	CTPDG006463
M6ACROT05940	.	.	M6ADIS0026	ND56: Unspecific body region injury	Discontinued in Phase 2	ONO-4819	Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734	9803828	Discontinued in Phase 2	D0O4XW	.	CTPDG006463
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Vemurafenib	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	Approved	D0Y9EW	DB08881	CTPDG000048
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dacarbazine	"Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide"	135398738	Approved	D0Y7ZU	DB00851	CTPDG000052
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Teplizumab	.	.	Phase 3	D0VH4V	.	CTPDG000096
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	LGX818	Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)	50922675	Approved	D0TK7R	DB11718	CTPDG000129
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Interferon Alfa-2b	Intron A; Viraferon	71306834	Approved	D0P0WV	.	CTPDG000225
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tremetinib	.	.	Approved	D0N7XI	.	CTPDG000261
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Cemiplimab	REGN2810; REGN-2810; REGN 2810	.	Approved	D0KG4Q	.	CTPDG000296
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	Approved	D0JB3H	DB12513	CTPDG013047
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Isoproterenol	"Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409"	3779	Approved	D0I8FI	DB01064	CTPDG012395
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Melacine	"Melanoma vaccine (Detox-B), Corixa; Melanoma theraccine (Detox-B), Biomira/Ribi; Melanoma vaccine (Detox-B), Biomira/Ribi; Melanomavaccine (Detox-B), Corixa/Schering-Plough"	.	Approved	D0HV7K	.	CTPDG000357
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Ingenol mebutate	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A	6918670	Phase 3	D0E9KA	DB05013	CTPDG000402
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	ARRY-162	"606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); NVP-ME"	10288191	Approved	D0C4LF	DB11967	CTPDG000440
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Relatlimab	.	.	Approved	D0A3WJ	.	CTPDG000466
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tc-99m tilmanocept	Lymphoseek (TN)	.	Approved	D09XVS	.	CTPDG000477
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Palladium Pd 103	Palladium-103	9793711	Approved	D09XOR	DB15016	CTPDG000478
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	HybriCell	"Dendritic cell-tumor cell hybrid vaccine (melanoma, RCC), Genoa"	.	Approved	D07YUH	.	CTPDG000538
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	MK-3475	.	.	Approved	D07DMY	.	CTPDG000581
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Ipilimumab	BMS-734016; MDX-010; MDX-101; Yervoy (TN)	.	Approved	D07BVI	.	CTPDG000585
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib + dabrafenib	.	11707110	Approved	D06AGH	DB08911	CTPDG000612
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dabrafenib	"1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436"	44462760	Approved	D05ROI	DB08912	CTPDG000623
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	99mTc-depreotide	NeoSpect; NeoTect; P829 Techtide; Technetium-99m P829; Technetium-99m depreotide; 99mTc-P829	.	Approved	D05HWX	.	CTPDG000641
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Talimogene Laherparepvec	IMLYGIC	.	Approved	D05BXY	.	CTPDG000649
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Treosulfan	"Tresulfan; Dimesyl-meso-erythritol; Erythritol, 1,4-dimethanesulfonate; Erythritol, dimesyl-, meso-; Dihydroxymyleran; Dihydroxybusulfan; 1,4-Di(methanesulfonate)erythritol; NSC 94160; L-Threityl dimesylate; Erythritol, 1,4-bis(methanesulfonate); Threitol-1,4-bismethanesulfonate, meso-; CB 40069; 1,4-Bis(methanesulfonyloxy)-2,3-butanediol; 1,4-Bis(methylsulfonyloxy)threitol; Threitol 1,4-bis(methanesulfonate); ERYTHRITOL, 1,4-DIMETHANESULFONATE, (meso)-; NCGC00181153-01; L-Threitol 1,4-dimethanesulfonate"	9882105	Approved	D04YPN	DB11678	CTPDG000652
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib	GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN	11707110	Approved	D04XVN	DB08911	CTPDG000654
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	OncoVAX	"Cancer vaccine, Vaccinogen; OncoVAX, Vaccinogen; Autologous vaccine (colon cancer), Vaccinogen; OncoVAX-CL, Intracel; Vaccine(colon cancer), Intracel; Vaccine (colon cancer), Vaccinogen"	.	Preregistration	D0UR1Z	.	CTPDG000855
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	MPL-containing Pollinex allergy desensitization vaccine	"HDM SC vaccine, Allergy Therapeutics; House dust mite SC vaccine, Allergy Therapeutics; Pollinex Quattro (house dust mite allergy vaccine); Quattro MPL (house dust mite allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (house dust mites); MPL-containing Pollinex allergy desensitization vaccine (house dust mites), Allergy Therapeutics"	.	Preregistration	D01FWR	.	CTPDG000859
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Tilsotolimod	IMO-2125	.	Phase 3	D6YD0X	.	CTPDG000932
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR-214	bempegaldesleukin	.	Phase 3	D5ISZ1	.	CTPDG000936
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	"Melanoma vaccine, University of Virginia"	"Vaccine (melanoma); Melanoma-specific antigens, Argonex; Peptide vaccine/autologous dendritic cells, Argonex; Vaccine (melanoma), Argonex; Vaccine (melanoma), University of Virginia"	.	Phase 3	D0Z3ES	.	CTPDG000967
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Velimogene aliplasmid	Allovectin (TN)	.	Phase 3	D0Y9YN	.	CTPDG000974
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Seviprotimut-L	.	.	Phase 3	D0V0AF	.	CTPDG001030
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melanoma vaccine	"NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie"	.	Phase 3	D0U9MJ	.	CTPDG001034
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Multi-epitope peptide melanoma vaccine	"Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b"	.	Phase 3	D0P5TG	.	CTPDG001094
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Canvaxin	"Cancer vaccine, CancerVax; Melanoma vaccine, John Wayne Cancer Institute; Polyvalent melanoma cancer vaccine (PMCV)"	.	Phase 3	D0M4TF	.	CTPDG001131
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Pegargiminase	ADI-PEG-20	.	Phase 2	D0KB0Y	.	CTPDG001159
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	RG7421+RG7204	Cobimetinib+vemurafenib; Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	.	Phase 3	D0I5EU	.	CTPDG001182
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	IMO-2125	.	.	Phase 3	D0FM5M	.	CTPDG001207
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Daromun	darleukin + fibromun	.	Phase 3	D0CR9L	.	CTPDG001250
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SD-101	"HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo"	.	Phase 1/2	D08RJM	.	CTPDG001321
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Javelin	MJV-101	104768	Phase 3	D08PCH	.	CTPDG001325
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Spartalizumab	.	.	Phase 3	D08JLH	.	CTPDG001331
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melapuldencel-T	.	.	Phase 3	D06ZJD	.	CTPDG001370
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PDR001	.	.	Phase 3	D05BAJ	.	CTPDG001407
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	GMK	(3-Deoxy-3-(3-Methoxy-Benzamido)-B-D-Galactopyranosyl)-(3-Deoxy-3-(3-Methoxy-Benzamido)-2-O-Sulfo-B-D-Galactopyranosyl)-Sulfide; 3-deoxy-3-[(3-methoxybenzoyl)amino]-beta-D-galactopyranosyl 3-deoxy-3-[(3-methoxybenzoyl)amino]-2-O-sulfo-1-thio-beta-D-galactopyranoside	73729035	Phase 3	D04ORP	.	CTPDG001419
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Mitumomab	"LuVax; MelVax; BEC-2; EMD-60205; IMC-BEC2; Antimelanoma antibody, ImClone/Merck KGaA; Antimetastatic agents, ImClone/Merck KGaA; Melanoma vaccine, ImClone/Merck KGaA; GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering"	.	Phase 3	D04FNR	.	CTPDG001426
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	QS-21	AC1L1U2U; C92H148O46; LS-173109; 124716-EP2295426A1	60866	Phase 3	D03WOW	.	CTPDG001432
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	RemuneX	.	.	Discontinued in Phase 3	D03PLR	.	CTPDG001440
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	177Lu-DOTA-octreotate	"Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate"	.	Phase 3	D02ZHW	.	CTPDG001450
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MAGE-A3 immunotherapeutic	.	.	Phase 3	D02MPT	.	CTPDG001467
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Imprime PGG	Imprime PGG (TN)	.	Phase 1/2	D0P6MW	.	CTPDG001538
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	FX005	"TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076"	11001318	Phase 2/3	D04DFR	DB11644	CTPDG001573
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	HF10	Canerpaturev	.	Phase 2	DZ4A1W	.	CTPDG001600
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	EDP-1503	.	.	Phase 2	DYU37E	.	CTPDG001603
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	mRNA-4157	.	.	Phase 2	DTY5W0	.	CTPDG001630
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tavokinogene telseplasmid	TAVO	.	Phase 2	DT7O8R	.	CTPDG001633
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	V937	.	.	Phase 2	DOYP92	.	CTPDG001656
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Lifileucel	LN-144	.	Phase 2	DL5C1W	.	CTPDG001689
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PVSRIPO	.	.	Phase 2	DIWL76	.	CTPDG001699
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ad-RTS-hIL-12	.	.	Phase 2	D90UZW	.	CTPDG001770
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BNT111	.	.	Phase 2	D62LIX	.	CTPDG001795
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN 1201	.	.	Phase 1	D3JN6C	.	CTPDG001826
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Dorgenmeltucel-L	.	.	Phase 2	D0ZO7A	.	CTPDG001855
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Cancer vaccine	"Cancer vaccine, AVAX/Thomas Jefferson University; Vaccine (melanoma), Thomas Jefferson; Vaccine (DNP-modified), Thomas Jefferson"	.	Phase 2	D0Y7TC	.	CTPDG001878
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK-2302025A	"PRAME ASCI (melanoma), GSK; Recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (melanoma), GlaxoSmithKline"	.	Phase 2	D0X0SK	.	CTPDG001906
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Interleukin-12 gene therapy	.	.	Phase 2	D0U3AL	.	CTPDG001993
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PF-4878691	PF-04878691; PF-4171455	10309114	Phase 2	D0T1FC	DB12476	CTPDG002028
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	SentoClone	"Autologous T lymphocyte therapy (malignant melanoma), SentoClone; Autologous Th1 cell therapy (malignant melanoma), SentoClone"	.	Phase 2	D0R9FM	.	CTPDG002064
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MAGE-3-transduced autologous T-cell vaccine	"M3TK anticancer vaccine, MolMed/Takara; MAGE-3-transduced autologous T-cell vaccine (anticancer);MAGE-3-transduced autologous T-cell vaccine (anticancer), MolMed SpA/Takara Bio"	.	Phase 2	D0Q0SK	.	CTPDG002100
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CB-10-01	.	.	Phase 2	D0NT1S	.	CTPDG002153
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APN-301	EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2	.	Phase 2	D0NS7A	.	CTPDG002155
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Multi-epitope tyrosinase/gp100 vaccine	"Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering"	.	Phase 2	D0N7FD	.	CTPDG002165
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Antigen-pulsed dendritic cell vaccine	Antigen-pulsed dendritic cell vaccine (melanoma)	.	Phase 2	D0MI0S	.	CTPDG002187
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Stage IV melanoma vaccine	"Stage IV melanoma vaccine, ARI; Stage IV melanoma vaccine, Adelaide Research & Innovation"	.	Phase 2	D0KC9U	.	CTPDG002255
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MKC-1106-MT	"Melanoma vaccine (MART-1/tyrosinase), Mannkind"	.	Phase 2	D0J7MQ	.	CTPDG002283
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Telomelysin	.	.	Phase 2	D0I3VV	.	CTPDG002315
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes	"Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma); Autologous anti-gp100 TCR gene-engineered PBLs (melanoma), NCI; Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma), National Cancer Institute"	.	Phase 2	D0I3VS	.	CTPDG002316
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tumor infiltrating lymphocyte	.	.	Phase 2	D0H8DS	.	CTPDG002334
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ontuxizumab	Amatuximab	.	Phase 2	D0FK9H	.	CTPDG002385
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Anti-CD3 activated vaccine-primed lymphocytes	"VPLN tumor vaccine, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer); Monoclonal antiobody activated vaccine-primed lymphocytes (cancer), University of Michigan; Vaccine-primed lymph node (VPLN) cells, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer), University of Michigan; Anti-CD3/anti-CD28 activated vaccine-primed lymphocytes (cancer), University of Michigan"	.	Phase 2	D0E8KO	.	CTPDG002417
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Resimmune	A-dmDT390-bisFv immunotoxin	.	Phase 1/2	D0C3TI	.	CTPDG002489
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ABX-IL8	.	.	Phase 2	D0BF9K	.	CTPDG002502
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ITIL-168	.	.	Phase 2	D0B6AZ	.	CTPDG002511
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi-8 PrimeBoost therapeutic melanoma vaccine	"Hi-8 MEL; Melanoma therapeutic vaccine, Oxxon; PSG2.Mel3; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxford BioMedica; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Lead Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Pharmaccine therapy (melanoma), Oxxon; DNA/MVA immunotherapy (melanoma), Oxxon; MEL-1 immunotherapy (melanoma), Oxxon; Melanoma immunotherapy (Prime-Boost), Oxxon"	.	Phase 2	D0A9BI	.	CTPDG002537
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN-1201	.	.	Phase 1	D0A3CH	.	CTPDG002550
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CYT-004-MelQbG10	"Immunodrug vaccine (melanoma), Cytos; QbG10 Immunodrug carrier (cancer), Cytos"	.	Phase 2	D08KAD	.	CTPDG002632
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Gp100:209-217(210M) peptide vaccine	"Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI"	.	Phase 2	D08DWM	.	CTPDG002646
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	LN-144	.	.	Phase 2	D08DIU	.	CTPDG002648
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MLN2480	"VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819"	25161177	Phase 2	D07IEU	DB15266	CTPDG002698
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ARC-100	SCHEMBL13011610	57339443	Phase 2	D07GCK	.	CTPDG002701
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	AG140699	.	.	Phase 2	D06KZL	.	CTPDG002747
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	E7016	"UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016"	11660296	Phase 2	D06DHB	.	CTPDG002770
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GR-MD-02	Belapectin	.	Phase 2	D06BKH	.	CTPDG002771
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PLX8394	.	90116675	Phase 2	D05HTS	.	CTPDG002807
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi8 melanoma vaccine	.	.	Phase 2	D04HMK	.	CTPDG002864
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GCAN 101	.	.	Phase 2	D03TNG	.	CTPDG002903
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MSB0010445	.	.	Phase 2	D03LAI	.	CTPDG002922
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	RAF265	927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594	11656518	Phase 2	D03AND	DB05984	CTPDG002939
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Urelumab	.	.	Phase 2	D02ZMB	.	CTPDG002942
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MORAb-004	.	.	Phase 2	D02RKG	.	CTPDG002961
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Leuvectin	"IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical"	.	Phase 2	D01WHC	.	CTPDG003004
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Polynoma-1	"Polyvalent melanoma vaccine, Vaccinoma"	.	Phase 2	D00DSV	.	CTPDG003100
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ENB003	"2364572-10-9; AAY8R26VDX; BQ 788-d2; BQ-788, di(methyl-d)-; CHEMBL5095234; D-Norleucine, N-((cis-2,6-di(methyl-d)-1-piperidinyl)carbonyl)-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl-, sodium salt; Enb 003; ENB 003 [WHO-DD]; ENB003; ENB-003; UNII-AAY8R26VDX; Vodudeutentan sodium"	145722637	Phase 1/2	DUOX13	.	CTPDG003137
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HL-085	.	.	Phase 1/2	DJ8TN2	.	CTPDG003174
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NKTR-262	.	.	Phase 1/2	D8JN5H	.	CTPDG003216
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Antigen-specific melanoma vaccine	.	.	Phase 1/2	D0Z2UY	.	CTPDG003269
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmuFact IMP321	.	.	Phase 1/2	D0U5AN	.	CTPDG003306
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LXS196	"XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide"	118873253	Phase 1/2	D0R7HL	.	CTPDG003336
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	AU-011	.	.	Phase 1/2	D0R0NX	.	CTPDG003341
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	TRX-518	"GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx"	.	Phase 1/2	D0J1MO	.	CTPDG003407
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	IMCnyeso	.	.	Phase 1/2	D0I9YM	.	CTPDG003414
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NCI-4650	.	.	Phase 1/2	D07YNC	.	CTPDG003518
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Ad-IL-12 DNA therapeutic	INXN-2001	.	Phase 1/2	D06LUI	.	CTPDG003539
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SCIB-1	"SCIB-5; SCIB-1 DNA vaccine (melanoma, TriGrid), Scancell; Anti-TRP-2/ anti-gp100 monoclonal antibody vaccine (melanoma), Scancell"	.	Phase 1/2	D06AWA	.	CTPDG003547
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmunoVEX-timelan	.	.	Phase 1/2	D01EYR	.	CTPDG003621
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	CLL442	.	.	Phase 1/2	D01DIM	.	CTPDG003623
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AV-MEL-1	.	.	Phase 1	DX06ZU	.	CTPDG003672
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CV8102	.	.	Phase 1	DVU2H8	.	CTPDG003683
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INXN 2001	.	.	Phase 1	DMP6A9	.	CTPDG003817
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CDX-1140	.	.	Phase 1	DKM7S3	.	CTPDG003841
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PF-07284890	"1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; 2573781-75-4; AR00504461; ARRY461; ARRY-461; ARRY-461; BDBM565133; CHEMBL5095256; CS-0564141; EX-A7593; GTPL12096; HY-147405; JNJ5N2RH5W; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; PF07284890; PF-07284890; PF-07284890; SCHEMBL22831935; Tinlorafenib; tinlorafenib [INN]; Tinlorafenib [USAN]; UNII-JNJ5N2RH5W; US11414404, Ex. # 10; WHO 12353"	155434855	Phase 1	DJ8QW7	.	CTPDG003866
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	XmAb20717	XmAb717	.	Phase 1	DD1TJ8	.	CTPDG003947
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SX-682	"1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-"	90467234	Phase 1	DAY4L1	.	CTPDG003976
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SB 11285	.	.	Phase 1	DA79HM	.	CTPDG003980
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CMP-001	vidutolimod	.	Phase 1	D7T5AN	.	CTPDG004031
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRT1419	.	.	Phase 1	D50CXM	.	CTPDG004103
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INCAGN2385	.	.	Phase 1	D4KTA9	.	CTPDG004112
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TBX-3400	.	.	Phase 1	D2DB5T	.	CTPDG004169
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ifx-Hu2.0	.	.	Phase 1	D1NC2O	.	CTPDG004188
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	VCL-1M01	"VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical"	.	Phase 1	D0ZM5E	.	CTPDG004215
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GPA-TriMAR-T cells	.	.	Phase 1	D0YU0L	.	CTPDG004240
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PTI-188	.	.	Phase 1	D0Y7SN	.	CTPDG004253
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Dendritic cancer cell vaccine	.	.	Phase 1	D0Y0RF	.	CTPDG004266
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	BETULINIC ACID	"472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624"	64971	Phase 1	D0R9YR	DB12480	CTPDG004453
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Multipeptide vaccine combination	"Multipeptide vaccine combination (melanoma); Multipeptide vaccine combination (melanoma), Ludwig; MAGE-10.A2+ Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig; MAGE-10.A2 + Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig/Columbia"	.	Phase 1	D0R2LY	.	CTPDG004464
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Adoptive T-cell therapy	Adoptive T-cell therapy (cancer)	.	Phase 1	D0P4JJ	.	CTPDG004523
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Vaccimel	"Melanoma cell line vaccine (cancer), Centro de Investigaciones Oncologicas; Autologous dendritic cells + allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; Dendritic cells + apoptotic/necrotic allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; DC/Apo-Nec vaccine (melanoma), Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires"	.	Phase 1	D0LT2Z	.	CTPDG004610
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Lipovaxin-MM	"Dendritic cell-specific antigen targeting vaccine (liposome/nanoparticle/intravenous, melanoma), Lipotek"	.	Phase 1	D0L2OT	.	CTPDG004636
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GSK-2241658A	"NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A"	.	Phase 1	D0IA5O	.	CTPDG004713
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ICON-1	.	.	Phase 1	D0H6UL	.	CTPDG004748
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PLX-4720	PLX 4720; PLX4720 (BRAF inhibitor)	24180719	Phase 1	D0F5JZ	DB06999	CTPDG004804
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AE-08	.	.	Phase 1	D0F5GF	.	CTPDG004805
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TAK-202	.	.	Phase 1	D0DT2S	.	CTPDG004844
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AEB701	.	.	Phase 1	D0B2NF	.	CTPDG004924
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	UV1 + GM-CSF vaccine	.	.	Phase 1	D09UMR	.	CTPDG004968
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AMEP	"(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U"	14017	Phase 1	D08XBF	.	CTPDG005023
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Melanoma DNA vaccine	.	.	Phase 1	D07YZQ	.	CTPDG005073
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DEDN-6526A	.	.	Phase 1	D07XXT	.	CTPDG005076
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	IL-2 pDNA	.	.	Phase 1	D07JSX	.	CTPDG005099
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AT13387	AT-13387	11955716	Phase 1	D06YSP	DB06306	CTPDG005131
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ioflubenzamide (131I)	"Solazed; Ioflubenzamide I-131; MIP-1104; MIP-1143; MIP-1144; MIP-1145; ZK-BA; Iodine-123-Solazed; Iodine-131-Solazed; MIP-1145-[123I]; MIP-1145-[131I]; Radiolabeled benzamides (melanoma), Bayer; Radiolabeled benzamides (melanoma), Molecular Insight; Iodine-123-ZK-BA; Iodine-131-ZK-BA; Melanin-targeting radiodiagnostic (melanoma), Bayer/Molecular Insight; Melanin-targeting radiotherapeutic (melanoma), Bayer/Molecular Insight; 123I-MIP-1145; 123I-Solazed; 123I-ZK-BA"	24828760	Phase 1	D06SYN	.	CTPDG005140
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SAM-6	.	.	Phase 1	D06PZC	.	CTPDG005148
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Flanvotumab	"IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly"	.	Phase 1	D05WQT	.	CTPDG005180
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CAR-T cells recognizing EpCAM	.	.	Phase 1	D04RNG	.	CTPDG005241
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DC-IL-12 DNA therapeutic	INXN-3001	.	Phase 1	D03OKS	.	CTPDG005298
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	LV305	NY-ESO-1 Zvex	.	Phase 1	D02XTT	.	CTPDG005333
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TTI-621	.	.	Phase 1	D01CUO	.	CTPDG005422
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRAME antigen-specific cancer immunotherapeutic	.	.	Phase 1	D00AHT	.	CTPDG005477
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	Nuleusin	"IL-2 (subcutaneous formulation, RCC/MM), 3SBio"	.	Discontinued in Phase 3	D0PE0D	.	CTPDG006342
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	IDD-3	"Uvidem; Dendritophage + melanoma tumor cell lysate; Melanoma vaccine, Immuno-Designed Molecules/ IDM Pharma; Vaccine (melanoma), Immuno-Designed Molecules /IDM Pharma"	.	Discontinued in Phase 2	D0PH0M	.	CTPDG006457
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	BIWB-1	"Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender"	.	Discontinued in Phase 2	D0C7OQ	.	CTPDG006543
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melanoma vaccine (ALVAC)	"Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur"	.	Discontinued in Phase 2	D0C1EO	.	CTPDG006547
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	TriGem	"Monoclonal antibody 1A7, Titan Pharmaceuticals; Anti-I17 antibody, Trilex"	.	Discontinued in Phase 2	D08GEX	.	CTPDG006583
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melaxin	"Autologous dendritoma vaccine (sc, melanoma), Oncolix"	.	Discontinued in Phase 2	D07FDV	.	CTPDG006596
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Ecromeximab	.	.	Discontinued in Phase 2	D05PWZ	.	CTPDG006614
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	XomaZyme-Mel	XMMME-0001-RTA	.	Discontinued in Phase 2	D03WSE	.	CTPDG006638
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Zeniplatin	CL-286558	56840898	Discontinued in Phase 2	D00CFB	.	CTPDG006680
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1/2	ODC-0501	"Dendritic cell vaccine (melanoma), ODC; Vaccine (melanoma), ODC"	.	Discontinued in Phase 1/2	D02FEJ	.	CTPDG006699
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG-7256	"B-raf inhibitor (melanoma), Roche/Plexxikon"	.	Discontinued in Phase 1	D0RV7J	.	CTPDG006750
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG7636	.	.	Discontinued in Phase 1	D0J0IJ	.	CTPDG006800
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	ABX-MA1	"Anti-MUC18 MAb, Abgenix"	.	Discontinued in Phase 1	D0G7YG	.	CTPDG006814
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	F-50040	"Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre"	.	Discontinued in Phase 1	D07CQJ	.	CTPDG006871
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Terminated	DISC GM-CSF	.	.	Terminated	D0X4UA	.	CTPDG007182
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Withaferin A	"Heat shock factor 1 inhibitor (melanoma), University of Kansas; HSF-1 inhibitor (melanoma), University of Kansas"	265237	Terminated	D0V3PN	.	CTPDG007199
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Terminated	SBP-002	"Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec"	.	Terminated	D0G0UZ	.	CTPDG007351
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Terminated	RAAV vaccine	.	.	Terminated	D0C3DH	.	CTPDG007389
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Novovac-M1	.	.	Terminated	D01CJB	.	CTPDG007576
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VLD-631	.	.	Investigative	D0ZE7B	.	CTPDG007618
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	SMT-C2100	.	.	Investigative	D0Z4YK	.	CTPDG007634
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TOCA-621	"Viral vector-delivered interferon gamma gene therapy (malignant melanoma), Tocagen"	.	Investigative	D0Z3ZF	.	CTPDG007636
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	NVX-412	.	.	Investigative	D0XU4O	.	CTPDG007687
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VitiGam	.	.	Investigative	D0X8EE	.	CTPDG007708
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	CGEN-791	.	.	Investigative	D0X4AN	.	CTPDG007726
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	IMX-MEL1	"Melanoma therapeutic vaccine, Imaxio"	.	Investigative	D0T6PF	.	CTPDG007851
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lm Melanoma	"Recombinant bacterial vector vaccine (melanoma), Aduro BioTech/New York University"	.	Investigative	D0R2YD	.	CTPDG007917
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	ADS-NPTMZ-1	.	.	Investigative	D0P6CQ	.	CTPDG007979
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Narciclasine	"Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one"	72376	Investigative	D0OQ1I	.	CTPDG007994
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico"	"Imaging agent (melanoma), NuView; 111In-DOTA-GlyGlu-CycMSH (melanoma), NuView/University of New Mexico"	.	Investigative	D0N7XY	.	CTPDG008036
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Ektomun	"Antibody (melanoma), Trion"	.	Investigative	D0L8TP	.	CTPDG008106
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PDS-0102	"Versamune-Melanoma; Vaccine (cationic lipid nanoparticle formulation, melanoma), PDS Biotechnology"	.	Investigative	D0H7OO	.	CTPDG008234
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MTI-SAM3	.	.	Investigative	D0E7IZ	.	CTPDG008339
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Box-5	"Wnt-5a antagonist (peptide, melanoma/metastasis), WntResearch"	.	Investigative	D0E0DS	.	CTPDG008356
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	20D75	.	.	Investigative	D0D3LZ	.	CTPDG008382
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	BCL-005	.	.	Investigative	D0C6XD	.	CTPDG008407
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	.	.	Investigative	D0A3SQ	.	CTPDG008495
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"1,3-bis(1,3-benzothiazol-2-ylthio)acetone"	"1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409"	1240423	Investigative	D07DZS	.	CTPDG008704
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PRAME-SLP	"Peptide vaccine(cancer), ISA Pharmaceuticals; Preferentially expressed antigen based vaccine (SLP technology/peptide, melanoma), ISA"	.	Investigative	D06RYG	.	CTPDG008736
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	AEZS-120	"Cancer vaccine (bacterial vector), University of Wurzburg/AEterna Zentaris"	.	Investigative	D06KGC	.	CTPDG008754
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	5-fluoro-1H-indole-2-carboxylic acid	"5-Fluoroindole-2-carboxylic acid; 399-76-8; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690"	1820	Investigative	D06BFH	.	CTPDG008772
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TriMixDC	"Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles"	.	Investigative	D04PFD	.	CTPDG008870
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	OP-03	"OP-03 program (prodrug, melanoma); OP-03 program (prodrug, melanoma), Onco-Pharmakon"	.	Investigative	D04EFB	.	CTPDG008905
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LG-723	.	.	Investigative	D01VZQ	.	CTPDG009059
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LY-1-100	"SMART derivatives (melanoma); LY-2-45; SMART derivatives (melanoma), University of Tennessee"	.	Investigative	D01NKF	.	CTPDG009090
M6ACROT05465	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lovaxin M	"HMW-MAA cancer vaccine (Listeria vector), Advaxis"	.	Investigative	D00QLG	.	CTPDG009162
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Vemurafenib	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	Approved	D0Y9EW	DB08881	CTPDG000048
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dacarbazine	"Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide"	135398738	Approved	D0Y7ZU	DB00851	CTPDG000052
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Teplizumab	.	.	Phase 3	D0VH4V	.	CTPDG000096
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	LGX818	Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)	50922675	Approved	D0TK7R	DB11718	CTPDG000129
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Interferon Alfa-2b	Intron A; Viraferon	71306834	Approved	D0P0WV	.	CTPDG000225
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tremetinib	.	.	Approved	D0N7XI	.	CTPDG000261
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Cemiplimab	REGN2810; REGN-2810; REGN 2810	.	Approved	D0KG4Q	.	CTPDG000296
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	Approved	D0JB3H	DB12513	CTPDG013047
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Isoproterenol	"Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409"	3779	Approved	D0I8FI	DB01064	CTPDG012395
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Melacine	"Melanoma vaccine (Detox-B), Corixa; Melanoma theraccine (Detox-B), Biomira/Ribi; Melanoma vaccine (Detox-B), Biomira/Ribi; Melanomavaccine (Detox-B), Corixa/Schering-Plough"	.	Approved	D0HV7K	.	CTPDG000357
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Ingenol mebutate	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A	6918670	Phase 3	D0E9KA	DB05013	CTPDG000402
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	ARRY-162	"606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); NVP-ME"	10288191	Approved	D0C4LF	DB11967	CTPDG000440
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Relatlimab	.	.	Approved	D0A3WJ	.	CTPDG000466
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tc-99m tilmanocept	Lymphoseek (TN)	.	Approved	D09XVS	.	CTPDG000477
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Palladium Pd 103	Palladium-103	9793711	Approved	D09XOR	DB15016	CTPDG000478
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	HybriCell	"Dendritic cell-tumor cell hybrid vaccine (melanoma, RCC), Genoa"	.	Approved	D07YUH	.	CTPDG000538
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	MK-3475	.	.	Approved	D07DMY	.	CTPDG000581
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Ipilimumab	BMS-734016; MDX-010; MDX-101; Yervoy (TN)	.	Approved	D07BVI	.	CTPDG000585
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib + dabrafenib	.	11707110	Approved	D06AGH	DB08911	CTPDG000612
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dabrafenib	"1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436"	44462760	Approved	D05ROI	DB08912	CTPDG000623
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	99mTc-depreotide	NeoSpect; NeoTect; P829 Techtide; Technetium-99m P829; Technetium-99m depreotide; 99mTc-P829	.	Approved	D05HWX	.	CTPDG000641
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Talimogene Laherparepvec	IMLYGIC	.	Approved	D05BXY	.	CTPDG000649
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Treosulfan	"Tresulfan; Dimesyl-meso-erythritol; Erythritol, 1,4-dimethanesulfonate; Erythritol, dimesyl-, meso-; Dihydroxymyleran; Dihydroxybusulfan; 1,4-Di(methanesulfonate)erythritol; NSC 94160; L-Threityl dimesylate; Erythritol, 1,4-bis(methanesulfonate); Threitol-1,4-bismethanesulfonate, meso-; CB 40069; 1,4-Bis(methanesulfonyloxy)-2,3-butanediol; 1,4-Bis(methylsulfonyloxy)threitol; Threitol 1,4-bis(methanesulfonate); ERYTHRITOL, 1,4-DIMETHANESULFONATE, (meso)-; NCGC00181153-01; L-Threitol 1,4-dimethanesulfonate"	9882105	Approved	D04YPN	DB11678	CTPDG000652
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib	GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN	11707110	Approved	D04XVN	DB08911	CTPDG000654
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	OncoVAX	"Cancer vaccine, Vaccinogen; OncoVAX, Vaccinogen; Autologous vaccine (colon cancer), Vaccinogen; OncoVAX-CL, Intracel; Vaccine(colon cancer), Intracel; Vaccine (colon cancer), Vaccinogen"	.	Preregistration	D0UR1Z	.	CTPDG000855
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	MPL-containing Pollinex allergy desensitization vaccine	"HDM SC vaccine, Allergy Therapeutics; House dust mite SC vaccine, Allergy Therapeutics; Pollinex Quattro (house dust mite allergy vaccine); Quattro MPL (house dust mite allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (house dust mites); MPL-containing Pollinex allergy desensitization vaccine (house dust mites), Allergy Therapeutics"	.	Preregistration	D01FWR	.	CTPDG000859
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Tilsotolimod	IMO-2125	.	Phase 3	D6YD0X	.	CTPDG000932
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR-214	bempegaldesleukin	.	Phase 3	D5ISZ1	.	CTPDG000936
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	"Melanoma vaccine, University of Virginia"	"Vaccine (melanoma); Melanoma-specific antigens, Argonex; Peptide vaccine/autologous dendritic cells, Argonex; Vaccine (melanoma), Argonex; Vaccine (melanoma), University of Virginia"	.	Phase 3	D0Z3ES	.	CTPDG000967
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Velimogene aliplasmid	Allovectin (TN)	.	Phase 3	D0Y9YN	.	CTPDG000974
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Seviprotimut-L	.	.	Phase 3	D0V0AF	.	CTPDG001030
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melanoma vaccine	"NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie"	.	Phase 3	D0U9MJ	.	CTPDG001034
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Multi-epitope peptide melanoma vaccine	"Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b"	.	Phase 3	D0P5TG	.	CTPDG001094
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Canvaxin	"Cancer vaccine, CancerVax; Melanoma vaccine, John Wayne Cancer Institute; Polyvalent melanoma cancer vaccine (PMCV)"	.	Phase 3	D0M4TF	.	CTPDG001131
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Pegargiminase	ADI-PEG-20	.	Phase 2	D0KB0Y	.	CTPDG001159
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	RG7421+RG7204	Cobimetinib+vemurafenib; Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	.	Phase 3	D0I5EU	.	CTPDG001182
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	IMO-2125	.	.	Phase 3	D0FM5M	.	CTPDG001207
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Daromun	darleukin + fibromun	.	Phase 3	D0CR9L	.	CTPDG001250
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SD-101	"HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo"	.	Phase 1/2	D08RJM	.	CTPDG001321
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Javelin	MJV-101	104768	Phase 3	D08PCH	.	CTPDG001325
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Spartalizumab	.	.	Phase 3	D08JLH	.	CTPDG001331
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melapuldencel-T	.	.	Phase 3	D06ZJD	.	CTPDG001370
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PDR001	.	.	Phase 3	D05BAJ	.	CTPDG001407
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	GMK	(3-Deoxy-3-(3-Methoxy-Benzamido)-B-D-Galactopyranosyl)-(3-Deoxy-3-(3-Methoxy-Benzamido)-2-O-Sulfo-B-D-Galactopyranosyl)-Sulfide; 3-deoxy-3-[(3-methoxybenzoyl)amino]-beta-D-galactopyranosyl 3-deoxy-3-[(3-methoxybenzoyl)amino]-2-O-sulfo-1-thio-beta-D-galactopyranoside	73729035	Phase 3	D04ORP	.	CTPDG001419
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Mitumomab	"LuVax; MelVax; BEC-2; EMD-60205; IMC-BEC2; Antimelanoma antibody, ImClone/Merck KGaA; Antimetastatic agents, ImClone/Merck KGaA; Melanoma vaccine, ImClone/Merck KGaA; GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering"	.	Phase 3	D04FNR	.	CTPDG001426
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	QS-21	AC1L1U2U; C92H148O46; LS-173109; 124716-EP2295426A1	60866	Phase 3	D03WOW	.	CTPDG001432
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	RemuneX	.	.	Discontinued in Phase 3	D03PLR	.	CTPDG001440
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	177Lu-DOTA-octreotate	"Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate"	.	Phase 3	D02ZHW	.	CTPDG001450
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MAGE-A3 immunotherapeutic	.	.	Phase 3	D02MPT	.	CTPDG001467
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Imprime PGG	Imprime PGG (TN)	.	Phase 1/2	D0P6MW	.	CTPDG001538
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	FX005	"TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076"	11001318	Phase 2/3	D04DFR	DB11644	CTPDG001573
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	HF10	Canerpaturev	.	Phase 2	DZ4A1W	.	CTPDG001600
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	EDP-1503	.	.	Phase 2	DYU37E	.	CTPDG001603
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	mRNA-4157	.	.	Phase 2	DTY5W0	.	CTPDG001630
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tavokinogene telseplasmid	TAVO	.	Phase 2	DT7O8R	.	CTPDG001633
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	V937	.	.	Phase 2	DOYP92	.	CTPDG001656
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Lifileucel	LN-144	.	Phase 2	DL5C1W	.	CTPDG001689
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PVSRIPO	.	.	Phase 2	DIWL76	.	CTPDG001699
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ad-RTS-hIL-12	.	.	Phase 2	D90UZW	.	CTPDG001770
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BNT111	.	.	Phase 2	D62LIX	.	CTPDG001795
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN 1201	.	.	Phase 1	D3JN6C	.	CTPDG001826
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Dorgenmeltucel-L	.	.	Phase 2	D0ZO7A	.	CTPDG001855
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Cancer vaccine	"Cancer vaccine, AVAX/Thomas Jefferson University; Vaccine (melanoma), Thomas Jefferson; Vaccine (DNP-modified), Thomas Jefferson"	.	Phase 2	D0Y7TC	.	CTPDG001878
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK-2302025A	"PRAME ASCI (melanoma), GSK; Recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (melanoma), GlaxoSmithKline"	.	Phase 2	D0X0SK	.	CTPDG001906
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Interleukin-12 gene therapy	.	.	Phase 2	D0U3AL	.	CTPDG001993
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PF-4878691	PF-04878691; PF-4171455	10309114	Phase 2	D0T1FC	DB12476	CTPDG002028
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	SentoClone	"Autologous T lymphocyte therapy (malignant melanoma), SentoClone; Autologous Th1 cell therapy (malignant melanoma), SentoClone"	.	Phase 2	D0R9FM	.	CTPDG002064
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MAGE-3-transduced autologous T-cell vaccine	"M3TK anticancer vaccine, MolMed/Takara; MAGE-3-transduced autologous T-cell vaccine (anticancer);MAGE-3-transduced autologous T-cell vaccine (anticancer), MolMed SpA/Takara Bio"	.	Phase 2	D0Q0SK	.	CTPDG002100
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CB-10-01	.	.	Phase 2	D0NT1S	.	CTPDG002153
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APN-301	EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2	.	Phase 2	D0NS7A	.	CTPDG002155
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Multi-epitope tyrosinase/gp100 vaccine	"Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering"	.	Phase 2	D0N7FD	.	CTPDG002165
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Antigen-pulsed dendritic cell vaccine	Antigen-pulsed dendritic cell vaccine (melanoma)	.	Phase 2	D0MI0S	.	CTPDG002187
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Stage IV melanoma vaccine	"Stage IV melanoma vaccine, ARI; Stage IV melanoma vaccine, Adelaide Research & Innovation"	.	Phase 2	D0KC9U	.	CTPDG002255
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MKC-1106-MT	"Melanoma vaccine (MART-1/tyrosinase), Mannkind"	.	Phase 2	D0J7MQ	.	CTPDG002283
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Telomelysin	.	.	Phase 2	D0I3VV	.	CTPDG002315
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes	"Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma); Autologous anti-gp100 TCR gene-engineered PBLs (melanoma), NCI; Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma), National Cancer Institute"	.	Phase 2	D0I3VS	.	CTPDG002316
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tumor infiltrating lymphocyte	.	.	Phase 2	D0H8DS	.	CTPDG002334
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ontuxizumab	Amatuximab	.	Phase 2	D0FK9H	.	CTPDG002385
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Anti-CD3 activated vaccine-primed lymphocytes	"VPLN tumor vaccine, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer); Monoclonal antiobody activated vaccine-primed lymphocytes (cancer), University of Michigan; Vaccine-primed lymph node (VPLN) cells, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer), University of Michigan; Anti-CD3/anti-CD28 activated vaccine-primed lymphocytes (cancer), University of Michigan"	.	Phase 2	D0E8KO	.	CTPDG002417
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Resimmune	A-dmDT390-bisFv immunotoxin	.	Phase 1/2	D0C3TI	.	CTPDG002489
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ABX-IL8	.	.	Phase 2	D0BF9K	.	CTPDG002502
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ITIL-168	.	.	Phase 2	D0B6AZ	.	CTPDG002511
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi-8 PrimeBoost therapeutic melanoma vaccine	"Hi-8 MEL; Melanoma therapeutic vaccine, Oxxon; PSG2.Mel3; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxford BioMedica; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Lead Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Pharmaccine therapy (melanoma), Oxxon; DNA/MVA immunotherapy (melanoma), Oxxon; MEL-1 immunotherapy (melanoma), Oxxon; Melanoma immunotherapy (Prime-Boost), Oxxon"	.	Phase 2	D0A9BI	.	CTPDG002537
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN-1201	.	.	Phase 1	D0A3CH	.	CTPDG002550
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CYT-004-MelQbG10	"Immunodrug vaccine (melanoma), Cytos; QbG10 Immunodrug carrier (cancer), Cytos"	.	Phase 2	D08KAD	.	CTPDG002632
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Gp100:209-217(210M) peptide vaccine	"Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI"	.	Phase 2	D08DWM	.	CTPDG002646
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	LN-144	.	.	Phase 2	D08DIU	.	CTPDG002648
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MLN2480	"VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819"	25161177	Phase 2	D07IEU	DB15266	CTPDG002698
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ARC-100	SCHEMBL13011610	57339443	Phase 2	D07GCK	.	CTPDG002701
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	AG140699	.	.	Phase 2	D06KZL	.	CTPDG002747
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	E7016	"UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016"	11660296	Phase 2	D06DHB	.	CTPDG002770
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GR-MD-02	Belapectin	.	Phase 2	D06BKH	.	CTPDG002771
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PLX8394	.	90116675	Phase 2	D05HTS	.	CTPDG002807
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi8 melanoma vaccine	.	.	Phase 2	D04HMK	.	CTPDG002864
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GCAN 101	.	.	Phase 2	D03TNG	.	CTPDG002903
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MSB0010445	.	.	Phase 2	D03LAI	.	CTPDG002922
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	RAF265	927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594	11656518	Phase 2	D03AND	DB05984	CTPDG002939
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Urelumab	.	.	Phase 2	D02ZMB	.	CTPDG002942
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MORAb-004	.	.	Phase 2	D02RKG	.	CTPDG002961
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Leuvectin	"IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical"	.	Phase 2	D01WHC	.	CTPDG003004
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Polynoma-1	"Polyvalent melanoma vaccine, Vaccinoma"	.	Phase 2	D00DSV	.	CTPDG003100
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ENB003	"2364572-10-9; AAY8R26VDX; BQ 788-d2; BQ-788, di(methyl-d)-; CHEMBL5095234; D-Norleucine, N-((cis-2,6-di(methyl-d)-1-piperidinyl)carbonyl)-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl-, sodium salt; Enb 003; ENB 003 [WHO-DD]; ENB003; ENB-003; UNII-AAY8R26VDX; Vodudeutentan sodium"	145722637	Phase 1/2	DUOX13	.	CTPDG003137
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HL-085	.	.	Phase 1/2	DJ8TN2	.	CTPDG003174
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NKTR-262	.	.	Phase 1/2	D8JN5H	.	CTPDG003216
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Antigen-specific melanoma vaccine	.	.	Phase 1/2	D0Z2UY	.	CTPDG003269
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmuFact IMP321	.	.	Phase 1/2	D0U5AN	.	CTPDG003306
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LXS196	"XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide"	118873253	Phase 1/2	D0R7HL	.	CTPDG003336
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	AU-011	.	.	Phase 1/2	D0R0NX	.	CTPDG003341
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	TRX-518	"GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx"	.	Phase 1/2	D0J1MO	.	CTPDG003407
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	IMCnyeso	.	.	Phase 1/2	D0I9YM	.	CTPDG003414
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NCI-4650	.	.	Phase 1/2	D07YNC	.	CTPDG003518
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Ad-IL-12 DNA therapeutic	INXN-2001	.	Phase 1/2	D06LUI	.	CTPDG003539
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SCIB-1	"SCIB-5; SCIB-1 DNA vaccine (melanoma, TriGrid), Scancell; Anti-TRP-2/ anti-gp100 monoclonal antibody vaccine (melanoma), Scancell"	.	Phase 1/2	D06AWA	.	CTPDG003547
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmunoVEX-timelan	.	.	Phase 1/2	D01EYR	.	CTPDG003621
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	CLL442	.	.	Phase 1/2	D01DIM	.	CTPDG003623
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AV-MEL-1	.	.	Phase 1	DX06ZU	.	CTPDG003672
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CV8102	.	.	Phase 1	DVU2H8	.	CTPDG003683
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INXN 2001	.	.	Phase 1	DMP6A9	.	CTPDG003817
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CDX-1140	.	.	Phase 1	DKM7S3	.	CTPDG003841
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PF-07284890	"1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; 2573781-75-4; AR00504461; ARRY461; ARRY-461; ARRY-461; BDBM565133; CHEMBL5095256; CS-0564141; EX-A7593; GTPL12096; HY-147405; JNJ5N2RH5W; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; PF07284890; PF-07284890; PF-07284890; SCHEMBL22831935; Tinlorafenib; tinlorafenib [INN]; Tinlorafenib [USAN]; UNII-JNJ5N2RH5W; US11414404, Ex. # 10; WHO 12353"	155434855	Phase 1	DJ8QW7	.	CTPDG003866
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	XmAb20717	XmAb717	.	Phase 1	DD1TJ8	.	CTPDG003947
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SX-682	"1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-"	90467234	Phase 1	DAY4L1	.	CTPDG003976
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SB 11285	.	.	Phase 1	DA79HM	.	CTPDG003980
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CMP-001	vidutolimod	.	Phase 1	D7T5AN	.	CTPDG004031
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRT1419	.	.	Phase 1	D50CXM	.	CTPDG004103
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INCAGN2385	.	.	Phase 1	D4KTA9	.	CTPDG004112
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TBX-3400	.	.	Phase 1	D2DB5T	.	CTPDG004169
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ifx-Hu2.0	.	.	Phase 1	D1NC2O	.	CTPDG004188
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	VCL-1M01	"VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical"	.	Phase 1	D0ZM5E	.	CTPDG004215
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GPA-TriMAR-T cells	.	.	Phase 1	D0YU0L	.	CTPDG004240
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PTI-188	.	.	Phase 1	D0Y7SN	.	CTPDG004253
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Dendritic cancer cell vaccine	.	.	Phase 1	D0Y0RF	.	CTPDG004266
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	BETULINIC ACID	"472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624"	64971	Phase 1	D0R9YR	DB12480	CTPDG004453
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Multipeptide vaccine combination	"Multipeptide vaccine combination (melanoma); Multipeptide vaccine combination (melanoma), Ludwig; MAGE-10.A2+ Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig; MAGE-10.A2 + Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig/Columbia"	.	Phase 1	D0R2LY	.	CTPDG004464
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Adoptive T-cell therapy	Adoptive T-cell therapy (cancer)	.	Phase 1	D0P4JJ	.	CTPDG004523
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Vaccimel	"Melanoma cell line vaccine (cancer), Centro de Investigaciones Oncologicas; Autologous dendritic cells + allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; Dendritic cells + apoptotic/necrotic allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; DC/Apo-Nec vaccine (melanoma), Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires"	.	Phase 1	D0LT2Z	.	CTPDG004610
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Lipovaxin-MM	"Dendritic cell-specific antigen targeting vaccine (liposome/nanoparticle/intravenous, melanoma), Lipotek"	.	Phase 1	D0L2OT	.	CTPDG004636
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GSK-2241658A	"NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A"	.	Phase 1	D0IA5O	.	CTPDG004713
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ICON-1	.	.	Phase 1	D0H6UL	.	CTPDG004748
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PLX-4720	PLX 4720; PLX4720 (BRAF inhibitor)	24180719	Phase 1	D0F5JZ	DB06999	CTPDG004804
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AE-08	.	.	Phase 1	D0F5GF	.	CTPDG004805
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TAK-202	.	.	Phase 1	D0DT2S	.	CTPDG004844
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AEB701	.	.	Phase 1	D0B2NF	.	CTPDG004924
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	UV1 + GM-CSF vaccine	.	.	Phase 1	D09UMR	.	CTPDG004968
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AMEP	"(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U"	14017	Phase 1	D08XBF	.	CTPDG005023
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Melanoma DNA vaccine	.	.	Phase 1	D07YZQ	.	CTPDG005073
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DEDN-6526A	.	.	Phase 1	D07XXT	.	CTPDG005076
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	IL-2 pDNA	.	.	Phase 1	D07JSX	.	CTPDG005099
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AT13387	AT-13387	11955716	Phase 1	D06YSP	DB06306	CTPDG005131
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ioflubenzamide (131I)	"Solazed; Ioflubenzamide I-131; MIP-1104; MIP-1143; MIP-1144; MIP-1145; ZK-BA; Iodine-123-Solazed; Iodine-131-Solazed; MIP-1145-[123I]; MIP-1145-[131I]; Radiolabeled benzamides (melanoma), Bayer; Radiolabeled benzamides (melanoma), Molecular Insight; Iodine-123-ZK-BA; Iodine-131-ZK-BA; Melanin-targeting radiodiagnostic (melanoma), Bayer/Molecular Insight; Melanin-targeting radiotherapeutic (melanoma), Bayer/Molecular Insight; 123I-MIP-1145; 123I-Solazed; 123I-ZK-BA"	24828760	Phase 1	D06SYN	.	CTPDG005140
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SAM-6	.	.	Phase 1	D06PZC	.	CTPDG005148
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Flanvotumab	"IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly"	.	Phase 1	D05WQT	.	CTPDG005180
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CAR-T cells recognizing EpCAM	.	.	Phase 1	D04RNG	.	CTPDG005241
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DC-IL-12 DNA therapeutic	INXN-3001	.	Phase 1	D03OKS	.	CTPDG005298
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	LV305	NY-ESO-1 Zvex	.	Phase 1	D02XTT	.	CTPDG005333
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TTI-621	.	.	Phase 1	D01CUO	.	CTPDG005422
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRAME antigen-specific cancer immunotherapeutic	.	.	Phase 1	D00AHT	.	CTPDG005477
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	Nuleusin	"IL-2 (subcutaneous formulation, RCC/MM), 3SBio"	.	Discontinued in Phase 3	D0PE0D	.	CTPDG006342
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	IDD-3	"Uvidem; Dendritophage + melanoma tumor cell lysate; Melanoma vaccine, Immuno-Designed Molecules/ IDM Pharma; Vaccine (melanoma), Immuno-Designed Molecules /IDM Pharma"	.	Discontinued in Phase 2	D0PH0M	.	CTPDG006457
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	BIWB-1	"Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender"	.	Discontinued in Phase 2	D0C7OQ	.	CTPDG006543
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melanoma vaccine (ALVAC)	"Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur"	.	Discontinued in Phase 2	D0C1EO	.	CTPDG006547
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	TriGem	"Monoclonal antibody 1A7, Titan Pharmaceuticals; Anti-I17 antibody, Trilex"	.	Discontinued in Phase 2	D08GEX	.	CTPDG006583
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melaxin	"Autologous dendritoma vaccine (sc, melanoma), Oncolix"	.	Discontinued in Phase 2	D07FDV	.	CTPDG006596
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Ecromeximab	.	.	Discontinued in Phase 2	D05PWZ	.	CTPDG006614
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	XomaZyme-Mel	XMMME-0001-RTA	.	Discontinued in Phase 2	D03WSE	.	CTPDG006638
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Zeniplatin	CL-286558	56840898	Discontinued in Phase 2	D00CFB	.	CTPDG006680
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1/2	ODC-0501	"Dendritic cell vaccine (melanoma), ODC; Vaccine (melanoma), ODC"	.	Discontinued in Phase 1/2	D02FEJ	.	CTPDG006699
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG-7256	"B-raf inhibitor (melanoma), Roche/Plexxikon"	.	Discontinued in Phase 1	D0RV7J	.	CTPDG006750
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG7636	.	.	Discontinued in Phase 1	D0J0IJ	.	CTPDG006800
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	ABX-MA1	"Anti-MUC18 MAb, Abgenix"	.	Discontinued in Phase 1	D0G7YG	.	CTPDG006814
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	F-50040	"Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre"	.	Discontinued in Phase 1	D07CQJ	.	CTPDG006871
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Terminated	DISC GM-CSF	.	.	Terminated	D0X4UA	.	CTPDG007182
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Withaferin A	"Heat shock factor 1 inhibitor (melanoma), University of Kansas; HSF-1 inhibitor (melanoma), University of Kansas"	265237	Terminated	D0V3PN	.	CTPDG007199
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Terminated	SBP-002	"Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec"	.	Terminated	D0G0UZ	.	CTPDG007351
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Terminated	RAAV vaccine	.	.	Terminated	D0C3DH	.	CTPDG007389
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Novovac-M1	.	.	Terminated	D01CJB	.	CTPDG007576
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VLD-631	.	.	Investigative	D0ZE7B	.	CTPDG007618
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	SMT-C2100	.	.	Investigative	D0Z4YK	.	CTPDG007634
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TOCA-621	"Viral vector-delivered interferon gamma gene therapy (malignant melanoma), Tocagen"	.	Investigative	D0Z3ZF	.	CTPDG007636
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	NVX-412	.	.	Investigative	D0XU4O	.	CTPDG007687
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VitiGam	.	.	Investigative	D0X8EE	.	CTPDG007708
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	CGEN-791	.	.	Investigative	D0X4AN	.	CTPDG007726
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	IMX-MEL1	"Melanoma therapeutic vaccine, Imaxio"	.	Investigative	D0T6PF	.	CTPDG007851
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lm Melanoma	"Recombinant bacterial vector vaccine (melanoma), Aduro BioTech/New York University"	.	Investigative	D0R2YD	.	CTPDG007917
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	ADS-NPTMZ-1	.	.	Investigative	D0P6CQ	.	CTPDG007979
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Narciclasine	"Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one"	72376	Investigative	D0OQ1I	.	CTPDG007994
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico"	"Imaging agent (melanoma), NuView; 111In-DOTA-GlyGlu-CycMSH (melanoma), NuView/University of New Mexico"	.	Investigative	D0N7XY	.	CTPDG008036
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Ektomun	"Antibody (melanoma), Trion"	.	Investigative	D0L8TP	.	CTPDG008106
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PDS-0102	"Versamune-Melanoma; Vaccine (cationic lipid nanoparticle formulation, melanoma), PDS Biotechnology"	.	Investigative	D0H7OO	.	CTPDG008234
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MTI-SAM3	.	.	Investigative	D0E7IZ	.	CTPDG008339
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Box-5	"Wnt-5a antagonist (peptide, melanoma/metastasis), WntResearch"	.	Investigative	D0E0DS	.	CTPDG008356
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	20D75	.	.	Investigative	D0D3LZ	.	CTPDG008382
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	BCL-005	.	.	Investigative	D0C6XD	.	CTPDG008407
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	.	.	Investigative	D0A3SQ	.	CTPDG008495
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"1,3-bis(1,3-benzothiazol-2-ylthio)acetone"	"1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409"	1240423	Investigative	D07DZS	.	CTPDG008704
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PRAME-SLP	"Peptide vaccine(cancer), ISA Pharmaceuticals; Preferentially expressed antigen based vaccine (SLP technology/peptide, melanoma), ISA"	.	Investigative	D06RYG	.	CTPDG008736
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	AEZS-120	"Cancer vaccine (bacterial vector), University of Wurzburg/AEterna Zentaris"	.	Investigative	D06KGC	.	CTPDG008754
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	5-fluoro-1H-indole-2-carboxylic acid	"5-Fluoroindole-2-carboxylic acid; 399-76-8; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690"	1820	Investigative	D06BFH	.	CTPDG008772
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TriMixDC	"Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles"	.	Investigative	D04PFD	.	CTPDG008870
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	OP-03	"OP-03 program (prodrug, melanoma); OP-03 program (prodrug, melanoma), Onco-Pharmakon"	.	Investigative	D04EFB	.	CTPDG008905
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LG-723	.	.	Investigative	D01VZQ	.	CTPDG009059
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LY-1-100	"SMART derivatives (melanoma); LY-2-45; SMART derivatives (melanoma), University of Tennessee"	.	Investigative	D01NKF	.	CTPDG009090
M6ACROT05473	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lovaxin M	"HMW-MAA cancer vaccine (Listeria vector), Advaxis"	.	Investigative	D00QLG	.	CTPDG009162
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Vemurafenib	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	Approved	D0Y9EW	DB08881	CTPDG000048
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dacarbazine	"Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide"	135398738	Approved	D0Y7ZU	DB00851	CTPDG000052
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Teplizumab	.	.	Phase 3	D0VH4V	.	CTPDG000096
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	LGX818	Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)	50922675	Approved	D0TK7R	DB11718	CTPDG000129
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Interferon Alfa-2b	Intron A; Viraferon	71306834	Approved	D0P0WV	.	CTPDG000225
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tremetinib	.	.	Approved	D0N7XI	.	CTPDG000261
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Cemiplimab	REGN2810; REGN-2810; REGN 2810	.	Approved	D0KG4Q	.	CTPDG000296
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	Approved	D0JB3H	DB12513	CTPDG013047
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Isoproterenol	"Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409"	3779	Approved	D0I8FI	DB01064	CTPDG012395
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Melacine	"Melanoma vaccine (Detox-B), Corixa; Melanoma theraccine (Detox-B), Biomira/Ribi; Melanoma vaccine (Detox-B), Biomira/Ribi; Melanomavaccine (Detox-B), Corixa/Schering-Plough"	.	Approved	D0HV7K	.	CTPDG000357
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Ingenol mebutate	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A	6918670	Phase 3	D0E9KA	DB05013	CTPDG000402
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	ARRY-162	"606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); NVP-ME"	10288191	Approved	D0C4LF	DB11967	CTPDG000440
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Relatlimab	.	.	Approved	D0A3WJ	.	CTPDG000466
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tc-99m tilmanocept	Lymphoseek (TN)	.	Approved	D09XVS	.	CTPDG000477
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Palladium Pd 103	Palladium-103	9793711	Approved	D09XOR	DB15016	CTPDG000478
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	HybriCell	"Dendritic cell-tumor cell hybrid vaccine (melanoma, RCC), Genoa"	.	Approved	D07YUH	.	CTPDG000538
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	MK-3475	.	.	Approved	D07DMY	.	CTPDG000581
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Ipilimumab	BMS-734016; MDX-010; MDX-101; Yervoy (TN)	.	Approved	D07BVI	.	CTPDG000585
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib + dabrafenib	.	11707110	Approved	D06AGH	DB08911	CTPDG000612
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dabrafenib	"1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436"	44462760	Approved	D05ROI	DB08912	CTPDG000623
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	99mTc-depreotide	NeoSpect; NeoTect; P829 Techtide; Technetium-99m P829; Technetium-99m depreotide; 99mTc-P829	.	Approved	D05HWX	.	CTPDG000641
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Talimogene Laherparepvec	IMLYGIC	.	Approved	D05BXY	.	CTPDG000649
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Treosulfan	"Tresulfan; Dimesyl-meso-erythritol; Erythritol, 1,4-dimethanesulfonate; Erythritol, dimesyl-, meso-; Dihydroxymyleran; Dihydroxybusulfan; 1,4-Di(methanesulfonate)erythritol; NSC 94160; L-Threityl dimesylate; Erythritol, 1,4-bis(methanesulfonate); Threitol-1,4-bismethanesulfonate, meso-; CB 40069; 1,4-Bis(methanesulfonyloxy)-2,3-butanediol; 1,4-Bis(methylsulfonyloxy)threitol; Threitol 1,4-bis(methanesulfonate); ERYTHRITOL, 1,4-DIMETHANESULFONATE, (meso)-; NCGC00181153-01; L-Threitol 1,4-dimethanesulfonate"	9882105	Approved	D04YPN	DB11678	CTPDG000652
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib	GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN	11707110	Approved	D04XVN	DB08911	CTPDG000654
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	OncoVAX	"Cancer vaccine, Vaccinogen; OncoVAX, Vaccinogen; Autologous vaccine (colon cancer), Vaccinogen; OncoVAX-CL, Intracel; Vaccine(colon cancer), Intracel; Vaccine (colon cancer), Vaccinogen"	.	Preregistration	D0UR1Z	.	CTPDG000855
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	MPL-containing Pollinex allergy desensitization vaccine	"HDM SC vaccine, Allergy Therapeutics; House dust mite SC vaccine, Allergy Therapeutics; Pollinex Quattro (house dust mite allergy vaccine); Quattro MPL (house dust mite allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (house dust mites); MPL-containing Pollinex allergy desensitization vaccine (house dust mites), Allergy Therapeutics"	.	Preregistration	D01FWR	.	CTPDG000859
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Tilsotolimod	IMO-2125	.	Phase 3	D6YD0X	.	CTPDG000932
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR-214	bempegaldesleukin	.	Phase 3	D5ISZ1	.	CTPDG000936
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	"Melanoma vaccine, University of Virginia"	"Vaccine (melanoma); Melanoma-specific antigens, Argonex; Peptide vaccine/autologous dendritic cells, Argonex; Vaccine (melanoma), Argonex; Vaccine (melanoma), University of Virginia"	.	Phase 3	D0Z3ES	.	CTPDG000967
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Velimogene aliplasmid	Allovectin (TN)	.	Phase 3	D0Y9YN	.	CTPDG000974
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Seviprotimut-L	.	.	Phase 3	D0V0AF	.	CTPDG001030
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melanoma vaccine	"NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie"	.	Phase 3	D0U9MJ	.	CTPDG001034
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Multi-epitope peptide melanoma vaccine	"Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b"	.	Phase 3	D0P5TG	.	CTPDG001094
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Canvaxin	"Cancer vaccine, CancerVax; Melanoma vaccine, John Wayne Cancer Institute; Polyvalent melanoma cancer vaccine (PMCV)"	.	Phase 3	D0M4TF	.	CTPDG001131
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Pegargiminase	ADI-PEG-20	.	Phase 2	D0KB0Y	.	CTPDG001159
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	RG7421+RG7204	Cobimetinib+vemurafenib; Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	.	Phase 3	D0I5EU	.	CTPDG001182
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	IMO-2125	.	.	Phase 3	D0FM5M	.	CTPDG001207
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Daromun	darleukin + fibromun	.	Phase 3	D0CR9L	.	CTPDG001250
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SD-101	"HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo"	.	Phase 1/2	D08RJM	.	CTPDG001321
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Javelin	MJV-101	104768	Phase 3	D08PCH	.	CTPDG001325
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Spartalizumab	.	.	Phase 3	D08JLH	.	CTPDG001331
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melapuldencel-T	.	.	Phase 3	D06ZJD	.	CTPDG001370
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PDR001	.	.	Phase 3	D05BAJ	.	CTPDG001407
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	GMK	(3-Deoxy-3-(3-Methoxy-Benzamido)-B-D-Galactopyranosyl)-(3-Deoxy-3-(3-Methoxy-Benzamido)-2-O-Sulfo-B-D-Galactopyranosyl)-Sulfide; 3-deoxy-3-[(3-methoxybenzoyl)amino]-beta-D-galactopyranosyl 3-deoxy-3-[(3-methoxybenzoyl)amino]-2-O-sulfo-1-thio-beta-D-galactopyranoside	73729035	Phase 3	D04ORP	.	CTPDG001419
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Mitumomab	"LuVax; MelVax; BEC-2; EMD-60205; IMC-BEC2; Antimelanoma antibody, ImClone/Merck KGaA; Antimetastatic agents, ImClone/Merck KGaA; Melanoma vaccine, ImClone/Merck KGaA; GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering"	.	Phase 3	D04FNR	.	CTPDG001426
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	QS-21	AC1L1U2U; C92H148O46; LS-173109; 124716-EP2295426A1	60866	Phase 3	D03WOW	.	CTPDG001432
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	RemuneX	.	.	Discontinued in Phase 3	D03PLR	.	CTPDG001440
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	177Lu-DOTA-octreotate	"Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate"	.	Phase 3	D02ZHW	.	CTPDG001450
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MAGE-A3 immunotherapeutic	.	.	Phase 3	D02MPT	.	CTPDG001467
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Imprime PGG	Imprime PGG (TN)	.	Phase 1/2	D0P6MW	.	CTPDG001538
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	FX005	"TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076"	11001318	Phase 2/3	D04DFR	DB11644	CTPDG001573
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	HF10	Canerpaturev	.	Phase 2	DZ4A1W	.	CTPDG001600
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	EDP-1503	.	.	Phase 2	DYU37E	.	CTPDG001603
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	mRNA-4157	.	.	Phase 2	DTY5W0	.	CTPDG001630
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tavokinogene telseplasmid	TAVO	.	Phase 2	DT7O8R	.	CTPDG001633
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	V937	.	.	Phase 2	DOYP92	.	CTPDG001656
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Lifileucel	LN-144	.	Phase 2	DL5C1W	.	CTPDG001689
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PVSRIPO	.	.	Phase 2	DIWL76	.	CTPDG001699
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ad-RTS-hIL-12	.	.	Phase 2	D90UZW	.	CTPDG001770
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BNT111	.	.	Phase 2	D62LIX	.	CTPDG001795
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN 1201	.	.	Phase 1	D3JN6C	.	CTPDG001826
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Dorgenmeltucel-L	.	.	Phase 2	D0ZO7A	.	CTPDG001855
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Cancer vaccine	"Cancer vaccine, AVAX/Thomas Jefferson University; Vaccine (melanoma), Thomas Jefferson; Vaccine (DNP-modified), Thomas Jefferson"	.	Phase 2	D0Y7TC	.	CTPDG001878
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK-2302025A	"PRAME ASCI (melanoma), GSK; Recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (melanoma), GlaxoSmithKline"	.	Phase 2	D0X0SK	.	CTPDG001906
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Interleukin-12 gene therapy	.	.	Phase 2	D0U3AL	.	CTPDG001993
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PF-4878691	PF-04878691; PF-4171455	10309114	Phase 2	D0T1FC	DB12476	CTPDG002028
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	SentoClone	"Autologous T lymphocyte therapy (malignant melanoma), SentoClone; Autologous Th1 cell therapy (malignant melanoma), SentoClone"	.	Phase 2	D0R9FM	.	CTPDG002064
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MAGE-3-transduced autologous T-cell vaccine	"M3TK anticancer vaccine, MolMed/Takara; MAGE-3-transduced autologous T-cell vaccine (anticancer);MAGE-3-transduced autologous T-cell vaccine (anticancer), MolMed SpA/Takara Bio"	.	Phase 2	D0Q0SK	.	CTPDG002100
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CB-10-01	.	.	Phase 2	D0NT1S	.	CTPDG002153
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APN-301	EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2	.	Phase 2	D0NS7A	.	CTPDG002155
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Multi-epitope tyrosinase/gp100 vaccine	"Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering"	.	Phase 2	D0N7FD	.	CTPDG002165
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Antigen-pulsed dendritic cell vaccine	Antigen-pulsed dendritic cell vaccine (melanoma)	.	Phase 2	D0MI0S	.	CTPDG002187
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Stage IV melanoma vaccine	"Stage IV melanoma vaccine, ARI; Stage IV melanoma vaccine, Adelaide Research & Innovation"	.	Phase 2	D0KC9U	.	CTPDG002255
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MKC-1106-MT	"Melanoma vaccine (MART-1/tyrosinase), Mannkind"	.	Phase 2	D0J7MQ	.	CTPDG002283
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Telomelysin	.	.	Phase 2	D0I3VV	.	CTPDG002315
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes	"Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma); Autologous anti-gp100 TCR gene-engineered PBLs (melanoma), NCI; Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma), National Cancer Institute"	.	Phase 2	D0I3VS	.	CTPDG002316
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tumor infiltrating lymphocyte	.	.	Phase 2	D0H8DS	.	CTPDG002334
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ontuxizumab	Amatuximab	.	Phase 2	D0FK9H	.	CTPDG002385
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Anti-CD3 activated vaccine-primed lymphocytes	"VPLN tumor vaccine, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer); Monoclonal antiobody activated vaccine-primed lymphocytes (cancer), University of Michigan; Vaccine-primed lymph node (VPLN) cells, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer), University of Michigan; Anti-CD3/anti-CD28 activated vaccine-primed lymphocytes (cancer), University of Michigan"	.	Phase 2	D0E8KO	.	CTPDG002417
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Resimmune	A-dmDT390-bisFv immunotoxin	.	Phase 1/2	D0C3TI	.	CTPDG002489
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ABX-IL8	.	.	Phase 2	D0BF9K	.	CTPDG002502
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ITIL-168	.	.	Phase 2	D0B6AZ	.	CTPDG002511
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi-8 PrimeBoost therapeutic melanoma vaccine	"Hi-8 MEL; Melanoma therapeutic vaccine, Oxxon; PSG2.Mel3; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxford BioMedica; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Lead Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Pharmaccine therapy (melanoma), Oxxon; DNA/MVA immunotherapy (melanoma), Oxxon; MEL-1 immunotherapy (melanoma), Oxxon; Melanoma immunotherapy (Prime-Boost), Oxxon"	.	Phase 2	D0A9BI	.	CTPDG002537
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN-1201	.	.	Phase 1	D0A3CH	.	CTPDG002550
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CYT-004-MelQbG10	"Immunodrug vaccine (melanoma), Cytos; QbG10 Immunodrug carrier (cancer), Cytos"	.	Phase 2	D08KAD	.	CTPDG002632
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Gp100:209-217(210M) peptide vaccine	"Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI"	.	Phase 2	D08DWM	.	CTPDG002646
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	LN-144	.	.	Phase 2	D08DIU	.	CTPDG002648
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MLN2480	"VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819"	25161177	Phase 2	D07IEU	DB15266	CTPDG002698
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ARC-100	SCHEMBL13011610	57339443	Phase 2	D07GCK	.	CTPDG002701
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	AG140699	.	.	Phase 2	D06KZL	.	CTPDG002747
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	E7016	"UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016"	11660296	Phase 2	D06DHB	.	CTPDG002770
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GR-MD-02	Belapectin	.	Phase 2	D06BKH	.	CTPDG002771
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PLX8394	.	90116675	Phase 2	D05HTS	.	CTPDG002807
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi8 melanoma vaccine	.	.	Phase 2	D04HMK	.	CTPDG002864
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GCAN 101	.	.	Phase 2	D03TNG	.	CTPDG002903
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MSB0010445	.	.	Phase 2	D03LAI	.	CTPDG002922
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	RAF265	927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594	11656518	Phase 2	D03AND	DB05984	CTPDG002939
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Urelumab	.	.	Phase 2	D02ZMB	.	CTPDG002942
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MORAb-004	.	.	Phase 2	D02RKG	.	CTPDG002961
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Leuvectin	"IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical"	.	Phase 2	D01WHC	.	CTPDG003004
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Polynoma-1	"Polyvalent melanoma vaccine, Vaccinoma"	.	Phase 2	D00DSV	.	CTPDG003100
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ENB003	"2364572-10-9; AAY8R26VDX; BQ 788-d2; BQ-788, di(methyl-d)-; CHEMBL5095234; D-Norleucine, N-((cis-2,6-di(methyl-d)-1-piperidinyl)carbonyl)-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl-, sodium salt; Enb 003; ENB 003 [WHO-DD]; ENB003; ENB-003; UNII-AAY8R26VDX; Vodudeutentan sodium"	145722637	Phase 1/2	DUOX13	.	CTPDG003137
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HL-085	.	.	Phase 1/2	DJ8TN2	.	CTPDG003174
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NKTR-262	.	.	Phase 1/2	D8JN5H	.	CTPDG003216
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Antigen-specific melanoma vaccine	.	.	Phase 1/2	D0Z2UY	.	CTPDG003269
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmuFact IMP321	.	.	Phase 1/2	D0U5AN	.	CTPDG003306
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LXS196	"XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide"	118873253	Phase 1/2	D0R7HL	.	CTPDG003336
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	AU-011	.	.	Phase 1/2	D0R0NX	.	CTPDG003341
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	TRX-518	"GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx"	.	Phase 1/2	D0J1MO	.	CTPDG003407
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	IMCnyeso	.	.	Phase 1/2	D0I9YM	.	CTPDG003414
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NCI-4650	.	.	Phase 1/2	D07YNC	.	CTPDG003518
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Ad-IL-12 DNA therapeutic	INXN-2001	.	Phase 1/2	D06LUI	.	CTPDG003539
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SCIB-1	"SCIB-5; SCIB-1 DNA vaccine (melanoma, TriGrid), Scancell; Anti-TRP-2/ anti-gp100 monoclonal antibody vaccine (melanoma), Scancell"	.	Phase 1/2	D06AWA	.	CTPDG003547
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmunoVEX-timelan	.	.	Phase 1/2	D01EYR	.	CTPDG003621
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	CLL442	.	.	Phase 1/2	D01DIM	.	CTPDG003623
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AV-MEL-1	.	.	Phase 1	DX06ZU	.	CTPDG003672
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CV8102	.	.	Phase 1	DVU2H8	.	CTPDG003683
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INXN 2001	.	.	Phase 1	DMP6A9	.	CTPDG003817
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CDX-1140	.	.	Phase 1	DKM7S3	.	CTPDG003841
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PF-07284890	"1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; 2573781-75-4; AR00504461; ARRY461; ARRY-461; ARRY-461; BDBM565133; CHEMBL5095256; CS-0564141; EX-A7593; GTPL12096; HY-147405; JNJ5N2RH5W; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; PF07284890; PF-07284890; PF-07284890; SCHEMBL22831935; Tinlorafenib; tinlorafenib [INN]; Tinlorafenib [USAN]; UNII-JNJ5N2RH5W; US11414404, Ex. # 10; WHO 12353"	155434855	Phase 1	DJ8QW7	.	CTPDG003866
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	XmAb20717	XmAb717	.	Phase 1	DD1TJ8	.	CTPDG003947
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SX-682	"1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-"	90467234	Phase 1	DAY4L1	.	CTPDG003976
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SB 11285	.	.	Phase 1	DA79HM	.	CTPDG003980
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CMP-001	vidutolimod	.	Phase 1	D7T5AN	.	CTPDG004031
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRT1419	.	.	Phase 1	D50CXM	.	CTPDG004103
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INCAGN2385	.	.	Phase 1	D4KTA9	.	CTPDG004112
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TBX-3400	.	.	Phase 1	D2DB5T	.	CTPDG004169
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ifx-Hu2.0	.	.	Phase 1	D1NC2O	.	CTPDG004188
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	VCL-1M01	"VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical"	.	Phase 1	D0ZM5E	.	CTPDG004215
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GPA-TriMAR-T cells	.	.	Phase 1	D0YU0L	.	CTPDG004240
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PTI-188	.	.	Phase 1	D0Y7SN	.	CTPDG004253
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Dendritic cancer cell vaccine	.	.	Phase 1	D0Y0RF	.	CTPDG004266
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	BETULINIC ACID	"472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624"	64971	Phase 1	D0R9YR	DB12480	CTPDG004453
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Multipeptide vaccine combination	"Multipeptide vaccine combination (melanoma); Multipeptide vaccine combination (melanoma), Ludwig; MAGE-10.A2+ Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig; MAGE-10.A2 + Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig/Columbia"	.	Phase 1	D0R2LY	.	CTPDG004464
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Adoptive T-cell therapy	Adoptive T-cell therapy (cancer)	.	Phase 1	D0P4JJ	.	CTPDG004523
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Vaccimel	"Melanoma cell line vaccine (cancer), Centro de Investigaciones Oncologicas; Autologous dendritic cells + allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; Dendritic cells + apoptotic/necrotic allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; DC/Apo-Nec vaccine (melanoma), Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires"	.	Phase 1	D0LT2Z	.	CTPDG004610
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Lipovaxin-MM	"Dendritic cell-specific antigen targeting vaccine (liposome/nanoparticle/intravenous, melanoma), Lipotek"	.	Phase 1	D0L2OT	.	CTPDG004636
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GSK-2241658A	"NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A"	.	Phase 1	D0IA5O	.	CTPDG004713
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ICON-1	.	.	Phase 1	D0H6UL	.	CTPDG004748
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PLX-4720	PLX 4720; PLX4720 (BRAF inhibitor)	24180719	Phase 1	D0F5JZ	DB06999	CTPDG004804
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AE-08	.	.	Phase 1	D0F5GF	.	CTPDG004805
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TAK-202	.	.	Phase 1	D0DT2S	.	CTPDG004844
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AEB701	.	.	Phase 1	D0B2NF	.	CTPDG004924
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	UV1 + GM-CSF vaccine	.	.	Phase 1	D09UMR	.	CTPDG004968
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AMEP	"(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U"	14017	Phase 1	D08XBF	.	CTPDG005023
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Melanoma DNA vaccine	.	.	Phase 1	D07YZQ	.	CTPDG005073
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DEDN-6526A	.	.	Phase 1	D07XXT	.	CTPDG005076
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	IL-2 pDNA	.	.	Phase 1	D07JSX	.	CTPDG005099
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AT13387	AT-13387	11955716	Phase 1	D06YSP	DB06306	CTPDG005131
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ioflubenzamide (131I)	"Solazed; Ioflubenzamide I-131; MIP-1104; MIP-1143; MIP-1144; MIP-1145; ZK-BA; Iodine-123-Solazed; Iodine-131-Solazed; MIP-1145-[123I]; MIP-1145-[131I]; Radiolabeled benzamides (melanoma), Bayer; Radiolabeled benzamides (melanoma), Molecular Insight; Iodine-123-ZK-BA; Iodine-131-ZK-BA; Melanin-targeting radiodiagnostic (melanoma), Bayer/Molecular Insight; Melanin-targeting radiotherapeutic (melanoma), Bayer/Molecular Insight; 123I-MIP-1145; 123I-Solazed; 123I-ZK-BA"	24828760	Phase 1	D06SYN	.	CTPDG005140
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SAM-6	.	.	Phase 1	D06PZC	.	CTPDG005148
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Flanvotumab	"IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly"	.	Phase 1	D05WQT	.	CTPDG005180
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CAR-T cells recognizing EpCAM	.	.	Phase 1	D04RNG	.	CTPDG005241
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DC-IL-12 DNA therapeutic	INXN-3001	.	Phase 1	D03OKS	.	CTPDG005298
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	LV305	NY-ESO-1 Zvex	.	Phase 1	D02XTT	.	CTPDG005333
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TTI-621	.	.	Phase 1	D01CUO	.	CTPDG005422
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRAME antigen-specific cancer immunotherapeutic	.	.	Phase 1	D00AHT	.	CTPDG005477
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	Nuleusin	"IL-2 (subcutaneous formulation, RCC/MM), 3SBio"	.	Discontinued in Phase 3	D0PE0D	.	CTPDG006342
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	IDD-3	"Uvidem; Dendritophage + melanoma tumor cell lysate; Melanoma vaccine, Immuno-Designed Molecules/ IDM Pharma; Vaccine (melanoma), Immuno-Designed Molecules /IDM Pharma"	.	Discontinued in Phase 2	D0PH0M	.	CTPDG006457
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	BIWB-1	"Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender"	.	Discontinued in Phase 2	D0C7OQ	.	CTPDG006543
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melanoma vaccine (ALVAC)	"Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur"	.	Discontinued in Phase 2	D0C1EO	.	CTPDG006547
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	TriGem	"Monoclonal antibody 1A7, Titan Pharmaceuticals; Anti-I17 antibody, Trilex"	.	Discontinued in Phase 2	D08GEX	.	CTPDG006583
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melaxin	"Autologous dendritoma vaccine (sc, melanoma), Oncolix"	.	Discontinued in Phase 2	D07FDV	.	CTPDG006596
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Ecromeximab	.	.	Discontinued in Phase 2	D05PWZ	.	CTPDG006614
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	XomaZyme-Mel	XMMME-0001-RTA	.	Discontinued in Phase 2	D03WSE	.	CTPDG006638
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Zeniplatin	CL-286558	56840898	Discontinued in Phase 2	D00CFB	.	CTPDG006680
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1/2	ODC-0501	"Dendritic cell vaccine (melanoma), ODC; Vaccine (melanoma), ODC"	.	Discontinued in Phase 1/2	D02FEJ	.	CTPDG006699
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG-7256	"B-raf inhibitor (melanoma), Roche/Plexxikon"	.	Discontinued in Phase 1	D0RV7J	.	CTPDG006750
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG7636	.	.	Discontinued in Phase 1	D0J0IJ	.	CTPDG006800
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	ABX-MA1	"Anti-MUC18 MAb, Abgenix"	.	Discontinued in Phase 1	D0G7YG	.	CTPDG006814
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	F-50040	"Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre"	.	Discontinued in Phase 1	D07CQJ	.	CTPDG006871
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Terminated	DISC GM-CSF	.	.	Terminated	D0X4UA	.	CTPDG007182
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Withaferin A	"Heat shock factor 1 inhibitor (melanoma), University of Kansas; HSF-1 inhibitor (melanoma), University of Kansas"	265237	Terminated	D0V3PN	.	CTPDG007199
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Terminated	SBP-002	"Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec"	.	Terminated	D0G0UZ	.	CTPDG007351
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Terminated	RAAV vaccine	.	.	Terminated	D0C3DH	.	CTPDG007389
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Novovac-M1	.	.	Terminated	D01CJB	.	CTPDG007576
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VLD-631	.	.	Investigative	D0ZE7B	.	CTPDG007618
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	SMT-C2100	.	.	Investigative	D0Z4YK	.	CTPDG007634
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TOCA-621	"Viral vector-delivered interferon gamma gene therapy (malignant melanoma), Tocagen"	.	Investigative	D0Z3ZF	.	CTPDG007636
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	NVX-412	.	.	Investigative	D0XU4O	.	CTPDG007687
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VitiGam	.	.	Investigative	D0X8EE	.	CTPDG007708
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	CGEN-791	.	.	Investigative	D0X4AN	.	CTPDG007726
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	IMX-MEL1	"Melanoma therapeutic vaccine, Imaxio"	.	Investigative	D0T6PF	.	CTPDG007851
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lm Melanoma	"Recombinant bacterial vector vaccine (melanoma), Aduro BioTech/New York University"	.	Investigative	D0R2YD	.	CTPDG007917
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	ADS-NPTMZ-1	.	.	Investigative	D0P6CQ	.	CTPDG007979
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Narciclasine	"Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one"	72376	Investigative	D0OQ1I	.	CTPDG007994
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico"	"Imaging agent (melanoma), NuView; 111In-DOTA-GlyGlu-CycMSH (melanoma), NuView/University of New Mexico"	.	Investigative	D0N7XY	.	CTPDG008036
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Ektomun	"Antibody (melanoma), Trion"	.	Investigative	D0L8TP	.	CTPDG008106
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PDS-0102	"Versamune-Melanoma; Vaccine (cationic lipid nanoparticle formulation, melanoma), PDS Biotechnology"	.	Investigative	D0H7OO	.	CTPDG008234
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MTI-SAM3	.	.	Investigative	D0E7IZ	.	CTPDG008339
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Box-5	"Wnt-5a antagonist (peptide, melanoma/metastasis), WntResearch"	.	Investigative	D0E0DS	.	CTPDG008356
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	20D75	.	.	Investigative	D0D3LZ	.	CTPDG008382
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	BCL-005	.	.	Investigative	D0C6XD	.	CTPDG008407
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	.	.	Investigative	D0A3SQ	.	CTPDG008495
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"1,3-bis(1,3-benzothiazol-2-ylthio)acetone"	"1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409"	1240423	Investigative	D07DZS	.	CTPDG008704
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PRAME-SLP	"Peptide vaccine(cancer), ISA Pharmaceuticals; Preferentially expressed antigen based vaccine (SLP technology/peptide, melanoma), ISA"	.	Investigative	D06RYG	.	CTPDG008736
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	AEZS-120	"Cancer vaccine (bacterial vector), University of Wurzburg/AEterna Zentaris"	.	Investigative	D06KGC	.	CTPDG008754
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	5-fluoro-1H-indole-2-carboxylic acid	"5-Fluoroindole-2-carboxylic acid; 399-76-8; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690"	1820	Investigative	D06BFH	.	CTPDG008772
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TriMixDC	"Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles"	.	Investigative	D04PFD	.	CTPDG008870
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	OP-03	"OP-03 program (prodrug, melanoma); OP-03 program (prodrug, melanoma), Onco-Pharmakon"	.	Investigative	D04EFB	.	CTPDG008905
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LG-723	.	.	Investigative	D01VZQ	.	CTPDG009059
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LY-1-100	"SMART derivatives (melanoma); LY-2-45; SMART derivatives (melanoma), University of Tennessee"	.	Investigative	D01NKF	.	CTPDG009090
M6ACROT05474	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lovaxin M	"HMW-MAA cancer vaccine (Listeria vector), Advaxis"	.	Investigative	D00QLG	.	CTPDG009162
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved in China	Toripalimab	.	.	Approved in China	D92OCI	.	CTPDG000020
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Vemurafenib	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	Approved	D0Y9EW	DB08881	CTPDG000048
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dacarbazine	"Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide"	135398738	Approved	D0Y7ZU	DB00851	CTPDG000052
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Teplizumab	.	.	Phase 3	D0VH4V	.	CTPDG000096
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	LGX818	Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)	50922675	Approved	D0TK7R	DB11718	CTPDG000129
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tebentafusp	.	.	Approved	D0S0BJ	.	CTPDG000162
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	Approved	D0R0FO	DB09078	CTPDG000192
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Interferon Alfa-2b	Intron A; Viraferon	71306834	Approved	D0P0WV	.	CTPDG000225
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tremetinib	.	.	Approved	D0N7XI	.	CTPDG000261
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Cemiplimab	REGN2810; REGN-2810; REGN 2810	.	Approved	D0KG4Q	.	CTPDG000296
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	Approved	D0JB3H	DB12513	CTPDG013047
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Isoproterenol	"Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409"	3779	Approved	D0I8FI	DB01064	CTPDG012395
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Thymalfasin	Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1	16130571	Phase 2	D0I5KX	.	CTPDG000346
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Melacine	"Melanoma vaccine (Detox-B), Corixa; Melanoma theraccine (Detox-B), Biomira/Ribi; Melanoma vaccine (Detox-B), Biomira/Ribi; Melanomavaccine (Detox-B), Corixa/Schering-Plough"	.	Approved	D0HV7K	.	CTPDG000357
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Ingenol mebutate	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A	6918670	Phase 3	D0E9KA	DB05013	CTPDG000402
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	ARRY-162	"606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); NVP-ME"	10288191	Approved	D0C4LF	DB11967	CTPDG000440
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Relatlimab	.	.	Approved	D0A3WJ	.	CTPDG000466
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Tc-99m tilmanocept	Lymphoseek (TN)	.	Approved	D09XVS	.	CTPDG000477
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Palladium Pd 103	Palladium-103	9793711	Approved	D09XOR	DB15016	CTPDG000478
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Pembrolizumab	.	.	Approved	D08ANZ	.	CTPDG000532
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	HybriCell	"Dendritic cell-tumor cell hybrid vaccine (melanoma, RCC), Genoa"	.	Approved	D07YUH	.	CTPDG000538
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	MK-3475	.	.	Approved	D07DMY	.	CTPDG000581
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Ipilimumab	BMS-734016; MDX-010; MDX-101; Yervoy (TN)	.	Approved	D07BVI	.	CTPDG000585
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib + dabrafenib	.	11707110	Approved	D06AGH	DB08911	CTPDG000612
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Dabrafenib	"1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436"	44462760	Approved	D05ROI	DB08912	CTPDG000623
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	99mTc-depreotide	NeoSpect; NeoTect; P829 Techtide; Technetium-99m P829; Technetium-99m depreotide; 99mTc-P829	.	Approved	D05HWX	.	CTPDG000641
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Talimogene Laherparepvec	IMLYGIC	.	Approved	D05BXY	.	CTPDG000649
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Treosulfan	"Tresulfan; Dimesyl-meso-erythritol; Erythritol, 1,4-dimethanesulfonate; Erythritol, dimesyl-, meso-; Dihydroxymyleran; Dihydroxybusulfan; 1,4-Di(methanesulfonate)erythritol; NSC 94160; L-Threityl dimesylate; Erythritol, 1,4-bis(methanesulfonate); Threitol-1,4-bismethanesulfonate, meso-; CB 40069; 1,4-Bis(methanesulfonyloxy)-2,3-butanediol; 1,4-Bis(methylsulfonyloxy)threitol; Threitol 1,4-bis(methanesulfonate); ERYTHRITOL, 1,4-DIMETHANESULFONATE, (meso)-; NCGC00181153-01; L-Threitol 1,4-dimethanesulfonate"	9882105	Approved	D04YPN	DB11678	CTPDG000652
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Trametinib	GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN	11707110	Approved	D04XVN	DB08911	CTPDG000654
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Approved	Nivolumab	.	.	Approved	D00GOV	.	CTPDG000818
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	OncoVAX	"Cancer vaccine, Vaccinogen; OncoVAX, Vaccinogen; Autologous vaccine (colon cancer), Vaccinogen; OncoVAX-CL, Intracel; Vaccine(colon cancer), Intracel; Vaccine (colon cancer), Vaccinogen"	.	Preregistration	D0UR1Z	.	CTPDG000855
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Preregistration	MPL-containing Pollinex allergy desensitization vaccine	"HDM SC vaccine, Allergy Therapeutics; House dust mite SC vaccine, Allergy Therapeutics; Pollinex Quattro (house dust mite allergy vaccine); Quattro MPL (house dust mite allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (house dust mites); MPL-containing Pollinex allergy desensitization vaccine (house dust mites), Allergy Therapeutics"	.	Preregistration	D01FWR	.	CTPDG000859
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Tilsotolimod	IMO-2125	.	Phase 3	D6YD0X	.	CTPDG000932
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR-214	bempegaldesleukin	.	Phase 3	D5ISZ1	.	CTPDG000936
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Nemvaleukin alfa	.	.	Phase 3	D1I0LQ	.	CTPDG000953
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	"Melanoma vaccine, University of Virginia"	"Vaccine (melanoma); Melanoma-specific antigens, Argonex; Peptide vaccine/autologous dendritic cells, Argonex; Vaccine (melanoma), Argonex; Vaccine (melanoma), University of Virginia"	.	Phase 3	D0Z3ES	.	CTPDG000967
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Velimogene aliplasmid	Allovectin (TN)	.	Phase 3	D0Y9YN	.	CTPDG000974
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Seviprotimut-L	.	.	Phase 3	D0V0AF	.	CTPDG001030
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melanoma vaccine	"NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie"	.	Phase 3	D0U9MJ	.	CTPDG001034
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Selumetinib	AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U	10127622	Phase 3	D0T5DP	DB11689	CTPDG001045
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	ABT-888	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	45480520	Phase 3	D0Q7UD	.	CTPDG001079
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Multi-epitope peptide melanoma vaccine	"Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b"	.	Phase 3	D0P5TG	.	CTPDG001094
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Canvaxin	"Cancer vaccine, CancerVax; Melanoma vaccine, John Wayne Cancer Institute; Polyvalent melanoma cancer vaccine (PMCV)"	.	Phase 3	D0M4TF	.	CTPDG001131
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PV-10	"632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium"	69438	Phase 3	D0L2VT	.	CTPDG001150
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Pegargiminase	ADI-PEG-20	.	Phase 2	D0KB0Y	.	CTPDG001159
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	RG7421+RG7204	Cobimetinib+vemurafenib; Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	.	Phase 3	D0I5EU	.	CTPDG001182
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	INCB24360	Epacadostat	135564890	Phase 2	D0G7MV	DB11717	CTPDG001199
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	IMO-2125	.	.	Phase 3	D0FM5M	.	CTPDG001207
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Cotellic	"Cobimetinib fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate"	16222096	Phase 3	D0FJ9I	DB05239	CTPDG001210
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tesetaxel	"DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE"	6918574	Phase 2	D0F9VH	DB12019	CTPDG001214
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	BMS-986205	"KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-"	121328278	Phase 3	D0DP5I	DB14986	CTPDG001231
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Daromun	darleukin + fibromun	.	Phase 3	D0CR9L	.	CTPDG001250
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SD-101	"HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo"	.	Phase 1/2	D08RJM	.	CTPDG001321
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Javelin	MJV-101	104768	Phase 3	D08PCH	.	CTPDG001325
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Spartalizumab	.	.	Phase 3	D08JLH	.	CTPDG001331
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Melapuldencel-T	.	.	Phase 3	D06ZJD	.	CTPDG001370
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	PDR001	.	.	Phase 3	D05BAJ	.	CTPDG001407
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	GMK	(3-Deoxy-3-(3-Methoxy-Benzamido)-B-D-Galactopyranosyl)-(3-Deoxy-3-(3-Methoxy-Benzamido)-2-O-Sulfo-B-D-Galactopyranosyl)-Sulfide; 3-deoxy-3-[(3-methoxybenzoyl)amino]-beta-D-galactopyranosyl 3-deoxy-3-[(3-methoxybenzoyl)amino]-2-O-sulfo-1-thio-beta-D-galactopyranoside	73729035	Phase 3	D04ORP	.	CTPDG001419
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	Mitumomab	"LuVax; MelVax; BEC-2; EMD-60205; IMC-BEC2; Antimelanoma antibody, ImClone/Merck KGaA; Antimetastatic agents, ImClone/Merck KGaA; Melanoma vaccine, ImClone/Merck KGaA; GD3 ganglioside (vaccine 1), Memorial Sloan-Kettering"	.	Phase 3	D04FNR	.	CTPDG001426
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	QS-21	AC1L1U2U; C92H148O46; LS-173109; 124716-EP2295426A1	60866	Phase 3	D03WOW	.	CTPDG001432
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	RemuneX	.	.	Discontinued in Phase 3	D03PLR	.	CTPDG001440
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	177Lu-DOTA-octreotate	"Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate"	.	Phase 3	D02ZHW	.	CTPDG001450
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	NKTR 214	.	.	Phase 3	D02QQE	.	CTPDG001461
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	MAGE-A3 immunotherapeutic	.	.	Phase 3	D02MPT	.	CTPDG001467
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	OT-101	.	.	Phase 2/3	DO5H6K	.	CTPDG001514
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Imprime PGG	Imprime PGG (TN)	.	Phase 1/2	D0P6MW	.	CTPDG001538
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	NLG8189	"1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189"	405012	Phase 2/3	D0B5HS	DB12827	CTPDG001548
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2/3	FX005	"TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076"	11001318	Phase 2/3	D04DFR	DB11644	CTPDG001573
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	HF10	Canerpaturev	.	Phase 2	DZ4A1W	.	CTPDG001600
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	EDP-1503	.	.	Phase 2	DYU37E	.	CTPDG001603
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	mRNA-4157	.	.	Phase 2	DTY5W0	.	CTPDG001630
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tavokinogene telseplasmid	TAVO	.	Phase 2	DT7O8R	.	CTPDG001633
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	V937	.	.	Phase 2	DOYP92	.	CTPDG001656
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Lifileucel	LN-144	.	Phase 2	DL5C1W	.	CTPDG001689
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PVSRIPO	.	.	Phase 2	DIWL76	.	CTPDG001699
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ad-RTS-hIL-12	.	.	Phase 2	D90UZW	.	CTPDG001770
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BNT111	.	.	Phase 2	D62LIX	.	CTPDG001795
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Voyager-V1	VSV-IFNBeta-NIS	.	Phase 2	D4AGB6	.	CTPDG001817
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN 1201	.	.	Phase 1	D3JN6C	.	CTPDG001826
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Dorgenmeltucel-L	.	.	Phase 2	D0ZO7A	.	CTPDG001855
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Cancer vaccine	"Cancer vaccine, AVAX/Thomas Jefferson University; Vaccine (melanoma), Thomas Jefferson; Vaccine (DNP-modified), Thomas Jefferson"	.	Phase 2	D0Y7TC	.	CTPDG001878
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK-2302025A	"PRAME ASCI (melanoma), GSK; Recombinant preferentially expressed antigen of melanoma immunotherapeutic vaccine (melanoma), GlaxoSmithKline"	.	Phase 2	D0X0SK	.	CTPDG001906
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Interleukin-12 gene therapy	.	.	Phase 2	D0U3AL	.	CTPDG001993
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PF-4878691	PF-04878691; PF-4171455	10309114	Phase 2	D0T1FC	DB12476	CTPDG002028
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	SentoClone	"Autologous T lymphocyte therapy (malignant melanoma), SentoClone; Autologous Th1 cell therapy (malignant melanoma), SentoClone"	.	Phase 2	D0R9FM	.	CTPDG002064
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MAGE-3-transduced autologous T-cell vaccine	"M3TK anticancer vaccine, MolMed/Takara; MAGE-3-transduced autologous T-cell vaccine (anticancer);MAGE-3-transduced autologous T-cell vaccine (anticancer), MolMed SpA/Takara Bio"	.	Phase 2	D0Q0SK	.	CTPDG002100
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CB-10-01	.	.	Phase 2	D0NT1S	.	CTPDG002153
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APN-301	EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2	.	Phase 2	D0NS7A	.	CTPDG002155
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Multi-epitope tyrosinase/gp100 vaccine	"Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering"	.	Phase 2	D0N7FD	.	CTPDG002165
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Antigen-pulsed dendritic cell vaccine	Antigen-pulsed dendritic cell vaccine (melanoma)	.	Phase 2	D0MI0S	.	CTPDG002187
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Stage IV melanoma vaccine	"Stage IV melanoma vaccine, ARI; Stage IV melanoma vaccine, Adelaide Research & Innovation"	.	Phase 2	D0KC9U	.	CTPDG002255
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MKC-1106-MT	"Melanoma vaccine (MART-1/tyrosinase), Mannkind"	.	Phase 2	D0J7MQ	.	CTPDG002283
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Telomelysin	.	.	Phase 2	D0I3VV	.	CTPDG002315
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes	"Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma); Autologous anti-gp100 TCR gene-engineered PBLs (melanoma), NCI; Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma), National Cancer Institute"	.	Phase 2	D0I3VS	.	CTPDG002316
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	IPI-549	"XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(("	91933883	Phase 2	D0I3LO	.	CTPDG002318
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Tumor infiltrating lymphocyte	.	.	Phase 2	D0H8DS	.	CTPDG002334
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TH-302	"evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174"	11984561	Phase 2	D0H1EA	DB06091	CTPDG002343
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Ontuxizumab	Amatuximab	.	Phase 2	D0FK9H	.	CTPDG002385
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Anti-CD3 activated vaccine-primed lymphocytes	"VPLN tumor vaccine, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer); Monoclonal antiobody activated vaccine-primed lymphocytes (cancer), University of Michigan; Vaccine-primed lymph node (VPLN) cells, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer), University of Michigan; Anti-CD3/anti-CD28 activated vaccine-primed lymphocytes (cancer), University of Michigan"	.	Phase 2	D0E8KO	.	CTPDG002417
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	TLPLDC	.	.	Phase 2	D0D0DH	.	CTPDG002463
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Coxsackievirus A21	Cavatak (TN)	.	Phase 1/2	D0C4BL	.	CTPDG002486
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Resimmune	A-dmDT390-bisFv immunotoxin	.	Phase 1/2	D0C3TI	.	CTPDG002489
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ABX-IL8	.	.	Phase 2	D0BF9K	.	CTPDG002502
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ITIL-168	.	.	Phase 2	D0B6AZ	.	CTPDG002511
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi-8 PrimeBoost therapeutic melanoma vaccine	"Hi-8 MEL; Melanoma therapeutic vaccine, Oxxon; PSG2.Mel3; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxford BioMedica; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Lead Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Pharmaccine therapy (melanoma), Oxxon; DNA/MVA immunotherapy (melanoma), Oxxon; MEL-1 immunotherapy (melanoma), Oxxon; Melanoma immunotherapy (Prime-Boost), Oxxon"	.	Phase 2	D0A9BI	.	CTPDG002537
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GRN-1201	.	.	Phase 1	D0A3CH	.	CTPDG002550
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	CYT-004-MelQbG10	"Immunodrug vaccine (melanoma), Cytos; QbG10 Immunodrug carrier (cancer), Cytos"	.	Phase 2	D08KAD	.	CTPDG002632
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GSK3377794	.	.	Phase 2	D08FWJ	.	CTPDG002641
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Gp100:209-217(210M) peptide vaccine	"Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI"	.	Phase 2	D08DWM	.	CTPDG002646
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	LN-144	.	.	Phase 2	D08DIU	.	CTPDG002648
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MLN2480	"VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819"	25161177	Phase 2	D07IEU	DB15266	CTPDG002698
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	ARC-100	SCHEMBL13011610	57339443	Phase 2	D07GCK	.	CTPDG002701
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	AG140699	.	.	Phase 2	D06KZL	.	CTPDG002747
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	E7016	"UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016"	11660296	Phase 2	D06DHB	.	CTPDG002770
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GR-MD-02	Belapectin	.	Phase 2	D06BKH	.	CTPDG002771
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	PLX8394	.	90116675	Phase 2	D05HTS	.	CTPDG002807
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Hi8 melanoma vaccine	.	.	Phase 2	D04HMK	.	CTPDG002864
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	GCAN 101	.	.	Phase 2	D03TNG	.	CTPDG002903
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MSB0010445	.	.	Phase 2	D03LAI	.	CTPDG002922
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	RAF265	927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594	11656518	Phase 2	D03AND	DB05984	CTPDG002939
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Urelumab	.	.	Phase 2	D02ZMB	.	CTPDG002942
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MORAb-004	.	.	Phase 2	D02RKG	.	CTPDG002961
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	APX005M	.	.	Phase 2	D01ZLK	.	CTPDG002998
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Leuvectin	"IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical"	.	Phase 2	D01WHC	.	CTPDG003004
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 2	Polynoma-1	"Polyvalent melanoma vaccine, Vaccinoma"	.	Phase 2	D00DSV	.	CTPDG003100
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ENB003	"2364572-10-9; AAY8R26VDX; BQ 788-d2; BQ-788, di(methyl-d)-; CHEMBL5095234; D-Norleucine, N-((cis-2,6-di(methyl-d)-1-piperidinyl)carbonyl)-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl-, sodium salt; Enb 003; ENB 003 [WHO-DD]; ENB003; ENB-003; UNII-AAY8R26VDX; Vodudeutentan sodium"	145722637	Phase 1/2	DUOX13	.	CTPDG003137
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	HL-085	.	.	Phase 1/2	DJ8TN2	.	CTPDG003174
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NKTR-262	.	.	Phase 1/2	D8JN5H	.	CTPDG003216
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Delolimogene mupadenorepvec	LOAd703	.	Phase 1/2	D5V7XP	.	CTPDG003234
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Antigen-specific melanoma vaccine	.	.	Phase 1/2	D0Z2UY	.	CTPDG003269
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmuFact IMP321	.	.	Phase 1/2	D0U5AN	.	CTPDG003306
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NY-ESO-TCR	.	.	Phase 1/2	D0TN1N	.	CTPDG003316
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LXS196	"XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide"	118873253	Phase 1/2	D0R7HL	.	CTPDG003336
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	AU-011	.	.	Phase 1/2	D0R0NX	.	CTPDG003341
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	MAGE-A10 TCR	.	.	Phase 1/2	D0L1CO	.	CTPDG003391
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	TRX-518	"GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx"	.	Phase 1/2	D0J1MO	.	CTPDG003407
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	IMCnyeso	.	.	Phase 1/2	D0I9YM	.	CTPDG003414
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	LAG525	.	.	Phase 1/2	D0E4LS	.	CTPDG003448
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	NCI-4650	.	.	Phase 1/2	D07YNC	.	CTPDG003518
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	Ad-IL-12 DNA therapeutic	INXN-2001	.	Phase 1/2	D06LUI	.	CTPDG003539
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	SCIB-1	"SCIB-5; SCIB-1 DNA vaccine (melanoma, TriGrid), Scancell; Anti-TRP-2/ anti-gp100 monoclonal antibody vaccine (melanoma), Scancell"	.	Phase 1/2	D06AWA	.	CTPDG003547
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ImmunoVEX-timelan	.	.	Phase 1/2	D01EYR	.	CTPDG003621
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	CLL442	.	.	Phase 1/2	D01DIM	.	CTPDG003623
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1/2	ONCOS-102	CGTG-102	.	Phase 1/2	D00NBW	.	CTPDG003631
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AV-MEL-1	.	.	Phase 1	DX06ZU	.	CTPDG003672
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CV8102	.	.	Phase 1	DVU2H8	.	CTPDG003683
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GEN-011	.	.	Phase 1	DR1YQ7	.	CTPDG003746
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INXN 2001	.	.	Phase 1	DMP6A9	.	CTPDG003817
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ADP-A2M10	.	.	Phase 1	DM38KC	.	CTPDG003822
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CDX-1140	.	.	Phase 1	DKM7S3	.	CTPDG003841
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PF-07284890	"1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; 2573781-75-4; AR00504461; ARRY461; ARRY-461; ARRY-461; BDBM565133; CHEMBL5095256; CS-0564141; EX-A7593; GTPL12096; HY-147405; JNJ5N2RH5W; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; PF07284890; PF-07284890; PF-07284890; SCHEMBL22831935; Tinlorafenib; tinlorafenib [INN]; Tinlorafenib [USAN]; UNII-JNJ5N2RH5W; US11414404, Ex. # 10; WHO 12353"	155434855	Phase 1	DJ8QW7	.	CTPDG003866
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	XmAb20717	XmAb717	.	Phase 1	DD1TJ8	.	CTPDG003947
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SX-682	"1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-"	90467234	Phase 1	DAY4L1	.	CTPDG003976
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SB 11285	.	.	Phase 1	DA79HM	.	CTPDG003980
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CMP-001	vidutolimod	.	Phase 1	D7T5AN	.	CTPDG004031
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRT1419	.	.	Phase 1	D50CXM	.	CTPDG004103
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	INCAGN2385	.	.	Phase 1	D4KTA9	.	CTPDG004112
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TBX-3400	.	.	Phase 1	D2DB5T	.	CTPDG004169
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ifx-Hu2.0	.	.	Phase 1	D1NC2O	.	CTPDG004188
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	VCL-1M01	"VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical"	.	Phase 1	D0ZM5E	.	CTPDG004215
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GPA-TriMAR-T cells	.	.	Phase 1	D0YU0L	.	CTPDG004240
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PTI-188	.	.	Phase 1	D0Y7SN	.	CTPDG004253
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Dendritic cancer cell vaccine	.	.	Phase 1	D0Y0RF	.	CTPDG004266
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	BETULINIC ACID	"472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624"	64971	Phase 1	D0R9YR	DB12480	CTPDG004453
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Multipeptide vaccine combination	"Multipeptide vaccine combination (melanoma); Multipeptide vaccine combination (melanoma), Ludwig; MAGE-10.A2+ Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig; MAGE-10.A2 + Melan-A ELA + NY-ESO-1b + tyrosinase + GM-CSF multipeptide vaccine (melanoma), Ludwig/Columbia"	.	Phase 1	D0R2LY	.	CTPDG004464
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	NEO-PV-01	.	.	Phase 1	D0Q6AU	.	CTPDG004481
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Adoptive T-cell therapy	Adoptive T-cell therapy (cancer)	.	Phase 1	D0P4JJ	.	CTPDG004523
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Vaccimel	"Melanoma cell line vaccine (cancer), Centro de Investigaciones Oncologicas; Autologous dendritic cells + allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; Dendritic cells + apoptotic/necrotic allogeneic melanoma cell lines vaccine, Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires; DC/Apo-Nec vaccine (melanoma), Centro de Investigaciones Oncologicas/ Universidad de Buenos Aires"	.	Phase 1	D0LT2Z	.	CTPDG004610
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Lipovaxin-MM	"Dendritic cell-specific antigen targeting vaccine (liposome/nanoparticle/intravenous, melanoma), Lipotek"	.	Phase 1	D0L2OT	.	CTPDG004636
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	GSK-2241658A	"NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A"	.	Phase 1	D0IA5O	.	CTPDG004713
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	ICON-1	.	.	Phase 1	D0H6UL	.	CTPDG004748
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PLX-4720	PLX 4720; PLX4720 (BRAF inhibitor)	24180719	Phase 1	D0F5JZ	DB06999	CTPDG004804
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AE-08	.	.	Phase 1	D0F5GF	.	CTPDG004805
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TAK-202	.	.	Phase 1	D0DT2S	.	CTPDG004844
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AEB701	.	.	Phase 1	D0B2NF	.	CTPDG004924
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	UV1 + GM-CSF vaccine	.	.	Phase 1	D09UMR	.	CTPDG004968
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AMEP	"(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U"	14017	Phase 1	D08XBF	.	CTPDG005023
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Melanoma DNA vaccine	.	.	Phase 1	D07YZQ	.	CTPDG005073
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DEDN-6526A	.	.	Phase 1	D07XXT	.	CTPDG005076
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	IL-2 pDNA	.	.	Phase 1	D07JSX	.	CTPDG005099
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	AT13387	AT-13387	11955716	Phase 1	D06YSP	DB06306	CTPDG005131
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Ioflubenzamide (131I)	"Solazed; Ioflubenzamide I-131; MIP-1104; MIP-1143; MIP-1144; MIP-1145; ZK-BA; Iodine-123-Solazed; Iodine-131-Solazed; MIP-1145-[123I]; MIP-1145-[131I]; Radiolabeled benzamides (melanoma), Bayer; Radiolabeled benzamides (melanoma), Molecular Insight; Iodine-123-ZK-BA; Iodine-131-ZK-BA; Melanin-targeting radiodiagnostic (melanoma), Bayer/Molecular Insight; Melanin-targeting radiotherapeutic (melanoma), Bayer/Molecular Insight; 123I-MIP-1145; 123I-Solazed; 123I-ZK-BA"	24828760	Phase 1	D06SYN	.	CTPDG005140
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	SAM-6	.	.	Phase 1	D06PZC	.	CTPDG005148
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	Flanvotumab	"IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly"	.	Phase 1	D05WQT	.	CTPDG005180
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	CAR-T cells recognizing EpCAM	.	.	Phase 1	D04RNG	.	CTPDG005241
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	DC-IL-12 DNA therapeutic	INXN-3001	.	Phase 1	D03OKS	.	CTPDG005298
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	LV305	NY-ESO-1 Zvex	.	Phase 1	D02XTT	.	CTPDG005333
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	TTI-621	.	.	Phase 1	D01CUO	.	CTPDG005422
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Phase 1	PRAME antigen-specific cancer immunotherapeutic	.	.	Phase 1	D00AHT	.	CTPDG005477
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 3	Nuleusin	"IL-2 (subcutaneous formulation, RCC/MM), 3SBio"	.	Discontinued in Phase 3	D0PE0D	.	CTPDG006342
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	IDD-3	"Uvidem; Dendritophage + melanoma tumor cell lysate; Melanoma vaccine, Immuno-Designed Molecules/ IDM Pharma; Vaccine (melanoma), Immuno-Designed Molecules /IDM Pharma"	.	Discontinued in Phase 2	D0PH0M	.	CTPDG006457
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	BIWB-1	"Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender"	.	Discontinued in Phase 2	D0C7OQ	.	CTPDG006543
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melanoma vaccine (ALVAC)	"Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur"	.	Discontinued in Phase 2	D0C1EO	.	CTPDG006547
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	TriGem	"Monoclonal antibody 1A7, Titan Pharmaceuticals; Anti-I17 antibody, Trilex"	.	Discontinued in Phase 2	D08GEX	.	CTPDG006583
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Melaxin	"Autologous dendritoma vaccine (sc, melanoma), Oncolix"	.	Discontinued in Phase 2	D07FDV	.	CTPDG006596
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Ecromeximab	.	.	Discontinued in Phase 2	D05PWZ	.	CTPDG006614
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	XomaZyme-Mel	XMMME-0001-RTA	.	Discontinued in Phase 2	D03WSE	.	CTPDG006638
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 2	Zeniplatin	CL-286558	56840898	Discontinued in Phase 2	D00CFB	.	CTPDG006680
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1/2	ODC-0501	"Dendritic cell vaccine (melanoma), ODC; Vaccine (melanoma), ODC"	.	Discontinued in Phase 1/2	D02FEJ	.	CTPDG006699
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG-7256	"B-raf inhibitor (melanoma), Roche/Plexxikon"	.	Discontinued in Phase 1	D0RV7J	.	CTPDG006750
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	RG7636	.	.	Discontinued in Phase 1	D0J0IJ	.	CTPDG006800
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	ABX-MA1	"Anti-MUC18 MAb, Abgenix"	.	Discontinued in Phase 1	D0G7YG	.	CTPDG006814
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Discontinued in Phase 1	F-50040	"Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre"	.	Discontinued in Phase 1	D07CQJ	.	CTPDG006871
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Preclinical	ANAVEX 1007	.	.	Preclinical	D0M6OW	.	CTPDG007064
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Terminated	DISC GM-CSF	.	.	Terminated	D0X4UA	.	CTPDG007182
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Withaferin A	"Heat shock factor 1 inhibitor (melanoma), University of Kansas; HSF-1 inhibitor (melanoma), University of Kansas"	265237	Terminated	D0V3PN	.	CTPDG007199
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Terminated	SBP-002	"Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec"	.	Terminated	D0G0UZ	.	CTPDG007351
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Terminated	RAAV vaccine	.	.	Terminated	D0C3DH	.	CTPDG007389
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Terminated	Novovac-M1	.	.	Terminated	D01CJB	.	CTPDG007576
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VLD-631	.	.	Investigative	D0ZE7B	.	CTPDG007618
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	SMT-C2100	.	.	Investigative	D0Z4YK	.	CTPDG007634
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TOCA-621	"Viral vector-delivered interferon gamma gene therapy (malignant melanoma), Tocagen"	.	Investigative	D0Z3ZF	.	CTPDG007636
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	NVX-412	.	.	Investigative	D0XU4O	.	CTPDG007687
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	VitiGam	.	.	Investigative	D0X8EE	.	CTPDG007708
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	CGEN-791	.	.	Investigative	D0X4AN	.	CTPDG007726
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	IMX-MEL1	"Melanoma therapeutic vaccine, Imaxio"	.	Investigative	D0T6PF	.	CTPDG007851
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lm Melanoma	"Recombinant bacterial vector vaccine (melanoma), Aduro BioTech/New York University"	.	Investigative	D0R2YD	.	CTPDG007917
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	ADS-NPTMZ-1	.	.	Investigative	D0P6CQ	.	CTPDG007979
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Narciclasine	"Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one"	72376	Investigative	D0OQ1I	.	CTPDG007994
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico"	"Imaging agent (melanoma), NuView; 111In-DOTA-GlyGlu-CycMSH (melanoma), NuView/University of New Mexico"	.	Investigative	D0N7XY	.	CTPDG008036
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Ektomun	"Antibody (melanoma), Trion"	.	Investigative	D0L8TP	.	CTPDG008106
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PDS-0102	"Versamune-Melanoma; Vaccine (cationic lipid nanoparticle formulation, melanoma), PDS Biotechnology"	.	Investigative	D0H7OO	.	CTPDG008234
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MTI-SAM3	.	.	Investigative	D0E7IZ	.	CTPDG008339
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Box-5	"Wnt-5a antagonist (peptide, melanoma/metastasis), WntResearch"	.	Investigative	D0E0DS	.	CTPDG008356
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	20D75	.	.	Investigative	D0D3LZ	.	CTPDG008382
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	BCL-005	.	.	Investigative	D0C6XD	.	CTPDG008407
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	.	.	Investigative	D0A3SQ	.	CTPDG008495
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	"1,3-bis(1,3-benzothiazol-2-ylthio)acetone"	"1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409"	1240423	Investigative	D07DZS	.	CTPDG008704
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	PRAME-SLP	"Peptide vaccine(cancer), ISA Pharmaceuticals; Preferentially expressed antigen based vaccine (SLP technology/peptide, melanoma), ISA"	.	Investigative	D06RYG	.	CTPDG008736
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	AEZS-120	"Cancer vaccine (bacterial vector), University of Wurzburg/AEterna Zentaris"	.	Investigative	D06KGC	.	CTPDG008754
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	5-fluoro-1H-indole-2-carboxylic acid	"5-Fluoroindole-2-carboxylic acid; 399-76-8; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690"	1820	Investigative	D06BFH	.	CTPDG008772
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	TriMixDC	"Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles"	.	Investigative	D04PFD	.	CTPDG008870
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	OP-03	"OP-03 program (prodrug, melanoma); OP-03 program (prodrug, melanoma), Onco-Pharmakon"	.	Investigative	D04EFB	.	CTPDG008905
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LG-723	.	.	Investigative	D01VZQ	.	CTPDG009059
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	LY-1-100	"SMART derivatives (melanoma); LY-2-45; SMART derivatives (melanoma), University of Tennessee"	.	Investigative	D01NKF	.	CTPDG009090
M6ACROT05688	.	.	M6ADIS0029	2C30: Melanoma	Investigative	Lovaxin M	"HMW-MAA cancer vaccine (Listeria vector), Advaxis"	.	Investigative	D00QLG	.	CTPDG009162
M6ACROT05481	.	.	M6ADIS0105	CA21: Emphysema	Approved	Zemaira	Alpha-1-antitrypsin	.	Approved	D9EC0G	.	CTPDG000019
M6ACROT05481	.	.	M6ADIS0105	CA21: Emphysema	Phase 2	Palovarotene	"R-667; RG-667; Retinoid receptor agonist, Roche; Ro-3300074; Ro-330074"	10295295	Phase 2	D0H8OH	DB12320	CTPDG000360
M6ACROT05481	.	.	M6ADIS0105	CA21: Emphysema	Approved	Glassia	Glassia (TN)	.	Approved	D04ELD	.	CTPDG000678
M6ACROT05481	.	.	M6ADIS0105	CA21: Emphysema	Discontinued in Phase 3	Cilomilast	"Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid"	151170	Discontinued in Phase 3	D02EMR	DB03849	CTPDG006389
M6ACROT05481	.	.	M6ADIS0105	CA21: Emphysema	Terminated	WIN-63759	"CHEMBL114992; SCHEMBL7305284; BDBM50036477; 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester(WIN63759); 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester"	9938355	Terminated	D00AWA	.	CTPDG007589
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Approved	LU302146	.	.	Approved	D0Y7OJ	.	CTPDG000053
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Approved	Epoprostenol	"Epoprostanol; Epoprostenolum; Flolan; PGX; Prostacyclin; Prostacycline; Prostacyclins; Vasocyclin; ProstaglandinI; Prostaglandin X; Prostaglandins X; PGI2; Prostacyclin I2; Prostaglandin I2; TRY 200; Epoprostenol (TN); Epoprostenol [USAN:INN]; Epoprostenolum [INN-Latin]; PG-I2; PGI(sub 2); Prostaglandin I(2); Try-200; U 53,217; U-53217; Epoprostenol (USAN/INN); KB-IV-24; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid"	5282411	Approved	D0V0IX	DB01240	CTPDG000110
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Approved	Tolazoline	"Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole"	5504	Approved	D03RZV	DB00797	CTPDG000699
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 4	Beraprost	"88430-50-6; 88430-50-6 (free acid); 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-; Beraprost (USAN); GTPL1967; SCHEMBL1554142; SCHEMBL1554145; BDBM85181; CAS_2352; NSC_2352; 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid; K578; D02720; L024061; Q5977854; (E)-4-(2-hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1H-benzo[d]cyclopenta[b]furan-5-yl)butanoic acid; 4-(2-Hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoic acid; 4-{4-hydroxy-3-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-trien-9-yl}butanoic acid"	5282428	Phase 4	D4Q5AW	.	CTPDG000840
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 3	Bardoxolone methyl	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4	400769	Phase 3	D0JU5X	DB05983	CTPDG015155
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 3	PF-1228305	Sitaxentan sodium; Sitaxsentan sodium	11477084	Phase 3	D08JWJ	.	CTPDG001330
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 2	AZD3427	.	.	Phase 2	DHR39I	.	CTPDG001705
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 2	99mTc-labelled adrenomedullin	"PulmoBind; DFH-12; Pulmonary disease imaging (intravenous), Pulmo BioTech; Pulmonary disease imaging (intravenous), PulmoScience; Technetium-99m labelled adrenomedullin (pulmonary disease), Pulmo BioTech; Technetium-99m labelled adrenomedullin (pulmonary disease), PulmoScience; 99mTc-labelled adrenomedullin (pulmonary disease), Pulmo BioTech"	.	Phase 2	D0WN1T	.	CTPDG001913
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 2	Ralinepag	"UNII-CQY12ZJN6E; CQY12ZJN6E; 1187856-49-0; Ralinepag [USAN:INN]; Ralinepag (USAN/INN); SCHEMBL1118504; SCHEMBL1118506; SCHEMBL12786473; CHEMBL3919269; CHEMBL3301604; AKOS027337124; DB12462; 2-((trans-4-((((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetic acid; Acetic acid, 2-((trans-4-(((((4-chlorophenyl)phenylamino)carbonyl)oxy)methyl)cyclohexyl)methoxy)-; HY-16751; CS-0012350; J3.614.088G; D10725"	44219292	Phase 2	D0M4TJ	DB12462	CTPDG002207
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 2	VentaProst	.	.	Phase 2	D0HG9P	.	CTPDG002327
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 1	Autologous cell based gene therapy	Autologous cell based gene therapy (pulmonary hypertension)	.	Phase 1	D0H3GK	.	CTPDG004754
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Phase 1	Dichloroacetate sodium	"Dichloroacetate sodium (pulmonary arterial hypertension), University of Alberta/Imperial College London"	517326	Phase 1	D01FQV	.	CTPDG005418
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Investigative	Prostacyclin analog	"Prostacyclin analog (deuterated, pulmonary hypertension)"	.	Investigative	D06ENH	.	CTPDG008764
M6ACROT02013	.	.	M6ADIS0032	BB01: Pulmonary hypertension	Investigative	DasKloster 0247-01	.	.	Investigative	D04UPJ	.	CTPDG008859
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Approved	Acipimox	Monted; Nedios; Olbemox; Olbetam; K 9321	5310993	Approved	D0S1NZ	DB09055	CTPDG000159
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 4	LAROPIPRANT	"571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B"	9867642	Phase 4	D0WL5V	DB11629	CTPDG009758
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 3	Anacetrapib	MK0859; Anacetrapib (USAN); MK-0859	11556427	Phase 3	D07HLS	DB06630	CTPDG001364
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2/3	PACTIMIBE	"189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309"	3081927	Phase 2/3	D02GWF	DB12971	CTPDG001578
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	K-134	"SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104"	9908900	Phase 2	D0S4SX	DB12685	CTPDG002043
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	BMS-582949	"623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446"	10409068	Phase 2	D0Q0AP	DB12696	CTPDG002102
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	VB-201	.	45138527	Phase 2	D0N2IE	DB15259	CTPDG002178
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	CSL-112	"Reconstituted HDL (acute coronary syndrome), CSL"	.	Phase 2	D0L8VA	.	CTPDG002226
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	MK-1903	"Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co"	49763030	Phase 2	D09TGC	.	CTPDG002559
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	DRL-17822	"CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's"	58689743	Phase 2	D07UJA	.	CTPDG002668
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	PRC-4016	.	78210211	Investigative	D03WAT	DB12990	CTPDG002892
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	K-604	BDBM86691	9892288	Phase 2	D03PYD	.	CTPDG002910
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	Revacept	"Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen"	.	Phase 2	D03BAC	.	CTPDG002936
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	DVC1-0101	"Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University"	.	Phase 2	D00IZD	.	CTPDG003085
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1/2	ATL-313	"DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data"	11627443	Phase 1/2	D08FHZ	DB12295	CTPDG003512
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	PSI-697	"UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic"	12004316	Phase 1	D0Z0AM	DB12211	CTPDG004239
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	SLV-342	.	.	Phase 1	D0Y9YG	.	CTPDG004250
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	LXR 623	LXR-623	16734800	Phase 1	D0R4EN	.	CTPDG004461
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	ATR-101	.	131678	Phase 1	D0MB2Z	.	CTPDG004594
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	XL-041	"XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb"	.	Phase 1	D0L0DZ	.	CTPDG004642
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BMS-852927	.	49787490	Phase 1	D0H4DR	.	CTPDG004751
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	CS-8080	"Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc"	16212738	Phase 1	D0GY1Y	.	CTPDG004758
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	ISIS-APOCIII	.	.	Phase 1	D0F6KM	.	CTPDG004803
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BMS-779788	.	59251511	Phase 1	D00QWU	.	CTPDG005446
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BAY-60-5521	"CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer"	11691871	Phase 1	D00JQE	.	CTPDG005460
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 3	Darapladib	SB 480848; Darapladib (USAN)	9939609	Discontinued in Phase 3	D0L5UO	DB06311	CTPDG006349
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 3	Acifran	Reductol; AY-25712	51576	Discontinued in Phase 3	D0K1HO	.	CTPDG006352
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	ET-642	"ETC-642; RLT peptide, Esperion; RLT peptide, Pfizer"	.	Discontinued in Phase 2	D0S3MY	.	CTPDG006440
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	SQ-32709	"farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330"	445713	Discontinued in Phase 2	D0N5HO	DB07780	CTPDG006469
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	CETi-1	"Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences"	.	Discontinued in Phase 2	D0J4KC	.	CTPDG006499
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	Gantofiban	CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester	135565976	Discontinued in Phase 2	D0H9WO	.	CTPDG006504
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	FCP-3P1	"CardioRex; Antihyperlipidemic, Forbes Medi-Tech"	60496	Discontinued in Phase 2	D0H7WA	.	CTPDG006506
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	Lifibrol	K-12148; U-83860; (R)-Lifibrol; (S)-Lifibrol; (S)-Lifibrol methyl ester	57112	Discontinued in Phase 2	D0BC4Q	DB12448	CTPDG006550
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	TA-7552	"TA 7552; 104756-72-1; 1-(3,4-Dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8-trimethoxynaphthalene; AC1L2U74; SCHEMBL8688163; DTXSID60146695; DTCYXOLBEPGOHV-UHFFFAOYSA-N; HY-100253; CS-0018404; dimethyl 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxynaphthalene-2,3-dicarboxylate; 2,3-Naphthalenedicarboxylic acid, 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxy-, dimethyl ester"	128664	Discontinued in Phase 2	D02RVE	.	CTPDG006650
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	RUS 3108	.	.	Discontinued in Phase 1	D0ZD6Y	.	CTPDG006704
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	GR-328713	GW-320449X; GW-328713X	.	Discontinued in Phase 1	D0SS6J	.	CTPDG006740
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	RG7418	BI204	.	Discontinued in Phase 1	D0MH1R	.	CTPDG006776
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3052334	SCHEMBL3959323	24742042	Discontinued in Phase 1	D0MF7U	.	CTPDG006777
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	Goxalapladib	"Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide"	11686305	Discontinued in Phase 1	D0MC3R	.	CTPDG006778
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	AC3056	.	.	Discontinued in Phase 1	D0L8OE	.	CTPDG006782
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3185043	.	.	Discontinued in Phase 1	D0K3GU	.	CTPDG006793
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	GSK568859	.	.	Discontinued in Phase 1	D0CA3J	.	CTPDG006824
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	NICANARTINE	"MRZ-3/124; 2,6-Di-tert-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol"	66001	Discontinued in Phase 1	D0A0FG	.	CTPDG006839
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3491165	PF-03491165	.	Discontinued in Phase 1	D09QIJ	.	CTPDG006846
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	SB-435495	.	10417440	Discontinued in Phase 1	D09NBM	.	CTPDG006847
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	P-0654	P-0655	.	Discontinued in Phase 1	D07IXD	.	CTPDG006868
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	CL-277082	"UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea"	125893	Discontinued in Phase 1	D06FCR	.	CTPDG006879
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	LF-08-0133	.	.	Discontinued in Phase 1	D04ZNG	.	CTPDG006891
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-807925	.	.	Discontinued in Phase 1	D04GVN	.	CTPDG006900
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	F-1394	"AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate"	6918210	Discontinued in Phase 1	D03QZB	.	CTPDG006904
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	CP-800569	"(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol"	6918520	Discontinued in Phase 1	D03MAD	.	CTPDG006907
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	APP-018	"D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis"	72941823	Discontinued in Phase 1	D03FPA	.	CTPDG006911
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	Nobiletin	"478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)"	72344	Preclinical	D4PG6A	.	CTPDG007008
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	Quinoxaline	WYE-111672; WYE-672	7045	Preclinical	D0U9RR	.	CTPDG007044
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	HL-004	TS-962	6426883	Preclinical	D09MJO	.	CTPDG007104
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	ETX-6107	"ETS-6107; ETS-6114; Antihypercholesterolemic agents (atherosclerosis), e-Therapeutics"	.	Preclinical	D05YRV	.	CTPDG007129
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	BAY-38-1315	BAY-19-4789	46880878	Preclinical	D05QXT	.	CTPDG007133
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	2164U90	BW-2164; BW-2164U90	9841699	Terminated	D0ZJ0A	.	CTPDG007163
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	GT-16-239	.	.	Terminated	D0YQ9G	.	CTPDG007167
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Cholazol	Cholestran	.	Terminated	D0XY4Q	.	CTPDG007178
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BB-476	.	9803625	Terminated	D0WU8Z	.	CTPDG007184
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGP-43371	"Cgp 43371; UNII-V97741GKF2; V97741GKF2; 123036-23-7; cgp43371; N,15-Didehydro-15-deoxo-1-deoxy-1,15-epoxy-4-O-methyl-3-(4-((2,4,6-trimethyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)"	6441203	Terminated	D0U8KA	.	CTPDG007206
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	AL-0671	AL-0670	57415651	Terminated	D0TB1X	.	CTPDG007216
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BIBX-79	175033-26-8; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide	501396	Terminated	D0S1XO	.	CTPDG007228
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CI-999	PD-138142-15	74083365	Terminated	D0PG0S	.	CTPDG007248
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Bio-Flow	.	.	Terminated	D0P1JV	.	CTPDG007254
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGS-24565	"Cgs 24565; 136583-72-7; N,15-Didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)"	6443293	Terminated	D0OL9V	.	CTPDG007259
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	TEI-6522	.	9953017	Terminated	D0OK8M	.	CTPDG007260
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	FR-145237	.	9850056	Terminated	D0O2AC	.	CTPDG007265
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	F-12509A	.	9862964	Terminated	D0O0JH	.	CTPDG007268
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	TA-993	"MB-3, Tanabe"	129579	Terminated	D0M9CV	.	CTPDG007277
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Barixibat	"BARI-1453; Bile acid resorption inhibitor, Aventis; HMR-1453; 1453, Aventis"	10234172	Terminated	D0LV0R	.	CTPDG007284
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	PD-146176	"PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, &gt; (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-"	297589	Terminated	D0J8RS	.	CTPDG007309
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BIBB-515	"BIBB 515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-"	501398	Terminated	D0I2YV	.	CTPDG007327
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	LF-7-0165c	.	.	Terminated	D0EA7H	.	CTPDG007362
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	SDZ-267-489	.	.	Terminated	D0D2RZ	.	CTPDG007377
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	WAY-121898	"136100-14-6; 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester; ACMC-20mw0l; SCHEMBL2597837; CHEMBL267052; ZINC14493; CTK0F3948; DTXSID30430876; 4-PHENOXYPHENYL 4-METHYL-1-PIPERIDINECARBOXYLATE"	9796754	Terminated	D0CS0D	.	CTPDG007381
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	SR12813	"SR 12813; 126411-39-0; SR-12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO"	446313	Terminated	D0C7RV	DB04466	CTPDG007385
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CP-230821	.	.	Terminated	D08MAR	.	CTPDG007439
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	T-686	"PAI-1 inhibitor, Tanabe"	6438903	Terminated	D08EIX	.	CTPDG007444
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	RPR-101821	.	.	Terminated	D08ALQ	.	CTPDG007445
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	MDL-29311	MDL-27272; MDL-29097	131127	Terminated	D07YUY	.	CTPDG007447
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CP-83101	"AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-"	6438614	Terminated	D07QSA	.	CTPDG007452
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	INCB3344	"INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer"	10008367	Terminated	D07KIJ	.	CTPDG007459
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGS-23425	"CHEMBL46882; N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic acid; cgs23425; SCHEMBL281877; DTXSID7040998; NOCAS_40998; CGS 23425; BDBM50036402; AKOS027327083; N-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-oxalamic acid; N-[3,5-dimethyl-4-(4''-hydroxy-3''-isopropylphenoxy)phenyl]oxamic acid; ({4-[4-hydroxy-3-(propan-2-yl)phenoxy]-3,5-dimethylphenyl}amino)(oxo)acetic acid"	9874938	Terminated	D07EGS	.	CTPDG007465
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	RP-73163	CHEMBL434418; BDBM50106700	44356696	Terminated	D06KFR	.	CTPDG007478
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Astenose	GM-1077; GMI-077	.	Terminated	D05HHP	.	CTPDG007498
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	S-12340	"S12340; S 12340; 144754-35-8; SCHEMBL4782175; 8-(3-(3,5-Diterbutyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 8-(3-(3,5-Di-tert-butyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 1-Oxa-3,8-diazaspiro(4.5)decan-2-one, 8-(3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)propyl)-"	9802991	Terminated	D04NSW	.	CTPDG007512
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	ZD-9720	ZD-7851	.	Terminated	D04GJX	.	CTPDG007516
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	IL1aQb	"IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos"	.	Terminated	D03VFV	.	CTPDG007524
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	NTE-122	"ACAT inhibitor, Nissin Food"	9830692	Terminated	D03JRJ	.	CTPDG007530
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	B-5354a	"B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo"	.	Terminated	D02YQJ	.	CTPDG007541
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	F-2833	"107430-45-5; F 2833; 2-[4-(2-chlorophenyl)phenyl]propan-2-ol; AC1L3UIQ; (2-Chloro-2'-(1,1')-4-biphenyl)-2-propanol; SCHEMBL10802061; DTXSID80148050; f2833; (1,1'-Biphenyl)-4-methanol, 2'-chloro-alpha,alpha-dimethyl-"	147118	Terminated	D00QOG	.	CTPDG007580
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	LF-13-0491c	.	.	Terminated	D00KXQ	.	CTPDG007583
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	FR-129169	.	9803486	Terminated	D00KQT	.	CTPDG007584
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	AM-1101	"Lactosylceramide synthase inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals; GAL T-2 inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals"	.	Investigative	D0Y9PQ	.	CTPDG007655
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Apovasc	CM-121; CM-125; CM-121 + CM-125	.	Investigative	D0Y3TX	.	CTPDG007668
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	KY-382	.	10454368	Investigative	D0V9MG	.	CTPDG007787
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Adiponectin mimetics	"Adiponectin mimetics (oral, type 2 diabetes/atherosclerosis/muscle metabolic diseases)"	.	Investigative	D0R1DX	.	CTPDG007921
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	HL-135	.	.	Investigative	D0Q9RW	.	CTPDG007935
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	KM-011	"Apo-A1 mimetic peptide (atherosclerosis), KineMed; Apolipoprotein-A1 mimetic peptide (atherosclerosis), KineMed"	.	Investigative	D0Q6OL	.	CTPDG007947
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	VULM-1457	"Acyl CoA cholesterol acyltransferase inhibitor (dyslipidemia/atherosclerosis), Univerzity Komenskeho v Bratislave"	.	Investigative	D0OH1O	.	CTPDG007998
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	ARI-1778	"KH-01503; Rev-D-4F; Reverse-D-4F; Apo-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 agonist (atherosclerosis), Abbott; Apolipoprotein-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Abbott; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Kos Pharmaceuticals; Apo-A1 agonist (atherosclerosis), Abbott/Arisaph"	.	Investigative	D0K7VM	.	CTPDG008136
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	GSK-1344386B	"CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline"	.	Investigative	D0C5XF	.	CTPDG008409
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	SCH-602539	"UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura"	16214871	Investigative	D0BV3B	.	CTPDG008432
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Radiolabeled VEGF	"Lu-scVEGF; Radiolabeled VEGF (cancer); Radiolabeled VEGF (cancer), Sibtech/Stanford; Technetium-99m-HYNIC-VEGF; Technetium-99m-single chain-VEGF; Lu-177-DOTA-PEG-scVEGF; 99mTc-HYNIC-VEGF; 99mTc-singlechain-VEGF"	.	Investigative	D0AT5Y	.	CTPDG008467
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	AG-4070	"LXR agonists (atherosclerosis); LXR agonists (atherosclerosis), F.Hoffmann-La Roche"	.	Investigative	D0A6WQ	.	CTPDG008485
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Integrin alpha-V/beta-3 receptor mab	"Integrin alpha-V/beta-3 receptor mAb (atherosclerosis); Integrin alpha-V/beta-3 antagonist (atherosclerosis), Vascular Pharmaceuticals; Integrin alpha-V/beta-3 receptor mAb (atherosclerosis), Vascular Pharmaceuticals"	.	Investigative	D0A5CH	.	CTPDG008491
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	ICI-245991	.	.	Investigative	D0A1DT	.	CTPDG008501
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	MK-6892	"Nicotinic acid 1 receptor (GPR109A) agonists, Merck"	135416394	Investigative	D09ZPN	.	CTPDG008504
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	BMS-753951	"Gadolinium chelate MR imaging agent (atherosclerosis), BMS"	.	Investigative	D09WMV	.	CTPDG008510
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	TGFTX-1	.	.	Investigative	D09OSM	.	CTPDG008530
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	INV-400	"INV-403; INV-404; INV-405; Invasc-400 series; SREBP transcription factor 2 stimulator (atherosclerosis), InVasc; Sterol regulatory element-binding protein 2 stimulator (atherosclerosis), InVasc"	.	Investigative	D09DJS	.	CTPDG008561
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	GX-401	.	.	Investigative	D07RME	.	CTPDG008665
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	RP-805	"Matrix metalloproteinase inhibitor (atherosclerosis); Matrix metalloproteinase inhibitor (atherosclerosis), Lantheus; RP-782-111In; Indium-111-RP-782; Technetium-99m-RP-805; Matrix metalloproteinase (MMP) inhibitor (tumor imaging), Bristol-Myers Squibb; 111In-RP-782; 99mTc-RP-805"	.	Investigative	D03YMD	.	CTPDG008917
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	RXP-470	"MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA"	102258832	Investigative	D03QXD	.	CTPDG008948
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	2NTX-99	"Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), Nile; Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), University of Milano"	10224454	Investigative	D02SAK	.	CTPDG009011
M6ACROT05435	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	BAY-1006451	[18F]-BAY-1006451	.	Investigative	D01FJN	.	CTPDG009122
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Approved	Acipimox	Monted; Nedios; Olbemox; Olbetam; K 9321	5310993	Approved	D0S1NZ	DB09055	CTPDG000159
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 4	LAROPIPRANT	"571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B"	9867642	Phase 4	D0WL5V	DB11629	CTPDG009758
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 3	Anacetrapib	MK0859; Anacetrapib (USAN); MK-0859	11556427	Phase 3	D07HLS	DB06630	CTPDG001364
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2/3	PACTIMIBE	"189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309"	3081927	Phase 2/3	D02GWF	DB12971	CTPDG001578
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	K-134	"SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104"	9908900	Phase 2	D0S4SX	DB12685	CTPDG002043
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	BMS-582949	"623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446"	10409068	Phase 2	D0Q0AP	DB12696	CTPDG002102
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	VB-201	.	45138527	Phase 2	D0N2IE	DB15259	CTPDG002178
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	CSL-112	"Reconstituted HDL (acute coronary syndrome), CSL"	.	Phase 2	D0L8VA	.	CTPDG002226
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	MK-1903	"Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co"	49763030	Phase 2	D09TGC	.	CTPDG002559
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	DRL-17822	"CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's"	58689743	Phase 2	D07UJA	.	CTPDG002668
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	PRC-4016	.	78210211	Investigative	D03WAT	DB12990	CTPDG002892
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	K-604	BDBM86691	9892288	Phase 2	D03PYD	.	CTPDG002910
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	Revacept	"Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen"	.	Phase 2	D03BAC	.	CTPDG002936
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	DVC1-0101	"Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University"	.	Phase 2	D00IZD	.	CTPDG003085
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1/2	ATL-313	"DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data"	11627443	Phase 1/2	D08FHZ	DB12295	CTPDG003512
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	PSI-697	"UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic"	12004316	Phase 1	D0Z0AM	DB12211	CTPDG004239
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	SLV-342	.	.	Phase 1	D0Y9YG	.	CTPDG004250
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	LXR 623	LXR-623	16734800	Phase 1	D0R4EN	.	CTPDG004461
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	ATR-101	.	131678	Phase 1	D0MB2Z	.	CTPDG004594
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	XL-041	"XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb"	.	Phase 1	D0L0DZ	.	CTPDG004642
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BMS-852927	.	49787490	Phase 1	D0H4DR	.	CTPDG004751
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	CS-8080	"Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc"	16212738	Phase 1	D0GY1Y	.	CTPDG004758
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	ISIS-APOCIII	.	.	Phase 1	D0F6KM	.	CTPDG004803
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BMS-779788	.	59251511	Phase 1	D00QWU	.	CTPDG005446
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BAY-60-5521	"CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer"	11691871	Phase 1	D00JQE	.	CTPDG005460
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 3	Darapladib	SB 480848; Darapladib (USAN)	9939609	Discontinued in Phase 3	D0L5UO	DB06311	CTPDG006349
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 3	Acifran	Reductol; AY-25712	51576	Discontinued in Phase 3	D0K1HO	.	CTPDG006352
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	ET-642	"ETC-642; RLT peptide, Esperion; RLT peptide, Pfizer"	.	Discontinued in Phase 2	D0S3MY	.	CTPDG006440
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	SQ-32709	"farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330"	445713	Discontinued in Phase 2	D0N5HO	DB07780	CTPDG006469
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	CETi-1	"Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences"	.	Discontinued in Phase 2	D0J4KC	.	CTPDG006499
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	Gantofiban	CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester	135565976	Discontinued in Phase 2	D0H9WO	.	CTPDG006504
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	FCP-3P1	"CardioRex; Antihyperlipidemic, Forbes Medi-Tech"	60496	Discontinued in Phase 2	D0H7WA	.	CTPDG006506
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	Lifibrol	K-12148; U-83860; (R)-Lifibrol; (S)-Lifibrol; (S)-Lifibrol methyl ester	57112	Discontinued in Phase 2	D0BC4Q	DB12448	CTPDG006550
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	TA-7552	"TA 7552; 104756-72-1; 1-(3,4-Dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8-trimethoxynaphthalene; AC1L2U74; SCHEMBL8688163; DTXSID60146695; DTCYXOLBEPGOHV-UHFFFAOYSA-N; HY-100253; CS-0018404; dimethyl 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxynaphthalene-2,3-dicarboxylate; 2,3-Naphthalenedicarboxylic acid, 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxy-, dimethyl ester"	128664	Discontinued in Phase 2	D02RVE	.	CTPDG006650
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	RUS 3108	.	.	Discontinued in Phase 1	D0ZD6Y	.	CTPDG006704
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	GR-328713	GW-320449X; GW-328713X	.	Discontinued in Phase 1	D0SS6J	.	CTPDG006740
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	RG7418	BI204	.	Discontinued in Phase 1	D0MH1R	.	CTPDG006776
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3052334	SCHEMBL3959323	24742042	Discontinued in Phase 1	D0MF7U	.	CTPDG006777
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	Goxalapladib	"Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide"	11686305	Discontinued in Phase 1	D0MC3R	.	CTPDG006778
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	AC3056	.	.	Discontinued in Phase 1	D0L8OE	.	CTPDG006782
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3185043	.	.	Discontinued in Phase 1	D0K3GU	.	CTPDG006793
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	GSK568859	.	.	Discontinued in Phase 1	D0CA3J	.	CTPDG006824
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	NICANARTINE	"MRZ-3/124; 2,6-Di-tert-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol"	66001	Discontinued in Phase 1	D0A0FG	.	CTPDG006839
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3491165	PF-03491165	.	Discontinued in Phase 1	D09QIJ	.	CTPDG006846
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	SB-435495	.	10417440	Discontinued in Phase 1	D09NBM	.	CTPDG006847
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	P-0654	P-0655	.	Discontinued in Phase 1	D07IXD	.	CTPDG006868
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	CL-277082	"UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea"	125893	Discontinued in Phase 1	D06FCR	.	CTPDG006879
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	LF-08-0133	.	.	Discontinued in Phase 1	D04ZNG	.	CTPDG006891
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-807925	.	.	Discontinued in Phase 1	D04GVN	.	CTPDG006900
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	F-1394	"AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate"	6918210	Discontinued in Phase 1	D03QZB	.	CTPDG006904
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	CP-800569	"(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol"	6918520	Discontinued in Phase 1	D03MAD	.	CTPDG006907
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	APP-018	"D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis"	72941823	Discontinued in Phase 1	D03FPA	.	CTPDG006911
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	Nobiletin	"478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)"	72344	Preclinical	D4PG6A	.	CTPDG007008
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	Quinoxaline	WYE-111672; WYE-672	7045	Preclinical	D0U9RR	.	CTPDG007044
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	HL-004	TS-962	6426883	Preclinical	D09MJO	.	CTPDG007104
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	ETX-6107	"ETS-6107; ETS-6114; Antihypercholesterolemic agents (atherosclerosis), e-Therapeutics"	.	Preclinical	D05YRV	.	CTPDG007129
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	BAY-38-1315	BAY-19-4789	46880878	Preclinical	D05QXT	.	CTPDG007133
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	2164U90	BW-2164; BW-2164U90	9841699	Terminated	D0ZJ0A	.	CTPDG007163
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	GT-16-239	.	.	Terminated	D0YQ9G	.	CTPDG007167
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Cholazol	Cholestran	.	Terminated	D0XY4Q	.	CTPDG007178
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BB-476	.	9803625	Terminated	D0WU8Z	.	CTPDG007184
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGP-43371	"Cgp 43371; UNII-V97741GKF2; V97741GKF2; 123036-23-7; cgp43371; N,15-Didehydro-15-deoxo-1-deoxy-1,15-epoxy-4-O-methyl-3-(4-((2,4,6-trimethyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)"	6441203	Terminated	D0U8KA	.	CTPDG007206
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	AL-0671	AL-0670	57415651	Terminated	D0TB1X	.	CTPDG007216
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BIBX-79	175033-26-8; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide	501396	Terminated	D0S1XO	.	CTPDG007228
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CI-999	PD-138142-15	74083365	Terminated	D0PG0S	.	CTPDG007248
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Bio-Flow	.	.	Terminated	D0P1JV	.	CTPDG007254
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGS-24565	"Cgs 24565; 136583-72-7; N,15-Didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)"	6443293	Terminated	D0OL9V	.	CTPDG007259
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	TEI-6522	.	9953017	Terminated	D0OK8M	.	CTPDG007260
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	FR-145237	.	9850056	Terminated	D0O2AC	.	CTPDG007265
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	F-12509A	.	9862964	Terminated	D0O0JH	.	CTPDG007268
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	TA-993	"MB-3, Tanabe"	129579	Terminated	D0M9CV	.	CTPDG007277
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Barixibat	"BARI-1453; Bile acid resorption inhibitor, Aventis; HMR-1453; 1453, Aventis"	10234172	Terminated	D0LV0R	.	CTPDG007284
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	PD-146176	"PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, &gt; (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-"	297589	Terminated	D0J8RS	.	CTPDG007309
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BIBB-515	"BIBB 515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-"	501398	Terminated	D0I2YV	.	CTPDG007327
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	LF-7-0165c	.	.	Terminated	D0EA7H	.	CTPDG007362
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	SDZ-267-489	.	.	Terminated	D0D2RZ	.	CTPDG007377
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	WAY-121898	"136100-14-6; 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester; ACMC-20mw0l; SCHEMBL2597837; CHEMBL267052; ZINC14493; CTK0F3948; DTXSID30430876; 4-PHENOXYPHENYL 4-METHYL-1-PIPERIDINECARBOXYLATE"	9796754	Terminated	D0CS0D	.	CTPDG007381
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	SR12813	"SR 12813; 126411-39-0; SR-12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO"	446313	Terminated	D0C7RV	DB04466	CTPDG007385
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CP-230821	.	.	Terminated	D08MAR	.	CTPDG007439
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	T-686	"PAI-1 inhibitor, Tanabe"	6438903	Terminated	D08EIX	.	CTPDG007444
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	RPR-101821	.	.	Terminated	D08ALQ	.	CTPDG007445
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	MDL-29311	MDL-27272; MDL-29097	131127	Terminated	D07YUY	.	CTPDG007447
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CP-83101	"AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-"	6438614	Terminated	D07QSA	.	CTPDG007452
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	INCB3344	"INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer"	10008367	Terminated	D07KIJ	.	CTPDG007459
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGS-23425	"CHEMBL46882; N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic acid; cgs23425; SCHEMBL281877; DTXSID7040998; NOCAS_40998; CGS 23425; BDBM50036402; AKOS027327083; N-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-oxalamic acid; N-[3,5-dimethyl-4-(4''-hydroxy-3''-isopropylphenoxy)phenyl]oxamic acid; ({4-[4-hydroxy-3-(propan-2-yl)phenoxy]-3,5-dimethylphenyl}amino)(oxo)acetic acid"	9874938	Terminated	D07EGS	.	CTPDG007465
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	RP-73163	CHEMBL434418; BDBM50106700	44356696	Terminated	D06KFR	.	CTPDG007478
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Astenose	GM-1077; GMI-077	.	Terminated	D05HHP	.	CTPDG007498
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	S-12340	"S12340; S 12340; 144754-35-8; SCHEMBL4782175; 8-(3-(3,5-Diterbutyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 8-(3-(3,5-Di-tert-butyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 1-Oxa-3,8-diazaspiro(4.5)decan-2-one, 8-(3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)propyl)-"	9802991	Terminated	D04NSW	.	CTPDG007512
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	ZD-9720	ZD-7851	.	Terminated	D04GJX	.	CTPDG007516
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	IL1aQb	"IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos"	.	Terminated	D03VFV	.	CTPDG007524
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	NTE-122	"ACAT inhibitor, Nissin Food"	9830692	Terminated	D03JRJ	.	CTPDG007530
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	B-5354a	"B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo"	.	Terminated	D02YQJ	.	CTPDG007541
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	F-2833	"107430-45-5; F 2833; 2-[4-(2-chlorophenyl)phenyl]propan-2-ol; AC1L3UIQ; (2-Chloro-2'-(1,1')-4-biphenyl)-2-propanol; SCHEMBL10802061; DTXSID80148050; f2833; (1,1'-Biphenyl)-4-methanol, 2'-chloro-alpha,alpha-dimethyl-"	147118	Terminated	D00QOG	.	CTPDG007580
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	LF-13-0491c	.	.	Terminated	D00KXQ	.	CTPDG007583
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	FR-129169	.	9803486	Terminated	D00KQT	.	CTPDG007584
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	AM-1101	"Lactosylceramide synthase inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals; GAL T-2 inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals"	.	Investigative	D0Y9PQ	.	CTPDG007655
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Apovasc	CM-121; CM-125; CM-121 + CM-125	.	Investigative	D0Y3TX	.	CTPDG007668
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	KY-382	.	10454368	Investigative	D0V9MG	.	CTPDG007787
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Adiponectin mimetics	"Adiponectin mimetics (oral, type 2 diabetes/atherosclerosis/muscle metabolic diseases)"	.	Investigative	D0R1DX	.	CTPDG007921
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	HL-135	.	.	Investigative	D0Q9RW	.	CTPDG007935
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	KM-011	"Apo-A1 mimetic peptide (atherosclerosis), KineMed; Apolipoprotein-A1 mimetic peptide (atherosclerosis), KineMed"	.	Investigative	D0Q6OL	.	CTPDG007947
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	VULM-1457	"Acyl CoA cholesterol acyltransferase inhibitor (dyslipidemia/atherosclerosis), Univerzity Komenskeho v Bratislave"	.	Investigative	D0OH1O	.	CTPDG007998
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	ARI-1778	"KH-01503; Rev-D-4F; Reverse-D-4F; Apo-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 agonist (atherosclerosis), Abbott; Apolipoprotein-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Abbott; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Kos Pharmaceuticals; Apo-A1 agonist (atherosclerosis), Abbott/Arisaph"	.	Investigative	D0K7VM	.	CTPDG008136
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	GSK-1344386B	"CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline"	.	Investigative	D0C5XF	.	CTPDG008409
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	SCH-602539	"UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura"	16214871	Investigative	D0BV3B	.	CTPDG008432
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Radiolabeled VEGF	"Lu-scVEGF; Radiolabeled VEGF (cancer); Radiolabeled VEGF (cancer), Sibtech/Stanford; Technetium-99m-HYNIC-VEGF; Technetium-99m-single chain-VEGF; Lu-177-DOTA-PEG-scVEGF; 99mTc-HYNIC-VEGF; 99mTc-singlechain-VEGF"	.	Investigative	D0AT5Y	.	CTPDG008467
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	AG-4070	"LXR agonists (atherosclerosis); LXR agonists (atherosclerosis), F.Hoffmann-La Roche"	.	Investigative	D0A6WQ	.	CTPDG008485
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Integrin alpha-V/beta-3 receptor mab	"Integrin alpha-V/beta-3 receptor mAb (atherosclerosis); Integrin alpha-V/beta-3 antagonist (atherosclerosis), Vascular Pharmaceuticals; Integrin alpha-V/beta-3 receptor mAb (atherosclerosis), Vascular Pharmaceuticals"	.	Investigative	D0A5CH	.	CTPDG008491
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	ICI-245991	.	.	Investigative	D0A1DT	.	CTPDG008501
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	MK-6892	"Nicotinic acid 1 receptor (GPR109A) agonists, Merck"	135416394	Investigative	D09ZPN	.	CTPDG008504
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	BMS-753951	"Gadolinium chelate MR imaging agent (atherosclerosis), BMS"	.	Investigative	D09WMV	.	CTPDG008510
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	TGFTX-1	.	.	Investigative	D09OSM	.	CTPDG008530
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	INV-400	"INV-403; INV-404; INV-405; Invasc-400 series; SREBP transcription factor 2 stimulator (atherosclerosis), InVasc; Sterol regulatory element-binding protein 2 stimulator (atherosclerosis), InVasc"	.	Investigative	D09DJS	.	CTPDG008561
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	GX-401	.	.	Investigative	D07RME	.	CTPDG008665
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	RP-805	"Matrix metalloproteinase inhibitor (atherosclerosis); Matrix metalloproteinase inhibitor (atherosclerosis), Lantheus; RP-782-111In; Indium-111-RP-782; Technetium-99m-RP-805; Matrix metalloproteinase (MMP) inhibitor (tumor imaging), Bristol-Myers Squibb; 111In-RP-782; 99mTc-RP-805"	.	Investigative	D03YMD	.	CTPDG008917
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	RXP-470	"MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA"	102258832	Investigative	D03QXD	.	CTPDG008948
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	2NTX-99	"Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), Nile; Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), University of Milano"	10224454	Investigative	D02SAK	.	CTPDG009011
M6ACROT05455	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	BAY-1006451	[18F]-BAY-1006451	.	Investigative	D01FJN	.	CTPDG009122
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Approved	Acipimox	Monted; Nedios; Olbemox; Olbetam; K 9321	5310993	Approved	D0S1NZ	DB09055	CTPDG000159
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 4	LAROPIPRANT	"571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B"	9867642	Phase 4	D0WL5V	DB11629	CTPDG009758
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 3	Anacetrapib	MK0859; Anacetrapib (USAN); MK-0859	11556427	Phase 3	D07HLS	DB06630	CTPDG001364
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2/3	PACTIMIBE	"189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309"	3081927	Phase 2/3	D02GWF	DB12971	CTPDG001578
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	LY3012212	Icrucumab	.	Phase 2	D0X2RL	.	CTPDG001904
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	K-134	"SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104"	9908900	Phase 2	D0S4SX	DB12685	CTPDG002043
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	BMS-582949	"623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446"	10409068	Phase 2	D0Q0AP	DB12696	CTPDG002102
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	VB-201	.	45138527	Phase 2	D0N2IE	DB15259	CTPDG002178
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	CSL-112	"Reconstituted HDL (acute coronary syndrome), CSL"	.	Phase 2	D0L8VA	.	CTPDG002226
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	MK-1903	"Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co"	49763030	Phase 2	D09TGC	.	CTPDG002559
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	DRL-17822	"CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's"	58689743	Phase 2	D07UJA	.	CTPDG002668
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	PRC-4016	.	78210211	Investigative	D03WAT	DB12990	CTPDG002892
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	K-604	BDBM86691	9892288	Phase 2	D03PYD	.	CTPDG002910
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	Revacept	"Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen"	.	Phase 2	D03BAC	.	CTPDG002936
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 2	DVC1-0101	"Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University"	.	Phase 2	D00IZD	.	CTPDG003085
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1/2	ATL-313	"DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data"	11627443	Phase 1/2	D08FHZ	DB12295	CTPDG003512
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	PSI-697	"UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic"	12004316	Phase 1	D0Z0AM	DB12211	CTPDG004239
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	SLV-342	.	.	Phase 1	D0Y9YG	.	CTPDG004250
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	LXR 623	LXR-623	16734800	Phase 1	D0R4EN	.	CTPDG004461
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	ATR-101	.	131678	Phase 1	D0MB2Z	.	CTPDG004594
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	MDCO-216	.	.	Phase 1	D0L1ZK	.	CTPDG004638
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	XL-041	"XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb"	.	Phase 1	D0L0DZ	.	CTPDG004642
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BMS-852927	.	49787490	Phase 1	D0H4DR	.	CTPDG004751
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	CS-8080	"Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc"	16212738	Phase 1	D0GY1Y	.	CTPDG004758
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	ISIS-APOCIII	.	.	Phase 1	D0F6KM	.	CTPDG004803
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BMS-779788	.	59251511	Phase 1	D00QWU	.	CTPDG005446
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Phase 1	BAY-60-5521	"CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer"	11691871	Phase 1	D00JQE	.	CTPDG005460
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Patented	Quinazoline derivative 13	PMID26936077-Compound-24	60161489	Patented	D0P2BJ	.	CTPDG005719
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 3	Darapladib	SB 480848; Darapladib (USAN)	9939609	Discontinued in Phase 3	D0L5UO	DB06311	CTPDG006349
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 3	Acifran	Reductol; AY-25712	51576	Discontinued in Phase 3	D0K1HO	.	CTPDG006352
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	ET-642	"ETC-642; RLT peptide, Esperion; RLT peptide, Pfizer"	.	Discontinued in Phase 2	D0S3MY	.	CTPDG006440
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	SQ-32709	"farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330"	445713	Discontinued in Phase 2	D0N5HO	DB07780	CTPDG006469
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	CETi-1	"Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences"	.	Discontinued in Phase 2	D0J4KC	.	CTPDG006499
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	Gantofiban	CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester	135565976	Discontinued in Phase 2	D0H9WO	.	CTPDG006504
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	FCP-3P1	"CardioRex; Antihyperlipidemic, Forbes Medi-Tech"	60496	Discontinued in Phase 2	D0H7WA	.	CTPDG006506
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	Lifibrol	K-12148; U-83860; (R)-Lifibrol; (S)-Lifibrol; (S)-Lifibrol methyl ester	57112	Discontinued in Phase 2	D0BC4Q	DB12448	CTPDG006550
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 2	TA-7552	"TA 7552; 104756-72-1; 1-(3,4-Dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8-trimethoxynaphthalene; AC1L2U74; SCHEMBL8688163; DTXSID60146695; DTCYXOLBEPGOHV-UHFFFAOYSA-N; HY-100253; CS-0018404; dimethyl 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxynaphthalene-2,3-dicarboxylate; 2,3-Naphthalenedicarboxylic acid, 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxy-, dimethyl ester"	128664	Discontinued in Phase 2	D02RVE	.	CTPDG006650
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	RUS 3108	.	.	Discontinued in Phase 1	D0ZD6Y	.	CTPDG006704
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	GR-328713	GW-320449X; GW-328713X	.	Discontinued in Phase 1	D0SS6J	.	CTPDG006740
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	RG7418	BI204	.	Discontinued in Phase 1	D0MH1R	.	CTPDG006776
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3052334	SCHEMBL3959323	24742042	Discontinued in Phase 1	D0MF7U	.	CTPDG006777
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	Goxalapladib	"Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide"	11686305	Discontinued in Phase 1	D0MC3R	.	CTPDG006778
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	AC3056	.	.	Discontinued in Phase 1	D0L8OE	.	CTPDG006782
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3185043	.	.	Discontinued in Phase 1	D0K3GU	.	CTPDG006793
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	GSK568859	.	.	Discontinued in Phase 1	D0CA3J	.	CTPDG006824
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	NICANARTINE	"MRZ-3/124; 2,6-Di-tert-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol"	66001	Discontinued in Phase 1	D0A0FG	.	CTPDG006839
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-3491165	PF-03491165	.	Discontinued in Phase 1	D09QIJ	.	CTPDG006846
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	SB-435495	.	10417440	Discontinued in Phase 1	D09NBM	.	CTPDG006847
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	P-0654	P-0655	.	Discontinued in Phase 1	D07IXD	.	CTPDG006868
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	CL-277082	"UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea"	125893	Discontinued in Phase 1	D06FCR	.	CTPDG006879
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	LF-08-0133	.	.	Discontinued in Phase 1	D04ZNG	.	CTPDG006891
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	PF-807925	.	.	Discontinued in Phase 1	D04GVN	.	CTPDG006900
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	F-1394	"AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate"	6918210	Discontinued in Phase 1	D03QZB	.	CTPDG006904
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	CP-800569	"(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol"	6918520	Discontinued in Phase 1	D03MAD	.	CTPDG006907
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Discontinued in Phase 1	APP-018	"D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis"	72941823	Discontinued in Phase 1	D03FPA	.	CTPDG006911
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	Nobiletin	"478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)"	72344	Preclinical	D4PG6A	.	CTPDG007008
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	Quinoxaline	WYE-111672; WYE-672	7045	Preclinical	D0U9RR	.	CTPDG007044
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	HL-004	TS-962	6426883	Preclinical	D09MJO	.	CTPDG007104
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	ETX-6107	"ETS-6107; ETS-6114; Antihypercholesterolemic agents (atherosclerosis), e-Therapeutics"	.	Preclinical	D05YRV	.	CTPDG007129
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Preclinical	BAY-38-1315	BAY-19-4789	46880878	Preclinical	D05QXT	.	CTPDG007133
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	2164U90	BW-2164; BW-2164U90	9841699	Terminated	D0ZJ0A	.	CTPDG007163
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	GT-16-239	.	.	Terminated	D0YQ9G	.	CTPDG007167
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Cholazol	Cholestran	.	Terminated	D0XY4Q	.	CTPDG007178
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BB-476	.	9803625	Terminated	D0WU8Z	.	CTPDG007184
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGP-43371	"Cgp 43371; UNII-V97741GKF2; V97741GKF2; 123036-23-7; cgp43371; N,15-Didehydro-15-deoxo-1-deoxy-1,15-epoxy-4-O-methyl-3-(4-((2,4,6-trimethyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)"	6441203	Terminated	D0U8KA	.	CTPDG007206
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	AL-0671	AL-0670	57415651	Terminated	D0TB1X	.	CTPDG007216
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BIBX-79	175033-26-8; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide	501396	Terminated	D0S1XO	.	CTPDG007228
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CI-999	PD-138142-15	74083365	Terminated	D0PG0S	.	CTPDG007248
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Bio-Flow	.	.	Terminated	D0P1JV	.	CTPDG007254
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGS-24565	"Cgs 24565; 136583-72-7; N,15-Didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)"	6443293	Terminated	D0OL9V	.	CTPDG007259
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	TEI-6522	.	9953017	Terminated	D0OK8M	.	CTPDG007260
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	FR-145237	.	9850056	Terminated	D0O2AC	.	CTPDG007265
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	F-12509A	.	9862964	Terminated	D0O0JH	.	CTPDG007268
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	TA-993	"MB-3, Tanabe"	129579	Terminated	D0M9CV	.	CTPDG007277
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Barixibat	"BARI-1453; Bile acid resorption inhibitor, Aventis; HMR-1453; 1453, Aventis"	10234172	Terminated	D0LV0R	.	CTPDG007284
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	PD-146176	"PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, &gt; (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-"	297589	Terminated	D0J8RS	.	CTPDG007309
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	BIBB-515	"BIBB 515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-"	501398	Terminated	D0I2YV	.	CTPDG007327
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	LF-7-0165c	.	.	Terminated	D0EA7H	.	CTPDG007362
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	SDZ-267-489	.	.	Terminated	D0D2RZ	.	CTPDG007377
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	WAY-121898	"136100-14-6; 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester; ACMC-20mw0l; SCHEMBL2597837; CHEMBL267052; ZINC14493; CTK0F3948; DTXSID30430876; 4-PHENOXYPHENYL 4-METHYL-1-PIPERIDINECARBOXYLATE"	9796754	Terminated	D0CS0D	.	CTPDG007381
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	SR12813	"SR 12813; 126411-39-0; SR-12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO"	446313	Terminated	D0C7RV	DB04466	CTPDG007385
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CP-230821	.	.	Terminated	D08MAR	.	CTPDG007439
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	T-686	"PAI-1 inhibitor, Tanabe"	6438903	Terminated	D08EIX	.	CTPDG007444
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	RPR-101821	.	.	Terminated	D08ALQ	.	CTPDG007445
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	MDL-29311	MDL-27272; MDL-29097	131127	Terminated	D07YUY	.	CTPDG007447
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CP-83101	"AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-"	6438614	Terminated	D07QSA	.	CTPDG007452
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	INCB3344	"INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer"	10008367	Terminated	D07KIJ	.	CTPDG007459
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	CGS-23425	"CHEMBL46882; N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic acid; cgs23425; SCHEMBL281877; DTXSID7040998; NOCAS_40998; CGS 23425; BDBM50036402; AKOS027327083; N-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-oxalamic acid; N-[3,5-dimethyl-4-(4''-hydroxy-3''-isopropylphenoxy)phenyl]oxamic acid; ({4-[4-hydroxy-3-(propan-2-yl)phenoxy]-3,5-dimethylphenyl}amino)(oxo)acetic acid"	9874938	Terminated	D07EGS	.	CTPDG007465
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	RP-73163	CHEMBL434418; BDBM50106700	44356696	Terminated	D06KFR	.	CTPDG007478
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	Astenose	GM-1077; GMI-077	.	Terminated	D05HHP	.	CTPDG007498
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	S-12340	"S12340; S 12340; 144754-35-8; SCHEMBL4782175; 8-(3-(3,5-Diterbutyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 8-(3-(3,5-Di-tert-butyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 1-Oxa-3,8-diazaspiro(4.5)decan-2-one, 8-(3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)propyl)-"	9802991	Terminated	D04NSW	.	CTPDG007512
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	ZD-9720	ZD-7851	.	Terminated	D04GJX	.	CTPDG007516
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	IL1aQb	"IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos"	.	Terminated	D03VFV	.	CTPDG007524
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	NTE-122	"ACAT inhibitor, Nissin Food"	9830692	Terminated	D03JRJ	.	CTPDG007530
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	B-5354a	"B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo"	.	Terminated	D02YQJ	.	CTPDG007541
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	F-2833	"107430-45-5; F 2833; 2-[4-(2-chlorophenyl)phenyl]propan-2-ol; AC1L3UIQ; (2-Chloro-2'-(1,1')-4-biphenyl)-2-propanol; SCHEMBL10802061; DTXSID80148050; f2833; (1,1'-Biphenyl)-4-methanol, 2'-chloro-alpha,alpha-dimethyl-"	147118	Terminated	D00QOG	.	CTPDG007580
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	LF-13-0491c	.	.	Terminated	D00KXQ	.	CTPDG007583
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Terminated	FR-129169	.	9803486	Terminated	D00KQT	.	CTPDG007584
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	AM-1101	"Lactosylceramide synthase inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals; GAL T-2 inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals"	.	Investigative	D0Y9PQ	.	CTPDG007655
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Apovasc	CM-121; CM-125; CM-121 + CM-125	.	Investigative	D0Y3TX	.	CTPDG007668
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	KY-382	.	10454368	Investigative	D0V9MG	.	CTPDG007787
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Adiponectin mimetics	"Adiponectin mimetics (oral, type 2 diabetes/atherosclerosis/muscle metabolic diseases)"	.	Investigative	D0R1DX	.	CTPDG007921
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	HL-135	.	.	Investigative	D0Q9RW	.	CTPDG007935
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	KM-011	"Apo-A1 mimetic peptide (atherosclerosis), KineMed; Apolipoprotein-A1 mimetic peptide (atherosclerosis), KineMed"	.	Investigative	D0Q6OL	.	CTPDG007947
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	VULM-1457	"Acyl CoA cholesterol acyltransferase inhibitor (dyslipidemia/atherosclerosis), Univerzity Komenskeho v Bratislave"	.	Investigative	D0OH1O	.	CTPDG007998
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	ARI-1778	"KH-01503; Rev-D-4F; Reverse-D-4F; Apo-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 agonist (atherosclerosis), Abbott; Apolipoprotein-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Abbott; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Kos Pharmaceuticals; Apo-A1 agonist (atherosclerosis), Abbott/Arisaph"	.	Investigative	D0K7VM	.	CTPDG008136
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	GSK-1344386B	"CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline"	.	Investigative	D0C5XF	.	CTPDG008409
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	SCH-602539	"UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura"	16214871	Investigative	D0BV3B	.	CTPDG008432
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Radiolabeled VEGF	"Lu-scVEGF; Radiolabeled VEGF (cancer); Radiolabeled VEGF (cancer), Sibtech/Stanford; Technetium-99m-HYNIC-VEGF; Technetium-99m-single chain-VEGF; Lu-177-DOTA-PEG-scVEGF; 99mTc-HYNIC-VEGF; 99mTc-singlechain-VEGF"	.	Investigative	D0AT5Y	.	CTPDG008467
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	AG-4070	"LXR agonists (atherosclerosis); LXR agonists (atherosclerosis), F.Hoffmann-La Roche"	.	Investigative	D0A6WQ	.	CTPDG008485
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	Integrin alpha-V/beta-3 receptor mab	"Integrin alpha-V/beta-3 receptor mAb (atherosclerosis); Integrin alpha-V/beta-3 antagonist (atherosclerosis), Vascular Pharmaceuticals; Integrin alpha-V/beta-3 receptor mAb (atherosclerosis), Vascular Pharmaceuticals"	.	Investigative	D0A5CH	.	CTPDG008491
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	ICI-245991	.	.	Investigative	D0A1DT	.	CTPDG008501
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	MK-6892	"Nicotinic acid 1 receptor (GPR109A) agonists, Merck"	135416394	Investigative	D09ZPN	.	CTPDG008504
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	BMS-753951	"Gadolinium chelate MR imaging agent (atherosclerosis), BMS"	.	Investigative	D09WMV	.	CTPDG008510
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	TGFTX-1	.	.	Investigative	D09OSM	.	CTPDG008530
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	INV-400	"INV-403; INV-404; INV-405; Invasc-400 series; SREBP transcription factor 2 stimulator (atherosclerosis), InVasc; Sterol regulatory element-binding protein 2 stimulator (atherosclerosis), InVasc"	.	Investigative	D09DJS	.	CTPDG008561
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	GX-401	.	.	Investigative	D07RME	.	CTPDG008665
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	RP-805	"Matrix metalloproteinase inhibitor (atherosclerosis); Matrix metalloproteinase inhibitor (atherosclerosis), Lantheus; RP-782-111In; Indium-111-RP-782; Technetium-99m-RP-805; Matrix metalloproteinase (MMP) inhibitor (tumor imaging), Bristol-Myers Squibb; 111In-RP-782; 99mTc-RP-805"	.	Investigative	D03YMD	.	CTPDG008917
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	RXP-470	"MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA"	102258832	Investigative	D03QXD	.	CTPDG008948
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	2NTX-99	"Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), Nile; Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), University of Milano"	10224454	Investigative	D02SAK	.	CTPDG009011
M6ACROT05556	.	.	M6ADIS0099	BD40: Atherosclerosis	Investigative	BAY-1006451	[18F]-BAY-1006451	.	Investigative	D01FJN	.	CTPDG009122
M6ACROT05436	.	.	M6ADIS0098	BA4Z: Acute coronary syndrome	Phase 2	MPC-25-IC	.	.	Phase 2	D5Q6FS	.	CTPDG001802
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Milrinone	"Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4&prime;-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile"	4197	Approved	D0Y9ZE	DB00235	CTPDG000045
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Prazosin	"Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone"	4893	Approved	D0WV3U	DB00457	CTPDG000075
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Carvedilol	"Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol"	2585	Approved	D0W9LX	DB01136	CTPDG000082
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Butizide	"BUTHIAZIDE; thiabutazide; Eunephran; isobutylhydrochlorothiazide; Saltucin; Butizid; 2043-38-1; Buthiazide [USAN]; Butizidum [INN-Latin]; Butizida [INN-Spanish]; EINECS 218-048-8; SU 6187; S 3500; Butizide [INN]; Butizide (INN); Buthiazide (USAN); 6-Chloro-3,4-dihydro-3-isobutyl-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3,4-dihydro-3-isobutyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(2-methylpropyl)-, 1,1-dioxide"	16274	Approved	D0W1QI	.	CTPDG000094
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Acetyldigitoxin	"Acedigal; Acetildigitoxina; Acetyldiginatin; Acetyldigitoxinum; Acigoxin; Acylanid; Acylanide; Adicin; Acetyldigitoxin [INN]; Desglucolanatoside A; Acetildigitoxina [INN-Spanish]; Acetyldigitoxin (INN); Acetyldigitoxinum [INN-Latin]; Acylanid (TN); Alpha-Acetyldigitoxin; Alpha-Acetyldigitoxins; Alpha-Monoacetyldigitoxin; Acetyl-digitoxin-alpha; Digitoxin 3'''-acetate; Digitoxin, 3'''-acetate; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate"	5284512	Approved	D0V3GA	DB00511	CTPDG000107
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Trimazosin	"Trimazosin hydrochloride; Trimazosin HCl; 53746-46-6; UNII-827T79ILE7; Trimazosin hydrochloride [USAN]; 827T79ILE7; Trimazosin hydrochloride monohydrate; Trimazosin hydrochloride (USAN); 35795-16-5 (Parent); Cardovar; Supres; Trimazosin hydrochlorid-1-wasser; AC1Q3ECH; CP 19106-1; AC1L21UN; SCHEMBL10363255; CHEMBL3989848; DTXSID40202021; Trimazosin monohydrochloride monohydrate; 2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylate monohydrochloride monohydrate; 1-Piperazinecarboxylic aci"	37264	Approved	D0T4WA	DB09206	CTPDG000140
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 3	Liothyronine	"3,3',5-Triiodo-L-thyronine; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine"	5920	Phase 3	D0S6JG	DB00279	CTPDG000152
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Bumetanide	"Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid"	2471	Approved	D0R7HO	DB00887	CTPDG000177
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Inamrinone Lactate	"Amrinone; inamrinone; 60719-84-8; Wincoram; Inocor; Cordemcura; Cartonic; 5-Amino-[3,4'-bipyridin]-6(1H)-one; Amrinonum [INN-Latin]; Amrinonum; Amrinona; Amrinona [INN-Spanish]; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; Win-40680; Amcoral; 5-Amino-(3,4'-bipyridin)-6(1H)-one; WIN 40680; AWD 08-250; 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; UNII-JUT23379TN; CCRIS 3794; Amrinone lactate; MLS000069829; EINECS 262-390-0; 5-amino-3,4'-bipyridin-6(1H)-one; BRN 0744819; 5-Amino(3,4'-bipyridin)-6(1H)-one; SMR000058850; CHEMBL12856; JUT23379TN"	3035194	Approved	D0R6TI	.	CTPDG000178
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Etozolin	"Etozoline; Elkapin; Etozolin [USAN:INN]; Etozoline [INN-French]; Etozolinum [INN-Latin]; Etozolino [INN-Spanish]; EINECS 200-794-0; GO 687; W2900A; NSC 310039; W 2900 A; 67432-21-7; 2-Carbethoxymethylene-3-methyl-5-piperidino-4-thiazolidone; 3-Methyl-4-oxo-5-piperidino-delta(sup2, alpha)thiazolidineacetic; Ethyl (Z)-(3-methyl-4-oxo-5-piperidino-thiazolidin-2-ylidene)acetate; 3-Methyl-4-oxo-5-piperidino-delta(sup 2,a)-thiazolidineacetic acid ethyl ester"	5743585	Approved	D0Q2AS	DB08982	CTPDG000207
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Furosemide	"Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid"	3440	Approved	D0PQ3G	DB00695	CTPDG000210
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Chlorothiazide	"Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	2720	Approved	D0M9WM	DB00880	CTPDG000268
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Torasemide	"Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea"	41781	Approved	D0J9XZ	DB00214	CTPDG000321
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Amiloride	"Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)"	16231	Approved	D0I0RJ	DB00594	CTPDG000354
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Bemetizide	"Dehydrosanol; Bemeticide; Pertensosanol; bemetizid; Bemetizide [INN:BAN]; Bemetizidum [INN-Latin]; Bemetizida [INN-Spanish]; DIU 60; 1824-52-8; EINECS 217-357-5; SU 7078; BRN 0631888; Bemetizidum; Bemetizida; 6-Chloro-3,4-dihydro-3-(alpha-methylbenzyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 3,4-dihydro-6-chloro-3-(alpha-methylbenzyl)-7-sulfamoyl-, 1,1-dioxide; 6-Chlor-3,4-dihydro-3-(alpha-methylbenzyl)-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide; bemetecide; AC1L2HCS"	72070	Approved	D0F0EP	.	CTPDG000395
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Spironolactone	"Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone"	5833	Approved	D0EP0C	DB00421	CTPDG000399
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Enoximone	"Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one"	53708	Approved	D0E0SW	DB04880	CTPDG000415
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Levosimendan	"Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile"	3033825	Approved	D0C4HG	DB00922	CTPDG000441
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Nesiritide	Natrecor (TN)	71308561	Approved	D05GRY	.	CTPDG000643
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Cilazapril	"Cilazaprilum; Cilazil; Dynorm; Inhibace; Inibace; Justor; Vascace; CILAZAPRIL MONOHYDRATE; Cilazapril anhydrous;Cilazapril hydrate; Cilazaprilum [Latin]; Cilazapril (INN); Cilazapril (USAN); Cilazapril (anhydrous); Cilazapril hydrate (JAN); Cilazapril, Anhydrous; Inhibace (TN); Ro 31-2848; Ro 31-2848 monohydrate; Ro 34-2848; Ro-312848; Ro-31-2848; Cilazapril [USAN:INN:BAN:JAN]; (1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl estermonohydrate; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate"	56330	Approved	D04GKO	DB01340	CTPDG000677
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Carperitide	"alpha-Atriopeptin; 89213-87-6; alpha-Human atriopeptin; Atriopeptin-28 (human); alpha-Atriopeptin (human); Human atriopeptin(1-28); SUN-4936; UNII-GZ8FA500J0; Human atriopeptin(99-126); CCRIS 4930; Triopeptin (human alpha-component); Atrial natriuretic factor (99-126); alpha-Human atrial natriuretic hormone; GZ8FA500J0; Atriopeptin; anp 1-28, human; Atrial natriuretic factor (1-28) (human, porcine); Atriopeptins; Atriopeptin-33(rat), 1-de-L-leucine-2-de-L-alanine-3-deglycine-4-de-L-proline-5-de-L-arginine-17-L-me"	16129708	Approved	D03VNJ	.	CTPDG000692
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Cyclothiazide	"Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide"	2910	Approved	D03CNS	DB00606	CTPDG000728
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Ramipril	"Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]"	5362129	Approved	D01STB	DB00178	CTPDG000775
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Hydroflumethiazide	"Bristab; Bristurin; Dihydroflumethazide; Dihydroflumethiazide; Diucardin; Diuredemina; Diurometon; Elodrin; Elodrine; Enjit; Finuret; Flutizide; Glomerulin; HFZ; Hidroalogen; Hidroflumetiazid; Hidroflumetiazida; Hydol; Hydrenox; Hydroflumethazide; Hydroflumethiazidum; Hydroflumethizide; Idroflumetiazide; Leodrine; Metflorylthiazidine; Metforylthiadiazin; Metforylthiazidin; Methforylthiazidine; NaClex; Olmagran; Rivosil; Robezon; Rodiuran; Rontyl; Saluron; Sisuril; Spandiuril; Trifluoromethylhydrazide; Trifluoromethylhydrothiazide; Vergonil; Component of Salutensin; Idroflumetiazide [DCIT]; SB01887; Di-ademil; Di-adenil; Hidroflumetiazida [INN-Spanish]; Hydroflumethiazidum [INN-Latin]; Naciex (glaxo); Saluron (TN); Hydroflumethiazide [INN:BAN:JAN]; Hydroflumethiazide (JAN/USP/INN); Ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide"	3647	Approved	D00WAM	DB00774	CTPDG000799
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Triamterene	"Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine"	5546	Approved	D00NKB	DB00384	CTPDG000811
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Ha-1a	Centoxin (TN)	.	Approved	D00EIB	.	CTPDG000827
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 3	INOmax nitric oxide	.	.	Phase 3	D0V6EC	.	CTPDG001018
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 3	BB3	"3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethylbenzofuran-6-sulfonamide; 765317-71-3; 3-(3,5-DIBROMO-4-HYDROXY-BENZOYL)-2-ETHYL-BENZOFURAN-6-SULFONIC ACID DIMETHYLAMIDE; 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethyl-1-benzofuran-6-sulfonamide; SCHEMBL4320310; AC1L9M79; 1t48; ZINC14881085; AKOS025404898; DB04142; AK174884; N,N-Dimethyl-2-ethyl-3-(3,5-dibromo-4-hydroxybenzoyl)benzofuran-6-sulfonamide; 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethylbenzofuran -6-sulfonamide"	448660	Phase 3	D0MY7F	DB04142	CTPDG001121
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 3	WC-3049	Intrinsa CHF	.	Phase 3	D0ET9N	.	CTPDG001220
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 3	RT-100	.	.	Phase 3	D0DU9I	.	CTPDG001230
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 3	Lixivaptan	"168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; BF-Derm1"	172997	Phase 3	D07EEN	DB06666	CTPDG012503
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2/3	MyoCell	MyoCell (TN)	.	Phase 2/3	D0O7CO	.	CTPDG001540
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	NAN-101	.	.	Phase 2	DJHY39	.	CTPDG001696
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	PL-3994	.	121488161	Phase 2	D0X8QO	.	CTPDG001894
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	T2c-001	"T2c-001-AMI; T2c-001-CHD; T2c-001-DCM; T2c-001-SW; Autologous bone marrow-derived endothelial progenitor cell therapy, Goethe University/t2cure; Autologous endothelial progenitor cells (myocardial infarction), Goethe University/t2cure; Endothelial progenitor cell therapy (ischemia), Goethe University/t2cure"	.	Phase 2	D0X6EM	.	CTPDG001898
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	"3,5-diiodothyropropionic acid"	DITPA)	160565	Phase 2	D0WM6E	DB12629	CTPDG001914
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	Long-actingloop diuretic	.	.	Phase 2	D0WG8A	.	CTPDG001917
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	Urocortin 2	Urocortin II; Urocortin-2; 351999-18-3	56843276	Phase 2	D0W2HG	.	CTPDG001937
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	IK-5001	.	.	Phase 2	D0B0NH	.	CTPDG002520
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 2	PL-3394	.	.	Phase 2	D05PXL	.	CTPDG002793
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 1/2	AdipoCell	.	.	Phase 1/2	D0X4OJ	.	CTPDG003289
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 1b	GGF	.	.	Phase 1b	D08WNO	.	CTPDG003639
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 1	SER-101	RO-1160367	.	Phase 1	D0S6GY	.	CTPDG004432
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 1	RWJ-676070	.	11157078	Phase 1	D0L6XQ	.	CTPDG004623
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 1	Myoblast cell transplantation therapy	.	.	Phase 1	D0L3VT	.	CTPDG004631
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Phase 1	REC-02	.	.	Phase 1	D0K6NW	.	CTPDG004655
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Withdrawn from market	Ticrynafen	"Tienilic acid; 40180-04-9; Thienylic acid; Selacryn; Diflurex; Ticrex; Acido tienilico; Acide tienilique; Acidum tienilicum; Tienilico acido; Tienilico acido [Spanish]; Ticrynafen [USAN]; Acido tienilico [INN-Spanish]; Acide tienilique [INN-French]; Acidum tienilicum [INN-Latin]; ANP 3624; C13H8Cl2O4S; SKF 62698; UNII-HC95205SY4; 2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid; CCRIS 5489; 4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid"	38409	Withdrawn from market	D0T0TZ	DB04831	CTPDG006313
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Investigative	CLP-1002	"Cross-linked polyelectrolyte polymer (CHF, kidney disease), Sorbent Therapeutics"	.	Investigative	D0KT4B	.	CTPDG008126
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Investigative	SL125	.	.	Investigative	D0I0NP	.	CTPDG008224
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Approved	Carvedilol	.	2585	Approved	D0D1HH	DB01136	CTPDG008386
M6ACROT05472	.	.	M6ADIS0101	BD10: Congestive heart failure	Investigative	"Gene therapy, congestive heart failure"	"Gene therapy (TheraPlas, congestive heart failure)"	.	Investigative	D06BEX	.	CTPDG008773
M6ACROT05477	.	.	M6ADIS0118	GB6Z: Kidney failure	Phase 2	LHW090	.	.	Phase 2	D08AHH	.	CTPDG002652
M6ACROT05478	.	.	M6ADIS0118	GB6Z: Kidney failure	Phase 2	LHW090	.	.	Phase 2	D08AHH	.	CTPDG002652
M6ACROT05479	.	.	M6ADIS0118	GB6Z: Kidney failure	Phase 2	LHW090	.	.	Phase 2	D08AHH	.	CTPDG002652
M6ACROT05480	.	.	M6ADIS0118	GB6Z: Kidney failure	Phase 2	LHW090	.	.	Phase 2	D08AHH	.	CTPDG002652
M6ACROT05500	.	.	M6ADIS0047	2A70: Lymphoma	Approved	Lisocabtagene maraleucel	JCAR017	.	Approved	D0M4WU	.	CTPDG000273
M6ACROT05500	.	.	M6ADIS0047	2A70: Lymphoma	Phase 2	MB-CART19.1	.	.	Phase 2	D0F1HT	.	CTPDG002406
M6ACROT05512	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Phase 2	CRD-007	.	.	Phase 2	D06JNC	.	CTPDG002754
M6ACROT05512	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Investigative	WAY-644	"MMP-12 inhibitor (aortic abdominal aneurysm), Pfizer; MMP-12 inhibitor (aortic abdominal aneurysm), Wyeth"	.	Investigative	D07NDK	.	CTPDG008678
M6ACROT05512	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Investigative	VDA-1124	"Granzyme B inhibitors (abdominal aortic aneurysms), viDA Therapeutics"	.	Investigative	D06UZS	.	CTPDG008731
M6ACROT05513	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Phase 2	CRD-007	.	.	Phase 2	D06JNC	.	CTPDG002754
M6ACROT05513	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Investigative	WAY-644	"MMP-12 inhibitor (aortic abdominal aneurysm), Pfizer; MMP-12 inhibitor (aortic abdominal aneurysm), Wyeth"	.	Investigative	D07NDK	.	CTPDG008678
M6ACROT05513	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Investigative	VDA-1124	"Granzyme B inhibitors (abdominal aortic aneurysms), viDA Therapeutics"	.	Investigative	D06UZS	.	CTPDG008731
M6ACROT05607	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Phase 2	CRD-007	.	.	Phase 2	D06JNC	.	CTPDG002754
M6ACROT05607	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Investigative	WAY-644	"MMP-12 inhibitor (aortic abdominal aneurysm), Pfizer; MMP-12 inhibitor (aortic abdominal aneurysm), Wyeth"	.	Investigative	D07NDK	.	CTPDG008678
M6ACROT05607	.	.	M6ADIS0102	BD50: Aortic aneurysm or dissection	Investigative	VDA-1124	"Granzyme B inhibitors (abdominal aortic aneurysms), viDA Therapeutics"	.	Investigative	D06UZS	.	CTPDG008731
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015143654Example29	.	Patented	D0ZE6H	.	CTPDG005522
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014078408Example26	.	.	Patented	D0YN0I	.	CTPDG005544
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2013009582Example76	.	.	Patented	D0Y0XJ	.	CTPDG005552
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpyrrolidine ether derivative 1	PMID28270021-Compound-WO2016020784Example11	.	Patented	D0X4LA	.	CTPDG005566
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 3	PMID28270021-Compound-WO2015092610Example164	.	Patented	D0X1LP	.	CTPDG005568
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Imidazo pyridine derivative 1	PMID28270021-Compound-WO2015200341Example96	.	Patented	D0WI7N	.	CTPDG005581
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2015042088Example12	.	.	Patented	D0VD5J	.	CTPDG005592
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[1,5-a]pyridine derivative 2"	PMID28270021-Compound-WO2013088257Example240	.	Patented	D0V9ZJ	.	CTPDG005597
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Tri-substituted urea derivative 1	PMID28270021-Compound-WO2013176970Example1	.	Patented	D0UQ2G	.	CTPDG005607
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 5	PMID28270021-Compound-WO2015148344Example152	.	Patented	D0UN4M	.	CTPDG005608
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2015042088Example11	.	.	Patented	D0U5XI	.	CTPDG005618
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrido[3,2-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012125668Example27	.	Patented	D0U3RD	.	CTPDG005624
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Five membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015148350Example36	.	Patented	D0T4CF	.	CTPDG005640
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 109	.	.	Patented	D0T0HM	.	CTPDG005644
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012137089cE-245677	.	Patented	D0S0II	.	CTPDG005658
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrido[3,2-d]pyrimidine derivative 2"	PMID28270021-Compound-WO2012125668Example12	.	Patented	D0RR8O	.	CTPDG005662
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[4,3-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053965Example3	.	Patented	D0RK6W	.	CTPDG005664
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014129431Example8-1	.	.	Patented	D0QT8L	.	CTPDG005690
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 201	.	.	Patented	D0PY0G	.	CTPDG005704
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-b]pyridine derivative 1"	PMID28270021-Compound-WO2008063888P-0171	.	Patented	D0P8SR	.	CTPDG005711
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1"	PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)	.	Patented	D0O8SX	.	CTPDG005733
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 3	PMID28270021-Compound-WO2015148354Example41	.	Patented	D0O0GZ	.	CTPDG005742
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 7	PMID28270021-Compound-WO2015148373Example36	.	Patented	D0N6NG	.	CTPDG005753
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Triazolo[4,3-b]pyridazine derivative 2"	PMID28270021-Compound-WO2012125667Example24	.	Patented	D0MZ7K	.	CTPDG005767
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example112	.	.	Patented	D0LK8E	.	CTPDG005792
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 5	PMID28270021-Compound-WO2015148373Example104	.	Patented	D0KC8X	.	CTPDG005811
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 495	.	.	Patented	D0K6IM	.	CTPDG005818
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 103	.	.	Patented	D0J4CA	.	CTPDG005843
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 4	PMID28270021-Compound-WO2015148354Example99	.	Patented	D0I9FU	.	CTPDG005859
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2013161919Example85-117	.	.	Patented	D0I2OO	.	CTPDG005866
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 1	PMID28270021-Compound-WO2015148354Example21(R or S)	.	Patented	D0HF1A	.	CTPDG005877
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015143654Example41	.	Patented	D0H3ZG	.	CTPDG005891
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 481	.	.	Patented	D0FL8A	.	CTPDG005922
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 2	PMID28270021-Compound-WO2015148354Example33(R or S)	.	Patented	D0F8BF	.	CTPDG005930
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 803	.	.	Patented	D0F2BF	.	CTPDG005937
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 4	PMID28270021-Compound-WO2015143654Example62	.	Patented	D0EC4Z	.	CTPDG005949
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 8	PMID28270021-Compound-WO2015148373Example41(S)	.	Patented	D0DY5R	.	CTPDG005959
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[3,2-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053968Example5	.	Patented	D0DQ5G	.	CTPDG005963
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[1,5-a]pyridine derivative 1"	PMID28270021-Compound-WO2013088256Example59	.	Patented	D0DN3Q	.	CTPDG005966
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Five membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015148350Example81	.	Patented	D0CY3U	.	CTPDG005992
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Tri-substituted urea derivative 2	PMID28270021-Compound-WO2013176970Example2	.	Patented	D0CG8N	.	CTPDG006004
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-(phenylpyrazolyl)benzamide derivative 1	PMID28270021-Compound-WO2013132376Example157	.	Patented	D0C3RK	.	CTPDG006014
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example80	.	.	Patented	D0BO1H	.	CTPDG006019
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example71	.	.	Patented	D08CZY	.	CTPDG006086
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpyrrolidine ether derivative 2	PMID28270021-Compound-WO2016020784Example12	.	Patented	D08BIH	.	CTPDG006090
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015143654Example60	.	Patented	D07VFQ	.	CTPDG006097
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 811	.	.	Patented	D07KVL	.	CTPDG006113
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 6	PMID28270021-Compound-WO2015148373Example111	.	Patented	D07CPL	.	CTPDG006126
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 9	PMID28270021-Compound-WO2015148373Example42(R)	.	Patented	D07AJO	.	CTPDG006129
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-b]pyridine derivative 2"	PMID28270021-Compound-WO2008063888P-0180	.	Patented	D06GOT	.	CTPDG006149
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 7	PMID28270021-Compound-WO2015148344Example96	.	Patented	D05MRY	.	CTPDG006168
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014078408Example1	.	.	Patented	D05AQT	.	CTPDG006179
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 2	PMID28270021-Compound-WO2015092610Example114	.	Patented	D04RXX	.	CTPDG006186
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 6	PMID28270021-Compound-WO2015148344Example59	.	Patented	D04JCD	.	CTPDG006197
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 6	PMID28270021-Compound-WO2015092610Example9	.	Patented	D04GCC	.	CTPDG006201
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	Five membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015148350Example76	.	Patented	D04BRW	.	CTPDG006207
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 5	PMID28270021-Compound-WO2015092610Example3	.	Patented	D03BAY	.	CTPDG006238
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2013009582Example16	.	.	Patented	D02ZQN	.	CTPDG006241
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 7	PMID28270021-Compound-WO2016009296Example15	.	Patented	D02OLJ	.	CTPDG006252
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-b]pyridine derivative 3"	PMID28270021-Compound-WO2010129570P-2061	.	Patented	D02IBX	.	CTPDG006259
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014152663 701	.	.	Patented	D02ETU	.	CTPDG006261
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 1	PMID28270021-Compound-WO2015092610Example113	.	Patented	D00XXZ	.	CTPDG006288
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 4	PMID28270021-Compound-WO2015092610Example2	.	Patented	D00FJH	.	CTPDG006308
M6ACROT05515	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example82	.	.	Patented	D00EUL	.	CTPDG006309
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015143654Example29	.	Patented	D0ZE6H	.	CTPDG005522
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014078408Example26	.	.	Patented	D0YN0I	.	CTPDG005544
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2013009582Example76	.	.	Patented	D0Y0XJ	.	CTPDG005552
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpyrrolidine ether derivative 1	PMID28270021-Compound-WO2016020784Example11	.	Patented	D0X4LA	.	CTPDG005566
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 3	PMID28270021-Compound-WO2015092610Example164	.	Patented	D0X1LP	.	CTPDG005568
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Imidazo pyridine derivative 1	PMID28270021-Compound-WO2015200341Example96	.	Patented	D0WI7N	.	CTPDG005581
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2015042088Example12	.	.	Patented	D0VD5J	.	CTPDG005592
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[1,5-a]pyridine derivative 2"	PMID28270021-Compound-WO2013088257Example240	.	Patented	D0V9ZJ	.	CTPDG005597
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Tri-substituted urea derivative 1	PMID28270021-Compound-WO2013176970Example1	.	Patented	D0UQ2G	.	CTPDG005607
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 5	PMID28270021-Compound-WO2015148344Example152	.	Patented	D0UN4M	.	CTPDG005608
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2015042088Example11	.	.	Patented	D0U5XI	.	CTPDG005618
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrido[3,2-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012125668Example27	.	Patented	D0U3RD	.	CTPDG005624
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Five membered heterocyclic benzamide derivative 1	PMID28270021-Compound-WO2015148350Example36	.	Patented	D0T4CF	.	CTPDG005640
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 109	.	.	Patented	D0T0HM	.	CTPDG005644
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 3"	PMID28270021-Compound-WO2012137089cE-245677	.	Patented	D0S0II	.	CTPDG005658
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrido[3,2-d]pyrimidine derivative 2"	PMID28270021-Compound-WO2012125668Example12	.	Patented	D0RR8O	.	CTPDG005662
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[4,3-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053965Example3	.	Patented	D0RK6W	.	CTPDG005664
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014129431Example8-1	.	.	Patented	D0QT8L	.	CTPDG005690
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 201	.	.	Patented	D0PY0G	.	CTPDG005704
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-b]pyridine derivative 1"	PMID28270021-Compound-WO2008063888P-0171	.	Patented	D0P8SR	.	CTPDG005711
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1"	PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)	.	Patented	D0O8SX	.	CTPDG005733
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 3	PMID28270021-Compound-WO2015148354Example41	.	Patented	D0O0GZ	.	CTPDG005742
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 7	PMID28270021-Compound-WO2015148373Example36	.	Patented	D0N6NG	.	CTPDG005753
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Triazolo[4,3-b]pyridazine derivative 2"	PMID28270021-Compound-WO2012125667Example24	.	Patented	D0MZ7K	.	CTPDG005767
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example112	.	.	Patented	D0LK8E	.	CTPDG005792
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 5	PMID28270021-Compound-WO2015148373Example104	.	Patented	D0KC8X	.	CTPDG005811
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 495	.	.	Patented	D0K6IM	.	CTPDG005818
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 103	.	.	Patented	D0J4CA	.	CTPDG005843
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 4	PMID28270021-Compound-WO2015148354Example99	.	Patented	D0I9FU	.	CTPDG005859
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2013161919Example85-117	.	.	Patented	D0I2OO	.	CTPDG005866
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 1	PMID28270021-Compound-WO2015148354Example21(R or S)	.	Patented	D0HF1A	.	CTPDG005877
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015143654Example41	.	Patented	D0H3ZG	.	CTPDG005891
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 481	.	.	Patented	D0FL8A	.	CTPDG005922
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 2	PMID28270021-Compound-WO2015148354Example33(R or S)	.	Patented	D0F8BF	.	CTPDG005930
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 803	.	.	Patented	D0F2BF	.	CTPDG005937
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 4	PMID28270021-Compound-WO2015143654Example62	.	Patented	D0EC4Z	.	CTPDG005949
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 8	PMID28270021-Compound-WO2015148373Example41(S)	.	Patented	D0DY5R	.	CTPDG005959
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[3,2-c]pyridine derivative 1"	PMID28270021-Compound-WO2014053968Example5	.	Patented	D0DQ5G	.	CTPDG005963
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrazolo[1,5-a]pyridine derivative 1"	PMID28270021-Compound-WO2013088256Example59	.	Patented	D0DN3Q	.	CTPDG005966
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Five membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015148350Example81	.	Patented	D0CY3U	.	CTPDG005992
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Tri-substituted urea derivative 2	PMID28270021-Compound-WO2013176970Example2	.	Patented	D0CG8N	.	CTPDG006004
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-(phenylpyrazolyl)benzamide derivative 1	PMID28270021-Compound-WO2013132376Example157	.	Patented	D0C3RK	.	CTPDG006014
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example80	.	.	Patented	D0BO1H	.	CTPDG006019
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example71	.	.	Patented	D08CZY	.	CTPDG006086
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpyrrolidine ether derivative 2	PMID28270021-Compound-WO2016020784Example12	.	Patented	D08BIH	.	CTPDG006090
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 3	PMID28270021-Compound-WO2015143654Example60	.	Patented	D07VFQ	.	CTPDG006097
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2010077680 811	.	.	Patented	D07KVL	.	CTPDG006113
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 6	PMID28270021-Compound-WO2015148373Example111	.	Patented	D07CPL	.	CTPDG006126
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Bicyclic heteroaryl benzamide derivative 9	PMID28270021-Compound-WO2015148373Example42(R)	.	Patented	D07AJO	.	CTPDG006129
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-b]pyridine derivative 2"	PMID28270021-Compound-WO2008063888P-0180	.	Patented	D06GOT	.	CTPDG006149
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 7	PMID28270021-Compound-WO2015148344Example96	.	Patented	D05MRY	.	CTPDG006168
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014078408Example1	.	.	Patented	D05AQT	.	CTPDG006179
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 2	PMID28270021-Compound-WO2015092610Example114	.	Patented	D04RXX	.	CTPDG006186
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Six-membered heterocyclic benzamide derivative 6	PMID28270021-Compound-WO2015148344Example59	.	Patented	D04JCD	.	CTPDG006197
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 6	PMID28270021-Compound-WO2015092610Example9	.	Patented	D04GCC	.	CTPDG006201
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	Five membered heterocyclic benzamide derivative 2	PMID28270021-Compound-WO2015148350Example76	.	Patented	D04BRW	.	CTPDG006207
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 5	PMID28270021-Compound-WO2015092610Example3	.	Patented	D03BAY	.	CTPDG006238
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2013009582Example16	.	.	Patented	D02ZQN	.	CTPDG006241
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 7	PMID28270021-Compound-WO2016009296Example15	.	Patented	D02OLJ	.	CTPDG006252
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	"Pyrrolo[2,3-b]pyridine derivative 3"	PMID28270021-Compound-WO2010129570P-2061	.	Patented	D02IBX	.	CTPDG006259
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2014152663 701	.	.	Patented	D02ETU	.	CTPDG006261
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 1	PMID28270021-Compound-WO2015092610Example113	.	Patented	D00XXZ	.	CTPDG006288
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	N-acylpiperidine ether derivative 4	PMID28270021-Compound-WO2015092610Example2	.	Patented	D00FJH	.	CTPDG006308
M6ACROT05516	.	.	M6ADIS0028	2C27: Thymoma	Patented	PMID28270021-Compound-WO2016054807Example82	.	.	Patented	D00EUL	.	CTPDG006309
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Phase 3	GS-6615	"Eleclazine; 1443211-72-0; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C"	71183216	Phase 3	D0A4UC	DB12394	CTPDG001277
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Phase 3	CHS-0214	.	.	Phase 3	D05FOF	.	CTPDG001406
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Phase 2/3	Autologous endothelial progenitor cell therapy	"Autologous endothelial progenitor cell therapy (ischemia); Autologous endothelial progenitor cell therapy (ischemia), IBRI; Autologous stem cell therapy (critical limb ischemia), IBRI; Autologous CD34+ cells (peripheral vascular disease), IBRI"	.	Phase 2/3	D0P1SA	.	CTPDG001539
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Phase 2	AC-607	"NG-0711; Adult mesenchymal stem cell therapy (acute kidney injury), AlloCure; Multipotent stromal cell therapy (acute renal injury), AlloCure"	11414137	Phase 2	D05MHI	.	CTPDG002798
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Phase 1/2	Allogeneic/autologous adult mesenchymal stem cell therapy	.	.	Phase 1/2	D02XXW	.	CTPDG003600
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Phase 1	Bone marrow stem cell therapy	Bone marrow stem cell therapy (congestive cardiomyopathy)	.	Phase 1	D05SJK	.	CTPDG005188
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Discontinued in Phase 1	CRE-319M2	.	.	Discontinued in Phase 1	D0U7CO	.	CTPDG006734
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Terminated	REN-1053	.	.	Terminated	D0WR7U	.	CTPDG007185
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	Zn-DPA-H	"Heart ischemia imaging agent, Molecular Targeting Technology"	.	Investigative	D0W9ZS	.	CTPDG007747
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	Anti-miR-199a oligonucleotides	Anti-miR-199a oligonucleotides (ischemic heart disease)	.	Investigative	D0S7HW	.	CTPDG007881
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	DX-2500	"Anti-FcRn antibody (autoimmune disorder), Dyax Corp"	.	Investigative	D0R3KS	.	CTPDG007914
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	MCP-205	"Delta opioid receptor agonist (cardiac ischemia), Mt Cook Pharma"	.	Investigative	D0O7NF	.	CTPDG008009
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	TAT-120	"MIP-120, Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease); Peptide Mst-1 inhibitors (ischemia), Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease), Vasade"	.	Investigative	D0A7HY	.	CTPDG008483
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	FHT-1106	.	.	Investigative	D08UXQ	.	CTPDG008587
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	Leonurine	SCM-198	161464	Investigative	D08KHD	.	CTPDG008613
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	NK-111	"Cardioprotectant (cardiac ischemia), Nara Biosciences; Myokine (cardiac ischemia), Nara Biosciences"	.	Investigative	D07KYK	.	CTPDG008689
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	EP-94	"Peptide enkephalin analogs (acute myocardial ischemia), Eribis; Opioid receptor modulator (repurfusion injury/myocardial infraction/ischemic heart disease), Eribis Pharmaceuticals"	.	Investigative	D02ZWJ	.	CTPDG008991
M6ACROT05554	.	.	M6ADIS0096	BA40-BA6Z: Ischemic heart disease	Investigative	MGN-7455	"Anti-miR-199 therapeutic (ischemic heart disease), miRagen Therapeutics"	.	Investigative	D00YNK	.	CTPDG009142
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Approved	NERIDRONIC ACID	"79778-41-9; Nerixia; Neridronic acid [INN]; (6-Amino-1-hydroxyhexane-1,1-diyl)diphosphonic acid; UNII-8U27U3RIN4; Acide neridronique [INN-French]; Acido neridronico [INN-Spanish]; Acidum neridronicum [INN-Latin]; CHEMBL55214; 8U27U3RIN4; NERIDRONATE SODIUM HYDRATE; (6-Amino-1-hydroxyhexylidene)diphosphonic acid; 6-Amino-1-hydroxyhexane-1,1-diphosphonate; 6-amino-1-hydroxyhexane-1,1-diyldiphosphonic acid; W-203821; Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis-"	71237	Approved	D0V8PA	DB11620	CTPDG000101
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Approved	Rh-bmp-2/acs	Infuse (TN)	.	Approved	D0I6FS	.	CTPDG000344
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Approved	Technetium TC 99M medronate	TC[99M] medronate	131704315	Approved	D0B4KH	DB09138	CTPDG000456
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 3	HMGB-1 protein and its fragments	"CTR-1; CTR-2; CTR-3; CTR-4; HMGB-1 protein and its fragments (wound healing/cartilage repair/bone matrixregeneration/ligaments and tendon repair); HMGB-1 protein and its fragments (wound healing/cartilage repair/bone matrix regeneration/ligaments and tendon repair), Bio3"	.	Phase 3	D0R8QX	.	CTPDG001067
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 2	Bafetinib	"859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide"	11387605	Phase 2	D0G0VV	DB11851	CTPDG002380
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 2	KUR-111	"I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter"	.	Phase 2	D0F4SN	.	CTPDG002403
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 2	MDAB-16	"Humanized antibody (cancer), Med discovery"	.	Phase 2	D02EFJ	.	CTPDG002985
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 1	KUR-112	.	.	Phase 1	D09TGD	.	CTPDG004976
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	GW-2592X	"Azepanone inhibitors, GlaxoSmithKline; Cathepsin K inhibitors (bone disorder); Cathepsin K inhibitors, SmithKline Beecham; GW-2637X; GW-2934X; GW-9696X; SB-237632; SB-244875; SB-267320; SB-271194; SB-327537; SB-331750; SB-357114; SB-432238; SB-553484; Cathepsin K inhibitors (bone disorder), GlaxoSmithKline"	.	Investigative	D0FJ3P	.	CTPDG007087
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	HR-004-1	"HR-004; Mesenchymal stem cell therapy (bone regeneration), Histocell/Laboratorios SALVAT"	.	Investigative	D0VP7D	.	CTPDG007776
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	WX-04554	"WX-07-0100117; Wnt pathway activators (bone healing and repair), Wintherix"	.	Investigative	D0T6AY	.	CTPDG007854
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	BRX-3	"RUNX2 modulator (bone disease), Biorunx; Runt-related transcription factor 2 modulator (bone disease), Biorunx"	.	Investigative	D0T1OR	.	CTPDG007867
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	TG-N	.	.	Investigative	D0R9XX	.	CTPDG007901
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	OLPADRONIC ACID SODIUM SALT	"Dimethyl-APD; IG-8801; 3-(Dimethylamino)-1-hydroxypropylidene-1,1-diphosphonic acid monosodium salt"	23663414	Investigative	D0OJ5M	.	CTPDG007997
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	HG-1429	"HMAAD57 modulator (immune/bone diseases), Human Genome Sciences; TREM2 modulator (immune/bone diseases), Human Genome Sciences; Triggering receptor expressed on myeloid cells 2 modulator (immune/bone diseases), Human Genome Sciences; Trem2a/2b/2c modulator (immune/bone diseases), Human Genome Sciences"	.	Investigative	D0G3UG	.	CTPDG008273
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	TGX-003	"MeniscoCelect; Allogeneic cell therapy (traumatic meniscus lesions), Tigenix"	.	Investigative	D0A3OA	.	CTPDG008496
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	PG-1014491	"PG-1014493; Farnesyl pyrophosphate synthase (FPS) bisphosphonate inhibitors (bone disorders), Procter & Gamble"	.	Investigative	D06QJG	.	CTPDG008740
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	ALSE-100	"RhoA inhibitors (cardiomyopathy/cancer and CNS/ocular/bone disorders); RhoA inhibitors (cardiomyopathy/cancer and CNS/ocular/bone disorders), Alseres"	.	Investigative	D05NJL	.	CTPDG008820
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	AB-0440a	"TSP-50 targeting monoclonal antibodies (bone loss/osteoporosis); Anti-testes specific protease 50 antibody (boneloss/osteoporosis), Alethia; TSP-50 targeting monoclonal antibodies (bone loss/osteoporosis), Alethia; AB-0440-targeting monoclonal antibodies (bone loss/osteoporosis), Alethia"	.	Investigative	D02DWN	.	CTPDG009037
M6ACROT05569	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	TG-D	.	.	Investigative	D01XMP	.	CTPDG009052
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Approved	NERIDRONIC ACID	"79778-41-9; Nerixia; Neridronic acid [INN]; (6-Amino-1-hydroxyhexane-1,1-diyl)diphosphonic acid; UNII-8U27U3RIN4; Acide neridronique [INN-French]; Acido neridronico [INN-Spanish]; Acidum neridronicum [INN-Latin]; CHEMBL55214; 8U27U3RIN4; NERIDRONATE SODIUM HYDRATE; (6-Amino-1-hydroxyhexylidene)diphosphonic acid; 6-Amino-1-hydroxyhexane-1,1-diphosphonate; 6-amino-1-hydroxyhexane-1,1-diyldiphosphonic acid; W-203821; Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis-"	71237	Approved	D0V8PA	DB11620	CTPDG000101
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Approved	Rh-bmp-2/acs	Infuse (TN)	.	Approved	D0I6FS	.	CTPDG000344
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Approved	Technetium TC 99M medronate	TC[99M] medronate	131704315	Approved	D0B4KH	DB09138	CTPDG000456
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 3	HMGB-1 protein and its fragments	"CTR-1; CTR-2; CTR-3; CTR-4; HMGB-1 protein and its fragments (wound healing/cartilage repair/bone matrixregeneration/ligaments and tendon repair); HMGB-1 protein and its fragments (wound healing/cartilage repair/bone matrix regeneration/ligaments and tendon repair), Bio3"	.	Phase 3	D0R8QX	.	CTPDG001067
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 2	Bafetinib	"859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide"	11387605	Phase 2	D0G0VV	DB11851	CTPDG002380
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 2	KUR-111	"I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter"	.	Phase 2	D0F4SN	.	CTPDG002403
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 2	MDAB-16	"Humanized antibody (cancer), Med discovery"	.	Phase 2	D02EFJ	.	CTPDG002985
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Phase 1	KUR-112	.	.	Phase 1	D09TGD	.	CTPDG004976
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	GW-2592X	"Azepanone inhibitors, GlaxoSmithKline; Cathepsin K inhibitors (bone disorder); Cathepsin K inhibitors, SmithKline Beecham; GW-2637X; GW-2934X; GW-9696X; SB-237632; SB-244875; SB-267320; SB-271194; SB-327537; SB-331750; SB-357114; SB-432238; SB-553484; Cathepsin K inhibitors (bone disorder), GlaxoSmithKline"	.	Investigative	D0FJ3P	.	CTPDG007087
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	HR-004-1	"HR-004; Mesenchymal stem cell therapy (bone regeneration), Histocell/Laboratorios SALVAT"	.	Investigative	D0VP7D	.	CTPDG007776
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	WX-04554	"WX-07-0100117; Wnt pathway activators (bone healing and repair), Wintherix"	.	Investigative	D0T6AY	.	CTPDG007854
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	BRX-3	"RUNX2 modulator (bone disease), Biorunx; Runt-related transcription factor 2 modulator (bone disease), Biorunx"	.	Investigative	D0T1OR	.	CTPDG007867
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	TG-N	.	.	Investigative	D0R9XX	.	CTPDG007901
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	OLPADRONIC ACID SODIUM SALT	"Dimethyl-APD; IG-8801; 3-(Dimethylamino)-1-hydroxypropylidene-1,1-diphosphonic acid monosodium salt"	23663414	Investigative	D0OJ5M	.	CTPDG007997
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	HG-1429	"HMAAD57 modulator (immune/bone diseases), Human Genome Sciences; TREM2 modulator (immune/bone diseases), Human Genome Sciences; Triggering receptor expressed on myeloid cells 2 modulator (immune/bone diseases), Human Genome Sciences; Trem2a/2b/2c modulator (immune/bone diseases), Human Genome Sciences"	.	Investigative	D0G3UG	.	CTPDG008273
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	TGX-003	"MeniscoCelect; Allogeneic cell therapy (traumatic meniscus lesions), Tigenix"	.	Investigative	D0A3OA	.	CTPDG008496
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	PG-1014491	"PG-1014493; Farnesyl pyrophosphate synthase (FPS) bisphosphonate inhibitors (bone disorders), Procter & Gamble"	.	Investigative	D06QJG	.	CTPDG008740
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	ALSE-100	"RhoA inhibitors (cardiomyopathy/cancer and CNS/ocular/bone disorders); RhoA inhibitors (cardiomyopathy/cancer and CNS/ocular/bone disorders), Alseres"	.	Investigative	D05NJL	.	CTPDG008820
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	AB-0440a	"TSP-50 targeting monoclonal antibodies (bone loss/osteoporosis); Anti-testes specific protease 50 antibody (boneloss/osteoporosis), Alethia; TSP-50 targeting monoclonal antibodies (bone loss/osteoporosis), Alethia; AB-0440-targeting monoclonal antibodies (bone loss/osteoporosis), Alethia"	.	Investigative	D02DWN	.	CTPDG009037
M6ACROT05570	.	.	M6ADIS0138	FC0Z: Diseases of the musculoskeletal system	Investigative	TG-D	.	.	Investigative	D01XMP	.	CTPDG009052
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Approved	Surfactant ta	Surfacten (TN)	.	Approved	D0P4EC	.	CTPDG000220
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Approved	Picrotoxin	"Cocculin; Cocculus; Picrotox; Picrotoxine; Picrotoxinum; Sesquiterpene; Coques du levant; Coques du levant [French];Fish berry; Indian berry; Oriental berry; P 1675; Picrotin-Picrotoxinin; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Picrotoxinin-picrotin; Picrotin, compound with picrotoxinin (1:1); Picrotin, compd. with picrotoxinin (1:1); Picrotoxinin, compd. with picrotin (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-& (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2"	31304	Approved	D0KR9U	DB00466	CTPDG000294
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Approved	Lucinactant	Surfaxin (TN)	145722609	Approved	D0F4HB	.	CTPDG000387
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Approved	Colfosceril palmitate	DPPC; Exosurf; Exosurf Neonatal; Exosurf Paedriatic; Surfexo Neonatal; BW-129Y83	452110	Approved	D0A1XS	DB09114	CTPDG000471
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Approved	Poractant alfa	.	.	Approved	D08SCQ	.	CTPDG000514
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Phase 3	HL-10	.	.	Phase 3	D04OGP	.	CTPDG001420
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Phase 2	BAY1097761	Adrenomedullin Pegol; PEG-ADM	.	Phase 2	DK8BS7	.	CTPDG001694
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Phase 2	Aerosurf	.	.	Phase 2	DIAM05	.	CTPDG001701
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Phase 2	ALT-836	.	.	Phase 2	D04DKL	.	CTPDG002876
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Phase 2	Pneumostem	.	.	Phase 2	D03YIX	.	CTPDG002885
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Phase 1	GSK1995057	.	.	Phase 1	D08ENB	.	CTPDG005060
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Terminated	ALS-886	.	.	Terminated	D0VS2M	.	CTPDG007194
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Terminated	TLC-C-53	Ventus; C-53	.	Terminated	D0U4WB	.	CTPDG007211
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Investigative	PYC-38	"Phylomer (acute respiratory distress), Phylogica"	.	Investigative	D0G6TX	.	CTPDG008264
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Investigative	ED1	"ethylenediamine scaffold, 10; BDBM31426; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid"	25181318	Investigative	D0G1SN	.	CTPDG008278
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Investigative	ACS-6	"H2S-donating sildenafil (ARDS), CTG Pharma"	11549436	Investigative	D05JLG	.	CTPDG008831
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Investigative	ED45	.	.	Investigative	D01NJE	.	CTPDG009091
M6ACROT05580	.	.	M6ADIS0134	CB00: Acute respiratory distress syndrome	Investigative	DD7	.	.	Investigative	D00QBV	.	CTPDG009165
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Approved	AlloDerm	"AlloCraft; Cymetra; GraftJacket; Repliform; Strattice; Graft tissue product, LifeCell"	.	Approved	D0EW5Y	.	CTPDG000396
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Phase 3	Trafermin	Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)	.	Phase 3	D0KV1Q	.	CTPDG001153
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Phase 2	RhGDF-5	"MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil"	.	Phase 2	D0V4IQ	.	CTPDG001964
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Phase 2	PerioPatch	.	.	Phase 2	D0U8IU	.	CTPDG001981
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Terminated	MSI-469	.	.	Terminated	D0H4GE	.	CTPDG007339
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Investigative	Sharon-3000	.	.	Investigative	D0E4TD	.	CTPDG008346
M6ACROT05654	.	.	M6ADIS0210	DA0C: Periodontitis 	Investigative	BT-301	PRF-K	.	Investigative	D03WTE	.	CTPDG008923
M6ACROT05657	.	.	M6ADIS0162	JA24: Pre-eclampsia	Phase 2	Digibind	"Digoxin Immune Fab (ovine); Ovine antidigoxin polyclonal antibody fragments (pre-eclampsia), BTG; Ovine antidigoxin polyclonal antibody fragments (pre-eclampsia), GlaxoSmithKline/Glenveigh"	.	Phase 2	D0ME1L	.	CTPDG001583
M6ACROT05658	.	.	M6ADIS0162	JA24: Pre-eclampsia	Phase 2	Digibind	"Digoxin Immune Fab (ovine); Ovine antidigoxin polyclonal antibody fragments (pre-eclampsia), BTG; Ovine antidigoxin polyclonal antibody fragments (pre-eclampsia), GlaxoSmithKline/Glenveigh"	.	Phase 2	D0ME1L	.	CTPDG001583
M6ACROT05738	.	.	M6ADIS0162	JA24: Pre-eclampsia	Phase 2	Digibind	"Digoxin Immune Fab (ovine); Ovine antidigoxin polyclonal antibody fragments (pre-eclampsia), BTG; Ovine antidigoxin polyclonal antibody fragments (pre-eclampsia), GlaxoSmithKline/Glenveigh"	.	Phase 2	D0ME1L	.	CTPDG001583
M6ACROT05680	.	.	M6ADIS0014	9B10: Cataract	Approved	Acetylcholine	"Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine; Miochol; Miochol-e"	187	Approved	D0Q9HF	DB03128	CTPDG000201
M6ACROT05680	.	.	M6ADIS0014	9B10: Cataract	Approved	Tirilazad mesylate	Freedox (TN)	104902	Approved	D04APR	.	CTPDG000683
M6ACROT05680	.	.	M6ADIS0014	9B10: Cataract	Approved	Chondroitin	"UNSATURATED CHONDROITIN DISACCHARIDE; chondroitin disaccharide; 4-DEOXY-L-THREO-HEX-4-ENOPYRANOSYLURONIC ACID-(1,3)-N-ACETYL-D-GALACTOSAMINE; (2R,3R,4S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid; (3R,4R)-2-{[(2R,3S,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid"	53477707	Approved	D02HYK	.	CTPDG000753
M6ACROT05680	.	.	M6ADIS0014	9B10: Cataract	Phase 2	C-KAD	"C-KAD ophthalmic solution (cataract/asteroid hyalosis/glaucoma); C-KAD ophthalmic solution (cataract/asteroid hyalosis/glaucoma), Chakshu; Chelating agent (ophthalmic solution, cataract/asteroid hyalosis/glaucoma), Chakshu"	.	Phase 2	D07WGE	.	CTPDG002664
M6ACROT05680	.	.	M6ADIS0014	9B10: Cataract	Investigative	LPO-1010CA	.	.	Investigative	D06HGM	.	CTPDG008758
M6ACROT05694	.	.	M6ADIS0250	2B52: Ewing's sarcoma	Phase 3	MK-4827	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226	24958200	Phase 3	D00BMF	DB11793	CTPDG001507
M6ACROT05694	.	.	M6ADIS0250	2B52: Ewing's sarcoma	Phase 3	FANG vaccine	FANG (TN)	.	Phase 3	D0Q4NX	.	CTPDG002092
M6ACROT05694	.	.	M6ADIS0250	2B52: Ewing's sarcoma	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT05694	.	.	M6ADIS0250	2B52: Ewing's sarcoma	Phase 1	pbi-shRNA EWS-FLI-Type 1	.	.	Phase 1	D31ZLD	.	CTPDG004147
M6ACROT05694	.	.	M6ADIS0250	2B52: Ewing's sarcoma	Phase 1	TK216	.	.	Phase 1	D0HU0A	.	CTPDG004737
M6ACROT05694	.	.	M6ADIS0250	2B52: Ewing's sarcoma	Clinical trial	Ganitumab	.	.	Clinical trial	D0GR6I	.	CTPDG005500
M6ACROT05719	.	.	M6ADIS0228	2A82: Leukemogenesis	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05720	.	.	M6ADIS0228	2A82: Leukemogenesis	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05721	.	.	M6ADIS0228	2A82: Leukemogenesis	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05722	.	.	M6ADIS0228	2A82: Leukemogenesis	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05723	.	.	M6ADIS0228	2A82: Leukemogenesis	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05724	.	.	M6ADIS0228	2A82: Leukemogenesis	Phase 1	AGS-67E	.	.	Phase 1	D04MBK	.	CTPDG005252
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Approved	Avapritinib	"1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine"	118023034	Approved	D0UO2P	DB15233	CTPDG000113
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Approved	Sunitinib	"Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)"	5329102	Approved	D0R0MW	DB01268	CTPDG000191
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Approved	Ripretinib	"1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-"	71584930	Approved	D09AAK	DB14840	CTPDG000507
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 3	Bezuclastinib	"1616385-51-3; 1H-Pyrazole-3-carboxamide, 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-; 2ROQ545LAG; 3,4-dimethyl-N-(2-phenyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazole-5-carboxamide; 3,4-Dimethyl-N-(2-phenyl-1H-pyrrolo(2,3-b)pyridin-5-yl)-1H-pyrazole-5-carboxamide; 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide; 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide; BDBM392363; Bezuclastinib; BEZUCLASTINIB [INN]; BEZUCLASTINIB [USAN]; Bezuclastinib [WHO-DD]; CGT9486; CGT-9486; CHEMBL5095229; CS-0376032; EX-A5975; GLXC-26827; GTPL11868; HY-145557; MS-24986; NVSHVYGIYPBTEZ-UHFFFAOYSA-N; PLX 9486 [WHO-DD]; PLX9486; PLX-9486; SCHEMBL15824576; UNII-2ROQ545LAG; US10301280, Compound P-2007; US10301280, Compound P-2164; WEJ"	75593308	Phase 3	DLC7Y9	.	CTPDG000897
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 3	Masitinib	790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide	10074640	Phase 3	D0MW0N	DB11526	CTPDG001124
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 3	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	Phase 3	D0J1GR	DB11832	CTPDG001173
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 2	BIIB 2024	.	.	Phase 2	D0J8BZ	.	CTPDG002282
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 1/2	PLX9486	CGT9486	.	Phase 1/2	D03MDY	.	CTPDG003590
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 1	DS-6157	.	.	Phase 1	DJ4X7D	.	CTPDG003870
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 1	XmAb18087	.	.	Phase 1	D0FU0O	.	CTPDG004790
M6ACROT05732	.	.	M6ADIS0174	2B5B: Gastrointestinal stromal tumor	Phase 1	CDX-0158	.	.	Phase 1	D03HKR	.	CTPDG005314
M6ACROT05739	.	.	M6ADIS0349	CA08: BackgroundAllergic rhinitis	Approved	Conjugated Estrogens	"Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt"	45357473	Approved	D0T0LU	.	CTPDG000142
M6ACROT05739	.	.	M6ADIS0349	CA08: BackgroundAllergic rhinitis	Approved	Carbinoxamine	"Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine"	2564	Approved	D00FGV	DB00748	CTPDG000823
M6ACROT05919	.	.	M6ADIS0349	CA08: BackgroundAllergic rhinitis	Approved	Conjugated Estrogens	"Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt"	45357473	Approved	D0T0LU	.	CTPDG000142
M6ACROT05919	.	.	M6ADIS0349	CA08: BackgroundAllergic rhinitis	Approved	Carbinoxamine	"Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine"	2564	Approved	D00FGV	DB00748	CTPDG000823
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	Natalizumab	.	.	Approved	D3LWJ7	.	CTPDG000026
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	Clofazimine	"2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine"	2794	Approved	D0S5UH	DB00845	CTPDG000153
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	MLN0002	Vedolizumab	.	Approved	D0PK5M	.	CTPDG000211
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	Vedolizmab	4168-17-6	.	Approved	D0N5ZS	.	CTPDG000263
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Metronidazole	APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ	4173	Phase 3	D0A2ZX	DB00916	CTPDG000468
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 4	Mercaptopurine	"6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)"	667490	Phase 4	D09UZO	DB01033	CTPDG000480
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Plecanatide	Trulance	70693500	Phase 3	D07FEC	DB13170	CTPDG000574
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Ozanimod	"1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1"	52938427	Phase 3	D07EDB	DB12612	CTPDG000577
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	Ritlecitinib	"CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one"	118115473	Approved	D02TUL	DB14924	CTPDG011203
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	"Citric acid, magnesium oxide, sodium picosulfate"	Prepopik (TN)	68654	Approved	D00TGR	.	CTPDG000803
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	PB006	Natalizumab Biosimilar	.	Phase 3	DWKI46	.	CTPDG000869
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Alofisel	.	.	Phase 3	DV29RW	.	CTPDG000872
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Brazikumab	.	.	Phase 3	DMS12U	.	CTPDG000895
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	SHR0302	"(3AR,5S,6AS)-N-(3-METHOXY-1,2,4-THIADIAZOL-5-YL)-5-(METHYL (7H-PYRROLO(2,3- D)PYRIMIDIN-4-YL)AMINO) HEXAHYDROCYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE; (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino) hexahydrocyclopenta(c)pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; 1445987-21-2; AC-36766; AKOS040759719; CHEMBL5095398; CS-0062969; CYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE, HEXAHYDRO-N-(3-METHOXY-1,2,4- THIADIAZOL-5-YL)-5-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-, (3A.ALPHA.,5.ALPHA.,6A.ALPHA.)-; Cyclopenta(c)pyrrole-2(1H)-carboxamide, hexahydro-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3aalpha,5alpha,6aalpha)-; EX-A5101; example 34 [WO2013091539A1]; F82248; GTPL11878; HY-112724; Ivarmacitinib; IVARMACITINIB [INN]; Ivarmacitinib [USAN]; K6K4B9Z5TV; MS-27180; NCGC00687790-01; rel-(3aR,5s,6aS)-N-(3-Methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; SCHEMBL15077696; SCHEMBL15077710; SCHEMBL16191633; SHR0302; SHR-0302; SHR0302 base; SHR0302 FREE BASE; SHR-0302 FREE BASE; UNII-K6K4B9Z5TV; US9527851, 34; US9527851, 74; WHO 11823"	71622431	Phase 3	DFK8Z5	.	CTPDG000908
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Remestemcel-L	MSC-100-IV	.	Phase 3	D1U5BA	.	CTPDG000950
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Entyvio	.	.	Phase 3	D0Y9GF	.	CTPDG000975
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	RHB-104	.	.	Phase 3	D0V1FP	.	CTPDG001024
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Etrolizumab	.	.	Phase 3	D0UH7R	.	CTPDG001033
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Alicaforsen	"Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)"	16197725	Phase 3	D0P9BT	.	CTPDG012321
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	AJM-300	"Alpha-4 integrin antagonist (inflammatory bowel disease), Ajinomoto"	.	Phase 3	D0M1WU	.	CTPDG001133
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Vercirnon	.	10343454	Phase 3	D0K3UQ	DB15250	CTPDG001168
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Discontinued in Phase 2	ABT-874	.	.	Discontinued in Phase 2	D0H1TL	.	CTPDG001193
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Application submitted	Sivelestat	"127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine"	107706	Application submitted	D0FT4R	DB12863	CTPDG001204
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Application submitted	SB2	"Antimony; 7440-36-0; Stibium metallicum; Antimony, metallic; UNII-9IT35J3UV3; Antymonowodor [Polish]; UNII-0VKZ97K3UB; 0VKZ97K3UB; Antimonwasserstoffes [German]; HSDB 785; 9IT35J3UV3; UN2676; Antymon; Antimonio; Antimoine; Antimony powder; MFCD00011211; Antimonyl citrate; Antimony, ion(Sb2+); Sb2+; stibanylidyne; Antimonide; Antymonowodor; Antimon; antimony atom; Antimony, citric acid complexes; antimony(0); Antimonwasserstoffes; EINECS 270-130-2; ANTIMONOUS HYDRIDE; ACMC-1BKT5; 51Sb; EC 231-146-5; AC1NS5Q0; Sb(0); ANT"	5354495	Application submitted	D0CU1T	DB13110	CTPDG001249
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Rifaximin DR	.	.	Phase 3	D0AJ5E	.	CTPDG001272
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	BI 655066	.	.	Phase 2	D0A0MS	.	CTPDG001286
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	GED-0301	"SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani"	.	Phase 3	D09FKY	.	CTPDG001312
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	MSC-100-IV	.	.	Phase 3	D07TSS	.	CTPDG001343
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	Prochymal	.	.	Phase 3	D03KDO	.	CTPDG001445
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 3	SHP647	.	.	Phase 3	D02QWK	.	CTPDG001459
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	MORF-057	.	.	Phase 2	DYZA20	.	CTPDG001601
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	BI 706321	.	.	Phase 2	DRWI71	.	CTPDG001640
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	TEV-48574	.	.	Phase 2	D82MSU	.	CTPDG001774
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	EB8018	"Sibofimloc; 1616113-45-1; Antibiotic-202; VRT-1353385; UNII-00OF00QZC4; 1-[2,7-Bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; 1-[2,7-bis({2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl})spiro[fluorene-9,4'-piperidine]-1'-yl]ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; Sibofimloc [INN]; Sibofimloc [USAN]; Sibofimloc (USAN/INN); CHEMBL4594305; SCHEMBL15836795; EX-A750; Antibiotic-202;VRT-1353385; MFCD28144726; WHO 10950; ZINC209678340; ACN-052475; CS-5487; DA-43714; HY-12820; B5896; D11825; J-690221; 1-(2,7-Bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol-8-yl)spiro(fluorene-9,4'-piperidin)-1'-yl)ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4a?piperidine]-1a?yl]ethanone; 8,8'-(1'-Acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol); D-Glycero-D-manno-oct-7-ynitol, 8,8'-(1'-acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-"	76684239	Phase 2	D72HXF	.	CTPDG001784
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	PRA023	.	.	Phase 2	D61PGU	.	CTPDG001797
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	ABBV-154	.	.	Phase 2	D2AQW7	.	CTPDG001839
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	Alequel	"Antigens (colitis), Enzo; Antigen-specific immune regulation therapy (Crohn`s), Enzo"	.	Phase 2	D0XO7Q	.	CTPDG001887
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	CC-1088	CDC801; CHEMBL88153; SCHEMBL185853; CDC-801; DDYUBCCTNHWSQM-UHFFFAOYSA-N; BDBM50216298; HY-U00179; CS-7247; 192819-27-5	9844338	Phase 2	D0U2DH	.	CTPDG001997
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	Anti-IP10	.	.	Phase 2	D0L7LH	.	CTPDG002232
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	APD371	"Olorinab; UNII-581F7DFA9B; 581F7DFA9B; Olorinab [USAN]; SCHEMBL11995430; 1268881-20-4; (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide; 1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-; (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic aci"	60164925	Phase 2	D0I4PW	DB14998	CTPDG002313
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	OPS-2071	.	.	Phase 2	D0GNF7	.	CTPDG002352
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	MEDI2070	.	.	Phase 2	D0F9XG	.	CTPDG002392
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	EGS-21	"Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem"	6475228	Phase 2	D0D4ZW	.	CTPDG002452
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	GSK2330811	.	.	Phase 2	D0D3TQ	.	CTPDG002456
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	STA-5326	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine	10173277	Phase 2	D0C9NJ	DB05611	CTPDG002477
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	MDX-1100	.	.	Phase 2	D0C1UF	.	CTPDG002495
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	NN8555	.	.	Phase 2	D06JUE	.	CTPDG002751
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	AMG-181	"Inflammatory bowel disease therapeutics, Amgen"	.	Phase 2	D04WQJ	.	CTPDG002830
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	SGX203	.	.	Phase 2	D04TFL	.	CTPDG002841
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 2	MT-1303	.	67418070	Phase 2	D00ISN	.	CTPDG003087
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1/2	EcoActive	.	.	Phase 1/2	D1P8BK	.	CTPDG003255
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	AZD7798	.	.	Phase 1	DE3LH7	.	CTPDG003939
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	OSSM-001	.	.	Phase 1	DAD62Z	.	CTPDG003977
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	ONS-3010	.	.	Phase 1	D0MI8Z	.	CTPDG004591
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	ATR-107	PF-05230900	.	Phase 1	D0M4MH	.	CTPDG004602
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	ChronsVax	Crohn's disease vaccine; IR-777	.	Phase 1	D0HJ5Y	.	CTPDG004739
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	AMG-139	"Anti-inflammatory agent (psoriasis, IBD), Amgen"	.	Phase 1	D0G3EU	.	CTPDG004779
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	TAK-828	"ICMFYVOUDGRBLG-NJMNTPMDSA-N; TAK828F; GTPL9867; TAK-828F; SCHEMBL17390967; SCHEMBL17390969; SCHEMBL17391123; ICMFYVOUDGRBLG-VFHHBZAHSA-N; ICMFYVOUDGRBLG-XVNUGVHUSA-N; compound 10 [PMID: 29510038]; E3V; {cis-3-[(5R)-5-[(7-fluoro-1,1-dimethyl-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridine-6(5H)-carbonyl]cyclobutyl}acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7,8-dihydro-1,6-naphthyridin-6 (5H)-yl)carbonyl)cyclobutyl)acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2"	118622692	Phase 1	D0D7CH	.	CTPDG004856
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	CrohnsVax	.	.	Phase 1	D0CY2Q	.	CTPDG004873
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	ETX201	.	.	Phase 1	D09KIG	.	CTPDG004995
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	VBY-129	"Cathepsin S inhibitor (oral, psoriasis), Virobay"	.	Phase 1	D07UKF	.	CTPDG005081
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	SAR252067	.	.	Phase 1	D06GAP	.	CTPDG005165
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	PF-06480605	.	.	Phase 1	D03IQD	.	CTPDG005312
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	ABBV-323	.	.	Phase 1	D01NZH	.	CTPDG005396
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Phase 1	CCX-025	"CCX-807; CCR9 chemokine receptor-targeting therapeutic (gastrointestinal diseases), ChemoCentryx"	.	Phase 1	D00YXU	.	CTPDG005427
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 6	PMID26651364-Compound-2f	.	Patented	D0ZR2O	.	CTPDG005515
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 3	PMID26651364-Compound-2c	.	Patented	D0ZD6N	.	CTPDG005525
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 2	PMID26651364-Compound-1b	.	Patented	D0Z6PF	.	CTPDG005529
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 2	PMID26651364-Compound-101	.	Patented	D0Z1ZA	.	CTPDG005535
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 16	PMID26651364-Compound-51	.	Patented	D0Z1YF	.	CTPDG005536
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-126b	.	.	Patented	D0YX4L	.	CTPDG005539
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-7d	.	.	Patented	D0Y3UB	.	CTPDG005549
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 7	PMID26651364-Compound-18	.	Patented	D0Y0SI	.	CTPDG005553
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 28	PMID26651364-Compound-64	.	Patented	D0XR1C	.	CTPDG005557
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 5	PMID26651364-Compound-104	.	Patented	D0XP5X	.	CTPDG005558
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	C-linked disaccharide biphenyl mannoside derivative 3	PMID26651364-Compound-88	.	Patented	D0XH4K	.	CTPDG005560
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 4	PMID26651364-Compound-103	.	Patented	D0X8AB	.	CTPDG005561
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-50	.	.	Patented	D0X7HN	.	CTPDG005562
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-118	.	.	Patented	D0X4TV	.	CTPDG005565
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 18	PMID26651364-Compound-80	.	Patented	D0WW9B	.	CTPDG005571
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Beta-cyclodextrin conjugate derivative 5	PMID26651364-Compound-133	.	Patented	D0WV9J	.	CTPDG005572
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-49	.	.	Patented	D0WO6C	.	CTPDG005576
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-111	.	.	Patented	D0WO2I	.	CTPDG005577
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 20	PMID26651364-Compound-55	.	Patented	D0W7VE	.	CTPDG005582
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5b	.	.	Patented	D0W1SE	.	CTPDG005585
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 23	PMID26651364-Compound-68b	.	Patented	D0VG0F	.	CTPDG005590
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-107	.	.	Patented	D0VF5B	.	CTPDG005591
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 9	PMID26651364-Compound-20	.	Patented	D0VB4T	.	CTPDG005594
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 1	PMID26651364-Compound-1a	.	Patented	D0VA1D	.	CTPDG005596
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-6d	.	.	Patented	D0UZ2S	.	CTPDG005604
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	C-linked disaccharide biphenyl mannoside derivative 2	PMID26651364-Compound-87	.	Patented	D0US5I	.	CTPDG005606
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-126a	.	.	Patented	D0UK1S	.	CTPDG005609
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 7	PMID26651364-Compound-31	.	Patented	D0UG9S	.	CTPDG005610
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 28	PMID26651364-Compound-73	.	Patented	D0UE3F	.	CTPDG005612
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 6	PMID26651364-Compound-Table2R1=n-alkyl04	.	Patented	D0UB8U	.	CTPDG005613
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 9	PMID26651364-Compound-95	.	Patented	D0TY1Q	.	CTPDG005627
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-113	.	.	Patented	D0TP8T	.	CTPDG005630
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 20	PMID26651364-Compound-82	.	Patented	D0T7VN	.	CTPDG005637
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 29	PMID26651364-Compound-74	.	Patented	D0T6NX	.	CTPDG005639
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 1	PMID26651364-Compound-25	.	Patented	D0SU0E	.	CTPDG005647
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-124	.	.	Patented	D0SR8I	.	CTPDG005648
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 3	PMID26651364-Compound-Table2R1=n-alkyl01	.	Patented	D0SE7V	.	CTPDG005649
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 11	PMID26651364-Compound-22	.	Patented	D0SD4Q	.	CTPDG005650
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 17	PMID26651364-Compound-52	.	Patented	D0RZ5E	.	CTPDG005659
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 22	PMID26651364-Compound-44	.	Patented	D0RG1Z	.	CTPDG005667
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 13	PMID26651364-Compound-37	.	Patented	D0RE0F	.	CTPDG005669
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 3	PMID26651364-Compound-102	.	Patented	D0R7YN	.	CTPDG005675
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 10	PMID26651364-Compound-21	.	Patented	D0R6FO	.	CTPDG005679
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 29	PMID26651364-Compound-65	.	Patented	D0R2GA	.	CTPDG005683
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 1	PMID26651364-Compound-2a	.	Patented	D0R1SQ	.	CTPDG005684
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 16	PMID26651364-Compound-78	.	Patented	D0R1GD	.	CTPDG005686
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-47	.	.	Patented	D0QU6N	.	CTPDG005689
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Beta-cyclodextrin conjugate derivative 2	PMID26651364-Compound-130	.	Patented	D0QQ5W	.	CTPDG005691
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5f	.	.	Patented	D0QM2O	.	CTPDG005693
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 23	PMID26651364-Compound-59	.	Patented	D0QL0X	.	CTPDG005694
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 13	PMID26651364-Compound-99	.	Patented	D0Q7QK	.	CTPDG005699
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-7e	.	.	Patented	D0Q1SX	.	CTPDG005702
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-9c	.	.	Patented	D0Q0XC	.	CTPDG005703
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-8d	.	.	Patented	D0P3SL	.	CTPDG005717
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-11c	.	.	Patented	D0OW6O	.	CTPDG005724
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 25	PMID26651364-Compound-61	.	Patented	D0OW1V	.	CTPDG005725
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 1	PMID26651364-Compound-100	.	Patented	D0OQ2R	.	CTPDG005727
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-8c	.	.	Patented	D0O8EX	.	CTPDG005735
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-10b	.	.	Patented	D0O4TC	.	CTPDG005738
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 8	PMID26651364-Compound-32	.	Patented	D0NB5P	.	CTPDG005748
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-106	.	.	Patented	D0N4WW	.	CTPDG005757
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 11	PMID26651364-Compound-35	.	Patented	D0N4TO	.	CTPDG005759
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 19	PMID26651364-Compound-54	.	Patented	D0N2AI	.	CTPDG005761
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-10d	.	.	Patented	D0MZ8J	.	CTPDG005766
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 5	PMID26651364-Compound-Table2R1=n-alkyl03	.	Patented	D0MO0Z	.	CTPDG005772
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Beta-cyclodextrin conjugate derivative 1	PMID26651364-Compound-129	.	Patented	D0M7XB	.	CTPDG005781
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-122	.	.	Patented	D0LZ1W	.	CTPDG005787
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-6c	.	.	Patented	D0L5OP	.	CTPDG005795
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 8	PMID26651364-Compound-19	.	Patented	D0L3JL	.	CTPDG005796
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 27	PMID26651364-Compound-72	.	Patented	D0L2QZ	.	CTPDG005797
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 4	PMID26651364-Compound-Table2R1=n-alkyl02	.	Patented	D0L1PO	.	CTPDG005799
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 6	PMID26651364-Compound-17	.	Patented	D0KX1A	.	CTPDG005802
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-9b	.	.	Patented	D0KG5U	.	CTPDG005807
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-46	.	.	Patented	D0KE8Q	.	CTPDG005809
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 27	PMID26651364-Compound-63	.	Patented	D0K7TE	.	CTPDG005816
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-112	.	.	Patented	D0K3DA	.	CTPDG005824
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 11	PMID26651364-Compound-3c	.	Patented	D0K2AA	.	CTPDG005825
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-127	.	.	Patented	D0J8HJ	.	CTPDG005837
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-4	.	.	Patented	D0J0LC	.	CTPDG005844
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-110	.	.	Patented	D0IF4J	.	CTPDG005855
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-117a	.	.	Patented	D0IB8D	.	CTPDG005857
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-9f	.	.	Patented	D0I2MR	.	CTPDG005867
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 18	PMID26651364-Compound-53	.	Patented	D0HE3B	.	CTPDG005880
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 11	PMID26651364-Compound-97	.	Patented	D0H7UR	.	CTPDG005884
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	C-linked disaccharide biphenyl mannoside derivative 1	PMID26651364-Compound-86	.	Patented	D0H4CL	.	CTPDG005890
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 19	PMID26651364-Compound-41	.	Patented	D0H1BZ	.	CTPDG005895
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 2	PMID26651364-Compound-2b	.	Patented	D0GV9F	.	CTPDG005902
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 22	PMID26651364-Compound-68a	.	Patented	D0GR3C	.	CTPDG005904
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-115	.	.	Patented	D0GP7L	.	CTPDG005905
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 9	PMID26651364-Compound-33	.	Patented	D0GM6O	.	CTPDG005906
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-10a	.	.	Patented	D0GB6Y	.	CTPDG005910
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 2	PMID26651364-Compound-13	.	Patented	D0G9KS	.	CTPDG005911
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 3	PMID26651364-Compound-14	.	Patented	D0FT4P	.	CTPDG005917
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-120	.	.	Patented	D0FS9V	.	CTPDG005918
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-6a	.	.	Patented	D0FL3H	.	CTPDG005923
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 13	PMID26651364-Compound-3e	.	Patented	D0FI3Q	.	CTPDG005928
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 6	PMID26651364-Compound-92	.	Patented	D0F6TN	.	CTPDG005931
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 30	PMID26651364-Compound-66	.	Patented	D0ET9M	.	CTPDG005944
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 14	PMID26651364-Compound-3f	.	Patented	D0EA9Y	.	CTPDG005952
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 15	PMID26651364-Compound-39	.	Patented	D0E9GD	.	CTPDG005953
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 11	PMID26651364-Compound-Table2R1=n-aryl02	.	Patented	D0E3DS	.	CTPDG005955
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5g	.	.	Patented	D0E1GC	.	CTPDG005957
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-6b	.	.	Patented	D0DW7A	.	CTPDG005960
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 10	PMID26651364-Compound-Table2R1=n-aryl01	.	Patented	D0DI6U	.	CTPDG005968
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 16	PMID26651364-Compound-3h	.	Patented	D0DI1T	.	CTPDG005969
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 12	PMID26651364-Compound-23	.	Patented	D0DH0Y	.	CTPDG005971
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 17	PMID26651364-Compound-79	.	Patented	D0D9MV	.	CTPDG005978
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 7	PMID26651364-Compound-Table2R1=n-alkyl05	.	Patented	D0D6OM	.	CTPDG005982
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 12	PMID26651364-Compound-98	.	Patented	D0D6HS	.	CTPDG005983
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-117b	.	.	Patented	D0D2QE	.	CTPDG005988
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 26	PMID26651364-Compound-71	.	Patented	D0CR8J	.	CTPDG005996
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-7c	.	.	Patented	D0CN7A	.	CTPDG005999
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5c	.	.	Patented	D0CN6Q	.	CTPDG006000
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Beta-cyclodextrin conjugate derivative 4	PMID26651364-Compound-132	.	Patented	D0CD7Q	.	CTPDG006007
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-45	.	.	Patented	D0C8EB	.	CTPDG006010
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 21	PMID26651364-Compound-56	.	Patented	D0BS3E	.	CTPDG006017
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 2	PMID26651364-Compound-26	.	Patented	D0BR9C	.	CTPDG006018
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-8b	.	.	Patented	D0B9LM	.	CTPDG006022
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 14	PMID26651364-Compound-76	.	Patented	D0B8RU	.	CTPDG006023
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	C-linked disaccharide biphenyl mannoside derivative 5	PMID26651364-Compound-90	.	Patented	D0B3CU	.	CTPDG006027
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 20	PMID26651364-Compound-42	.	Patented	D0B1HT	.	CTPDG006031
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-10c	.	.	Patented	D0AY0H	.	CTPDG006033
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 15	PMID26651364-Compound-77	.	Patented	D0AM0A	.	CTPDG006038
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-7b	.	.	Patented	D0AK2Y	.	CTPDG006039
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 4	PMID26651364-Compound-2d	.	Patented	D0A8RV	.	CTPDG006041
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-9e	.	.	Patented	D0A8GW	.	CTPDG006043
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 4	PMID26651364-Compound-28	.	Patented	D0A3PP	.	CTPDG006046
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 24	PMID26651364-Compound-69	.	Patented	D09ZCA	.	CTPDG006051
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 7	PMID26651364-Compound-2g	.	Patented	D09TKY	.	CTPDG006054
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 13	PMID26651364-Compound-24	.	Patented	D09SLI	.	CTPDG006056
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 7	PMID26651364-Compound-93	.	Patented	D09LWZ	.	CTPDG006058
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-105	.	.	Patented	D09LWP	.	CTPDG006059
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5a	.	.	Patented	D09JDV	.	CTPDG006061
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-8a	.	.	Patented	D09EXQ	.	CTPDG006064
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 18	PMID26651364-Compound-40	.	Patented	D09EIQ	.	CTPDG006066
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 1	PMID26651364-Compound-12	.	Patented	D09BGB	.	CTPDG006068
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-48	.	.	Patented	D08WZC	.	CTPDG006073
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 8	PMID26651364-Compound-94	.	Patented	D08OXD	.	CTPDG006081
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 5	PMID26651364-Compound-2e	.	Patented	D08BNB	.	CTPDG006088
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 23	PMID26651364-Compound-85	.	Patented	D08BLZ	.	CTPDG006089
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 8	PMID26651364-Compound-Table2R1=n-alkyl06	.	Patented	D07RQA	.	CTPDG006101
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-119	.	.	Patented	D07RAA	.	CTPDG006102
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 17	PMID26651364-Compound-3i	.	Patented	D07QAH	.	CTPDG006104
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 21	PMID26651364-Compound-83	.	Patented	D07PVX	.	CTPDG006105
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 12	PMID26651364-Compound-Table2R1=n-aryl03	.	Patented	D07POS	.	CTPDG006106
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 22	PMID26651364-Compound-84	.	Patented	D07KCA	.	CTPDG006114
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Alkyl mannoside derivative 9	PMID26651364-Compound-Table2R1=n-alkyl07	.	Patented	D07HOP	.	CTPDG006117
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 12	PMID26651364-Compound-3d	.	Patented	D07GAN	.	CTPDG006120
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 5	PMID26651364-Compound-16	.	Patented	D06SWT	.	CTPDG006136
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 26	PMID26651364-Compound-62	.	Patented	D06PNN	.	CTPDG006141
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5e	.	.	Patented	D05ZHZ	.	CTPDG006155
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-6e	.	.	Patented	D05XGH	.	CTPDG006156
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 14	PMID26651364-Compound-38	.	Patented	D05WWX	.	CTPDG006157
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-11b	.	.	Patented	D05OMO	.	CTPDG006165
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 5	PMID26651364-Compound-29	.	Patented	D05JAS	.	CTPDG006169
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-123	.	.	Patented	D05HKC	.	CTPDG006170
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-9a	.	.	Patented	D05CBP	.	CTPDG006175
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Mannoside derivative 10	PMID26651364-Compound-96	.	Patented	D05BUD	.	CTPDG006176
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-126c	.	.	Patented	D05BTL	.	CTPDG006177
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 30	PMID26651364-Compound-75	.	Patented	D05AZE	.	CTPDG006178
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-125	.	.	Patented	D04PKX	.	CTPDG006189
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-128	.	.	Patented	D04NXG	.	CTPDG006192
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	C-linked disaccharide biphenyl mannoside derivative 4	PMID26651364-Compound-89	.	Patented	D03WXM	.	CTPDG006214
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 25	PMID26651364-Compound-70	.	Patented	D03WJB	.	CTPDG006215
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 3	PMID26651364-Compound-27	.	Patented	D03RXE	.	CTPDG006222
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 12	PMID26651364-Compound-36	.	Patented	D03KAV	.	CTPDG006225
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-108	.	.	Patented	D03JFJ	.	CTPDG006226
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 4	PMID26651364-Compound-15	.	Patented	D03ITZ	.	CTPDG006227
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-121	.	.	Patented	D03HHG	.	CTPDG006228
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 10	PMID26651364-Compound-34	.	Patented	D03CTH	.	CTPDG006236
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 15	PMID26651364-Compound-3g	.	Patented	D02ZYV	.	CTPDG006239
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	C-linked disaccharide biphenyl mannoside derivative 6	PMID26651364-Compound-91	.	Patented	D02XNH	.	CTPDG006244
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Aryl mannoside derivative 19	PMID26651364-Compound-81	.	Patented	D02WWT	.	CTPDG006245
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-9d	.	.	Patented	D02UDO	.	CTPDG006248
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-7a	.	.	Patented	D02NDP	.	CTPDG006256
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 9	PMID26651364-Compound-3a	.	Patented	D02HPF	.	CTPDG006260
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 10	PMID26651364-Compound-3b	.	Patented	D02DFJ	.	CTPDG006263
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 31	PMID26651364-Compound-67	.	Patented	D02AAD	.	CTPDG006264
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 21	PMID26651364-Compound-43	.	Patented	D01ZKE	.	CTPDG006265
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5d	.	.	Patented	D01RHK	.	CTPDG006270
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biphenyl mannoside derivative 6	PMID26651364-Compound-30	.	Patented	D01PBX	.	CTPDG006273
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-114	.	.	Patented	D01CND	.	CTPDG006282
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-109	.	.	Patented	D00XKE	.	CTPDG006289
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Beta-cyclodextrin conjugate derivative 3	PMID26651364-Compound-131	.	Patented	D00XEM	.	CTPDG006291
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 8	PMID26651364-Compound-2h	.	Patented	D00RQW	.	CTPDG006296
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-116	.	.	Patented	D00RDO	.	CTPDG006298
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	PMID26651364-Compound-5	.	.	Patented	D00KKD	.	CTPDG006307
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Patented	Biaryl mannoside derivative 24	PMID26651364-Compound-60	.	Patented	D00COH	.	CTPDG006311
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Discontinued in Phase 3	CDP571	.	.	Discontinued in Phase 3	D0S2GT	.	CTPDG006338
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Discontinued in Phase 2	ISIS 104838	.	.	Discontinued in Phase 2	D0FX3P	.	CTPDG006520
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Terminated	TNFQb therapeutic vaccines	"TNFQb; CYT-020-TNFQb; TNF-targeted vaccine (inflammation, Immunodrug), Cytos Biotechnology; TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease); TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos; Immunodrug vaccines (TNF) (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos"	.	Terminated	D06MJP	.	CTPDG007477
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Approved	Mycophenolic acid	.	446541	Approved	D0Z8EV	DB01024	CTPDG007624
M6ACROT05769	.	.	M6ADIS0381	DD70: Crohn disease	Investigative	STP-432	"Multi-targeted siRNA therapeutic (nanoparticle, Crohns disease), Sirnaomics"	.	Investigative	D0QR8B	.	CTPDG007927
M6ACROT05818	.	.	M6ADIS0258	8E47: Diabetic encephalopathy	Phase 2	Fosdenopterin	"CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec"	135463437	Phase 2	D07GTW	.	CTPDG000570
M6ACROT05818	.	.	M6ADIS0258	8E47: Diabetic encephalopathy	Phase 3	SA-237	"Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai"	.	Phase 3	D0Y1ZU	.	CTPDG000983
M6ACROT05818	.	.	M6ADIS0258	8E47: Diabetic encephalopathy	Phase 3	BQ788	"(2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752"	16759603	Phase 3	D08IXA	.	CTPDG001334
M6ACROT05818	.	.	M6ADIS0258	8E47: Diabetic encephalopathy	Phase 2	MEDI-551	.	.	Phase 2	D0R3ZE	.	CTPDG002072
M6ACROT05818	.	.	M6ADIS0258	8E47: Diabetic encephalopathy	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT00003	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 12"	SCHEMBL17669987; BDBM308061	121268883	Patented	D05GPF	.	CTPDG015018
M6ACROT00003	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 2"	SCHEMBL17669993; LHUVPYZTQHNXRU-UHFFFAOYSA-N; BDBM308050; 1-{2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothien-5-yl}-3-[4-chloro-3-(trifluoromethyl)phenyl]urea; 1-(2-(2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl)benzo[b]thiophen-5-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea	121268887	Patented	D0QZ4B	.	CTPDG015019
M6ACROT00003	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 9"	SCHEMBL17670002; OGVARLFWIBVKET-UHFFFAOYSA-N; BDBM308058; N-[3-({5-[2-(3-hydroxypropyl)-2H-tetrazol-5-yl]pyridin-3-yl}ethynyl)phenyl]-3-methyl-2-furamide	121268893	Patented	D0Z0BQ	.	CTPDG015020
M6ACROT00003	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	ASN-11124542	AC1O5VPR; ASN 11124542	6490494	Investigative	D0C1DQ	.	CTPDG015021
M6ACROT00003	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	indirubin derivative E804	indirubin E804; compound 2 [PMID: 21632247]	6419764	Investigative	D0N9DU	.	CTPDG015022
M6ACROT00003	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00010	Gap junction gamma-1 protein (GJC1)	CXG1_HUMAN	.	.	Investigative	octanol	"1-octanol; Octan-1-ol; 111-87-5; N-octanol; Capryl alcohol; Octyl alcohol; caprylic alcohol; n-Octyl alcohol; Heptyl carbinol; 1-Hydroxyoctane; Primary octyl alcohol; Alcohol C-8; n-Octan-1-ol; Octilin; Sipol L8; Alfol 8; Lorol 20; Dytol M-83; n-Caprylic alcohol; 1-Octyl alcohol; n-Heptyl carbinol; EPAL 8; octyl-alcohol; Alcohols, C6-12; N-octyl-alcohol; Octyl alcohol, normal-primary; C8 alcohol; Fatty alcohol(C8); Octyl alcohol, primary; Caswell No. 611A; Octyl alcohol (natural); FEMA Number 2800; Lorol C 8-98; n-Capryl alcohol"	957	Investigative	D00VJY	DB12452	CTPDG014669
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	P-276	"CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development"	23643976	Phase 2	D0W8IY	.	CTPDG010902
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	P276-00	CHEMBL2312181; SCHEMBL1180418	23643975	Phase 2	D05IRT	.	CTPDG010904
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	P1446A-05	.	67409219	Phase 1	D0DX4J	DB15157	CTPDG004841
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	PF-07220060	.	.	Phase 1	DZJ3D5	.	CTPDG003644
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Imidazo pyridine derivative 3	PMID26161698-Compound-22	46937330	Patented	D0WT7D	.	CTPDG010910
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 10"	PMID26161698-Compound-2	53378895	Patented	D04AKA	.	CTPDG010912
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID26161698-Compound-17	.	739323	Patented	D0FQ6V	.	CTPDG010913
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	CHEMBL521733; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	787236	Investigative	D03VDM	.	CTPDG010920
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea	5330597	Investigative	D0G4JS	.	CTPDG010921
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea	5330595	Investigative	D0M8CO	.	CTPDG010922
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-Pyridin-2-yl-3-quinolin-5-yl-urea	Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea	5330598	Investigative	D0T2VG	.	CTPDG010923
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea	5330596	Investigative	D0X1NW	.	CTPDG010924
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Ro-0505124	RO0505124	9911652	Investigative	D09RYV	.	CTPDG010927
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00011	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00027	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00027	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00027	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00028	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00028	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00028	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00029	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00029	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00029	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00030	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00030	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00030	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00031	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00031	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00031	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00032	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00032	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00032	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00045	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00045	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00045	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00051	Fibronectin (FN1)	FINC_HUMAN	.	.	Approved	Ocriplasmin	.	.	Approved	D0Y7XG	.	CTPDG014046
M6ACROT00051	Fibronectin (FN1)	FINC_HUMAN	.	.	Phase 2	L19-TNF-alpha	Fibromun	.	Phase 2	D0GZ3A	.	CTPDG014047
M6ACROT00053	Fibronectin (FN1)	FINC_HUMAN	.	.	Approved	Ocriplasmin	.	.	Approved	D0Y7XG	.	CTPDG014046
M6ACROT00053	Fibronectin (FN1)	FINC_HUMAN	.	.	Phase 2	L19-TNF-alpha	Fibromun	.	Phase 2	D0GZ3A	.	CTPDG014047
M6ACROT00055	Fibronectin (FN1)	FINC_HUMAN	.	.	Approved	Ocriplasmin	.	.	Approved	D0Y7XG	.	CTPDG014046
M6ACROT00055	Fibronectin (FN1)	FINC_HUMAN	.	.	Phase 2	L19-TNF-alpha	Fibromun	.	Phase 2	D0GZ3A	.	CTPDG014047
M6ACROT00057	Fibronectin (FN1)	FINC_HUMAN	.	.	Approved	Ocriplasmin	.	.	Approved	D0Y7XG	.	CTPDG014046
M6ACROT00057	Fibronectin (FN1)	FINC_HUMAN	.	.	Phase 2	L19-TNF-alpha	Fibromun	.	Phase 2	D0GZ3A	.	CTPDG014047
M6ACROT00060	Tankyrase (TNKS)	TNKS1_HUMAN	.	.	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT00060	Tankyrase (TNKS)	TNKS1_HUMAN	.	.	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT00061	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 12"	SCHEMBL17669987; BDBM308061	121268883	Patented	D05GPF	.	CTPDG015018
M6ACROT00061	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 2"	SCHEMBL17669993; LHUVPYZTQHNXRU-UHFFFAOYSA-N; BDBM308050; 1-{2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothien-5-yl}-3-[4-chloro-3-(trifluoromethyl)phenyl]urea; 1-(2-(2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl)benzo[b]thiophen-5-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea	121268887	Patented	D0QZ4B	.	CTPDG015019
M6ACROT00061	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 9"	SCHEMBL17670002; OGVARLFWIBVKET-UHFFFAOYSA-N; BDBM308058; N-[3-({5-[2-(3-hydroxypropyl)-2H-tetrazol-5-yl]pyridin-3-yl}ethynyl)phenyl]-3-methyl-2-furamide	121268893	Patented	D0Z0BQ	.	CTPDG015020
M6ACROT00061	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	ASN-11124542	AC1O5VPR; ASN 11124542	6490494	Investigative	D0C1DQ	.	CTPDG015021
M6ACROT00061	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	indirubin derivative E804	indirubin E804; compound 2 [PMID: 21632247]	6419764	Investigative	D0N9DU	.	CTPDG015022
M6ACROT00061	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	TG02	SB1317; 937270-47-8; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	Phase 1/2	D0P0KN	.	CTPDG013443
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AZD-5438	"602306-29-6; AZD5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	Phase 1	D06WHY	.	CTPDG005133
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	Phase 1	D07DTV	DB08142	CTPDG005118
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	Phase 1	D0PL7P	DB15425	CTPDG004504
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	Phase 1	D0S5RC	DB05969	CTPDG004433
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Fluorinated compound 1	PMID26161698-Compound-15	.	Patented	D09ISI	.	CTPDG013444
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"4-amino-3,5-di-substituted-thiazole derivative 1"	PMID26161698-Compound-54	.	Patented	D0JU4Z	.	CTPDG013445
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 11	PMID26161698-Compound-16	.	Patented	D02KWX	.	CTPDG013446
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	PMID26161698-Compound-27	73508010	Patented	D03EYT	.	CTPDG013447
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Alkyl sulfone derivative 1	PMID26161698-Compound-29	73672849	Patented	D05UJQ	.	CTPDG013448
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Aniline derivative 1	PMID26161698-Compound-33	59176838	Patented	D06QPW	.	CTPDG013449
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 1	PMID26161698-Compound-35	44253187	Patented	D07QIP	.	CTPDG013450
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-phenyl-pyrimidin-4-amine derivative 1	PMID26161698-Compound-30	74763288	Patented	D0AY5G	.	CTPDG013451
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID26161698-Compound-25	.	71618654	Patented	D0GQ7L	.	CTPDG013452
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diaryl amine derivative 1	PMID26161698-Compound-23	71515733	Patented	D0P4NP	.	CTPDG013453
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Flavopiridol analog 1	PMID26161698-Compound-5	86272549	Patented	D0P9WR	.	CTPDG013454
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	PMID26161698-Compound-31	73891126	Patented	D0QS2B	.	CTPDG013455
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Pyrazolo-triazine derivative 2	PMID26161698-Compound-14	71731909	Patented	D0T6CM	.	CTPDG013456
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"1,5-di-substituted pyridine derivative 1"	PMID26161698-Compound-26	60197050	Patented	D0UU0V	.	CTPDG013457
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	PMID26161698-Compound-28	74767011	Patented	D0V7RP	.	CTPDG013458
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Naphthyridine and isoquinoline derivative 1	PMID26161698-Compound-51	.	Patented	D08WJG	.	CTPDG013393
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 2	PMID26161698-Compound-36	71561915	Patented	D01CJE	.	CTPDG013394
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diamidothiazole derivative 1	PMID26161698-Compound-53	25256147	Patented	D0LR2Y	.	CTPDG013332
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrazolo[1,5-a]-1,3,5-triazine derivative 1"	PMID26161698-Compound-12	.	Patented	D0NB7Y	.	CTPDG013395
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Roscovitine derivative 1	PMID26161698-Compound-8	73353575	Patented	D07DUX	.	CTPDG013396
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 3	SCH 727965	Dinaciclib; SCH-727965	46926350	Discontinued in Phase 3	D0D3PX	DB12021	CTPDG013398
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	Preclinical	D0WS1V	DB02733	CTPDG007034
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	Olomoucine	"101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	Terminated	D00BPA	DB02116	CTPDG013399
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	Investigative	D01LPG	DB08134	CTPDG013460
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	Investigative	D03BZV	DB04607	CTPDG013461
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	Investigative	D06FIQ	DB07203	CTPDG013462
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BOHEMINE	189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	Investigative	D07ADR	.	CTPDG013463
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-phenyl-1H-pyrazole-3-carboxamide	"124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	Investigative	D07ODE	DB08135	CTPDG013464
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-hydroxynaphthalene-1-sulfonamide	"17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	Investigative	D07SGT	DB08132	CTPDG013465
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	Investigative	D0D3HB	DB08133	CTPDG013466
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	Investigative	D0I1SZ	DB08768	CTPDG013467
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	Investigative	D0I9VN	DB02603	CTPDG013468
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	Investigative	D0M5PI	.	CTPDG013469
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	Investigative	D0MK6D	DB02647	CTPDG013470
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	Investigative	D0P7RO	.	CTPDG013471
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	Investigative	D0QI7H	DB06948	CTPDG013472
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	Investigative	D0T4SJ	.	CTPDG007860
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	Investigative	D0T5AH	.	CTPDG007858
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	Investigative	D0U0GE	DB02091	CTPDG013473
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	Investigative	D0V1NK	.	CTPDG007806
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-Amino-6-Chloropyrazine	"33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	Investigative	D0W0PF	DB02297	CTPDG013474
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	Investigative	D0Y6DX	DB08233	CTPDG013475
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	Investigative	D01FJB	.	CTPDG013476
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	Investigative	D02ZYA	.	CTPDG013478
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	Investigative	D03XKK	.	CTPDG013480
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	JNJ-7706621	"443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	Investigative	D04NGS	.	CTPDG013404
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	GW-8510	.	3536	Investigative	D04RBG	.	CTPDG013482
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-265246	BMS 265246; BMS265246	135402864	Investigative	D05SZH	.	CTPDG013405
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	RESCOVITINE	CHEMBL1087791	46881287	Investigative	D07AEC	.	CTPDG013485
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	Investigative	D07JHG	.	CTPDG013486
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15"	5687	Investigative	D0KH5T	DB03365	CTPDG010119
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Oxindole 95	.	.	Investigative	D0MS4R	.	CTPDG013496
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	CVT-313	AC1OCFD4; NG 26	6918386	Investigative	D0P2WA	.	CTPDG013408
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	Investigative	D0R1FT	DB02407	CTPDG013497
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6027	.	398148	Investigative	D0U8YN	DB08312	CTPDG013498
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 8	SCHEMBL2991886; CHEMBL406102	24801181	Investigative	D01PEF	.	CTPDG013502
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Purvalanol A	Purvalanola; AC1L1JD0; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	Investigative	D07OAT	DB04751	CTPDG013410
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk1/2 inhibitor III	"443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664"	5330812	Investigative	D07OCA	DB07664	CTPDG013411
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 1	"341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	Investigative	D08KSQ	.	CTPDG013503
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 4	SCHEMBL3001373; CHEMBL406464	24801697	Investigative	D0B9YR	.	CTPDG013504
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Lysine Nz-Carboxylic Acid	N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	Investigative	D0CC0B	DB03801	CTPDG013505
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 6	CHEMBL406463; SCHEMBL2999009	24801185	Investigative	D0D0ZQ	.	CTPDG013506
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	Investigative	D0F0AX	.	CTPDG013412
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aminopurvalanol A	NG-97	6604931	Investigative	D0G2GA	.	CTPDG013413
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	9-Nitropaullone	"Alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	Investigative	D0H3EV	DB04014	CTPDG013414
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 5	"1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	Investigative	D0H6CQ	DB08182	CTPDG013507
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SU9516	"377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	Investigative	D0L3FK	DB03428	CTPDG013415
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 3	"954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	Investigative	D0S8VE	DB08178	CTPDG013508
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 2	"SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	Investigative	D0U1WL	.	CTPDG013509
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid"	3708	Investigative	D0G2CT	DB02519	CTPDG013416
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	Investigative	D0S7IE	.	CTPDG013511
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Double Oxidized Cysteine	.	6398956	Investigative	D0H1GU	.	CTPDG013512
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00063	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	TG02	SB1317; 937270-47-8; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	Phase 1/2	D0P0KN	.	CTPDG013443
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AZD-5438	"602306-29-6; AZD5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	Phase 1	D06WHY	.	CTPDG005133
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	Phase 1	D07DTV	DB08142	CTPDG005118
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	Phase 1	D0PL7P	DB15425	CTPDG004504
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	Phase 1	D0S5RC	DB05969	CTPDG004433
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Fluorinated compound 1	PMID26161698-Compound-15	.	Patented	D09ISI	.	CTPDG013444
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"4-amino-3,5-di-substituted-thiazole derivative 1"	PMID26161698-Compound-54	.	Patented	D0JU4Z	.	CTPDG013445
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 11	PMID26161698-Compound-16	.	Patented	D02KWX	.	CTPDG013446
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	PMID26161698-Compound-27	73508010	Patented	D03EYT	.	CTPDG013447
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Alkyl sulfone derivative 1	PMID26161698-Compound-29	73672849	Patented	D05UJQ	.	CTPDG013448
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Aniline derivative 1	PMID26161698-Compound-33	59176838	Patented	D06QPW	.	CTPDG013449
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 1	PMID26161698-Compound-35	44253187	Patented	D07QIP	.	CTPDG013450
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-phenyl-pyrimidin-4-amine derivative 1	PMID26161698-Compound-30	74763288	Patented	D0AY5G	.	CTPDG013451
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID26161698-Compound-25	.	71618654	Patented	D0GQ7L	.	CTPDG013452
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diaryl amine derivative 1	PMID26161698-Compound-23	71515733	Patented	D0P4NP	.	CTPDG013453
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Flavopiridol analog 1	PMID26161698-Compound-5	86272549	Patented	D0P9WR	.	CTPDG013454
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	PMID26161698-Compound-31	73891126	Patented	D0QS2B	.	CTPDG013455
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Pyrazolo-triazine derivative 2	PMID26161698-Compound-14	71731909	Patented	D0T6CM	.	CTPDG013456
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"1,5-di-substituted pyridine derivative 1"	PMID26161698-Compound-26	60197050	Patented	D0UU0V	.	CTPDG013457
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	PMID26161698-Compound-28	74767011	Patented	D0V7RP	.	CTPDG013458
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Naphthyridine and isoquinoline derivative 1	PMID26161698-Compound-51	.	Patented	D08WJG	.	CTPDG013393
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 2	PMID26161698-Compound-36	71561915	Patented	D01CJE	.	CTPDG013394
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diamidothiazole derivative 1	PMID26161698-Compound-53	25256147	Patented	D0LR2Y	.	CTPDG013332
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrazolo[1,5-a]-1,3,5-triazine derivative 1"	PMID26161698-Compound-12	.	Patented	D0NB7Y	.	CTPDG013395
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Roscovitine derivative 1	PMID26161698-Compound-8	73353575	Patented	D07DUX	.	CTPDG013396
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 3	SCH 727965	Dinaciclib; SCH-727965	46926350	Discontinued in Phase 3	D0D3PX	DB12021	CTPDG013398
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	Preclinical	D0WS1V	DB02733	CTPDG007034
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	Olomoucine	"101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	Terminated	D00BPA	DB02116	CTPDG013399
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	Investigative	D01LPG	DB08134	CTPDG013460
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	Investigative	D03BZV	DB04607	CTPDG013461
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	Investigative	D06FIQ	DB07203	CTPDG013462
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BOHEMINE	189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	Investigative	D07ADR	.	CTPDG013463
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-phenyl-1H-pyrazole-3-carboxamide	"124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	Investigative	D07ODE	DB08135	CTPDG013464
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-hydroxynaphthalene-1-sulfonamide	"17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	Investigative	D07SGT	DB08132	CTPDG013465
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	Investigative	D0D3HB	DB08133	CTPDG013466
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	Investigative	D0I1SZ	DB08768	CTPDG013467
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	Investigative	D0I9VN	DB02603	CTPDG013468
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	Investigative	D0M5PI	.	CTPDG013469
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	Investigative	D0MK6D	DB02647	CTPDG013470
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	Investigative	D0P7RO	.	CTPDG013471
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	Investigative	D0QI7H	DB06948	CTPDG013472
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	Investigative	D0T4SJ	.	CTPDG007860
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	Investigative	D0T5AH	.	CTPDG007858
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	Investigative	D0U0GE	DB02091	CTPDG013473
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	Investigative	D0V1NK	.	CTPDG007806
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-Amino-6-Chloropyrazine	"33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	Investigative	D0W0PF	DB02297	CTPDG013474
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	Investigative	D0Y6DX	DB08233	CTPDG013475
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	Investigative	D01FJB	.	CTPDG013476
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	Investigative	D02ZYA	.	CTPDG013478
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	Investigative	D03XKK	.	CTPDG013480
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	JNJ-7706621	"443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	Investigative	D04NGS	.	CTPDG013404
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	GW-8510	.	3536	Investigative	D04RBG	.	CTPDG013482
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-265246	BMS 265246; BMS265246	135402864	Investigative	D05SZH	.	CTPDG013405
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	RESCOVITINE	CHEMBL1087791	46881287	Investigative	D07AEC	.	CTPDG013485
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	Investigative	D07JHG	.	CTPDG013486
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15"	5687	Investigative	D0KH5T	DB03365	CTPDG010119
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Oxindole 95	.	.	Investigative	D0MS4R	.	CTPDG013496
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	CVT-313	AC1OCFD4; NG 26	6918386	Investigative	D0P2WA	.	CTPDG013408
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	Investigative	D0R1FT	DB02407	CTPDG013497
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6027	.	398148	Investigative	D0U8YN	DB08312	CTPDG013498
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 8	SCHEMBL2991886; CHEMBL406102	24801181	Investigative	D01PEF	.	CTPDG013502
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Purvalanol A	Purvalanola; AC1L1JD0; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	Investigative	D07OAT	DB04751	CTPDG013410
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk1/2 inhibitor III	"443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664"	5330812	Investigative	D07OCA	DB07664	CTPDG013411
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 1	"341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	Investigative	D08KSQ	.	CTPDG013503
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 4	SCHEMBL3001373; CHEMBL406464	24801697	Investigative	D0B9YR	.	CTPDG013504
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Lysine Nz-Carboxylic Acid	N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	Investigative	D0CC0B	DB03801	CTPDG013505
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 6	CHEMBL406463; SCHEMBL2999009	24801185	Investigative	D0D0ZQ	.	CTPDG013506
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	Investigative	D0F0AX	.	CTPDG013412
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aminopurvalanol A	NG-97	6604931	Investigative	D0G2GA	.	CTPDG013413
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	9-Nitropaullone	"Alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	Investigative	D0H3EV	DB04014	CTPDG013414
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 5	"1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	Investigative	D0H6CQ	DB08182	CTPDG013507
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SU9516	"377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	Investigative	D0L3FK	DB03428	CTPDG013415
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 3	"954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	Investigative	D0S8VE	DB08178	CTPDG013508
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 2	"SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	Investigative	D0U1WL	.	CTPDG013509
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid"	3708	Investigative	D0G2CT	DB02519	CTPDG013416
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	Investigative	D0S7IE	.	CTPDG013511
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Double Oxidized Cysteine	.	6398956	Investigative	D0H1GU	.	CTPDG013512
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00064	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00069	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00081	Filamin-A (FLNA)	FLNA_HUMAN	.	.	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT00081	Filamin-A (FLNA)	FLNA_HUMAN	.	.	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT00082	Filamin-A (FLNA)	FLNA_HUMAN	.	.	Phase 2	PTI-125	"UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6"	46195331	Phase 2	D6ETD2	.	CTPDG001789
M6ACROT00082	Filamin-A (FLNA)	FLNA_HUMAN	.	.	Phase 1	PTI-125	.	.	Phase 1	D0X2HJ	.	CTPDG004292
M6ACROT00083	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Approved	E-2007	"Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one"	9924495	Approved	D0U3ED	DB08883	CTPDG012702
M6ACROT00083	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Phase 2	Paliroden	SR-57667; SR-57667B	11567682	Phase 2	D05KVC	DB05454	CTPDG012703
M6ACROT00083	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	ATPO	"252930-37-3; (R,S)-2-Amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid; 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid; ATPO, solid; AC1NECDZ; Lopac0_000092; SCHEMBL4318475; CHEMBL265301; GTPL4141; DTXSID70404915; MolPort-003-940-289; HMS3261F20; HMS3260C06; Tox21_500589; Tox21_500092; MFCD03452828; LP00092; LP00589; CCG-204187; NCGC00261274-01; NCGC00260777-01; NCGC00015093-05; NCGC00015093-02; NCGC00093594-01; NCGC00015093-04; NCGC00093594-02; NCGC00015093-03; EU-0100092; A 7845"	4615193	Investigative	D03VBJ	.	CTPDG012704
M6ACROT00083	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	(S)-5-fluorowillardiine	"5-Fluorowillardiine; (S)-(-)-5-fluorowillardiine; 140187-23-1; FLUORO-WILLARDIINE; (S)-F-Willardiine; 2-AMINO-3-(5-FLUORO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; CHEMBL123132; CHEBI:42549; 3-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; (S)-alpha-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimmidinepropanoic acid; 3-(5-fluorouracil-1-yl)-L-alanine; (2S)-2-amino-3-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propanoic acid; (S)-(-)-5-fluorowillardine"	126569	Investigative	D09LXQ	DB02966	CTPDG012705
M6ACROT00083	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	[3H]AMPA	"alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ampa; 74341-63-2; 77521-29-0; (RS)-AMPA; AMPA (pharmaceutical); CHEMBL13378; CHEBI:34018; 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo-; gamma-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; dl-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; (+-)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D,L-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid"	1221	Investigative	D0G1UE	.	CTPDG012706
M6ACROT00083	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	[3H]CNQX	"6-Cyano-7-nitroquinoxaline-2,3-dione; CNQX; 115066-14-3; 7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile; UNII-6OTE87SCCW; FG 9065; 6OTE87SCCW; FG-9065; 6-Cyano-2,3-dihydroxy-7-nitroquinoxaline; CHEBI:34468; 1,4-dihydro-2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile; 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-; ST50405216; 2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; FG9065; AC1MWAKF; Tocris-0190; Biomol-NT_000200"	3721046	Investigative	D0E5UQ	.	CTPDG012707
M6ACROT00084	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Approved	E-2007	"Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one"	9924495	Approved	D0U3ED	DB08883	CTPDG012702
M6ACROT00084	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Phase 2	Paliroden	SR-57667; SR-57667B	11567682	Phase 2	D05KVC	DB05454	CTPDG012703
M6ACROT00084	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	ATPO	"252930-37-3; (R,S)-2-Amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid; 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid; ATPO, solid; AC1NECDZ; Lopac0_000092; SCHEMBL4318475; CHEMBL265301; GTPL4141; DTXSID70404915; MolPort-003-940-289; HMS3261F20; HMS3260C06; Tox21_500589; Tox21_500092; MFCD03452828; LP00092; LP00589; CCG-204187; NCGC00261274-01; NCGC00260777-01; NCGC00015093-05; NCGC00015093-02; NCGC00093594-01; NCGC00015093-04; NCGC00093594-02; NCGC00015093-03; EU-0100092; A 7845"	4615193	Investigative	D03VBJ	.	CTPDG012704
M6ACROT00084	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	(S)-5-fluorowillardiine	"5-Fluorowillardiine; (S)-(-)-5-fluorowillardiine; 140187-23-1; FLUORO-WILLARDIINE; (S)-F-Willardiine; 2-AMINO-3-(5-FLUORO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; CHEMBL123132; CHEBI:42549; 3-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; (S)-alpha-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimmidinepropanoic acid; 3-(5-fluorouracil-1-yl)-L-alanine; (2S)-2-amino-3-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propanoic acid; (S)-(-)-5-fluorowillardine"	126569	Investigative	D09LXQ	DB02966	CTPDG012705
M6ACROT00084	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	[3H]AMPA	"alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ampa; 74341-63-2; 77521-29-0; (RS)-AMPA; AMPA (pharmaceutical); CHEMBL13378; CHEBI:34018; 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo-; gamma-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; dl-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; (+-)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D,L-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid"	1221	Investigative	D0G1UE	.	CTPDG012706
M6ACROT00084	Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2)	GRIA2_HUMAN	.	.	Investigative	[3H]CNQX	"6-Cyano-7-nitroquinoxaline-2,3-dione; CNQX; 115066-14-3; 7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile; UNII-6OTE87SCCW; FG 9065; 6OTE87SCCW; FG-9065; 6-Cyano-2,3-dihydroxy-7-nitroquinoxaline; CHEBI:34468; 1,4-dihydro-2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile; 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-; ST50405216; 2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; FG9065; AC1MWAKF; Tocris-0190; Biomol-NT_000200"	3721046	Investigative	D0E5UQ	.	CTPDG012707
M6ACROT00087	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 12"	SCHEMBL17669987; BDBM308061	121268883	Patented	D05GPF	.	CTPDG015018
M6ACROT00087	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 2"	SCHEMBL17669993; LHUVPYZTQHNXRU-UHFFFAOYSA-N; BDBM308050; 1-{2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothien-5-yl}-3-[4-chloro-3-(trifluoromethyl)phenyl]urea; 1-(2-(2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl)benzo[b]thiophen-5-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea	121268887	Patented	D0QZ4B	.	CTPDG015019
M6ACROT00087	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Patented	"US9650366, 9"	SCHEMBL17670002; OGVARLFWIBVKET-UHFFFAOYSA-N; BDBM308058; N-[3-({5-[2-(3-hydroxypropyl)-2H-tetrazol-5-yl]pyridin-3-yl}ethynyl)phenyl]-3-methyl-2-furamide	121268893	Patented	D0Z0BQ	.	CTPDG015020
M6ACROT00087	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	ASN-11124542	AC1O5VPR; ASN 11124542	6490494	Investigative	D0C1DQ	.	CTPDG015021
M6ACROT00087	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	indirubin derivative E804	indirubin E804; compound 2 [PMID: 21632247]	6419764	Investigative	D0N9DU	.	CTPDG015022
M6ACROT00087	Tyrosine-protein kinase EIF2AK2 (eIF2AK2/p68)	E2AK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	PMID26666870-Compound-16	.	.	Patented	D00KXJ	.	CTPDG014988
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 1	PMID26666870-Compound-17	.	Patented	D0FL0T	.	CTPDG014989
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 2	PMID26666870-Compound-18	.	Patented	D0II7X	.	CTPDG014990
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 1	PMID26666870-Compound-19	.	Patented	D00RRB	.	CTPDG014991
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 5	PMID26666870-Compound-23	.	Patented	D01BGG	.	CTPDG014992
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 7	PMID26666870-Compound-25	.	Patented	D04IFL	.	CTPDG014993
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 8	PMID26666870-Compound-26	.	Patented	D05NRG	.	CTPDG014994
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 9	PMID26666870-Compound-27	.	Patented	D09VIE	.	CTPDG014995
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 6	PMID26666870-Compound-24	.	Patented	D0J1RB	.	CTPDG014996
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 3	PMID26666870-Compound-21	.	Patented	D0TP0S	.	CTPDG014997
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 2	PMID26666870-Compound-20	.	Patented	D0WI1G	.	CTPDG014998
M6ACROT00092	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 4	PMID26666870-Compound-22	.	Patented	D0Z6IS	.	CTPDG014999
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	PMID26666870-Compound-16	.	.	Patented	D00KXJ	.	CTPDG014988
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 1	PMID26666870-Compound-17	.	Patented	D0FL0T	.	CTPDG014989
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 2	PMID26666870-Compound-18	.	Patented	D0II7X	.	CTPDG014990
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 1	PMID26666870-Compound-19	.	Patented	D00RRB	.	CTPDG014991
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 5	PMID26666870-Compound-23	.	Patented	D01BGG	.	CTPDG014992
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 7	PMID26666870-Compound-25	.	Patented	D04IFL	.	CTPDG014993
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 8	PMID26666870-Compound-26	.	Patented	D05NRG	.	CTPDG014994
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 9	PMID26666870-Compound-27	.	Patented	D09VIE	.	CTPDG014995
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 6	PMID26666870-Compound-24	.	Patented	D0J1RB	.	CTPDG014996
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 3	PMID26666870-Compound-21	.	Patented	D0TP0S	.	CTPDG014997
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 2	PMID26666870-Compound-20	.	Patented	D0WI1G	.	CTPDG014998
M6ACROT00093	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 4	PMID26666870-Compound-22	.	Patented	D0Z6IS	.	CTPDG014999
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	PMID26666870-Compound-16	.	.	Patented	D00KXJ	.	CTPDG014988
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 1	PMID26666870-Compound-17	.	Patented	D0FL0T	.	CTPDG014989
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 2	PMID26666870-Compound-18	.	Patented	D0II7X	.	CTPDG014990
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 1	PMID26666870-Compound-19	.	Patented	D00RRB	.	CTPDG014991
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 5	PMID26666870-Compound-23	.	Patented	D01BGG	.	CTPDG014992
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 7	PMID26666870-Compound-25	.	Patented	D04IFL	.	CTPDG014993
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 8	PMID26666870-Compound-26	.	Patented	D05NRG	.	CTPDG014994
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 9	PMID26666870-Compound-27	.	Patented	D09VIE	.	CTPDG014995
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 6	PMID26666870-Compound-24	.	Patented	D0J1RB	.	CTPDG014996
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 3	PMID26666870-Compound-21	.	Patented	D0TP0S	.	CTPDG014997
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 2	PMID26666870-Compound-20	.	Patented	D0WI1G	.	CTPDG014998
M6ACROT00094	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 4	PMID26666870-Compound-22	.	Patented	D0Z6IS	.	CTPDG014999
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Approved	Romiplostim	.	5329098	Approved	D01PZD	DB06436	CTPDG009981
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Phase 1	IK-175	.	.	Phase 1	D5D6ZM	.	CTPDG012891
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Phase 1	BAY 2416964	"2242464-44-2; BAY2416964; SCHEMBL20471217; BCP33103; EX-A4271; MFCD32693912; NSC825713; s8995; NSC-825713; BAY-2416964; HY-135829; CS-0114330; BAY-2416964;BAY2416964; ClC1=CC=C(C=C1)C=1C=C(C(N(N=1)C=1C=NN(C=1)C)=O)C(=O)N[C@H](CO)C; (S)-6-(4-Chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide"	135303769	Phase 1	DMVR61	.	CTPDG003814
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Clinical trial	AT-177	.	.	Clinical trial	DNEH27	.	CTPDG005479
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Preclinical	CB7993113	.	.	Preclinical	D49AGF	.	CTPDG007010
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Preclinical	"2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester"	.	.	Preclinical	DQ3NC4	.	CTPDG012892
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Investigative	"6-Formylindolo[3,2-b]carbazole"	"Indolo[3,2-b]carbazole-6-carbaldehyde; 1555757-10-2; indolo[3,2-b]carbazole-12-carbaldehyde; SCHEMBL528518; ANW-57186; MFCD23140892; ZINC39957465; AKOS015837457; AKOS025396684; FT-0678209"	22245026	Investigative	DFBJ28	.	CTPDG012893
M6ACROT00112	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Investigative	CH-223191	"301326-22-7; CH 223191; CH223191; UNII-HYE7315Z4C; HYE7315Z4C; CHEMBL1743245; AhR Antagonist; 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide; 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide; 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide; (E)-1-methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide; 1-methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide; 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide; CBDivE_007629; SCHEMBL363547; DTXSID5058698; AOB1977; EX-A771; SYN5007; CHEBI:125508; HMS3412G22; HMS3676G22; HMS3750E07; BCP12814; ZINC4762981; BDBM50525572; MFCD00377884; s7711; SBB081907; STK837883; 2-Methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azophenyl)-amide; AKOS000629906; AKOS026750492; ZINC100550218; ZINC254429865; CCG-267843; CS-3905; MCULE-3225752823; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-((2-methylphenyl)azo)phenyl)-; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-(2-(2-methylphenyl)diazenyl)phenyl)-; AC-32878; AS-16374; HY-12684; QC-11824; FT-0696668; X3558; J-017795; BRD-K22314899-001-01-6; Q27216129; Q27280162; 1-methyl-N-{2-methyl-4-[2-(2-methylphenyl)diazen-1-yl]phenyl}-1H-pyrazole-5-carboxamide; N-{2-methyl-4-[(2-methylphenyl)diazenyl]phenyl}(1-methylpyrazol-5-yl)carboxami de"	3091786	Investigative	DL36FJ	.	CTPDG007596
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Approved	Arsenic trioxide	Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)	14888	Approved	D07VIK	.	CTPDG013366
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Phase 2	SAR-113945	S-0100229; S-0100658	.	Phase 2	D0AE3U	.	CTPDG013367
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Phase 2	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	Phase 2	D0V3CK	.	CTPDG001968
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Phase 2	Parthenolide	"20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, &gt; MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21"	7251185	Phase 2	D0M4KE	.	CTPDG013368
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Phase 1	IMD-0354	"IMD-2560; IMD-2560); I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign; I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD; IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD; IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD"	5081913	Phase 1	D0Z5DM	.	CTPDG013369
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Discontinued in Phase 1	MLN0415	SCHEMBL3805703	86630595	Discontinued in Phase 1	D06ZYC	.	CTPDG006872
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	5-amino-2-phenyl-oxazole-4-carboxylic acid amide	CHEMBL207987; 5-amino-2-phenyloxazole-4-carboxylic acid amide; 99185-68-9	11708263	Investigative	D00XDG	.	CTPDG013370
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide	"5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide; CHEMBL382993; CTK6B8237; MolPort-000-894-518; SBB024037; BDBM50186628; STK351079; ZINC12394806; AKOS000313592; MCULE-2038651256"	11543063	Investigative	D01FPX	.	CTPDG013371
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	3-amino-benzo[b]thiophene-2-carboxylic acid amide	"3-amino-1-benzothiophene-2-carboxamide; 37839-59-1; 3-Aminobenzo[b]thiophene-2-carboxamide; CHEMBL211002; Benzo[b]thiophene-2-carboxamide, 3-amino-; 3-aminobenzo[b]thiophene-2-carboxylic acid amide; AC1LGIJV; SCHEMBL6609258; CTK1B5350; DTXSID80356350; MolPort-002-798-643; ZINC339150; STL134701; BDBM50186634; AKOS001782516; CCG-127335; MCULE-9206749194; NE38914; EN300-88534"	821974	Investigative	D03PVS	.	CTPDG013372
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	2-amino-5-phenylthiophene-3-carboxamide	"4815-35-4; 2-Amino-5-phenyl-thiophene-3-carboxylic acid amide; CHEMBL382565; 2-AMINO-5-PHENYL-3-THIOPHENECARBOXAMIDE; EN300-04586; AC1LDZKQ; ACMC-209kch; 3-thiophenecarboxamide, 2-amino-5-phenyl-; AC1Q5DNT; CBMicro_037044; Cambridge id 5914467; AC1Q4Z6N; Oprea1_326775; Oprea1_445444; SCHEMBL3510525; ZINC87504; CTK4J0691; DTXSID60351580; UHEGYTDIDBFUJD-UHFFFAOYSA-N; MolPort-000-223-057; HMS1757A19; ZX-AL001522; ANW-30639; STK346852; SBB015475; BDBM50186655; AKOS000274130; ACM4815354"	703965	Investigative	D06CBR	.	CTPDG013373
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide	"175137-05-0; CHEMBL444884; 515142-45-7; 2-Thiophenecarboxamide,3-amino-5-(4-chlorophenyl)-; AC1MBTGN; 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxamide; SCHEMBL4097325; CTK4D5319; DTXSID90373351; MQYJPACEBWKWEH-UHFFFAOYSA-N; MolPort-000-150-990; ZX-AT016871; ZINC2556119; SBB101177; BDBM50186632; 5704AD; AKOS022181810; AJ-39853; ACM175137050; RT-019539; FT-0704094; 3-Amino-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid amide"	2756390	Investigative	D08VQM	.	CTPDG013374
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	"6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine"	"CHEMBL311108; CTK7E1320; ZINC13588156; BDBM50137196; AKOS015965750; 6-phenylthieno[3,2-d]pyrimidin-4-ylamine"	11499583	Investigative	D09PLJ	.	CTPDG013375
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	2-amino-quinoline-3-carboxylic acid amide	"2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463"	5200228	Investigative	D0N1UB	.	CTPDG013376
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	SC-514	"354812-17-2; Sc 514; SC514; 4-Amino-[2,3'-bithiophene]-5-carboxamide; 3-amino-5-(thiophen-3-yl)thiophene-2-carboxamide; CHEMBL193093; IKK-2 Inhibitor, SC-514; 5-(Thien-3-yl)-3-aminothiophene-2-carboxamide; C9H8N2OS2; GK 01140; Curator_000007; 4-Amino-[2,3-bithiophene]-5-carboxamide; BiomolKI_000076; BiomolKI2_000080; AC1MD9M6; 3-amino-5-thiophen-3-ylthiophene-2-carboxamide; Oprea1_591652; SCHEMBL4082097; KS-00000XLB; CHEBI:92464; ZINC81904; CTK8E9458; BDBM26098; SYN5231"	2807869	Investigative	D0T6VA	.	CTPDG013377
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	4-amino-biphenyl-3-carboxylic acid amide	"CHEMBL207940; 5-phenylanthranilamide; 2-amino-5-phenylbenzamide; SCHEMBL3781950; Amino-substituted benzamide, 8c; BDBM27462; ZINC13686738"	11600944	Investigative	D0UP6G	.	CTPDG013378
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	Staurosporine	"Staurosporin; (+)-Staurosporine; Antibiotic 230; 62996-74-1; Antibiotic AM 2282; CCRIS 3272; AM-2282; UNII-H88EPA0A3N; Alkaloid AM-2282 from Streptomyces; H88EPA0A3N; CHEMBL388978; CHEBI:15738; CGP 39360; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-"	44259	Investigative	D0E3TC	DB02010	CTPDG013379
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	5-Bromo-6-methoxy-9H-beta-carboline	5-bromo-6-methoxy-beta-carboline; CHEMBL310975; SCHEMBL6465779; BDBM50130233	11414735	Investigative	D01OBJ	.	CTPDG013380
M6ACROT00114	Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	IKKB_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Phase 2	RG7625	"Petesicatib; UNII-A26QO95U37; A26QO95U37; RG-7625; RO-5459072; Petesicatib [INN]; SCHEMBL700776; GTPL9855; KXAAIORSMACJSI-AEFFLSMTSA-N; RO5459072; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; 1252637-35-6; (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; (2s,4r)-4-[4-(1-me"	59543597	Phase 2	D0DQ2D	DB15297	CTPDG014106
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Phase 1	VBY- 891	VBY-891	.	Phase 1	D01REJ	.	CTPDG014107
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Phase 1	VBY- 036	VBY-036	.	Phase 1	D07ODC	.	CTPDG014108
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Phase 1	VBY-129	"Cathepsin S inhibitor (oral, psoriasis), Virobay"	.	Phase 1	D07UKF	.	CTPDG005081
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Phase 1	SAR-114137	.	9828551	Phase 1	D08KIB	.	CTPDG013693
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	Phenylalanine derivative 1	PMID27998201-Compound-21	.	Patented	D01MKD	.	CTPDG014067
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-7	.	73294953	Patented	D0JD5W	.	CTPDG014068
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-15	.	.	Patented	D0MR9V	.	CTPDG013696
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	PMID27998201-Compound-14	44229370	Patented	D0QM0D	.	CTPDG013697
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-6	.	.	Patented	D0X1AF	.	CTPDG014069
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-17	.	.	Patented	D06XTA	.	CTPDG014070
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID25399719-Compound-17	.	.	Patented	D06LLT	.	CTPDG013698
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Patented	PMID27998201-Compound-12	.	.	Patented	D06XCD	.	CTPDG006131
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Discontinued in Phase 1	RG-7236	RG7236	.	Discontinued in Phase 1	D0D3KG	.	CTPDG014109
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Preclinical	RO5461111	.	.	Preclinical	DC9J1Y	.	CTPDG014110
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Preclinical	L-006235-1	"294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235"	9912381	Preclinical	D0Z0PR	.	CTPDG013703
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Terminated	CRA-028129	.	.	Terminated	D0K0IW	.	CTPDG007306
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	6-(3-(trifluoromethyl)phenyl)picolinonitrile	"CHEMBL1210691; 833457-45-7; SCHEMBL9954071; CTK3D2833; DTXSID80678807; BDBM50322920; 6-[3-(Trifluoromethyl)phenyl]pyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 6-[3-(trifluoromethyl)phenyl]-"	49863205	Investigative	D01IFO	.	CTPDG014111
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-Phe-Ala-LeuVSMe	CHEMBL207284	11534772	Investigative	D01NCW	.	CTPDG014112
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide	CHEMBL1288588	52945617	Investigative	D02FPU	.	CTPDG014113
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-Pro-Ala-LeuVSMe	CHEMBL207670	11505372	Investigative	D05MDE	.	CTPDG014114
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile	"dipeptide-derived nitrile, 38; CHEMBL200338; BDBM20117"	11652399	Investigative	D07SOQ	.	CTPDG014115
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	AM-3840	"Cathepsin S inihibitors (oral, autoimmune disease/pain), Amura"	.	Investigative	D08WDP	.	CTPDG014116
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Ac-hPhe-Leu-Gly-LeuVSMe	CHEMBL209243	11713852	Investigative	D09GZQ	.	CTPDG014117
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-t-ButylGln-Ala-LeuVSMe	CHEMBL438612	11621748	Investigative	D09IMK	.	CTPDG014118
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-MetO2-Ala-LeuVSMe	CHEMBL383730	11585523	Investigative	D0B3US	.	CTPDG014119
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Fsn-0503	"Cathepsin S mAb (cancer), Fusion"	.	Investigative	D0G3PK	.	CTPDG008275
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	VBY- 285	"VBY-285; Cathepsin S inhibitor (neuropathic pain, oral), Virobay"	.	Investigative	D0J0HV	.	CTPDG014120
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Glu(OtBu)-Ala-LeuVSMe	CHEMBL208015	11621207	Investigative	D0K0KT	.	CTPDG014121
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	"2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL"	TF5	46937163	Investigative	D0M8WX	DB08611	CTPDG014122
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	BF/PC-18	"PC18-BF; Cathepsin S inhibitor (inflammation), Biofrontera"	.	Investigative	D0P5RJ	.	CTPDG014123
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-hPhe-Ala-LeuVSMe	CHEMBL446443	11714476	Investigative	D0RL4S	.	CTPDG014124
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	JNJ-10329670	"Cathepsin S inhibitors (autoimmune disease); Cathepsin S inhibitors (autoimmune disease), J&J PRD; Cathepsin S inhibitors (autoimmune disease), Johnson & Johnson"	10168449	Investigative	D0V5LJ	.	CTPDG014125
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Clik60	.	.	Investigative	D0Y8LO	.	CTPDG014126
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile	CHEMBL1077194	46881498	Investigative	D01JGB	.	CTPDG013721
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	4-propyl-6-m-tolylpyrimidine-2-carbonitrile	CHEMBL1082859; SCHEMBL4453859	46881451	Investigative	D04BGT	.	CTPDG013726
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Ac-hPhe-Leu-Ala-LeuVSMe	CHEMBL207579	11556056	Investigative	D05VEV	.	CTPDG014127
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	"P2,P3 Ketoamide derivative"	CHEMBL186650; SCHEMBL14260244; AAYZJXOZLLKNGZ-DEOSSOPVSA-N; BDBM50152530	10129151	Investigative	D05WZF	.	CTPDG013727
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Ac-hPhe-Leu-Phe-LeuVSMe	CHEMBL379669; BDBM50186702	11693148	Investigative	D06NEB	.	CTPDG014128
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	PMID22686657C(R)-26	GTPL6535; BDBM50392215	60148519	Investigative	D06WQP	.	CTPDG014129
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile	"dipeptide-derived nitrile, 6; CHEMBL383816; BDBM20086; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]butyl]carbamate"	11514386	Investigative	D0A7ER	.	CTPDG013731
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-Leu-Ala-LeuVSMe	CHEMBL207403	11534625	Investigative	D0I0MU	.	CTPDG014130
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile	"dipeptide-derived nitrile, 23; CHEMBL371893; BDBM20102; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamate"	11551481	Investigative	D0JF8D	.	CTPDG014085
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	CHEMBL207196	11513217	Investigative	D0QY3R	.	CTPDG014131
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile	CHEMBL1085423; SCHEMBL5796281	11694425	Investigative	D0U4TY	.	CTPDG013737
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	"dipeptide-derived nitrile, 9; CHEMBL197113; BDBM20088; tert-butyl N-[(1S,2R)-1-[(cyanomethyl)carbamoyl]-2-methylbutyl]carbamate"	23648531	Investigative	D01YNC	.	CTPDG013738
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	"N-(tert-butoxycarbonyl)-L-valyl-glycine-nitrile; 191033-03-1; dipeptide-derived nitrile, 5; CHEMBL200004; BDBM20085; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-methylpropyl]carbamate"	14774521	Investigative	D06VIP	.	CTPDG013739
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	"dipeptide-derived nitrile, 13; CHEMBL383584; BDBM20092; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]pentyl]carbamate"	11637576	Investigative	D07FLB	.	CTPDG013740
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 44; CHEMBL200235; BDBM20120"	11696652	Investigative	D07RSA	.	CTPDG013741
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	"dipeptide-derived nitrile, 7; CHEMBL200160; SCHEMBL6257676; BDBM20087; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate"	11492732	Investigative	D09AHN	.	CTPDG013742
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-acetyl-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 42; CHEMBL197181; SCHEMBL15634553; BDBM20118; ITHLBMBCVIAAIX-LBPRGKRZSA-N; ZINC13676602; (N-acetyl-l-phenylalanyl)aminoacetonitrile; SR-03000002938; SR-03000002938-1; (S)-2-Acetamido-N-(cyanomethyl)-3-phenylpropanamide"	11086036	Investigative	D0A8OV	.	CTPDG013743
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	"dipeptidyl nitrile, 1; Cbz-Leu-NH-CH2-CN; JMC487688 Compound 8; CHEMBL200161; SCHEMBL6183068; BDBM19768; UFXQLUZNMRVTPU-AWEZNQCLSA-N; 2-[(Z-L-Leu-)Amino]ethanenitrile; benzyl (S)-1-cyanomethylcarbamoyl-3-methylbutylcarbamate; benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate"	11702208	Investigative	D0G8OD	.	CTPDG013744
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-benzoyl-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 43; SCHEMBL5517755; CHEMBL371466; BDBM20119"	11702265	Investigative	D0JN8Q	.	CTPDG013745
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	"dipeptide-derived nitrile, 12; CHEMBL381847; BDBM20091; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-(methylsulfanyl)propyl]carbamate"	11709032	Investigative	D0U0XG	.	CTPDG013746
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	E-64	66701-25-5; CHEMBL189382; AC1NEEQI; SCHEMBL13283063; HMS3369L13; trans-Epoxysuccinyl-leucylamido-[4-guanidino]butane; [L-3-trans-carboxy-oxiran-2-carbonyl]-Leu-agmatin; trans-Epoxysuccinyl-leucylamido- [4-guanidino]butane; [L -3-trans-carboxy- oxiran-2-carbonyl]-Leu-agmatin; 3-({1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl}carbamoyl)oxirane-2-carboxylic acid; 3-[[1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid	123985	Investigative	D09FGQ	.	CTPDG014132
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	L-873724	"UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	Investigative	D0D0LD	.	CTPDG008390
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	GNF-PF-5434	"CHEMBL486232; N~2~-(MORPHOLIN-4-YLCARBONYL)-N~1~-[(1S,2E)-1-(2-PHENYLETHYL)-3-(PHENYLSULFONYL)PROP-2-ENYL]-D-LEUCINAMIDE; MORPHOLINE-4-CARBOXYLIC ACID (1-(3-BENZENESULFONYL-1-PHENETHYLALLYLCARBAMOYL)-3-METHYLBUTYL)-AMIDE; N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide; AC1NRAGB; SCHEMBL7352997; BDBM50243232; K-11017; 4-Morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-"	5287864	Investigative	D0L9VP	.	CTPDG013748
M6ACROT00120	Cathepsin S (CTSS)	CATS_HUMAN	.	.	Investigative	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	Investigative	D0G6XS	.	CTPDG010555
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Approved	Trimethoprim	Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN]	5578	Approved	D0AO5H	DB00440	CTPDG011304
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Approved	Leucovorin Calcium	Leucovorin Calcium Preservative Free; Wellcovorin	135403647	Approved	D0B6TW	.	CTPDG000453
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Approved	Methotrexate Sodium	Methotrexate disodium salt; 7413-34-5; Sodium methotrexate; MTX disodium; methotrexate disodium; UNII-3IG1E710ZN; 3IG1E710ZN; CHEBI:50679; Amethopterin sodium; Disodium methotrexate; Methotrexat dinatrium; Mexate-Aq Preserved; Methotrexate sodium salt; EINECS 231-022-0; 59-05-2 (Parent); Methotrexate Preservative Free; 4-Amino-N(sup 10)-methylpteroylglutamic acid disodium salt; METHOTREXATE SODIUM PRESERVATIVE FREE	11329481	Approved	D0D3DU	.	CTPDG000425
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Approved	Aminosalicylic Acid	"4-Aminosalicylic acid; 65-49-6; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium"	4649	Approved	D01WJL	DB00233	CTPDG011305
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Application submitted	Iclaprim	"192314-93-5; AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; RO-48-2622; Mersarex; 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine; Iclaprim [USAN:INN]; Iclaprim (USAN/INN); 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; AR 100; AC1Q4WM5; SCHEMBL379386; CHEMBL134561; AC1L4U54; SCHEMBL12899446; CTK4E0971; BDBM18070; Iclaprim [INN]; AR-102; AR-100001; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine"	213043	Application submitted	D04LBC	DB06358	CTPDG001423
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Phase 2	CH-4051	.	11532464	Phase 2	D02OTK	.	CTPDG002967
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Phase 2	PIRITREXIM	"72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	Phase 2	D09AYQ	DB03695	CTPDG002591
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Phase 1	MDAM (y-methylene-10-deazaaminopterin)	.	.	Phase 1	D0DO5J	.	CTPDG004846
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Phase 1	L-MDAM	"176857-41-3; UNII-W9CXL7O6LL; W9CXL7O6LL; GAMMA-METHYLENE-10-DEAZAAMINOPTERIN; MDAM; SCHEMBL1065136; ZINC1542008; KB-78169; Z-3290; L-Glutamic acid, N-(4-(2-(2,4-diamino-6-pteridinyl)ethyl)benzoyl)-4-methylene-; (2S)-2-[4-[2-(2,4-Diamino-6-pteridinyl)ethyl]benzoylamino]-4-methyleneglutaric acid"	9803852	Phase 1	D0S9OH	.	CTPDG004424
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Phase 1	VYR 006	.	.	Phase 1	D9ZQ7T	.	CTPDG011307
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Discontinued in Phase 2	TNP-351	"N-[4-[3-(2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid"	5487322	Discontinued in Phase 2	D00CQW	.	CTPDG006679
M6ACROT00123	Dihydrofolate reductase (DHFR)	DYR_HUMAN	.	.	Preclinical	1954U89	.	177894	Preclinical	D05HCO	.	CTPDG007136
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00124	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Approved	ISIS 1570	.	.	Approved	D00OTT	.	CTPDG012320
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Phase 3	Alicaforsen	"Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)"	16197725	Phase 3	D0P9BT	.	CTPDG012321
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Terminated	INXC-ICAM1	"Antisense ICAM-1-TCS, Inex; ICAM-1 antisense (inflammation), INEX; Transmembrane carrier system (antisense ICAM-1), Inex; Antisense (ICAM-1, inflammation), INEX"	.	Terminated	D0M0UV	.	CTPDG012322
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 11159	.	.	Investigative	D00FAL	.	CTPDG012323
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 3224	.	.	Investigative	D02TKV	.	CTPDG012324
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 1931	.	.	Investigative	D02ZMH	.	CTPDG012325
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	PIPERROLEIN B	"Piperolein B; Piperoleine B; 30505-89-6; CHEMBL256214; MEGxp0_000205; SCHEMBL15471329; ACon1_000259; FAXXHNWVMKTOFF-UXBLZVDNSA-N; MCULE-4025815326; NCGC00180733-01; BRD-K04771916-001-01-8; Piperidine, 1-[(8E)-9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-; (8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-[3,4-(methylenedioxy)phenyl]-8-nonenoyl]-, (E)-; (E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-, ("	21580213	Investigative	D03YAG	.	CTPDG012326
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 2974	.	.	Investigative	D06SDT	.	CTPDG012327
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	Dehydropipernonaline	"107584-38-3; Dehydropipernoline; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl]-, (E,E,E)-; Piperidine, 1-(9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl)-, (E,E,E)-; AC1O5SQM; CHEMBL483708; MolPort-039-101-180; KAYVDASZRFLFRZ-PQECNABGSA-N; N-(9-(3,4-Methylenedioxyphenyl)-2,4,8-nonatrienoyl)piperidine; ZINC14658239; 9-(3,4-Methylenedioxy)-2,4,8-nonatrienoic acid piperidide; (2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one; Piperidine, 1-[(2E,4E,8E)-9-(1"	6439947	Investigative	D0H0FG	.	CTPDG012328
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 3067	.	.	Investigative	D0J1FW	.	CTPDG012329
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 11665	.	.	Investigative	D0K7HI	.	CTPDG012330
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	PIPERNONALINE	"CHEMBL450332; PKLGRWSJBLGIBF-JMQWPVDRSA-N; MolPort-006-668-470; ZINC14658236; Pipernonaline, &gt; 9-(3,4-Methylenedioxyphenyl)-2,8-nonadienoic acid piperidide; 1-[9-(1,3-Benzodioxol-5-yl)-1-oxo-2,8-nonadienyl]piperidine, 9CI; (2E,8E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one; (2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one"	9974595	Investigative	D0S2UZ	.	CTPDG012331
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS 11158	.	.	Investigative	D0V8KH	.	CTPDG012332
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	Pellitorin	"Pellitorine; 18836-52-7; trans-Pellitorin; (E,E)-N-(2-Methylpropyl)-2,4-decadienamide; (E,E)-N-Isobutyl-2,4-decadienamide; N-Isobutyldeca-trans-2,trans-4-dienamide; UNII-8IS5231171; 2,4-DECADIENAMIDE, N-ISOBUTYL-, (E,E)-; 2,4-Decadienamide, N-(2-methylpropyl)-, (E,E)-; BRN 1725967; AI3-19560; CHEBI:69686; MAGQQZHFHJDIRE-BNFZFUHLSA-N; Pellitorine (6CI); 2,4-Decadienamide, N-(2-methylpropyl)-, (2E,4E)-; 8IS5231171; (2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide; N-(2-Methylpropyl)-2,4-Decadienamide; Optaflow A"	5318516	Investigative	D0ZH9W	.	CTPDG012333
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	A-286982	"280749-17-9; UNII-5I8WFS075A; A 286982; CHEMBL19677; 5I8WFS075A; C24H27N3O4S; (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one; SCHEMBL5829786; GTPL6592; SCHEMBL12063498; AOB1772; SYN5060; MolPort-023-277-110; ZINC602716; BDBM50092956; AKOS024458044; API0010263; Piperazine, 1-acetyl-4-((2E)-3-(4-((2-(1-methylethyl)phenyl)thio)-3-nitrophenyl)-1-oxo-2-propenyl)-; (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one; AS-16426"	9846729	Investigative	D07XCA	.	CTPDG012334
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Approved	lifitegrast	"Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; SAR-1119; SHP606; SPD606"	11965427	Approved	D0Q9EV	DB11611	CTPDG012366
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Phase 3	Alicaforsen	"Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)"	16197725	Phase 3	D0P9BT	.	CTPDG012321
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Phase 2	APC-8015F	"CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon"	.	Phase 2	D0XH8X	.	CTPDG012367
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Phase 1	AIC100	.	.	Phase 1	DP0NU9	.	CTPDG003776
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Terminated	A-252444.0	A-155918; A-205804; A-241548	.	Terminated	D09GGO	.	CTPDG012368
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Terminated	MOR-102	"MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys"	.	Terminated	D0M8JF	.	CTPDG007279
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Terminated	GI-270384X	.	.	Terminated	D0RR4T	.	CTPDG012369
M6ACROT00125	Intercellular adhesion molecule 1 (ICAM1)	ICAM1_HUMAN	.	.	Investigative	ISIS-1939	136216-59-6	.	Investigative	D02BRA	.	CTPDG012370
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 3792	.	.	Investigative	D02TPS	.	CTPDG015425
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 3801	.	.	Investigative	D02WXX	.	CTPDG015426
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	SYMBIOPOLYOL	.	46872950	Investigative	D04RGN	.	CTPDG015427
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 5876	.	.	Investigative	D08YCI	.	CTPDG015428
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 5875	.	.	Investigative	D0A7AV	.	CTPDG015429
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 3804	.	.	Investigative	D0A7SE	.	CTPDG015430
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 5884	.	.	Investigative	D0J7IV	.	CTPDG015431
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 3805	.	.	Investigative	D0P3FU	.	CTPDG015432
M6ACROT00126	Vascular cell adhesion protein 1 (VCAM1)	VCAM1_HUMAN	.	.	Investigative	ISIS 5874	.	.	Investigative	D0R5NX	.	CTPDG015433
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 3	RG7388	"Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	Phase 3	D0OC4O	DB12325	CTPDG001098
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 2	AMG 232	KRT-232	58573469	Phase 2	D0C1WR	DB15299	CTPDG002493
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 2	ALRN-6924	.	.	Phase 2	D07UKT	.	CTPDG013838
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 1/2	ASTX295	.	.	Phase 1/2	DE7N6F	.	CTPDG003183
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 1	DS-3032	.	.	Phase 1	D08JSQ	.	CTPDG005049
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 1	RG7775	.	.	Phase 1	D08TNG	.	CTPDG005030
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 1	JNJ-26854165	"Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474"	11609586	Phase 1	D0B3GF	DB12027	CTPDG004922
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 1	BI 907828	.	.	Phase 1	DW3AX4	.	CTPDG003678
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	MI-219	"CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide"	24877503	Investigative	DNY16U	.	CTPDG013839
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	ISIS 16518	.	.	Investigative	D02JFF	.	CTPDG009023
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	PLSQETFSDLWKLLPEN-NH2	CHEMBL267823	44412124	Investigative	D08YAF	.	CTPDG015271
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	NSC-66811	NSC 66811; 6964-62-1; 2-METHYL-7-[PHENYL(PHENYLAMINO)METHYL]-8-QUINOLINOL; 7-[anilino(phenyl)methyl]-2-methylquinolin-8-ol; 7-(Anilino(phenyl)-methyl)-2-methyl-8-quinolinol; 2-methyl-7-(phenyl(phenylamino)methyl)quinolin-8-ol; 8-Hydroxy-2-methyl-7-[phenyl(phenylamino)methyl]quinoline; NSC66811; AC1L6NIN; AC1Q79MP; 7-(anilino(phenyl)methyl)-2-methyl-8-quinolinol; SCHEMBL1241576; CHEMBL210778; BDBM31206; CTK5D0724; DTXSID30290119; MolPort-008-431-978; BCP07490; 2152AH; AKOS003020553; AKOS016050521; AK260645; M2390	248986	Investigative	D0C0TN	.	CTPDG015272
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	ISIS 16507	.	.	Investigative	D0Y3JR	.	CTPDG007671
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00127	E3 ubiquitin-protein ligase Mdm2 (Mdm2)	MDM2_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 2	ASTX660	"YCXOHEXZVKOGEV-DNRQZRRGSA-N; 1799328-86-1; SCHEMBL16830758; CS-8216; HY-109565; 1-(6-(4-fluorobenzyl)-5-(hydroxymethyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2R,5R)-5-methyl-2-(((R)-3-methylmorpholino)methyl)piperazin-1-yl)ethan-1-one"	118169620	Phase 2	D01NUR	.	CTPDG003022
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 1/2	AEG35156	.	.	Phase 1/2	D0C1JP	.	CTPDG003464
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Terminated	EMBELIN	"550-24-3; Embelic acid; Emberine; 2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione; 2,5-Dihydroxy-3-undecyl-1,4-benzoquinone; 2,5-Dihydroxy-3-undecyl-p-benzoquinone; 2,5-Dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione; UNII-SHC6U8F5ER; CHEBI:4778; Embelin, Embelia ribes; C17H26O4; NSC91874; XIAP inhibitor, Embelin; EINECS 208-979-8; NSC 91874; SHC6U8F5ER; BRN 1885786; Apoptosis Activator III, Embelin; AK115155; p-Benzoquinone, 2,5-dihydroxy-3-undecyl-; SR-01000597536; Spectrum_001513; Tocris-2156; SpecPlus_000501"	3218	Terminated	D05HSW	.	CTPDG014391
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	ARPFAQK-FAM	CHEMBL441156	44460581	Investigative	D09BKS	.	CTPDG014392
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	AVPIAQKSEK-FAM	CHEMBL404788	44460469	Investigative	D0E7NV	.	CTPDG014393
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	SM-337	"CHEMBL504559; GTPL7732; SCHEMBL12851753; BDBM50273699; (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-3-(2-phenylacetyl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide"	25172871	Investigative	D03KZH	.	CTPDG014394
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	SM-131	CHEMBL514738	44589292	Investigative	D0BW7P	.	CTPDG014395
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	BV-6	BV6	23657864	Investigative	D0O4UQ	.	CTPDG014396
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	SM-122	"CHEMBL481422; Smac peptide mimetic 20; GTPL8855; SCHEMBL12105346; BDBM26218; bicyclic Smac peptide mimetic, 20; (3S,6S,10aS)-N-benzhydryl-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-2,3,6,7,8,9,10,10a-octahydro-1H-pyrrolo[1,2-a]azocine-3-carboxamide"	24754886	Investigative	D0Q7TL	.	CTPDG014397
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Investigative	AZD5582	AZD 5582; AZD-5582	49847690	Investigative	D0VK7M	.	CTPDG014398
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 3	AT-406	"1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143"	25022340	Phase 3	D03MXK	.	CTPDG014522
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 1/2	Birinapant	"1260251-31-7; Birinapant (TL32711); TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide"	49836020	Phase 1/2	D0E8NP	DB11782	CTPDG002416
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 1/2	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	Phase 1/2	D03YOS	DB04915	CTPDG003583
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 1	HGS-1029	"AEG-40056; AEG-40057; AEG-40706; AEG-40730; AEG-40826; XIAP antagonists (anticancer), Aegera; Inhibitor of apoptosis (IAP) protein antagonists (cancer), Aegera/HGS; XIAP antagonists (small molecule, cancer), Aegera/HGS; Inhibitory apoptosis protein (IAP) antagonists (apoptosis stimulators, cancer), Aegera/HGS"	.	Phase 1	D02AMG	.	CTPDG005368
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 1	GDC-0152	GDC 0152; GDC0152	46940575	Phase 1	D07CLV	DB12380	CTPDG005122
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Phase 1	APG-1387	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706	73336238	Phase 1	D0NP8P	.	CTPDG004564
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-40	.	76282560	Patented	D00VXV	.	CTPDG014524
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-29	.	90155550	Patented	D01JEH	.	CTPDG014525
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-15	.	.	Patented	D03JHD	.	CTPDG014526
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-31	.	.	Patented	D03TQU	.	CTPDG014527
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-30	.	73603510	Patented	D08UPQ	.	CTPDG014528
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-14	.	.	Patented	D0EZ9G	.	CTPDG014529
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-39	.	76283048	Patented	D0G9CR	.	CTPDG014530
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-33	.	.	Patented	D0K2PK	.	CTPDG014531
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-28	.	.	Patented	D0NB0V	.	CTPDG014532
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-10	.	46175910	Patented	D0P9PZ	.	CTPDG014533
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-11	.	.	Patented	D0PF7S	.	CTPDG014534
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-32	.	72710867	Patented	D0Q1XF	.	CTPDG014535
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-26	.	.	Patented	D0S0XT	.	CTPDG014536
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-13	.	73296970	Patented	D0U5TX	.	CTPDG014537
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-12	.	.	Patented	D0UT1G	.	CTPDG014538
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-45	.	56924622	Patented	D0UU7G	.	CTPDG014539
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-3	.	90126716	Patented	D02UOD	.	CTPDG014540
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-4	.	.	Patented	D02ZHC	.	CTPDG014541
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-21	.	49818910	Patented	D03DQW	.	CTPDG014542
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-42	.	.	Patented	D03PTG	.	CTPDG014543
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-22	.	53239649	Patented	D03VPP	.	CTPDG014544
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-37	.	57389344	Patented	D07FRU	.	CTPDG014545
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-36	.	.	Patented	D0AC8H	.	CTPDG014546
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-20	.	67478013	Patented	D0CV9K	.	CTPDG014547
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-38	.	.	Patented	D0GF3P	.	CTPDG014548
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-5	.	.	Patented	D0ID3R	.	CTPDG014549
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-41	.	.	Patented	D0M3BY	.	CTPDG014550
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-19	.	.	Patented	D0MH4B	.	CTPDG014551
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-7	.	.	Patented	D0O8ZD	.	CTPDG014552
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-6	.	58491512	Patented	D09VAX	.	CTPDG014553
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-27	.	49847690	Patented	D0B6KC	.	CTPDG014554
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-43	.	52919959	Patented	D0HY5Q	.	CTPDG014555
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-1	.	68265428	Patented	D0R3YM	.	CTPDG014556
M6ACROT00128	X-linked inhibitor of apoptosis (XIAP)	XIAP_HUMAN	.	.	Patented	PMID25980951-Compound-44	.	71661892	Patented	D0YN1X	.	CTPDG014557
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00129	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	BI-853520	.	.	Phase 1	D00KNI	.	CTPDG005456
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	PF-562271	PF-00562271	11713159	Phase 1	D01SJT	.	CTPDG005383
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	VS-4718	PND-1186	25073775	Phase 1	D0A6VD	DB15273	CTPDG004942
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	GSK-2256098	"Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline"	46214930	Phase 1	D0B9MR	.	CTPDG004911
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	CEP-37440	"Dual ALK/FAK inhibitor (cancer), Cephalon; Dual anaplastic lymphoma kinase/focal adhesion kinase inhibitor (cancer),Cephalon"	71721648	Phase 1	D0N6NM	DB13060	CTPDG004580
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	IN10018	.	.	Phase 1	D1EW3O	.	CTPDG014242
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Patented	"1,2,4-triazolo[1,5a]pyridine derivative 1"	PMID27774824-Compound-Figure8compoundA	.	Patented	D07XYI	.	CTPDG009392
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Investigative	PMID23414845C30	4i4f; GTPL7864; BDBM50430287; 1BR	70698427	Investigative	D0AY0F	.	CTPDG014243
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT00131	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00149	Cyclin dependent kinase 13 (CDK13)	CDK13_HUMAN	.	.	Investigative	THZ531	"1702809-17-3; THZ-531; (R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide; CHEMBL4163879; THZ531 HCl; THZ-531 HCl; SCHEMBL16655248; SCHEMBL16655252; CHEBI:143122; THZ 531; (E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide; AMY16834; BCP28996; EX-A1532; BDBM50528813; NSC821656; s6595; NSC-821656; SB18810; AC-31604; BS-16034; HY-103618; CS-0015451; J3.623.785F; CN(C)CC=CC(=O)Nc1ccc(cc1)C(=O)N1CCC[C@H](C1)Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12; (2E)-N-(4-{[(3R)-3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}piperidin-1-yl]carbonyl}phenyl)-4-(dimethylamino)but-2-enamide"	118025540	Investigative	D7RK2M	.	CTPDG007608
M6ACROT00152	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	"2,4-epi-neodysiherbaine"	"2,4-epi-neoDH"	73755077	Investigative	D00VEZ	.	CTPDG015461
M6ACROT00152	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	domoic acid	domoate; NSC 288031	5282253	Investigative	D09KRH	DB02852	CTPDG015462
M6ACROT00152	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	dysiherbaine	"(2r,3ar,6s,7r,7ar)-2-[(2s)-2-Amino-2-Carboxyethyl]-6-Hydroxy-7-(Methylamino)hexahydro-2h-Furo[3,2-B]pyran-2-Carboxylic Acid; DYH; CHEMBL221142; GTPL4185; SCHEMBL12409079; BDBM85740; (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid (non-preferred name); (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)-hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid"	9839436	Investigative	D0K6AF	.	CTPDG015463
M6ACROT00152	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	SYM2081	"KRKRAOXTGDJWNI-DMTCNVIQSA-L; (2S,4R)-2-amino-4-methylpentanedioate; [3H](2S,4R)-4-methylglutamate; [3H]SYM2081; [(3)H]4MG; (2S,4R)-Me-Glu; GTPL4317; GTPL4075; compound 52 [PMID:"	21117106	Investigative	D0S8AN	.	CTPDG015464
M6ACROT00152	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	[3H]kainate	"(2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4231; GTPL4085; KAINATE"	73755076	Investigative	D04PFN	.	CTPDG015465
M6ACROT00153	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	"2,4-epi-neodysiherbaine"	"2,4-epi-neoDH"	73755077	Investigative	D00VEZ	.	CTPDG015461
M6ACROT00153	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	domoic acid	domoate; NSC 288031	5282253	Investigative	D09KRH	DB02852	CTPDG015462
M6ACROT00153	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	dysiherbaine	"(2r,3ar,6s,7r,7ar)-2-[(2s)-2-Amino-2-Carboxyethyl]-6-Hydroxy-7-(Methylamino)hexahydro-2h-Furo[3,2-B]pyran-2-Carboxylic Acid; DYH; CHEMBL221142; GTPL4185; SCHEMBL12409079; BDBM85740; (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid (non-preferred name); (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)-hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid"	9839436	Investigative	D0K6AF	.	CTPDG015463
M6ACROT00153	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	SYM2081	"KRKRAOXTGDJWNI-DMTCNVIQSA-L; (2S,4R)-2-amino-4-methylpentanedioate; [3H](2S,4R)-4-methylglutamate; [3H]SYM2081; [(3)H]4MG; (2S,4R)-Me-Glu; GTPL4317; GTPL4075; compound 52 [PMID:"	21117106	Investigative	D0S8AN	.	CTPDG015464
M6ACROT00153	Glutamate ionotropic receptor kainate type subunit 2 (GRIK2)	GRIK2_HUMAN	.	.	Investigative	[3H]kainate	"(2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4231; GTPL4085; KAINATE"	73755076	Investigative	D04PFN	.	CTPDG015465
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00155	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00156	Integrin subunit alpha 2 (ITGA2)	ITA2_HUMAN	.	.	Phase 2	E7820	"289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075"	196970	Phase 2	D02BQE	DB12505	CTPDG002990
M6ACROT00156	Integrin subunit alpha 2 (ITGA2)	ITA2_HUMAN	.	.	Investigative	MAGGIEMYCIN	"81341-47-1; methyl (1R,2R)-2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate; AC1Q6OOS; CTK3E8246; DTXSID70231061; AC1L3370; 1-naphthacenecarboxylic acid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester,(1r-trans)-; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester, (1R-trans)-"	133657	Investigative	D08PYJ	.	CTPDG014471
M6ACROT00156	Integrin subunit alpha 2 (ITGA2)	ITA2_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603	44418280	Investigative	D01ZJF	.	CTPDG014472
M6ACROT00156	Integrin subunit alpha 2 (ITGA2)	ITA2_HUMAN	.	.	Investigative	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	Investigative	D0G7QJ	.	CTPDG014473
M6ACROT00156	Integrin subunit alpha 2 (ITGA2)	ITA2_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	Investigative	D0TP8S	.	CTPDG014474
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Phase 2	PMX-53	"YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam"	6918468	Phase 2	D0G2XE	.	CTPDG002376
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	Alpha-methylcubebin	CHEMBL520915	44575384	Investigative	D00GOQ	.	CTPDG013164
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	MEDIORESINOL	CHEMBL513023; (-) Medioresinol; AC1L7B3T; BDBM50259877; NSC329245; NSC-329245	181681	Investigative	D00RGP	.	CTPDG013165
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-yatein	"Yatein; Dihydroanhydropodorhizol; 40456-50-6; (-)-deoxypodorhizone; Deoxypodorhizone; AC1L9DHE; CHEBI:4553; CHEMBL471067; C22H24O7; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]tetrahydrofuran-2-one; 2(3H)-Furanone, 4-(1,3-benzodioxol-5-ylmethyl)dihydro-3-[(3,4,5-trimethoxyphenyl)methyl]-, (3R,4R)-; Deoxypodorhizon; SCHEMBL1037807; DTXSID50193471; MolPort-035-706-087; GMLDZDDTZKXJLU-JKSUJKDBSA-N"	442835	Investigative	D01FBL	.	CTPDG013166
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine"	"Pyridine, 3-[5-(1,3-dithiolan-2-yl)-2-furanyl]-; 859239-21-7; 3-[5-(1,3-dithiolan-2-yl)furan-2-yl]pyridine; CHEMBL215174; SCHEMBL3608709; CTK2I3856; BDBM12362; DTXSID40475410; nicotine 3-heteroaromatic analogue 17"	11993867	Investigative	D02EAP	.	CTPDG013167
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-cubebinin	CHEMBL480296; BDBM50259873	44575401	Investigative	D02HSP	.	CTPDG013168
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	PALMATINE	"3486-67-7; Berbericinine; O,O-Dimethyldemethyleneberberine; Palmatin; Burasaine; UNII-G50C034217; 7,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxyberbinium; Dibenzo[a,g]quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-; BRN 1555498; GNF-PF-4086; CHEBI:16096; 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo[a,g]quinolizinium; 2,3,9,10-tetramethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium; 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo(a,g)quinolizinium; Dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-; G50C034217"	19009	Investigative	D02SGJ	.	CTPDG013169
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"1,2-Diacetoxylycorine"	"1,2-Diacetyllycorine; CHEMBL465295; Lycorin diacetate; LYCORINE DIACETATE; 1,2-Di-O-acetyllycorine; SCHEMBL12319317; BDBM50293602; (1S,17S,18S,19S)-17-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.6.1.0^{2,10}.0^{4,8}.0^{15,19}]nonadeca-2,4(8),9,15-tetraen-18-yl acetate"	10429288	Investigative	D02TKC	.	CTPDG013170
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	Geranylcoumarin	CHEMBL241896	44429171	Investigative	D03DMA	.	CTPDG013171
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-cubebininolide	"CHEMBL479314; Cordigerin; (-)-Cordigerine; VUNCHONBJWJYID-DLBZAZTESA-N; BDBM50259868; (3R,4R)-3,4-bis(3,4,5-Trimethoxybenzyl)dihydrofuran-2(3H)-one; 2(3H)-Furanone, dihydro-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]-, (3R-trans)-; 2(3H)-Furanone, dihydro-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]-, (3R,4R)-"	13916150	Investigative	D05KIF	.	CTPDG013172
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-dihydroclusin	CHEMBL469916; 73149-51-6; AC1L7BWU; DTXSID10318502; BDBM50259874; NSC332042; NSC-332042	332806	Investigative	D06MLU	.	CTPDG013173
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-(3-methylthiophen-2-yl)pyridine	"CHEMBL179669; Pyridine, 3-(3-methyl-2-thienyl)-; 837376-35-9; SCHEMBL3606167; BDBM12351; CTK3D1375; DTXSID20635313; nicotine 3-heteroaromatic analogue 4; US8609708, 4"	23646069	Investigative	D06TRS	.	CTPDG013174
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-thujaplicatintrimethyl ether	"Thujaplicatin methyl ether; UNII-2VJD5SJF7V; 2VJD5SJF7V; CHEMBL469917; 6512-67-0; 2(3H)-Furanone, dihydro-3-((4-hydroxy-3,5-dimethoxyphenyl)methyl)-4-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S-trans)-; 3-O-Methylthujaplicatin; AC1Q6MJF; AC1L4V25; CTK2F4686; DTXSID40215434; BDBM50259876; 2(3h)-furanone, dihydro-3-((4-hydroxy-3,5-dimethoxyphenyl)methyl)-4-((4-hydroxy-3-methoxyphenyl)methyl)-,(3s-trans)-"	192827	Investigative	D08BOH	.	CTPDG013175
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	DIETHOXYFLOURESCEIN	"CHEMBL1257567; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 3',6'-diethoxy-; 21934-70-3; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-diethoxy-; AC1Q6MMX; AC1L4PB7; 3',6'-Diethoxyfluorescein; SCHEMBL6404797; XAPFGEPPWZRGFN-UHFFFAOYSA-N; BDBM50328442; AKOS028111348"	161373	Investigative	D08FZC	.	CTPDG013176
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine	"CHEMBL564408; 1-Acetoxy-2-TBS-lycorine; BDBM50293601; (1S,2S,3a1S,12bS)-2-(tert-butyldimethylsilyloxy)-2,3a1,4,5,7,12b-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-1-yl acetate"	44191463	Investigative	D08TSE	.	CTPDG013177
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	1-Acetoxylycorine	"1-O-Acetyllycorine; 1-Acetyllycorine; CHEMBL251077; CHEBI:31045; C12166; AC1L9EZ8; SCHEMBL12319390; BDBM50221063; acetic acid (1S,2S,12bS,12cS)-2-hydroxy-1,2,4,5,12b,12c-hexahydro-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-1-yl ester; (1S,2S,12bS,12cS)-1,2-Diol-2,4,5,7, 12b,12c-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1-acetate"	443672	Investigative	D09REF	.	CTPDG013178
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-clusin	CHEMBL479701; BDBM50259867	44575398	Investigative	D09VMS	.	CTPDG013179
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	ETHOXYCLUSIN	CHEMBL480295	44575400	Investigative	D0A1SJ	.	CTPDG013180
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"(8R,8'R)-4-hydroxycubebinone"	"CHEMBL482034; AC1MHYPL; (8R,8''R)-4-hydroxycubebinone; BDBM50259848; 2(3H)-furanone, dihydro-4-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-3-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-, (3R,4R)-"	3013841	Investigative	D0B2ZB	.	CTPDG013181
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime	"SCHEMBL3649264; 2-Thiophenecarboxaldehyde, 5-(3-pyridinyl)-, oxime"	91196339	Investigative	D0C7JC	.	CTPDG013182
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	BERGAPTOL	"486-60-2; 5-Hydroxypsoralen; 4-Hydroxy-7H-furo[3,2-g]chromen-7-one; 5-Hydroxyfuranocoumarin; Psoralin, 5-hydroxy-; UNII-KTC8ANI30F; 4-Hydroxybergapten; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-hydroxy-; NSC341958; KTC8ANI30F; 4-oxidanylfuro[3,2-g]chromen-7-one; NSC 341958; 5-Hydroxy-6,7-furanocoumarin; CHEMBL242711; CHEBI:17377; GIJHDGJRTUSBJR-UHFFFAOYSA-N; 4-hydroxyfuro[3,2-g]chromen-7-one; AK158894; Bergaptols; 5-Hydroxy-Psoralen; 5-Hydroxyfurocoumarin; AC1NQWYH; 5-HYDROXY-PSORALIN; 7H-Furo[3, 4-hydroxy-; BSPBio_002390"	5280371	Investigative	D0D5YP	.	CTPDG013183
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	2-tert-Butyldimethylsilyloxylycorine	CHEMBL558873; SCHEMBL12270994; BDBM50293600	44191462	Investigative	D0E2GV	.	CTPDG013184
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	5-(2-phenethylpiperazin-1-yl)-1H-indazole	CHEMBL1170373; SCHEMBL2944873	49798218	Investigative	D0F5AQ	.	CTPDG013185
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	GSK-8062	"UNII-37IS6K16XE; 37IS6K16XE; 6-(4-{[3-(2,6-Dichlorophenyl)-5-(1-Methylethyl)isoxazol-4-Yl]methoxy}phenyl)naphthalene-1-Carboxylic Acid; TUOXXRMLFZBSTB-UHFFFAOYSA-N; 943549-47-1; SCHEMBL2115258; CHEMBL476302; Naphthoic acid-based analog, 1b; BDBM30329; GSK8062; 1-Naphthalenecarboxylic acid, 6-(4-((3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl)methoxy)phenyl)-; 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1-naphthalenecarboxylic acid"	16214849	Investigative	D0G9YL	.	CTPDG013186
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	TILIROSIDE	"20316-62-5; Tribuloside; Trans-Tiliroside; UNII-15M04TXR9M; CHEMBL266564; 15M04TXR9M; CHEBI:80944; 22153-44-2; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, 6'-ester with 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AC1NSZRJ; SCHEMBL23597; Tiliroside, analytical standard; MEGxp0_000169; MolPort-001-740-347; ZINC17654711; BDBM50241244; AKOS015896718; MCULE-6075035042; NCGC00163634-01; LS-123660; W1685; kaempferol 3-O-(6""-O-p-coumaroyl)-glucoside; C17140"	5320686	Investigative	D0IB3K	.	CTPDG013187
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-(5-((methylthio)methyl)furan-2-yl)pyridine	"859239-20-6; Pyridine, 3-[5-[(methylthio)methyl]-2-furanyl]-; SCHEMBL3611062; CHEMBL214990; CTK2I3857; BDBM12361; DTXSID60475412; QSLAHFFHHYZNQL-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 15"	11993873	Investigative	D0J1IE	.	CTPDG013188
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	Go-Y026	"CHEMBL493001; SCHEMBL2743841; SCHEMBL2743839; GO-Y-026; BDBM50258200; 1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one; 1,5-Bis(3,5-dimethoxy-4-hydroxyphenyl)-1,4-pentadien-3-one"	10691533	Investigative	D0K4LS	.	CTPDG013189
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(-)-cubebin	"Cubebin; 18423-69-3; beta-cubebin; UNII-J237078S8A; (2s,3r,4r)-3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydrofuran-2-ol; EINECS 242-300-6; Tetrahydro-3,4-dipiperonylfuran-2-ol; (8R,8'R,9S)-cubebin; AI3-62265; CHEMBL399831; CHEBI:65684; J237078S8A; 2-Furanol, 3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydro-; Cubebine; 9-Hydroxy-3,4:3',4'-bis(methylenedioxy)-9,9'-epoxylignan; 3,4-bis(2H-1,3-benzodioxol-5-ylmethyl)oxolan-2-ol; .beta.-Cubebin; 2-Furanol, tetrahydro-3,4-dipiperonyl-; AC1Q59VI; AC1L3KW2; SCHEMBL4884683"	117443	Investigative	D0NC3P	.	CTPDG013190
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-(pyridin-3-yl)prop-2-yn-1-amine	"777856-62-9; 2-PROPYN-1-AMINE, 3-(3-PYRIDINYL)-; CHEMBL360541; SCHEMBL3603698; CTK2G6074; BDBM12348; DTXSID90460412; MolPort-014-472-743; BGKUWZFWNZFRMO-UHFFFAOYSA-N; ZINC13607158; nicotine 3-heteroaromatic analogue 3a; AKOS010148504; MCULE-3042424640; NE58716; US8609708, 3; Z1333761438"	11263510	Investigative	D0O1HH	.	CTPDG013191
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	Alpha-Hydroxy-Midazolam	"1'-hydroxymidazolam; 1-Hydroxymidazolam; alpha-Hydroxymidazolam; 1-Hydroxymethylmidazolam; 59468-90-5; UNII-E5142BN92Z; CHEMBL1188; QHSMEGADRFZVNE-UHFFFAOYSA-N; E5142BN92Z; C18H13ClFN3O; 1-OH-Mdz; 8-Chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-1-methanol; [8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methanol; 8-Chloro-6-(2-fluorophenyl)-4H-imidazo(1,5-a)(1,4)benzodiazepine-1-methanol; 1'-Hydroxy Midazolam; AC1L32ZB; SCHEMBL7310758; DTXSID50208175"	107917	Investigative	D0Q7QU	.	CTPDG013192
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"2,5-bis(4-hydroxybenzylidene)cyclopentanone"	"NSC666766; CHEMBL452101; AC1LVVMV; SCHEMBL14473242; MolPort-000-640-539; ZINC5955757; BDBM50264922; AKOS001331259; NSC-666766; 2,5-Bis[(E)-4-hydroxybenzylidene]cyclopentanone; (2E,5E)-2,5-bis[(4-hydroxyphenyl)methylene]cyclopentanone"	1712706	Investigative	D0S0QN	.	CTPDG013193
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"(8R,8'R,9'S)-5-methoxyclusin"	CHEMBL482233; BDBM50259849	11259008	Investigative	D0T4AC	.	CTPDG013194
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	JATRORRHIZINE	"3621-38-3; neprotin; jateorrhizine; Yatrorizine; UNII-091S1F8V5Q; CHEMBL251055; CHEBI:6087; GNF-PF-220; 7,8,13,13a-tetradehydro-3-hydroxy-2,9,10-trimethoxyberbinium; 091S1F8V5Q; 2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol; Dibenzo[a,g]quinolizinium, 5,6-dihydro-3-hydroxy-2,9,10-trimethoxy-; 3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium; 3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino-[3,2-a]isoquinolin-7-ium; NSC645313; NSC150445; NSC209410"	72323	Investigative	D0V0NM	.	CTPDG013195
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	2-fluoro-5-(3-methylthiophen-2-yl)pyridine	"CHEMBL179621; 837376-37-1; Pyridine, 2-fluoro-5-(3-methyl-2-thienyl)-; SCHEMBL957977; BDBM12354; CTK3D1374; DTXSID90456895; RYGQGRAICBWYPW-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 7; US8609708,10"	11148236	Investigative	D0VD5O	.	CTPDG013196
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	HINOKININ	"(-)-Hinokinin; 26543-89-5; CHEBI:5722; CHEMBL242011; (3R,4R)-3,4-Bis(benzo[d][1,3]dioxol-5-ylmethyl)dihydrofuran-2(3H)-one; (3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-one; (3R-trans)-3,4-bis(1,3-benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-one; hinoquinin; (-)-hinoquinin; AC1L9DKH; Epitope ID:116880; SCHEMBL1121862; MolPort-039-338-821; ZINC1872258; BDBM50218812; AKOS027324070; LS-190466; C10627; (2r,3r)-2,3-di-(3,4-methylenedioxybenzyl)-butyrolactone"	442879	Investigative	D0X3CF	.	CTPDG013197
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine	CHEMBL113018; SCHEMBL14129876; BDBM50138231	44341256	Investigative	D00PYW	.	CTPDG013198
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	DIHYDROCUBEBIN	"(-)-Dihydrocubebin; 24563-03-9; (2R,3R)-2,3-bis(1,3-benzodioxol-5-ylmethyl)butane-1,4-diol; CHEMBL486597; CHEBI:543841; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, (R-(R*,R*))-; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, [R-(R*,R*)]-; Cubebin, dihydro-; AC1Q6ZWV; AC1L4VHK; SCHEMBL15775181; CTK4F3896; DTXSID00179301; JKCVMTYNARDGET-HOTGVXAUSA-N; ZINC899938; BDBM50241937; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, (R*,R*)-(-)-; 1,4-Butanediol, 2,3-dipiperonyl-, (-)-; C10558"	193042	Investigative	D00TOF	.	CTPDG013199
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"3,3-(1,3-Thiazole-2,5-diyl)diphenol"	"CHEMBL456379; SCHEMBL1181184; BDBM25832; hydroxyphenyl substituted thiazole, 4"	25093374	Investigative	D00YNA	.	CTPDG013200
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine	CHEMBL179529	44388719	Investigative	D01ARE	.	CTPDG013201
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	CHEMBL262968; SCHEMBL14130000; BDBM50138237	44341278	Investigative	D02DTR	.	CTPDG013202
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	CHEMBL113227; SCHEMBL14130001; BDBM50138238	44341260	Investigative	D03KXT	.	CTPDG013203
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	4-(6-Methoxynaphthalen-2-yl)isoquinoline	CHEMBL500394; BDBM50272368	24754344	Investigative	D06CWR	.	CTPDG013204
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine	CHEMBL493082	25130848	Investigative	D06JYY	.	CTPDG013205
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"1H-1,2,3-benzotriazol-1-amine"	"1-aminobenzotriazole; 1614-12-6; 1H-Benzotriazol-1-amine; 1H-benzo[d][1,2,3]triazol-1-amine; 1-Benzotriazolamine; benzotriazol-1-amine; 1-Abtz; 1H-1,2,3-Benzotriazol-1-ylamine; UNII-9EFF75BJ1O; NSC 114498; 9EFF75BJ1O; CHEMBL101168; benzotriazolylamine; MFCD00132902; NSC656987; 1-Aminobenzotriazole, 98%; AK-830/25033013; Q-102063; 1-benzotriazolylamine; benzotriazol-1-ylamine; PubChem19954; rarechem aq nn 0550; ACMC-1BVFA; AC1L1BBK; timtec-bb sbb004208; Lopac-A-3940; ABT"	1367	Investigative	D07ANY	.	CTPDG013206
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"1,1':4',1''-terphenyl-3,3''-diol"	"[1,1':4',1'']Terphenyl-3,3''-diol"	44542195	Investigative	D07JOZ	.	CTPDG013207
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	1-(4-Butoxy-phenyl)-1H-imidazole	CHEMBL112532; SCHEMBL14129854; 1-(4-Butoxyphenyl)-1H-imidazole; ZINC13530153	11321889	Investigative	D07VHB	.	CTPDG013208
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one"	"CHEMBL462093; 2(1H)-Naphthalenone,3,4-dihydro-6-(3-pyridinyl)-; BDBM50273703"	25180108	Investigative	D07WLT	.	CTPDG013209
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine	CHEMBL447591; SCHEMBL3004402; SEXSHORPOJSDHK-UHFFFAOYSA-N; BDBM50272250; ZINC40979781	24827305	Investigative	D08IDC	.	CTPDG013210
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine	CHEMBL112592; SCHEMBL14129997; BDBM50138232	44341428	Investigative	D0B0LC	.	CTPDG013211
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)"	"SCHEMBL3194096; CHEMBL1173532; BDBM50322698; rel-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane"	24802842	Investigative	D0G6BJ	.	CTPDG013212
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	SCHEMBL3260073; CHEMBL1172744; BDBM50322697	24803184	Investigative	D0J4CB	.	CTPDG013213
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	"6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)"	"CHEMBL1173087; BDBM50322696; rac-6-(3,4-dichlorophenyl)-5-methoxy-1-1-methoxybut-3-enyl)-3-azabicyclo[4.1.0]heptane"	49799108	Investigative	D0K3EW	.	CTPDG013214
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol	"CHEMBL462513; SCHEMBL1180467; BDBM25853; ZINC40393334; 4,3'-(2,4-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 25"	25093389	Investigative	D0NM0P	.	CTPDG013215
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	CHEMBL115876; SCHEMBL14129965; BDBM50138233	44341234	Investigative	D0U7BJ	.	CTPDG013216
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	(5-pyridin-3-yl-furan-2-yl)methanethiol	"2-Furanmethanethiol, 5-(3-pyridinyl)-; 859239-19-3; CHEMBL214784; SCHEMBL3611340; CTK2I3858; BDBM12360; DTXSID30475409; GLMNDKCXHHOKIQ-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 14; [5-(pyridin-3-yl)furan-2-yl]methanethiol"	11993866	Investigative	D0YP4A	.	CTPDG013217
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	CHEMBL569862; SCHEMBL1180208	25192621	Investigative	D01RZP	.	CTPDG013218
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	CHEMBL577338; SCHEMBL1180589	25192477	Investigative	D0M0KX	.	CTPDG013219
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol	1122660-25-6; 4-(5-(3-Hydroxyphenyl)thiophen-2-yl)-2-methylphenol; 3-(5-(4-hydroxy-3-methylphenyl)thiophen-2-yl)phenol; CHEMBL570596; AK160974; 3-(5-(4-Hydroxy-3-methylphenyl)-thiophen-2-yl)phenol; SCHEMBL1180399; MolPort-028-616-334; ZINC45254284; BDBM50299633; AKOS024463871; DS-9818; QC-10086; AJ-110394; AX8293985	25192475	Investigative	D0Y2RL	.	CTPDG013220
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	4-(2-(4-tert-butylphenylthio)ethyl)-1H-imidazole; 4-(2-(40-tert-butylphenylthio)ethyl)-1H-imidazole	46222048	Investigative	D01JXM	.	CTPDG013221
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	ML-3375	CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	9795838	Investigative	D09HBZ	.	CTPDG013222
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	ML-3403	p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine	6419739	Investigative	D0W4FF	.	CTPDG013223
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	ML-3163	ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine	9845197	Investigative	D08DSJ	.	CTPDG013224
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	6-(3-hydroxyphenyl)-2-naphthol; 6-(3-hydroxyphenyl)naphthalen-2-ol	10192730	Investigative	D0P8PK	.	CTPDG009713
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT00160	Cytochrome P450 family 3 subfamily A member 4 (CYP3A4)	CP3A4_HUMAN	.	.	Phase 2	AVI-4557	.	.	Phase 2	D0J6FE	.	CTPDG014605
M6ACROT00161	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	BI6015	BI 6015; BI-6015	3269393	Investigative	D02RRY	.	CTPDG015388
M6ACROT00161	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	Lauric Acid	"DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate"	3893	Investigative	D0N0UC	DB03017	CTPDG013952
M6ACROT00161	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	MYRISTIC ACID	"Tetradecanoic acid; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2"	11005	Investigative	D08OBF	DB08231	CTPDG013953
M6ACROT00166	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	BI6015	BI 6015; BI-6015	3269393	Investigative	D02RRY	.	CTPDG015388
M6ACROT00166	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	Lauric Acid	"DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate"	3893	Investigative	D0N0UC	DB03017	CTPDG013952
M6ACROT00166	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	MYRISTIC ACID	"Tetradecanoic acid; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2"	11005	Investigative	D08OBF	DB08231	CTPDG013953
M6ACROT00167	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	BI6015	BI 6015; BI-6015	3269393	Investigative	D02RRY	.	CTPDG015388
M6ACROT00167	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	Lauric Acid	"DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate"	3893	Investigative	D0N0UC	DB03017	CTPDG013952
M6ACROT00167	Hepatocyte nuclear factor 4 alpha (HNF4A)	HNF4A_HUMAN	.	.	Investigative	MYRISTIC ACID	"Tetradecanoic acid; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2"	11005	Investigative	D08OBF	DB08231	CTPDG013953
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138649	.	.	Investigative	D07NRU	.	CTPDG015374
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138647	.	.	Investigative	D0D7NA	.	CTPDG015375
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138616	.	.	Investigative	D0DH8B	.	CTPDG015376
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138678	.	.	Investigative	D0LF3W	.	CTPDG015377
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138612	.	.	Investigative	D0O2ZR	.	CTPDG015378
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138648	.	.	Investigative	D0O4MI	.	CTPDG015379
M6ACROT00171	Endoribonuclease Dicer (DICER1)	DICER_HUMAN	.	.	Investigative	ISIS 138613	.	.	Investigative	D0OV0E	.	CTPDG015380
M6ACROT00180	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT00180	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT00180	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT00180	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT00181	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00181	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00181	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00192	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptide analog 8	PMID26394986-Compound-2	.	Patented	D0JF5K	.	CTPDG014924
M6ACROT00192	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00192	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00192	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00192	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00192	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Discontinued in Phase 2	AVT-02 UE	.	.	Discontinued in Phase 2	D03WRN	.	CTPDG014925
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1/2	HH2710	.	.	Phase 1/2	D1KIY9	.	CTPDG003257
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1/2	ASTX029	.	.	Phase 1/2	DM1FD5	.	CTPDG003165
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	LY3214996	"JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one"	121408882	Phase 1	D0TN3Q	.	CTPDG004398
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	VAN-10-4-eluting stent	"INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde"	.	Phase 1	D08KNG	.	CTPDG013513
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	GDC-0994	.	71727581	Phase 1	D0Q4IX	DB15281	CTPDG004487
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	JSI-1187	.	.	Phase 1	DBU16T	.	CTPDG003963
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Preclinical	COR-D	.	.	Preclinical	DOJ6D9	.	CTPDG006976
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	AEZS-131	"ERK inhibitor (cancer), AEterna"	.	Investigative	D07NEE	.	CTPDG008677
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	SCH772984	SCH-772984	24866313	Investigative	D08XVZ	.	CTPDG013514
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	ERK inhibitor III	AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine	5721470	Investigative	D0C5AD	.	CTPDG013515
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	SCHEMBL6659391	11195892	Investigative	D0Q1AC	.	CTPDG013516
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	FR-180204	"865362-74-9; FR 180204; FR180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685"	11493598	Investigative	D0ZG4G	DB07794	CTPDG013517
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	DEBROMOHYMENIALDISINE	.	135451156	Investigative	D01WAI	DB04367	CTPDG013339
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Phosphonothreonine	"phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid"	10976469	Investigative	D05BHG	DB02482	CTPDG013391
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	Investigative	D0G2VC	.	CTPDG011474
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT00193	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00198	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT00200	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	pregnenolone-16alpha-carbonitrile	"16alpha-carbonitrile, pregnenolone"	15032	Investigative	D01BJB	.	CTPDG015317
M6ACROT00200	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	trihydroxycholestane	"5beta-Cholestane-3alpha,7alpha,12alpha-triol; Trihydroxycoprostane; 3,7,12-Trihydroxycholestane; 547-96-6; 5-b-Cholestane-3a ,7a ,12a-triol; (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol; 3alpha,7alpha,12alpha-Trihydroxycoprostane; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestane; 3,7,12-Trihydroxycoprostane; A,5; A)-cholestane-3,7,12-triol; AC1L4NRJ"	160520	Investigative	D0FI7B	.	CTPDG015318
M6ACROT00200	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	schisandrin A	(-)-deoxyschisandrin; (-)-dimethylgomisin J	155256	Investigative	D0Y4YV	.	CTPDG015319
M6ACROT00200	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	3-keto-lithocholic acid	dehydrolithocholic acid; 3-keto-LCA	5283906	Investigative	D06RBG	.	CTPDG015320
M6ACROT00200	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	Hyperforin	"11079-53-1; hyperforine; hiperforina; UNII-RM741E34FP; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; HSDB 7646; (+)-Hyperforin; Spectrum5_002025; SCHEMBL98723; CHEMBL501711; GTPL2764; SCHEMBL15557965; Hyperforin, &gt"	441298	Investigative	D09VTJ	DB01892	CTPDG015321
M6ACROT00200	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT00201	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	pregnenolone-16alpha-carbonitrile	"16alpha-carbonitrile, pregnenolone"	15032	Investigative	D01BJB	.	CTPDG015317
M6ACROT00201	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	trihydroxycholestane	"5beta-Cholestane-3alpha,7alpha,12alpha-triol; Trihydroxycoprostane; 3,7,12-Trihydroxycholestane; 547-96-6; 5-b-Cholestane-3a ,7a ,12a-triol; (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol; 3alpha,7alpha,12alpha-Trihydroxycoprostane; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestane; 3,7,12-Trihydroxycoprostane; A,5; A)-cholestane-3,7,12-triol; AC1L4NRJ"	160520	Investigative	D0FI7B	.	CTPDG015318
M6ACROT00201	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	schisandrin A	(-)-deoxyschisandrin; (-)-dimethylgomisin J	155256	Investigative	D0Y4YV	.	CTPDG015319
M6ACROT00201	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	3-keto-lithocholic acid	dehydrolithocholic acid; 3-keto-LCA	5283906	Investigative	D06RBG	.	CTPDG015320
M6ACROT00201	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	Hyperforin	"11079-53-1; hyperforine; hiperforina; UNII-RM741E34FP; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; HSDB 7646; (+)-Hyperforin; Spectrum5_002025; SCHEMBL98723; CHEMBL501711; GTPL2764; SCHEMBL15557965; Hyperforin, &gt"	441298	Investigative	D09VTJ	DB01892	CTPDG015321
M6ACROT00201	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT00202	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	pregnenolone-16alpha-carbonitrile	"16alpha-carbonitrile, pregnenolone"	15032	Investigative	D01BJB	.	CTPDG015317
M6ACROT00202	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	trihydroxycholestane	"5beta-Cholestane-3alpha,7alpha,12alpha-triol; Trihydroxycoprostane; 3,7,12-Trihydroxycholestane; 547-96-6; 5-b-Cholestane-3a ,7a ,12a-triol; (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol; 3alpha,7alpha,12alpha-Trihydroxycoprostane; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestane; 3,7,12-Trihydroxycoprostane; A,5; A)-cholestane-3,7,12-triol; AC1L4NRJ"	160520	Investigative	D0FI7B	.	CTPDG015318
M6ACROT00202	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	schisandrin A	(-)-deoxyschisandrin; (-)-dimethylgomisin J	155256	Investigative	D0Y4YV	.	CTPDG015319
M6ACROT00202	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	3-keto-lithocholic acid	dehydrolithocholic acid; 3-keto-LCA	5283906	Investigative	D06RBG	.	CTPDG015320
M6ACROT00202	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	Hyperforin	"11079-53-1; hyperforine; hiperforina; UNII-RM741E34FP; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; HSDB 7646; (+)-Hyperforin; Spectrum5_002025; SCHEMBL98723; CHEMBL501711; GTPL2764; SCHEMBL15557965; Hyperforin, &gt"	441298	Investigative	D09VTJ	DB01892	CTPDG015321
M6ACROT00202	Nuclear receptor subfamily 1 group I member 2 (NR1I2)	NR1I2_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00203	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	TG02	SB1317; 937270-47-8; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	Phase 1/2	D0P0KN	.	CTPDG013443
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AZD-5438	"602306-29-6; AZD5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	Phase 1	D06WHY	.	CTPDG005133
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	Phase 1	D07DTV	DB08142	CTPDG005118
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	Phase 1	D0PL7P	DB15425	CTPDG004504
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	Phase 1	D0S5RC	DB05969	CTPDG004433
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Fluorinated compound 1	PMID26161698-Compound-15	.	Patented	D09ISI	.	CTPDG013444
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"4-amino-3,5-di-substituted-thiazole derivative 1"	PMID26161698-Compound-54	.	Patented	D0JU4Z	.	CTPDG013445
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 11	PMID26161698-Compound-16	.	Patented	D02KWX	.	CTPDG013446
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	PMID26161698-Compound-27	73508010	Patented	D03EYT	.	CTPDG013447
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Alkyl sulfone derivative 1	PMID26161698-Compound-29	73672849	Patented	D05UJQ	.	CTPDG013448
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Aniline derivative 1	PMID26161698-Compound-33	59176838	Patented	D06QPW	.	CTPDG013449
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 1	PMID26161698-Compound-35	44253187	Patented	D07QIP	.	CTPDG013450
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-phenyl-pyrimidin-4-amine derivative 1	PMID26161698-Compound-30	74763288	Patented	D0AY5G	.	CTPDG013451
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID26161698-Compound-25	.	71618654	Patented	D0GQ7L	.	CTPDG013452
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diaryl amine derivative 1	PMID26161698-Compound-23	71515733	Patented	D0P4NP	.	CTPDG013453
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Flavopiridol analog 1	PMID26161698-Compound-5	86272549	Patented	D0P9WR	.	CTPDG013454
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	PMID26161698-Compound-31	73891126	Patented	D0QS2B	.	CTPDG013455
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Pyrazolo-triazine derivative 2	PMID26161698-Compound-14	71731909	Patented	D0T6CM	.	CTPDG013456
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"1,5-di-substituted pyridine derivative 1"	PMID26161698-Compound-26	60197050	Patented	D0UU0V	.	CTPDG013457
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	PMID26161698-Compound-28	74767011	Patented	D0V7RP	.	CTPDG013458
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Naphthyridine and isoquinoline derivative 1	PMID26161698-Compound-51	.	Patented	D08WJG	.	CTPDG013393
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 2	PMID26161698-Compound-36	71561915	Patented	D01CJE	.	CTPDG013394
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diamidothiazole derivative 1	PMID26161698-Compound-53	25256147	Patented	D0LR2Y	.	CTPDG013332
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrazolo[1,5-a]-1,3,5-triazine derivative 1"	PMID26161698-Compound-12	.	Patented	D0NB7Y	.	CTPDG013395
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Roscovitine derivative 1	PMID26161698-Compound-8	73353575	Patented	D07DUX	.	CTPDG013396
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 3	SCH 727965	Dinaciclib; SCH-727965	46926350	Discontinued in Phase 3	D0D3PX	DB12021	CTPDG013398
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	Preclinical	D0WS1V	DB02733	CTPDG007034
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	Olomoucine	"101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	Terminated	D00BPA	DB02116	CTPDG013399
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	Investigative	D01LPG	DB08134	CTPDG013460
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	Investigative	D03BZV	DB04607	CTPDG013461
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	Investigative	D06FIQ	DB07203	CTPDG013462
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BOHEMINE	189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	Investigative	D07ADR	.	CTPDG013463
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-phenyl-1H-pyrazole-3-carboxamide	"124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	Investigative	D07ODE	DB08135	CTPDG013464
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-hydroxynaphthalene-1-sulfonamide	"17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	Investigative	D07SGT	DB08132	CTPDG013465
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	Investigative	D0D3HB	DB08133	CTPDG013466
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	Investigative	D0I1SZ	DB08768	CTPDG013467
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	Investigative	D0I9VN	DB02603	CTPDG013468
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	Investigative	D0M5PI	.	CTPDG013469
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	Investigative	D0MK6D	DB02647	CTPDG013470
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	Investigative	D0P7RO	.	CTPDG013471
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	Investigative	D0QI7H	DB06948	CTPDG013472
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	Investigative	D0T4SJ	.	CTPDG007860
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	Investigative	D0T5AH	.	CTPDG007858
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	Investigative	D0U0GE	DB02091	CTPDG013473
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	Investigative	D0V1NK	.	CTPDG007806
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-Amino-6-Chloropyrazine	"33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	Investigative	D0W0PF	DB02297	CTPDG013474
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	Investigative	D0Y6DX	DB08233	CTPDG013475
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	Investigative	D01FJB	.	CTPDG013476
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	Investigative	D02ZYA	.	CTPDG013478
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	Investigative	D03XKK	.	CTPDG013480
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	JNJ-7706621	"443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	Investigative	D04NGS	.	CTPDG013404
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	GW-8510	.	3536	Investigative	D04RBG	.	CTPDG013482
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-265246	BMS 265246; BMS265246	135402864	Investigative	D05SZH	.	CTPDG013405
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	RESCOVITINE	CHEMBL1087791	46881287	Investigative	D07AEC	.	CTPDG013485
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	Investigative	D07JHG	.	CTPDG013486
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15"	5687	Investigative	D0KH5T	DB03365	CTPDG010119
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Oxindole 95	.	.	Investigative	D0MS4R	.	CTPDG013496
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	CVT-313	AC1OCFD4; NG 26	6918386	Investigative	D0P2WA	.	CTPDG013408
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	Investigative	D0R1FT	DB02407	CTPDG013497
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6027	.	398148	Investigative	D0U8YN	DB08312	CTPDG013498
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 8	SCHEMBL2991886; CHEMBL406102	24801181	Investigative	D01PEF	.	CTPDG013502
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Purvalanol A	Purvalanola; AC1L1JD0; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	Investigative	D07OAT	DB04751	CTPDG013410
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk1/2 inhibitor III	"443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664"	5330812	Investigative	D07OCA	DB07664	CTPDG013411
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 1	"341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	Investigative	D08KSQ	.	CTPDG013503
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 4	SCHEMBL3001373; CHEMBL406464	24801697	Investigative	D0B9YR	.	CTPDG013504
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Lysine Nz-Carboxylic Acid	N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	Investigative	D0CC0B	DB03801	CTPDG013505
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 6	CHEMBL406463; SCHEMBL2999009	24801185	Investigative	D0D0ZQ	.	CTPDG013506
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	Investigative	D0F0AX	.	CTPDG013412
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aminopurvalanol A	NG-97	6604931	Investigative	D0G2GA	.	CTPDG013413
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	9-Nitropaullone	"Alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	Investigative	D0H3EV	DB04014	CTPDG013414
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 5	"1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	Investigative	D0H6CQ	DB08182	CTPDG013507
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SU9516	"377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	Investigative	D0L3FK	DB03428	CTPDG013415
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 3	"954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	Investigative	D0S8VE	DB08178	CTPDG013508
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 2	"SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	Investigative	D0U1WL	.	CTPDG013509
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid"	3708	Investigative	D0G2CT	DB02519	CTPDG013416
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	Investigative	D0S7IE	.	CTPDG013511
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Double Oxidized Cysteine	.	6398956	Investigative	D0H1GU	.	CTPDG013512
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00204	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	P-276	"CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development"	23643976	Phase 2	D0W8IY	.	CTPDG010902
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	P276-00	CHEMBL2312181; SCHEMBL1180418	23643975	Phase 2	D05IRT	.	CTPDG010904
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	P1446A-05	.	67409219	Phase 1	D0DX4J	DB15157	CTPDG004841
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	PF-07220060	.	.	Phase 1	DZJ3D5	.	CTPDG003644
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Imidazo pyridine derivative 3	PMID26161698-Compound-22	46937330	Patented	D0WT7D	.	CTPDG010910
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 10"	PMID26161698-Compound-2	53378895	Patented	D04AKA	.	CTPDG010912
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID26161698-Compound-17	.	739323	Patented	D0FQ6V	.	CTPDG010913
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	CHEMBL521733; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	787236	Investigative	D03VDM	.	CTPDG010920
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea	5330597	Investigative	D0G4JS	.	CTPDG010921
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea	5330595	Investigative	D0M8CO	.	CTPDG010922
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-Pyridin-2-yl-3-quinolin-5-yl-urea	Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea	5330598	Investigative	D0T2VG	.	CTPDG010923
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea	5330596	Investigative	D0X1NW	.	CTPDG010924
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Ro-0505124	RO0505124	9911652	Investigative	D09RYV	.	CTPDG010927
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00205	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00206	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00228	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT00228	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT00228	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00417	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT00418	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00431	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00432	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00433	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00436	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00437	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT00438	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT00441	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT00442	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT00443	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT00444	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT00445	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT00452	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT00452	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1	ABBV-CX-2029	.	.	Phase 1	D58AMF	.	CTPDG014793
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00453	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00454	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00455	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00456	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00457	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00458	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00459	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00460	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00461	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 2	RG7155	.	.	Phase 2	D06NQH	.	CTPDG002742
M6ACROT00461	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	Emactuzumab	.	.	Phase 1	D00MJI	.	CTPDG005452
M6ACROT00461	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	PLX73086	.	.	Phase 1	D0PL8D	.	CTPDG004503
M6ACROT00461	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	MSC110	Lacnotuzumab	.	Phase 1	D18QIB	.	CTPDG014468
M6ACROT00462	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 2	RG7155	.	.	Phase 2	D06NQH	.	CTPDG002742
M6ACROT00462	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	Emactuzumab	.	.	Phase 1	D00MJI	.	CTPDG005452
M6ACROT00462	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	PLX73086	.	.	Phase 1	D0PL8D	.	CTPDG004503
M6ACROT00462	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	MSC110	Lacnotuzumab	.	Phase 1	D18QIB	.	CTPDG014468
M6ACROT00463	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT00464	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT00469	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 3	MyoCell SDF-1	"Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart"	.	Phase 3	D0DR4W	.	CTPDG014680
M6ACROT00469	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT00469	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 2	SDF-1	JVS-100	.	Phase 2	D07YLO	.	CTPDG014681
M6ACROT00469	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 1	NOX-A12	"Ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON; SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON; CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation), Noxxon"	.	Phase 1	D0D8MG	.	CTPDG014682
M6ACROT00469	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 1	REC-02	.	.	Phase 1	D0K6NW	.	CTPDG004655
M6ACROT00470	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 3	MyoCell SDF-1	"Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart"	.	Phase 3	D0DR4W	.	CTPDG014680
M6ACROT00470	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 3	Dociparstat sodium	DSTAT	.	Phase 3	D5VRX2	.	CTPDG000934
M6ACROT00470	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 2	SDF-1	JVS-100	.	Phase 2	D07YLO	.	CTPDG014681
M6ACROT00470	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 1	NOX-A12	"Ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON; SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON; CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation), Noxxon"	.	Phase 1	D0D8MG	.	CTPDG014682
M6ACROT00470	Stromal cell-derived factor 1 (CXCL12)	SDF1_HUMAN	.	.	Phase 1	REC-02	.	.	Phase 1	D0K6NW	.	CTPDG004655
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00478	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00479	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00480	Caspase-2 (CASP2)	CASP2_HUMAN	.	.	Phase 3	QPI-1007	"SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals"	.	Phase 3	D06ZFV	.	CTPDG014701
M6ACROT00482	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT00482	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT00482	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT00482	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT00489	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT00490	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT00491	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT00492	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00517	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00518	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00519	Protein c-Fos (FOS)	FOS_HUMAN	.	.	Investigative	ISIS 10639	.	.	Investigative	D0Z2OW	.	CTPDG015498
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00523	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00524	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00525	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00526	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00527	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00528	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00529	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00530	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00537	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Dusigitumab	.	.	Phase 2	D09TQY	.	CTPDG014730
M6ACROT00537	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Xentuzumab	.	.	Phase 2	D04DNB	.	CTPDG014731
M6ACROT00538	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Dusigitumab	.	.	Phase 2	D09TQY	.	CTPDG014730
M6ACROT00538	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Xentuzumab	.	.	Phase 2	D04DNB	.	CTPDG014731
M6ACROT00539	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Dusigitumab	.	.	Phase 2	D09TQY	.	CTPDG014730
M6ACROT00539	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Xentuzumab	.	.	Phase 2	D04DNB	.	CTPDG014731
M6ACROT00540	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00541	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00542	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00543	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00544	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00545	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00546	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00547	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00548	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00549	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00566	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00567	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00568	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00569	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00570	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00571	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00572	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00573	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00574	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00575	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00576	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00577	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00581	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT00582	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00584	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00585	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00586	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00587	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00588	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00603	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT00603	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT00603	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT00603	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT00604	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT00604	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT00604	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT00604	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT00605	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT00605	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT00605	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT00605	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT00609	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT00609	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT00609	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT00609	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT00609	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT00609	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00611	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00612	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT00613	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT00616	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT00617	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT00618	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT00619	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00622	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Ranibizumab	"Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)"	.	Approved	D04EYG	.	CTPDG012421
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Brolucizumab	.	.	Approved	D5DO9L	.	CTPDG012422
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Faricimab	RO6867461; RG7716	.	Approved	D9MWL4	.	CTPDG012423
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Rituximab	.	24801580	Phase 3	D08CGU	.	CTPDG012424
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Trastuzumab	"Lithocholic acid; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,"	9903	Phase 3	D04SLF	.	CTPDG009886
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	Abicipar pegol	.	.	Phase 2	D0CJ7Z	.	CTPDG012426
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RO5520985	.	.	Phase 2	D0I8YS	.	CTPDG012427
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	SNN-0029	"VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech"	.	Phase 1/2	D0E7RQ	.	CTPDG012428
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	MP0250	.	.	Phase 1/2	D0ME7Q	.	CTPDG012429
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	AT001/r84	.	.	Phase 1	D0NO1A	.	CTPDG004566
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	MP-0112	"DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan"	10464700	Phase 1	D0V3HP	.	CTPDG012430
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	SFLT-01	"AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme"	.	Phase 1	D0YZ4T	.	CTPDG012431
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	ABI-011	.	.	Phase 1	D0P4KU	.	CTPDG004522
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 17	PMID28621580-Compound-WO2012089137c13	.	Patented	D00ZFY	.	CTPDG012432
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 16	PMID28621580-Compound-WO2012028106c12	.	Patented	D01CKB	.	CTPDG012433
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 18	PMID28621580-Compound-WO2014086102c29	.	Patented	D01DJZ	.	CTPDG012434
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 11	PMID28621580-Compound-WO2016059057	.	Patented	D01IFD	.	CTPDG012435
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 2	PMID28621580-Compound-US20130096136c42	71522446	Patented	D01OEF	.	CTPDG012436
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 16	PMID28621580-Compound-WO2013037293c26	.	Patented	D03HPW	.	CTPDG012437
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 22	PMID28621580-Compound-WO2014040243c18	.	Patented	D03SZN	.	CTPDG012438
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 1"	PMID28621580-Compound-WO2013032797c63	.	Patented	D03VXQ	.	CTPDG012439
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"1,6-naphyridine-4-ketone fused heterocyclic derivative 1"	PMID28621580-Compound-WO2013097753c65	.	Patented	D04UKD	.	CTPDG012440
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 5	PMID28621580-Compound-US20160096832c60	.	Patented	D05GVV	.	CTPDG006171
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013112959C68	.	.	Patented	D05LBH	.	CTPDG012441
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 23	PMID28621580-Compound-WO2014201127c20	.	Patented	D05WTW	.	CTPDG012442
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 7	PMID28621580-Compound-WO2013112950c37	.	Patented	D06ARD	.	CTPDG012443
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 9	PMID28621580-Compound-WO2010066684c55	.	Patented	D07ESG	.	CTPDG012444
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 4	PMID28621580-Compound-WO2012127012c31	.	Patented	D07UJJ	.	CTPDG012445
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 5	PMID28621580-Compound-WO2013015657c41	.	Patented	D08INZ	.	CTPDG012446
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 15	PMID28621580-Compound-US20160096828c21	.	Patented	D08XDA	.	CTPDG012447
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 3	PMID28621580-Compound-WO2012125123	.	Patented	D09GWR	.	CTPDG012448
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 7	PMID28621580-Compound-US20169233968c59	.	Patented	D09KYB	.	CTPDG006060
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 18	PMID28621580-Compound-WO2012094451c15	.	Patented	D0A5NC	.	CTPDG012449
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 21	PMID28621580-Compound-WO2015117551c25	.	Patented	D0A8SH	.	CTPDG012450
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 10	PMID28621580-Compound-WO2014000686c53	.	Patented	D0A9RY	.	CTPDG012451
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 7	PMID28621580-Compound-WO2013044362c44	.	Patented	D0BA5J	.	CTPDG012452
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 6	PMID28621580-Compound-WO2013040515c36	.	Patented	D0BL4H	.	CTPDG012453
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 7	PMID28621580-Compound-WO2014055998	.	Patented	D0CE1R	.	CTPDG006006
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 2	PMID28621580-Compound-WO2012088563	.	Patented	D0D0AX	.	CTPDG012454
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 3	PMID28621580-Compound-US20140336108c48	.	Patented	D0D7SL	.	CTPDG012455
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 8	PMID28621580-Compound-WO2014029250c45	.	Patented	D0DA6B	.	CTPDG012456
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 19	PMID28621580-Compound-WO2012139499c14	.	Patented	D0DI5S	.	CTPDG012457
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 13	PMID28621580-Compound-WO2012088506c23	.	Patented	D0E5IJ	.	CTPDG012458
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 11	PMID28621580-Compound-WO2014139458c54	.	Patented	D0EE3P	.	CTPDG012459
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 8	PMID28621580-Compound-US20169296747c52	.	Patented	D0FK5P	.	CTPDG012460
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 10	PMID28621580-Compound-WO2014127335c34	.	Patented	D0FK6Y	.	CTPDG012461
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 8	PMID28621580-Compound-WO2014113859c33	.	Patented	D0FL6P	.	CTPDG012462
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 10	PMID28621580-Compound-WO2014040242c47	.	Patented	D0FY2Q	.	CTPDG012463
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 14	PMID28621580-Compound-WO2012139019c24	.	Patented	D0HO5B	.	CTPDG012464
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2014079545C69	.	.	Patented	D0HX9S	.	CTPDG012465
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 14	PMID28621580-Compound-US20140256819c19	.	Patented	D0I6WJ	.	CTPDG012466
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 11	PMID28621580-Compound-WO2015075483c49	.	Patented	D0IZ8B	.	CTPDG012467
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 9	PMID28621580-Compound-WO2014029251c46	.	Patented	D0KW0F	.	CTPDG012468
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 5	PMID28621580-Compound-WO2012171487c32	.	Patented	D0M2XJ	.	CTPDG012469
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 4	PMID28621580-Compound-WO2012169934c40	.	Patented	D0M9KZ	.	CTPDG005777
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 3	PMID28621580-Compound-US20150158854c39	.	Patented	D0MA6I	.	CTPDG012470
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 2	PMID28621580-Compound-US20130165458c38	.	Patented	D0O5IA	.	CTPDG012471
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 17	PMID28621580-Compound-WO2014086102c28	.	Patented	D0O8RZ	.	CTPDG012472
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 19	PMID28621580-Compound-WO2014102377c27	.	Patented	D0Q4XV	.	CTPDG012473
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 6	PMID28621580-Compound-WO2013044361c43	.	Patented	D0S4XH	.	CTPDG012474
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 9	PMID28621580-Compound-WO2014127214c35	.	Patented	D0SH2Y	.	CTPDG012475
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1	PMID28621580-Compound-WO2013101954c67	.	Patented	D0T1GG	.	CTPDG005642
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013036866C66	.	.	Patented	D0T9DV	.	CTPDG005634
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 8	PMID28621580-Compound-WO2014081202	.	Patented	D0U6PW	.	CTPDG012476
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 6	PMID28621580-Compound-US20160096837c61	.	Patented	D0V7OF	.	CTPDG005600
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 20	PMID28621580-Compound-WO2013037292c17	60171803	Patented	D0VI1V	.	CTPDG012477
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 15	PMID28621580-Compound-WO2012139019c25	.	Patented	D0VX5Y	.	CTPDG012478
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 9	PMID28621580-Compound-WO2016044219	.	Patented	D0WL5P	.	CTPDG005578
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 1	PMID28621580-Compound-WO2012004631	.	Patented	D0X2BP	.	CTPDG012479
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 20	PMID28621580-Compound-WO2015117551c24	.	Patented	D0X2MF	.	CTPDG012480
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 21	PMID28621580-Compound-WO2013107225c16	.	Patented	D0XS0Z	.	CTPDG012481
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 4	PMID28621580-Compound-WO2012161372	.	Patented	D0Y2IV	.	CTPDG012482
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 12	PMID28621580-Compound-WO2012088506c22	.	Patented	D0Z0SY	.	CTPDG012483
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 2"	PMID28621580-Compound-WO2013032797c64	.	Patented	D0ZE2J	.	CTPDG012484
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Discontinued in Phase 3	Bevasiranib	.	.	Discontinued in Phase 3	D0YG4I	.	CTPDG012485
M6ACROT00625	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Terminated	ALN-VEG01	"RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck"	.	Terminated	D05ITS	.	CTPDG015424
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Ranibizumab	"Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)"	.	Approved	D04EYG	.	CTPDG012421
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Brolucizumab	.	.	Approved	D5DO9L	.	CTPDG012422
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Faricimab	RO6867461; RG7716	.	Approved	D9MWL4	.	CTPDG012423
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Rituximab	.	24801580	Phase 3	D08CGU	.	CTPDG012424
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Trastuzumab	"Lithocholic acid; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,"	9903	Phase 3	D04SLF	.	CTPDG009886
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	Abicipar pegol	.	.	Phase 2	D0CJ7Z	.	CTPDG012426
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RO5520985	.	.	Phase 2	D0I8YS	.	CTPDG012427
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	SNN-0029	"VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech"	.	Phase 1/2	D0E7RQ	.	CTPDG012428
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	MP0250	.	.	Phase 1/2	D0ME7Q	.	CTPDG012429
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	AT001/r84	.	.	Phase 1	D0NO1A	.	CTPDG004566
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	MP-0112	"DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan"	10464700	Phase 1	D0V3HP	.	CTPDG012430
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	SFLT-01	"AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme"	.	Phase 1	D0YZ4T	.	CTPDG012431
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	ABI-011	.	.	Phase 1	D0P4KU	.	CTPDG004522
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 17	PMID28621580-Compound-WO2012089137c13	.	Patented	D00ZFY	.	CTPDG012432
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 16	PMID28621580-Compound-WO2012028106c12	.	Patented	D01CKB	.	CTPDG012433
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 18	PMID28621580-Compound-WO2014086102c29	.	Patented	D01DJZ	.	CTPDG012434
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 11	PMID28621580-Compound-WO2016059057	.	Patented	D01IFD	.	CTPDG012435
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 2	PMID28621580-Compound-US20130096136c42	71522446	Patented	D01OEF	.	CTPDG012436
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 16	PMID28621580-Compound-WO2013037293c26	.	Patented	D03HPW	.	CTPDG012437
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 22	PMID28621580-Compound-WO2014040243c18	.	Patented	D03SZN	.	CTPDG012438
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 1"	PMID28621580-Compound-WO2013032797c63	.	Patented	D03VXQ	.	CTPDG012439
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"1,6-naphyridine-4-ketone fused heterocyclic derivative 1"	PMID28621580-Compound-WO2013097753c65	.	Patented	D04UKD	.	CTPDG012440
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 5	PMID28621580-Compound-US20160096832c60	.	Patented	D05GVV	.	CTPDG006171
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013112959C68	.	.	Patented	D05LBH	.	CTPDG012441
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 23	PMID28621580-Compound-WO2014201127c20	.	Patented	D05WTW	.	CTPDG012442
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 7	PMID28621580-Compound-WO2013112950c37	.	Patented	D06ARD	.	CTPDG012443
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 9	PMID28621580-Compound-WO2010066684c55	.	Patented	D07ESG	.	CTPDG012444
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 4	PMID28621580-Compound-WO2012127012c31	.	Patented	D07UJJ	.	CTPDG012445
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 5	PMID28621580-Compound-WO2013015657c41	.	Patented	D08INZ	.	CTPDG012446
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 15	PMID28621580-Compound-US20160096828c21	.	Patented	D08XDA	.	CTPDG012447
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 3	PMID28621580-Compound-WO2012125123	.	Patented	D09GWR	.	CTPDG012448
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 7	PMID28621580-Compound-US20169233968c59	.	Patented	D09KYB	.	CTPDG006060
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 18	PMID28621580-Compound-WO2012094451c15	.	Patented	D0A5NC	.	CTPDG012449
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 21	PMID28621580-Compound-WO2015117551c25	.	Patented	D0A8SH	.	CTPDG012450
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 10	PMID28621580-Compound-WO2014000686c53	.	Patented	D0A9RY	.	CTPDG012451
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 7	PMID28621580-Compound-WO2013044362c44	.	Patented	D0BA5J	.	CTPDG012452
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 6	PMID28621580-Compound-WO2013040515c36	.	Patented	D0BL4H	.	CTPDG012453
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 7	PMID28621580-Compound-WO2014055998	.	Patented	D0CE1R	.	CTPDG006006
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 2	PMID28621580-Compound-WO2012088563	.	Patented	D0D0AX	.	CTPDG012454
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 3	PMID28621580-Compound-US20140336108c48	.	Patented	D0D7SL	.	CTPDG012455
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 8	PMID28621580-Compound-WO2014029250c45	.	Patented	D0DA6B	.	CTPDG012456
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 19	PMID28621580-Compound-WO2012139499c14	.	Patented	D0DI5S	.	CTPDG012457
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 13	PMID28621580-Compound-WO2012088506c23	.	Patented	D0E5IJ	.	CTPDG012458
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 11	PMID28621580-Compound-WO2014139458c54	.	Patented	D0EE3P	.	CTPDG012459
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 8	PMID28621580-Compound-US20169296747c52	.	Patented	D0FK5P	.	CTPDG012460
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 10	PMID28621580-Compound-WO2014127335c34	.	Patented	D0FK6Y	.	CTPDG012461
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 8	PMID28621580-Compound-WO2014113859c33	.	Patented	D0FL6P	.	CTPDG012462
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 10	PMID28621580-Compound-WO2014040242c47	.	Patented	D0FY2Q	.	CTPDG012463
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 14	PMID28621580-Compound-WO2012139019c24	.	Patented	D0HO5B	.	CTPDG012464
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2014079545C69	.	.	Patented	D0HX9S	.	CTPDG012465
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 14	PMID28621580-Compound-US20140256819c19	.	Patented	D0I6WJ	.	CTPDG012466
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 11	PMID28621580-Compound-WO2015075483c49	.	Patented	D0IZ8B	.	CTPDG012467
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 9	PMID28621580-Compound-WO2014029251c46	.	Patented	D0KW0F	.	CTPDG012468
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 5	PMID28621580-Compound-WO2012171487c32	.	Patented	D0M2XJ	.	CTPDG012469
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 4	PMID28621580-Compound-WO2012169934c40	.	Patented	D0M9KZ	.	CTPDG005777
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 3	PMID28621580-Compound-US20150158854c39	.	Patented	D0MA6I	.	CTPDG012470
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 2	PMID28621580-Compound-US20130165458c38	.	Patented	D0O5IA	.	CTPDG012471
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 17	PMID28621580-Compound-WO2014086102c28	.	Patented	D0O8RZ	.	CTPDG012472
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 19	PMID28621580-Compound-WO2014102377c27	.	Patented	D0Q4XV	.	CTPDG012473
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 6	PMID28621580-Compound-WO2013044361c43	.	Patented	D0S4XH	.	CTPDG012474
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 9	PMID28621580-Compound-WO2014127214c35	.	Patented	D0SH2Y	.	CTPDG012475
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1	PMID28621580-Compound-WO2013101954c67	.	Patented	D0T1GG	.	CTPDG005642
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013036866C66	.	.	Patented	D0T9DV	.	CTPDG005634
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 8	PMID28621580-Compound-WO2014081202	.	Patented	D0U6PW	.	CTPDG012476
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 6	PMID28621580-Compound-US20160096837c61	.	Patented	D0V7OF	.	CTPDG005600
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 20	PMID28621580-Compound-WO2013037292c17	60171803	Patented	D0VI1V	.	CTPDG012477
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 15	PMID28621580-Compound-WO2012139019c25	.	Patented	D0VX5Y	.	CTPDG012478
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 9	PMID28621580-Compound-WO2016044219	.	Patented	D0WL5P	.	CTPDG005578
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 1	PMID28621580-Compound-WO2012004631	.	Patented	D0X2BP	.	CTPDG012479
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 20	PMID28621580-Compound-WO2015117551c24	.	Patented	D0X2MF	.	CTPDG012480
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 21	PMID28621580-Compound-WO2013107225c16	.	Patented	D0XS0Z	.	CTPDG012481
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 4	PMID28621580-Compound-WO2012161372	.	Patented	D0Y2IV	.	CTPDG012482
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 12	PMID28621580-Compound-WO2012088506c22	.	Patented	D0Z0SY	.	CTPDG012483
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 2"	PMID28621580-Compound-WO2013032797c64	.	Patented	D0ZE2J	.	CTPDG012484
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Discontinued in Phase 3	Bevasiranib	.	.	Discontinued in Phase 3	D0YG4I	.	CTPDG012485
M6ACROT00626	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Terminated	ALN-VEG01	"RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck"	.	Terminated	D05ITS	.	CTPDG015424
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT00627	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT00631	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT00633	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT00633	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT00633	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT00633	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00649	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00650	Protein c-Fos (FOS)	FOS_HUMAN	.	.	Investigative	ISIS 10639	.	.	Investigative	D0Z2OW	.	CTPDG015498
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00655	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00656	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00657	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT00658	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00660	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT00663	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT00664	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Approved	Gemcitabine	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	60750	Approved	D03UVS	DB00441	CTPDG000694
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Approved	Hydroxyurea	"Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA"	3657	Approved	D07CWD	DB01005	CTPDG011041
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 2	Triapine	"236392-56-6; 143621-35-6; 3-Apct; Pan 811; 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP; UNII-U4XIL4091C; NSC 663249; 200933-27-3; OCX 191; 2-((3-Aminopyridin-2-yl)methylene)hydrazinecarbothioamide; C7H9N5S; PAN-811; U4XIL4091C; 3-aminopyridine-2-carbaldehyde-thiosemicarbazone; [(E)-(3-amino-2-pyridyl)methyleneamino]thiourea; 3-Aminopyridine-2-carboxaldehyde- thiosemicarbazone; Hydrazinecarbothioamide, 2-((3-amino-2-pyridinyl)methylene)-; (E)-2-((3-aminopyridin-2-yl)methylene)hydrazinecarbothioamide"	9571836	Phase 2	D0DT1R	DB11940	CTPDG011042
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 1	CALAA-01	"Ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando"	.	Phase 1	D0A1GR	.	CTPDG004950
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 1	LY-2334737	"Gem prodrug (cancer), Eli Lilly; Gemcitabine prodrug (cancer), Lilly"	11646777	Phase 1	D0F2JY	DB12906	CTPDG004812
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Discontinued in Phase 2	Gallium maltolate	GaM	9846339	Discontinued in Phase 2	D05ACQ	DB05420	CTPDG011043
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT00665	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Preclinical	NKP-46	FFC-11; KP-46	.	Preclinical	D0V2RK	.	CTPDG007040
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Approved	Gemcitabine	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	60750	Approved	D03UVS	DB00441	CTPDG000694
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Approved	Hydroxyurea	"Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA"	3657	Approved	D07CWD	DB01005	CTPDG011041
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 2	Triapine	"236392-56-6; 143621-35-6; 3-Apct; Pan 811; 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP; UNII-U4XIL4091C; NSC 663249; 200933-27-3; OCX 191; 2-((3-Aminopyridin-2-yl)methylene)hydrazinecarbothioamide; C7H9N5S; PAN-811; U4XIL4091C; 3-aminopyridine-2-carbaldehyde-thiosemicarbazone; [(E)-(3-amino-2-pyridyl)methyleneamino]thiourea; 3-Aminopyridine-2-carboxaldehyde- thiosemicarbazone; Hydrazinecarbothioamide, 2-((3-amino-2-pyridinyl)methylene)-; (E)-2-((3-aminopyridin-2-yl)methylene)hydrazinecarbothioamide"	9571836	Phase 2	D0DT1R	DB11940	CTPDG011042
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 2	CO-101	"methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester"	9828310	Phase 2	D0V0CJ	DB12564	CTPDG001969
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 1	CALAA-01	"Ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando"	.	Phase 1	D0A1GR	.	CTPDG004950
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Phase 1	LY-2334737	"Gem prodrug (cancer), Eli Lilly; Gemcitabine prodrug (cancer), Lilly"	11646777	Phase 1	D0F2JY	DB12906	CTPDG004812
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Discontinued in Phase 2	Gallium maltolate	GaM	9846339	Discontinued in Phase 2	D05ACQ	DB05420	CTPDG011043
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Discontinued in Phase 2	"MDL 101,731"	"Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331"	6435808	Discontinued in Phase 2	D05HZI	DB06433	CTPDG006619
M6ACROT00666	Ribonucleotide reductase regulatory subunit M2 (RRM2)	RIR2_HUMAN	.	.	Preclinical	NKP-46	FFC-11; KP-46	.	Preclinical	D0V2RK	.	CTPDG007040
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Metastat	.	54678924	Phase 1	D0IJ7O	DB11647	CTPDG009945
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9b)	.	.	Patented	D0A9ZW	.	CTPDG009946
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9a)	.	58107501	Patented	D0LS4Y	.	CTPDG009948
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14)	.	.	Patented	D0O8RQ	.	CTPDG009949
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9c)	.	.	Patented	D0S3PN	.	CTPDG009951
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure11(3)	.	.	Patented	D0Y1LO	.	CTPDG009953
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure10(2a)	.	.	Patented	D05GAP	.	CTPDG009716
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	Discontinued in Phase 3	D01EUF	.	CTPDG006392
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Preclinical	RO-26-2853	.	.	Preclinical	D0C0ME	.	CTPDG007096
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	L-696418	CHEMBL8494; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	Terminated	D08CEE	.	CTPDG009721
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-3644	SCHEMBL609641	9822724	Terminated	D08WBF	.	CTPDG007429
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-1101	CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	Terminated	D05VNG	.	CTPDG009722
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Lithospermic acid	"28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	Investigative	D06ALC	.	CTPDG009954
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SC-74020	CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	Investigative	D08NSS	DB01630	CTPDG009955
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Clinopodic acid C	"CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	Investigative	D0H9BL	.	CTPDG009956
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	Investigative	D0T1FR	.	CTPDG009957
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PD-169469	CHEMBL42420; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	Investigative	D02EFQ	.	CTPDG009959
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; BDBM50180608	44406790	Investigative	D05JPV	.	CTPDG009960
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PNU-107859	"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	Investigative	D0F7BE	DB07390	CTPDG009964
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	Investigative	D0ZB6O	.	CTPDG009968
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT00667	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Metastat	.	54678924	Phase 1	D0IJ7O	DB11647	CTPDG009945
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9b)	.	.	Patented	D0A9ZW	.	CTPDG009946
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9a)	.	58107501	Patented	D0LS4Y	.	CTPDG009948
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14)	.	.	Patented	D0O8RQ	.	CTPDG009949
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9c)	.	.	Patented	D0S3PN	.	CTPDG009951
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure11(3)	.	.	Patented	D0Y1LO	.	CTPDG009953
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure10(2a)	.	.	Patented	D05GAP	.	CTPDG009716
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	Discontinued in Phase 3	D01EUF	.	CTPDG006392
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Preclinical	RO-26-2853	.	.	Preclinical	D0C0ME	.	CTPDG007096
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	L-696418	CHEMBL8494; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	Terminated	D08CEE	.	CTPDG009721
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-3644	SCHEMBL609641	9822724	Terminated	D08WBF	.	CTPDG007429
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-1101	CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	Terminated	D05VNG	.	CTPDG009722
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Lithospermic acid	"28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	Investigative	D06ALC	.	CTPDG009954
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SC-74020	CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	Investigative	D08NSS	DB01630	CTPDG009955
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Clinopodic acid C	"CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	Investigative	D0H9BL	.	CTPDG009956
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	Investigative	D0T1FR	.	CTPDG009957
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PD-169469	CHEMBL42420; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	Investigative	D02EFQ	.	CTPDG009959
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; BDBM50180608	44406790	Investigative	D05JPV	.	CTPDG009960
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PNU-107859	"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	Investigative	D0F7BE	DB07390	CTPDG009964
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	Investigative	D0ZB6O	.	CTPDG009968
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT00668	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Metastat	.	54678924	Phase 1	D0IJ7O	DB11647	CTPDG009945
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9b)	.	.	Patented	D0A9ZW	.	CTPDG009946
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9a)	.	58107501	Patented	D0LS4Y	.	CTPDG009948
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14)	.	.	Patented	D0O8RQ	.	CTPDG009949
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9c)	.	.	Patented	D0S3PN	.	CTPDG009951
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure11(3)	.	.	Patented	D0Y1LO	.	CTPDG009953
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure10(2a)	.	.	Patented	D05GAP	.	CTPDG009716
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	Discontinued in Phase 3	D01EUF	.	CTPDG006392
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Preclinical	RO-26-2853	.	.	Preclinical	D0C0ME	.	CTPDG007096
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	L-696418	CHEMBL8494; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	Terminated	D08CEE	.	CTPDG009721
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-3644	SCHEMBL609641	9822724	Terminated	D08WBF	.	CTPDG007429
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-1101	CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	Terminated	D05VNG	.	CTPDG009722
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Lithospermic acid	"28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	Investigative	D06ALC	.	CTPDG009954
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SC-74020	CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	Investigative	D08NSS	DB01630	CTPDG009955
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Clinopodic acid C	"CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	Investigative	D0H9BL	.	CTPDG009956
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	Investigative	D0T1FR	.	CTPDG009957
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PD-169469	CHEMBL42420; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	Investigative	D02EFQ	.	CTPDG009959
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; BDBM50180608	44406790	Investigative	D05JPV	.	CTPDG009960
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PNU-107859	"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	Investigative	D0F7BE	DB07390	CTPDG009964
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	Investigative	D0ZB6O	.	CTPDG009968
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT00669	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Metastat	.	54678924	Phase 1	D0IJ7O	DB11647	CTPDG009945
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9b)	.	.	Patented	D0A9ZW	.	CTPDG009946
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9a)	.	58107501	Patented	D0LS4Y	.	CTPDG009948
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14)	.	.	Patented	D0O8RQ	.	CTPDG009949
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9c)	.	.	Patented	D0S3PN	.	CTPDG009951
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure11(3)	.	.	Patented	D0Y1LO	.	CTPDG009953
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure10(2a)	.	.	Patented	D05GAP	.	CTPDG009716
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	Discontinued in Phase 3	D01EUF	.	CTPDG006392
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Preclinical	RO-26-2853	.	.	Preclinical	D0C0ME	.	CTPDG007096
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	L-696418	CHEMBL8494; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	Terminated	D08CEE	.	CTPDG009721
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-3644	SCHEMBL609641	9822724	Terminated	D08WBF	.	CTPDG007429
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-1101	CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	Terminated	D05VNG	.	CTPDG009722
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Lithospermic acid	"28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	Investigative	D06ALC	.	CTPDG009954
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SC-74020	CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	Investigative	D08NSS	DB01630	CTPDG009955
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Clinopodic acid C	"CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	Investigative	D0H9BL	.	CTPDG009956
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	Investigative	D0T1FR	.	CTPDG009957
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PD-169469	CHEMBL42420; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	Investigative	D02EFQ	.	CTPDG009959
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; BDBM50180608	44406790	Investigative	D05JPV	.	CTPDG009960
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PNU-107859	"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	Investigative	D0F7BE	DB07390	CTPDG009964
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	Investigative	D0ZB6O	.	CTPDG009968
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT00670	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT00676	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT00679	Krueppel-like factor 4 (KLF4)	KLF4_HUMAN	.	.	Phase 1	APTO-253	.	11960271	Phase 1	D07TRP	.	CTPDG005083
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02001	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02002	Collagen alpha-2(I) chain (COL1A2)	CO1A2_HUMAN	.	.	Phase 2	Solubilized type 1 native bovine collagen	"Solubilized type 1 native bovine collagen (oral, scleroderma); Solubilized type 1 native bovine collagen (oral, scleroderma), arGentis/University of Tennessee"	.	Phase 2	D02CFV	.	CTPDG014657
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02002	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02003	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02004	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02005	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	Approved	D00WCX	DB01393	CTPDG011257
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Pemafibrate	K-877	11526038	Approved	D04QIE	DB15212	CTPDG011258
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	Approved	D07XGR	DB01039	CTPDG011259
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	Approved	D0EJ6O	DB09064	CTPDG011260
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	Phase 3	D0LW1Y	DB05187	CTPDG011261
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	Phase 2	D0I5IM	DB12988	CTPDG011262
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	GFT14	.	.	Phase 2	D0RJ0V	.	CTPDG011263
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ZYH7	.	.	Phase 2	DE6GF4	.	CTPDG011264
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	CDT-fenofibrate	.	.	Phase 1	D00HYD	.	CTPDG011265
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	AVE0897	.	.	Phase 1	D01UJK	.	CTPDG005376
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	TPST-1120	.	.	Phase 1	DF8M1T	.	CTPDG003920
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 3	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	Discontinued in Phase 3	D0B9EN	DB08915	CTPDG006365
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	Discontinued in Phase 2	D08LZI	.	CTPDG011266
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	Discontinued in Phase 2	D0B8JQ	.	CTPDG011267
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	Discontinued in Phase 2	D0Q8UU	.	CTPDG011268
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	Discontinued in Phase 2	D0R5QQ	.	CTPDG011269
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	AR-H049020	.	.	Discontinued in Phase 1	D04FTB	.	CTPDG011270
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	DRF 10945	.	.	Discontinued in Phase 1	D0W3YW	.	CTPDG011271
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	MP-136	.	.	Discontinued in Phase 1	D0Z3XO	.	CTPDG011272
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	Preclinical	D04PBS	.	CTPDG011273
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	PIRINIXIC ACID	"50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	Preclinical	D09XCX	.	CTPDG011274
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	Terminated	D03CUS	.	CTPDG011275
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	KRP-105	.	.	Terminated	D0BB1X	.	CTPDG011276
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW7647	GW-7647; GW 7647	3392731	Investigative	D00TFA	.	CTPDG011277
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	CP-775146	CP775146	10410059	Investigative	D01KPN	.	CTPDG011278
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	Investigative	D05CLM	.	CTPDG011279
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	Investigative	D06RRD	.	CTPDG011280
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	BMS-687453	"1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	Investigative	D08UWZ	.	CTPDG011281
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	Investigative	D0EN7T	.	CTPDG011282
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	Investigative	D0G9IP	.	CTPDG011283
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	Investigative	D0K6TI	.	CTPDG011284
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LL-6531	"PPAR modulators (diabetes), Lupin"	.	Investigative	D0K8HA	.	CTPDG011285
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	Investigative	D0S4GK	DB01890	CTPDG011286
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus"	5281727	Investigative	D00AII	.	CTPDG011287
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT02019	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	N-oleoylethanolamide	n-Oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; NOE	5283454	Investigative	D07MBC	.	CTPDG011298
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02019	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	Approved	D00WCX	DB01393	CTPDG011257
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Pemafibrate	K-877	11526038	Approved	D04QIE	DB15212	CTPDG011258
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	Approved	D07XGR	DB01039	CTPDG011259
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	Approved	D0EJ6O	DB09064	CTPDG011260
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	Phase 3	D0LW1Y	DB05187	CTPDG011261
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	Phase 2	D0I5IM	DB12988	CTPDG011262
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	GFT14	.	.	Phase 2	D0RJ0V	.	CTPDG011263
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ZYH7	.	.	Phase 2	DE6GF4	.	CTPDG011264
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	CDT-fenofibrate	.	.	Phase 1	D00HYD	.	CTPDG011265
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	AVE0897	.	.	Phase 1	D01UJK	.	CTPDG005376
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	TPST-1120	.	.	Phase 1	DF8M1T	.	CTPDG003920
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 3	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	Discontinued in Phase 3	D0B9EN	DB08915	CTPDG006365
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	Discontinued in Phase 2	D08LZI	.	CTPDG011266
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	Discontinued in Phase 2	D0B8JQ	.	CTPDG011267
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	Discontinued in Phase 2	D0Q8UU	.	CTPDG011268
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	Discontinued in Phase 2	D0R5QQ	.	CTPDG011269
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	AR-H049020	.	.	Discontinued in Phase 1	D04FTB	.	CTPDG011270
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	DRF 10945	.	.	Discontinued in Phase 1	D0W3YW	.	CTPDG011271
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	MP-136	.	.	Discontinued in Phase 1	D0Z3XO	.	CTPDG011272
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	Preclinical	D04PBS	.	CTPDG011273
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	PIRINIXIC ACID	"50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	Preclinical	D09XCX	.	CTPDG011274
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	Terminated	D03CUS	.	CTPDG011275
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	KRP-105	.	.	Terminated	D0BB1X	.	CTPDG011276
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW7647	GW-7647; GW 7647	3392731	Investigative	D00TFA	.	CTPDG011277
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	CP-775146	CP775146	10410059	Investigative	D01KPN	.	CTPDG011278
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	Investigative	D05CLM	.	CTPDG011279
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	Investigative	D06RRD	.	CTPDG011280
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	BMS-687453	"1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	Investigative	D08UWZ	.	CTPDG011281
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	Investigative	D0EN7T	.	CTPDG011282
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	Investigative	D0G9IP	.	CTPDG011283
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	Investigative	D0K6TI	.	CTPDG011284
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LL-6531	"PPAR modulators (diabetes), Lupin"	.	Investigative	D0K8HA	.	CTPDG011285
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	Investigative	D0S4GK	DB01890	CTPDG011286
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus"	5281727	Investigative	D00AII	.	CTPDG011287
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT02020	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	N-oleoylethanolamide	n-Oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; NOE	5283454	Investigative	D07MBC	.	CTPDG011298
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02020	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	Approved	D00WCX	DB01393	CTPDG011257
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Pemafibrate	K-877	11526038	Approved	D04QIE	DB15212	CTPDG011258
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	Approved	D07XGR	DB01039	CTPDG011259
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	Approved	D0EJ6O	DB09064	CTPDG011260
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	Phase 3	D0LW1Y	DB05187	CTPDG011261
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	Phase 2	D0I5IM	DB12988	CTPDG011262
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	GFT14	.	.	Phase 2	D0RJ0V	.	CTPDG011263
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ZYH7	.	.	Phase 2	DE6GF4	.	CTPDG011264
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	CDT-fenofibrate	.	.	Phase 1	D00HYD	.	CTPDG011265
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	AVE0897	.	.	Phase 1	D01UJK	.	CTPDG005376
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	TPST-1120	.	.	Phase 1	DF8M1T	.	CTPDG003920
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 3	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	Discontinued in Phase 3	D0B9EN	DB08915	CTPDG006365
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	Discontinued in Phase 2	D08LZI	.	CTPDG011266
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	Discontinued in Phase 2	D0B8JQ	.	CTPDG011267
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	Discontinued in Phase 2	D0Q8UU	.	CTPDG011268
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	Discontinued in Phase 2	D0R5QQ	.	CTPDG011269
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	AR-H049020	.	.	Discontinued in Phase 1	D04FTB	.	CTPDG011270
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	DRF 10945	.	.	Discontinued in Phase 1	D0W3YW	.	CTPDG011271
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	MP-136	.	.	Discontinued in Phase 1	D0Z3XO	.	CTPDG011272
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	Preclinical	D04PBS	.	CTPDG011273
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	PIRINIXIC ACID	"50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	Preclinical	D09XCX	.	CTPDG011274
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	Terminated	D03CUS	.	CTPDG011275
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	KRP-105	.	.	Terminated	D0BB1X	.	CTPDG011276
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW7647	GW-7647; GW 7647	3392731	Investigative	D00TFA	.	CTPDG011277
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	CP-775146	CP775146	10410059	Investigative	D01KPN	.	CTPDG011278
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	Investigative	D05CLM	.	CTPDG011279
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	Investigative	D06RRD	.	CTPDG011280
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	BMS-687453	"1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	Investigative	D08UWZ	.	CTPDG011281
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	Investigative	D0EN7T	.	CTPDG011282
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	Investigative	D0G9IP	.	CTPDG011283
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	Investigative	D0K6TI	.	CTPDG011284
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LL-6531	"PPAR modulators (diabetes), Lupin"	.	Investigative	D0K8HA	.	CTPDG011285
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	Investigative	D0S4GK	DB01890	CTPDG011286
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus"	5281727	Investigative	D00AII	.	CTPDG011287
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT02021	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	N-oleoylethanolamide	n-Oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; NOE	5283454	Investigative	D07MBC	.	CTPDG011298
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02021	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	Approved	D00WCX	DB01393	CTPDG011257
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Pemafibrate	K-877	11526038	Approved	D04QIE	DB15212	CTPDG011258
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	Approved	D07XGR	DB01039	CTPDG011259
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	Approved	D0EJ6O	DB09064	CTPDG011260
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	Phase 3	D0LW1Y	DB05187	CTPDG011261
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	Phase 2	D0I5IM	DB12988	CTPDG011262
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	GFT14	.	.	Phase 2	D0RJ0V	.	CTPDG011263
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ZYH7	.	.	Phase 2	DE6GF4	.	CTPDG011264
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	CDT-fenofibrate	.	.	Phase 1	D00HYD	.	CTPDG011265
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	AVE0897	.	.	Phase 1	D01UJK	.	CTPDG005376
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	TPST-1120	.	.	Phase 1	DF8M1T	.	CTPDG003920
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 3	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	Discontinued in Phase 3	D0B9EN	DB08915	CTPDG006365
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	Discontinued in Phase 2	D08LZI	.	CTPDG011266
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	Discontinued in Phase 2	D0B8JQ	.	CTPDG011267
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	Discontinued in Phase 2	D0Q8UU	.	CTPDG011268
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	Discontinued in Phase 2	D0R5QQ	.	CTPDG011269
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	AR-H049020	.	.	Discontinued in Phase 1	D04FTB	.	CTPDG011270
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	DRF 10945	.	.	Discontinued in Phase 1	D0W3YW	.	CTPDG011271
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	MP-136	.	.	Discontinued in Phase 1	D0Z3XO	.	CTPDG011272
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	Preclinical	D04PBS	.	CTPDG011273
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	PIRINIXIC ACID	"50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	Preclinical	D09XCX	.	CTPDG011274
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	Terminated	D03CUS	.	CTPDG011275
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	KRP-105	.	.	Terminated	D0BB1X	.	CTPDG011276
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW7647	GW-7647; GW 7647	3392731	Investigative	D00TFA	.	CTPDG011277
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	CP-775146	CP775146	10410059	Investigative	D01KPN	.	CTPDG011278
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	Investigative	D05CLM	.	CTPDG011279
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	Investigative	D06RRD	.	CTPDG011280
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	BMS-687453	"1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	Investigative	D08UWZ	.	CTPDG011281
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	Investigative	D0EN7T	.	CTPDG011282
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	Investigative	D0G9IP	.	CTPDG011283
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	Investigative	D0K6TI	.	CTPDG011284
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LL-6531	"PPAR modulators (diabetes), Lupin"	.	Investigative	D0K8HA	.	CTPDG011285
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	Investigative	D0S4GK	DB01890	CTPDG011286
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus"	5281727	Investigative	D00AII	.	CTPDG011287
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT02022	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	N-oleoylethanolamide	n-Oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; NOE	5283454	Investigative	D07MBC	.	CTPDG011298
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02022	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	Approved	D00WCX	DB01393	CTPDG011257
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Pemafibrate	K-877	11526038	Approved	D04QIE	DB15212	CTPDG011258
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	Approved	D07XGR	DB01039	CTPDG011259
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	Approved	D0EJ6O	DB09064	CTPDG011260
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	Phase 3	D0LW1Y	DB05187	CTPDG011261
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	Phase 2	D0I5IM	DB12988	CTPDG011262
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	GFT14	.	.	Phase 2	D0RJ0V	.	CTPDG011263
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ZYH7	.	.	Phase 2	DE6GF4	.	CTPDG011264
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	CDT-fenofibrate	.	.	Phase 1	D00HYD	.	CTPDG011265
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	AVE0897	.	.	Phase 1	D01UJK	.	CTPDG005376
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	TPST-1120	.	.	Phase 1	DF8M1T	.	CTPDG003920
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 3	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	Discontinued in Phase 3	D0B9EN	DB08915	CTPDG006365
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	Discontinued in Phase 2	D08LZI	.	CTPDG011266
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	Discontinued in Phase 2	D0B8JQ	.	CTPDG011267
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	Discontinued in Phase 2	D0Q8UU	.	CTPDG011268
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	Discontinued in Phase 2	D0R5QQ	.	CTPDG011269
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	AR-H049020	.	.	Discontinued in Phase 1	D04FTB	.	CTPDG011270
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	DRF 10945	.	.	Discontinued in Phase 1	D0W3YW	.	CTPDG011271
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	MP-136	.	.	Discontinued in Phase 1	D0Z3XO	.	CTPDG011272
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	Preclinical	D04PBS	.	CTPDG011273
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	PIRINIXIC ACID	"50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	Preclinical	D09XCX	.	CTPDG011274
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	Terminated	D03CUS	.	CTPDG011275
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	KRP-105	.	.	Terminated	D0BB1X	.	CTPDG011276
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW7647	GW-7647; GW 7647	3392731	Investigative	D00TFA	.	CTPDG011277
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	CP-775146	CP775146	10410059	Investigative	D01KPN	.	CTPDG011278
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	Investigative	D05CLM	.	CTPDG011279
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	Investigative	D06RRD	.	CTPDG011280
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	BMS-687453	"1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	Investigative	D08UWZ	.	CTPDG011281
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	Investigative	D0EN7T	.	CTPDG011282
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	Investigative	D0G9IP	.	CTPDG011283
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	Investigative	D0K6TI	.	CTPDG011284
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LL-6531	"PPAR modulators (diabetes), Lupin"	.	Investigative	D0K8HA	.	CTPDG011285
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	Investigative	D0S4GK	DB01890	CTPDG011286
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus"	5281727	Investigative	D00AII	.	CTPDG011287
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT02023	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	N-oleoylethanolamide	n-Oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; NOE	5283454	Investigative	D07MBC	.	CTPDG011298
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02023	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	Approved	D00WCX	DB01393	CTPDG011257
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Pemafibrate	K-877	11526038	Approved	D04QIE	DB15212	CTPDG011258
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	Approved	D07XGR	DB01039	CTPDG011259
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	Approved	D0EJ6O	DB09064	CTPDG011260
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	Phase 3	D0LW1Y	DB05187	CTPDG011261
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	Phase 2	D0I5IM	DB12988	CTPDG011262
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	GFT14	.	.	Phase 2	D0RJ0V	.	CTPDG011263
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ZYH7	.	.	Phase 2	DE6GF4	.	CTPDG011264
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	CDT-fenofibrate	.	.	Phase 1	D00HYD	.	CTPDG011265
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	AVE0897	.	.	Phase 1	D01UJK	.	CTPDG005376
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	TPST-1120	.	.	Phase 1	DF8M1T	.	CTPDG003920
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 3	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	Discontinued in Phase 3	D0B9EN	DB08915	CTPDG006365
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	Discontinued in Phase 2	D08LZI	.	CTPDG011266
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	Discontinued in Phase 2	D0B8JQ	.	CTPDG011267
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	Discontinued in Phase 2	D0Q8UU	.	CTPDG011268
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	Discontinued in Phase 2	D0R5QQ	.	CTPDG011269
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	AR-H049020	.	.	Discontinued in Phase 1	D04FTB	.	CTPDG011270
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	Discontinued in Phase 1	D09SLU	.	CTPDG006844
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	DRF 10945	.	.	Discontinued in Phase 1	D0W3YW	.	CTPDG011271
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	MP-136	.	.	Discontinued in Phase 1	D0Z3XO	.	CTPDG011272
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	Preclinical	D04PBS	.	CTPDG011273
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	PIRINIXIC ACID	"50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	Preclinical	D09XCX	.	CTPDG011274
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	Preclinical	D0U2FN	.	CTPDG007045
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	Terminated	D03CUS	.	CTPDG011275
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	KRP-105	.	.	Terminated	D0BB1X	.	CTPDG011276
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW7647	GW-7647; GW 7647	3392731	Investigative	D00TFA	.	CTPDG011277
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	CP-775146	CP775146	10410059	Investigative	D01KPN	.	CTPDG011278
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	Investigative	D05CLM	.	CTPDG011279
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	Investigative	D06RRD	.	CTPDG011280
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	BMS-687453	"1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	Investigative	D08UWZ	.	CTPDG011281
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	Investigative	D0EN7T	.	CTPDG011282
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	Investigative	D0G9IP	.	CTPDG011283
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	Investigative	D0K6TI	.	CTPDG011284
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LL-6531	"PPAR modulators (diabetes), Lupin"	.	Investigative	D0K8HA	.	CTPDG011285
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	Investigative	D0S4GK	DB01890	CTPDG011286
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus"	5281727	Investigative	D00AII	.	CTPDG011287
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT02024	Peroxisome proliferator-activated receptor alpha (PPARalpha/PPARA)	PPARA_HUMAN	.	.	Investigative	N-oleoylethanolamide	n-Oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; NOE	5283454	Investigative	D07MBC	.	CTPDG011298
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02024	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02025	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02026	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02029	Krueppel-like factor 4 (KLF4)	KLF4_HUMAN	.	.	Phase 1	APTO-253	.	11960271	Phase 1	D07TRP	.	CTPDG005083
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02030	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02031	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02032	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02033	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02034	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02035	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02035	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Phase 3	GED-0301	"SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani"	.	Phase 3	D09FKY	.	CTPDG001312
M6ACROT02035	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Phase 3	GED-0301	"SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani"	.	Phase 3	D09FKY	.	CTPDG001312
M6ACROT02035	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28466	.	.	Investigative	D01VBU	.	CTPDG014691
M6ACROT02035	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28477	.	.	Investigative	D03BSQ	.	CTPDG014692
M6ACROT02035	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28465	.	.	Investigative	D0AL2R	.	CTPDG014693
M6ACROT02035	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28472	.	.	Investigative	D0E0WX	.	CTPDG014694
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02036	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02036	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT02036	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT02036	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02037	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02038	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02038	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Phase 3	GED-0301	"SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani"	.	Phase 3	D09FKY	.	CTPDG001312
M6ACROT02038	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Phase 3	GED-0301	"SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani"	.	Phase 3	D09FKY	.	CTPDG001312
M6ACROT02038	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28466	.	.	Investigative	D01VBU	.	CTPDG014691
M6ACROT02038	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28477	.	.	Investigative	D03BSQ	.	CTPDG014692
M6ACROT02038	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28465	.	.	Investigative	D0AL2R	.	CTPDG014693
M6ACROT02038	Mothers against decapentaplegic homolog 7 (SMAD7)	SMAD7_HUMAN	.	.	Investigative	ISIS 28472	.	.	Investigative	D0E0WX	.	CTPDG014694
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02039	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02039	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT02039	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT02039	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02040	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02041	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02042	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02043	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02044	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02044	Neurogenic locus notch homolog protein 2 (NOTCH2)	NOTC2_HUMAN	.	.	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02045	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02045	Neurogenic locus notch homolog protein 2 (NOTCH2)	NOTC2_HUMAN	.	.	Phase 2	Tarextumab	.	.	Phase 2	D01QLP	.	CTPDG003018
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02046	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02047	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02048	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02049	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02050	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02051	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02052	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02053	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02054	Insulin-like growth factor-binding protein 3 (IGFBP3)	IBP3_HUMAN	.	.	Phase 2	Salvianolic acid B	"115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0"	11629084	Phase 2	D2GV9Q	.	CTPDG014799
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02054	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02055	Insulin-like growth factor-binding protein 3 (IGFBP3)	IBP3_HUMAN	.	.	Phase 2	Salvianolic acid B	"115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0"	11629084	Phase 2	D2GV9Q	.	CTPDG014799
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02055	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02056	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02056	Insulin-like growth factor-binding protein 3 (IGFBP3)	IBP3_HUMAN	.	.	Phase 2	Salvianolic acid B	"115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0"	11629084	Phase 2	D2GV9Q	.	CTPDG014799
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02057	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02057	Insulin-like growth factor-binding protein 3 (IGFBP3)	IBP3_HUMAN	.	.	Phase 2	Salvianolic acid B	"115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0"	11629084	Phase 2	D2GV9Q	.	CTPDG014799
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02058	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02059	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02060	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02061	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02062	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02063	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02064	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02065	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02066	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02067	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02068	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02069	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02070	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02071	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02072	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02073	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02074	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02075	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT02075	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT02075	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02075	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02075	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02075	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02076	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02077	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluocinolone Acetonide	"Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide"	6215	Approved	D02QJH	DB00591	CTPDG010556
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Triamcinolone	"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone"	31307	Approved	D03BLF	DB00620	CTPDG010557
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mometasone	"Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione"	441335	Approved	D03HYX	DB00764	CTPDG010558
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Valerate	Beta-val; Betaderm; Betatrex; Dermabet; Valnac	16533	Approved	D03SXE	.	CTPDG010559
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortamate	"Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate"	84088	Approved	D05RXI	DB00769	CTPDG010560
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Benzoate	Uticort	5282492	Approved	D06CWH	.	CTPDG010561
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Methylprednisolone	Depo-medrol; M-predrol; Medrol; Medrol Acetate	6741	Approved	D08PIQ	DB00959	CTPDG000519
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Deflazacort	C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927	189821	Approved	D09WYX	DB11921	CTPDG000479
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone	"378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate"	9782	Approved	D0CW1P	DB00443	CTPDG010562
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisolone	"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos"	5755	Approved	D0D1SG	DB00860	CTPDG000427
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Flunisolide	"Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione"	82153	Approved	D0FM2P	DB00180	CTPDG010563
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Meprednisone	Betapar	5284587	Approved	D0I5DS	DB09383	CTPDG000347
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortisone	"Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone"	5754	Approved	D0KR5B	DB00741	CTPDG010565
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluticasone	"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate"	5311101	Approved	D0LC6K	DB13867	CTPDG010566
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone sodium phosphate	"EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel"	16961	Approved	D0NA8U	.	CTPDG010567
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluorometholone	"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione"	9878	Approved	D0P0HT	DB00324	CTPDG000227
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mifepristone	"Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma"	55245	Approved	D0Z4EI	DB00834	CTPDG000034
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	FST-201	"Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics"	.	Phase 3	D00TPW	.	CTPDG010568
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	Mapracorat	"BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb"	24795088	Phase 3	D01IUS	DB12041	CTPDG010569
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	CORT-125134	"relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui"	73051463	Phase 3	D03WNG	DB14976	CTPDG001433
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	TLC599	.	.	Phase 3	D4R1JE	.	CTPDG010570
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	IONIS-GCCRRX	.	.	Phase 2	D01HYQ	.	CTPDG003038
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG-34517	"11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one"	9867361	Phase 2	D05MDJ	DB05423	CTPDG010571
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	LAS-41002	"Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall"	.	Phase 2	D05RXW	.	CTPDG010572
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	DE-110	"Selective glucocorticoid receptor agonist (allergy), Santen"	.	Phase 2	D0I1DZ	.	CTPDG010573
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	TPI-1020	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate	.	Phase 2	D0T5TU	.	CTPDG002016
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT113176	"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone; {(4aR)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)benzene-1-sulfonyl]-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a- yl}(pyridin-2-yl)methanone; 1496508-34-9; AKOS040756862; BDBM50265674; CHEMBL3734774; CORT113176; CORT-113176; CS-0204060; Dazucorilant; Dazucorilant [INN]; DAZUCORILANT [USAN]; HR4RD5RBJ6; HY-132811; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)-2-pyridinyl-; Methanone, [(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-2-pyridinyl-; MS-30438; SCHEMBL15455041; UNII-HR4RD5RBJ6"	72192163	Phase 2	DWSG41	.	CTPDG010574
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG 34517/34850	"Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]"	9576789	Phase 2	D0E2WF	.	CTPDG002431
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	BAY 86-5044	"Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE"	6918548	Phase 2	D0L3HU	.	CTPDG010575
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	IBI-20089	.	.	Phase 1	D0J6UV	.	CTPDG010576
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	PT-150	"(11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; CHEMBL3545391; PT150; PT-150; SCH 900636; SCH-900636; SCHEMBL11914193"	9824013	Phase 1	D9HQE2	.	CTPDG010577
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	NM-135	"Glucocorticoid, Nissin Food"	9963271	Discontinued in Phase 2	D03RCP	.	CTPDG010578
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	AZD-5423	"1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-"	24825740	Discontinued in Phase 2	D09UFV	DB12280	CTPDG006566
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	WC-3027	"SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG"	.	Discontinued in Phase 2	D0G2CQ	.	CTPDG006518
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Terminated	Org-34116	.	.	Terminated	D0I7EX	.	CTPDG010579
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"Hexane-1,6-Diol"	"1,6-HEXANEDIOL; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6hexanediol; 1.6-hexanediol; 1,6 hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; hexan-1,6-diol; 1,6-hexan-diol"	12374	Investigative	D0O0ZU	DB02210	CTPDG010580
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	Investigative	D02UVH	.	CTPDG010581
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT125281	"Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-"	118092367	Phase 2	D07UIS	.	CTPDG013015
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ISIS-GCCR	.	.	Phase 2	D0F8XK	.	CTPDG013016
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	ORIC-101	VNLTWJIWEYPBIF-SXJSTINISA-N; 2222344-98-9	134415769	Phase 1	D0HE7C	.	CTPDG004742
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	A-348441	CHEMBL219684; SCHEMBL699533; BDBM50195155; KB-3305	9854142	Phase 1	D0W8OJ	.	CTPDG004312
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine	CHEMBL292721; SCHEMBL7234473; MVULNNIYAGEMCC-UHFFFAOYSA-N; BDBM50144165	18189209	Investigative	D05XVM	.	CTPDG013017
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU26988	RU 26988; RU-26988	123987	Investigative	D06TOI	.	CTPDG013018
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	ENDIANDRIN A	"CHEMBL228274; BDBM50216277; 4,4''-((1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl)bis(2-methoxyphenol)"	16756780	Investigative	D09FQL	.	CTPDG013019
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094231; SCHEMBL4285350; BDBM50316561; 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888441	Investigative	D0D6GI	.	CTPDG013020
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094208; BDBM50316566; 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888467	Investigative	D0EG5G	.	CTPDG013021
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)"	"SCHEMBL4280142; CHEMBL1095541; BDBM50316555; 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethan-1-ol"	46888391	Investigative	D0N8UD	.	CTPDG013022
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromene	CHEMBL63422	44305900	Investigative	D0O5ZG	.	CTPDG013023
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	DI-O-METHYLENDIANDRIN A	CHEMBL388363	16756782	Investigative	D0PR2T	.	CTPDG013024
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	OXDEX	"Dexamethasone-17-carboxamide; CHEMBL483096; 82137-90-4; DX-17-Carboxamide; 17-Dxb; 17-Carboxamide dexamethasone; Dexamethasone-17beta-carboxamide; AC1L1YA1; DTXSID30231582; BDBM50271344; Androsta-1,4-diene-17-carboxamide, 9-fluoro-11,17-dihydroxy-16-methyl-3-oxo-, (11beta,16alpha,17alpha)-; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxamide"	63052	Investigative	D0S9KH	.	CTPDG013025
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU28362	RU-28362	123790	Investigative	D0Z7YK	.	CTPDG013026
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	deoxycorticosterone	11-deoxycorticosterone; 21-hydroxyprogesterone	6166	Investigative	D04SQY	.	CTPDG013027
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU-43044	"CHEMBL78704; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)"	9823099	Investigative	D07KWO	.	CTPDG013028
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE"	"Corticosterone; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705"	5753	Investigative	D03TNT	DB04652	CTPDG013029
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LG-120838	"CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene"	9951771	Investigative	D09OKK	.	CTPDG013030
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	Epierenone	CHEMBL237122; SCHEMBL13806060	44433505	Investigative	D0XS0R	.	CTPDG013031
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LGD-5552	CHEMBL259820; SCHEMBL4166143	24816375	Investigative	D08KQM	.	CTPDG011429
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	AL-43	"AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene"	9906282	Investigative	D0GR5L	.	CTPDG011430
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-409069	"CHEMBL78625; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol"	9819614	Investigative	D0J7XZ	.	CTPDG009711
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-394531	"UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)"	9820558	Investigative	D0L5IC	.	CTPDG009712
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT02078	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02078	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02079	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Larotrectinib	"UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470"	46188928	Approved	D07TOK	DB14723	CTPDG000549
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Macrocycle derivative 13	PMID28270010-Compound-Figure21-a	123787452	Patented	D00DXC	.	CTPDG012297
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Cyclopenta[d]pyrimidine derivative 1	PMID28270010-Compound-Figure28	76283234	Patented	D0NS6S	.	CTPDG012298
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure24-b	.	118009787	Patented	D07RLB	.	CTPDG012299
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-1	.	118256282	Patented	D0J9ZG	.	CTPDG012300
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-2	.	118256311	Patented	D0T2OX	.	CTPDG012301
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-3	.	118256189	Patented	D0V5AG	.	CTPDG012302
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	TrkB NAM	"TrkB negative allosteric modulators (neurodegenerative diseases); TrkB NAM program (neurodegenerative diseases), Addex; TrkB negative allosteric modulators (neurodegenerative diseases), Addex"	.	Investigative	D0D1HR	.	CTPDG012303
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	GNF-5837	GNF 5837; GNF5837	59397065	Investigative	D02RWC	.	CTPDG012304
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	AZD1332	AZD 1332; AZD-1332	49831044	Investigative	D0MH1X	.	CTPDG012305
M6ACROT02080	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	PMID24432909C8e	4cd0; GTPL8137; ZINC98050687; BDBM50448785; NCGC00485046-01; P-355; AWJ	72710568	Investigative	D0K5UF	.	CTPDG012306
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02080	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02081	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02081	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluocinolone Acetonide	"Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide"	6215	Approved	D02QJH	DB00591	CTPDG010556
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Triamcinolone	"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone"	31307	Approved	D03BLF	DB00620	CTPDG010557
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mometasone	"Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione"	441335	Approved	D03HYX	DB00764	CTPDG010558
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Valerate	Beta-val; Betaderm; Betatrex; Dermabet; Valnac	16533	Approved	D03SXE	.	CTPDG010559
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortamate	"Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate"	84088	Approved	D05RXI	DB00769	CTPDG010560
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Benzoate	Uticort	5282492	Approved	D06CWH	.	CTPDG010561
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Methylprednisolone	Depo-medrol; M-predrol; Medrol; Medrol Acetate	6741	Approved	D08PIQ	DB00959	CTPDG000519
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Deflazacort	C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927	189821	Approved	D09WYX	DB11921	CTPDG000479
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone	"378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate"	9782	Approved	D0CW1P	DB00443	CTPDG010562
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisolone	"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos"	5755	Approved	D0D1SG	DB00860	CTPDG000427
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Flunisolide	"Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione"	82153	Approved	D0FM2P	DB00180	CTPDG010563
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Meprednisone	Betapar	5284587	Approved	D0I5DS	DB09383	CTPDG000347
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortisone	"Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone"	5754	Approved	D0KR5B	DB00741	CTPDG010565
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluticasone	"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate"	5311101	Approved	D0LC6K	DB13867	CTPDG010566
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone sodium phosphate	"EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel"	16961	Approved	D0NA8U	.	CTPDG010567
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluorometholone	"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione"	9878	Approved	D0P0HT	DB00324	CTPDG000227
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mifepristone	"Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma"	55245	Approved	D0Z4EI	DB00834	CTPDG000034
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	FST-201	"Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics"	.	Phase 3	D00TPW	.	CTPDG010568
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	Mapracorat	"BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb"	24795088	Phase 3	D01IUS	DB12041	CTPDG010569
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	CORT-125134	"relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui"	73051463	Phase 3	D03WNG	DB14976	CTPDG001433
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	TLC599	.	.	Phase 3	D4R1JE	.	CTPDG010570
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	IONIS-GCCRRX	.	.	Phase 2	D01HYQ	.	CTPDG003038
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG-34517	"11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one"	9867361	Phase 2	D05MDJ	DB05423	CTPDG010571
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	LAS-41002	"Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall"	.	Phase 2	D05RXW	.	CTPDG010572
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	DE-110	"Selective glucocorticoid receptor agonist (allergy), Santen"	.	Phase 2	D0I1DZ	.	CTPDG010573
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	TPI-1020	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate	.	Phase 2	D0T5TU	.	CTPDG002016
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT113176	"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone; {(4aR)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)benzene-1-sulfonyl]-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a- yl}(pyridin-2-yl)methanone; 1496508-34-9; AKOS040756862; BDBM50265674; CHEMBL3734774; CORT113176; CORT-113176; CS-0204060; Dazucorilant; Dazucorilant [INN]; DAZUCORILANT [USAN]; HR4RD5RBJ6; HY-132811; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)-2-pyridinyl-; Methanone, [(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-2-pyridinyl-; MS-30438; SCHEMBL15455041; UNII-HR4RD5RBJ6"	72192163	Phase 2	DWSG41	.	CTPDG010574
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG 34517/34850	"Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]"	9576789	Phase 2	D0E2WF	.	CTPDG002431
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	BAY 86-5044	"Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE"	6918548	Phase 2	D0L3HU	.	CTPDG010575
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	IBI-20089	.	.	Phase 1	D0J6UV	.	CTPDG010576
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	PT-150	"(11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; CHEMBL3545391; PT150; PT-150; SCH 900636; SCH-900636; SCHEMBL11914193"	9824013	Phase 1	D9HQE2	.	CTPDG010577
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	NM-135	"Glucocorticoid, Nissin Food"	9963271	Discontinued in Phase 2	D03RCP	.	CTPDG010578
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	AZD-5423	"1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-"	24825740	Discontinued in Phase 2	D09UFV	DB12280	CTPDG006566
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	WC-3027	"SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG"	.	Discontinued in Phase 2	D0G2CQ	.	CTPDG006518
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Terminated	Org-34116	.	.	Terminated	D0I7EX	.	CTPDG010579
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"Hexane-1,6-Diol"	"1,6-HEXANEDIOL; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6hexanediol; 1.6-hexanediol; 1,6 hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; hexan-1,6-diol; 1,6-hexan-diol"	12374	Investigative	D0O0ZU	DB02210	CTPDG010580
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	Investigative	D02UVH	.	CTPDG010581
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT125281	"Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-"	118092367	Phase 2	D07UIS	.	CTPDG013015
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ISIS-GCCR	.	.	Phase 2	D0F8XK	.	CTPDG013016
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	ORIC-101	VNLTWJIWEYPBIF-SXJSTINISA-N; 2222344-98-9	134415769	Phase 1	D0HE7C	.	CTPDG004742
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	A-348441	CHEMBL219684; SCHEMBL699533; BDBM50195155; KB-3305	9854142	Phase 1	D0W8OJ	.	CTPDG004312
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine	CHEMBL292721; SCHEMBL7234473; MVULNNIYAGEMCC-UHFFFAOYSA-N; BDBM50144165	18189209	Investigative	D05XVM	.	CTPDG013017
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU26988	RU 26988; RU-26988	123987	Investigative	D06TOI	.	CTPDG013018
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	ENDIANDRIN A	"CHEMBL228274; BDBM50216277; 4,4''-((1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl)bis(2-methoxyphenol)"	16756780	Investigative	D09FQL	.	CTPDG013019
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094231; SCHEMBL4285350; BDBM50316561; 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888441	Investigative	D0D6GI	.	CTPDG013020
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094208; BDBM50316566; 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888467	Investigative	D0EG5G	.	CTPDG013021
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)"	"SCHEMBL4280142; CHEMBL1095541; BDBM50316555; 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethan-1-ol"	46888391	Investigative	D0N8UD	.	CTPDG013022
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromene	CHEMBL63422	44305900	Investigative	D0O5ZG	.	CTPDG013023
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	DI-O-METHYLENDIANDRIN A	CHEMBL388363	16756782	Investigative	D0PR2T	.	CTPDG013024
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	OXDEX	"Dexamethasone-17-carboxamide; CHEMBL483096; 82137-90-4; DX-17-Carboxamide; 17-Dxb; 17-Carboxamide dexamethasone; Dexamethasone-17beta-carboxamide; AC1L1YA1; DTXSID30231582; BDBM50271344; Androsta-1,4-diene-17-carboxamide, 9-fluoro-11,17-dihydroxy-16-methyl-3-oxo-, (11beta,16alpha,17alpha)-; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxamide"	63052	Investigative	D0S9KH	.	CTPDG013025
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU28362	RU-28362	123790	Investigative	D0Z7YK	.	CTPDG013026
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	deoxycorticosterone	11-deoxycorticosterone; 21-hydroxyprogesterone	6166	Investigative	D04SQY	.	CTPDG013027
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU-43044	"CHEMBL78704; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)"	9823099	Investigative	D07KWO	.	CTPDG013028
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE"	"Corticosterone; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705"	5753	Investigative	D03TNT	DB04652	CTPDG013029
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LG-120838	"CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene"	9951771	Investigative	D09OKK	.	CTPDG013030
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	Epierenone	CHEMBL237122; SCHEMBL13806060	44433505	Investigative	D0XS0R	.	CTPDG013031
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LGD-5552	CHEMBL259820; SCHEMBL4166143	24816375	Investigative	D08KQM	.	CTPDG011429
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	AL-43	"AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene"	9906282	Investigative	D0GR5L	.	CTPDG011430
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-409069	"CHEMBL78625; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol"	9819614	Investigative	D0J7XZ	.	CTPDG009711
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-394531	"UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)"	9820558	Investigative	D0L5IC	.	CTPDG009712
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT02082	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02082	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02083	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Larotrectinib	"UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470"	46188928	Approved	D07TOK	DB14723	CTPDG000549
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Macrocycle derivative 13	PMID28270010-Compound-Figure21-a	123787452	Patented	D00DXC	.	CTPDG012297
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Cyclopenta[d]pyrimidine derivative 1	PMID28270010-Compound-Figure28	76283234	Patented	D0NS6S	.	CTPDG012298
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure24-b	.	118009787	Patented	D07RLB	.	CTPDG012299
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-1	.	118256282	Patented	D0J9ZG	.	CTPDG012300
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-2	.	118256311	Patented	D0T2OX	.	CTPDG012301
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-3	.	118256189	Patented	D0V5AG	.	CTPDG012302
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	TrkB NAM	"TrkB negative allosteric modulators (neurodegenerative diseases); TrkB NAM program (neurodegenerative diseases), Addex; TrkB negative allosteric modulators (neurodegenerative diseases), Addex"	.	Investigative	D0D1HR	.	CTPDG012303
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	GNF-5837	GNF 5837; GNF5837	59397065	Investigative	D02RWC	.	CTPDG012304
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	AZD1332	AZD 1332; AZD-1332	49831044	Investigative	D0MH1X	.	CTPDG012305
M6ACROT02084	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	PMID24432909C8e	4cd0; GTPL8137; ZINC98050687; BDBM50448785; NCGC00485046-01; P-355; AWJ	72710568	Investigative	D0K5UF	.	CTPDG012306
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02084	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02085	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02085	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluocinolone Acetonide	"Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide"	6215	Approved	D02QJH	DB00591	CTPDG010556
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Triamcinolone	"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone"	31307	Approved	D03BLF	DB00620	CTPDG010557
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mometasone	"Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione"	441335	Approved	D03HYX	DB00764	CTPDG010558
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Valerate	Beta-val; Betaderm; Betatrex; Dermabet; Valnac	16533	Approved	D03SXE	.	CTPDG010559
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortamate	"Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate"	84088	Approved	D05RXI	DB00769	CTPDG010560
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Benzoate	Uticort	5282492	Approved	D06CWH	.	CTPDG010561
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Methylprednisolone	Depo-medrol; M-predrol; Medrol; Medrol Acetate	6741	Approved	D08PIQ	DB00959	CTPDG000519
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Deflazacort	C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927	189821	Approved	D09WYX	DB11921	CTPDG000479
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone	"378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate"	9782	Approved	D0CW1P	DB00443	CTPDG010562
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisolone	"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos"	5755	Approved	D0D1SG	DB00860	CTPDG000427
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Flunisolide	"Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione"	82153	Approved	D0FM2P	DB00180	CTPDG010563
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Meprednisone	Betapar	5284587	Approved	D0I5DS	DB09383	CTPDG000347
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortisone	"Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone"	5754	Approved	D0KR5B	DB00741	CTPDG010565
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluticasone	"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate"	5311101	Approved	D0LC6K	DB13867	CTPDG010566
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone sodium phosphate	"EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel"	16961	Approved	D0NA8U	.	CTPDG010567
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluorometholone	"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione"	9878	Approved	D0P0HT	DB00324	CTPDG000227
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mifepristone	"Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma"	55245	Approved	D0Z4EI	DB00834	CTPDG000034
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	FST-201	"Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics"	.	Phase 3	D00TPW	.	CTPDG010568
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	Mapracorat	"BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb"	24795088	Phase 3	D01IUS	DB12041	CTPDG010569
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	CORT-125134	"relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui"	73051463	Phase 3	D03WNG	DB14976	CTPDG001433
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	TLC599	.	.	Phase 3	D4R1JE	.	CTPDG010570
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	IONIS-GCCRRX	.	.	Phase 2	D01HYQ	.	CTPDG003038
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG-34517	"11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one"	9867361	Phase 2	D05MDJ	DB05423	CTPDG010571
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	LAS-41002	"Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall"	.	Phase 2	D05RXW	.	CTPDG010572
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	DE-110	"Selective glucocorticoid receptor agonist (allergy), Santen"	.	Phase 2	D0I1DZ	.	CTPDG010573
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	TPI-1020	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate	.	Phase 2	D0T5TU	.	CTPDG002016
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT113176	"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone; {(4aR)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)benzene-1-sulfonyl]-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a- yl}(pyridin-2-yl)methanone; 1496508-34-9; AKOS040756862; BDBM50265674; CHEMBL3734774; CORT113176; CORT-113176; CS-0204060; Dazucorilant; Dazucorilant [INN]; DAZUCORILANT [USAN]; HR4RD5RBJ6; HY-132811; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)-2-pyridinyl-; Methanone, [(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-2-pyridinyl-; MS-30438; SCHEMBL15455041; UNII-HR4RD5RBJ6"	72192163	Phase 2	DWSG41	.	CTPDG010574
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG 34517/34850	"Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]"	9576789	Phase 2	D0E2WF	.	CTPDG002431
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	BAY 86-5044	"Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE"	6918548	Phase 2	D0L3HU	.	CTPDG010575
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	IBI-20089	.	.	Phase 1	D0J6UV	.	CTPDG010576
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	PT-150	"(11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; CHEMBL3545391; PT150; PT-150; SCH 900636; SCH-900636; SCHEMBL11914193"	9824013	Phase 1	D9HQE2	.	CTPDG010577
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	NM-135	"Glucocorticoid, Nissin Food"	9963271	Discontinued in Phase 2	D03RCP	.	CTPDG010578
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	AZD-5423	"1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-"	24825740	Discontinued in Phase 2	D09UFV	DB12280	CTPDG006566
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	WC-3027	"SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG"	.	Discontinued in Phase 2	D0G2CQ	.	CTPDG006518
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Terminated	Org-34116	.	.	Terminated	D0I7EX	.	CTPDG010579
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"Hexane-1,6-Diol"	"1,6-HEXANEDIOL; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6hexanediol; 1.6-hexanediol; 1,6 hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; hexan-1,6-diol; 1,6-hexan-diol"	12374	Investigative	D0O0ZU	DB02210	CTPDG010580
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	Investigative	D02UVH	.	CTPDG010581
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT125281	"Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-"	118092367	Phase 2	D07UIS	.	CTPDG013015
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ISIS-GCCR	.	.	Phase 2	D0F8XK	.	CTPDG013016
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	ORIC-101	VNLTWJIWEYPBIF-SXJSTINISA-N; 2222344-98-9	134415769	Phase 1	D0HE7C	.	CTPDG004742
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	A-348441	CHEMBL219684; SCHEMBL699533; BDBM50195155; KB-3305	9854142	Phase 1	D0W8OJ	.	CTPDG004312
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine	CHEMBL292721; SCHEMBL7234473; MVULNNIYAGEMCC-UHFFFAOYSA-N; BDBM50144165	18189209	Investigative	D05XVM	.	CTPDG013017
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU26988	RU 26988; RU-26988	123987	Investigative	D06TOI	.	CTPDG013018
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	ENDIANDRIN A	"CHEMBL228274; BDBM50216277; 4,4''-((1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl)bis(2-methoxyphenol)"	16756780	Investigative	D09FQL	.	CTPDG013019
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094231; SCHEMBL4285350; BDBM50316561; 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888441	Investigative	D0D6GI	.	CTPDG013020
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094208; BDBM50316566; 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888467	Investigative	D0EG5G	.	CTPDG013021
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)"	"SCHEMBL4280142; CHEMBL1095541; BDBM50316555; 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethan-1-ol"	46888391	Investigative	D0N8UD	.	CTPDG013022
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromene	CHEMBL63422	44305900	Investigative	D0O5ZG	.	CTPDG013023
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	DI-O-METHYLENDIANDRIN A	CHEMBL388363	16756782	Investigative	D0PR2T	.	CTPDG013024
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	OXDEX	"Dexamethasone-17-carboxamide; CHEMBL483096; 82137-90-4; DX-17-Carboxamide; 17-Dxb; 17-Carboxamide dexamethasone; Dexamethasone-17beta-carboxamide; AC1L1YA1; DTXSID30231582; BDBM50271344; Androsta-1,4-diene-17-carboxamide, 9-fluoro-11,17-dihydroxy-16-methyl-3-oxo-, (11beta,16alpha,17alpha)-; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxamide"	63052	Investigative	D0S9KH	.	CTPDG013025
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU28362	RU-28362	123790	Investigative	D0Z7YK	.	CTPDG013026
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	deoxycorticosterone	11-deoxycorticosterone; 21-hydroxyprogesterone	6166	Investigative	D04SQY	.	CTPDG013027
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU-43044	"CHEMBL78704; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)"	9823099	Investigative	D07KWO	.	CTPDG013028
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE"	"Corticosterone; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705"	5753	Investigative	D03TNT	DB04652	CTPDG013029
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LG-120838	"CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene"	9951771	Investigative	D09OKK	.	CTPDG013030
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	Epierenone	CHEMBL237122; SCHEMBL13806060	44433505	Investigative	D0XS0R	.	CTPDG013031
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LGD-5552	CHEMBL259820; SCHEMBL4166143	24816375	Investigative	D08KQM	.	CTPDG011429
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	AL-43	"AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene"	9906282	Investigative	D0GR5L	.	CTPDG011430
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-409069	"CHEMBL78625; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol"	9819614	Investigative	D0J7XZ	.	CTPDG009711
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-394531	"UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)"	9820558	Investigative	D0L5IC	.	CTPDG009712
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT02086	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02086	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02087	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Larotrectinib	"UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470"	46188928	Approved	D07TOK	DB14723	CTPDG000549
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Macrocycle derivative 13	PMID28270010-Compound-Figure21-a	123787452	Patented	D00DXC	.	CTPDG012297
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Cyclopenta[d]pyrimidine derivative 1	PMID28270010-Compound-Figure28	76283234	Patented	D0NS6S	.	CTPDG012298
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure24-b	.	118009787	Patented	D07RLB	.	CTPDG012299
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-1	.	118256282	Patented	D0J9ZG	.	CTPDG012300
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-2	.	118256311	Patented	D0T2OX	.	CTPDG012301
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-3	.	118256189	Patented	D0V5AG	.	CTPDG012302
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	TrkB NAM	"TrkB negative allosteric modulators (neurodegenerative diseases); TrkB NAM program (neurodegenerative diseases), Addex; TrkB negative allosteric modulators (neurodegenerative diseases), Addex"	.	Investigative	D0D1HR	.	CTPDG012303
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	GNF-5837	GNF 5837; GNF5837	59397065	Investigative	D02RWC	.	CTPDG012304
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	AZD1332	AZD 1332; AZD-1332	49831044	Investigative	D0MH1X	.	CTPDG012305
M6ACROT02088	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	PMID24432909C8e	4cd0; GTPL8137; ZINC98050687; BDBM50448785; NCGC00485046-01; P-355; AWJ	72710568	Investigative	D0K5UF	.	CTPDG012306
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02088	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02089	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02089	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluocinolone Acetonide	"Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide"	6215	Approved	D02QJH	DB00591	CTPDG010556
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Triamcinolone	"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone"	31307	Approved	D03BLF	DB00620	CTPDG010557
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mometasone	"Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione"	441335	Approved	D03HYX	DB00764	CTPDG010558
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Valerate	Beta-val; Betaderm; Betatrex; Dermabet; Valnac	16533	Approved	D03SXE	.	CTPDG010559
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortamate	"Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate"	84088	Approved	D05RXI	DB00769	CTPDG010560
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone Benzoate	Uticort	5282492	Approved	D06CWH	.	CTPDG010561
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Methylprednisolone	Depo-medrol; M-predrol; Medrol; Medrol Acetate	6741	Approved	D08PIQ	DB00959	CTPDG000519
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Deflazacort	C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927	189821	Approved	D09WYX	DB11921	CTPDG000479
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Betamethasone	"378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate"	9782	Approved	D0CW1P	DB00443	CTPDG010562
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisolone	"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos"	5755	Approved	D0D1SG	DB00860	CTPDG000427
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Flunisolide	"Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione"	82153	Approved	D0FM2P	DB00180	CTPDG010563
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Meprednisone	Betapar	5284587	Approved	D0I5DS	DB09383	CTPDG000347
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Prednisone	"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione"	5865	Approved	D0IL7L	DB00635	CTPDG010564
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	Approved	D0IT2G	DB01234	CTPDG000333
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Hydrocortisone	"Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone"	5754	Approved	D0KR5B	DB00741	CTPDG010565
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluticasone	"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate"	5311101	Approved	D0LC6K	DB13867	CTPDG010566
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Dexamethasone sodium phosphate	"EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel"	16961	Approved	D0NA8U	.	CTPDG010567
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Fluorometholone	"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione"	9878	Approved	D0P0HT	DB00324	CTPDG000227
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Budesonide	"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione"	5281004	Approved	D0Y7IU	DB01222	CTPDG000055
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	GW685698X	"Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate"	9854489	Approved	D0Y7JU	DB08906	CTPDG000054
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Mifepristone	"Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma"	55245	Approved	D0Z4EI	DB00834	CTPDG000034
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	FST-201	"Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics"	.	Phase 3	D00TPW	.	CTPDG010568
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	Mapracorat	"BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb"	24795088	Phase 3	D01IUS	DB12041	CTPDG010569
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	CORT-125134	"relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui"	73051463	Phase 3	D03WNG	DB14976	CTPDG001433
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 3	TLC599	.	.	Phase 3	D4R1JE	.	CTPDG010570
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	IONIS-GCCRRX	.	.	Phase 2	D01HYQ	.	CTPDG003038
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG-34517	"11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one"	9867361	Phase 2	D05MDJ	DB05423	CTPDG010571
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	LAS-41002	"Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall"	.	Phase 2	D05RXW	.	CTPDG010572
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline"	.	Phase 2	D06XSB	.	CTPDG002715
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	DE-110	"Selective glucocorticoid receptor agonist (allergy), Santen"	.	Phase 2	D0I1DZ	.	CTPDG010573
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	GW-870086-X	"Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline"	.	Phase 2	D0M8VL	.	CTPDG002190
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ETIPREDNOL DICLOACETATE	"BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester"	9935073	Phase 2	D0OR8W	DB05442	CTPDG002126
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	TPI-1020	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate	.	Phase 2	D0T5TU	.	CTPDG002016
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT113176	"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone; {(4aR)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)benzene-1-sulfonyl]-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a- yl}(pyridin-2-yl)methanone; 1496508-34-9; AKOS040756862; BDBM50265674; CHEMBL3734774; CORT113176; CORT-113176; CS-0204060; Dazucorilant; Dazucorilant [INN]; DAZUCORILANT [USAN]; HR4RD5RBJ6; HY-132811; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)-2-pyridinyl-; Methanone, [(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-2-pyridinyl-; MS-30438; SCHEMBL15455041; UNII-HR4RD5RBJ6"	72192163	Phase 2	DWSG41	.	CTPDG010574
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ORG 34517/34850	"Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]"	9576789	Phase 2	D0E2WF	.	CTPDG002431
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	BAY 86-5044	"Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE"	6918548	Phase 2	D0L3HU	.	CTPDG010575
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	IBI-20089	.	.	Phase 1	D0J6UV	.	CTPDG010576
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	NCX-1015	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone	101123241	Phase 1	D0OS8C	.	CTPDG004531
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	PT-150	"(11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; CHEMBL3545391; PT150; PT-150; SCH 900636; SCH-900636; SCHEMBL11914193"	9824013	Phase 1	D9HQE2	.	CTPDG010577
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	GSK870086	.	.	Discontinued in Phase 2	D01NUG	.	CTPDG006662
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	NM-135	"Glucocorticoid, Nissin Food"	9963271	Discontinued in Phase 2	D03RCP	.	CTPDG010578
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	AZD-5423	"1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-"	24825740	Discontinued in Phase 2	D09UFV	DB12280	CTPDG006566
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 2	WC-3027	"SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG"	.	Discontinued in Phase 2	D0G2CQ	.	CTPDG006518
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Discontinued in Phase 1	PF-251802	"PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer"	.	Discontinued in Phase 1	D03CHE	.	CTPDG006912
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Terminated	Org-34116	.	.	Terminated	D0I7EX	.	CTPDG010579
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"Hexane-1,6-Diol"	"1,6-HEXANEDIOL; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6hexanediol; 1.6-hexanediol; 1,6 hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; hexan-1,6-diol; 1,6-hexan-diol"	12374	Investigative	D0O0ZU	DB02210	CTPDG010580
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	Investigative	D02UVH	.	CTPDG010581
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Approved	Vamorolone	"vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317"	3035000	Approved	D0F6YM	DB15114	CTPDG013014
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	CORT125281	"Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-"	118092367	Phase 2	D07UIS	.	CTPDG013015
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 2	ISIS-GCCR	.	.	Phase 2	D0F8XK	.	CTPDG013016
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	ORIC-101	VNLTWJIWEYPBIF-SXJSTINISA-N; 2222344-98-9	134415769	Phase 1	D0HE7C	.	CTPDG004742
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	AZD9567	"ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide"	121248172	Phase 1	D0SZ1G	.	CTPDG004418
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Phase 1	A-348441	CHEMBL219684; SCHEMBL699533; BDBM50195155; KB-3305	9854142	Phase 1	D0W8OJ	.	CTPDG004312
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine	CHEMBL292721; SCHEMBL7234473; MVULNNIYAGEMCC-UHFFFAOYSA-N; BDBM50144165	18189209	Investigative	D05XVM	.	CTPDG013017
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU26988	RU 26988; RU-26988	123987	Investigative	D06TOI	.	CTPDG013018
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	ENDIANDRIN A	"CHEMBL228274; BDBM50216277; 4,4''-((1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl)bis(2-methoxyphenol)"	16756780	Investigative	D09FQL	.	CTPDG013019
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094231; SCHEMBL4285350; BDBM50316561; 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888441	Investigative	D0D6GI	.	CTPDG013020
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)"	"CHEMBL1094208; BDBM50316566; 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol"	46888467	Investigative	D0EG5G	.	CTPDG013021
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)"	"SCHEMBL4280142; CHEMBL1095541; BDBM50316555; 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethan-1-ol"	46888391	Investigative	D0N8UD	.	CTPDG013022
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	1-Methoxy-6-phenyl-6H-benzo[c]chromene	CHEMBL63422	44305900	Investigative	D0O5ZG	.	CTPDG013023
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	DI-O-METHYLENDIANDRIN A	CHEMBL388363	16756782	Investigative	D0PR2T	.	CTPDG013024
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	OXDEX	"Dexamethasone-17-carboxamide; CHEMBL483096; 82137-90-4; DX-17-Carboxamide; 17-Dxb; 17-Carboxamide dexamethasone; Dexamethasone-17beta-carboxamide; AC1L1YA1; DTXSID30231582; BDBM50271344; Androsta-1,4-diene-17-carboxamide, 9-fluoro-11,17-dihydroxy-16-methyl-3-oxo-, (11beta,16alpha,17alpha)-; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxamide"	63052	Investigative	D0S9KH	.	CTPDG013025
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU28362	RU-28362	123790	Investigative	D0Z7YK	.	CTPDG013026
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	deoxycorticosterone	11-deoxycorticosterone; 21-hydroxyprogesterone	6166	Investigative	D04SQY	.	CTPDG013027
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	RU-43044	"CHEMBL78704; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)"	9823099	Investigative	D07KWO	.	CTPDG013028
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	"(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE"	"Corticosterone; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705"	5753	Investigative	D03TNT	DB04652	CTPDG013029
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LG-120838	"CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene"	9951771	Investigative	D09OKK	.	CTPDG013030
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	Epierenone	CHEMBL237122; SCHEMBL13806060	44433505	Investigative	D0XS0R	.	CTPDG013031
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	LGD-5552	CHEMBL259820; SCHEMBL4166143	24816375	Investigative	D08KQM	.	CTPDG011429
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	AL-43	"AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene"	9906282	Investigative	D0GR5L	.	CTPDG011430
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-409069	"CHEMBL78625; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol"	9819614	Investigative	D0J7XZ	.	CTPDG009711
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	CP-394531	"UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)"	9820558	Investigative	D0L5IC	.	CTPDG009712
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	WAY-214950	SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	Investigative	D0V4RZ	.	CTPDG013032
M6ACROT02090	Glucocorticoid receptor (NR3C1)	GCR_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02090	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02091	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Larotrectinib	"UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470"	46188928	Approved	D07TOK	DB14723	CTPDG000549
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Approved	Entrectinib	"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK"	25141092	Approved	D0O0LS	DB11986	CTPDG000249
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Macrocycle derivative 13	PMID28270010-Compound-Figure21-a	123787452	Patented	D00DXC	.	CTPDG012297
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Cyclopenta[d]pyrimidine derivative 1	PMID28270010-Compound-Figure28	76283234	Patented	D0NS6S	.	CTPDG012298
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2016054807Example1	.	.	Patented	D00MGO	.	CTPDG006304
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure24-b	.	118009787	Patented	D07RLB	.	CTPDG012299
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 4"	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)	.	Patented	D0AG2A	.	CTPDG006040
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	3-amino-5-benzyl-substituted indazole derivative 1	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)	.	Patented	D0AU4G	.	CTPDG006034
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-1	.	118256282	Patented	D0J9ZG	.	CTPDG012300
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270021-Compound-WO2015042088Example4	.	.	Patented	D0M8VS	.	CTPDG005779
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-2	.	118256311	Patented	D0T2OX	.	CTPDG012301
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	PMID28270010-Compound-Figure5-3	.	118256189	Patented	D0V5AG	.	CTPDG012302
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Patented	Azaindazole amide derivative 1	PMID28270021-Compound-WO2014016434Example30	.	Patented	D0Y1NH	.	CTPDG005551
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	TrkB NAM	"TrkB negative allosteric modulators (neurodegenerative diseases); TrkB NAM program (neurodegenerative diseases), Addex; TrkB negative allosteric modulators (neurodegenerative diseases), Addex"	.	Investigative	D0D1HR	.	CTPDG012303
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	GNF-5837	GNF 5837; GNF5837	59397065	Investigative	D02RWC	.	CTPDG012304
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	AZD1332	AZD 1332; AZD-1332	49831044	Investigative	D0MH1X	.	CTPDG012305
M6ACROT02092	BDNF/NT-3 growth factors receptor (NTRK2)	NTRK2_HUMAN	.	.	Investigative	PMID24432909C8e	4cd0; GTPL8137; ZINC98050687; BDBM50448785; NCGC00485046-01; P-355; AWJ	72710568	Investigative	D0K5UF	.	CTPDG012306
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02092	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02093	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02093	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT02094	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT02095	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02101	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02102	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02103	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02106	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02107	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02108	Methyl-CpG-binding protein 2  (MECP2)	MECP2_HUMAN	.	.	Phase 1	AVXS-201	.	.	Phase 1	DE94CW	.	CTPDG014800
M6ACROT02109	CD24 molecule (CD24)	CD24_HUMAN	.	.	Investigative	BsAb cG7-MICA	.	.	Investigative	D0FZ7D	.	CTPDG015503
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02111	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02112	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02116	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02117	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02118	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02119	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02120	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02121	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02122	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT02123	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02123	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02124	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1/2	131I-radretumab	"L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP"	.	Phase 1/2	D0H4GT	.	CTPDG014059
M6ACROT02124	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1	OS2966	.	.	Phase 1	DB8MR6	.	CTPDG014060
M6ACROT02124	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1	JSM 6427	.	.	Phase 1	D0ZT4J	.	CTPDG014061
M6ACROT02124	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	MK-0668	"UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-"	11433918	Investigative	D09XED	.	CTPDG014062
M6ACROT02124	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT02124	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02124	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02125	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02126	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02127	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02128	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02129	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02130	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02131	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT02132	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02132	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02133	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1/2	131I-radretumab	"L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP"	.	Phase 1/2	D0H4GT	.	CTPDG014059
M6ACROT02133	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1	OS2966	.	.	Phase 1	DB8MR6	.	CTPDG014060
M6ACROT02133	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1	JSM 6427	.	.	Phase 1	D0ZT4J	.	CTPDG014061
M6ACROT02133	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	MK-0668	"UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-"	11433918	Investigative	D09XED	.	CTPDG014062
M6ACROT02133	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT02133	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02133	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02134	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02134	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02135	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02136	"6-phosphogluconate dehydrogenase, decarboxylating (6PGD/PGD)"	6PGD_HUMAN	.	.	Approved	GHRP-2	"Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy"	6918245	Approved	D08VRX	.	CTPDG012103
M6ACROT02136	"6-phosphogluconate dehydrogenase, decarboxylating (6PGD/PGD)"	6PGD_HUMAN	.	.	Investigative	5-deoxy-5-phosphono-D-arabinonate	.	56603745	Investigative	D04LDP	.	CTPDG012104
M6ACROT02136	"6-phosphogluconate dehydrogenase, decarboxylating (6PGD/PGD)"	6PGD_HUMAN	.	.	Investigative	4-phospho-D-erythronate	"4-phosphoerythronate; 4-phospho-D-erythronic acid; 4-Phospho D-Erythronate; 57229-25-1; CHEBI:49003; 4-O-phosphono-D-erythronic acid; (2R,3R)-2,3-dihydroxy-4-(phosphonooxy)butanoic acid; 2bet; AC1L9MYX; SCHEMBL420471; CHEMBL1160945; CTK1E1186; DTXSID70332305; ZINC3869897; DER; AKOS030570437; DB03108; FT-0673861; C03393; (2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid; [R-(R*,R*)]-2,3-Dihydroxy-4-(phosphonooxy)butanoic Acid; Butanoic acid, 2,3-dihydroxy-4-(phosphonooxy)-, (2R,3R)-"	449304	Investigative	D0C4VG	DB03108	CTPDG012105
M6ACROT02136	"6-phosphogluconate dehydrogenase, decarboxylating (6PGD/PGD)"	6PGD_HUMAN	.	.	Investigative	6-Phosphogluconic Acid	"6-Phosphogluconate; 921-62-0; 6-phospho-D-gluconic acid; 6-phospho-D-gluconate; 6-O-phosphono-D-gluconic acid; Gluconic acid-6-phosphate; (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(phosphonooxy)hexanoic acid; UNII-W31WK7B8U0; D-Gluconic acid 6-(dihydrogen phosphate); CHEBI:48928; W31WK7B8U0; CHEMBL1230513; BIRSGZKFKXLSJQ-SQOUGZDYSA-N; 1pgp; 6PG; 6-phosphogluconic acid barium salt; C6H13O10P; 6-p-gluconate; EINECS 213-069-9; D-Gluconic acid, 6-(dihydrogen phosphate); bmse000198; AC1Q6RV2; AC1L3M6P; SCHEMBL50297"	91493	Investigative	D0E4AN	DB02076	CTPDG012106
M6ACROT02136	"6-phosphogluconate dehydrogenase, decarboxylating (6PGD/PGD)"	6PGD_HUMAN	.	.	Investigative	"(2R)-2-Methyl-4,5-dideoxy"	.	11064567	Investigative	D0P9DD	.	CTPDG012107
M6ACROT02136	"6-phosphogluconate dehydrogenase, decarboxylating (6PGD/PGD)"	6PGD_HUMAN	.	.	Investigative	Pyrophosphate 2-	dihydrogen diphosphate; diphosphate(2-); AC1L1JDO; CHEBI:45212; H2P2O7(2-)	4995	Investigative	D0A1DU	.	CTPDG012108
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02136	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02137	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Approved	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	Approved	D02WCI	DB04951	CTPDG012335
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	IND submitted	A435	.	.	IND submitted	D8UKA4	.	CTPDG000863
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2	Disitertide	"NAFB-001; Disitertide cream (skin disorders), Digna"	9833838	Phase 2	D0C4WC	.	CTPDG012336
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ACE-1334	.	.	Phase 1	D8NZ7T	.	CTPDG012337
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	SRK-181	.	.	Phase 1	DFZJ79	.	CTPDG003913
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ABBV-151	.	.	Phase 1	DKCI94	.	CTPDG003846
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Discontinued in Phase 2	Mannose phosphate	SCHEMBL285569; SB17274	73014169	Discontinued in Phase 2	D0U3DX	.	CTPDG012338
M6ACROT02138	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Investigative	ART-144	"Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals"	.	Investigative	D08OLR	.	CTPDG012339
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02138	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02139	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02140	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02140	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT02140	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT02140	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02141	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02141	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02142	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02143	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02145	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02145	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT02146	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02146	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02147	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02148	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02149	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02149	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02150	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02150	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT02151	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02151	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02152	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02153	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02154	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02154	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02155	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02156	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02158	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02158	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT02159	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02159	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02160	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02161	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02162	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02162	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02163	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02163	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT02164	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02164	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02165	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02166	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02167	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02167	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02168	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02169	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02171	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02171	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT02172	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02172	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02173	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02174	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02175	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02175	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02176	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02176	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT02177	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02177	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02178	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02179	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02180	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02180	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02181	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02182	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT02184	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02184	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT02185	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02185	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02186	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02187	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02188	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02188	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02189	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02189	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT02190	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02190	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02191	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02192	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	Penciclovir	39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2	135398748	Approved	D07BYK	DB00299	CTPDG010582
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Preregistration	TK-DLI	"TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara"	.	Preregistration	D08AMJ	.	CTPDG010583
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	FV-100	"CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy"	71587897	Phase 3	D04QPD	.	CTPDG010584
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2	HQK-1004	"Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest"	23622962	Phase 2	D05RRA	.	CTPDG002789
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Ad-OC-hsvTK/valacyclovir	"Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute"	.	Phase 1	D02KBE	.	CTPDG010585
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	"Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama"	.	Phase 1	D0FY1W	.	CTPDG004786
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-Hydroxypropylthymine	"6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139"	1865	Investigative	D00CEO	DB04139	CTPDG010586
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	3-(2-propyn-1-yl)thymidine	3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872	11323459	Investigative	D01CUJ	.	CTPDG010587
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	ITdU	"3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-"	76	Investigative	D01VKE	.	CTPDG010588
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	"AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate"	449489	Investigative	D04GXW	DB02324	CTPDG010589
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CHEMBL219905	16098875	Investigative	D07GKK	.	CTPDG010590
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	(South)-Methanocarba-Thymidine	"south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921"	447628	Investigative	D07OOW	DB02921	CTPDG010591
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-(Dihydroxy-Isobutyl)-Thymine	"DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione"	1855	Investigative	D08AOD	DB02500	CTPDG010592
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-propyl-2'-deoxyuridine	"27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione"	160155	Investigative	D0C7YS	.	CTPDG010593
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-(bromovinyl)deoxyuridine	CHEMBL261850; SCHEMBL4314668; BDBM50375781	25323027	Investigative	D0D7FB	.	CTPDG010594
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	9-(4-Hydroxybutyl)-N2-Phenylguanine	"HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one"	135415618	Investigative	D0G5VO	DB02495	CTPDG010595
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-iodo-2'-deoxyuridine	"CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil"	512326	Investigative	D0HO0W	.	CTPDG010596
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine"	"3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione"	452142	Investigative	D0O7GD	.	CTPDG010597
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	BVDU-MP	SCHEMBL4287705	46936977	Investigative	D0PC2Y	.	CTPDG010598
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, S-Isomer"	"(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731"	445210	Investigative	D0R0EI	DB03000	CTPDG010599
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine	.	448110	Investigative	D0S4SQ	.	CTPDG010600
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Bromothienyldeoxyuridine	"CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione"	446725	Investigative	D0ST5A	DB03804	CTPDG010601
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[7-(triphenylmethoxy)heptyl]thymine	"CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-"	16098874	Investigative	D0W8AD	.	CTPDG010602
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, R-Isomer"	"14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-"	445211	Investigative	D0X1HX	DB02765	CTPDG010603
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Edoxudine	"5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine; MCULE-3445830855; ST056929"	66377	Investigative	D0Y4MD	DB13421	CTPDG010604
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	N2-(3-trifluoromethylphenyl)guanine	.	135435057	Investigative	D0YJ5W	.	CTPDG010605
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-Deoxyuridine	"951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615"	13712	Investigative	D00CVB	DB02256	CTPDG010606
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[5-(triphenylmethoxy)pentyl]thymine	"CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-"	16098859	Investigative	D00KWL	.	CTPDG010607
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Deoxythymidine	"Thymidine; 50-89-5; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748"	5789	Investigative	D01GLG	DB04485	CTPDG010608
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[6-(triphenylmethoxy)hexyl]thymine	"CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-"	44418795	Investigative	D02CCD	.	CTPDG010609
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	"CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"""" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate"	447202	Investigative	D04BBF	DB03280	CTPDG010610
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	"CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione"	6477686	Investigative	D0I6UV	.	CTPDG010611
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Thymidine-5'-Phosphate	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)	9700	Investigative	D0ZH0I	DB01643	CTPDG010612
M6ACROT02193	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-deoxythymidine triphosphate	"Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 5'-TTP; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE"	64968	Investigative	D09WYY	DB02452	CTPDG010613
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02193	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02193	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02193	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02194	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT02194	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT02194	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02194	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02194	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02194	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02195	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02195	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02195	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02195	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02196	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02196	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02196	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 3	Hu5F9-G4	.	.	Phase 3	D09JYL	.	CTPDG014715
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 2/3	Evorpacept	ALX148	.	Phase 2/3	DRP8H0	.	CTPDG001512
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 2	PF-07901801	maplirpacept	.	Phase 2	D6SJ0B	.	CTPDG001786
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1/2	ALX148	.	.	Phase 1/2	D0J7UL	.	CTPDG014716
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1/2	DSP-107	.	.	Phase 1/2	D1WB6Z	.	CTPDG003254
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1/2	AO-176	.	.	Phase 1/2	DA4W1I	.	CTPDG003208
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	TTI-621	.	.	Phase 1	D01CUO	.	CTPDG005422
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	TTI-622	.	.	Phase 1	D5FCP1	.	CTPDG004093
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	IBI188	.	.	Phase 1	D5V2HR	.	CTPDG014717
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	TJC4	TJ011133	.	Phase 1	DEUC70	.	CTPDG003927
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	CC-90002	.	.	Phase 1	DI8WC4	.	CTPDG003882
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	IMC-002	.	.	Phase 1	DTHR46	.	CTPDG003714
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	ZL-1201	.	.	Phase 1	DY7D9A	.	CTPDG003658
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	TG-1801	NI-1701	.	Phase 1	D8UNG2	.	CTPDG004010
M6ACROT02197	Leukocyte surface antigen CD47 (CD47)	CD47_HUMAN	.	.	Phase 1	SL-172154	.	.	Phase 1	DKUF26	.	CTPDG003840
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02197	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02197	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02197	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02198	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02198	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02198	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02199	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02199	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02199	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02200	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02200	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02200	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02200	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02201	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02201	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02201	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02202	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT02202	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Phase 1/2	KB-004	"Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios"	.	Phase 1/2	D0FJ9W	.	CTPDG014492
M6ACROT02202	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Investigative	PMID21561767C8h	GTPL8170; BDBM50345579	46864270	Investigative	D02BXJ	.	CTPDG010061
M6ACROT02202	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Investigative	PMID19788238C66	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160	44478401	Investigative	D05FXD	.	CTPDG014156
M6ACROT02202	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Investigative	PMID23489211C20	PCM126; GTPL8124; BDBM50428059	71718651	Investigative	D0X8BU	.	CTPDG014157
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02202	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02202	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Patented	"US9217012, 10"	SCHEMBL19222783; CHEMBL3969776; BDBM199180	122198705	Patented	D0CW5D	.	CTPDG015073
M6ACROT02202	Protein tyrosine phosphatase non-receptor type 13 (PTPN13)	PTN13_HUMAN	.	.	Investigative	ISIS 18473	.	.	Investigative	D09VLX	.	CTPDG015074
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02203	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT02204	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02204	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 2	PINOCEMBRIN	"480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-"	68071	Phase 2	D0G5CS	.	CTPDG014282
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 1	NARINGENIN	"5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone"	932	Phase 1	D02ABO	.	CTPDG014283
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	DIOSMETIN	"520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246"	5281612	Investigative	D00RFY	DB11259	CTPDG014284
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISOSAKUTANETIN	"Isosakuranetin; 480-43-3; 4'-Methylnaringenin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone"	160481	Investigative	D01FJE	.	CTPDG014285
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFERIDE	"491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD"	5281666	Investigative	D04DYO	.	CTPDG014286
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TAMARIXETIN	"603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7"	5281699	Investigative	D06PZE	.	CTPDG014287
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan"	"CHEMBL43396; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552"	10105252	Investigative	D06VXW	.	CTPDG014288
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ERIODICTYOL	"(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT"	440735	Investigative	D08AIJ	.	CTPDG014289
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	HOMOERIODICTYOL	"(-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672"	73635	Investigative	D0CR8V	.	CTPDG014290
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide"	"N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910"	2321450	Investigative	D0J9OG	.	CTPDG014291
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine"	"CHEMBL43013; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine"	11957947	Investigative	D0T9IK	.	CTPDG014292
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene"	"CHEMBL42428; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene"	9834747	Investigative	D0Z1AL	.	CTPDG014293
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	CHRYSOERIOL	"491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514"	5280666	Investigative	D01FGM	.	CTPDG014294
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISORHAMNETIN	"480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z"	5281654	Investigative	D07YDN	.	CTPDG014295
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ACACETIN	"480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC"	5280442	Investigative	D0NS1S	.	CTPDG014296
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	Investigative	D0O9NE	.	CTPDG013143
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Galangin	"548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one"	5281616	Investigative	D0Y7HG	.	CTPDG014297
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT02205	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFEROL	"520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe"	5280863	Investigative	D0G3TK	DB01852	CTPDG014298
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02205	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02206	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02206	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02206	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02206	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02206	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02207	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02207	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02208	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02208	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02208	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02208	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02209	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02209	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02210	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02210	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02211	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02211	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02211	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02211	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02211	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02212	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02212	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02213	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02213	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02213	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02213	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02214	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02215	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02215	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02216	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02217	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02218	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02218	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02219	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02219	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02219	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02219	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02219	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02220	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02220	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02221	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02221	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02221	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02221	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02222	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02222	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02223	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02223	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02224	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02225	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT02226	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT02226	Sequestosome-1 (SQSTM1)	SQSTM_HUMAN	.	.	Preclinical	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	Preclinical	D02NEZ	.	CTPDG015396
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02227	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT02228	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02228	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 2	PINOCEMBRIN	"480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-"	68071	Phase 2	D0G5CS	.	CTPDG014282
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 1	NARINGENIN	"5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone"	932	Phase 1	D02ABO	.	CTPDG014283
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	DIOSMETIN	"520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246"	5281612	Investigative	D00RFY	DB11259	CTPDG014284
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISOSAKUTANETIN	"Isosakuranetin; 480-43-3; 4'-Methylnaringenin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone"	160481	Investigative	D01FJE	.	CTPDG014285
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFERIDE	"491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD"	5281666	Investigative	D04DYO	.	CTPDG014286
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TAMARIXETIN	"603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7"	5281699	Investigative	D06PZE	.	CTPDG014287
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan"	"CHEMBL43396; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552"	10105252	Investigative	D06VXW	.	CTPDG014288
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ERIODICTYOL	"(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT"	440735	Investigative	D08AIJ	.	CTPDG014289
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	HOMOERIODICTYOL	"(-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672"	73635	Investigative	D0CR8V	.	CTPDG014290
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide"	"N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910"	2321450	Investigative	D0J9OG	.	CTPDG014291
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine"	"CHEMBL43013; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine"	11957947	Investigative	D0T9IK	.	CTPDG014292
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene"	"CHEMBL42428; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene"	9834747	Investigative	D0Z1AL	.	CTPDG014293
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	CHRYSOERIOL	"491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514"	5280666	Investigative	D01FGM	.	CTPDG014294
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISORHAMNETIN	"480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z"	5281654	Investigative	D07YDN	.	CTPDG014295
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ACACETIN	"480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC"	5280442	Investigative	D0NS1S	.	CTPDG014296
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	Investigative	D0O9NE	.	CTPDG013143
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Galangin	"548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one"	5281616	Investigative	D0Y7HG	.	CTPDG014297
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT02229	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFEROL	"520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe"	5280863	Investigative	D0G3TK	DB01852	CTPDG014298
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02229	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02230	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02230	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02230	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02230	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02230	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02231	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02231	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02232	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02232	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02232	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02232	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02233	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02233	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02234	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02234	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02235	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02235	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02235	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02235	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02235	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02236	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02236	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02237	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02237	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02237	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02237	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02238	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02239	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02239	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02240	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02241	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02242	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02242	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02243	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02243	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02243	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02243	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02243	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02244	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02244	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02245	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02245	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02245	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02245	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02246	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02246	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02247	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02247	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02248	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02249	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02250	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02250	Sequestosome-1 (SQSTM1)	SQSTM_HUMAN	.	.	Preclinical	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	Preclinical	D02NEZ	.	CTPDG015396
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02251	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT02252	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02252	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02253	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 2	PINOCEMBRIN	"480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-"	68071	Phase 2	D0G5CS	.	CTPDG014282
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 1	NARINGENIN	"5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone"	932	Phase 1	D02ABO	.	CTPDG014283
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	DIOSMETIN	"520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246"	5281612	Investigative	D00RFY	DB11259	CTPDG014284
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISOSAKUTANETIN	"Isosakuranetin; 480-43-3; 4'-Methylnaringenin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone"	160481	Investigative	D01FJE	.	CTPDG014285
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFERIDE	"491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD"	5281666	Investigative	D04DYO	.	CTPDG014286
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TAMARIXETIN	"603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7"	5281699	Investigative	D06PZE	.	CTPDG014287
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan"	"CHEMBL43396; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552"	10105252	Investigative	D06VXW	.	CTPDG014288
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ERIODICTYOL	"(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT"	440735	Investigative	D08AIJ	.	CTPDG014289
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	HOMOERIODICTYOL	"(-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672"	73635	Investigative	D0CR8V	.	CTPDG014290
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide"	"N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910"	2321450	Investigative	D0J9OG	.	CTPDG014291
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine"	"CHEMBL43013; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine"	11957947	Investigative	D0T9IK	.	CTPDG014292
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene"	"CHEMBL42428; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene"	9834747	Investigative	D0Z1AL	.	CTPDG014293
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	CHRYSOERIOL	"491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514"	5280666	Investigative	D01FGM	.	CTPDG014294
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISORHAMNETIN	"480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z"	5281654	Investigative	D07YDN	.	CTPDG014295
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ACACETIN	"480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC"	5280442	Investigative	D0NS1S	.	CTPDG014296
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	Investigative	D0O9NE	.	CTPDG013143
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Galangin	"548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one"	5281616	Investigative	D0Y7HG	.	CTPDG014297
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT02253	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFEROL	"520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe"	5280863	Investigative	D0G3TK	DB01852	CTPDG014298
M6ACROT02254	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02254	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02254	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02254	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02254	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02255	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02255	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02256	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02256	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02256	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02256	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02257	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02257	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02258	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02258	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02259	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02259	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02259	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02259	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02259	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02260	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02260	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02261	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02261	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02261	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02261	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02262	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02263	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02263	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02264	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02265	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02266	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02266	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT02267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT02267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT02267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02267	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02268	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02268	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02269	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02269	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 2	LY2928057	.	.	Phase 2	D0IN8Z	.	CTPDG014574
M6ACROT02269	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	Ferroportin mab	.	.	Phase 1	D07SQT	.	CTPDG014575
M6ACROT02269	Solute carrier family 40 member 1 (FPN1)	S40A1_HUMAN	.	.	Phase 1	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	Phase 1	D5W7BG	.	CTPDG014576
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02270	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 2	ISIS-FGFR4	.	.	Phase 2	D0SL8T	.	CTPDG002031
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	Phase 1/2	D08EQD	.	CTPDG003514
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	Phase 1	D0D6XT	DB15169	CTPDG014389
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	Phase 1	D0XZ1D	.	CTPDG014390
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Phase 1/2	INCB62079	.	.	Phase 1/2	D0BE8H	.	CTPDG003466
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	Investigative	D08HZN	.	CTPDG008623
M6ACROT02270	Fibroblast growth factor receptor 4 (FGFR4)	FGFR4_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT02271	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02271	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02272	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02273	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT02274	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT02274	Sequestosome-1 (SQSTM1)	SQSTM_HUMAN	.	.	Preclinical	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	Preclinical	D02NEZ	.	CTPDG015396
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	Phase 2	D0U8XE	DB12411	CTPDG011504
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	MGCD265	"MGCD-265; 875337-44-3; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	Phase 2	D08FDX	.	CTPDG011506
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	Phase 1/2	D00LGR	DB15187	CTPDG011507
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	Enapotamab vedotin	.	.	Phase 1/2	DI0ZA3	.	CTPDG003179
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	DS-1205	.	.	Phase 1	D06THG	.	CTPDG011508
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	A416	.	.	Phase 1	DMLY68	.	CTPDG003818
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	PF-07265807	PF-5807; ARRY-067	.	Phase 1	DP4KH3	.	CTPDG003774
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	INCB81776	INCB081776	.	Phase 1	DQX83Z	.	CTPDG003749
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	Cu-anti-hAXL	.	.	Preclinical	D4JS3A	.	CTPDG011509
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	DP-3975	.	.	Preclinical	D4K2CQ	.	CTPDG011510
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	YW327.6S2	.	.	Preclinical	D50NHR	.	CTPDG011511
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	GL21.T	.	.	Preclinical	DU9RB1	.	CTPDG011512
M6ACROT02276	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Investigative	LDC1267	"1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	Investigative	D09TFN	.	CTPDG011513
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT03005	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Disulfiram analog 1	PMID25468267-Compound-26	6451399	Patented	D05PXW	.	CTPDG014965
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Selenium compound 2	PMID25468267-Compound-29	21928	Patented	D09YFD	.	CTPDG014966
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Disulfiram analog 2	PMID25468267-Compound-27	575125	Patented	D0JQ9Z	.	CTPDG014967
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Selenium compound 1	PMID25468267-Compound-28	23427	Patented	D0X2AU	.	CTPDG014968
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Selenium compound 3	PMID25468267-Compound-30	3194	Patented	D0X6SJ	DB12610	CTPDG014969
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03005	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT03006	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Disulfiram analog 1	PMID25468267-Compound-26	6451399	Patented	D05PXW	.	CTPDG014965
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Selenium compound 2	PMID25468267-Compound-29	21928	Patented	D09YFD	.	CTPDG014966
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Disulfiram analog 2	PMID25468267-Compound-27	575125	Patented	D0JQ9Z	.	CTPDG014967
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Selenium compound 1	PMID25468267-Compound-28	23427	Patented	D0X2AU	.	CTPDG014968
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Selenium compound 3	PMID25468267-Compound-30	3194	Patented	D0X6SJ	DB12610	CTPDG014969
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03006	Lysine-specific demethylase 4A (KDM4A)	KDM4A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03007	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03008	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03008	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03009	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03010	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03010	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03011	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03012	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03012	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03013	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT03014	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT03014	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03014	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT03015	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT03015	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03015	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT03016	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT03016	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03016	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT03017	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT03017	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03017	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT03018	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT03018	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03018	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Approved	Siltuximab	.	.	Approved	D07NJN	.	CTPDG011389
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Olokizumab	.	.	Phase 3	D00NUG	.	CTPDG001498
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Ziltivekimab	.	.	Phase 3	DF86OC	.	CTPDG011390
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	RG6179	.	.	Phase 3	DWJM12	.	CTPDG011391
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 3	Sirukumab	.	.	Phase 3	D01XVF	.	CTPDG001477
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	Clazakizumab	.	.	Phase 2	D04RMM	.	CTPDG002846
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	CDP-6038	.	.	Phase 2	D07TCS	.	CTPDG002671
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	ALD-518	.	.	Phase 2	D0N0BW	.	CTPDG002179
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	YSIL6	.	.	Phase 2	D0VS2W	.	CTPDG001945
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 2	PF-04236921	.	.	Phase 2	D06NXG	.	CTPDG002741
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	Gerilimzumab	.	.	Phase 1	D07IVS	.	CTPDG005102
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	MEDI5117	.	.	Phase 1	D0DT8Y	.	CTPDG004842
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	C326	.	.	Phase 1	D0GJ1U	.	CTPDG004764
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	Phase 1	D0OK5R	.	CTPDG011392
M6ACROT03019	Interleukin 6 (IL6)	IL6_HUMAN	.	.	Phase 1	SAR444419	.	.	Phase 1	DKX8W5	.	CTPDG011323
M6ACROT03019	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03019	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	Phase 2	D0U8XE	DB12411	CTPDG011504
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	MGCD265	"MGCD-265; 875337-44-3; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	Phase 2	D08FDX	.	CTPDG011506
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	Phase 1/2	D00LGR	DB15187	CTPDG011507
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	Enapotamab vedotin	.	.	Phase 1/2	DI0ZA3	.	CTPDG003179
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	DS-1205	.	.	Phase 1	D06THG	.	CTPDG011508
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	A416	.	.	Phase 1	DMLY68	.	CTPDG003818
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	PF-07265807	PF-5807; ARRY-067	.	Phase 1	DP4KH3	.	CTPDG003774
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	INCB81776	INCB081776	.	Phase 1	DQX83Z	.	CTPDG003749
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	Cu-anti-hAXL	.	.	Preclinical	D4JS3A	.	CTPDG011509
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	DP-3975	.	.	Preclinical	D4K2CQ	.	CTPDG011510
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	YW327.6S2	.	.	Preclinical	D50NHR	.	CTPDG011511
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	GL21.T	.	.	Preclinical	DU9RB1	.	CTPDG011512
M6ACROT03020	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Investigative	LDC1267	"1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	Investigative	D09TFN	.	CTPDG011513
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 4"	PMID25468267-Compound-37	66667765	Patented	D02FWO	.	CTPDG014973
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 1"	PMID25468267-Compound-34	56589666	Patented	D04KUD	.	CTPDG014974
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-56	.	90093146	Patented	D07CYB	.	CTPDG014975
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 5"	PMID25468267-Compound-38	56589667	Patented	D0BK5N	.	CTPDG014976
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-47	.	53392493	Patented	D0L5RA	.	CTPDG014977
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 7"	PMID25468267-Compound-40	56643890	Patented	D0Q5IR	.	CTPDG014978
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 3"	PMID25468267-Compound-36	66666946	Patented	D0RP4W	.	CTPDG014979
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Flavonoid derivative 6	PMID25468267-Compound-1	.	Patented	D0S8AZ	.	CTPDG014980
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-55	.	.	Patented	D0U3KT	.	CTPDG014981
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 2"	PMID25468267-Compound-35	.	Patented	D0UQ2R	.	CTPDG014982
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 6"	PMID25468267-Compound-39	66667268	Patented	D0Z2YB	.	CTPDG014983
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03020	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	Phase 2	D0U8XE	DB12411	CTPDG011504
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	MGCD265	"MGCD-265; 875337-44-3; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	Phase 2	D08FDX	.	CTPDG011506
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	Phase 1/2	D00LGR	DB15187	CTPDG011507
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	Enapotamab vedotin	.	.	Phase 1/2	DI0ZA3	.	CTPDG003179
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	DS-1205	.	.	Phase 1	D06THG	.	CTPDG011508
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	A416	.	.	Phase 1	DMLY68	.	CTPDG003818
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	PF-07265807	PF-5807; ARRY-067	.	Phase 1	DP4KH3	.	CTPDG003774
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	INCB81776	INCB081776	.	Phase 1	DQX83Z	.	CTPDG003749
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	Cu-anti-hAXL	.	.	Preclinical	D4JS3A	.	CTPDG011509
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	DP-3975	.	.	Preclinical	D4K2CQ	.	CTPDG011510
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	YW327.6S2	.	.	Preclinical	D50NHR	.	CTPDG011511
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	GL21.T	.	.	Preclinical	DU9RB1	.	CTPDG011512
M6ACROT03021	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Investigative	LDC1267	"1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	Investigative	D09TFN	.	CTPDG011513
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	Phase 2	D0U8XE	DB12411	CTPDG011504
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	MGCD265	"MGCD-265; 875337-44-3; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	Phase 2	D08FDX	.	CTPDG011506
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	Phase 1/2	D00LGR	DB15187	CTPDG011507
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	Enapotamab vedotin	.	.	Phase 1/2	DI0ZA3	.	CTPDG003179
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	DS-1205	.	.	Phase 1	D06THG	.	CTPDG011508
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	A416	.	.	Phase 1	DMLY68	.	CTPDG003818
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	PF-07265807	PF-5807; ARRY-067	.	Phase 1	DP4KH3	.	CTPDG003774
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	INCB81776	INCB081776	.	Phase 1	DQX83Z	.	CTPDG003749
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	Cu-anti-hAXL	.	.	Preclinical	D4JS3A	.	CTPDG011509
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	DP-3975	.	.	Preclinical	D4K2CQ	.	CTPDG011510
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	YW327.6S2	.	.	Preclinical	D50NHR	.	CTPDG011511
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	GL21.T	.	.	Preclinical	DU9RB1	.	CTPDG011512
M6ACROT03022	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Investigative	LDC1267	"1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	Investigative	D09TFN	.	CTPDG011513
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	Phase 2	D0U8XE	DB12411	CTPDG011504
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	MGCD265	"MGCD-265; 875337-44-3; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	Phase 2	D08FDX	.	CTPDG011506
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	Phase 1/2	D00LGR	DB15187	CTPDG011507
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	Enapotamab vedotin	.	.	Phase 1/2	DI0ZA3	.	CTPDG003179
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	DS-1205	.	.	Phase 1	D06THG	.	CTPDG011508
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	A416	.	.	Phase 1	DMLY68	.	CTPDG003818
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	PF-07265807	PF-5807; ARRY-067	.	Phase 1	DP4KH3	.	CTPDG003774
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	INCB81776	INCB081776	.	Phase 1	DQX83Z	.	CTPDG003749
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	Cu-anti-hAXL	.	.	Preclinical	D4JS3A	.	CTPDG011509
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	DP-3975	.	.	Preclinical	D4K2CQ	.	CTPDG011510
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	YW327.6S2	.	.	Preclinical	D50NHR	.	CTPDG011511
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	GL21.T	.	.	Preclinical	DU9RB1	.	CTPDG011512
M6ACROT03023	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Investigative	LDC1267	"1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	Investigative	D09TFN	.	CTPDG011513
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Approved	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	Approved	D04KZY	DB12141	CTPDG000668
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	Phase 2	D0U8XE	DB12411	CTPDG011504
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	Phase 1/2	D0X9VR	.	CTPDG001891
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	Mecbotamab vedotin	HTBA3011; HTBA3012	.	Phase 2	DYI4L2	.	CTPDG001606
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	MGCD265	"MGCD-265; 875337-44-3; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	Phase 2	D08FDX	.	CTPDG011506
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 2	BI-505	.	.	Phase 2	D0Q7OE	.	CTPDG002087
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	Phase 1/2	D00LGR	DB15187	CTPDG011507
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	Enapotamab vedotin	.	.	Phase 1/2	DI0ZA3	.	CTPDG003179
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1/2	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	Phase 1/2	DA1MG8	.	CTPDG003210
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	DS-1205	.	.	Phase 1	D06THG	.	CTPDG011508
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	AVB-S6-500	.	.	Phase 1	D0Y5QA	.	CTPDG004256
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	A416	.	.	Phase 1	DMLY68	.	CTPDG003818
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	ONO-7475	.	.	Phase 1	D0VH4T	.	CTPDG004333
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	PF-07265807	PF-5807; ARRY-067	.	Phase 1	DP4KH3	.	CTPDG003774
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	INCB81776	INCB081776	.	Phase 1	DQX83Z	.	CTPDG003749
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	Cu-anti-hAXL	.	.	Preclinical	D4JS3A	.	CTPDG011509
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	DP-3975	.	.	Preclinical	D4K2CQ	.	CTPDG011510
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	YW327.6S2	.	.	Preclinical	D50NHR	.	CTPDG011511
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Preclinical	GL21.T	.	.	Preclinical	DU9RB1	.	CTPDG011512
M6ACROT03024	Tyrosine-protein kinase receptor UFO (AXL)	UFO_HUMAN	.	.	Investigative	LDC1267	"1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	Investigative	D09TFN	.	CTPDG011513
M6ACROT03036	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03036	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03037	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03037	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03038	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03039	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03044	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03044	Bone morphogenetic protein 2 (BMP2)	BMP2_HUMAN	.	.	Phase 3	DWP-431	"Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong"	.	Phase 3	D03HDV	.	CTPDG014663
M6ACROT03045	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03045	Bone morphogenetic protein 2 (BMP2)	BMP2_HUMAN	.	.	Phase 3	DWP-431	"Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong"	.	Phase 3	D03HDV	.	CTPDG014663
M6ACROT03047	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03049	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT03049	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT03050	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT03056	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03057	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03057	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03058	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03058	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03059	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03060	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03060	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03061	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03062	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	CC-90011	"UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y"	118483201	Phase 2	DB5UA2	.	CTPDG013958
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	CC-90011	.	.	Phase 1	D04GNG	.	CTPDG005259
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	GSK2879552	.	66571643	Phase 1	D0I4ZN	.	CTPDG013959
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-16	.	.	Patented	D02YGX	.	CTPDG013960
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-41	.	.	Patented	D05FVW	.	CTPDG013961
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 2	PMID27019002-Compound-35	.	Patented	D05HBM	.	CTPDG013962
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28a	.	.	Patented	D06XEU	.	CTPDG013963
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 5	PMID27019002-Compound-25c	.	Patented	D07IAO	.	CTPDG013964
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 17	PMID27019002-Compound-39	.	Patented	D07LKA	.	CTPDG013965
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31b	.	.	Patented	D08FVR	.	CTPDG013966
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 3	PMID27019002-Compound-35a	.	Patented	D08WMK	.	CTPDG013967
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 1	PMID27019002-Compound-23	.	Patented	D0B6GK	.	CTPDG013968
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N6-cyclopropyllydine derivative 1	PMID27019002-Compound-30	.	Patented	D0BE4Z	.	CTPDG013969
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 1	PMID27019002-Compound-18	.	Patented	D0BG7B	.	CTPDG013970
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 7	PMID27019002-Compound-29e	.	Patented	D0C0PK	.	CTPDG013971
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 4	PMID27019002-Compound-25b	.	Patented	D0C1TH	.	CTPDG013972
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-45	.	.	Patented	D0D9CK	.	CTPDG013973
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-13	.	.	Patented	D0DD4I	.	CTPDG013974
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-49	.	.	Patented	D0DL5J	.	CTPDG013975
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 4	PMID27019002-Compound-29b	.	Patented	D0F1CT	.	CTPDG013976
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42b	.	.	Patented	D0GA7D	.	CTPDG013977
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31a	.	.	Patented	D0I9QC	.	CTPDG013978
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43c	.	.	Patented	D0J1HQ	.	CTPDG013979
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 3	PMID27019002-Compound-25a	.	Patented	D0JE6I	.	CTPDG013980
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 4	PMID27019002-Compound-36	.	Patented	D0KR0I	.	CTPDG013981
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 6	PMID27019002-Compound-29d	.	Patented	D0KZ5T	.	CTPDG013982
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 16	PMID27019002-Compound-38	.	Patented	D0L0DT	.	CTPDG013983
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28	.	.	Patented	D0L4OH	.	CTPDG013984
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 2	PMID27019002-Compound-22a	.	Patented	D0LK8A	.	CTPDG013985
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 5	PMID27019002-Compound-29c	.	Patented	D0LR6D	.	CTPDG013986
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43b	.	.	Patented	D0MO5Y	.	CTPDG013987
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 18	PMID27019002-Compound-40	.	Patented	D0N2QZ	.	CTPDG013988
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 3	PMID27019002-Compound-29a	.	Patented	D0NJ6B	.	CTPDG013989
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20b	.	.	Patented	D0O2WW	.	CTPDG013990
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-50	.	.	Patented	D0P4NF	.	CTPDG013991
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 8	PMID27019002-Compound-32	.	Patented	D0R7RY	.	CTPDG013992
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43a	.	.	Patented	D0RC0G	.	CTPDG013993
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 1	PMID27019002-Compound-14	.	Patented	D0U1DY	.	CTPDG013994
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-7	.	.	Patented	D0U4DT	.	CTPDG013995
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42a	.	.	Patented	D0UG5Q	.	CTPDG013996
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37a	.	.	Patented	D0VB7F	.	CTPDG013997
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-44	.	.	Patented	D0W8XM	.	CTPDG013998
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21a	.	.	Patented	D0YI0V	.	CTPDG013999
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37b	.	.	Patented	D0YX4R	.	CTPDG014000
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 11	PMID27019002-Compound-33c	.	Patented	D02CIX	.	CTPDG014002
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-11	.	.	Patented	D02WXS	.	CTPDG014003
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20a	.	.	Patented	D03MPD	.	CTPDG014004
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 9	PMID27019002-Compound-33a	.	Patented	D04PWX	.	CTPDG014005
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-13	.	.	Patented	D06KBT	.	CTPDG014006
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 3	PMID27019002-Compound-22b	.	Patented	D06VMN	.	CTPDG014007
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 13	PMID27019002-Compound-33e	.	Patented	D07DIJ	.	CTPDG014008
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-48	.	.	Patented	D09OMM	.	CTPDG014010
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-10	.	.	Patented	D0AI6J	.	CTPDG014011
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-12	.	.	Patented	D0E7SF	.	CTPDG014012
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-9	.	.	Patented	D0IO2A	.	CTPDG014013
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-14	.	.	Patented	D0PM2S	.	CTPDG014014
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-15	.	.	Patented	D0Q1EG	.	CTPDG014015
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 12	PMID27019002-Compound-33d	.	Patented	D0R2YA	.	CTPDG014016
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 10	PMID27019002-Compound-33b	.	Patented	D0W9VF	.	CTPDG014018
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-47	.	.	Patented	D0WO5W	.	CTPDG014019
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-17	.	.	Patented	D0WT1Z	.	CTPDG014020
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 2	PMID27019002-Compound-19a	.	Patented	D0XH9M	.	CTPDG014021
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-46	.	.	Patented	D0Z7HE	.	CTPDG014022
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclic peptide derivative 1	PMID27019002-Compound-compound11	.	Patented	D04OEV	.	CTPDG014023
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 1	PMID27019002-Compound-22d	.	Patented	D07NTA	.	CTPDG014024
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 3	PMID27019002-Compound-19b	.	Patented	D08IOP	.	CTPDG014025
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 2	PMID27019002-Compound-26a-h	.	Patented	D04OHC	.	CTPDG014027
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 3	PMID27019002-Compound-27a-m	.	Patented	D0O7IH	.	CTPDG014028
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	OG-L002	"1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride"	56639570	Investigative	D0C8SX	.	CTPDG014029
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	GSK-LSD1	"GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3"	71522234	Investigative	D0EV7U	.	CTPDG014030
M6ACROT03063	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	NCL-1	GTPL7024; ZINC94568752	73755256	Investigative	D0L6TQ	.	CTPDG014031
M6ACROT03064	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03065	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03068	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03069	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03069	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03070	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03070	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03073	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 2	ADU-S100	MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885	135390762	Phase 2	D0N6VS	.	CTPDG014686
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 2	ADU- S100	.	.	Phase 2	DCIX20	.	CTPDG014687
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 2	MK-1454	.	.	Phase 2	DQ4OU8	.	CTPDG014688
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1/2	IMSA101	.	.	Phase 1/2	DC37YW	.	CTPDG003198
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	BMS-986301	.	.	Phase 1	D2KOX5	.	CTPDG004164
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	MK-2118	.	.	Phase 1	D4JU8H	.	CTPDG004116
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	XMT-2056	.	.	Phase 1	D7AT3H	.	CTPDG004046
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	TAK-500	.	.	Phase 1	D9ICV2	.	CTPDG003998
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	SB 11285	.	.	Phase 1	DA79HM	.	CTPDG003980
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	E7766	.	.	Phase 1	DO7D1L	.	CTPDG003788
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	GSK3745417	.	.	Phase 1	DQ6J0W	.	CTPDG003756
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	A296	.	.	Phase 1	DTV17S	.	CTPDG003710
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	TAK-676	.	.	Phase 1	DTYQ45	.	CTPDG003708
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	SNX281	.	.	Phase 1	DUA7N4	.	CTPDG003703
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	SYNB1891	.	.	Phase 1	DUR0F6	.	CTPDG003699
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Investigative	C-178	"329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide"	2866412	Investigative	D7CI5F	.	CTPDG014689
M6ACROT03076	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Investigative	C-176	314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1	1103958	Investigative	DP2F6W	.	CTPDG014690
M6ACROT03080	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03080	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03081	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03082	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-52	.	117603070	Patented	D02YLT	.	CTPDG013815
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72a	.	.	Patented	D03KOH	.	CTPDG013816
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47c	.	72948227	Patented	D07KQB	.	CTPDG013817
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-70	.	122669618	Patented	D08CYC	.	CTPDG013818
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71b	.	.	Patented	D0BV4M	.	CTPDG013819
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72b	.	.	Patented	D0E7TU	.	CTPDG013820
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47a	.	72722126	Patented	D0L1NO	.	CTPDG013821
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-50	.	.	Patented	D0M7GG	.	CTPDG013822
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47b	.	72950863	Patented	D0NG9V	.	CTPDG013823
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71a	.	.	Patented	D0O1LX	.	CTPDG013824
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47d	.	72948224	Patented	D0SP7T	.	CTPDG013825
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-12	.	78425879	Patented	D0UE9B	.	CTPDG013826
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-68b	.	.	Patented	D0GD6R	.	CTPDG013827
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-9,10-dihydroanthracene-9-carboxamide"	CHEMBL575482; SCHEMBL4541357	45482666	Investigative	D03BQS	.	CTPDG013829
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylacetamide"	"Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt"	239512	Investigative	D03QOD	.	CTPDG013830
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-hydroxy-9H-xanthene-9-carboxamide	"CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446"	44626296	Investigative	D06IMY	.	CTPDG013831
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(3-fluorophenyl)-N-hydroxyacetamide"	CHEMBL574594; SCHEMBL4536216	45482630	Investigative	D0A4HF	.	CTPDG013832
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-fluorophenyl)-N-hydroxyacetamide"	CHEMBL573190; SCHEMBL2841871	45482672	Investigative	D0FN5D	.	CTPDG013833
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylpropanamide"	CHEMBL585365; SCHEMBL2844474	45482660	Investigative	D0I4RK	.	CTPDG013834
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-chlorophenyl)-N-hydroxyacetamide"	CHEMBL572805; SCHEMBL2848402	45482643	Investigative	D0PK9V	.	CTPDG013835
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03083	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT03083	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-52	.	117603070	Patented	D02YLT	.	CTPDG013815
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72a	.	.	Patented	D03KOH	.	CTPDG013816
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47c	.	72948227	Patented	D07KQB	.	CTPDG013817
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-70	.	122669618	Patented	D08CYC	.	CTPDG013818
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71b	.	.	Patented	D0BV4M	.	CTPDG013819
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72b	.	.	Patented	D0E7TU	.	CTPDG013820
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47a	.	72722126	Patented	D0L1NO	.	CTPDG013821
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-50	.	.	Patented	D0M7GG	.	CTPDG013822
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47b	.	72950863	Patented	D0NG9V	.	CTPDG013823
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71a	.	.	Patented	D0O1LX	.	CTPDG013824
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47d	.	72948224	Patented	D0SP7T	.	CTPDG013825
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-12	.	78425879	Patented	D0UE9B	.	CTPDG013826
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-68b	.	.	Patented	D0GD6R	.	CTPDG013827
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-9,10-dihydroanthracene-9-carboxamide"	CHEMBL575482; SCHEMBL4541357	45482666	Investigative	D03BQS	.	CTPDG013829
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylacetamide"	"Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt"	239512	Investigative	D03QOD	.	CTPDG013830
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-hydroxy-9H-xanthene-9-carboxamide	"CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446"	44626296	Investigative	D06IMY	.	CTPDG013831
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(3-fluorophenyl)-N-hydroxyacetamide"	CHEMBL574594; SCHEMBL4536216	45482630	Investigative	D0A4HF	.	CTPDG013832
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-fluorophenyl)-N-hydroxyacetamide"	CHEMBL573190; SCHEMBL2841871	45482672	Investigative	D0FN5D	.	CTPDG013833
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylpropanamide"	CHEMBL585365; SCHEMBL2844474	45482660	Investigative	D0I4RK	.	CTPDG013834
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-chlorophenyl)-N-hydroxyacetamide"	CHEMBL572805; SCHEMBL2848402	45482643	Investigative	D0PK9V	.	CTPDG013835
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03084	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT03084	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT03085	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03085	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	TG02	SB1317; 937270-47-8; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	Phase 1/2	D0P0KN	.	CTPDG013443
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AZD-5438	"602306-29-6; AZD5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	Phase 1	D06WHY	.	CTPDG005133
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	Phase 1	D07DTV	DB08142	CTPDG005118
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	Phase 1	D0PL7P	DB15425	CTPDG004504
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	Phase 1	D0S5RC	DB05969	CTPDG004433
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Fluorinated compound 1	PMID26161698-Compound-15	.	Patented	D09ISI	.	CTPDG013444
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"4-amino-3,5-di-substituted-thiazole derivative 1"	PMID26161698-Compound-54	.	Patented	D0JU4Z	.	CTPDG013445
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 11	PMID26161698-Compound-16	.	Patented	D02KWX	.	CTPDG013446
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	PMID26161698-Compound-27	73508010	Patented	D03EYT	.	CTPDG013447
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Alkyl sulfone derivative 1	PMID26161698-Compound-29	73672849	Patented	D05UJQ	.	CTPDG013448
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Aniline derivative 1	PMID26161698-Compound-33	59176838	Patented	D06QPW	.	CTPDG013449
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 1	PMID26161698-Compound-35	44253187	Patented	D07QIP	.	CTPDG013450
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-phenyl-pyrimidin-4-amine derivative 1	PMID26161698-Compound-30	74763288	Patented	D0AY5G	.	CTPDG013451
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID26161698-Compound-25	.	71618654	Patented	D0GQ7L	.	CTPDG013452
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diaryl amine derivative 1	PMID26161698-Compound-23	71515733	Patented	D0P4NP	.	CTPDG013453
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Flavopiridol analog 1	PMID26161698-Compound-5	86272549	Patented	D0P9WR	.	CTPDG013454
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	PMID26161698-Compound-31	73891126	Patented	D0QS2B	.	CTPDG013455
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Pyrazolo-triazine derivative 2	PMID26161698-Compound-14	71731909	Patented	D0T6CM	.	CTPDG013456
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"1,5-di-substituted pyridine derivative 1"	PMID26161698-Compound-26	60197050	Patented	D0UU0V	.	CTPDG013457
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	PMID26161698-Compound-28	74767011	Patented	D0V7RP	.	CTPDG013458
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Naphthyridine and isoquinoline derivative 1	PMID26161698-Compound-51	.	Patented	D08WJG	.	CTPDG013393
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 2	PMID26161698-Compound-36	71561915	Patented	D01CJE	.	CTPDG013394
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diamidothiazole derivative 1	PMID26161698-Compound-53	25256147	Patented	D0LR2Y	.	CTPDG013332
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrazolo[1,5-a]-1,3,5-triazine derivative 1"	PMID26161698-Compound-12	.	Patented	D0NB7Y	.	CTPDG013395
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Roscovitine derivative 1	PMID26161698-Compound-8	73353575	Patented	D07DUX	.	CTPDG013396
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 3	SCH 727965	Dinaciclib; SCH-727965	46926350	Discontinued in Phase 3	D0D3PX	DB12021	CTPDG013398
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	Preclinical	D0WS1V	DB02733	CTPDG007034
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	Olomoucine	"101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	Terminated	D00BPA	DB02116	CTPDG013399
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	Investigative	D01LPG	DB08134	CTPDG013460
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	Investigative	D03BZV	DB04607	CTPDG013461
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	Investigative	D06FIQ	DB07203	CTPDG013462
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BOHEMINE	189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	Investigative	D07ADR	.	CTPDG013463
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-phenyl-1H-pyrazole-3-carboxamide	"124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	Investigative	D07ODE	DB08135	CTPDG013464
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-hydroxynaphthalene-1-sulfonamide	"17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	Investigative	D07SGT	DB08132	CTPDG013465
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	Investigative	D0D3HB	DB08133	CTPDG013466
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	Investigative	D0I1SZ	DB08768	CTPDG013467
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	Investigative	D0I9VN	DB02603	CTPDG013468
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	Investigative	D0M5PI	.	CTPDG013469
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	Investigative	D0MK6D	DB02647	CTPDG013470
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	Investigative	D0P7RO	.	CTPDG013471
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	Investigative	D0QI7H	DB06948	CTPDG013472
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	Investigative	D0T4SJ	.	CTPDG007860
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	Investigative	D0T5AH	.	CTPDG007858
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	Investigative	D0U0GE	DB02091	CTPDG013473
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	Investigative	D0V1NK	.	CTPDG007806
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-Amino-6-Chloropyrazine	"33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	Investigative	D0W0PF	DB02297	CTPDG013474
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	Investigative	D0Y6DX	DB08233	CTPDG013475
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	Investigative	D01FJB	.	CTPDG013476
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	Investigative	D02ZYA	.	CTPDG013478
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	Investigative	D03XKK	.	CTPDG013480
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	JNJ-7706621	"443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	Investigative	D04NGS	.	CTPDG013404
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	GW-8510	.	3536	Investigative	D04RBG	.	CTPDG013482
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-265246	BMS 265246; BMS265246	135402864	Investigative	D05SZH	.	CTPDG013405
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	RESCOVITINE	CHEMBL1087791	46881287	Investigative	D07AEC	.	CTPDG013485
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	Investigative	D07JHG	.	CTPDG013486
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15"	5687	Investigative	D0KH5T	DB03365	CTPDG010119
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Oxindole 95	.	.	Investigative	D0MS4R	.	CTPDG013496
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	CVT-313	AC1OCFD4; NG 26	6918386	Investigative	D0P2WA	.	CTPDG013408
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	Investigative	D0R1FT	DB02407	CTPDG013497
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6027	.	398148	Investigative	D0U8YN	DB08312	CTPDG013498
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 8	SCHEMBL2991886; CHEMBL406102	24801181	Investigative	D01PEF	.	CTPDG013502
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Purvalanol A	Purvalanola; AC1L1JD0; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	Investigative	D07OAT	DB04751	CTPDG013410
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk1/2 inhibitor III	"443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664"	5330812	Investigative	D07OCA	DB07664	CTPDG013411
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 1	"341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	Investigative	D08KSQ	.	CTPDG013503
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 4	SCHEMBL3001373; CHEMBL406464	24801697	Investigative	D0B9YR	.	CTPDG013504
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Lysine Nz-Carboxylic Acid	N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	Investigative	D0CC0B	DB03801	CTPDG013505
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 6	CHEMBL406463; SCHEMBL2999009	24801185	Investigative	D0D0ZQ	.	CTPDG013506
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	Investigative	D0F0AX	.	CTPDG013412
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aminopurvalanol A	NG-97	6604931	Investigative	D0G2GA	.	CTPDG013413
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	9-Nitropaullone	"Alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	Investigative	D0H3EV	DB04014	CTPDG013414
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 5	"1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	Investigative	D0H6CQ	DB08182	CTPDG013507
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SU9516	"377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	Investigative	D0L3FK	DB03428	CTPDG013415
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 3	"954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	Investigative	D0S8VE	DB08178	CTPDG013508
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 2	"SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	Investigative	D0U1WL	.	CTPDG013509
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid"	3708	Investigative	D0G2CT	DB02519	CTPDG013416
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	Investigative	D0S7IE	.	CTPDG013511
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Double Oxidized Cysteine	.	6398956	Investigative	D0H1GU	.	CTPDG013512
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03086	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03086	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03086	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	TG02	SB1317; 937270-47-8; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	Phase 1/2	D0P0KN	.	CTPDG013443
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AZD-5438	"602306-29-6; AZD5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	Phase 1	D06WHY	.	CTPDG005133
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	Phase 1	D07DTV	DB08142	CTPDG005118
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	Phase 1	D0PL7P	DB15425	CTPDG004504
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	Phase 1	D0S5RC	DB05969	CTPDG004433
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Fluorinated compound 1	PMID26161698-Compound-15	.	Patented	D09ISI	.	CTPDG013444
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"4-amino-3,5-di-substituted-thiazole derivative 1"	PMID26161698-Compound-54	.	Patented	D0JU4Z	.	CTPDG013445
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 11	PMID26161698-Compound-16	.	Patented	D02KWX	.	CTPDG013446
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	PMID26161698-Compound-27	73508010	Patented	D03EYT	.	CTPDG013447
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Alkyl sulfone derivative 1	PMID26161698-Compound-29	73672849	Patented	D05UJQ	.	CTPDG013448
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Aniline derivative 1	PMID26161698-Compound-33	59176838	Patented	D06QPW	.	CTPDG013449
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 1	PMID26161698-Compound-35	44253187	Patented	D07QIP	.	CTPDG013450
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-phenyl-pyrimidin-4-amine derivative 1	PMID26161698-Compound-30	74763288	Patented	D0AY5G	.	CTPDG013451
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID26161698-Compound-25	.	71618654	Patented	D0GQ7L	.	CTPDG013452
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diaryl amine derivative 1	PMID26161698-Compound-23	71515733	Patented	D0P4NP	.	CTPDG013453
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Flavopiridol analog 1	PMID26161698-Compound-5	86272549	Patented	D0P9WR	.	CTPDG013454
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	PMID26161698-Compound-31	73891126	Patented	D0QS2B	.	CTPDG013455
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Pyrazolo-triazine derivative 2	PMID26161698-Compound-14	71731909	Patented	D0T6CM	.	CTPDG013456
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"1,5-di-substituted pyridine derivative 1"	PMID26161698-Compound-26	60197050	Patented	D0UU0V	.	CTPDG013457
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	PMID26161698-Compound-28	74767011	Patented	D0V7RP	.	CTPDG013458
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Naphthyridine and isoquinoline derivative 1	PMID26161698-Compound-51	.	Patented	D08WJG	.	CTPDG013393
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 2	PMID26161698-Compound-36	71561915	Patented	D01CJE	.	CTPDG013394
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diamidothiazole derivative 1	PMID26161698-Compound-53	25256147	Patented	D0LR2Y	.	CTPDG013332
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrazolo[1,5-a]-1,3,5-triazine derivative 1"	PMID26161698-Compound-12	.	Patented	D0NB7Y	.	CTPDG013395
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Roscovitine derivative 1	PMID26161698-Compound-8	73353575	Patented	D07DUX	.	CTPDG013396
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 3	SCH 727965	Dinaciclib; SCH-727965	46926350	Discontinued in Phase 3	D0D3PX	DB12021	CTPDG013398
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	Preclinical	D0WS1V	DB02733	CTPDG007034
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	Olomoucine	"101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	Terminated	D00BPA	DB02116	CTPDG013399
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	Investigative	D01LPG	DB08134	CTPDG013460
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	Investigative	D03BZV	DB04607	CTPDG013461
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	Investigative	D06FIQ	DB07203	CTPDG013462
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BOHEMINE	189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	Investigative	D07ADR	.	CTPDG013463
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-phenyl-1H-pyrazole-3-carboxamide	"124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	Investigative	D07ODE	DB08135	CTPDG013464
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-hydroxynaphthalene-1-sulfonamide	"17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	Investigative	D07SGT	DB08132	CTPDG013465
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	Investigative	D0D3HB	DB08133	CTPDG013466
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	Investigative	D0I1SZ	DB08768	CTPDG013467
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	Investigative	D0I9VN	DB02603	CTPDG013468
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	Investigative	D0M5PI	.	CTPDG013469
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	Investigative	D0MK6D	DB02647	CTPDG013470
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	Investigative	D0P7RO	.	CTPDG013471
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	Investigative	D0QI7H	DB06948	CTPDG013472
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	Investigative	D0T4SJ	.	CTPDG007860
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	Investigative	D0T5AH	.	CTPDG007858
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	Investigative	D0U0GE	DB02091	CTPDG013473
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	Investigative	D0V1NK	.	CTPDG007806
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-Amino-6-Chloropyrazine	"33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	Investigative	D0W0PF	DB02297	CTPDG013474
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	Investigative	D0Y6DX	DB08233	CTPDG013475
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	Investigative	D01FJB	.	CTPDG013476
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	Investigative	D02ZYA	.	CTPDG013478
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	Investigative	D03XKK	.	CTPDG013480
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	JNJ-7706621	"443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	Investigative	D04NGS	.	CTPDG013404
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	GW-8510	.	3536	Investigative	D04RBG	.	CTPDG013482
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-265246	BMS 265246; BMS265246	135402864	Investigative	D05SZH	.	CTPDG013405
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	RESCOVITINE	CHEMBL1087791	46881287	Investigative	D07AEC	.	CTPDG013485
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	Investigative	D07JHG	.	CTPDG013486
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15"	5687	Investigative	D0KH5T	DB03365	CTPDG010119
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Oxindole 95	.	.	Investigative	D0MS4R	.	CTPDG013496
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	CVT-313	AC1OCFD4; NG 26	6918386	Investigative	D0P2WA	.	CTPDG013408
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	Investigative	D0R1FT	DB02407	CTPDG013497
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6027	.	398148	Investigative	D0U8YN	DB08312	CTPDG013498
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 8	SCHEMBL2991886; CHEMBL406102	24801181	Investigative	D01PEF	.	CTPDG013502
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Purvalanol A	Purvalanola; AC1L1JD0; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	Investigative	D07OAT	DB04751	CTPDG013410
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk1/2 inhibitor III	"443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664"	5330812	Investigative	D07OCA	DB07664	CTPDG013411
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 1	"341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	Investigative	D08KSQ	.	CTPDG013503
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 4	SCHEMBL3001373; CHEMBL406464	24801697	Investigative	D0B9YR	.	CTPDG013504
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Lysine Nz-Carboxylic Acid	N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	Investigative	D0CC0B	DB03801	CTPDG013505
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 6	CHEMBL406463; SCHEMBL2999009	24801185	Investigative	D0D0ZQ	.	CTPDG013506
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	Investigative	D0F0AX	.	CTPDG013412
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aminopurvalanol A	NG-97	6604931	Investigative	D0G2GA	.	CTPDG013413
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	9-Nitropaullone	"Alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	Investigative	D0H3EV	DB04014	CTPDG013414
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 5	"1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	Investigative	D0H6CQ	DB08182	CTPDG013507
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SU9516	"377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	Investigative	D0L3FK	DB03428	CTPDG013415
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 3	"954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	Investigative	D0S8VE	DB08178	CTPDG013508
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 2	"SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	Investigative	D0U1WL	.	CTPDG013509
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid"	3708	Investigative	D0G2CT	DB02519	CTPDG013416
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	Investigative	D0S7IE	.	CTPDG013511
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Double Oxidized Cysteine	.	6398956	Investigative	D0H1GU	.	CTPDG013512
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03087	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03087	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03087	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03088	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT03088	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1	ABBV-CX-2029	.	.	Phase 1	D58AMF	.	CTPDG014793
M6ACROT03089	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT03089	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1	ABBV-CX-2029	.	.	Phase 1	D58AMF	.	CTPDG014793
M6ACROT03090	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT03090	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1	ABBV-CX-2029	.	.	Phase 1	D58AMF	.	CTPDG014793
M6ACROT03091	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1/2	CX2029	.	.	Phase 1/2	DZ1F3N	.	CTPDG003121
M6ACROT03091	Transferrin receptor protein 1 (TFRC)	TFR1_HUMAN	.	.	Phase 1	ABBV-CX-2029	.	.	Phase 1	D58AMF	.	CTPDG014793
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Phase 2	CXA10	.	.	Phase 2	DF1JO7	.	CTPDG013052
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-8	.	66546002	Patented	D01GTU	.	CTPDG013073
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 4"	PMID28454500-Compound-31	.	Patented	D01MZI	.	CTPDG013074
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-36	.	121289252	Patented	D01PKZ	.	CTPDG013075
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 4	PMID28454500-Compound-19	118567653	Patented	D02SPI	.	CTPDG013078
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 1	PMID28454500-Compound-38	.	Patented	D02YNU	.	CTPDG013079
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Vinyl sulfone derivative 1	PMID28454500-Compound-20	73053707	Patented	D04ILM	.	CTPDG013080
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 2"	PMID28454500-Compound-29	.	Patented	D06LEF	.	CTPDG013081
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Diterpenoid derivative 1	PMID28454500-Compound-47	132210477	Patented	D09FZF	.	CTPDG013082
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-13	.	73335601	Patented	D0AJ2T	.	CTPDG013084
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-12	.	.	Patented	D0AX4Q	.	CTPDG013086
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 1"	PMID28454500-Compound-28	.	Patented	D0AZ8T	.	CTPDG013087
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-41	.	11000442	Patented	D0C1PB	.	CTPDG013088
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 2	PMID28454500-Compound-17	118567519	Patented	D0EO3S	.	CTPDG013089
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-34	.	121289250	Patented	D0FH6P	.	CTPDG013090
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-33	.	121289344	Patented	D0FM3Q	.	CTPDG013091
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 3	PMID28454500-Compound-18	.	Patented	D0G1LS	.	CTPDG013092
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-50	.	193653	Patented	D0G4EK	DB04339	CTPDG013093
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-3	.	.	Patented	D0JH8Z	.	CTPDG013095
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Pyridyl compound 1	PMID28454500-Compound-15	.	Patented	D0KX0J	.	CTPDG013096
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-32	.	121289291	Patented	D0L1JQ	.	CTPDG013097
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-40	.	5316743	Patented	D0MQ3X	.	CTPDG013099
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-35	.	121289348	Patented	D0MX0Q	.	CTPDG013101
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-49	.	.	Patented	D0N1VC	.	CTPDG013102
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-9	.	66546189	Patented	D0N9GH	.	CTPDG013103
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Diterpenoid derivative 2	PMID28454500-Compound-48	132210549	Patented	D0Q9QQ	.	CTPDG013107
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-11	.	68066028	Patented	D0RM4V	.	CTPDG013108
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-37	.	121289347	Patented	D0SA1N	.	CTPDG013109
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 1	PMID28454500-Compound-16	53262706	Patented	D0U9TR	.	CTPDG013110
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 3"	PMID28454500-Compound-30	.	Patented	D0VA2G	.	CTPDG013111
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 2	PMID28454500-Compound-39	.	Patented	D0VW9H	.	CTPDG013112
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-10	.	68066062	Patented	D0WN1Y	.	CTPDG013113
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Trepenoid derivative 1	PMID28454500-Compound-14	.	Patented	D0XL2V	.	CTPDG013115
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Preclinical	VCB101	.	.	Preclinical	D46EBX	.	CTPDG014789
M6ACROT03092	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Preclinical	VCB102	.	.	Preclinical	DG07UD	.	CTPDG006986
M6ACROT03095	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT03095	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT03095	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT03095	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT03095	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03095	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03096	Histone-lysine N-methyltransferase SUV39H1  (SUV39H1)	SUV91_HUMAN	.	.	Investigative	chaetocin	"Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime"	11657687	Investigative	D04FNI	.	CTPDG015382
M6ACROT03098	Histone-lysine N-methyltransferase SUV39H1  (SUV39H1)	SUV91_HUMAN	.	.	Investigative	chaetocin	"Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime"	11657687	Investigative	D04FNI	.	CTPDG015382
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03100	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03101	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03102	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03103	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03106	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03106	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03106	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03107	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT03107	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT03107	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT03107	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT03108	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT03108	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT03108	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT03108	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT03109	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT03109	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT03109	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT03109	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT03110	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT03110	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT03110	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT03110	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT03115	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03115	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03116	Lysine-specific demethylase 2A (KDM2A)	KDM2A_HUMAN	.	.	Investigative	daminozide	DMASA; SADH; B 995; Alar; Kylar; B-NINE	15331	Investigative	D0B2WZ	.	CTPDG015474
M6ACROT03116	Lysine-specific demethylase 2A (KDM2A)	KDM2A_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03117	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03117	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03118	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03118	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03119	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03120	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03121	Annexin A1 (ANXA1)	ANXA1_HUMAN	.	.	Approved	Difluprednate	Durezol (TN)	443936	Approved	D01ZOG	DB06781	CTPDG012888
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03121	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03124	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03125	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03126	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03127	Histone deacetylase 7 (HDAC7)	HDAC7_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03128	Large neutral amino acids transporter small subunit 1 (SLC7A5)	LAT1_HUMAN	.	.	Investigative	"(+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid"	"2-Aminotetralin-2-carboxylic acid; 74444-77-2; D,L-2-Aminotetralin-2-carboxylic acid; 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid; 6331-63-1; CHEMBL8708; 2-amino-3,4-dihydro-1H-naphthalene-2-carboxylic acid; 2-Amino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid; 2-AMINO-1,2,3,4-TETRAHYDRO-2-NAPHTHALENECARBOXYLIC ACID; 2-Naphthalenecarboxylic acid, 2-amino-1,2,3,4-tetrahydro-; ACMC-20apiw; ACMC-20apfh; CB 1647; AC1L5ULH; SCHEMBL268919; NIOSH/QL2303010"	235533	Investigative	D01BCL	.	CTPDG015326
M6ACROT03128	Large neutral amino acids transporter small subunit 1 (SLC7A5)	LAT1_HUMAN	.	.	Investigative	BCH	"20448-79-7; 2-Amino-2-norbornanecarboxylic acid; 2-Aminobicyclo[2.2.1]heptane-2-carboxylic acid; 2-Aminonorbornane-2-carboxylic acid; MPUVBVXDFRDIPT-UHFFFAOYSA-N; Bicyclo[2.2.1]heptane-2-carboxylicacid, 2-amino-; b-BCH; 2-Amino-2-carboxy-bicyclo-2,2,1-heptane; AC1L3GVN; AC1Q5TB7; 2-Aminobicyclo(2,2,1)heptane-2-carboxylic acid; SCHEMBL202772; GTPL4700; CHEMBL2074957; CTK1A1593; MolPort-003-928-121; 2-amino-2-norbornane carboxylic acid; AKOS016044739; AKOS002666381; VZ23542; MCULE-9216762478; Norbornane-2-carboxylic acid, 2-amino"	115288	Investigative	D05BOD	.	CTPDG015327
M6ACROT03128	Large neutral amino acids transporter small subunit 1 (SLC7A5)	LAT1_HUMAN	.	.	Investigative	(+/-)-2-Aminoindane-2-carboxylic acid	"27473-62-7; 2-Amino-2-indancarboxylic acid; 2-amino-2,3-dihydro-1H-indene-2-carboxylic acid; 2-Aminoindane-2-carboxylic acid; 2-AMINOINDAN-2-CARBOXYLIC ACID; 2-Aminoindan-2-carboxylicacid; 2-Amino-indan-2-carboxylic acid; 2-amino-1,3-dihydroindene-2-carboxylic acid; CHEMBL1082953; 2-azanyl-1,3-dihydroindene-2-carboxylic acid; 1H-Indene-2-carboxylicacid, 2-amino-2,3-dihydro-; 2-amino-2-indancarboxylicacid; NSC70943; AC1L5IQE; AC1Q50FV; AC1Q5UK7; SCHEMBL122942; 1H-Indene-2-carboxylic acid"	250936	Investigative	D0SC5V	.	CTPDG015328
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Dolasetron	"Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate"	3033818	Approved	D00YLW	DB00757	CTPDG012708
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron	"Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one"	6337614	Approved	D04FVU	DB00377	CTPDG012709
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Alosetron	"Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride"	2099	Approved	D06GKN	DB00969	CTPDG012710
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Tropisetron	"Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate"	656665	Approved	D0K0KH	DB11699	CTPDG012711
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Procaine	"Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester"	4914	Approved	D0TZ1G	DB00721	CTPDG012712
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Levetiracetam	"102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Leviteracetam; Torleva; Levetiracetam [INN]; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam"	5284583	Approved	D0E1XL	DB01202	CTPDG012713
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron + fosnetupitant	.	.	Approved	D0K5IP	.	CTPDG012714
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Phase 3	Cilansetron	Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)	6918107	Phase 3	D0Z2MB	DB04885	CTPDG012715
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 3	BEMESETRON	"3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo"	671690	Discontinued in Phase 3	D0V3GT	.	CTPDG012716
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	YM-114	"KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride"	132963	Discontinued in Phase 2	D02WGN	.	CTPDG012717
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	Norcisapride	"84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176"	3019427	Discontinued in Phase 2	D0K1SZ	.	CTPDG012718
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Preclinical	ATI-17000	"CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one,"	5311194	Preclinical	D0M1YN	.	CTPDG012719
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	AS-8112	.	.	Terminated	D08KDP	.	CTPDG012720
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	BP4.879a	.	5311254	Terminated	D0V1SD	.	CTPDG012721
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	5-hydroxyindole	"1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole  [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ"	16054	Investigative	D00EJS	.	CTPDG012722
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	TMB-8	"8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06"	5494	Investigative	D01WXA	.	CTPDG012723
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea	CHEMBL1086332; SCHEMBL13527422	46831055	Investigative	D02OYL	.	CTPDG012724
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"10,11-dihydro-5H-dibenzo[b,f]azepine"	"Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N"	10308	Investigative	D04KGK	.	CTPDG012725
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane"	CHEMBL611082; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862	9794818	Investigative	D07ZZD	.	CTPDG012726
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(2'-Indolecarbonyloxy)-nortropane	CHEMBL596256; BDBM50304333	46226582	Investigative	D0C3AJ	.	CTPDG012727
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	FLUPENTIXOLE	"(E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol"	5281878	Investigative	D0M4RW	.	CTPDG012728
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]ramosetron	.	91827343	Investigative	D0O5PQ	.	CTPDG012729
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane	CHEMBL593963; BDBM50304334	46226590	Investigative	D0S8ZJ	.	CTPDG012730
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]GR65630	[3H]-GR65630	5311136	Investigative	D0T3QZ	.	CTPDG012731
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H](S)-zacopride	GTPL4074	53321935	Investigative	D0UV6L	.	CTPDG012732
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	BRL-24682	"Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-"	9797313	Investigative	D00PCE	.	CTPDG012733
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	6-(4-Methyl-piperazin-1-yl)-phenanthridine	"CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)-"	9993659	Investigative	D04AXY	.	CTPDG012734
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	trichloroethanol	"2,2,2-TRICHLOROETHANOL; 115-20-8; Trichlorethanol; Trichloroethyl alcohol; Ethanol, 2,2,2-trichloro-; 2,2,2-Trichloro-1-ethanol; (Hydroxymethyl)trichloromethane; 2,2,2-Trichloroethyl alcohol; 2,2,2-Trichloroethan-1-ol; C2H3Cl3O; UNII-AW835AJ62N; NSC 66407; beta-trichloroethanol; CCRIS 6763; CCl3CH2OH; EINECS 204-071-0; 2,2,2-trichloro-ethanol; 2,2,2-tris-chloroethanol; BRN 1697495; AW835AJ62N; CHEBI:28094; KPWDGTGXUYRARH-UHFFFAOYSA-N; .beta.,.beta.,.beta-Trichloroethanol; 2,2,2-Trichloroethanol, 99%; 4yas"	8259	Investigative	D06IRE	.	CTPDG012735
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid	CHEMBL468498; AC1LEONH; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid	715494	Investigative	D0G3MD	.	CTPDG012736
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-phenylbiguanide	"phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide"	4780	Investigative	D0H4NK	.	CTPDG012737
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(S)-zacopride	CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide	6604914	Investigative	D0I4BZ	.	CTPDG012738
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	PH-709829	PTGWFYYEAUFEAS-ZYHUDNBSSA-N; CHEMBL403858; PHA-709829; SCHEMBL844377; GTPL3997; BDBM50377050	10107234	Investigative	D0IP9V	.	CTPDG012739
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Benzyl-piperazin-1-yl)-benzothiazole	"2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191"	1484933	Investigative	D0L1NS	.	CTPDG012740
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]granisetron	[3H]-granisetron; [3H]-BRL-43694	3510	Investigative	D0P2HR	.	CTPDG012741
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	meta-chlorphenylbiguanide	"m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide"	1354	Investigative	D0SA4A	.	CTPDG012742
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole	CHEMBL289060; BDBM50014174	14742545	Investigative	D0TJ6Z	.	CTPDG012743
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	CP-810123	"UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane"	11184481	Investigative	D0X7HD	.	CTPDG012744
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	bilobalide	"33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448"	73581	Investigative	D0B0TK	.	CTPDG012745
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Methyl-piperazin-1-yl)-quinoline	"N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080"	5013	Investigative	D0G2BS	.	CTPDG012746
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-((naphthalen-2-yloxy)methyl)piperidine	4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158	24691160	Investigative	D01FFX	.	CTPDG012747
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	MESULERGINE	"Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206"	68848	Investigative	D0K5NZ	.	CTPDG012748
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	CHEMBL444985	44592241	Investigative	D06QIQ	.	CTPDG012749
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	QUIPAZINE	"4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259"	5011	Investigative	D08BCF	.	CTPDG012750
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5-chloro-3,4-dihydroquinazolin-2-amine"	"CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0"	13702393	Investigative	D0Y9TL	.	CTPDG012751
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-methyl-5-HT	2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin	1574	Investigative	D00CRA	.	CTPDG012752
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5,6-dichloro-3,4-dihydroquinazolin-2-amine"	"Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369"	9904281	Investigative	D08VGJ	.	CTPDG012753
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	SEROTONIN	"5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790"	5202	Investigative	D0F6CD	DB08839	CTPDG012754
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	A-987306	"SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS*,11aS*)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR*,11aR*)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine"	44538833	Investigative	D0F9QT	.	CTPDG012755
M6ACROT03129	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-36	.	.	Patented	D04JWR	.	CTPDG014972
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03129	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Dolasetron	"Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate"	3033818	Approved	D00YLW	DB00757	CTPDG012708
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron	"Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one"	6337614	Approved	D04FVU	DB00377	CTPDG012709
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Alosetron	"Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride"	2099	Approved	D06GKN	DB00969	CTPDG012710
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Tropisetron	"Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate"	656665	Approved	D0K0KH	DB11699	CTPDG012711
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Procaine	"Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester"	4914	Approved	D0TZ1G	DB00721	CTPDG012712
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Levetiracetam	"102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Leviteracetam; Torleva; Levetiracetam [INN]; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam"	5284583	Approved	D0E1XL	DB01202	CTPDG012713
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron + fosnetupitant	.	.	Approved	D0K5IP	.	CTPDG012714
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Phase 3	Cilansetron	Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)	6918107	Phase 3	D0Z2MB	DB04885	CTPDG012715
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 3	BEMESETRON	"3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo"	671690	Discontinued in Phase 3	D0V3GT	.	CTPDG012716
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	YM-114	"KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride"	132963	Discontinued in Phase 2	D02WGN	.	CTPDG012717
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	Norcisapride	"84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176"	3019427	Discontinued in Phase 2	D0K1SZ	.	CTPDG012718
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Preclinical	ATI-17000	"CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one,"	5311194	Preclinical	D0M1YN	.	CTPDG012719
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	AS-8112	.	.	Terminated	D08KDP	.	CTPDG012720
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	BP4.879a	.	5311254	Terminated	D0V1SD	.	CTPDG012721
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	5-hydroxyindole	"1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole  [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ"	16054	Investigative	D00EJS	.	CTPDG012722
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	TMB-8	"8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06"	5494	Investigative	D01WXA	.	CTPDG012723
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea	CHEMBL1086332; SCHEMBL13527422	46831055	Investigative	D02OYL	.	CTPDG012724
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"10,11-dihydro-5H-dibenzo[b,f]azepine"	"Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N"	10308	Investigative	D04KGK	.	CTPDG012725
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane"	CHEMBL611082; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862	9794818	Investigative	D07ZZD	.	CTPDG012726
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(2'-Indolecarbonyloxy)-nortropane	CHEMBL596256; BDBM50304333	46226582	Investigative	D0C3AJ	.	CTPDG012727
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	FLUPENTIXOLE	"(E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol"	5281878	Investigative	D0M4RW	.	CTPDG012728
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]ramosetron	.	91827343	Investigative	D0O5PQ	.	CTPDG012729
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane	CHEMBL593963; BDBM50304334	46226590	Investigative	D0S8ZJ	.	CTPDG012730
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]GR65630	[3H]-GR65630	5311136	Investigative	D0T3QZ	.	CTPDG012731
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H](S)-zacopride	GTPL4074	53321935	Investigative	D0UV6L	.	CTPDG012732
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	BRL-24682	"Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-"	9797313	Investigative	D00PCE	.	CTPDG012733
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	6-(4-Methyl-piperazin-1-yl)-phenanthridine	"CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)-"	9993659	Investigative	D04AXY	.	CTPDG012734
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	trichloroethanol	"2,2,2-TRICHLOROETHANOL; 115-20-8; Trichlorethanol; Trichloroethyl alcohol; Ethanol, 2,2,2-trichloro-; 2,2,2-Trichloro-1-ethanol; (Hydroxymethyl)trichloromethane; 2,2,2-Trichloroethyl alcohol; 2,2,2-Trichloroethan-1-ol; C2H3Cl3O; UNII-AW835AJ62N; NSC 66407; beta-trichloroethanol; CCRIS 6763; CCl3CH2OH; EINECS 204-071-0; 2,2,2-trichloro-ethanol; 2,2,2-tris-chloroethanol; BRN 1697495; AW835AJ62N; CHEBI:28094; KPWDGTGXUYRARH-UHFFFAOYSA-N; .beta.,.beta.,.beta-Trichloroethanol; 2,2,2-Trichloroethanol, 99%; 4yas"	8259	Investigative	D06IRE	.	CTPDG012735
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid	CHEMBL468498; AC1LEONH; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid	715494	Investigative	D0G3MD	.	CTPDG012736
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-phenylbiguanide	"phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide"	4780	Investigative	D0H4NK	.	CTPDG012737
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(S)-zacopride	CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide	6604914	Investigative	D0I4BZ	.	CTPDG012738
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	PH-709829	PTGWFYYEAUFEAS-ZYHUDNBSSA-N; CHEMBL403858; PHA-709829; SCHEMBL844377; GTPL3997; BDBM50377050	10107234	Investigative	D0IP9V	.	CTPDG012739
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Benzyl-piperazin-1-yl)-benzothiazole	"2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191"	1484933	Investigative	D0L1NS	.	CTPDG012740
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]granisetron	[3H]-granisetron; [3H]-BRL-43694	3510	Investigative	D0P2HR	.	CTPDG012741
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	meta-chlorphenylbiguanide	"m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide"	1354	Investigative	D0SA4A	.	CTPDG012742
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole	CHEMBL289060; BDBM50014174	14742545	Investigative	D0TJ6Z	.	CTPDG012743
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	CP-810123	"UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane"	11184481	Investigative	D0X7HD	.	CTPDG012744
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	bilobalide	"33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448"	73581	Investigative	D0B0TK	.	CTPDG012745
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Methyl-piperazin-1-yl)-quinoline	"N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080"	5013	Investigative	D0G2BS	.	CTPDG012746
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-((naphthalen-2-yloxy)methyl)piperidine	4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158	24691160	Investigative	D01FFX	.	CTPDG012747
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	MESULERGINE	"Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206"	68848	Investigative	D0K5NZ	.	CTPDG012748
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	CHEMBL444985	44592241	Investigative	D06QIQ	.	CTPDG012749
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	QUIPAZINE	"4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259"	5011	Investigative	D08BCF	.	CTPDG012750
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5-chloro-3,4-dihydroquinazolin-2-amine"	"CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0"	13702393	Investigative	D0Y9TL	.	CTPDG012751
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-methyl-5-HT	2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin	1574	Investigative	D00CRA	.	CTPDG012752
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5,6-dichloro-3,4-dihydroquinazolin-2-amine"	"Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369"	9904281	Investigative	D08VGJ	.	CTPDG012753
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	SEROTONIN	"5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790"	5202	Investigative	D0F6CD	DB08839	CTPDG012754
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	A-987306	"SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS*,11aS*)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR*,11aR*)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine"	44538833	Investigative	D0F9QT	.	CTPDG012755
M6ACROT03130	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-36	.	.	Patented	D04JWR	.	CTPDG014972
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03130	Histone deacetylase 11 (HDAC11)	HDA11_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03131	Lymphocyte function-associated antigen 3 (CD58)	LFA3_HUMAN	.	.	Approved	Alefacept	Amevive (TN)	.	Approved	D09ZSO	.	CTPDG012889
M6ACROT03131	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03131	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03132	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 2	RG7155	.	.	Phase 2	D06NQH	.	CTPDG002742
M6ACROT03132	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	Emactuzumab	.	.	Phase 1	D00MJI	.	CTPDG005452
M6ACROT03132	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	PLX73086	.	.	Phase 1	D0PL8D	.	CTPDG004503
M6ACROT03132	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	MSC110	Lacnotuzumab	.	Phase 1	D18QIB	.	CTPDG014468
M6ACROT03132	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03132	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03133	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03133	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03133	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03133	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03133	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03134	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03135	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03136	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03136	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03137	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03137	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03138	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03138	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	CC-90011	"UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y"	118483201	Phase 2	DB5UA2	.	CTPDG013958
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	CC-90011	.	.	Phase 1	D04GNG	.	CTPDG005259
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	GSK2879552	.	66571643	Phase 1	D0I4ZN	.	CTPDG013959
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-16	.	.	Patented	D02YGX	.	CTPDG013960
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-41	.	.	Patented	D05FVW	.	CTPDG013961
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 2	PMID27019002-Compound-35	.	Patented	D05HBM	.	CTPDG013962
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28a	.	.	Patented	D06XEU	.	CTPDG013963
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 5	PMID27019002-Compound-25c	.	Patented	D07IAO	.	CTPDG013964
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 17	PMID27019002-Compound-39	.	Patented	D07LKA	.	CTPDG013965
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31b	.	.	Patented	D08FVR	.	CTPDG013966
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 3	PMID27019002-Compound-35a	.	Patented	D08WMK	.	CTPDG013967
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 1	PMID27019002-Compound-23	.	Patented	D0B6GK	.	CTPDG013968
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N6-cyclopropyllydine derivative 1	PMID27019002-Compound-30	.	Patented	D0BE4Z	.	CTPDG013969
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 1	PMID27019002-Compound-18	.	Patented	D0BG7B	.	CTPDG013970
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 7	PMID27019002-Compound-29e	.	Patented	D0C0PK	.	CTPDG013971
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 4	PMID27019002-Compound-25b	.	Patented	D0C1TH	.	CTPDG013972
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-45	.	.	Patented	D0D9CK	.	CTPDG013973
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-13	.	.	Patented	D0DD4I	.	CTPDG013974
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-49	.	.	Patented	D0DL5J	.	CTPDG013975
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 4	PMID27019002-Compound-29b	.	Patented	D0F1CT	.	CTPDG013976
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42b	.	.	Patented	D0GA7D	.	CTPDG013977
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31a	.	.	Patented	D0I9QC	.	CTPDG013978
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43c	.	.	Patented	D0J1HQ	.	CTPDG013979
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 3	PMID27019002-Compound-25a	.	Patented	D0JE6I	.	CTPDG013980
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 4	PMID27019002-Compound-36	.	Patented	D0KR0I	.	CTPDG013981
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 6	PMID27019002-Compound-29d	.	Patented	D0KZ5T	.	CTPDG013982
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 16	PMID27019002-Compound-38	.	Patented	D0L0DT	.	CTPDG013983
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28	.	.	Patented	D0L4OH	.	CTPDG013984
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 2	PMID27019002-Compound-22a	.	Patented	D0LK8A	.	CTPDG013985
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 5	PMID27019002-Compound-29c	.	Patented	D0LR6D	.	CTPDG013986
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43b	.	.	Patented	D0MO5Y	.	CTPDG013987
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 18	PMID27019002-Compound-40	.	Patented	D0N2QZ	.	CTPDG013988
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 3	PMID27019002-Compound-29a	.	Patented	D0NJ6B	.	CTPDG013989
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20b	.	.	Patented	D0O2WW	.	CTPDG013990
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-50	.	.	Patented	D0P4NF	.	CTPDG013991
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 8	PMID27019002-Compound-32	.	Patented	D0R7RY	.	CTPDG013992
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43a	.	.	Patented	D0RC0G	.	CTPDG013993
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 1	PMID27019002-Compound-14	.	Patented	D0U1DY	.	CTPDG013994
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-7	.	.	Patented	D0U4DT	.	CTPDG013995
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42a	.	.	Patented	D0UG5Q	.	CTPDG013996
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37a	.	.	Patented	D0VB7F	.	CTPDG013997
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-44	.	.	Patented	D0W8XM	.	CTPDG013998
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21a	.	.	Patented	D0YI0V	.	CTPDG013999
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37b	.	.	Patented	D0YX4R	.	CTPDG014000
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 11	PMID27019002-Compound-33c	.	Patented	D02CIX	.	CTPDG014002
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-11	.	.	Patented	D02WXS	.	CTPDG014003
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20a	.	.	Patented	D03MPD	.	CTPDG014004
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 9	PMID27019002-Compound-33a	.	Patented	D04PWX	.	CTPDG014005
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-13	.	.	Patented	D06KBT	.	CTPDG014006
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 3	PMID27019002-Compound-22b	.	Patented	D06VMN	.	CTPDG014007
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 13	PMID27019002-Compound-33e	.	Patented	D07DIJ	.	CTPDG014008
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-48	.	.	Patented	D09OMM	.	CTPDG014010
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-10	.	.	Patented	D0AI6J	.	CTPDG014011
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-12	.	.	Patented	D0E7SF	.	CTPDG014012
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-9	.	.	Patented	D0IO2A	.	CTPDG014013
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-14	.	.	Patented	D0PM2S	.	CTPDG014014
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-15	.	.	Patented	D0Q1EG	.	CTPDG014015
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 12	PMID27019002-Compound-33d	.	Patented	D0R2YA	.	CTPDG014016
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 10	PMID27019002-Compound-33b	.	Patented	D0W9VF	.	CTPDG014018
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-47	.	.	Patented	D0WO5W	.	CTPDG014019
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-17	.	.	Patented	D0WT1Z	.	CTPDG014020
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 2	PMID27019002-Compound-19a	.	Patented	D0XH9M	.	CTPDG014021
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-46	.	.	Patented	D0Z7HE	.	CTPDG014022
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclic peptide derivative 1	PMID27019002-Compound-compound11	.	Patented	D04OEV	.	CTPDG014023
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 1	PMID27019002-Compound-22d	.	Patented	D07NTA	.	CTPDG014024
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 3	PMID27019002-Compound-19b	.	Patented	D08IOP	.	CTPDG014025
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 2	PMID27019002-Compound-26a-h	.	Patented	D04OHC	.	CTPDG014027
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 3	PMID27019002-Compound-27a-m	.	Patented	D0O7IH	.	CTPDG014028
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	OG-L002	"1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride"	56639570	Investigative	D0C8SX	.	CTPDG014029
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	GSK-LSD1	"GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3"	71522234	Investigative	D0EV7U	.	CTPDG014030
M6ACROT03139	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	NCL-1	GTPL7024; ZINC94568752	73755256	Investigative	D0L6TQ	.	CTPDG014031
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	CC-90011	"UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y"	118483201	Phase 2	DB5UA2	.	CTPDG013958
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	CC-90011	.	.	Phase 1	D04GNG	.	CTPDG005259
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	GSK2879552	.	66571643	Phase 1	D0I4ZN	.	CTPDG013959
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-16	.	.	Patented	D02YGX	.	CTPDG013960
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-41	.	.	Patented	D05FVW	.	CTPDG013961
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 2	PMID27019002-Compound-35	.	Patented	D05HBM	.	CTPDG013962
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28a	.	.	Patented	D06XEU	.	CTPDG013963
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 5	PMID27019002-Compound-25c	.	Patented	D07IAO	.	CTPDG013964
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 17	PMID27019002-Compound-39	.	Patented	D07LKA	.	CTPDG013965
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31b	.	.	Patented	D08FVR	.	CTPDG013966
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 3	PMID27019002-Compound-35a	.	Patented	D08WMK	.	CTPDG013967
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 1	PMID27019002-Compound-23	.	Patented	D0B6GK	.	CTPDG013968
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N6-cyclopropyllydine derivative 1	PMID27019002-Compound-30	.	Patented	D0BE4Z	.	CTPDG013969
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 1	PMID27019002-Compound-18	.	Patented	D0BG7B	.	CTPDG013970
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 7	PMID27019002-Compound-29e	.	Patented	D0C0PK	.	CTPDG013971
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 4	PMID27019002-Compound-25b	.	Patented	D0C1TH	.	CTPDG013972
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-45	.	.	Patented	D0D9CK	.	CTPDG013973
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-13	.	.	Patented	D0DD4I	.	CTPDG013974
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-49	.	.	Patented	D0DL5J	.	CTPDG013975
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 4	PMID27019002-Compound-29b	.	Patented	D0F1CT	.	CTPDG013976
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42b	.	.	Patented	D0GA7D	.	CTPDG013977
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31a	.	.	Patented	D0I9QC	.	CTPDG013978
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43c	.	.	Patented	D0J1HQ	.	CTPDG013979
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 3	PMID27019002-Compound-25a	.	Patented	D0JE6I	.	CTPDG013980
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 4	PMID27019002-Compound-36	.	Patented	D0KR0I	.	CTPDG013981
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 6	PMID27019002-Compound-29d	.	Patented	D0KZ5T	.	CTPDG013982
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 16	PMID27019002-Compound-38	.	Patented	D0L0DT	.	CTPDG013983
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28	.	.	Patented	D0L4OH	.	CTPDG013984
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 2	PMID27019002-Compound-22a	.	Patented	D0LK8A	.	CTPDG013985
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 5	PMID27019002-Compound-29c	.	Patented	D0LR6D	.	CTPDG013986
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43b	.	.	Patented	D0MO5Y	.	CTPDG013987
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 18	PMID27019002-Compound-40	.	Patented	D0N2QZ	.	CTPDG013988
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 3	PMID27019002-Compound-29a	.	Patented	D0NJ6B	.	CTPDG013989
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20b	.	.	Patented	D0O2WW	.	CTPDG013990
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-50	.	.	Patented	D0P4NF	.	CTPDG013991
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 8	PMID27019002-Compound-32	.	Patented	D0R7RY	.	CTPDG013992
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43a	.	.	Patented	D0RC0G	.	CTPDG013993
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 1	PMID27019002-Compound-14	.	Patented	D0U1DY	.	CTPDG013994
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-7	.	.	Patented	D0U4DT	.	CTPDG013995
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42a	.	.	Patented	D0UG5Q	.	CTPDG013996
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37a	.	.	Patented	D0VB7F	.	CTPDG013997
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-44	.	.	Patented	D0W8XM	.	CTPDG013998
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21a	.	.	Patented	D0YI0V	.	CTPDG013999
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37b	.	.	Patented	D0YX4R	.	CTPDG014000
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 11	PMID27019002-Compound-33c	.	Patented	D02CIX	.	CTPDG014002
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-11	.	.	Patented	D02WXS	.	CTPDG014003
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20a	.	.	Patented	D03MPD	.	CTPDG014004
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 9	PMID27019002-Compound-33a	.	Patented	D04PWX	.	CTPDG014005
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-13	.	.	Patented	D06KBT	.	CTPDG014006
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 3	PMID27019002-Compound-22b	.	Patented	D06VMN	.	CTPDG014007
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 13	PMID27019002-Compound-33e	.	Patented	D07DIJ	.	CTPDG014008
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-48	.	.	Patented	D09OMM	.	CTPDG014010
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-10	.	.	Patented	D0AI6J	.	CTPDG014011
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-12	.	.	Patented	D0E7SF	.	CTPDG014012
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-9	.	.	Patented	D0IO2A	.	CTPDG014013
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-14	.	.	Patented	D0PM2S	.	CTPDG014014
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-15	.	.	Patented	D0Q1EG	.	CTPDG014015
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 12	PMID27019002-Compound-33d	.	Patented	D0R2YA	.	CTPDG014016
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 10	PMID27019002-Compound-33b	.	Patented	D0W9VF	.	CTPDG014018
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-47	.	.	Patented	D0WO5W	.	CTPDG014019
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-17	.	.	Patented	D0WT1Z	.	CTPDG014020
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 2	PMID27019002-Compound-19a	.	Patented	D0XH9M	.	CTPDG014021
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-46	.	.	Patented	D0Z7HE	.	CTPDG014022
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclic peptide derivative 1	PMID27019002-Compound-compound11	.	Patented	D04OEV	.	CTPDG014023
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 1	PMID27019002-Compound-22d	.	Patented	D07NTA	.	CTPDG014024
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 3	PMID27019002-Compound-19b	.	Patented	D08IOP	.	CTPDG014025
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 2	PMID27019002-Compound-26a-h	.	Patented	D04OHC	.	CTPDG014027
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 3	PMID27019002-Compound-27a-m	.	Patented	D0O7IH	.	CTPDG014028
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	OG-L002	"1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride"	56639570	Investigative	D0C8SX	.	CTPDG014029
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	GSK-LSD1	"GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3"	71522234	Investigative	D0EV7U	.	CTPDG014030
M6ACROT03140	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	NCL-1	GTPL7024; ZINC94568752	73755256	Investigative	D0L6TQ	.	CTPDG014031
M6ACROT03142	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03142	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03142	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03142	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03142	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03142	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03144	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	Diaryl amine derivative 4	PMID28092474-Compound-9	.	Patented	D0XN2W	.	CTPDG013149
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	RGFP966	RGFP-966	56650312	Investigative	D00HXX	.	CTPDG014401
M6ACROT03145	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	droxinostat	NS-41080; NS41080	568416	Investigative	D00VXM	.	CTPDG013162
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	Diaryl amine derivative 4	PMID28092474-Compound-9	.	Patented	D0XN2W	.	CTPDG013149
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	RGFP966	RGFP-966	56650312	Investigative	D00HXX	.	CTPDG014401
M6ACROT03146	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	droxinostat	NS-41080; NS41080	568416	Investigative	D00VXM	.	CTPDG013162
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Phase 1	Citarinostat	ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942	53340426	Phase 1	D01WKZ	DB15449	CTPDG005375
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Phase 1	KA2507	.	.	Phase 1	D0O6SA	.	CTPDG004548
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	Sulfonamide derivative 16	PMID29886770-Compound-Figure6	.	Patented	D05OKZ	.	CTPDG013144
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-15	.	122439227	Patented	D0H5GP	.	CTPDG013145
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-14	.	.	Patented	D0N6WW	.	CTPDG013146
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-16	.	122616384	Patented	D0TO3O	.	CTPDG013147
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	Diaryl amine derivative 4	PMID28092474-Compound-9	.	Patented	D0XN2W	.	CTPDG013149
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	IKH-25	"HDAC-6 inhibitors (cancer), Ikerchem"	.	Investigative	D00JIX	.	CTPDG009182
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	(S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide	"thiolate analogue, 26a; CHEMBL235911; SCHEMBL16338810; BDBM19139"	23634888	Investigative	D01DOV	.	CTPDG013150
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Tubacin	"537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166"	6675804	Investigative	D04KQF	.	CTPDG008886
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	ST-2741	CHEMBL564876; SCHEMBL1306499; BDBM50297444	11993691	Investigative	D05OVV	.	CTPDG013151
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide	CHEMBL507114; SCHEMBL5330834	25216936	Investigative	D0G3ZH	.	CTPDG013152
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	PMID19111466C7d	GTPL7056; BDBM50255914	16661454	Investigative	D0G6DH	.	CTPDG013153
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	UCL-67022	"HDAC inhibitor (multiple myeloma), ST Barts/UCL"	.	Investigative	D0L0LR	.	CTPDG008125
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	PMID20947351C16	GTPL7057; BDBM50331106	50908800	Investigative	D0MC9C	.	CTPDG013154
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide	CHEMBL454438; SCHEMBL5359458; CGIYOYXFUHZSMD-UHFFFAOYSA-N	25216938	Investigative	D0Q4AV	.	CTPDG013155
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	NQN-1	PPM-18; NSC 73233	4882	Investigative	D0Q4EG	.	CTPDG013156
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-phenyl-6-(sulfamoylamino)hexanamide	CHEMBL474097; SCHEMBL5326902	25216937	Investigative	D0R8JK	.	CTPDG013157
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide	CHEMBL475301; SCHEMBL5327672	23634372	Investigative	D0T8AJ	.	CTPDG013158
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide	CHEMBL337584; TWZ-109	44359538	Investigative	D0X4VO	.	CTPDG013159
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide	CHEMBL475714; SCHEMBL5458681	44591342	Investigative	D0XU0G	.	CTPDG013160
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	NILTUBACIN	"Probes1_000174; Probes2_000141; AC1O7Y2N; CHEMBL1213539; SCHEMBL14476139; DIOX-H_003550; 8-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]anilino]-8-oxooctanoic acid"	6675803	Investigative	D0L7HP	.	CTPDG013161
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	droxinostat	NS-41080; NS41080	568416	Investigative	D00VXM	.	CTPDG013162
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03148	Protein deacetylase HDAC6  (HDAC6)	HDAC6_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MEDI4736	.	.	Phase 3	D04RRZ	.	CTPDG001416
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	KN046	.	.	Phase 3	DLOQ25	.	CTPDG012817
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	KN035	Envafolimab	.	Phase 2	D0GF2R	.	CTPDG002356
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	CX-072	.	.	Phase 2	D0Z2BO	.	CTPDG001867
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	INCB86550	.	.	Phase 2	DKM79E	.	CTPDG001693
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	M7824	.	.	Phase 2	D05FPZ	.	CTPDG002813
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	BGB-A333	.	.	Phase 1/2	DC5VW9	.	CTPDG003195
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	Phase 1/2	DS6VD0	.	CTPDG003143
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3300054	.	.	Phase 1	D08HSS	.	CTPDG005054
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MSB2311	.	.	Phase 1	D0A8AU	.	CTPDG004941
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1	BMS-936559	.	Phase 1	D0KP9A	.	CTPDG004646
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FAZ053	.	.	Phase 1	D0LU1O	.	CTPDG004609
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1 CSR T cells	.	.	Phase 1	D0W7UD	.	CTPDG012818
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	BMS-986189	.	.	Phase 1	D0X1GN	.	CTPDG012819
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	.	.	Phase 1	D2Z6WF	.	CTPDG004150
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PD-L1 t-haNK	.	.	Phase 1	DH42RF	.	CTPDG003899
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	KD033	.	.	Phase 1	DJVR06	.	CTPDG003860
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	Phase 1	D09PPU	.	CTPDG004985
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FS118	.	.	Phase 1	D0XO9F	.	CTPDG004272
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MCLA-145	.	.	Phase 1	D2QY0Z	.	CTPDG004156
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	GEN1046	.	.	Phase 1	D3HBJ1	.	CTPDG004139
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	ALPN-202	.	.	Phase 1	D82UVG	.	CTPDG004022
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	TAK-252	SL-279252	.	Phase 1	D9SL1N	.	CTPDG003989
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	INBRX-105	.	.	Phase 1	DA1X5W	.	CTPDG003983
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3415244	.	.	Phase 1	DC8HR6	.	CTPDG003954
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	A337	.	.	Phase 1	DL97UQ	.	CTPDG003833
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example2	.	117941742	Patented	D0OK1S	.	CTPDG005729
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example1	.	117951478	Patented	D0WQ9X	.	CTPDG005575
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure7	PMID30247903Compound7	.	Investigative	D01TGF	.	CTPDG012820
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	CA-327	.	.	Investigative	D04ILU	.	CTPDG012821
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure8	PMID30247903Compound8	.	Investigative	D04QGF	.	CTPDG012822
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure5	PMID30247903Compound5	.	Investigative	D07BOF	.	CTPDG012823
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure12	PMID30247903Compound12	.	Investigative	D09BYN	.	CTPDG012824
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure9	PMID30247903Compound9	.	Investigative	D0GG6N	.	CTPDG012825
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure6	PMID30247903Compound6	.	Investigative	D0TN4F	.	CTPDG012826
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure10	PMID30247903Compound10	.	Investigative	D0XL3N	.	CTPDG012827
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH011	.	.	Investigative	DA91UG	.	CTPDG007607
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH010	.	.	Investigative	DBTI39	.	CTPDG007604
M6ACROT03149	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	RG6084	.	.	Phase 1	DJX7K9	.	CTPDG014810
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03149	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03150	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	Belnacasan	"Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765)"	11398092	Phase 2	D0HK3N	.	CTPDG014158
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	Nivocasan	GS-9450; LB-84451	11633038	Phase 2	D0Z2JF	DB12720	CTPDG014159
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	AC-201	.	.	Phase 2	D0WP2R	.	CTPDG001911
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Patented	Ac-YVAD-FMK	.	.	Patented	D04KIH	.	CTPDG014160
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Patented	Ac-YVAD-cmk	.	.	Patented	D07AVV	.	CTPDG014161
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Terminated	L-709049	Ac-Yvad-cho; 143313-51-3; Acetyl-tyrosyl-valyl-alanyl-aspartal; Caspase-1 Inhibitor I; CHEMBL37630; Ac-Tyr-Val-Ala-Asp-H; IL-1beta Converting Enzyme (ICE) Inhibitor I; acetyl-Tyr-Val-Ala-Asp-aldehyde; N-acetyl-Tyr-Val-Ala-Asp-aldehyde; (3S)-3-[(2S)-2-[(2S)-2-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]-4-oxobutanoic acid; Ac-Tyr-Val-Ala-Asp-Aldehyde; AC1NSK2K; SCHEMBL4349143; BDBM10355; MolPort-016-580-695; N-acetyl-Tyr-Val-Ala-Asp aldehyde; ZINC3915255; 1600AH; NCGC00167338-01	5311139	Terminated	D0F9FA	.	CTPDG014162
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	YVAD	.	9847365	Investigative	D0B3WF	.	CTPDG014163
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	Z-YVAD-CHO	CHEMBL159822	44407073	Investigative	D0P3XJ	.	CTPDG014164
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	Z-VAD-CHO	CHEMBL320954; ZVAD-CHO; BDBM50176519; (S)-3-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-butyric acid	10112904	Investigative	D0X8XO	.	CTPDG014165
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	Z-YVAD-FMK	benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone; caspase-1 Inhibitor VI	644196	Investigative	D0YX4V	.	CTPDG014166
M6ACROT03151	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	M826	compound 4sx	9851134	Investigative	D00YNW	.	CTPDG014167
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03151	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03154	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT03154	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT03154	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT03154	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT03155	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03155	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03155	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03155	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03155	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03156	Amino acid transporter heavy chain SLC3A2 (SLC3A2)	4F2_HUMAN	.	.	Phase 1	IGN523	.	.	Phase 1	D0OQ5R	.	CTPDG004532
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	Diaryl amine derivative 4	PMID28092474-Compound-9	.	Patented	D0XN2W	.	CTPDG013149
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	RGFP966	RGFP-966	56650312	Investigative	D00HXX	.	CTPDG014401
M6ACROT03158	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	droxinostat	NS-41080; NS41080	568416	Investigative	D00VXM	.	CTPDG013162
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 4"	PMID25468267-Compound-37	66667765	Patented	D02FWO	.	CTPDG014973
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 1"	PMID25468267-Compound-34	56589666	Patented	D04KUD	.	CTPDG014974
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-56	.	90093146	Patented	D07CYB	.	CTPDG014975
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 5"	PMID25468267-Compound-38	56589667	Patented	D0BK5N	.	CTPDG014976
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-47	.	53392493	Patented	D0L5RA	.	CTPDG014977
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 7"	PMID25468267-Compound-40	56643890	Patented	D0Q5IR	.	CTPDG014978
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 3"	PMID25468267-Compound-36	66666946	Patented	D0RP4W	.	CTPDG014979
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Flavonoid derivative 6	PMID25468267-Compound-1	.	Patented	D0S8AZ	.	CTPDG014980
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-55	.	.	Patented	D0U3KT	.	CTPDG014981
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 2"	PMID25468267-Compound-35	.	Patented	D0UQ2R	.	CTPDG014982
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 6"	PMID25468267-Compound-39	66667268	Patented	D0Z2YB	.	CTPDG014983
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03159	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03163	DNA repair protein RAD51 homolog 1 (RAD51)	RAD51_HUMAN	.	.	Phase 1/2	CYT-0851	.	.	Phase 1/2	DR5VQ1	.	CTPDG003148
M6ACROT03163	DNA repair protein RAD51 homolog 1 (RAD51)	RAD51_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03165	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03165	Polycomb protein EED (EED)	EED_HUMAN	.	.	Phase 1/2	MAK683	"XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663"	121412508	Phase 1/2	D0UO0C	.	CTPDG003299
M6ACROT03165	Polycomb protein EED (EED)	EED_HUMAN	.	.	Phase 1	ORIC-944	.	.	Phase 1	DPS29T	.	CTPDG014728
M6ACROT03165	Polycomb protein EED (EED)	EED_HUMAN	.	.	Investigative	A-395	"CHEMBL4104741; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine; GTPL9525; SCHEMBL19549392; BDBM223987; BDBM50241662; A-395 hydrochloride, >=98% (HPLC); HY-101512; CS-0021615; J3.609.234C; A-395 (5); A392089148-72-9; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]pyrrolidin-3-amine; 2089148-71-8; rac-(3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine (4); rel-(3R,4S)-1-(7-Fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine"	123132213	Investigative	DQ0V7Y	.	CTPDG014729
M6ACROT03169	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03169	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03170	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03171	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03171	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03172	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03173	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03173	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03174	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03174	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03175	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03176	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	CC-90011	"UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y"	118483201	Phase 2	DB5UA2	.	CTPDG013958
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	CC-90011	.	.	Phase 1	D04GNG	.	CTPDG005259
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	GSK2879552	.	66571643	Phase 1	D0I4ZN	.	CTPDG013959
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-16	.	.	Patented	D02YGX	.	CTPDG013960
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-41	.	.	Patented	D05FVW	.	CTPDG013961
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 2	PMID27019002-Compound-35	.	Patented	D05HBM	.	CTPDG013962
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28a	.	.	Patented	D06XEU	.	CTPDG013963
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 5	PMID27019002-Compound-25c	.	Patented	D07IAO	.	CTPDG013964
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 17	PMID27019002-Compound-39	.	Patented	D07LKA	.	CTPDG013965
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31b	.	.	Patented	D08FVR	.	CTPDG013966
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 3	PMID27019002-Compound-35a	.	Patented	D08WMK	.	CTPDG013967
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 1	PMID27019002-Compound-23	.	Patented	D0B6GK	.	CTPDG013968
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N6-cyclopropyllydine derivative 1	PMID27019002-Compound-30	.	Patented	D0BE4Z	.	CTPDG013969
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 1	PMID27019002-Compound-18	.	Patented	D0BG7B	.	CTPDG013970
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 7	PMID27019002-Compound-29e	.	Patented	D0C0PK	.	CTPDG013971
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 4	PMID27019002-Compound-25b	.	Patented	D0C1TH	.	CTPDG013972
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-45	.	.	Patented	D0D9CK	.	CTPDG013973
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-13	.	.	Patented	D0DD4I	.	CTPDG013974
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-49	.	.	Patented	D0DL5J	.	CTPDG013975
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 4	PMID27019002-Compound-29b	.	Patented	D0F1CT	.	CTPDG013976
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42b	.	.	Patented	D0GA7D	.	CTPDG013977
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31a	.	.	Patented	D0I9QC	.	CTPDG013978
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43c	.	.	Patented	D0J1HQ	.	CTPDG013979
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 3	PMID27019002-Compound-25a	.	Patented	D0JE6I	.	CTPDG013980
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 4	PMID27019002-Compound-36	.	Patented	D0KR0I	.	CTPDG013981
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 6	PMID27019002-Compound-29d	.	Patented	D0KZ5T	.	CTPDG013982
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 16	PMID27019002-Compound-38	.	Patented	D0L0DT	.	CTPDG013983
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28	.	.	Patented	D0L4OH	.	CTPDG013984
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 2	PMID27019002-Compound-22a	.	Patented	D0LK8A	.	CTPDG013985
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 5	PMID27019002-Compound-29c	.	Patented	D0LR6D	.	CTPDG013986
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43b	.	.	Patented	D0MO5Y	.	CTPDG013987
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 18	PMID27019002-Compound-40	.	Patented	D0N2QZ	.	CTPDG013988
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 3	PMID27019002-Compound-29a	.	Patented	D0NJ6B	.	CTPDG013989
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20b	.	.	Patented	D0O2WW	.	CTPDG013990
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-50	.	.	Patented	D0P4NF	.	CTPDG013991
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 8	PMID27019002-Compound-32	.	Patented	D0R7RY	.	CTPDG013992
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43a	.	.	Patented	D0RC0G	.	CTPDG013993
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 1	PMID27019002-Compound-14	.	Patented	D0U1DY	.	CTPDG013994
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-7	.	.	Patented	D0U4DT	.	CTPDG013995
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42a	.	.	Patented	D0UG5Q	.	CTPDG013996
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37a	.	.	Patented	D0VB7F	.	CTPDG013997
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-44	.	.	Patented	D0W8XM	.	CTPDG013998
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21a	.	.	Patented	D0YI0V	.	CTPDG013999
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37b	.	.	Patented	D0YX4R	.	CTPDG014000
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 11	PMID27019002-Compound-33c	.	Patented	D02CIX	.	CTPDG014002
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-11	.	.	Patented	D02WXS	.	CTPDG014003
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20a	.	.	Patented	D03MPD	.	CTPDG014004
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 9	PMID27019002-Compound-33a	.	Patented	D04PWX	.	CTPDG014005
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-13	.	.	Patented	D06KBT	.	CTPDG014006
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 3	PMID27019002-Compound-22b	.	Patented	D06VMN	.	CTPDG014007
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 13	PMID27019002-Compound-33e	.	Patented	D07DIJ	.	CTPDG014008
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-48	.	.	Patented	D09OMM	.	CTPDG014010
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-10	.	.	Patented	D0AI6J	.	CTPDG014011
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-12	.	.	Patented	D0E7SF	.	CTPDG014012
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-9	.	.	Patented	D0IO2A	.	CTPDG014013
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-14	.	.	Patented	D0PM2S	.	CTPDG014014
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-15	.	.	Patented	D0Q1EG	.	CTPDG014015
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 12	PMID27019002-Compound-33d	.	Patented	D0R2YA	.	CTPDG014016
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 10	PMID27019002-Compound-33b	.	Patented	D0W9VF	.	CTPDG014018
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-47	.	.	Patented	D0WO5W	.	CTPDG014019
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-17	.	.	Patented	D0WT1Z	.	CTPDG014020
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 2	PMID27019002-Compound-19a	.	Patented	D0XH9M	.	CTPDG014021
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-46	.	.	Patented	D0Z7HE	.	CTPDG014022
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclic peptide derivative 1	PMID27019002-Compound-compound11	.	Patented	D04OEV	.	CTPDG014023
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 1	PMID27019002-Compound-22d	.	Patented	D07NTA	.	CTPDG014024
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 3	PMID27019002-Compound-19b	.	Patented	D08IOP	.	CTPDG014025
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 2	PMID27019002-Compound-26a-h	.	Patented	D04OHC	.	CTPDG014027
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 3	PMID27019002-Compound-27a-m	.	Patented	D0O7IH	.	CTPDG014028
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	OG-L002	"1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride"	56639570	Investigative	D0C8SX	.	CTPDG014029
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	GSK-LSD1	"GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3"	71522234	Investigative	D0EV7U	.	CTPDG014030
M6ACROT03177	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	NCL-1	GTPL7024; ZINC94568752	73755256	Investigative	D0L6TQ	.	CTPDG014031
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03178	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03178	Polycomb protein EED (EED)	EED_HUMAN	.	.	Phase 1/2	MAK683	"XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663"	121412508	Phase 1/2	D0UO0C	.	CTPDG003299
M6ACROT03178	Polycomb protein EED (EED)	EED_HUMAN	.	.	Phase 1	ORIC-944	.	.	Phase 1	DPS29T	.	CTPDG014728
M6ACROT03178	Polycomb protein EED (EED)	EED_HUMAN	.	.	Investigative	A-395	"CHEMBL4104741; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine; GTPL9525; SCHEMBL19549392; BDBM223987; BDBM50241662; A-395 hydrochloride, >=98% (HPLC); HY-101512; CS-0021615; J3.609.234C; A-395 (5); A392089148-72-9; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]pyrrolidin-3-amine; 2089148-71-8; rac-(3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine (4); rel-(3R,4S)-1-(7-Fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine"	123132213	Investigative	DQ0V7Y	.	CTPDG014729
M6ACROT03179	Histone-lysine N-methyltransferase SUV39H1  (SUV39H1)	SUV91_HUMAN	.	.	Investigative	chaetocin	"Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime"	11657687	Investigative	D04FNI	.	CTPDG015382
M6ACROT03180	Histone-lysine N-methyltransferase SUV39H1  (SUV39H1)	SUV91_HUMAN	.	.	Investigative	chaetocin	"Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime"	11657687	Investigative	D04FNI	.	CTPDG015382
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03187	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03187	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103473	.	.	Investigative	D07HIJ	.	CTPDG015370
M6ACROT03187	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103471	.	.	Investigative	D07RVX	.	CTPDG015371
M6ACROT03187	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103489	.	.	Investigative	D0Q3KN	.	CTPDG015372
M6ACROT03187	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103486	.	.	Investigative	D0S4BJ	.	CTPDG015373
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03188	Histone deacetylase 9  (HDAC9)	HDAC9_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03188	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103473	.	.	Investigative	D07HIJ	.	CTPDG015370
M6ACROT03188	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103471	.	.	Investigative	D07RVX	.	CTPDG015371
M6ACROT03188	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103489	.	.	Investigative	D0Q3KN	.	CTPDG015372
M6ACROT03188	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103486	.	.	Investigative	D0S4BJ	.	CTPDG015373
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-52	.	117603070	Patented	D02YLT	.	CTPDG013815
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72a	.	.	Patented	D03KOH	.	CTPDG013816
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47c	.	72948227	Patented	D07KQB	.	CTPDG013817
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-70	.	122669618	Patented	D08CYC	.	CTPDG013818
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71b	.	.	Patented	D0BV4M	.	CTPDG013819
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72b	.	.	Patented	D0E7TU	.	CTPDG013820
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47a	.	72722126	Patented	D0L1NO	.	CTPDG013821
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-50	.	.	Patented	D0M7GG	.	CTPDG013822
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47b	.	72950863	Patented	D0NG9V	.	CTPDG013823
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71a	.	.	Patented	D0O1LX	.	CTPDG013824
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47d	.	72948224	Patented	D0SP7T	.	CTPDG013825
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-12	.	78425879	Patented	D0UE9B	.	CTPDG013826
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-68b	.	.	Patented	D0GD6R	.	CTPDG013827
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-9,10-dihydroanthracene-9-carboxamide"	CHEMBL575482; SCHEMBL4541357	45482666	Investigative	D03BQS	.	CTPDG013829
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylacetamide"	"Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt"	239512	Investigative	D03QOD	.	CTPDG013830
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-hydroxy-9H-xanthene-9-carboxamide	"CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446"	44626296	Investigative	D06IMY	.	CTPDG013831
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(3-fluorophenyl)-N-hydroxyacetamide"	CHEMBL574594; SCHEMBL4536216	45482630	Investigative	D0A4HF	.	CTPDG013832
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-fluorophenyl)-N-hydroxyacetamide"	CHEMBL573190; SCHEMBL2841871	45482672	Investigative	D0FN5D	.	CTPDG013833
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylpropanamide"	CHEMBL585365; SCHEMBL2844474	45482660	Investigative	D0I4RK	.	CTPDG013834
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-chlorophenyl)-N-hydroxyacetamide"	CHEMBL572805; SCHEMBL2848402	45482643	Investigative	D0PK9V	.	CTPDG013835
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03189	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03192	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03192	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03192	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03196	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03197	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03198	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03199	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03200	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03201	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03202	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03203	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	Diaryl amine derivative 4	PMID28092474-Compound-9	.	Patented	D0XN2W	.	CTPDG013149
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	RGFP966	RGFP-966	56650312	Investigative	D00HXX	.	CTPDG014401
M6ACROT03206	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	droxinostat	NS-41080; NS41080	568416	Investigative	D00VXM	.	CTPDG013162
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	Diaryl amine derivative 4	PMID28092474-Compound-9	.	Patented	D0XN2W	.	CTPDG013149
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	RGFP966	RGFP-966	56650312	Investigative	D00HXX	.	CTPDG014401
M6ACROT03207	Histone deacetylase 3  (HDAC3)	HDAC3_HUMAN	.	.	Investigative	droxinostat	NS-41080; NS41080	568416	Investigative	D00VXM	.	CTPDG013162
M6ACROT03208	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03208	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03213	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03214	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT03214	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT03214	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03214	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT03215	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1/2	131I-radretumab	"L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP"	.	Phase 1/2	D0H4GT	.	CTPDG014059
M6ACROT03215	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1	OS2966	.	.	Phase 1	DB8MR6	.	CTPDG014060
M6ACROT03215	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Phase 1	JSM 6427	.	.	Phase 1	D0ZT4J	.	CTPDG014061
M6ACROT03215	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	MK-0668	"UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-"	11433918	Investigative	D09XED	.	CTPDG014062
M6ACROT03215	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT03215	Integrin beta-1 (ITGB1)	ITB1_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03218	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03219	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03221	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03222	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03222	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03223	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03223	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03223	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03223	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03223	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03223	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03225	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03225	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03226	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03226	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03228	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Propoxyphene Hydrochloride	Darvon; Dolene; Kesso-gesic; Prophene 65; Propoxyphene Hydrochloride 65; Darvon-n; Propoxyphene Napsylate	15424	Approved	D03HCZ	.	CTPDG011514
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Levomethadyl Acetate	"LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)"	15130	Approved	D05PIZ	DB01227	CTPDG011515
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Anileridine Hydrochloride	Anileridine Phosphate; Leritine	31338	Approved	D05ZTJ	.	CTPDG011516
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Buprenorphine	"Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone  (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M"	644073	Approved	D06AWE	DB00921	CTPDG011517
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Naloxegol	NKTR-118	56959087	Approved	D07LCF	DB09049	CTPDG011518
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Alvimopan	"Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid"	5488548	Approved	D0D7KC	DB06274	CTPDG011519
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Fentanyl	"Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	3345	Approved	D0E1WI	DB00813	CTPDG011520
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Alfentanil	"Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide"	51263	Approved	D0G5QB	DB00802	CTPDG011521
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Methadyl Acetate	"ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate"	10517	Approved	D0GR0T	DB01433	CTPDG011522
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Buprenorphine + naloxone	"Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461"	6321408	Approved	D0H2JP	.	CTPDG011523
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Diphenoxylate	"Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride"	13505	Approved	D0J2TN	DB01081	CTPDG011524
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Naldemedine Tosylate	.	56837137	Approved	D0Q2HO	.	CTPDG011525
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Remifentanil	"Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester"	60815	Approved	D0T5OX	DB00899	CTPDG011526
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Morphine	Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr	5288826	Approved	D0WE3O	DB00295	CTPDG000078
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Naloxone	"Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one"	5284596	Approved	D0X3FX	DB01183	CTPDG011527
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Hydrocodone	"Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug"	5284569	Approved	D0X5KF	DB00956	CTPDG011528
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Anileridine	"Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester"	8944	Approved	D0X6HD	DB00913	CTPDG011529
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Nalfurafine hcl	"Nalfurafine hydrochloride; TRK-820; Remitch; Nalfurafine (hydrochloride); 152658-17-8; UNII-25CC4N0P8J; 25CC4N0P8J; CHEMBL490665; AC 820; Nalfurafine hydrochloride [USAN:JAN]; (-)-17-(Cyclopropylmethyl)-3,14; A-dihydroxy-4,5; A-epoxy-6; A-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan Hydrochloride; (2E)-N-[(5; A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide Hydrochloride; SCHEMBL19856501; DTXSID70426071; DJSFYNINGIMKAG-FQJQBBMWSA-N; BCP15625; Remitch (TN)"	6918287	Approved	D02RXG	.	CTPDG011530
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Oxycodone	.	5284603	Approved	D03SKD	DB00497	CTPDG011531
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Methylnaltrexone bromide	"Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, &gt; W-5330; CHIR-01020"	5361917	Approved	D03YVO	.	CTPDG011044
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Hydromorphone	"Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug"	5284570	Approved	D04JHN	DB00327	CTPDG011532
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Eluxadoline	MuDelta	11250029	Approved	D09ZXR	DB09272	CTPDG011533
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Levopropoxyphene Napsylate Anhydrous	Novrad	6604497	Approved	D0HF0W	.	CTPDG011534
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Tapentadol hydrochloride	"Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL"	9838021	Approved	D0K4MH	.	CTPDG011535
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 3	Morphine-6-glucuronide	"Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide"	5360621	Phase 3	D01UXW	DB06409	CTPDG011536
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 3	GRT-6005	"Cebranopadol; 863513-91-1; GRT6005; UNII-7GDW9S3GN3; GRT 6005; 7GDW9S3GN3; Cebranopadol [USAN:INN]; Cebranopadol (USAN/INN); Cebranopadol(GRT-6005); SCHEMBL566256; SCHEMBL154336; GTPL8866; CHEMBL3545616; CHEMBL2364605; SCHEMBL10035739; CHEMBL3962932; SCHEMBL19336241; SCHEMBL14183935; MolPort-039-063-422; BDBM177926; ZINC3950145; EX-A1095; BCP09612; BDBM50101095; BDBM50101112; AKOS032953927; AKOS025402576; AKOS025290738; DB12830; CS-1323; SB16531; NCGC00378895-01; AK170452; HY-15536; AS-35183; Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal; GRT 6005/06"	11848225	Phase 3	D03TBJ	DB12830	CTPDG011537
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 3	NKTR-181	.	73673720	Phase 3	D0K2ID	DB14146	CTPDG011538
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	TD-1211	"Axelopran; UNII-85U7ROB149; 85U7ROB149; 949904-48-7; Axelopran [USAN:INN]; TD 1211; SCHEMBL1773803; SCHEMBL1773801; CHEMBL3137313; AKOS027337117; SB16947; DB12013; Benzamide, 3-((3-endo)-8-(2-((cyclohexylmethyl)((2S)-2,3-dihydroxy-1-oxopropyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)-"	67156338	Phase 2	D02INX	DB12013	CTPDG011539
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	OPNT001	.	.	Phase 2	D04PUO	.	CTPDG011540
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	ALKS33	Samidorphan	11667832	Phase 2	D0T0ZW	DB12543	CTPDG011541
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	Met-enkephalin	"H-Tyr-Gly-Gly-Phe-Met-OH; 58569-55-4; Tyr-Gly-Gly-Phe-Met-OH; METENKEFALIN; [Met]enkephalin; [5-Methionine]Enkephalin; TYR-GLY-GLY-PHE-MET; Enkephalin M; UNII-9JEZ9OD3AS; (Met5)-enkephalin; Lupex; 9JEZ9OD3AS; CHEMBL13786; CHEBI:6618; ENKEPHALIN, METHIONINE; Opioid growth factor; [Met5]-ENKEPHALIN; [Met5]Enkephalin acetate salt hydrate; Porcine beta-endorphin 1-5; (2S,5S,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic"	443363	Phase 2	D0V5WL	DB12668	CTPDG011542
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	ORP-101	"1820753-68-1; 6,14-ETHENOMORPHINAN-7-METHANOL, 3,3'-(1,2-ETHANEDIYLBIS(OXY))BIS(17-(CYCLOPROPYLMETHYL)-.ALPHA.-(1,1-DIMETHYLETHYL)-4,5-EPOXY-18,19-DIHYDRO-6-METHOXY-.ALPHA.-METHYL-, (.ALPHA.S,5.ALPHA.,7.ALPHA.)-(.ALPHA.'S,5'.ALPHA.,7'.ALPHA.)-; 6,14-Ethenomorphinan-7-methanol, 3,3'-(1,2-ethanediylbis(oxy))bis(17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(alpha'S,5'alpha,7'alpha)-; Buprenorphine dimer; CHEMBL4594402; EX-A6870; ORP-101; SCHEMBL19231198; SE6KE496VO; UNII-SE6KE496VO"	92042890	Phase 2	DW7OF1	.	CTPDG011543
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	Carfentanil	Carfentanyl; Carfentanila; Carfentanilum; Wildnil; 59708-52-0; Carfentanil [INN]; Carfentanila [Spanish]; UNII-LA9DTA2L8F; Carfentanilum [INN-Latin]; Carfentanila [INN-Spanish]; Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate; CHEBI:61084; Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate; Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate; 4-((1-Oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester	62156	Phase 2	D03PJU	DB01535	CTPDG011544
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	TPM-1/Morphine	.	.	Phase 2	D0LU5Q	.	CTPDG011545
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	Cyt-1010	.	44129692	Phase 1	D05ONA	.	CTPDG011546
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	GSK1521498	GSK-1521498; GSK-1521498B	24737629	Phase 1	D0G1YO	DB12886	CTPDG004781
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	TRV734	.	.	Phase 1	D0OK6F	.	CTPDG004534
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	NOCICEPTIN	"Orphanin FQ; Nociceptin/orphanin FQ; 170713-75-4; Orphanin FQ (rat); Orphanin FQ (swine); Orphanin FQ (human); Nociceptin (1-17); UNII-7AYI9N34FF; Orphanin FQ (pig); 7AYI9N34FF; CHEBI:80266; Human nociceptin; L-Glutamine, L-phenylalanylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-alanyl-L-asparaginyl-; Nociceptin (human); Nociceptin(1-17)-OH; FGGFTGARKSARKLANQ; Orphaninfq(swine)(9ci); GTPL1681; CHEMBL396460; BDBM50004178; AKOS024458690"	16131448	Phase 1	D0W4YO	.	CTPDG011547
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	AIKO-150	"6beta-Naltrexol; beta-Naltrexol; 6beta-Hydroxynaltrexone; 6alpha-Hydroxynaltrexone; 49625-89-0; 6alpha-Naltrexol; UNII-J0W963M37T; CHEMBL140278; J0W963M37T; naltrexol; Naltrexone-6-beta-ol; alpha-Naltrexol; 6beta-Naltrexone; 6alpha-Naltrexone; 6-alpha-naltrexol; N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine; SCHEMBL679700; DTXSID80197942; JLVNEHKORQFVQJ-PYIJOLGTSA-N; ZINC6092289; BDBM50001709; NCGC00165851-01; FT-0672600; Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol"	5486554	Phase 1	D00HBR	.	CTPDG011548
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	MCP-201	.	.	Phase 1	D01AKU	.	CTPDG011549
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	SALVINORIN A	"Salvinorin; Divinorin A; 83729-01-5; UNII-T56W91NG6J; CHEMBL445332; T56W91NG6J; CHEBI:67900; 2H-Naphtho(2,1-c)pyran-7-carboxylic acid, 9-(acetyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2S-(2alpha,4aalpha,6abeta,7beta,9beta,10aalpha,10bbeta))-; (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)dodechydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester; (-)-Salvinorin A; herbal ecstasy; Mexican mint; salvinorin-A; Salvonorin A; Diviner's S"	128563	Phase 1	D06EXA	DB12327	CTPDG011550
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	BCH-2687	.	.	Discontinued in Phase 2	D01PCE	.	CTPDG011551
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	Transdur-sufentanil	Sufentanil transdermal patch	65494	Discontinued in Phase 2	D01SJC	.	CTPDG011552
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	ADL-5945	OpRA III	.	Discontinued in Phase 2	D09MTC	.	CTPDG011553
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	TREFENTANIL HYDROCHLORIDE	"A-3665; ANQ-3665; Trefentanil hydrochloride < Rec INNM; N-[1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-N-(2-fluorophenyl)propionamide hydrochloride; 1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[N-(2-fluorophenyl)propionamido]-4-phenylpiperidine hydrochloride"	60727	Discontinued in Phase 2	D0IW4R	.	CTPDG011554
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	Frakefamide	"BCH-3963; LEF-553; LEF-576; SPD-759; LEF, AstraZeneca/BioChem Pharma"	9829352	Discontinued in Phase 2	D0N1HL	.	CTPDG011555
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	MIRFENTANIL HYDROCHLORIDE	A-3508 hydrochloride; ANQ-3508 HCl; Mirfentanil hydrochloride < Rec INNM; OHM-10579 (free base); N-(1-Phenethyl-4-piperidinyl)-N-(2-pyrazinyl)furan-2-carboxamide hydrochloride	60697	Discontinued in Phase 2	D0O0AH	.	CTPDG011556
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	DPI-3290	"DPI-3290W93; (+)-3-[1(R)-[4-Allyl-2(S),5(R)-dimethylpiperazin-1-yl]-1-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide; 3290W93"	9826770	Discontinued in Phase 2	D0G1YN	.	CTPDG011557
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	Dynorphin a	"80448-90-4; Dynorphin A porcine; Dynorphin-(1-17); UNII-9M18T0TD14; 9M18T0TD14; MFCD00076351; Dynorphin A1-17; Dynorphin A (swine); Dynorphin acetate; Dynorphin A (1-17), porcine; JMNJYGMAUMANNW-FIXZTSJVSA-N; BDBM50096785; AKOS024457469; Dynorphin A porcine, &gt; NCGC00167144-01"	16133805	Discontinued in Phase 2	D0Y8SK	.	CTPDG011558
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 1	ADL-7445	"Mu-opioid antagonists (opioid-induced bowel disorder), Adolor; 14-beta-aminonaltrexone"	.	Discontinued in Phase 1	D03MNS	.	CTPDG011559
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 1	KN-203	"Mu-opioid recceptor agonist (urinary incontinence), Grunenthal/KeyNeurotek"	.	Discontinued in Phase 1	D0T9MQ	.	CTPDG011560
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 1	VP004	.	.	Discontinued in Phase 1	D0J5XZ	.	CTPDG011561
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Preclinical	GNTI	G 3416; GNTI di-trifluoroacetate; Guanidinyl-naltrindole di-trifluoroacetate; 5'-Guanidinonaltrindole di(trifluoroacetate) salt hydrate; 5'-Guanidinylnaltrindole dihydrochloride	9826034	Preclinical	D0X6SZ	.	CTPDG007027
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Preclinical	LY-25582	"3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; LY-255582; LY255582; CHEMBL300662; 119193-09-8; LY 255582; SCHEMBL2740453; AOB5354; (3R,4R)3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; ZINC3783617; BDBM50045775; NCGC00408804-01; AS-16869; LY255582, &gt; 3-[(3R,4R)-1-((S)-3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; 3-((3R,4R)-1-((S)-3-cyclohexyl-3-hydroxypropyl)-3,4-dimethylpiperidin-4-yl)phenol; 1-Piperidinepropanol,"	9906198	Preclinical	D0C2QF	.	CTPDG007095
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	443C81	BW 443C; BW-443C81	101630908	Terminated	D0E8SE	.	CTPDG007363
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	BCH-150	.	.	Terminated	D0J8XO	.	CTPDG011562
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	Sameridine	"143257-97-0; UNII-NQP2Y50Y6B; NQP2Y50Y6B; Sameridine [INN]; sameridine[inn]; AC1Q5ICP; SCHEMBL419071; AC1L24E2; CHEMBL2104504; DTXSID30162367; 4-Piperidinecarboxamide,N-ethyl-1-hexyl-N-methyl-4-phenyl-; ZINC3797855; AKOS015909863; N-Ethyl-1-hexyl-N-methyl-4-phenylisonipecotamide; I14-31849"	65996	Terminated	D0K9TC	.	CTPDG011563
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	DBO-11	166374-49-8; Naxifylline (USAN/INN)	23724971	Terminated	D0PE1A	.	CTPDG007250
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	DBO-17	.	10042211	Terminated	D0XH1H	.	CTPDG007179
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	BIPHALIN	"(Tyr-ala-gly-phe-NH2)2; D-Enk-O; Dala(2); D-ENK; Bis(tyr-ala-gly-phenh2)hydrazide; CHEMBL200199; 83916-01-2; (Tyrosyl-alanyl-glycyl-phenylalaninamide)dimer; Bis(tyrosyl-alanyl-glycyl-phenylalaninamide)hydrazide; L-Phenylalanine, N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-, 2-(N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)hydrazide; enkephalin dimer; AC1NUPQ3; BDBM21014; DTXSID80232802; ZINC150345473; LS-187519; LS-186863"	5487663	Terminated	D0LX5D	.	CTPDG011564
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	SB-213698	TAN-67	9950038	Terminated	D08YUP	.	CTPDG011565
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	SNF-9007	CHEMBL407057; BDBM21146; Asp-Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid	9898185	Terminated	D0W8TS	.	CTPDG011566
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Sar-Phe-D-2-Nal-NH	CHEMBL254927; BDBM50232770	44447368	Investigative	D00NZP	.	CTPDG011567
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NE-2	.	.	Investigative	D00PQS	.	CTPDG011568
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CODEINONE	"6-Codeinone; 467-13-0; UNII-22B5AW0ANN; (5alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one; EINECS 207-386-1; BRN 0094188; 22B5AW0ANN; CHEBI:18399; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; 6-Oxocodeine; (-)-Codeinone; SCHEMBL100655; CHEMBL257627; DTXSID70196909; XYYVYLMBEZUESM-CMKMFDCUSA-N; ZINC4097036; API0000487; LS-92114; C06171; 7,8-Didehydro-4,5; A-epoxy-3-methoxy-17-methyl-morphinan-6-one"	5459910	Investigative	D00PYB	.	CTPDG011569
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AIKO-152	"AIKO-150 + opioid analgesic (pain/opiate dependence), Aiko Biotechnology"	.	Investigative	D00YMN	.	CTPDG011570
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-Phe-NH-]2	CHEMBL386887	44390628	Investigative	D01ESN	.	CTPDG011571
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DC6S	.	44414725	Investigative	D01MHO	.	CTPDG011572
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Hfe-Phe-NH2	CHEMBL378466	14991618	Investigative	D01MKM	.	CTPDG011573
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AIKO-151	"Mu-opioid antagonist (oral, opiate dependence), Aiko Biotechnology"	.	Investigative	D02VUL	.	CTPDG011574
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MM3A6S	CHEMBL379928	10454860	Investigative	D02YXR	.	CTPDG011575
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	BREMAZOCINE	"(-)-Bremazocine; Bremazocine, (-)-; 75684-07-0; 2-(1-Hydroxy-cyclopropylmethyl)-5-ethyl-9,9-dimethyl-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-, (2R)-; SureCN157210; AC1Q2C6X; SCHEMBL157210; CHEBI:3171; GTPL1603; ZINC3870315; PDSP2_001570; PDSP1_001586; C11791; UNII-ISF76M2DBE component ZDXGFIXMPOUDFF-XLIONFOSSA-N"	443406	Investigative	D03BUD	.	CTPDG011576
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Hfe-Pro-NH2	CHEMBL380286	44413086	Investigative	D03NCF	.	CTPDG011577
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NCT-400	.	.	Investigative	D03PCP	.	CTPDG011578
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-(NMe)Phe-D-Pro-NH2	CHEMBL163808	44375783	Investigative	D04IHL	.	CTPDG011579
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide	CHEMBL235560; SCHEMBL3702023; JKDWSAGAQLISRL-UHFFFAOYSA-N; BDBM50219927	44434931	Investigative	D04JCJ	.	CTPDG011580
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phg-NH2	CHEMBL378111	44413074	Investigative	D04MYP	.	CTPDG011581
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SL-3111	CHEMBL143592; SCHEMBL9881223; BDBM50068132	9909743	Investigative	D05CRC	.	CTPDG011582
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-Phg-NH2	CHEMBL208990	44413117	Investigative	D05ETG	.	CTPDG011583
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Sar-Phe-D-2-Nal-NH2	CHEMBL254926	44447367	Investigative	D05HOH	.	CTPDG011584
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-D-pro-L-Phe-D-trp-L-Phe-NH2	CHEMBL450818	44583427	Investigative	D05XCV	.	CTPDG011585
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[D-Ala2]Met-enkephalinamide	CHEMBL287480	44280469	Investigative	D05XPU	.	CTPDG011586
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ORIPAVINE	"UNII-575AOU51CR; 467-04-9; EINECS 207-385-6; BRN 0046094; CHEBI:7782; 575AOU51CR; 6,7,8,14-Tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methyl-morphinan-3-ol; (5alpha)-6,7,8,14-Tetradehydro-4,5-epoxy-6-methoxy-17-methylmorphinan-3-ol; Morphinan-3-ol, 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methyl-; 3-O-demethyl-thebaine; SCHEMBL37889; 4-27-00-02270 (Beilstein Handbook Reference); CHEMBL437602; DEA No. 9330; SCHEMBL19880919; DTXSID10196908; ZKLXUUYLEHCAMF-UUWFMWQGSA-N; Oripavine 0.1 mg/ml in Methanol"	5462306	Investigative	D05YXS	.	CTPDG011587
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YGGWL-NH2	CHEMBL504973	44577308	Investigative	D06ESC	.	CTPDG011588
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KIN-4044	"Mu opioid antagonist (NSCLC), Kinentia"	.	Investigative	D06LCW	.	CTPDG011589
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-NMePhe	CHEMBL583426	45483974	Investigative	D06QLG	.	CTPDG011590
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3B6S	CHEMBL209751	44414877	Investigative	D06YVE	.	CTPDG011591
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Endomorphins	"EM-1; EM-2; Endomorphins (chronic inflammation); Endomorphin EM-1, University of Bristol; Endomorphin EM-2, University of Bristol; Endomorphins (chronic inflammation), University of Bristol"	.	Investigative	D07GZG	.	CTPDG011592
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DM3A6S	CHEMBL437682	44414785	Investigative	D07UJV	.	CTPDG011593
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Hfe-NH2	CHEMBL211147	14991612	Investigative	D07XXX	.	CTPDG011594
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(+/-)-TRANS-U-50488 METHANESULFONATE	NCG-C00093883-01	9912313	Investigative	D08QSN	.	CTPDG011595
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol	"CHEMBL285250; 27107-68-2; CTK0I5787; DTXSID80494706; BDBM50000570; AKOS022657931; 3-(2-Methyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol; Phenol, 3-(2-methyl-2-azabicyclo[3.3.1]non-5-yl)-; 2-Methyl-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonane"	12368881	Investigative	D08UZJ	.	CTPDG011596
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AKUAMMINE	.	13491909	Investigative	D09FVG	.	CTPDG011597
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Semorphone	"(-)-4,5alpha-Epoxy-3,14-dihydroxy-17-(2-methoxyethyl)morphinan-6-one hydrochloride; (-)-4,5alpha-Epoxy-3,14-dihydroxy-N-(2-methoxyethyl)morphinan-6-one hydrochloride; MR-2264 (free base); MRZ-2264 (free base); N-(2-Methoxyethyl)noroxymorphone hydrochloride; Semorphone hydrochloride"	5491906	Investigative	D09MXM	.	CTPDG011598
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YGWFL-NH2	CHEMBL455502	44577349	Investigative	D09TCT	.	CTPDG011599
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YRFB	CHEMBL215513	44416268	Investigative	D0A1XG	.	CTPDG011600
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NRT-300	NCT-300	.	Investigative	D0C0FG	.	CTPDG011601
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2	"CHEMBL124941; BDBM50001459; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid"	44348645	Investigative	D0C1AN	.	CTPDG011602
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phg-Pro-NH2	CHEMBL425421	44413146	Investigative	D0C2ZW	.	CTPDG011603
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C6S	CHEMBL1417	44414814	Investigative	D0D0XP	.	CTPDG011604
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-2-Nal-NH2	CHEMBL375070	11498201	Investigative	D0D1VB	.	CTPDG011605
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2	.	73345457	Investigative	D0E7CA	.	CTPDG011606
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-Ala-Bn	CHEMBL577748	45487600	Investigative	D0F8CD	.	CTPDG011607
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	naloxonazine	NSC 612113	9576413	Investigative	D0G1IF	.	CTPDG011608
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phg-Phe-NH2	CHEMBL211119	44413203	Investigative	D0G2BN	.	CTPDG011609
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KNT-5	.	46232162	Investigative	D0G2YV	.	CTPDG011610
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	CHEMBL243724; BDBM50201411; N alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	44428306	Investigative	D0HL7Q	.	CTPDG011611
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-L-Phe-D-trp-L-Phe-D-pro-NH2	CHEMBL442612	44583428	Investigative	D0I1ZN	.	CTPDG011612
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DM3B6S	CHEMBL213737	44414801	Investigative	D0IC5F	.	CTPDG011613
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Ala-Bn	CHEMBL577749	45487602	Investigative	D0IQ0S	.	CTPDG011614
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YPAA-NH2	CHEMBL466147	44577307	Investigative	D0IU2K	.	CTPDG011615
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KIN-3031	"Mu opioid angonist (CNS formulation, pain), Kinentia"	.	Investigative	D0J0ZU	.	CTPDG011616
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-Val-Bn	CHEMBL577746	44555371	Investigative	D0J5IR	.	CTPDG011617
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-NH-CH2-]2	CHEMBL180286	44390664	Investigative	D0J9DO	.	CTPDG011618
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YAWF-NH2	CHEMBL445690	44577306	Investigative	D0JX3P	.	CTPDG011619
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Trp-D-Val-Bn	CHEMBL577745	44555370	Investigative	D0KQ8A	.	CTPDG011620
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2	"CHEMBL330991; BDBM50001460; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionyl}-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid"	10485385	Investigative	D0KW4Y	.	CTPDG011621
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YPWA-NH2	CHEMBL512955	44577305	Investigative	D0N3GU	.	CTPDG011622
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ethylmorphine	"Codethyline; DIONINE; 76-58-4; Morphine, ethyl-; Ethyl morphine; UNII-RWO67D87EU; Ethylmorphine [BAN]; 3-O-Ethylmorphine; EINECS 200-970-7; RWO67D87EU; CHEBI:4902; DEA No. 9190; Dionin; Ethylmorphine (BAN); NCGC00168251-01; Ethomorphine; Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol; Morphine 3-ethyl ether; AC1Q37UW; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-ethoxy-17-methyl-"	5359271	Investigative	D0N5QC	DB01466	CTPDG011623
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	THEBAINE	"Paramorphine; 3-O-Methyl-oripavin; 115-37-7; UNII-2P9MKG8GX7; Thebain; 4,5alpha-Epoxy-3,6-dimethoxy-17-methyl-6,8-morphinadien; EINECS 204-084-1; 2P9MKG8GX7; (5R,9R,13S)-4,5-Epoxy-3,6-dimethoxy-9alpha-methyl-6,8-morphinadien; CHEBI:9519; DEA No. 9333; NCGC00160239-01; DSSTox_RID_81337; DSSTox_CID_26099; DSSTox_GSID_46099; Morphinan, 6,7,8,14-tetradehydro-4,5-alpha-epoxy-3,6-dimethoxy-17-methyl-; 3,6-dimethoxy-17-methyl-6,7,8,14-tetradehydro-4,5alpha-epoxymorphinan"	5324289	Investigative	D0O2LD	.	CTPDG011624
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-Phe-NH-CH2-]2	CHEMBL409336	44390629	Investigative	D0O7XU	.	CTPDG011625
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-YGGFL-NH2	CHEMBL500212	15747210	Investigative	D0P2DF	.	CTPDG011626
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(R)-spiro-Aba-Gly-Phe-NH2	CHEMBL401142	24755139	Investigative	D0P2QV	.	CTPDG011627
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2	CHEMBL274400	44316657	Investigative	D0P7YV	.	CTPDG011628
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MORPHICEPTIN	"Deproceptin; Tyr-pro-phe-pro amide; Tyr-pro-phe-D-pro-NH2; beta-Casomorphine(1-4) amide; NH(4)-Tyr-pro-phe-pro-conh(2); Tyr-Pro-Phe-Pro-NH2; Tyrosyl-prolyl-phenylalanyl-D-prolinamide; UNII-97TZA8ANPC; H-Tyr-Pro-Phe-Pro-NH2; L-Tyrosyl-L-prolyl-L-phenylalanyl-L-prolinamide; 74135-04-9; b-Casomorphin-4-amide; 97TZA8ANPC; CHEMBL362991; L-Prolinamide, L-tyrosyl-L-prolyl-L-phenylalanyl-"	119303	Investigative	D0R0OZ	.	CTPDG011629
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DIHYDROAKUAMMINE	.	44576039	Investigative	D0R1MB	.	CTPDG011630
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(2-benzylisoindolin-5-yloxy)nicotinamide	CHEMBL238362; SCHEMBL3690327; GGVSFVBTUMOASO-UHFFFAOYSA-N; BDBM50226248	44434060	Investigative	D0R2VL	.	CTPDG011631
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Trp-Gly-Bn	CHEMBL570634	45487601	Investigative	D0R6VX	.	CTPDG011632
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CYPRODIME	"CHEMBL322796; N-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one; SCHEMBL3619261; BDBM50148071; ZINC13580323; NCGC00344512-01; Morphinan-6-one, 17-(cyclopropylmethyl)-4,14-dimethoxy-; (-)-N-(Cycloproylmethyl)-4,14-dimethoxymorphinan-6-one(Cyprodime); 17-cyclopropylmethyl-3,10-dimethoxy-(1R,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one; 17-cyclopropylmethyl-10-hydroxy-4,14-dimethoxy-(1S,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3-dien-6-one(cyprodime)"	5748293	Investigative	D0S3TZ	.	CTPDG011633
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MORPHINONE	"467-02-7; UNII-28MBK63MAW; EINECS 207-384-0; BRN 0042464; 28MBK63MAW; Didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-one; CHEBI:16315; (5alpha)-7,8-Didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3-hydroxy-17-methyl-, (5-alpha)-; SCHEMBL427946; CHEMBL255467; CTK1D7902; DTXSID50196907; ZINC4095712; AKOS030240636; LS-92113; C01735; 3-hydroxy-17-methyl-7,8-didehydro-4,5-epoxy-5alpha-morphinan-6-one"	5459823	Investigative	D0S5BJ	.	CTPDG011634
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	PL017	3-N-Me-Phe-morphiceptin; PL-017; PL 017	115335	Investigative	D0S6BX	.	CTPDG011635
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ADC-5510	"ADC-02265510; ADL-5510; Centrally acting mu opoid receptor antagonists, Adolor"	.	Investigative	D0TA3V	.	CTPDG011636
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MM3B6S	CHEMBL211374	44414811	Investigative	D0TT5V	.	CTPDG011637
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3S	.	.	Investigative	D0V0PY	.	CTPDG011638
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Trp-D-Ala-Bn	CHEMBL577747	44555372	Investigative	D0W3PR	.	CTPDG011639
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Beta-funaltrexamine	"beta-Fna; Naltrexone fumarate methyl ester; 72782-05-9; CHEMBL473136; CHEBI:81527; 2-Butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (E)-; Beta Funaltrexamine; Beta-Funeltrexamine; SCHEMBL1240811; GTPL1631; ZINC3995756; PDSP2_001549; PDSP2_000394; BDBM50247803; NCGC00163180-01; LS-47116; C18127; methyl 3-[4-cyclopropylmethyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ylcarbamoyl]-"	5311018	Investigative	D0WT7H	.	CTPDG011640
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KRP-110	IDDBCP262221	.	Investigative	D0WX3N	.	CTPDG011641
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2	CHEMBL124435; BDBM50001462; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-indane-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid	10010455	Investigative	D0X1SN	.	CTPDG011642
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KRP-100	"Mu opioid receptor antagonist, Kyorin"	.	Investigative	D0X4RU	.	CTPDG011643
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-NH-]2	CHEMBL179946	44390663	Investigative	D0Z9YE	.	CTPDG011644
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-ser-Gly-Phe-Leu-Thr-OH	CHEMBL246479	44439907	Investigative	D00FXL	.	CTPDG011645
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(R)-Aba-Gly-Phe-NH2	CHEMBL250448	24755140	Investigative	D00FZN	.	CTPDG011646
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys-NH-Ph	SCHEMBL8224099	25050067	Investigative	D00LLO	.	CTPDG011647
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-NH-CH2-Bid	"(3S)-N-[(1H-Benzimidazole-2-ylmethyl)carbamoylmethyl]-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide"	44375729	Investigative	D00MEM	.	CTPDG011648
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-D-Asp-N(Me)-Ph	CHEMBL502302	25033947	Investigative	D00QLH	.	CTPDG011649
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid	CHEMBL444197	25033951	Investigative	D00WBU	.	CTPDG011650
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)	CHEMBL208916	44412290	Investigative	D00WEV	.	CTPDG011651
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-Phe-Pro-NH2	CHEMBL162564	44376104	Investigative	D00XQV	.	CTPDG011652
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-mCpa-ala-Gly-Phe-leu-OH	CHEMBL246682	44439875	Investigative	D01HOP	.	CTPDG011653
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2	CHEMBL371856	44399141	Investigative	D01JSA	.	CTPDG011654
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH	CHEMBL370701	44399025	Investigative	D01MFM	.	CTPDG011655
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-ala-Gly-Phe-Met-OH	CHEMBL246572	44439910	Investigative	D01SDX	.	CTPDG011656
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Phe-Met-NH2	Tyr-DAla-Gly-Phe-Met-NH2	10371120	Investigative	D01TKS	.	CTPDG011657
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"Tyr-Pro-3,5Dmp-Phe-NH2"	CHEMBL413892	16736272	Investigative	D02GMU	.	CTPDG011658
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-CH2-NH2	CHEMBL241010	44436392	Investigative	D02IQG	.	CTPDG011659
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG	CHEMBL441930	44416445	Investigative	D02TPK	.	CTPDG011660
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OCH2CH3	CHEMBL505502	44586191	Investigative	D02WUZ	.	CTPDG011661
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	CHEMBL243189; BDBM50201412; N alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	44428304	Investigative	D03BFH	.	CTPDG011662
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)	CHEMBL426320	44412158	Investigative	D03BRB	.	CTPDG011663
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Orn-Aic-Glu]-NH2	CHEMBL106849	44336496	Investigative	D03CKF	.	CTPDG011664
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone"	CHEMBL200890	44405233	Investigative	D03HXN	.	CTPDG011665
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	2-Benzylaminomethyl-3-hydroxymorphinan	CHEMBL578173	44626544	Investigative	D03KAQ	.	CTPDG011666
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	PTI-601	.	.	Investigative	D03PMB	.	CTPDG011667
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M6S	.	.	Investigative	D03RSA	.	CTPDG011668
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Antanal 1	CHEMBL507442	44568843	Investigative	D03VSJ	.	CTPDG011669
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KETOCYCLAZOCINE	.	23724935	Investigative	D03WYO	.	CTPDG011670
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	UFP-502	"CHEMBL109390; H-Dmt-Tic-NH-CH2-Bid; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide; BDBM50179191; (S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide"	10345770	Investigative	D03YDG	.	CTPDG011671
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-D-Asp-NH-Ph	CHEMBL498799	25033945	Investigative	D04BII	.	CTPDG011672
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dimethylthiambutene	"Dimethibutin; Ohton; Dimetiltiambuteno; Aminobutene; Dimethylthiambutenum; Kobaton; N,N,1-Trimethyl-3,3-di-2-thienylallylamine; 3-Dimethylamino-1,1-bis(2-thienyl)-1-butene; 524-84-5; 3-Dimethylamino-1,1-di-(2'-thienyl)-1-butene; Dimetiltiambutene [DCIT]; N,N,1-Trimethyl-3,3-di(2-thienyl)-2-propenylamine; Dimetiltiambuteno [INN-Spanish]; Dimethylthiambutenum [INN-Latin]; Dimethylthiambutene [INN:BAN:DCF]; 338C48; Allylamine, N,N,1-trimethyl-3,3-di-2-thienyl-; BRN 0084891; DEA No. 9619; CHEBI:59781; NIH4542"	10668	Investigative	D04EZN	DB01444	CTPDG011673
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Asp-NH-Bzl	CHEMBL450566	25034010	Investigative	D04IIB	.	CTPDG011674
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Etorphine	"19-Propylorvinol; 6,14-Ethenomorphinan-7-methanol, 4,5-epoxy-3-hydroxy-6-methoxy-.alpha.,17-dimethyl-.alpha.-propyl-, [5.alpha.,7.alpha.(R)]-; 7.alpha.-Etorphine; AC1LARGT; ETORPHINE - HCI; GTPL1625; SCHEMBL10031275; Oripavine, 6,14-endo-ethylenetetrahydro-7-(1-hydroxy-1-methylbutyl)-; BDBM82425; CAHCBJPUTCKATP-UHFFFAOYSA-N; M99; CAS_61677; NSC_61677; FT-0668440; L024016; Tetrahydro-7-.alpha.-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine; 6,14-endo-Ethenotetrahydrooripavine, 7.alpha.-(1-hydroxy-1-methylbuty"	644209	Investigative	D04JCK	.	CTPDG011675
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H	CHEMBL392469	44436371	Investigative	D04KHE	.	CTPDG011676
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-Phe-Pro-NH2	.	44375782	Investigative	D04POA	.	CTPDG011677
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2	.	73346987	Investigative	D04QXM	.	CTPDG011678
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Trp-D-2-Nal-NH2	CHEMBL218433	16105563	Investigative	D04RPI	.	CTPDG011679
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Tic-Phe-Phe-OH	"Tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine; TIPP; 146369-65-5; Tyr-tic-phe-phe-OH; CHEMBL191751; L-Phenylalanine, L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-phenylalanyl-; Tyr-Tic-Phe-PheOH; AC1LD8RR; TIPP (opioid antagonist); DTXSID60163362; ZINC3942635; BDBM50068664; tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl- phenylalanyl-phenylalanine; L-Tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L- phenylalanyl-L-phenylalanine; 147780-77-6"	644210	Investigative	D04SFK	.	CTPDG011680
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(2-phenethylisoindolin-5-yloxy)nicotinamide	CHEMBL235154; SCHEMBL3696847	44434061	Investigative	D04VJE	.	CTPDG011681
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	UFP-512	"CHEMBL442577; GTPL9006; BDBM50272169; H-Dmt-Tic-NH-CH(CH2-COOH)-Bid; H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid; (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1H-benzimidazol-2-yl)propanoic acid; (S)-3-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-(1H-benzo[d]imidazol-2-yl)propanoic acid"	10918703	Investigative	D05AFV	.	CTPDG011682
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SPIROINDANYLOXYMORPHONE	"7-Spiroindanyloxymorphone; SIOM; 7-(Spiroindano)Oxymorphone; CHEMBL399708; 150380-34-0; SCHEMBL12013205; 7-(2'-spiroindanyl)oxymorphone; 7-(2''-spiroindanyl)oxymorphone; BDBM50297170; 1',3',7,7a,8,9-Hexahydro-3,7a-dihydroxy-12-methylspiro(6H-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2H)inden)-5(4aH)-one (4aR-(4aalpha,7aalpha,8alpha,9calpha))-; Spiro(6H-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2H)inden)-5(4aH)-one, 1',3',7,7a,8,9-hexahydro-3,7a-dihydroxy-12-methyl-, (4aR-(4aalpha"	44444966	Investigative	D05EWZ	.	CTPDG011683
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2	.	44376180	Investigative	D05GFM	.	CTPDG011684
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-N(Me)-Ph	CHEMBL500937	25034012	Investigative	D05KIQ	.	CTPDG011685
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H	CHEMBL375359	16100411	Investigative	D05KIS	.	CTPDG011686
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH"	CHEMBL375094	44418912	Investigative	D05NYR	.	CTPDG011687
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NalBzOH	"Naloxone benzoylhydrazone; 119630-94-3; 6-Desoxy-6-benzoylhydrazido-N-allyl-14-hydroxydihydronormorphinone; Benzoic acid, ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene)hydrazide; Lopac0_000882; [(5alpha)-4,5-Epoxy-; MLS000860072; Naloxone benzoylhydrazone, solid; SCHEMBL15423902; CHEMBL1256836; MolPort-003-958-927; MFCD05662358; AKOS024456586; CCG-204964; NCGC00092281-03; NCGC00092281-02; NCGC00092281-04; NCGC00092281-01; SMR000326930; N-165; EU-0100882; SR-01000075513; SR-01000075513-1"	9601084	Investigative	D05ZYZ	.	CTPDG011688
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CTAP	.	44309215	Investigative	D06BAU	.	CTPDG011689
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Leucine-enkephalin	YGGFL; URLZCHNOLZSCCA-UHFFFAOYSA-N; 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; Spectrum_001429; AC1L1GYW; Spectrum5_000656; Spectrum4_001048; Spectrum2_001177; Spectrum3_001521; AC1Q1P3H; KBioSS_001909; KBioGR_001316; BSPBio_002902	461776	Investigative	D06EES	.	CTPDG011690
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-457	CHEMBL242967; BDBM50210558	44429060	Investigative	D06SZI	.	CTPDG011691
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DADLE	"63631-40-3; H-TYR-D-ALA-GLY-PHE-D-LEU-OH; DADL; (D-Ala2,D-Leu5)-Enkephalin; [D-Ala2, D-Leu5]-enkephalin; CHEMBL340032; BW-180C; Tyr-D-Ala-Gly-Phe-D-Leu; (2R,5S,11R,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-isobutyl-11-methyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic acid; (2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; UNII-HB4QD9GL6F; HB4QD9GL6F; DADLE-OH; AC1OCEJN; ZINC14952092; H-Tyr-D-Ala-Gly-Phe-D-Leu"	6917707	Investigative	D06YMS	DB08856	CTPDG011692
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	CHEMBL384571	44369487	Investigative	D07AUG	.	CTPDG011693
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol"	CHEMBL208801	11645313	Investigative	D07BPA	.	CTPDG011694
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Dmt-Phe-NH2	CHEMBL228512	44424809	Investigative	D07BXN	.	CTPDG011695
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2	.	15088039	Investigative	D07DTN	.	CTPDG011696
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2	CHEMBL29078; Tyr-Ala-Phe-Asp-Val-Val-Gly; GTPL1615	10033203	Investigative	D07GQE	.	CTPDG011697
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-Gly-Gly-Phe-Leu-OH	CHEMBL247759	44439882	Investigative	D07JIQ	.	CTPDG011698
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2	CHEMBL32202; BDBM50009180; 3-(2-{2-[2-(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-4-methylsulfanyl-butyrylamino}-3-phenyl-propionylamino)-3-(1H-imidazol-4-yl)-propionylamino]-4-methyl-pentanoylamino}-4-methylsulfanyl-butyrylamino)-succinamic ac	14504437	Investigative	D07LXZ	.	CTPDG011699
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]	CHEMBL506211	44583388	Investigative	D07QUY	.	CTPDG011700
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)	CHEMBL413950	44316483	Investigative	D08BOD	.	CTPDG011701
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-isobutylnoroxymorphone	"CHEMBL490418; 17-Isobutyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; SCHEMBL3835355; OEQLILQNMUXCHV-XFWGSAIBSA-N"	25178033	Investigative	D08BST	.	CTPDG011702
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H	CHEMBL372130	44405653	Investigative	D08CJB	.	CTPDG011703
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,10-bis-(Dmt-Tic-amino)decane"	CHEMBL373192	44405160	Investigative	D08COK	.	CTPDG011704
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Bta	CHEMBL258704	44451667	Investigative	D08CXZ	.	CTPDG011705
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-Phg-Phe-NH2	CHEMBL210247	44413216	Investigative	D08FGQ	.	CTPDG011706
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KNT-63	CHEMBL593980	46225291	Investigative	D08FYQ	.	CTPDG011707
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SB-0304	CHEMBL409225	11641503	Investigative	D08LIT	.	CTPDG011708
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Aba-Gly-NH-CH2-Ph	CHEMBL208683; BDBM50189920	11664525	Investigative	D08SCK	.	CTPDG011709
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-(NMe)Phe-Pro-NH2	.	44375819	Investigative	D08STW	.	CTPDG011710
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone"	CHEMBL381874	44405208	Investigative	D08VOC	.	CTPDG011711
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Phe-D-trp]	CHEMBL502411; SCHEMBL7980647	44583373	Investigative	D09BWX	.	CTPDG011712
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-K-(NH2)-YRFB	CHEMBL412939	44416444	Investigative	D09CTG	.	CTPDG011713
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph	SCHEMBL8222648	25050225	Investigative	D09DAM	.	CTPDG011714
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-2',6'-dimethyltyrosine-Tic-OH"	"CHEMBL571492; 2,6-Dimethyl-L-Tyr-L-Tic-OH; BDBM50299565; H-2'',6''-dimethyltyrosine-Tic-OH; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid"	15384271	Investigative	D09GQP	.	CTPDG011715
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Aba-Gly-NH-CH2-Bid	CHEMBL211543	11721803	Investigative	D09GSD	.	CTPDG011716
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	FLUPERAMIDE	"UNII-6H13T09362; 53179-10-5; CHEMBL421665; 6H13T09362; R-18910; Fluperamide [USAN:INN]; AC1L2ZCI; AC1Q4JI5; SCHEMBL120826; ZINC4216287; BDBM50017686; R 18,910; 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; 4-(4-Chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide; 4-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide; 1-Piperidinebutanamide, 4-(4-"	131534	Investigative	D09KBQ	.	CTPDG011717
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)	XFKPEXYNTQLONY-MPYJOUPCSA-N; CHEMBL450263	25033949	Investigative	D09MBV	.	CTPDG011718
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Ala-D-pro-L-Phe-D-trp]	CHEMBL499595; SCHEMBL7991248	44583393	Investigative	D09SBU	.	CTPDG011719
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-mCpa-ser-Gly-Phe-Leu-Thr-OH	CHEMBL393867	44439901	Investigative	D0A9AJ	.	CTPDG011720
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Z)-NH-Ph	.	25050066	Investigative	D0AJ9D	.	CTPDG011721
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-N(CH3)2	CHEMBL505975	44586190	Investigative	D0B1JC	.	CTPDG011722
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Mmp-Phe-NH	CHEMBL413676	16736675	Investigative	D0C4QH	.	CTPDG011723
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	CHEMBL390271; BDBM50201414; N alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	44428305	Investigative	D0C5RC	.	CTPDG011724
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2	CHEMBL384284	44316656	Investigative	D0C9XB	.	CTPDG011725
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dynorphin(1-8)	.	44273338	Investigative	D0D1WB	.	CTPDG011726
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Tyr-D-trp]	CHEMBL486388	44583375	Investigative	D0D5VD	.	CTPDG011727
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KNT-62	CHEMBL594654	46906981	Investigative	D0D6KZ	.	CTPDG011728
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DM6S	CHEMBL385448	44414783	Investigative	D0D6OA	.	CTPDG011729
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid	CHEMBL386309; SCHEMBL8228625	25050223	Investigative	D0D8DZ	.	CTPDG011730
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(-)-eseroline	"Eseroline; UNII-Q22H41O18D; CHEMBL310934; CHEBI:48845; C13H18N2O; HKGWQUVGHPDEBZ-OLZOCXBDSA-N; Q22H41O18D; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol; 469-22-7; (3as-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-"	119198	Investigative	D0D9RL	.	CTPDG011731
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,4-bis-(Dmt-Tic-amino)butane"	CHEMBL370197	44405158	Investigative	D0DN6A	.	CTPDG011732
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-2034	"MR 2034; (-)-alpha-(1R,5R,9R)-5,9-Dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-((tetrahydro-2-furanyl)methyl)-, (2R-(2-alpha,3(R*),6-alpha,11R*))-; 57236-85-8; AC1Q7AHJ; (2r,6r)-6,11-dimethyl-3-[(2r)-tetrahydrofuran-2-ylmethyl]-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; BDBM81932; MR2034; LS-90624; CAS_57236-85-8"	123980	Investigative	D0DO6P	.	CTPDG011733
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG	CHEMBL414736	44416159	Investigative	D0E3RQ	.	CTPDG011734
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH"	CHEMBL219482	44418911	Investigative	D0E7NL	.	CTPDG011735
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-NH-Ph	"CHEMBL501451; BDBM50272081; (3S)-N-(Phenylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid phenylcarbamoylmethyl-amide"	11016572	Investigative	D0ED2I	.	CTPDG011736
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Ac)-NH-Ph	SCHEMBL8228366	25050226	Investigative	D0EG7I	.	CTPDG011737
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DSLET	"DSTLE; Dislet; [D-Ser2, Leu5, Thr6]-enkephalin"	107847	Investigative	D0EM9A	.	CTPDG011738
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2"	CHEMBL415426	44418917	Investigative	D0ES7P	.	CTPDG011739
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc	CHEMBL413644	44408590	Investigative	D0F1XY	.	CTPDG011740
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-cyclopropylpiperidin-4-ol	CHEMBL398039	44430024	Investigative	D0F8AX	.	CTPDG011741
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Tmp-Phe-NH	CHEMBL389023	16736706	Investigative	D0FT9J	.	CTPDG011742
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-NH-Bzl	"CHEMBL458631; H-Dmt-Tic-Gly-NH-CH2-Ph; GTPL9838; BDBM50266025; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (benzylcarbamoyl-methyl)-amide; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-N-(2-(benzylamino)-2-oxoethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; (3S)-N-(Benzylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide"	10864183	Investigative	D0H1BU	.	CTPDG011743
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Imp-Phe-NH2	CHEMBL434559	16736710	Investigative	D0H2RF	.	CTPDG011744
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AMINOFENTANYL	CHEMBL385168; BDBM50191054	44416393	Investigative	D0H3QK	.	CTPDG011745
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3Pr6S	CHEMBL385048; 3-Propionylmorphine 6-sulfate	44414843	Investigative	D0H6AA	.	CTPDG011746
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2	.	44331204	Investigative	D0H8WV	.	CTPDG011747
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-NHCH3	CHEMBL453689	44586189	Investigative	D0HF0I	.	CTPDG011748
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Phe-D-1-Nal-NH2	CHEMBL385583	16105560	Investigative	D0I1BJ	.	CTPDG011749
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2	.	73345456	Investigative	D0I9IX	.	CTPDG011750
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone"	CHEMBL198800	44405192	Investigative	D0J2IK	.	CTPDG011751
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DELTORPHIN-II	"Delt II; Delt-II; (Ala(2))deltorphin II; deltorphin II, Ala(2)-; (Ala(2),glu(4))deltorphin; Deltorphin, ala(2)-glu(4)-; Tyr-ala-phe-glu-val-val-gly-NH2; Deltorphin, alanyl(2)-glutamyl(4)-; Glycinamide, L-tyrosyl-D-alanyl-L-phenylalanyl-L-alpha-glutamyl-L-valyl-L-valyl-; AC1L3XB1; LS-72217"	123795	Investigative	D0J7XM	.	CTPDG011752
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-1029	.	71716573	Investigative	D0K0XT	.	CTPDG011753
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Dmp-Phe-NH2	CHEMBL266122	10371367	Investigative	D0K2OK	.	CTPDG011754
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DELTORPHIN	Dermenkephalin; Deltorphin A; 119975-64-3; CHEMBL20775; CHEBI:81455; Tyr-met-phe-his-leu-met-asp-NH2; AC1MHYOS; DTXSID60152630; BDBM50000518; Tyrosyl-methionyl-phenylalanyl-histidyl-leucyl-methionyl-aspartamide; ZINC169301619	3035060	Investigative	D0K4AC	.	CTPDG011755
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-Phe-D-Pro-NH2	.	44375820	Investigative	D0L3DM	.	CTPDG011756
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-ImidPh	CHEMBL259917	44451637	Investigative	D0L9NB	.	CTPDG011757
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-2266	"Mrz 2266 BS; MR 2266; MR-2266-BS; (-)-Mr 2266; (-)-2-(3-Furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan; 56649-76-4; (+/-)-2-(3-Furylmethyl)-2'-hydroxy-5,9alpha-diethyl-6,7-benzomorphan hydrochloride; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,6R,11R)-; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R-(2alpha,6alpha,11R*))-; Mr1302 MS; Mr2267; Mr 2267; SCHEMBL4404993; BDBM82508; Mr2266; ZINC5492542; CAS_56649-76-4"	3034816	Investigative	D0M4DI	.	CTPDG011758
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2	CHEMBL411335	44412234	Investigative	D0M6BL	.	CTPDG011759
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH"	"CHEMBL555206; BDBM50299557; H-2'',6''-dimethyltyrosine-Tic-Phe-Phe-OH; (S)-2-((S)-2-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-phenylpropanamido)-3-phenylpropanoic acid"	45273695	Investigative	D0M6CZ	.	CTPDG011760
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Phe-D-2-Nal-NH2	.	.	Investigative	D0MP7Z	.	CTPDG011761
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CTOP	"Ctop-NH2; CTOPA; CHEMBL507214; 103429-31-8; AC1NSJX5; H-D-Phe-c[Cys-Tyr-DTrp-Orn-Thr-Pen]-Thr-NH2; GTPL1674; CTOP, &gt; BDBM50252861; (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide"	2884	Investigative	D0MZ2A	.	CTPDG011762
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Indn	CHEMBL260127	44451639	Investigative	D0N1AO	.	CTPDG011763
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Antanal 2	CHEMBL454035	44568844	Investigative	D0N5TL	.	CTPDG011764
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OC(CH3)3	CHEMBL500195	44586192	Investigative	D0NB7S	.	CTPDG011765
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DERMORPHIN	77614-16-5; H-Tyr-D-ala-phe-gly-tyr-pro-ser-NH2; UNII-2SEC01B703; DERMORPHIN ACETATE; Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide; CHEMBL278789; 2SEC01B703; Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2; AC1NUNYZ; YAFGYPS-NH2; SCHEMBL237169; Tyr-Ala-Phe-Gly-Tyr-Pro-Ser; DTXSID40228281; HY-P0244	5485199	Investigative	D0NE3U	.	CTPDG011766
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OCH3	CHEMBL361922; Tyr-Pro-Phe-Phe-OMe	44390652	Investigative	D0O4KY	.	CTPDG011767
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid	SCHEMBL8230993; CHEMBL377960	25050224	Investigative	D0O7NC	.	CTPDG011768
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2"	CHEMBL269314	44418915	Investigative	D0P1CP	.	CTPDG011769
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-1526	.	73352838	Investigative	D0P2GB	.	CTPDG011770
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Asp-N(Me)-Ph	CHEMBL448360	25034014	Investigative	D0P2KV	.	CTPDG011771
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide	CHEMBL594511	44596230	Investigative	D0P2LE	.	CTPDG011772
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2"	CHEMBL218781	44418916	Investigative	D0P4PM	.	CTPDG011773
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Glu-NH-(CH2)5-NH2	CHEMBL225479	44421433	Investigative	D0P5EI	.	CTPDG011774
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]	CHEMBL507127	44583387	Investigative	D0P5IH	.	CTPDG011775
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2	.	44376060	Investigative	D0P6AR	.	CTPDG011776
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Indl	CHEMBL408975	44451665	Investigative	D0P8NZ	.	CTPDG011777
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Asp-NH-Ph	CHEMBL501202	25033885	Investigative	D0PN1A	.	CTPDG011778
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-ala-Gly-Phe-leu-OH	CHEMBL247064	44439877	Investigative	D0PN3P	.	CTPDG011779
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	.	91931233	Investigative	D0Q0UQ	.	CTPDG011780
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac	CHEMBL408889	44408417	Investigative	D0Q1PN	.	CTPDG011781
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)	CHEMBL499099; BDBM50272228	25034016	Investigative	D0Q2HZ	.	CTPDG011782
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Tyr-D-pro-L-Phe-D-trp]	CHEMBL506217	44583374	Investigative	D0Q6CF	.	CTPDG011783
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(S)-Aba-Gly-Phe-NH2	CHEMBL399796	24755070	Investigative	D0Q7SS	.	CTPDG011784
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys-NH-CH2-Ph	.	44415604	Investigative	D0R1DY	.	CTPDG011785
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid	CHEMBL212172	16082947	Investigative	D0R3GD	.	CTPDG011786
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH"	CHEMBL375095	44418913	Investigative	D0R4KJ	.	CTPDG011787
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH"	CHEMBL376453	44418914	Investigative	D0R4YD	.	CTPDG011788
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Apa-ala-Gly-Phe-leu-OH	CHEMBL247363	44439872	Investigative	D0R9AP	.	CTPDG011789
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane"	CHEMBL370399	44405153	Investigative	D0R9LV	.	CTPDG011790
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph	.	44415603	Investigative	D0R9XD	.	CTPDG011791
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	CHEMBL268162	44369523	Investigative	D0RR4X	.	CTPDG011792
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,6-bis-(Dmt-Tic-amino)hexane"	CHEMBL197185	44405159	Investigative	D0S3LK	.	CTPDG011793
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ZYKLOPHIN	GTPL9193; CHEMBL574568	45483651	Investigative	D0S9UH	.	CTPDG011794
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3P6S	CHEMBL213228	44414864	Investigative	D0TH8E	.	CTPDG011795
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CARBOXYFENTANYL	"CHEBI:61106; CHEMBL216239; 4-oxo-4-{phenyl[1-(2-phenylethyl)piperidin-4-yl]amino}butanoic acid; 4-anilidopiperidine, 8; Epitope ID:153518; SCHEMBL5163413; BDBM21114; ZINC14975441; 4-Oxo-4-[N-(1-phenethylpiperidine-4-yl)anilino]butyric acid; 3-{phenyl[1-(2-phenylethyl)piperidin-4-yl]carbamoyl}propanoic acid"	23635044	Investigative	D0U3ZL	.	CTPDG011796
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H	CHEMBL198909	44405656	Investigative	D0U4LU	.	CTPDG011797
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol"	CHEMBL212743; SCHEMBL14506371	11580459	Investigative	D0U5OP	.	CTPDG011798
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OCH2OH	CHEMBL522293	24857893	Investigative	D0U8YU	.	CTPDG011799
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone"	CHEMBL373668	44405182	Investigative	D0UV1C	.	CTPDG011800
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Imid	CHEMBL407957	44451610	Investigative	D0V2PM	.	CTPDG011801
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-NHNH2	CHEMBL180777	24857892	Investigative	D0V3GN	.	CTPDG011802
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[3H]U69593	"U-69593; U69593; 96744-75-1; U 69593; UNII-J5S4K6TKTG; U 69,593; J5S4K6TKTG; N-Methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzeneacetamide; CHEBI:73357; n-methyl-2-phenyl-n-[(5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]dec-8-yl]acetamide; Benzeneacetamide, N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-, (5alpha,7alpha,8beta)-(-)-; NCGC00163179-01; DSSTox_CID_26326; DSSTox_RID_81542; U69,593; DSSTox_GSID_46326; [3H]-U69593"	105104	Investigative	D0V3OY	.	CTPDG011803
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Boa	CHEMBL258458	44451689	Investigative	D0V8UG	.	CTPDG011804
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Glu-NH2	.	11156202	Investigative	D0W8MP	.	CTPDG011805
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3A6S	CHEMBL214040; 3-Acetylmorphine 6-sulfate; 3-O-acetylmorphine-6-sulfate	44414842	Investigative	D0WZ7J	.	CTPDG011806
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid	CHEMBL378082	25050370	Investigative	D0X2HA	.	CTPDG011807
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3IBu6S	CHEMBL211576	44414863	Investigative	D0X2HT	.	CTPDG011808
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H	CHEMBL380590	44405654	Investigative	D0X4YC	.	CTPDG011809
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cdp-ser-Gly-Phe-Leu-Thr-OH	CHEMBL247760	44439905	Investigative	D0X5TB	.	CTPDG011810
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)	CHEMBL437283	44316364	Investigative	D0X9SP	.	CTPDG011811
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(S)-spiro-Aba-Gly-Phe-NH2	CHEMBL401143	24755069	Investigative	D0X9TT	.	CTPDG011812
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Aba-Gly-NH-Ph	CHEMBL377392	11635818	Investigative	D0Y2HI	.	CTPDG011813
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-K-(NH2)-YAFGYPS	CHEMBL404792	44416158	Investigative	D0Y2MT	.	CTPDG011814
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Emp-Phe-NH2	CHEMBL375274	16736708	Investigative	D0Y5TF	.	CTPDG011815
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-Phe-D-Pro-NH2	.	44376061	Investigative	D0Y5UN	.	CTPDG011816
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Ala-Phe-NH2	YPAF-NH2	44428865	Investigative	D0Y9RD	.	CTPDG011817
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Oxymorphone semicarbazone hydrochloride	CHEMBL1202432; Oxymorphone Semicarbazone HCl	49860169	Investigative	D0YK5E	.	CTPDG011818
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Tic-Cha-Phe-OH	CHEMBL197937	9809581	Investigative	D0Z5UG	.	CTPDG011819
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Dap(6DMN)-Phe-NH2	CHEMBL207661	44412206	Investigative	D0ZI5Z	.	CTPDG011820
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2"	CHEMBL218782	44418918	Investigative	D0ZQ7L	.	CTPDG011821
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-Methylthiofentanyl	"3-Methyl-thiofentanyl; UNII-C9C204973M; 86052-04-2; CHEBI:53763; N-(3-Methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide; C9C204973M; Propanamide, N-(3-methyl-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-; N-{3-methyl-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; DEA No. 9833; 3-Methylthiofentanil; Epitope ID:153515; AC1Q5I8I; AC1L1WU2; SCHEMBL1742151; CHEMBL2365680; DB01439; FT-0672232"	62296	Investigative	D00HIG	DB01439	CTPDG011822
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(-)-cyclorphan	"CHEMBL291468; BDBM50105483; 17-cyclopropylmethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol; 17-cyclopropylmethyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol"	44299063	Investigative	D00JAT	.	CTPDG011823
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	5-(4-((phenethylamino)methyl)phenoxy)picolinamide	CHEMBL236376; SCHEMBL3771658	44434951	Investigative	D00JPB	.	CTPDG011824
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-117	CHEMBL1790045; (-)3-hydroxy-N-propargylmorphinan; BDBM50366764	6602241	Investigative	D00NRB	.	CTPDG011825
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	CHEMBL568757	44627900	Investigative	D00SDP	.	CTPDG011826
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-isopropylpiperidin-4-ol	CHEMBL233721	44430025	Investigative	D00XZH	.	CTPDG011827
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 4; CHEMBL205965; BDBM21134; (3S)-3-[(2S)-2-[(2S)-2-(2-{[(2R)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11693641	Investigative	D01ADK	.	CTPDG011828
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	BUTORPHAN	CHEMBL301160; MCL-101; SCHEMBL11805323; ZINC3982790; 3-Hydroxy-N-cyclobutylmethylmorphinan; BDBM50135808; 3-hydroxy-n-cyclobutylmethyl morphinan	9804450	Investigative	D01EPU	.	CTPDG011829
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-tert-butylpiperidin-4-ol	CHEMBL234771	10314141	Investigative	D01MUV	.	CTPDG011830
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	8-carboxamidocyclazocine	"CHEMBL58646; 8-CAC; SCHEMBL12014004; (6S,11R)-3-Cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8-carboxylic acid amide; PDSP1_000954; PDSP2_000939"	10086063	Investigative	D01RFG	.	CTPDG011831
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	quadazocine	"(-)-WIN 44,441; (-)-quadazocine"	115077	Investigative	D02BER	.	CTPDG011832
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-methyl-4'-methyldihydromorphinone	CHEMBL607018	44415081	Investigative	D02FZW	.	CTPDG011833
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-443	CHEMBL394624	44427184	Investigative	D02IMZ	.	CTPDG011834
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cpa-Gly-Gly-Phe-Met-OH	CHEMBL391580	11250396	Investigative	D02PIG	.	CTPDG011835
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-450	CHEMBL373984; BDBM50194274	16083055	Investigative	D02RYZ	.	CTPDG011836
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	CHEMBL373489	44415255	Investigative	D03QWP	.	CTPDG011837
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	OXYMORPHINDOLE	"ACMC-20di42; AC1L9G6X; CHEMBL1985511; CTK7J9928; 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol,5,6,7,8,14,14b-hexahydro-7-methyl-, (4bS,8R,8aS,14bR)-; NSC707844; NSC-707844; NCI60_038277"	5491897	Investigative	D03UFD	.	CTPDG011838
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-458	CHEMBL390912; BDBM50210556	44429061	Investigative	D03UHT	.	CTPDG011839
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	CHEMBL442483	44408525	Investigative	D03WGS	.	CTPDG011840
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Naltrexone-6-alpha-ol	"CHEMBL468469; 20410-98-4; SCHEMBL679581; ZINC1656961; BDBM50254511; FT-0672601; 17-(Cyclopropylmethyl)-4,5; A-epoxy-morphinan-3,6; A,14-triol; A)-17-(Cyclopropylmethyl)-4,5-epoxy-morphinan-3,6,14-triol; 6alpha-Naltrexol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	16099582	Investigative	D04JFL	.	CTPDG011841
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-139	CHEMBL203251	44406697	Investigative	D04PPP	.	CTPDG011842
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Dmt-Phe-NH2	CHEMBL388800	44424810	Investigative	D04UFM	.	CTPDG011843
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-429	CHEMBL397035	44427178	Investigative	D04UIK	.	CTPDG011844
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	naltriben	"Naltrindole benzofuran; 4,8-Methano-5H-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a(9H)-diol, 7-(cyclopropylmethyl)-6,7,8,14b-tetrahydro-, (8R-(4bS*,8alpha,8beta,14bbeta))-; 111555-58-9; C26H25NO4; [3H]naltriben; [3H]-naltriben; NTB; naltrindolebenzofuran; GTPL1640; SCHEMBL1240717; CHEMBL100940; GTPL3828; BDBM82552; HMS2089G18; ZINC3874478; PDSP2_001551; LS-172157; CAS_111555-58-9; C20166; AB00691672-07"	5486827	Investigative	D05ANN	.	CTPDG011845
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Phe-Phe-NH2	"CHEMBL331325; 596792-36-8; Dmt-endomorphin-2; CTK1E6813; DTXSID10435187; BDBM50149384; AKOS030610408; L-Phenylalaninamide, 2,6-dimethyl-L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-1-[(S)-2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide"	10077295	Investigative	D05EZE	.	CTPDG011846
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CYCLORPHAN	"17-(Cyclopropylmethyl)morphinan-3-ol; 4163-15-9; UNII-U6Z73N36V0; EINECS 224-007-5; CHEMBL49269; (-)-3-Hydroxy-N-cyclopropylmethylmorphinan; U6Z73N36V0; Morphinan, (-)-3-hydroxy-N-cyclopropylmethyl-; Morphinan-3-ol, 17-(cyclopropylmethyl)- (8CI,9CI); SCHEMBL159134; CTK4I5050; ZINC4215487; PDSP2_000668; BDBM50135800; N-cyclopropylmethyl 3-hydroxymorphinan; 3-Hydroxy-N-cyclopropylmethylmorphinan; LS-91818; (-)-17-(Cyclopropylmethyl)morphinan-3-ol; (-)-3-Hydroxy-N-cycloproypylmethylmorphinan Mandelate"	5359966	Investigative	D05FEQ	.	CTPDG011847
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-145	.	10462426	Investigative	D05JSY	.	CTPDG011848
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NORBINALTORPHIMINE	"nor-Binaltorphimine; UNII-36OOQ86QM1; 36OOQ86QM1; CHEBI:81529; C18130; 4,8:11,15-Dimethano-20H-bisbenzofuro(2,3-a:3',2'-i)dipyrido(4,3-b:3',4'-h)carbazole-1,8a,10a,18-tetrol, 7,12-bis(cyclopropylmethyl)-5,6,7,8,9,10,11,12,13,14,19a,20b-dodecahydro-20-methyl-, (8R-(4bR*,8alpha,8abeta,10aalpha,11beta,14aR*,19aalpha,20bbeta))-; Nor-Binaltorphamine; (-)-norbinaltorphimine; NOR-BNI (HCI)2; Lopac0_000806; GTPL1642; CHEMBL573214; SCHEMBL12013206; BDBM82551; APSUXPSYBJVPPS-YAUKWVCOSA-N"	5480230	Investigative	D05QJS	.	CTPDG011849
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	CHEMBL210770; SCHEMBL14280723; NRIVFQIOYWIUPX-UHFFFAOYSA-N; BDBM50185792	44413409	Investigative	D05RII	.	CTPDG011850
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"Dmt-Pro-3,5Dmp-Phe-NH2"	CHEMBL389949	16736676	Investigative	D05TOY	.	CTPDG011851
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[3H]diprenorphine	"[15,16-3H]diprenorphine"	6858272	Investigative	D05YNT	.	CTPDG011852
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6beta-naltrexol HCl	"CHEMBL558140; UNII-765G11MG24; 765G11MG24; 55488-86-3; Naltrexone metabolite 6; A-Naltrexol (hydrochloride); 6beta-Naltrexol hydrochloride; HY-G0019; 6beta-Hydroxynaltrexone hydrochloride; Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, hydrochloride, (5alpha,6beta)-; Naltrexone metabolite 6AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Naltrexol (hydrochloride)"	45110000	Investigative	D05ZIH	.	CTPDG011853
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-153	.	11411315	Investigative	D06IXE	.	CTPDG011854
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Phe-L-trp]	CHEMBL506616; CJ-15208; SCHEMBL12368055	44583372	Investigative	D06KFX	.	CTPDG011855
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Mmp-Phe-NH2	CHEMBL389948	16737287	Investigative	D06MWG	.	CTPDG011856
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CYCLAZOCINE	"(-)-cyclazocine; 7313-86-2; l-Cyclazocine; (-)-cis-Cyclazocine; A-Cyclazocine; AC1L55DZ; GTPL1604; CTK8F1400; DTXSID20617937; MCV 4512; (2R,6R,11R)-3-(Cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; NIH 10450; AKOS030242899; FT-0665329"	19143	Investigative	D06NST	.	CTPDG011857
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-433	CHEMBL245049	44427174	Investigative	D06OKE	.	CTPDG011858
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	CHEMBL433814; SCHEMBL9520650	44426806	Investigative	D06PVO	.	CTPDG011859
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NRP290	.	.	Investigative	D06WTI	.	CTPDG011860
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M6G thiosaccharide analogue	.	.	Investigative	D07AAK	.	CTPDG011861
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-434	CHEMBL241824	44427176	Investigative	D07DFD	.	CTPDG011862
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylethyl)piperidin-4-ol	CHEMBL230249	9925737	Investigative	D07FCB	.	CTPDG011863
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-446	CHEMBL428038; BDBM50210549	44429064	Investigative	D07HFU	.	CTPDG011864
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	CHEMBL220333	16116088	Investigative	D07JZS	.	CTPDG011865
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-435	CHEMBL242046	44427180	Investigative	D08IWF	.	CTPDG011866
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2"	"CHEMBL261390; BDBM21007; C-terminal modified bifunctional peptide, 1; [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate"	24768351	Investigative	D08KSJ	.	CTPDG011867
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	"tDADAE(9); CHEMBL229440; BDBM21126; (5S,8R,10E,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid"	16733487	Investigative	D08NJB	.	CTPDG011868
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol"	CHEMBL171118	44382932	Investigative	D08ORS	.	CTPDG011869
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 3; CHEMBL408330; BDBM21133; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11528076	Investigative	D08QKT	.	CTPDG011870
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-182	CHEMBL49143; 3-aminobutorphan; 3-Amino-N-cyclobutylmethylmorphinan	11255361	Investigative	D08RPH	.	CTPDG011871
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	TQ-1017	.	.	Investigative	D08YCS	.	CTPDG011872
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-447	CHEMBL394573; BDBM50210555	44429063	Investigative	D09DUE	.	CTPDG011873
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	CHEMBL568989	44627904	Investigative	D09FLC	.	CTPDG011874
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	CHEMBL571998; MCL-610	44627790	Investigative	D09RUY	.	CTPDG011875
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-183	CHEMBL390866; SCHEMBL14419223	11303119	Investigative	D09UKS	.	CTPDG011876
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Deprotected cogener of M6G	CHEMBL362202	44390358	Investigative	D0A5MU	.	CTPDG011877
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-144	"CHEMBL147511; BDBM50135806; di[17-cyclobutylmethyl-(1R,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] sebacate"	9897164	Investigative	D0B8MY	.	CTPDG011878
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-428	CHEMBL242048	44427183	Investigative	D0C2UQ	.	CTPDG011879
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2"	"CHEMBL406030; BDBM21013; C-terminal modified bifunctional peptide, 6"	24768356	Investigative	D0C6RQ	.	CTPDG011880
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-448	CHEMBL242968; BDBM50210550	44429062	Investigative	D0C7MP	.	CTPDG011881
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	"CHEMBL261608; BDBM21009; C-terminal modified bifunctional peptide, 2; benzyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate"	24768352	Investigative	D0CK8C	.	CTPDG011882
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Dcp1]Dyn A(1-11)-NH2	CHEMBL412997	44415282	Investigative	D0CX0I	.	CTPDG011883
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SN-23	CHEMBL564538	45270599	Investigative	D0D3UB	.	CTPDG011884
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-desoxonaltrexone	"CHEMBL511816; SCHEMBL3825815; XBPQMXFKKJADMC-WOUAJJJCSA-N; BDBM50278385; 3,14-Dihydroxy-17-cyclopropylmethyl-4,5alpha-epoxymorphinan"	13374610	Investigative	D0D8AN	.	CTPDG011885
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	CHEMBL393971	10427620	Investigative	D0D9BB	.	CTPDG011886
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-(4-((phenethylamino)methyl)phenoxy)benzamide	CHEMBL238317; SCHEMBL3692341; FARQYUHOSNLRKV-UHFFFAOYSA-N; BDBM50219921	44434950	Investigative	D0E0TD	.	CTPDG011887
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Imp-Phe-NH2	CHEMBL228516	16737137	Investigative	D0E1FQ	.	CTPDG011888
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	14-O-phenylpropylnaltrexone	CHEMBL514774; SCHEMBL3167650; BDBM50249017	44565511	Investigative	D0E6GH	.	CTPDG011889
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MC-CAM	"CHEMBL386272; BDBM50195674; BDBM50091405; 14-[(4-Chlorocinnamoyl)amino]-4,5alpha-epoxy-17-(cyclopropylmethyl)-3-methoxymorphinan-6-one; 1N-[4-cyclopropylmethyl-10-methoxy-14-oxo-(17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-17-yl]-3-(4-chlorophenyl)-(E)-2-propenamide(Methyoclocinnamox (MC-CAM))"	44417373	Investigative	D0F1EB	.	CTPDG011890
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-432	CHEMBL242047	44427182	Investigative	D0F4AN	.	CTPDG011891
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DAMGO	"DAGO; glyol; Dagol; DAMGE; 78123-71-4; 2-Ala-4-mephe-5-gly-enkephalin; Tyr-ala-gly-(nme)phe-gly-ol; Enkephalin, ala(2)-mephe(4)-gly(5)-; RX 783006; (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin; Ala(2)-mephe(4)-gly-ol(5) enkephalin; CHEBI:272; CHEMBL38874; Tyr-D-Ala-Gly-MePhe-Gly-ol; Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-; H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol; Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-; [3H]DAMGO; L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-"	5462471	Investigative	D0F8CV	.	CTPDG011892
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DPDPE	"2,5-Pen-enkephalin; (D-Pen2,D-Pen5)-Enkephalin; Enkephalin, D-penicillamine (2,5)-; (4s,7s,13s)-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-13-(l-tyrosylamino)-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid; DPLPE; c[D-Pen(2,5)]-enkephalin; CHEMBL31421; CHEBI:73356; Enkephalin, penicillamine(2,5)-; cyclo-[D-Pen(2,5)]-enkephalin; 88373-73-3; D-penicillamine-(2,5)-enkephalin; H-Tyr-c(D-Pen-Gly-Phe-D-Pen)-OH; [D-Pen(2)-D-Pen(5)]-enkephaline; H-Tyr-cyclo-(D-Pen-Gly-Phe-D-Pen)-OH; [3H]DPDPE; D-Valine, L-tyros"	104787	Investigative	D0G4NM	DB08861	CTPDG011893
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	CHEMBL448998	25129135	Investigative	D0G6GC	.	CTPDG011894
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-147	CHEMBL242756; SCHEMBL14419222; Aminothiazolo-N-Cyclopropylmorphinan	9798655	Investigative	D0G7FB	.	CTPDG011895
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	CHEMBL236170; SCHEMBL3697663; FZBJOVYOONJNIG-UHFFFAOYSA-N; BDBM50219917	44434946	Investigative	D0H0KP	.	CTPDG011896
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	dynorphin B	rimorphin	25075991	Investigative	D0H0OO	.	CTPDG011897
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cdp-Gly-Gly-Phe-Leu-OH	CHEMBL246739	44439880	Investigative	D0HB6O	.	CTPDG011898
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dimepheptanol	"Methadol; Racemethadol; Pangerin; Bimethadol; 545-90-4; NIH 2933; Betamethadol; Betametadol; 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL; 3-HEPTANOL, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-; Dimepheptanolum; Dimefeptanol; Dimefeptanolo; Bimethadolum; (-)-beta-Methadol; Betametadolo [DCIT]; (3S,6R)-Methadol; beta-Methadol, (-)-; Betametadol [INN-Spanish]; Dimefeptanolo [DCIT]; Betamethadolum [INN-Latin]; 3-Heptanol,4-diphenyl-, hydrochloride; Betamethadol [INN:BAN:DCF]; DEA No. 9609; Dimefeptanol [INN-Spanish]; Dimepheptanolum [IN"	28397	Investigative	D0HC3H	.	CTPDG011899
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	CHEMBL220219	16116220	Investigative	D0HV6H	.	CTPDG011900
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	CHEMBL238361; SCHEMBL3702187	44434058	Investigative	D0I1NG	.	CTPDG011901
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-mTyr-D-pro-L-Phe-D-trp]	CHEMBL510506	44583376	Investigative	D0I2CE	.	CTPDG011902
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	CHEMBL218651	16100409	Investigative	D0I9PH	.	CTPDG011903
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	PHENAZOCINE	"PHENAZOCINE HYDROBROMIDE; Narphen; Phenazocine (+-)- hydrobromide; EINECS 214-982-5; 1239-04-9; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocin-8-ol hydrobromide; 2'-Hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan hydrobromide; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-phenethyl-, hydrobromide; NIH 7519 hydrobromide; AC1L24DX; C22H27NO.HBr; SCHEMBL396395; PHENETHYLAZOCINE BROMIDE; 127-35-5 (Parent); CHEMBL2107297; DTXSID20872382; AKOS022180090; LS-90611"	14707	Investigative	D0I9SX	.	CTPDG011904
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	CHEMBL393675	44430013	Investigative	D0IL9H	.	CTPDG011905
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-445	CHEMBL243195; BDBM50210553	44429065	Investigative	D0IY2V	.	CTPDG011906
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-449	CHEMBL427862	44427177	Investigative	D0J3NK	.	CTPDG011907
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-(17-Methylmorphinan-3-yl)-N'-phenylurea	CHEMBL568829; BDBM50303599	44628003	Investigative	D0K1BV	.	CTPDG011908
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-431	CHEMBL241823	44427175	Investigative	D0K4XQ	.	CTPDG011909
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Tmp-Phe-NH2	CHEMBL228503	16737135	Investigative	D0KL5N	.	CTPDG011910
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	CHEMBL386043	44415281	Investigative	D0L0NI	.	CTPDG011911
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2"	"CHEMBL438389; BDBM21012; C-terminal modified bifunctional peptide, 5"	24768355	Investigative	D0L2CT	.	CTPDG011912
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-149	CHEMBL299220; 3-aminocyclorphan; SCHEMBL13383188; 3-Amino-N-cyclopropylmethylmorphinan; ZINC13532322	11392313	Investigative	D0L5DN	.	CTPDG011913
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	LOFENTANIL	"Lofentanil oxalate; Lofentanil oxalate [USAN]; Lofentanil oxalate (USAN); 61380-41-4; Lofentaniloxalat; R 34995; EINECS 262-750-7; cis-(-)-4-(Methoxycarbonyl)-3-methyl-1-phenethyl-4-(N-phenylpropionylamino)piperidinium hydrogen oxalate; R 34,995; AC1L23D4; (-)-Methyl cis-3-methyl-1-phenethyl-4-(N-phenylpropionamido)isonipecotate oxalate (1:1); FT-0670830; D04764; UNII-6C1599T3OQ component CBKLICUQYUTWQL-XWGBWKJCSA-N; methyl (3S,4R)-3-methyl-1-phenethyl-4-(N-propanoylanilino)piperidine-4-carboxylate"	10070040	Investigative	D0L6QN	DB09174	CTPDG011914
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Gly-Gly-Phe-Met-NH2	"[Met5]-Enkephalin Amide; [Met5]-Enkephalin, amide; CHEMBL247368; 60117-17-1; Tyr-Gly-Gly-Phe-Met-NH2; Met-enkephalinamide; L-Methioninamide, L-tyrosylglycylglycyl-L-phenylalanyl-; Enkephalinamide-met-; Methionine enkephalinamide; AC1L3X5D; CTK2F3118; HY-P1467; ZINC28893234; BDBM50207823; AKOS030610304; CS-0044396; A833448; (2S)-2-[[(2S)-2-[2-[2-[[(2S)-2-azanyl-3-(4-hydroxyphenyl)propanoyl]amino]ethanoylamino]ethanoylamino]-3-phenyl-propanoyl]amino]-4-methylsulfanyl-butanamide"	123704	Investigative	D0L8LX	.	CTPDG011915
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ELAEOCARPENINE	.	16747727	Investigative	D0M1YV	.	CTPDG011916
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Beta-endorphin	"UNII-3S51P4W3XQ; 3S51P4W3XQ; 61214-51-5; LPH (61-91); beta-Endorphin, human; SCHEMBL6238339; CHEMBL1866903; EINECS 262-330-3; beta-Endorphin human, &gt; NCGC00163196-01; NCGC00163196-02; 27-L-Tyrosine-31-L-glutamic acid-beta-endorphin (sheep); beta-Endorphin (sheep), 27-L-tyrosine-31-L-glutamic acid-"	16132316	Investigative	D0N8LP	.	CTPDG011917
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-451	CHEMBL384915; H-Dmt-Tic-beta-Ala-OH	16083058	Investigative	D0NA7G	.	CTPDG011918
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	normorphine	"466-97-7; Desmethylmorphine; UNII-XUI1Y24IMI; Demethylmorphine; N-Normorphine; XUI1Y24IMI; NSC 270042; CHEBI:7633; ONBWJWYUHXVEJS-ZTYRTETDSA-N; Normorfina [INN-Spanish]; Normorphinum [INN-Latin]; 4,5-Epoxy-3,6-dihydroxymorphin-7-ene; Normorphine [INN:BAN:DCF]; Normorfina; Normorphinum; EINECS 207-381-4; N-Demethylmorphine; BRN 5297209; CHEMBL1227; DEA No. 9313; Normorphine (7,8-Didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol)"	5462508	Investigative	D0NV5N	.	CTPDG011919
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	CHEMBL237066; 6-[4-(2-benzylamino-ethyl)-phenoxy]-nicotinamide; SCHEMBL3698270; FCDWJNPFPYAKET-UHFFFAOYSA-N; BDBM50219925	44434057	Investigative	D0O1JD	.	CTPDG011920
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Diprenorphine	"14357-78-9; UNII-1F0L5N25ZZ; CHEMBL281786; CHEBI:4650; 1F0L5N25ZZ; DEA No. 9058; M50-50 Injection; Diprenorphine [INN:BAN]; Diprenorphinum [INN-Latin]; Diprenorfina [INN-Spanish]; Diprenorphinum; Diprenorfina; EINECS 238-325-7; 21-Cyclopropyl-6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylethyl)-6,14-endo-ethanooripavine; Diprenorfin; (5 ,7 )-17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- , -dimethyl-6,14-ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4"	443408	Investigative	D0O6SB	DB01548	CTPDG011921
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	"CHEMBL272665; BDBM21011; C-terminal modified bifunctional peptide, 4"	24768354	Investigative	D0P0RB	.	CTPDG011922
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	2-Hydroxymethyl-3-hydroxymorphinan	CHEMBL570449	44626540	Investigative	D0P5QI	.	CTPDG011923
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	CHEMBL571560; MCL-630	44627901	Investigative	D0P6FF	.	CTPDG011924
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-154	"CHEMBL151872; BDBM50135811; (1R,9R,10R)-17-(cyclobutylmethyl)-4-[(10-{[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-yl]oxy}decyl)oxy]-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene"	44365804	Investigative	D0Q5AJ	.	CTPDG011925
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	"CHEMBL271619; BDBM21010; C-terminal modified bifunctional peptide, 3"	24768353	Investigative	D0Q7HG	.	CTPDG011926
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	"rDADAE (11); CHEMBL229441; BDBM21127; single bond H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; reduced bond-c[2-D-allylglycine, 5-D-allylglycine]enkephalin; (5S,8R,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid"	16733489	Investigative	D0R1AB	.	CTPDG011927
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	HERKINORIN	"CHEMBL363324; 862073-77-6; BF3DNCA methyl ester; 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester; SCHEMBL3540059; DTXSID30235444; MolPort-003-983-869; PYDQMXRFUVDCHC-XAGHGKQISA-N; ZINC28461930; BDBM50170678; (3S,4aR,4bS,6S,8R,8aR,10aR)-6-Benzoyloxy-3-furan-3-yl-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester"	11431898	Investigative	D0R4QF	.	CTPDG011928
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ENDOMORPHIN-1	"Endomorphin 1; 189388-22-5; Tyr-Pro-Trp-Phe-Nh2; H-Tyr-Pro-Trp-Phe-NH2; CHEMBL316446; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-tryptophyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide"	5311080	Investigative	D0R5TA	.	CTPDG011929
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Clocinnamox	"Methoclocinnamox; C-CAM; 14-beta-(4-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorpmorphine mesylate; Clocinnamox mesylate; 117332-69-1; 2-Propenamide, 3-(4-chlorophenyl)-N-((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-oxomorphinan-14-yl)-, monomethanesulfonate; NIH 10443 mesylate; NIH 10989; SCHEMBL4404383; AKOS024259103"	6540640	Investigative	D0R6VF	.	CTPDG011930
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	"cDADAE(8); CHEMBL375025; BDBM21125; (5S,8R,10Z,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid"	16733485	Investigative	D0R7LY	.	CTPDG011931
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cdp-ala-Gly-Phe-leu-OH	CHEMBL247758	44439876	Investigative	D0S5FN	.	CTPDG011932
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	CHEMBL217957	16100407	Investigative	D0S7SO	.	CTPDG011933
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	CHEMBL372823	44406704	Investigative	D0SC3W	.	CTPDG011934
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ethylketocyclazocine	CHEMBL71301; AC1L28LJ; GTPL1602; BDBM50017232; L024009	443409	Investigative	D0T5EI	.	CTPDG011935
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-desoxy-3-carboxamidonaltrexone	"CHEMBL56695; SCHEMBL2785528; QAICPHMNUHNDMC-WUHBCXKYSA-N; BDBM50128411; 6-Oxo-17-(cyclopropylmethyl)-14-hydroxy-4,5alpha-epoxymorphinan-3-carboxamide; (5a)-17-(cyclopropylmethyl)-14-hydroxy-6-oxo-4,5-epoxymorphinan-3-carboxamide"	10021946	Investigative	D0T6OQ	.	CTPDG011936
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Emp-Phe-NH2	CHEMBL374818	16736880	Investigative	D0TB4A	.	CTPDG011937
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	METAZOCINE	"Methobenzmorphan; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-; NSC611380; 3734-52-9; 2'-Hydroxy-2,5,9-trimethyl-6,7-benzomorphan; AC1Q7AHP; AC1L1XA2; SCHEMBL26347; CHEMBL33376; YGSVZRIZCHZUHB-UHFFFAOYSA-N; PDSP1_001246; PDSP2_001230; NSC-611380; LS-90663; LS-90665"	62518	Investigative	D0TN0D	.	CTPDG011938
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SN-28	CHEMBL552308; SCHEMBL16248949	44467662	Investigative	D0TO0E	.	CTPDG011939
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ETONITAZENE	"Etonitazine; Etonitazinum; Ciba 20-684BA; ARC 1G2; Etobedolum; 911-65-9; Etonitazenum [INN-Latin]; NIH 7607; Etonitazeno [INN-Spanish]; Etonitazene [INN:BAN:DCF]; UNII-9U3GT3353T; EINECS 213-009-1; Ba-20684; Ba 20684; BRN 0363324; CHEMBL312040; DEA No. 9624; PXDBZSCGSQSKST-UHFFFAOYSA-N; C22H28N4O3; 9U3GT3353T; 1-(2-(Diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1-(2-Diethylaminoethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1H-Benzimidazole-1-ethanamine, 2-((4-ethoxyphenyl)methyl)-N,N-diethyl-5-nitro-"	13493	Investigative	D0U3UM	DB01462	CTPDG011940
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cpa-Gly-Gly-Phe-Met-NH2	CHEMBL246956	44439866	Investigative	D0U7JS	.	CTPDG011941
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SN-11	CHEMBL559518	23642304	Investigative	D0UG8H	.	CTPDG011942
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Benzyl derivative of M6G	CHEMBL366917	44390359	Investigative	D0UR7D	.	CTPDG011943
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 15; CHEMBL205306; BDBM21145; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11722088	Investigative	D0V0RB	.	CTPDG011944
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	CHEMBL216640; Dynorphin A (1-11) amide; Dynorphin A(1-11) amide; 79985-48-1; Dyn A(1-11)-NH2; Linear Dyn A-(1-11)NH2; BDBM50010704; BDBM50033143; H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-NH2; Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-D-Lys-NH2; TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS-TRP-ASP-ASN-GLN-NH2	10677974	Investigative	D0VO7C	.	CTPDG011945
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	CHEMBL570225	44627903	Investigative	D0W0CO	.	CTPDG011946
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-444	CHEMBL263096	44427179	Investigative	D0W2DN	.	CTPDG011947
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	CHEMBL220327	44420667	Investigative	D0W6OP	.	CTPDG011948
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Dmp-Phe-NH2	CHEMBL228409	16736727	Investigative	D0X0XV	.	CTPDG011949
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	CHEMBL373572	44420674	Investigative	D0X6BU	.	CTPDG011950
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	"CHEMBL336381; CCK-Opioid Peptide, 6; BDBM21136; (3S)-3-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11061906	Investigative	D0X7LC	.	CTPDG011951
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	CHEMBL569724; BDBM50303601	44626534	Investigative	D0Y5ZP	.	CTPDG011952
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	CHEMBL234543	44430012	Investigative	D0Y7KE	.	CTPDG011953
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	RTI-5989-31	SCHEMBL6288083	22977851	Investigative	D0Y8NO	.	CTPDG011954
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-((benzylamino)methyl)phenoxy)nicotinamide	CHEMBL238316; SCHEMBL3700197; LUBVSQAMVPXMBJ-UHFFFAOYSA-N; BDBM50219916	44434949	Investigative	D0YU5H	.	CTPDG011955
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Leu5]enkephalin	"[Leu5]-Enkephalin; 58822-25-6; Enkephalin; Enkephalin L; [Leu 5]enkephalin; UNII-RI01R707R6; [5-Leucine]Enkephalin; Tyr-Gly-Gly-Phe-Leu-OH; CHEMBL8234; H-Tyr-Gly-Gly-Phe-Leu-OH; CHEBI:89656; RI01R707R6; Enkephalins; L-Leucine, N-(N-(N-(N-L-tyrosylglycyl)glycyl)-L-phenylalanyl)-; Leucyl-enkephalin"	9985128	Investigative	D0Z5JD	.	CTPDG011956
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-mTyr-D-trp]	CHEMBL509201	44583386	Investigative	D0Z8JX	.	CTPDG011957
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-Methylfentanyl	"Mefentanyl; 3-MF; 42045-86-3; N-(3-Methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide; F 7209; DEA No. 9813; Propanamide, N-(3-methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-; CHEBI:61092; N-(3-Methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide; N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide; 3-methyl-fentanyl; C23H30N2O; 3-Methylfentanil; AC1L1WAM; Epitope ID:153511; AC1Q5I8R; SCHEMBL2337401; HSDB 8379; CTK1D6517; MLQRZXNZHAOCHQ-UHFFFAOYSA-N; DB01571; LS-119344; R-26800"	61996	Investigative	D0ZH3G	DB01571	CTPDG011958
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ENDOMORPHIN 2	"Endomorphin-2; 141801-26-5; H-Tyr-Pro-Phe-Phe-NH2; UNII-3PH5M0466G; CHEMBL333357; 3PH5M0466G; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide"	5311081	Investigative	D00TNR	.	CTPDG011959
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	CHEMBL230145	44426807	Investigative	D00YCW	.	CTPDG011960
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 1; CHEMBL218763; BDBM21131; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	9811733	Investigative	D01AQC	.	CTPDG011961
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	CHEMBL389665	9820782	Investigative	D01WMU	.	CTPDG011962
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol"	CHEMBL495074; SCHEMBL471335; BDBM50252834	25129433	Investigative	D02EIB	.	CTPDG011963
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 7; CHEMBL382051; BDBM21137; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11051303	Investigative	D03EPA	.	CTPDG011964
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-ethoxy-4-phenylpiperidine	CHEMBL229016	10022129	Investigative	D03PTV	.	CTPDG011965
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	"CHEMBL1257578; CHEMBL1223815; SCHEMBL15031381; BDBM50325848; BDBM50327244; AZ-MTAB, &gt; ZINC101363709"	49765077	Investigative	D03RBD	.	CTPDG011966
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-butylpiperidin-4-ol	CHEMBL397761; SCHEMBL13597038	22970051	Investigative	D03UJW	.	CTPDG011967
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	CHEMBL231607	44426812	Investigative	D04ZQX	.	CTPDG011968
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 14; CHEMBL383458; BDBM21144; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11520765	Investigative	D06BRA	.	CTPDG011969
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	CHEMBL233494	44430018	Investigative	D06MQG	.	CTPDG011970
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-phenylpiperidin-4-ol	CHEMBL228690	10269001	Investigative	D06PHT	.	CTPDG011971
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-p-tolylpiperidin-4-ol	CHEMBL393985	9924923	Investigative	D07CIU	.	CTPDG011972
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 11; CHEMBL206974; BDBM21141; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11556976	Investigative	D07ICW	.	CTPDG011973
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 9; CHEMBL208479; BDBM21139; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11564210	Investigative	D07LQQ	.	CTPDG011974
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	CHEMBL232067; BDBM50210228	10093682	Investigative	D07NMH	.	CTPDG011975
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-hexylpiperidin-4-ol	CHEMBL234773	44430026	Investigative	D08DVV	.	CTPDG011976
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	CHEMBL231664	44430029	Investigative	D08QBU	.	CTPDG011977
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-cyclohexylpiperidin-4-ol	CHEMBL394695	10043439	Investigative	D08TFY	.	CTPDG011978
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-o-tolylpiperidin-4-ol	CHEMBL232273	20481138	Investigative	D09BYD	.	CTPDG011979
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 13; CHEMBL379405; BDBM21143; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11136782	Investigative	D09EMR	.	CTPDG011980
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	CHEMBL388123	9863568	Investigative	D09FJY	.	CTPDG011981
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	CHEMBL395838	44430008	Investigative	D09LRO	.	CTPDG011982
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol"	CHEMBL397945	44426814	Investigative	D09VRT	.	CTPDG011983
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dihydromorphine	"Paramorphan; 7,8-DIHYDROMORPHINE; 6-alpha-Hydromorphol; 509-60-4; Dihydromorfin [Czech]; UNII-C3S5FRP6JW; Hydromorphine; Paramorfan; Morphine, dihydro-; EINECS 208-100-8; C3S5FRP6JW; NSC 117865; Dihydromorfin; CHEBI:4575; DEA No. 9145; Morphinan-3,6alpha-diol, 4,5alpha-epoxy-17-methyl-; Morphinan-3,6-alpha-diol, 4,5-alpha-epoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; 7,8-Dihydromorphin; 1421-28-9; dihydromorphin"	5359421	Investigative	D0B7GU	DB01565	CTPDG011984
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	CHEMBL233323	10315818	Investigative	D0D0UP	.	CTPDG011985
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	O-DESMETHYL TRAMADOL	"O-Desmethyltramadol; CHEMBL1400; (-)-O-Desmethyl Tramadol; 80456-81-1; 2-[(Dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol; CHEMBL201556; O-Demethyl tramadol; tramadol M1 metabolite; Mono-O-demethyltramadol; 144830-15-9; 3-{(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenol; 3-((1R,2R)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol; (+)-O-Desmethyltramadol; SCHEMBL2517055; CTK8E8372; UWJUQVWARXYRCG-HIFRSBDPSA-N; ZINC2509756; BDBM50176258; BDBM50176263; Phenol, 3-(2-((dimethylamino)me"	9838803	Investigative	D0D5QV	.	CTPDG011986
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 12; CHEMBL408083; BDBM21142; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11614928	Investigative	D0E2OG	.	CTPDG011987
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	CHEMBL401234	10384734	Investigative	D0G4FA	.	CTPDG011988
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	CHEMBL390279	44426827	Investigative	D0G7DF	.	CTPDG011989
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-m-tolylpiperidin-4-ol	CHEMBL437380	44430009	Investigative	D0J5JO	.	CTPDG011990
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	CHEMBL375412	44408484	Investigative	D0J7GJ	.	CTPDG011991
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	CHEMBL232476	44430007	Investigative	D0JH5D	.	CTPDG011992
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	CHEMBL405192	44408524	Investigative	D0N6DN	.	CTPDG011993
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	CHEMBL230253	44426810	Investigative	D0O7JV	.	CTPDG011994
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	CHEMBL390882	44426808	Investigative	D0P3FP	.	CTPDG011995
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-methoxy-4-phenylpiperidine	CHEMBL228965	10043898	Investigative	D0Q9TQ	.	CTPDG011996
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	CHEMBL232066	10089987	Investigative	D0QH4A	.	CTPDG011997
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	CHEMBL374325	44408526	Investigative	D0QP2S	.	CTPDG011998
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 2; CHEMBL382349; BDBM21132; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11040230	Investigative	D0R4GI	.	CTPDG011999
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	CHEMBL228687	44426817	Investigative	D0T4ZY	.	CTPDG012000
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	CHEMBL233493	44430016	Investigative	D0T9KE	.	CTPDG012001
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 10; CHEMBL218327; BDBM21140; H-Tyr-DPhe-Gly-DTrp-NMeNle-Asp-Phe-NH(2); (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	10942040	Investigative	D0TR0U	.	CTPDG012002
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 8; CHEMBL262172; BDBM21138; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	10909103	Investigative	D0U6OA	.	CTPDG012003
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	CHEMBL386212	16100410	Investigative	D0V9DY	.	CTPDG012004
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	CHEMBL392753	10091033	Investigative	D0W3VT	.	CTPDG012005
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-phenyl-4-propoxypiperidine	CHEMBL229017	10317947	Investigative	D0X4SX	.	CTPDG012006
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	CHEMBL228793	44426828	Investigative	D0XX1Y	.	CTPDG012007
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	CHEMBL231874	10336926	Investigative	D0Y5LJ	.	CTPDG012008
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-benzylpiperidin-4-ol	CHEMBL231661	44430028	Investigative	D0ZE2W	.	CTPDG012009
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ICI-199441	"115199-84-3; ICI-199,441 HYDROCHLORIDE; ICI 199,441 hydrochloride; Ici 199441; Ici 199,441; AC1MIZCX; N-(2-(N-Methyl-3,4-dichlorophenylacetamido)-2-phenylethyl)pyrrolidine; SCHEMBL7647023; CTK8E9897; MolPort-023-275-929; AKOS024458644; (S)-3,4-Dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)benzeneacetamide monohydrochloride; RT-013313; B6448; J-003264; Benzeneacetamide, 3,4-dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-, monohydrochloride, (S)-"	3082718	Investigative	D03SAV	.	CTPDG012010
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	FALCARINDIOL	"55297-87-5; 1,9-Heptadecadiene-4,6-diyne-3,8-diol; Heptadeca-1,9-diene-4,6-diyne-3,8-diol; AC1L1FO2; SCHEMBL16680213; CTK1C6414; 225110-25-8; AKOS030230026; AN-40378; 4CN-1774"	5281148	Investigative	D08UOX	.	CTPDG012011
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide"	CHEMBL550063; SCHEMBL10266987; BDBM50297313	44254503	Investigative	D0L9YP	.	CTPDG012012
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SOMATOSTATIN	51110-01-1; Somiaton; Panhibin; Aminopan; Somatostatin acetate; SRIF; Somatotropin release-inhibiting factor; Somatotropin release-inhibiting hormone; Growth hormone release-inhibiting factor; CCRIS 7071; EINECS 256-969-7; Growth hormone release-inhibiting hormone; AY 24910; Growth hormone release inhibiting factor; Somatostatin 1-14; Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys; NCGC00181005-01; 61950-59-2; [D-Trp8]-SOMATOSTATIN; SCHEMBL3046327	16129706	Investigative	D0T5RO	DB09099	CTPDG012013
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(+/-)-nantenine	.	181743	Investigative	D0L5MW	.	CTPDG012014
M6ACROT03231	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03231	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Propoxyphene Hydrochloride	Darvon; Dolene; Kesso-gesic; Prophene 65; Propoxyphene Hydrochloride 65; Darvon-n; Propoxyphene Napsylate	15424	Approved	D03HCZ	.	CTPDG011514
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Levomethadyl Acetate	"LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)"	15130	Approved	D05PIZ	DB01227	CTPDG011515
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Anileridine Hydrochloride	Anileridine Phosphate; Leritine	31338	Approved	D05ZTJ	.	CTPDG011516
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Buprenorphine	"Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone  (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M"	644073	Approved	D06AWE	DB00921	CTPDG011517
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Naloxegol	NKTR-118	56959087	Approved	D07LCF	DB09049	CTPDG011518
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Alvimopan	"Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid"	5488548	Approved	D0D7KC	DB06274	CTPDG011519
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Fentanyl	"Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	3345	Approved	D0E1WI	DB00813	CTPDG011520
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Alfentanil	"Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide"	51263	Approved	D0G5QB	DB00802	CTPDG011521
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Methadyl Acetate	"ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate"	10517	Approved	D0GR0T	DB01433	CTPDG011522
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Buprenorphine + naloxone	"Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461"	6321408	Approved	D0H2JP	.	CTPDG011523
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Diphenoxylate	"Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride"	13505	Approved	D0J2TN	DB01081	CTPDG011524
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Naldemedine Tosylate	.	56837137	Approved	D0Q2HO	.	CTPDG011525
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Remifentanil	"Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester"	60815	Approved	D0T5OX	DB00899	CTPDG011526
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Morphine	Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr	5288826	Approved	D0WE3O	DB00295	CTPDG000078
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Naloxone	"Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one"	5284596	Approved	D0X3FX	DB01183	CTPDG011527
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Hydrocodone	"Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug"	5284569	Approved	D0X5KF	DB00956	CTPDG011528
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Anileridine	"Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester"	8944	Approved	D0X6HD	DB00913	CTPDG011529
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Nalfurafine hcl	"Nalfurafine hydrochloride; TRK-820; Remitch; Nalfurafine (hydrochloride); 152658-17-8; UNII-25CC4N0P8J; 25CC4N0P8J; CHEMBL490665; AC 820; Nalfurafine hydrochloride [USAN:JAN]; (-)-17-(Cyclopropylmethyl)-3,14; A-dihydroxy-4,5; A-epoxy-6; A-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan Hydrochloride; (2E)-N-[(5; A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide Hydrochloride; SCHEMBL19856501; DTXSID70426071; DJSFYNINGIMKAG-FQJQBBMWSA-N; BCP15625; Remitch (TN)"	6918287	Approved	D02RXG	.	CTPDG011530
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Oxycodone	.	5284603	Approved	D03SKD	DB00497	CTPDG011531
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Methylnaltrexone bromide	"Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, &gt; W-5330; CHIR-01020"	5361917	Approved	D03YVO	.	CTPDG011044
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Hydromorphone	"Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug"	5284570	Approved	D04JHN	DB00327	CTPDG011532
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Eluxadoline	MuDelta	11250029	Approved	D09ZXR	DB09272	CTPDG011533
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Levopropoxyphene Napsylate Anhydrous	Novrad	6604497	Approved	D0HF0W	.	CTPDG011534
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Approved	Tapentadol hydrochloride	"Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL"	9838021	Approved	D0K4MH	.	CTPDG011535
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 3	Morphine-6-glucuronide	"Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide"	5360621	Phase 3	D01UXW	DB06409	CTPDG011536
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 3	GRT-6005	"Cebranopadol; 863513-91-1; GRT6005; UNII-7GDW9S3GN3; GRT 6005; 7GDW9S3GN3; Cebranopadol [USAN:INN]; Cebranopadol (USAN/INN); Cebranopadol(GRT-6005); SCHEMBL566256; SCHEMBL154336; GTPL8866; CHEMBL3545616; CHEMBL2364605; SCHEMBL10035739; CHEMBL3962932; SCHEMBL19336241; SCHEMBL14183935; MolPort-039-063-422; BDBM177926; ZINC3950145; EX-A1095; BCP09612; BDBM50101095; BDBM50101112; AKOS032953927; AKOS025402576; AKOS025290738; DB12830; CS-1323; SB16531; NCGC00378895-01; AK170452; HY-15536; AS-35183; Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal; GRT 6005/06"	11848225	Phase 3	D03TBJ	DB12830	CTPDG011537
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 3	NKTR-181	.	73673720	Phase 3	D0K2ID	DB14146	CTPDG011538
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	TD-1211	"Axelopran; UNII-85U7ROB149; 85U7ROB149; 949904-48-7; Axelopran [USAN:INN]; TD 1211; SCHEMBL1773803; SCHEMBL1773801; CHEMBL3137313; AKOS027337117; SB16947; DB12013; Benzamide, 3-((3-endo)-8-(2-((cyclohexylmethyl)((2S)-2,3-dihydroxy-1-oxopropyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)-"	67156338	Phase 2	D02INX	DB12013	CTPDG011539
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	OPNT001	.	.	Phase 2	D04PUO	.	CTPDG011540
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	ALKS33	Samidorphan	11667832	Phase 2	D0T0ZW	DB12543	CTPDG011541
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	Met-enkephalin	"H-Tyr-Gly-Gly-Phe-Met-OH; 58569-55-4; Tyr-Gly-Gly-Phe-Met-OH; METENKEFALIN; [Met]enkephalin; [5-Methionine]Enkephalin; TYR-GLY-GLY-PHE-MET; Enkephalin M; UNII-9JEZ9OD3AS; (Met5)-enkephalin; Lupex; 9JEZ9OD3AS; CHEMBL13786; CHEBI:6618; ENKEPHALIN, METHIONINE; Opioid growth factor; [Met5]-ENKEPHALIN; [Met5]Enkephalin acetate salt hydrate; Porcine beta-endorphin 1-5; (2S,5S,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic"	443363	Phase 2	D0V5WL	DB12668	CTPDG011542
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	ORP-101	"1820753-68-1; 6,14-ETHENOMORPHINAN-7-METHANOL, 3,3'-(1,2-ETHANEDIYLBIS(OXY))BIS(17-(CYCLOPROPYLMETHYL)-.ALPHA.-(1,1-DIMETHYLETHYL)-4,5-EPOXY-18,19-DIHYDRO-6-METHOXY-.ALPHA.-METHYL-, (.ALPHA.S,5.ALPHA.,7.ALPHA.)-(.ALPHA.'S,5'.ALPHA.,7'.ALPHA.)-; 6,14-Ethenomorphinan-7-methanol, 3,3'-(1,2-ethanediylbis(oxy))bis(17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(alpha'S,5'alpha,7'alpha)-; Buprenorphine dimer; CHEMBL4594402; EX-A6870; ORP-101; SCHEMBL19231198; SE6KE496VO; UNII-SE6KE496VO"	92042890	Phase 2	DW7OF1	.	CTPDG011543
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	Carfentanil	Carfentanyl; Carfentanila; Carfentanilum; Wildnil; 59708-52-0; Carfentanil [INN]; Carfentanila [Spanish]; UNII-LA9DTA2L8F; Carfentanilum [INN-Latin]; Carfentanila [INN-Spanish]; Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate; CHEBI:61084; Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate; Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate; 4-((1-Oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester	62156	Phase 2	D03PJU	DB01535	CTPDG011544
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 2	TPM-1/Morphine	.	.	Phase 2	D0LU5Q	.	CTPDG011545
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	Cyt-1010	.	44129692	Phase 1	D05ONA	.	CTPDG011546
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	GSK1521498	GSK-1521498; GSK-1521498B	24737629	Phase 1	D0G1YO	DB12886	CTPDG004781
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	TRV734	.	.	Phase 1	D0OK6F	.	CTPDG004534
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	NOCICEPTIN	"Orphanin FQ; Nociceptin/orphanin FQ; 170713-75-4; Orphanin FQ (rat); Orphanin FQ (swine); Orphanin FQ (human); Nociceptin (1-17); UNII-7AYI9N34FF; Orphanin FQ (pig); 7AYI9N34FF; CHEBI:80266; Human nociceptin; L-Glutamine, L-phenylalanylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-alanyl-L-asparaginyl-; Nociceptin (human); Nociceptin(1-17)-OH; FGGFTGARKSARKLANQ; Orphaninfq(swine)(9ci); GTPL1681; CHEMBL396460; BDBM50004178; AKOS024458690"	16131448	Phase 1	D0W4YO	.	CTPDG011547
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	AIKO-150	"6beta-Naltrexol; beta-Naltrexol; 6beta-Hydroxynaltrexone; 6alpha-Hydroxynaltrexone; 49625-89-0; 6alpha-Naltrexol; UNII-J0W963M37T; CHEMBL140278; J0W963M37T; naltrexol; Naltrexone-6-beta-ol; alpha-Naltrexol; 6beta-Naltrexone; 6alpha-Naltrexone; 6-alpha-naltrexol; N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine; SCHEMBL679700; DTXSID80197942; JLVNEHKORQFVQJ-PYIJOLGTSA-N; ZINC6092289; BDBM50001709; NCGC00165851-01; FT-0672600; Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol"	5486554	Phase 1	D00HBR	.	CTPDG011548
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	MCP-201	.	.	Phase 1	D01AKU	.	CTPDG011549
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Phase 1	SALVINORIN A	"Salvinorin; Divinorin A; 83729-01-5; UNII-T56W91NG6J; CHEMBL445332; T56W91NG6J; CHEBI:67900; 2H-Naphtho(2,1-c)pyran-7-carboxylic acid, 9-(acetyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2S-(2alpha,4aalpha,6abeta,7beta,9beta,10aalpha,10bbeta))-; (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)dodechydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester; (-)-Salvinorin A; herbal ecstasy; Mexican mint; salvinorin-A; Salvonorin A; Diviner's S"	128563	Phase 1	D06EXA	DB12327	CTPDG011550
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	BCH-2687	.	.	Discontinued in Phase 2	D01PCE	.	CTPDG011551
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	Transdur-sufentanil	Sufentanil transdermal patch	65494	Discontinued in Phase 2	D01SJC	.	CTPDG011552
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	ADL-5945	OpRA III	.	Discontinued in Phase 2	D09MTC	.	CTPDG011553
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	TREFENTANIL HYDROCHLORIDE	"A-3665; ANQ-3665; Trefentanil hydrochloride < Rec INNM; N-[1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-N-(2-fluorophenyl)propionamide hydrochloride; 1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[N-(2-fluorophenyl)propionamido]-4-phenylpiperidine hydrochloride"	60727	Discontinued in Phase 2	D0IW4R	.	CTPDG011554
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	Frakefamide	"BCH-3963; LEF-553; LEF-576; SPD-759; LEF, AstraZeneca/BioChem Pharma"	9829352	Discontinued in Phase 2	D0N1HL	.	CTPDG011555
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	MIRFENTANIL HYDROCHLORIDE	A-3508 hydrochloride; ANQ-3508 HCl; Mirfentanil hydrochloride < Rec INNM; OHM-10579 (free base); N-(1-Phenethyl-4-piperidinyl)-N-(2-pyrazinyl)furan-2-carboxamide hydrochloride	60697	Discontinued in Phase 2	D0O0AH	.	CTPDG011556
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	DPI-3290	"DPI-3290W93; (+)-3-[1(R)-[4-Allyl-2(S),5(R)-dimethylpiperazin-1-yl]-1-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide; 3290W93"	9826770	Discontinued in Phase 2	D0G1YN	.	CTPDG011557
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 2	Dynorphin a	"80448-90-4; Dynorphin A porcine; Dynorphin-(1-17); UNII-9M18T0TD14; 9M18T0TD14; MFCD00076351; Dynorphin A1-17; Dynorphin A (swine); Dynorphin acetate; Dynorphin A (1-17), porcine; JMNJYGMAUMANNW-FIXZTSJVSA-N; BDBM50096785; AKOS024457469; Dynorphin A porcine, &gt; NCGC00167144-01"	16133805	Discontinued in Phase 2	D0Y8SK	.	CTPDG011558
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 1	ADL-7445	"Mu-opioid antagonists (opioid-induced bowel disorder), Adolor; 14-beta-aminonaltrexone"	.	Discontinued in Phase 1	D03MNS	.	CTPDG011559
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 1	KN-203	"Mu-opioid recceptor agonist (urinary incontinence), Grunenthal/KeyNeurotek"	.	Discontinued in Phase 1	D0T9MQ	.	CTPDG011560
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Discontinued in Phase 1	VP004	.	.	Discontinued in Phase 1	D0J5XZ	.	CTPDG011561
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Preclinical	GNTI	G 3416; GNTI di-trifluoroacetate; Guanidinyl-naltrindole di-trifluoroacetate; 5'-Guanidinonaltrindole di(trifluoroacetate) salt hydrate; 5'-Guanidinylnaltrindole dihydrochloride	9826034	Preclinical	D0X6SZ	.	CTPDG007027
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Preclinical	LY-25582	"3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; LY-255582; LY255582; CHEMBL300662; 119193-09-8; LY 255582; SCHEMBL2740453; AOB5354; (3R,4R)3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; ZINC3783617; BDBM50045775; NCGC00408804-01; AS-16869; LY255582, &gt; 3-[(3R,4R)-1-((S)-3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; 3-((3R,4R)-1-((S)-3-cyclohexyl-3-hydroxypropyl)-3,4-dimethylpiperidin-4-yl)phenol; 1-Piperidinepropanol,"	9906198	Preclinical	D0C2QF	.	CTPDG007095
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	443C81	BW 443C; BW-443C81	101630908	Terminated	D0E8SE	.	CTPDG007363
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	BCH-150	.	.	Terminated	D0J8XO	.	CTPDG011562
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	Sameridine	"143257-97-0; UNII-NQP2Y50Y6B; NQP2Y50Y6B; Sameridine [INN]; sameridine[inn]; AC1Q5ICP; SCHEMBL419071; AC1L24E2; CHEMBL2104504; DTXSID30162367; 4-Piperidinecarboxamide,N-ethyl-1-hexyl-N-methyl-4-phenyl-; ZINC3797855; AKOS015909863; N-Ethyl-1-hexyl-N-methyl-4-phenylisonipecotamide; I14-31849"	65996	Terminated	D0K9TC	.	CTPDG011563
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	DBO-11	166374-49-8; Naxifylline (USAN/INN)	23724971	Terminated	D0PE1A	.	CTPDG007250
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	DBO-17	.	10042211	Terminated	D0XH1H	.	CTPDG007179
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	BIPHALIN	"(Tyr-ala-gly-phe-NH2)2; D-Enk-O; Dala(2); D-ENK; Bis(tyr-ala-gly-phenh2)hydrazide; CHEMBL200199; 83916-01-2; (Tyrosyl-alanyl-glycyl-phenylalaninamide)dimer; Bis(tyrosyl-alanyl-glycyl-phenylalaninamide)hydrazide; L-Phenylalanine, N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-, 2-(N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)hydrazide; enkephalin dimer; AC1NUPQ3; BDBM21014; DTXSID80232802; ZINC150345473; LS-187519; LS-186863"	5487663	Terminated	D0LX5D	.	CTPDG011564
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	SB-213698	TAN-67	9950038	Terminated	D08YUP	.	CTPDG011565
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Terminated	SNF-9007	CHEMBL407057; BDBM21146; Asp-Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid	9898185	Terminated	D0W8TS	.	CTPDG011566
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Sar-Phe-D-2-Nal-NH	CHEMBL254927; BDBM50232770	44447368	Investigative	D00NZP	.	CTPDG011567
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NE-2	.	.	Investigative	D00PQS	.	CTPDG011568
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CODEINONE	"6-Codeinone; 467-13-0; UNII-22B5AW0ANN; (5alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one; EINECS 207-386-1; BRN 0094188; 22B5AW0ANN; CHEBI:18399; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; 6-Oxocodeine; (-)-Codeinone; SCHEMBL100655; CHEMBL257627; DTXSID70196909; XYYVYLMBEZUESM-CMKMFDCUSA-N; ZINC4097036; API0000487; LS-92114; C06171; 7,8-Didehydro-4,5; A-epoxy-3-methoxy-17-methyl-morphinan-6-one"	5459910	Investigative	D00PYB	.	CTPDG011569
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AIKO-152	"AIKO-150 + opioid analgesic (pain/opiate dependence), Aiko Biotechnology"	.	Investigative	D00YMN	.	CTPDG011570
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-Phe-NH-]2	CHEMBL386887	44390628	Investigative	D01ESN	.	CTPDG011571
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DC6S	.	44414725	Investigative	D01MHO	.	CTPDG011572
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Hfe-Phe-NH2	CHEMBL378466	14991618	Investigative	D01MKM	.	CTPDG011573
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AIKO-151	"Mu-opioid antagonist (oral, opiate dependence), Aiko Biotechnology"	.	Investigative	D02VUL	.	CTPDG011574
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MM3A6S	CHEMBL379928	10454860	Investigative	D02YXR	.	CTPDG011575
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	BREMAZOCINE	"(-)-Bremazocine; Bremazocine, (-)-; 75684-07-0; 2-(1-Hydroxy-cyclopropylmethyl)-5-ethyl-9,9-dimethyl-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-, (2R)-; SureCN157210; AC1Q2C6X; SCHEMBL157210; CHEBI:3171; GTPL1603; ZINC3870315; PDSP2_001570; PDSP1_001586; C11791; UNII-ISF76M2DBE component ZDXGFIXMPOUDFF-XLIONFOSSA-N"	443406	Investigative	D03BUD	.	CTPDG011576
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Hfe-Pro-NH2	CHEMBL380286	44413086	Investigative	D03NCF	.	CTPDG011577
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NCT-400	.	.	Investigative	D03PCP	.	CTPDG011578
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-(NMe)Phe-D-Pro-NH2	CHEMBL163808	44375783	Investigative	D04IHL	.	CTPDG011579
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide	CHEMBL235560; SCHEMBL3702023; JKDWSAGAQLISRL-UHFFFAOYSA-N; BDBM50219927	44434931	Investigative	D04JCJ	.	CTPDG011580
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phg-NH2	CHEMBL378111	44413074	Investigative	D04MYP	.	CTPDG011581
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SL-3111	CHEMBL143592; SCHEMBL9881223; BDBM50068132	9909743	Investigative	D05CRC	.	CTPDG011582
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-Phg-NH2	CHEMBL208990	44413117	Investigative	D05ETG	.	CTPDG011583
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Sar-Phe-D-2-Nal-NH2	CHEMBL254926	44447367	Investigative	D05HOH	.	CTPDG011584
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-D-pro-L-Phe-D-trp-L-Phe-NH2	CHEMBL450818	44583427	Investigative	D05XCV	.	CTPDG011585
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[D-Ala2]Met-enkephalinamide	CHEMBL287480	44280469	Investigative	D05XPU	.	CTPDG011586
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ORIPAVINE	"UNII-575AOU51CR; 467-04-9; EINECS 207-385-6; BRN 0046094; CHEBI:7782; 575AOU51CR; 6,7,8,14-Tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methyl-morphinan-3-ol; (5alpha)-6,7,8,14-Tetradehydro-4,5-epoxy-6-methoxy-17-methylmorphinan-3-ol; Morphinan-3-ol, 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methyl-; 3-O-demethyl-thebaine; SCHEMBL37889; 4-27-00-02270 (Beilstein Handbook Reference); CHEMBL437602; DEA No. 9330; SCHEMBL19880919; DTXSID10196908; ZKLXUUYLEHCAMF-UUWFMWQGSA-N; Oripavine 0.1 mg/ml in Methanol"	5462306	Investigative	D05YXS	.	CTPDG011587
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YGGWL-NH2	CHEMBL504973	44577308	Investigative	D06ESC	.	CTPDG011588
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KIN-4044	"Mu opioid antagonist (NSCLC), Kinentia"	.	Investigative	D06LCW	.	CTPDG011589
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-NMePhe	CHEMBL583426	45483974	Investigative	D06QLG	.	CTPDG011590
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3B6S	CHEMBL209751	44414877	Investigative	D06YVE	.	CTPDG011591
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Endomorphins	"EM-1; EM-2; Endomorphins (chronic inflammation); Endomorphin EM-1, University of Bristol; Endomorphin EM-2, University of Bristol; Endomorphins (chronic inflammation), University of Bristol"	.	Investigative	D07GZG	.	CTPDG011592
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DM3A6S	CHEMBL437682	44414785	Investigative	D07UJV	.	CTPDG011593
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Hfe-NH2	CHEMBL211147	14991612	Investigative	D07XXX	.	CTPDG011594
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(+/-)-TRANS-U-50488 METHANESULFONATE	NCG-C00093883-01	9912313	Investigative	D08QSN	.	CTPDG011595
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol	"CHEMBL285250; 27107-68-2; CTK0I5787; DTXSID80494706; BDBM50000570; AKOS022657931; 3-(2-Methyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol; Phenol, 3-(2-methyl-2-azabicyclo[3.3.1]non-5-yl)-; 2-Methyl-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonane"	12368881	Investigative	D08UZJ	.	CTPDG011596
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AKUAMMINE	.	13491909	Investigative	D09FVG	.	CTPDG011597
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Semorphone	"(-)-4,5alpha-Epoxy-3,14-dihydroxy-17-(2-methoxyethyl)morphinan-6-one hydrochloride; (-)-4,5alpha-Epoxy-3,14-dihydroxy-N-(2-methoxyethyl)morphinan-6-one hydrochloride; MR-2264 (free base); MRZ-2264 (free base); N-(2-Methoxyethyl)noroxymorphone hydrochloride; Semorphone hydrochloride"	5491906	Investigative	D09MXM	.	CTPDG011598
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YGWFL-NH2	CHEMBL455502	44577349	Investigative	D09TCT	.	CTPDG011599
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YRFB	CHEMBL215513	44416268	Investigative	D0A1XG	.	CTPDG011600
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NRT-300	NCT-300	.	Investigative	D0C0FG	.	CTPDG011601
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2	"CHEMBL124941; BDBM50001459; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid"	44348645	Investigative	D0C1AN	.	CTPDG011602
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phg-Pro-NH2	CHEMBL425421	44413146	Investigative	D0C2ZW	.	CTPDG011603
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C6S	CHEMBL1417	44414814	Investigative	D0D0XP	.	CTPDG011604
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-2-Nal-NH2	CHEMBL375070	11498201	Investigative	D0D1VB	.	CTPDG011605
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2	.	73345457	Investigative	D0E7CA	.	CTPDG011606
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-Ala-Bn	CHEMBL577748	45487600	Investigative	D0F8CD	.	CTPDG011607
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	naloxonazine	NSC 612113	9576413	Investigative	D0G1IF	.	CTPDG011608
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phg-Phe-NH2	CHEMBL211119	44413203	Investigative	D0G2BN	.	CTPDG011609
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KNT-5	.	46232162	Investigative	D0G2YV	.	CTPDG011610
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	CHEMBL243724; BDBM50201411; N alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	44428306	Investigative	D0HL7Q	.	CTPDG011611
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-L-Phe-D-trp-L-Phe-D-pro-NH2	CHEMBL442612	44583428	Investigative	D0I1ZN	.	CTPDG011612
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DM3B6S	CHEMBL213737	44414801	Investigative	D0IC5F	.	CTPDG011613
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Ala-Bn	CHEMBL577749	45487602	Investigative	D0IQ0S	.	CTPDG011614
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YPAA-NH2	CHEMBL466147	44577307	Investigative	D0IU2K	.	CTPDG011615
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KIN-3031	"Mu opioid angonist (CNS formulation, pain), Kinentia"	.	Investigative	D0J0ZU	.	CTPDG011616
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-D-Val-Bn	CHEMBL577746	44555371	Investigative	D0J5IR	.	CTPDG011617
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-NH-CH2-]2	CHEMBL180286	44390664	Investigative	D0J9DO	.	CTPDG011618
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YAWF-NH2	CHEMBL445690	44577306	Investigative	D0JX3P	.	CTPDG011619
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Trp-D-Val-Bn	CHEMBL577745	44555370	Investigative	D0KQ8A	.	CTPDG011620
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2	"CHEMBL330991; BDBM50001460; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionyl}-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid"	10485385	Investigative	D0KW4Y	.	CTPDG011621
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	YPWA-NH2	CHEMBL512955	44577305	Investigative	D0N3GU	.	CTPDG011622
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ethylmorphine	"Codethyline; DIONINE; 76-58-4; Morphine, ethyl-; Ethyl morphine; UNII-RWO67D87EU; Ethylmorphine [BAN]; 3-O-Ethylmorphine; EINECS 200-970-7; RWO67D87EU; CHEBI:4902; DEA No. 9190; Dionin; Ethylmorphine (BAN); NCGC00168251-01; Ethomorphine; Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol; Morphine 3-ethyl ether; AC1Q37UW; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-ethoxy-17-methyl-"	5359271	Investigative	D0N5QC	DB01466	CTPDG011623
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	THEBAINE	"Paramorphine; 3-O-Methyl-oripavin; 115-37-7; UNII-2P9MKG8GX7; Thebain; 4,5alpha-Epoxy-3,6-dimethoxy-17-methyl-6,8-morphinadien; EINECS 204-084-1; 2P9MKG8GX7; (5R,9R,13S)-4,5-Epoxy-3,6-dimethoxy-9alpha-methyl-6,8-morphinadien; CHEBI:9519; DEA No. 9333; NCGC00160239-01; DSSTox_RID_81337; DSSTox_CID_26099; DSSTox_GSID_46099; Morphinan, 6,7,8,14-tetradehydro-4,5-alpha-epoxy-3,6-dimethoxy-17-methyl-; 3,6-dimethoxy-17-methyl-6,7,8,14-tetradehydro-4,5alpha-epoxymorphinan"	5324289	Investigative	D0O2LD	.	CTPDG011624
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-Phe-NH-CH2-]2	CHEMBL409336	44390629	Investigative	D0O7XU	.	CTPDG011625
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-YGGFL-NH2	CHEMBL500212	15747210	Investigative	D0P2DF	.	CTPDG011626
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(R)-spiro-Aba-Gly-Phe-NH2	CHEMBL401142	24755139	Investigative	D0P2QV	.	CTPDG011627
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2	CHEMBL274400	44316657	Investigative	D0P7YV	.	CTPDG011628
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MORPHICEPTIN	"Deproceptin; Tyr-pro-phe-pro amide; Tyr-pro-phe-D-pro-NH2; beta-Casomorphine(1-4) amide; NH(4)-Tyr-pro-phe-pro-conh(2); Tyr-Pro-Phe-Pro-NH2; Tyrosyl-prolyl-phenylalanyl-D-prolinamide; UNII-97TZA8ANPC; H-Tyr-Pro-Phe-Pro-NH2; L-Tyrosyl-L-prolyl-L-phenylalanyl-L-prolinamide; 74135-04-9; b-Casomorphin-4-amide; 97TZA8ANPC; CHEMBL362991; L-Prolinamide, L-tyrosyl-L-prolyl-L-phenylalanyl-"	119303	Investigative	D0R0OZ	.	CTPDG011629
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DIHYDROAKUAMMINE	.	44576039	Investigative	D0R1MB	.	CTPDG011630
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(2-benzylisoindolin-5-yloxy)nicotinamide	CHEMBL238362; SCHEMBL3690327; GGVSFVBTUMOASO-UHFFFAOYSA-N; BDBM50226248	44434060	Investigative	D0R2VL	.	CTPDG011631
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Trp-Gly-Bn	CHEMBL570634	45487601	Investigative	D0R6VX	.	CTPDG011632
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CYPRODIME	"CHEMBL322796; N-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one; SCHEMBL3619261; BDBM50148071; ZINC13580323; NCGC00344512-01; Morphinan-6-one, 17-(cyclopropylmethyl)-4,14-dimethoxy-; (-)-N-(Cycloproylmethyl)-4,14-dimethoxymorphinan-6-one(Cyprodime); 17-cyclopropylmethyl-3,10-dimethoxy-(1R,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one; 17-cyclopropylmethyl-10-hydroxy-4,14-dimethoxy-(1S,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3-dien-6-one(cyprodime)"	5748293	Investigative	D0S3TZ	.	CTPDG011633
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MORPHINONE	"467-02-7; UNII-28MBK63MAW; EINECS 207-384-0; BRN 0042464; 28MBK63MAW; Didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-one; CHEBI:16315; (5alpha)-7,8-Didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3-hydroxy-17-methyl-, (5-alpha)-; SCHEMBL427946; CHEMBL255467; CTK1D7902; DTXSID50196907; ZINC4095712; AKOS030240636; LS-92113; C01735; 3-hydroxy-17-methyl-7,8-didehydro-4,5-epoxy-5alpha-morphinan-6-one"	5459823	Investigative	D0S5BJ	.	CTPDG011634
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	PL017	3-N-Me-Phe-morphiceptin; PL-017; PL 017	115335	Investigative	D0S6BX	.	CTPDG011635
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ADC-5510	"ADC-02265510; ADL-5510; Centrally acting mu opoid receptor antagonists, Adolor"	.	Investigative	D0TA3V	.	CTPDG011636
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MM3B6S	CHEMBL211374	44414811	Investigative	D0TT5V	.	CTPDG011637
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3S	.	.	Investigative	D0V0PY	.	CTPDG011638
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Trp-D-Ala-Bn	CHEMBL577747	44555372	Investigative	D0W3PR	.	CTPDG011639
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Beta-funaltrexamine	"beta-Fna; Naltrexone fumarate methyl ester; 72782-05-9; CHEMBL473136; CHEBI:81527; 2-Butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (E)-; Beta Funaltrexamine; Beta-Funeltrexamine; SCHEMBL1240811; GTPL1631; ZINC3995756; PDSP2_001549; PDSP2_000394; BDBM50247803; NCGC00163180-01; LS-47116; C18127; methyl 3-[4-cyclopropylmethyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ylcarbamoyl]-"	5311018	Investigative	D0WT7H	.	CTPDG011640
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KRP-110	IDDBCP262221	.	Investigative	D0WX3N	.	CTPDG011641
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2	CHEMBL124435; BDBM50001462; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-indane-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid	10010455	Investigative	D0X1SN	.	CTPDG011642
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KRP-100	"Mu opioid receptor antagonist, Kyorin"	.	Investigative	D0X4RU	.	CTPDG011643
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Tyr-Pro-Phe-NH-]2	CHEMBL179946	44390663	Investigative	D0Z9YE	.	CTPDG011644
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-ser-Gly-Phe-Leu-Thr-OH	CHEMBL246479	44439907	Investigative	D00FXL	.	CTPDG011645
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(R)-Aba-Gly-Phe-NH2	CHEMBL250448	24755140	Investigative	D00FZN	.	CTPDG011646
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys-NH-Ph	SCHEMBL8224099	25050067	Investigative	D00LLO	.	CTPDG011647
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-NH-CH2-Bid	"(3S)-N-[(1H-Benzimidazole-2-ylmethyl)carbamoylmethyl]-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide"	44375729	Investigative	D00MEM	.	CTPDG011648
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-D-Asp-N(Me)-Ph	CHEMBL502302	25033947	Investigative	D00QLH	.	CTPDG011649
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid	CHEMBL444197	25033951	Investigative	D00WBU	.	CTPDG011650
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)	CHEMBL208916	44412290	Investigative	D00WEV	.	CTPDG011651
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-Phe-Pro-NH2	CHEMBL162564	44376104	Investigative	D00XQV	.	CTPDG011652
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-mCpa-ala-Gly-Phe-leu-OH	CHEMBL246682	44439875	Investigative	D01HOP	.	CTPDG011653
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2	CHEMBL371856	44399141	Investigative	D01JSA	.	CTPDG011654
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH	CHEMBL370701	44399025	Investigative	D01MFM	.	CTPDG011655
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-ala-Gly-Phe-Met-OH	CHEMBL246572	44439910	Investigative	D01SDX	.	CTPDG011656
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Phe-Met-NH2	Tyr-DAla-Gly-Phe-Met-NH2	10371120	Investigative	D01TKS	.	CTPDG011657
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"Tyr-Pro-3,5Dmp-Phe-NH2"	CHEMBL413892	16736272	Investigative	D02GMU	.	CTPDG011658
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-CH2-NH2	CHEMBL241010	44436392	Investigative	D02IQG	.	CTPDG011659
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG	CHEMBL441930	44416445	Investigative	D02TPK	.	CTPDG011660
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OCH2CH3	CHEMBL505502	44586191	Investigative	D02WUZ	.	CTPDG011661
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	CHEMBL243189; BDBM50201412; N alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	44428304	Investigative	D03BFH	.	CTPDG011662
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)	CHEMBL426320	44412158	Investigative	D03BRB	.	CTPDG011663
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Orn-Aic-Glu]-NH2	CHEMBL106849	44336496	Investigative	D03CKF	.	CTPDG011664
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone"	CHEMBL200890	44405233	Investigative	D03HXN	.	CTPDG011665
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	2-Benzylaminomethyl-3-hydroxymorphinan	CHEMBL578173	44626544	Investigative	D03KAQ	.	CTPDG011666
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	PTI-601	.	.	Investigative	D03PMB	.	CTPDG011667
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M6S	.	.	Investigative	D03RSA	.	CTPDG011668
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Antanal 1	CHEMBL507442	44568843	Investigative	D03VSJ	.	CTPDG011669
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KETOCYCLAZOCINE	.	23724935	Investigative	D03WYO	.	CTPDG011670
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	UFP-502	"CHEMBL109390; H-Dmt-Tic-NH-CH2-Bid; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide; BDBM50179191; (S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide"	10345770	Investigative	D03YDG	.	CTPDG011671
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-D-Asp-NH-Ph	CHEMBL498799	25033945	Investigative	D04BII	.	CTPDG011672
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dimethylthiambutene	"Dimethibutin; Ohton; Dimetiltiambuteno; Aminobutene; Dimethylthiambutenum; Kobaton; N,N,1-Trimethyl-3,3-di-2-thienylallylamine; 3-Dimethylamino-1,1-bis(2-thienyl)-1-butene; 524-84-5; 3-Dimethylamino-1,1-di-(2'-thienyl)-1-butene; Dimetiltiambutene [DCIT]; N,N,1-Trimethyl-3,3-di(2-thienyl)-2-propenylamine; Dimetiltiambuteno [INN-Spanish]; Dimethylthiambutenum [INN-Latin]; Dimethylthiambutene [INN:BAN:DCF]; 338C48; Allylamine, N,N,1-trimethyl-3,3-di-2-thienyl-; BRN 0084891; DEA No. 9619; CHEBI:59781; NIH4542"	10668	Investigative	D04EZN	DB01444	CTPDG011673
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Asp-NH-Bzl	CHEMBL450566	25034010	Investigative	D04IIB	.	CTPDG011674
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Etorphine	"19-Propylorvinol; 6,14-Ethenomorphinan-7-methanol, 4,5-epoxy-3-hydroxy-6-methoxy-.alpha.,17-dimethyl-.alpha.-propyl-, [5.alpha.,7.alpha.(R)]-; 7.alpha.-Etorphine; AC1LARGT; ETORPHINE - HCI; GTPL1625; SCHEMBL10031275; Oripavine, 6,14-endo-ethylenetetrahydro-7-(1-hydroxy-1-methylbutyl)-; BDBM82425; CAHCBJPUTCKATP-UHFFFAOYSA-N; M99; CAS_61677; NSC_61677; FT-0668440; L024016; Tetrahydro-7-.alpha.-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine; 6,14-endo-Ethenotetrahydrooripavine, 7.alpha.-(1-hydroxy-1-methylbuty"	644209	Investigative	D04JCK	.	CTPDG011675
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H	CHEMBL392469	44436371	Investigative	D04KHE	.	CTPDG011676
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-Phe-Pro-NH2	.	44375782	Investigative	D04POA	.	CTPDG011677
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2	.	73346987	Investigative	D04QXM	.	CTPDG011678
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Trp-D-2-Nal-NH2	CHEMBL218433	16105563	Investigative	D04RPI	.	CTPDG011679
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Tic-Phe-Phe-OH	"Tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine; TIPP; 146369-65-5; Tyr-tic-phe-phe-OH; CHEMBL191751; L-Phenylalanine, L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-phenylalanyl-; Tyr-Tic-Phe-PheOH; AC1LD8RR; TIPP (opioid antagonist); DTXSID60163362; ZINC3942635; BDBM50068664; tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl- phenylalanyl-phenylalanine; L-Tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L- phenylalanyl-L-phenylalanine; 147780-77-6"	644210	Investigative	D04SFK	.	CTPDG011680
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(2-phenethylisoindolin-5-yloxy)nicotinamide	CHEMBL235154; SCHEMBL3696847	44434061	Investigative	D04VJE	.	CTPDG011681
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	UFP-512	"CHEMBL442577; GTPL9006; BDBM50272169; H-Dmt-Tic-NH-CH(CH2-COOH)-Bid; H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid; (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1H-benzimidazol-2-yl)propanoic acid; (S)-3-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-(1H-benzo[d]imidazol-2-yl)propanoic acid"	10918703	Investigative	D05AFV	.	CTPDG011682
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SPIROINDANYLOXYMORPHONE	"7-Spiroindanyloxymorphone; SIOM; 7-(Spiroindano)Oxymorphone; CHEMBL399708; 150380-34-0; SCHEMBL12013205; 7-(2'-spiroindanyl)oxymorphone; 7-(2''-spiroindanyl)oxymorphone; BDBM50297170; 1',3',7,7a,8,9-Hexahydro-3,7a-dihydroxy-12-methylspiro(6H-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2H)inden)-5(4aH)-one (4aR-(4aalpha,7aalpha,8alpha,9calpha))-; Spiro(6H-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2H)inden)-5(4aH)-one, 1',3',7,7a,8,9-hexahydro-3,7a-dihydroxy-12-methyl-, (4aR-(4aalpha"	44444966	Investigative	D05EWZ	.	CTPDG011683
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2	.	44376180	Investigative	D05GFM	.	CTPDG011684
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-N(Me)-Ph	CHEMBL500937	25034012	Investigative	D05KIQ	.	CTPDG011685
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H	CHEMBL375359	16100411	Investigative	D05KIS	.	CTPDG011686
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH"	CHEMBL375094	44418912	Investigative	D05NYR	.	CTPDG011687
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NalBzOH	"Naloxone benzoylhydrazone; 119630-94-3; 6-Desoxy-6-benzoylhydrazido-N-allyl-14-hydroxydihydronormorphinone; Benzoic acid, ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene)hydrazide; Lopac0_000882; [(5alpha)-4,5-Epoxy-; MLS000860072; Naloxone benzoylhydrazone, solid; SCHEMBL15423902; CHEMBL1256836; MolPort-003-958-927; MFCD05662358; AKOS024456586; CCG-204964; NCGC00092281-03; NCGC00092281-02; NCGC00092281-04; NCGC00092281-01; SMR000326930; N-165; EU-0100882; SR-01000075513; SR-01000075513-1"	9601084	Investigative	D05ZYZ	.	CTPDG011688
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CTAP	.	44309215	Investigative	D06BAU	.	CTPDG011689
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Leucine-enkephalin	YGGFL; URLZCHNOLZSCCA-UHFFFAOYSA-N; 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; Spectrum_001429; AC1L1GYW; Spectrum5_000656; Spectrum4_001048; Spectrum2_001177; Spectrum3_001521; AC1Q1P3H; KBioSS_001909; KBioGR_001316; BSPBio_002902	461776	Investigative	D06EES	.	CTPDG011690
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-457	CHEMBL242967; BDBM50210558	44429060	Investigative	D06SZI	.	CTPDG011691
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DADLE	"63631-40-3; H-TYR-D-ALA-GLY-PHE-D-LEU-OH; DADL; (D-Ala2,D-Leu5)-Enkephalin; [D-Ala2, D-Leu5]-enkephalin; CHEMBL340032; BW-180C; Tyr-D-Ala-Gly-Phe-D-Leu; (2R,5S,11R,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-isobutyl-11-methyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic acid; (2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; UNII-HB4QD9GL6F; HB4QD9GL6F; DADLE-OH; AC1OCEJN; ZINC14952092; H-Tyr-D-Ala-Gly-Phe-D-Leu"	6917707	Investigative	D06YMS	DB08856	CTPDG011692
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	CHEMBL384571	44369487	Investigative	D07AUG	.	CTPDG011693
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol"	CHEMBL208801	11645313	Investigative	D07BPA	.	CTPDG011694
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Dmt-Phe-NH2	CHEMBL228512	44424809	Investigative	D07BXN	.	CTPDG011695
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2	.	15088039	Investigative	D07DTN	.	CTPDG011696
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2	CHEMBL29078; Tyr-Ala-Phe-Asp-Val-Val-Gly; GTPL1615	10033203	Investigative	D07GQE	.	CTPDG011697
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-Gly-Gly-Phe-Leu-OH	CHEMBL247759	44439882	Investigative	D07JIQ	.	CTPDG011698
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2	CHEMBL32202; BDBM50009180; 3-(2-{2-[2-(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-4-methylsulfanyl-butyrylamino}-3-phenyl-propionylamino)-3-(1H-imidazol-4-yl)-propionylamino]-4-methyl-pentanoylamino}-4-methylsulfanyl-butyrylamino)-succinamic ac	14504437	Investigative	D07LXZ	.	CTPDG011699
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]	CHEMBL506211	44583388	Investigative	D07QUY	.	CTPDG011700
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)	CHEMBL413950	44316483	Investigative	D08BOD	.	CTPDG011701
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-isobutylnoroxymorphone	"CHEMBL490418; 17-Isobutyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; SCHEMBL3835355; OEQLILQNMUXCHV-XFWGSAIBSA-N"	25178033	Investigative	D08BST	.	CTPDG011702
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H	CHEMBL372130	44405653	Investigative	D08CJB	.	CTPDG011703
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,10-bis-(Dmt-Tic-amino)decane"	CHEMBL373192	44405160	Investigative	D08COK	.	CTPDG011704
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Bta	CHEMBL258704	44451667	Investigative	D08CXZ	.	CTPDG011705
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-Phg-Phe-NH2	CHEMBL210247	44413216	Investigative	D08FGQ	.	CTPDG011706
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KNT-63	CHEMBL593980	46225291	Investigative	D08FYQ	.	CTPDG011707
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SB-0304	CHEMBL409225	11641503	Investigative	D08LIT	.	CTPDG011708
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Aba-Gly-NH-CH2-Ph	CHEMBL208683; BDBM50189920	11664525	Investigative	D08SCK	.	CTPDG011709
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-(NMe)Phe-Pro-NH2	.	44375819	Investigative	D08STW	.	CTPDG011710
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone"	CHEMBL381874	44405208	Investigative	D08VOC	.	CTPDG011711
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Phe-D-trp]	CHEMBL502411; SCHEMBL7980647	44583373	Investigative	D09BWX	.	CTPDG011712
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-K-(NH2)-YRFB	CHEMBL412939	44416444	Investigative	D09CTG	.	CTPDG011713
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph	SCHEMBL8222648	25050225	Investigative	D09DAM	.	CTPDG011714
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-2',6'-dimethyltyrosine-Tic-OH"	"CHEMBL571492; 2,6-Dimethyl-L-Tyr-L-Tic-OH; BDBM50299565; H-2'',6''-dimethyltyrosine-Tic-OH; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid"	15384271	Investigative	D09GQP	.	CTPDG011715
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Aba-Gly-NH-CH2-Bid	CHEMBL211543	11721803	Investigative	D09GSD	.	CTPDG011716
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	FLUPERAMIDE	"UNII-6H13T09362; 53179-10-5; CHEMBL421665; 6H13T09362; R-18910; Fluperamide [USAN:INN]; AC1L2ZCI; AC1Q4JI5; SCHEMBL120826; ZINC4216287; BDBM50017686; R 18,910; 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; 4-(4-Chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide; 4-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide; 1-Piperidinebutanamide, 4-(4-"	131534	Investigative	D09KBQ	.	CTPDG011717
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)	XFKPEXYNTQLONY-MPYJOUPCSA-N; CHEMBL450263	25033949	Investigative	D09MBV	.	CTPDG011718
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Ala-D-pro-L-Phe-D-trp]	CHEMBL499595; SCHEMBL7991248	44583393	Investigative	D09SBU	.	CTPDG011719
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-mCpa-ser-Gly-Phe-Leu-Thr-OH	CHEMBL393867	44439901	Investigative	D0A9AJ	.	CTPDG011720
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Z)-NH-Ph	.	25050066	Investigative	D0AJ9D	.	CTPDG011721
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-N(CH3)2	CHEMBL505975	44586190	Investigative	D0B1JC	.	CTPDG011722
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Mmp-Phe-NH	CHEMBL413676	16736675	Investigative	D0C4QH	.	CTPDG011723
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	CHEMBL390271; BDBM50201414; N alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	44428305	Investigative	D0C5RC	.	CTPDG011724
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2	CHEMBL384284	44316656	Investigative	D0C9XB	.	CTPDG011725
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dynorphin(1-8)	.	44273338	Investigative	D0D1WB	.	CTPDG011726
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Tyr-D-trp]	CHEMBL486388	44583375	Investigative	D0D5VD	.	CTPDG011727
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	KNT-62	CHEMBL594654	46906981	Investigative	D0D6KZ	.	CTPDG011728
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DM6S	CHEMBL385448	44414783	Investigative	D0D6OA	.	CTPDG011729
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid	CHEMBL386309; SCHEMBL8228625	25050223	Investigative	D0D8DZ	.	CTPDG011730
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(-)-eseroline	"Eseroline; UNII-Q22H41O18D; CHEMBL310934; CHEBI:48845; C13H18N2O; HKGWQUVGHPDEBZ-OLZOCXBDSA-N; Q22H41O18D; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol; 469-22-7; (3as-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-"	119198	Investigative	D0D9RL	.	CTPDG011731
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,4-bis-(Dmt-Tic-amino)butane"	CHEMBL370197	44405158	Investigative	D0DN6A	.	CTPDG011732
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-2034	"MR 2034; (-)-alpha-(1R,5R,9R)-5,9-Dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-((tetrahydro-2-furanyl)methyl)-, (2R-(2-alpha,3(R*),6-alpha,11R*))-; 57236-85-8; AC1Q7AHJ; (2r,6r)-6,11-dimethyl-3-[(2r)-tetrahydrofuran-2-ylmethyl]-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; BDBM81932; MR2034; LS-90624; CAS_57236-85-8"	123980	Investigative	D0DO6P	.	CTPDG011733
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG	CHEMBL414736	44416159	Investigative	D0E3RQ	.	CTPDG011734
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH"	CHEMBL219482	44418911	Investigative	D0E7NL	.	CTPDG011735
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-NH-Ph	"CHEMBL501451; BDBM50272081; (3S)-N-(Phenylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid phenylcarbamoylmethyl-amide"	11016572	Investigative	D0ED2I	.	CTPDG011736
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Ac)-NH-Ph	SCHEMBL8228366	25050226	Investigative	D0EG7I	.	CTPDG011737
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DSLET	"DSTLE; Dislet; [D-Ser2, Leu5, Thr6]-enkephalin"	107847	Investigative	D0EM9A	.	CTPDG011738
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2"	CHEMBL415426	44418917	Investigative	D0ES7P	.	CTPDG011739
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc	CHEMBL413644	44408590	Investigative	D0F1XY	.	CTPDG011740
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-cyclopropylpiperidin-4-ol	CHEMBL398039	44430024	Investigative	D0F8AX	.	CTPDG011741
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Tmp-Phe-NH	CHEMBL389023	16736706	Investigative	D0FT9J	.	CTPDG011742
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Gly-NH-Bzl	"CHEMBL458631; H-Dmt-Tic-Gly-NH-CH2-Ph; GTPL9838; BDBM50266025; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (benzylcarbamoyl-methyl)-amide; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-N-(2-(benzylamino)-2-oxoethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; (3S)-N-(Benzylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide"	10864183	Investigative	D0H1BU	.	CTPDG011743
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Imp-Phe-NH2	CHEMBL434559	16736710	Investigative	D0H2RF	.	CTPDG011744
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	AMINOFENTANYL	CHEMBL385168; BDBM50191054	44416393	Investigative	D0H3QK	.	CTPDG011745
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3Pr6S	CHEMBL385048; 3-Propionylmorphine 6-sulfate	44414843	Investigative	D0H6AA	.	CTPDG011746
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2	.	44331204	Investigative	D0H8WV	.	CTPDG011747
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-NHCH3	CHEMBL453689	44586189	Investigative	D0HF0I	.	CTPDG011748
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Phe-D-1-Nal-NH2	CHEMBL385583	16105560	Investigative	D0I1BJ	.	CTPDG011749
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2	.	73345456	Investigative	D0I9IX	.	CTPDG011750
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone"	CHEMBL198800	44405192	Investigative	D0J2IK	.	CTPDG011751
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DELTORPHIN-II	"Delt II; Delt-II; (Ala(2))deltorphin II; deltorphin II, Ala(2)-; (Ala(2),glu(4))deltorphin; Deltorphin, ala(2)-glu(4)-; Tyr-ala-phe-glu-val-val-gly-NH2; Deltorphin, alanyl(2)-glutamyl(4)-; Glycinamide, L-tyrosyl-D-alanyl-L-phenylalanyl-L-alpha-glutamyl-L-valyl-L-valyl-; AC1L3XB1; LS-72217"	123795	Investigative	D0J7XM	.	CTPDG011752
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-1029	.	71716573	Investigative	D0K0XT	.	CTPDG011753
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Dmp-Phe-NH2	CHEMBL266122	10371367	Investigative	D0K2OK	.	CTPDG011754
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DELTORPHIN	Dermenkephalin; Deltorphin A; 119975-64-3; CHEMBL20775; CHEBI:81455; Tyr-met-phe-his-leu-met-asp-NH2; AC1MHYOS; DTXSID60152630; BDBM50000518; Tyrosyl-methionyl-phenylalanyl-histidyl-leucyl-methionyl-aspartamide; ZINC169301619	3035060	Investigative	D0K4AC	.	CTPDG011755
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-D-Phe-D-Pro-NH2	.	44375820	Investigative	D0L3DM	.	CTPDG011756
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-ImidPh	CHEMBL259917	44451637	Investigative	D0L9NB	.	CTPDG011757
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-2266	"Mrz 2266 BS; MR 2266; MR-2266-BS; (-)-Mr 2266; (-)-2-(3-Furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan; 56649-76-4; (+/-)-2-(3-Furylmethyl)-2'-hydroxy-5,9alpha-diethyl-6,7-benzomorphan hydrochloride; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,6R,11R)-; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R-(2alpha,6alpha,11R*))-; Mr1302 MS; Mr2267; Mr 2267; SCHEMBL4404993; BDBM82508; Mr2266; ZINC5492542; CAS_56649-76-4"	3034816	Investigative	D0M4DI	.	CTPDG011758
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2	CHEMBL411335	44412234	Investigative	D0M6BL	.	CTPDG011759
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH"	"CHEMBL555206; BDBM50299557; H-2'',6''-dimethyltyrosine-Tic-Phe-Phe-OH; (S)-2-((S)-2-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-phenylpropanamido)-3-phenylpropanoic acid"	45273695	Investigative	D0M6CZ	.	CTPDG011760
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Phe-D-2-Nal-NH2	.	.	Investigative	D0MP7Z	.	CTPDG011761
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CTOP	"Ctop-NH2; CTOPA; CHEMBL507214; 103429-31-8; AC1NSJX5; H-D-Phe-c[Cys-Tyr-DTrp-Orn-Thr-Pen]-Thr-NH2; GTPL1674; CTOP, &gt; BDBM50252861; (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide"	2884	Investigative	D0MZ2A	.	CTPDG011762
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Indn	CHEMBL260127	44451639	Investigative	D0N1AO	.	CTPDG011763
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Antanal 2	CHEMBL454035	44568844	Investigative	D0N5TL	.	CTPDG011764
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OC(CH3)3	CHEMBL500195	44586192	Investigative	D0NB7S	.	CTPDG011765
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DERMORPHIN	77614-16-5; H-Tyr-D-ala-phe-gly-tyr-pro-ser-NH2; UNII-2SEC01B703; DERMORPHIN ACETATE; Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide; CHEMBL278789; 2SEC01B703; Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2; AC1NUNYZ; YAFGYPS-NH2; SCHEMBL237169; Tyr-Ala-Phe-Gly-Tyr-Pro-Ser; DTXSID40228281; HY-P0244	5485199	Investigative	D0NE3U	.	CTPDG011766
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OCH3	CHEMBL361922; Tyr-Pro-Phe-Phe-OMe	44390652	Investigative	D0O4KY	.	CTPDG011767
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid	SCHEMBL8230993; CHEMBL377960	25050224	Investigative	D0O7NC	.	CTPDG011768
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2"	CHEMBL269314	44418915	Investigative	D0P1CP	.	CTPDG011769
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MR-1526	.	73352838	Investigative	D0P2GB	.	CTPDG011770
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Asp-N(Me)-Ph	CHEMBL448360	25034014	Investigative	D0P2KV	.	CTPDG011771
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide	CHEMBL594511	44596230	Investigative	D0P2LE	.	CTPDG011772
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2"	CHEMBL218781	44418916	Investigative	D0P4PM	.	CTPDG011773
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Glu-NH-(CH2)5-NH2	CHEMBL225479	44421433	Investigative	D0P5EI	.	CTPDG011774
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]	CHEMBL507127	44583387	Investigative	D0P5IH	.	CTPDG011775
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2	.	44376060	Investigative	D0P6AR	.	CTPDG011776
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Indl	CHEMBL408975	44451665	Investigative	D0P8NZ	.	CTPDG011777
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Asp-NH-Ph	CHEMBL501202	25033885	Investigative	D0PN1A	.	CTPDG011778
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Aba-ala-Gly-Phe-leu-OH	CHEMBL247064	44439877	Investigative	D0PN3P	.	CTPDG011779
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	.	91931233	Investigative	D0Q0UQ	.	CTPDG011780
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac	CHEMBL408889	44408417	Investigative	D0Q1PN	.	CTPDG011781
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)	CHEMBL499099; BDBM50272228	25034016	Investigative	D0Q2HZ	.	CTPDG011782
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Tyr-D-pro-L-Phe-D-trp]	CHEMBL506217	44583374	Investigative	D0Q6CF	.	CTPDG011783
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(S)-Aba-Gly-Phe-NH2	CHEMBL399796	24755070	Investigative	D0Q7SS	.	CTPDG011784
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys-NH-CH2-Ph	.	44415604	Investigative	D0R1DY	.	CTPDG011785
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid	CHEMBL212172	16082947	Investigative	D0R3GD	.	CTPDG011786
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH"	CHEMBL375095	44418913	Investigative	D0R4KJ	.	CTPDG011787
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH"	CHEMBL376453	44418914	Investigative	D0R4YD	.	CTPDG011788
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Apa-ala-Gly-Phe-leu-OH	CHEMBL247363	44439872	Investigative	D0R9AP	.	CTPDG011789
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane"	CHEMBL370399	44405153	Investigative	D0R9LV	.	CTPDG011790
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph	.	44415603	Investigative	D0R9XD	.	CTPDG011791
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	CHEMBL268162	44369523	Investigative	D0RR4X	.	CTPDG011792
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1,6-bis-(Dmt-Tic-amino)hexane"	CHEMBL197185	44405159	Investigative	D0S3LK	.	CTPDG011793
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ZYKLOPHIN	GTPL9193; CHEMBL574568	45483651	Investigative	D0S9UH	.	CTPDG011794
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3P6S	CHEMBL213228	44414864	Investigative	D0TH8E	.	CTPDG011795
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CARBOXYFENTANYL	"CHEBI:61106; CHEMBL216239; 4-oxo-4-{phenyl[1-(2-phenylethyl)piperidin-4-yl]amino}butanoic acid; 4-anilidopiperidine, 8; Epitope ID:153518; SCHEMBL5163413; BDBM21114; ZINC14975441; 4-Oxo-4-[N-(1-phenethylpiperidine-4-yl)anilino]butyric acid; 3-{phenyl[1-(2-phenylethyl)piperidin-4-yl]carbamoyl}propanoic acid"	23635044	Investigative	D0U3ZL	.	CTPDG011796
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H	CHEMBL198909	44405656	Investigative	D0U4LU	.	CTPDG011797
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol"	CHEMBL212743; SCHEMBL14506371	11580459	Investigative	D0U5OP	.	CTPDG011798
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-OCH2OH	CHEMBL522293	24857893	Investigative	D0U8YU	.	CTPDG011799
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone"	CHEMBL373668	44405182	Investigative	D0UV1C	.	CTPDG011800
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Imid	CHEMBL407957	44451610	Investigative	D0V2PM	.	CTPDG011801
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Phe-Phe-NHNH2	CHEMBL180777	24857892	Investigative	D0V3GN	.	CTPDG011802
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[3H]U69593	"U-69593; U69593; 96744-75-1; U 69593; UNII-J5S4K6TKTG; U 69,593; J5S4K6TKTG; N-Methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzeneacetamide; CHEBI:73357; n-methyl-2-phenyl-n-[(5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]dec-8-yl]acetamide; Benzeneacetamide, N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-, (5alpha,7alpha,8beta)-(-)-; NCGC00163179-01; DSSTox_CID_26326; DSSTox_RID_81542; U69,593; DSSTox_GSID_46326; [3H]-U69593"	105104	Investigative	D0V3OY	.	CTPDG011803
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH2-Boa	CHEMBL258458	44451689	Investigative	D0V8UG	.	CTPDG011804
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-Glu-NH2	.	11156202	Investigative	D0W8MP	.	CTPDG011805
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3A6S	CHEMBL214040; 3-Acetylmorphine 6-sulfate; 3-O-acetylmorphine-6-sulfate	44414842	Investigative	D0WZ7J	.	CTPDG011806
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid	CHEMBL378082	25050370	Investigative	D0X2HA	.	CTPDG011807
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M3IBu6S	CHEMBL211576	44414863	Investigative	D0X2HT	.	CTPDG011808
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H	CHEMBL380590	44405654	Investigative	D0X4YC	.	CTPDG011809
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cdp-ser-Gly-Phe-Leu-Thr-OH	CHEMBL247760	44439905	Investigative	D0X5TB	.	CTPDG011810
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)	CHEMBL437283	44316364	Investigative	D0X9SP	.	CTPDG011811
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-(S)-spiro-Aba-Gly-Phe-NH2	CHEMBL401143	24755069	Investigative	D0X9TT	.	CTPDG011812
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Dmt-Aba-Gly-NH-Ph	CHEMBL377392	11635818	Investigative	D0Y2HI	.	CTPDG011813
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Ac-RYYRIK-K-(NH2)-YAFGYPS	CHEMBL404792	44416158	Investigative	D0Y2MT	.	CTPDG011814
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-Emp-Phe-NH2	CHEMBL375274	16736708	Investigative	D0Y5TF	.	CTPDG011815
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Pro-L-Phe-D-Pro-NH2	.	44376061	Investigative	D0Y5UN	.	CTPDG011816
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Ala-Phe-NH2	YPAF-NH2	44428865	Investigative	D0Y9RD	.	CTPDG011817
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Oxymorphone semicarbazone hydrochloride	CHEMBL1202432; Oxymorphone Semicarbazone HCl	49860169	Investigative	D0YK5E	.	CTPDG011818
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Tic-Cha-Phe-OH	CHEMBL197937	9809581	Investigative	D0Z5UG	.	CTPDG011819
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Pro-Dap(6DMN)-Phe-NH2	CHEMBL207661	44412206	Investigative	D0ZI5Z	.	CTPDG011820
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2"	CHEMBL218782	44418918	Investigative	D0ZQ7L	.	CTPDG011821
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-Methylthiofentanyl	"3-Methyl-thiofentanyl; UNII-C9C204973M; 86052-04-2; CHEBI:53763; N-(3-Methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide; C9C204973M; Propanamide, N-(3-methyl-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-; N-{3-methyl-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; DEA No. 9833; 3-Methylthiofentanil; Epitope ID:153515; AC1Q5I8I; AC1L1WU2; SCHEMBL1742151; CHEMBL2365680; DB01439; FT-0672232"	62296	Investigative	D00HIG	DB01439	CTPDG011822
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(-)-cyclorphan	"CHEMBL291468; BDBM50105483; 17-cyclopropylmethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol; 17-cyclopropylmethyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol"	44299063	Investigative	D00JAT	.	CTPDG011823
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	5-(4-((phenethylamino)methyl)phenoxy)picolinamide	CHEMBL236376; SCHEMBL3771658	44434951	Investigative	D00JPB	.	CTPDG011824
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-117	CHEMBL1790045; (-)3-hydroxy-N-propargylmorphinan; BDBM50366764	6602241	Investigative	D00NRB	.	CTPDG011825
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	CHEMBL568757	44627900	Investigative	D00SDP	.	CTPDG011826
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-isopropylpiperidin-4-ol	CHEMBL233721	44430025	Investigative	D00XZH	.	CTPDG011827
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 4; CHEMBL205965; BDBM21134; (3S)-3-[(2S)-2-[(2S)-2-(2-{[(2R)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11693641	Investigative	D01ADK	.	CTPDG011828
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	BUTORPHAN	CHEMBL301160; MCL-101; SCHEMBL11805323; ZINC3982790; 3-Hydroxy-N-cyclobutylmethylmorphinan; BDBM50135808; 3-hydroxy-n-cyclobutylmethyl morphinan	9804450	Investigative	D01EPU	.	CTPDG011829
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-tert-butylpiperidin-4-ol	CHEMBL234771	10314141	Investigative	D01MUV	.	CTPDG011830
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	8-carboxamidocyclazocine	"CHEMBL58646; 8-CAC; SCHEMBL12014004; (6S,11R)-3-Cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8-carboxylic acid amide; PDSP1_000954; PDSP2_000939"	10086063	Investigative	D01RFG	.	CTPDG011831
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	quadazocine	"(-)-WIN 44,441; (-)-quadazocine"	115077	Investigative	D02BER	.	CTPDG011832
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-methyl-4'-methyldihydromorphinone	CHEMBL607018	44415081	Investigative	D02FZW	.	CTPDG011833
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-443	CHEMBL394624	44427184	Investigative	D02IMZ	.	CTPDG011834
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cpa-Gly-Gly-Phe-Met-OH	CHEMBL391580	11250396	Investigative	D02PIG	.	CTPDG011835
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-450	CHEMBL373984; BDBM50194274	16083055	Investigative	D02RYZ	.	CTPDG011836
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	CHEMBL373489	44415255	Investigative	D03QWP	.	CTPDG011837
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	OXYMORPHINDOLE	"ACMC-20di42; AC1L9G6X; CHEMBL1985511; CTK7J9928; 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol,5,6,7,8,14,14b-hexahydro-7-methyl-, (4bS,8R,8aS,14bR)-; NSC707844; NSC-707844; NCI60_038277"	5491897	Investigative	D03UFD	.	CTPDG011838
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-458	CHEMBL390912; BDBM50210556	44429061	Investigative	D03UHT	.	CTPDG011839
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	CHEMBL442483	44408525	Investigative	D03WGS	.	CTPDG011840
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Naltrexone-6-alpha-ol	"CHEMBL468469; 20410-98-4; SCHEMBL679581; ZINC1656961; BDBM50254511; FT-0672601; 17-(Cyclopropylmethyl)-4,5; A-epoxy-morphinan-3,6; A,14-triol; A)-17-(Cyclopropylmethyl)-4,5-epoxy-morphinan-3,6,14-triol; 6alpha-Naltrexol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material"	16099582	Investigative	D04JFL	.	CTPDG011841
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-139	CHEMBL203251	44406697	Investigative	D04PPP	.	CTPDG011842
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Dmt-Phe-NH2	CHEMBL388800	44424810	Investigative	D04UFM	.	CTPDG011843
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-429	CHEMBL397035	44427178	Investigative	D04UIK	.	CTPDG011844
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	naltriben	"Naltrindole benzofuran; 4,8-Methano-5H-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a(9H)-diol, 7-(cyclopropylmethyl)-6,7,8,14b-tetrahydro-, (8R-(4bS*,8alpha,8beta,14bbeta))-; 111555-58-9; C26H25NO4; [3H]naltriben; [3H]-naltriben; NTB; naltrindolebenzofuran; GTPL1640; SCHEMBL1240717; CHEMBL100940; GTPL3828; BDBM82552; HMS2089G18; ZINC3874478; PDSP2_001551; LS-172157; CAS_111555-58-9; C20166; AB00691672-07"	5486827	Investigative	D05ANN	.	CTPDG011845
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Phe-Phe-NH2	"CHEMBL331325; 596792-36-8; Dmt-endomorphin-2; CTK1E6813; DTXSID10435187; BDBM50149384; AKOS030610408; L-Phenylalaninamide, 2,6-dimethyl-L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-1-[(S)-2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide"	10077295	Investigative	D05EZE	.	CTPDG011846
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CYCLORPHAN	"17-(Cyclopropylmethyl)morphinan-3-ol; 4163-15-9; UNII-U6Z73N36V0; EINECS 224-007-5; CHEMBL49269; (-)-3-Hydroxy-N-cyclopropylmethylmorphinan; U6Z73N36V0; Morphinan, (-)-3-hydroxy-N-cyclopropylmethyl-; Morphinan-3-ol, 17-(cyclopropylmethyl)- (8CI,9CI); SCHEMBL159134; CTK4I5050; ZINC4215487; PDSP2_000668; BDBM50135800; N-cyclopropylmethyl 3-hydroxymorphinan; 3-Hydroxy-N-cyclopropylmethylmorphinan; LS-91818; (-)-17-(Cyclopropylmethyl)morphinan-3-ol; (-)-3-Hydroxy-N-cycloproypylmethylmorphinan Mandelate"	5359966	Investigative	D05FEQ	.	CTPDG011847
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-145	.	10462426	Investigative	D05JSY	.	CTPDG011848
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NORBINALTORPHIMINE	"nor-Binaltorphimine; UNII-36OOQ86QM1; 36OOQ86QM1; CHEBI:81529; C18130; 4,8:11,15-Dimethano-20H-bisbenzofuro(2,3-a:3',2'-i)dipyrido(4,3-b:3',4'-h)carbazole-1,8a,10a,18-tetrol, 7,12-bis(cyclopropylmethyl)-5,6,7,8,9,10,11,12,13,14,19a,20b-dodecahydro-20-methyl-, (8R-(4bR*,8alpha,8abeta,10aalpha,11beta,14aR*,19aalpha,20bbeta))-; Nor-Binaltorphamine; (-)-norbinaltorphimine; NOR-BNI (HCI)2; Lopac0_000806; GTPL1642; CHEMBL573214; SCHEMBL12013206; BDBM82551; APSUXPSYBJVPPS-YAUKWVCOSA-N"	5480230	Investigative	D05QJS	.	CTPDG011849
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	CHEMBL210770; SCHEMBL14280723; NRIVFQIOYWIUPX-UHFFFAOYSA-N; BDBM50185792	44413409	Investigative	D05RII	.	CTPDG011850
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"Dmt-Pro-3,5Dmp-Phe-NH2"	CHEMBL389949	16736676	Investigative	D05TOY	.	CTPDG011851
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[3H]diprenorphine	"[15,16-3H]diprenorphine"	6858272	Investigative	D05YNT	.	CTPDG011852
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6beta-naltrexol HCl	"CHEMBL558140; UNII-765G11MG24; 765G11MG24; 55488-86-3; Naltrexone metabolite 6; A-Naltrexol (hydrochloride); 6beta-Naltrexol hydrochloride; HY-G0019; 6beta-Hydroxynaltrexone hydrochloride; Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, hydrochloride, (5alpha,6beta)-; Naltrexone metabolite 6AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Naltrexol (hydrochloride)"	45110000	Investigative	D05ZIH	.	CTPDG011853
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-153	.	11411315	Investigative	D06IXE	.	CTPDG011854
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-Phe-L-trp]	CHEMBL506616; CJ-15208; SCHEMBL12368055	44583372	Investigative	D06KFX	.	CTPDG011855
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Mmp-Phe-NH2	CHEMBL389948	16737287	Investigative	D06MWG	.	CTPDG011856
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	CYCLAZOCINE	"(-)-cyclazocine; 7313-86-2; l-Cyclazocine; (-)-cis-Cyclazocine; A-Cyclazocine; AC1L55DZ; GTPL1604; CTK8F1400; DTXSID20617937; MCV 4512; (2R,6R,11R)-3-(Cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; NIH 10450; AKOS030242899; FT-0665329"	19143	Investigative	D06NST	.	CTPDG011857
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-433	CHEMBL245049	44427174	Investigative	D06OKE	.	CTPDG011858
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	CHEMBL433814; SCHEMBL9520650	44426806	Investigative	D06PVO	.	CTPDG011859
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	NRP290	.	.	Investigative	D06WTI	.	CTPDG011860
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	M6G thiosaccharide analogue	.	.	Investigative	D07AAK	.	CTPDG011861
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-434	CHEMBL241824	44427176	Investigative	D07DFD	.	CTPDG011862
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylethyl)piperidin-4-ol	CHEMBL230249	9925737	Investigative	D07FCB	.	CTPDG011863
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-446	CHEMBL428038; BDBM50210549	44429064	Investigative	D07HFU	.	CTPDG011864
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	CHEMBL220333	16116088	Investigative	D07JZS	.	CTPDG011865
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-435	CHEMBL242046	44427180	Investigative	D08IWF	.	CTPDG011866
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2"	"CHEMBL261390; BDBM21007; C-terminal modified bifunctional peptide, 1; [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate"	24768351	Investigative	D08KSJ	.	CTPDG011867
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	"tDADAE(9); CHEMBL229440; BDBM21126; (5S,8R,10E,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid"	16733487	Investigative	D08NJB	.	CTPDG011868
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol"	CHEMBL171118	44382932	Investigative	D08ORS	.	CTPDG011869
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 3; CHEMBL408330; BDBM21133; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11528076	Investigative	D08QKT	.	CTPDG011870
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-182	CHEMBL49143; 3-aminobutorphan; 3-Amino-N-cyclobutylmethylmorphinan	11255361	Investigative	D08RPH	.	CTPDG011871
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	TQ-1017	.	.	Investigative	D08YCS	.	CTPDG011872
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-447	CHEMBL394573; BDBM50210555	44429063	Investigative	D09DUE	.	CTPDG011873
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	CHEMBL568989	44627904	Investigative	D09FLC	.	CTPDG011874
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	CHEMBL571998; MCL-610	44627790	Investigative	D09RUY	.	CTPDG011875
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-183	CHEMBL390866; SCHEMBL14419223	11303119	Investigative	D09UKS	.	CTPDG011876
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Deprotected cogener of M6G	CHEMBL362202	44390358	Investigative	D0A5MU	.	CTPDG011877
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-144	"CHEMBL147511; BDBM50135806; di[17-cyclobutylmethyl-(1R,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] sebacate"	9897164	Investigative	D0B8MY	.	CTPDG011878
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-428	CHEMBL242048	44427183	Investigative	D0C2UQ	.	CTPDG011879
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2"	"CHEMBL406030; BDBM21013; C-terminal modified bifunctional peptide, 6"	24768356	Investigative	D0C6RQ	.	CTPDG011880
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-448	CHEMBL242968; BDBM50210550	44429062	Investigative	D0C7MP	.	CTPDG011881
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	"CHEMBL261608; BDBM21009; C-terminal modified bifunctional peptide, 2; benzyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate"	24768352	Investigative	D0CK8C	.	CTPDG011882
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Dcp1]Dyn A(1-11)-NH2	CHEMBL412997	44415282	Investigative	D0CX0I	.	CTPDG011883
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SN-23	CHEMBL564538	45270599	Investigative	D0D3UB	.	CTPDG011884
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-desoxonaltrexone	"CHEMBL511816; SCHEMBL3825815; XBPQMXFKKJADMC-WOUAJJJCSA-N; BDBM50278385; 3,14-Dihydroxy-17-cyclopropylmethyl-4,5alpha-epoxymorphinan"	13374610	Investigative	D0D8AN	.	CTPDG011885
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	CHEMBL393971	10427620	Investigative	D0D9BB	.	CTPDG011886
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-(4-((phenethylamino)methyl)phenoxy)benzamide	CHEMBL238317; SCHEMBL3692341; FARQYUHOSNLRKV-UHFFFAOYSA-N; BDBM50219921	44434950	Investigative	D0E0TD	.	CTPDG011887
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Imp-Phe-NH2	CHEMBL228516	16737137	Investigative	D0E1FQ	.	CTPDG011888
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	14-O-phenylpropylnaltrexone	CHEMBL514774; SCHEMBL3167650; BDBM50249017	44565511	Investigative	D0E6GH	.	CTPDG011889
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MC-CAM	"CHEMBL386272; BDBM50195674; BDBM50091405; 14-[(4-Chlorocinnamoyl)amino]-4,5alpha-epoxy-17-(cyclopropylmethyl)-3-methoxymorphinan-6-one; 1N-[4-cyclopropylmethyl-10-methoxy-14-oxo-(17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-17-yl]-3-(4-chlorophenyl)-(E)-2-propenamide(Methyoclocinnamox (MC-CAM))"	44417373	Investigative	D0F1EB	.	CTPDG011890
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-432	CHEMBL242047	44427182	Investigative	D0F4AN	.	CTPDG011891
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DAMGO	"DAGO; glyol; Dagol; DAMGE; 78123-71-4; 2-Ala-4-mephe-5-gly-enkephalin; Tyr-ala-gly-(nme)phe-gly-ol; Enkephalin, ala(2)-mephe(4)-gly(5)-; RX 783006; (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin; Ala(2)-mephe(4)-gly-ol(5) enkephalin; CHEBI:272; CHEMBL38874; Tyr-D-Ala-Gly-MePhe-Gly-ol; Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-; H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol; Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-; [3H]DAMGO; L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-"	5462471	Investigative	D0F8CV	.	CTPDG011892
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	DPDPE	"2,5-Pen-enkephalin; (D-Pen2,D-Pen5)-Enkephalin; Enkephalin, D-penicillamine (2,5)-; (4s,7s,13s)-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-13-(l-tyrosylamino)-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid; DPLPE; c[D-Pen(2,5)]-enkephalin; CHEMBL31421; CHEBI:73356; Enkephalin, penicillamine(2,5)-; cyclo-[D-Pen(2,5)]-enkephalin; 88373-73-3; D-penicillamine-(2,5)-enkephalin; H-Tyr-c(D-Pen-Gly-Phe-D-Pen)-OH; [D-Pen(2)-D-Pen(5)]-enkephaline; H-Tyr-cyclo-(D-Pen-Gly-Phe-D-Pen)-OH; [3H]DPDPE; D-Valine, L-tyros"	104787	Investigative	D0G4NM	DB08861	CTPDG011893
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	CHEMBL448998	25129135	Investigative	D0G6GC	.	CTPDG011894
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-147	CHEMBL242756; SCHEMBL14419222; Aminothiazolo-N-Cyclopropylmorphinan	9798655	Investigative	D0G7FB	.	CTPDG011895
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	CHEMBL236170; SCHEMBL3697663; FZBJOVYOONJNIG-UHFFFAOYSA-N; BDBM50219917	44434946	Investigative	D0H0KP	.	CTPDG011896
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	dynorphin B	rimorphin	25075991	Investigative	D0H0OO	.	CTPDG011897
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cdp-Gly-Gly-Phe-Leu-OH	CHEMBL246739	44439880	Investigative	D0HB6O	.	CTPDG011898
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dimepheptanol	"Methadol; Racemethadol; Pangerin; Bimethadol; 545-90-4; NIH 2933; Betamethadol; Betametadol; 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL; 3-HEPTANOL, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-; Dimepheptanolum; Dimefeptanol; Dimefeptanolo; Bimethadolum; (-)-beta-Methadol; Betametadolo [DCIT]; (3S,6R)-Methadol; beta-Methadol, (-)-; Betametadol [INN-Spanish]; Dimefeptanolo [DCIT]; Betamethadolum [INN-Latin]; 3-Heptanol,4-diphenyl-, hydrochloride; Betamethadol [INN:BAN:DCF]; DEA No. 9609; Dimefeptanol [INN-Spanish]; Dimepheptanolum [IN"	28397	Investigative	D0HC3H	.	CTPDG011899
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	CHEMBL220219	16116220	Investigative	D0HV6H	.	CTPDG011900
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	CHEMBL238361; SCHEMBL3702187	44434058	Investigative	D0I1NG	.	CTPDG011901
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-mTyr-D-pro-L-Phe-D-trp]	CHEMBL510506	44583376	Investigative	D0I2CE	.	CTPDG011902
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	CHEMBL218651	16100409	Investigative	D0I9PH	.	CTPDG011903
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	PHENAZOCINE	"PHENAZOCINE HYDROBROMIDE; Narphen; Phenazocine (+-)- hydrobromide; EINECS 214-982-5; 1239-04-9; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocin-8-ol hydrobromide; 2'-Hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan hydrobromide; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-phenethyl-, hydrobromide; NIH 7519 hydrobromide; AC1L24DX; C22H27NO.HBr; SCHEMBL396395; PHENETHYLAZOCINE BROMIDE; 127-35-5 (Parent); CHEMBL2107297; DTXSID20872382; AKOS022180090; LS-90611"	14707	Investigative	D0I9SX	.	CTPDG011904
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	CHEMBL393675	44430013	Investigative	D0IL9H	.	CTPDG011905
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-445	CHEMBL243195; BDBM50210553	44429065	Investigative	D0IY2V	.	CTPDG011906
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-449	CHEMBL427862	44427177	Investigative	D0J3NK	.	CTPDG011907
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-(17-Methylmorphinan-3-yl)-N'-phenylurea	CHEMBL568829; BDBM50303599	44628003	Investigative	D0K1BV	.	CTPDG011908
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-431	CHEMBL241823	44427175	Investigative	D0K4XQ	.	CTPDG011909
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Tmp-Phe-NH2	CHEMBL228503	16737135	Investigative	D0KL5N	.	CTPDG011910
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	CHEMBL386043	44415281	Investigative	D0L0NI	.	CTPDG011911
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2"	"CHEMBL438389; BDBM21012; C-terminal modified bifunctional peptide, 5"	24768355	Investigative	D0L2CT	.	CTPDG011912
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-149	CHEMBL299220; 3-aminocyclorphan; SCHEMBL13383188; 3-Amino-N-cyclopropylmethylmorphinan; ZINC13532322	11392313	Investigative	D0L5DN	.	CTPDG011913
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	LOFENTANIL	"Lofentanil oxalate; Lofentanil oxalate [USAN]; Lofentanil oxalate (USAN); 61380-41-4; Lofentaniloxalat; R 34995; EINECS 262-750-7; cis-(-)-4-(Methoxycarbonyl)-3-methyl-1-phenethyl-4-(N-phenylpropionylamino)piperidinium hydrogen oxalate; R 34,995; AC1L23D4; (-)-Methyl cis-3-methyl-1-phenethyl-4-(N-phenylpropionamido)isonipecotate oxalate (1:1); FT-0670830; D04764; UNII-6C1599T3OQ component CBKLICUQYUTWQL-XWGBWKJCSA-N; methyl (3S,4R)-3-methyl-1-phenethyl-4-(N-propanoylanilino)piperidine-4-carboxylate"	10070040	Investigative	D0L6QN	DB09174	CTPDG011914
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-Gly-Gly-Phe-Met-NH2	"[Met5]-Enkephalin Amide; [Met5]-Enkephalin, amide; CHEMBL247368; 60117-17-1; Tyr-Gly-Gly-Phe-Met-NH2; Met-enkephalinamide; L-Methioninamide, L-tyrosylglycylglycyl-L-phenylalanyl-; Enkephalinamide-met-; Methionine enkephalinamide; AC1L3X5D; CTK2F3118; HY-P1467; ZINC28893234; BDBM50207823; AKOS030610304; CS-0044396; A833448; (2S)-2-[[(2S)-2-[2-[2-[[(2S)-2-azanyl-3-(4-hydroxyphenyl)propanoyl]amino]ethanoylamino]ethanoylamino]-3-phenyl-propanoyl]amino]-4-methylsulfanyl-butanamide"	123704	Investigative	D0L8LX	.	CTPDG011915
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ELAEOCARPENINE	.	16747727	Investigative	D0M1YV	.	CTPDG011916
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Beta-endorphin	"UNII-3S51P4W3XQ; 3S51P4W3XQ; 61214-51-5; LPH (61-91); beta-Endorphin, human; SCHEMBL6238339; CHEMBL1866903; EINECS 262-330-3; beta-Endorphin human, &gt; NCGC00163196-01; NCGC00163196-02; 27-L-Tyrosine-31-L-glutamic acid-beta-endorphin (sheep); beta-Endorphin (sheep), 27-L-tyrosine-31-L-glutamic acid-"	16132316	Investigative	D0N8LP	.	CTPDG011917
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-451	CHEMBL384915; H-Dmt-Tic-beta-Ala-OH	16083058	Investigative	D0NA7G	.	CTPDG011918
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	normorphine	"466-97-7; Desmethylmorphine; UNII-XUI1Y24IMI; Demethylmorphine; N-Normorphine; XUI1Y24IMI; NSC 270042; CHEBI:7633; ONBWJWYUHXVEJS-ZTYRTETDSA-N; Normorfina [INN-Spanish]; Normorphinum [INN-Latin]; 4,5-Epoxy-3,6-dihydroxymorphin-7-ene; Normorphine [INN:BAN:DCF]; Normorfina; Normorphinum; EINECS 207-381-4; N-Demethylmorphine; BRN 5297209; CHEMBL1227; DEA No. 9313; Normorphine (7,8-Didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol)"	5462508	Investigative	D0NV5N	.	CTPDG011919
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	CHEMBL237066; 6-[4-(2-benzylamino-ethyl)-phenoxy]-nicotinamide; SCHEMBL3698270; FCDWJNPFPYAKET-UHFFFAOYSA-N; BDBM50219925	44434057	Investigative	D0O1JD	.	CTPDG011920
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Diprenorphine	"14357-78-9; UNII-1F0L5N25ZZ; CHEMBL281786; CHEBI:4650; 1F0L5N25ZZ; DEA No. 9058; M50-50 Injection; Diprenorphine [INN:BAN]; Diprenorphinum [INN-Latin]; Diprenorfina [INN-Spanish]; Diprenorphinum; Diprenorfina; EINECS 238-325-7; 21-Cyclopropyl-6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylethyl)-6,14-endo-ethanooripavine; Diprenorfin; (5 ,7 )-17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- , -dimethyl-6,14-ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4"	443408	Investigative	D0O6SB	DB01548	CTPDG011921
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	"CHEMBL272665; BDBM21011; C-terminal modified bifunctional peptide, 4"	24768354	Investigative	D0P0RB	.	CTPDG011922
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	2-Hydroxymethyl-3-hydroxymorphinan	CHEMBL570449	44626540	Investigative	D0P5QI	.	CTPDG011923
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	CHEMBL571560; MCL-630	44627901	Investigative	D0P6FF	.	CTPDG011924
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-154	"CHEMBL151872; BDBM50135811; (1R,9R,10R)-17-(cyclobutylmethyl)-4-[(10-{[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-yl]oxy}decyl)oxy]-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene"	44365804	Investigative	D0Q5AJ	.	CTPDG011925
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	"CHEMBL271619; BDBM21010; C-terminal modified bifunctional peptide, 3"	24768353	Investigative	D0Q7HG	.	CTPDG011926
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	"rDADAE (11); CHEMBL229441; BDBM21127; single bond H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; reduced bond-c[2-D-allylglycine, 5-D-allylglycine]enkephalin; (5S,8R,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid"	16733489	Investigative	D0R1AB	.	CTPDG011927
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	HERKINORIN	"CHEMBL363324; 862073-77-6; BF3DNCA methyl ester; 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester; SCHEMBL3540059; DTXSID30235444; MolPort-003-983-869; PYDQMXRFUVDCHC-XAGHGKQISA-N; ZINC28461930; BDBM50170678; (3S,4aR,4bS,6S,8R,8aR,10aR)-6-Benzoyloxy-3-furan-3-yl-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester"	11431898	Investigative	D0R4QF	.	CTPDG011928
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ENDOMORPHIN-1	"Endomorphin 1; 189388-22-5; Tyr-Pro-Trp-Phe-Nh2; H-Tyr-Pro-Trp-Phe-NH2; CHEMBL316446; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-tryptophyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide"	5311080	Investigative	D0R5TA	.	CTPDG011929
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Clocinnamox	"Methoclocinnamox; C-CAM; 14-beta-(4-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorpmorphine mesylate; Clocinnamox mesylate; 117332-69-1; 2-Propenamide, 3-(4-chlorophenyl)-N-((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-oxomorphinan-14-yl)-, monomethanesulfonate; NIH 10443 mesylate; NIH 10989; SCHEMBL4404383; AKOS024259103"	6540640	Investigative	D0R6VF	.	CTPDG011930
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	"cDADAE(8); CHEMBL375025; BDBM21125; (5S,8R,10Z,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid"	16733485	Investigative	D0R7LY	.	CTPDG011931
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cdp-ala-Gly-Phe-leu-OH	CHEMBL247758	44439876	Investigative	D0S5FN	.	CTPDG011932
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	CHEMBL217957	16100407	Investigative	D0S7SO	.	CTPDG011933
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	CHEMBL372823	44406704	Investigative	D0SC3W	.	CTPDG011934
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ethylketocyclazocine	CHEMBL71301; AC1L28LJ; GTPL1602; BDBM50017232; L024009	443409	Investigative	D0T5EI	.	CTPDG011935
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-desoxy-3-carboxamidonaltrexone	"CHEMBL56695; SCHEMBL2785528; QAICPHMNUHNDMC-WUHBCXKYSA-N; BDBM50128411; 6-Oxo-17-(cyclopropylmethyl)-14-hydroxy-4,5alpha-epoxymorphinan-3-carboxamide; (5a)-17-(cyclopropylmethyl)-14-hydroxy-6-oxo-4,5-epoxymorphinan-3-carboxamide"	10021946	Investigative	D0T6OQ	.	CTPDG011936
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Emp-Phe-NH2	CHEMBL374818	16736880	Investigative	D0TB4A	.	CTPDG011937
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	METAZOCINE	"Methobenzmorphan; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-; NSC611380; 3734-52-9; 2'-Hydroxy-2,5,9-trimethyl-6,7-benzomorphan; AC1Q7AHP; AC1L1XA2; SCHEMBL26347; CHEMBL33376; YGSVZRIZCHZUHB-UHFFFAOYSA-N; PDSP1_001246; PDSP2_001230; NSC-611380; LS-90663; LS-90665"	62518	Investigative	D0TN0D	.	CTPDG011938
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SN-28	CHEMBL552308; SCHEMBL16248949	44467662	Investigative	D0TO0E	.	CTPDG011939
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ETONITAZENE	"Etonitazine; Etonitazinum; Ciba 20-684BA; ARC 1G2; Etobedolum; 911-65-9; Etonitazenum [INN-Latin]; NIH 7607; Etonitazeno [INN-Spanish]; Etonitazene [INN:BAN:DCF]; UNII-9U3GT3353T; EINECS 213-009-1; Ba-20684; Ba 20684; BRN 0363324; CHEMBL312040; DEA No. 9624; PXDBZSCGSQSKST-UHFFFAOYSA-N; C22H28N4O3; 9U3GT3353T; 1-(2-(Diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1-(2-Diethylaminoethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1H-Benzimidazole-1-ethanamine, 2-((4-ethoxyphenyl)methyl)-N,N-diethyl-5-nitro-"	13493	Investigative	D0U3UM	DB01462	CTPDG011940
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Cpa-Gly-Gly-Phe-Met-NH2	CHEMBL246956	44439866	Investigative	D0U7JS	.	CTPDG011941
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SN-11	CHEMBL559518	23642304	Investigative	D0UG8H	.	CTPDG011942
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Benzyl derivative of M6G	CHEMBL366917	44390359	Investigative	D0UR7D	.	CTPDG011943
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 15; CHEMBL205306; BDBM21145; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11722088	Investigative	D0V0RB	.	CTPDG011944
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	CHEMBL216640; Dynorphin A (1-11) amide; Dynorphin A(1-11) amide; 79985-48-1; Dyn A(1-11)-NH2; Linear Dyn A-(1-11)NH2; BDBM50010704; BDBM50033143; H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-NH2; Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-D-Lys-NH2; TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS-TRP-ASP-ASN-GLN-NH2	10677974	Investigative	D0VO7C	.	CTPDG011945
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	CHEMBL570225	44627903	Investigative	D0W0CO	.	CTPDG011946
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	MCL-444	CHEMBL263096	44427179	Investigative	D0W2DN	.	CTPDG011947
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	CHEMBL220327	44420667	Investigative	D0W6OP	.	CTPDG011948
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dmt-Pro-Dmp-Phe-NH2	CHEMBL228409	16736727	Investigative	D0X0XV	.	CTPDG011949
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	CHEMBL373572	44420674	Investigative	D0X6BU	.	CTPDG011950
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	"CHEMBL336381; CCK-Opioid Peptide, 6; BDBM21136; (3S)-3-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11061906	Investigative	D0X7LC	.	CTPDG011951
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	CHEMBL569724; BDBM50303601	44626534	Investigative	D0Y5ZP	.	CTPDG011952
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	CHEMBL234543	44430012	Investigative	D0Y7KE	.	CTPDG011953
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	RTI-5989-31	SCHEMBL6288083	22977851	Investigative	D0Y8NO	.	CTPDG011954
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	6-(4-((benzylamino)methyl)phenoxy)nicotinamide	CHEMBL238316; SCHEMBL3700197; LUBVSQAMVPXMBJ-UHFFFAOYSA-N; BDBM50219916	44434949	Investigative	D0YU5H	.	CTPDG011955
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	[Leu5]enkephalin	"[Leu5]-Enkephalin; 58822-25-6; Enkephalin; Enkephalin L; [Leu 5]enkephalin; UNII-RI01R707R6; [5-Leucine]Enkephalin; Tyr-Gly-Gly-Phe-Leu-OH; CHEMBL8234; H-Tyr-Gly-Gly-Phe-Leu-OH; CHEBI:89656; RI01R707R6; Enkephalins; L-Leucine, N-(N-(N-(N-L-tyrosylglycyl)glycyl)-L-phenylalanyl)-; Leucyl-enkephalin"	9985128	Investigative	D0Z5JD	.	CTPDG011956
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	C[L-Phe-D-pro-L-mTyr-D-trp]	CHEMBL509201	44583386	Investigative	D0Z8JX	.	CTPDG011957
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	3-Methylfentanyl	"Mefentanyl; 3-MF; 42045-86-3; N-(3-Methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide; F 7209; DEA No. 9813; Propanamide, N-(3-methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-; CHEBI:61092; N-(3-Methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide; N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide; 3-methyl-fentanyl; C23H30N2O; 3-Methylfentanil; AC1L1WAM; Epitope ID:153511; AC1Q5I8R; SCHEMBL2337401; HSDB 8379; CTK1D6517; MLQRZXNZHAOCHQ-UHFFFAOYSA-N; DB01571; LS-119344; R-26800"	61996	Investigative	D0ZH3G	DB01571	CTPDG011958
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ENDOMORPHIN 2	"Endomorphin-2; 141801-26-5; H-Tyr-Pro-Phe-Phe-NH2; UNII-3PH5M0466G; CHEMBL333357; 3PH5M0466G; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide"	5311081	Investigative	D00TNR	.	CTPDG011959
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	CHEMBL230145	44426807	Investigative	D00YCW	.	CTPDG011960
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 1; CHEMBL218763; BDBM21131; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	9811733	Investigative	D01AQC	.	CTPDG011961
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	CHEMBL389665	9820782	Investigative	D01WMU	.	CTPDG011962
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol"	CHEMBL495074; SCHEMBL471335; BDBM50252834	25129433	Investigative	D02EIB	.	CTPDG011963
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 7; CHEMBL382051; BDBM21137; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11051303	Investigative	D03EPA	.	CTPDG011964
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-ethoxy-4-phenylpiperidine	CHEMBL229016	10022129	Investigative	D03PTV	.	CTPDG011965
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	"CHEMBL1257578; CHEMBL1223815; SCHEMBL15031381; BDBM50325848; BDBM50327244; AZ-MTAB, &gt; ZINC101363709"	49765077	Investigative	D03RBD	.	CTPDG011966
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-butylpiperidin-4-ol	CHEMBL397761; SCHEMBL13597038	22970051	Investigative	D03UJW	.	CTPDG011967
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	CHEMBL231607	44426812	Investigative	D04ZQX	.	CTPDG011968
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 14; CHEMBL383458; BDBM21144; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11520765	Investigative	D06BRA	.	CTPDG011969
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	CHEMBL233494	44430018	Investigative	D06MQG	.	CTPDG011970
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-phenylpiperidin-4-ol	CHEMBL228690	10269001	Investigative	D06PHT	.	CTPDG011971
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-p-tolylpiperidin-4-ol	CHEMBL393985	9924923	Investigative	D07CIU	.	CTPDG011972
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 11; CHEMBL206974; BDBM21141; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11556976	Investigative	D07ICW	.	CTPDG011973
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 9; CHEMBL208479; BDBM21139; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11564210	Investigative	D07LQQ	.	CTPDG011974
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	CHEMBL232067; BDBM50210228	10093682	Investigative	D07NMH	.	CTPDG011975
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-hexylpiperidin-4-ol	CHEMBL234773	44430026	Investigative	D08DVV	.	CTPDG011976
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	CHEMBL231664	44430029	Investigative	D08QBU	.	CTPDG011977
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-cyclohexylpiperidin-4-ol	CHEMBL394695	10043439	Investigative	D08TFY	.	CTPDG011978
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-o-tolylpiperidin-4-ol	CHEMBL232273	20481138	Investigative	D09BYD	.	CTPDG011979
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 13; CHEMBL379405; BDBM21143; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11136782	Investigative	D09EMR	.	CTPDG011980
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	CHEMBL388123	9863568	Investigative	D09FJY	.	CTPDG011981
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	CHEMBL395838	44430008	Investigative	D09LRO	.	CTPDG011982
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol"	CHEMBL397945	44426814	Investigative	D09VRT	.	CTPDG011983
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Dihydromorphine	"Paramorphan; 7,8-DIHYDROMORPHINE; 6-alpha-Hydromorphol; 509-60-4; Dihydromorfin [Czech]; UNII-C3S5FRP6JW; Hydromorphine; Paramorfan; Morphine, dihydro-; EINECS 208-100-8; C3S5FRP6JW; NSC 117865; Dihydromorfin; CHEBI:4575; DEA No. 9145; Morphinan-3,6alpha-diol, 4,5alpha-epoxy-17-methyl-; Morphinan-3,6-alpha-diol, 4,5-alpha-epoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; 7,8-Dihydromorphin; 1421-28-9; dihydromorphin"	5359421	Investigative	D0B7GU	DB01565	CTPDG011984
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	CHEMBL233323	10315818	Investigative	D0D0UP	.	CTPDG011985
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	O-DESMETHYL TRAMADOL	"O-Desmethyltramadol; CHEMBL1400; (-)-O-Desmethyl Tramadol; 80456-81-1; 2-[(Dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol; CHEMBL201556; O-Demethyl tramadol; tramadol M1 metabolite; Mono-O-demethyltramadol; 144830-15-9; 3-{(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenol; 3-((1R,2R)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol; (+)-O-Desmethyltramadol; SCHEMBL2517055; CTK8E8372; UWJUQVWARXYRCG-HIFRSBDPSA-N; ZINC2509756; BDBM50176258; BDBM50176263; Phenol, 3-(2-((dimethylamino)me"	9838803	Investigative	D0D5QV	.	CTPDG011986
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 12; CHEMBL408083; BDBM21142; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11614928	Investigative	D0E2OG	.	CTPDG011987
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	CHEMBL401234	10384734	Investigative	D0G4FA	.	CTPDG011988
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	CHEMBL390279	44426827	Investigative	D0G7DF	.	CTPDG011989
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-m-tolylpiperidin-4-ol	CHEMBL437380	44430009	Investigative	D0J5JO	.	CTPDG011990
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	CHEMBL375412	44408484	Investigative	D0J7GJ	.	CTPDG011991
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	CHEMBL232476	44430007	Investigative	D0JH5D	.	CTPDG011992
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	CHEMBL405192	44408524	Investigative	D0N6DN	.	CTPDG011993
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	CHEMBL230253	44426810	Investigative	D0O7JV	.	CTPDG011994
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	CHEMBL390882	44426808	Investigative	D0P3FP	.	CTPDG011995
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-methoxy-4-phenylpiperidine	CHEMBL228965	10043898	Investigative	D0Q9TQ	.	CTPDG011996
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	CHEMBL232066	10089987	Investigative	D0QH4A	.	CTPDG011997
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	CHEMBL374325	44408526	Investigative	D0QP2S	.	CTPDG011998
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 2; CHEMBL382349; BDBM21132; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	11040230	Investigative	D0R4GI	.	CTPDG011999
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	CHEMBL228687	44426817	Investigative	D0T4ZY	.	CTPDG012000
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	CHEMBL233493	44430016	Investigative	D0T9KE	.	CTPDG012001
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	"CCK-Opioid Peptide, 10; CHEMBL218327; BDBM21140; H-Tyr-DPhe-Gly-DTrp-NMeNle-Asp-Phe-NH(2); (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	10942040	Investigative	D0TR0U	.	CTPDG012002
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	"CCK-Opioid Peptide, 8; CHEMBL262172; BDBM21138; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid"	10909103	Investigative	D0U6OA	.	CTPDG012003
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	CHEMBL386212	16100410	Investigative	D0V9DY	.	CTPDG012004
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	CHEMBL392753	10091033	Investigative	D0W3VT	.	CTPDG012005
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-phenyl-4-propoxypiperidine	CHEMBL229017	10317947	Investigative	D0X4SX	.	CTPDG012006
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	CHEMBL228793	44426828	Investigative	D0XX1Y	.	CTPDG012007
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	CHEMBL231874	10336926	Investigative	D0Y5LJ	.	CTPDG012008
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	1-benzhydryl-4-benzylpiperidin-4-ol	CHEMBL231661	44430028	Investigative	D0ZE2W	.	CTPDG012009
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	ICI-199441	"115199-84-3; ICI-199,441 HYDROCHLORIDE; ICI 199,441 hydrochloride; Ici 199441; Ici 199,441; AC1MIZCX; N-(2-(N-Methyl-3,4-dichlorophenylacetamido)-2-phenylethyl)pyrrolidine; SCHEMBL7647023; CTK8E9897; MolPort-023-275-929; AKOS024458644; (S)-3,4-Dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)benzeneacetamide monohydrochloride; RT-013313; B6448; J-003264; Benzeneacetamide, 3,4-dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-, monohydrochloride, (S)-"	3082718	Investigative	D03SAV	.	CTPDG012010
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	FALCARINDIOL	"55297-87-5; 1,9-Heptadecadiene-4,6-diyne-3,8-diol; Heptadeca-1,9-diene-4,6-diyne-3,8-diol; AC1L1FO2; SCHEMBL16680213; CTK1C6414; 225110-25-8; AKOS030230026; AN-40378; 4CN-1774"	5281148	Investigative	D08UOX	.	CTPDG012011
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	"4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide"	CHEMBL550063; SCHEMBL10266987; BDBM50297313	44254503	Investigative	D0L9YP	.	CTPDG012012
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	SOMATOSTATIN	51110-01-1; Somiaton; Panhibin; Aminopan; Somatostatin acetate; SRIF; Somatotropin release-inhibiting factor; Somatotropin release-inhibiting hormone; Growth hormone release-inhibiting factor; CCRIS 7071; EINECS 256-969-7; Growth hormone release-inhibiting hormone; AY 24910; Growth hormone release inhibiting factor; Somatostatin 1-14; Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys; NCGC00181005-01; 61950-59-2; [D-Trp8]-SOMATOSTATIN; SCHEMBL3046327	16129706	Investigative	D0T5RO	DB09099	CTPDG012013
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	(+/-)-nantenine	.	181743	Investigative	D0L5MW	.	CTPDG012014
M6ACROT03232	Mu-type opioid receptor (OPRM1)	OPRM_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03232	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03233	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03234	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03235	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Pioglitazone	"111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1"	4829	Approved	D03OFF	DB01132	CTPDG011129
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Troglitazone	"Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione"	5591	Approved	D06XZW	DB00197	CTPDG011130
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 4	Glitazone	"74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087"	10198397	Phase 4	D0S2BV	.	CTPDG011131
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rivoglitazone	"CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen"	3055168	Phase 3	D08PFA	DB09200	CTPDG011132
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Balaglitazone	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645	9889200	Phase 3	D0F3NH	DB12781	CTPDG011133
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	FARGLITAZAR	"GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-"	170364	Phase 3	D0M0SS	.	CTPDG011134
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rosiglitazone + simvastatin	.	23644561	Phase 3	D0Q6IW	.	CTPDG001082
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Leriglitazone	"146062-44-4; 1-Hydroxypioglitazone; 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; A1-01710; AKOS015856344; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE; BDBM50530214; CHEBI:82937; CHEMBL1267; CS-0067030; D11603; DB15021; DTXSID30399914; FT-0643388; HY-117727; Hydroxy Pioglitazone (M-IV); Hydroxy Pioglitazone-D5 (Major) (M-IV); Hydroxypioglitazone; J-008187; K824X25AYA; Leriglitazone; Leriglitazone (USAN/INN); LERIGLITAZONE [INN]; Leriglitazone [USAN]; MIN-102; OXVFDZYQLGRLCD-UHFFFAOYSA-N; Pioglitazone, hydroxy; Q27156475; SCHEMBL4098326; UNII-K824X25AYA; WHO 10868; ZINC01482947"	4147757	Phase 3	DCA13V	DB15021	CTPDG011135
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rosiglitazone + metformin	"Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]"	5329099	Phase 3	D0A1AQ	DB12072	CTPDG010074
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2/3	MBX-102	"Arhalofenate; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV"	12082259	Phase 2/3	D0X7VB	DB11811	CTPDG011140
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	FK-614	"ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus"	9869229	Phase 2	D00PJJ	DB12557	CTPDG003073
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	MBX-2044	"MBX-102 analogs, Metabolex"	.	Phase 2	D08NPG	.	CTPDG002626
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	GED-0507-34-Levo	GED-0507; GED-0507-34; GED-0507-34E2	67008033	Phase 2	D0E6ME	.	CTPDG011141
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	CHS-131	.	.	Phase 2	D0P5SU	.	CTPDG011142
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	OMS405	.	.	Phase 2	D0W0JP	.	CTPDG011143
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	CLX-0921	CLX-090502; CLX-090503; CLX-090717; CLX-092402	9958278	Phase 1	D06TWE	.	CTPDG005139
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	Englitazone sodium	"Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt"	13728795	Phase 1	D08EEU	.	CTPDG005061
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Spirolaxine derivative 1	PMID25416646-Compound-Figure2-L	.	Patented	D03GFB	.	CTPDG011148
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Phenylpropionic acid derivative 1	PMID25416646-Compound-Figure2-D	.	Patented	D09OXG	.	CTPDG011149
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	A-substituted phenylpropionic acid derivative 1	PMID25416646-Compound-Figure2-c	.	Patented	D0E9GF	.	CTPDG011150
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-K	.	10229498	Patented	D0G3KY	DB05490	CTPDG011151
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-N	.	.	Patented	D0GG5K	.	CTPDG011152
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	MRL24	MRL 24	9958543	Patented	D0H5FI	.	CTPDG011153
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Sulfonamide derivative 18	PMID25416646-Compound-Figure2-M	.	Patented	D0HT9C	.	CTPDG011154
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Crystalline anhydrous toluene derivative 1	PMID25416646-Compound-Figure2-H	.	Patented	D0M4RD	.	CTPDG011155
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	A-substituted phenylpropionic acid derivative 2	PMID25416646-Compound-Figure2-E	.	Patented	D0M5YQ	.	CTPDG011156
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Biaromatic compound 1	PMID25416646-Compound-Figure2-A	.	Patented	D0O8PR	.	CTPDG011157
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	MRL20	CHEMBL181937; (2s)-2-(2-{[1-(4-Methoxybenzoyl)-2-Methyl-5-(Trifluoromethoxy)-1h-Indol-3-Yl]methyl}phenoxy)propanoic Acid; SCHEMBL5172443; GTPL6742; BDBM50157936; (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid; (2S)-2-[2-({1-[(4-methoxyphenyl)carbonyl]-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl}methyl)phenoxy]propanoic acid; (S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid	10143056	Patented	D0PO7F	.	CTPDG011158
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Fused ring compound 1	PMID25416646-Compound-Figure2-G	.	Patented	D0SL0K	.	CTPDG011159
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	3-phenyl acrylic acid derivative 1	PMID25416646-Compound-Figure2-B	.	Patented	D0SV6U	.	CTPDG011160
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Thiazolidine dione crystalline derivative 1	PMID25416646-Compound-Figure2-I	9832447	Patented	D0TF0T	DB11894	CTPDG011161
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Fused aromatic compound 1	PMID25416646-Compound-Figure2-F	.	Patented	D0UG1W	.	CTPDG011162
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-J	.	.	Patented	D0UH5B	.	CTPDG011163
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Cannabinoid quinone derivative 1	PMID25416646-Compound-Figure3-A	.	Patented	D0ZO0D	.	CTPDG011164
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-E	.	.	Patented	D0LA6O	.	CTPDG011167
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Phenylpyridine derivative 3	PMID25416646-Compound-Figure5-G	.	Patented	D0NF8V	.	CTPDG011168
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	PMID25416646-Compound-Figure5-F	.	Patented	D0U6AW	.	CTPDG011170
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-C	.	.	Patented	D0V0JN	.	CTPDG011171
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	YM-440	"2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]"	9890786	Discontinued in Phase 2	D0KL3K	.	CTPDG011172
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	DS-6930	.	.	Discontinued in Phase 1	D0Z6OI	.	CTPDG011176
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Preclinical	Ciglitazone	"74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01"	2750	Preclinical	D03GWY	DB09201	CTPDG011179
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	SB-219994	SB-219993	9845965	Terminated	D00YGA	.	CTPDG011181
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AKP-320	"Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis"	.	Terminated	D04JVX	.	CTPDG007513
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	Edaglitazone	Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602	9825701	Terminated	D08VKZ	DB06519	CTPDG007430
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	DARGLITAZONE	"CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione"	60870	Terminated	D0N1EF	DB14034	CTPDG011182
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	Terminated	D0LB4T	.	CTPDG007286
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"15-deoxy-Delta(12, 14)-prostaglandin J(2)"	"15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2"	5311211	Investigative	D01PGU	.	CTPDG011185
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	LT175; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03	11483970	Investigative	D06MDX	DB08121	CTPDG011186
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	3-(5-methoxy-1H-indol-3-yl)propanoic acid	"39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175"	181137	Investigative	D0E5HC	DB07723	CTPDG011187
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid	11149906	Investigative	D0H4US	DB07842	CTPDG011188
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid	11460087	Investigative	D0J3UU	DB08760	CTPDG011189
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW7845	GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)	9870584	Investigative	D0O2US	.	CTPDG011190
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid"	"13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH"	6443013	Investigative	D0Z5TV	DB06926	CTPDG011191
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	9-hydroxyoctadecadienoic acid	"(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic"	5312830	Investigative	D0SZ4T	DB07302	CTPDG011193
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	2-chloro-5-nitro-N-phenylbenzamide	"GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	Investigative	D00ACX	DB07863	CTPDG011195
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Bardoxolone methyl	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4	400769	Phase 3	D0JU5X	DB05983	CTPDG015155
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	Terminated	D0LB4T	.	CTPDG007286
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-9-nitrooctadec-9-enoic acid	9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid	11645581	Investigative	D01RPM	.	CTPDG015156
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	tagitinin A	59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01	181254	Investigative	D01UVA	.	CTPDG015157
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	T0070907	"2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21"	2777391	Investigative	D03BPG	.	CTPDG015158
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW1929	GW 1929; GW-1929	6518171	Investigative	D04DYM	.	CTPDG015159
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-9-Nitrohexadec-9-enoicAcid	CHEMBL560513; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047	44220886	Investigative	D04FVX	.	CTPDG015160
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-10-nitrooctadec-9-enoic acid	"10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N"	24836820	Investigative	D06IHG	DB15026	CTPDG015161
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	SB-213068	CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)	9843045	Investigative	D06NHI	.	CTPDG015162
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	tirotundin	56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657	9975297	Investigative	D06OBX	.	CTPDG015163
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-aspartic acid	H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632	7019108	Investigative	D06UVY	.	CTPDG015164
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	BRL-48482	"SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione"	9822139	Investigative	D07IHY	.	CTPDG015165
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	nTzDpa	"118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3"	9954280	Investigative	D08QKF	.	CTPDG015166
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	COOH	LS-191838	10025649	Investigative	D0A1SP	.	CTPDG015167
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105990	.	.	Investigative	D0B2UF	.	CTPDG015168
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 106008	.	.	Investigative	D0B9MZ	.	CTPDG015169
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE A	"CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762579	Investigative	D0D0FQ	.	CTPDG015170
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105987	.	.	Investigative	D0G3IV	.	CTPDG015171
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-glutamine	CHEMBL476173; SCHEMBL5970454	25187914	Investigative	D0G9AI	.	CTPDG015172
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	PAT5A	GTPL2709	18980163	Investigative	D0HI6O	.	CTPDG015173
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GNF-PF-2893	MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea	2815701	Investigative	D0I2DF	.	CTPDG015174
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-asparagine	CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid	7020170	Investigative	D0IW8V	.	CTPDG015175
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-2-aminoadipic acid	CHEMBL515773	25185696	Investigative	D0J9ZA	.	CTPDG015176
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-764406	L 764406; L764406	9818466	Investigative	D0L4PT	.	CTPDG015177
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-arginine	"CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH  inverted exclamation mark currency 2 HCl"	25186251	Investigative	D0M7AT	.	CTPDG015178
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105989	.	.	Investigative	D0NW8N	.	CTPDG015179
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	[125I]SB-236636	"GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid"	73755028	Investigative	D0P1US	.	CTPDG015180
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	BADGE	"SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane"	2286	Investigative	D0Q4EU	DB14083	CTPDG015181
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-5-Nitrooctadec-5-enoic Acid	CHEMBL561776; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050	44220888	Investigative	D0Q4UD	.	CTPDG015182
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE C	"CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24180661	Investigative	D0R9VV	.	CTPDG015183
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE B	"CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762580	Investigative	D0RL8P	.	CTPDG015184
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW0072	GW 0072	449532	Investigative	D0SO9Q	.	CTPDG015185
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	[3H]GW2331	"GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid"	10624977	Investigative	D0T8JM	.	CTPDG015186
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE D	CHEMBL400132; BDBM50228361	24762578	Investigative	D0U5HX	.	CTPDG015187
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-10-Nitrohexadec-9-enoic Acid	CHEMBL564368; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N	44220887	Investigative	D0W9WU	.	CTPDG015188
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-leucine	"H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid"	6997510	Investigative	D0X3RZ	.	CTPDG015189
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	PD-068235	CHEMBL455856; BDBM50266362; PD-068253	44581800	Investigative	D0X9UJ	.	CTPDG015190
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	Ploglitazone	.	12944192	Investigative	D0Z2CY	.	CTPDG015191
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-6-Nitrooctadec-5-enoic Acid	CHEMBL569372	44220889	Investigative	D0Z4NW	.	CTPDG015192
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GNF-PF-3037	SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide	1160447	Investigative	D0P8XE	.	CTPDG015193
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	2-chloro-5-nitro-N-phenylbenzamide	"GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	Investigative	D00ACX	DB07863	CTPDG011195
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-783483	F3MethylAA	9935197	Investigative	D08QXD	.	CTPDG015062
M6ACROT03237	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	LG100754	LG 100754; LG754	6442223	Investigative	D0Q9FZ	.	CTPDG012495
M6ACROT03237	Activated leukocyte cell adhesion molecule (ALCAM)	CD166_HUMAN	.	.	Phase 2	CX2009	.	.	Phase 2	D1PC9J	.	CTPDG001842
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03238	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03239	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT03239	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03239	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03240	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT03240	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03240	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03242	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03242	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03243	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03243	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03243	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03243	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03244	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03246	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT03246	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03247	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03247	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03247	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03247	Histone-lysine N-methyltransferase EZH1 (EZH1)	EZH1_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03248	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03249	Leucine rich repeat containing G protein-coupled receptor 5 (LGR5)	LGR5_HUMAN	.	.	Phase 1	BNC-101	.	.	Phase 1	DD6AZ5	.	CTPDG003946
M6ACROT03249	Leucine rich repeat containing G protein-coupled receptor 5 (LGR5)	LGR5_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT03249	Leucine rich repeat containing G protein-coupled receptor 5 (LGR5)	LGR5_HUMAN	.	.	Preclinical	BNC-102	.	.	Preclinical	D2ZI3H	.	CTPDG007014
M6ACROT03249	Leucine rich repeat containing G protein-coupled receptor 5 (LGR5)	LGR5_HUMAN	.	.	Investigative	KM-4056	"Anti-LGR5 monoclonal antibody (cancer), Kyowa Hakko Kirin"	.	Investigative	D0X1YZ	.	CTPDG007734
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03253	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03254	Histone deacetylase 5 (HDAC5)	HDAC5_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT03255	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 4"	PMID25468267-Compound-37	66667765	Patented	D02FWO	.	CTPDG014973
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 1"	PMID25468267-Compound-34	56589666	Patented	D04KUD	.	CTPDG014974
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-56	.	90093146	Patented	D07CYB	.	CTPDG014975
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 5"	PMID25468267-Compound-38	56589667	Patented	D0BK5N	.	CTPDG014976
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-47	.	53392493	Patented	D0L5RA	.	CTPDG014977
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 7"	PMID25468267-Compound-40	56643890	Patented	D0Q5IR	.	CTPDG014978
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 3"	PMID25468267-Compound-36	66666946	Patented	D0RP4W	.	CTPDG014979
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Flavonoid derivative 6	PMID25468267-Compound-1	.	Patented	D0S8AZ	.	CTPDG014980
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-55	.	.	Patented	D0U3KT	.	CTPDG014981
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 2"	PMID25468267-Compound-35	.	Patented	D0UQ2R	.	CTPDG014982
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 6"	PMID25468267-Compound-39	66667268	Patented	D0Z2YB	.	CTPDG014983
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03256	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 4"	PMID25468267-Compound-37	66667765	Patented	D02FWO	.	CTPDG014973
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 1"	PMID25468267-Compound-34	56589666	Patented	D04KUD	.	CTPDG014974
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-56	.	90093146	Patented	D07CYB	.	CTPDG014975
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 5"	PMID25468267-Compound-38	56589667	Patented	D0BK5N	.	CTPDG014976
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-47	.	53392493	Patented	D0L5RA	.	CTPDG014977
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 7"	PMID25468267-Compound-40	56643890	Patented	D0Q5IR	.	CTPDG014978
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 3"	PMID25468267-Compound-36	66666946	Patented	D0RP4W	.	CTPDG014979
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Flavonoid derivative 6	PMID25468267-Compound-1	.	Patented	D0S8AZ	.	CTPDG014980
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-55	.	.	Patented	D0U3KT	.	CTPDG014981
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 2"	PMID25468267-Compound-35	.	Patented	D0UQ2R	.	CTPDG014982
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 6"	PMID25468267-Compound-39	66667268	Patented	D0Z2YB	.	CTPDG014983
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03257	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 4"	PMID25468267-Compound-37	66667765	Patented	D02FWO	.	CTPDG014973
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 1"	PMID25468267-Compound-34	56589666	Patented	D04KUD	.	CTPDG014974
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-56	.	90093146	Patented	D07CYB	.	CTPDG014975
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 5"	PMID25468267-Compound-38	56589667	Patented	D0BK5N	.	CTPDG014976
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-47	.	53392493	Patented	D0L5RA	.	CTPDG014977
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 7"	PMID25468267-Compound-40	56643890	Patented	D0Q5IR	.	CTPDG014978
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 3"	PMID25468267-Compound-36	66666946	Patented	D0RP4W	.	CTPDG014979
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Flavonoid derivative 6	PMID25468267-Compound-1	.	Patented	D0S8AZ	.	CTPDG014980
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-55	.	.	Patented	D0U3KT	.	CTPDG014981
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 2"	PMID25468267-Compound-35	.	Patented	D0UQ2R	.	CTPDG014982
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 6"	PMID25468267-Compound-39	66667268	Patented	D0Z2YB	.	CTPDG014983
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03258	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 4"	PMID25468267-Compound-37	66667765	Patented	D02FWO	.	CTPDG014973
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 1"	PMID25468267-Compound-34	56589666	Patented	D04KUD	.	CTPDG014974
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-56	.	90093146	Patented	D07CYB	.	CTPDG014975
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 5"	PMID25468267-Compound-38	56589667	Patented	D0BK5N	.	CTPDG014976
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-47	.	53392493	Patented	D0L5RA	.	CTPDG014977
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 7"	PMID25468267-Compound-40	56643890	Patented	D0Q5IR	.	CTPDG014978
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 3"	PMID25468267-Compound-36	66666946	Patented	D0RP4W	.	CTPDG014979
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Flavonoid derivative 6	PMID25468267-Compound-1	.	Patented	D0S8AZ	.	CTPDG014980
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-55	.	.	Patented	D0U3KT	.	CTPDG014981
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 2"	PMID25468267-Compound-35	.	Patented	D0UQ2R	.	CTPDG014982
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	"Pyrido[1,2-a]indole-1.-carboxylic acid analog 6"	PMID25468267-Compound-39	66667268	Patented	D0Z2YB	.	CTPDG014983
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	Hydroxamate analog 1	PMID25468267-Compound-31	.	Patented	D0MJ4L	.	CTPDG014970
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Patented	PMID25468267-Compound-46	.	53392492	Patented	D09NCT	.	CTPDG014971
M6ACROT03259	Lysine-specific demethylase 4C (KDM4C)	KDM4C_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT03276	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03276	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03277	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03277	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Approved	Emapalumab	Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X	.	Approved	D0UI7K	.	CTPDG011332
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 3	Fumaric acid	"Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)"	444972	Phase 3	D03GOO	DB01677	CTPDG001446
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1/2	VIR-201	.	.	Phase 1/2	D0I5QV	.	CTPDG011333
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1	AMG 811	.	.	Phase 1	D06FLP	.	CTPDG011334
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1	CIGB-128	"HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB"	.	Phase 1	D06NDP	.	CTPDG011335
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	TAK-603	.	153980	Discontinued in Phase 2	D0H6PX	.	CTPDG011336
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	TG-1042	"TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene"	.	Discontinued in Phase 2	D0Z9MR	.	CTPDG006396
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	CRx-191	.	.	Discontinued in Phase 2	D0VA2I	.	CTPDG006416
M6ACROT03278	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Preclinical	VPM-4-001	"Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management"	.	Preclinical	D0WD6K	.	CTPDG011337
M6ACROT03278	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03278	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03279	C-X-C motif chemokine 9 (Cxcl9)	CXCL9_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT03279	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03279	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	BMS-936557	"Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex"	.	Phase 2	D00YWL	.	CTPDG014460
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	NI-0801	"Anti-interferon inducible protein 10, NovImmune"	.	Phase 2	D03VNB	.	CTPDG014461
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	MDX-1100	.	.	Phase 2	D0C1UF	.	CTPDG002495
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	Anti-IP10	.	.	Phase 2	D0L7LH	.	CTPDG002232
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	JT02	.	.	Phase 2	D0VE3U	.	CTPDG014462
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT03280	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Investigative	N-Methylleucine	"N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191"	6951123	Investigative	D0F6OK	DB04487	CTPDG014463
M6ACROT03280	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03280	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03281	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptide analog 8	PMID26394986-Compound-2	.	Patented	D0JF5K	.	CTPDG014924
M6ACROT03281	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03281	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03281	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03281	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03281	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Discontinued in Phase 2	AVT-02 UE	.	.	Discontinued in Phase 2	D03WRN	.	CTPDG014925
M6ACROT03281	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03281	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03282	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03282	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03283	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03283	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03284	Krueppel-like factor 4 (KLF4)	KLF4_HUMAN	.	.	Phase 1	APTO-253	.	11960271	Phase 1	D07TRP	.	CTPDG005083
M6ACROT03284	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03284	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03285	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03285	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03286	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03286	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03287	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03287	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03288	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03288	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03289	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03289	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03290	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptide analog 8	PMID26394986-Compound-2	.	Patented	D0JF5K	.	CTPDG014924
M6ACROT03290	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03290	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03290	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03290	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03290	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Discontinued in Phase 2	AVT-02 UE	.	.	Discontinued in Phase 2	D03WRN	.	CTPDG014925
M6ACROT03290	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03290	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03291	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03291	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03292	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03292	Lysine-specific demethylase 5C (KDM5C)	KDM5C_HUMAN	.	.	Investigative	IOX2	compound 6	54685215	Investigative	D0WA3E	.	CTPDG015387
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03293	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03294	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03295	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03296	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03297	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Phase 3	O6-Benzylguanine alkylade	KRX-0402; O6-Benzylguanine (BG)	.	Phase 3	D0S0HA	.	CTPDG013434
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	"6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine"	"101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine"	181029	Investigative	D04RNU	.	CTPDG013435
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	"6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine"	"CHEMBL121479; 127116-64-7; 2,4-Pyrimidinediamine, 5-nitro-6-(phenylmethoxy)-; ACMC-20msby; SCHEMBL3309544; CTK0F6457; DTXSID40431990; VLVHHGNPHBVEIG-UHFFFAOYSA-N; BDBM50062813; AKOS030620964; 6-Benzyloxy-5-nitropyrimidine-2,4-diamine; 2,4-Diamino-6-benzyloxy-5-nitropyrimidine"	9860003	Investigative	D07BTU	.	CTPDG013436
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	6-Benzyloxy-9H-purin-2-ylamine	"6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine"	4578	Investigative	D0B5BG	DB11919	CTPDG013437
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	Benzylcysteine	"S-Benzyl-L-cysteine; H-Cys(Bzl)-OH; Poly-S-benzylcysteine; (R)-S-Benzylcysteine; (R)-2-amino-3-(benzylthio)propanoic acid; (S)-Benzyl-L-Cys; cysteine, s-(phenylmethyl)-; CHEMBL63130; UNII-9VRE13M548; GHBAYRBVXCRIHT-VIFPVBQESA-N; 9VRE13M548; MFCD00002613; NSC 523123; 25988-62-9; (2R)-2-amino-3-benzylsulfanyl-propanoic acid; B-1025; J-300089; D-S-butylcysteine; BCS; (2R)-2-amino-3-(phenylmethylthio)propanoic acid"	193613	Investigative	D0S0JL	DB04531	CTPDG013438
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	6-Allyloxy-9H-purin-2-ylamine	"CHEMBL325053; 50663-54-2; O6-Allylguanine; O6-Substituted Guanine Deriv. 15; 6-prop-2-enoxy-7H-purin-2-amine; NU 2028; AC1L45IB; SCHEMBL1263549; BDBM5475; 6-(prop-2-en-1-yloxy)-9H-purin-2-amine; 9H-Purin-2-amine, 6-(2-propen-1-yloxy)-"	179571	Investigative	D0Z8EI	.	CTPDG013439
M6ACROT03297	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	S-Methylcysteine	"7728-98-5; H-DL-Cys(Me)-OH; H-D-HoCys-OH; S-Methyl-DL-cysteine; USAF CB-24; Methylcysteine; 2-amino-3-(methylsulfanyl)propanoic acid; 19651-44-6; 1-carboxy-2-methylthioethylamine; Methylcysteine, L-; ALANINE, 3-(METHYLTHIO)-, L-; EINECS 231-787-0; Methylcysteine #; S-Methyl cysteine; DL-S-Methylcysteine; DL-S-Methyl-Cys-OH; DL-Cysteine, S-methyl-; AC1Q5S9H; AC1L5E8F; SCHEMBL110459; ACMC-209a03; IDIDJDIHTAOVLG-UHFFFAOYSA-; CTK0E0884; IDIDJDIHTAOVLG-UHFFFAOYSA-N; MolPort-003-876-437; NSC15387; NSC-15387; AKOS022154885"	24417	Investigative	D0CU4Q	DB02216	CTPDG013440
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03298	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03299	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03300	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03301	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Phase 3	O6-Benzylguanine alkylade	KRX-0402; O6-Benzylguanine (BG)	.	Phase 3	D0S0HA	.	CTPDG013434
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	"6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine"	"101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine"	181029	Investigative	D04RNU	.	CTPDG013435
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	"6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine"	"CHEMBL121479; 127116-64-7; 2,4-Pyrimidinediamine, 5-nitro-6-(phenylmethoxy)-; ACMC-20msby; SCHEMBL3309544; CTK0F6457; DTXSID40431990; VLVHHGNPHBVEIG-UHFFFAOYSA-N; BDBM50062813; AKOS030620964; 6-Benzyloxy-5-nitropyrimidine-2,4-diamine; 2,4-Diamino-6-benzyloxy-5-nitropyrimidine"	9860003	Investigative	D07BTU	.	CTPDG013436
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	6-Benzyloxy-9H-purin-2-ylamine	"6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine"	4578	Investigative	D0B5BG	DB11919	CTPDG013437
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	Benzylcysteine	"S-Benzyl-L-cysteine; H-Cys(Bzl)-OH; Poly-S-benzylcysteine; (R)-S-Benzylcysteine; (R)-2-amino-3-(benzylthio)propanoic acid; (S)-Benzyl-L-Cys; cysteine, s-(phenylmethyl)-; CHEMBL63130; UNII-9VRE13M548; GHBAYRBVXCRIHT-VIFPVBQESA-N; 9VRE13M548; MFCD00002613; NSC 523123; 25988-62-9; (2R)-2-amino-3-benzylsulfanyl-propanoic acid; B-1025; J-300089; D-S-butylcysteine; BCS; (2R)-2-amino-3-(phenylmethylthio)propanoic acid"	193613	Investigative	D0S0JL	DB04531	CTPDG013438
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	6-Allyloxy-9H-purin-2-ylamine	"CHEMBL325053; 50663-54-2; O6-Allylguanine; O6-Substituted Guanine Deriv. 15; 6-prop-2-enoxy-7H-purin-2-amine; NU 2028; AC1L45IB; SCHEMBL1263549; BDBM5475; 6-(prop-2-en-1-yloxy)-9H-purin-2-amine; 9H-Purin-2-amine, 6-(2-propen-1-yloxy)-"	179571	Investigative	D0Z8EI	.	CTPDG013439
M6ACROT03301	Methylated-DNA--protein-cysteine methyltransferase (MGMT)	MGMT_HUMAN	.	.	Investigative	S-Methylcysteine	"7728-98-5; H-DL-Cys(Me)-OH; H-D-HoCys-OH; S-Methyl-DL-cysteine; USAF CB-24; Methylcysteine; 2-amino-3-(methylsulfanyl)propanoic acid; 19651-44-6; 1-carboxy-2-methylthioethylamine; Methylcysteine, L-; ALANINE, 3-(METHYLTHIO)-, L-; EINECS 231-787-0; Methylcysteine #; S-Methyl cysteine; DL-S-Methylcysteine; DL-S-Methyl-Cys-OH; DL-Cysteine, S-methyl-; AC1Q5S9H; AC1L5E8F; SCHEMBL110459; ACMC-209a03; IDIDJDIHTAOVLG-UHFFFAOYSA-; CTK0E0884; IDIDJDIHTAOVLG-UHFFFAOYSA-N; MolPort-003-876-437; NSC15387; NSC-15387; AKOS022154885"	24417	Investigative	D0CU4Q	DB02216	CTPDG013440
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03302	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03303	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Approved	Tapinarof	GSK-2894512	6439522	Approved	D03DMB	DB06083	CTPDG012890
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Approved	Romiplostim	.	5329098	Approved	D01PZD	DB06436	CTPDG009981
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Phase 2	RVT-505	.	.	Phase 2	D0AF5P	.	CTPDG002527
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Phase 1	IK-175	.	.	Phase 1	D5D6ZM	.	CTPDG012891
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Phase 1	BAY 2416964	"2242464-44-2; BAY2416964; SCHEMBL20471217; BCP33103; EX-A4271; MFCD32693912; NSC825713; s8995; NSC-825713; BAY-2416964; HY-135829; CS-0114330; BAY-2416964;BAY2416964; ClC1=CC=C(C=C1)C=1C=C(C(N(N=1)C=1C=NN(C=1)C)=O)C(=O)N[C@H](CO)C; (S)-6-(4-Chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide"	135303769	Phase 1	DMVR61	.	CTPDG003814
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Clinical trial	AT-177	.	.	Clinical trial	DNEH27	.	CTPDG005479
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Preclinical	CB7993113	.	.	Preclinical	D49AGF	.	CTPDG007010
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Preclinical	"2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester"	.	.	Preclinical	DQ3NC4	.	CTPDG012892
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Investigative	"6-Formylindolo[3,2-b]carbazole"	"Indolo[3,2-b]carbazole-6-carbaldehyde; 1555757-10-2; indolo[3,2-b]carbazole-12-carbaldehyde; SCHEMBL528518; ANW-57186; MFCD23140892; ZINC39957465; AKOS015837457; AKOS025396684; FT-0678209"	22245026	Investigative	DFBJ28	.	CTPDG012893
M6ACROT03304	Aryl hydrocarbon receptor (AHR)	AHR_HUMAN	.	.	Investigative	CH-223191	"301326-22-7; CH 223191; CH223191; UNII-HYE7315Z4C; HYE7315Z4C; CHEMBL1743245; AhR Antagonist; 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide; 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide; 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide; (E)-1-methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide; 1-methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide; 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide; CBDivE_007629; SCHEMBL363547; DTXSID5058698; AOB1977; EX-A771; SYN5007; CHEBI:125508; HMS3412G22; HMS3676G22; HMS3750E07; BCP12814; ZINC4762981; BDBM50525572; MFCD00377884; s7711; SBB081907; STK837883; 2-Methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azophenyl)-amide; AKOS000629906; AKOS026750492; ZINC100550218; ZINC254429865; CCG-267843; CS-3905; MCULE-3225752823; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-((2-methylphenyl)azo)phenyl)-; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-(2-(2-methylphenyl)diazenyl)phenyl)-; AC-32878; AS-16374; HY-12684; QC-11824; FT-0696668; X3558; J-017795; BRD-K22314899-001-01-6; Q27216129; Q27280162; 1-methyl-N-{2-methyl-4-[2-(2-methylphenyl)diazen-1-yl]phenyl}-1H-pyrazole-5-carboxamide; N-{2-methyl-4-[(2-methylphenyl)diazenyl]phenyl}(1-methylpyrazol-5-yl)carboxami de"	3091786	Investigative	DL36FJ	.	CTPDG007596
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03304	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03305	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03307	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Approved	Pexidartinib	PLX-3397	25151352	Approved	D09TAB	DB12978	CTPDG013033
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 3	Sulfatinib	"Anticancer agents, Hutchison; HMPL-012; Kinase inhibitors (cancer), Hutchison; VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison"	52920501	Phase 3	D05PWX	DB15106	CTPDG010073
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 2	AMB-05X	.	.	Phase 2	DWD3V2	.	CTPDG013034
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 2	ARRY-382	.	.	Phase 2	D05JAA	.	CTPDG002803
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 2	BLZ-945	"CSF-1R inhibitor (bone cancer); CSF-1R inhibitor (bone cancer), Novartis"	46184986	Phase 2	D08NDE	.	CTPDG012312
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 2	Cabiralizumab	.	.	Phase 2	D0YO4B	.	CTPDG001873
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1/2	DCC-3014	"Vimseltinib; UNII-PX9FTM69BF; PX9FTM69BF; DCC3014; 1628606-05-2; 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one; 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one; Vimseltinib [INN]; SCHEMBL16047448; GTPL11190; EX-A4700; NSC828316; NSC-828316; example 10 [WO2014145025A2]; HY-136256; CS-0121044; 3-Methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3H)-pyrimidinone; 4(3H)-Pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-"	86267612	Phase 1/2	D9RH0V	.	CTPDG003212
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1/2	FPA-008	.	.	Phase 1/2	D08ZQI	.	CTPDG013035
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	SNDX-6352	.	.	Phase 1	D04CTD	.	CTPDG005268
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	DCC-3014	.	.	Phase 1	D0M5XJ	.	CTPDG004601
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	Axatilamab	SNDX-6352	.	Phase 1	D3ZN5U	.	CTPDG004126
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	ABSK021	.	.	Phase 1	D6FTN1	.	CTPDG004065
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	EI1071	.	.	Phase 1	DYK5U6	.	CTPDG003654
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	PLX7486	.	.	Phase 1	D07PSL	.	CTPDG005089
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Patented	PMID28270010-Compound-Figure24-a	.	11617559	Patented	D0X9VS	.	CTPDG013036
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Patented	Pyridine derivative 20	PMID27646564-Compound-5-2	.	Patented	D0NB1V	.	CTPDG009983
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Patented	Pyridine derivative 21	PMID27646564-Compound-5-3	.	Patented	D0O0AW	.	CTPDG009984
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Patented	Pyridine derivative 22	PMID27646564-Compound-5-4	.	Patented	D0O4TA	.	CTPDG009985
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Patented	Pyridine derivative 19	PMID27646564-Compound-5-1	.	Patented	D0T7BE	.	CTPDG009986
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Patented	Pyridine derivative 18	PMID27646564-Compound-5	.	Patented	D0AK1F	.	CTPDG009987
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Investigative	GW-2580	GW2580; cFMS receptor tyrosine kinase inhibitor; GW632580X	11617559	Investigative	D0D6MH	.	CTPDG015238
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Investigative	Ki-20227	Ki 20227; Ki20227	9869779	Investigative	D08BJR	.	CTPDG010142
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Investigative	GTP-14564	"GTP 14564; 34823-86-4; 3-Phenyl-1H-benzofuro[3,2-c]pyrazole; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden; CHEMBL406375; 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole; 3-Phenyl-1H-benzofuro(3,2-c)pyrazole; AC1MPHAI; SCHEMBL2550165; GTPL5982; CHEBI:92300; DTXSID10188363; MolPort-002-816-012; HMS3268J15; HMS3229E17; ZINC5387628; HSCI1_000176; BDBM50375646; AKOS024456938; MCULE-3563628731; CCG-206757; NCGC00159539-01; AI-204/33265070; J-019773; BRD-K16664969-001-02-5; BRD-K16664969-001-01-7"	3385203	Investigative	D0UN9O	.	CTPDG010706
M6ACROT03308	Macrophage colony-stimulating factor 1 receptor (CSF1R)	CSF1R_HUMAN	.	.	Investigative	JNJ-28312141	JNJ 28312141	11676971	Investigative	D0Y4BL	.	CTPDG015239
M6ACROT03308	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03309	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT03310	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT03312	Tenascin (TNC)	TENA_HUMAN	.	.	Phase 2	F-16-IL-2 fusion protein	"Teleukin; F-16-IL-2; F-16-IL-2 fusion protein (cancer); F-16-IL-2 fusion protein (cancer), Philogen"	.	Phase 2	D0F1ZI	.	CTPDG002405
M6ACROT03312	Tenascin (TNC)	TENA_HUMAN	.	.	Phase 1/2	F-16-131I	"Tenarad; Radiolabeled scFv antibody F-16 (solid tumor/hematological malignancy), Philogen"	.	Phase 1/2	D0G1IG	.	CTPDG014673
M6ACROT03312	Tenascin (TNC)	TENA_HUMAN	.	.	Phase 1	8H9	.	.	Phase 1	D06JAL	.	CTPDG005160
M6ACROT03312	Tenascin (TNC)	TENA_HUMAN	.	.	Terminated	131I-81C6	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6	.	Terminated	D07ZKK	.	CTPDG007446
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Approved	Cromoglicate	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)	2882	Approved	D06NSS	DB01003	CTPDG000598
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Approved	Amlexanox	"ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid"	2161	Approved	D0G5UB	DB01025	CTPDG010618
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 2	NVP-AUY922	"Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide"	135539077	Phase 2	D05BYA	.	CTPDG002817
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 2	BIIB-021	"CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma"	16736529	Phase 2	D05HWN	DB12359	CTPDG010619
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 2	KW-2478	"819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide"	23116322	Phase 2	D08PYO	.	CTPDG002619
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 2	VER 50589	.	135446210	Phase 2	D09XGB	DB06964	CTPDG010620
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Discontinued in Phase 3	Tanespimycin	"CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374"	6505803	Discontinued in Phase 3	D0SC2J	DB05134	CTPDG002037
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 2	Efungumab	"Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec"	.	Phase 2	D0Y9PZ	.	CTPDG010622
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1/2	SNX-5422	"908115-27-5; PF-04929113; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah"	44195571	Phase 1/2	D07MPL	DB06070	CTPDG010623
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	PU3	"9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE; 352519-21-2; CHEMBL113690; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine; 1uym; 1uy6; Purine-Based Inhibitor 1; AC1L9MK5; PU-3; SCHEMBL2604975; BDBM15374; CTK1B7081; DTXSID40332291; ZINC3832013; AKOS030562182; DB02754; KB-275186; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-"	448965	Phase 1	D02PGP	DB02754	CTPDG005348
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	Debio 0932	.	44156921	Phase 1	D02TTL	.	CTPDG005341
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	Phase 1	D03LRU	.	CTPDG005304
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	AT13387	AT-13387	11955716	Phase 1	D06YSP	DB06306	CTPDG005131
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	BIIB 028	.	.	Phase 1	D0H3VK	.	CTPDG004752
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	RTA-901	.	.	Phase 1	D0ME2T	.	CTPDG010624
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Phase 1	PU-AD	.	.	Phase 1	D0V9MT	.	CTPDG004337
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Discontinued in Phase 3	HBP-347	"HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University"	.	Discontinued in Phase 3	D03IKZ	.	CTPDG010625
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Discontinued in Phase 2	Geldanamycin	"GDM; GMY; Geldanamicin; Geldanomycin; Geldaramycin; Antibiotic U 29135; BODIPY-labeled Geldanamycin; Geldanamycin (9CI); Geldanamycin, Streptomyces hygroscopicus; U-29135; Antibiotic (U-29,135); [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv."	5288382	Discontinued in Phase 2	D03PKI	DB02424	CTPDG010626
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Discontinued in Phase 1	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	Discontinued in Phase 1	D0BM6S	DB13023	CTPDG006829
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Preclinical	CCT-018159	"CCT 018159; CCT018159; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol"	984170	Preclinical	D00OCB	DB07594	CTPDG007155
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Preclinical	KOS-2484	"KOS-2539; KOS-2540; HSP90 inhibitors (cancer), Kosan"	.	Preclinical	D0X5YU	.	CTPDG007028
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Terminated	EC-154	"Heat shock protein 90 inhibitors (cancer), Biogen Idec; Hsp 90inhibitors (cancer), Biogen Idec"	.	Terminated	D0KC7K	.	CTPDG007300
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-"	"CHEMBL326564; PU6; 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-9H-purin-6-amine; 1uy9; Purine-Based Inhibitor 4; AC1L9MK7; BDBM15377; DB08436; 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(2H-1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(1,3-Benzodioxole-5-ylmethyl)-9-butyl-9H-purine-6-amine"	448968	Investigative	D00PMS	DB08436	CTPDG010627
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine	CHEMBL109612; AC1NRCWL; 1uy8; Purine-Based Inhibitor 3; SCHEMBL1966787; BDBM15376; BWLWUGBHOXIUBP-UHFFFAOYSA-N; DB03809; 8-(3-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine; 9-Butyl-8-(3-methoxy-benzyl)-9H-purin-6-ylamine	5289228	Investigative	D01GGU	DB03809	CTPDG010628
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	KOSN1559	.	.	Investigative	D02IIL	.	CTPDG009027
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	ZEARALANONE	"Zanone; 5975-78-0; (S)-Zearalanone; UNII-133DU2F2VS; CCRIS 9235; MLS000069626; P 1502; SMR000058193; CHEMBL491499; 133DU2F2VS; CHEBI:35051; beta-Resorcylic acid, 6-(10-hydroxy-6-oxoundecyl)-, mu-lactone; (S)-3,4,5,6,9,10,11,12-Octahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10,11,12-octahydro-14,16-dihydroxy-3-methyl-, (S)-; 2,4-DIHYDROXY-6-[10-HYDROXY-6-OXO-UNDECYL]BENZOIC ACID MICRO-LACTONE"	108003	Investigative	D05GKC	.	CTPDG010629
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	17-desmethoxy-17-aminogeldanamycin	"UNII-SLQ1AJG3VB; SLQ1AJG3VB; 17-Aminogeldanamycin; 17-Amino-17-demethoxygeldanamycin; Geldanamycin, 17-amino-17-demethoxy-; 17-Amino Geldanamycin; SCHEMBL8250568; SCHEMBL16226317; XYFFWTYOFPSZRM-TWNAANEASA-N; DB13023; 1174669-94-3"	91929099	Investigative	D05RTH	.	CTPDG010630
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine	"CHEMBL112834; 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine; 376629-53-7; PU4; AC1NRCWI; 1uy7; Purine-Based Inhibitor 2; SCHEMBL4320278; CTK1A9432; BDBM15375; DTXSID80415355; AKOS030562187; DB03899; 8-(4-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(4-methoxyphenyl)methyl]-"	5289227	Investigative	D05UTX	DB03899	CTPDG010631
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	GNF-PF-67	"Toxoflavin; Toxoflavine; Xanthothricin; Xanthotricin; 84-82-2; Xanthothricin (VAN); UNII-5N5YI4IP1P; NSC 67078; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,6-Dimethylpyrimido(5,4-e)-as-triazine-5,7(1H,6H)-dione; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; BRN 0021014; 5N5YI4IP1P; MLS000087831; CHEBI:80729; NSC67078; 1,6-Dimethyl-5,7-dioxo-1,5,6,7-tetrahydropyrimido(5,4-E)-as-triazine-5,7(1H,6H)-dione; SMR000024051; Pyrimido(5,4-e)-as-triazine-5,7-(1H,6H)-dione, 1,6-dimethyl-"	66541	Investigative	D07WDQ	.	CTPDG010632
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine	"4-(2-methoxy-ethoxy)-6-methyl-pyrimidin-2-ylamine; 75435-54-0; 2wi1; AC1MWPG2; pyrimidin-2-amine, 11; CHEMBL538937; SCHEMBL10752783; BDBM33223; CCG-774; VCJHOFUOIQHNBC-UHFFFAOYSA-N; AKOS017529730; DB08786; 2-amino-4-(2-methoxyethoxy)-6-methylpyrimidine; 4-Methyl-6-(2-methoxyethoxy)pyrimidine-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidine-2-ylamine"	3777900	Investigative	D08CZD	DB08786	CTPDG010633
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE"	"6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine; 2qf6; HSP90 Inhibitor, 1; SCHEMBL10822557; BDBM81729; DB07319"	13373715	Investigative	D0D3BP	DB07319	CTPDG010634
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	PU24S	.	.	Investigative	D0D5KQ	.	CTPDG008376
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	Macbecin	.	433447	Investigative	D0H0KA	.	CTPDG008249
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	SNX-2112	"908112-43-6; SNX 2112; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide; UNII-10C9P3FFOW; PF-04928473; 10C9P3FFOW; CHEMBL560895; SNX-2112 (PF-04928473); 945626-71-1; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4-hydroxycyclohexyl)amino]benzamide"	24772860	Investigative	D0K0TJ	.	CTPDG010635
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol"	"1-(2,4,6-trihydroxybenzoyl)pyrrole; 288839-58-7; 3eko; CHEMBL513225; DB08443; 2-(1-Pyrrolylcarbonyl)benzene-1,3,5-triol; 2-(pyrrole-1-carbonyl)benzene-1,3,5-triol"	11160307	Investigative	D0K4RN	DB08443	CTPDG010636
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	RHEIN	"478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6"	10168	Investigative	D0M2TY	DB13174	CTPDG010637
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	VER-49009	.	4369536	Investigative	D0T4MS	DB07495	CTPDG010638
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	Radicicol	AC1L1JGN; CHEMBL3972342; CTK6B6269	6323491	Investigative	D0ZA6G	DB03758	CTPDG010639
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	Geldanamycin-estradiol hybrid	.	.	Investigative	D0H6OS	.	CTPDG009710
M6ACROT03315	Heat shock protein HSP 90-alpha (HSP90/HSP90AA1)	HS90A_HUMAN	.	.	Investigative	"2-Methyl-2,4-Pentanediol"	"107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN"	7870	Investigative	D06GOK	.	CTPDG010640
M6ACROT03321	Nuclear factor NF-kappa-B p105 subunit (NF-Kappa-B/NFKB1)	NFKB1_HUMAN	.	.	Phase 2	P54	.	.	Phase 2	D0V3LM	.	CTPDG001967
M6ACROT03321	Nuclear factor NF-kappa-B p105 subunit (NF-Kappa-B/NFKB1)	NFKB1_HUMAN	.	.	Phase 2	CAT 1004	.	.	Phase 2	D06TZZ	.	CTPDG002728
M6ACROT03325	Oxidized low-density lipoprotein receptor 1 (OLR1)	OLR1_HUMAN	.	.	Phase 2	MEDI6570	.	.	Phase 2	DFG87U	.	CTPDG014790
M6ACROT03325	Oxidized low-density lipoprotein receptor 1 (OLR1)	OLR1_HUMAN	.	.	Discontinued in Phase 1	RG7418	BI204	.	Discontinued in Phase 1	D0MH1R	.	CTPDG006776
M6ACROT03327	Thrombospondin 1 (THBS1)	TSP1_HUMAN	.	.	Phase 2	ABT-510	N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide	6918562	Phase 2	D0G4MB	DB05434	CTPDG002370
M6ACROT03327	Thrombospondin 1 (THBS1)	TSP1_HUMAN	.	.	Phase 2	CVX-045	"CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer"	.	Phase 2	D0S0KP	.	CTPDG002053
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03327	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03328	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03328	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03329	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03330	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03331	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT03332	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03333	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03333	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03334	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03334	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03335	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03335	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03336	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03336	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03337	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03337	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03338	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03338	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03339	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03339	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03340	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03340	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03340	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03341	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03341	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03341	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03342	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03342	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03342	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03343	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03343	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03343	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03344	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03344	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03344	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03345	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03345	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03345	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03346	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03346	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03346	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptide analog 8	PMID26394986-Compound-2	.	Patented	D0JF5K	.	CTPDG014924
M6ACROT03346	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03346	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03346	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03346	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03346	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Discontinued in Phase 2	AVT-02 UE	.	.	Discontinued in Phase 2	D03WRN	.	CTPDG014925
M6ACROT03347	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03347	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03348	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03348	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03349	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03349	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03350	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03350	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03351	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03351	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03352	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03352	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03353	Dickkopf-related protein 3 (DKK3)	DKK3_HUMAN	.	.	Phase 1/2	REIC gene therapy	.	.	Phase 1/2	D0D2XA	.	CTPDG014719
M6ACROT03353	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03353	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03354	Dickkopf-related protein 3 (DKK3)	DKK3_HUMAN	.	.	Phase 1/2	REIC gene therapy	.	.	Phase 1/2	D0D2XA	.	CTPDG014719
M6ACROT03354	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03354	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03355	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03356	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03357	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03358	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03359	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03360	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03360	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03361	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03362	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03363	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03364	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03364	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03365	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03366	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT03366	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03367	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03367	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03368	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03368	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-74	.	72946782	Patented	D0N2FN	.	CTPDG013148
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; SCHEMBL8158442	25065930	Investigative	D01AVS	.	CTPDG013340
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	Investigative	D01TSM	.	CTPDG013341
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	Investigative	D02TQA	.	CTPDG013342
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; SCHEMBL8143763	25065710	Investigative	D03TNE	.	CTPDG013343
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; SCHEMBL8144856	25065713	Investigative	D03TQD	.	CTPDG013344
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	Investigative	D05RWU	.	CTPDG013345
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	Investigative	D06IWR	.	CTPDG013346
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	Investigative	D06YYY	.	CTPDG013347
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096	46887378	Investigative	D07BMT	.	CTPDG013348
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	Investigative	D07WSB	.	CTPDG013349
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	Investigative	D08USK	.	CTPDG013350
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	Investigative	D08YLO	.	CTPDG013351
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"N8,2-dihydroxy-N1-phenyloctanediamide"	CHEMBL251009; SCHEMBL8144564	25065929	Investigative	D09SVH	.	CTPDG013352
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	Investigative	D0A4KW	.	CTPDG013353
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; SCHEMBL3292226; SCHEMBL3290139	42632368	Investigative	D0AK8Q	.	CTPDG013354
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; SCHEMBL8150833	25065931	Investigative	D0D2US	.	CTPDG013355
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; SCHEMBL8152458	25065925	Investigative	D0FI2F	.	CTPDG013356
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	Investigative	D0H4SC	.	CTPDG013357
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651	46830328	Investigative	D0I2KC	.	CTPDG013358
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; SCHEMBL7045815	22915475	Investigative	D0K3MR	.	CTPDG013359
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)benzamide	CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	Investigative	D0MD7H	.	CTPDG013360
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063	46887475	Investigative	D0Q4LX	.	CTPDG013361
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)benzamide	"2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	Investigative	D0U8FC	.	CTPDG013362
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	Investigative	D0W2PX	.	CTPDG013363
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	Investigative	D0W9BH	.	CTPDG013364
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278	46887333	Investigative	D0Y4SD	.	CTPDG013365
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03369	Histone deacetylase 2 (HDAC2)	HDAC2_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03369	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188780	.	.	Investigative	D02DUM	.	CTPDG015447
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188763	.	.	Investigative	D09NLT	.	CTPDG015448
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188761	.	.	Investigative	D09XIQ	.	CTPDG015449
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188778	.	.	Investigative	D0D6YO	.	CTPDG015450
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188782	.	.	Investigative	D0L0JX	.	CTPDG015451
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188781	.	.	Investigative	D0L0WC	.	CTPDG015452
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188759	.	.	Investigative	D0N1RP	.	CTPDG015453
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188757	.	.	Investigative	D0O3QM	.	CTPDG015454
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	ISIS 188755	.	.	Investigative	D0U0OE	.	CTPDG015455
M6ACROT03370	Forkhead box protein O1 (FOXO1)	FOXO1_HUMAN	.	.	Investigative	AS-1708727	.	.	Investigative	D0W9KE	.	CTPDG015460
M6ACROT03373	Neurogenic locus notch homolog protein 1 (NOTCH1)	NOTC1_HUMAN	.	.	Phase 1/2	LY3039478	"Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-"	71236992	Phase 1/2	D08WOW	DB12050	CTPDG003499
M6ACROT03373	Neurogenic locus notch homolog protein 1 (NOTCH1)	NOTC1_HUMAN	.	.	Phase 1	OMP-52M51	.	.	Phase 1	D0X3YY	.	CTPDG004287
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03377	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03381	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT03382	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03385	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03386	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03387	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03390	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03394	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT03395	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03398	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03399	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03400	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03403	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03403	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03404	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03404	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03405	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03405	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03406	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03407	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03408	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT03409	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03411	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	"Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene"	8189	Investigative	D0OD8N	DB02078	CTPDG010615
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	CEP-6331	"2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365"	9823787	Investigative	D07IHM	.	CTPDG010616
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	JNJ-10198409	"627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814"	9797370	Investigative	D0YZ7H	.	CTPDG010060
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	PMID15546730C2	UNII-N9PH4O199D; N9PH4O199D; GTPL8136; BDBM13268	11153014	Investigative	D08RZB	.	CTPDG010617
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	CEP-5104	"C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364"	23378546	Investigative	D09QBA	.	CTPDG010150
M6ACROT03414	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT03417	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT03418	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03418	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 1	TP-1454	.	.	Phase 1	DLN0P8	.	CTPDG003830
M6ACROT03419	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03419	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03419	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT03420	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03422	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	"Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene"	8189	Investigative	D0OD8N	DB02078	CTPDG010615
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	CEP-6331	"2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365"	9823787	Investigative	D07IHM	.	CTPDG010616
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	JNJ-10198409	"627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814"	9797370	Investigative	D0YZ7H	.	CTPDG010060
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	PMID15546730C2	UNII-N9PH4O199D; N9PH4O199D; GTPL8136; BDBM13268	11153014	Investigative	D08RZB	.	CTPDG010617
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	CEP-5104	"C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364"	23378546	Investigative	D09QBA	.	CTPDG010150
M6ACROT03425	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT03428	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT03429	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT03429	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 1	TP-1454	.	.	Phase 1	DLN0P8	.	CTPDG003830
M6ACROT03430	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03430	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03430	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03431	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03431	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03431	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03431	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03432	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03433	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03434	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03435	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03436	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03437	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03438	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03438	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03439	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03439	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03440	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03440	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03441	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03441	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03442	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03442	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03443	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03443	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03444	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03444	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Approved	Prasterone	"Dehydroepiandrosterone; DHEA; 53-43-0; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone"	5881	Approved	D0K0EK	DB01708	CTPDG000316
M6ACROT03444	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Phase 3	EPIANDROSTERONE	"481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2"	441302	Phase 3	D0O8FW	.	CTPDG010895
M6ACROT03444	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT03444	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Investigative	Hydroxyacetic Acid	"glycolic acid; 2-Hydroxyacetic acid; 79-14-1; Glycollic acid; Hydroxyethanoic acid; Acetic acid, hydroxy-; glycolate; Caswell No. 470; alpha-Hydroxyacetic acid; Kyselina glykolova; Kyselina glykolova [Czech]; Kyselina hydroxyoctova; HOCH2COOH; 2-Hydroxyethanoic acid; Kyselina hydroxyoctova [Czech]; Glycocide; EPA Pesticide Chemical Code 000101; GlyPure; HSDB 5227; NSC 166; Acetic acid, 2-hydroxy-; AI3-15362; UNII-0WT12SX38S; GlyPure 70; BRN 1209322; GLYCOLLATE; C2H4O3; Acetic acid, hydroxy-, homopolymer; EINECS 201-"	757	Investigative	D01HNP	DB03085	CTPDG010896
M6ACROT03444	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Investigative	Metazamide	"UNII-T3Y0F5VOB8; 14058-90-3; GPA-878; T3Y0F5VOB8; Metazamidum; 1-(4-methoxyphenyl)-5-methyl-2,3-dihydro-1H-imidazol-2-one; Metazamide [INN]; Metazamid; GPA 878; AC1L1B4L; 3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one; 1-(4-Methoxyphenyl)-5-methyl-4-imidazolin-2-on; ZINC472; SCHEMBL193544; CHEMBL2104723; DTXSID80161441; MolPort-027-352-367; AKOS017548002; 1-(p-Methoxyphenyl)-5-methyl-4-imidazolin-2-one; 4-Imidazolin-2-one, 1-(4-methoxyphenyl)-5-methyl-"	26433	Investigative	D0FF3D	.	CTPDG010897
M6ACROT03444	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Investigative	2'-Monophosphoadenosine 5'-Diphosphoribose	"53-59-8; Cozymase II; Codehydrogenase II; TPN (nucleotide); Codehydrase II; Nadide phosphate; NAD phosphate; EINECS 200-178-1; BRN 3885115; nicotinamide adenine dinucleotide phosphate; CHEBI:44409; beta-NADP; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; beta-TPN; TPN-ox; nadp nicotinamide-adenine-dinucleotide phosphate; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen p"	46936685	Investigative	D0J2FY	.	CTPDG009874
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03445	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Approved	Nicotinamide	"Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide"	936	Approved	D06NVJ	DB02701	CTPDG010707
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Approved	Niraparib Tosylate	1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059	78357761	Approved	D0DN0W	.	CTPDG010708
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 3	Nicaraven	AVS; Antevan; Antevas	71234	Phase 3	D0Z2UW	DB06397	CTPDG010709
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	AG140699	.	.	Phase 2	D06KZL	.	CTPDG002747
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	AZD5305	"16MZ1V3RBT; 2589531-76-8; 2-Pyridinecarboxamide, 5-(4-((7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl)-1-piperazinyl)-N-methyl-; 2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl-; 5-(4-((7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide; 5-[4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methylpicolinamide; 5-[4-[(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 5-{4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3- yl)methyl]piperazin-1-yl}-N-methylpyridine-2- carboxamide; AC-37130; Azd 5305; AZD 5305 [WHO-DD]; AZD5305; AZD-5305; AZD-5305 [WHO-DD]; CHEMBL5095220; CS-0163534; E80364; EX-A5234; example 4 [WO2021013735]; GTPL11526; HY-132167; MS-26971; NSC834196; NSC-834196; Saruparib; saruparib [INN]; SCHEMBL22912701; SY295016; UNII-16MZ1V3RBT"	155586901	Phase 2	D0YTM9	.	CTPDG010710
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 1/2	AMXI 5001	.	.	Phase 1/2	D8TE4F	.	CTPDG003215
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 1	NMS-03305293	NMS-P293	.	Phase 1	DO0LP3	.	CTPDG003794
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1"	PMID27841036-Compound-6	.	Patented	D01KFW	.	CTPDG010711
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Benzimidazole carboxamide derivative 1	PMID27841036-Compound-I	.	Patented	D01PYO	.	CTPDG010712
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	PMID27841036-Compound-33	.	56649297	Patented	D02KMI	.	CTPDG010713
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4"	PMID27841036-Compound-9	.	Patented	D02QFM	.	CTPDG010714
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine ketone derivative 1	PMID27841036-Compound-16	89608436	Patented	D05ZBB	.	CTPDG010715
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Quinazolinedione derivative 3	PMID27841036-Compound-13	59663666	Patented	D08KAH	.	CTPDG010716
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 2	PMID27841036-Compound-3	.	Patented	D08YPU	.	CTPDG010717
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3"	PMID27841036-Compound-8	.	Patented	D09HUV	.	CTPDG010718
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	7-azaindole derivative 8	PMID27841036-Compound-10	73669300	Patented	D09WUA	.	CTPDG010719
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5"	PMID27841036-Compound-IV	.	Patented	D09ZIM	.	CTPDG010720
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine ketone derivative 3	PMID27841036-Compound-18	71598692	Patented	D0AN7Z	.	CTPDG010721
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Dihydropyrido phthalazinone derivative 1	PMID27841036-Compound-21	136265073	Patented	D0B3QI	.	CTPDG010722
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine ketone derivative 2	PMID27841036-Compound-17	71571973	Patented	D0B4FV	.	CTPDG010723
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Tricyclic indole compound 13	PMID27841036-Compound-XVI	.	Patented	D0E9JI	.	CTPDG010724
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	3-phenyl isoquinolin-1(2H) derivative 2	PMID27841036-Compound-VII	.	Patented	D0G8HX	.	CTPDG010725
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 5	PMID27841036-Compound-III	.	Patented	D0GH4V	.	CTPDG010726
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Quinazolinedione derivative 2	PMID27841036-Compound-12	68388735	Patented	D0IX2C	.	CTPDG010727
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Quinazolinedione derivative 1	PMID27841036-Compound-11	66546486	Patented	D0J2SR	.	CTPDG010728
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Dihydropyrido phthalazinone derivative 2	PMID27841036-Compound-22	136334008	Patented	D0J4GY	.	CTPDG010729
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2"	PMID27841036-Compound-7	.	Patented	D0M0WS	.	CTPDG010730
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine derivative 3	PMID27841036-Compound-19	71678316	Patented	D0M9TG	.	CTPDG010731
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Tetra-hydro-quinoline derivative 1	PMID27841036-Compound-VIII	.	Patented	D0MP4W	.	CTPDG010732
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 1	PMID27841036-Compound-2	.	Patented	D0O9FC	.	CTPDG010733
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 3	PMID27841036-Compound-4	.	Patented	D0R0PO	.	CTPDG010734
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 4	PMID27841036-Compound-5	.	Patented	D0Z5DI	.	CTPDG010735
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Dihydrodiazepinocarbazolone derivative 1	PMID27841036-Compound-26	71626523	Patented	D0P3YA	.	CTPDG010736
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Tetra-cyclic pyridophthalazinone derivative 1	PMID27841036-Compound-25	.	Patented	D0Z8IR	.	CTPDG010737
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	3-phenyl isoquinolin-1(2H) derivative 1	PMID27841036-Compound-20	89588629	Patented	D0TD8R	.	CTPDG010738
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Preclinical	CPH-102	"IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma"	.	Preclinical	D04ABS	.	CTPDG007140
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Preclinical	PJ34	"344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341"	4858	Preclinical	D04WDX	DB08348	CTPDG010739
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Terminated	NU1025	.	135398517	Terminated	D0O3FX	DB02690	CTPDG010740
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Ethynylquinoline-8-carboxamide	"CHEMBL501330; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268"	25208746	Investigative	D00OZA	.	CTPDG010741
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one	.	135471356	Investigative	D00TUB	.	CTPDG010742
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	N-(4-Phenylthiazol-2-yl)isonicotinamide	"N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062"	790259	Investigative	D00WMC	.	CTPDG010743
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	5-Chloro-2-methyl-3H-quinazolin-4-one	.	135875707	Investigative	D01EVX	.	CTPDG010744
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BZ3	"5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T"	13872	Investigative	D01RXM	.	CTPDG010745
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide	"2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide"	1511	Investigative	D01YIR	DB04010	CTPDG010746
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	CEP-6800	"UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione"	9948440	Investigative	D02GPJ	.	CTPDG010747
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	ANG-2864	"PARP inhibitor (ischemia/cancer), Angion Biomedica"	.	Investigative	D02JHW	.	CTPDG009022
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Methoxybenzamide	"5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848"	98487	Investigative	D02MPP	DB03073	CTPDG010748
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-Benzyl-2H-indazole-7-carboxamide	CHEMBL1094951; SCHEMBL2268172	44549372	Investigative	D02QZF	.	CTPDG010749
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	CHEMBL201723	44407565	Investigative	D02XLC	.	CTPDG010750
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"4-amino-1,8-naphthalimide"	"1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE"	1720	Investigative	D03JTS	DB07096	CTPDG010751
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione"	CHEMBL373066; pyrroloisoindoledione	44407700	Investigative	D03VNZ	.	CTPDG010752
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline"	11736764	Investigative	D04ATU	.	CTPDG010753
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	EB-47	"EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)"	9871899	Investigative	D04AYN	.	CTPDG010754
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BZ6	.	41673734	Investigative	D04LDH	.	CTPDG010755
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-methoxyphenyl)quinoline-8-carboxamide	"CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-"	25209058	Investigative	D04TDX	.	CTPDG010756
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline"	11288114	Investigative	D04UPQ	.	CTPDG010757
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide	"CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152"	690181	Investigative	D04ZQJ	.	CTPDG010758
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	ANG-2684	"ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica"	.	Investigative	D05APM	.	CTPDG010759
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	CHEMBL380940; SCHEMBL5828673	44407566	Investigative	D05GMW	.	CTPDG010760
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2,3-dihydro-1H-benzo[de]isoquinolin-1-one"	"CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210"	10130246	Investigative	D05HJG	.	CTPDG010761
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"5-amino-3,4-dihydroisoquinolin-1(2H)-one"	"129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419"	18369509	Investigative	D05RXG	.	CTPDG010762
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	KR-33889	"KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT"	.	Investigative	D05SYO	.	CTPDG010763
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	CHEMBL194684	44403402	Investigative	D05WYN	.	CTPDG010764
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	AG-014376	"CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one"	9797108	Investigative	D05XMG	.	CTPDG010765
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Hydroxy-benzamide	"3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787"	342403	Investigative	D05ZTI	.	CTPDG010766
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methoxy-2-phenyl-3H-quinazolin-4-one	.	135439437	Investigative	D06NKJ	.	CTPDG010767
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	Quinoline-8-carboxamide	8-Quinolinecarboxamide; 55706-61-1; CCRIS 6967; CHEMBL502330; HPQRQAOVNXWEEQ-UHFFFAOYSA-N; 8-Carbamoylquinoline; 8-Quinolinecarboxamide #; AC1L44SC; SCHEMBL460456; CTK5A4047; quinoline-8-carboxylic acid amide; DTXSID00204243; MolPort-005-722-305; ZINC6095019; BDBM50255266; AKOS008969900; NE38855; MCULE-7978956907; LS-188644; KB-259682	150664	Investigative	D07AGU	.	CTPDG010768
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190932	Investigative	D07BBR	.	CTPDG010769
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135457978	Investigative	D07BPT	.	CTPDG010770
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2H-Isoquinolin-1-one	"1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273"	10284	Investigative	D07CRG	.	CTPDG010771
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	KU-58684	SCHEMBL863338; 623578-11-0	11725479	Investigative	D07QPV	.	CTPDG010772
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2,8-Dimethyl-3H-quinazolin-4-one"	.	135463574	Investigative	D07SRJ	.	CTPDG010773
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	5-aminoisoquinolin-1(2H)-one	"93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197"	2072	Investigative	D07WPL	.	CTPDG010774
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	INO-1002	"PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek"	.	Investigative	D08AOV	.	CTPDG008641
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-(4-aminophenyl)quinoxaline-5-carboxamide	"CHEMBL443077; quinoxaline analogue, 3f; SCHEMBL7112515"	25218519	Investigative	D08GMO	.	CTPDG010775
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide"	"2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424"	49799912	Investigative	D08OUR	.	CTPDG010776
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	4-benzylphthalazin-1(2H)-one	"4-Benzyl-1(2H)-phthalazinone; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #"	616651	Investigative	D08QWR	.	CTPDG010777
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Methylquinoline-8-carboxamide	"CHEMBL504998; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267"	25208598	Investigative	D08XPZ	.	CTPDG010778
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	"3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2"	657038	Investigative	D08ZVM	DB03509	CTPDG010779
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135407310	Investigative	D0B2WX	.	CTPDG010780
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	HYDAMTIQ	"PARP-1 inhibitor (brain ischemia), University of Perugia"	.	Investigative	D0CA2S	.	CTPDG010781
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190929	Investigative	D0E0QT	.	CTPDG010782
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	PD-128763	"5-Methyl-3,4-dihydroisoquinolin-1(2H)-one; 129075-56-5; 3,4-Dihydro-5-methyl-1(2H)-isoquinolinone; 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE; 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl-; CHEBI:41928; PD128763; CHEMBL125200; 5-methyl-3,4-dihydro-2H-isoquinolin-1-one; 3,4-dihydro-5-methylisoquinolinone; 1(2H)-Isoquinolinone,3,4-dihydro-5-methyl-; 5-methyl-1,2,3,4-tetrahydroisoquinolin-1-one; DHQ; PD 128763; dihydroisoquinolinone, 1; AC1L3WIO; ACMC-1C7L4; SCHEMBL831538; AMBZ0075; KS-00000QFP; CTK4B6146; BDBM27682"	148140	Investigative	D0E2VC	DB03722	CTPDG010783
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methyl-2-phenyl-3H-quinazolin-4-one	.	135531482	Investigative	D0E5EW	.	CTPDG010784
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	TI3	"RB106; CHEMBL419499; [(2S)-2-SULFANYL-3-PHENYLPROPANOYL]-GLY-(5-PHENYLPROLINE); 1qf2; AC1L9LL2; BDBM50051785; DB02669; N-[(S)-2-Mercapto-3-phenylpropionyl]-Gly-[(5R)-5-phenyl-L-Pro-]-OH; N-[(2S)-3-phenyl-2-sulfanylpropanoyl]glycyl-(5R)-5-phenyl-L-proline; (2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid; (2S,5R)-1-[2-((S)-2-Mercapto-3-phenyl-propionylamino)-acetyl]-5-phenyl-pyrrolidine-2-carboxylic acid"	448087	Investigative	D0E7UW	DB02669	CTPDG010785
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"3-aminobenzo[c][1,5]naphthyridin-6(5H)-one"	"CHEMBL106154; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9"	16221809	Investigative	D0EI6X	.	CTPDG010786
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	S-111	"PARP1 inhibitor (cancer), Sentinel Oncology"	.	Investigative	D0EQ1J	.	CTPDG008329
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	Thieno-phenanthridin-6-one	.	.	Investigative	D0EW8Y	.	CTPDG010787
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	CHEMBL194535	44403357	Investigative	D0F8ZI	.	CTPDG010788
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one"	"CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one"	345678	Investigative	D0FF4M	.	CTPDG010789
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135492389	Investigative	D0G5VD	.	CTPDG010790
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one	.	135463623	Investigative	D0GA0Y	.	CTPDG010791
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	CHEMBL373210	44403404	Investigative	D0GJ8U	.	CTPDG010792
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide"	CHEMBL1096560; SCHEMBL2265205	44549505	Investigative	D0I2AF	.	CTPDG010793
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-phenyl-2H-indazole-7-carboxamide	CHEMBL594298; SCHEMBL1422404; BDBM50306166	44549251	Investigative	D0IX3I	.	CTPDG010794
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	Carba-Nicotinamide-Adenine-Dinucleotide	"Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m"	163884	Investigative	D0JD1O	DB02498	CTPDG010795
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-aminobenzamide	"3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde"	1645	Investigative	D0K2PD	.	CTPDG010796
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Ethenylquinoline-8-carboxamide	"CHEMBL481793; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270"	25208747	Investigative	D0K7JT	.	CTPDG010797
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Phenylquinoline-8-carboxamide	CHEMBL450259; BDBM50255264	25208596	Investigative	D0L1NQ	.	CTPDG010798
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-(4-methoxyphenyl)quinoxaline-5-carboxamide	"CHEMBL519443; quinoxaline analogue, 3e; SCHEMBL7045177"	9965481	Investigative	D0L1RZ	.	CTPDG010799
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	TI4	.	91808049	Investigative	D0L6LO	.	CTPDG010800
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"Benzo[c][1,5]naphthyridin-6(5H)-one"	"CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one"	10535869	Investigative	D0M6WJ	.	CTPDG010801
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-(4-cyanophenyl)quinoxaline-5-carboxamide	"CHEMBL481603; quinoxaline analogue, 3c; SCHEMBL7108289"	25218518	Investigative	D0M9TW	.	CTPDG010802
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione"	CHEMBL201907; SCHEMBL2086780; ZINC28569089	11506860	Investigative	D0NU5Z	.	CTPDG010803
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190931	Investigative	D0O0GA	.	CTPDG010804
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Hydroxy-2-phenyl-3H-quinazolin-4-one	.	135528341	Investigative	D0O6WW	.	CTPDG010805
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135417274	Investigative	D0OF1I	.	CTPDG010806
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1099295; SCHEMBL2264064	44549375	Investigative	D0PT1K	.	CTPDG010807
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BPI-704001	"BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma"	.	Investigative	D0R7FS	.	CTPDG007906
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	CHEMBL370869; SCHEMBL5381581	18382004	Investigative	D0R7HU	.	CTPDG010808
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-Methylquinoline-8-carboxamide	"CHEMBL471966; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220"	21195867	Investigative	D0S8HZ	.	CTPDG010809
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methoxy-2-methyl-3H-quinazolin-4-one	.	135411146	Investigative	D0T3SY	.	CTPDG010810
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Prop-1-ynylquinoline-8-carboxamide	CHEMBL504903; ZINC40829471	25208905	Investigative	D0T5TT	.	CTPDG010811
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094952; SCHEMBL2265265	44549373	Investigative	D0TH7S	.	CTPDG010812
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one	.	135508369	Investigative	D0U5WY	.	CTPDG010813
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Ethylquinoline-8-carboxamide	"CHEMBL453989; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269"	25208904	Investigative	D0UF0U	.	CTPDG010814
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	A-620223	"A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott"	9925908	Investigative	D0VY5O	DB07330	CTPDG007773
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	DR2313	.	135522417	Investigative	D0W7XH	DB07677	CTPDG010815
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one	.	135547083	Investigative	D0WO3P	.	CTPDG010816
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094953; SCHEMBL2265628	44549374	Investigative	D0XZ5D	.	CTPDG010817
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135471354	Investigative	D0Y1MH	.	CTPDG010818
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-ethylquinoline-8-carboxamide	"CHEMBL526128; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330"	25208752	Investigative	D0Z3PB	.	CTPDG010819
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-phenylquinoline-8-carboxamide	CHEMBL480429; SCHEMBL6442515; ZINC3939668	44156952	Investigative	D0Z9DY	.	CTPDG010820
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BZ5	.	46241905	Investigative	D0ZK3L	.	CTPDG010821
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	ME0328	ME-0328; compound 5b [PMID 24188023]	135566764	Investigative	D04QRM	.	CTPDG010822
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala"	TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic	5289469	Investigative	D09SZG	DB02597	CTPDG010823
M6ACROT03445	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	S-070	"S-158; Targeted synergy program (solid tumor), Sentinel Oncology; Chk1/PARP-1 inhibitors (cancer); Chk1/PARP-1 inhibitors (cancer), Sentinel Oncology"	.	Investigative	D0P4DG	.	CTPDG007983
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03446	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03447	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03447	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03447	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03447	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03448	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03449	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03450	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03450	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03451	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03452	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03453	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03454	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03455	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03456	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03456	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03457	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03458	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03459	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03460	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03460	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03461	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03462	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03463	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT03463	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT03464	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	Penciclovir	39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2	135398748	Approved	D07BYK	DB00299	CTPDG010582
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Preregistration	TK-DLI	"TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara"	.	Preregistration	D08AMJ	.	CTPDG010583
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	FV-100	"CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy"	71587897	Phase 3	D04QPD	.	CTPDG010584
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2	HQK-1004	"Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest"	23622962	Phase 2	D05RRA	.	CTPDG002789
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Ad-OC-hsvTK/valacyclovir	"Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute"	.	Phase 1	D02KBE	.	CTPDG010585
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	"Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama"	.	Phase 1	D0FY1W	.	CTPDG004786
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-Hydroxypropylthymine	"6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139"	1865	Investigative	D00CEO	DB04139	CTPDG010586
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	3-(2-propyn-1-yl)thymidine	3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872	11323459	Investigative	D01CUJ	.	CTPDG010587
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	ITdU	"3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-"	76	Investigative	D01VKE	.	CTPDG010588
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	"AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate"	449489	Investigative	D04GXW	DB02324	CTPDG010589
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CHEMBL219905	16098875	Investigative	D07GKK	.	CTPDG010590
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	(South)-Methanocarba-Thymidine	"south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921"	447628	Investigative	D07OOW	DB02921	CTPDG010591
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-(Dihydroxy-Isobutyl)-Thymine	"DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione"	1855	Investigative	D08AOD	DB02500	CTPDG010592
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-propyl-2'-deoxyuridine	"27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione"	160155	Investigative	D0C7YS	.	CTPDG010593
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-(bromovinyl)deoxyuridine	CHEMBL261850; SCHEMBL4314668; BDBM50375781	25323027	Investigative	D0D7FB	.	CTPDG010594
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	9-(4-Hydroxybutyl)-N2-Phenylguanine	"HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one"	135415618	Investigative	D0G5VO	DB02495	CTPDG010595
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-iodo-2'-deoxyuridine	"CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil"	512326	Investigative	D0HO0W	.	CTPDG010596
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine"	"3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione"	452142	Investigative	D0O7GD	.	CTPDG010597
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	BVDU-MP	SCHEMBL4287705	46936977	Investigative	D0PC2Y	.	CTPDG010598
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, S-Isomer"	"(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731"	445210	Investigative	D0R0EI	DB03000	CTPDG010599
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine	.	448110	Investigative	D0S4SQ	.	CTPDG010600
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Bromothienyldeoxyuridine	"CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione"	446725	Investigative	D0ST5A	DB03804	CTPDG010601
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[7-(triphenylmethoxy)heptyl]thymine	"CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-"	16098874	Investigative	D0W8AD	.	CTPDG010602
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, R-Isomer"	"14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-"	445211	Investigative	D0X1HX	DB02765	CTPDG010603
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Edoxudine	"5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine; MCULE-3445830855; ST056929"	66377	Investigative	D0Y4MD	DB13421	CTPDG010604
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	N2-(3-trifluoromethylphenyl)guanine	.	135435057	Investigative	D0YJ5W	.	CTPDG010605
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-Deoxyuridine	"951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615"	13712	Investigative	D00CVB	DB02256	CTPDG010606
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[5-(triphenylmethoxy)pentyl]thymine	"CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-"	16098859	Investigative	D00KWL	.	CTPDG010607
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Deoxythymidine	"Thymidine; 50-89-5; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748"	5789	Investigative	D01GLG	DB04485	CTPDG010608
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[6-(triphenylmethoxy)hexyl]thymine	"CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-"	44418795	Investigative	D02CCD	.	CTPDG010609
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	"CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"""" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate"	447202	Investigative	D04BBF	DB03280	CTPDG010610
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	"CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione"	6477686	Investigative	D0I6UV	.	CTPDG010611
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Thymidine-5'-Phosphate	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)	9700	Investigative	D0ZH0I	DB01643	CTPDG010612
M6ACROT03467	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-deoxythymidine triphosphate	"Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 5'-TTP; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE"	64968	Investigative	D09WYY	DB02452	CTPDG010613
M6ACROT03469	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03469	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03470	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03470	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03471	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03471	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03472	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03472	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03473	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03473	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03474	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03474	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03475	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03475	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03476	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03476	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03476	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03476	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03476	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03477	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03477	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03477	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03477	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03477	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03478	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03478	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MEDI4736	.	.	Phase 3	D04RRZ	.	CTPDG001416
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	KN046	.	.	Phase 3	DLOQ25	.	CTPDG012817
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	KN035	Envafolimab	.	Phase 2	D0GF2R	.	CTPDG002356
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	CX-072	.	.	Phase 2	D0Z2BO	.	CTPDG001867
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	INCB86550	.	.	Phase 2	DKM79E	.	CTPDG001693
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	M7824	.	.	Phase 2	D05FPZ	.	CTPDG002813
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	BGB-A333	.	.	Phase 1/2	DC5VW9	.	CTPDG003195
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	Phase 1/2	DS6VD0	.	CTPDG003143
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3300054	.	.	Phase 1	D08HSS	.	CTPDG005054
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MSB2311	.	.	Phase 1	D0A8AU	.	CTPDG004941
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1	BMS-936559	.	Phase 1	D0KP9A	.	CTPDG004646
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FAZ053	.	.	Phase 1	D0LU1O	.	CTPDG004609
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1 CSR T cells	.	.	Phase 1	D0W7UD	.	CTPDG012818
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	BMS-986189	.	.	Phase 1	D0X1GN	.	CTPDG012819
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	.	.	Phase 1	D2Z6WF	.	CTPDG004150
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PD-L1 t-haNK	.	.	Phase 1	DH42RF	.	CTPDG003899
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	KD033	.	.	Phase 1	DJVR06	.	CTPDG003860
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	Phase 1	D09PPU	.	CTPDG004985
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FS118	.	.	Phase 1	D0XO9F	.	CTPDG004272
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MCLA-145	.	.	Phase 1	D2QY0Z	.	CTPDG004156
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	GEN1046	.	.	Phase 1	D3HBJ1	.	CTPDG004139
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	ALPN-202	.	.	Phase 1	D82UVG	.	CTPDG004022
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	TAK-252	SL-279252	.	Phase 1	D9SL1N	.	CTPDG003989
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	INBRX-105	.	.	Phase 1	DA1X5W	.	CTPDG003983
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3415244	.	.	Phase 1	DC8HR6	.	CTPDG003954
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	A337	.	.	Phase 1	DL97UQ	.	CTPDG003833
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example2	.	117941742	Patented	D0OK1S	.	CTPDG005729
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example1	.	117951478	Patented	D0WQ9X	.	CTPDG005575
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure7	PMID30247903Compound7	.	Investigative	D01TGF	.	CTPDG012820
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	CA-327	.	.	Investigative	D04ILU	.	CTPDG012821
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure8	PMID30247903Compound8	.	Investigative	D04QGF	.	CTPDG012822
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure5	PMID30247903Compound5	.	Investigative	D07BOF	.	CTPDG012823
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure12	PMID30247903Compound12	.	Investigative	D09BYN	.	CTPDG012824
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure9	PMID30247903Compound9	.	Investigative	D0GG6N	.	CTPDG012825
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure6	PMID30247903Compound6	.	Investigative	D0TN4F	.	CTPDG012826
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure10	PMID30247903Compound10	.	Investigative	D0XL3N	.	CTPDG012827
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH011	.	.	Investigative	DA91UG	.	CTPDG007607
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH010	.	.	Investigative	DBTI39	.	CTPDG007604
M6ACROT03479	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	RG6084	.	.	Phase 1	DJX7K9	.	CTPDG014810
M6ACROT03479	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03479	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03480	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03480	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03481	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03482	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03482	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03483	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03483	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03484	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03484	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03485	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03485	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03486	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03486	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03487	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03487	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03488	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03488	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03489	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03489	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03490	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03490	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03491	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	Preclinical	DJ1Q9B	.	CTPDG014822
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	BIX-01294	BIX01294; BIX 01294	25150857	Preclinical	D06PPL	.	CTPDG014823
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Preclinical	A-366	A 366; A366	76285486	Preclinical	D0C5EG	.	CTPDG007094
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0321	UNC-0321; UNC 0321	46901937	Investigative	D0CX4W	.	CTPDG014824
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	BRD9539	BRD-9539; BRD 9539	73755260	Investigative	D0RO9T	.	CTPDG014825
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	Investigative	D0BI4T	.	CTPDG014826
M6ACROT03492	Histone-lysine N-methyltransferase EHMT2 (EHMT2)	EHMT2_HUMAN	.	.	Investigative	UNC0638	1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	Investigative	D0GK7A	.	CTPDG014827
M6ACROT03492	Protein-tyrosine kinase 2-beta (PYK2)	FAK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	Alpelisib	"1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	Approved	D0W7HE	DB12015	CTPDG011196
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Approved	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	Approved	D0S5LD	DB12483	CTPDG011197
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2/3	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	Phase 2/3	D0UP1Z	DB12108	CTPDG001031
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 3	Buparlisib	BKM120	16654980	Phase 3	D01QSO	DB11666	CTPDG011199
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	MLN1117	.	70798655	Phase 1/2	D0Y2NS	DB14935	CTPDG003277
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1/2	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	Phase 1/2	D05CBJ	DB13051	CTPDG011200
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	BLY719	.	.	Phase 1	D01LMM	.	CTPDG005400
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	LY3849524	LOXO 783	.	Phase 1	D8IJR1	.	CTPDG011201
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	Phase 1	DYF2N4	.	CTPDG011202
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03498	PI3-kinase subunit alpha (PI3k/PIK3CA)	PK3CA_HUMAN	.	.	Investigative	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	Investigative	DOR1I0	.	CTPDG007594
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03499	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Novolimus	.	9854320	Approved	D03FCF	.	CTPDG010151
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Temsirolimus	Torisel	6918289	Approved	D0ES1Q	.	CTPDG000398
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Everolimus	"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress"	6442177	Approved	D0K3QS	DB01590	CTPDG000313
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	Approved	D0V7WS	.	CTPDG000104
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	Sirolimus	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	Approved	D03LJR	DB00877	CTPDG000714
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Approved	PF-04449913	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	Approved	D0S5LO	DB11978	CTPDG000154
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 3	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	Phase 3	D0O3CV	DB06233	CTPDG010152
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	Phase 2	D03DPZ	DB11836	CTPDG002935
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	OSI-027	.	135398516	Phase 2	D0H7XL	DB12387	CTPDG002335
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	ABI-009	.	.	Phase 2	D0W3UV	.	CTPDG001927
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	Discontinued in Phase 1/2	D00KTV	DB12681	CTPDG003082
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SAR245409	.	16123056	Phase 2	D01PGR	DB12400	CTPDG003020
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	Phase 2	D03NJY	.	CTPDG010154
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	Phase 2	D0D8JB	DB11896	CTPDG002445
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	LY3023414	.	57519748	Phase 2	D0H1WC	DB12167	CTPDG002342
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PF-04691502	"1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	Phase 2	D0N5JZ	DB11974	CTPDG002170
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	GDC-0980/RG7422	"Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S"	25254071	Phase 2	D0O6VZ	DB12180	CTPDG010155
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	Phase 2	D0VG0D	DB11651	CTPDG001950
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	PQR309	"Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	Phase 2	D0TU7B	DB14846	CTPDG010156
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 2	AZD2014	"1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	Phase 2	D0Z2UQ	DB11925	CTPDG001865
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	Phase 1/2	D05EXN	DB12570	CTPDG003554
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	Phase 1/2	D0X7IN	.	CTPDG003287
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1/2	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	Phase 1/2	D03IXK	DB13062	CTPDG010157
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	BI 860585	.	.	Phase 1	D08PSC	.	CTPDG005036
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	LAM-001	.	.	Phase 1	D0QN5M	.	CTPDG010158
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-3078	.	.	Phase 1	D0R9VX	.	CTPDG004455
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	GDC-0349	MTORC1/2 inhibitors	59239165	Phase 1	D0U8QH	DB13072	CTPDG010159
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	CERC 006	"(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M"	135398516	Phase 1	D1RLY2	DB12387	CTPDG010160
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	DS-7423	.	.	Phase 1	D0X4RT	.	CTPDG004285
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	Phase 1	D0Y0FE	.	CTPDG004269
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Phase 1	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	Phase 1	D0U3DP	DB12986	CTPDG004379
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1/2	AZD8055	"1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	Discontinued in Phase 1/2	D0K1VK	DB12774	CTPDG006687
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Discontinued in Phase 1	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	Discontinued in Phase 1	D0H5MX	.	CTPDG010166
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Terminated	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	Terminated	D05SXC	.	CTPDG007490
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; SCHEMBL4442909	25069592	Investigative	D00GQM	.	CTPDG010167
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Rapamycin complexed with immunophilin FKBP12	.	.	Investigative	D01AQN	.	CTPDG010168
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	C-16-(S)-3-methylindolerapamycin	CHEMBL503885	44576240	Investigative	D02TCF	.	CTPDG010169
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	Investigative	D03XRZ	.	CTPDG008919
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	Investigative	D05SOW	.	CTPDG008799
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	Investigative	D07JKB	.	CTPDG010170
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	Investigative	D07NFT	.	CTPDG008676
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	Investigative	D08BTX	.	CTPDG008638
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	Investigative	D09FBN	.	CTPDG010171
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	Investigative	D09VHS	.	CTPDG008512
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	Investigative	D0A8ES	.	CTPDG010172
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; SCHEMBL4439490	25074311	Investigative	D0AH8Q	.	CTPDG010173
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	Investigative	D0E1YN	.	CTPDG008349
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; SCHEMBL4438208	25074312	Investigative	D0F1SI	.	CTPDG010174
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	torin 1	Torin-1	49836027	Investigative	D0H0HR	.	CTPDG010175
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	Investigative	D0H4KF	.	CTPDG008242
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	Investigative	D0J9PK	.	CTPDG008164
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	Investigative	D0N9TK	.	CTPDG008030
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	Investigative	D0P0UV	.	CTPDG010176
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	3-(6-morpholino-9H-purin-2-yl)phenol	CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	Investigative	D0TC5H	.	CTPDG010177
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	AP-21967	CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	Investigative	D0U8GR	.	CTPDG010178
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630	46225260	Investigative	D0Y1DR	.	CTPDG010179
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	Investigative	D2B7WM	.	CTPDG007614
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	Investigative	D02ELN	.	CTPDG009034
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	Investigative	D05RSS	.	CTPDG008805
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP-242	PP242; TORKinib	135565635	Investigative	D0H2CM	.	CTPDG010180
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	CU-906	.	.	Investigative	D0JD4S	.	CTPDG008160
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	Investigative	D0QE9F	.	CTPDG007933
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	Investigative	D0T0BY	.	CTPDG010181
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; SCHEMBL3545107	10017389	Investigative	D0X7TB	.	CTPDG010182
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	Investigative	D0W1ST	.	CTPDG010183
M6ACROT03500	Serine/threonine-protein kinase mTOR (MTOR)	MTOR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT03502	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Phase 3	Cadi-05	"Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila"	.	Phase 3	D0V0JR	.	CTPDG013941
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Phase 2	MCS-18	"Helleborus purpurascens-derived anti-inflammatory analgesic (injection, autoimmune disease), DoNatur"	.	Phase 2	D03ONZ	.	CTPDG014402
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Phase 2	OPN-305	"OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona"	.	Phase 2	D0VI9P	.	CTPDG014403
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Phase 1/2	Lipoteichoic acid	"Oncomycin; Lipoteichoic acid (cancer); Lipoteichoic acid (cancer), Lunamed; TLR-2 modulator (subcutaneous, solid tumor), LUNAMeD; Toll like receptor-2 modulator (subcutaneous, solid tumor), LUNAMeD"	137349712	Phase 1/2	D00UVU	.	CTPDG003626
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Phase 1/2	MALP-2S	.	.	Phase 1/2	D0K3SM	.	CTPDG003397
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Phase 1	OM-174	"UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate"	9833422	Phase 1	D09POQ	.	CTPDG004986
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Discontinued in Phase 1	F-50040	"Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre"	.	Discontinued in Phase 1	D07CQJ	.	CTPDG006871
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Investigative	CBLB-612	"Recombinant flagellin proteins (injectable, radiation induced bone marrow deficiency), Cleveland BioLabs; CBLB-600 series (injectable, radiation sickness), Cleveland BioLabs"	.	Investigative	D04UYT	.	CTPDG014404
M6ACROT03503	Toll-like receptor 2 (TLR2)	TLR2_HUMAN	.	.	Investigative	S-(Dimethylarsenic)Cysteine	[[(S)-2-Amino-2-carboxyethyl]thio]dimethylarsenic	46936846	Investigative	D08TGY	.	CTPDG013568
M6ACROT03504	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03504	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03505	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03505	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03506	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03506	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03507	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03507	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03507	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03508	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03508	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03509	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03509	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03509	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03510	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03510	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Clinical trial	KGP94	CHEMBL1269632; BDBM50330030	25234575	Clinical trial	D0X6QL	.	CTPDG014065
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-1	.	826236	Patented	D0J0WG	.	CTPDG014066
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-19	.	100951597	Patented	D0ZN3M	.	CTPDG005518
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	Phenylalanine derivative 1	PMID27998201-Compound-21	.	Patented	D01MKD	.	CTPDG014067
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-7	.	73294953	Patented	D0JD5W	.	CTPDG014068
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-6	.	.	Patented	D0X1AF	.	CTPDG014069
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-17	.	.	Patented	D06XTA	.	CTPDG014070
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID25399719-Compound-17	.	.	Patented	D06LLT	.	CTPDG013698
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-12	.	.	Patented	D06XCD	.	CTPDG006131
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	L-006235-1	"294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235"	9912381	Preclinical	D0Z0PR	.	CTPDG013703
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	[(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone	CHEMBL602092	46232847	Investigative	D00VAN	.	CTPDG014071
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone	CHEMBL1271493	52942034	Investigative	D01CSE	.	CTPDG014072
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	CAA0225	"CAA-0225; GTPL6532; (2S,3S)-2-N-[(1S)-1-(benzylcarbamoyl)-2-phenylethyl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide"	50909779	Investigative	D01YTS	.	CTPDG014073
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	BIPHENYL-4-YL-ACETALDEHYDE	"2-([1,1'-biphenyl]-4-yl)acetaldehyde; 61502-90-7; 2-(4-phenylphenyl)acetaldehyde; 4-biphenylacetaldehyde; 2-{[1,1'-biphenyl]-4-yl}acetaldehyde; AC1MRDQD; (biphenyl-4-yl)ethanone; SCHEMBL850634; 2-(biphenyl-4-yl)acetaldehyde; CTK2D8632; DTXSID30392980; OIDMZCMVYZLDLI-UHFFFAOYSA-N; MolPort-020-915-677; [1,1'-Biphenyl]-4-acetaldehyde; ZINC2581188; AKOS006278290; AS-49992; BP4"	3491292	Investigative	D02RWL	.	CTPDG014074
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Peptide alpha-keto-beta-aldehyde-based inhibitors	CHEMBL48605; BDBM50090643; (3S)-3-[(Ac-L-Leu-L-Leu-)Amino]-6-guanidino-2-oxohexanal; (S)-2-Acetylamino-4-methyl-pentanoic acid {(S)-1-[(S)-4-guanidino-1-(2-oxo-acetyl)-butylcarbamoyl]-3-methyl-butyl}-amide	10095492	Investigative	D08TWJ	.	CTPDG014075
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	(3-Bromobenzoylpyridine)thiosemicarbazone	CHEMBL1269715	52940642	Investigative	D09NBP	.	CTPDG014076
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	"1-(1,3-diphenylpropylidene)thiosemicarbazide"	CHEMBL429858; BDBM50377591	44449925	Investigative	D0B4JS	.	CTPDG014077
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile	"Compound 3{8,12}; CHEMBL255079"	24777047	Investigative	D0J7OM	.	CTPDG014078
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	[2-Phenylacetophenone]thiosemicarbazone	CHEMBL1269810	52945875	Investigative	D0LL1F	.	CTPDG014079
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Bis(3-Fluorophenyl)-ketone]thiosemicarbazone	CHEMBL602732	46232386	Investigative	D0M3AP	.	CTPDG014080
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile	"Compound 3{8,17}; CHEMBL400454"	24778186	Investigative	D0MD6D	.	CTPDG014081
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	CHEMBL402465	15722900	Investigative	D03JYN	.	CTPDG014082
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	.	136002679	Investigative	D04DFX	.	CTPDG014083
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	CHEMBL590497	46232967	Investigative	D0B2JC	.	CTPDG014084
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile	"dipeptide-derived nitrile, 23; CHEMBL371893; BDBM20102; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamate"	11551481	Investigative	D0JF8D	.	CTPDG014085
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	(S)-tert-butyl 1-oxohexan-2-ylcarbamate	"CHEMBL96875; ((S)-1-Formyl-pentyl)-carbamic acid tert-butyl ester; BML-244; Carbamic acid, [(1S)-1-formylpentyl]-, 1,1-dimethylethyl ester; SCHEMBL3285479; CTK0G6629; OBMGXPJNZKYOQY-VIFPVBQESA-N; ZINC13588585; BDBM50137790; AKOS030572335; tert-butyl(1S)-1-formylpentylcarbamate; CCG-207873; 2(S)-(tert-Butoxycarbonylamino)hexanal; tert-butyl (1S)-1-formylpentylcarbamate; (2S)-2-(tert-Butoxycarbonylamino)hexanal; (S)-2-(tert-butoxycarbonylamino)-5-methylpentanal"	10420833	Investigative	D0T7QF	.	CTPDG013736
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	"dipeptide-derived nitrile, 9; CHEMBL197113; BDBM20088; tert-butyl N-[(1S,2R)-1-[(cyanomethyl)carbamoyl]-2-methylbutyl]carbamate"	23648531	Investigative	D01YNC	.	CTPDG013738
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	"N-(tert-butoxycarbonyl)-L-valyl-glycine-nitrile; 191033-03-1; dipeptide-derived nitrile, 5; CHEMBL200004; BDBM20085; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-methylpropyl]carbamate"	14774521	Investigative	D06VIP	.	CTPDG013739
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	"dipeptide-derived nitrile, 13; CHEMBL383584; BDBM20092; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]pentyl]carbamate"	11637576	Investigative	D07FLB	.	CTPDG013740
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 44; CHEMBL200235; BDBM20120"	11696652	Investigative	D07RSA	.	CTPDG013741
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	"dipeptide-derived nitrile, 7; CHEMBL200160; SCHEMBL6257676; BDBM20087; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate"	11492732	Investigative	D09AHN	.	CTPDG013742
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-acetyl-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 42; CHEMBL197181; SCHEMBL15634553; BDBM20118; ITHLBMBCVIAAIX-LBPRGKRZSA-N; ZINC13676602; (N-acetyl-l-phenylalanyl)aminoacetonitrile; SR-03000002938; SR-03000002938-1; (S)-2-Acetamido-N-(cyanomethyl)-3-phenylpropanamide"	11086036	Investigative	D0A8OV	.	CTPDG013743
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	"dipeptidyl nitrile, 1; Cbz-Leu-NH-CH2-CN; JMC487688 Compound 8; CHEMBL200161; SCHEMBL6183068; BDBM19768; UFXQLUZNMRVTPU-AWEZNQCLSA-N; 2-[(Z-L-Leu-)Amino]ethanenitrile; benzyl (S)-1-cyanomethylcarbamoyl-3-methylbutylcarbamate; benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate"	11702208	Investigative	D0G8OD	.	CTPDG013744
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-benzoyl-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 43; SCHEMBL5517755; CHEMBL371466; BDBM20119"	11702265	Investigative	D0JN8Q	.	CTPDG013745
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	"dipeptide-derived nitrile, 12; CHEMBL381847; BDBM20091; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-(methylsulfanyl)propyl]carbamate"	11709032	Investigative	D0U0XG	.	CTPDG013746
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester	10062714	Investigative	D0VE0F	DB07593	CTPDG013747
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Cysteinesulfonic Acid	"Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889"	72886	Investigative	D05AMX	DB03661	CTPDG014086
M6ACROT03511	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	L-873724	"UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	Investigative	D0D0LD	.	CTPDG008390
M6ACROT03511	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03511	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03512	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03512	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03513	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03513	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03514	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03514	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03515	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03515	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03516	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03516	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03516	Serine/threonine-protein kinase Nek2 (NEK2)	NEK2_HUMAN	.	.	Investigative	PMID21627121C2	GTPL8149; BDBM50418829	16662746	Investigative	D0C3KE	.	CTPDG015390
M6ACROT03516	Serine/threonine-protein kinase Nek2 (NEK2)	NEK2_HUMAN	.	.	Investigative	PMID20936789C31	GTPL8180; BDBM50330575	49837564	Investigative	D0K0UJ	.	CTPDG015391
M6ACROT03516	Serine/threonine-protein kinase Nek2 (NEK2)	NEK2_HUMAN	.	.	Investigative	GSK579289A	compound 25 [PMID 19237286]; GSK-579289A	16051023	Investigative	D0X1RH	.	CTPDG013814
M6ACROT03517	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03518	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03519	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03520	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03520	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03521	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03522	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03522	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03523	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Clinical trial	KGP94	CHEMBL1269632; BDBM50330030	25234575	Clinical trial	D0X6QL	.	CTPDG014065
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-1	.	826236	Patented	D0J0WG	.	CTPDG014066
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-19	.	100951597	Patented	D0ZN3M	.	CTPDG005518
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	Phenylalanine derivative 1	PMID27998201-Compound-21	.	Patented	D01MKD	.	CTPDG014067
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-7	.	73294953	Patented	D0JD5W	.	CTPDG014068
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-6	.	.	Patented	D0X1AF	.	CTPDG014069
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-17	.	.	Patented	D06XTA	.	CTPDG014070
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-9	.	78108715	Patented	D04VGR	.	CTPDG006182
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID25399719-Compound-17	.	.	Patented	D06LLT	.	CTPDG013698
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-5	.	46202117	Patented	D05OIU	.	CTPDG006166
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Patented	PMID27998201-Compound-12	.	.	Patented	D06XCD	.	CTPDG006131
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	CLIK-148	SCHEMBL7207304	9801663	Preclinical	DW24LQ	.	CTPDG006963
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	CLIK-181	J3.633.044I	132504749	Preclinical	DYU3I8	.	CTPDG006958
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	SD1002	.	.	Preclinical	DCZ16N	.	CTPDG006990
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	Z-Phe-Ala-diazomethylketone	"71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	Preclinical	DM69TL	.	CTPDG006980
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	SD1003	.	.	Preclinical	DSM03D	.	CTPDG006968
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Preclinical	L-006235-1	"294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235"	9912381	Preclinical	D0Z0PR	.	CTPDG013703
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	[(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone	CHEMBL602092	46232847	Investigative	D00VAN	.	CTPDG014071
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone	CHEMBL1271493	52942034	Investigative	D01CSE	.	CTPDG014072
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	CAA0225	"CAA-0225; GTPL6532; (2S,3S)-2-N-[(1S)-1-(benzylcarbamoyl)-2-phenylethyl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide"	50909779	Investigative	D01YTS	.	CTPDG014073
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	BIPHENYL-4-YL-ACETALDEHYDE	"2-([1,1'-biphenyl]-4-yl)acetaldehyde; 61502-90-7; 2-(4-phenylphenyl)acetaldehyde; 4-biphenylacetaldehyde; 2-{[1,1'-biphenyl]-4-yl}acetaldehyde; AC1MRDQD; (biphenyl-4-yl)ethanone; SCHEMBL850634; 2-(biphenyl-4-yl)acetaldehyde; CTK2D8632; DTXSID30392980; OIDMZCMVYZLDLI-UHFFFAOYSA-N; MolPort-020-915-677; [1,1'-Biphenyl]-4-acetaldehyde; ZINC2581188; AKOS006278290; AS-49992; BP4"	3491292	Investigative	D02RWL	.	CTPDG014074
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Peptide alpha-keto-beta-aldehyde-based inhibitors	CHEMBL48605; BDBM50090643; (3S)-3-[(Ac-L-Leu-L-Leu-)Amino]-6-guanidino-2-oxohexanal; (S)-2-Acetylamino-4-methyl-pentanoic acid {(S)-1-[(S)-4-guanidino-1-(2-oxo-acetyl)-butylcarbamoyl]-3-methyl-butyl}-amide	10095492	Investigative	D08TWJ	.	CTPDG014075
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	(3-Bromobenzoylpyridine)thiosemicarbazone	CHEMBL1269715	52940642	Investigative	D09NBP	.	CTPDG014076
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	"1-(1,3-diphenylpropylidene)thiosemicarbazide"	CHEMBL429858; BDBM50377591	44449925	Investigative	D0B4JS	.	CTPDG014077
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile	"Compound 3{8,12}; CHEMBL255079"	24777047	Investigative	D0J7OM	.	CTPDG014078
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	[2-Phenylacetophenone]thiosemicarbazone	CHEMBL1269810	52945875	Investigative	D0LL1F	.	CTPDG014079
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Bis(3-Fluorophenyl)-ketone]thiosemicarbazone	CHEMBL602732	46232386	Investigative	D0M3AP	.	CTPDG014080
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile	"Compound 3{8,17}; CHEMBL400454"	24778186	Investigative	D0MD6D	.	CTPDG014081
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	CHEMBL402465	15722900	Investigative	D03JYN	.	CTPDG014082
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	.	136002679	Investigative	D04DFX	.	CTPDG014083
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	CHEMBL590497	46232967	Investigative	D0B2JC	.	CTPDG014084
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile	"dipeptide-derived nitrile, 23; CHEMBL371893; BDBM20102; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamate"	11551481	Investigative	D0JF8D	.	CTPDG014085
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	(S)-tert-butyl 1-oxohexan-2-ylcarbamate	"CHEMBL96875; ((S)-1-Formyl-pentyl)-carbamic acid tert-butyl ester; BML-244; Carbamic acid, [(1S)-1-formylpentyl]-, 1,1-dimethylethyl ester; SCHEMBL3285479; CTK0G6629; OBMGXPJNZKYOQY-VIFPVBQESA-N; ZINC13588585; BDBM50137790; AKOS030572335; tert-butyl(1S)-1-formylpentylcarbamate; CCG-207873; 2(S)-(tert-Butoxycarbonylamino)hexanal; tert-butyl (1S)-1-formylpentylcarbamate; (2S)-2-(tert-Butoxycarbonylamino)hexanal; (S)-2-(tert-butoxycarbonylamino)-5-methylpentanal"	10420833	Investigative	D0T7QF	.	CTPDG013736
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	"dipeptide-derived nitrile, 9; CHEMBL197113; BDBM20088; tert-butyl N-[(1S,2R)-1-[(cyanomethyl)carbamoyl]-2-methylbutyl]carbamate"	23648531	Investigative	D01YNC	.	CTPDG013738
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	"N-(tert-butoxycarbonyl)-L-valyl-glycine-nitrile; 191033-03-1; dipeptide-derived nitrile, 5; CHEMBL200004; BDBM20085; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-methylpropyl]carbamate"	14774521	Investigative	D06VIP	.	CTPDG013739
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	"dipeptide-derived nitrile, 13; CHEMBL383584; BDBM20092; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]pentyl]carbamate"	11637576	Investigative	D07FLB	.	CTPDG013740
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 44; CHEMBL200235; BDBM20120"	11696652	Investigative	D07RSA	.	CTPDG013741
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	"dipeptide-derived nitrile, 7; CHEMBL200160; SCHEMBL6257676; BDBM20087; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate"	11492732	Investigative	D09AHN	.	CTPDG013742
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-acetyl-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 42; CHEMBL197181; SCHEMBL15634553; BDBM20118; ITHLBMBCVIAAIX-LBPRGKRZSA-N; ZINC13676602; (N-acetyl-l-phenylalanyl)aminoacetonitrile; SR-03000002938; SR-03000002938-1; (S)-2-Acetamido-N-(cyanomethyl)-3-phenylpropanamide"	11086036	Investigative	D0A8OV	.	CTPDG013743
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	"dipeptidyl nitrile, 1; Cbz-Leu-NH-CH2-CN; JMC487688 Compound 8; CHEMBL200161; SCHEMBL6183068; BDBM19768; UFXQLUZNMRVTPU-AWEZNQCLSA-N; 2-[(Z-L-Leu-)Amino]ethanenitrile; benzyl (S)-1-cyanomethylcarbamoyl-3-methylbutylcarbamate; benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate"	11702208	Investigative	D0G8OD	.	CTPDG013744
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-benzoyl-phenylalanyl-glycine-nitrile	"phenylalanine derivative, 43; SCHEMBL5517755; CHEMBL371466; BDBM20119"	11702265	Investigative	D0JN8Q	.	CTPDG013745
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	"dipeptide-derived nitrile, 12; CHEMBL381847; BDBM20091; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-(methylsulfanyl)propyl]carbamate"	11709032	Investigative	D0U0XG	.	CTPDG013746
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester	10062714	Investigative	D0VE0F	DB07593	CTPDG013747
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	Cysteinesulfonic Acid	"Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889"	72886	Investigative	D05AMX	DB03661	CTPDG014086
M6ACROT03524	Procathepsin L (CTSL)	CATL1_HUMAN	.	.	Investigative	L-873724	"UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	Investigative	D0D0LD	.	CTPDG008390
M6ACROT03524	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03525	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03526	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03527	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03528	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03529	Serine/threonine-protein kinase Nek2 (NEK2)	NEK2_HUMAN	.	.	Investigative	PMID21627121C2	GTPL8149; BDBM50418829	16662746	Investigative	D0C3KE	.	CTPDG015390
M6ACROT03529	Serine/threonine-protein kinase Nek2 (NEK2)	NEK2_HUMAN	.	.	Investigative	PMID20936789C31	GTPL8180; BDBM50330575	49837564	Investigative	D0K0UJ	.	CTPDG015391
M6ACROT03529	Serine/threonine-protein kinase Nek2 (NEK2)	NEK2_HUMAN	.	.	Investigative	GSK579289A	compound 25 [PMID 19237286]; GSK-579289A	16051023	Investigative	D0X1RH	.	CTPDG013814
M6ACROT03529	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	CC-90011	"UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y"	118483201	Phase 2	DB5UA2	.	CTPDG013958
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	CC-90011	.	.	Phase 1	D04GNG	.	CTPDG005259
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	GSK2879552	.	66571643	Phase 1	D0I4ZN	.	CTPDG013959
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-16	.	.	Patented	D02YGX	.	CTPDG013960
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-41	.	.	Patented	D05FVW	.	CTPDG013961
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 2	PMID27019002-Compound-35	.	Patented	D05HBM	.	CTPDG013962
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28a	.	.	Patented	D06XEU	.	CTPDG013963
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 5	PMID27019002-Compound-25c	.	Patented	D07IAO	.	CTPDG013964
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 17	PMID27019002-Compound-39	.	Patented	D07LKA	.	CTPDG013965
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31b	.	.	Patented	D08FVR	.	CTPDG013966
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 3	PMID27019002-Compound-35a	.	Patented	D08WMK	.	CTPDG013967
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 1	PMID27019002-Compound-23	.	Patented	D0B6GK	.	CTPDG013968
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N6-cyclopropyllydine derivative 1	PMID27019002-Compound-30	.	Patented	D0BE4Z	.	CTPDG013969
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 1	PMID27019002-Compound-18	.	Patented	D0BG7B	.	CTPDG013970
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 7	PMID27019002-Compound-29e	.	Patented	D0C0PK	.	CTPDG013971
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 4	PMID27019002-Compound-25b	.	Patented	D0C1TH	.	CTPDG013972
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-45	.	.	Patented	D0D9CK	.	CTPDG013973
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-13	.	.	Patented	D0DD4I	.	CTPDG013974
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-49	.	.	Patented	D0DL5J	.	CTPDG013975
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 4	PMID27019002-Compound-29b	.	Patented	D0F1CT	.	CTPDG013976
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42b	.	.	Patented	D0GA7D	.	CTPDG013977
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31a	.	.	Patented	D0I9QC	.	CTPDG013978
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43c	.	.	Patented	D0J1HQ	.	CTPDG013979
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 3	PMID27019002-Compound-25a	.	Patented	D0JE6I	.	CTPDG013980
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 4	PMID27019002-Compound-36	.	Patented	D0KR0I	.	CTPDG013981
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 6	PMID27019002-Compound-29d	.	Patented	D0KZ5T	.	CTPDG013982
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 16	PMID27019002-Compound-38	.	Patented	D0L0DT	.	CTPDG013983
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28	.	.	Patented	D0L4OH	.	CTPDG013984
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 2	PMID27019002-Compound-22a	.	Patented	D0LK8A	.	CTPDG013985
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 5	PMID27019002-Compound-29c	.	Patented	D0LR6D	.	CTPDG013986
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43b	.	.	Patented	D0MO5Y	.	CTPDG013987
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 18	PMID27019002-Compound-40	.	Patented	D0N2QZ	.	CTPDG013988
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 3	PMID27019002-Compound-29a	.	Patented	D0NJ6B	.	CTPDG013989
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20b	.	.	Patented	D0O2WW	.	CTPDG013990
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-50	.	.	Patented	D0P4NF	.	CTPDG013991
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 8	PMID27019002-Compound-32	.	Patented	D0R7RY	.	CTPDG013992
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43a	.	.	Patented	D0RC0G	.	CTPDG013993
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 1	PMID27019002-Compound-14	.	Patented	D0U1DY	.	CTPDG013994
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-7	.	.	Patented	D0U4DT	.	CTPDG013995
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42a	.	.	Patented	D0UG5Q	.	CTPDG013996
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37a	.	.	Patented	D0VB7F	.	CTPDG013997
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-44	.	.	Patented	D0W8XM	.	CTPDG013998
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21a	.	.	Patented	D0YI0V	.	CTPDG013999
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37b	.	.	Patented	D0YX4R	.	CTPDG014000
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 11	PMID27019002-Compound-33c	.	Patented	D02CIX	.	CTPDG014002
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-11	.	.	Patented	D02WXS	.	CTPDG014003
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20a	.	.	Patented	D03MPD	.	CTPDG014004
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 9	PMID27019002-Compound-33a	.	Patented	D04PWX	.	CTPDG014005
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-13	.	.	Patented	D06KBT	.	CTPDG014006
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 3	PMID27019002-Compound-22b	.	Patented	D06VMN	.	CTPDG014007
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 13	PMID27019002-Compound-33e	.	Patented	D07DIJ	.	CTPDG014008
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-48	.	.	Patented	D09OMM	.	CTPDG014010
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-10	.	.	Patented	D0AI6J	.	CTPDG014011
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-12	.	.	Patented	D0E7SF	.	CTPDG014012
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-9	.	.	Patented	D0IO2A	.	CTPDG014013
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-14	.	.	Patented	D0PM2S	.	CTPDG014014
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-15	.	.	Patented	D0Q1EG	.	CTPDG014015
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 12	PMID27019002-Compound-33d	.	Patented	D0R2YA	.	CTPDG014016
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 10	PMID27019002-Compound-33b	.	Patented	D0W9VF	.	CTPDG014018
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-47	.	.	Patented	D0WO5W	.	CTPDG014019
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-17	.	.	Patented	D0WT1Z	.	CTPDG014020
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 2	PMID27019002-Compound-19a	.	Patented	D0XH9M	.	CTPDG014021
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-46	.	.	Patented	D0Z7HE	.	CTPDG014022
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclic peptide derivative 1	PMID27019002-Compound-compound11	.	Patented	D04OEV	.	CTPDG014023
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 1	PMID27019002-Compound-22d	.	Patented	D07NTA	.	CTPDG014024
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 3	PMID27019002-Compound-19b	.	Patented	D08IOP	.	CTPDG014025
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 2	PMID27019002-Compound-26a-h	.	Patented	D04OHC	.	CTPDG014027
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 3	PMID27019002-Compound-27a-m	.	Patented	D0O7IH	.	CTPDG014028
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	OG-L002	"1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride"	56639570	Investigative	D0C8SX	.	CTPDG014029
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	GSK-LSD1	"GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3"	71522234	Investigative	D0EV7U	.	CTPDG014030
M6ACROT03530	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	NCL-1	GTPL7024; ZINC94568752	73755256	Investigative	D0L6TQ	.	CTPDG014031
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	IMG-7289	"KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide"	122460381	Phase 2	D03EOZ	DB15126	CTPDG002932
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	Vafidemstat	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	D5NAL9	.	CTPDG001804
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	CC-90011	"UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y"	118483201	Phase 2	DB5UA2	.	CTPDG013958
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 2	ORY-2001	"(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N"	66714983	Phase 2	DL50ZE	.	CTPDG001691
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1/2	INCB59872	.	.	Phase 1/2	D0R7CD	.	CTPDG003338
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	CC-90011	.	.	Phase 1	D04GNG	.	CTPDG005259
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	GSK2879552	.	66571643	Phase 1	D0I4ZN	.	CTPDG013959
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	Seclidemstat	"UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide"	135565033	Phase 1	DCWT40	.	CTPDG003949
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Phase 1	TAS-1440	.	.	Phase 1	DI17KH	.	CTPDG003888
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-16	.	.	Patented	D02YGX	.	CTPDG013960
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-41	.	.	Patented	D05FVW	.	CTPDG013961
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 2	PMID27019002-Compound-35	.	Patented	D05HBM	.	CTPDG013962
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28a	.	.	Patented	D06XEU	.	CTPDG013963
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 5	PMID27019002-Compound-25c	.	Patented	D07IAO	.	CTPDG013964
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 17	PMID27019002-Compound-39	.	Patented	D07LKA	.	CTPDG013965
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31b	.	.	Patented	D08FVR	.	CTPDG013966
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 3	PMID27019002-Compound-35a	.	Patented	D08WMK	.	CTPDG013967
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 1	PMID27019002-Compound-23	.	Patented	D0B6GK	.	CTPDG013968
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N6-cyclopropyllydine derivative 1	PMID27019002-Compound-30	.	Patented	D0BE4Z	.	CTPDG013969
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 1	PMID27019002-Compound-18	.	Patented	D0BG7B	.	CTPDG013970
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 7	PMID27019002-Compound-29e	.	Patented	D0C0PK	.	CTPDG013971
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 4	PMID27019002-Compound-25b	.	Patented	D0C1TH	.	CTPDG013972
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-45	.	.	Patented	D0D9CK	.	CTPDG013973
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-13	.	.	Patented	D0DD4I	.	CTPDG013974
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-49	.	.	Patented	D0DL5J	.	CTPDG013975
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 4	PMID27019002-Compound-29b	.	Patented	D0F1CT	.	CTPDG013976
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42b	.	.	Patented	D0GA7D	.	CTPDG013977
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-31a	.	.	Patented	D0I9QC	.	CTPDG013978
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43c	.	.	Patented	D0J1HQ	.	CTPDG013979
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Aryl cyclopropylamine derivative 3	PMID27019002-Compound-25a	.	Patented	D0JE6I	.	CTPDG013980
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 4	PMID27019002-Compound-36	.	Patented	D0KR0I	.	CTPDG013981
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 6	PMID27019002-Compound-29d	.	Patented	D0KZ5T	.	CTPDG013982
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 16	PMID27019002-Compound-38	.	Patented	D0L0DT	.	CTPDG013983
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-28	.	.	Patented	D0L4OH	.	CTPDG013984
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 2	PMID27019002-Compound-22a	.	Patented	D0LK8A	.	CTPDG013985
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 5	PMID27019002-Compound-29c	.	Patented	D0LR6D	.	CTPDG013986
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43b	.	.	Patented	D0MO5Y	.	CTPDG013987
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Pyrimidine derivative 18	PMID27019002-Compound-40	.	Patented	D0N2QZ	.	CTPDG013988
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 3	PMID27019002-Compound-29a	.	Patented	D0NJ6B	.	CTPDG013989
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20b	.	.	Patented	D0O2WW	.	CTPDG013990
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-50	.	.	Patented	D0P4NF	.	CTPDG013991
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 8	PMID27019002-Compound-32	.	Patented	D0R7RY	.	CTPDG013992
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-43a	.	.	Patented	D0RC0G	.	CTPDG013993
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Benzenamine derivative 1	PMID27019002-Compound-14	.	Patented	D0U1DY	.	CTPDG013994
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-7	.	.	Patented	D0U4DT	.	CTPDG013995
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-42a	.	.	Patented	D0UG5Q	.	CTPDG013996
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37a	.	.	Patented	D0VB7F	.	CTPDG013997
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-44	.	.	Patented	D0W8XM	.	CTPDG013998
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21a	.	.	Patented	D0YI0V	.	CTPDG013999
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-37b	.	.	Patented	D0YX4R	.	CTPDG014000
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 4	PMID27019002-Compound-22c	.	Patented	D01CIK	.	CTPDG014001
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 11	PMID27019002-Compound-33c	.	Patented	D02CIX	.	CTPDG014002
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-11	.	.	Patented	D02WXS	.	CTPDG014003
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-20a	.	.	Patented	D03MPD	.	CTPDG014004
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 9	PMID27019002-Compound-33a	.	Patented	D04PWX	.	CTPDG014005
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-13	.	.	Patented	D06KBT	.	CTPDG014006
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 3	PMID27019002-Compound-22b	.	Patented	D06VMN	.	CTPDG014007
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 13	PMID27019002-Compound-33e	.	Patented	D07DIJ	.	CTPDG014008
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21b	.	.	Patented	D07MQD	.	CTPDG014009
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-48	.	.	Patented	D09OMM	.	CTPDG014010
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-10	.	.	Patented	D0AI6J	.	CTPDG014011
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-12	.	.	Patented	D0E7SF	.	CTPDG014012
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-9	.	.	Patented	D0IO2A	.	CTPDG014013
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-14	.	.	Patented	D0PM2S	.	CTPDG014014
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID25399762-Compound-Table 6-15	.	.	Patented	D0Q1EG	.	CTPDG014015
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 12	PMID27019002-Compound-33d	.	Patented	D0R2YA	.	CTPDG014016
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-21c	.	.	Patented	D0UE4K	.	CTPDG014017
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclopropylamine derivative 10	PMID27019002-Compound-33b	.	Patented	D0W9VF	.	CTPDG014018
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-47	.	.	Patented	D0WO5W	.	CTPDG014019
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-17	.	.	Patented	D0WT1Z	.	CTPDG014020
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 2	PMID27019002-Compound-19a	.	Patented	D0XH9M	.	CTPDG014021
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	PMID27019002-Compound-46	.	.	Patented	D0Z7HE	.	CTPDG014022
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Cyclic peptide derivative 1	PMID27019002-Compound-compound11	.	Patented	D04OEV	.	CTPDG014023
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Heteroaryl-cyclopropylamine derivative 1	PMID27019002-Compound-22d	.	Patented	D07NTA	.	CTPDG014024
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 3	PMID27019002-Compound-19b	.	Patented	D08IOP	.	CTPDG014025
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	N-(2-phenylcyclopropyl) amino acid derivative 1	PMID27019002-Compound-19	.	Patented	D0UL9U	.	CTPDG014026
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 2	PMID27019002-Compound-26a-h	.	Patented	D04OHC	.	CTPDG014027
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Patented	Tarnylcypromine derivative 3	PMID27019002-Compound-27a-m	.	Patented	D0O7IH	.	CTPDG014028
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	OG-L002	"1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride"	56639570	Investigative	D0C8SX	.	CTPDG014029
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	GSK-LSD1	"GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3"	71522234	Investigative	D0EV7U	.	CTPDG014030
M6ACROT03531	Lysine-specific histone demethylase 1A (KDM1A)	KDM1A_HUMAN	.	.	Investigative	NCL-1	GTPL7024; ZINC94568752	73755256	Investigative	D0L6TQ	.	CTPDG014031
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT03531	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT03532	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT03533	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT03533	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03534	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03535	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03536	WD repeat-containing protein 5 (WDR5)	WDR5_HUMAN	.	.	Investigative	OICR-9429	"1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	Investigative	D0XI3W	.	CTPDG015499
M6ACROT03537	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT03538	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT03538	Lysine-specific demethylase 5B  (KDM5B)	KDM5B_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03539	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03539	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03539	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03539	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03540	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03541	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03541	Nuclear factor NF-kappa-B p105 subunit (NF-Kappa-B/NFKB1)	NFKB1_HUMAN	.	.	Phase 2	P54	.	.	Phase 2	D0V3LM	.	CTPDG001967
M6ACROT03541	Nuclear factor NF-kappa-B p105 subunit (NF-Kappa-B/NFKB1)	NFKB1_HUMAN	.	.	Phase 2	CAT 1004	.	.	Phase 2	D06TZZ	.	CTPDG002728
M6ACROT03542	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03542	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 4	Ozagrel	"Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika"	5282440	Phase 4	D0C7AA	DB12017	CTPDG013845
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 2	Dilmapimod	"SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602"	10297982	Phase 2	D0K0JQ	DB12140	CTPDG013846
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-O2	.	.	Patented	D03JFK	.	CTPDG013847
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-L2	.	.	Patented	D08OJQ	.	CTPDG013848
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-L3	.	.	Patented	D0G7LB	.	CTPDG013849
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-L1	.	.	Patented	D0Q8CR	.	CTPDG013783
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-F2	.	.	Patented	D06JRV	.	CTPDG013790
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	FR167653	"HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818"	135484078	Discontinued in Phase 1	D05QMG	.	CTPDG006886
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	SB 235699	"4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-"	9797240	Discontinued in Phase 1	D0W0AM	.	CTPDG006724
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Terminated	SC-102	"4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl); SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings"	12106168	Terminated	D0O7BW	DB07829	CTPDG007263
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Terminated	SB 203580	152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV	176155	Terminated	D0F8DL	.	CTPDG012581
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	9-Benzyl-6-phenylsulfanyl-9H-purine	SCHEMBL6662063	11347708	Investigative	D00ODN	.	CTPDG013850
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL198563	11703439	Investigative	D00PPB	.	CTPDG013851
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	UCB-1277763	"P38 kinase inhibitors (inflammation), UCB"	.	Investigative	D00YRF	.	CTPDG013852
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Small molecule 34	3-(2-(4-pyridyl)ethyl)indole; 3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE; INHIBITOR OF P38 KINASE; 3-(2-(Pyridin-4-yl)ethyl)-1H-indole; 3-[2-(pyridin-4-yl)ethyl]-1H-indole; 3-(2-Pyridin-4-yl-ethyl)-1H-indole; L12; Maybridge1_000718; Cambridge id 5373101; AC1L1E9J; Oprea1_574113; Oprea1_420786; SCHEMBL735580; CHEMBL193156; HMS543I14; ZINC94256; BDBM13346; UUEYCHLWAOBOHG-UHFFFAOYSA-N; 1w84; MolPort-001-886-488; HMS3604M06; 3-[2-(4-pyridyl)-ethyl]-indole; STL328644; CCG-45397; 3-[2-(4-Pyridyl)ethyl]-1H-indole; AKOS000545583; MCULE-4657429599	27934	Investigative	D01CRK	DB01953	CTPDG013853
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	SB-218655	1bmk; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyrimidin-2-amine; 4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE; 165806-51-9; SB 218655; C14316; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; SB5; AC1L1JRC; AC1Q4ON9; SCHEMBL4323457; CHEMBL590753; BDBM15238; CTK4D2173; DTXSID50274456; sb218655; AKOS030547879	5172	Investigative	D02NKV	DB03980	CTPDG013854
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine	SCHEMBL6659707	11336624	Investigative	D03XYK	.	CTPDG013855
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-Phenylsulfanyl-9H-purine	"Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402"	95065	Investigative	D04CRB	.	CTPDG013856
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Talmapimod	"SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]"	9871074	Investigative	D04HWF	DB05412	CTPDG013857
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	CHEMBL1091737	46886448	Investigative	D07TTR	.	CTPDG013858
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Dihydro-quinolinone	"553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%"	64796	Investigative	D08BIP	.	CTPDG013859
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone	"54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR"	15311937	Investigative	D08WFC	.	CTPDG013860
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5	5326871	Investigative	D09GQO	DB08093	CTPDG013861
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PMID22521646C12	GTPL8125; BDBM50420761	25060878	Investigative	D09OKU	.	CTPDG013862
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(4-methyl-benzyl)-4-phenoxy-benzamide	CHEMBL199174; AC1OVMY0; BDBM50174096	7916852	Investigative	D09XVY	.	CTPDG013863
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	2-Chlorophenol	"o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N"	7245	Investigative	D09ZZI	DB03110	CTPDG013864
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	GSK-280	"P38 kinase inhibitors (inflammation), GSK"	.	Investigative	D0DK2X	.	CTPDG013865
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	SB-216995	PYRIDINYLIMIDAZOLE; CHEMBL96741; sb216995; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE; SB6; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine; 1bl6; AC1L1JR9; SCHEMBL4915662; CTK7C0283; BDBM15237; ZINC2047872; DB08522	5171	Investigative	D0E4LU	DB08522	CTPDG013866
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL199074	44405448	Investigative	D0H8RU	.	CTPDG013867
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PHA-666859	"SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer"	.	Investigative	D0L1NU	.	CTPDG013868
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine	CHEMBL176245	11175093	Investigative	D0L3DF	.	CTPDG013869
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	SB-227931	CHEMBL371720; BDBM50173166	44404442	Investigative	D0M2OL	.	CTPDG013870
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	CHEMBL198832	44405454	Investigative	D0N9HX	.	CTPDG013871
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-(4-Fluoro-phenylsulfanyl)-9H-purine	6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603	11265091	Investigative	D0Q8HM	.	CTPDG013872
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389	2352168	Investigative	D0QS9T	DB07459	CTPDG013873
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	DP-802	"P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera"	.	Investigative	D0S4BP	.	CTPDG013874
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Ro-3201195	"[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE; CHEMBL203567; CHEBI:45116; Ro 320-1195; 2gfs; PQB; [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl](3-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)methanone; aminopyrazole 63; RO3201195; AC1NS1L4; SCHEMBL4108597; BDBM15754; IJDQETGUEUJVTB-HNNXBMFYSA-N; DB08424; Ro-320-1195; J3.504.577E; UNII-TE3ESF890C component IJDQETGUEUJVTB-HNNXBMFYSA-N; 5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}benzoyl]pyrazole"	5327067	Investigative	D0S6GE	DB08424	CTPDG013875
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine	CHEMBL198334; BDBM50173628	11277481	Investigative	D0S9SX	.	CTPDG013876
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Triazolopyridine	"CP-808844; 6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3-ISOPROPYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE; 1zzl; AC1NRDFA; Triazolopyridine deriv. 25; SCHEMBL40860; CHEMBL194322; BDBM15414; DB04797; 6-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridine; 6-[4-(4-Fluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine; 4-(4-fluorophenyl)-5-[3-(propan-2-yl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-1,3-oxazole"	5289514	Investigative	D0X5CM	DB04797	CTPDG013877
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	3-(Benzyloxy)Pyridin-2-Amine	"2-Amino-3-benzyloxypyridine; 24016-03-3; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ"	90334	Investigative	D09DRF	DB02352	CTPDG013878
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-Benzylsulfanyl-9H-purine	"Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine"	93558	Investigative	D0BH7S	.	CTPDG013879
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	"CHEMBL383177; N,3-diphenyl-1H-indazol-6-amine; SCHEMBL6582340"	10236389	Investigative	D0H2PE	.	CTPDG013880
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	IN-1130	"UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide"	11676119	Investigative	D0K6YK	.	CTPDG013881
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	"4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine"	"4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-"	11481564	Investigative	D0M3CT	.	CTPDG013882
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	RWJ-68354	"CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165"	9819053	Investigative	D06NUL	.	CTPDG013883
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	GW-788388	452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606	10202642	Investigative	D0C3AD	.	CTPDG008418
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	IN-1166	"UNII-86NAB50A9A; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3"	16654987	Investigative	D0H6ZP	.	CTPDG013884
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Oxindole 94	"SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol"	5169	Investigative	D0VC0I	.	CTPDG012699
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ZM-336372	ZM 336372; 208260-29-1; ZM336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231	5730	Investigative	D00NWF	.	CTPDG013885
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ML-3375	CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	9795838	Investigative	D09HBZ	.	CTPDG013222
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-o-tolylquinazolin-2-amine	CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815	16086113	Investigative	D09HXU	.	CTPDG010143
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ML-3403	p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine	6419739	Investigative	D0W4FF	.	CTPDG013223
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ML-3163	ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine	9845197	Investigative	D08DSJ	.	CTPDG013224
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	Investigative	D0G2VC	.	CTPDG011474
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	Investigative	D02UVH	.	CTPDG010581
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03543	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03543	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03543	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 2	SEphB4-HSA	.	.	Phase 2	DXWP72	.	CTPDG001611
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 1	KO-947	"ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947"	136653617	Phase 1	D0A1DG	.	CTPDG004951
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 1	MK-8353	"KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide"	58282870	Phase 1	D0L1GD	.	CTPDG004641
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	SNEWIQPRLPQH	CHEMBL448652	44560069	Investigative	D0H3IS	.	CTPDG014155
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	PMID19788238C66	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160	44478401	Investigative	D05FXD	.	CTPDG014156
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT03544	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	PMID23489211C20	PCM126; GTPL8124; BDBM50428059	71718651	Investigative	D0X8BU	.	CTPDG014157
M6ACROT03544	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03544	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03545	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03545	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03546	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03546	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03547	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03547	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03547	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03548	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03548	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03548	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03549	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03549	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03549	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT03550	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03550	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03550	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03550	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03550	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03551	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03551	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03552	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03552	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03553	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03553	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03554	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03554	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03555	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03555	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03556	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03556	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03556	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT03556	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT03556	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT03557	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03557	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03558	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03558	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03559	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03559	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03560	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03560	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03561	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03561	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03562	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03562	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03563	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03563	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03563	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03564	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03564	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03565	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03565	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Approved	Emapalumab	Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X	.	Approved	D0UI7K	.	CTPDG011332
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 3	Fumaric acid	"Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)"	444972	Phase 3	D03GOO	DB01677	CTPDG001446
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1/2	VIR-201	.	.	Phase 1/2	D0I5QV	.	CTPDG011333
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1	AMG 811	.	.	Phase 1	D06FLP	.	CTPDG011334
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1	CIGB-128	"HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB"	.	Phase 1	D06NDP	.	CTPDG011335
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	TAK-603	.	153980	Discontinued in Phase 2	D0H6PX	.	CTPDG011336
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	TG-1042	"TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene"	.	Discontinued in Phase 2	D0Z9MR	.	CTPDG006396
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	CRx-191	.	.	Discontinued in Phase 2	D0VA2I	.	CTPDG006416
M6ACROT03566	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Preclinical	VPM-4-001	"Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management"	.	Preclinical	D0WD6K	.	CTPDG011337
M6ACROT03566	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03566	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03567	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03567	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03567	C-X-C motif chemokine 9 (Cxcl9)	CXCL9_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	BMS-936557	"Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex"	.	Phase 2	D00YWL	.	CTPDG014460
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	NI-0801	"Anti-interferon inducible protein 10, NovImmune"	.	Phase 2	D03VNB	.	CTPDG014461
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	MDX-1100	.	.	Phase 2	D0C1UF	.	CTPDG002495
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	Anti-IP10	.	.	Phase 2	D0L7LH	.	CTPDG002232
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	JT02	.	.	Phase 2	D0VE3U	.	CTPDG014462
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT03568	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Investigative	N-Methylleucine	"N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191"	6951123	Investigative	D0F6OK	DB04487	CTPDG014463
M6ACROT03568	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03568	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03569	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03569	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03569	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptide analog 8	PMID26394986-Compound-2	.	Patented	D0JF5K	.	CTPDG014924
M6ACROT03569	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03569	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03569	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03569	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03569	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Discontinued in Phase 2	AVT-02 UE	.	.	Discontinued in Phase 2	D03WRN	.	CTPDG014925
M6ACROT03570	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03570	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03571	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03571	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03571	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT03572	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03572	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Approved	Pro-urokinase	Thrombolyse (TN)	.	Approved	D03VNX	.	CTPDG010519
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Approved	Urokinase	.	.	Approved	D0E8UO	.	CTPDG010520
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 4	PAI-1	"PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-"	3246941	Phase 4	D03ZJE	DB08324	CTPDG010521
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 3	Amediplase	"Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol"	154656	Phase 3	D0G6ZG	.	CTPDG010522
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 2	Upamostat	WX-671	9830667	Phase 2	D03KGH	.	CTPDG010523
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 2	Saruplase	"Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal"	.	Phase 2	D0G5UW	.	CTPDG010524
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 1/2	HTU-PA	"Human tissue urokinase type plasminogen activator, Global Biotech"	.	Phase 1/2	D01HHJ	.	CTPDG010525
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Clinical trial	PMID18163548C4	"7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12"	449051	Clinical trial	D00EPS	.	CTPDG010526
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Discontinued in Phase 2	PAI-2	"N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt"	443433	Discontinued in Phase 2	D0D3VA	.	CTPDG010527
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Discontinued in Phase 1/2	WX-UK1	"UKI-1; UNII-00LOF6890B; CHEMBL107955; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6"	9895194	Discontinued in Phase 1/2	D08INO	.	CTPDG006693
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Terminated	B-428	.	1747	Terminated	D0K1PR	.	CTPDG007303
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	UPA-targeted oncolytic Sendai virus	"BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC"	.	Investigative	D00LDI	.	CTPDG009178
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	CRA_10655	AC1O4QGF	447480	Investigative	D01LCS	DB02526	CTPDG010528
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	5-Methylsulfanyl-thiophene-2-carboxamidine	"CHEMBL28890; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine"	10313318	Investigative	D02XJW	.	CTPDG010529
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	ATN-658	"ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin"	.	Investigative	D03BWQ	.	CTPDG008984
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine"	"94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N"	180621	Investigative	D03NLL	DB07129	CTPDG010530
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	B-623	149732-37-6	9820186	Investigative	D05DNW	.	CTPDG010531
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-chloro-1-guanidino-7-isoquinolinesulphonamide	223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline	16658353	Investigative	D06CJP	.	CTPDG010532
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-Amino-5-Hydroxy-Benzimidazole	.	162636	Investigative	D09KKF	DB03729	CTPDG010533
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide	447732	Investigative	D0A8WP	DB01977	CTPDG010534
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"Thieno[2,3-B]Pyridine-2-Carboxamidine"	"amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538"	5438	Investigative	D0B1AK	DB03876	CTPDG010535
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Recombinant human pro-urokinase	Recombinant human pro-urokinase (myocardial infarction)	.	Investigative	D0D1TX	.	CTPDG010536
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	"AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea"	4286	Investigative	D0EV6B	DB03782	CTPDG010537
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-guanidino-benzyl)-carbamic acid benzyl ester	CHEMBL391969	44436702	Investigative	D0F6EZ	.	CTPDG010538
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	SCHEMBL20553177; DB07122	16758228	Investigative	D0ZM9M	DB07122	CTPDG010539
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	"4-methoxy-N'-(phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide"	695069	Investigative	D02AKP	.	CTPDG010540
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	ATF-HI-8	"urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University"	.	Investigative	D05ABK	.	CTPDG010541
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-guanidino-7-isoquinolinesulphonamide	"SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine"	16658352	Investigative	D0K4PK	.	CTPDG010542
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	CRA_8696	AC1O4QGN	447476	Investigative	D0K7YL	DB03159	CTPDG010543
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline	16658631	Investigative	D00PEJ	.	CTPDG010544
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	"BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone"	674641	Investigative	D00WFQ	.	CTPDG010545
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-iodobenzo[b]thiophene 2-carboxamidine	amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium	1746	Investigative	D05MJU	DB03136	CTPDG010546
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	"BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627"	674651	Investigative	D06LPR	.	CTPDG010547
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	"(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide"	6852210	Investigative	D0SP2I	.	CTPDG010548
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	"AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1"	674656	Investigative	D05ZIP	.	CTPDG010549
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Benzamidine	Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395	2332	Investigative	D07SFI	.	CTPDG010550
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	"(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole"	699665	Investigative	D08OCS	.	CTPDG010551
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	"AC1LERN1; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide"	716930	Investigative	D0IU5E	.	CTPDG010552
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone"	"AC1LDSBN; BAS 02052919; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1"	674628	Investigative	D0X1OY	.	CTPDG010553
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium	1507	Investigative	D08OLP	DB02463	CTPDG010554
M6ACROT03573	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	Investigative	D0G6XS	.	CTPDG010555
M6ACROT03573	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03573	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03574	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03574	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03575	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03575	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03576	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03576	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03577	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03577	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1/2	CAR-T cells targeting EphA2	.	.	Phase 1/2	D05OHY	.	CTPDG014491
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1/2	BT5528	.	.	Phase 1/2	DS5C0K	.	CTPDG003145
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1	DS-8895	.	.	Phase 1	D03YBJ	.	CTPDG005279
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1	MEDI-547	"MedImmune, MedImmune/AstraZeneca"	.	Phase 1	D0B8MS	.	CTPDG004913
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Preclinical	MEDI-543	"MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune"	.	Preclinical	D0W8HP	.	CTPDG007036
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	PMID21561767C8h	GTPL8170; BDBM50345579	46864270	Investigative	D02BXJ	.	CTPDG010061
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	PMID19788238C66	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160	44478401	Investigative	D05FXD	.	CTPDG014156
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT03578	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	PMID23489211C20	PCM126; GTPL8124; BDBM50428059	71718651	Investigative	D0X8BU	.	CTPDG014157
M6ACROT03578	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03578	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Ranibizumab	"Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)"	.	Approved	D04EYG	.	CTPDG012421
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Brolucizumab	.	.	Approved	D5DO9L	.	CTPDG012422
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Faricimab	RO6867461; RG7716	.	Approved	D9MWL4	.	CTPDG012423
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Rituximab	.	24801580	Phase 3	D08CGU	.	CTPDG012424
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Trastuzumab	"Lithocholic acid; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,"	9903	Phase 3	D04SLF	.	CTPDG009886
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	Abicipar pegol	.	.	Phase 2	D0CJ7Z	.	CTPDG012426
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RO5520985	.	.	Phase 2	D0I8YS	.	CTPDG012427
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	SNN-0029	"VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech"	.	Phase 1/2	D0E7RQ	.	CTPDG012428
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	MP0250	.	.	Phase 1/2	D0ME7Q	.	CTPDG012429
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	AT001/r84	.	.	Phase 1	D0NO1A	.	CTPDG004566
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	MP-0112	"DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan"	10464700	Phase 1	D0V3HP	.	CTPDG012430
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	SFLT-01	"AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme"	.	Phase 1	D0YZ4T	.	CTPDG012431
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	ABI-011	.	.	Phase 1	D0P4KU	.	CTPDG004522
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 17	PMID28621580-Compound-WO2012089137c13	.	Patented	D00ZFY	.	CTPDG012432
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 16	PMID28621580-Compound-WO2012028106c12	.	Patented	D01CKB	.	CTPDG012433
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 18	PMID28621580-Compound-WO2014086102c29	.	Patented	D01DJZ	.	CTPDG012434
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 11	PMID28621580-Compound-WO2016059057	.	Patented	D01IFD	.	CTPDG012435
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 2	PMID28621580-Compound-US20130096136c42	71522446	Patented	D01OEF	.	CTPDG012436
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 16	PMID28621580-Compound-WO2013037293c26	.	Patented	D03HPW	.	CTPDG012437
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 22	PMID28621580-Compound-WO2014040243c18	.	Patented	D03SZN	.	CTPDG012438
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 1"	PMID28621580-Compound-WO2013032797c63	.	Patented	D03VXQ	.	CTPDG012439
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"1,6-naphyridine-4-ketone fused heterocyclic derivative 1"	PMID28621580-Compound-WO2013097753c65	.	Patented	D04UKD	.	CTPDG012440
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 5	PMID28621580-Compound-US20160096832c60	.	Patented	D05GVV	.	CTPDG006171
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013112959C68	.	.	Patented	D05LBH	.	CTPDG012441
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 23	PMID28621580-Compound-WO2014201127c20	.	Patented	D05WTW	.	CTPDG012442
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 7	PMID28621580-Compound-WO2013112950c37	.	Patented	D06ARD	.	CTPDG012443
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 9	PMID28621580-Compound-WO2010066684c55	.	Patented	D07ESG	.	CTPDG012444
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 4	PMID28621580-Compound-WO2012127012c31	.	Patented	D07UJJ	.	CTPDG012445
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 5	PMID28621580-Compound-WO2013015657c41	.	Patented	D08INZ	.	CTPDG012446
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 15	PMID28621580-Compound-US20160096828c21	.	Patented	D08XDA	.	CTPDG012447
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 3	PMID28621580-Compound-WO2012125123	.	Patented	D09GWR	.	CTPDG012448
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 7	PMID28621580-Compound-US20169233968c59	.	Patented	D09KYB	.	CTPDG006060
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 18	PMID28621580-Compound-WO2012094451c15	.	Patented	D0A5NC	.	CTPDG012449
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 21	PMID28621580-Compound-WO2015117551c25	.	Patented	D0A8SH	.	CTPDG012450
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 10	PMID28621580-Compound-WO2014000686c53	.	Patented	D0A9RY	.	CTPDG012451
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 7	PMID28621580-Compound-WO2013044362c44	.	Patented	D0BA5J	.	CTPDG012452
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 6	PMID28621580-Compound-WO2013040515c36	.	Patented	D0BL4H	.	CTPDG012453
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 7	PMID28621580-Compound-WO2014055998	.	Patented	D0CE1R	.	CTPDG006006
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 2	PMID28621580-Compound-WO2012088563	.	Patented	D0D0AX	.	CTPDG012454
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 3	PMID28621580-Compound-US20140336108c48	.	Patented	D0D7SL	.	CTPDG012455
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 8	PMID28621580-Compound-WO2014029250c45	.	Patented	D0DA6B	.	CTPDG012456
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 19	PMID28621580-Compound-WO2012139499c14	.	Patented	D0DI5S	.	CTPDG012457
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 13	PMID28621580-Compound-WO2012088506c23	.	Patented	D0E5IJ	.	CTPDG012458
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 11	PMID28621580-Compound-WO2014139458c54	.	Patented	D0EE3P	.	CTPDG012459
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 8	PMID28621580-Compound-US20169296747c52	.	Patented	D0FK5P	.	CTPDG012460
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 10	PMID28621580-Compound-WO2014127335c34	.	Patented	D0FK6Y	.	CTPDG012461
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 8	PMID28621580-Compound-WO2014113859c33	.	Patented	D0FL6P	.	CTPDG012462
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 10	PMID28621580-Compound-WO2014040242c47	.	Patented	D0FY2Q	.	CTPDG012463
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 14	PMID28621580-Compound-WO2012139019c24	.	Patented	D0HO5B	.	CTPDG012464
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2014079545C69	.	.	Patented	D0HX9S	.	CTPDG012465
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 14	PMID28621580-Compound-US20140256819c19	.	Patented	D0I6WJ	.	CTPDG012466
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 11	PMID28621580-Compound-WO2015075483c49	.	Patented	D0IZ8B	.	CTPDG012467
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 9	PMID28621580-Compound-WO2014029251c46	.	Patented	D0KW0F	.	CTPDG012468
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 5	PMID28621580-Compound-WO2012171487c32	.	Patented	D0M2XJ	.	CTPDG012469
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 4	PMID28621580-Compound-WO2012169934c40	.	Patented	D0M9KZ	.	CTPDG005777
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 3	PMID28621580-Compound-US20150158854c39	.	Patented	D0MA6I	.	CTPDG012470
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 2	PMID28621580-Compound-US20130165458c38	.	Patented	D0O5IA	.	CTPDG012471
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 17	PMID28621580-Compound-WO2014086102c28	.	Patented	D0O8RZ	.	CTPDG012472
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 19	PMID28621580-Compound-WO2014102377c27	.	Patented	D0Q4XV	.	CTPDG012473
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 6	PMID28621580-Compound-WO2013044361c43	.	Patented	D0S4XH	.	CTPDG012474
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 9	PMID28621580-Compound-WO2014127214c35	.	Patented	D0SH2Y	.	CTPDG012475
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1	PMID28621580-Compound-WO2013101954c67	.	Patented	D0T1GG	.	CTPDG005642
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013036866C66	.	.	Patented	D0T9DV	.	CTPDG005634
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 8	PMID28621580-Compound-WO2014081202	.	Patented	D0U6PW	.	CTPDG012476
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 6	PMID28621580-Compound-US20160096837c61	.	Patented	D0V7OF	.	CTPDG005600
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 20	PMID28621580-Compound-WO2013037292c17	60171803	Patented	D0VI1V	.	CTPDG012477
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 15	PMID28621580-Compound-WO2012139019c25	.	Patented	D0VX5Y	.	CTPDG012478
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 9	PMID28621580-Compound-WO2016044219	.	Patented	D0WL5P	.	CTPDG005578
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 1	PMID28621580-Compound-WO2012004631	.	Patented	D0X2BP	.	CTPDG012479
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 20	PMID28621580-Compound-WO2015117551c24	.	Patented	D0X2MF	.	CTPDG012480
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 21	PMID28621580-Compound-WO2013107225c16	.	Patented	D0XS0Z	.	CTPDG012481
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 4	PMID28621580-Compound-WO2012161372	.	Patented	D0Y2IV	.	CTPDG012482
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 12	PMID28621580-Compound-WO2012088506c22	.	Patented	D0Z0SY	.	CTPDG012483
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 2"	PMID28621580-Compound-WO2013032797c64	.	Patented	D0ZE2J	.	CTPDG012484
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Discontinued in Phase 3	Bevasiranib	.	.	Discontinued in Phase 3	D0YG4I	.	CTPDG012485
M6ACROT03579	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Terminated	ALN-VEG01	"RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck"	.	Terminated	D05ITS	.	CTPDG015424
M6ACROT03579	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03579	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03580	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03580	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03581	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03581	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03582	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03582	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03583	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03583	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03584	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03584	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03585	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03585	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03586	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03586	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03587	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03587	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03587	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03587	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03587	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03587	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 4	Ozagrel	"Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika"	5282440	Phase 4	D0C7AA	DB12017	CTPDG013845
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 3	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	Phase 3	D0C8DD	DB12270	CTPDG001255
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 2a	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	Phase 2a	D0D9AH	DB05470	CTPDG001587
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 2	Dilmapimod	"SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602"	10297982	Phase 2	D0K0JQ	DB12140	CTPDG013846
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Phase 2	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	Phase 2	D02NNV	DB07138	CTPDG002970
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-O2	.	.	Patented	D03JFK	.	CTPDG013847
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-L2	.	.	Patented	D08OJQ	.	CTPDG013848
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-L3	.	.	Patented	D0G7LB	.	CTPDG013849
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-L1	.	.	Patented	D0Q8CR	.	CTPDG013783
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-F2	.	.	Patented	D06JRV	.	CTPDG013790
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 2	PAMAPIMOD	"449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	Discontinued in Phase 2	D04WCI	.	CTPDG006625
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	Discontinued in Phase 1	D04YHW	DB06518	CTPDG006892
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	FR167653	"HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818"	135484078	Discontinued in Phase 1	D05QMG	.	CTPDG006886
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	SB-242235	193746-75-7; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	Discontinued in Phase 1	D0A9KI	.	CTPDG006835
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Discontinued in Phase 1	SB 235699	"4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-"	9797240	Discontinued in Phase 1	D0W0AM	.	CTPDG006724
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Terminated	SC-102	"4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl); SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings"	12106168	Terminated	D0O7BW	DB07829	CTPDG007263
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Terminated	SB 203580	152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV	176155	Terminated	D0F8DL	.	CTPDG012581
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	9-Benzyl-6-phenylsulfanyl-9H-purine	SCHEMBL6662063	11347708	Investigative	D00ODN	.	CTPDG013850
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL198563	11703439	Investigative	D00PPB	.	CTPDG013851
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	UCB-1277763	"P38 kinase inhibitors (inflammation), UCB"	.	Investigative	D00YRF	.	CTPDG013852
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Small molecule 34	3-(2-(4-pyridyl)ethyl)indole; 3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE; INHIBITOR OF P38 KINASE; 3-(2-(Pyridin-4-yl)ethyl)-1H-indole; 3-[2-(pyridin-4-yl)ethyl]-1H-indole; 3-(2-Pyridin-4-yl-ethyl)-1H-indole; L12; Maybridge1_000718; Cambridge id 5373101; AC1L1E9J; Oprea1_574113; Oprea1_420786; SCHEMBL735580; CHEMBL193156; HMS543I14; ZINC94256; BDBM13346; UUEYCHLWAOBOHG-UHFFFAOYSA-N; 1w84; MolPort-001-886-488; HMS3604M06; 3-[2-(4-pyridyl)-ethyl]-indole; STL328644; CCG-45397; 3-[2-(4-Pyridyl)ethyl]-1H-indole; AKOS000545583; MCULE-4657429599	27934	Investigative	D01CRK	DB01953	CTPDG013853
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	SB-218655	1bmk; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyrimidin-2-amine; 4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE; 165806-51-9; SB 218655; C14316; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; SB5; AC1L1JRC; AC1Q4ON9; SCHEMBL4323457; CHEMBL590753; BDBM15238; CTK4D2173; DTXSID50274456; sb218655; AKOS030547879	5172	Investigative	D02NKV	DB03980	CTPDG013854
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine	SCHEMBL6659707	11336624	Investigative	D03XYK	.	CTPDG013855
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-Phenylsulfanyl-9H-purine	"Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402"	95065	Investigative	D04CRB	.	CTPDG013856
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Talmapimod	"SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]"	9871074	Investigative	D04HWF	DB05412	CTPDG013857
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	CHEMBL1091737	46886448	Investigative	D07TTR	.	CTPDG013858
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Dihydro-quinolinone	"553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%"	64796	Investigative	D08BIP	.	CTPDG013859
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone	"54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR"	15311937	Investigative	D08WFC	.	CTPDG013860
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5	5326871	Investigative	D09GQO	DB08093	CTPDG013861
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PMID22521646C12	GTPL8125; BDBM50420761	25060878	Investigative	D09OKU	.	CTPDG013862
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(4-methyl-benzyl)-4-phenoxy-benzamide	CHEMBL199174; AC1OVMY0; BDBM50174096	7916852	Investigative	D09XVY	.	CTPDG013863
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	2-Chlorophenol	"o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N"	7245	Investigative	D09ZZI	DB03110	CTPDG013864
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	GSK-280	"P38 kinase inhibitors (inflammation), GSK"	.	Investigative	D0DK2X	.	CTPDG013865
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	SB-216995	PYRIDINYLIMIDAZOLE; CHEMBL96741; sb216995; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE; SB6; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine; 1bl6; AC1L1JR9; SCHEMBL4915662; CTK7C0283; BDBM15237; ZINC2047872; DB08522	5171	Investigative	D0E4LU	DB08522	CTPDG013866
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL199074	44405448	Investigative	D0H8RU	.	CTPDG013867
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PHA-666859	"SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer"	.	Investigative	D0L1NU	.	CTPDG013868
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine	CHEMBL176245	11175093	Investigative	D0L3DF	.	CTPDG013869
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	SB-227931	CHEMBL371720; BDBM50173166	44404442	Investigative	D0M2OL	.	CTPDG013870
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	CHEMBL198832	44405454	Investigative	D0N9HX	.	CTPDG013871
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-(4-Fluoro-phenylsulfanyl)-9H-purine	6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603	11265091	Investigative	D0Q8HM	.	CTPDG013872
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389	2352168	Investigative	D0QS9T	DB07459	CTPDG013873
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	DP-802	"P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera"	.	Investigative	D0S4BP	.	CTPDG013874
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Ro-3201195	"[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE; CHEMBL203567; CHEBI:45116; Ro 320-1195; 2gfs; PQB; [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl](3-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)methanone; aminopyrazole 63; RO3201195; AC1NS1L4; SCHEMBL4108597; BDBM15754; IJDQETGUEUJVTB-HNNXBMFYSA-N; DB08424; Ro-320-1195; J3.504.577E; UNII-TE3ESF890C component IJDQETGUEUJVTB-HNNXBMFYSA-N; 5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}benzoyl]pyrazole"	5327067	Investigative	D0S6GE	DB08424	CTPDG013875
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine	CHEMBL198334; BDBM50173628	11277481	Investigative	D0S9SX	.	CTPDG013876
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Triazolopyridine	"CP-808844; 6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3-ISOPROPYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE; 1zzl; AC1NRDFA; Triazolopyridine deriv. 25; SCHEMBL40860; CHEMBL194322; BDBM15414; DB04797; 6-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridine; 6-[4-(4-Fluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine; 4-(4-fluorophenyl)-5-[3-(propan-2-yl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-1,3-oxazole"	5289514	Investigative	D0X5CM	DB04797	CTPDG013877
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	3-(Benzyloxy)Pyridin-2-Amine	"2-Amino-3-benzyloxypyridine; 24016-03-3; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ"	90334	Investigative	D09DRF	DB02352	CTPDG013878
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-Benzylsulfanyl-9H-purine	"Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine"	93558	Investigative	D0BH7S	.	CTPDG013879
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	"CHEMBL383177; N,3-diphenyl-1H-indazol-6-amine; SCHEMBL6582340"	10236389	Investigative	D0H2PE	.	CTPDG013880
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	IN-1130	"UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide"	11676119	Investigative	D0K6YK	.	CTPDG013881
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	"4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine"	"4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-"	11481564	Investigative	D0M3CT	.	CTPDG013882
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	RWJ-68354	"CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165"	9819053	Investigative	D06NUL	.	CTPDG013883
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	GW-788388	452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606	10202642	Investigative	D0C3AD	.	CTPDG008418
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	IN-1166	"UNII-86NAB50A9A; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3"	16654987	Investigative	D0H6ZP	.	CTPDG013884
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Oxindole 94	"SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol"	5169	Investigative	D0VC0I	.	CTPDG012699
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ZM-336372	ZM 336372; 208260-29-1; ZM336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231	5730	Investigative	D00NWF	.	CTPDG013885
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ML-3375	CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	9795838	Investigative	D09HBZ	.	CTPDG013222
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	6-o-tolylquinazolin-2-amine	CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815	16086113	Investigative	D09HXU	.	CTPDG010143
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ML-3403	p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine	6419739	Investigative	D0W4FF	.	CTPDG013223
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	ML-3163	ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine	9845197	Investigative	D08DSJ	.	CTPDG013224
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	Investigative	D0G2VC	.	CTPDG011474
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	Investigative	D02UVH	.	CTPDG010581
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03588	Mitogen-activated protein kinase 14 (p38/MAPK14)	MK14_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03588	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03588	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03588	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03588	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03588	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03588	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 2	SEphB4-HSA	.	.	Phase 2	DXWP72	.	CTPDG001611
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 1	KO-947	"ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947"	136653617	Phase 1	D0A1DG	.	CTPDG004951
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Phase 1	MK-8353	"KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide"	58282870	Phase 1	D0L1GD	.	CTPDG004641
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	SNEWIQPRLPQH	CHEMBL448652	44560069	Investigative	D0H3IS	.	CTPDG014155
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	PMID19788238C66	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160	44478401	Investigative	D05FXD	.	CTPDG014156
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT03589	Ephrin type-B receptor 2 (ERK/EPHB2)	EPHB2_HUMAN	.	.	Investigative	PMID23489211C20	PCM126; GTPL8124; BDBM50428059	71718651	Investigative	D0X8BU	.	CTPDG014157
M6ACROT03589	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03589	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03589	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03589	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03589	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03589	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03590	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03590	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03590	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03590	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03590	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03590	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03591	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03591	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03591	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03591	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03591	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03591	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03592	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03592	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03592	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03592	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03592	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03592	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03592	G1/S-specific cyclin-E1 (CCNE1)	CCNE1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03593	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT03593	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03593	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03593	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03593	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03593	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03593	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03594	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03594	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03594	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03594	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03594	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03594	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03594	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT03595	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03595	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03595	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03595	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03595	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03595	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03595	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03595	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03595	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03596	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03596	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03596	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03596	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03596	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03596	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03597	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03597	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03597	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03597	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03597	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03597	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03598	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03598	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03598	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03598	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03598	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03598	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03599	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03599	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03599	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03599	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03599	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03599	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03600	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03600	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03600	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03600	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03600	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03600	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03601	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT03601	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT03601	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT03601	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03601	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03601	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03601	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03601	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03601	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03602	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03602	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03602	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03602	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03602	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03602	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03603	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03603	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03603	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03603	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03603	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03603	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03604	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03604	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03604	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03604	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03604	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03604	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03605	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03605	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03605	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03605	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03605	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03605	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03606	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03606	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03606	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03606	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03606	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03606	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03607	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03607	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03607	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03607	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03607	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03607	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03608	Lactate dehydrogenase A (LDHA)	LDHA_HUMAN	.	.	Approved	Nedosiran	nedosiran	.	Approved	DZ8DF0	.	CTPDG013136
M6ACROT03608	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03608	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03608	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03608	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03608	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03608	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03609	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03609	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03609	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03609	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03609	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03609	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03610	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03610	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03610	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03610	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03610	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03610	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Approved	Emapalumab	Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X	.	Approved	D0UI7K	.	CTPDG011332
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 3	Fumaric acid	"Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)"	444972	Phase 3	D03GOO	DB01677	CTPDG001446
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1/2	VIR-201	.	.	Phase 1/2	D0I5QV	.	CTPDG011333
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1	AMG 811	.	.	Phase 1	D06FLP	.	CTPDG011334
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Phase 1	CIGB-128	"HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB"	.	Phase 1	D06NDP	.	CTPDG011335
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	TAK-603	.	153980	Discontinued in Phase 2	D0H6PX	.	CTPDG011336
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	Fontolizumab	Fontolizumab (USAN/INN)	.	Discontinued in Phase 2	D0N4ND	.	CTPDG006470
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	TG-1042	"TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene"	.	Discontinued in Phase 2	D0Z9MR	.	CTPDG006396
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Discontinued in Phase 2	CRx-191	.	.	Discontinued in Phase 2	D0VA2I	.	CTPDG006416
M6ACROT03611	Interferon gamma (IFN-gamma)	IFNG_HUMAN	.	.	Preclinical	VPM-4-001	"Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management"	.	Preclinical	D0WD6K	.	CTPDG011337
M6ACROT03611	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03611	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03611	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03611	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03611	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03611	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03612	C-X-C motif chemokine 9 (Cxcl9)	CXCL9_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT03612	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03612	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03612	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03612	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03612	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03612	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	BMS-936557	"Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex"	.	Phase 2	D00YWL	.	CTPDG014460
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	NI-0801	"Anti-interferon inducible protein 10, NovImmune"	.	Phase 2	D03VNB	.	CTPDG014461
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	MDX-1100	.	.	Phase 2	D0C1UF	.	CTPDG002495
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	Anti-IP10	.	.	Phase 2	D0L7LH	.	CTPDG002232
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 2	JT02	.	.	Phase 2	D0VE3U	.	CTPDG014462
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT03613	C-X-C motif chemokine 10 (Cxcl10)	CXL10_HUMAN	.	.	Investigative	N-Methylleucine	"N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191"	6951123	Investigative	D0F6OK	DB04487	CTPDG014463
M6ACROT03613	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03613	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03613	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03613	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03613	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03613	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03614	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03614	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03614	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03614	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03614	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03614	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03614	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptide analog 8	PMID26394986-Compound-2	.	Patented	D0JF5K	.	CTPDG014924
M6ACROT03614	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03614	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03614	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03614	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03614	Transcription factor ISGF-3 components p91/p84 (Stat1)	STAT1_HUMAN	.	.	Discontinued in Phase 2	AVT-02 UE	.	.	Discontinued in Phase 2	D03WRN	.	CTPDG014925
M6ACROT03615	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03615	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03615	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03615	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03615	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03615	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03616	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03616	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03616	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03616	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03616	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03616	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03616	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT03617	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03617	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03617	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03617	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03617	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03617	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Approved	Pro-urokinase	Thrombolyse (TN)	.	Approved	D03VNX	.	CTPDG010519
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Approved	Urokinase	.	.	Approved	D0E8UO	.	CTPDG010520
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 4	PAI-1	"PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-"	3246941	Phase 4	D03ZJE	DB08324	CTPDG010521
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 3	Amediplase	"Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol"	154656	Phase 3	D0G6ZG	.	CTPDG010522
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 2	Upamostat	WX-671	9830667	Phase 2	D03KGH	.	CTPDG010523
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 2	Saruplase	"Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal"	.	Phase 2	D0G5UW	.	CTPDG010524
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 1/2	HTU-PA	"Human tissue urokinase type plasminogen activator, Global Biotech"	.	Phase 1/2	D01HHJ	.	CTPDG010525
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Clinical trial	PMID18163548C4	"7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12"	449051	Clinical trial	D00EPS	.	CTPDG010526
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Discontinued in Phase 2	PAI-2	"N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt"	443433	Discontinued in Phase 2	D0D3VA	.	CTPDG010527
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Discontinued in Phase 1/2	WX-UK1	"UKI-1; UNII-00LOF6890B; CHEMBL107955; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6"	9895194	Discontinued in Phase 1/2	D08INO	.	CTPDG006693
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Terminated	B-428	.	1747	Terminated	D0K1PR	.	CTPDG007303
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	UPA-targeted oncolytic Sendai virus	"BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC"	.	Investigative	D00LDI	.	CTPDG009178
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	CRA_10655	AC1O4QGF	447480	Investigative	D01LCS	DB02526	CTPDG010528
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	5-Methylsulfanyl-thiophene-2-carboxamidine	"CHEMBL28890; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine"	10313318	Investigative	D02XJW	.	CTPDG010529
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	ATN-658	"ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin"	.	Investigative	D03BWQ	.	CTPDG008984
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine"	"94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N"	180621	Investigative	D03NLL	DB07129	CTPDG010530
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	B-623	149732-37-6	9820186	Investigative	D05DNW	.	CTPDG010531
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-chloro-1-guanidino-7-isoquinolinesulphonamide	223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline	16658353	Investigative	D06CJP	.	CTPDG010532
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-Amino-5-Hydroxy-Benzimidazole	.	162636	Investigative	D09KKF	DB03729	CTPDG010533
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide	447732	Investigative	D0A8WP	DB01977	CTPDG010534
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"Thieno[2,3-B]Pyridine-2-Carboxamidine"	"amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538"	5438	Investigative	D0B1AK	DB03876	CTPDG010535
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Recombinant human pro-urokinase	Recombinant human pro-urokinase (myocardial infarction)	.	Investigative	D0D1TX	.	CTPDG010536
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	"AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea"	4286	Investigative	D0EV6B	DB03782	CTPDG010537
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-guanidino-benzyl)-carbamic acid benzyl ester	CHEMBL391969	44436702	Investigative	D0F6EZ	.	CTPDG010538
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	SCHEMBL20553177; DB07122	16758228	Investigative	D0ZM9M	DB07122	CTPDG010539
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	"4-methoxy-N'-(phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide"	695069	Investigative	D02AKP	.	CTPDG010540
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	ATF-HI-8	"urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University"	.	Investigative	D05ABK	.	CTPDG010541
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-guanidino-7-isoquinolinesulphonamide	"SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine"	16658352	Investigative	D0K4PK	.	CTPDG010542
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	CRA_8696	AC1O4QGN	447476	Investigative	D0K7YL	DB03159	CTPDG010543
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline	16658631	Investigative	D00PEJ	.	CTPDG010544
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	"BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone"	674641	Investigative	D00WFQ	.	CTPDG010545
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-iodobenzo[b]thiophene 2-carboxamidine	amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium	1746	Investigative	D05MJU	DB03136	CTPDG010546
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	"BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627"	674651	Investigative	D06LPR	.	CTPDG010547
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	"(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide"	6852210	Investigative	D0SP2I	.	CTPDG010548
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	"AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1"	674656	Investigative	D05ZIP	.	CTPDG010549
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Benzamidine	Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395	2332	Investigative	D07SFI	.	CTPDG010550
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	"(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole"	699665	Investigative	D08OCS	.	CTPDG010551
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	"AC1LERN1; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide"	716930	Investigative	D0IU5E	.	CTPDG010552
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone"	"AC1LDSBN; BAS 02052919; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1"	674628	Investigative	D0X1OY	.	CTPDG010553
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium	1507	Investigative	D08OLP	DB02463	CTPDG010554
M6ACROT03618	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	Investigative	D0G6XS	.	CTPDG010555
M6ACROT03618	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03618	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03618	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03618	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03618	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03618	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03619	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03619	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03619	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03619	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03619	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03619	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03620	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03620	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03620	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03620	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03620	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03620	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03621	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03621	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03621	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03621	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03621	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03621	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03622	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03622	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03622	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03622	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03622	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03622	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1/2	CAR-T cells targeting EphA2	.	.	Phase 1/2	D05OHY	.	CTPDG014491
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1/2	BT5528	.	.	Phase 1/2	DS5C0K	.	CTPDG003145
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1	DS-8895	.	.	Phase 1	D03YBJ	.	CTPDG005279
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Phase 1	MEDI-547	"MedImmune, MedImmune/AstraZeneca"	.	Phase 1	D0B8MS	.	CTPDG004913
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Preclinical	MEDI-543	"MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune"	.	Preclinical	D0W8HP	.	CTPDG007036
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	PMID21561767C8h	GTPL8170; BDBM50345579	46864270	Investigative	D02BXJ	.	CTPDG010061
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	PMID19788238C66	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160	44478401	Investigative	D05FXD	.	CTPDG014156
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT03623	Ephrin type-A receptor 2 (EphA2)	EPHA2_HUMAN	.	.	Investigative	PMID23489211C20	PCM126; GTPL8124; BDBM50428059	71718651	Investigative	D0X8BU	.	CTPDG014157
M6ACROT03623	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03623	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03623	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03623	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03623	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03623	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Ranibizumab	"Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)"	.	Approved	D04EYG	.	CTPDG012421
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	Approved	D04KBL	.	CTPDG000670
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Brolucizumab	.	.	Approved	D5DO9L	.	CTPDG012422
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Faricimab	RO6867461; RG7716	.	Approved	D9MWL4	.	CTPDG012423
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Approved	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	Approved	D0C9ET	.	CTPDG000434
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Rituximab	.	24801580	Phase 3	D08CGU	.	CTPDG012424
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Bevacizumab + Trastuzumab	"Lithocholic acid; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,"	9903	Phase 3	D04SLF	.	CTPDG009886
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 3	Avastin+/-Tarceva	"Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS"	3806	Phase 3	D0C0NH	.	CTPDG012425
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	Abicipar pegol	.	.	Phase 2	D0CJ7Z	.	CTPDG012426
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	Phase 2	D05VVX	.	CTPDG002782
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RG7221	.	.	Phase 2	D06FTM	.	CTPDG002764
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 2	RO5520985	.	.	Phase 2	D0I8YS	.	CTPDG012427
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	SNN-0029	"VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech"	.	Phase 1/2	D0E7RQ	.	CTPDG012428
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1/2	MP0250	.	.	Phase 1/2	D0ME7Q	.	CTPDG012429
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	AT001/r84	.	.	Phase 1	D0NO1A	.	CTPDG004566
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	MP-0112	"DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan"	10464700	Phase 1	D0V3HP	.	CTPDG012430
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	Navicixizumab	.	.	Phase 1	D00IVN	.	CTPDG005462
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	SFLT-01	"AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme"	.	Phase 1	D0YZ4T	.	CTPDG012431
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Phase 1	ABI-011	.	.	Phase 1	D0P4KU	.	CTPDG004522
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 17	PMID28621580-Compound-WO2012089137c13	.	Patented	D00ZFY	.	CTPDG012432
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 16	PMID28621580-Compound-WO2012028106c12	.	Patented	D01CKB	.	CTPDG012433
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 18	PMID28621580-Compound-WO2014086102c29	.	Patented	D01DJZ	.	CTPDG012434
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 11	PMID28621580-Compound-WO2016059057	.	Patented	D01IFD	.	CTPDG012435
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 2	PMID28621580-Compound-US20130096136c42	71522446	Patented	D01OEF	.	CTPDG012436
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 16	PMID28621580-Compound-WO2013037293c26	.	Patented	D03HPW	.	CTPDG012437
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 22	PMID28621580-Compound-WO2014040243c18	.	Patented	D03SZN	.	CTPDG012438
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 1"	PMID28621580-Compound-WO2013032797c63	.	Patented	D03VXQ	.	CTPDG012439
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	PMID28621580-Compound-WO2012084683c62	.	Patented	D04PKQ	.	CTPDG006190
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"1,6-naphyridine-4-ketone fused heterocyclic derivative 1"	PMID28621580-Compound-WO2013097753c65	.	Patented	D04UKD	.	CTPDG012440
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 5	PMID28621580-Compound-US20160096832c60	.	Patented	D05GVV	.	CTPDG006171
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013112959C68	.	.	Patented	D05LBH	.	CTPDG012441
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 23	PMID28621580-Compound-WO2014201127c20	.	Patented	D05WTW	.	CTPDG012442
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 7	PMID28621580-Compound-WO2013112950c37	.	Patented	D06ARD	.	CTPDG012443
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2015089220C70	.	.	Patented	D07AVU	.	CTPDG006128
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 9	PMID28621580-Compound-WO2010066684c55	.	Patented	D07ESG	.	CTPDG012444
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 4	PMID28621580-Compound-WO2012127012c31	.	Patented	D07UJJ	.	CTPDG012445
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 5	PMID28621580-Compound-WO2013015657c41	.	Patented	D08INZ	.	CTPDG012446
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 15	PMID28621580-Compound-US20160096828c21	.	Patented	D08XDA	.	CTPDG012447
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 3	PMID28621580-Compound-WO2012125123	.	Patented	D09GWR	.	CTPDG012448
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 7	PMID28621580-Compound-US20169233968c59	.	Patented	D09KYB	.	CTPDG006060
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 18	PMID28621580-Compound-WO2012094451c15	.	Patented	D0A5NC	.	CTPDG012449
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 21	PMID28621580-Compound-WO2015117551c25	.	Patented	D0A8SH	.	CTPDG012450
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 10	PMID28621580-Compound-WO2014000686c53	.	Patented	D0A9RY	.	CTPDG012451
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 7	PMID28621580-Compound-WO2013044362c44	.	Patented	D0BA5J	.	CTPDG012452
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 6	PMID28621580-Compound-WO2013040515c36	.	Patented	D0BL4H	.	CTPDG012453
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 7	PMID28621580-Compound-WO2014055998	.	Patented	D0CE1R	.	CTPDG006006
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 2	PMID28621580-Compound-WO2012088563	.	Patented	D0D0AX	.	CTPDG012454
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 3	PMID28621580-Compound-US20140336108c48	.	Patented	D0D7SL	.	CTPDG012455
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 8	PMID28621580-Compound-WO2014029250c45	.	Patented	D0DA6B	.	CTPDG012456
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 19	PMID28621580-Compound-WO2012139499c14	.	Patented	D0DI5S	.	CTPDG012457
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 13	PMID28621580-Compound-WO2012088506c23	.	Patented	D0E5IJ	.	CTPDG012458
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 11	PMID28621580-Compound-WO2014139458c54	.	Patented	D0EE3P	.	CTPDG012459
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 8	PMID28621580-Compound-US20169296747c52	.	Patented	D0FK5P	.	CTPDG012460
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 10	PMID28621580-Compound-WO2014127335c34	.	Patented	D0FK6Y	.	CTPDG012461
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 8	PMID28621580-Compound-WO2014113859c33	.	Patented	D0FL6P	.	CTPDG012462
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 10	PMID28621580-Compound-WO2014040242c47	.	Patented	D0FY2Q	.	CTPDG012463
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 14	PMID28621580-Compound-WO2012139019c24	.	Patented	D0HO5B	.	CTPDG012464
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2014079545C69	.	.	Patented	D0HX9S	.	CTPDG012465
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 14	PMID28621580-Compound-US20140256819c19	.	Patented	D0I6WJ	.	CTPDG012466
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 11	PMID28621580-Compound-WO2015075483c49	.	Patented	D0IZ8B	.	CTPDG012467
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 9	PMID28621580-Compound-WO2014029251c46	.	Patented	D0KW0F	.	CTPDG012468
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 5	PMID28621580-Compound-WO2012171487c32	.	Patented	D0M2XJ	.	CTPDG012469
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 4	PMID28621580-Compound-WO2012169934c40	.	Patented	D0M9KZ	.	CTPDG005777
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 3	PMID28621580-Compound-US20150158854c39	.	Patented	D0MA6I	.	CTPDG012470
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 2	PMID28621580-Compound-US20130165458c38	.	Patented	D0O5IA	.	CTPDG012471
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 17	PMID28621580-Compound-WO2014086102c28	.	Patented	D0O8RZ	.	CTPDG012472
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 19	PMID28621580-Compound-WO2014102377c27	.	Patented	D0Q4XV	.	CTPDG012473
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyridine derivative 6	PMID28621580-Compound-WO2013044361c43	.	Patented	D0S4XH	.	CTPDG012474
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Quinoline and quinazoline derivative 9	PMID28621580-Compound-WO2014127214c35	.	Patented	D0SH2Y	.	CTPDG012475
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1	PMID28621580-Compound-WO2013101954c67	.	Patented	D0T1GG	.	CTPDG005642
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	PMID28621580-Compound-WO2013036866C66	.	.	Patented	D0T9DV	.	CTPDG005634
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 8	PMID28621580-Compound-WO2014081202	.	Patented	D0U6PW	.	CTPDG012476
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Pyrimidine derivative 6	PMID28621580-Compound-US20160096837c61	.	Patented	D0V7OF	.	CTPDG005600
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 20	PMID28621580-Compound-WO2013037292c17	60171803	Patented	D0VI1V	.	CTPDG012477
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 15	PMID28621580-Compound-WO2012139019c25	.	Patented	D0VX5Y	.	CTPDG012478
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 9	PMID28621580-Compound-WO2016044219	.	Patented	D0WL5P	.	CTPDG005578
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 1	PMID28621580-Compound-WO2012004631	.	Patented	D0X2BP	.	CTPDG012479
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 20	PMID28621580-Compound-WO2015117551c24	.	Patented	D0X2MF	.	CTPDG012480
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Carbamide derivative 21	PMID28621580-Compound-WO2013107225c16	.	Patented	D0XS0Z	.	CTPDG012481
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Antibodie derivative 4	PMID28621580-Compound-WO2012161372	.	Patented	D0Y2IV	.	CTPDG012482
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	Indoline derivative 12	PMID28621580-Compound-WO2012088506c22	.	Patented	D0Z0SY	.	CTPDG012483
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Patented	"Oxetane 3,3-dicarboxamide compound 2"	PMID28621580-Compound-WO2013032797c64	.	Patented	D0ZE2J	.	CTPDG012484
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Discontinued in Phase 3	Bevasiranib	.	.	Discontinued in Phase 3	D0YG4I	.	CTPDG012485
M6ACROT03624	Vascular endothelial growth factor A (VEGFA)	VEGFA_HUMAN	.	.	Terminated	ALN-VEG01	"RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck"	.	Terminated	D05ITS	.	CTPDG015424
M6ACROT03624	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03624	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03624	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03624	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03624	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03624	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03625	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03625	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03625	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03625	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03625	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03625	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03626	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03626	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03626	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03626	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03626	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03626	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03627	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03627	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03627	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03627	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03627	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03627	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03628	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03628	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03628	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03628	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03628	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03628	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03629	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03629	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03629	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03629	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03629	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03629	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03630	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03630	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03630	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03630	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03630	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03630	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03631	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	AZ505	AZ 505; AZ-505	24961094	Preclinical	D06ONB	.	CTPDG007125
M6ACROT03631	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	LLY-507	1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126	91623361	Preclinical	D0X3RK	.	CTPDG007031
M6ACROT03631	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ032597	.	.	Preclinical	D35SKV	.	CTPDG007013
M6ACROT03631	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	EPZ033294	.	.	Preclinical	DDC63W	.	CTPDG006989
M6ACROT03631	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	A-893	"1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide"	91757965	Preclinical	DELC48	.	CTPDG014820
M6ACROT03631	N-lysine methyltransferase SMYD2 (SMYD2)	SMYD2_HUMAN	.	.	Preclinical	BAY 598	"BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide"	117072551	Preclinical	DT6P8M	.	CTPDG014821
M6ACROT03632	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03632	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03633	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT03633	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	GDC-0199	.	49846579	Approved	D00PBX	DB11581	CTPDG000809
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	Approved	D06DLI	DB12243	CTPDG011431
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Approved	Taxol	"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-"	36314	Approved	D0C4RB	DB01229	CTPDG000437
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Oblimersen	.	118984457	Phase 3	D05RJP	.	CTPDG001393
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	RG7601	.	.	Phase 3	D0I6OI	.	CTPDG011432
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	Taxol/Paraplatin/Herceptin	Paclitaxel/carboplatin/trastuzumab	.	Phase 3	D0J6PY	.	CTPDG009887
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Gossypol	"303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	Phase 2	D0Z0HH	DB13044	CTPDG011435
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PI-88/Taxotere	PI-88/docetaxel	.	Phase 2	D0K8LB	.	CTPDG002261
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	Phase 2	D02OZK	DB12191	CTPDG002966
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	Phase 1/2	D2Y7ZG	.	CTPDG011436
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	APG-1252	.	.	Phase 1/2	D4WN2M	.	CTPDG011437
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	AZD0466	.	.	Phase 1/2	DQ1P6X	.	CTPDG011438
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BCL201	.	.	Phase 1	D0C6YQ	.	CTPDG011439
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Pc4	"Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	Phase 1	D0L2YF	.	CTPDG004635
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BGB-11417	.	.	Phase 1	D74BRK	.	CTPDG004051
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LP-108	.	.	Phase 1	DBY42T	.	CTPDG003962
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	LOXO-338	.	.	Phase 1	DJLX87	.	CTPDG011440
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	VOB560	S 65487	.	Phase 1	DP63FS	.	CTPDG003773
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	AI-850	.	.	Phase 1	D03UDW	.	CTPDG005289
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	Irofulven/Taxotere	MGI 114/docetaxel	.	Phase 1	D05CHN	.	CTPDG005221
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 2	PMID27744724-Compound-16	.	Patented	D0C2DV	.	CTPDG011441
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-10	.	.	Patented	D0IS8R	.	CTPDG011442
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-21	.	.	Patented	D0J9FN	.	CTPDG011443
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	Indole-based analog 3	PMID27744724-Compound-17	.	Patented	D0MZ7I	.	CTPDG011444
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Patented	PMID27744724-Compound-18	.	.	Patented	D0TU3N	.	CTPDG011445
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Terminated	ABT-737	"852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	Terminated	D0L8WH	.	CTPDG011446
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	WL-276	.	.	Investigative	D04HAA	.	CTPDG008897
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	CHEMBL214965; SCHEMBL15313847	16090304	Investigative	D04RTY	.	CTPDG011447
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	Investigative	D06AQG	.	CTPDG011448
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	Investigative	D0S0YV	.	CTPDG011449
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	Investigative	D0V7PX	.	CTPDG007790
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	CHEMBL214839; BDBM50196033	16090303	Investigative	D0X0CS	.	CTPDG011450
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	"4,5-dibenzylbenzene-1,2-diol"	"4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	Investigative	D0D6BH	.	CTPDG011451
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	TW-37	"877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	Investigative	D00LHS	.	CTPDG011452
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	QEDIIRNIARHLAQVGDSMDR	.	77280325	Investigative	D0S6IW	.	CTPDG011453
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 2	PNT-2258	.	.	Phase 2	D07ACL	.	CTPDG002711
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1/2	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	Phase 1/2	D00GAM	.	CTPDG014620
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Phase 1	BP1002	.	.	Phase 1	DBPV74	.	CTPDG014621
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Thalidomide	.	91865905	Investigative	D00DDR	.	CTPDG009197
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Irinotecan	.	91865905	Investigative	D05IAN	.	CTPDG008834
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + G-CSF	.	91865905	Investigative	D0B0HK	.	CTPDG008463
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Fludarabine	.	91865905	Investigative	D0LM3T	.	CTPDG008092
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	Investigative	D0Q5NZ	.	CTPDG014622
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Paclitaxel	.	91865905	Investigative	D0S1FM	.	CTPDG014623
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dexamethasone	.	91865905	Investigative	D0W8ZE	.	CTPDG007750
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + Dacarbazine	.	91865905	Investigative	D0XU1I	.	CTPDG007688
M6ACROT03634	Apoptosis regulator Bcl-2 (BCL2)	BCL2_HUMAN	.	.	Investigative	G3139 + cytarabine (ARA-C)	.	91865905	Investigative	D0XU9F	.	CTPDG007686
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03634	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03635	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03635	Apoptosis regulator BAX (BAX)	BAX_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03636	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Phase 1	PAC1	PAC-1	135421197	Phase 1	D01YIF	DB13048	CTPDG014224
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"5-(piperidin-1-ylsulfonyl)indoline-2,3-dione"	"329905-79-5; 5-(piperidin-1-ylsulfonyl)-1H-indole-2,3-dione; 5-(Piperidine-1-sulfonyl)-1H-indole-2,3-dione; 5-[1-(Piperidinyl)sulfonyl]isatin; Isatin Sulfonamide 21; AC1N3S5Q; CHEMBL61320; BDBM10310; DTXSID40399501; MolPort-000-149-258; ZX-BK002316; ZINC2944779; MIX-0755; STK894352; BBL021638; 2990AJ; AKOS005144288; MCULE-6394963078; 5-(Piperidinosulfonyl)indoline-2,3-dione; AJ-44313; ACM329905795; AX8291419; H8238; 5-(piperidinosulfonyl)-1H-indole-2,3-dione"	4117383	Investigative	D01XMM	.	CTPDG014225
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	SJ-8002	"Piperazine derivative (anticancer), Samjin/ImQuest"	.	Investigative	D02DOK	.	CTPDG009038
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	AZ10417808	AZ-10417808; AZ 10417808	135665263	Investigative	D03JDL	.	CTPDG014226
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"2-phenethylisoquinoline-1,3,4-trione"	"CHEMBL382860; SCHEMBL13442858; Isoquinoline-1,3,4-trione 2d; BDBM10251; CTK7H5068; AKOS015966189; 2-PHENETHYL-ISOQUINOLINE-1,3,4-TRIONE"	11652039	Investigative	D05GGE	.	CTPDG014227
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"2-benzylisoquinoline-1,3,4-trione"	"21640-35-7; 2-BENZYL-ISOQUINOLINE-1,3,4-TRIONE; CHEMBL382859; SCHEMBL13442853; Isoquinoline-1,3,4-trione 2c; BDBM10250; CTK4E7388; DTXSID80463477; ZINC13683129; AKOS015966149; FCH2821819; ACM21640357; 2-Benzylisoquinoline-1,3,4(2H)-trione; 2-Benzylisoquinoline-1,3,4(2H,4H)-trione; 1,3,4(2H)-Isoquinolinetrione,2-(phenylmethyl)-"	11357566	Investigative	D09AED	.	CTPDG014228
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione"	"CHEMBL205983; SCHEMBL13442854; Isoquinoline-1,3,4-trione 2e; CTK7A3832; BDBM10252; AKOS015966190; 2-(4-METHOXY-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE"	11522185	Investigative	D09GKA	.	CTPDG014229
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"5-(azetidin-1-ylsulfonyl)indoline-2,3-dione"	"5-[1-(Azetidinyl)sulfonyl]isatin; Isatin Sulfonamide 19; 1H-Indole-2,3-dione, 5-(1-azetidinylsulfonyl)-; CHEMBL64789; SCHEMBL6535690; BDBM10308; 220510-08-7; 5-(Azetidine-1-ylsulfonyl)indoline-2,3-dione"	9903426	Investigative	D0B6VI	.	CTPDG014230
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"2-allylisoquinoline-1,3,4-trione"	"807334-89-0; 1,3,4(2H)-Isoquinolinetrione, 2-(2-propenyl)-; CHEMBL381777; Isoquinoline-1,3,4-trione 2b; SCHEMBL13442855; CTK2I7309; BDBM10249; DTXSID20469711; ZINC13683126; AKOS015966148"	11629882	Investigative	D0B8HU	.	CTPDG014231
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"5-(azepan-1-ylsulfonyl)indoline-2,3-dione"	"1H-Azepine, 1-[(2,3-dihydro-2,3-dioxo-1H-indol-5-yl)sulfonyl]hexahydro-; 220510-14-5; Isatin Sulfonamide 22; 5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione; CHEMBL302461; SCHEMBL6535562; CTK0I8877; BDBM10311; DTXSID20431675; 5-(azepane-1-sulfonyl)-2,3-dihydro-1H-indole-2,3-dione"	9839586	Investigative	D0D4RW	.	CTPDG014232
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"2-methylisoquinoline-1,3,4-trione"	"2-methylisoquinoline-1,3,4(2H)-trione; 21640-33-5; 2-methyl-isoquinoline-1,3,4-trione; 2-methyl-1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; N-methylphthalonimide; AC1LVZDH; AC1Q3XNZ; 1,3,4(2H)-Isoquinolinetrione, 2-methyl-; CHEMBL381480; SCHEMBL13442852; Isoquinoline-1,3,4-trione 2a; CTK4E7387; BDBM10248; DTXSID90364926; MolPort-001-798-932; ZINC2030689; CS-D0370; FCH830488; STK368698; AKOS005444509; MCULE-7985115369; ACM21640335; 2-methyl-1,3,4(2H)-isoquinolinetrione; AK325966"	1714901	Investigative	D0FZ7W	.	CTPDG014233
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione"	"CHEMBL203552; SCHEMBL13442861; Isoquinoline-1,3,4-trione 2f; CTK7C0409; BDBM10253; AKOS015966191; 2-(4-FLUORO-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE"	11680763	Investigative	D0L3PO	.	CTPDG014234
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione"	"220510-17-8; 5-(Pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione; Isatin Sulfonamide 20; 5-pyrrolidinylsulfonylisatin; AC1N3S5K; 5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione; SCHEMBL2486952; CHEMBL305545; BDBM10309; DTXSID80399500; QKCWUYHXHMXOLG-UHFFFAOYSA-N; ZINC2944777; 5-[1-(pyrrolidinyl)sulfonyl]isatin; 2991AJ; AKOS024262065; AJ-44312; 5-(Pyrrolizinosulfonyl)indoline-2,3-dione; AX8291337; FT-0734877; 5-(Pyrrolidin-1-ylsulfonyl)-1H-indole-2,3-dione"	4117381	Investigative	D0N5MU	.	CTPDG014235
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	Ac-Asp-Glu-Val-Asp-CHO	"ICE INHIBITOR; AC1L1HX4; SCHEMBL13194679; AL010; AKOS015916330; AN-30897; N-Acetyl-Asp-Glu-Val-Asp-al, &gt; =95%, powder; I14-51535; 4-[(2-acetamido-4-hydroxy-4-oxobutanoyl)amino]-5-[[1-[(4-hydroxy-1,4-dioxobutan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid; 4-(3-carboxy-2-acetamidopropanamido)-4-({1-[(1-carboxy-3-oxopropan-2-yl)carbamoyl]-2-methylpropyl}carbamoyl)butanoic acid"	4330	Investigative	D0P0XF	.	CTPDG014236
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	PETCM	1-(trichloromethyl)-2-(4-pyridine)ethanol	224859	Investigative	D0T5GV	.	CTPDG014237
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	Ac-DEVD-CHO	"169332-60-9; Caspase-3 Inhibitor I; N-acetyl-asp-glu-val-asp-al; acetyl-aspartyl-glutamyl-valyl-aspartal; Ac-Asp-Glu-Val-Asp-Aldehyde; AC-ASP-GLU-VAL-ASP-H; CHEMBL417149; CHEBI:59385; 184179-08-6; (4S,7S,10S,13S)-7-(2-carboxyethyl)-4-(carboxymethyl)-13-formyl-10-isopropyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecan-15-oic acid; acetyl-Asp-Glu-Val-Asp-aldehyde; acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp-aldehyde"	644345	Investigative	D0L9AX	.	CTPDG014238
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	Glionitrin A	CHEMBL550491	25243252	Investigative	D0Y2TI	.	CTPDG007672
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	"Isoquinoline-1,3,4(2H)-trione"	"Phthalonimide; 1,3,4(2H)-Isoquinolinetrione; 521-73-3; isoquinoline-1,3,4-trione; 1,3,4-(2H)ISOQUINOLINETRIONE; UNII-BM68CV5X6Q; NSC 407248; BRN 0383773; BM68CV5X6Q; 1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; isoquinoline-1,3,4-(2H)-trione; 3deh; NSC407248; AC1L1VMV; 5-21-11-00575 (Beilstein Handbook Reference); 1,4(2H)-Isoquinolinetrione; SCHEMBL1122624; Isoquinoline-1,3,4-trione 1; CHEMBL206435; CTK1H0848; BDBM10247; DTXSID40200103; ZINC1599708; FCH844329; ACM521733; AKOS006276226; NSC-407248"	10640	Investigative	D0V6DX	.	CTPDG014239
M6ACROT03636	Caspase-3 (CASP3)	CASP3_HUMAN	.	.	Investigative	M826	compound 4sx	9851134	Investigative	D00YNW	.	CTPDG014167
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT03637	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03637	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03638	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Phase 1	NNI-362	.	.	Phase 1	D6KWF3	.	CTPDG004060
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Clinical trial	PF-4708671	PF4708671; PF 4708671	51371303	Clinical trial	D0Y4LI	.	CTPDG005482
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Patented	PMID27410995-Compound-Figure3c	.	.	Patented	D02ABC	.	CTPDG013441
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Patented	"Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1"	PMID27410995-Compound-Figure3d	.	Patented	D0BN4A	.	CTPDG013442
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	Investigative	D0G2VC	.	CTPDG011474
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03638	Ribosomal protein S6 kinase beta-1 (RPS6KB1/p70S6K)	KS6B1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03639	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT03639	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03640	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03641	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03642	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03643	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03644	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03645	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03646	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03647	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03648	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03648	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03648	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03648	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03649	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03650	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03651	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03651	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03651	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03651	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03652	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03653	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03654	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Phase 3	ABC294640	915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8	15604015	Phase 3	D0X6BX	DB12764	CTPDG000992
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Investigative	(R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide	CHEMBL572687; SCHEMBL1312879; QJTVTVAQRCRXSM-QGZVFWFLSA-N	45254608	Investigative	D01UUZ	.	CTPDG014577
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Investigative	(S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide	CHEMBL568698; SCHEMBL1311633; UKLIXHBQCDTKPU-IBGZPJMESA-N	45256207	Investigative	D01XSX	.	CTPDG014578
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Investigative	(R)-2-amino-3-(4-octylphenylamino)propan-1-ol	CHEMBL572686; SCHEMBL1312243	45255203	Investigative	D0E3LA	.	CTPDG014579
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Investigative	ROMe	(R)-FTY720-OMe	71458556	Investigative	D0H2LN	.	CTPDG014580
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Investigative	DIMETHYLSPINGOSINE	"N,N-Dimethylsphing-4-enine; D-erythro-N,N-dimethylsphingosine; N,N-Dimethylspingosine; CHEMBL322333; CHEBI:78759; D-erythro-Sphingosine, N,N-Dimethyl-; N,N-Dimethylsphingenine; N,N-dimethyl-erythro-sphingosine; N,N-Dimethyl-D-erythrosphingenine; N-dimethylsphingosine; AC1NQZUP; C13914; N,N-Dimethyl-4-sphingenine; BSPBio_001420; N,N-Dimethylsphingosine, oil; SCHEMBL121927; SCHEMBL5493697; BML3-C12; Dimethyl Sphingosine (d18:1)"	5282309	Investigative	D0M9DT	.	CTPDG014581
M6ACROT03654	Sphingosine kinase 2 (SPHK2)	SPHK2_HUMAN	.	.	Investigative	(S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide	CHEMBL583979; SCHEMBL1311702; QJTVTVAQRCRXSM-KRWDZBQOSA-N	45483175	Investigative	D0TC4I	.	CTPDG014582
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03655	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Approved	Nicotinamide	"Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide"	936	Approved	D06NVJ	DB02701	CTPDG010707
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Approved	KU-0058948	"CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	Approved	D09LSX	DB08058	CTPDG000490
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Approved	Niraparib Tosylate	1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059	78357761	Approved	D0DN0W	.	CTPDG010708
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 3	Nicaraven	AVS; Antevan; Antevas	71234	Phase 3	D0Z2UW	DB06397	CTPDG010709
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	AG140699	.	.	Phase 2	D06KZL	.	CTPDG002747
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	AZD5305	"16MZ1V3RBT; 2589531-76-8; 2-Pyridinecarboxamide, 5-(4-((7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl)-1-piperazinyl)-N-methyl-; 2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl-; 5-(4-((7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide; 5-[4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methylpicolinamide; 5-[4-[(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 5-{4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3- yl)methyl]piperazin-1-yl}-N-methylpyridine-2- carboxamide; AC-37130; Azd 5305; AZD 5305 [WHO-DD]; AZD5305; AZD-5305; AZD-5305 [WHO-DD]; CHEMBL5095220; CS-0163534; E80364; EX-A5234; example 4 [WO2021013735]; GTPL11526; HY-132167; MS-26971; NSC834196; NSC-834196; Saruparib; saruparib [INN]; SCHEMBL22912701; SY295016; UNII-16MZ1V3RBT"	155586901	Phase 2	D0YTM9	.	CTPDG010710
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	PMID27841036-Compound-37	2X-121	135565981	Phase 2	D0F5TD	.	CTPDG002399
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 2	Stenoparib	.	.	Phase 2	DP48WE	.	CTPDG001655
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 1/2	AMXI 5001	.	.	Phase 1/2	D8TE4F	.	CTPDG003215
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Phase 1	NMS-03305293	NMS-P293	.	Phase 1	DO0LP3	.	CTPDG003794
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1"	PMID27841036-Compound-6	.	Patented	D01KFW	.	CTPDG010711
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Benzimidazole carboxamide derivative 1	PMID27841036-Compound-I	.	Patented	D01PYO	.	CTPDG010712
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	PMID27841036-Compound-33	.	56649297	Patented	D02KMI	.	CTPDG010713
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4"	PMID27841036-Compound-9	.	Patented	D02QFM	.	CTPDG010714
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine ketone derivative 1	PMID27841036-Compound-16	89608436	Patented	D05ZBB	.	CTPDG010715
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Quinazolinedione derivative 3	PMID27841036-Compound-13	59663666	Patented	D08KAH	.	CTPDG010716
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 2	PMID27841036-Compound-3	.	Patented	D08YPU	.	CTPDG010717
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3"	PMID27841036-Compound-8	.	Patented	D09HUV	.	CTPDG010718
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	7-azaindole derivative 8	PMID27841036-Compound-10	73669300	Patented	D09WUA	.	CTPDG010719
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5"	PMID27841036-Compound-IV	.	Patented	D09ZIM	.	CTPDG010720
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine ketone derivative 3	PMID27841036-Compound-18	71598692	Patented	D0AN7Z	.	CTPDG010721
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Dihydropyrido phthalazinone derivative 1	PMID27841036-Compound-21	136265073	Patented	D0B3QI	.	CTPDG010722
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine ketone derivative 2	PMID27841036-Compound-17	71571973	Patented	D0B4FV	.	CTPDG010723
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Tricyclic indole compound 13	PMID27841036-Compound-XVI	.	Patented	D0E9JI	.	CTPDG010724
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	3-phenyl isoquinolin-1(2H) derivative 2	PMID27841036-Compound-VII	.	Patented	D0G8HX	.	CTPDG010725
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 5	PMID27841036-Compound-III	.	Patented	D0GH4V	.	CTPDG010726
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Quinazolinedione derivative 2	PMID27841036-Compound-12	68388735	Patented	D0IX2C	.	CTPDG010727
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Quinazolinedione derivative 1	PMID27841036-Compound-11	66546486	Patented	D0J2SR	.	CTPDG010728
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Dihydropyrido phthalazinone derivative 2	PMID27841036-Compound-22	136334008	Patented	D0J4GY	.	CTPDG010729
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	"3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2"	PMID27841036-Compound-7	.	Patented	D0M0WS	.	CTPDG010730
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Phthalazine derivative 3	PMID27841036-Compound-19	71678316	Patented	D0M9TG	.	CTPDG010731
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Tetra-hydro-quinoline derivative 1	PMID27841036-Compound-VIII	.	Patented	D0MP4W	.	CTPDG010732
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 1	PMID27841036-Compound-2	.	Patented	D0O9FC	.	CTPDG010733
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 3	PMID27841036-Compound-4	.	Patented	D0R0PO	.	CTPDG010734
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	4-Carboxamido-isoindolinone derivative 4	PMID27841036-Compound-5	.	Patented	D0Z5DI	.	CTPDG010735
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Dihydrodiazepinocarbazolone derivative 1	PMID27841036-Compound-26	71626523	Patented	D0P3YA	.	CTPDG010736
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	Tetra-cyclic pyridophthalazinone derivative 1	PMID27841036-Compound-25	.	Patented	D0Z8IR	.	CTPDG010737
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Patented	3-phenyl isoquinolin-1(2H) derivative 1	PMID27841036-Compound-20	89588629	Patented	D0TD8R	.	CTPDG010738
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Preclinical	CPH-102	"IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma"	.	Preclinical	D04ABS	.	CTPDG007140
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Preclinical	PJ34	"344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341"	4858	Preclinical	D04WDX	DB08348	CTPDG010739
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Terminated	NU1025	.	135398517	Terminated	D0O3FX	DB02690	CTPDG010740
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Ethynylquinoline-8-carboxamide	"CHEMBL501330; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268"	25208746	Investigative	D00OZA	.	CTPDG010741
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one	.	135471356	Investigative	D00TUB	.	CTPDG010742
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	N-(4-Phenylthiazol-2-yl)isonicotinamide	"N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062"	790259	Investigative	D00WMC	.	CTPDG010743
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	5-Chloro-2-methyl-3H-quinazolin-4-one	.	135875707	Investigative	D01EVX	.	CTPDG010744
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BZ3	"5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T"	13872	Investigative	D01RXM	.	CTPDG010745
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide	"2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide"	1511	Investigative	D01YIR	DB04010	CTPDG010746
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	CEP-6800	"UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione"	9948440	Investigative	D02GPJ	.	CTPDG010747
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	ANG-2864	"PARP inhibitor (ischemia/cancer), Angion Biomedica"	.	Investigative	D02JHW	.	CTPDG009022
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Methoxybenzamide	"5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848"	98487	Investigative	D02MPP	DB03073	CTPDG010748
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-Benzyl-2H-indazole-7-carboxamide	CHEMBL1094951; SCHEMBL2268172	44549372	Investigative	D02QZF	.	CTPDG010749
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	CHEMBL201723	44407565	Investigative	D02XLC	.	CTPDG010750
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"4-amino-1,8-naphthalimide"	"1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE"	1720	Investigative	D03JTS	DB07096	CTPDG010751
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione"	CHEMBL373066; pyrroloisoindoledione	44407700	Investigative	D03VNZ	.	CTPDG010752
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline"	11736764	Investigative	D04ATU	.	CTPDG010753
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	EB-47	"EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)"	9871899	Investigative	D04AYN	.	CTPDG010754
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BZ6	.	41673734	Investigative	D04LDH	.	CTPDG010755
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-methoxyphenyl)quinoline-8-carboxamide	"CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-"	25209058	Investigative	D04TDX	.	CTPDG010756
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline"	11288114	Investigative	D04UPQ	.	CTPDG010757
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide	"CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152"	690181	Investigative	D04ZQJ	.	CTPDG010758
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	ANG-2684	"ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica"	.	Investigative	D05APM	.	CTPDG010759
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	CHEMBL380940; SCHEMBL5828673	44407566	Investigative	D05GMW	.	CTPDG010760
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2,3-dihydro-1H-benzo[de]isoquinolin-1-one"	"CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210"	10130246	Investigative	D05HJG	.	CTPDG010761
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"5-amino-3,4-dihydroisoquinolin-1(2H)-one"	"129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419"	18369509	Investigative	D05RXG	.	CTPDG010762
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	KR-33889	"KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT"	.	Investigative	D05SYO	.	CTPDG010763
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	CHEMBL194684	44403402	Investigative	D05WYN	.	CTPDG010764
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	AG-014376	"CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one"	9797108	Investigative	D05XMG	.	CTPDG010765
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Hydroxy-benzamide	"3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787"	342403	Investigative	D05ZTI	.	CTPDG010766
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methoxy-2-phenyl-3H-quinazolin-4-one	.	135439437	Investigative	D06NKJ	.	CTPDG010767
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	Quinoline-8-carboxamide	8-Quinolinecarboxamide; 55706-61-1; CCRIS 6967; CHEMBL502330; HPQRQAOVNXWEEQ-UHFFFAOYSA-N; 8-Carbamoylquinoline; 8-Quinolinecarboxamide #; AC1L44SC; SCHEMBL460456; CTK5A4047; quinoline-8-carboxylic acid amide; DTXSID00204243; MolPort-005-722-305; ZINC6095019; BDBM50255266; AKOS008969900; NE38855; MCULE-7978956907; LS-188644; KB-259682	150664	Investigative	D07AGU	.	CTPDG010768
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190932	Investigative	D07BBR	.	CTPDG010769
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135457978	Investigative	D07BPT	.	CTPDG010770
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2H-Isoquinolin-1-one	"1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273"	10284	Investigative	D07CRG	.	CTPDG010771
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	KU-58684	SCHEMBL863338; 623578-11-0	11725479	Investigative	D07QPV	.	CTPDG010772
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2,8-Dimethyl-3H-quinazolin-4-one"	.	135463574	Investigative	D07SRJ	.	CTPDG010773
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	5-aminoisoquinolin-1(2H)-one	"93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197"	2072	Investigative	D07WPL	.	CTPDG010774
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	INO-1002	"PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek"	.	Investigative	D08AOV	.	CTPDG008641
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-(4-aminophenyl)quinoxaline-5-carboxamide	"CHEMBL443077; quinoxaline analogue, 3f; SCHEMBL7112515"	25218519	Investigative	D08GMO	.	CTPDG010775
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide"	"2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424"	49799912	Investigative	D08OUR	.	CTPDG010776
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	4-benzylphthalazin-1(2H)-one	"4-Benzyl-1(2H)-phthalazinone; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #"	616651	Investigative	D08QWR	.	CTPDG010777
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Methylquinoline-8-carboxamide	"CHEMBL504998; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267"	25208598	Investigative	D08XPZ	.	CTPDG010778
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	"3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2"	657038	Investigative	D08ZVM	DB03509	CTPDG010779
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135407310	Investigative	D0B2WX	.	CTPDG010780
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	HYDAMTIQ	"PARP-1 inhibitor (brain ischemia), University of Perugia"	.	Investigative	D0CA2S	.	CTPDG010781
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190929	Investigative	D0E0QT	.	CTPDG010782
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	PD-128763	"5-Methyl-3,4-dihydroisoquinolin-1(2H)-one; 129075-56-5; 3,4-Dihydro-5-methyl-1(2H)-isoquinolinone; 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE; 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl-; CHEBI:41928; PD128763; CHEMBL125200; 5-methyl-3,4-dihydro-2H-isoquinolin-1-one; 3,4-dihydro-5-methylisoquinolinone; 1(2H)-Isoquinolinone,3,4-dihydro-5-methyl-; 5-methyl-1,2,3,4-tetrahydroisoquinolin-1-one; DHQ; PD 128763; dihydroisoquinolinone, 1; AC1L3WIO; ACMC-1C7L4; SCHEMBL831538; AMBZ0075; KS-00000QFP; CTK4B6146; BDBM27682"	148140	Investigative	D0E2VC	DB03722	CTPDG010783
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methyl-2-phenyl-3H-quinazolin-4-one	.	135531482	Investigative	D0E5EW	.	CTPDG010784
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	TI3	"RB106; CHEMBL419499; [(2S)-2-SULFANYL-3-PHENYLPROPANOYL]-GLY-(5-PHENYLPROLINE); 1qf2; AC1L9LL2; BDBM50051785; DB02669; N-[(S)-2-Mercapto-3-phenylpropionyl]-Gly-[(5R)-5-phenyl-L-Pro-]-OH; N-[(2S)-3-phenyl-2-sulfanylpropanoyl]glycyl-(5R)-5-phenyl-L-proline; (2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid; (2S,5R)-1-[2-((S)-2-Mercapto-3-phenyl-propionylamino)-acetyl]-5-phenyl-pyrrolidine-2-carboxylic acid"	448087	Investigative	D0E7UW	DB02669	CTPDG010785
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"3-aminobenzo[c][1,5]naphthyridin-6(5H)-one"	"CHEMBL106154; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9"	16221809	Investigative	D0EI6X	.	CTPDG010786
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	S-111	"PARP1 inhibitor (cancer), Sentinel Oncology"	.	Investigative	D0EQ1J	.	CTPDG008329
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	Thieno-phenanthridin-6-one	.	.	Investigative	D0EW8Y	.	CTPDG010787
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	CHEMBL194535	44403357	Investigative	D0F8ZI	.	CTPDG010788
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one"	"CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one"	345678	Investigative	D0FF4M	.	CTPDG010789
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135492389	Investigative	D0G5VD	.	CTPDG010790
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one	.	135463623	Investigative	D0GA0Y	.	CTPDG010791
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	CHEMBL373210	44403404	Investigative	D0GJ8U	.	CTPDG010792
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide"	CHEMBL1096560; SCHEMBL2265205	44549505	Investigative	D0I2AF	.	CTPDG010793
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-phenyl-2H-indazole-7-carboxamide	CHEMBL594298; SCHEMBL1422404; BDBM50306166	44549251	Investigative	D0IX3I	.	CTPDG010794
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	Carba-Nicotinamide-Adenine-Dinucleotide	"Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m"	163884	Investigative	D0JD1O	DB02498	CTPDG010795
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-aminobenzamide	"3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde"	1645	Investigative	D0K2PD	.	CTPDG010796
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Ethenylquinoline-8-carboxamide	"CHEMBL481793; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270"	25208747	Investigative	D0K7JT	.	CTPDG010797
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Phenylquinoline-8-carboxamide	CHEMBL450259; BDBM50255264	25208596	Investigative	D0L1NQ	.	CTPDG010798
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-(4-methoxyphenyl)quinoxaline-5-carboxamide	"CHEMBL519443; quinoxaline analogue, 3e; SCHEMBL7045177"	9965481	Investigative	D0L1RZ	.	CTPDG010799
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	TI4	.	91808049	Investigative	D0L6LO	.	CTPDG010800
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"Benzo[c][1,5]naphthyridin-6(5H)-one"	"CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one"	10535869	Investigative	D0M6WJ	.	CTPDG010801
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-(4-cyanophenyl)quinoxaline-5-carboxamide	"CHEMBL481603; quinoxaline analogue, 3c; SCHEMBL7108289"	25218518	Investigative	D0M9TW	.	CTPDG010802
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione"	CHEMBL201907; SCHEMBL2086780; ZINC28569089	11506860	Investigative	D0NU5Z	.	CTPDG010803
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190931	Investigative	D0O0GA	.	CTPDG010804
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Hydroxy-2-phenyl-3H-quinazolin-4-one	.	135528341	Investigative	D0O6WW	.	CTPDG010805
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135417274	Investigative	D0OF1I	.	CTPDG010806
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1099295; SCHEMBL2264064	44549375	Investigative	D0PT1K	.	CTPDG010807
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BPI-704001	"BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma"	.	Investigative	D0R7FS	.	CTPDG007906
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	CHEMBL370869; SCHEMBL5381581	18382004	Investigative	D0R7HU	.	CTPDG010808
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-Methylquinoline-8-carboxamide	"CHEMBL471966; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220"	21195867	Investigative	D0S8HZ	.	CTPDG010809
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	8-Methoxy-2-methyl-3H-quinazolin-4-one	.	135411146	Investigative	D0T3SY	.	CTPDG010810
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Prop-1-ynylquinoline-8-carboxamide	CHEMBL504903; ZINC40829471	25208905	Investigative	D0T5TT	.	CTPDG010811
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094952; SCHEMBL2265265	44549373	Investigative	D0TH7S	.	CTPDG010812
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one	.	135508369	Investigative	D0U5WY	.	CTPDG010813
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	3-Ethylquinoline-8-carboxamide	"CHEMBL453989; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269"	25208904	Investigative	D0UF0U	.	CTPDG010814
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	A-620223	"A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott"	9925908	Investigative	D0VY5O	DB07330	CTPDG007773
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	DR2313	.	135522417	Investigative	D0W7XH	DB07677	CTPDG010815
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one	.	135547083	Investigative	D0WO3P	.	CTPDG010816
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094953; SCHEMBL2265628	44549374	Investigative	D0XZ5D	.	CTPDG010817
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135471354	Investigative	D0Y1MH	.	CTPDG010818
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-ethylquinoline-8-carboxamide	"CHEMBL526128; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330"	25208752	Investigative	D0Z3PB	.	CTPDG010819
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	2-phenylquinoline-8-carboxamide	CHEMBL480429; SCHEMBL6442515; ZINC3939668	44156952	Investigative	D0Z9DY	.	CTPDG010820
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	BZ5	.	46241905	Investigative	D0ZK3L	.	CTPDG010821
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	ME0328	ME-0328; compound 5b [PMID 24188023]	135566764	Investigative	D04QRM	.	CTPDG010822
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala"	TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic	5289469	Investigative	D09SZG	DB02597	CTPDG010823
M6ACROT03656	Poly [ADP-ribose] polymerase 1 (PARP1)	PARP1_HUMAN	.	.	Investigative	S-070	"S-158; Targeted synergy program (solid tumor), Sentinel Oncology; Chk1/PARP-1 inhibitors (cancer); Chk1/PARP-1 inhibitors (cancer), Sentinel Oncology"	.	Investigative	D0P4DG	.	CTPDG007983
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03656	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03657	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03658	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03659	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03660	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03660	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT03660	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT03660	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03661	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03662	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03663	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03664	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT03665	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03665	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03666	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT03667	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	P-276	"CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development"	23643976	Phase 2	D0W8IY	.	CTPDG010902
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 2	P276-00	CHEMBL2312181; SCHEMBL1180418	23643975	Phase 2	D05IRT	.	CTPDG010904
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	P1446A-05	.	67409219	Phase 1	D0DX4J	DB15157	CTPDG004841
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	PF-07220060	.	.	Phase 1	DZJ3D5	.	CTPDG003644
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Imidazo pyridine derivative 3	PMID26161698-Compound-22	46937330	Patented	D0WT7D	.	CTPDG010910
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 10"	PMID26161698-Compound-2	53378895	Patented	D04AKA	.	CTPDG010912
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID26161698-Compound-17	.	739323	Patented	D0FQ6V	.	CTPDG010913
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	CHEMBL521733; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	787236	Investigative	D03VDM	.	CTPDG010920
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea	5330597	Investigative	D0G4JS	.	CTPDG010921
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea	5330595	Investigative	D0M8CO	.	CTPDG010922
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-Pyridin-2-yl-3-quinolin-5-yl-urea	Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea	5330598	Investigative	D0T2VG	.	CTPDG010923
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea	5330596	Investigative	D0X1NW	.	CTPDG010924
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	Ro-0505124	RO0505124	9911652	Investigative	D09RYV	.	CTPDG010927
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05003	Cyclin-dependent kinase 4 (CDK4)	CDK4_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05004	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05004	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05004	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05008	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05008	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05008	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 2	Semapimod	"CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences"	5745214	Phase 2	D01WKE	DB12094	CTPDG014465
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 2	BGB-3245	.	.	Phase 2	DMYS25	.	CTPDG001672
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	GDC-5573	RG6185	.	Phase 1	D0VS9E	.	CTPDG004328
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	Belvarafenib	"1446113-23-0; UNII-31M3WLJ3KG; 31M3WLJ3KG; 4-Amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide; CHEMBL3977543; SCHEMBL15066408; BDBM185591; BCP31233; EX-A3061; s8853; HM95573; BS-15746; HY-109080; CS-0039257; Belvarafenib(GDC5573, HM95573, RG6185); US9156852, 116; 4-Amino-N-(1-(3-chloro-2-fluorophenylamino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide; V1Y"	89655386	Phase 1	DU98JH	.	CTPDG003704
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 2	MLN2480	"VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819"	25161177	Phase 2	D07IEU	DB15266	CTPDG002698
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	LXH254	"UEPXBTCUIIGYCY-UHFFFAOYSA-N; SCHEMBL16094629; BDBM88120; HY-112089; CS-0043317; US9694016, 1156; 1800398-38-2; N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide"	90456533	Phase 1	D0T4QA	.	CTPDG014587
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	ICo-007	.	.	Phase 1	D0W2BK	.	CTPDG014588
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	LErafAON	"RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm"	.	Phase 1	D0W9QI	.	CTPDG004308
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	SPN-803	.	.	Phase 1	D02DXC	.	CTPDG013912
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Phase 1	RG7304	.	74890577	Phase 1	D06EFW	.	CTPDG005168
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 10707	.	.	Investigative	D01KEF	.	CTPDG014589
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 9058	.	.	Investigative	D01LYK	.	CTPDG014590
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	"5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid"	CHEMBL216668	44418518	Investigative	D05UPS	.	CTPDG014591
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 7853	.	.	Investigative	D07JHY	.	CTPDG014592
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 7855	.	.	Investigative	D07QVR	.	CTPDG014593
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 7851	.	.	Investigative	D07XKC	.	CTPDG014594
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 15770	.	.	Investigative	D08KOD	.	CTPDG008612
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 11061	.	.	Investigative	D09IOO	.	CTPDG014595
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 7848	.	.	Investigative	D0E7WU	.	CTPDG014596
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 6717	.	.	Investigative	D0K5WH	.	CTPDG014597
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 6720	.	.	Investigative	D0LG0E	.	CTPDG014598
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 6729	.	.	Investigative	D0OV7O	.	CTPDG014599
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 7849	.	.	Investigative	D0Q1UM	.	CTPDG014600
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	L-790070	"CHEMBL303144; 189442-43-1; MRK-48; SCHEMBL4025110; BDBM15459; CTK4E0131; DTXSID50430959; 4-[1-methyl-2-(piperidin-4-yl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine; 4-{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl}-N-[(1S)-1-phenylethyl]pyridin-2-amine; 2-PYRIDINAMINE, 4-[1-METHYL-2-(4-PIPERIDINYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOL-5-YL]-N-[(1S)-1-PHENYLETHYL]-"	9806182	Investigative	D0QN6U	.	CTPDG014601
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ISIS 7847	.	.	Investigative	D0R9BP	.	CTPDG014602
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	SCHEMBL6660879	44387948	Investigative	D02TYK	.	CTPDG014490
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	PLX-ORI3	"Omni-Raf inhibitors (cancer); Omni-Raf inhibitors (cancer), Plexxikon"	.	Investigative	D06YMT	.	CTPDG008713
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	6-Benzylsulfanyl-9H-purine	"Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine"	93558	Investigative	D0BH7S	.	CTPDG013879
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	GW-5074	"gw5074; 220904-83-6; GW 5074; Raf1 Kinase Inhibitor I; UNII-B7W8RS1GG2; B7W8RS1GG2; CHEMBL72365; 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone; 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one; (3Z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one; (Z)-3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodoindolin-2-one; SR-01000075897; STO521; 3-(3,5-Dibromo-4-hydroxybenzyliden)-5-iodo-1,3-dihydroindol-2-one; Tocris-1381"	5924208	Investigative	D0Z5TQ	.	CTPDG014603
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	ZM-336372	ZM 336372; 208260-29-1; ZM336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231	5730	Investigative	D00NWF	.	CTPDG013885
M6ACROT05009	RAF proto-oncogene serine/threonine-protein kinase (RAF1)	RAF1_HUMAN	.	.	Investigative	DEBROMOHYMENIALDISINE	.	135451156	Investigative	D01WAI	DB04367	CTPDG013339
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	Penciclovir	39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2	135398748	Approved	D07BYK	DB00299	CTPDG010582
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Preregistration	TK-DLI	"TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara"	.	Preregistration	D08AMJ	.	CTPDG010583
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	FV-100	"CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy"	71587897	Phase 3	D04QPD	.	CTPDG010584
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2	HQK-1004	"Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest"	23622962	Phase 2	D05RRA	.	CTPDG002789
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Ad-OC-hsvTK/valacyclovir	"Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute"	.	Phase 1	D02KBE	.	CTPDG010585
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	"Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama"	.	Phase 1	D0FY1W	.	CTPDG004786
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-Hydroxypropylthymine	"6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139"	1865	Investigative	D00CEO	DB04139	CTPDG010586
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	3-(2-propyn-1-yl)thymidine	3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872	11323459	Investigative	D01CUJ	.	CTPDG010587
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	ITdU	"3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-"	76	Investigative	D01VKE	.	CTPDG010588
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	"AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate"	449489	Investigative	D04GXW	DB02324	CTPDG010589
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CHEMBL219905	16098875	Investigative	D07GKK	.	CTPDG010590
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	(South)-Methanocarba-Thymidine	"south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921"	447628	Investigative	D07OOW	DB02921	CTPDG010591
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-(Dihydroxy-Isobutyl)-Thymine	"DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione"	1855	Investigative	D08AOD	DB02500	CTPDG010592
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-propyl-2'-deoxyuridine	"27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione"	160155	Investigative	D0C7YS	.	CTPDG010593
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-(bromovinyl)deoxyuridine	CHEMBL261850; SCHEMBL4314668; BDBM50375781	25323027	Investigative	D0D7FB	.	CTPDG010594
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	9-(4-Hydroxybutyl)-N2-Phenylguanine	"HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one"	135415618	Investigative	D0G5VO	DB02495	CTPDG010595
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-iodo-2'-deoxyuridine	"CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil"	512326	Investigative	D0HO0W	.	CTPDG010596
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine"	"3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione"	452142	Investigative	D0O7GD	.	CTPDG010597
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	BVDU-MP	SCHEMBL4287705	46936977	Investigative	D0PC2Y	.	CTPDG010598
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, S-Isomer"	"(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731"	445210	Investigative	D0R0EI	DB03000	CTPDG010599
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine	.	448110	Investigative	D0S4SQ	.	CTPDG010600
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Bromothienyldeoxyuridine	"CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione"	446725	Investigative	D0ST5A	DB03804	CTPDG010601
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[7-(triphenylmethoxy)heptyl]thymine	"CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-"	16098874	Investigative	D0W8AD	.	CTPDG010602
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, R-Isomer"	"14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-"	445211	Investigative	D0X1HX	DB02765	CTPDG010603
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Edoxudine	"5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine; MCULE-3445830855; ST056929"	66377	Investigative	D0Y4MD	DB13421	CTPDG010604
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	N2-(3-trifluoromethylphenyl)guanine	.	135435057	Investigative	D0YJ5W	.	CTPDG010605
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-Deoxyuridine	"951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615"	13712	Investigative	D00CVB	DB02256	CTPDG010606
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[5-(triphenylmethoxy)pentyl]thymine	"CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-"	16098859	Investigative	D00KWL	.	CTPDG010607
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Deoxythymidine	"Thymidine; 50-89-5; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748"	5789	Investigative	D01GLG	DB04485	CTPDG010608
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[6-(triphenylmethoxy)hexyl]thymine	"CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-"	44418795	Investigative	D02CCD	.	CTPDG010609
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	"CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"""" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate"	447202	Investigative	D04BBF	DB03280	CTPDG010610
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	"CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione"	6477686	Investigative	D0I6UV	.	CTPDG010611
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Thymidine-5'-Phosphate	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)	9700	Investigative	D0ZH0I	DB01643	CTPDG010612
M6ACROT05011	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-deoxythymidine triphosphate	"Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 5'-TTP; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE"	64968	Investigative	D09WYY	DB02452	CTPDG010613
M6ACROT05012	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05012	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05012	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05013	Fascin (FSCN1)	FSCN1_HUMAN	.	.	Phase 1	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	Phase 1	D0C2NT	DB14995	CTPDG004893
M6ACROT05020	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	2-Ethoxypropanoic acid	"53103-75-6; 2-ethoxypropionic acid; MFCD09940775; Propanoic acid, 2-ethoxy-; SCHEMBL142064; DTXSID00570733; 2-Ethoxypropanoic acid, AldrichCPR; STL508457; AKOS000184266; AKOS016903919; MCULE-2185795311; SY040144; DB-104575; EN300-39488; Y-6023"	15268841	Preclinical	D4RGV9	.	CTPDG014832
M6ACROT05020	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	KL001	309928-48-1; N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; SMR000106264; MLS000110334; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; KL-001; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-[(furan-2-yl)methyl]methanesulfonamide; N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(furan-2-ylmethyl)methanesulfonamide; CBMicro_005790; ChemDiv2_003790; Oprea1_152161; Oprea1_419357; MLS002540427; MLS006011739; CHEMBL1498001; SCHEMBL15380452; BDBM56256; cid_2888648; HMS1379M06; HMS2371E17; SMSF0015860; STK839587; AKOS000581142; AKOS016386481; CB08282; MCULE-8116422943; IDI1_002505; NCGC00079434-02; NCGC00079434-03; NCGC00079434-06; BIM-0006034.P001; KL001(KL-001;KL 001); EU-0005302; ST50257205; 10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; doi:10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; SR-01000436091; SR-01000436091-1; BRD-A94580299-001-08-8; F1345-0456; (3-carbazol-9-yl-2-hydroxypropyl)(2-furylmethyl)(methylsulfonyl)amine; N-(3-carbazol-9-yl-2-hydroxy-propyl)-N-(2-furfuryl)methanesulfonamide; N-[3-(9-carbazolyl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-oxidanyl-propyl)-N-(furan-2-ylmethyl)methanesulfonamide	2888648	Preclinical	D95KWS	.	CTPDG014833
M6ACROT05020	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	SHP656	.	.	Preclinical	DG90VQ	.	CTPDG014834
M6ACROT05020	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	TH301	.	.	Preclinical	DOZQ70	.	CTPDG014835
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Dolasetron	"Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate"	3033818	Approved	D00YLW	DB00757	CTPDG012708
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron	"Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one"	6337614	Approved	D04FVU	DB00377	CTPDG012709
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Alosetron	"Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride"	2099	Approved	D06GKN	DB00969	CTPDG012710
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Tropisetron	"Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate"	656665	Approved	D0K0KH	DB11699	CTPDG012711
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Procaine	"Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester"	4914	Approved	D0TZ1G	DB00721	CTPDG012712
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Levetiracetam	"102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Leviteracetam; Torleva; Levetiracetam [INN]; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam"	5284583	Approved	D0E1XL	DB01202	CTPDG012713
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron + fosnetupitant	.	.	Approved	D0K5IP	.	CTPDG012714
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Phase 3	Cilansetron	Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)	6918107	Phase 3	D0Z2MB	DB04885	CTPDG012715
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 3	BEMESETRON	"3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo"	671690	Discontinued in Phase 3	D0V3GT	.	CTPDG012716
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	YM-114	"KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride"	132963	Discontinued in Phase 2	D02WGN	.	CTPDG012717
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	Norcisapride	"84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176"	3019427	Discontinued in Phase 2	D0K1SZ	.	CTPDG012718
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Preclinical	ATI-17000	"CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one,"	5311194	Preclinical	D0M1YN	.	CTPDG012719
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	AS-8112	.	.	Terminated	D08KDP	.	CTPDG012720
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	BP4.879a	.	5311254	Terminated	D0V1SD	.	CTPDG012721
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	5-hydroxyindole	"1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole  [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ"	16054	Investigative	D00EJS	.	CTPDG012722
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	TMB-8	"8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06"	5494	Investigative	D01WXA	.	CTPDG012723
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea	CHEMBL1086332; SCHEMBL13527422	46831055	Investigative	D02OYL	.	CTPDG012724
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"10,11-dihydro-5H-dibenzo[b,f]azepine"	"Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N"	10308	Investigative	D04KGK	.	CTPDG012725
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane"	CHEMBL611082; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862	9794818	Investigative	D07ZZD	.	CTPDG012726
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(2'-Indolecarbonyloxy)-nortropane	CHEMBL596256; BDBM50304333	46226582	Investigative	D0C3AJ	.	CTPDG012727
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	FLUPENTIXOLE	"(E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol"	5281878	Investigative	D0M4RW	.	CTPDG012728
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]ramosetron	.	91827343	Investigative	D0O5PQ	.	CTPDG012729
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane	CHEMBL593963; BDBM50304334	46226590	Investigative	D0S8ZJ	.	CTPDG012730
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]GR65630	[3H]-GR65630	5311136	Investigative	D0T3QZ	.	CTPDG012731
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H](S)-zacopride	GTPL4074	53321935	Investigative	D0UV6L	.	CTPDG012732
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	BRL-24682	"Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-"	9797313	Investigative	D00PCE	.	CTPDG012733
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	6-(4-Methyl-piperazin-1-yl)-phenanthridine	"CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)-"	9993659	Investigative	D04AXY	.	CTPDG012734
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	trichloroethanol	"2,2,2-TRICHLOROETHANOL; 115-20-8; Trichlorethanol; Trichloroethyl alcohol; Ethanol, 2,2,2-trichloro-; 2,2,2-Trichloro-1-ethanol; (Hydroxymethyl)trichloromethane; 2,2,2-Trichloroethyl alcohol; 2,2,2-Trichloroethan-1-ol; C2H3Cl3O; UNII-AW835AJ62N; NSC 66407; beta-trichloroethanol; CCRIS 6763; CCl3CH2OH; EINECS 204-071-0; 2,2,2-trichloro-ethanol; 2,2,2-tris-chloroethanol; BRN 1697495; AW835AJ62N; CHEBI:28094; KPWDGTGXUYRARH-UHFFFAOYSA-N; .beta.,.beta.,.beta-Trichloroethanol; 2,2,2-Trichloroethanol, 99%; 4yas"	8259	Investigative	D06IRE	.	CTPDG012735
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid	CHEMBL468498; AC1LEONH; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid	715494	Investigative	D0G3MD	.	CTPDG012736
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-phenylbiguanide	"phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide"	4780	Investigative	D0H4NK	.	CTPDG012737
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(S)-zacopride	CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide	6604914	Investigative	D0I4BZ	.	CTPDG012738
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	PH-709829	PTGWFYYEAUFEAS-ZYHUDNBSSA-N; CHEMBL403858; PHA-709829; SCHEMBL844377; GTPL3997; BDBM50377050	10107234	Investigative	D0IP9V	.	CTPDG012739
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Benzyl-piperazin-1-yl)-benzothiazole	"2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191"	1484933	Investigative	D0L1NS	.	CTPDG012740
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]granisetron	[3H]-granisetron; [3H]-BRL-43694	3510	Investigative	D0P2HR	.	CTPDG012741
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	meta-chlorphenylbiguanide	"m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide"	1354	Investigative	D0SA4A	.	CTPDG012742
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole	CHEMBL289060; BDBM50014174	14742545	Investigative	D0TJ6Z	.	CTPDG012743
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	CP-810123	"UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane"	11184481	Investigative	D0X7HD	.	CTPDG012744
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	bilobalide	"33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448"	73581	Investigative	D0B0TK	.	CTPDG012745
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Methyl-piperazin-1-yl)-quinoline	"N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080"	5013	Investigative	D0G2BS	.	CTPDG012746
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-((naphthalen-2-yloxy)methyl)piperidine	4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158	24691160	Investigative	D01FFX	.	CTPDG012747
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	MESULERGINE	"Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206"	68848	Investigative	D0K5NZ	.	CTPDG012748
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	CHEMBL444985	44592241	Investigative	D06QIQ	.	CTPDG012749
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	QUIPAZINE	"4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259"	5011	Investigative	D08BCF	.	CTPDG012750
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5-chloro-3,4-dihydroquinazolin-2-amine"	"CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0"	13702393	Investigative	D0Y9TL	.	CTPDG012751
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-methyl-5-HT	2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin	1574	Investigative	D00CRA	.	CTPDG012752
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5,6-dichloro-3,4-dihydroquinazolin-2-amine"	"Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369"	9904281	Investigative	D08VGJ	.	CTPDG012753
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	SEROTONIN	"5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790"	5202	Investigative	D0F6CD	DB08839	CTPDG012754
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	A-987306	"SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS*,11aS*)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR*,11aR*)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine"	44538833	Investigative	D0F9QT	.	CTPDG012755
M6ACROT05021	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Dolasetron	"Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate"	3033818	Approved	D00YLW	DB00757	CTPDG012708
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron	"Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one"	6337614	Approved	D04FVU	DB00377	CTPDG012709
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Alosetron	"Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride"	2099	Approved	D06GKN	DB00969	CTPDG012710
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Tropisetron	"Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate"	656665	Approved	D0K0KH	DB11699	CTPDG012711
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Procaine	"Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester"	4914	Approved	D0TZ1G	DB00721	CTPDG012712
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Levetiracetam	"102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Leviteracetam; Torleva; Levetiracetam [INN]; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam"	5284583	Approved	D0E1XL	DB01202	CTPDG012713
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Approved	Palonosetron + fosnetupitant	.	.	Approved	D0K5IP	.	CTPDG012714
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Phase 3	Cilansetron	Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)	6918107	Phase 3	D0Z2MB	DB04885	CTPDG012715
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 3	BEMESETRON	"3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo"	671690	Discontinued in Phase 3	D0V3GT	.	CTPDG012716
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	YM-114	"KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride"	132963	Discontinued in Phase 2	D02WGN	.	CTPDG012717
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Discontinued in Phase 2	Norcisapride	"84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176"	3019427	Discontinued in Phase 2	D0K1SZ	.	CTPDG012718
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Preclinical	ATI-17000	"CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one,"	5311194	Preclinical	D0M1YN	.	CTPDG012719
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	AS-8112	.	.	Terminated	D08KDP	.	CTPDG012720
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Terminated	BP4.879a	.	5311254	Terminated	D0V1SD	.	CTPDG012721
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	5-hydroxyindole	"1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole  [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ"	16054	Investigative	D00EJS	.	CTPDG012722
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	TMB-8	"8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06"	5494	Investigative	D01WXA	.	CTPDG012723
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea	CHEMBL1086332; SCHEMBL13527422	46831055	Investigative	D02OYL	.	CTPDG012724
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"10,11-dihydro-5H-dibenzo[b,f]azepine"	"Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N"	10308	Investigative	D04KGK	.	CTPDG012725
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane"	CHEMBL611082; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862	9794818	Investigative	D07ZZD	.	CTPDG012726
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(2'-Indolecarbonyloxy)-nortropane	CHEMBL596256; BDBM50304333	46226582	Investigative	D0C3AJ	.	CTPDG012727
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	FLUPENTIXOLE	"(E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol"	5281878	Investigative	D0M4RW	.	CTPDG012728
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]ramosetron	.	91827343	Investigative	D0O5PQ	.	CTPDG012729
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane	CHEMBL593963; BDBM50304334	46226590	Investigative	D0S8ZJ	.	CTPDG012730
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]GR65630	[3H]-GR65630	5311136	Investigative	D0T3QZ	.	CTPDG012731
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H](S)-zacopride	GTPL4074	53321935	Investigative	D0UV6L	.	CTPDG012732
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	BRL-24682	"Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-"	9797313	Investigative	D00PCE	.	CTPDG012733
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	6-(4-Methyl-piperazin-1-yl)-phenanthridine	"CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)-"	9993659	Investigative	D04AXY	.	CTPDG012734
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	trichloroethanol	"2,2,2-TRICHLOROETHANOL; 115-20-8; Trichlorethanol; Trichloroethyl alcohol; Ethanol, 2,2,2-trichloro-; 2,2,2-Trichloro-1-ethanol; (Hydroxymethyl)trichloromethane; 2,2,2-Trichloroethyl alcohol; 2,2,2-Trichloroethan-1-ol; C2H3Cl3O; UNII-AW835AJ62N; NSC 66407; beta-trichloroethanol; CCRIS 6763; CCl3CH2OH; EINECS 204-071-0; 2,2,2-trichloro-ethanol; 2,2,2-tris-chloroethanol; BRN 1697495; AW835AJ62N; CHEBI:28094; KPWDGTGXUYRARH-UHFFFAOYSA-N; .beta.,.beta.,.beta-Trichloroethanol; 2,2,2-Trichloroethanol, 99%; 4yas"	8259	Investigative	D06IRE	.	CTPDG012735
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid	CHEMBL468498; AC1LEONH; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid	715494	Investigative	D0G3MD	.	CTPDG012736
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	1-phenylbiguanide	"phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide"	4780	Investigative	D0H4NK	.	CTPDG012737
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	(S)-zacopride	CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide	6604914	Investigative	D0I4BZ	.	CTPDG012738
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	PH-709829	PTGWFYYEAUFEAS-ZYHUDNBSSA-N; CHEMBL403858; PHA-709829; SCHEMBL844377; GTPL3997; BDBM50377050	10107234	Investigative	D0IP9V	.	CTPDG012739
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Benzyl-piperazin-1-yl)-benzothiazole	"2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191"	1484933	Investigative	D0L1NS	.	CTPDG012740
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	[3H]granisetron	[3H]-granisetron; [3H]-BRL-43694	3510	Investigative	D0P2HR	.	CTPDG012741
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	meta-chlorphenylbiguanide	"m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide"	1354	Investigative	D0SA4A	.	CTPDG012742
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole	CHEMBL289060; BDBM50014174	14742545	Investigative	D0TJ6Z	.	CTPDG012743
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	CP-810123	"UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane"	11184481	Investigative	D0X7HD	.	CTPDG012744
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	bilobalide	"33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448"	73581	Investigative	D0B0TK	.	CTPDG012745
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-(4-Methyl-piperazin-1-yl)-quinoline	"N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080"	5013	Investigative	D0G2BS	.	CTPDG012746
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-((naphthalen-2-yloxy)methyl)piperidine	4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158	24691160	Investigative	D01FFX	.	CTPDG012747
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	MESULERGINE	"Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206"	68848	Investigative	D0K5NZ	.	CTPDG012748
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	CHEMBL444985	44592241	Investigative	D06QIQ	.	CTPDG012749
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	QUIPAZINE	"4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259"	5011	Investigative	D08BCF	.	CTPDG012750
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5-chloro-3,4-dihydroquinazolin-2-amine"	"CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0"	13702393	Investigative	D0Y9TL	.	CTPDG012751
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	2-methyl-5-HT	2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin	1574	Investigative	D00CRA	.	CTPDG012752
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	"5,6-dichloro-3,4-dihydroquinazolin-2-amine"	"Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369"	9904281	Investigative	D08VGJ	.	CTPDG012753
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	SEROTONIN	"5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790"	5202	Investigative	D0F6CD	DB08839	CTPDG012754
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	A-987306	"SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS*,11aS*)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR*,11aR*)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine"	44538833	Investigative	D0F9QT	.	CTPDG012755
M6ACROT05022	5-hydroxytryptamine receptor 3A (HTR3A)	5HT3A_HUMAN	.	.	Investigative	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	Investigative	D0T2RY	.	CTPDG011121
M6ACROT05027	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT05032	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Phase 2	Zunsemetinib	"(-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; (R)-Zunsemetinib; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1639791-42-6; 1640282-42-3; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; AKOS040756965; Ati 450; ATI 450 [WHO-DD]; ATI450; ATI-450; AX2VWG0ZCR; BDBM175242; CDD450; CDD-450; CHEMBL3704901; CS-0204147; CS-0374185; EX-A6292; GTPL11681; HY-139553; HY-139553A; MS-29543; SCHEMBL16279876; UNII-AX2VWG0ZCR; US9115089, 49; WHO 11983; zunsemetinib; Zunsemetinib [INN]; Zunsemetinib [USAN:INN]; Zunsemetinib [USAN]; Zunsemetinib M-atropisomer"	86291496	Phase 2	DQ15ZM	.	CTPDG001651
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Phase 1/2	CBP-501	"UNII-XH2662798I; 565434-85-7; XH2662798I; Cdc25C phosphatase (211-221); CBP501; CBP 501; SCHEMBL17101340; Z-3278; D-Arginine, 4-benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D-  arginyl-D-arginyl-D-glutaminyl-D-arginyl-"	16156006	Phase 1/2	D02NNN	.	CTPDG014515
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Phase 1	MMI-0100	"Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix"	.	Phase 1	D0S7NS	.	CTPDG004431
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Investigative	PF-3644022	PF3644022; PF 3644022	44631903	Investigative	D06QBJ	DB07430	CTPDG014516
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Investigative	CMPD1	MAPKAPK2a inhibitor	11382492	Investigative	D0O7UT	.	CTPDG014517
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Investigative	PMID17480064C16	"724711-21-1; 3fhr; 2jbp; 2jbo; P4O; Pyrrolopyridine, 16; Kinome_3179; 3r2y; GTPL8177; BDBM30185; ZINC16052855; AKOS027322581; DB08358; KB-19275; DB-013997; FT-0745988"	10389239	Investigative	D0EW9J	DB08358	CTPDG014518
M6ACROT05034	MAP kinase-activated protein kinase 2 (MAPKAPK2)	MAPK2_HUMAN	.	.	Investigative	PMID19364658C33	GTPL8163; BDBM50259563	25207521	Investigative	D01YWE	.	CTPDG014519
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05035	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT05037	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT05039	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Approved	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	Approved	D0E6XR	DB01254	CTPDG010614
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	"Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene"	8189	Investigative	D0OD8N	DB02078	CTPDG010615
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	CEP-6331	"2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365"	9823787	Investigative	D07IHM	.	CTPDG010616
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	JNJ-10198409	"627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814"	9797370	Investigative	D0YZ7H	.	CTPDG010060
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	PMID15546730C2	UNII-N9PH4O199D; N9PH4O199D; GTPL8136; BDBM13268	11153014	Investigative	D08RZB	.	CTPDG010617
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	CEP-5104	"C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364"	23378546	Investigative	D09QBA	.	CTPDG010150
M6ACROT05042	Tyrosine-protein kinase Fyn (FYN)	FYN_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05045	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05046	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05046	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 1	TP-1454	.	.	Phase 1	DLN0P8	.	CTPDG003830
M6ACROT05047	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05047	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05047	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05052	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT05052	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT05052	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT05052	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT05054	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT05055	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05055	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05055	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05056	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT05058	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05058	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05058	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Piperazine urea derivative 2	PMID26413912-Compound-48	.	Patented	D00ZCD	.	CTPDG014956
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Carbamoyl oxime derivative 1	PMID26413912-Compound-29	.	Patented	D0C3OH	.	CTPDG014957
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Carbamate derivative 6	PMID26413912-Compound-33	.	Patented	D0I6VK	.	CTPDG014958
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Carbamate derivative 5	PMID26413912-Compound-32	.	Patented	D0X9GL	.	CTPDG014959
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Carbamate derivative 4	PMID26413912-Compound-31	.	Patented	D0ZU3R	.	CTPDG014960
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Ethylaminopyrimidine derivative 1	PMID26413912-Compound-73	44203832	Patented	D01THA	.	CTPDG014961
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	PMID26413912-Compound-84	.	91008342	Patented	D0B7CW	.	CTPDG014962
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Carbamide derivative 1	PMID26413912-Compound-49	54576693	Patented	D0IA7Z	DB15173	CTPDG014963
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Pyrimidinyl ethylenediamine derivative 1	PMID26413912-Compound-79	51037025	Patented	D0M1ND	.	CTPDG014964
M6ACROT05059	Fatty-acid amide hydrolase 1 (FAAH)	FAAH1_HUMAN	.	.	Patented	Carbamate derivative 2	PMID26413912-Compound-27	.	Patented	D0S8TB	.	CTPDG012564
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	Phase 3	D04FYL	.	CTPDG001424
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 3	QPI-1002	.	.	Phase 3	D0D5ZU	.	CTPDG014050
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2/3	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	Phase 2/3	DY4OZ6	.	CTPDG011434
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	Phase 2	D02EOH	.	CTPDG002982
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APR-246	Eprenetapopt	52918385	Phase 2	D03XTY	DB11684	CTPDG002887
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	Phase 2	D0CO9B	.	CTPDG002471
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Kevetrin	.	437740	Phase 2	D0K7DV	DB13010	CTPDG002262
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	INGN-225	"Cancer vaccine (p53), Introgen"	.	Phase 2	D0V2SP	.	CTPDG014051
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	Phase 2	D0V5JH	.	CTPDG001959
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	APG-115	"15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	Phase 2	D04SXL	.	CTPDG013837
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	Phase 1/2	D0KK4N	.	CTPDG014052
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	Phase 1	D03YSQ	DB12541	CTPDG005275
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	Phase 1	D05CPS	.	CTPDG014053
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	Phase 1	D0G7YS	.	CTPDG014054
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	COTI-2	"UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	Phase 1	D0G8CU	.	CTPDG004769
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	CGM097	.	53240420	Phase 1	D0Q7AG	.	CTPDG004479
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1	HDM201	.	71678098	Phase 1	D01KTG	.	CTPDG005403
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Discontinued in Phase 2	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	Discontinued in Phase 2	D05AHK	.	CTPDG006623
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	Terminated	D02NYK	.	CTPDG014055
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Terminated	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	Terminated	D0LG1K	.	CTPDG007285
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	Investigative	D08PLU	DB08363	CTPDG014056
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NUTLIN-3	"548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	Investigative	D01QKK	.	CTPDG014057
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	NU-8231	SCHEMBL2454464; CHEMBL360944	11648438	Investigative	D0F1SN	.	CTPDG014058
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	OPI-1002	.	.	Phase 2	D02CKH	.	CTPDG002989
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 2	Cenersen	.	56841947	Phase 2	D0K4VW	.	CTPDG002266
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Investigative	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	Investigative	D0T8EL	.	CTPDG014604
M6ACROT05064	Cellular tumor antigen p53 (TP53/p53)	P53_HUMAN	.	.	Phase 1/2	PC14586	.	.	Phase 1/2	D53CGK	.	CTPDG003241
M6ACROT05067	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114197	.	.	Investigative	D04FHQ	.	CTPDG015475
M6ACROT05067	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114184	.	.	Investigative	D05FIN	.	CTPDG015476
M6ACROT05067	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114232	.	.	Investigative	D08ZWA	.	CTPDG015477
M6ACROT05067	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114170	.	.	Investigative	D0G8CN	.	CTPDG015478
M6ACROT05069	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114197	.	.	Investigative	D04FHQ	.	CTPDG015475
M6ACROT05069	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114184	.	.	Investigative	D05FIN	.	CTPDG015476
M6ACROT05069	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114232	.	.	Investigative	D08ZWA	.	CTPDG015477
M6ACROT05069	Transcription factor E2F3 (E2F3)	E2F3_HUMAN	.	.	Investigative	ISIS 114170	.	.	Investigative	D0G8CN	.	CTPDG015478
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Approved	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	Approved	D0JB3H	DB12513	CTPDG013047
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	SFX-01	.	.	Phase 2	D02NMR	.	CTPDG013048
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	ABT-RTA-408	.	.	Phase 2	D0K7NI	.	CTPDG013049
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	OT-551	"Tempol-H prodrug, Othera"	10131000	Phase 2	D0P1IX	DB05650	CTPDG013050
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	OT551	.	.	Phase 2	DHG2O3	.	CTPDG013051
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	CXA10	.	.	Phase 2	DF1JO7	.	CTPDG013052
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 1	HPP971	ANT 401	.	Phase 1	D9ZEM7	.	CTPDG013053
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzamide derivative 6	PMID28454500-Compound-86	90448888	Patented	D00PGP	.	CTPDG013054
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 1	PMID28454500-Compound-79	736095	Patented	D03RTM	.	CTPDG013055
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-93	.	77174	Patented	D04YKV	.	CTPDG013056
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-92	.	.	Patented	D05EMI	.	CTPDG013057
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 3	PMID28454500-Compound-89	15943058	Patented	D06KOH	.	CTPDG013058
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 2	PMID28454500-Compound-80	650480	Patented	D07TEZ	.	CTPDG013059
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Thiazole derivative 3	PMID28454500-Compound-84	1383822	Patented	D0D8KO	.	CTPDG013060
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzamide derivative 5	PMID28454500-Compound-85	.	Patented	D0DE0Y	.	CTPDG013061
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 3	PMID28454500-Compound-81	.	Patented	D0G8CF	.	CTPDG013062
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 4	PMID28454500-Compound-82	17609434	Patented	D0M2ZX	.	CTPDG013063
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 2	PMID28454500-Compound-88	3365475	Patented	D0ND6T	.	CTPDG013064
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-96	.	2761171	Patented	D0O5ZK	DB00609	CTPDG013065
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-94	.	23527	Patented	D0P9ZD	.	CTPDG013066
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-91	.	.	Patented	D0PF4H	.	CTPDG013067
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 1	PMID28454500-Compound-87	15943048	Patented	D0R2AI	.	CTPDG013068
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-95	.	21450	Patented	D0RO7A	.	CTPDG013069
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Thiazole derivative 2	PMID28454500-Compound-83	1298265	Patented	D0T2LN	.	CTPDG013070
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 4	PMID28454500-Compound-90	3886018	Patented	D0T7WW	.	CTPDG013071
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-57	.	135315519	Patented	D00TVL	.	CTPDG013072
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-8	.	66546002	Patented	D01GTU	.	CTPDG013073
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 4"	PMID28454500-Compound-31	.	Patented	D01MZI	.	CTPDG013074
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-36	.	121289252	Patented	D01PKZ	.	CTPDG013075
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Naphthalene derivative 1	PMID28454500-Compound-62	3294285	Patented	D02FWA	.	CTPDG013076
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-58	.	.	Patented	D02JFV	.	CTPDG013077
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 4	PMID28454500-Compound-19	118567653	Patented	D02SPI	.	CTPDG013078
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 1	PMID28454500-Compound-38	.	Patented	D02YNU	.	CTPDG013079
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Vinyl sulfone derivative 1	PMID28454500-Compound-20	73053707	Patented	D04ILM	.	CTPDG013080
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 2"	PMID28454500-Compound-29	.	Patented	D06LEF	.	CTPDG013081
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Diterpenoid derivative 1	PMID28454500-Compound-47	132210477	Patented	D09FZF	.	CTPDG013082
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1-phenyl-1,3,4-triazole derivative 1"	PMID28454500-Compound-76	74229666	Patented	D09MSN	.	CTPDG013083
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-13	.	73335601	Patented	D0AJ2T	.	CTPDG013084
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1-phenyl-1,3,4-triazole derivative 2"	PMID28454500-Compound-77	1327659	Patented	D0AR0L	.	CTPDG013085
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-12	.	.	Patented	D0AX4Q	.	CTPDG013086
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 1"	PMID28454500-Compound-28	.	Patented	D0AZ8T	.	CTPDG013087
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-41	.	11000442	Patented	D0C1PB	.	CTPDG013088
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 2	PMID28454500-Compound-17	118567519	Patented	D0EO3S	.	CTPDG013089
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-34	.	121289250	Patented	D0FH6P	.	CTPDG013090
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-33	.	121289344	Patented	D0FM3Q	.	CTPDG013091
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 3	PMID28454500-Compound-18	.	Patented	D0G1LS	.	CTPDG013092
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-50	.	193653	Patented	D0G4EK	DB04339	CTPDG013093
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1-phenyl-1,3,4-triazole derivative 3"	PMID28454500-Compound-78	3071025	Patented	D0I2DV	.	CTPDG013094
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-3	.	.	Patented	D0JH8Z	.	CTPDG013095
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Pyridyl compound 1	PMID28454500-Compound-15	.	Patented	D0KX0J	.	CTPDG013096
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-32	.	121289291	Patented	D0L1JQ	.	CTPDG013097
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-60	.	.	Patented	D0LL7V	.	CTPDG013098
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-40	.	5316743	Patented	D0MQ3X	.	CTPDG013099
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	3-phenyl propanoic derivative 2	PMID28454500-Compound-68	.	Patented	D0MS7G	.	CTPDG013100
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-35	.	121289348	Patented	D0MX0Q	.	CTPDG013101
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-49	.	.	Patented	D0N1VC	.	CTPDG013102
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-9	.	66546189	Patented	D0N9GH	.	CTPDG013103
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-59	.	.	Patented	D0O3KN	.	CTPDG013104
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	3-phenyl propanoic derivative 1	PMID28454500-Compound-67	4685764	Patented	D0O6LW	.	CTPDG013105
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	3-phenyl propanoic derivative 3	PMID28454500-Compound-69	.	Patented	D0Q8JZ	.	CTPDG013106
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Diterpenoid derivative 2	PMID28454500-Compound-48	132210549	Patented	D0Q9QQ	.	CTPDG013107
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-11	.	68066028	Patented	D0RM4V	.	CTPDG013108
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-37	.	121289347	Patented	D0SA1N	.	CTPDG013109
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 1	PMID28454500-Compound-16	53262706	Patented	D0U9TR	.	CTPDG013110
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 3"	PMID28454500-Compound-30	.	Patented	D0VA2G	.	CTPDG013111
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 2	PMID28454500-Compound-39	.	Patented	D0VW9H	.	CTPDG013112
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-10	.	68066062	Patented	D0WN1Y	.	CTPDG013113
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1,2,3,4-tetrahydroisoquinoline derivative 1"	PMID28454500-Compound-61	.	Patented	D0WR1I	.	CTPDG013114
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Trepenoid derivative 1	PMID28454500-Compound-14	.	Patented	D0XL2V	.	CTPDG013115
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Preclinical	CAT4001	.	.	Preclinical	D24EPJ	.	CTPDG013116
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Preclinical	M102	.	.	Preclinical	DA85KQ	.	CTPDG013117
M6ACROT05072	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Preclinical	TFM735	.	.	Preclinical	DPJ05C	.	CTPDG013118
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Approved	Sotorasib	"AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-"	137278711	Approved	D0R7LD	DB15569	CTPDG000176
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Approved	Adagrasib	"2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-"	138611145	Approved	DUQV41	.	CTPDG000004
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 3	JDQ443	"(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580"	156501355	Phase 3	D37IQM	.	CTPDG000943
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 1/2	LY3499446	.	.	Phase 1/2	DEXM29	.	CTPDG003182
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 1	RG6330	GDC-6036	.	Phase 1	DDZ6B0	.	CTPDG003941
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 1	JNJ-74699157	.	.	Phase 1	DZY4R2	.	CTPDG003641
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 1	AZD4785	IONIS-KRAS-2.5RX	.	Phase 1	D0DT5H	.	CTPDG004843
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 1	BI 1701963	.	.	Phase 1	DR4K0V	.	CTPDG003745
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 2	GI-4000 + gemcitabine	.	.	Phase 2	D0KK9V	.	CTPDG002251
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 2	SiG12D-LODER	.	.	Phase 2	DNH67V	.	CTPDG001664
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Phase 1	ASP3082	.	.	Phase 1	DL81ME	.	CTPDG003834
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Investigative	ISIS 6958	.	.	Investigative	D04GPF	.	CTPDG015406
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Investigative	PNT-300	"KRAS gene inhibitor (cancer), ProNAi"	.	Investigative	D09ENF	.	CTPDG008560
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Investigative	ISIS 7453	.	.	Investigative	D0A4MW	.	CTPDG015407
M6ACROT05073	GTPase KRas (KRAS)	RASK_HUMAN	.	.	Investigative	ISIS 6957	.	.	Investigative	D0O2LY	.	CTPDG015408
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	BDBM50363780	CHEMBL1945260; CHEMBL1962973	49847188	Patented	D00RNS	.	CTPDG015063
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	BDBM50363782	CHEMBL1945264; CHEMBL1962780	49847118	Patented	D07NKC	.	CTPDG015064
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	AC1LFGWU	"Oprea1_144688; SCHEMBL16409995; ZINC310666; STK508156; AKOS003273711; MCULE-1481833521; ST45014551; SR-01000248344; SR-01000248344-1; 8-(4-methyl(1,2,4-triazol-3-ylthio))-5-nitroquinoline; 8-[(4-methyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline; 8-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline"	802800	Patented	D07YHN	.	CTPDG015065
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	ZINC915379	"CHEMBL2315467; BAS 02073268; SCHEMBL16409978; BDBM50424850; AKOS000586084; MCULE-1228568202; 3-Benzylsulfanyl-5-phenoxymethyl-4-phenyl-4H-[1,2,4]triazole"	1162727	Patented	D0F6NT	.	CTPDG015066
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	"US9359293, TM"	SCHEMBL18103197; CHEMBL3940508; BDBM234208	71533676	Patented	D0MW0K	.	CTPDG015067
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	"US9359293, TA"	SCHEMBL18103200; CHEMBL3892393; BDBM234205	122580129	Patented	D0PL1I	.	CTPDG015068
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	BDBM50363773	CHEMBL1945137; CHEMBL1962885	49847196	Patented	D0V2UZ	.	CTPDG015069
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	"US9359293, TB"	SCHEMBL18103198; CHEMBL3968962; BDBM234206	122580127	Patented	D0X9SE	.	CTPDG015070
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Patented	AC1LOJYQ	"SCHEMBL16409996; ZINC1076986; 3-[(4-nitrophenyl)methylsulfanyl]-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole; MCULE-8783896159"	1264500	Patented	D0Y1WA	.	CTPDG015071
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Investigative	AGK2	AGK-2; AGK 2	2130404	Investigative	D0E3NT	.	CTPDG015072
M6ACROT05082	NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	SIR2_HUMAN	.	.	Investigative	INDUS-815C	"VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech"	.	Investigative	D0IR8J	.	CTPDG008183
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112000	.	.	Investigative	D00LSM	.	CTPDG015409
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112022	.	.	Investigative	D00SQD	.	CTPDG015410
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112019	.	.	Investigative	D04XOE	.	CTPDG015411
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112005	.	.	Investigative	D06QZK	.	CTPDG015412
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112002	.	.	Investigative	D07FSX	.	CTPDG015413
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112023	.	.	Investigative	D07RUF	.	CTPDG015414
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111992	.	.	Investigative	D0D9OL	.	CTPDG015415
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112003	.	.	Investigative	D0GD1R	.	CTPDG015416
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111997	.	.	Investigative	D0H0YU	.	CTPDG015417
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112004	.	.	Investigative	D0H6OL	.	CTPDG015418
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112001	.	.	Investigative	D0N7OK	.	CTPDG015419
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112024	.	.	Investigative	D0QU6S	.	CTPDG015420
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112020	.	.	Investigative	D0T0XZ	.	CTPDG015421
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111993	.	.	Investigative	D0Y4TS	.	CTPDG015422
M6ACROT05082	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112021	.	.	Investigative	D0Z4RI	.	CTPDG015423
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Approved	Teprotumumab	RV001	.	Approved	D0EN0W	.	CTPDG010641
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Approved	Mecasermin	Increlex (TN)	.	Approved	D0F3JT	.	CTPDG010642
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Approved	Somatomedin-1	Igef (TN)	.	Approved	D0N3NZ	.	CTPDG010643
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 3	OSI-906	"Linsitinib; 867160-71-2; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/"	11640390	Phase 3	D01GFX	DB06075	CTPDG001489
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2/3	Rinfabate	"RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed"	.	Phase 2/3	D06APK	.	CTPDG001567
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	AMG 479	.	.	Phase 2	D00AKR	.	CTPDG010644
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	VPI-2690B	.	.	Phase 2	D00VKK	.	CTPDG010645
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	AXL-1717	"BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum"	72435	Phase 2	D01SJS	DB12802	CTPDG003015
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	R1507	.	5376617	Phase 2	D03BHM	.	CTPDG010646
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	Cyclolignan picropodophyllin	"PPP; IGF-1R inhibitor (cancer), Karolinska"	.	Phase 1	D01OYS	.	CTPDG010647
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	RG-7010	"R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche"	.	Phase 1	D03WNN	.	CTPDG005284
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	HF-0299	.	.	Phase 1	D0L1ZM	.	CTPDG010648
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	BIIB 022	.	.	Phase 1	D0O7QQ	.	CTPDG010649
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	FPI-1434	.	.	Phase 1	D4JYH3	.	CTPDG004114
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	SAR446159	.	.	Phase 1	D10KTZ	.	CTPDG010650
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Discontinued in Phase 2	AVE-1642	"EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis"	.	Discontinued in Phase 2	D00BPE	.	CTPDG010651
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Discontinued in Phase 1/2	KW-2450	.	56847547	Discontinued in Phase 1/2	D0M3OR	.	CTPDG009931
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Discontinued in Phase 1	Figitumumab	"AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid"	.	Discontinued in Phase 1	D0U6KH	.	CTPDG006735
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Preclinical	BMS-695735	.	135441202	Preclinical	D0LF0O	.	CTPDG007066
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	NVP-ADW742	"475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	Investigative	D06NMZ	.	CTPDG008744
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	JB-1	JB1	25150849	Investigative	D0O0RY	.	CTPDG008020
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	"4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240677; BDBM50326006	43680262	Investigative	D0L7MM	.	CTPDG009939
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	"4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240676; BDBM50326004	43743432	Investigative	D0W9KO	.	CTPDG009940
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	Investigative	D0G6XS	.	CTPDG010555
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	Alpha-D-Mannose	"alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/"	185698	Investigative	D07LUR	.	CTPDG010653
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Preclinical	ATL-1101	.	.	Preclinical	D01QKD	.	CTPDG007152
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	AG 1024	tyrphostin AG 1024; AG-1024; AG1024	2044	Investigative	D01ODR	.	CTPDG015333
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	PQ401	PQ 401; IGF-1R inhibitor II; PQ-401	9549305	Investigative	D0B4SU	.	CTPDG015334
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	GSK1511931	GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]	44581765	Investigative	D0E4LC	.	CTPDG015335
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	AZD3463	AZD-3463; CS-1382; HY-15609; KB-154896	56599293	Investigative	D0O7LU	.	CTPDG015336
M6ACROT05083	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	GSK-1838705A	GSK 1838705A; GSK1838705A	25182616	Investigative	D06PJW	.	CTPDG009943
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112000	.	.	Investigative	D00LSM	.	CTPDG015409
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112022	.	.	Investigative	D00SQD	.	CTPDG015410
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112019	.	.	Investigative	D04XOE	.	CTPDG015411
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112005	.	.	Investigative	D06QZK	.	CTPDG015412
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112002	.	.	Investigative	D07FSX	.	CTPDG015413
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112023	.	.	Investigative	D07RUF	.	CTPDG015414
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111992	.	.	Investigative	D0D9OL	.	CTPDG015415
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112003	.	.	Investigative	D0GD1R	.	CTPDG015416
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111997	.	.	Investigative	D0H0YU	.	CTPDG015417
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112004	.	.	Investigative	D0H6OL	.	CTPDG015418
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112001	.	.	Investigative	D0N7OK	.	CTPDG015419
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112024	.	.	Investigative	D0QU6S	.	CTPDG015420
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112020	.	.	Investigative	D0T0XZ	.	CTPDG015421
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111993	.	.	Investigative	D0Y4TS	.	CTPDG015422
M6ACROT05085	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112021	.	.	Investigative	D0Z4RI	.	CTPDG015423
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Investigative	NI-105	"Tau protein modulator (neurodegenerative disease); Tau protein modulator (neurodegenerative disease), Biogen Idec; Tau protein modulator (neurodegenerative disease), Neurimmune Therapeutics"	10065825	Investigative	D03LGX	.	CTPDG014660
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Investigative	AL-408	"AL-108 analog (neurodegenerative diseases), Allon"	.	Investigative	D0D2GZ	.	CTPDG014661
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Investigative	BLV-0703	"BLV-200703; KTP-NH2; TAU-targeting compound (CNS disorders), Bioalvo"	.	Investigative	D0T9PL	.	CTPDG014662
M6ACROT05087	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Patented	PMID28766366-Compound-Scheme22Middle	.	.	Patented	D0I3LY	.	CTPDG015000
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 3	Davunetide	"NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics"	.	Phase 3	D0V1FF	.	CTPDG014658
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 3	TRx0237	"951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide"	23651551	Phase 3	D5FSV8	.	CTPDG000937
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 3	LMT-X	"Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx"	.	Phase 3	D05XDZ	.	CTPDG001387
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2/3	E2814	.	.	Phase 2/3	DQ02VJ	.	CTPDG001513
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	PBT-2	"AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana"	10016012	Phase 2	D00GXL	DB05565	CTPDG003090
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	RG6100	.	.	Phase 2	D01EJG	.	CTPDG003047
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	Tau-binding PET tracer	"T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens"	71059746	Phase 2	D02IJA	DB15033	CTPDG002977
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	BIIB092	.	.	Phase 2	D0I8FS	.	CTPDG014659
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	JNJ-63733657	.	.	Phase 2	DJH56Z	.	CTPDG001697
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	Semorinemab	RO7105705	.	Phase 2	D96UBZ	.	CTPDG001768
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 2	Bepranemab	RG6416	.	Phase 2	DK6BL5	.	CTPDG001695
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	LY3303560	.	.	Phase 1	D02DZK	.	CTPDG005363
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	PTI-80	.	.	Phase 1	D0P8YJ	.	CTPDG004512
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	PRX-005	.	.	Phase 1	DMSL68	.	CTPDG003815
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	APNmAb005	.	.	Phase 1	DO31MK	.	CTPDG003792
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	BEY2153	.	.	Phase 1	DFM7X6	.	CTPDG003916
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Phase 1	Lu AF87908	.	.	Phase 1	DPU26Z	.	CTPDG003764
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Investigative	NI-105	"Tau protein modulator (neurodegenerative disease); Tau protein modulator (neurodegenerative disease), Biogen Idec; Tau protein modulator (neurodegenerative disease), Neurimmune Therapeutics"	10065825	Investigative	D03LGX	.	CTPDG014660
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Investigative	AL-408	"AL-108 analog (neurodegenerative diseases), Allon"	.	Investigative	D0D2GZ	.	CTPDG014661
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Investigative	BLV-0703	"BLV-200703; KTP-NH2; TAU-targeting compound (CNS disorders), Bioalvo"	.	Investigative	D0T9PL	.	CTPDG014662
M6ACROT05088	Microtubule-associated protein tau (TAU)	TAU_HUMAN	.	.	Patented	PMID28766366-Compound-Scheme22Middle	.	.	Patented	D0I3LY	.	CTPDG015000
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT05097	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05098	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05103	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05103	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05103	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05104	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05104	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05104	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05107	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05107	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05107	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Approved	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	Approved	D0JB3H	DB12513	CTPDG013047
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	SFX-01	.	.	Phase 2	D02NMR	.	CTPDG013048
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	ABT-RTA-408	.	.	Phase 2	D0K7NI	.	CTPDG013049
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	OT-551	"Tempol-H prodrug, Othera"	10131000	Phase 2	D0P1IX	DB05650	CTPDG013050
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	OT551	.	.	Phase 2	DHG2O3	.	CTPDG013051
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 2	CXA10	.	.	Phase 2	DF1JO7	.	CTPDG013052
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Phase 1	HPP971	ANT 401	.	Phase 1	D9ZEM7	.	CTPDG013053
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzamide derivative 6	PMID28454500-Compound-86	90448888	Patented	D00PGP	.	CTPDG013054
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 1	PMID28454500-Compound-79	736095	Patented	D03RTM	.	CTPDG013055
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-93	.	77174	Patented	D04YKV	.	CTPDG013056
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-92	.	.	Patented	D05EMI	.	CTPDG013057
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 3	PMID28454500-Compound-89	15943058	Patented	D06KOH	.	CTPDG013058
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 2	PMID28454500-Compound-80	650480	Patented	D07TEZ	.	CTPDG013059
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Thiazole derivative 3	PMID28454500-Compound-84	1383822	Patented	D0D8KO	.	CTPDG013060
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzamide derivative 5	PMID28454500-Compound-85	.	Patented	D0DE0Y	.	CTPDG013061
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 3	PMID28454500-Compound-81	.	Patented	D0G8CF	.	CTPDG013062
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Benzo[d]oxazole derivative 4	PMID28454500-Compound-82	17609434	Patented	D0M2ZX	.	CTPDG013063
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 2	PMID28454500-Compound-88	3365475	Patented	D0ND6T	.	CTPDG013064
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-96	.	2761171	Patented	D0O5ZK	DB00609	CTPDG013065
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-94	.	23527	Patented	D0P9ZD	.	CTPDG013066
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-91	.	.	Patented	D0PF4H	.	CTPDG013067
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 1	PMID28454500-Compound-87	15943048	Patented	D0R2AI	.	CTPDG013068
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-95	.	21450	Patented	D0RO7A	.	CTPDG013069
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Thiazole derivative 2	PMID28454500-Compound-83	1298265	Patented	D0T2LN	.	CTPDG013070
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	4-(2-cyclohexylethoxy) aniline derivative 4	PMID28454500-Compound-90	3886018	Patented	D0T7WW	.	CTPDG013071
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-57	.	135315519	Patented	D00TVL	.	CTPDG013072
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-8	.	66546002	Patented	D01GTU	.	CTPDG013073
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 4"	PMID28454500-Compound-31	.	Patented	D01MZI	.	CTPDG013074
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-36	.	121289252	Patented	D01PKZ	.	CTPDG013075
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Naphthalene derivative 1	PMID28454500-Compound-62	3294285	Patented	D02FWA	.	CTPDG013076
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-58	.	.	Patented	D02JFV	.	CTPDG013077
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 4	PMID28454500-Compound-19	118567653	Patented	D02SPI	.	CTPDG013078
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 1	PMID28454500-Compound-38	.	Patented	D02YNU	.	CTPDG013079
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Vinyl sulfone derivative 1	PMID28454500-Compound-20	73053707	Patented	D04ILM	.	CTPDG013080
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 2"	PMID28454500-Compound-29	.	Patented	D06LEF	.	CTPDG013081
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Diterpenoid derivative 1	PMID28454500-Compound-47	132210477	Patented	D09FZF	.	CTPDG013082
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1-phenyl-1,3,4-triazole derivative 1"	PMID28454500-Compound-76	74229666	Patented	D09MSN	.	CTPDG013083
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-13	.	73335601	Patented	D0AJ2T	.	CTPDG013084
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1-phenyl-1,3,4-triazole derivative 2"	PMID28454500-Compound-77	1327659	Patented	D0AR0L	.	CTPDG013085
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-12	.	.	Patented	D0AX4Q	.	CTPDG013086
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 1"	PMID28454500-Compound-28	.	Patented	D0AZ8T	.	CTPDG013087
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-41	.	11000442	Patented	D0C1PB	.	CTPDG013088
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 2	PMID28454500-Compound-17	118567519	Patented	D0EO3S	.	CTPDG013089
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-34	.	121289250	Patented	D0FH6P	.	CTPDG013090
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-33	.	121289344	Patented	D0FM3Q	.	CTPDG013091
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 3	PMID28454500-Compound-18	.	Patented	D0G1LS	.	CTPDG013092
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-50	.	193653	Patented	D0G4EK	DB04339	CTPDG013093
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1-phenyl-1,3,4-triazole derivative 3"	PMID28454500-Compound-78	3071025	Patented	D0I2DV	.	CTPDG013094
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-3	.	.	Patented	D0JH8Z	.	CTPDG013095
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Pyridyl compound 1	PMID28454500-Compound-15	.	Patented	D0KX0J	.	CTPDG013096
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-32	.	121289291	Patented	D0L1JQ	.	CTPDG013097
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-60	.	.	Patented	D0LL7V	.	CTPDG013098
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-40	.	5316743	Patented	D0MQ3X	.	CTPDG013099
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	3-phenyl propanoic derivative 2	PMID28454500-Compound-68	.	Patented	D0MS7G	.	CTPDG013100
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-35	.	121289348	Patented	D0MX0Q	.	CTPDG013101
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-49	.	.	Patented	D0N1VC	.	CTPDG013102
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-9	.	66546189	Patented	D0N9GH	.	CTPDG013103
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-59	.	.	Patented	D0O3KN	.	CTPDG013104
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	3-phenyl propanoic derivative 1	PMID28454500-Compound-67	4685764	Patented	D0O6LW	.	CTPDG013105
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	3-phenyl propanoic derivative 3	PMID28454500-Compound-69	.	Patented	D0Q8JZ	.	CTPDG013106
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Diterpenoid derivative 2	PMID28454500-Compound-48	132210549	Patented	D0Q9QQ	.	CTPDG013107
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-11	.	68066028	Patented	D0RM4V	.	CTPDG013108
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-37	.	121289347	Patented	D0SA1N	.	CTPDG013109
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Chalcone derivative 1	PMID28454500-Compound-16	53262706	Patented	D0U9TR	.	CTPDG013110
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 3"	PMID28454500-Compound-30	.	Patented	D0VA2G	.	CTPDG013111
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 2	PMID28454500-Compound-39	.	Patented	D0VW9H	.	CTPDG013112
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	PMID28454500-Compound-10	.	68066062	Patented	D0WN1Y	.	CTPDG013113
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	"1,2,3,4-tetrahydroisoquinoline derivative 1"	PMID28454500-Compound-61	.	Patented	D0WR1I	.	CTPDG013114
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Patented	Trepenoid derivative 1	PMID28454500-Compound-14	.	Patented	D0XL2V	.	CTPDG013115
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Preclinical	CAT4001	.	.	Preclinical	D24EPJ	.	CTPDG013116
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Preclinical	M102	.	.	Preclinical	DA85KQ	.	CTPDG013117
M6ACROT05108	Nuclear factor erythroid 2-related factor 2 (NFE2L2)	NF2L2_HUMAN	.	.	Preclinical	TFM735	.	.	Preclinical	DPJ05C	.	CTPDG013118
M6ACROT05115	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05115	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05115	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05116	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT05123	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT05127	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05127	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05127	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT05143	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1/2	HH2710	.	.	Phase 1/2	D1KIY9	.	CTPDG003257
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1/2	ASTX029	.	.	Phase 1/2	DM1FD5	.	CTPDG003165
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	LY3214996	"JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one"	121408882	Phase 1	D0TN3Q	.	CTPDG004398
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	VAN-10-4-eluting stent	"INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde"	.	Phase 1	D08KNG	.	CTPDG013513
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	GDC-0994	.	71727581	Phase 1	D0Q4IX	DB15281	CTPDG004487
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	JSI-1187	.	.	Phase 1	DBU16T	.	CTPDG003963
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Preclinical	COR-D	.	.	Preclinical	DOJ6D9	.	CTPDG006976
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	AEZS-131	"ERK inhibitor (cancer), AEterna"	.	Investigative	D07NEE	.	CTPDG008677
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	SCH772984	SCH-772984	24866313	Investigative	D08XVZ	.	CTPDG013514
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	ERK inhibitor III	AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine	5721470	Investigative	D0C5AD	.	CTPDG013515
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	SCHEMBL6659391	11195892	Investigative	D0Q1AC	.	CTPDG013516
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	FR-180204	"865362-74-9; FR 180204; FR180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685"	11493598	Investigative	D0ZG4G	DB07794	CTPDG013517
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	DEBROMOHYMENIALDISINE	.	135451156	Investigative	D01WAI	DB04367	CTPDG013339
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Phosphonothreonine	"phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid"	10976469	Investigative	D05BHG	DB02482	CTPDG013391
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	Investigative	D0G2VC	.	CTPDG011474
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT05144	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Approved	Capivasertib	"1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	Approved	D01ZAQ	DB12218	CTPDG012898
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	GDC-0068	RG7440	24788740	Phase 3	D0I4TH	DB11743	CTPDG012899
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 3	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	Phase 3	D0I6VU	DB06486	CTPDG001180
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	GSK2110183	.	46843057	Phase 2	D02NXM	DB11648	CTPDG002968
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	RX-0201	.	.	Phase 2	D07SYZ	.	CTPDG002672
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	Trametinib + 2141795	.	11707110	Phase 2	D0S5WP	DB08911	CTPDG002041
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	Phase 2	D0X7CV	.	CTPDG012900
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	ARQ 092	Miransertib	53262401	Phase 2	D07DWF	DB14982	CTPDG012901
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1/2	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	Phase 1/2	D09CCZ	.	CTPDG003495
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	BMS-754807	"1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	Phase 1	D02QWY	DB15399	CTPDG012902
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	ARQ 751	.	.	Phase 1	D0L8PZ	.	CTPDG004619
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Phase 1	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	Phase 1	D06HYF	DB15431	CTPDG005162
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Patented	PMID28460551-Compound-6	.	.	Patented	D07QBF	.	CTPDG012903
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Terminated	Squalestatin 1	"Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	Terminated	D0O1AV	.	CTPDG007267
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	MYRIOCIN	"thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	Investigative	D07MQF	.	CTPDG012904
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	LD-101	AKT-SI-1	24773090	Investigative	D09DGE	.	CTPDG008563
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-674563	A 674563; A674563	11314340	Investigative	D0CM6T	DB08568	CTPDG012905
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Lactoquinomycin	SCHEMBL12324296	12967404	Investigative	D0F8HX	.	CTPDG012906
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	Investigative	D0N7CY	.	CTPDG008037
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	A-443654	A-4436554	10172943	Investigative	D0OX1T	DB08073	CTPDG012907
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	Investigative	D0PX5F	.	CTPDG007967
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	Investigative	D0RZ1H	.	CTPDG012908
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	ALM-301	"Akt inhibitors (cancer), Almac"	.	Investigative	D0V1ES	.	CTPDG007809
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BX-517	"BX517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	Investigative	D0L5AB	.	CTPDG012909
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"Inositol 1,3,4,5-Tetrakisphosphate"	"Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	Investigative	D0MH9X	DB01863	CTPDG012910
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one"	5908088	Investigative	D00ATA	.	CTPDG012911
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	Investigative	D05APZ	.	CTPDG012912
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	SB-747651A	"CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	Investigative	D0I1FJ	.	CTPDG012913
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	PMID20005102C1	GTPL8181; BDBM50305878; B99	46225540	Investigative	D0L2WP	.	CTPDG012914
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT05145	RAC-alpha serine/threonine-protein kinase (AKT1)	AKT1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 2	BVD-523	.	11719003	Phase 2	D01IED	DB13930	CTPDG003035
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1/2	HH2710	.	.	Phase 1/2	D1KIY9	.	CTPDG003257
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1/2	ASTX029	.	.	Phase 1/2	DM1FD5	.	CTPDG003165
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	LY3214996	"JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one"	121408882	Phase 1	D0TN3Q	.	CTPDG004398
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	VAN-10-4-eluting stent	"INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde"	.	Phase 1	D08KNG	.	CTPDG013513
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	GDC-0994	.	71727581	Phase 1	D0Q4IX	DB15281	CTPDG004487
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Phase 1	JSI-1187	.	.	Phase 1	DBU16T	.	CTPDG003963
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Preclinical	COR-D	.	.	Preclinical	DOJ6D9	.	CTPDG006976
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Terminated	SB220025	3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	Terminated	D09ICC	DB04338	CTPDG007421
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	AEZS-131	"ERK inhibitor (cancer), AEterna"	.	Investigative	D07NEE	.	CTPDG008677
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	SCH772984	SCH-772984	24866313	Investigative	D08XVZ	.	CTPDG013514
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	ERK inhibitor III	AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine	5721470	Investigative	D0C5AD	.	CTPDG013515
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	SCHEMBL6659391	11195892	Investigative	D0Q1AC	.	CTPDG013516
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	FR-180204	"865362-74-9; FR 180204; FR180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685"	11493598	Investigative	D0ZG4G	DB07794	CTPDG013517
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	DEBROMOHYMENIALDISINE	.	135451156	Investigative	D01WAI	DB04367	CTPDG013339
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Phosphonothreonine	"phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid"	10976469	Investigative	D05BHG	DB02482	CTPDG013391
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	Investigative	D0G2VC	.	CTPDG011474
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	Investigative	D0N6ES	.	CTPDG011477
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT05146	Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1)	MK01_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05148	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05149	Hepatocyte nuclear factor 1-alpha (HNF1A/TCF1)	HNF1A_HUMAN	.	.	Phase 1/2	Norleucine	"L-Norleucine; 327-57-1; H-Nle-OH; (S)-2-Aminohexanoic acid; Glycoleucine; Caprine; L-(+)-Norleucine; L-2-Aminohexanoic acid; 2-Aminocaproic acid; L-2-Aminohexanoate; L-Aminohexanoate; alpha-Aminocaproic acid; (2S)-2-aminohexanoic acid; (S)-(+)-2-Aminohexanoic acid; Norleucine (VAN); L-Aminohexanoic acid; Hexanoic acid, 2-amino-, (S)-; 2S-amino-hexanoic acid; (S)-2-Aminocaproic acid; (S)-Norleucine; NSC 10378; L(+)-Norleucine; UNII-832C8OV84S; EINECS 206-321-4; BRN 1721750; NLE; CHEBI:18347; LRQKBLKVPFOOQJ-YFKPBYRVSA-N"	21236	Phase 1/2	D00EFT	DB15458	CTPDG014671
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05154	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	Amooranin	"MCH-100XC2; Caspase-8 stimulator/apoptosis stimulator/cell cycle inhibitor (cancer), Dharma Biomedical; P-glycoprotein modulator (small molecule therapeutic/natural product, cancer/autoimmune diseases/inflammatory diseases), Dharma BioMedical"	11503749	Investigative	D08LIU	.	CTPDG014922
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	Acetyl-Ile-Glu-Thr-Asp-aldehyde	"Ac-IETD-CHO; 191338-86-0; CHEMBL478695; Ac-Ile-Glu-Thr-Asp-CHO; SCHEMBL20257131; N-acetyl-Ile-Glu-Thr-Asp-aldehyde; ZINC14947181; BDBM50340547; Acetyl-isoleucyl-glutamyl-threonyl-aspartal; 338A860; N-Acetyl-Ile-Glu-Thr-Asp-al, ~99% (TLC), powder; (4S)-4-{[(1S,2R)-1-{[(2S)-1-carboxy-3-oxopropan-2-yl]carbamoyl}-2-hydroxypropyl]carbamoyl}-4-[(2S,3S)-2-acetamido-3-methylpentanamido]butanoic acid"	11466200	Investigative	D0N8TA	.	CTPDG014923
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	Glionitrin A	CHEMBL550491	25243252	Investigative	D0Y2TI	.	CTPDG007672
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	ISIS 107612	.	.	Investigative	D00JXJ	.	CTPDG015200
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	ISIS 107676	.	.	Investigative	D04RGM	.	CTPDG015201
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	ISIS 107681	.	.	Investigative	D06YDM	.	CTPDG015202
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	ISIS 107652	.	.	Investigative	D06ZTM	.	CTPDG015203
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	ISIS 107642	.	.	Investigative	D07QZA	.	CTPDG015204
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	Acetyl-Ile-Glu-Thr-Asp-aldehyde	"Ac-IETD-CHO; 191338-86-0; CHEMBL478695; Ac-Ile-Glu-Thr-Asp-CHO; SCHEMBL20257131; N-acetyl-Ile-Glu-Thr-Asp-aldehyde; ZINC14947181; BDBM50340547; Acetyl-isoleucyl-glutamyl-threonyl-aspartal; 338A860; N-Acetyl-Ile-Glu-Thr-Asp-al, ~99% (TLC), powder; (4S)-4-{[(1S,2R)-1-{[(2S)-1-carboxy-3-oxopropan-2-yl]carbamoyl}-2-hydroxypropyl]carbamoyl}-4-[(2S,3S)-2-acetamido-3-methylpentanamido]butanoic acid"	11466200	Investigative	D0N8TA	.	CTPDG014923
M6ACROT05157	Caspase-8 (CASP8)	CASP8_HUMAN	.	.	Investigative	"Isoquinoline-1,3,4(2H)-trione"	"Phthalonimide; 1,3,4(2H)-Isoquinolinetrione; 521-73-3; isoquinoline-1,3,4-trione; 1,3,4-(2H)ISOQUINOLINETRIONE; UNII-BM68CV5X6Q; NSC 407248; BRN 0383773; BM68CV5X6Q; 1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; isoquinoline-1,3,4-(2H)-trione; 3deh; NSC407248; AC1L1VMV; 5-21-11-00575 (Beilstein Handbook Reference); 1,4(2H)-Isoquinolinetrione; SCHEMBL1122624; Isoquinoline-1,3,4-trione 1; CHEMBL206435; CTK1H0848; BDBM10247; DTXSID40200103; ZINC1599708; FCH844329; ACM521733; AKOS006276226; NSC-407248"	10640	Investigative	D0V6DX	.	CTPDG014239
M6ACROT05158	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT05159	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05161	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT05161	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT05161	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT05161	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 2	APG-101	"CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix"	.	Phase 2	D0N4JI	.	CTPDG014488
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 1	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	Phase 1	D0Q6SF	.	CTPDG004480
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	F61F12	"Anti-Fas mAb (cancer), IMED"	.	Investigative	D0N1DG	.	CTPDG008050
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	APG-103	"CD95 receptor inhibitor (inflammatory disease), Apogenix"	.	Investigative	D0QA7X	.	CTPDG014489
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	2-aminophenoxazine-3-one	"Questiomycin A; 2-Amino-3H-phenoxazin-3-one; 2-Aminophenoxazin-3-one; 1916-59-2; 2-Aminophenoxazon; 2-Aminophenoxazone; 3-Aminophenoxazone; 2-Amino-3-phenoxazone; 3H-Phenoxazin-3-one, 2-amino-; Isophenoxazine; 2-amino-phenoxazin-3-one; NSC 94945; MLS000736964; CHEBI:17293; SMR000528446; BRN 0014215; Questinomycine A; 3H-Phenoxazin-3-one,2-amino-; AV toxin C; 2-Aminophenoxazinone; Phx-3 cpd; Phx-3; 2-amino-3-phenoxazinone; 2-azanylphenoxazin-3-one; Acrospermum viticola toxin C; NCIOpen2_006212; 4-27-00-05519 (Beilstein Handbook Reference); cid_72725; CHEMBL146710; SCHEMBL2609261; BDBM76155; DTXSID60172691; HMS2270F19; NSC94945; ZINC4095812; MFCD00207317; NSC-94945; 2-acetylamino-(3h)-phenoxazin-3-one; AKOS027339724; NCGC00246903-01; AS-47041; C02161; J-012388; BRD-K66640612-001-05-8; Q15424786"	72725	Investigative	DAQ31P	.	CTPDG007605
M6ACROT05162	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	ISIS 17020	.	.	Investigative	D0J1SU	.	CTPDG015441
M6ACROT05163	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05163	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05163	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05165	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103473	.	.	Investigative	D07HIJ	.	CTPDG015370
M6ACROT05165	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103471	.	.	Investigative	D07RVX	.	CTPDG015371
M6ACROT05165	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103489	.	.	Investigative	D0Q3KN	.	CTPDG015372
M6ACROT05165	Dual specificity protein phosphatase 9 (DUSP9)	DUS9_HUMAN	.	.	Investigative	ISIS 103486	.	.	Investigative	D0S4BJ	.	CTPDG015373
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estrone	"Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one"	5870	Approved	D00ZFP	DB00655	CTPDG000795
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Conjugated estrogens b	Enjuvia (TN)	.	Approved	D01ICU	.	CTPDG009437
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Raloxifene	"Raloxifene (extended-release, CDT)"	5035	Approved	D01XBA	DB00481	CTPDG009438
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Ospemifene	"128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271; 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; UNII-B0P231ILBK; CCRIS 9205; B0P231ILBK; CHEBI:73275; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; senshio; Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol; Ophena; Ospemifene [USAN:INN:BAN]; Deaminotoremifene; Osphena (TN); Deaminohydroxytoremifene; AC1MI19T; C24H23ClO2"	3036505	Approved	D02CTS	DB04938	CTPDG009439
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estropipate	"7280-37-7; Piperazine estrone sulfate; Harmogen; Ogen; Ortho-Est; UNII-SVI38UY019; Piperazine estronesulfate; Sulestrex; SVI38UY019; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1); OGEN 2.5; Estropipate (USP); OGEN 5; Ogen (TN); OGEN .625; OGEN 1.25; EINECS 230-696-3; piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate; Piperazine oestrone sulphate; Conjugated estrogens: piperazine estrone sulfate; Estrone hydrogen sulf"	5284555	Approved	D03IUY	.	CTPDG009440
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Quinestrol	"EECPE; Eston; Estrovis; Estrovister; Plestrovis; Quilea; Quinestrolo; Quinestrolum; Quinestrolo [DCIT]; Estrovis 4000; W 3566; Estrovis (TN); Ethinyl Estradiol 3-Cyclopentyl Ether; Qui-Lea; Quinestrolum [INN-Latin]; W-3566; Quinestrol (USAN/INN); Quinestrol [USAN:INN:BAN]; Estradiol-17-beta 3-cyclopentyl ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol"	9046	Approved	D04UZT	DB04575	CTPDG009441
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Toremifene	"Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine"	3005573	Approved	D04VFJ	DB00539	CTPDG009442
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Ethinyl Estradiol	"Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta"	5991	Approved	D06NXY	DB00977	CTPDG009443
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Tamoxifen	"10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen"	2733526	Approved	D07KSG	DB00675	CTPDG009444
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Elacestrant	"ER-306323; ER-308698; SERMs, Eisai/Radius; Selective estrogen receptor modulators, Eisai/Radius"	23642301	Approved	D07KUN	DB06374	CTPDG009445
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estradiol Valerate	Delestrogen	13791	Approved	D07VBA	DB13956	CTPDG009446
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estradiol	"Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol"	5757	Approved	D08QMX	DB00783	CTPDG009447
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Danazol	"Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol"	28417	Approved	D09IPV	DB01406	CTPDG009448
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Dienestrol	"Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol"	667476	Approved	D09ZQN	DB00890	CTPDG009449
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Conjugated estrogens a	Conestin (TN)	.	Approved	D0A2RG	.	CTPDG009450
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Promestriene	BCP9000134; VA11593; A824465; I06-0300	9883915	Approved	D0C4NY	.	CTPDG009451
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Clomifene	"Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine"	1548953	Approved	D0CT9Y	DB06735	CTPDG009452
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Clomiphene Citrate	Clomid; Milophene; Serophene	3033832	Approved	D0I5WB	.	CTPDG009453
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Mestranol	"Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol"	6291	Approved	D0J1ML	DB01357	CTPDG009454
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Fulvestrant	"Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI"	104741	Approved	D0JO7Y	DB00947	CTPDG009455
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Fosfestrol	"Diethylstilbestrol diphosphate; 522-40-7; Phosphestrol; Phosphoestrolum; Honvan; Stilbestrol diphosphate; Desdp; Diethylstilbestryl diphosphate; Diethylstilbesterol diphosphate; ST52-Asta; Fosfestrolum [INN-Latin]; UNII-A0E0NMA80F; CCRIS 2778; (E)-Hex-3-ene-3,4-diylbis(4,1-phenylene) bis(dihydrogen phosphate); C18H22O8P2; EINECS 208-328-8; A0E0NMA80F; CHEBI:4532; Diethylstilbestrol diphosphate [USP]; NCGC00181335-01; Stilphostrol (TN); alpha,alpha'-Diethyl-(E)-4,4'-stilbenediol bis(dihydrogen phosphate)"	3032325	Approved	D0JO8Z	.	CTPDG000317
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Bazedoxifene	Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424	154257	Approved	D0JY8T	DB06401	CTPDG009456
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Gestrinone	Dimetrose (TN)	27812	Approved	D0M5RF	DB11619	CTPDG009457
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Cenestin	Sodium equilin sulfate; Equilin sodium sulfate; Climopax; Estratab; 16680-47-0; Sodium equilin 3-monosulfate; Emopremarin; Novoconestron; Climestrone; Promarit; Primarin; Premarose; Premaril; Menotrol; Ganeake; Estropan; Estrifol; Premarina; Palopause; Menogen; Mannest; Hyphorin; Formatrix; Estromed; Equigyne; Prempak; Oestrilin; Menotab; Kestrin; Glyestrin; Estroate; Equilin 3-Sulfate Sodium Salt; Conjugen; Conestron; Ayerogen; Theogen; Sukingpo	23676225	Approved	D0N6YV	.	CTPDG009458
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Esterified estrogens	.	.	Approved	D0R6RE	.	CTPDG009459
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Premarin/Trimegestone	Conjugated estrogen tablets	.	Approved	D0S1UW	.	CTPDG009460
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estradiol Acetate	Femring	9818306	Approved	D0T7ZQ	DB13952	CTPDG009461
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estradiol Cypionate	Depo-estradiol	9403	Approved	D0U0XD	DB13954	CTPDG009462
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Nomegestrol acetate	Lutenyl (TN)	91668	Approved	D0V2JK	DB13981	CTPDG009463
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Levormeloxifene	"Centchroman; Centron; Ormeloxifene; Saheli; NNC-46-0020; Non-steroidal (oral, contraception/cancer); Non-steroidal (oral, contraception/cancer), Central Drug Research Institute (CDRI)"	35805	Approved	D0W9GA	DB13310	CTPDG009464
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Cyclofenil	"2624-43-3; Ondogyne; Cyclofenyl; Cyclophenyl; Cyclopenil; Fertodur; Sanocrisin; Cyclophenil; Sexovar; Rehibin; Sexadieno; Sexovid; Ondonid; Oginex; (Cyclohexylidenemethylene)bis(4,1-phenylene) diacetate; Neoclym; ICI 48213; Cyclofenilum [INN-Latin]; Ciclofenilo [INN-Spanish]; NSC 86464; H 3452; F 6066; UNII-J468V64WZ1; Cyclofenil [INN:BAN:DCF:JAN]; 4,4'-(Cyclohexylidenemethylene)diphenol diacetate ester; C23H24O4; EINECS 220-089-1; Bis(p-hydroxyphenyl)cyclohexyldienemethane diacetate; BRN 2014687; AI3-52271; F-6066"	2898	Approved	D0X1EZ	DB13472	CTPDG000073
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Diethylstilbestrol	"Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol ""2"" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol"	448537	Approved	D0Y2NE	DB00255	CTPDG009465
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estriol	"Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene"	5756	Approved	D0Z1FX	DB04573	CTPDG009466
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Mitotane	"Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane"	4211	Approved	D0Z5OE	DB00648	CTPDG009467
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	ARZOXIFENE	"182133-25-1; UNII-E569WG6E60; LY 353381; E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; Arzoxifene [INN]; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; AC1L4522; AN-538; AKOS030631785; SB19713; KB-05502; FT-0751607; 124708-EP2295426A1; 124708-EP2295427A1; 124708-EP2292592A1; 124708-EP2292576A2; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)"	179337	Approved	D06LOQ	DB06249	CTPDG009468
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Lasofoxifene	"Oporia; 180916-16-9; rac-Lasofoxifene; CP 336156; Fablyn; UNII-337G83N988; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CHEMBL328190; 337G83N988; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 180915-78-0; CP-336,156; LASOFOXIFENE HCL; Lasofoxifene [INN:BAN]; AC1L50OI; SCHEMBL26815; GTPL7542; CTK8F1062; BDBM20606; DTXSID50171037; GXESHMAMLJKROZ-IAPPQJPRSA-N; ZINC3918428; BCP03626; AKOS030241621; AN-3516; BCP9000842; DB06202; Lasofoxifene [INN]; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; AZD9639"	216416	Approved	D09NMD	DB06202	CTPDG009469
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Approved	Estrogen	.	.	Approved	D0M8PD	.	CTPDG009470
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	Synthetic conjugated estrogen	"Bijuva; Bithena; DR-2041; SCE-A Vaginal Cream; Synthetic conjugated estrogen (cream, vulvovaginal atrophy); Synthetic conjugated estrogen (cream, vulvovaginal atrophy), Teva"	.	Phase 3	D02BAE	.	CTPDG009471
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	Trimegestone/ethinyl estradiol	.	.	Phase 3	D0C6XR	.	CTPDG009472
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	TZTX-001	Teverelix LA; TX 12-001-HR	.	Phase 3	D0IC7A	.	CTPDG001179
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	Acolbifene	EM-652; 182167-02-8; UNII-815LJ9X0D1; 815LJ9X0D1; EM 652; Acolbifene [INN:BAN]; SCH 57068; AC1L4EAA; SCHEMBL406183; CHEMBL68055; CTK4F5320; SCH-57068; HY-16023A; ( )-(2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-1-benzopyran-7-ol; CS-0007143; (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol; (S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol	155435	Phase 3	D0XB0T	.	CTPDG009473
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	NE3107	.	.	Phase 3	D9I6QG	.	CTPDG000924
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	Giredestrant	"(1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)-3-AZETIDINYL)AMINO)PHENYL)-.BETA.,.BETA.-DIFLUORO-1,3,4,9-TETRAHYDRO-3-METHYL-2H-PYRIDO(3,4-B)INDOLE-2-PROPANOL; 1953133-47-5; 28P3DU6DB3; 2H-PYRIDO(3,4-B)INDOLE-2-PROPANOL, 1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)-3-AZETIDINYL)AMINO)PHENYL)-.BETA.,.BETA.-DIFLUORO-1,3,4,9-TETRAHYDRO-3-METHYL-, (1R,3R)-; 2H-Pyrido(3,4-b)indole-2-propanol, 1-(2,6-difluoro-4-((1-(3-fluoropropyl)-3-azetidinyl)amino)phenyl)-beta,beta-difluoro-1,3,4,9-tetrahydro-3-methyl-, (1R,3R)-; 3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido(3,4-b)indol-2-yl)-2,2-difluoropropan-1-ol; 3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoropropan-1-ol; 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol; 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol; 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoro-propan-1-ol; AC-37111; AKOS040733254; AT22918; BDBM50572808; CHEMBL4650316; compound 35 [PMID: 34251202]; CS-0116370; EX-A3541; GDC9545; GDC-9545; Giredestrant; Giredestrant [INN]; Giredestrant [USAN:INN]; Giredestrant [USAN]; GIREDESTRANT [WHO-DD]; GTPL12715; HY-109176; MS-29682; NSC827275; NSC-827275; RG6171; RG-6171; RO7197597; RO-7197597; SCHEMBL17839430; UNII-28P3DU6DB3; WHO 11226; ZNM"	121410806	Phase 3	DGW9U7	.	CTPDG009474
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	Imlunestrant	"(5R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol; (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol; 2408840-26-4; 5H-(1)Benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5R)-; 9CXQ3PF69U; BDBM443429; CHEMBL5095183; CS-0376104; EX-A6123; Example 1B {WO2020014435A1]; GLXC-26209; GTPL12896; HY-145572; Imlunestrant; IMLUNESTRANT [INN]; Imlunestrant [USAN]; Ly 3484356; LY3484356; LY-3484356; SCHEMBL22002569; UNII-9CXQ3PF69U; US10654866, Example 1A; UVBQMXOKKDCBJN-MUUNZHRXSA-N; WHO 12039"	146603228	Phase 3	DON71B	.	CTPDG009475
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	NPC-01	"LEP pill; Low dose estrogen progestin pill (dysmenorrhea), Nobelpharma"	.	Phase 3	D0VF3C	.	CTPDG009476
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 3	Premarin/Pravachol	Estrogen/pravastatin	.	Phase 3	D0G7IV	.	CTPDG009477
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	ARN-810	.	56941241	Phase 2	D00JFE	DB12253	CTPDG009478
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	SR 16234	"229634-98-4; TS 108; TAS-108; SR16234; UNII-9B29N23K7E; 9B29N23K7E; SCHEMBL2836841; DTXSID30177512; C33H47NO3.C6H8O7; (7alpha)-21-(4-((Diethylamino)methyl)-2-methoxyphenoxy)-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate; Y1847; 354808-47-2; (7R,8S,9S,13R,14S,17R)-17-(2-(4-((Diethylamino)methyl)-2-methoxyphenoxy)ethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol 2-hydroxypropane-1,2,3-tricarboxylate"	9874874	Phase 2	D02PYN	DB05966	CTPDG009479
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	Afimoxifene	"4-Hydroxytamoxifen; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol"	449459	Phase 2	D09NST	DB04468	CTPDG009480
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	GTx-758	.	46861578	Phase 2	D0E7FM	DB14969	CTPDG009481
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	ICARITIN	"118525-40-9; UNII-UFE666UELY; UFE666UELY; CHEMBL498485; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; Icartin; Anhydroicaritin; AC1NSXIV; Icaritin(Anhydroicaritin); MLS006010055; BIDD:ER0021; SCHEMBL4223542; Icaritin, &gt; DTXSID00152154; MolPort-020-006-012; TUUXBSASAQJECY-UHFFFAOYSA-N; HY-N0678; ZINC14762797; BDBM50272527; AKOS015896858; CS-3679; DB12672; NCGC00345813-01; AK168251; SMR004701218"	5318980	Phase 2	D0L0BX	DB12672	CTPDG009482
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	Estetrol	"Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer); Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer), Pantarhei; Estrogen receptor modulator (oral, contraception/hormone deficiency/autoimmune disease/breast cancer/prostate cancer/osteoporosis/cardiovascular disease), Pantarhei"	27125	Phase 2	D0L3TR	DB12235	CTPDG009483
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	Endoxifen	"Endoxifen (topical formulation, cancer); Endoxifen (topical formulation, cancer), Jina Pharmaceuticals; Tamoxifen metabolite (topical formulation, cancer), Jina Pharmaceuticals"	10090750	Phase 2	D0W4EB	.	CTPDG009484
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 2	AZD9833	"AZD-9833; UNII-JUP57A8EPZ; JUP57A8EPZ; 2222844-89-3; Camizestrant; Camizestrant [USAN]; SCHEMBL20089710; NSC828717; WHO 11592; NSC-828717; HY-136255; AZ14066724; CS-0121043; 3-Pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3H-pyrazolo(4,3-F)isoquinolin-6-yl)-"	134453496	Phase 2	DATO92	.	CTPDG009485
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1/2	H3B-6545	"JPFTZIJTXCHJNE-HMOQVRKWSA-N; SCHEMBL18261010; HY-112596; CS-0047714; (2e)-N,N-dimethyl-4-{[2-({5-[(1z)-4,4,4-trifluoro-1-(3-fluoro-1h-indazol-5-yl)-2-phenylbut-1-en-1-yl]pyridin-2-yl}oxy)ethyl]amino}but-2-enamide"	124091040	Phase 1/2	D0Z5VW	.	CTPDG009486
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1/2	ZN-c5	.	.	Phase 1/2	DJ1W5R	.	CTPDG009487
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1/2	OP-1250	.	.	Phase 1/2	DZ91HE	.	CTPDG009488
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	CC-8490	.	.	Phase 1	D03YGP	.	CTPDG005276
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	CHF-4227	"CHF-3316; CHF-4056; SERMs, Chiesi; Selective estrogen receptor modulators, Chiesi; CHF-3316.01"	9912639	Phase 1	D08OUV	.	CTPDG009489
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	ATD transdermal gel	.	.	Phase 1	D09BQO	.	CTPDG009490
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	D-0502	.	.	Phase 1	D09OJI	.	CTPDG009491
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	TTC-352	.	.	Phase 1	D0NZ3C	.	CTPDG009492
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	AZD9496	"DFBDRVGWBHBJNR-BBNFHIFMSA-N; 1639042-08-2; UNII-DA9P7LN909; DA9P7LN909; CHEMBL3623004; AZD-9496; (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid; SCHEMBL16266273; SCHEMBL16266275; MolPort-044-560-384; EX-A1326; s8372; BDBM50125052; ZINC219669733; AKOS030526632; AC-29011; HY-12870; Selective estrogen"	86287635	Phase 1	D0X1OW	DB15138	CTPDG009493
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	G1T-48	.	.	Phase 1	DG38QS	.	CTPDG009494
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	LY3484356	.	.	Phase 1	DH4Y3O	.	CTPDG009495
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	AC0682	.	.	Phase 1	DI9GC3	.	CTPDG009496
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	SCO-120	.	.	Phase 1	DNTW18	.	CTPDG009497
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Phase 1	TTC-352	"Sherpa TTC-352; UNII-65ILH3Y0MI; 65ILH3Y0MI; CHEMBL3763743; 1607819-68-0; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol; SCHEMBL15658409; BDBM50145856; J3.603.123I; 2-(4-Hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxyl)benzo[b]thiophen-6-ol; Selective human estrogen-receptor alpha partial agonist TTC-352; Benzo(b)thiophene-6-ol, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-; V9J"	74222430	Phase 1	DT4WU3	.	CTPDG009498
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Withdrawn from market	Chlorotrianisene	"Anisene; Chloortrianisestrol; Chlorestrolo; Chlorotrianisenum; Chlorotrianisestrol; Chlorotrianisine; Chlorotrianizen; Chlorotrisin; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Chlortrianizen; Clorestrolo; Clorotrianisene; Clorotrianiseno; Clorotrisin; Hormonisene; Khlortrianizen; Merbentul; Metace; Rianil; TACE; Triagen; Trianisestrol; Chlorotrianisene [Nonsteroidal oestrogens]; Clorotrianisene [DCIT]; Chlorotrianisene (INN); Chlorotrianisene [BAN:INN]; Chlorotrianisene [INN:BAN]; Chlorotrianisenum [INN-Latin]; Clorotrianiseno [INN-Spanish]; TACE (TN); Tace (pharmaceutical); Tace-fn; Chlorotris(p-methoxyphenyl)ethylene; Tri-p-anisylchloroethylene; Tris(p-methoxyphenyl)chloroethylene; 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris[4-(methyloxy)benzene]; 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene"	11289	Withdrawn from market	D0X0KJ	DB00269	CTPDG009499
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Withdrawn from market	HEXESTROL	"Dihydrodiethylstilbestrol; Vitestrol; Hexoestrolum; Exestrol; 5635-50-7; Stilbestrol, dihydro-; 4,4'-(1,2-Diethylethylene)diphenol; 4,4'-(hexane-3,4-diyl)diphenol; Synoestrolum; Hexanestrol; Cycloestrol; Esestrolo [DCIT]; Phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-; Hexestrolum [INN-Latin]; Hexane, 3,4-bis(4-hydroxyphenyl)-; EINECS 227-082-2; 3,4-Bis(p-hydroxyphenyl)hexane; Hormoestrol; Syntrogene; Synthovo; Phenol, 4,4'-(1,2-diethylethylene)di-; CHEBI:31669; PBBGSZCBWVPOOL-UHFFFAOYSA-N; Hexestrol [INN]"	3606	Withdrawn from market	D0C4FT	.	CTPDG009500
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Withdrawn from market	BITHIONOL	"97-18-7; Actamer; Bithin; 2,2'-Thiobis(4,6-dichlorophenol); Lorothidol; Bitionol; Bithionol sulfide; Bisoxyphen; Bidiphen; Lorothiodol; Bitin; Nobacter; Bithionolate; Neopellis; Vancide BL; Usaf B-22; Bithional; Bithionolum; 2-Hydroxy-3,5-dichlorophenyl sulfide; TKhsd; Bis(2-hydroxy-3,5-dichlorophenyl) sulfide; Bis(3,5-dichloro-2-hydroxyphenyl) sulfide; 2,2'-sulfanediylbis(4,6-dichlorophenol); Caswell No. 852; Bitionol [INN-Spanish]; XL 7; Bithionolum [INN-Latin]; 2,2'-Dihydroxy-3,3',5,5'-tetrachlorodiphenyl sulfide"	2406	Withdrawn from market	D0QQ1J	DB04813	CTPDG009501
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 3	IoGen	"Oral iodine-based therapy (fibrocystic breast disease), Symbollon; Oral iodine-based therapy (fibrocystic breast disease), Symbollon/Gardant"	.	Discontinued in Phase 3	D01OML	.	CTPDG009502
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 3	Miproxifene	Miproxifene phosphate; TAT-59	3037015	Discontinued in Phase 3	D02VFB	.	CTPDG006388
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 3	Idoxifene	CB-7432; SB-223030	3034011	Discontinued in Phase 3	D0GR2J	.	CTPDG009503
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 3	EM-800	"UNII-XCR716LECP; XCR716LECP; 182167-03-9; Em 800; SCH 57050; BIDD:ER0061; SCHEMBL1821303; CHEMBL308234; 189021-25-8; (s)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-meth-yl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2h-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate"	9873952	Discontinued in Phase 3	D0MU0S	.	CTPDG009504
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 2	NP-50301	"IDESTRIN; Estrogen ester (eyedrop, dry eye syndrome), Nascent"	.	Discontinued in Phase 2	D01AXT	.	CTPDG009505
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 2	SR-90067	"Estradiol spray (menopausis), Sanofi-Synthelabo"	.	Discontinued in Phase 2	D04BIG	.	CTPDG009506
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 2	Panomifene	Panomifine; EGIS-5650	3033654	Discontinued in Phase 2	D04HVB	.	CTPDG006630
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 2	SERM-3339	"HMR-3339; SERM compound, Aventis"	.	Discontinued in Phase 2	D04MNL	.	CTPDG009507
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 2	Droloxifene	E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen	3033767	Discontinued in Phase 2	D0R2JS	.	CTPDG009508
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 2	ERA-923	"Pipendoxifene; UNII-TPC5Q8496G; 198480-55-6; CHEMBL44426; TPC5Q8496G; Pipendoxifene [INN]; ERA 923; AC1O5FKF; SCHEMBL134583; JICOGKJOQXTAIP-UHFFFAOYSA-N; ZINC602799; BDBM50099587; AKOS030631784; DB05414; 2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol; US8815934, No 97; US8815934, No 107; 2-(p-Hydroxyphenyl)-3-methyl-1-(p-(2-piperidinoethoxy)benzyl)indol-5-ol; 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol"	6433099	Discontinued in Phase 2	D0R8TB	DB05414	CTPDG009509
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 1	HRT	"HRT (oral); IP-1162; IP-1163; IP-1164; HRT (oral), Shire"	.	Discontinued in Phase 1	D0B6HS	.	CTPDG009510
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 1	MX-4509	"17alpha-Estradiol; 57-91-0; Alfatradiol; Epiestradiol; 17-alpha-Estradiol; 3,17-Dihydroxyestratriene; 17a-estradiol; Estradiol-17alpha; Epiestrol; 17-Epiestradiol; Estra-1,3,5(10)-triene-3,17alpha-diol; 17alpha estradiol; NSC 20293; UNII-3VQ38D63M7; Alfatradiol [INN]; Oestradiol-17alpha; 17alpha-Oestradiol; Estradiol, 17alpha-; CHEBI:17160; VOXZDWNPVJITMN-SFFUCWETSA-N; 3VQ38D63M7; 17-epi-Estradiol; Alfatradiol (INN); Oestradiol-17-alpha; MITO-4509; Parkinsons therapeutics, MitoKor; Drug screening (Parkinsons), MitoKor; Estrogen analogs (Parkinsons), Mitokor"	68570	Discontinued in Phase 1	D05BCA	.	CTPDG009511
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Discontinued in Phase 1	HE2100	"Androstenediol; Hermaphrodiol; 5-Androstenediol; Androst-5-enediol; 521-17-5; Androst-5-ene-3beta,17beta-diol; Neumune; 3beta,17beta-Dihydroxyandrost-5-ene; delta(sup 5)-Androstenediol; Androstenediol [JAN]; UNII-95PS51EMXY; Androst-5-enediol (VAN); (3beta,17beta)-androst-5-ene-3,17-diol; 5-AED; 3beta,17beta-Dihydroxy-5-androstene; androst-5-en-3beta,17beta-diol; EINECS 208-306-8; NSC 12163; 95PS51EMXY; ANDROST-5-ENE-3-beta,17-beta-DIOL; CHEMBL440283; CHEBI:2710; (3-beta,17-beta)-Androst-5-ene-3,17-diol; delta(sup"	10634	Discontinued in Phase 1	D08DZZ	DB01524	CTPDG009512
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Preclinical	BN-AO-014	"Selective estrogen receptor modulators (genitourinary atrophy); Selective estrogen receptor modulators (genitourinary atrophy), Bionovo"	.	Preclinical	D01EXY	.	CTPDG009513
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Preclinical	BN-OD-026	"Selective estrogen receptor modulators (colon/breast cancer); BN-RP-006-OHA; Selective estrogen receptor modulators (colon/breast cancer), Bionovo"	.	Preclinical	D06YGP	.	CTPDG007120
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Preclinical	BN-DF-037	"Selective estrogen receptor modulators (osteoporosis); BN-EU-036; Selective estrogen receptor modulators (osteoporosis), Bionovo; BN-AM-008-XG; BN-PC-049-BK"	.	Preclinical	D0N6YN	.	CTPDG009514
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Preclinical	BN-AA-003-NY	"Selective estrogen receptor modulators (menopause symptoms); Selective estrogen receptor modulators (menopause symptoms), Bionovo"	.	Preclinical	D0P5NU	.	CTPDG009515
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Preclinical	BN-CB-045	"Selective estrogen receptor modulators (female sexual dysfunction); BN-ES-022; Selective estrogen receptor modulators (female sexual dysfunction), Bionovo"	.	Preclinical	D0QI9N	.	CTPDG009516
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Preclinical	BN-GU-005-DHP	"Selective estrogen receptor modulators (arthralgia); Selective estrogen receptor modulators (arthralgia), Bionovo"	.	Preclinical	D0QX9U	.	CTPDG009517
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Terminated	Tamoxifen methyl iodide	"Tamoxifen methiodide; CHEMBL1213783; MLS002701640; AC1MHWIV; N-Methyltamoxifen iodide; 107256-99-5; PXJJOGITBQXZEQ-JTHROIFXSA-M; NSC630510; NSC-630510; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N,N-trimethylethanaminium iodide; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium iodide; Ethanaminium, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N,N-trimethyl-, iodide, (Z)-"	3033898	Terminated	D0J4ZH	.	CTPDG009518
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Terminated	Zindoxifene	D-16726	65645	Terminated	D0TR4Z	.	CTPDG009519
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Terminated	ICI-164384	"Ici 164384; 98007-99-9; UNII-84LT43726C; ICI M164384; ICI 164,384; CHEMBL1222035; N-n-Butyl-N-methyl-11-(3,17beta-dihydroxyestra-1,3,5(10)-trien-7alpha-yl)undecanamide; 84LT43726C; N-BUTYL-11-[(7R,8R,9S,13S,14S,17S)-3,17-DIHYDROXY-13-METHYL-7,8,9,11,12,13,14,15,16,17-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-7-YL]-N-METHYLUNDECANAMIDE; Estra-1,3,5(10)-triene-7-undecanamide, N-butyl-3,17-dihydroxy-N-methyl-, (7alpha,17beta)-; AOE"	104772	Terminated	D09AAM	DB03860	CTPDG009520
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Terminated	ZK-119010	"ZK 119010; UNII-80Z22M837F; CHEMBL46903; 80Z22M837F; 127451-69-8; AC1L2YAG; 2-(4-Hydroxyphenyl)-3-methyl-1-(6-(1-pyrrolidinyl)hexyl)indol-5-ol; SCHEMBL9028173; DTXSID50155574; zk119010; BDBM50099586; 1H-Indol-5-ol, 2-(4-hydroxyphenyl)-3-methyl-1-(6-(1-pyrrolidinyl)hexyl)-; LS-191850; 2-(4-hydroxyphenyl)-3-methyl-1-(6-pyrrolidin-1-ylhexyl)indol-5-ol"	130936	Terminated	D0H5CV	.	CTPDG007337
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Terminated	LY-117018	"Lilly 117018; LY 117018; 63676-25-5; CHEBI:90187; LY 139478; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}methanone; 6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl 4-(2-(1-pyrrolidinyl)ethoxy) phenyl ketone; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-; PHENETHIPYLONE; 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-pyrrolidinyl)ethoxy] phenyl ketone; LY117018; AC1L2XRN; AC1Q5D9H; CHEMBL10030"	104946	Terminated	D0SM0J	.	CTPDG009521
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	JNJ-17148066	CHEMBL1088485; SCHEMBL14277842; BDBM50310388	44597742	Investigative	D00DJX	.	CTPDG009522
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide	CHEMBL203860	44407802	Investigative	D00XLU	.	CTPDG009523
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE"	"PhIP; 105650-23-5; 1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2-amine; 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; UNII-909C6UN66T; CHEBI:76290; 909C6UN66T; 1-Methyl-6-phenyl-1H-imidazo(4,5-b)pyridin-2-amine; PIQ; 2-AMINO-1-METHYL-6-PHENYL-IMIDAZO [4,5-b] PYRIDINE; 1H-Imidazo(4,5-b)pyridin-2-amine, 1-methyl-6-phenyl- (9CI); CCRIS 2954; HSDB 7768; BRN 5951264; ACMC-1BRGI; AC1Q4WMI; (3H)PhIP; AC1L1BO3; SCHEMBL151718; CHEMBL1213271; DTXSID3037628; CTK0I0185"	1530	Investigative	D00ZAJ	DB08398	CTPDG009524
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	SNG-8006	"Estrogen receptor alpha-36 antagonist (osteoporosis), Shenogen Pharma"	.	Investigative	D01NDN	.	CTPDG009525
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide	CHEMBL382873	44407801	Investigative	D01XCA	.	CTPDG009526
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL	"848142-62-1; 3-chloro-2-(4-hydroxyphenyl)indazol-5-ol; CHEMBL180071; CTK2I5101; DTXSID40463812; Indazole-Cl, &gt; ZINC13609473; AKOS030536245; DB07708; 2-(p-Hydroxyphenyl)-3-chloro-2H-indazole-5-ol; 2H-Indazol-5-ol, 3-chloro-2-(4-hydroxyphenyl)-"	11368987	Investigative	D01ZRX	DB07708	CTPDG009527
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2,4-diisobutylamino-6-isopentylpyrimidine"	CHEMBL347927; ZINC13559143; BDBM50138886	9994500	Investigative	D02GLM	.	CTPDG009528
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	JNJ-26529152	CHEMBL1088483; BDBM50310372	10323679	Investigative	D02TPO	.	CTPDG009529
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	SNG-8033	"Estrogen receptor alpha 36 inhibitor (leukemia), Shenogen Pharma"	.	Investigative	D03AVA	.	CTPDG009530
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2,4-Dibenzylamino-6-isopentylpyrimidine"	CHEMBL494121	25128804	Investigative	D03BOO	.	CTPDG009531
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	SNG-8023	"Estrogen receptor alpha 36 inhibitor (breast cancer), Shenogen Pharma; Monoclonal antibody (breast cancer), Shenogen Pharma"	.	Investigative	D03NWC	.	CTPDG009532
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	LTERHKILHRLLQEGSPSD	.	91935928	Investigative	D04PEM	.	CTPDG009533
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	GW7604	.	9799518	Investigative	D04SAO	.	CTPDG009534
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-benzyl-2,6-diisobutylamino-pyrimidine"	CHEMBL493703	25130896	Investigative	D04TPC	.	CTPDG009535
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one	SCHEMBL1700973	46914767	Investigative	D05QTG	.	CTPDG009536
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine"	CHEMBL494706; BDBM50253380	25128814	Investigative	D07HBQ	.	CTPDG009537
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Carboron Cluster with phenol	.	.	Investigative	D07KXE	.	CTPDG009538
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol	"CHEMBL415864; 1,1-Bis(4-hydroxyphenyl)-2-phenylethylene; 4,4'-(2-Phenylethene-1,1-Diyl)diphenol; 66422-18-2; Bhpe-1,1; SCHEMBL641985; AC1MI565; CTK5C4724; 4-(1,2-diphenyl-vinyl)-phenol; BDBM50023749; ZINC13492380; Phenol, 4,4'-(phenylethenylidene)bis-; 1,1-bis(4-hydroxyphenyl)-2-phenylethene; 4-[1-(4-hydroxyphenyl)-2-phenylethenyl]phenol"	3017674	Investigative	D07TGS	.	CTPDG009539
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	MPrP	.	135857091	Investigative	D07TGW	.	CTPDG009540
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Tamoxifen isopropyl bromide	.	46919124	Investigative	D08GWS	.	CTPDG009541
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	17-METHYL-17-ALPHA-DIHYDROEQUILENIN	"2b1z; ZINC5048688; DB06871; 17beta-Methyl-17alpha-dihydroequilenin; 17M; (13alpha,17beta)-17-methylestra-1(10),2,4,6,8-pentaene-3,17-diol"	9549180	Investigative	D08JCJ	DB06871	CTPDG009542
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide	CHEMBL203515	44407806	Investigative	D08LVT	.	CTPDG009543
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	SNG-163	"SGIC-163; ER-a36 inhibitor (cancer), Shenogen"	.	Investigative	D09BDK	.	CTPDG008571
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	GSK-5182	"GSK5182; GSK 5182; 877387-37-6; (Z)-4-(1-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-HYDROXY-2-PHENYLPENT-1-ENYL)PHENOL; TXF; 4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-5-hydroxy-2-phenylpent-1-en-1-yl]phenol; 2ewp; AC1OA9V8; GTPL8908; CHEMBL201013; SCHEMBL20534177; BDBM22435; AOB1629; EX-A2580; ZINC14978677; 4-hydroxytamoxifen (4-OHT) analog, 15; 4-[(z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-hydroxy-2-phenylpent-1-enyl]phenol; 4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol"	6852176	Investigative	D09NFD	.	CTPDG009544
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide	CHEMBL379234; Enamine_001944; Oprea1_552384; AC1M697W; SCHEMBL10904389; MolPort-004-000-970; HMS1399I08; ZINC3251814; BDBM50177761; AKOS008967166; MCULE-9434872926; N-ethyl-4-hydroxy-N-phenylbenzene-1-sulfonamide; Z56821525	2368773	Investigative	D09ULU	.	CTPDG009545
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	JNJ-19398990	CHEMBL1085429; BDBM50310424	10029432	Investigative	D09UQU	.	CTPDG009546
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol	.	135503667	Investigative	D09WEK	.	CTPDG009547
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL	CHEMBL180517	11149479	Investigative	D0A8CS	DB07712	CTPDG009548
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	N-allyl-4-hydroxy-N-phenylbenzenesulfonamide	CHEMBL426849	44407887	Investigative	D0AD8G	.	CTPDG009549
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol	.	135407148	Investigative	D0C4VX	.	CTPDG009550
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Tamoxifen ethyl bromide	.	49863610	Investigative	D0C6UR	.	CTPDG009551
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"6-butyl-2,4-dipropylaminopyrimidine"	CHEMBL352024; BDBM50138883; ZINC13559144	11276767	Investigative	D0C9XW	.	CTPDG009552
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	RG6046	.	.	Investigative	D0E3UW	.	CTPDG009553
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	STX	"Selective estrogen receptor modulator (menopause-associated symptoms), Oregon Health & Science University"	6852124	Investigative	D0E6AP	DB08576	CTPDG009554
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol	.	135524867	Investigative	D0F8LS	.	CTPDG009555
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one	SCHEMBL1701136	46914766	Investigative	D0GH1I	.	CTPDG009556
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	SERMs	"SERMs (cancer); SERMs (cancer), CEAMED; Selective estrogen receptor modulators (cancer), CEAMAD"	.	Investigative	D0GY3R	.	CTPDG008251
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"6-ethyl-2,4-diisobutylaminopyrimidine"	CHEMBL484451	25133613	Investigative	D0H6MZ	.	CTPDG009557
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol	.	135525228	Investigative	D0H8ZT	.	CTPDG009558
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Org-37663	.	.	Investigative	D0I6QZ	.	CTPDG009559
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide	CHEMBL204664	44407886	Investigative	D0J3PM	.	CTPDG009560
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol	.	135511848	Investigative	D0J6KN	.	CTPDG009561
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL"	.	135566322	Investigative	D0K5LX	DB08048	CTPDG009562
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol	"91221-46-4; 1,1-Bis(4-hydroxyphenyl)-2-phenylbut-1-ene; 1,1-Bis(4-hydroxyphenyl)-2-phenyl-1-butene; CHEMBL149791; 4,4'-(2-phenylbut-1-ene-1,1-diyl)diphenol; Tamoxifen bis-phenol; 1,1-Bhpe; Tamoxifenbisphenol; AC1L1YAG; SCHEMBL639225; CTK5G9076; DTXSID50238452; BPKSDMHGDYTXLI-UHFFFAOYSA-N; ZINC1849484; BDBM50121317; AKOS030254689; KB-09832; 4,4'-(2-Phenyl-1-butenylidene)bisphenol; B5114; FT-0663304; Phenol, 4,4'-(2-phenyl-1-butenylidene)bis-"	63059	Investigative	D0K8QD	.	CTPDG009563
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-hydroxy-N-phenyl-N-propylbenzenesulfonamide	CHEMBL205070	44407885	Investigative	D0L0RK	.	CTPDG009564
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	N-butyl-4-hydroxy-N-phenylbenzenesulfonamide	CHEMBL203810; BDBM50177754	44407804	Investigative	D0M4LQ	.	CTPDG009565
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one	"CHEMBL115109; 97846-18-9; 4H-1-Benzopyran-4-one, 3-(4-hydroxyphenyl)-7-(1-methylethoxy)-; ACMC-20m1ro; SCHEMBL1701110; CTK3G8070; DTXSID70440494; 7-Isopropoxy-4'-hydroxyisoflavone; BDBM50104874; ZINC13864225; AKOS030553087; 3-(4-Hydroxy-phenyl)-7-isopropoxy-chromen-4-one"	10469827	Investigative	D0O9UY	.	CTPDG009566
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol	CHEMBL357824; SCHEMBL19158863; BDBM50121321	11782482	Investigative	D0OV3S	.	CTPDG009567
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol	.	135458016	Investigative	D0Q4VG	.	CTPDG009568
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol	CHEMBL150461; SCHEMBL18882768	11141183	Investigative	D0Q6MS	.	CTPDG009569
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Tamoxifen butyl bromide	.	11547961	Investigative	D0S5RI	.	CTPDG009570
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Estriol E3	"Estriol E3 (oral formulation, multiple sclerosis)"	.	Investigative	D0V4DH	.	CTPDG009571
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-(1,2-Diphenyl-but-1-enyl)-phenol"	"CHEMBL50995; 4-(1,2-Diphenyl-1-butenyl)phenol; Monophenoltamoxifen; 4-[(Z)-1,2-diphenylbut-1-enyl]phenol; AC1O4GB8; SCHEMBL5354173; BDBM50121319; ZINC29469549; 69967-80-2; LS-104581"	6366969	Investigative	D0V7OK	.	CTPDG009572
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol	.	135476471	Investigative	D0V7ZI	.	CTPDG009573
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	TSERaM	"TSERaM (menopausal weight gain); TSERaM (menopausal weight gain), Bionovo; Tissue-selective estrogen receptor alpha modulators (menopausal weight gain), Bionovo"	.	Investigative	D0W1YZ	.	CTPDG009574
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	JNJ-26529126	CHEMBL1088343; BDBM50310407	9848809	Investigative	D0X0RJ	.	CTPDG009575
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"5-hydroxy-2-phenylisoindoline-1,3-dione"	"CHEMBL276030; 4-Hydroxy-N-phenylphthalimide; 3975-50-6; 5-hydroxy-2-phenyl-isoindole-1,3-dione; SCHEMBL8615277; CTK1B3719; DTXSID80445430; HCUAWJNHCZEMJS-UHFFFAOYSA-N; ZINC26020837; BDBM50088673; 5-hydroxy-2-phenyl-1H-isoindole-1,3(2H)-dione; 1H-Isoindole-1,3(2H)-dione, 5-hydroxy-2-phenyl-"	10823890	Investigative	D0X6LK	.	CTPDG009576
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol	CHEMBL356693	10871661	Investigative	D0XC3V	.	CTPDG009577
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	methyl-piperidino-pyrazole	.	135484659	Investigative	D0XF9F	.	CTPDG009578
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	propylpyrazoletriol	.	5040063	Investigative	D0Y8UF	.	CTPDG009579
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-hydroxy-N,N-diphenylbenzenesulfonamide"	CHEMBL203061; SCHEMBL2114599	23582387	Investigative	D0Z9ZY	.	CTPDG009580
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol	"Metahexes trol; 3,3'-Hexestrol; Metahexestrol; 3,3'-Hes; 68266-24-0; meso-3,4-Bis(3'-hydroxyphenyl)hexane; BRN 3971661; NSC-297,170; meso-3,3'-(1,2-Diethylethylene)diphenol; NSC-297170; (R*,S*)-3,3'-(1,2-Diethyl-1,2-ethanediyl)bisphenol; Phenol, 3,3'-(1,2-diethyl-1,2-ethanediyl)bis-, (R*,S*)-; Phenol, 3,3'-((1R,2S)-1,2-diethyl-1,2-ethanediyl)bis-, rel-; UNII-DSF584X94B; DSF584X94B; NSC 297170; 3-[4-(3-hydroxyphenyl)hexan-3-yl]phenol; AC1L2OPY; 1,2-Diethyl-1,2-bis(3'-hydroxyphenyl)ethane; AC1Q79WV; CHEMBL18268; SCHEMBL5014485"	100424	Investigative	D00AAU	.	CTPDG009581
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-quinolin-6-ol	.	135987619	Investigative	D00CWN	.	CTPDG009582
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Nafoxidine	"1845-11-0; Nafoxidine [INN]; Nafoxidinum [INN-Latin]; Nafoxidina [INN-Spanish]; UNII-4RIY10WM82; U-11000A; BRN 1440873; CHEMBL28211; 4RIY10WM82; CHEBI:34881; NSC 70735; C29H31NO2; JEYWNNAZDLFBFF-UHFFFAOYSA-N; 1-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine; Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-; 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine; Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl"	4416	Investigative	D00FUO	.	CTPDG009583
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime"	.	11780703	Investigative	D00HUB	.	CTPDG009584
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol	.	135449109	Investigative	D00HZT	.	CTPDG009585
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL206547; SCHEMBL6828050	10445833	Investigative	D00IXB	.	CTPDG009586
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(3-phenyl-1H-indol-2-yl)phenol	CHEMBL199766; SCHEMBL7040440; BDBM50175418	44405867	Investigative	D00NEK	.	CTPDG009587
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol"	CHEMBL34709	10881256	Investigative	D00OLH	.	CTPDG009588
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4,10-dimethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL206582; SCHEMBL6924719	10399473	Investigative	D00URP	.	CTPDG009589
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	.	135458122	Investigative	D00ZBL	.	CTPDG009590
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol	CHEMBL195389; SCHEMBL4077781; YIKDKHNOMWERET-UHFFFAOYSA-N; ZINC13645062; BDBM50168377	10192794	Investigative	D01GPY	.	CTPDG009591
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL	CHEMBL364092; 1-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol; 4NA; 1yy4; AC1O0UUG; 1-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3933824; YHEHVRSGKUYDON-UHFFFAOYSA-N; ZINC13645009; BDBM50168323	6102690	Investigative	D01KJU	DB07119	CTPDG009592
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol	.	135495079	Investigative	D01KSR	.	CTPDG009593
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol	CHEMBL183367; SCHEMBL3933889; GLVGKXBQPYTMGJ-UHFFFAOYSA-N; ZINC3817709; BDBM50154056; 2-(6-hydroxynaphthalen-1-yl)benzo[d]oxazol-5-ol	9993627	Investigative	D01QXL	.	CTPDG009594
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol"	"CHEMBL24950; SCHEMBL6286195; BDBM50123206; 2-(3-hydroxyphenyl)-1,2''-spirobi[1H-indene]-5-ol"	9901869	Investigative	D01SWO	.	CTPDG009595
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-chloro-4-(4-hydroxyphenyl)salicylaldoxime	.	91066436	Investigative	D01UAO	.	CTPDG009596
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL	"2-(4-Hydroxy-phenyl)-benzofuran-5-ol; 2-(4-hydroxyphenyl)-1-benzofuran-5-ol; CHEMBL367588; 52814-86-5; 2-(4-Hydroxyphenyl)benzofuran-5-ol; AC1LCVQT; 1u9e; SCHEMBL3922677; CTK1G1983; DTXSID60349669; SNNNDCMXZYWCCI-UHFFFAOYSA-N; ZINC3816519; BDBM50152627; SBB096959; AKOS030555876; DB07032; 2-(4-hydroxyphenyl)benzo[b]furan-5-ol; 5-Benzofuranol,"	656936	Investigative	D01WCA	DB07032	CTPDG009597
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	COUMESTROL	"479-13-0; Cumoestrol; Cumoesterol; Cumostrol; Coumesterol; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 7,12-Dihydroxycoumestan; 3,9-Dihydroxycoumestan; UNII-V7NW98OB34; NSC 22842; CCRIS 7311; NSC22842; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; EINECS 207-525-6; BRN 0266702; CHEMBL30707; MLS000738006; V7NW98OB34; CHEBI:3908; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-"	5281707	Investigative	D02DML	.	CTPDG009598
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol"	CHEMBL38266	11131781	Investigative	D02DVT	.	CTPDG009599
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol	.	136048731	Investigative	D02EJM	.	CTPDG009600
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	.	135502634	Investigative	D02HGS	.	CTPDG009601
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol	.	135492380	Investigative	D02JJU	.	CTPDG009602
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol	.	135442595	Investigative	D02LCC	.	CTPDG009603
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL195311; SCHEMBL3932692; FNSIACDWDZGUHN-UHFFFAOYSA-N; BDBM50168347; ZINC13645053	10308197	Investigative	D02OKF	.	CTPDG009604
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	DIHYDRORALOXIFENE	CHEMBL14955; BDBM50217538; ZINC15919388	15788490	Investigative	D02VIW	.	CTPDG009605
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol"	"CHEMBL144431; SCHEMBL6283932; BDBM50123207; 2-(3-hydroxyphenyl)-1,2''-spirobi[1H-indene]-6-ol"	10131379	Investigative	D03DVM	.	CTPDG009606
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol"	"Ici-3188; 1,1,2-Tris(4-hydroxyphenyl)prop-1-ene; 68373-13-7; 4-[1,1-bis(4-hydroxyphenyl)prop-1-en-2-yl]phenol; Phenol, 4,4',4''-(1-methyl-1-ethenyl-2-ylidene)tris-; Ici 3188; AC1MJ4DX; CHEMBL38103; CTK2F3093; DTXSID20218504; AKOS030547870"	3085373	Investigative	D03EOD	.	CTPDG009607
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	.	135499774	Investigative	D03GYS	.	CTPDG009608
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"8-(2,2-dimethylpropyl)naringenin"	.	16066665	Investigative	D03QHG	.	CTPDG009609
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol"	.	135522275	Investigative	D03RYU	.	CTPDG009610
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol	CHEMBL361226; SCHEMBL3928011; KEWMBPCQWDVBAS-UHFFFAOYSA-N	10286022	Investigative	D03XEU	.	CTPDG009611
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol	.	135474202	Investigative	D04EAY	.	CTPDG009612
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"R,R-THC"	"(R,R)-THC; 138090-06-9; (R,R)-cis-Diethyl tetrahydro-2,8-chrysenediol; CHEMBL282489; 221368-54-3; (5R,11R)-5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol; (R,R)-5,11-DIETHYL-5,6,11,12-TETRAHYDRO-2,8-CHRYSENEDIOL; (R,R)-cis-Diethyltetrahydro-2,8-chrysenediol; (R,R)-5,11-CIS-DIETHYL-5,6,11,12-TETRAHYDROCHRYSENE-2,8-DIOL; Lopac-D-8690; AC1L9K5Y; Lopac0_000463; MLS002153151; BIDD:ER0043; GTPL2822; DTXSID6040749; SCHEMBL13352540; CTK4E8744; MolPort-003-941-174; HMS3268D03; HMS3261M08; HMS2232C18; ZINC3940885; Tox21_500463"	446849	Investigative	D04SEX	.	CTPDG009613
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol	.	135519317	Investigative	D04WHH	.	CTPDG009614
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol"	CHEMBL192876; SCHEMBL4456831; YTFVBUBYMJJWQZ-UHFFFAOYSA-N; ZINC13645103; BDBM50168322	10149584	Investigative	D05FUY	.	CTPDG009615
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	.	135546593	Investigative	D05JKC	.	CTPDG009616
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol	.	135409725	Investigative	D05JPW	.	CTPDG009617
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-n-undecylnaringenin	.	44418726	Investigative	D05KXP	.	CTPDG009618
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol	CHEMBL184448; SCHEMBL3922992	10236250	Investigative	D05YIU	.	CTPDG009619
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	BROUSSONIN A	73731-87-0; CHEMBL465879; Biooussonin A; AC1NST4K; 2-[3-(4-hydroxyphenyl)propyl]-5-methoxyphenol; SCHEMBL774802; MSNVBURPCQDLEP-UHFFFAOYSA-N; MolPort-019-937-120; BDBM50251012; ZINC13341109; MCULE-7164788732	5315502	Investigative	D06DDT	.	CTPDG009620
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol"	CHEMBL38222	10948394	Investigative	D06DNN	.	CTPDG009621
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	.	135442585	Investigative	D06OAL	.	CTPDG009622
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	WAY200070	"WAY 200070; 440122-66-7; WAY-200070; CHEMBL188528; 7-BROMO-2-(4-HYDROXYPHENYL)-1,3-BENZOXAZOL-5-OL; 7-Bromo-2-(4-hydroxy-phenyl)-benzooxazol-5-ol; SCHEMBL3930187; ZINC9308; GTPL4052; CTK1D2551; DTXSID80432027; MolPort-023-276-777; BAAILVWEAXFTSF-UHFFFAOYSA-N; BCP28989; WAY-00005; BDBM50154088; ZINC138816775; AKOS024457585; CS-6398; HY-101271; RT-016254; B7386; 7-bromo-2-(4-hydroxyphenyl)-5-benzoxazolol; 5-Benzoxazolol, 7-bromo-2-(4-hydroxyphenyl)-; 7-bromo-2-(4-hydroxyphenyl)benzo[d]oxazol-5-ol; WAY-200070, &gt"	135418373	Investigative	D06SCS	.	CTPDG009623
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-phenyl)-naphthalen-2-ol	CHEMBL191974; 6-(4-hydroxyphenyl)-2-naphthol; SCHEMBL2699234; SKPPZWVFPOQPOT-UHFFFAOYSA-N; ZINC13644983	11459006	Investigative	D07LUI	.	CTPDG009624
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol	.	135409756	Investigative	D07VPM	.	CTPDG009625
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol	CHEMBL372030; SCHEMBL3927148; FGIUXCLAHODWKV-UHFFFAOYSA-N; BDBM50168320; ZINC13645024	10308075	Investigative	D07XBD	.	CTPDG009626
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-methylnaringenin	"CHEMBL426154; MolPort-039-339-073; ZINC14814929; 5,7,4'-Trihydroxy-8-methylflavanone"	44418717	Investigative	D07XUY	.	CTPDG009627
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol	.	135474625	Investigative	D08FLV	.	CTPDG009628
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol	.	135496133	Investigative	D08HCF	.	CTPDG009629
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL363367; SCHEMBL3923941; IVJIWGTXXHDRCU-UHFFFAOYSA-N; BDBM50168384; ZINC13645099	10214699	Investigative	D08VDX	.	CTPDG009630
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol"	.	135496123	Investigative	D08WDN	.	CTPDG009631
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-benzooxazol-6-ol	.	135471161	Investigative	D09CQC	.	CTPDG009632
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-(4-Hydroxy-phenyl)-naphthalen-2-ol	CHEMBL191715; 7-(4-Hydroxyphenyl)-2-naphthol; SCHEMBL3932603; NSCZTZNRMFWAIY-UHFFFAOYSA-N; ZINC13645002; BDBM50168330	10171409	Investigative	D09DEK	.	CTPDG009633
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-(3-methylbutyl)naringenin	.	44418728	Investigative	D09NOH	.	CTPDG009634
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4,7-dimethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL378798; SCHEMBL6830103	9991961	Investigative	D09PXU	.	CTPDG009635
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol	.	135528620	Investigative	D09TQE	.	CTPDG009636
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3'-Methoxy-4'Hydroxyclomiphene	"CHEMBL955; 3-Methoxy-4-hydroxyclomiphene; AC1MIWC3; SCHEMBL20193223; 3''-Methoxy-4''Hydroxyclomiphene; BDBM50020285; 4-{2-Chloro-1-[4-(2-diethylamino-ethoxy)-phenyl]-2-phenyl-vinyl}-2-methoxy-phenol; Phenol, 4-(2-chloro-1-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylethenyl)-2-methoxy-; 4-[(Z)-2-chloro-1-[4-(2-diethylaminoethyloxy)phenyl]-2-phenylethenyl]-2-methoxyphenol; 4-(2-Chloro-1-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylethenyl)-2-methoxyphenol"	3081117	Investigative	D0A1JP	.	CTPDG009637
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol	.	135528621	Investigative	D0AD3U	.	CTPDG009638
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol	.	135526958	Investigative	D0B1HP	.	CTPDG009639
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Trans-hydroxytamoxifen	.	5284643	Investigative	D0B4VV	.	CTPDG009640
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one"	CHEMBL206600; SCHEMBL6828078	10331951	Investigative	D0C5FY	.	CTPDG009641
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol	CHEMBL365290; SCHEMBL1119325; FUWUZPRNKPGRGX-UHFFFAOYSA-N	10285954	Investigative	D0C6AP	.	CTPDG009642
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol"	.	135545334	Investigative	D0C9XK	.	CTPDG009643
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL195878; SCHEMBL3926652; MAFQDFZNSVYFEW-UHFFFAOYSA-N; ZINC13645034; BDBM50168350	10125290	Investigative	D0CC6R	.	CTPDG009644
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-benzylnaringenin	.	44418733	Investigative	D0D1LB	.	CTPDG009645
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol	.	135454786	Investigative	D0DK9S	.	CTPDG009646
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL192386; SCHEMBL3924505; KBQSRNQTSRTYGN-UHFFFAOYSA-N; ZINC13645086; BDBM50168353	10308090	Investigative	D0FD6Z	.	CTPDG009647
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-Naphthalen-1-yl-benzooxazol-6-ol	CHEMBL188527; 2-(naphthalen-1-yl)benzo[d]oxazol-6-ol; SCHEMBL6311736; LYJKLNQQSXCGDI-UHFFFAOYSA-N; BDBM50154077; ZINC12353755	10244394	Investigative	D0H1CO	.	CTPDG009648
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol	CHEMBL195788; SCHEMBL3935673; MYVOVZDBAWARDP-UHFFFAOYSA-N; ZINC13645031; BDBM50168340	10308268	Investigative	D0H2FI	.	CTPDG009649
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL204025; SCHEMBL6827956	9993278	Investigative	D0H5HI	.	CTPDG009650
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one"	CHEMBL206226	44408971	Investigative	D0HM8Y	.	CTPDG009651
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(3-Hydroxy-phenyl)-naphthalen-1-ol	CHEMBL193010; 6-(3-hydroxyphenyl)-1-naphthol; SCHEMBL3010784; HXKYTCGOCJUQSE-UHFFFAOYSA-N; ZINC13644987	11447703	Investigative	D0HR8L	.	CTPDG009652
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol"	CHEMBL37775	10246180	Investigative	D0I1NX	.	CTPDG009653
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol	CHEMBL200483; SCHEMBL6440186	44405888	Investigative	D0I5HZ	.	CTPDG009654
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	.	135421237	Investigative	D0J0AG	.	CTPDG009655
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-n-heptylnaringenin	.	44418724	Investigative	D0J2NG	.	CTPDG009656
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(2-phenyl-1H-indol-3-yl)phenol	CHEMBL371012; SCHEMBL7041571; OITCYCYIUVYFKQ-UHFFFAOYSA-N; BDBM50175419; 4-(2-Phenyl-1H-indol-3-yl)-phenol	13896065	Investigative	D0K0IC	.	CTPDG009657
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol	.	135443280	Investigative	D0K1TW	.	CTPDG009658
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL365999; SCHEMBL4012132; UVRXGDFVCKYIGU-UHFFFAOYSA-N; BDBM50168370; ZINC13645074	10286087	Investigative	D0K6TE	.	CTPDG009659
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol	CHEMBL183782; SCHEMBL3927964; UBYHIUUMRHTEFF-UHFFFAOYSA-N	10286352	Investigative	D0L2MU	.	CTPDG009660
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-Naphthalen-2-yl-phenol	4-(naphthalen-2-yl)phenol; 6336-82-9; 4-(2-Naphthyl)phenol; 4-naphthalen-2-ylphenol; CHEMBL194772; NSC-39892; 2-(4-HYDROXYPHENYL)NAPHTHALENE; NSC39892; AC1L5XK9; AC1Q7B9I; SCHEMBL234529; KS-00000ORV; CTK5B8841; DTXSID70284931; NIRHUNSXEDESLN-UHFFFAOYSA-N; MolPort-015-145-553; ZINC1671629; MFCD18312886; KM0737; BDBM50168385; ANW-73541; AKOS016007751; IMED1575423883; KB-40006; AK-50357; AJ-29221; TC-162286; AX8212912; 4CH-024303	236868	Investigative	D0L3AX	.	CTPDG009661
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol	.	135424609	Investigative	D0L6IQ	.	CTPDG009662
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-n-pentylnaringenin	.	44418723	Investigative	D0LI0M	.	CTPDG009663
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol	CHEMBL195786; SCHEMBL5980579; DSBWWPDVDPKMHN-UHFFFAOYSA-N; ZINC13645027; BDBM50168344	11414445	Investigative	D0M0XL	.	CTPDG009664
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol"	CHEMBL191716; SCHEMBL3934682; DZGRIHNLLUZLTL-UHFFFAOYSA-N; BDBM50168366; ZINC13645080	10308207	Investigative	D0MY8V	.	CTPDG009665
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-benzooxazol-5-ol	.	135405741	Investigative	D0N0OY	.	CTPDG009666
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4',5,7-trihydroxy-6,8-dimethylisoflavone"	"CHEMBL512579; AC1LCTEG; SCHEMBL571136; BDBM50250906; 4'',5,7-trihydroxy-6,8-dimethylisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethylchromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethyl-4H-chromen-4-one; 5,7-Dihydroxy-3-(4-hydroxy-phenyl)-6,8-dimethyl-chromen-4-one; 4H-1-benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethyl-"	637048	Investigative	D0NN0V	.	CTPDG009667
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2-phenyl-1,2'-spirobi[1H-indene]-5'-ol"	"CHEMBL439806; SCHEMBL6283895; BDBM50123212; 2-phenyl-1,2''-spirobi[1H-indene]-5''-ol"	12133211	Investigative	D0O2KP	.	CTPDG009668
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL381337; SCHEMBL6828067	10060956	Investigative	D0O5KR	.	CTPDG009669
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL206584; SCHEMBL6830345	10061675	Investigative	D0O6FX	.	CTPDG009670
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	ZK-164015	ZK 164015; 177583-70-9; 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL; CHEMBL184074; SCHEMBL7133598; CHEBI:92087; CTK4D6535; DTXSID00430964; MolPort-006-822-606; HMS3268P09; ZINC8022535; AKOS024456974; NCGC00092322-01; RT-016336; B6960; J-011295; BRD-K05151076-001-01-8	9806489	Investigative	D0P0FN	.	CTPDG009671
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol	CHEMBL427180; SCHEMBL3932725; TWSSGPRRAGPVKD-UHFFFAOYSA-N; BDBM50168373; ZINC13645059	10125342	Investigative	D0P6FN	.	CTPDG009672
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2,3-diphenyl-1H-indole"	"2,3-Diphenylindole; 3469-20-3; 1H-Indole, 2,3-diphenyl-; CHEMBL200719; GYGKJNGSQQORRG-UHFFFAOYSA-N; Indole, 2,3-diphenyl-; NSC17363; EINECS 222-432-0; Indole,3-diphenyl-; Cyto5A2; AC1Q1HUE; 1H-Indole,3-diphenyl-; AC1Q4W1P; AC1L2S6L; Oprea1_738570; 2,3-Diphenyl-1H-indole #; SCHEMBL3864662; CTK1C3291; KS-00000FNK; DTXSID50188241; MolPort-001-804-408; ZINC1036850; STK080838; BDBM50175411; RW3400; NSC-17363; CCG-46312; AKOS001022174; ACM3469203; MCULE-8938765915; VI30149; ACN-036136; 7J-655S; QC-2111; CC-07034; AK-81890"	77020	Investigative	D0P7PK	.	CTPDG009673
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol"	.	135486039	Investigative	D0R7AG	.	CTPDG009674
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Doxorubicin-Formaldehyde Conjugate	.	44397072	Investigative	D0RI6O	.	CTPDG009675
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	.	135409723	Investigative	D0S0SZ	.	CTPDG009676
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol"	.	135430305	Investigative	D0S2ZJ	.	CTPDG009677
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL194936; SCHEMBL3936480; IPBYYNRPJBGKET-UHFFFAOYSA-N; ZINC13645011; BDBM50168334	10149684	Investigative	D0S6NV	.	CTPDG009678
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol"	CHEMBL380362	11777167	Investigative	D0S8EB	.	CTPDG009679
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-Phenyl-naphthalen-2-ol	CHEMBL194718; 7-Phenyl-2-naphthol; 7-Phenylnaphthalene-2-ol; SCHEMBL5981104; MLFRZWHPLMDWES-UHFFFAOYSA-N; BDBM50168338	11458674	Investigative	D0SR8Q	.	CTPDG009680
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one"	CHEMBL380720	44408769	Investigative	D0U0ZE	.	CTPDG009681
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	.	4369550	Investigative	D0U2VA	DB07009	CTPDG009682
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol	"Phenol, 4,4'-indole-2,3-diyldi-; BRN 1541731; 4,4'-Indole-2,3-diyldiphenol; CHEMBL200232; 5890-93-7; SCHEMBL7037980; AC1L46D4; DTXSID90207642; ZINC3638330; BDBM50175412; LS-104733; 4,4'-[1H-Indole-2,3-diyl]bis(phenol)"	201385	Investigative	D0U7KV	.	CTPDG009683
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-Phenyl-naphthalen-2-ol	6-phenyl-2-naphthol; 6-Phenylnaphthalene-2-ol; CHEMBL191714; SCHEMBL3019399; PZOXFBPKKGTQDZ-UHFFFAOYSA-N; ZINC13644999	10125182	Investigative	D0UV9G	.	CTPDG009684
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol"	CHEMBL192621; SCHEMBL3924515; AUZLISXBMGKYGA-UHFFFAOYSA-N; ZINC13645047; BDBM50168333	10214708	Investigative	D0V6KJ	.	CTPDG009685
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol	.	135528624	Investigative	D0V7QZ	.	CTPDG009686
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol	CHEMBL192102; SCHEMBL3927262; INNGVLJQICTRAF-UHFFFAOYSA-N; BDBM50168362	10171886	Investigative	D0VN2R	.	CTPDG009687
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-n-propylnaringenin	.	44418722	Investigative	D0W0LG	.	CTPDG009688
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol"	.	135522274	Investigative	D0W2YR	.	CTPDG009689
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	.	135503567	Investigative	D0W3FF	.	CTPDG009690
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	EFFUSOL	"73166-28-6; NSC 371300; 5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol; UNII-S436Y000RU; CHEMBL205119; S436Y000RU; 1-methyl-5-vinyl-9,10-dihydrophenanthrene-2,7-diol; NSC-371300; 2,7-Phenanthrenediol, 5-ethenyl-9,10-dihydro-1-methyl-; NSC371300; AC1L2PII; AC1Q7B8H; CTK8D4698; DTXSID00223419; MolPort-042-624-482; ZINC1588038; BDBM50180512; FT-0667825"	100801	Investigative	D0W4WF	.	CTPDG009691
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-n-nonylnaringenin	.	44418725	Investigative	D0W5HT	.	CTPDG009692
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol"	"CHEMBL281499; SCHEMBL6286186; BDBM50123205; 2-(4-hydroxyphenyl)-1,2''-spirobi[1H-indene]-5-ol"	9945207	Investigative	D0X2VK	.	CTPDG009693
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL193727; SCHEMBL3924993; QTDYCKGQBCKMGC-UHFFFAOYSA-N; ZINC13645068; BDBM50168372	10236221	Investigative	D0X4VN	.	CTPDG009694
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol"	CHEMBL195289; SCHEMBL3930290; VLJUOFGVEJAFFK-UHFFFAOYSA-N; ZINC13645040; BDBM50168359	10308206	Investigative	D0X7DJ	.	CTPDG009695
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	8-(2-methylpropyl)naringenin	.	44418729	Investigative	D0Y2LJ	.	CTPDG009696
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	WAY-169916	.	135461982	Investigative	D0Y9BO	DB08047	CTPDG009697
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	"CHEMBL189077; 2-(6-hydroxynaphthalen-1-yl)benzo[d]oxazol-6-ol; SCHEMBL3926798; ZRGCERZQAHMXNC-UHFFFAOYSA-N; BDBM50154135; 595566-69-1; 6-Benzoxazolol,2-(6-hydroxy-1-naphthalenyl)-"	10062042	Investigative	D0YH4T	.	CTPDG009698
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol	.	135494488	Investigative	D0YW4C	.	CTPDG009699
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	"1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol"	CHEMBL26865	11638264	Investigative	D0Z0UC	.	CTPDG009700
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	CHEMBL192782; SCHEMBL3925203; VQATUPWMFYRKSD-UHFFFAOYSA-N; BDBM50168380; ZINC13645014	10214633	Investigative	D0ZT4U	.	CTPDG009701
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	7-(3-Hydroxy-phenyl)-naphthalen-2-ol	7-(3-hydroxyphenyl)-2-naphthol	10171410	Investigative	D01IAT	.	CTPDG009702
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	4-chloro-2-(4-hydroxyphenyl)quinolin-6-ol	135519319	Investigative	D01TUB	.	CTPDG009703
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	4-bromo-2-(4-hydroxyphenyl)quinolin-6-ol	135454802	Investigative	D03CBX	.	CTPDG009704
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	4-ethynyl-2-(4-hydroxyphenyl)quinolin-6-ol	135524856	Investigative	D08SJL	.	CTPDG009705
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	4-ethyl-2-(4-hydroxyphenyl)quinolin-6-ol	135430317	Investigative	D09FWS	.	CTPDG009706
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(4-Hydroxy-phenyl)-naphthalen-1-ol	6-(4-hydroxyphenyl)-1-naphthol	10308021	Investigative	D0H8PI	.	CTPDG009707
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol	2-(4-hydroxyphenyl)-4-vinylquinolin-6-ol	135409729	Investigative	D0K7HR	.	CTPDG009708
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	SOPHORAFLAVANONE B	"8-Prenylnaringenin; 53846-50-7; Flavaprenin; (-)-(2S)-8-dimethylallylnaringenin; (S)-8-dimethylallylnaringenin; YS04; CHEMBL376915; CHEBI:50207; (-)-(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-4H-chromen-4-one; (s)-8-prenylnaringenin; 8-dimethylallylnaringenin; AC1LA3DM; UNII-5L872SZR8X; 8-prenylnaringenin (8-PN); BIDD:ER0149; cid_509245; SCHEMBL1171435; 5L872SZR8X; ZINC39452; CTK5J8800; BDBM19460"	509245	Investigative	D0S8AV	.	CTPDG009709
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	Geldanamycin-estradiol hybrid	.	.	Investigative	D0H6OS	.	CTPDG009710
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	CP-409069	"CHEMBL78625; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol"	9819614	Investigative	D0J7XZ	.	CTPDG009711
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	CP-394531	"UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)"	9820558	Investigative	D0L5IC	.	CTPDG009712
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	6-(3-hydroxyphenyl)-2-naphthol; 6-(3-hydroxyphenyl)naphthalen-2-ol	10192730	Investigative	D0P8PK	.	CTPDG009713
M6ACROT05171	Estrogen receptor (ESR1)	ESR1_HUMAN	.	.	Investigative	daidzein	"486-66-8; 4',7-Dihydroxyisoflavone; Daidzeol; 7,4'-Dihydroxyisoflavone; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; UNII-6287WC5J2L; CCRIS 7600; K 251b; 4,7-Dihydroxyisoflavone; EINECS 207-635-4; BRN 0231523; CHEMBL8145; 4',7-Dihydroxy-iso-flavone; d-(+)-alpha-methylbenzylamine; ,7-Dihydroxyisoflavone; DIADZEIN"	5281708	Investigative	D0SY2M	DB13182	CTPDG009714
M6ACROT05172	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05172	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05172	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT05173	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Approved	Glucosamine	"Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose"	439213	Approved	D07NSU	DB01296	CTPDG011338
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Approved	Rilonacept	Rilonacept (USAN/INN)	.	Approved	D09DBY	.	CTPDG000503
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Approved	Gallium nitrate	Ganite (TN)	61635	Approved	D0R4ZT	DB05260	CTPDG011339
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Approved	Canakinumab	Ilaris (TN)	.	Approved	D0TD2G	.	CTPDG000130
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 4	Diacerein	"13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692"	26248	Phase 4	D0N1FS	DB11994	CTPDG011340
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 3	XOMA 052	Gevokizumab	.	Phase 3	D0C4KT	.	CTPDG001257
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 2	LY-2189102	"Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly"	.	Phase 2	D02DJG	.	CTPDG011341
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 2	ABT-981	.	.	Phase 2	D01WQQ	.	CTPDG011342
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 2	AC-201	.	.	Phase 2	D0WP2R	.	CTPDG001911
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 1	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	Phase 1	D00EHX	DB12899	CTPDG005470
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Phase 1	CYT-013-IL1bQb	"Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos"	.	Phase 1	D09YAS	.	CTPDG011343
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Discontinued in Phase 1/2	CDP-484	"Anti-IL-1 beta FAb-PEG, Celltech"	.	Discontinued in Phase 1/2	D05FVX	.	CTPDG011344
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Preclinical	Celastrol	"Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid"	122724	Preclinical	D0I9XH	.	CTPDG007077
M6ACROT05180	Interleukin-1 beta (IL1B)	IL1B_HUMAN	.	.	Investigative	DVD-Ig	"DVD-Ig (arthritis); DVD-Ig (arthritis), Abbott; Dual anti-CD20/CD3 immunoglobulin, Abbott; Dual anti-TNF/PGE2 innunoglobulin, Abbott; Dual anti-IL-1 alpha/beta immunoglobulin (arthritis), Abbott; Dual anti-IL-12/IL-18 immunoglobulin, Abbott; 1D4.1-2.5; 1D4.1-ABT325"	.	Investigative	D0K8YK	.	CTPDG008132
M6ACROT05181	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05181	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05181	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05182	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05182	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05182	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05183	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05183	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05183	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05184	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT05184	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT05184	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT05185	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT05185	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT05185	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT05186	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT05186	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT05186	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT05187	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	PF-06473871	.	.	Phase 2	D2AYS0	.	CTPDG001838
M6ACROT05187	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	RXI-109	A45sd-RxNA	.	Phase 2	D4ZLC2	.	CTPDG001810
M6ACROT05187	CCN family member 2 (CTGF)	CCN2_HUMAN	.	.	Phase 2	OLX10010	OLX 101A	.	Phase 2	DHB2K8	.	CTPDG001707
M6ACROT05188	Collagen alpha-2(I) chain (COL1A2)	CO1A2_HUMAN	.	.	Phase 2	Solubilized type 1 native bovine collagen	"Solubilized type 1 native bovine collagen (oral, scleroderma); Solubilized type 1 native bovine collagen (oral, scleroderma), arGentis/University of Tennessee"	.	Phase 2	D02CFV	.	CTPDG014657
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Phase 3	Tadekinig alfa	.	.	Phase 3	DF6UP7	.	CTPDG014280
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Phase 2	GSK-1070806	"Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK"	.	Phase 2	D06XDS	.	CTPDG002721
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Phase 1	MEDI-2338	.	.	Phase 1	D05UCW	.	CTPDG005186
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Phase 1	Iboctadekin	.	.	Phase 1	D0A8HN	.	CTPDG004940
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Phase 1	Iboctadekin + Doxil	.	5478883	Phase 1	D0F3PU	.	CTPDG004810
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Phase 1	Iboctadekin + rituximab	Pepstatin A; 26305-03-3; Pepstatine; Ahpatinin C; UNII-V6Y2T27Q1U; MLS002222329; Iva-Val-Val-Sta-Ala-Sta-OH; V6Y2T27Q1U; CHEMBL296588; 39324-30-6; FAXGPCHRFPCXOO-LXTPJMTPSA-N; C34H63N5O9; NCGC00161670-06; Pepstatin (nonspecific); DSSTox_RID_81334; DSSTox_CID_26095; DSSTox_GSID_46095; CCRIS 3603; Pepstatina; Pepstatinum; Pepstatin (VAN); Ia Quinidine	.	Phase 1	D0J2VB	.	CTPDG014281
M6ACROT05191	Interleukin-18 (IL18)	IL18_HUMAN	.	.	Discontinued in Phase 1	IL-18BP	.	.	Discontinued in Phase 1	D0I1BQ	.	CTPDG006804
M6ACROT05192	"Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2)"	HMCS2_HUMAN	.	.	Investigative	Acetoacetyl-Coenzyme A	"acetoacetyl-CoA; Acetoacetyl coenzyme A; 3-acetoacetyl-CoA; Acetoacetyl coa; S-Acetoacetyl-CoA; S-Acetoacetylcoenzyme A; 1420-36-6; S-Acetoacetyl-coenzym A; S-acetoacetyl-coenzyme A; OJFDKHTZOUZBOS-CITAKDKDSA-N; acetoacetyl-S-CoA; S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-oxobutanethioate; s-acetoacetyl coenzyme a; bofuranosyl]-; 1dub"	92153	Investigative	D06CGD	DB03059	CTPDG015324
M6ACROT05192	"Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2)"	HMCS2_HUMAN	.	.	Investigative	3-Sulfinoalanine	"2-amino-3-sulfinopropanoic acid; 2381-08-0; Alanine 3-sulfinic acid; Cysteine hydrogen sulfite ester; L-Cysteinesulfinic acid monohydrate; Alanine, 3-sulfino-; UNII-56X032NVQL; 56X032NVQL; Cysteinesulfinic acid, L-; AC1Q5S9C; MLS000859909; SCHEMBL443654; AC1L18I0; GTPL4695; CHEMBL1702607; 2-Amino-3-sulfinopropionic acid; BDBM86194; NSC_109; CAS_109; ADVPTQAUNPRNPO-UHFFFAOYSA-N; HMS3369H02; HMS3266C09; HMS2235M21; EINECS 214-228-5; AKOS022145786; SMR000326770; ST45022126; 207121-48-0"	1549098	Investigative	D0E8JM	DB02153	CTPDG015325
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 2	PINOCEMBRIN	"480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-"	68071	Phase 2	D0G5CS	.	CTPDG014282
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 1	NARINGENIN	"5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone"	932	Phase 1	D02ABO	.	CTPDG014283
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	DIOSMETIN	"520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246"	5281612	Investigative	D00RFY	DB11259	CTPDG014284
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISOSAKUTANETIN	"Isosakuranetin; 480-43-3; 4'-Methylnaringenin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone"	160481	Investigative	D01FJE	.	CTPDG014285
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFERIDE	"491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD"	5281666	Investigative	D04DYO	.	CTPDG014286
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TAMARIXETIN	"603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7"	5281699	Investigative	D06PZE	.	CTPDG014287
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan"	"CHEMBL43396; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552"	10105252	Investigative	D06VXW	.	CTPDG014288
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ERIODICTYOL	"(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT"	440735	Investigative	D08AIJ	.	CTPDG014289
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	HOMOERIODICTYOL	"(-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672"	73635	Investigative	D0CR8V	.	CTPDG014290
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide"	"N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910"	2321450	Investigative	D0J9OG	.	CTPDG014291
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine"	"CHEMBL43013; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine"	11957947	Investigative	D0T9IK	.	CTPDG014292
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene"	"CHEMBL42428; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene"	9834747	Investigative	D0Z1AL	.	CTPDG014293
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	CHRYSOERIOL	"491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514"	5280666	Investigative	D01FGM	.	CTPDG014294
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISORHAMNETIN	"480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z"	5281654	Investigative	D07YDN	.	CTPDG014295
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ACACETIN	"480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC"	5280442	Investigative	D0NS1S	.	CTPDG014296
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	Investigative	D0O9NE	.	CTPDG013143
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Galangin	"548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one"	5281616	Investigative	D0Y7HG	.	CTPDG014297
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT05193	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFEROL	"520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe"	5280863	Investigative	D0G3TK	DB01852	CTPDG014298
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 2	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	Phase 2	D07PRH	.	CTPDG002678
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 2	APG-101	"CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix"	.	Phase 2	D0N4JI	.	CTPDG014488
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Phase 1	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	Phase 1	D0Q6SF	.	CTPDG004480
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	F61F12	"Anti-Fas mAb (cancer), IMED"	.	Investigative	D0N1DG	.	CTPDG008050
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	APG-103	"CD95 receptor inhibitor (inflammatory disease), Apogenix"	.	Investigative	D0QA7X	.	CTPDG014489
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	2-aminophenoxazine-3-one	"Questiomycin A; 2-Amino-3H-phenoxazin-3-one; 2-Aminophenoxazin-3-one; 1916-59-2; 2-Aminophenoxazon; 2-Aminophenoxazone; 3-Aminophenoxazone; 2-Amino-3-phenoxazone; 3H-Phenoxazin-3-one, 2-amino-; Isophenoxazine; 2-amino-phenoxazin-3-one; NSC 94945; MLS000736964; CHEBI:17293; SMR000528446; BRN 0014215; Questinomycine A; 3H-Phenoxazin-3-one,2-amino-; AV toxin C; 2-Aminophenoxazinone; Phx-3 cpd; Phx-3; 2-amino-3-phenoxazinone; 2-azanylphenoxazin-3-one; Acrospermum viticola toxin C; NCIOpen2_006212; 4-27-00-05519 (Beilstein Handbook Reference); cid_72725; CHEMBL146710; SCHEMBL2609261; BDBM76155; DTXSID60172691; HMS2270F19; NSC94945; ZINC4095812; MFCD00207317; NSC-94945; 2-acetylamino-(3h)-phenoxazin-3-one; AKOS027339724; NCGC00246903-01; AS-47041; C02161; J-012388; BRD-K66640612-001-05-8; Q15424786"	72725	Investigative	DAQ31P	.	CTPDG007605
M6ACROT05203	Tumor necrosis factor receptor superfamily member 6 (FAS)	TNR6_HUMAN	.	.	Investigative	ISIS 17020	.	.	Investigative	D0J1SU	.	CTPDG015441
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Momelotinib	Cyt387; 1056634-68-4; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide	25062766	Approved	D0D5ZJ	DB11763	CTPDG009343
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Abrocitinib	.	78323835	Approved	D05PCM	DB14973	CTPDG000627
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 3	SHR0302	"(3AR,5S,6AS)-N-(3-METHOXY-1,2,4-THIADIAZOL-5-YL)-5-(METHYL (7H-PYRROLO(2,3- D)PYRIMIDIN-4-YL)AMINO) HEXAHYDROCYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE; (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino) hexahydrocyclopenta(c)pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; 1445987-21-2; AC-36766; AKOS040759719; CHEMBL5095398; CS-0062969; CYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE, HEXAHYDRO-N-(3-METHOXY-1,2,4- THIADIAZOL-5-YL)-5-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-, (3A.ALPHA.,5.ALPHA.,6A.ALPHA.)-; Cyclopenta(c)pyrrole-2(1H)-carboxamide, hexahydro-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3aalpha,5alpha,6aalpha)-; EX-A5101; example 34 [WO2013091539A1]; F82248; GTPL11878; HY-112724; Ivarmacitinib; IVARMACITINIB [INN]; Ivarmacitinib [USAN]; K6K4B9Z5TV; MS-27180; NCGC00687790-01; rel-(3aR,5s,6aS)-N-(3-Methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; SCHEMBL15077696; SCHEMBL15077710; SCHEMBL16191633; SHR0302; SHR-0302; SHR0302 base; SHR0302 FREE BASE; SHR-0302 FREE BASE; UNII-K6K4B9Z5TV; US9527851, 34; US9527851, 74; WHO 11823"	71622431	Phase 3	DFK8Z5	.	CTPDG000908
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	INCB54707	.	.	Phase 2	D0HJ1R	.	CTPDG011499
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	CTP-543	.	.	Phase 2	D01UAU	.	CTPDG003011
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	INCB039110	Examlpe 294 [WO2011112662]	53380437	Phase 2	D09AFI	DB12154	CTPDG002595
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	ATI-501	.	.	Phase 2	D6INZ9	.	CTPDG011205
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	Phase 2	D6N5UC	.	CTPDG001788
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	CTP-543	"Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-"	72704611	Phase 2	DU10JI	.	CTPDG009348
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	TD-8236	.	.	Phase 2	D2KTG5	.	CTPDG001835
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	Phase 2	D0BI3N	DB15499	CTPDG002499
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1/2	ALXN2075	.	.	Phase 1/2	D2JZ3U	.	CTPDG009350
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	AZD0449	.	.	Phase 1	D63WFO	.	CTPDG004072
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	KN-002	.	.	Phase 1	DI19BZ	.	CTPDG003887
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	AZD4604	"(2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-; 2241039-81-4; AKOS040733485; AT39356; AZD4604; AZD-4604; BDBM488779; CHEMBL4447181; CS-0101485; EX-A5343; example 35 [WO2018134213A1]; GTPL11716; HY-126294; JAC34RRR7S; JAK1-IN-7; londamocitinib; MS-30607; SCHEMBL20399395; UNII-JAC34RRR7S; US10961228, Example 35"	135240395	Phase 1	DX72LV	.	CTPDG003666
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	PF-07295324	.	.	Phase 1	DXVA93	.	CTPDG003662
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	GDC-0214	"1831144-46-7; AKOS040759985; BDBM232517; CHEMBL3964801; EX-A6434; GDC0214; GDC-0214; GTPL12318; iJak-381; N-(3-(5-Chloro-2-(difluoromethoxy)phenyl)-1-(2-(4-((2-cyanoethyl)(methyl)amino)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide; RG6151; RG-6151; SCHEMBL17271636; US9346815, 63"	118522534	Phase 1	DZ2RH6	.	CTPDG003649
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cyclohexyl azetidine derivative 1	PMID27774824-Compound-Figure13Example1	.	Patented	D00GJY	.	CTPDG011500
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bipyrazole derivative 1	PMID27774824-Compound-Figure13Example17	.	Patented	D0H3KF	.	CTPDG011501
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic compound 3	PMID27774824-Compound-Figure13Example20	.	Patented	D0OS1N	.	CTPDG011502
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Triazolo-pyridine derivative 1	PMID27774822-Compound-Figure7ExampleI-286	.	Patented	D00JUI	.	CTPDG009355
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Imidazopyridazine derivative 2	PMID27774824-Compound-Figure5Example75	.	Patented	D00PTE	.	CTPDG011217
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridone derivative 2	PMID27774822-Compound-Figure2ExampleII-92	.	Patented	D03PBI	.	CTPDG009357
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774822-Compound-Figure7Example63	.	.	Patented	D04OCD	.	CTPDG009359
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cyclic cyanoethypypazole derivative 1	PMID27774822-Compound-Figure2Example14-1	.	Patented	D05GEL	.	CTPDG009360
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridone derivative 1	PMID27774822-Compound-Figure2Example1-19	.	Patented	D06MQB	.	CTPDG009361
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Imidazopyridazine derivative 1	PMID27774824-Compound-Figure5Example1	.	Patented	D07BND	.	CTPDG011219
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure6Example6	.	.	Patented	D0F3BK	.	CTPDG009369
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Geminally-substituted cyanoethylpypazolo pyridone derivative 1	PMID27774822-Compound-Figure2Example17-32	.	Patented	D0H6XN	.	CTPDG009370
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cyanomethyl pypazole carboxamide derivative 1	PMID27774822-Compound-Figure2Example40-85	.	Patented	D0K2RW	.	CTPDG009374
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Geminally-substituted cyanoethylpypazolo pyridone derivative 2	PMID27774822-Compound-Figure2Example5-84	.	Patented	D0KI5F	.	CTPDG009375
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cycloalkyl nitrile pyrazolo pyridone derivative 1	PMID27774822-Compound-Figure2Example15-71	.	Patented	D0PB5X	.	CTPDG009381
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure7Example10	.	.	Patented	D0PM8K	.	CTPDG009382
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cycloalkyl nitrile pyrazolo pyridone derivative 2	PMID27774822-Compound-Figure2Example3-9	.	Patented	D0S4TH	.	CTPDG009385
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridone derivative 3	PMID27774822-Compound-Figure9Example4	.	Patented	D0T6CY	.	CTPDG011503
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cycloalkyl nitrile pyrazole carboxamide derivative 1	PMID27774822-Compound-Figure2Example1-4	.	Patented	D0V0KI	.	CTPDG009386
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 11"	PMID27774824-Compound-Figure13Example25	.	Patented	D0VQ7P	.	CTPDG009388
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Ruxolitinib derivative 2	PMID27774824-Compound-Figure4Example4	.	Patented	D01EYJ	.	CTPDG009391
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Five-and-six-membered heterocyclic compound 1	PMID27774822-Compound-Figure8compoundT-38	.	Patented	D08WPB	.	CTPDG009393
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrazolopyridine derivative 4	PMID27774822-Compound-Figure9Example1	.	Patented	D09RUN	.	CTPDG009394
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrole six-membered heteroaryl ring derivative 1	PMID27774822-Compound-Figure1Example6	.	Patented	D09UBE	.	CTPDG009395
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure2Example4	.	.	Patented	D0A6RG	.	CTPDG009396
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic compound 1	PMID27774824-Compound-Figure1Example1	.	Patented	D0G0FK	.	CTPDG009397
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Isoxazole derivative 1	PMID27774822-Compound-Figure11compound1	.	Patented	D0G9MM	.	CTPDG009398
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774822-Compound-Figure1Example20	.	.	Patented	D0M3CB	.	CTPDG009400
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Isoxazole derivative 2	PMID27774822-Compound-Figure11compound2	.	Patented	D0TX2G	.	CTPDG009401
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridine derivative 3	PMID27774822-Compound-Figure8Example55	.	Patented	D0VR6E	.	CTPDG009402
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	N-methylmethanesulfonamide derivative 1	PMID27774822-Compound-Figure4Example22	.	Patented	D0XH7H	.	CTPDG011225
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1	PMID27774824-Compound-Figure5Example25	.	Patented	D0Y2IM	.	CTPDG009403
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrole derivative 7	PMID27774822-Compound-Figure3compound229	.	Patented	D0YJ4D	.	CTPDG009404
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Benzimidazole derivative 7	PMID27774824-Compound-Figure11Example15	.	Patented	D01CRX	.	CTPDG009405
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 1	PMID27774824-Compound-Figure7compound23	.	Patented	D01FVC	.	CTPDG009406
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrazolopyridine derivative 3	PMID27774822-Compound-Figure5Example131	.	Patented	D03QAY	.	CTPDG009407
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic pyrrolopyridine compound 1	PMID27774822-Compound-Figure3Example45	.	Patented	D04BOW	.	CTPDG009408
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Aminooxazole carboxamide derivative 1	PMID27774822-Compound-Figure6Example25	.	Patented	D05AXE	.	CTPDG009409
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 6"	PMID27774822-Compound-Figure5Example10	.	Patented	D0FQ4Z	.	CTPDG009410
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure6Example12	.	.	Patented	D0GB7G	.	CTPDG009411
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 8"	PMID27774822-Compound-Figure5Example2	.	Patented	D0KL3B	.	CTPDG009412
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 2	PMID27774824-Compound-Figure7Example103	.	Patented	D0LR6J	.	CTPDG009413
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic compound 11	PMID27774822-Compound-Figure7Example34	.	Patented	D0LS1O	.	CTPDG009414
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic heterocycle derivative 5	PMID27774822-Compound-Figure7Example4	.	Patented	D0M2WA	.	CTPDG009415
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774822-Compound-Figure11Example5	.	.	Patented	D0RJ3W	.	CTPDG009416
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 3	PMID27774824-Compound-Figure7Example25	.	Patented	D0S6XT	.	CTPDG009417
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 4	PMID27774824-Compound-Figure7Example83	.	Patented	D0SJ1Q	.	CTPDG009418
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure3Example18	.	.	Patented	D0U1HA	.	CTPDG009419
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 7"	PMID27774822-Compound-Figure5Example14	.	Patented	D0U5FZ	.	CTPDG009420
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrimidopyridazinone derivative 2	PMID27774824-Compound-Figure10Example7	.	Patented	D0WA1V	.	CTPDG009421
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic heterocycle derivative 1	PMID27774822-Compound-Figure3Example81	.	Patented	D0X1FD	.	CTPDG009422
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Imidazo[4,5-c]pyridine derivative 1"	PMID27774824-Compound-Figure11Example228	.	Patented	D07PTU	.	CTPDG011226
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2up	.	.	Patented	D0WZ8N	.	CTPDG009423
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Aminotriazolopyridine derivative 1	PMID27774824-Compound-Figure11Example1down	.	Patented	D09ALF	.	CTPDG009425
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Imidazo[4,5-c]pyridine derivative 2"	PMID27774824-Compound-Figure11Example82	.	Patented	D0VJ1R	.	CTPDG009426
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure11Example1up	.	.	Patented	D0YR8S	.	CTPDG009427
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrazolo[4,3-c]pyridine derivative 2"	PMID27774824-Compound-Figure7compound1	.	Patented	D09PIS	.	CTPDG009428
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Investigative	ZM-39923	"ZM39923; 273727-89-2; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09"	3797	Investigative	D0YX5U	.	CTPDG011232
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Investigative	PMID24359159C19a	UNII-7N5LJ2Z26C; 7N5LJ2Z26C; GTPL6977; BDBM50446982	45275255	Investigative	D0US9O	.	CTPDG009435
M6ACROT05208	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Upadacitinib	ABT-494	58557659	Approved	D07JAG	DB15091	CTPDG000565
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Momelotinib	Cyt387; 1056634-68-4; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide	25062766	Approved	D0D5ZJ	DB11763	CTPDG009343
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	Approved	D04LKS	DB08877	CTPDG009344
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Abrocitinib	.	78323835	Approved	D05PCM	DB14973	CTPDG000627
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Approved	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	Approved	D0Y7IC	DB11817	CTPDG000056
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 3	SHR0302	"(3AR,5S,6AS)-N-(3-METHOXY-1,2,4-THIADIAZOL-5-YL)-5-(METHYL (7H-PYRROLO(2,3- D)PYRIMIDIN-4-YL)AMINO) HEXAHYDROCYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE; (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino) hexahydrocyclopenta(c)pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; 1445987-21-2; AC-36766; AKOS040759719; CHEMBL5095398; CS-0062969; CYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE, HEXAHYDRO-N-(3-METHOXY-1,2,4- THIADIAZOL-5-YL)-5-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-, (3A.ALPHA.,5.ALPHA.,6A.ALPHA.)-; Cyclopenta(c)pyrrole-2(1H)-carboxamide, hexahydro-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3aalpha,5alpha,6aalpha)-; EX-A5101; example 34 [WO2013091539A1]; F82248; GTPL11878; HY-112724; Ivarmacitinib; IVARMACITINIB [INN]; Ivarmacitinib [USAN]; K6K4B9Z5TV; MS-27180; NCGC00687790-01; rel-(3aR,5s,6aS)-N-(3-Methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; SCHEMBL15077696; SCHEMBL15077710; SCHEMBL16191633; SHR0302; SHR-0302; SHR0302 base; SHR0302 FREE BASE; SHR-0302 FREE BASE; UNII-K6K4B9Z5TV; US9527851, 34; US9527851, 74; WHO 11823"	71622431	Phase 3	DFK8Z5	.	CTPDG000908
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 3	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A"	57928403	Phase 3	D06EIC	DB11708	CTPDG001382
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	GSK2586184	GSK-2586184	44603362	Phase 2	D06HZA	.	CTPDG011498
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	INCB54707	.	.	Phase 2	D0HJ1R	.	CTPDG011499
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	GLPG-0634	"Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK"	49831257	Phase 2	D0SG7B	DB14845	CTPDG002033
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	EQ121	.	.	Phase 2	DD6A7P	.	CTPDG001744
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	CTP-543	.	.	Phase 2	D01UAU	.	CTPDG003011
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	INCB039110	Examlpe 294 [WO2011112662]	53380437	Phase 2	D09AFI	DB12154	CTPDG002595
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	PF-06700841	"BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone"	118878093	Phase 2	D0V4DX	DB15003	CTPDG001965
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	ATI-501	.	.	Phase 2	D6INZ9	.	CTPDG011205
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	Phase 2	D6N5UC	.	CTPDG001788
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	A223	.	.	Phase 2	DH0A6O	.	CTPDG001709
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	CTP-543	"Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-"	72704611	Phase 2	DU10JI	.	CTPDG009348
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	TD-8236	.	.	Phase 2	D2KTG5	.	CTPDG001835
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 2	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	Phase 2	D0BI3N	DB15499	CTPDG002499
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1/2	ALXN2075	.	.	Phase 1/2	D2JZ3U	.	CTPDG009350
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	AZD0449	.	.	Phase 1	D63WFO	.	CTPDG004072
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	KN-002	.	.	Phase 1	DI19BZ	.	CTPDG003887
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	AZD4604	"(2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-; 2241039-81-4; AKOS040733485; AT39356; AZD4604; AZD-4604; BDBM488779; CHEMBL4447181; CS-0101485; EX-A5343; example 35 [WO2018134213A1]; GTPL11716; HY-126294; JAC34RRR7S; JAK1-IN-7; londamocitinib; MS-30607; SCHEMBL20399395; UNII-JAC34RRR7S; US10961228, Example 35"	135240395	Phase 1	DX72LV	.	CTPDG003666
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	PF-07295324	.	.	Phase 1	DXVA93	.	CTPDG003662
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Phase 1	GDC-0214	"1831144-46-7; AKOS040759985; BDBM232517; CHEMBL3964801; EX-A6434; GDC0214; GDC-0214; GTPL12318; iJak-381; N-(3-(5-Chloro-2-(difluoromethoxy)phenyl)-1-(2-(4-((2-cyanoethyl)(methyl)amino)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide; RG6151; RG-6151; SCHEMBL17271636; US9346815, 63"	118522534	Phase 1	DZ2RH6	.	CTPDG003649
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cyclohexyl azetidine derivative 1	PMID27774824-Compound-Figure13Example1	.	Patented	D00GJY	.	CTPDG011500
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bipyrazole derivative 1	PMID27774824-Compound-Figure13Example17	.	Patented	D0H3KF	.	CTPDG011501
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic compound 3	PMID27774824-Compound-Figure13Example20	.	Patented	D0OS1N	.	CTPDG011502
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Triazolo-pyridine derivative 1	PMID27774822-Compound-Figure7ExampleI-286	.	Patented	D00JUI	.	CTPDG009355
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Imidazopyridazine derivative 2	PMID27774824-Compound-Figure5Example75	.	Patented	D00PTE	.	CTPDG011217
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridone derivative 2	PMID27774822-Compound-Figure2ExampleII-92	.	Patented	D03PBI	.	CTPDG009357
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774822-Compound-Figure7Example63	.	.	Patented	D04OCD	.	CTPDG009359
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cyclic cyanoethypypazole derivative 1	PMID27774822-Compound-Figure2Example14-1	.	Patented	D05GEL	.	CTPDG009360
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridone derivative 1	PMID27774822-Compound-Figure2Example1-19	.	Patented	D06MQB	.	CTPDG009361
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Imidazopyridazine derivative 1	PMID27774824-Compound-Figure5Example1	.	Patented	D07BND	.	CTPDG011219
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure6Example6	.	.	Patented	D0F3BK	.	CTPDG009369
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Geminally-substituted cyanoethylpypazolo pyridone derivative 1	PMID27774822-Compound-Figure2Example17-32	.	Patented	D0H6XN	.	CTPDG009370
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cyanomethyl pypazole carboxamide derivative 1	PMID27774822-Compound-Figure2Example40-85	.	Patented	D0K2RW	.	CTPDG009374
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Geminally-substituted cyanoethylpypazolo pyridone derivative 2	PMID27774822-Compound-Figure2Example5-84	.	Patented	D0KI5F	.	CTPDG009375
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cycloalkyl nitrile pyrazolo pyridone derivative 1	PMID27774822-Compound-Figure2Example15-71	.	Patented	D0PB5X	.	CTPDG009381
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure7Example10	.	.	Patented	D0PM8K	.	CTPDG009382
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cycloalkyl nitrile pyrazolo pyridone derivative 2	PMID27774822-Compound-Figure2Example3-9	.	Patented	D0S4TH	.	CTPDG009385
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridone derivative 3	PMID27774822-Compound-Figure9Example4	.	Patented	D0T6CY	.	CTPDG011503
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Cycloalkyl nitrile pyrazole carboxamide derivative 1	PMID27774822-Compound-Figure2Example1-4	.	Patented	D0V0KI	.	CTPDG009386
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 11"	PMID27774824-Compound-Figure13Example25	.	Patented	D0VQ7P	.	CTPDG009388
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Ruxolitinib derivative 2	PMID27774824-Compound-Figure4Example4	.	Patented	D01EYJ	.	CTPDG009391
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Five-and-six-membered heterocyclic compound 1	PMID27774822-Compound-Figure8compoundT-38	.	Patented	D08WPB	.	CTPDG009393
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrazolopyridine derivative 4	PMID27774822-Compound-Figure9Example1	.	Patented	D09RUN	.	CTPDG009394
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrole six-membered heteroaryl ring derivative 1	PMID27774822-Compound-Figure1Example6	.	Patented	D09UBE	.	CTPDG009395
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure2Example4	.	.	Patented	D0A6RG	.	CTPDG009396
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic compound 1	PMID27774824-Compound-Figure1Example1	.	Patented	D0G0FK	.	CTPDG009397
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Isoxazole derivative 1	PMID27774822-Compound-Figure11compound1	.	Patented	D0G9MM	.	CTPDG009398
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774822-Compound-Figure1Example20	.	.	Patented	D0M3CB	.	CTPDG009400
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Isoxazole derivative 2	PMID27774822-Compound-Figure11compound2	.	Patented	D0TX2G	.	CTPDG009401
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrolo-pyridine derivative 3	PMID27774822-Compound-Figure8Example55	.	Patented	D0VR6E	.	CTPDG009402
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	N-methylmethanesulfonamide derivative 1	PMID27774822-Compound-Figure4Example22	.	Patented	D0XH7H	.	CTPDG011225
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1	PMID27774824-Compound-Figure5Example25	.	Patented	D0Y2IM	.	CTPDG009403
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrrole derivative 7	PMID27774822-Compound-Figure3compound229	.	Patented	D0YJ4D	.	CTPDG009404
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Benzimidazole derivative 7	PMID27774824-Compound-Figure11Example15	.	Patented	D01CRX	.	CTPDG009405
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 1	PMID27774824-Compound-Figure7compound23	.	Patented	D01FVC	.	CTPDG009406
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrazolopyridine derivative 3	PMID27774822-Compound-Figure5Example131	.	Patented	D03QAY	.	CTPDG009407
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic pyrrolopyridine compound 1	PMID27774822-Compound-Figure3Example45	.	Patented	D04BOW	.	CTPDG009408
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Aminooxazole carboxamide derivative 1	PMID27774822-Compound-Figure6Example25	.	Patented	D05AXE	.	CTPDG009409
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 6"	PMID27774822-Compound-Figure5Example10	.	Patented	D0FQ4Z	.	CTPDG009410
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure6Example12	.	.	Patented	D0GB7G	.	CTPDG009411
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 8"	PMID27774822-Compound-Figure5Example2	.	Patented	D0KL3B	.	CTPDG009412
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 2	PMID27774824-Compound-Figure7Example103	.	Patented	D0LR6J	.	CTPDG009413
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic compound 11	PMID27774822-Compound-Figure7Example34	.	Patented	D0LS1O	.	CTPDG009414
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic heterocycle derivative 5	PMID27774822-Compound-Figure7Example4	.	Patented	D0M2WA	.	CTPDG009415
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774822-Compound-Figure11Example5	.	.	Patented	D0RJ3W	.	CTPDG009416
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 3	PMID27774824-Compound-Figure7Example25	.	Patented	D0S6XT	.	CTPDG009417
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Bis-aminopyrimidine derivative 4	PMID27774824-Compound-Figure7Example83	.	Patented	D0SJ1Q	.	CTPDG009418
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure3Example18	.	.	Patented	D0U1HA	.	CTPDG009419
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 7"	PMID27774822-Compound-Figure5Example14	.	Patented	D0U5FZ	.	CTPDG009420
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Pyrimidopyridazinone derivative 2	PMID27774824-Compound-Figure10Example7	.	Patented	D0WA1V	.	CTPDG009421
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Tricyclic heterocycle derivative 1	PMID27774822-Compound-Figure3Example81	.	Patented	D0X1FD	.	CTPDG009422
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Imidazo[4,5-c]pyridine derivative 1"	PMID27774824-Compound-Figure11Example228	.	Patented	D07PTU	.	CTPDG011226
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2up	.	.	Patented	D0WZ8N	.	CTPDG009423
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	Aminotriazolopyridine derivative 1	PMID27774824-Compound-Figure11Example1down	.	Patented	D09ALF	.	CTPDG009425
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Imidazo[4,5-c]pyridine derivative 2"	PMID27774824-Compound-Figure11Example82	.	Patented	D0VJ1R	.	CTPDG009426
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	PMID27774824-Compound-Figure11Example1up	.	.	Patented	D0YR8S	.	CTPDG009427
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Patented	"Pyrazolo[4,3-c]pyridine derivative 2"	PMID27774824-Compound-Figure7compound1	.	Patented	D09PIS	.	CTPDG009428
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Discontinued in Phase 2	INCB47986	.	.	Discontinued in Phase 2	D0HB4E	.	CTPDG006503
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Investigative	ZM-39923	"ZM39923; 273727-89-2; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09"	3797	Investigative	D0YX5U	.	CTPDG011232
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Investigative	PMID24359159C19a	UNII-7N5LJ2Z26C; 7N5LJ2Z26C; GTPL6977; BDBM50446982	45275255	Investigative	D0US9O	.	CTPDG009435
M6ACROT05209	Tyrosine-protein kinase JAK1 (JAK1)	JAK1_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112000	.	.	Investigative	D00LSM	.	CTPDG015409
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112022	.	.	Investigative	D00SQD	.	CTPDG015410
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112019	.	.	Investigative	D04XOE	.	CTPDG015411
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112005	.	.	Investigative	D06QZK	.	CTPDG015412
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112002	.	.	Investigative	D07FSX	.	CTPDG015413
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112023	.	.	Investigative	D07RUF	.	CTPDG015414
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111992	.	.	Investigative	D0D9OL	.	CTPDG015415
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112003	.	.	Investigative	D0GD1R	.	CTPDG015416
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111997	.	.	Investigative	D0H0YU	.	CTPDG015417
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112004	.	.	Investigative	D0H6OL	.	CTPDG015418
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112001	.	.	Investigative	D0N7OK	.	CTPDG015419
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112024	.	.	Investigative	D0QU6S	.	CTPDG015420
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112020	.	.	Investigative	D0T0XZ	.	CTPDG015421
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111993	.	.	Investigative	D0Y4TS	.	CTPDG015422
M6ACROT05212	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112021	.	.	Investigative	D0Z4RI	.	CTPDG015423
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT05215	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT05216	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05216	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05216	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05217	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05217	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05217	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05220	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Approved	Prasterone	"Dehydroepiandrosterone; DHEA; 53-43-0; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone"	5881	Approved	D0K0EK	DB01708	CTPDG000316
M6ACROT05220	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Phase 3	EPIANDROSTERONE	"481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2"	441302	Phase 3	D0O8FW	.	CTPDG010895
M6ACROT05220	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Discontinued in Phase 2	CBF-BS2	KSB-302	.	Discontinued in Phase 2	D05JCG	.	CTPDG006617
M6ACROT05220	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Investigative	Hydroxyacetic Acid	"glycolic acid; 2-Hydroxyacetic acid; 79-14-1; Glycollic acid; Hydroxyethanoic acid; Acetic acid, hydroxy-; glycolate; Caswell No. 470; alpha-Hydroxyacetic acid; Kyselina glykolova; Kyselina glykolova [Czech]; Kyselina hydroxyoctova; HOCH2COOH; 2-Hydroxyethanoic acid; Kyselina hydroxyoctova [Czech]; Glycocide; EPA Pesticide Chemical Code 000101; GlyPure; HSDB 5227; NSC 166; Acetic acid, 2-hydroxy-; AI3-15362; UNII-0WT12SX38S; GlyPure 70; BRN 1209322; GLYCOLLATE; C2H4O3; Acetic acid, hydroxy-, homopolymer; EINECS 201-"	757	Investigative	D01HNP	DB03085	CTPDG010896
M6ACROT05220	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Investigative	Metazamide	"UNII-T3Y0F5VOB8; 14058-90-3; GPA-878; T3Y0F5VOB8; Metazamidum; 1-(4-methoxyphenyl)-5-methyl-2,3-dihydro-1H-imidazol-2-one; Metazamide [INN]; Metazamid; GPA 878; AC1L1B4L; 3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one; 1-(4-Methoxyphenyl)-5-methyl-4-imidazolin-2-on; ZINC472; SCHEMBL193544; CHEMBL2104723; DTXSID80161441; MolPort-027-352-367; AKOS017548002; 1-(p-Methoxyphenyl)-5-methyl-4-imidazolin-2-one; 4-Imidazolin-2-one, 1-(4-methoxyphenyl)-5-methyl-"	26433	Investigative	D0FF3D	.	CTPDG010897
M6ACROT05220	Glucose-6-phosphate dehydrogenase (G6PD)	G6PD_HUMAN	.	.	Investigative	2'-Monophosphoadenosine 5'-Diphosphoribose	"53-59-8; Cozymase II; Codehydrogenase II; TPN (nucleotide); Codehydrase II; Nadide phosphate; NAD phosphate; EINECS 200-178-1; BRN 3885115; nicotinamide adenine dinucleotide phosphate; CHEBI:44409; beta-NADP; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; beta-TPN; TPN-ox; nadp nicotinamide-adenine-dinucleotide phosphate; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen p"	46936685	Investigative	D0J2FY	.	CTPDG009874
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112000	.	.	Investigative	D00LSM	.	CTPDG015409
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112022	.	.	Investigative	D00SQD	.	CTPDG015410
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112019	.	.	Investigative	D04XOE	.	CTPDG015411
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112005	.	.	Investigative	D06QZK	.	CTPDG015412
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112002	.	.	Investigative	D07FSX	.	CTPDG015413
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112023	.	.	Investigative	D07RUF	.	CTPDG015414
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111992	.	.	Investigative	D0D9OL	.	CTPDG015415
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112003	.	.	Investigative	D0GD1R	.	CTPDG015416
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111997	.	.	Investigative	D0H0YU	.	CTPDG015417
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112004	.	.	Investigative	D0H6OL	.	CTPDG015418
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112001	.	.	Investigative	D0N7OK	.	CTPDG015419
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112024	.	.	Investigative	D0QU6S	.	CTPDG015420
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112020	.	.	Investigative	D0T0XZ	.	CTPDG015421
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111993	.	.	Investigative	D0Y4TS	.	CTPDG015422
M6ACROT05220	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112021	.	.	Investigative	D0Z4RI	.	CTPDG015423
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 2	ADU-S100	MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885	135390762	Phase 2	D0N6VS	.	CTPDG014686
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 2	ADU- S100	.	.	Phase 2	DCIX20	.	CTPDG014687
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 2	MK-1454	.	.	Phase 2	DQ4OU8	.	CTPDG014688
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1/2	IMSA101	.	.	Phase 1/2	DC37YW	.	CTPDG003198
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	BMS-986301	.	.	Phase 1	D2KOX5	.	CTPDG004164
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	MK-2118	.	.	Phase 1	D4JU8H	.	CTPDG004116
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	XMT-2056	.	.	Phase 1	D7AT3H	.	CTPDG004046
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	TAK-500	.	.	Phase 1	D9ICV2	.	CTPDG003998
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	SB 11285	.	.	Phase 1	DA79HM	.	CTPDG003980
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	E7766	.	.	Phase 1	DO7D1L	.	CTPDG003788
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	GSK3745417	.	.	Phase 1	DQ6J0W	.	CTPDG003756
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	A296	.	.	Phase 1	DTV17S	.	CTPDG003710
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	TAK-676	.	.	Phase 1	DTYQ45	.	CTPDG003708
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	SNX281	.	.	Phase 1	DUA7N4	.	CTPDG003703
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Phase 1	SYNB1891	.	.	Phase 1	DUR0F6	.	CTPDG003699
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Investigative	C-178	"329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide"	2866412	Investigative	D7CI5F	.	CTPDG014689
M6ACROT05222	Stimulator of interferon genes protein (STING1)	STING_HUMAN	.	.	Investigative	C-176	314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1	1103958	Investigative	DP2F6W	.	CTPDG014690
M6ACROT05223	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT05223	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT05223	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT05223	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT05224	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT05224	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT05224	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT05224	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT05226	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2a/ATP2A2)	AT2A2_HUMAN	.	.	Phase 2	Mydicar	Mydicar (TN)	.	Phase 2	D01NXF	.	CTPDG014470
M6ACROT05226	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2a/ATP2A2)	AT2A2_HUMAN	.	.	Phase 2	Gallopamil	"16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; GSK 796406"	1234	Phase 2	D00ERV	DB12923	CTPDG003096
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Metastat	.	54678924	Phase 1	D0IJ7O	DB11647	CTPDG009945
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9b)	.	.	Patented	D0A9ZW	.	CTPDG009946
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9a)	.	58107501	Patented	D0LS4Y	.	CTPDG009948
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14)	.	.	Patented	D0O8RQ	.	CTPDG009949
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9c)	.	.	Patented	D0S3PN	.	CTPDG009951
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure11(3)	.	.	Patented	D0Y1LO	.	CTPDG009953
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure10(2a)	.	.	Patented	D05GAP	.	CTPDG009716
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	Discontinued in Phase 3	D01EUF	.	CTPDG006392
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Preclinical	RO-26-2853	.	.	Preclinical	D0C0ME	.	CTPDG007096
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	L-696418	CHEMBL8494; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	Terminated	D08CEE	.	CTPDG009721
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-3644	SCHEMBL609641	9822724	Terminated	D08WBF	.	CTPDG007429
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-1101	CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	Terminated	D05VNG	.	CTPDG009722
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Lithospermic acid	"28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	Investigative	D06ALC	.	CTPDG009954
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SC-74020	CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	Investigative	D08NSS	DB01630	CTPDG009955
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Clinopodic acid C	"CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	Investigative	D0H9BL	.	CTPDG009956
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	Investigative	D0T1FR	.	CTPDG009957
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PD-169469	CHEMBL42420; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	Investigative	D02EFQ	.	CTPDG009959
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; BDBM50180608	44406790	Investigative	D05JPV	.	CTPDG009960
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PNU-107859	"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	Investigative	D0F7BE	DB07390	CTPDG009964
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	Investigative	D0ZB6O	.	CTPDG009968
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT05231	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Approved	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	Approved	D00MDP	DB05100	CTPDG009715
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	Phase 3	D05VZE	DB00786	CTPDG001389
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Metastat	.	54678924	Phase 1	D0IJ7O	DB11647	CTPDG009945
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9b)	.	.	Patented	D0A9ZW	.	CTPDG009946
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9a)	.	58107501	Patented	D0LS4Y	.	CTPDG009948
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14)	.	.	Patented	D0O8RQ	.	CTPDG009949
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure16(9c)	.	.	Patented	D0S3PN	.	CTPDG009951
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure11(3)	.	.	Patented	D0Y1LO	.	CTPDG009953
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure10(2a)	.	.	Patented	D05GAP	.	CTPDG009716
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	Discontinued in Phase 3	D0Q1CD	DB06276	CTPDG006341
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 3	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	Discontinued in Phase 3	D01EUF	.	CTPDG006392
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Preclinical	RO-26-2853	.	.	Preclinical	D0C0ME	.	CTPDG007096
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	L-696418	CHEMBL8494; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	Terminated	D08CEE	.	CTPDG009721
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-3644	SCHEMBL609641	9822724	Terminated	D08WBF	.	CTPDG007429
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	BB-1101	CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	Terminated	D05VNG	.	CTPDG009722
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Lithospermic acid	"28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	Investigative	D06ALC	.	CTPDG009954
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SC-74020	CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	Investigative	D08NSS	DB01630	CTPDG009955
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Clinopodic acid C	"CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	Investigative	D0H9BL	.	CTPDG009956
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	Investigative	D0T1FR	.	CTPDG009957
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PD-169469	CHEMBL42420; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	Investigative	D02EFQ	.	CTPDG009959
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; BDBM50180608	44406790	Investigative	D05JPV	.	CTPDG009960
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	PNU-107859	"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	Investigative	D0F7BE	DB07390	CTPDG009964
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	Investigative	D0ZB6O	.	CTPDG009968
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT05232	72 kDa type IV collagenase (MMP2)	MMP2_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	DP-b99	"343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid"	9810955	Phase 3	D04PWT	.	CTPDG013225
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 1/2	BLZ-100	Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6	121488172	Phase 1/2	D0I8KA	.	CTPDG013226
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(13)	.	.	Patented	D0LP0D	.	CTPDG013227
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(12)	.	.	Patented	D00ZZJ	.	CTPDG013228
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(10)	.	.	Patented	D09ATD	.	CTPDG013229
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(11)	.	.	Patented	D0L6HL	.	CTPDG013230
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Preclinical	DX-2802	.	.	Preclinical	D05VEP	.	CTPDG007131
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	CT-1746	.	9930721	Terminated	D0O7DU	.	CTPDG013231
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"2-Amino-N,3,3-Trimethylbutanamide"	"AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241"	3496445	Investigative	D00CWH	.	CTPDG013232
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	PMID15055993C1a	GTPL6514; BDBM50131385	9910222	Investigative	D03WJG	.	CTPDG013233
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Carboxylated glucosamine	.	44411803	Investigative	D03ZDZ	.	CTPDG013234
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Methotrexate gamma-L-phenylalaninehydroxamic acid	CHEMBL396296	16216218	Investigative	D04PAW	.	CTPDG013235
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Methyl-5-phenyl-pyrimidine-2,4,6-trione"	"Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione"	66160	Investigative	D09GIL	.	CTPDG013236
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	ARP100	ARP 100; ARP-100	10044321	Investigative	D0Q4TA	.	CTPDG013237
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Ro 28-2653	"Ro-28-2653; 261956-22-3; CHEMBL456911; SCHEMBL726759; SCHEMBL8471189; EX-A2614; BDBM50363130; ZINC33975062; Ro28-2653; KB-275261; 5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione"	9832179	Investigative	D0Z4LO	.	CTPDG013238
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	PMID23631440C29e	GTPL8578; BDBM50433865	46175162	Investigative	D07DRT	.	CTPDG013239
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid	644601	Investigative	D03SNK	.	CTPDG013240
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"N-hydroxy-2,3-bis(phenylsulfonamido)propanamide"	CHEMBL496717	24857837	Investigative	D07SPC	.	CTPDG013241
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729	651854	Investigative	D0V9GS	.	CTPDG013242
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	SL422	analogue 55f [PMID: 11472217]	10344307	Investigative	D07GEL	.	CTPDG013243
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT05233	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	DP-b99	"343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid"	9810955	Phase 3	D04PWT	.	CTPDG013225
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	GS-5745	.	56776542	Phase 3	D0WL0Q	.	CTPDG001005
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	Andecaliximab	.	.	Phase 3	D0Z6SP	.	CTPDG000963
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 1/2	BLZ-100	Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6	121488172	Phase 1/2	D0I8KA	.	CTPDG013226
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Phase 1	Neovastat	.	.	Phase 1	D0T4BL	.	CTPDG004408
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(13)	.	.	Patented	D0LP0D	.	CTPDG013227
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(12)	.	.	Patented	D00ZZJ	.	CTPDG013228
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(10)	.	.	Patented	D09ATD	.	CTPDG013229
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-SB-3CT	.	.	Patented	D0DB0Z	.	CTPDG009947
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure17(11)	.	.	Patented	D0L6HL	.	CTPDG013230
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure13(4)	.	.	Patented	D0Q4QB	.	CTPDG009950
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-LonimacranthoideVII	.	.	Patented	D0W7HO	.	CTPDG009952
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Patented	PMID29130358-Compound-Figure18(14a)	.	.	Patented	D0X6GG	.	CTPDG009717
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Discontinued in Phase 2	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	Discontinued in Phase 2	D05WTZ	.	CTPDG006611
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Discontinued in Phase 2	RS-130830	CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	Discontinued in Phase 2	D03BOZ	DB08490	CTPDG009719
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Preclinical	DX-2802	.	.	Preclinical	D05VEP	.	CTPDG007131
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	CT-1746	.	9930721	Terminated	D0O7DU	.	CTPDG013231
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	CDP-845	.	.	Terminated	D02GYD	.	CTPDG007554
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	Terminated	D0E5GY	.	CTPDG007368
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Terminated	SC-44463	"CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	Terminated	D0Y1XT	DB07926	CTPDG009723
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"2-Amino-N,3,3-Trimethylbutanamide"	"AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241"	3496445	Investigative	D00CWH	.	CTPDG013232
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	PMID15055993C1a	GTPL6514; BDBM50131385	9910222	Investigative	D03WJG	.	CTPDG013233
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Carboxylated glucosamine	.	44411803	Investigative	D03ZDZ	.	CTPDG013234
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Methotrexate gamma-L-phenylalaninehydroxamic acid	CHEMBL396296	16216218	Investigative	D04PAW	.	CTPDG013235
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Methyl-5-phenyl-pyrimidine-2,4,6-trione"	"Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione"	66160	Investigative	D09GIL	.	CTPDG013236
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	ARP100	ARP 100; ARP-100	10044321	Investigative	D0Q4TA	.	CTPDG013237
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Ro 28-2653	"Ro-28-2653; 261956-22-3; CHEMBL456911; SCHEMBL726759; SCHEMBL8471189; EX-A2614; BDBM50363130; ZINC33975062; Ro28-2653; KB-275261; 5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione"	9832179	Investigative	D0Z4LO	.	CTPDG013238
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879	44428667	Investigative	D01HKU	.	CTPDG009958
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	PMID23631440C29e	GTPL8578; BDBM50433865	46175162	Investigative	D07DRT	.	CTPDG013239
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	Investigative	D07LTB	.	CTPDG009961
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Methotrexate gamma-hydroxamic acid	CHEMBL244883	44428664	Investigative	D0B0UI	.	CTPDG009962
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	Investigative	D0E5MB	.	CTPDG009963
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	Investigative	D0K4TI	.	CTPDG009965
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	CHEMBL175282; BDBM50099116	44385624	Investigative	D0Q9LC	.	CTPDG009966
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Roche 28-2653	.	56603788	Investigative	D0U7CD	.	CTPDG009967
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	Investigative	D00RNA	.	CTPDG009969
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid	644601	Investigative	D03SNK	.	CTPDG013240
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"N-hydroxy-2,3-bis(phenylsulfonamido)propanamide"	CHEMBL496717	24857837	Investigative	D07SPC	.	CTPDG013241
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990	44446277	Investigative	D08ICI	.	CTPDG009970
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	3-(4-Phenylethynylbenzoyl)nonanoic acid	CHEMBL201298	11581319	Investigative	D0A5MV	.	CTPDG009971
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Folate gamma-hydroxamic acid	.	136177317	Investigative	D0P8EY	.	CTPDG009972
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729	651854	Investigative	D0V9GS	.	CTPDG013242
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	Investigative	D0Y7NV	.	CTPDG009973
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid	11391583	Investigative	D0G3YZ	.	CTPDG009974
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875	11609208	Investigative	D0L4EO	.	CTPDG009975
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	Ro-37-9790	CHEMBL306412; BDBM50290086	44313734	Investigative	D0XL8K	.	CTPDG009743
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	SL422	analogue 55f [PMID: 11472217]	10344307	Investigative	D07GEL	.	CTPDG013243
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT05234	Matrix metalloproteinase-9 (MMP9)	MMP9_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif2	.	.	Patented	D03EML	.	CTPDG014817
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif1	.	.	Patented	D0PT1W	.	CTPDG014818
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-03	.	.	Preclinical	D0AN9V	.	CTPDG007097
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P22077	"1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone"	46931953	Preclinical	D2K6DU	.	CTPDG014819
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	HBX19818	"HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F"	73349008	Preclinical	DA0OZ2	.	CTPDG006994
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-01	.	.	Preclinical	DRJU35	.	CTPDG006972
M6ACROT05235	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P5091	"882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one"	2819993	Preclinical	DV3KC5	.	CTPDG006966
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif2	.	.	Patented	D03EML	.	CTPDG014817
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif1	.	.	Patented	D0PT1W	.	CTPDG014818
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-03	.	.	Preclinical	D0AN9V	.	CTPDG007097
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P22077	"1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone"	46931953	Preclinical	D2K6DU	.	CTPDG014819
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	HBX19818	"HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F"	73349008	Preclinical	DA0OZ2	.	CTPDG006994
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-01	.	.	Preclinical	DRJU35	.	CTPDG006972
M6ACROT05236	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P5091	"882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one"	2819993	Preclinical	DV3KC5	.	CTPDG006966
M6ACROT05237	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05237	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05237	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05238	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT05238	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT05238	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT05238	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT05238	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT05238	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MEDI4736	.	.	Phase 3	D04RRZ	.	CTPDG001416
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	KN046	.	.	Phase 3	DLOQ25	.	CTPDG012817
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	KN035	Envafolimab	.	Phase 2	D0GF2R	.	CTPDG002356
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	CX-072	.	.	Phase 2	D0Z2BO	.	CTPDG001867
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	INCB86550	.	.	Phase 2	DKM79E	.	CTPDG001693
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	M7824	.	.	Phase 2	D05FPZ	.	CTPDG002813
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	BGB-A333	.	.	Phase 1/2	DC5VW9	.	CTPDG003195
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	Phase 1/2	DS6VD0	.	CTPDG003143
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3300054	.	.	Phase 1	D08HSS	.	CTPDG005054
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MSB2311	.	.	Phase 1	D0A8AU	.	CTPDG004941
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1	BMS-936559	.	Phase 1	D0KP9A	.	CTPDG004646
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FAZ053	.	.	Phase 1	D0LU1O	.	CTPDG004609
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1 CSR T cells	.	.	Phase 1	D0W7UD	.	CTPDG012818
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	BMS-986189	.	.	Phase 1	D0X1GN	.	CTPDG012819
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	.	.	Phase 1	D2Z6WF	.	CTPDG004150
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PD-L1 t-haNK	.	.	Phase 1	DH42RF	.	CTPDG003899
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	KD033	.	.	Phase 1	DJVR06	.	CTPDG003860
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	Phase 1	D09PPU	.	CTPDG004985
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FS118	.	.	Phase 1	D0XO9F	.	CTPDG004272
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MCLA-145	.	.	Phase 1	D2QY0Z	.	CTPDG004156
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	GEN1046	.	.	Phase 1	D3HBJ1	.	CTPDG004139
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	ALPN-202	.	.	Phase 1	D82UVG	.	CTPDG004022
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	TAK-252	SL-279252	.	Phase 1	D9SL1N	.	CTPDG003989
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	INBRX-105	.	.	Phase 1	DA1X5W	.	CTPDG003983
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3415244	.	.	Phase 1	DC8HR6	.	CTPDG003954
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	A337	.	.	Phase 1	DL97UQ	.	CTPDG003833
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example2	.	117941742	Patented	D0OK1S	.	CTPDG005729
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example1	.	117951478	Patented	D0WQ9X	.	CTPDG005575
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure7	PMID30247903Compound7	.	Investigative	D01TGF	.	CTPDG012820
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	CA-327	.	.	Investigative	D04ILU	.	CTPDG012821
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure8	PMID30247903Compound8	.	Investigative	D04QGF	.	CTPDG012822
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure5	PMID30247903Compound5	.	Investigative	D07BOF	.	CTPDG012823
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure12	PMID30247903Compound12	.	Investigative	D09BYN	.	CTPDG012824
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure9	PMID30247903Compound9	.	Investigative	D0GG6N	.	CTPDG012825
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure6	PMID30247903Compound6	.	Investigative	D0TN4F	.	CTPDG012826
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure10	PMID30247903Compound10	.	Investigative	D0XL3N	.	CTPDG012827
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH011	.	.	Investigative	DA91UG	.	CTPDG007607
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH010	.	.	Investigative	DBTI39	.	CTPDG007604
M6ACROT05239	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	RG6084	.	.	Phase 1	DJX7K9	.	CTPDG014810
M6ACROT05242	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT05242	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT05242	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT05242	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT05242	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT05242	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 3	Talabostat	"Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro"	6918572	Phase 3	D0FQ2U	DB06182	CTPDG014274
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 2	BIBH 1	.	.	Phase 2	D0N7LA	.	CTPDG002164
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 1	RG7461	.	.	Phase 1	D0V7GS	.	CTPDG004345
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 1	AMG 506	.	.	Phase 1	DN2F9A	.	CTPDG003812
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Preclinical	FAP5-DM1	.	.	Preclinical	DO7HS1	.	CTPDG006977
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Preclinical	PT630	.	.	Preclinical	D7K0GP	.	CTPDG010998
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	MIP-1231	"MIP-1232; MIP-1233; MIP-1259; MIP-1260; MIP-1271; MIP-1272; Seprase inhibitors (cancer, imaging); Iodine-131-MIP-1232; Seprase inhibitors (cancer, imaging), Molecular Insight; FAP-alpha antagonists (cancer, imaging), Molecular Insight; Fibroblast-activating protein antagonists (cancer, imaging), Molecular Insight"	.	Investigative	D01HTS	.	CTPDG009107
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	FE-999040	"FAP inhibitors, Vantia; Fibroblast activation protein inhibitors (sc/oral, cancer/pulmonary fibrosis/IBD), Vantia"	.	Investigative	D0A9WW	.	CTPDG008477
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	VA-119930	"Fibroblast activation protein inhibitors (IBD), Vantia; Seprase inhibitor (IBD), Vantia"	.	Investigative	D0M9SD	.	CTPDG014275
M6ACROT05244	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	ARI-3099	compound 6 [PMID: 23594271]; compound 226 [PMID: 24997602]; Py(D)AlaboroPro	71655266	Investigative	D03DNV	.	CTPDG014276
M6ACROT05248	Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA)	SHPS1_HUMAN	.	.	Phase 1	FSI-189	.	.	Phase 1	DJ29KW	.	CTPDG014803
M6ACROT05248	Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA)	SHPS1_HUMAN	.	.	Phase 1	CC-95251	.	.	Phase 1	DKL3Z7	.	CTPDG003842
M6ACROT05248	Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA)	SHPS1_HUMAN	.	.	Phase 1	BI 765063	OSE-172	.	Phase 1	DZBV67	.	CTPDG003645
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif2	.	.	Patented	D03EML	.	CTPDG014817
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif1	.	.	Patented	D0PT1W	.	CTPDG014818
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-03	.	.	Preclinical	D0AN9V	.	CTPDG007097
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P22077	"1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone"	46931953	Preclinical	D2K6DU	.	CTPDG014819
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	HBX19818	"HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F"	73349008	Preclinical	DA0OZ2	.	CTPDG006994
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-01	.	.	Preclinical	DRJU35	.	CTPDG006972
M6ACROT05249	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P5091	"882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one"	2819993	Preclinical	DV3KC5	.	CTPDG006966
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif2	.	.	Patented	D03EML	.	CTPDG014817
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Patented	PMID26077642-Compound-Vif1	.	.	Patented	D0PT1W	.	CTPDG014818
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-03	.	.	Preclinical	D0AN9V	.	CTPDG007097
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P22077	"1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone"	46931953	Preclinical	D2K6DU	.	CTPDG014819
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	HBX19818	"HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F"	73349008	Preclinical	DA0OZ2	.	CTPDG006994
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	ADC-01	.	.	Preclinical	DRJU35	.	CTPDG006972
M6ACROT05250	Ubiquitin carboxyl-terminal hydrolase 7 (USP7)	UBP7_HUMAN	.	.	Preclinical	P5091	"882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one"	2819993	Preclinical	DV3KC5	.	CTPDG006966
M6ACROT05251	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05251	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05251	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05252	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT05252	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT05252	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT05252	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT05252	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT05252	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MEDI4736	.	.	Phase 3	D04RRZ	.	CTPDG001416
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	KN046	.	.	Phase 3	DLOQ25	.	CTPDG012817
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	KN035	Envafolimab	.	Phase 2	D0GF2R	.	CTPDG002356
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	CX-072	.	.	Phase 2	D0Z2BO	.	CTPDG001867
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	INCB86550	.	.	Phase 2	DKM79E	.	CTPDG001693
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	M7824	.	.	Phase 2	D05FPZ	.	CTPDG002813
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	BGB-A333	.	.	Phase 1/2	DC5VW9	.	CTPDG003195
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	Phase 1/2	DS6VD0	.	CTPDG003143
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3300054	.	.	Phase 1	D08HSS	.	CTPDG005054
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MSB2311	.	.	Phase 1	D0A8AU	.	CTPDG004941
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1	BMS-936559	.	Phase 1	D0KP9A	.	CTPDG004646
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FAZ053	.	.	Phase 1	D0LU1O	.	CTPDG004609
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1 CSR T cells	.	.	Phase 1	D0W7UD	.	CTPDG012818
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	BMS-986189	.	.	Phase 1	D0X1GN	.	CTPDG012819
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	.	.	Phase 1	D2Z6WF	.	CTPDG004150
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PD-L1 t-haNK	.	.	Phase 1	DH42RF	.	CTPDG003899
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	KD033	.	.	Phase 1	DJVR06	.	CTPDG003860
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	Phase 1	D09PPU	.	CTPDG004985
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FS118	.	.	Phase 1	D0XO9F	.	CTPDG004272
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MCLA-145	.	.	Phase 1	D2QY0Z	.	CTPDG004156
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	GEN1046	.	.	Phase 1	D3HBJ1	.	CTPDG004139
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	ALPN-202	.	.	Phase 1	D82UVG	.	CTPDG004022
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	TAK-252	SL-279252	.	Phase 1	D9SL1N	.	CTPDG003989
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	INBRX-105	.	.	Phase 1	DA1X5W	.	CTPDG003983
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3415244	.	.	Phase 1	DC8HR6	.	CTPDG003954
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	A337	.	.	Phase 1	DL97UQ	.	CTPDG003833
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example2	.	117941742	Patented	D0OK1S	.	CTPDG005729
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example1	.	117951478	Patented	D0WQ9X	.	CTPDG005575
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure7	PMID30247903Compound7	.	Investigative	D01TGF	.	CTPDG012820
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	CA-327	.	.	Investigative	D04ILU	.	CTPDG012821
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure8	PMID30247903Compound8	.	Investigative	D04QGF	.	CTPDG012822
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure5	PMID30247903Compound5	.	Investigative	D07BOF	.	CTPDG012823
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure12	PMID30247903Compound12	.	Investigative	D09BYN	.	CTPDG012824
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure9	PMID30247903Compound9	.	Investigative	D0GG6N	.	CTPDG012825
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure6	PMID30247903Compound6	.	Investigative	D0TN4F	.	CTPDG012826
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure10	PMID30247903Compound10	.	Investigative	D0XL3N	.	CTPDG012827
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH011	.	.	Investigative	DA91UG	.	CTPDG007607
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH010	.	.	Investigative	DBTI39	.	CTPDG007604
M6ACROT05253	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	RG6084	.	.	Phase 1	DJX7K9	.	CTPDG014810
M6ACROT05256	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT05256	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT05256	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT05256	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT05256	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT05256	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 3	Talabostat	"Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro"	6918572	Phase 3	D0FQ2U	DB06182	CTPDG014274
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 2	BIBH 1	.	.	Phase 2	D0N7LA	.	CTPDG002164
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 2	Sibrotuzumab	.	.	Phase 2	DVX3H0	.	CTPDG001622
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 1	RG7461	.	.	Phase 1	D0V7GS	.	CTPDG004345
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 1	AMG 506	.	.	Phase 1	DN2F9A	.	CTPDG003812
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Phase 1	NG-641	.	.	Phase 1	D1A8NU	.	CTPDG004198
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Preclinical	FAP5-DM1	.	.	Preclinical	DO7HS1	.	CTPDG006977
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Preclinical	PT630	.	.	Preclinical	D7K0GP	.	CTPDG010998
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	MIP-1231	"MIP-1232; MIP-1233; MIP-1259; MIP-1260; MIP-1271; MIP-1272; Seprase inhibitors (cancer, imaging); Iodine-131-MIP-1232; Seprase inhibitors (cancer, imaging), Molecular Insight; FAP-alpha antagonists (cancer, imaging), Molecular Insight; Fibroblast-activating protein antagonists (cancer, imaging), Molecular Insight"	.	Investigative	D01HTS	.	CTPDG009107
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	FE-999040	"FAP inhibitors, Vantia; Fibroblast activation protein inhibitors (sc/oral, cancer/pulmonary fibrosis/IBD), Vantia"	.	Investigative	D0A9WW	.	CTPDG008477
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	VA-119930	"Fibroblast activation protein inhibitors (IBD), Vantia; Seprase inhibitor (IBD), Vantia"	.	Investigative	D0M9SD	.	CTPDG014275
M6ACROT05258	Prolyl endopeptidase FAP (FAP)	SEPR_HUMAN	.	.	Investigative	ARI-3099	compound 6 [PMID: 23594271]; compound 226 [PMID: 24997602]; Py(D)AlaboroPro	71655266	Investigative	D03DNV	.	CTPDG014276
M6ACROT05262	Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA)	SHPS1_HUMAN	.	.	Phase 1	FSI-189	.	.	Phase 1	DJ29KW	.	CTPDG014803
M6ACROT05262	Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA)	SHPS1_HUMAN	.	.	Phase 1	CC-95251	.	.	Phase 1	DKL3Z7	.	CTPDG003842
M6ACROT05262	Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA)	SHPS1_HUMAN	.	.	Phase 1	BI 765063	OSE-172	.	Phase 1	DZBV67	.	CTPDG003645
M6ACROT05266	High mobility group protein B1 (HMGB1)	HMGB1_HUMAN	.	.	Investigative	2-Sulfhydryl-Ethanol	"beta-Mercaptoethanol; 2-mercaptoethanol; 60-24-2; Thioglycol; Mercaptoethanol; Ethanol, 2-mercapto-; 2-Sulfanylethanol; 2-Thioethanol; Thioethylene glycol; 2-Hydroxyethanethiol; 2-Hydroxyethyl mercaptan; 2-Hydroxy-1-ethanethiol; Thiomonoglycol; Monothioglycol; 2-Mercapto-1-ethanol; 1-Ethanol-2-thiol; Hydroxyethyl mercaptan; Monothioethylene glycol; 2-Mercaptoethyl alcohol; 2-ME; Mercaptoetanol; Ethylene glycol, monothio-; 1-Hydroxy-2-mercaptoethane; 1-Mercapto-2-hydroxyethane; 2-Hydroxyethylmercaptan; Emery 5791; USAF EK-4196"	1567	Investigative	D0Q5FV	DB03345	CTPDG012420
M6ACROT05267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT05267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT05267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT05267	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT05273	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2/3	AMO-02	.	.	Phase 2/3	D0BS5E	.	CTPDG013264
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	Phase 2	D0UT7X	DB12129	CTPDG001972
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	Phase 2	D4USX5	.	CTPDG013265
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	Phase 2	D0Z1DH	DB11913	CTPDG001868
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 2	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Phase 2	D5MF8Y	.	CTPDG013266
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Phase 1/2	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	Phase 1/2	D0D1UQ	.	CTPDG013267
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	TDZD-8	"327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8"	4124851	Patented	D06KNK	.	CTPDG013268
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	AR-A014418	"487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be"	448014	Patented	D0A3MV	DB01950	CTPDG006047
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	PMID26161698-Compound-18	.	136273305	Patented	D0F7DS	.	CTPDG013269
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	CHIR-99021	CHIR99021; CHIR 99021; CT-99021; CT99021	9956119	Patented	D0YK9D	.	CTPDG013270
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Patented	KENPAULLONE	"142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one"	3820	Patented	D00PWQ	.	CTPDG013271
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Discontinued in Phase 1	AZD-1080	.	135564570	Discontinued in Phase 1	D0MC0O	.	CTPDG006779
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	Terminated	D07YNH	.	CTPDG007448
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717	23643731	Investigative	D00AAN	.	CTPDG013272
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	Investigative	D00HUP	.	CTPDG013273
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476	49863103	Investigative	D00XUF	.	CTPDG013274
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	Investigative	D01IPF	.	CTPDG013275
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	Investigative	D01MEP	.	CTPDG013276
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	Investigative	D01OJG	.	CTPDG013277
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128	23643732	Investigative	D01RKI	.	CTPDG013278
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	Investigative	D02OPH	DB01793	CTPDG013279
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	Investigative	D02ZIY	.	CTPDG013280
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine E	.	6474830	Investigative	D03GQF	.	CTPDG013281
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	Investigative	D03OED	.	CTPDG013282
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	Investigative	D04ACJ	.	CTPDG013283
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	Investigative	D04VBD	.	CTPDG013284
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Manzamine Y	"CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	Investigative	D05GIC	.	CTPDG013285
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	IM-12	"1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	Investigative	D05SXF	.	CTPDG013286
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; SCHEMBL6489338	22319484	Investigative	D06YMZ	.	CTPDG013287
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; SCHEMBL6490520	10266409	Investigative	D07IVD	.	CTPDG013288
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"(2'Z,3'E)-7-Azaindirubin-3'-oxime"	.	44614397	Investigative	D07MZD	.	CTPDG013289
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; SCHEMBL4493121	10085013	Investigative	D07PTD	.	CTPDG013290
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Neo-kauluamine	.	44448144	Investigative	D09AEV	.	CTPDG013291
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176	22319483	Investigative	D09BQY	.	CTPDG013292
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	Investigative	D09ITI	.	CTPDG013293
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	6-deoxymanzamine X	.	44445400	Investigative	D09RYG	.	CTPDG013294
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	Investigative	D0A9MY	.	CTPDG013295
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	Investigative	D0C9OT	.	CTPDG013296
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PAULLONE	"142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	Investigative	D0D5ZL	.	CTPDG013297
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	CHEMBL252520	23643836	Investigative	D0E2XM	.	CTPDG013298
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	Investigative	D0E6GC	.	CTPDG013299
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	Investigative	D0F5EI	.	CTPDG013300
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-METHYL-8-METHOXY-MANZAMINE A	.	23643639	Investigative	D0I3US	.	CTPDG013301
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	Investigative	D0IL0G	.	CTPDG013302
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	Investigative	D0M3SC	.	CTPDG013303
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"12,13-DEHYDROMANZAMINE A"	CHEMBL268202	23643835	Investigative	D0NL1F	.	CTPDG013304
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	Investigative	D0Q3KS	.	CTPDG013305
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	Investigative	D0R5EF	.	CTPDG013306
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	Investigative	D0R6TL	.	CTPDG013307
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	9-N-ETHYL-8-ETHOXY-MANZAMINE A	CHEMBL403562	23643537	Investigative	D0R7QL	.	CTPDG013308
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	Investigative	D0S3RP	.	CTPDG013309
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	Investigative	D0T1CE	.	CTPDG013310
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	Investigative	D0T8CQ	.	CTPDG013311
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; BDBM50322829	46894038	Investigative	D0V6HG	.	CTPDG013312
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	Investigative	D0WN1N	.	CTPDG007741
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98023	CT-98014	9847557	Investigative	D0X4CO	.	CTPDG013313
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	Investigative	D0X4KR	.	CTPDG013314
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	Investigative	D0YM4A	.	CTPDG013315
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CHIR-98014	CHIR98014; CHIR 98014	53396311	Investigative	D04ZWF	.	CTPDG013316
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	Investigative	D05NKG	.	CTPDG013317
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	indirubin deriv. 8a	.	135398521	Investigative	D0B3ZB	.	CTPDG013318
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	LEUCETTAMINE B	CHEMBL485053; SCHEMBL13219029	10037501	Investigative	D0K1DR	.	CTPDG013319
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	SB-415286	"SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	Investigative	D0N4WB	.	CTPDG013320
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	MANZAMINE A	104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	Investigative	D0Q4QF	.	CTPDG013321
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	Investigative	D0Q7TO	DB08454	CTPDG013322
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Quinoxaline1	.	438981	Investigative	D0R5FH	.	CTPDG013323
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	Investigative	D04QCF	.	CTPDG013325
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	Investigative	D0DR8N	.	CTPDG013326
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Thieno analogue of kenpaullone	"Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	Investigative	D0TF9P	.	CTPDG013327
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	L-779450	"303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	Investigative	D06WJA	.	CTPDG013328
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	STAUROSPORINONE	.	.	Investigative	D0GB4V	.	CTPDG011475
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	CI-1040	.	6918454	Investigative	D0B9BU	DB12429	CTPDG011478
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	Investigative	D0O1YH	DB04462	CTPDG011479
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05278	Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)	GSK3B_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Phase 2	Stannsoporfin	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)	23725028	Phase 2	D02JAY	.	CTPDG014087
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	2-Phenylheme	.	17753777	Investigative	D02AVZ	DB03906	CTPDG014088
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Biliverdine Ix Alpha	"biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2"	5280353	Investigative	D06SCF	DB02073	CTPDG014089
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Verdoheme	.	11963948	Investigative	D06UNX	.	CTPDG014090
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Tin protoporphyrin	"AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid"	24197550	Investigative	D0HX0D	.	CTPDG014091
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride	20541332	Investigative	D0K1NM	DB07342	CTPDG014092
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	12-Phenylheme	.	5287448	Investigative	D0S8UN	.	CTPDG014093
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand"	3776	Investigative	D0W7LK	DB02325	CTPDG011331
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Formic Acid	"formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235"	284	Investigative	D06EWG	DB01942	CTPDG014094
M6ACROT05279	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Phase 2	Stannsoporfin	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)	23725028	Phase 2	D02JAY	.	CTPDG014087
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	2-Phenylheme	.	17753777	Investigative	D02AVZ	DB03906	CTPDG014088
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Biliverdine Ix Alpha	"biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2"	5280353	Investigative	D06SCF	DB02073	CTPDG014089
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Verdoheme	.	11963948	Investigative	D06UNX	.	CTPDG014090
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Tin protoporphyrin	"AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid"	24197550	Investigative	D0HX0D	.	CTPDG014091
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride	20541332	Investigative	D0K1NM	DB07342	CTPDG014092
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	12-Phenylheme	.	5287448	Investigative	D0S8UN	.	CTPDG014093
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand"	3776	Investigative	D0W7LK	DB02325	CTPDG011331
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Formic Acid	"formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235"	284	Investigative	D06EWG	DB01942	CTPDG014094
M6ACROT05280	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05282	Bone morphogenetic protein 2 (BMP2)	BMP2_HUMAN	.	.	Phase 3	DWP-431	"Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong"	.	Phase 3	D03HDV	.	CTPDG014663
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Approved	Teprotumumab	RV001	.	Approved	D0EN0W	.	CTPDG010641
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Approved	Mecasermin	Increlex (TN)	.	Approved	D0F3JT	.	CTPDG010642
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Approved	Somatomedin-1	Igef (TN)	.	Approved	D0N3NZ	.	CTPDG010643
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 3	OSI-906	"Linsitinib; 867160-71-2; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/"	11640390	Phase 3	D01GFX	DB06075	CTPDG001489
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2/3	Rinfabate	"RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed"	.	Phase 2/3	D06APK	.	CTPDG001567
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	AMG 479	.	.	Phase 2	D00AKR	.	CTPDG010644
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	VPI-2690B	.	.	Phase 2	D00VKK	.	CTPDG010645
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	AXL-1717	"BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum"	72435	Phase 2	D01SJS	DB12802	CTPDG003015
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	R1507	.	5376617	Phase 2	D03BHM	.	CTPDG010646
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	Cixutumumab	LY3012217	.	Phase 2	D0E5DP	.	CTPDG002426
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 2	MM-141	.	.	Phase 2	D00BUO	.	CTPDG003106
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	Cyclolignan picropodophyllin	"PPP; IGF-1R inhibitor (cancer), Karolinska"	.	Phase 1	D01OYS	.	CTPDG010647
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	RG-7010	"R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche"	.	Phase 1	D03WNN	.	CTPDG005284
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	HF-0299	.	.	Phase 1	D0L1ZM	.	CTPDG010648
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	BIIB 022	.	.	Phase 1	D0O7QQ	.	CTPDG010649
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	FPI-1434	.	.	Phase 1	D4JYH3	.	CTPDG004114
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Phase 1	SAR446159	.	.	Phase 1	D10KTZ	.	CTPDG010650
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Discontinued in Phase 2	AVE-1642	"EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis"	.	Discontinued in Phase 2	D00BPE	.	CTPDG010651
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Discontinued in Phase 1/2	KW-2450	.	56847547	Discontinued in Phase 1/2	D0M3OR	.	CTPDG009931
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Discontinued in Phase 1	Figitumumab	"AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid"	.	Discontinued in Phase 1	D0U6KH	.	CTPDG006735
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Preclinical	BMS-695735	.	135441202	Preclinical	D0LF0O	.	CTPDG007066
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	NVP-ADW742	"475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	Investigative	D06NMZ	.	CTPDG008744
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	JB-1	JB1	25150849	Investigative	D0O0RY	.	CTPDG008020
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	"4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240677; BDBM50326006	43680262	Investigative	D0L7MM	.	CTPDG009939
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	"4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240676; BDBM50326004	43743432	Investigative	D0W9KO	.	CTPDG009940
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine"	33113	Investigative	D00ICA	.	CTPDG010652
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	Investigative	D0G6XS	.	CTPDG010555
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	Alpha-D-Mannose	"alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/"	185698	Investigative	D07LUR	.	CTPDG010653
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Preclinical	ATL-1101	.	.	Preclinical	D01QKD	.	CTPDG007152
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	AG 1024	tyrphostin AG 1024; AG-1024; AG1024	2044	Investigative	D01ODR	.	CTPDG015333
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	PQ401	PQ 401; IGF-1R inhibitor II; PQ-401	9549305	Investigative	D0B4SU	.	CTPDG015334
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	GSK1511931	GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]	44581765	Investigative	D0E4LC	.	CTPDG015335
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	AZD3463	AZD-3463; CS-1382; HY-15609; KB-154896	56599293	Investigative	D0O7LU	.	CTPDG015336
M6ACROT05294	Insulin-like growth factor 1 receptor (IGF1R)	IGF1R_HUMAN	.	.	Investigative	GSK-1838705A	GSK 1838705A; GSK1838705A	25182616	Investigative	D06PJW	.	CTPDG009943
M6ACROT05300	Fibronectin (FN1)	FINC_HUMAN	.	.	Approved	Ocriplasmin	.	.	Approved	D0Y7XG	.	CTPDG014046
M6ACROT05300	Fibronectin (FN1)	FINC_HUMAN	.	.	Phase 2	L19-TNF-alpha	Fibromun	.	Phase 2	D0GZ3A	.	CTPDG014047
M6ACROT05303	Ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5)	UCHL5_HUMAN	.	.	Patented	PMID26077642-Compound-Figure3A	.	.	Patented	D0A8EN	.	CTPDG014814
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112000	.	.	Investigative	D00LSM	.	CTPDG015409
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112022	.	.	Investigative	D00SQD	.	CTPDG015410
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112019	.	.	Investigative	D04XOE	.	CTPDG015411
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112005	.	.	Investigative	D06QZK	.	CTPDG015412
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112002	.	.	Investigative	D07FSX	.	CTPDG015413
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112023	.	.	Investigative	D07RUF	.	CTPDG015414
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111992	.	.	Investigative	D0D9OL	.	CTPDG015415
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112003	.	.	Investigative	D0GD1R	.	CTPDG015416
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111997	.	.	Investigative	D0H0YU	.	CTPDG015417
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112004	.	.	Investigative	D0H6OL	.	CTPDG015418
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112001	.	.	Investigative	D0N7OK	.	CTPDG015419
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112024	.	.	Investigative	D0QU6S	.	CTPDG015420
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112020	.	.	Investigative	D0T0XZ	.	CTPDG015421
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111993	.	.	Investigative	D0Y4TS	.	CTPDG015422
M6ACROT05303	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112021	.	.	Investigative	D0Z4RI	.	CTPDG015423
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Phase 1	EDP-322	"EP-16322; Antibacterial (oral, Gram-positive infections), Enanta; EDP-MRSA-1 (oral), Enanta"	.	Phase 1	D09LSY	.	CTPDG013137
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Phase 1	W-198	5-Bromotetrandrine	9831563	Phase 1	D0GS2W	.	CTPDG004760
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Application submitted	CBT-1	.	.	Application submitted	D06XVF	.	CTPDG006377
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 3	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	Discontinued in Phase 3	D06DCL	.	CTPDG006379
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 2	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	Discontinued in Phase 2	D02VJY	DB04851	CTPDG006649
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 2	Tariquidar	"Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide"	148201	Discontinued in Phase 2	D04RLX	DB06240	CTPDG013139
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 2	S-9788	"S9788; S 9788; CHEMBL85156; 140945-01-3; 6-(4-(2,2-di(4-Fluorophenyl)ethylamino)-1-piperidinyl)-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine; 1,3,5-Triazine-2,4-diamine, 6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)-1-piperidinyl)-N,N'-di-2-propenyl-; AC1L32YH; SCHEMBL1527824; DTXSID80161502; GERNFWKTMKWULM-UHFFFAOYSA-N; BDBM50053888; LS-187603; LS-186957; N,N''-Diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine; H2O"	107903	Discontinued in Phase 2	D0CO2M	.	CTPDG006540
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 1	XR-9051	"Multidrug resistance inhibitor, Xenova"	9917447	Discontinued in Phase 1	D01GDH	.	CTPDG006929
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 1	Elacridar	"Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro"	119373	Discontinued in Phase 1	D09FGX	DB04881	CTPDG006855
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Discontinued in Phase 1	ONT-093	"MDR inhibitors, Ontogen; OC-144-093"	6450807	Discontinued in Phase 1	D0SR4G	DB14069	CTPDG006741
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	"6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol"	CHEMBL362997; BDBM50186758	11536458	Investigative	D05XGZ	.	CTPDG013140
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	"[1,1':2',1'']-terphenyl-4,3'',5''-triol"	CHEMBL208098; BDBM50186757; ZINC35856323	11579996	Investigative	D03PLP	.	CTPDG013141
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	XR-9456	CHEMBL346292; SCHEMBL7170174; BDBM50375810	15511439	Investigative	D04GYT	.	CTPDG011125
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	XR-9504	CHEMBL258896; SCHEMBL7168501	22004473	Investigative	D09HIM	.	CTPDG011126
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	XR-9544	CHEMBL444075; SCHEMBL14290581; BDBM50375811	15511440	Investigative	D0A4TF	.	CTPDG011127
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	"4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl"	CHEMBL379687; BDBM50186763	11537051	Investigative	D0AW4W	.	CTPDG013142
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	XR-9577	CHEMBL428402	15950351	Investigative	D0S8CE	.	CTPDG011128
M6ACROT05307	ATP-dependent translocase ABCB1 (ABCB1)	MDR1_HUMAN	.	.	Investigative	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	Investigative	D0O9NE	.	CTPDG013143
M6ACROT05310	Cyclin-dependent kinase 19 (CDK19)	CDK19_HUMAN	.	.	Phase 1	SEL120	"SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride"	73776232	Phase 1	DOJG79	.	CTPDG003781
M6ACROT05311	Cystine/glutamate transporter (SLC7A11)	XCT_HUMAN	.	.	Phase 2	SXC-2023	.	.	Phase 2	D1KO3P	.	CTPDG014801
M6ACROT05314	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05314	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 1	TP-1454	.	.	Phase 1	DLN0P8	.	CTPDG003830
M6ACROT05315	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05316	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05316	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 1	TP-1454	.	.	Phase 1	DLN0P8	.	CTPDG003830
M6ACROT05317	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05319	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05319	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05319	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05320	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05320	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05320	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05322	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 2a	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	Phase 2a	D09EFC	DB12088	CTPDG001589
M6ACROT05322	Pyruvate kinase PKM (PKM2/PKM)	KPYM_HUMAN	.	.	Phase 1	TP-1454	.	.	Phase 1	DLN0P8	.	CTPDG003830
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT05323	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT05324	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Approved	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	Approved	D05QDC	DB00459	CTPDG000625
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 3	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	Phase 3	D01IGZ	DB12155	CTPDG001487
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 2	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	Phase 2	D02MRN	DB05475	CTPDG012015
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	Phase 1/2	D0D9LJ	DB05513	CTPDG003455
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	OPB-31121	.	.	Phase 1/2	D0E7IM	.	CTPDG012016
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	IMX-110	.	.	Phase 1/2	D0H7DM	.	CTPDG003425
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	GLG-801	.	.	Phase 1/2	D0P7IL	.	CTPDG012017
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	Phase 1/2	D0IV4C	DB12679	CTPDG012018
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	Phase 1/2	DUI59O	.	CTPDG003138
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-51602	.	.	Phase 1	D01FFC	.	CTPDG005419
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	TAK-114	.	.	Phase 1	D01RCM	.	CTPDG005387
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	Phase 1	D3U8YR	.	CTPDG012019
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	DSP-0337	.	.	Phase 1	DLJN17	.	CTPDG003831
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	OPB-111077	.	.	Phase 1	DN81JB	.	CTPDG003801
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 2	PMID26394986-Compound-29	67206397	Patented	D00FUZ	.	CTPDG012020
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 3	PMID26394986-Compound-5	24772856	Patented	D02CJU	.	CTPDG012021
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-11	.	341	Patented	D02ILH	.	CTPDG012022
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 5	PMID26394986-Compound-49	.	Patented	D02KDA	.	CTPDG012023
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 6	PMID26394986-Compound-18	72550504	Patented	D03ARS	.	CTPDG012024
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 2	PMID26394986-Compound-67	56946870	Patented	D03HEP	.	CTPDG012025
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 1	PMID26394986-Compound-3	.	Patented	D03VMP	.	CTPDG012026
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 1	PMID26394986-Compound-28	4253236	Patented	D03XAK	.	CTPDG012027
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 4	PMID26394986-Compound-16	72545583	Patented	D04ANB	.	CTPDG012028
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-12	.	237973	Patented	D04GVY	.	CTPDG012029
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-21	.	73672447	Patented	D06RBL	.	CTPDG012030
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 5	PMID26394986-Compound-17	72188643	Patented	D08EID	.	CTPDG012031
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-20	.	76336555	Patented	D08ETA	.	CTPDG012032
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-43	.	46911017	Patented	D08SEP	.	CTPDG012033
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-50	.	9881541	Patented	D09BOL	.	CTPDG012034
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-44	.	65064	Patented	D09CKU	DB12116	CTPDG012035
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-51	.	118707758	Patented	D09SYX	.	CTPDG012036
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 3	PMID26394986-Compound-14a	73333953	Patented	D09ZCV	.	CTPDG012037
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Quinoline carboxamide derivative 3	PMID26394986-Compound-30	67204713	Patented	D0D8RR	.	CTPDG012038
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 62	PMID26394986-Compound-23	72543768	Patented	D0DC3S	.	CTPDG012039
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 63	PMID26394986-Compound-24	72705159	Patented	D0ET3L	.	CTPDG012040
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 3	PMID26394986-Compound-47	5281612	Patented	D0EV5U	DB11259	CTPDG012041
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptide analog 7	PMID26394986-Compound-1	.	Patented	D0EW9W	.	CTPDG012042
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 1	PMID26394986-Compound-13a	68075823	Patented	D0EX9O	.	CTPDG012043
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 1	PMID26394986-Compound-66	.	Patented	D0FH4G	.	CTPDG012044
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Gold-complexed thiosaccharide derivative 3	PMID26394986-Compound-68	.	Patented	D0J1US	.	CTPDG012045
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-22	.	2662	Patented	D0KP0U	DB00482	CTPDG012046
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 65	PMID26394986-Compound-26	72705348	Patented	D0M5AR	.	CTPDG012047
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 64	PMID26394986-Compound-25	72705347	Patented	D0M8OV	.	CTPDG012048
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-42	.	9799188	Patented	D0MA8T	.	CTPDG012049
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 2	PMID26394986-Compound-4	.	Patented	D0QR1I	.	CTPDG012050
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Pyrazole derivative 66	PMID26394986-Compound-27	.	Patented	D0S0UL	.	CTPDG012051
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-52	.	.	Patented	D0T1GB	.	CTPDG012052
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	Patented	D0U7LL	.	CTPDG012053
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Salicylic acid derivative 7	PMID26394986-Compound-19	72545832	Patented	D0V3PA	.	CTPDG012054
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-53	.	25226944	Patented	D0V7HS	.	CTPDG012055
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 1	PMID26394986-Compound-45	5280445	Patented	D0V7NH	DB15584	CTPDG012056
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-54	.	25226945	Patented	D0WW1Z	.	CTPDG012057
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 4	PMID26394986-Compound-6	.	Patented	D0X6QQ	.	CTPDG012058
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-13	.	24767791	Patented	D0Y0OQ	.	CTPDG012059
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Tri-substituted purine derivative 1	PMID26394986-Compound-9	71770709	Patented	D0Y2PO	.	CTPDG012060
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 4	PMID26394986-Compound-48	5280343	Patented	D0Y3DN	DB04216	CTPDG012061
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Flavonoid derivative 2	PMID26394986-Compound-46	.	Patented	D0Z8BD	.	CTPDG012062
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure16	.	.	Patented	D0ZQ8T	.	CTPDG012063
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-Figure17	.	.	Patented	D0ZS8Q	.	CTPDG012064
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Oxazole derivative 1	PMID26394986-Compound-8	24768190	Patented	D0EZ6V	.	CTPDG012065
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 2	PMID26394986-Compound-33	68019246	Patented	D0IC8O	.	CTPDG009371
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Curcumin analog 1	PMID26394986-Compound-32	11487078	Patented	D0WD1Z	.	CTPDG009390
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Peptidomimetic analog 5	PMID26394986-Compound-7	9870708	Patented	D0XQ3F	.	CTPDG012066
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	Platinum IV complexe 1	PMID26394986-Compound-69	.	Patented	D01BVU	.	CTPDG012067
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Patented	PMID26394986-Compound-10	.	252682	Patented	D0TU0X	.	CTPDG012068
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	Investigative	D06PZK	.	CTPDG012069
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1/2	ISIS-STAT3	.	.	Phase 1/2	D0B4MK	.	CTPDG003472
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Phase 1	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	Phase 1	D09CLC	.	CTPDG005011
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113187	.	.	Investigative	D03MRO	.	CTPDG014695
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113176	.	.	Investigative	D07XRC	.	CTPDG014696
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113209	.	.	Investigative	D09YBP	.	CTPDG014697
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 113210	.	.	Investigative	D0E3ZU	.	CTPDG014698
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17148	.	.	Investigative	D0O3DZ	.	CTPDG014699
M6ACROT05325	Signal transducer and activator of transcription 3 (STAT3)	STAT3_HUMAN	.	.	Investigative	ISIS 17152	.	.	Investigative	D0W2FY	.	CTPDG014700
M6ACROT05326	Ferritin heavy chain (FTH1)	FRIH_HUMAN	.	.	Phase 1/2	Ferritarg P	"Ferritarg; Ferrotarg P; Hodgkins disease therapy (polyclonal antibody), MAT Biopharma; Y90 anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; Yttrium-90 anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; Yttrium-90 anti-ferritin polyclonal antibody (refractory Hodgkin! s disease), MAT Biopharma; 90Y-labelled anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; 90Y-labelled polyclonal IgG (Hodgkins disease), MAT Biopharma; 90Y-labelled polyclonal immunoglobulin G (Hogkinsdisease), MAT biopharma"	.	Phase 1/2	D0D8KU	.	CTPDG014464
M6ACROT05327	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05327	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05327	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05328	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT05329	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT05329	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT05329	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT05329	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT05330	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 2	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	Phase 2	D0TH5H	.	CTPDG002003
M6ACROT05330	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	BMS-986299	.	.	Phase 1	D75LNO	.	CTPDG004049
M6ACROT05330	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Phase 1	Selnoflast	"1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687"	137402358	Phase 1	D7KRB9	.	CTPDG014732
M6ACROT05330	"NACHT, LRR and PYD domains-containing protein 3 (NLRP3)"	NLRP3_HUMAN	.	.	Investigative	MCC950	"210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	Investigative	D09FGL	.	CTPDG014733
M6ACROT05335	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Approved	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	Approved	D05YAG	.	CTPDG000616
M6ACROT05335	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	Phase 1/2	D00GBZ	.	CTPDG012864
M6ACROT05335	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT05335	Catenin beta-1 (CTNNB1/Beta-catenin)	CTNB1_HUMAN	.	.	Phase 1	Tegavivint	"1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP"	46212391	Phase 1	D54WUR	.	CTPDG012866
M6ACROT05336	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT05337	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT05341	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	Phase 2	D0Q9UX	.	CTPDG002080
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	Phase 2	D01UMT	DB05608	CTPDG003007
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 2	R-roscovitine	"Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	Phase 2	D05ADP	DB06195	CTPDG002820
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	TG02	SB1317; 937270-47-8; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	Phase 1/2	D0P0KN	.	CTPDG013443
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AZD-5438	"602306-29-6; AZD5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	Phase 1	D06WHY	.	CTPDG005133
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	Phase 1	D07DTV	DB08142	CTPDG005118
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PF-07104091	.	.	Phase 1	D5TH2B	.	CTPDG004083
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	Phase 1	D0PL7P	DB15425	CTPDG004504
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	Phase 1	D0IX4B	DB13035	CTPDG004703
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	Phase 1	D0P1CV	DB12686	CTPDG004527
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	Phase 1	D0S5RC	DB05969	CTPDG004433
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Fluorinated compound 1	PMID26161698-Compound-15	.	Patented	D09ISI	.	CTPDG013444
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"4-amino-3,5-di-substituted-thiazole derivative 1"	PMID26161698-Compound-54	.	Patented	D0JU4Z	.	CTPDG013445
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 11	PMID26161698-Compound-16	.	Patented	D02KWX	.	CTPDG013446
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	PMID26161698-Compound-27	73508010	Patented	D03EYT	.	CTPDG013447
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Palbociclib/ribociclib analog 1	PMID26161698-Compound-4	89798202	Patented	D03HED	.	CTPDG010911
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Alkyl sulfone derivative 1	PMID26161698-Compound-29	73672849	Patented	D05UJQ	.	CTPDG013448
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Aniline derivative 1	PMID26161698-Compound-33	59176838	Patented	D06QPW	.	CTPDG013449
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 1	PMID26161698-Compound-35	44253187	Patented	D07QIP	.	CTPDG013450
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-phenyl-pyrimidin-4-amine derivative 1	PMID26161698-Compound-30	74763288	Patented	D0AY5G	.	CTPDG013451
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID26161698-Compound-25	.	71618654	Patented	D0GQ7L	.	CTPDG013452
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diaryl amine derivative 1	PMID26161698-Compound-23	71515733	Patented	D0P4NP	.	CTPDG013453
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Flavopiridol analog 1	PMID26161698-Compound-5	86272549	Patented	D0P9WR	.	CTPDG013454
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	PMID26161698-Compound-31	73891126	Patented	D0QS2B	.	CTPDG013455
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Pyrazolo-triazine derivative 2	PMID26161698-Compound-14	71731909	Patented	D0T6CM	.	CTPDG013456
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"1,5-di-substituted pyridine derivative 1"	PMID26161698-Compound-26	60197050	Patented	D0UU0V	.	CTPDG013457
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	PMID26161698-Compound-28	74767011	Patented	D0V7RP	.	CTPDG013458
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 9"	PMID26161698-Compound-1	44818950	Patented	D08KKC	.	CTPDG010914
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Naphthyridine and isoquinoline derivative 1	PMID26161698-Compound-51	.	Patented	D08WJG	.	CTPDG013393
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	4-(thiazol-5-yl)-pyrimidine derivative 2	PMID26161698-Compound-36	71561915	Patented	D01CJE	.	CTPDG013394
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Diamidothiazole derivative 1	PMID26161698-Compound-53	25256147	Patented	D0LR2Y	.	CTPDG013332
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Indole-based analog 13	PMID26161698-Compound-20	73293	Patented	D0LX6X	.	CTPDG010915
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Pyrazolo[1,5-a]-1,3,5-triazine derivative 1"	PMID26161698-Compound-12	.	Patented	D0NB7Y	.	CTPDG013395
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Roscovitine derivative 1	PMID26161698-Compound-8	73353575	Patented	D07DUX	.	CTPDG013396
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	PMID25991433-Compound-A1	.	.	Patented	D0H4HD	.	CTPDG010917
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 3	SCH 727965	Dinaciclib; SCH-727965	46926350	Discontinued in Phase 3	D0D3PX	DB12021	CTPDG013398
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 2	BAY 10-00394	roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	Discontinued in Phase 2	D0NV9O	.	CTPDG010919
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	Discontinued in Phase 1	D04FHB	DB08094	CTPDG006902
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Discontinued in Phase 1	ZK 304709	1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	Discontinued in Phase 1	D00VBT	.	CTPDG006936
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Preclinical	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	Preclinical	D0WS1V	DB02733	CTPDG007034
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	Olomoucine	"101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	Terminated	D00BPA	DB02116	CTPDG013399
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	Investigative	D01LPG	DB08134	CTPDG013460
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	Investigative	D03BZV	DB04607	CTPDG013461
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	Investigative	D06FIQ	DB07203	CTPDG013462
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BOHEMINE	189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	Investigative	D07ADR	.	CTPDG013463
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-phenyl-1H-pyrazole-3-carboxamide	"124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	Investigative	D07ODE	DB08135	CTPDG013464
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-hydroxynaphthalene-1-sulfonamide	"17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	Investigative	D07SGT	DB08132	CTPDG013465
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	Investigative	D0D3HB	DB08133	CTPDG013466
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	Investigative	D0I1SZ	DB08768	CTPDG013467
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	Investigative	D0I9VN	DB02603	CTPDG013468
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	Investigative	D0M5PI	.	CTPDG013469
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	Investigative	D0MK6D	DB02647	CTPDG013470
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	Investigative	D0P7RO	.	CTPDG013471
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	Investigative	D0QI7H	DB06948	CTPDG013472
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	Investigative	D0T4SJ	.	CTPDG007860
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	Investigative	D0T5AH	.	CTPDG007858
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	Investigative	D0U0GE	DB02091	CTPDG013473
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	Investigative	D0V1NK	.	CTPDG007806
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	2-Amino-6-Chloropyrazine	"33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	Investigative	D0W0PF	DB02297	CTPDG013474
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	Investigative	D0Y6DX	DB08233	CTPDG013475
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	Investigative	D01FJB	.	CTPDG013476
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime"	.	46222473	Investigative	D01PSU	.	CTPDG013477
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	Investigative	D02ZYA	.	CTPDG013478
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime"	.	46222697	Investigative	D03KLM	.	CTPDG013479
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	Investigative	D03XKK	.	CTPDG013480
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime"	.	46223585	Investigative	D04AGE	.	CTPDG013481
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	JNJ-7706621	"443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	Investigative	D04NGS	.	CTPDG013404
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	GW-8510	.	3536	Investigative	D04RBG	.	CTPDG013482
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-265246	BMS 265246; BMS265246	135402864	Investigative	D05SZH	.	CTPDG013405
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime"	.	46222694	Investigative	D06GLV	.	CTPDG013483
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime"	.	46222474	Investigative	D06XIW	.	CTPDG013484
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	RESCOVITINE	CHEMBL1087791	46881287	Investigative	D07AEC	.	CTPDG013485
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk4 inhibitor III	"Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	Investigative	D07HPE	.	CTPDG010925
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	Investigative	D07JHG	.	CTPDG013486
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime"	.	46222693	Investigative	D0B1LM	.	CTPDG013487
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	44417638	Investigative	D0F3OM	.	CTPDG013488
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	5-nitroindirubin-3'-oxime	.	11450099	Investigative	D0GP3R	.	CTPDG013489
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime"	.	46222696	Investigative	D0H0EN	.	CTPDG013490
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime"	.	46222472	Investigative	D0I6AE	.	CTPDG013491
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime"	.	46222470	Investigative	D0J3RS	.	CTPDG013492
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime"	.	46222245	Investigative	D0JR0G	.	CTPDG013493
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15"	5687	Investigative	D0KH5T	DB03365	CTPDG010119
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime"	.	46222476	Investigative	D0L5PI	.	CTPDG013494
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime"	.	46223584	Investigative	D0M4XD	.	CTPDG013495
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Oxindole 95	.	.	Investigative	D0MS4R	.	CTPDG013496
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	CVT-313	AC1OCFD4; NG 26	6918386	Investigative	D0P2WA	.	CTPDG013408
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	Investigative	D0R1FT	DB02407	CTPDG013497
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6027	.	398148	Investigative	D0U8YN	DB08312	CTPDG013498
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NSC-625987	NSC 625987	3004085	Investigative	D0VD8B	.	CTPDG010928
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime"	.	46222698	Investigative	D0W2FM	.	CTPDG013499
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime"	.	46222244	Investigative	D0YZ9Y	.	CTPDG013500
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine	IN1538; RP106	3641059	Investigative	D00SEC	.	CTPDG013501
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 8	SCHEMBL2991886; CHEMBL406102	24801181	Investigative	D01PEF	.	CTPDG013502
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 1	"551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	Investigative	D02DLC	.	CTPDG010929
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Purvalanol A	Purvalanola; AC1L1JD0; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	Investigative	D07OAT	DB04751	CTPDG013410
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Cdk1/2 inhibitor III	"443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664"	5330812	Investigative	D07OCA	DB07664	CTPDG013411
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 1	"341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	Investigative	D08KSQ	.	CTPDG013503
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 4	SCHEMBL3001373; CHEMBL406464	24801697	Investigative	D0B9YR	.	CTPDG013504
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Lysine Nz-Carboxylic Acid	N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	Investigative	D0CC0B	DB03801	CTPDG013505
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 6	CHEMBL406463; SCHEMBL2999009	24801185	Investigative	D0D0ZQ	.	CTPDG013506
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	K00024	indolocarbazole deriv. 4(d)	5330797	Investigative	D0D5HQ	.	CTPDG010930
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	Investigative	D0F0AX	.	CTPDG013412
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aminopurvalanol A	NG-97	6604931	Investigative	D0G2GA	.	CTPDG013413
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	9-Nitropaullone	"Alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	Investigative	D0H3EV	DB04014	CTPDG013414
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 5	"1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	Investigative	D0H6CQ	DB08182	CTPDG013507
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	SU9516	"377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	Investigative	D0L3FK	DB03428	CTPDG013415
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PYRAZOLOPYRIDAZINE 2	"pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	Investigative	D0O0VP	.	CTPDG010931
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 3	"954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	Investigative	D0S8VE	DB08178	CTPDG013508
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	MERIOLIN 2	"SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	Investigative	D0U1WL	.	CTPDG013509
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID18986805C9b	GTPL8160; BDBM50246396; ZINC38224644	11675054	Investigative	D0P6JS	.	CTPDG010932
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol"	.	9964499	Investigative	D0W0BL	.	CTPDG013510
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid"	3708	Investigative	D0G2CT	DB02519	CTPDG013416
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	Investigative	D0S7IE	.	CTPDG013511
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	Investigative	D0Y5RO	DB07126	CTPDG010933
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	aloisine A	"4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	Investigative	D02XHC	DB07364	CTPDG013417
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	Investigative	D04WFN	.	CTPDG010934
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-912	BX 912; BX912	11754511	Investigative	D0IX7Y	.	CTPDG010147
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BX-795	BX795; BX 795	10077147	Investigative	D0RG0Z	.	CTPDG010149
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	PMID19115845C89S	3du8; GTPL8114; BDBM27380; DB07149	16757525	Investigative	D0T8NU	DB07149	CTPDG013330
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	Double Oxidized Cysteine	.	6398956	Investigative	D0H1GU	.	CTPDG013512
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05345	Cyclin-dependent kinase 2 (CDK2)	CDK2_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05347	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT05350	Cystathionine beta-synthsae (CBS)	CBS_HUMAN	.	.	Phase 1/2	OT-58	.	.	Phase 1/2	D87TMY	.	CTPDG014791
M6ACROT05350	Cystathionine beta-synthsae (CBS)	CBS_HUMAN	.	.	Investigative	aminooxyacetic acid	"(aminooxy)acetic acid; 2-(Aminooxy)acetic acid; AOAA; carboxymethoxylamine; 645-88-5; Carboxymethoxyamine; ACETIC ACID, (AMINOOXY)-; Aminooxyacetate; Aminooxy-acetic acid; (Carboxymethoxy)amine; (o-Carboxymethyl)hydroxylamine; aminoxyacetic acid; UNII-14I68GI3OQ; BRN 0878238; C2H5NO3; 14I68GI3OQ; U 7524; NQRKYASMKDDGHT-UHFFFAOYSA-N; u-7524; AOA; Aminooxyacetic acid hemihydrochloride; Carboxymethoxylamine hemihydrochloride; aminoxy-acetic acid; amino-oxyacetic acid; AOA hemihydrochloride; 2-aminooxyacetic acid"	286	Investigative	D01BTV	DB02079	CTPDG014792
M6ACROT05350	Cystathionine beta-synthsae (CBS)	CBS_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114563	.	.	Investigative	D01KCM	.	CTPDG015490
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114559	.	.	Investigative	D03NEA	.	CTPDG015491
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114531	.	.	Investigative	D08WJY	.	CTPDG015492
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114527	.	.	Investigative	D0AJ0H	.	CTPDG015493
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114537	.	.	Investigative	D0E5FG	.	CTPDG015494
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 14548	.	.	Investigative	D0L3NU	.	CTPDG015495
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114532	.	.	Investigative	D0LY0E	.	CTPDG015496
M6ACROT05351	Zinc finger protein 217 (ZNF217)	ZN217_HUMAN	.	.	Investigative	ISIS 114530	.	.	Investigative	D0N5CF	.	CTPDG015497
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	Approved	D0L5RW	DB06809	CTPDG012109
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Approved	Motixafortide	.	91865076	Approved	D0T6CN	DB14939	CTPDG000136
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Ulocuplumab	.	.	Phase 3	D0C3LQ	.	CTPDG001258
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	Phase 3	D0GG9P	.	CTPDG012110
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 3	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	Phase 3	D0O2XQ	DB05501	CTPDG012111
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	Phase 2	D06KGI	DB11970	CTPDG012112
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 2	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	Phase 2	D0FV8P	.	CTPDG012113
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	Phase 1/2	D01TJM	.	CTPDG012114
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1/2	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	Phase 1/2	D08XQV	DB15265	CTPDG003496
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	Phase 1	D09MPD	.	CTPDG012115
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	Phase 1	D0AZ3Y	.	CTPDG012116
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	MSX-122	.	11687907	Phase 1	D0E5JC	DB12715	CTPDG004831
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	PF-06747143	.	.	Phase 1	D0LC5L	.	CTPDG004616
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	BMS-936564	.	.	Phase 1	D0Z8JR	.	CTPDG004225
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	LY2624587	.	.	Phase 1	D3KZ6M	.	CTPDG004136
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Phase 1	GMI-1359	.	.	Phase 1	DBDW09	.	CTPDG003967
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	Garnocestim	SB-251353	.	Discontinued in Phase 1	D0H5KK	.	CTPDG012117
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Discontinued in Phase 1	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	Discontinued in Phase 1	D0I4OX	.	CTPDG006802
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Preclinical	MAb173	.	.	Preclinical	D2NU0H	.	CTPDG007015
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Terminated	KRH-2731	.	.	Terminated	D00FJS	.	CTPDG012118
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536	44418888	Investigative	D00GII	.	CTPDG012119
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993	44418891	Investigative	D00XBM	.	CTPDG012120
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806	44418892	Investigative	D02UES	.	CTPDG012121
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	Investigative	D03QJA	.	CTPDG012122
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	AT-009	.	.	Investigative	D04ATE	.	CTPDG008913
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169	44418894	Investigative	D04BVW	.	CTPDG012123
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120	44418872	Investigative	D04PDF	.	CTPDG012124
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421	44418887	Investigative	D04TED	.	CTPDG012125
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	Investigative	D04TIO	.	CTPDG012126
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135	44418885	Investigative	D04XHX	.	CTPDG012127
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	KUR-CXCR4	.	.	Investigative	D05IXH	.	CTPDG012128
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1t	IT1t	25147749	Investigative	D05VQJ	.	CTPDG012129
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862	44418895	Investigative	D05YHT	.	CTPDG012130
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	Investigative	D06EBJ	.	CTPDG008766
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	isothiourea-1a	IT1a	11176403	Investigative	D06MBD	.	CTPDG012131
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	Investigative	D07IZP	.	CTPDG012132
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	Investigative	D07VDF	.	CTPDG012133
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T134	GTPL852	16197445	Investigative	D08NJD	.	CTPDG012134
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075	44418890	Investigative	D08XRM	.	CTPDG012135
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219	44418893	Investigative	D08YYV	.	CTPDG012136
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	Investigative	D0A7GH	.	CTPDG012137
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850	44418889	Investigative	D0B8VW	.	CTPDG012138
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811	44418879	Investigative	D0BH8K	.	CTPDG012139
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429	44418869	Investigative	D0FQ3G	.	CTPDG012140
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	Investigative	D0I6AN	.	CTPDG012141
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636	44418880	Investigative	D0K0SO	.	CTPDG012142
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440	44418868	Investigative	D0K9KQ	.	CTPDG012143
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	Investigative	D0L3GH	.	CTPDG012144
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108	44418865	Investigative	D0M6RQ	.	CTPDG012145
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991	44418878	Investigative	D0P7UV	.	CTPDG012146
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474	11158428	Investigative	D0Q3MM	.	CTPDG012147
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	Investigative	D0Q7XS	.	CTPDG012148
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	Investigative	D0R4WT	.	CTPDG012149
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096	44418886	Investigative	D0S0GV	.	CTPDG012150
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990	44418873	Investigative	D0S0PU	.	CTPDG012151
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637	44418883	Investigative	D0ST1U	.	CTPDG012152
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	Investigative	D0TL6C	.	CTPDG012153
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	Investigative	D0Y3OX	.	CTPDG012154
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339	11331592	Investigative	D0ZO3C	.	CTPDG012155
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	CXCL8	Interleukin-8; CHEMBL411250; IL-8	74974005	Investigative	D07PHS	.	CTPDG008669
M6ACROT05352	C-X-C chemokine receptor type 4 (CXCR4)	CXCR4_HUMAN	.	.	Investigative	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	Investigative	D09PZD	.	CTPDG012156
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 2	PINOCEMBRIN	"480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-"	68071	Phase 2	D0G5CS	.	CTPDG014282
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Phase 1	NARINGENIN	"5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone"	932	Phase 1	D02ABO	.	CTPDG014283
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	DIOSMETIN	"520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246"	5281612	Investigative	D00RFY	DB11259	CTPDG014284
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISOSAKUTANETIN	"Isosakuranetin; 480-43-3; 4'-Methylnaringenin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone"	160481	Investigative	D01FJE	.	CTPDG014285
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFERIDE	"491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD"	5281666	Investigative	D04DYO	.	CTPDG014286
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TAMARIXETIN	"603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7"	5281699	Investigative	D06PZE	.	CTPDG014287
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan"	"CHEMBL43396; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552"	10105252	Investigative	D06VXW	.	CTPDG014288
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ERIODICTYOL	"(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT"	440735	Investigative	D08AIJ	.	CTPDG014289
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	HOMOERIODICTYOL	"(-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672"	73635	Investigative	D0CR8V	.	CTPDG014290
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide"	"N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910"	2321450	Investigative	D0J9OG	.	CTPDG014291
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine"	"CHEMBL43013; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine"	11957947	Investigative	D0T9IK	.	CTPDG014292
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	"2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene"	"CHEMBL42428; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene"	9834747	Investigative	D0Z1AL	.	CTPDG014293
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	CHRYSOERIOL	"491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514"	5280666	Investigative	D01FGM	.	CTPDG014294
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ISORHAMNETIN	"480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z"	5281654	Investigative	D07YDN	.	CTPDG014295
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	ACACETIN	"480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC"	5280442	Investigative	D0NS1S	.	CTPDG014296
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	Investigative	D0O9NE	.	CTPDG013143
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Galangin	"548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one"	5281616	Investigative	D0Y7HG	.	CTPDG014297
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT05353	Cytochrome P450 1B1 (CYP1B1)	CP1B1_HUMAN	.	.	Investigative	KAEMPFEROL	"520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe"	5280863	Investigative	D0G3TK	DB01852	CTPDG014298
M6ACROT05358	Oxidized low-density lipoprotein receptor 1 (OLR1)	OLR1_HUMAN	.	.	Phase 2	MEDI6570	.	.	Phase 2	DFG87U	.	CTPDG014790
M6ACROT05358	Oxidized low-density lipoprotein receptor 1 (OLR1)	OLR1_HUMAN	.	.	Discontinued in Phase 1	RG7418	BI204	.	Discontinued in Phase 1	D0MH1R	.	CTPDG006776
M6ACROT05359	Oxidized low-density lipoprotein receptor 1 (OLR1)	OLR1_HUMAN	.	.	Phase 2	MEDI6570	.	.	Phase 2	DFG87U	.	CTPDG014790
M6ACROT05359	Oxidized low-density lipoprotein receptor 1 (OLR1)	OLR1_HUMAN	.	.	Discontinued in Phase 1	RG7418	BI204	.	Discontinued in Phase 1	D0MH1R	.	CTPDG006776
M6ACROT05361	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Phase 2	Ifabotuzumab	.	.	Phase 2	D08NZG	.	CTPDG002624
M6ACROT05361	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Phase 1/2	KB-004	"Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios"	.	Phase 1/2	D0FJ9W	.	CTPDG014492
M6ACROT05361	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Investigative	PMID21561767C8h	GTPL8170; BDBM50345579	46864270	Investigative	D02BXJ	.	CTPDG010061
M6ACROT05361	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Investigative	PMID19788238C66	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160	44478401	Investigative	D05FXD	.	CTPDG014156
M6ACROT05361	Ephrin type-A receptor 3 (EPHA3)	EPHA3_HUMAN	.	.	Investigative	PMID23489211C20	PCM126; GTPL8124; BDBM50428059	71718651	Investigative	D0X8BU	.	CTPDG014157
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Approved	"Interferon Alfa-2a, Recombinant"	Roferon A (TN)	.	Approved	D09PMV	.	CTPDG010064
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Approved	Palifermin	Kepivance; Kepivance (TN); Palifermin (USAN/INN)	.	Approved	D0O7GU	.	CTPDG010065
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 3	Trafermin	Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)	.	Phase 3	D0KV1Q	.	CTPDG001153
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 3	E-3810	"Lucitanib; AL-3810; E-3810, EOS"	25031915	Phase 3	D02WVT	DB11845	CTPDG001454
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 2	LY2874455	"1254473-64-7; LY-2874455; UNII-E9M363811V; CHEMBL3828009; E9M363811V; AK186860; LY 2874455; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; GKJCVYLDJWTWQU-CXLRFSCWSA-N; SCHEMBL298446; SCHEMBL298445; QCR-90; GTPL8104; DTXSID20154776; MolPort-044-724-281; MolPort-023-219-117; EX-A1340; BCP04756; ZINC73069242; BDBM50189781; 2529AH; s7057; AKOS027251051"	46944259	Phase 2	D0D4VV	DB13022	CTPDG002453
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 2	Debio 1347	.	66555680	Phase 2	D0XT0W	DB12903	CTPDG001886
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 1/2	AEE-788	"AEE; AEE 788; AEE788; GNF-Pf-5343; AEE-788, NVP-AEE 788, AEE788"	10297043	Phase 1/2	D0G2QH	DB12558	CTPDG003432
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 1	BAY1179470	.	.	Phase 1	D0L6RF	.	CTPDG004625
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 1	Alofanib	"1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid"	86280646	Phase 1	D47MOS	.	CTPDG004124
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Phase 1	RLY-4008	.	.	Phase 1	DU1DL0	.	CTPDG003707
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Investigative	Anti-FGFR2 humanized mab	"HuGAL-FR21; HuGAL-FR22; Anti-FGFR2 humanized mAb (cancer); Anti-FGFR2 humanized mAb (cancer), Galaxy"	.	Investigative	D02VPS	.	CTPDG008999
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Investigative	Platelet factor 4 (PF-4)	"Platelet factor 4 (59-70); 88145-47-5; PF4 (59-70); DTXSID30236855; L-Serine, N-(N-(N-(N-(N2-(N2-(N-(N-(N2-(N2-(N-L-leucyl-L-tyrosyl)-L-lysyl)-L-lysyl)-L-isoleucyl)-L-isoleucyl)-L-lysyl)-L-lysyl)-L-leucyl)-L-leucyl)-L-alpha-glutamyl)-, (6R-(6alpha,7beta(Z)))-"	56842294	Investigative	D0IE6Z	.	CTPDG010068
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Investigative	PK 11195	"1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; 85532-75-8; PK-11195; PK11195; RP 52028; BRN 4264456; CHEBI:73290; N-sec-butyl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-(butan-2-yl)-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-; SMR000058427; SR-01000076240; Biomol-NT_000287; AC1L1B9T; DSSTox_RID_79625; Interferon alfa (IFN-alpha)"	1345	Investigative	D0VN4K	.	CTPDG010069
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Investigative	TG-100435	"CHEMBL230686; SCHEMBL4266197; ZINC28702706; BDBM50198782; US8481536, 367; US8481536, 575; ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine); 7-(2,6-dichlorophenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine"	11562302	Investigative	D0H1OK	.	CTPDG010070
M6ACROT05362	Fibroblast growth factor receptor 2 (FGFR2)	FGFR2_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05365	Growth factor receptor-bound protein 2 (GRB2)	GRB2_HUMAN	.	.	Phase 2	BP-100-1-01	.	.	Phase 2	D0L3KA	.	CTPDG002238
M6ACROT05366	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05366	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05366	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	Approved	D0RX7Z	DB02594	CTPDG000164
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Approved	Penciclovir	39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2	135398748	Approved	D07BYK	DB00299	CTPDG010582
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Preregistration	TK-DLI	"TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara"	.	Preregistration	D08AMJ	.	CTPDG010583
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	FV-100	"CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy"	71587897	Phase 3	D04QPD	.	CTPDG010584
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 3	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	Phase 3	D0X4NF	.	CTPDG000996
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2/3	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	Phase 2/3	D0Z9LP	DB03312	CTPDG001528
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 2	HQK-1004	"Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest"	23622962	Phase 2	D05RRA	.	CTPDG002789
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Ad-OC-hsvTK/valacyclovir	"Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute"	.	Phase 1	D02KBE	.	CTPDG010585
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	"Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama"	.	Phase 1	D0FY1W	.	CTPDG004786
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Phase 1	Rilapladib	.	9918381	Phase 1	D05GZD	DB05119	CTPDG005208
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Discontinued in Phase 3	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	Discontinued in Phase 3	D0W8RX	.	CTPDG006330
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-Hydroxypropylthymine	"6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139"	1865	Investigative	D00CEO	DB04139	CTPDG010586
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	3-(2-propyn-1-yl)thymidine	3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872	11323459	Investigative	D01CUJ	.	CTPDG010587
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	ITdU	"3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-"	76	Investigative	D01VKE	.	CTPDG010588
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	"AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate"	449489	Investigative	D04GXW	DB02324	CTPDG010589
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CHEMBL219905	16098875	Investigative	D07GKK	.	CTPDG010590
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	(South)-Methanocarba-Thymidine	"south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921"	447628	Investigative	D07OOW	DB02921	CTPDG010591
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	6-(Dihydroxy-Isobutyl)-Thymine	"DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione"	1855	Investigative	D08AOD	DB02500	CTPDG010592
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-propyl-2'-deoxyuridine	"27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione"	160155	Investigative	D0C7YS	.	CTPDG010593
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-(bromovinyl)deoxyuridine	CHEMBL261850; SCHEMBL4314668; BDBM50375781	25323027	Investigative	D0D7FB	.	CTPDG010594
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	9-(4-Hydroxybutyl)-N2-Phenylguanine	"HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one"	135415618	Investigative	D0G5VO	DB02495	CTPDG010595
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	L-5-iodo-2'-deoxyuridine	"CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil"	512326	Investigative	D0HO0W	.	CTPDG010596
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine"	"3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione"	452142	Investigative	D0O7GD	.	CTPDG010597
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	BVDU-MP	SCHEMBL4287705	46936977	Investigative	D0PC2Y	.	CTPDG010598
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, S-Isomer"	"(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731"	445210	Investigative	D0R0EI	DB03000	CTPDG010599
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine	.	448110	Investigative	D0S4SQ	.	CTPDG010600
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	5-Bromothienyldeoxyuridine	"CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione"	446725	Investigative	D0ST5A	DB03804	CTPDG010601
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[7-(triphenylmethoxy)heptyl]thymine	"CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-"	16098874	Investigative	D0W8AD	.	CTPDG010602
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	"9-Hydroxypropyladenine, R-Isomer"	"14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-"	445211	Investigative	D0X1HX	DB02765	CTPDG010603
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Edoxudine	"5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine; MCULE-3445830855; ST056929"	66377	Investigative	D0Y4MD	DB13421	CTPDG010604
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	N2-(3-trifluoromethylphenyl)guanine	.	135435057	Investigative	D0YJ5W	.	CTPDG010605
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-Deoxyuridine	"951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615"	13712	Investigative	D00CVB	DB02256	CTPDG010606
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[5-(triphenylmethoxy)pentyl]thymine	"CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-"	16098859	Investigative	D00KWL	.	CTPDG010607
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Deoxythymidine	"Thymidine; 50-89-5; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748"	5789	Investigative	D01GLG	DB04485	CTPDG010608
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[6-(triphenylmethoxy)hexyl]thymine	"CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-"	44418795	Investigative	D02CCD	.	CTPDG010609
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	"CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"""" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate"	447202	Investigative	D04BBF	DB03280	CTPDG010610
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	"CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione"	6477686	Investigative	D0I6UV	.	CTPDG010611
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	Thymidine-5'-Phosphate	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)	9700	Investigative	D0ZH0I	DB01643	CTPDG010612
M6ACROT05367	"Thymidine kinase, cytosolic (TK1)"	KITH_HUMAN	.	.	Investigative	2'-deoxythymidine triphosphate	"Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 5'-TTP; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE"	64968	Investigative	D09WYY	DB02452	CTPDG010613
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Necitumumab	LY3012211	.	Approved	D03WPP	.	CTPDG009207
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	HEGF	.	.	Approved	D05GGP	.	CTPDG000644
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Erlotinib	"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline"	176870	Approved	D07POC	DB00530	CTPDG009208
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Gefitinib	"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine"	123631	Approved	D09XZB	DB00317	CTPDG000476
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	Approved	D0HU9H	.	CTPDG009209
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	Approved	D0N5OV	.	CTPDG009210
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	BIBW 2992	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	Approved	D05UFG	DB08916	CTPDG009211
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Nitroglycerin	"Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401"	4510	Approved	D07YDE	DB00727	CTPDG000539
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF"	56841751	Approved	D08TPS	.	CTPDG009212
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	NERATINIB MALEATE	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	Approved	D0U1ZV	.	CTPDG009214
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	Approved	D03MNN	.	CTPDG009215
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Dacomitinib	PF-00299804	11511120	Approved	D06XXH	DB11963	CTPDG009216
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	Approved	D08CDI	DB01259	CTPDG009217
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	Approved	D0F0ZE	DB04862	CTPDG009218
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	Approved	D0G6QF	DB05294	CTPDG000371
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	Approved	D0W5HK	DB00398	CTPDG000090
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Registered	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	Registered	D06WRJ	.	CTPDG009219
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Rindopepimut	.	.	Phase 3	D05FRP	.	CTPDG001405
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	Phase 3	D0CR8H	.	CTPDG001251
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	DE-766	.	.	Phase 3	D0FJ1W	.	CTPDG001212
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	EGF816	.	72703790	Phase 3	D0K7FY	.	CTPDG009220
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	Phase 3	D0M4AV	DB11907	CTPDG009221
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Zalutumumab	.	.	Phase 3	D0R4PW	.	CTPDG009222
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	Phase 3	DDH8L6	.	CTPDG009223
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	ASP1929	Cetuximab sarotalocan	.	Phase 3	DWK96T	.	CTPDG009224
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	A140	.	.	Phase 3	DXZ31K	.	CTPDG009225
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	Bevacizumab + Erlotinib	.	.	Phase 3	D09BKY	.	CTPDG001316
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	Phase 3	D0Q9CY	DB11828	CTPDG009226
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Indium-111	ABT-806	.	Phase 2/3	D0F3KC	.	CTPDG001547
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2/3	Varlitinib	"845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	Phase 2/3	D00NYJ	DB05944	CTPDG009227
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ASP8273	.	71667668	Phase 2	D02BYZ	DB12036	CTPDG009228
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABT-414	.	.	Phase 2	D06XIT	.	CTPDG009229
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Depatuxizumab	.	.	Phase 2	D0A6CC	.	CTPDG009230
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	Phase 2	D0BZ7V	.	CTPDG002496
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	Phase 2	D0C3LL	.	CTPDG002490
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	RM-1929	.	.	Phase 2	D0FN4T	.	CTPDG009231
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CetuGEX	.	.	Phase 2	D0K9MC	.	CTPDG002258
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	ABX-EGF	.	.	Phase 2	D0P9RG	.	CTPDG009232
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	Phase 2	D0S3PO	DB05524	CTPDG009233
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	Phase 2	D00YER	DB12114	CTPDG003056
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Pazopanib + Tyverb/Tykerb	.	10113978	Phase 2	D03UKJ	DB06589	CTPDG009234
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	Phase 2	D09BZJ	.	CTPDG002584
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	Phase 2	D0T5JS	.	CTPDG009235
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-599626	"714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	Phase 2	D0U4FF	DB12318	CTPDG001990
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	Phase 2	DUW81M	DB14944	CTPDG009236
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	VATALANIB	"212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	Phase 2	D0P6DJ	DB04879	CTPDG002115
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	BMS-690514	BMS 690514; BMS690514	11349170	Phase 2	D0R6UV	DB11665	CTPDG002068
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 2	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	Phase 2	D0YB3W	DB05424	CTPDG009237
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CART-EGFR	.	.	Phase 1/2	D04DHZ	.	CTPDG003577
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	Phase 1/2	D05ETC	.	CTPDG009238
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR CART	.	.	Phase 1/2	D0G1ZU	.	CTPDG009239
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	Phase 1/2	D0S8BG	.	CTPDG009240
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	TAK-186	.	.	Phase 1/2	DC1GH7	.	CTPDG003199
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	ZN-e4	.	.	Phase 1/2	DF0PR6	.	CTPDG009241
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EMB-01	.	.	Phase 1/2	DWQ6J1	.	CTPDG003135
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	BDTX-189	2414572-47-5; EX-A4379	154824631	Phase 1/2	D9FJ5V	.	CTPDG003214
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	AFM24	.	.	Phase 1/2	DK8QG3	.	CTPDG003169
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Sym013	.	.	Phase 1/2	D0FF2G	.	CTPDG003436
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1b	S-222611	.	.	Phase 1b	D0V4XY	.	CTPDG009242
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SYN004	.	.	Phase 1	D00KML	.	CTPDG005457
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	Phase 1	D00RMC	DB12966	CTPDG009243
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	IMGN289	.	.	Phase 1	D04HSH	.	CTPDG005257
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AST-1306	Allitinib; Allitinib tosylate	24739943	Phase 1	D04OLK	.	CTPDG005247
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 595	.	.	Phase 1	D05LMC	.	CTPDG009244
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	HER-2/HER-1 vaccine	HER-2/HER-1 vaccine (solid tumors)	.	Phase 1	D0E7RC	.	CTPDG004827
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFR806-specific CAR T cell	.	.	Phase 1	D0I7ZH	.	CTPDG004717
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	PF-05230907	.	.	Phase 1	D0JS0W	.	CTPDG009245
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	Phase 1	D0N3PC	.	CTPDG004585
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFR CAR T	.	.	Phase 1	D0T0SE	.	CTPDG009246
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AP32788	.	.	Phase 1	D0X7BN	.	CTPDG009247
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CLN-081	.	.	Phase 1	D68RMI	.	CTPDG009248
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MM-151	.	.	Phase 1	D01NAP	.	CTPDG005398
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	Phase 1	D08JAN	.	CTPDG005051
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-HER3/EGFR DAF	.	.	Phase 1	D0JW2O	.	CTPDG009249
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	BCA101	.	.	Phase 1	D0U7XJ	.	CTPDG004370
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CUDC-101	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	Phase 1	D0Z4RC	DB12174	CTPDG004231
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	SI-B001	.	.	Phase 1	D6JM8Z	.	CTPDG009250
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CX-904	AMG 651	.	Phase 1	D73FNL	.	CTPDG009251
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	MCLA-158	.	.	Phase 1	DV8I4Q	.	CTPDG003692
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	Phase 1	D0U3XL	.	CTPDG004378
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	"Pyrrolo[2,3-d]pyrimidine derivative 24"	PMID28705083-Compound-22	90468938	Patented	D0Z2PC	.	CTPDG009253
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	Discontinued in Phase 2	D07GFF	.	CTPDG006595
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 2	RG7160	.	.	Discontinued in Phase 2	D0E2CQ	.	CTPDG006536
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	Discontinued in Phase 1	D0Q7HO	.	CTPDG006756
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	Discontinued in Phase 1	D02RZL	.	CTPDG006914
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Discontinued in Phase 1	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	Discontinued in Phase 1	D0A9OV	DB12682	CTPDG006834
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	Preclinical	D0V2FZ	.	CTPDG009254
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Preclinical	EGFR/IGFR tandem adnectin	BMS-964210	.	Preclinical	D0TI4U	.	CTPDG007051
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	Terminated	D02GFZ	.	CTPDG009255
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-52411	DAPH	1697	Terminated	D03QTP	.	CTPDG007525
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	CGP-53353	"145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	Terminated	D0HO1S	.	CTPDG009256
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Terminated	AZD-9935	.	.	Terminated	D0Y1YX	.	CTPDG007176
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	Investigative	D00TJF	.	CTPDG009257
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	Investigative	D00VZA	.	CTPDG009258
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	CHEMBL250523; BDBM50222432	44442168	Investigative	D00WZG	.	CTPDG009259
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	Investigative	D01NTW	.	CTPDG009260
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	Investigative	D01SQP	.	CTPDG009071
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	Investigative	D01WDI	.	CTPDG009261
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-styrylquinazoline"	CHEMBL250925	44442181	Investigative	D01WXV	.	CTPDG009262
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	Investigative	D02FGG	.	CTPDG009031
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD182905	.	.	Investigative	D02GCE	.	CTPDG009263
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	Investigative	D02KVB	.	CTPDG009264
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	Investigative	D02RIG	.	CTPDG009265
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	Investigative	D02ZRO	.	CTPDG009266
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	Investigative	D03ATU	.	CTPDG009267
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EGFR inhibitor	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	Investigative	D03BJB	.	CTPDG009268
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	CHEMBL399371	44442182	Investigative	D03CVQ	.	CTPDG009269
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	Investigative	D03MTY	.	CTPDG008958
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	Investigative	D03WEN	.	CTPDG009270
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ICR 62	.	.	Investigative	D03ZIW	.	CTPDG009271
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	Investigative	D04GCH	.	CTPDG008899
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-00213	"CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	Investigative	D04HGN	.	CTPDG009272
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	CHEMBL251123	44442183	Investigative	D04LXG	.	CTPDG009273
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	Investigative	D05ARF	.	CTPDG009274
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	Investigative	D05MEY	.	CTPDG008824
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	OSI-75	.	.	Investigative	D06QEQ	.	CTPDG009275
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; SCHEMBL16693054; BDBM50187134	15984068	Investigative	D06UEK	.	CTPDG009276
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-02876	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	Investigative	D07CZM	.	CTPDG009277
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	Investigative	D07IHD	.	CTPDG009278
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID8568816C56	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010	2857	Investigative	D07UYV	.	CTPDG009279
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	Investigative	D08RXW	.	CTPDG008596
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR mab	.	.	Investigative	D09RXX	.	CTPDG009280
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	Investigative	D0A0JL	.	CTPDG009281
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	Investigative	D0AC7C	.	CTPDG008474
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	Investigative	D0AH2V	.	CTPDG009282
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	Investigative	D0B4PH	.	CTPDG009283
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	Investigative	D0B8DE	.	CTPDG009284
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	Investigative	D0C5WE	.	CTPDG008410
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	Investigative	D0C9KC	.	CTPDG009285
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	Investigative	D0CY9O	.	CTPDG008392
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	Investigative	D0D0GS	.	CTPDG009286
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	Investigative	D0D0YK	.	CTPDG009287
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	Investigative	D0DF3Z	.	CTPDG009288
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	CHEMBL7914; SCHEMBL8834183; BDBM50040920	10360970	Investigative	D0EH6L	.	CTPDG009289
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	Investigative	D0EP1G	.	CTPDG009290
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	Investigative	D0F6FZ	.	CTPDG009291
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	Investigative	D0G4HR	.	CTPDG009292
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	Investigative	D0G9KD	.	CTPDG009293
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	Investigative	D0GB7F	.	CTPDG009294
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	TGF alpha	TGF alpha (neurological damage)	.	Investigative	D0H3FX	.	CTPDG009295
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	Investigative	D0H3UI	.	CTPDG009296
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	Investigative	D0HM5W	.	CTPDG009297
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	CHEMBL473320; SCHEMBL5616932	11696664	Investigative	D0I7RA	.	CTPDG009298
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	Investigative	D0J3EA	.	CTPDG008175
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol"	.	5328050	Investigative	D0J9WO	.	CTPDG009299
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	CHEMBL250318; BDBM50222435	44442165	Investigative	D0K2VO	.	CTPDG009300
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	Investigative	D0K2YY	.	CTPDG009301
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	Investigative	D0K3FG	.	CTPDG008145
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	Investigative	D0K7GD	.	CTPDG009302
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	Investigative	D0KN1L	.	CTPDG009303
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	Investigative	D0L3SN	.	CTPDG009304
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	Investigative	D0NH7M	.	CTPDG009305
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	Investigative	D0NJ3Q	.	CTPDG009306
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	2-methoxy-4-(2-nitrovinyl)phenol	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	Investigative	D0O9UR	.	CTPDG009307
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MG-111	"134865-04-6; EGF, Hitachi"	16143379	Investigative	D0P0JW	.	CTPDG009308
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	CHEMBL250315; SCHEMBL6180450; BDBM50222433	18770812	Investigative	D0P2GE	.	CTPDG009309
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	Investigative	D0R2RV	.	CTPDG007918
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	CHEMBL250924; BDBM50222419	44442180	Investigative	D0S9QP	.	CTPDG009310
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	Investigative	D0T7OS	.	CTPDG007850
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	BPIQ-I	"174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	Investigative	D0U6WB	.	CTPDG009311
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	Investigative	D0V0JV	.	CTPDG009312
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-(2-nitrovinyl)phenol	"4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	Investigative	D0W1BE	.	CTPDG009313
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	Investigative	D0W2PQ	.	CTPDG009314
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	Investigative	D0WD8R	.	CTPDG007745
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	Investigative	D0X4UE	.	CTPDG009315
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	Investigative	D0Y1LD	.	CTPDG007677
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	Investigative	D0Y2AM	.	CTPDG009316
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	NRC-2694	.	16129168	Investigative	D0Y6MD	.	CTPDG007661
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Cochliobolic acid	"CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	Investigative	D0ZT9D	.	CTPDG009317
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-168393	"PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	Investigative	D01VFR	DB07662	CTPDG009318
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	Investigative	D01WYI	.	CTPDG009319
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	CHEMBL98798	44331231	Investigative	D03HLH	.	CTPDG009320
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	CHEMBL101581	44331083	Investigative	D05QMN	.	CTPDG009321
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	LAVENDUSTIN A	"125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	Investigative	D0D9TU	.	CTPDG009322
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PF 5208766	WAY-178357	.	Investigative	D0J2CP	.	CTPDG009323
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	Investigative	D0J5SK	.	CTPDG009324
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	Investigative	D0N8TQ	DB08462	CTPDG009325
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	AG-213	.	667601	Investigative	D0Q3GG	.	CTPDG009326
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	Investigative	D0Q8GX	.	CTPDG007942
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	10-hydroxy-18-methoxybetaenone	CHEMBL498247; BDBM50269144	10644450	Investigative	D0W6CE	.	CTPDG009327
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	Investigative	D0X4OU	.	CTPDG009328
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Tyrphostin ag-1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	Investigative	D0ZH1U	.	CTPDG009329
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	CL-387785	"194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	Investigative	D00TZD	.	CTPDG009330
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HDS-029	HDS 029	11566580	Investigative	D05FFT	.	CTPDG009331
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	WHI-P154	.	3795	Investigative	D0E5IP	.	CTPDG008344
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PMID24915291C38	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6	71556703	Investigative	D06BJG	.	CTPDG009332
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	HKI-9924129	.	5311104	Investigative	D0D5EW	.	CTPDG009333
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	Investigative	D0GW4Q	.	CTPDG009334
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PD-0166326	PD-166326	447700	Investigative	D0P3JW	DB08339	CTPDG009335
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	PP121	PP-121; PP 121	24905142	Investigative	D03EHM	DB08052	CTPDG009336
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Osimertinib	Tagrisso	71496458	Approved	D0O8GK	DB09330	CTPDG009213
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Patented	PMID27774824-Compound-Figure9Example2down	.	.	Patented	D01DBB	.	CTPDG009424
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Approved	Mobocertinib	"1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate"	118607832	Approved	DI4HA7	.	CTPDG000009
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	DZD9008	.	.	Phase 1/2	DM8Y2N	.	CTPDG003164
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 3	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	Phase 3	D0FV3K	DB15327	CTPDG014583
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	Phase 1/2	D06VFF	.	CTPDG014584
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	Phase 1/2	D09BZS	.	CTPDG014585
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	Phase 1	D0M8YM	DB14993	CTPDG004597
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFRvIII CAR transduced PBL	.	.	Phase 1/2	D08RJY	.	CTPDG003502
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	EGFRvIII CAR	.	.	Phase 1/2	D0LU4N	.	CTPDG014644
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1/2	Anti-EGFR V III CAR-T cells	.	.	Phase 1/2	D0Q4EJ	.	CTPDG014645
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII CAR T cells	.	.	Phase 1	D01LWE	.	CTPDG014646
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T cells targeting EGFRviii	.	.	Phase 1	D03CMZ	.	CTPDG014647
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	Anti-EGFRvIII CAR T cells	.	.	Phase 1	D09OSC	.	CTPDG014648
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CART-EGFRvIII T cells	.	.	Phase 1	D0B5PV	.	CTPDG014649
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	EGFRvIII-CARs	.	.	Phase 1	D0PT2M	.	CTPDG014650
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	CAR-T Cells targeting EGFRvIII	.	.	Phase 1	D0ZQ6N	.	CTPDG004213
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	RG6156	.	.	Phase 1	DF8X5N	.	CTPDG003919
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	AMG 596	.	.	Phase 1	DOJ6E8	.	CTPDG014651
M6ACROT05378	Epidermal growth factor receptor (EGFR)	EGFR_HUMAN	.	.	Phase 1	D2C7	.	.	Phase 1	DR4ND6	.	CTPDG009252
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Phase 2	CXA10	.	.	Phase 2	DF1JO7	.	CTPDG013052
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-8	.	66546002	Patented	D01GTU	.	CTPDG013073
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 4"	PMID28454500-Compound-31	.	Patented	D01MZI	.	CTPDG013074
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-36	.	121289252	Patented	D01PKZ	.	CTPDG013075
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 4	PMID28454500-Compound-19	118567653	Patented	D02SPI	.	CTPDG013078
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 1	PMID28454500-Compound-38	.	Patented	D02YNU	.	CTPDG013079
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Vinyl sulfone derivative 1	PMID28454500-Compound-20	73053707	Patented	D04ILM	.	CTPDG013080
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 2"	PMID28454500-Compound-29	.	Patented	D06LEF	.	CTPDG013081
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Diterpenoid derivative 1	PMID28454500-Compound-47	132210477	Patented	D09FZF	.	CTPDG013082
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-13	.	73335601	Patented	D0AJ2T	.	CTPDG013084
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-12	.	.	Patented	D0AX4Q	.	CTPDG013086
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 1"	PMID28454500-Compound-28	.	Patented	D0AZ8T	.	CTPDG013087
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-41	.	11000442	Patented	D0C1PB	.	CTPDG013088
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 2	PMID28454500-Compound-17	118567519	Patented	D0EO3S	.	CTPDG013089
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-34	.	121289250	Patented	D0FH6P	.	CTPDG013090
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-33	.	121289344	Patented	D0FM3Q	.	CTPDG013091
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 3	PMID28454500-Compound-18	.	Patented	D0G1LS	.	CTPDG013092
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-50	.	193653	Patented	D0G4EK	DB04339	CTPDG013093
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-3	.	.	Patented	D0JH8Z	.	CTPDG013095
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Pyridyl compound 1	PMID28454500-Compound-15	.	Patented	D0KX0J	.	CTPDG013096
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-32	.	121289291	Patented	D0L1JQ	.	CTPDG013097
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-40	.	5316743	Patented	D0MQ3X	.	CTPDG013099
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-35	.	121289348	Patented	D0MX0Q	.	CTPDG013101
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-49	.	.	Patented	D0N1VC	.	CTPDG013102
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-9	.	66546189	Patented	D0N9GH	.	CTPDG013103
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Diterpenoid derivative 2	PMID28454500-Compound-48	132210549	Patented	D0Q9QQ	.	CTPDG013107
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-11	.	68066028	Patented	D0RM4V	.	CTPDG013108
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-37	.	121289347	Patented	D0SA1N	.	CTPDG013109
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Chalcone derivative 1	PMID28454500-Compound-16	53262706	Patented	D0U9TR	.	CTPDG013110
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	"Pyrazino[2,1-a]isoquinolin derivative 3"	PMID28454500-Compound-30	.	Patented	D0VA2G	.	CTPDG013111
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	2-hydroxybenzamide derivative 2	PMID28454500-Compound-39	.	Patented	D0VW9H	.	CTPDG013112
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	PMID28454500-Compound-10	.	68066062	Patented	D0WN1Y	.	CTPDG013113
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Patented	Trepenoid derivative 1	PMID28454500-Compound-14	.	Patented	D0XL2V	.	CTPDG013115
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Preclinical	VCB101	.	.	Preclinical	D46EBX	.	CTPDG014789
M6ACROT05380	Kelch-like ECH-associated protein 1 (KEAP1)	KEAP1_HUMAN	.	.	Preclinical	VCB102	.	.	Preclinical	DG07UD	.	CTPDG006986
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05395	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 3	XEMILOFIBAN	"Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate"	60957	Discontinued in Phase 3	D07EXV	.	CTPDG014838
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 1	DMP-802	"CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid"	9812185	Discontinued in Phase 1	D0K0NP	.	CTPDG014839
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-709780	"CHEMBL32960; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid"	9885190	Terminated	D03GCN	.	CTPDG014840
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-8857	"CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid"	9933077	Terminated	D03QHI	.	CTPDG014841
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SKF-107260	"F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)"	164393	Terminated	D08CQL	.	CTPDG014842
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-738167	"CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)"	153986	Terminated	D08LIG	.	CTPDG014843
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	DMP-757	"CHEMBL65617; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid"	10031011	Terminated	D0U4ZY	.	CTPDG014844
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-5054	CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	Terminated	D0Z0XQ	.	CTPDG014845
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	Terminated	D0G9BX	.	CTPDG014846
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SB-223245	"CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid"	9823503	Terminated	D0LT1S	.	CTPDG014847
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-739758	"CHEMBL78760; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid"	9958398	Investigative	D01XUU	.	CTPDG014848
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 25237	.	.	Investigative	D02MYZ	.	CTPDG014849
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ROXIFIBAN	"UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy"	177230	Investigative	D04BHL	.	CTPDG014850
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RWJ-53419	CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	Investigative	D04XTP	.	CTPDG014851
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-750034	CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	Investigative	D05AGK	.	CTPDG014852
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-756568	CHEMBL96097; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	Investigative	D06LHH	.	CTPDG014853
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SC-54701A	"UNII-TN585Y92BI; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)"	9862322	Investigative	D08RLR	.	CTPDG014854
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-734115	"CHEMBL40502; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)"	9913833	Investigative	D0C8LA	.	CTPDG014855
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-207043	CHEMBL606910	52942958	Investigative	D0M7KS	.	CTPDG014856
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 196103	.	.	Investigative	D0Q2ZS	.	CTPDG014857
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-746233	"CHEMBL79294; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid"	10324223	Investigative	D0S8DT	.	CTPDG014858
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-767679	"CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-"	177364	Investigative	D0W5ZK	.	CTPDG014859
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfF)	CHEMBL380434	10699123	Investigative	D00YBU	.	CTPDG014860
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	Investigative	D01AXA	.	CTPDG014861
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	Investigative	D01BZH	.	CTPDG014862
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	Investigative	D01MGI	.	CTPDG014863
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603	44418280	Investigative	D01ZJF	.	CTPDG014472
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	Investigative	D03KLT	.	CTPDG014864
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	Investigative	D03YLY	.	CTPDG014865
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]2	.	91936295	Investigative	D04MCL	.	CTPDG014866
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	Investigative	D04WVG	.	CTPDG014867
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693	10416726	Investigative	D05EWB	.	CTPDG014868
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	Investigative	D05GXK	.	CTPDG014869
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2	CHEMBL414385	44388431	Investigative	D05MJG	.	CTPDG014870
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	Investigative	D05VEC	.	CTPDG014871
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	Investigative	D06JLN	.	CTPDG014872
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser	"96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-"	123811	Investigative	D06LKH	.	CTPDG014873
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	Investigative	D07QJD	.	CTPDG014874
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfMeF)	CHEMBL383747	44408450	Investigative	D07UOF	.	CTPDG014875
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077	11505585	Investigative	D08CFM	.	CTPDG014876
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	Investigative	D08DSG	.	CTPDG014877
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	Investigative	D09PLA	.	CTPDG014878
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RGDechi	.	91936353	Investigative	D0D4QZ	.	CTPDG014879
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	Investigative	D0G7QJ	.	CTPDG014473
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo(RGDfV) (control)	CHEMBL206344	44409460	Investigative	D0G8JI	.	CTPDG014880
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590	11643340	Investigative	D0H4EK	.	CTPDG014881
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISONIPECOTAMIDE	"Piperidine-4-carboxamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide"	3772	Investigative	D0H4MB	.	CTPDG014882
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309	9831456	Investigative	D0I5BY	.	CTPDG014883
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	CYCLORGDFV	"cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid"	9851104	Investigative	D0ID6U	.	CTPDG014884
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	Investigative	D0J6SP	.	CTPDG014885
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2-PTX conjugate	.	91933274	Investigative	D0K5DM	.	CTPDG014886
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]1	.	91936298	Investigative	D0L2PQ	.	CTPDG014887
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	Investigative	D0LF7W	.	CTPDG014888
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser-Pro-Lys	"Grgdspk; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-"	130667	Investigative	D0LV6B	.	CTPDG014889
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589	11636164	Investigative	D0M0BN	.	CTPDG014890
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574	10372586	Investigative	D0M6NQ	.	CTPDG014891
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]2	.	91936297	Investigative	D0N9NA	.	CTPDG014892
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	Investigative	D0O6DN	.	CTPDG014893
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	Investigative	D0O9FL	.	CTPDG014894
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]1	CHEMBL438186	44409497	Investigative	D0P4RB	.	CTPDG014895
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide"	"CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01"	558969	Investigative	D0R9AD	.	CTPDG014896
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	Investigative	D0R9GW	.	CTPDG014897
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ST-1646	CHEMBL392303	44439175	Investigative	D0R9SJ	.	CTPDG014898
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo[RGDfK(cypate)]	CHEMBL407126	44409643	Investigative	D0T1II	.	CTPDG014899
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	Investigative	D0TP8S	.	CTPDG014474
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	Investigative	D0U0VF	.	CTPDG014900
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066	44408397	Investigative	D0U2NV	.	CTPDG014901
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	Investigative	D0UE7H	.	CTPDG014902
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]2	.	91936296	Investigative	D0UO0Y	.	CTPDG014903
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056	9986643	Investigative	D0V0JC	.	CTPDG014904
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	Investigative	D0W6CJ	.	CTPDG014905
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"C[RGDf-(S,R)-alpha-Dfm-F]"	CHEMBL379911	11614485	Investigative	D0WK2F	.	CTPDG014906
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	AcDRGDS	CHEMBL241297; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	Investigative	D0X4EE	.	CTPDG014907
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]1	.	91936299	Investigative	D0Y8UD	.	CTPDG014908
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	Investigative	D0Z6WZ	.	CTPDG014909
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT05396	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT05419	Serine/threonine-protein kinase LATS2 (LATS2)	LATS2_HUMAN	.	.	Investigative	PMID20684608C35	GTPL8209; BDBM50324574	46864283	Investigative	D0R3MO	.	CTPDG012938
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05422	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05423	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05427	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05427	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05427	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05428	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05428	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05428	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Approved	Pemigatinib	"Unii-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828"	86705695	Approved	D0O6UY	DB15102	CTPDG010066
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 4	Trapidil	"Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991"	5531	Phase 4	D0U2CV	DB09283	CTPDG000833
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 3	BMS-582664	"Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester"	11154925	Phase 3	D03WQS	DB11865	CTPDG012895
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 3	TKI258	"Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one"	135611162	Phase 3	D07OZR	.	CTPDG001353
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 3	E-3810	"Lucitanib; AL-3810; E-3810, EOS"	25031915	Phase 3	D02WVT	DB11845	CTPDG001454
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 2	B-701	"VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester"	95987	Phase 2	D0G6CF	.	CTPDG002363
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 2	Recifercept	TA-46	.	Phase 2	DBA40S	.	CTPDG012896
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 2	Debio 1347	.	66555680	Phase 2	D0XT0W	DB12903	CTPDG001886
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 1/2	AEE-788	"AEE; AEE 788; AEE788; GNF-Pf-5343; AEE-788, NVP-AEE 788, AEE788"	10297043	Phase 1/2	D0G2QH	DB12558	CTPDG003432
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 1	Anti-FGFR3	.	.	Phase 1	D0V0BO	.	CTPDG004357
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Phase 1	SAR442501	.	.	Phase 1	D9FMA2	.	CTPDG012897
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Investigative	AV-370	"Anti-FGF3 receptor antibody (cancer), AVEO Pharmaceuticals"	.	Investigative	D03HGW	.	CTPDG008974
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Investigative	SU5402	215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid	5289418	Investigative	D0A4XJ	DB08577	CTPDG008492
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Investigative	"5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol"	"9-Hydroxyellipticine; 9-Hydroxyellipticin; 51131-85-2; Hydroxyellipticine; ELLIPTICINE, 9-HYDROXY-; UNII-9G4A3ET6XG; IGIG 929; Hydroxy-9 ellipticine [French]; EINECS 257-000-0; NSC 237070; NSC 210717; 9G4A3ET6XG; CHEMBL26559; CHEBI:88297; C17H14N2O; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazol-9-ol; 6H-Pyrido(4,3-b)carbazol-9-ol, 5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazol-9-ol, 5,11-dimethyl-; 9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; Hydroxy-9 ellipticine"	91643	Investigative	D05FFB	.	CTPDG010046
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Investigative	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	Investigative	D0R6OM	.	CTPDG007907
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Investigative	PMID21493067C1d	GTPL8123; BDBM50343726	53232451	Investigative	D02NNT	.	CTPDG009436
M6ACROT05430	Fibroblast growth factor receptor 3 (FGFR3)	FGFR3_HUMAN	.	.	Investigative	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	Investigative	D09XIL	.	CTPDG009338
M6ACROT05437	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05437	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05437	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05438	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05438	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05438	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05453	Neurogenic locus notch homolog protein 1 (NOTCH1)	NOTC1_HUMAN	.	.	Phase 1/2	LY3039478	"Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-"	71236992	Phase 1/2	D08WOW	DB12050	CTPDG003499
M6ACROT05453	Neurogenic locus notch homolog protein 1 (NOTCH1)	NOTC1_HUMAN	.	.	Phase 1	OMP-52M51	.	.	Phase 1	D0X3YY	.	CTPDG004287
M6ACROT05465	Homeodomain-interacting protein kinase 2 (HIPK2)	HIPK2_HUMAN	.	.	Investigative	PMID24900749C1a	GTPL8128; BDBM50437434	72163809	Investigative	D04TPA	.	CTPDG015471
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	Belnacasan	"Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765)"	11398092	Phase 2	D0HK3N	.	CTPDG014158
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	PRALNACASAN	"VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide"	153270	Phase 2	D0U6WQ	DB04875	CTPDG001987
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	Nivocasan	GS-9450; LB-84451	11633038	Phase 2	D0Z2JF	DB12720	CTPDG014159
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Phase 2	AC-201	.	.	Phase 2	D0WP2R	.	CTPDG001911
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Patented	Ac-YVAD-FMK	.	.	Patented	D04KIH	.	CTPDG014160
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Patented	Ac-YVAD-cmk	.	.	Patented	D07AVV	.	CTPDG014161
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Terminated	VE-16084	"ICE inhibitors, Sanofi Winthrop; WIN-67694"	10009105	Terminated	D0A3HF	.	CTPDG007405
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Terminated	L-709049	Ac-Yvad-cho; 143313-51-3; Acetyl-tyrosyl-valyl-alanyl-aspartal; Caspase-1 Inhibitor I; CHEMBL37630; Ac-Tyr-Val-Ala-Asp-H; IL-1beta Converting Enzyme (ICE) Inhibitor I; acetyl-Tyr-Val-Ala-Asp-aldehyde; N-acetyl-Tyr-Val-Ala-Asp-aldehyde; (3S)-3-[(2S)-2-[(2S)-2-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]-4-oxobutanoic acid; Ac-Tyr-Val-Ala-Asp-Aldehyde; AC1NSK2K; SCHEMBL4349143; BDBM10355; MolPort-016-580-695; N-acetyl-Tyr-Val-Ala-Asp aldehyde; ZINC3915255; 1600AH; NCGC00167338-01	5311139	Terminated	D0F9FA	.	CTPDG014162
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Terminated	SDZ-224-015	VE-13045	101925102	Terminated	D0K1CL	.	CTPDG007304
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	YVAD	.	9847365	Investigative	D0B3WF	.	CTPDG014163
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	Z-YVAD-CHO	CHEMBL159822	44407073	Investigative	D0P3XJ	.	CTPDG014164
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	Z-VAD-CHO	CHEMBL320954; ZVAD-CHO; BDBM50176519; (S)-3-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-butyric acid	10112904	Investigative	D0X8XO	.	CTPDG014165
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	Z-YVAD-FMK	benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone; caspase-1 Inhibitor VI	644196	Investigative	D0YX4V	.	CTPDG014166
M6ACROT05484	Caspase-1 (CASP1)	CASP1_HUMAN	.	.	Investigative	M826	compound 4sx	9851134	Investigative	D00YNW	.	CTPDG014167
M6ACROT05505	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT05515	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05515	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05515	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05516	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05516	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05516	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05525	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	Approved	D00UZR	DB09073	CTPDG010898
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	Approved	D01HVT	.	CTPDG010899
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	Approved	D05SBO	DB12001	CTPDG010900
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	Approved	D0AP9E	DB15442	CTPDG010901
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Approved	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	Approved	D07ESC	DB05676	CTPDG000576
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 3	LEE011	"Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	Phase 3	D08MXP	DB11730	CTPDG001328
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 2	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	Phase 2	D0WU1O	.	CTPDG010903
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	GLR2007	.	.	Phase 1/2	D4IS0G	.	CTPDG010905
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	FCN-437	.	.	Phase 1/2	D8ZV2Q	.	CTPDG010906
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1/2	NUV-422	.	.	Phase 1/2	D70HZT	.	CTPDG010907
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	G1T28-1	.	.	Phase 1	D01XZG	.	CTPDG005374
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	RGT-419B	.	.	Phase 1	DYH94Z	.	CTPDG010908
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Phase 1	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	Phase 1	DKCU40	.	CTPDG003845
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-49	.	.	Patented	D07TVO	.	CTPDG010161
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-51	.	.	Patented	D0KH7Q	.	CTPDG010162
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	"Isoquinoline 1,3-dione derivative 1"	PMID26161698-Compound-49	.	Patented	D0W4MN	.	CTPDG010916
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-48	.	.	Patented	D0WJ3W	.	CTPDG010163
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-47	.	.	Patented	D0X5VI	.	CTPDG010164
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	PMID25726713-Compound-50	.	.	Patented	D0Y8JF	.	CTPDG010165
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Preclinical	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	Preclinical	D07ZJC	.	CTPDG007117
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	Terminated	D0Y6HA	.	CTPDG007172
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Terminated	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	Terminated	D0Z0KD	.	CTPDG010067
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	Investigative	D09OAH	.	CTPDG010926
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Deschloroflavopiridol	.	102397231	Investigative	D0CI3C	.	CTPDG011233
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	Investigative	D0J4ON	.	CTPDG011234
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	Chrysin	"480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	Investigative	D01UYI	DB15581	CTPDG011235
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	APIGENIN	"520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	Investigative	D00RIX	DB07352	CTPDG011237
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05536	Cyclin-dependent kinase 6 (CDK6)	CDK6_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Approved	Meprobamate	"Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455"	4064	Approved	D0Y4AW	DB00371	CTPDG011238
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Phase 2	Bryostatin-1	Bryostatin 1; 83314-01-6	5280757	Phase 2	D0E6AH	.	CTPDG002423
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Terminated	CDE-6960	"Protein kinase C epsilon/theta inhibitors (inflammation); PKC epsilon/theta inhibitors (inflammation), Devgen; Protein kinase C epsilon/theta inhibitors (inflammation), Devgen"	.	Terminated	D0J7CE	.	CTPDG011239
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Terminated	LY-317644	CHEMBL294120; BDBM50285193	15391529	Terminated	D0X0HN	.	CTPDG011240
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Terminated	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	Terminated	D0R5ZR	.	CTPDG011241
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	Phorbol 12-myristate	"Phorbol-12-myristate; Phorbol-12-monomyristate; BRN 2319156; (1ar,1bs,4ar,7as,7bs,8r,9r,9as)-4a,7b,9a-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl tetradecanoate; 20839-06-9; Tetradecanoic acid, 1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b,9a-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa(3,4)benz(1,2-e)azulen-9-yl ester, (1aR-(1a-alpha,1b-beta,4a-beta,7a-alpha,7b-alpha,8-alpha,9-beta,9a-alpha))-"	107854	Investigative	D0D4ZL	.	CTPDG011242
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"[2,2':5',2'']Terthiophen-4-yl-methanol"	CHEMBL76100; BDBM50217032	44313272	Investigative	D00TWA	.	CTPDG011243
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	"Phenol, 4,4'-(3-methyl-1-butenylidene)bis-; 66422-07-9; CHEMBL156843; CTK1J4765; DTXSID70441143; ZINC13650255"	10515117	Investigative	D02PUV	.	CTPDG011244
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile"	CHEMBL305128	14537253	Investigative	D02QME	.	CTPDG011245
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde"	CHEMBL74983; BDBM50217036	9972316	Investigative	D05LRV	.	CTPDG011246
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	Ro-32-0557	CHEMBL538718	44274749	Investigative	D09TSC	.	CTPDG011247
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile"	CHEMBL303801	14537255	Investigative	D09XIE	.	CTPDG011248
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile"	CHEMBL304867	14537244	Investigative	D0A8MN	.	CTPDG011249
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"[2,2':5',2'']Terthiophene-4-carbaldehyde"	CHEMBL73495; BDBM50217040	44313051	Investigative	D0D3MR	.	CTPDG011250
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	"4,4'-(Cycloheptylidenemethylene)diphenol; 4,4'-(Cycloheptylidenemethanediyl)diphenol; 14303-48-1; CHEMBL154947; SCHEMBL3468370; CTK0F0060; DTXSID10469043; XVTAYJKFHUKWSR-UHFFFAOYSA-N; 4,4'-(Cycloheptylidenemethylene)bis(phenol); Phenol, 4-[cycloheptylidene(4-hydroxyphenyl)methyl]-"	11587420	Investigative	D0Q3GQ	.	CTPDG011251
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"2,3,3-Triphenyl-acrylonitrile"	"Triphenylacrylonitrile; 2,3,3-Triphenylacrylonitrile; Triphenylcyanoethylene; 6304-33-2; Acrylonitrile, triphenyl-; 2,3,3-triphenylprop-2-enenitrile; alpha,beta-Diphenylcinnamonitrile; ACRYLONITRILE, 2,3,3-TRIPHENYL-; EINECS 228-610-4; NSC 42900; 2,3,3-Trifenylakrylonitril [Czech]; BRN 1980289; alpha-(Diphenylmethylene)benzeneacetic acid; AI3-63069; MLS002608486; CHEBI:34217; Benzeneacetic acid, alpha-(diphenylmethylene)-; NSC42900; Benzeneacetonitrile, .alpha.-(diphenylmethylene)-"	22743	Investigative	D0S9UK	.	CTPDG011252
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile"	"3,3-bis(4-hydroxyphenyl)-2-phenylprop-2-enenitrile; CHEMBL65053"	14537247	Investigative	D0T0UH	.	CTPDG011253
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	"4,4'-(cyclohexylidenemethylene)diphenol; 5189-40-2; Cyclofenil diphenol; 4,4'-Cyclohexylidenemethylenediphenol; UNII-00W4083OML; EINECS 225-972-5; BRN 2055864; F 6060; 4-[cyclohexylidene(4-hydroxyphenyl)methyl]phenol; 4-(Cyclohexylidene(4-hydroxyphenyl)methyl)phenol; 00W4083OML; 4,4-Cyclohexylidenemethylenediphenol; Phenol, 4-(cyclohexylidene(4-hydroxyphenyl)methyl)-; alpha-Cyclohexylidene-alpha-(p-hydroxyphenyl)-p-cresol; p-CRESOL, alpha-CYCLOHEXYLIDENE-alpha-(p-HYDROXYPHENYL)-; AC1L2HYB"	21260	Investigative	D0V9SW	.	CTPDG011254
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	LY-326449	"CHEMBL292495; BDBM50052039; 3,4-[[(S)-3-Oxa-4-(hydroxymethyl)hexane-1,6-diyl]bis(1H-indole-1,3-diyl)]-3-pyrroline-2,5-dione"	10455969	Investigative	D06ZCX	.	CTPDG011255
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Terminated	BALANOL	"63590-19-2; Azepinostatin; CHEMBL60254; Balanol, 1; 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid; BA1; (-)-Balanol; (3R-trans)-Balanol; AC1NRA6W; SCHEMBL62128; MEGxm0_000504; GTPL8142; BDBM3149; Acyclic Balanol Analog (-)-1; BDBM36607; ACon0_001438; ZINC3871640; MCULE-9310625171; 167937-47-5; FT-0662471; 33879-EP2275420A1; 33879-EP2295416A2; 33879-EP2295055A2; 33879-EP2311453A1; 33879-EP2305642A2; 33879-EP2298764A1; 33879-EP2298765A1; 33879-EP2298748A2"	5287736	Terminated	D0R2TM	.	CTPDG011458
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	ISIS 7942	.	.	Investigative	D02VLL	.	CTPDG015273
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	ISIS 7948	.	.	Investigative	D09RFD	.	CTPDG015274
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	chelerythrine	broussonpapyrine; cheleritrine; chelerythrine hydroxide; toddalin	2703	Investigative	D0T9ZL	.	CTPDG015275
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	8-Octyl-benzolactam-V9	CHEMBL206866; 8-Octylbenzolactam-V9	11574614	Investigative	D04AXH	.	CTPDG015250
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	PROSTRATIN	.	454217	Investigative	D04JNZ	.	CTPDG011473
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	Bisindolylmaleimide-I	"Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	Investigative	D0TO6S	DB03777	CTPDG012915
M6ACROT05554	Protein kinase C epsilon (PRKCE)	KPCE_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Phase 4	Dichloroacetate	"2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050"	25975	Phase 4	D7I9JH	.	CTPDG000839
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 4	PMID25684022-Compound-WO2012058176 27(6)	.	Patented	D00LMA	.	CTPDG006305
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrazole derivative 61	PMID25684022-Compound-US20090111799	.	Patented	D00MLJ	.	CTPDG006303
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 37(4-6)	.	.	Patented	D00SVK	.	CTPDG006295
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 3	PMID25684022-Compound-WO2012058176 26(5)	.	Patented	D00ZXR	.	CTPDG006285
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrimidine derivative 3	PMID25684022-Compound-WO2011076327	.	Patented	D02MMG	.	CTPDG006257
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 15	PMID25684022-Compound-WO2012044157 4(58)	.	Patented	D02USE	.	CTPDG006246
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Thieno[3,2-c]pyridine-7-carboxamide derivative 2"	PMID25684022-Compound-WO2006106326c2	.	Patented	D03GFZ	.	CTPDG006232
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 9	PMID25684022-Compound-WO2012058176 32(20)	.	Patented	D03WFI	.	CTPDG006216
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 24	PMID25684022-Compound-WO2012036974 18(27)	.	Patented	D04BBA	.	CTPDG006209
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 12	PMID25684022-Compound-WO2012044157 1(1.5)	.	Patented	D04BBT	.	CTPDG006208
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 41(1.3)	.	.	Patented	D04EDM	.	CTPDG006204
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 17	PMID25684022-Compound-WO2012044157 6(360)	.	Patented	D04MHV	.	CTPDG006195
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 27	PMID25684022-Compound-WO2012036974 21(40)	.	Patented	D04QRX	.	CTPDG006188
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2008079988	.	.	Patented	D04UHW	.	CTPDG006183
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyridinone carboxamide derivative 1	PMID25684022-Compound-WO2010007116	.	Patented	D05GMT	.	CTPDG006172
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 4	PMID25684022-Compound-US20120208819 1(1.5)	.	Patented	D05OTD	.	CTPDG006164
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Thieno[3,2-c]pyridine-7-carboxamide derivative 1"	PMID25684022-Compound-WO2006106326c1	.	Patented	D06BSG	.	CTPDG006153
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 9	PMID25684022-Compound-US20130165450 18(27)	.	Patented	D06LCB	.	CTPDG006146
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2009153313	.	.	Patented	D06LLS	.	CTPDG006145
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 40(1.2)	.	.	Patented	D06LSZ	.	CTPDG006144
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 12	PMID25684022-Compound-US20130165450 21(40)	.	Patented	D06PTW	.	CTPDG006140
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2004087707	.	.	Patented	D06RGW	.	CTPDG006139
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Benzimidazole and imidazopyridine derivative 1	PMID25684022-Compound-WO2011006567	.	Patented	D06WAN	.	CTPDG006133
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 14	PMID25684022-Compound-US20130165450 24(45)	.	Patented	D06WXJ	.	CTPDG006132
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 38(5-7)	.	.	Patented	D07FMW	.	CTPDG006122
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 9	PMID25684022-Compound-US20120208819 6(360)	.	Patented	D07HOA	.	CTPDG006118
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 10	PMID25684022-Compound-US20120208819 7(402)	.	Patented	D07IQE	.	CTPDG006116
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 11	PMID25684022-Compound-US20130165450 20(38)	.	Patented	D07MSB	.	CTPDG006111
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 36(3-5)	.	.	Patented	D07XBA	.	CTPDG006096
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 45(1.5)	.	.	Patented	D07ZKE	.	CTPDG006093
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 29	PMID25684022-Compound-WO2012036974 24(45)	.	Patented	D07ZMG	.	CTPDG006092
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2008005457	.	.	Patented	D08EGT	.	CTPDG006085
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 2	PMID25684022-Compound-WO2012058176 25(3)	.	Patented	D08SNT	.	CTPDG006078
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 7	PMID25684022-Compound-US20130165450 16(16)	.	Patented	D08YPQ	.	CTPDG006071
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 11	PMID25684022-Compound-US20120208819 8(443)	.	Patented	D09BNP	.	CTPDG006067
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 39(1.1)	.	.	Patented	D09FQP	.	CTPDG006063
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 8	PMID25684022-Compound-US20120208819 5(355)	.	Patented	D0AM2D	.	CTPDG006036
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 20	PMID25684022-Compound-WO2012036974 14(14)	.	Patented	D0B2GM	.	CTPDG006030
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 36(3-5)	.	.	Patented	D0B8OB	.	CTPDG006024
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2010127754	.	.	Patented	D0C6VX	.	CTPDG006011
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Indazole derivative 1	PMID25684022-Compound-WO2003064397	.	Patented	D0CK8H	.	CTPDG006002
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic-carboxamide derivative 2	PMID25684022-Compound-WO2011044157	.	Patented	D0CQ1M	.	CTPDG005998
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 6	PMID25684022-Compound-US20120208819 3(7.6)	.	Patented	D0D0ML	.	CTPDG005991
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Imidazo quinoline derivative 1	PMID25684022-Compound-WO2008054238	.	Patented	D0D5YE	.	CTPDG005984
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 16	PMID25684022-Compound-WO2012036974 10(4)	.	Patented	D0D8PF	.	CTPDG005979
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2012135799 42(1.4)	.	.	Patented	D0DC2P	.	CTPDG005977
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Bis-indolylmaleimide derivative 1	PMID25684022-Compound-WO2005041953	.	Patented	D0DM2G	.	CTPDG005967
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 23	PMID25684022-Compound-WO2012036974 17(23)	.	Patented	D0DO6K	.	CTPDG005965
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 14	PMID25684022-Compound-WO2012044157 3(7.6)	.	Patented	D0EH9Z	.	CTPDG005947
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 18	PMID25684022-Compound-WO2012036974 12(12)	.	Patented	D0FJ4A	.	CTPDG005926
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 18	PMID25684022-Compound-WO2012044157 7(402)	.	Patented	D0FW3M	.	CTPDG005916
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 17	PMID25684022-Compound-WO2012036974 11(5)	.	Patented	D0GE6F	.	CTPDG005909
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 6	PMID25684022-Compound-WO2012058176 29(8)	.	Patented	D0GH9W	.	CTPDG005907
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 19	PMID25684022-Compound-WO2012036974 13(13)	.	Patented	D0GY8G	.	CTPDG005899
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 4	PMID25684022-Compound-US20130165450 13(13)	.	Patented	D0H6AF	.	CTPDG005888
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 1	PMID25684022-Compound-WO2012058176 24(47)	.	Patented	D0H7SO	.	CTPDG005885
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 13	PMID25684022-Compound-WO2012044157 2(2.4)	.	Patented	D0HI8X	.	CTPDG005875
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 2	PMID25684022-Compound-US20130165450 11(5)	.	Patented	D0HP8K	.	CTPDG005874
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrazolopyridines and imidazopyridine derivative 1	PMID25684022-Compound-WO2010017047	.	Patented	D0I1YQ	.	CTPDG005868
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Dibenzo [c,f]-[2,7]naphthyridine derivative 1"	PMID25684022-Compound-US20070135429	.	Patented	D0I5KI	.	CTPDG005863
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 38(5-7)	.	.	Patented	D0IO2X	.	CTPDG005850
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Benzonaphthyridine derivative 2	PMID25684022-Compound-WO2008109613	.	Patented	D0IR8B	.	CTPDG005847
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 5	PMID25684022-Compound-US20120208819 2(2.4)	.	Patented	D0J9DI	.	CTPDG005835
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 25	PMID25684022-Compound-WO2012036974 19(36)	.	Patented	D0JR0F	.	CTPDG005831
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 10	PMID25684022-Compound-US20130165450 19(36)	.	Patented	D0K8XT	.	CTPDG005814
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 22	PMID25684022-Compound-WO2012036974 16(16)	.	Patented	D0KN7T	.	CTPDG005804
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 5	PMID25684022-Compound-WO2012058176 28(7)	.	Patented	D0MG4D	.	CTPDG005776
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2008107444	.	.	Patented	D0MI3E	.	CTPDG005774
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 7	PMID25684022-Compound-WO2012058176 30(12)	.	Patented	D0MW7L	.	CTPDG005770
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 35(1-11)	.	.	Patented	D0P0WF	.	CTPDG005721
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrimidinone derivative 1	PMID25684022-Compound-WO2010007114	.	Patented	D0P1VT	.	CTPDG005720
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 21	PMID25684022-Compound-WO2012036974 15(15)	.	Patented	D0P6PT	.	CTPDG005715
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 8	PMID25684022-Compound-US20130165450 17(23)	.	Patented	D0PD2I	.	CTPDG005709
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1"	PMID25684022-Compound-WO2010120854	.	Patented	D0PJ7M	.	CTPDG005708
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 1	PMID25684022-Compound-US20130165450 10(4)	.	Patented	D0Q6RC	.	CTPDG005700
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 15	PMID25684022-Compound-US20130165450 9(2)	.	Patented	D0Q8JK	.	CTPDG005698
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 28	PMID25684022-Compound-WO2012036974 23(41)	.	Patented	D0QV1E	.	CTPDG005688
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2012135799 43(1.5)	.	.	Patented	D0R0SJ	.	CTPDG005687
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 3	PMID25684022-Compound-US20130165450 12(12)	.	Patented	D0R3VG	.	CTPDG005680
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 44(1.4)	.	.	Patented	D0RE3R	.	CTPDG005668
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 16	PMID25684022-Compound-WO2012044157 5(355)	.	Patented	D0RH6G	.	CTPDG005666
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2006015124	.	.	Patented	D0RP4U	.	CTPDG005663
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic-carboxamide derivative 1	PMID25684022-Compound-WO2010065384	.	Patented	D0RY6M	.	CTPDG005660
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 35(1-11)	.	.	Patented	D0SB4A	.	CTPDG005652
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 10	PMID25684022-Compound-WO2012058176 33(21)	.	Patented	D0TB2H	.	CTPDG005633
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Benzonaphthyridine derivative 1	PMID25684022-Compound-WO2008109599	.	Patented	D0U3IS	.	CTPDG005625
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 5	PMID25684022-Compound-US20130165450 14(14)	.	Patented	D0U5HB	.	CTPDG005620
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 26	PMID25684022-Compound-WO2012036974 20(38)	.	Patented	D0U7LW	.	CTPDG005616
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 7	PMID25684022-Compound-US20120208819 4(58)	.	Patented	D0W3JC	.	CTPDG005584
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 8	PMID25684022-Compound-WO2012058176 31(13)	.	Patented	D0WT9J	.	CTPDG005573
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 19	PMID25684022-Compound-WO2012044157 8(443)	.	Patented	D0WX4H	.	CTPDG005570
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 37(4-6)	.	.	Patented	D0Y0RG	.	CTPDG005554
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-EP20041486488	.	.	Patented	D0YD1Q	.	CTPDG005547
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 30	PMID25684022-Compound-WO2012036974 9(2)	.	Patented	D0Z3HW	.	CTPDG005534
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 6	PMID25684022-Compound-US20130165450 15(15)	.	Patented	D0Z5HL	.	CTPDG005530
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Indolinone derivative 1	PMID25684022-Compound-US200607105563	11161844	Patented	D0ZE5U	.	CTPDG005523
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 13	PMID25684022-Compound-US20130165450 23(41)	.	Patented	D0ZG0K	.	CTPDG005520
M6ACROT05556	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1"	PMID25684022-Compound-WO2010019637	.	Patented	D0ZV9P	.	CTPDG005513
M6ACROT05558	Neurotrophic factor BDNF precursor form (BDNF)	BDNF_HUMAN	.	.	Phase 2	PYM-50028	Cogane; Smilagenin; P-58; P-63	.	Phase 2	D0M2TG	.	CTPDG014672
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Approved	Sulfinpyrazone	"Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione"	5342	Approved	D03DEI	DB01138	CTPDG011122
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Approved	Benzbromarone	"Acifugan; Azubromaron; Benzbromaron; Benzbromaronratiopharm; Benzbromaronum; Benzobromarona; Besuric; Desuric; Exurate; Harolan; Hipurik; Minuric; Narcaricin; Normurat; Uricovac; Urinorm; Uroleap; Aliud Brand of Benzbromarone; Benzbromaron AL; Benzbromaron ratiopharm; Benzbromarone Aliud Brand; Benzbromarone Heumann Brand; Benzbromarone Sanfer Brand; Benzbromarone ratiopharm Brand; Heumann Brand of Benzbromarone; Ratiopharm Brand of Benzbromarone; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; L 2214; L2214; MJ 10061; NCI85433; AL, Benzbromaron; Benzbromaron-ratiopharm; Benzbromaronum [INN-Latin]; Benzobromarona [INN-Spanish]; L 2214-Labaz; L-2214; Uroleap (TN); Benzbromarone [USAN:INN:BAN]; Methanone, (3; Benzbromarone (JP15/USAN/INN); KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN"	2333	Approved	D0Z3DY	DB12319	CTPDG011123
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Investigative	Pyrrolopyrimidine	.	577022	Investigative	D0KX3H	.	CTPDG011124
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Investigative	XR-9456	CHEMBL346292; SCHEMBL7170174; BDBM50375810	15511439	Investigative	D04GYT	.	CTPDG011125
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Investigative	XR-9504	CHEMBL258896; SCHEMBL7168501	22004473	Investigative	D09HIM	.	CTPDG011126
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Investigative	XR-9544	CHEMBL444075; SCHEMBL14290581; BDBM50375811	15511440	Investigative	D0A4TF	.	CTPDG011127
M6ACROT05566	ATP binding cassette subfamily C member 1 (ABCC1 blood group) (ABCC1)	MRP1_HUMAN	.	.	Investigative	XR-9577	CHEMBL428402	15950351	Investigative	D0S8CE	.	CTPDG011128
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Phase 3	VB-111	.	.	Phase 3	D0S4LV	.	CTPDG001057
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Phase 2	Drug 2862277	.	.	Phase 2	D07LMO	.	CTPDG014475
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Phase 1	GSK1995057	.	.	Phase 1	D08ENB	.	CTPDG005060
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Phase 1	AVX-470	"Anti-TNF antibody (oral, IBD), Avaxia Biologics"	.	Phase 1	D03HIG	.	CTPDG005315
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Terminated	Anti-IFN gamma	"AGT-1; Anti-IFN gamma (autoimmune diseases); Anti-cytokine antibodies, Advanced Biotherapy; Anti-cytokine therapy, Advanced Biotherapy; Anti-IFN gamma (autoimmune diseases), Advanced Biotherapy"	.	Terminated	D0R4OD	.	CTPDG014476
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	TNFR1 NAM	"TNFR1 negative allosteric modulators, Addex"	.	Investigative	D03IMU	.	CTPDG014477
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	NM-9405	"Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc"	.	Investigative	D08TQK	.	CTPDG008591
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	TNFmab	TNFmab (rheumatoid arthritis)	.	Investigative	D0B6WV	.	CTPDG008449
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	ADS-0101	"ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta"	.	Investigative	D0G9XS	.	CTPDG008257
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	Recombinant human TNF receptor	"Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals"	.	Investigative	D0P4WI	.	CTPDG007982
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	TNFcept	TNFcept (rheumatoid arthritis)	.	Investigative	D0U4QQ	.	CTPDG007829
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	NM-2014	.	.	Investigative	D0W0BN	.	CTPDG007772
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	ALF-421	"CORM-A1; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation); Carbon monoxide-releasing molecules (inflammatory diseases), Alfama; Macromolecular carrier-linked CORMs (inflammation), Alfama; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation), Alfama"	.	Investigative	D0W7FG	.	CTPDG007758
M6ACROT05580	Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	TNR1A_HUMAN	.	.	Investigative	Anti-TNF human mabs	"Anti-TNF human mAbs (autoimmune disease); Anti-TNF human mAbs (autoimmune disease), Xencor; Anti-TNF human monoclonal antibodies (autoimmune disease), Xencor"	.	Investigative	D0X8SM	.	CTPDG014478
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05584	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05585	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Phase 2	GS-4977	.	.	Phase 2	D0D0OT	.	CTPDG014569
M6ACROT05585	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Phase 2	GS-4997	.	71245288	Phase 2	D0RN3S	DB14916	CTPDG014570
M6ACROT05585	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Investigative	MSC2032964A	"CHEMBL3330170; MSC 2032964A; 1124381-43-6; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-pyridinecarboxamide; XUKGFHHTSUKORV-UHFFFAOYSA-N; SCHEMBL2788575; GTPL8076; MolPort-039-338-069; ZINC59102467; BDBM50023727; AKOS027470238; MRF-0000032; NCGC00479218-01; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide"	25214468	Investigative	D0F0XZ	.	CTPDG014571
M6ACROT05585	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Investigative	PMID23147077C10	GTPL8133; BDBM50334268; ZINC43193842; MRF-0000031; NCGC00344859-04	24944925	Investigative	D0Q0YV	.	CTPDG014572
M6ACROT05586	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Phase 2	GS-4977	.	.	Phase 2	D0D0OT	.	CTPDG014569
M6ACROT05586	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Phase 2	GS-4997	.	71245288	Phase 2	D0RN3S	DB14916	CTPDG014570
M6ACROT05586	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Investigative	MSC2032964A	"CHEMBL3330170; MSC 2032964A; 1124381-43-6; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-pyridinecarboxamide; XUKGFHHTSUKORV-UHFFFAOYSA-N; SCHEMBL2788575; GTPL8076; MolPort-039-338-069; ZINC59102467; BDBM50023727; AKOS027470238; MRF-0000032; NCGC00479218-01; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide"	25214468	Investigative	D0F0XZ	.	CTPDG014571
M6ACROT05586	Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	M3K5_HUMAN	.	.	Investigative	PMID23147077C10	GTPL8133; BDBM50334268; ZINC43193842; MRF-0000031; NCGC00344859-04	24944925	Investigative	D0Q0YV	.	CTPDG014572
M6ACROT05589	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05593	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05607	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05613	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT05613	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT05613	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT05613	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT05613	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT05613	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT05614	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05616	Forkhead box protein M1 (FOXM1)	FOXM1_HUMAN	.	.	Investigative	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	Investigative	D01FSW	.	CTPDG015459
M6ACROT05617	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Phase 1	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	Phase 1	D00SIA	.	CTPDG005441
M6ACROT05617	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113048	.	.	Investigative	D01KTF	.	CTPDG015442
M6ACROT05617	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113020	.	.	Investigative	D08YXP	.	CTPDG015443
M6ACROT05617	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113022	.	.	Investigative	D09RTT	.	CTPDG015444
M6ACROT05617	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113019	.	.	Investigative	D0E4IZ	.	CTPDG015445
M6ACROT05617	Transcription factor E2F1 (E2F1)	E2F1_HUMAN	.	.	Investigative	ISIS 113021	.	.	Investigative	D0WM1A	.	CTPDG015446
M6ACROT05618	Krueppel-like factor 4 (KLF4)	KLF4_HUMAN	.	.	Phase 1	APTO-253	.	11960271	Phase 1	D07TRP	.	CTPDG005083
M6ACROT05623	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05623	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05623	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05629	Serine/threonine-protein kinase 4 (STK4)	STK4_HUMAN	.	.	Investigative	TAT-120	"MIP-120, Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease); Peptide Mst-1 inhibitors (ischemia), Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease), Vasade"	.	Investigative	D0A7HY	.	CTPDG008483
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 3	CPI-0610	.	57389999	Phase 3	D01LVE	.	CTPDG014405
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1/2	PLX2853	.	.	Phase 1/2	D07GHA	.	CTPDG003528
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1/2	RVX-208	.	24871506	Phase 1/2	D0N7WW	.	CTPDG003366
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1/2	INCB57643	.	.	Phase 1/2	D0P7FM	.	CTPDG003353
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1/2	OTX-015	MK 8628	9936746	Phase 1/2	D02YNI	DB15189	CTPDG003598
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1	TEN010	.	.	Phase 1	D0B5PK	.	CTPDG004918
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1	AZD5153	"RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe"	118693659	Phase 1	D0PH9I	.	CTPDG004505
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1	GSK525762	GSK-525762	46943432	Phase 1	D07OFM	.	CTPDG005095
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	Phase 1	D05ICT	.	CTPDG005206
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Phase 1	(+)-JQ1	"1268524-70-4; (+)-JQ-1; JQ1 compound; JQ-1; UNII-1MRH0IMX0W; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-JQ1; 1MRH0IMX0W; JQ1; CHEMBL1957266; AK109409; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3"	46907787	Phase 1	D0ZW4W	.	CTPDG004209
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-23	.	118437924	Patented	D00MXR	.	CTPDG014406
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Aminocyclopentenone compound 1	PMID26924192-Compound-93	117928501	Patented	D04HTM	.	CTPDG014407
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrazole and thiophene derivative 4	PMID26924192-Compound-92	118487470	Patented	D05LTB	.	CTPDG014408
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Benzothiazepine analog 12	PMID26924192-Compound-99	118080061	Patented	D07CSE	.	CTPDG014409
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-20	.	118437927	Patented	D07IYX	.	CTPDG014410
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-24	.	91971319	Patented	D08BCK	.	CTPDG014411
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Aminocyclopentenone compound 2	PMID26924192-Compound-94	117928438	Patented	D08JHQ	.	CTPDG014412
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 3	PMID26924192-Compound-36	122553422	Patented	D09FVR	.	CTPDG014413
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Aminocyclopentenone compound 5	PMID26924192-Compound-97	117928680	Patented	D09QSH	.	CTPDG014414
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Aminocyclopentenone compound 6	PMID26924192-Compound-98	.	Patented	D0AU3O	.	CTPDG014415
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-22	.	118437971	Patented	D0C9RQ	.	CTPDG014416
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-31	.	124182114	Patented	D0CB8D	.	CTPDG014417
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrazole and thiophene derivative 2	PMID26924192-Compound-90	118487503	Patented	D0EN4B	.	CTPDG014418
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-25	.	118437925	Patented	D0FN6F	.	CTPDG014419
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 4	PMID26924192-Compound-37	118095161	Patented	D0HO8V	.	CTPDG014420
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrazole and thiophene derivative 3	PMID26924192-Compound-91	136991243	Patented	D0J4QG	.	CTPDG014421
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Aminocyclopentenone compound 3	PMID26924192-Compound-95	117928427	Patented	D0KF8C	.	CTPDG014422
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Aminocyclopentenone compound 4	PMID26924192-Compound-96	117928624	Patented	D0N6JZ	.	CTPDG014423
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 2	PMID26924192-Compound-35	118095207	Patented	D0PE1R	.	CTPDG014424
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Benzothiazepine analog 11	PMID26924192-Compound-101	118080527	Patented	D0S5ID	.	CTPDG014425
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrazole and thiophene derivative 1	PMID26924192-Compound-89	92045047	Patented	D0SQ0F	.	CTPDG014426
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-21	.	118437931	Patented	D0XM8B	.	CTPDG014427
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 5	PMID26924192-Compound-38	118095173	Patented	D0XR9Y	.	CTPDG014428
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Benzothiazepine analog 10	PMID26924192-Compound-100	118079255	Patented	D0Y7YC	.	CTPDG014429
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-30	.	124182286	Patented	D0L7SK	.	CTPDG014430
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-32	.	91864635	Patented	D0SB3H	.	CTPDG014431
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-33	.	124182231	Patented	D0VB3P	.	CTPDG014432
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 1	PMID26924192-Compound-34	122553486	Patented	D0YM3G	.	CTPDG014433
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-104	.	118548317	Patented	D03NWT	.	CTPDG014434
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-102	.	102004282	Patented	D03RPJ	.	CTPDG014435
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-103	.	118542373	Patented	D05XXS	.	CTPDG014436
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Patented	PMID26924192-Compound-105	.	118548311	Patented	D0NN4U	.	CTPDG014437
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	XD1	colchicein; colchiceine; NSC33411	234105	Investigative	D01DMN	.	CTPDG014438
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID25703523C7d	43U; GTPL8304	90684387	Investigative	D01EVE	.	CTPDG014439
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	isoxazole azepine compound 3	.	57345400	Investigative	D01YSN	.	CTPDG014440
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PFI-1	QCR-192; HY-16586; PF-6405761	71271629	Investigative	D03LNF	.	CTPDG014441
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	MS436	.	135566899	Investigative	D09HBR	.	CTPDG014442
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	CPI-203	CPI203; CPI 203	71291068	Investigative	D0C2JS	.	CTPDG014443
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	BzT-7	"CHEMBL1958337; 8-Chloro-1,4-Dimethyl-6-Phenyl-4h-[1,2,4]triazolo[4,3-A][1,3,4]benzotriazepine; 3u5l; GTPL7515; SCHEMBL11468349; UYIVCPRWMLOCSB-UHFFFAOYSA-N; BDBM50365263; 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4)benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4 )benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a) (1,3,4)benzotriazepine"	20350618	Investigative	D0M5DB	.	CTPDG014444
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID23517011C9	GTPL7517; BDBM50430836	71624782	Investigative	D0O2RX	.	CTPDG014445
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	MS417	"Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6"	59190723	Investigative	D0T3YY	.	CTPDG014446
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID25408830C3	GSK-5959; 901245-65-6; GSK5959; GSK 5959; 4uye; GTPL7811; MolPort-004-921-361; HMS1821D17; EX-A2263; BCP16039; ZINC8594565; BDBM50032912; AKOS000481208; MCULE-6727694163; CS-4867; NCGC00107508-01; HY-18665; C301-5895; 9F9; N-[	15990224	Investigative	D03BTJ	.	CTPDG014447
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID25408830C1	BAS 08314227; 4uyd; AC1LLXEX; ChemDiv2_002770; MLS000100042; GTPL7809; MolPort-001-912-793; HMS2483G18; HMS1376N20; ZINC812404; BDBM50032913; AKOS001788033; MCULE-4972680634; SMR000081748; V1T	1091852	Investigative	D09ZPM	.	CTPDG014448
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID21851057C4d	GTPL7516; BDBM50353596	54669868	Investigative	D0H3TC	.	CTPDG014449
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID25408830C2	AC1LNW3E; MLS000663364; GTPL7810; MolPort-002-097-893; HMS2628P17; HMS3438L21; ZINC1063855; BDBM50032921; STL431755; AKOS000445117; MCULE-6603148725; CCG-129099; SMR000300929; SR-01000295962; SR-01000295962-1	1253361	Investigative	D0J6XI	.	CTPDG014450
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	GW841819X	KB-75882	13953710	Investigative	D03LIP	.	CTPDG014451
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID24000170C36	GTPL7521	75124304	Investigative	D0C2XT	.	CTPDG014452
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	PMID24000170C38	GTPL7522	75124305	Investigative	D0Q2GK	.	CTPDG014453
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	I-BET151	GSK1210151A	52912189	Investigative	D0WU1S	.	CTPDG014454
M6ACROT05646	Bromodomain-containing protein 4 (BRD4)	BRD4_HUMAN	.	.	Investigative	XD14	"1370888-71-3; XD 14; 4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; CHEMBL3787231; 4-acetyl-N-(5-(N,N-diethylsulfamoyl)-2-hydroxyphenyl)-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; 4lyw; GTPL7524; SCHEMBL16181763; AOB6049; MolPort-010-365-022; XD-14; EX-A1864; ZINC59367920; BDBM50158909; AKOS025293503; NE41584; MCULE-3472066147; Z606699744"	52670832	Investigative	D07FGY	.	CTPDG014455
M6ACROT05647	Interleukin-33 (IL33)	IL33_HUMAN	.	.	Phase 3	Tozorakimab	.	.	Phase 3	D0YFN1	.	CTPDG000973
M6ACROT05647	Interleukin-33 (IL33)	IL33_HUMAN	.	.	Phase 3	SAR440340	Itepekimab	.	Phase 3	D8U1EX	.	CTPDG000926
M6ACROT05647	Interleukin-33 (IL33)	IL33_HUMAN	.	.	Phase 3	MEDI3506	Tozorakimab	.	Phase 3	DOTF14	.	CTPDG000890
M6ACROT05647	Interleukin-33 (IL33)	IL33_HUMAN	.	.	Phase 3	Itepekimab	.	.	Phase 3	DPT90B	.	CTPDG000886
M6ACROT05647	Interleukin-33 (IL33)	IL33_HUMAN	.	.	Phase 1	AMG 282	.	.	Phase 1	D07GDR	.	CTPDG005110
M6ACROT05647	Interleukin-33 (IL33)	IL33_HUMAN	.	.	Phase 1	PF-07264660	.	.	Phase 1	D1LP4B	.	CTPDG004189
M6ACROT05652	Dihydropyrimidinase-related protein 2 (DPYSL2)	DPYL2_HUMAN	.	.	Approved	Lacosamide	"Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide"	219078	Approved	D05OFX	DB06218	CTPDG012894
M6ACROT05655	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT05656	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT05663	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05663	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05663	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-52	.	117603070	Patented	D02YLT	.	CTPDG013815
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72a	.	.	Patented	D03KOH	.	CTPDG013816
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47c	.	72948227	Patented	D07KQB	.	CTPDG013817
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-70	.	122669618	Patented	D08CYC	.	CTPDG013818
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71b	.	.	Patented	D0BV4M	.	CTPDG013819
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-72b	.	.	Patented	D0E7TU	.	CTPDG013820
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47a	.	72722126	Patented	D0L1NO	.	CTPDG013821
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-50	.	.	Patented	D0M7GG	.	CTPDG013822
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47b	.	72950863	Patented	D0NG9V	.	CTPDG013823
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-71a	.	.	Patented	D0O1LX	.	CTPDG013824
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-47d	.	72948224	Patented	D0SP7T	.	CTPDG013825
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-12	.	78425879	Patented	D0UE9B	.	CTPDG013826
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-68b	.	.	Patented	D0GD6R	.	CTPDG013827
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-45a	.	86302836	Patented	D0YN2T	.	CTPDG013828
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-9,10-dihydroanthracene-9-carboxamide"	CHEMBL575482; SCHEMBL4541357	45482666	Investigative	D03BQS	.	CTPDG013829
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylacetamide"	"Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt"	239512	Investigative	D03QOD	.	CTPDG013830
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-hydroxy-9H-xanthene-9-carboxamide	"CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446"	44626296	Investigative	D06IMY	.	CTPDG013831
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(3-fluorophenyl)-N-hydroxyacetamide"	CHEMBL574594; SCHEMBL4536216	45482630	Investigative	D0A4HF	.	CTPDG013832
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-fluorophenyl)-N-hydroxyacetamide"	CHEMBL573190; SCHEMBL2841871	45482672	Investigative	D0FN5D	.	CTPDG013833
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"N-hydroxy-2,2-diphenylpropanamide"	CHEMBL585365; SCHEMBL2844474	45482660	Investigative	D0I4RK	.	CTPDG013834
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"2,2-bis(4-chlorophenyl)-N-hydroxyacetamide"	CHEMBL572805; SCHEMBL2848402	45482643	Investigative	D0PK9V	.	CTPDG013835
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	santacruzamate A	CAY10683	72946782	Investigative	D09RKA	.	CTPDG013163
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	Investigative	D0R7JA	.	CTPDG013836
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT05671	Histone deacetylase 4 (HDAC4)	HDAC4_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT05681	ADAM metallopeptidase domain 9 (ADAM9)	ADAM9_HUMAN	.	.	Phase 1	IMGC936	.	.	Phase 1	DA4O8C	.	CTPDG003982
M6ACROT05682	ADAM metallopeptidase domain 9 (ADAM9)	ADAM9_HUMAN	.	.	Phase 1	IMGC936	.	.	Phase 1	DA4O8C	.	CTPDG003982
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MEDI4736	.	.	Phase 3	D04RRZ	.	CTPDG001416
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	KN046	.	.	Phase 3	DLOQ25	.	CTPDG012817
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	KN035	Envafolimab	.	Phase 2	D0GF2R	.	CTPDG002356
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	CX-072	.	.	Phase 2	D0Z2BO	.	CTPDG001867
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	INCB86550	.	.	Phase 2	DKM79E	.	CTPDG001693
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	M7824	.	.	Phase 2	D05FPZ	.	CTPDG002813
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	BGB-A333	.	.	Phase 1/2	DC5VW9	.	CTPDG003195
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	Phase 1/2	DS6VD0	.	CTPDG003143
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3300054	.	.	Phase 1	D08HSS	.	CTPDG005054
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MSB2311	.	.	Phase 1	D0A8AU	.	CTPDG004941
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1	BMS-936559	.	Phase 1	D0KP9A	.	CTPDG004646
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FAZ053	.	.	Phase 1	D0LU1O	.	CTPDG004609
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1 CSR T cells	.	.	Phase 1	D0W7UD	.	CTPDG012818
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	BMS-986189	.	.	Phase 1	D0X1GN	.	CTPDG012819
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	.	.	Phase 1	D2Z6WF	.	CTPDG004150
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PD-L1 t-haNK	.	.	Phase 1	DH42RF	.	CTPDG003899
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	KD033	.	.	Phase 1	DJVR06	.	CTPDG003860
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	Phase 1	D09PPU	.	CTPDG004985
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FS118	.	.	Phase 1	D0XO9F	.	CTPDG004272
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MCLA-145	.	.	Phase 1	D2QY0Z	.	CTPDG004156
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	GEN1046	.	.	Phase 1	D3HBJ1	.	CTPDG004139
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	ALPN-202	.	.	Phase 1	D82UVG	.	CTPDG004022
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	TAK-252	SL-279252	.	Phase 1	D9SL1N	.	CTPDG003989
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	INBRX-105	.	.	Phase 1	DA1X5W	.	CTPDG003983
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3415244	.	.	Phase 1	DC8HR6	.	CTPDG003954
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	A337	.	.	Phase 1	DL97UQ	.	CTPDG003833
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example2	.	117941742	Patented	D0OK1S	.	CTPDG005729
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example1	.	117951478	Patented	D0WQ9X	.	CTPDG005575
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure7	PMID30247903Compound7	.	Investigative	D01TGF	.	CTPDG012820
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	CA-327	.	.	Investigative	D04ILU	.	CTPDG012821
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure8	PMID30247903Compound8	.	Investigative	D04QGF	.	CTPDG012822
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure5	PMID30247903Compound5	.	Investigative	D07BOF	.	CTPDG012823
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure12	PMID30247903Compound12	.	Investigative	D09BYN	.	CTPDG012824
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure9	PMID30247903Compound9	.	Investigative	D0GG6N	.	CTPDG012825
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure6	PMID30247903Compound6	.	Investigative	D0TN4F	.	CTPDG012826
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure10	PMID30247903Compound10	.	Investigative	D0XL3N	.	CTPDG012827
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH011	.	.	Investigative	DA91UG	.	CTPDG007607
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH010	.	.	Investigative	DBTI39	.	CTPDG007604
M6ACROT05686	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	RG6084	.	.	Phase 1	DJX7K9	.	CTPDG014810
M6ACROT05699	Integrin subunit alpha 1 (ITGA1)	ITA1_HUMAN	.	.	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05700	Integrin subunit alpha 1 (ITGA1)	ITA1_HUMAN	.	.	Phase 2	SAN-300	.	.	Phase 2	D0B5VA	.	CTPDG002512
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 3	MLN8237	Alisertib	24771867	Phase 3	D0S4JK	DB05220	CTPDG001058
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 3	AT9283	.	135398495	Phase 3	D05PZB	.	CTPDG001395
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 3	Rosiglitazone + metformin	"Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]"	5329099	Phase 3	D0A1AQ	DB12072	CTPDG010074
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 2	ENMD-2076	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159	16041424	Phase 2	D0S7HM	.	CTPDG002039
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 2	VX-680	"Tozasertib; MK 0457; VX 680; VX6; L-001281814; MK-045; MK-0457; Tozasertib (USAN); VX-68; MK-0457, Tozasertib, VX680, VX-680; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide"	5494449	Phase 2	D02XNW	.	CTPDG002944
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 2	ABT-348	"ILORASERTIB; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea"	46207586	Phase 2	D08HOM	DB11694	CTPDG013381
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 2	PHA-739358	"Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d"	11442891	Phase 2	D02RJY	DB11778	CTPDG013382
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1/2	LY3295668	"1919888-06-4; (2R,4R)-1-(3-Chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid; AK-01; LY-3295668; (2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-({3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}methyl)-2-methylpiperidine-4-carboxylic acid; UNII-1WX8O5XV4R; 1WX8O5XV4R; SCHEMBL17747406; NSC816863; NSC-816863; Aurora A kinase inhibitor LY3295668; HY-114258; CS-0080775; LY3295668 (AK-01); A16869; (2R,4R)-1-[(3-Chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid; 1-((3-Chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2R,4R)-,4-piperidinecarboxylic acid; 4-Piperidinecarboxylic acid, 1-((3-chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2R,4R)-; EG7"	121333423	Phase 1/2	D3QEZ2	.	CTPDG003245
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	MLN8054	ZZL; MLN-8054	11712649	Phase 1	D0A5MC	DB13061	CTPDG004943
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	TAS-119	.	.	Phase 1	D0L3RO	.	CTPDG004632
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	VIC-1911	TAS 119	.	Phase 1	D6FX2G	.	CTPDG004064
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	R763	.	11569967	Phase 1	D0E5XA	DB06347	CTPDG013383
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	MK-5108	"1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689"	24748204	Phase 1	D0J6AB	DB12556	CTPDG004689
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	HPP-607	.	.	Phase 1	D05LKZ	.	CTPDG005201
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	CYC116	"693228-63-6; CYC-116; CHEMBL482967; Kinome_636; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2uue; CYC 116; GPSZYOIFQZPWEJ-UHFFFAOYSA-N; 2c5t; AC1O4WKE; MLS006011244; SCHEMBL2074998; SYN1034; EX-A753; CYC-116/CYC116; MolPort-009-679-476; HMS3244O12; HMS3244P11; BCPP000273"	6420138	Phase 1	D0CY1B	.	CTPDG004874
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	AMG 900	AMG-900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N	24856041	Phase 1	D0EJ3B	.	CTPDG004822
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Phase 1	SNS-314	SN-314	24995524	Phase 1	D0OA5G	DB07361	CTPDG004536
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Discontinued in Phase 1	PF-03814735	"942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide"	51346455	Discontinued in Phase 1	D0H7AC	DB13059	CTPDG006807
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	2-(1H-pyrazol-3-yl)-1H-benzimidazole	.	763936	Investigative	D04YQF	DB08065	CTPDG013384
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	ZM-447439	331771-20-1; ZM447439; ZM 447439; N-[4-[[6-METHOXY-7-[3-(4-MORPHOLINYL)PROPOXY]-4-QUINAZOLINYL]AMINO]PHENYL]BENZAMIDE; TCMDC-125873; UNII-RSN3P9776R; CHEMBL202721; RSN3P9776R; N-(4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)benzamide; C29H31N5O4; N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide; N-(4-{[6-Methoxy-7-(3-Morpholin-4-Ylpropoxy)quinazolin-4-Yl]amino}phenyl)benzamide	9914412	Investigative	D0QC0W	.	CTPDG013385
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	"4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL1089985; SCHEMBL2239177; 1H-Pyrrolo[2,3-b]pyridine, 4-(1H-pyrazol-4-yl)-; BDBM50315770"	46885627	Investigative	D04MYT	.	CTPDG013386
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	7-fluoroindirubin-3-oxime	.	11845975	Investigative	D00TKJ	.	CTPDG013387
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	Indirubin-3-acetoxime	.	136043837	Investigative	D06AGN	.	CTPDG013388
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	Indirubin-3-methoxime	.	136043836	Investigative	D0V6LP	.	CTPDG013389
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	6-bromoindirubin-3-oxime	6-bromoindirubin-3'-oxime (BIO)	448949	Investigative	D06OAH	DB03444	CTPDG013390
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	Phosphonothreonine	"phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid"	10976469	Investigative	D05BHG	DB02482	CTPDG013391
M6ACROT05726	Aurora kinase A (AURKA)	AURKA_HUMAN	.	.	Investigative	Indirubin-3'-monoxime	"indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070"	3707	Investigative	D0Y0ES	DB02052	CTPDG013392
M6ACROT05729	Krueppel-like factor 4 (KLF4)	KLF4_HUMAN	.	.	Phase 1	APTO-253	.	11960271	Phase 1	D07TRP	.	CTPDG005083
M6ACROT05730	Krueppel-like factor 4 (KLF4)	KLF4_HUMAN	.	.	Phase 1	APTO-253	.	11960271	Phase 1	D07TRP	.	CTPDG005083
M6ACROT05743	Gap junction alpha-1 protein (GJA1)	CXA1_HUMAN	.	.	Phase 3	Granexin gel	alphaCT1	.	Phase 3	D01NWV	.	CTPDG001483
M6ACROT05743	Gap junction alpha-1 protein (GJA1)	CXA1_HUMAN	.	.	Phase 3	Act1	51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794	.	Phase 3	D04WBT	.	CTPDG014666
M6ACROT05743	Gap junction alpha-1 protein (GJA1)	CXA1_HUMAN	.	.	Phase 2	HCB1019	.	.	Phase 2	DZEF27	.	CTPDG014667
M6ACROT05743	Gap junction alpha-1 protein (GJA1)	CXA1_HUMAN	.	.	Phase 1/2	ALMB-0168	.	.	Phase 1/2	DXAI94	.	CTPDG003131
M6ACROT05743	Gap junction alpha-1 protein (GJA1)	CXA1_HUMAN	.	.	Phase 1	ALMB-0166	.	.	Phase 1	DJR71Z	.	CTPDG014668
M6ACROT05743	Gap junction alpha-1 protein (GJA1)	CXA1_HUMAN	.	.	Investigative	octanol	"1-octanol; Octan-1-ol; 111-87-5; N-octanol; Capryl alcohol; Octyl alcohol; caprylic alcohol; n-Octyl alcohol; Heptyl carbinol; 1-Hydroxyoctane; Primary octyl alcohol; Alcohol C-8; n-Octan-1-ol; Octilin; Sipol L8; Alfol 8; Lorol 20; Dytol M-83; n-Caprylic alcohol; 1-Octyl alcohol; n-Heptyl carbinol; EPAL 8; octyl-alcohol; Alcohols, C6-12; N-octyl-alcohol; Octyl alcohol, normal-primary; C8 alcohol; Fatty alcohol(C8); Octyl alcohol, primary; Caswell No. 611A; Octyl alcohol (natural); FEMA Number 2800; Lorol C 8-98; n-Capryl alcohol"	957	Investigative	D00VJY	DB12452	CTPDG014669
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Pioglitazone	"111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1"	4829	Approved	D03OFF	DB01132	CTPDG011129
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Troglitazone	"Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione"	5591	Approved	D06XZW	DB00197	CTPDG011130
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 4	Glitazone	"74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087"	10198397	Phase 4	D0S2BV	.	CTPDG011131
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rivoglitazone	"CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen"	3055168	Phase 3	D08PFA	DB09200	CTPDG011132
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Balaglitazone	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645	9889200	Phase 3	D0F3NH	DB12781	CTPDG011133
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	FARGLITAZAR	"GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-"	170364	Phase 3	D0M0SS	.	CTPDG011134
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rosiglitazone + simvastatin	.	23644561	Phase 3	D0Q6IW	.	CTPDG001082
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Leriglitazone	"146062-44-4; 1-Hydroxypioglitazone; 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; A1-01710; AKOS015856344; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE; BDBM50530214; CHEBI:82937; CHEMBL1267; CS-0067030; D11603; DB15021; DTXSID30399914; FT-0643388; HY-117727; Hydroxy Pioglitazone (M-IV); Hydroxy Pioglitazone-D5 (Major) (M-IV); Hydroxypioglitazone; J-008187; K824X25AYA; Leriglitazone; Leriglitazone (USAN/INN); LERIGLITAZONE [INN]; Leriglitazone [USAN]; MIN-102; OXVFDZYQLGRLCD-UHFFFAOYSA-N; Pioglitazone, hydroxy; Q27156475; SCHEMBL4098326; UNII-K824X25AYA; WHO 10868; ZINC01482947"	4147757	Phase 3	DCA13V	DB15021	CTPDG011135
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rosiglitazone + metformin	"Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]"	5329099	Phase 3	D0A1AQ	DB12072	CTPDG010074
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2/3	MBX-102	"Arhalofenate; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV"	12082259	Phase 2/3	D0X7VB	DB11811	CTPDG011140
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	FK-614	"ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus"	9869229	Phase 2	D00PJJ	DB12557	CTPDG003073
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	MBX-2044	"MBX-102 analogs, Metabolex"	.	Phase 2	D08NPG	.	CTPDG002626
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	GED-0507-34-Levo	GED-0507; GED-0507-34; GED-0507-34E2	67008033	Phase 2	D0E6ME	.	CTPDG011141
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	CHS-131	.	.	Phase 2	D0P5SU	.	CTPDG011142
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	OMS405	.	.	Phase 2	D0W0JP	.	CTPDG011143
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	CLX-0921	CLX-090502; CLX-090503; CLX-090717; CLX-092402	9958278	Phase 1	D06TWE	.	CTPDG005139
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	Englitazone sodium	"Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt"	13728795	Phase 1	D08EEU	.	CTPDG005061
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Spirolaxine derivative 1	PMID25416646-Compound-Figure2-L	.	Patented	D03GFB	.	CTPDG011148
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Phenylpropionic acid derivative 1	PMID25416646-Compound-Figure2-D	.	Patented	D09OXG	.	CTPDG011149
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	A-substituted phenylpropionic acid derivative 1	PMID25416646-Compound-Figure2-c	.	Patented	D0E9GF	.	CTPDG011150
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-K	.	10229498	Patented	D0G3KY	DB05490	CTPDG011151
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-N	.	.	Patented	D0GG5K	.	CTPDG011152
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	MRL24	MRL 24	9958543	Patented	D0H5FI	.	CTPDG011153
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Sulfonamide derivative 18	PMID25416646-Compound-Figure2-M	.	Patented	D0HT9C	.	CTPDG011154
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Crystalline anhydrous toluene derivative 1	PMID25416646-Compound-Figure2-H	.	Patented	D0M4RD	.	CTPDG011155
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	A-substituted phenylpropionic acid derivative 2	PMID25416646-Compound-Figure2-E	.	Patented	D0M5YQ	.	CTPDG011156
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Biaromatic compound 1	PMID25416646-Compound-Figure2-A	.	Patented	D0O8PR	.	CTPDG011157
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	MRL20	CHEMBL181937; (2s)-2-(2-{[1-(4-Methoxybenzoyl)-2-Methyl-5-(Trifluoromethoxy)-1h-Indol-3-Yl]methyl}phenoxy)propanoic Acid; SCHEMBL5172443; GTPL6742; BDBM50157936; (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid; (2S)-2-[2-({1-[(4-methoxyphenyl)carbonyl]-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl}methyl)phenoxy]propanoic acid; (S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid	10143056	Patented	D0PO7F	.	CTPDG011158
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Fused ring compound 1	PMID25416646-Compound-Figure2-G	.	Patented	D0SL0K	.	CTPDG011159
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	3-phenyl acrylic acid derivative 1	PMID25416646-Compound-Figure2-B	.	Patented	D0SV6U	.	CTPDG011160
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Thiazolidine dione crystalline derivative 1	PMID25416646-Compound-Figure2-I	9832447	Patented	D0TF0T	DB11894	CTPDG011161
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Fused aromatic compound 1	PMID25416646-Compound-Figure2-F	.	Patented	D0UG1W	.	CTPDG011162
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-J	.	.	Patented	D0UH5B	.	CTPDG011163
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Cannabinoid quinone derivative 1	PMID25416646-Compound-Figure3-A	.	Patented	D0ZO0D	.	CTPDG011164
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-E	.	.	Patented	D0LA6O	.	CTPDG011167
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Phenylpyridine derivative 3	PMID25416646-Compound-Figure5-G	.	Patented	D0NF8V	.	CTPDG011168
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	PMID25416646-Compound-Figure5-F	.	Patented	D0U6AW	.	CTPDG011170
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-C	.	.	Patented	D0V0JN	.	CTPDG011171
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	YM-440	"2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]"	9890786	Discontinued in Phase 2	D0KL3K	.	CTPDG011172
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	DS-6930	.	.	Discontinued in Phase 1	D0Z6OI	.	CTPDG011176
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Preclinical	Ciglitazone	"74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01"	2750	Preclinical	D03GWY	DB09201	CTPDG011179
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	SB-219994	SB-219993	9845965	Terminated	D00YGA	.	CTPDG011181
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AKP-320	"Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis"	.	Terminated	D04JVX	.	CTPDG007513
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	Edaglitazone	Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602	9825701	Terminated	D08VKZ	DB06519	CTPDG007430
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	DARGLITAZONE	"CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione"	60870	Terminated	D0N1EF	DB14034	CTPDG011182
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	Terminated	D0LB4T	.	CTPDG007286
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"15-deoxy-Delta(12, 14)-prostaglandin J(2)"	"15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2"	5311211	Investigative	D01PGU	.	CTPDG011185
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	LT175; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03	11483970	Investigative	D06MDX	DB08121	CTPDG011186
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	3-(5-methoxy-1H-indol-3-yl)propanoic acid	"39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175"	181137	Investigative	D0E5HC	DB07723	CTPDG011187
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid	11149906	Investigative	D0H4US	DB07842	CTPDG011188
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid	11460087	Investigative	D0J3UU	DB08760	CTPDG011189
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW7845	GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)	9870584	Investigative	D0O2US	.	CTPDG011190
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid"	"13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH"	6443013	Investigative	D0Z5TV	DB06926	CTPDG011191
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	9-hydroxyoctadecadienoic acid	"(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic"	5312830	Investigative	D0SZ4T	DB07302	CTPDG011193
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	2-chloro-5-nitro-N-phenylbenzamide	"GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	Investigative	D00ACX	DB07863	CTPDG011195
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Bardoxolone methyl	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4	400769	Phase 3	D0JU5X	DB05983	CTPDG015155
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	Terminated	D0LB4T	.	CTPDG007286
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-9-nitrooctadec-9-enoic acid	9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid	11645581	Investigative	D01RPM	.	CTPDG015156
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	tagitinin A	59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01	181254	Investigative	D01UVA	.	CTPDG015157
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	T0070907	"2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21"	2777391	Investigative	D03BPG	.	CTPDG015158
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW1929	GW 1929; GW-1929	6518171	Investigative	D04DYM	.	CTPDG015159
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-9-Nitrohexadec-9-enoicAcid	CHEMBL560513; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047	44220886	Investigative	D04FVX	.	CTPDG015160
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-10-nitrooctadec-9-enoic acid	"10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N"	24836820	Investigative	D06IHG	DB15026	CTPDG015161
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	SB-213068	CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)	9843045	Investigative	D06NHI	.	CTPDG015162
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	tirotundin	56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657	9975297	Investigative	D06OBX	.	CTPDG015163
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-aspartic acid	H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632	7019108	Investigative	D06UVY	.	CTPDG015164
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	BRL-48482	"SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione"	9822139	Investigative	D07IHY	.	CTPDG015165
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	nTzDpa	"118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3"	9954280	Investigative	D08QKF	.	CTPDG015166
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	COOH	LS-191838	10025649	Investigative	D0A1SP	.	CTPDG015167
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105990	.	.	Investigative	D0B2UF	.	CTPDG015168
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 106008	.	.	Investigative	D0B9MZ	.	CTPDG015169
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE A	"CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762579	Investigative	D0D0FQ	.	CTPDG015170
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105987	.	.	Investigative	D0G3IV	.	CTPDG015171
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-glutamine	CHEMBL476173; SCHEMBL5970454	25187914	Investigative	D0G9AI	.	CTPDG015172
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	PAT5A	GTPL2709	18980163	Investigative	D0HI6O	.	CTPDG015173
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GNF-PF-2893	MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea	2815701	Investigative	D0I2DF	.	CTPDG015174
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-asparagine	CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid	7020170	Investigative	D0IW8V	.	CTPDG015175
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-2-aminoadipic acid	CHEMBL515773	25185696	Investigative	D0J9ZA	.	CTPDG015176
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-764406	L 764406; L764406	9818466	Investigative	D0L4PT	.	CTPDG015177
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-arginine	"CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH  inverted exclamation mark currency 2 HCl"	25186251	Investigative	D0M7AT	.	CTPDG015178
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105989	.	.	Investigative	D0NW8N	.	CTPDG015179
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	[125I]SB-236636	"GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid"	73755028	Investigative	D0P1US	.	CTPDG015180
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	BADGE	"SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane"	2286	Investigative	D0Q4EU	DB14083	CTPDG015181
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-5-Nitrooctadec-5-enoic Acid	CHEMBL561776; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050	44220888	Investigative	D0Q4UD	.	CTPDG015182
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE C	"CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24180661	Investigative	D0R9VV	.	CTPDG015183
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE B	"CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762580	Investigative	D0RL8P	.	CTPDG015184
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW0072	GW 0072	449532	Investigative	D0SO9Q	.	CTPDG015185
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	[3H]GW2331	"GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid"	10624977	Investigative	D0T8JM	.	CTPDG015186
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE D	CHEMBL400132; BDBM50228361	24762578	Investigative	D0U5HX	.	CTPDG015187
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-10-Nitrohexadec-9-enoic Acid	CHEMBL564368; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N	44220887	Investigative	D0W9WU	.	CTPDG015188
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-leucine	"H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid"	6997510	Investigative	D0X3RZ	.	CTPDG015189
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	PD-068235	CHEMBL455856; BDBM50266362; PD-068253	44581800	Investigative	D0X9UJ	.	CTPDG015190
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	Ploglitazone	.	12944192	Investigative	D0Z2CY	.	CTPDG015191
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-6-Nitrooctadec-5-enoic Acid	CHEMBL569372	44220889	Investigative	D0Z4NW	.	CTPDG015192
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GNF-PF-3037	SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide	1160447	Investigative	D0P8XE	.	CTPDG015193
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	2-chloro-5-nitro-N-phenylbenzamide	"GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	Investigative	D00ACX	DB07863	CTPDG011195
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-783483	F3MethylAA	9935197	Investigative	D08QXD	.	CTPDG015062
M6ACROT05745	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	LG100754	LG 100754; LG754	6442223	Investigative	D0Q9FZ	.	CTPDG012495
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Pioglitazone	"111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1"	4829	Approved	D03OFF	DB01132	CTPDG011129
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Troglitazone	"Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione"	5591	Approved	D06XZW	DB00197	CTPDG011130
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	Approved	D0K5ER	.	CTPDG000306
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	Approved	D0K8IX	DB11898	CTPDG000299
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Approved	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	Approved	D04BCB	DB09198	CTPDG000682
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 4	Glitazone	"74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087"	10198397	Phase 4	D0S2BV	.	CTPDG011131
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rivoglitazone	"CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen"	3055168	Phase 3	D08PFA	DB09200	CTPDG011132
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Balaglitazone	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645	9889200	Phase 3	D0F3NH	DB12781	CTPDG011133
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	FARGLITAZAR	"GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-"	170364	Phase 3	D0M0SS	.	CTPDG011134
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rosiglitazone + simvastatin	.	23644561	Phase 3	D0Q6IW	.	CTPDG001082
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Leriglitazone	"146062-44-4; 1-Hydroxypioglitazone; 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; A1-01710; AKOS015856344; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE; BDBM50530214; CHEBI:82937; CHEMBL1267; CS-0067030; D11603; DB15021; DTXSID30399914; FT-0643388; HY-117727; Hydroxy Pioglitazone (M-IV); Hydroxy Pioglitazone-D5 (Major) (M-IV); Hydroxypioglitazone; J-008187; K824X25AYA; Leriglitazone; Leriglitazone (USAN/INN); LERIGLITAZONE [INN]; Leriglitazone [USAN]; MIN-102; OXVFDZYQLGRLCD-UHFFFAOYSA-N; Pioglitazone, hydroxy; Q27156475; SCHEMBL4098326; UNII-K824X25AYA; WHO 10868; ZINC01482947"	4147757	Phase 3	DCA13V	DB15021	CTPDG011135
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Ragaglitazar	DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	Phase 3	D02NHD	DB07675	CTPDG011136
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	Phase 3	D0F5JH	.	CTPDG001217
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	TESAGLITAZAR	251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	Phase 3	D0H1NL	DB07399	CTPDG011137
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	MURAGLITAZAR	331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	Phase 3	D0M3UT	DB06510	CTPDG011138
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	Phase 3	D0T7MN	.	CTPDG011139
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Imiglitazar	TAK-559	9890879	Phase 3	D0VU5M	DB12511	CTPDG001015
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Rosiglitazone + metformin	"Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]"	5329099	Phase 3	D0A1AQ	DB12072	CTPDG010074
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2/3	MBX-102	"Arhalofenate; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV"	12082259	Phase 2/3	D0X7VB	DB11811	CTPDG011140
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	FK-614	"ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus"	9869229	Phase 2	D00PJJ	DB12557	CTPDG003073
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	Phase 2	D02TGD	DB09199	CTPDG002956
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	MBX-2044	"MBX-102 analogs, Metabolex"	.	Phase 2	D08NPG	.	CTPDG002626
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	GED-0507-34-Levo	GED-0507; GED-0507-34; GED-0507-34E2	67008033	Phase 2	D0E6ME	.	CTPDG011141
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	CHS-131	.	.	Phase 2	D0P5SU	.	CTPDG011142
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	OMS405	.	.	Phase 2	D0W0JP	.	CTPDG011143
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	Phase 2	D04BPS	DB12662	CTPDG011144
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	Phase 2	D0PP8G	.	CTPDG011145
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 2	T3D-959	.	.	Phase 2	D53BEH	.	CTPDG001808
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1/2	T3D-959	.	.	Phase 1/2	D0ZT8A	.	CTPDG003262
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	CLX-0921	CLX-090502; CLX-090503; CLX-090717; CLX-092402	9958278	Phase 1	D06TWE	.	CTPDG005139
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	DSP-8658	.	.	Phase 1	D07IGC	.	CTPDG005103
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	Englitazone sodium	"Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt"	13728795	Phase 1	D08EEU	.	CTPDG005061
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	Phase 1	D03RJZ	.	CTPDG011146
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 1	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	Phase 1	D0AX9S	.	CTPDG011147
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Spirolaxine derivative 1	PMID25416646-Compound-Figure2-L	.	Patented	D03GFB	.	CTPDG011148
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Phenylpropionic acid derivative 1	PMID25416646-Compound-Figure2-D	.	Patented	D09OXG	.	CTPDG011149
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	A-substituted phenylpropionic acid derivative 1	PMID25416646-Compound-Figure2-c	.	Patented	D0E9GF	.	CTPDG011150
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-K	.	10229498	Patented	D0G3KY	DB05490	CTPDG011151
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-N	.	.	Patented	D0GG5K	.	CTPDG011152
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	MRL24	MRL 24	9958543	Patented	D0H5FI	.	CTPDG011153
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Sulfonamide derivative 18	PMID25416646-Compound-Figure2-M	.	Patented	D0HT9C	.	CTPDG011154
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Crystalline anhydrous toluene derivative 1	PMID25416646-Compound-Figure2-H	.	Patented	D0M4RD	.	CTPDG011155
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	A-substituted phenylpropionic acid derivative 2	PMID25416646-Compound-Figure2-E	.	Patented	D0M5YQ	.	CTPDG011156
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Biaromatic compound 1	PMID25416646-Compound-Figure2-A	.	Patented	D0O8PR	.	CTPDG011157
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	MRL20	CHEMBL181937; (2s)-2-(2-{[1-(4-Methoxybenzoyl)-2-Methyl-5-(Trifluoromethoxy)-1h-Indol-3-Yl]methyl}phenoxy)propanoic Acid; SCHEMBL5172443; GTPL6742; BDBM50157936; (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid; (2S)-2-[2-({1-[(4-methoxyphenyl)carbonyl]-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl}methyl)phenoxy]propanoic acid; (S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid	10143056	Patented	D0PO7F	.	CTPDG011158
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Fused ring compound 1	PMID25416646-Compound-Figure2-G	.	Patented	D0SL0K	.	CTPDG011159
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	3-phenyl acrylic acid derivative 1	PMID25416646-Compound-Figure2-B	.	Patented	D0SV6U	.	CTPDG011160
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Thiazolidine dione crystalline derivative 1	PMID25416646-Compound-Figure2-I	9832447	Patented	D0TF0T	DB11894	CTPDG011161
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Fused aromatic compound 1	PMID25416646-Compound-Figure2-F	.	Patented	D0UG1W	.	CTPDG011162
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure2-J	.	.	Patented	D0UH5B	.	CTPDG011163
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Cannabinoid quinone derivative 1	PMID25416646-Compound-Figure3-A	.	Patented	D0ZO0D	.	CTPDG011164
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-H	.	.	Patented	D05AUY	.	CTPDG011165
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Flavonoid derivative 8	PMID25416646-Compound-Figure5-B	.	Patented	D0HW6Y	.	CTPDG011166
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-E	.	.	Patented	D0LA6O	.	CTPDG011167
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	Phenylpyridine derivative 3	PMID25416646-Compound-Figure5-G	.	Patented	D0NF8V	.	CTPDG011168
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-A	.	.	Patented	D0O5IN	.	CTPDG011169
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	PMID25416646-Compound-Figure5-F	.	Patented	D0U6AW	.	CTPDG011170
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Patented	PMID25416646-Compound-Figure5-C	.	.	Patented	D0V0JN	.	CTPDG011171
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	YM-440	"2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]"	9890786	Discontinued in Phase 2	D0KL3K	.	CTPDG011172
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	KRP-297	"MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	Discontinued in Phase 2	D02RAU	.	CTPDG006651
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Reglixane	.	.	Discontinued in Phase 2	D02ZKL	.	CTPDG011173
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	Discontinued in Phase 2	D0W2IU	.	CTPDG011174
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Sodelglitazar	"447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	Discontinued in Phase 2	D01JGG	.	CTPDG011175
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	Indeglitazar	PLX-204	11395145	Discontinued in Phase 2	D09OHP	DB07724	CTPDG006570
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 2	GSK-677954	SCHEMBL2065429	56603715	Discontinued in Phase 2	D0S6KX	.	CTPDG006439
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	DS-6930	.	.	Discontinued in Phase 1	D0Z6OI	.	CTPDG011176
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	Discontinued in Phase 1	D06PHO	.	CTPDG011177
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Discontinued in Phase 1	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	Discontinued in Phase 1	D0B0EB	.	CTPDG011178
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Preclinical	Ciglitazone	"74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01"	2750	Preclinical	D03GWY	DB09201	CTPDG011179
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Preclinical	MC-3002	"PPAR dual agonists, MaxoCore"	.	Preclinical	D08WOE	.	CTPDG011180
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	SB-219994	SB-219993	9845965	Terminated	D00YGA	.	CTPDG011181
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AKP-320	"Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis"	.	Terminated	D04JVX	.	CTPDG007513
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	Edaglitazone	Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602	9825701	Terminated	D08VKZ	DB06519	CTPDG007430
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	DARGLITAZONE	"CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione"	60870	Terminated	D0N1EF	DB14034	CTPDG011182
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	Terminated	D0I0RF	.	CTPDG007331
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	Terminated	D0LB4T	.	CTPDG007286
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	Sipoglitazar	TAK-654	9825652	Terminated	D0OW6Z	.	CTPDG011183
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	Terminated	D0V0TT	.	CTPDG011184
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"15-deoxy-Delta(12, 14)-prostaglandin J(2)"	"15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2"	5311211	Investigative	D01PGU	.	CTPDG011185
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	LT175; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03	11483970	Investigative	D06MDX	DB08121	CTPDG011186
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	3-(5-methoxy-1H-indol-3-yl)propanoic acid	"39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175"	181137	Investigative	D0E5HC	DB07723	CTPDG011187
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid	11149906	Investigative	D0H4US	DB07842	CTPDG011188
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid	11460087	Investigative	D0J3UU	DB08760	CTPDG011189
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW7845	GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)	9870584	Investigative	D0O2US	.	CTPDG011190
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid"	"13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH"	6443013	Investigative	D0Z5TV	DB06926	CTPDG011191
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	Investigative	D01POG	.	CTPDG011192
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	9-hydroxyoctadecadienoic acid	"(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic"	5312830	Investigative	D0SZ4T	DB07302	CTPDG011193
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ZY H2	ZYH2	.	Investigative	D0Z4MH	.	CTPDG011194
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	2-chloro-5-nitro-N-phenylbenzamide	"GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	Investigative	D00ACX	DB07863	CTPDG011195
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	DB-900	.	.	Investigative	D01ARG	.	CTPDG009136
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Phase 3	Bardoxolone methyl	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4	400769	Phase 3	D0JU5X	DB05983	CTPDG015155
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Terminated	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	Terminated	D0LB4T	.	CTPDG007286
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-9-nitrooctadec-9-enoic acid	9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid	11645581	Investigative	D01RPM	.	CTPDG015156
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	tagitinin A	59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01	181254	Investigative	D01UVA	.	CTPDG015157
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	T0070907	"2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21"	2777391	Investigative	D03BPG	.	CTPDG015158
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW1929	GW 1929; GW-1929	6518171	Investigative	D04DYM	.	CTPDG015159
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-9-Nitrohexadec-9-enoicAcid	CHEMBL560513; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047	44220886	Investigative	D04FVX	.	CTPDG015160
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-10-nitrooctadec-9-enoic acid	"10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N"	24836820	Investigative	D06IHG	DB15026	CTPDG015161
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	SB-213068	CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)	9843045	Investigative	D06NHI	.	CTPDG015162
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	tirotundin	56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657	9975297	Investigative	D06OBX	.	CTPDG015163
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-aspartic acid	H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632	7019108	Investigative	D06UVY	.	CTPDG015164
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	BRL-48482	"SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione"	9822139	Investigative	D07IHY	.	CTPDG015165
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	nTzDpa	"118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3"	9954280	Investigative	D08QKF	.	CTPDG015166
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	COOH	LS-191838	10025649	Investigative	D0A1SP	.	CTPDG015167
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105990	.	.	Investigative	D0B2UF	.	CTPDG015168
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 106008	.	.	Investigative	D0B9MZ	.	CTPDG015169
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE A	"CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762579	Investigative	D0D0FQ	.	CTPDG015170
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105987	.	.	Investigative	D0G3IV	.	CTPDG015171
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-glutamine	CHEMBL476173; SCHEMBL5970454	25187914	Investigative	D0G9AI	.	CTPDG015172
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	PAT5A	GTPL2709	18980163	Investigative	D0HI6O	.	CTPDG015173
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GNF-PF-2893	MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea	2815701	Investigative	D0I2DF	.	CTPDG015174
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-asparagine	CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid	7020170	Investigative	D0IW8V	.	CTPDG015175
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-2-aminoadipic acid	CHEMBL515773	25185696	Investigative	D0J9ZA	.	CTPDG015176
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-764406	L 764406; L764406	9818466	Investigative	D0L4PT	.	CTPDG015177
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-arginine	"CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH  inverted exclamation mark currency 2 HCl"	25186251	Investigative	D0M7AT	.	CTPDG015178
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	ISIS 105989	.	.	Investigative	D0NW8N	.	CTPDG015179
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	[125I]SB-236636	"GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid"	73755028	Investigative	D0P1US	.	CTPDG015180
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	BADGE	"SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane"	2286	Investigative	D0Q4EU	DB14083	CTPDG015181
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-5-Nitrooctadec-5-enoic Acid	CHEMBL561776; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050	44220888	Investigative	D0Q4UD	.	CTPDG015182
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE C	"CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24180661	Investigative	D0R9VV	.	CTPDG015183
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE B	"CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762580	Investigative	D0RL8P	.	CTPDG015184
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GW0072	GW 0072	449532	Investigative	D0SO9Q	.	CTPDG015185
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	[3H]GW2331	"GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid"	10624977	Investigative	D0T8JM	.	CTPDG015186
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	CHLOROCYCLINONE D	CHEMBL400132; BDBM50228361	24762578	Investigative	D0U5HX	.	CTPDG015187
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-10-Nitrohexadec-9-enoic Acid	CHEMBL564368; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N	44220887	Investigative	D0W9WU	.	CTPDG015188
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-Tryptophan-L-leucine	"H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid"	6997510	Investigative	D0X3RZ	.	CTPDG015189
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	PD-068235	CHEMBL455856; BDBM50266362; PD-068253	44581800	Investigative	D0X9UJ	.	CTPDG015190
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	Ploglitazone	.	12944192	Investigative	D0Z2CY	.	CTPDG015191
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-6-Nitrooctadec-5-enoic Acid	CHEMBL569372	44220889	Investigative	D0Z4NW	.	CTPDG015192
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	Investigative	D00EOP	.	CTPDG011288
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	TZD18	TZD 18; TZD-18	9827261	Investigative	D04JOG	.	CTPDG011289
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	Investigative	D06GYO	.	CTPDG011290
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	reglitazar	JTT-501	154000	Investigative	D08XGH	DB04971	CTPDG011291
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	DRF 2519	"5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	Investigative	D0M8VN	.	CTPDG011292
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	Investigative	D0M9LL	.	CTPDG011293
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732	44221101	Investigative	D0P5QM	.	CTPDG011294
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	GNF-PF-3037	SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide	1160447	Investigative	D0P8XE	.	CTPDG015193
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	LY-465608	LY465608; LY 465608	9890319	Investigative	D0Z7OX	.	CTPDG011295
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	2-chloro-5-nitro-N-phenylbenzamide	"GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	Investigative	D00ACX	DB07863	CTPDG011195
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-796449	"UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	Investigative	D09JII	.	CTPDG011296
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-165461	"CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	Investigative	D0F0MP	.	CTPDG011297
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	L-783483	F3MethylAA	9935197	Investigative	D08QXD	.	CTPDG015062
M6ACROT05746	Peroxisome proliferator-activated receptor gamma (PPARG)	PPARG_HUMAN	.	.	Investigative	LG100754	LG 100754; LG754	6442223	Investigative	D0Q9FZ	.	CTPDG012495
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05758	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05759	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05760	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT05760	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT05760	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT05769	"Spectrin beta, non-erythrocytic 1 (SPTBN1)"	SPTB2_HUMAN	.	.	Phase 1	ABT-413	.	.	Phase 1	D01QKZ	.	CTPDG005390
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Preregistration	MPL-containing Pollinex allergy desensitization vaccine	"Pollinex Quattro (ragweed allergy vaccine); Quattro MPL (ragweed allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (ragweed); Ragweed SC vaccine, Allergy Therapeutics/AllerPharma; MPL-containing Pollinex allergy desensitization vaccine (ragweed), AllergyTherapeutics/AllerPharma"	.	Preregistration	D08KNK	.	CTPDG013938
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 3	Resatorvid	TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate	11703255	Phase 3	D0E4GG	DB05943	CTPDG013939
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 3	ERITORAN	UNII-551541VI0Y; E5564; CHEMBL501259; CHEBI:68609; 185955-34-4; 551541VI0Y; Eritoran [INN]; 3-O-decyl-2-deoxy-6-O-{2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11E)-octadec-11-enoylamino]-4-O-phosphonato-beta-D-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-O-phosphono-alpha-D-glucopyranose; 3-O-Decyl-2-Deoxy-6-O-{2-Deoxy-3-O-[(3r)-3-Methoxydecyl]-6-O-Methyl-2-[(11z)-Octadec-11-Enoylamino]-4-O-Phosphono-Beta-D-Glucopyranosyl}-2-[(3-Oxotetradecanoyl)amino]-1-O-Phosphono-Alpha-D-Glucopyranose; B1287	6912404	Phase 3	D0SJ8Q	DB04933	CTPDG013940
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 3	Cadi-05	"Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila"	.	Phase 3	D0V0JR	.	CTPDG013941
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 2	G100	"Caffeine, 8-((3-methoxypropyl)amino)-; 8-((3-Methoxypropyl)amino)caffeine; BRN 1086127; 95982-26-6; 8-(gamma-Methoxypropyl)-aminocoffein [German]; 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione; 8-[(3-methoxypropyl)amino]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(gamma-Methoxypropyl)-aminocoffein; AC1L1M3J; CTK5H8490; DTXSID70242056; MolPort-002-837-706; CCG-22657; ZINC17172964; AKOS001669223; MCULE-8333260193; LS-48594; EU-0014431; G-100; AO-343/41780992"	56998	Phase 2	D0MD5M	.	CTPDG013942
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 1	NI-0101	"TLR4 monoclonal antibody therapy (autoimmune and inflammatory diseases), Novimmune"	.	Phase 1	D04MZP	.	CTPDG013943
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 1	GSK1795091	.	.	Phase 1	D0MM4H	.	CTPDG004590
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 1	CRX-675	RC-529	.	Phase 1	D0O2MO	.	CTPDG013944
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Phase 1	OM-174	"UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate"	9833422	Phase 1	D09POQ	.	CTPDG004986
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Discontinued in Phase 1	CS-4771	.	288	Discontinued in Phase 1	D09LZA	.	CTPDG013945
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Terminated	LZ-8	"Lzip; FIP-gts; Ling Zhi-8; Protein adjuvant, Yeastern"	.	Terminated	D06TTS	.	CTPDG013946
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	OM-294-DP	.	.	Investigative	D00GLW	.	CTPDG009191
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	OM-197-MP-AC	.	.	Investigative	D02SGT	.	CTPDG009010
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	CRX-526	"UNII-8NLO017HHA; 8NLO017HHA; CHEMBL505526; BDBM50275658; 245515-64-4; Hexanoic acid, (1R)-1-(2-(((1S)-1-carboxy-2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)-2-(((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)amino)-4-O-phosphono-beta-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester; N-[(3R)-3-(Hexanoyloxy)myristoyl]-O-[2-[[(3R)-3-(hexanoyloxy)myristoyl]amino]-3-O-[(3R)-3-(hexanoyloxy)myristoyl]-4-O-phosphono-2-deoxy-beta-D-glucopyranosyl]-L-serine"	24849153	Investigative	D06MKE	.	CTPDG013947
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	6-(2-aminophenoxy)benzo[d]isothiazol-3-amine	CHEMBL458612; SCHEMBL14241034; ZINC3818486; BDBM50274720; AKOS022180470; AJ-45722	44224215	Investigative	D0J0GM	.	CTPDG013948
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	Fibronectin extra domain A	"Fibronectin extra domain A (vaccine adjuvant); Fibronectin extra domain A (vaccine adjuvant), Digna Biotech; TLR-4 antagonist (protein recombinant, vaccination), Digna Biotech/University of Navarra"	.	Investigative	D0NB4V	.	CTPDG013949
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	AS04	.	.	Investigative	D0Q7RV	.	CTPDG013950
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	3-Hydroxy-Myristic Acid	3-hydroxymyristate; 3-hydroxytetradecanoate; beta-hydroxymyristate; 3-hydroxy myristic acid; 3-hydroxytetradecanoate(1-)	5288266	Investigative	D0A0GD	DB02767	CTPDG013951
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	TriMixDC	"Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles"	.	Investigative	D04PFD	.	CTPDG008870
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	Lauric Acid	"DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate"	3893	Investigative	D0N0UC	DB03017	CTPDG013952
M6ACROT05772	Toll-like receptor 4 (TLR4)	TLR4_HUMAN	.	.	Investigative	MYRISTIC ACID	"Tetradecanoic acid; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2"	11005	Investigative	D08OBF	DB08231	CTPDG013953
M6ACROT05796	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	2-Ethoxypropanoic acid	"53103-75-6; 2-ethoxypropionic acid; MFCD09940775; Propanoic acid, 2-ethoxy-; SCHEMBL142064; DTXSID00570733; 2-Ethoxypropanoic acid, AldrichCPR; STL508457; AKOS000184266; AKOS016903919; MCULE-2185795311; SY040144; DB-104575; EN300-39488; Y-6023"	15268841	Preclinical	D4RGV9	.	CTPDG014832
M6ACROT05796	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	KL001	309928-48-1; N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; SMR000106264; MLS000110334; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; KL-001; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-[(furan-2-yl)methyl]methanesulfonamide; N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(furan-2-ylmethyl)methanesulfonamide; CBMicro_005790; ChemDiv2_003790; Oprea1_152161; Oprea1_419357; MLS002540427; MLS006011739; CHEMBL1498001; SCHEMBL15380452; BDBM56256; cid_2888648; HMS1379M06; HMS2371E17; SMSF0015860; STK839587; AKOS000581142; AKOS016386481; CB08282; MCULE-8116422943; IDI1_002505; NCGC00079434-02; NCGC00079434-03; NCGC00079434-06; BIM-0006034.P001; KL001(KL-001;KL 001); EU-0005302; ST50257205; 10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; doi:10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; SR-01000436091; SR-01000436091-1; BRD-A94580299-001-08-8; F1345-0456; (3-carbazol-9-yl-2-hydroxypropyl)(2-furylmethyl)(methylsulfonyl)amine; N-(3-carbazol-9-yl-2-hydroxy-propyl)-N-(2-furfuryl)methanesulfonamide; N-[3-(9-carbazolyl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-oxidanyl-propyl)-N-(furan-2-ylmethyl)methanesulfonamide	2888648	Preclinical	D95KWS	.	CTPDG014833
M6ACROT05796	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	SHP656	.	.	Preclinical	DG90VQ	.	CTPDG014834
M6ACROT05796	Cryptochrome circadian regulator 2 (CRY2)	CRY2_HUMAN	.	.	Preclinical	TH301	.	.	Preclinical	DOZQ70	.	CTPDG014835
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 3	Resveratrol	"Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol"	445154	Phase 3	D0U3EP	DB02709	CTPDG001036
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	GSK2245840	"Gepirone hydrochloride; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	Phase 2	D04JNI	DB12186	CTPDG002861
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	Phase 2	D0E3LP	DB13978	CTPDG013886
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 2	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	Phase 2	D0TU7V	.	CTPDG001999
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT2379	.	.	Phase 1	D0O3EP	.	CTPDG004551
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Phase 1	SRT3025	.	46245047	Phase 1	D0X3TI	.	CTPDG004288
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Salermide	.	.	Patented	D02QKC	.	CTPDG013887
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	CAMBINOL	"14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040"	3246390	Patented	D04JZE	DB15493	CTPDG013888
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509CAY10602	.	.	Patented	D06IHB	.	CTPDG013889
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Patented	PMID25435179-Compound-WO2012106509Tenovin-6	.	.	Patented	D0PE8E	.	CTPDG013890
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Discontinued in Phase 2	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	Discontinued in Phase 2	D0R3EL	.	CTPDG006446
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Meta-sirtinol	.	135461039	Investigative	D00LYI	.	CTPDG013891
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	Investigative	D02AYX	.	CTPDG013892
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(R)-sirtinol	.	1376646	Investigative	D02EWM	.	CTPDG013893
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	Investigative	D03EGA	.	CTPDG013894
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	Investigative	D05UDU	.	CTPDG008793
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	splitomicin	"1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	Investigative	D09SUO	.	CTPDG013895
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	Investigative	D0E1QP	.	CTPDG013896
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	(S)-sirtinol	.	1376645	Investigative	D0F1KR	.	CTPDG013897
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Para-sirtinol	.	135491748	Investigative	D0UO1E	.	CTPDG013898
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX"	5083	Investigative	D0M5FF	.	CTPDG011476
M6ACROT05804	NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	SIR1_HUMAN	.	.	Investigative	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	Investigative	D0L8HO	.	CTPDG011256
M6ACROT05805	Thrombospondin 1 (THBS1)	TSP1_HUMAN	.	.	Phase 2	ABT-510	N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide	6918562	Phase 2	D0G4MB	DB05434	CTPDG002370
M6ACROT05805	Thrombospondin 1 (THBS1)	TSP1_HUMAN	.	.	Phase 2	CVX-045	"CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer"	.	Phase 2	D0S0KP	.	CTPDG002053
M6ACROT05823	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT05823	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT05823	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Approved	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	Approved	D02WCI	DB04951	CTPDG012335
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	IND submitted	A435	.	.	IND submitted	D8UKA4	.	CTPDG000863
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2	Disitertide	"NAFB-001; Disitertide cream (skin disorders), Digna"	9833838	Phase 2	D0C4WC	.	CTPDG012336
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ACE-1334	.	.	Phase 1	D8NZ7T	.	CTPDG012337
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	SRK-181	.	.	Phase 1	DFZJ79	.	CTPDG003913
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ABBV-151	.	.	Phase 1	DKCI94	.	CTPDG003846
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Discontinued in Phase 2	Mannose phosphate	SCHEMBL285569; SB17274	73014169	Discontinued in Phase 2	D0U3DX	.	CTPDG012338
M6ACROT05830	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Investigative	ART-144	"Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals"	.	Investigative	D08OLR	.	CTPDG012339
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05830	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Approved	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	Approved	D02WCI	DB04951	CTPDG012335
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	IND submitted	A435	.	.	IND submitted	D8UKA4	.	CTPDG000863
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2	Disitertide	"NAFB-001; Disitertide cream (skin disorders), Digna"	9833838	Phase 2	D0C4WC	.	CTPDG012336
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ACE-1334	.	.	Phase 1	D8NZ7T	.	CTPDG012337
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	SRK-181	.	.	Phase 1	DFZJ79	.	CTPDG003913
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ABBV-151	.	.	Phase 1	DKCI94	.	CTPDG003846
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Discontinued in Phase 2	Mannose phosphate	SCHEMBL285569; SB17274	73014169	Discontinued in Phase 2	D0U3DX	.	CTPDG012338
M6ACROT05831	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Investigative	ART-144	"Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals"	.	Investigative	D08OLR	.	CTPDG012339
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05831	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Approved	Cerulenin	"Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide"	5282054	Approved	D03ZFG	DB01034	CTPDG012090
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Phase 2	TVB-2640	.	.	Phase 2	D0K9BV	.	CTPDG012091
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Preclinical	FAS1	.	.	Preclinical	D04RSI	.	CTPDG012092
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Preclinical	FSA2	.	.	Preclinical	D0R2SW	.	CTPDG012093
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	GSK2194069	GSK-2194069; GSK 2194069	67376285	Investigative	D03VGO	.	CTPDG012094
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	MT-061	"Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera"	.	Investigative	D06SYA	.	CTPDG012095
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	Anti-Fas mabs	"Anti-Fas mAbs (misfolded proteins, cancer); Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Apexigen; Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Epitomics; Anti-Fas mAbs (misfolded proteins, cancer), Amorfix/Apexigen"	.	Investigative	D07WAF	.	CTPDG008653
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	MG-28	"FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia"	.	Investigative	D09IGF	.	CTPDG008551
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one	"CHEMBL377646; SCHEMBL4456699; BDBM50189477; 2(1H)-Quinolinone, 4-hydroxy-8-nitro-3-phenyl-"	54737904	Investigative	D0BY6E	.	CTPDG012096
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one	CHEMBL413773; SCHEMBL4469573; ZINC36185238; BDBM50189455	54737894	Investigative	D0QP7C	.	CTPDG012097
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	FAS-031	"FASi; FAS inhibitors (cancer); FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson"	.	Investigative	D0X6AU	.	CTPDG007716
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	C75	"C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-"	4248455	Investigative	D07MXA	.	CTPDG008679
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	2-Hexadecynoic acid	hexadec-2-ynoic acid; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494	151047	Investigative	D05HRK	.	CTPDG012098
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	GALLOCATECHIN GALLATE	"(-)-Gallocatechin gallate; 4233-96-9; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,"	5276890	Investigative	D07KXK	.	CTPDG012099
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	(-)-CATECHINGALLATE	"(-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG"	6419835	Investigative	D0RB1V	.	CTPDG012100
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	biochanin A	"491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether"	5280373	Investigative	D0S9YX	DB15334	CTPDG012101
M6ACROT05838	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	MORIN	"480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]"	5281670	Investigative	D0NJ4H	.	CTPDG012102
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Approved	Cerulenin	"Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide"	5282054	Approved	D03ZFG	DB01034	CTPDG012090
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Phase 2	TVB-2640	.	.	Phase 2	D0K9BV	.	CTPDG012091
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Phase 2	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	Phase 2	DE2U5N	.	CTPDG001737
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Preclinical	FAS1	.	.	Preclinical	D04RSI	.	CTPDG012092
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Preclinical	FSA2	.	.	Preclinical	D0R2SW	.	CTPDG012093
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	GSK2194069	GSK-2194069; GSK 2194069	67376285	Investigative	D03VGO	.	CTPDG012094
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	MT-061	"Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera"	.	Investigative	D06SYA	.	CTPDG012095
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	Anti-Fas mabs	"Anti-Fas mAbs (misfolded proteins, cancer); Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Apexigen; Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Epitomics; Anti-Fas mAbs (misfolded proteins, cancer), Amorfix/Apexigen"	.	Investigative	D07WAF	.	CTPDG008653
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	MG-28	"FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia"	.	Investigative	D09IGF	.	CTPDG008551
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one	"CHEMBL377646; SCHEMBL4456699; BDBM50189477; 2(1H)-Quinolinone, 4-hydroxy-8-nitro-3-phenyl-"	54737904	Investigative	D0BY6E	.	CTPDG012096
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one	CHEMBL413773; SCHEMBL4469573; ZINC36185238; BDBM50189455	54737894	Investigative	D0QP7C	.	CTPDG012097
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	FAS-031	"FASi; FAS inhibitors (cancer); FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson"	.	Investigative	D0X6AU	.	CTPDG007716
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	C75	"C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-"	4248455	Investigative	D07MXA	.	CTPDG008679
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	2-Hexadecynoic acid	hexadec-2-ynoic acid; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494	151047	Investigative	D05HRK	.	CTPDG012098
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	GALLOCATECHIN GALLATE	"(-)-Gallocatechin gallate; 4233-96-9; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,"	5276890	Investigative	D07KXK	.	CTPDG012099
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1"	5281614	Investigative	D0MF5Y	DB07795	CTPDG011236
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	(-)-CATECHINGALLATE	"(-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG"	6419835	Investigative	D0RB1V	.	CTPDG012100
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	biochanin A	"491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether"	5280373	Investigative	D0S9YX	DB15334	CTPDG012101
M6ACROT05841	Fatty acid synthsae (FASN)	FAS_HUMAN	.	.	Investigative	MORIN	"480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]"	5281670	Investigative	D0NJ4H	.	CTPDG012102
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Phase 2	Stannsoporfin	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)	23725028	Phase 2	D02JAY	.	CTPDG014087
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	2-Phenylheme	.	17753777	Investigative	D02AVZ	DB03906	CTPDG014088
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Biliverdine Ix Alpha	"biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2"	5280353	Investigative	D06SCF	DB02073	CTPDG014089
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Verdoheme	.	11963948	Investigative	D06UNX	.	CTPDG014090
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Tin protoporphyrin	"AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid"	24197550	Investigative	D0HX0D	.	CTPDG014091
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride	20541332	Investigative	D0K1NM	DB07342	CTPDG014092
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	12-Phenylheme	.	5287448	Investigative	D0S8UN	.	CTPDG014093
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand"	3776	Investigative	D0W7LK	DB02325	CTPDG011331
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Formic Acid	"formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235"	284	Investigative	D06EWG	DB01942	CTPDG014094
M6ACROT05844	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Phase 2	Stannsoporfin	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)	23725028	Phase 2	D02JAY	.	CTPDG014087
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	2-Phenylheme	.	17753777	Investigative	D02AVZ	DB03906	CTPDG014088
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Biliverdine Ix Alpha	"biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2"	5280353	Investigative	D06SCF	DB02073	CTPDG014089
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Verdoheme	.	11963948	Investigative	D06UNX	.	CTPDG014090
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Tin protoporphyrin	"AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid"	24197550	Investigative	D0HX0D	.	CTPDG014091
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride	20541332	Investigative	D0K1NM	DB07342	CTPDG014092
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	12-Phenylheme	.	5287448	Investigative	D0S8UN	.	CTPDG014093
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand"	3776	Investigative	D0W7LK	DB02325	CTPDG011331
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Formic Acid	"formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235"	284	Investigative	D06EWG	DB01942	CTPDG014094
M6ACROT05845	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Phase 2	Stannsoporfin	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)	23725028	Phase 2	D02JAY	.	CTPDG014087
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	2-Phenylheme	.	17753777	Investigative	D02AVZ	DB03906	CTPDG014088
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Biliverdine Ix Alpha	"biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2"	5280353	Investigative	D06SCF	DB02073	CTPDG014089
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Verdoheme	.	11963948	Investigative	D06UNX	.	CTPDG014090
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Tin protoporphyrin	"AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid"	24197550	Investigative	D0HX0D	.	CTPDG014091
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride	20541332	Investigative	D0K1NM	DB07342	CTPDG014092
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	12-Phenylheme	.	5287448	Investigative	D0S8UN	.	CTPDG014093
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand"	3776	Investigative	D0W7LK	DB02325	CTPDG011331
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Formic Acid	"formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235"	284	Investigative	D06EWG	DB01942	CTPDG014094
M6ACROT05846	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Phase 2	Stannsoporfin	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)	23725028	Phase 2	D02JAY	.	CTPDG014087
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	2-Phenylheme	.	17753777	Investigative	D02AVZ	DB03906	CTPDG014088
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Biliverdine Ix Alpha	"biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2"	5280353	Investigative	D06SCF	DB02073	CTPDG014089
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Verdoheme	.	11963948	Investigative	D06UNX	.	CTPDG014090
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Tin protoporphyrin	"AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid"	24197550	Investigative	D0HX0D	.	CTPDG014091
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride	20541332	Investigative	D0K1NM	DB07342	CTPDG014092
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	12-Phenylheme	.	5287448	Investigative	D0S8UN	.	CTPDG014093
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand"	3776	Investigative	D0W7LK	DB02325	CTPDG011331
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Formic Acid	"formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235"	284	Investigative	D06EWG	DB01942	CTPDG014094
M6ACROT05847	Heme oxygenase 1 (HMOX1)	HMOX1_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT05850	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT05853	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05854	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05854	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT05855	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05855	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05856	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT05856	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	Approved	D07OJZ	DB11791	CTPDG010654
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	Approved	D0R8QG	DB15133	CTPDG000172
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Cabozantinib	Cabometyx; Cometriq	25102847	Approved	D0IQ6P	DB08875	CTPDG000334
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Amivantamab	.	.	Approved	DQ5X1Z	.	CTPDG000006
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Approved	Crizotinib	Xalkori (TN); novel ALK inhibitors	11626560	Approved	D03ZBT	DB08865	CTPDG010655
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	RG3638	Onartuzumab	.	Phase 3	D0H9PT	.	CTPDG001189
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	Phase 3	D0LW0T	DB12048	CTPDG001139
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Beperminogene perplasmid	.	.	Phase 3	D0N1YF	.	CTPDG010656
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 3	Tivantinib	"905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	Phase 3	D0ZI1F	DB12200	CTPDG000957
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2/3	MGCD516	Sitravatinib	25212148	Phase 2/3	D05BLN	DB15036	CTPDG001568
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	Phase 2	D03SXS	.	CTPDG002904
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	Phase 2	D07ARN	DB15382	CTPDG002710
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Emibetuzumab	.	.	Phase 2	D0FE7D	.	CTPDG002388
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 337	.	44181686	Phase 2	D0G0BL	.	CTPDG002382
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	AMG 208	"AMG-208; 1002304-34-8; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	Phase 2	D0OK2N	DB08079	CTPDG002128
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	Phase 2	D0R0YW	.	CTPDG002076
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	Telisotuzumab vedotin	ABBV-399	.	Phase 2	D42TUS	.	CTPDG010657
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	Phase 2	DV3Y7F	.	CTPDG001627
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	CMX-2043	.	49802864	Phase 2	D01TBJ	DB12795	CTPDG003014
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	LY2801653	"Merestinib; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	Phase 2	D06EGV	DB12381	CTPDG002767
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 2	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	Phase 2	D0D1GF	DB12307	CTPDG002459
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	Phase 1/2	D09ZNL	.	CTPDG010658
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Anti-C-met CAR-T cells	.	.	Phase 1/2	D0A3OE	.	CTPDG003477
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	BMS-777607	"1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	Phase 1/2	D0O6WV	DB12064	CTPDG010659
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	Sym015	.	.	Phase 1/2	D0B4OK	.	CTPDG003471
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1/2	MK-2461	MK 2461	44137946	Phase 1/2	D00DRL	.	CTPDG003636
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	REGN5093	.	.	Phase 1	D01FSX	.	CTPDG010660
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N"	17754438	Phase 1	D01LCC	DB12848	CTPDG005402
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABBV-399	.	.	Phase 1	D02EOR	.	CTPDG005362
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	Phase 1	D04XUJ	.	CTPDG005230
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	MK-8033	"1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	Phase 1	D05OMT	.	CTPDG005193
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Autologous T Cells Expressing MET scFv CAR	.	.	Phase 1	D0D1HI	.	CTPDG004870
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	ABT-700	.	.	Phase 1	D0I2IY	.	CTPDG004729
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	Phase 1	D0N6VK	.	CTPDG010661
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	EMD-1204831	.	25134692	Phase 1	D0Y8UV	.	CTPDG004252
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	Phase 1	D0YT8P	DB13113	CTPDG004241
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	SGX523	"SGX-523; SGX523, SGX-523"	24779724	Phase 1	D0ZU5F	DB08584	CTPDG004211
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TR1801-ADC	.	.	Phase 1	DU6H8Z	.	CTPDG003705
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	LY3164530	.	.	Phase 1	D01IJM	.	CTPDG005408
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	Phase 1	D09ETH	DB11977	CTPDG010082
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	Phase 1	D1TNJ2	.	CTPDG004182
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	BPI-9016 M	.	.	Phase 1	D95YSW	.	CTPDG004001
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	AZD9592	.	.	Phase 1	DN47VK	.	CTPDG003809
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	Phase 1	D7M8LI	.	CTPDG004035
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	Phase 1	D7HZ3T	.	CTPDG004042
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Phase 1	Altiratinib	.	54576299	Phase 1	D0FA6S	.	CTPDG004800
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	Mteron-F1	.	.	Preclinical	D0NO6E	.	CTPDG010663
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Preclinical	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	Preclinical	D1AD6L	.	CTPDG007019
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-805	.	.	Investigative	D00FZA	.	CTPDG009193
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PHA-665752	"477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	Investigative	D00TBD	.	CTPDG009156
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	Investigative	D03LZK	.	CTPDG008961
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	Investigative	D05GSI	.	CTPDG008837
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	Investigative	D07CFW	.	CTPDG010664
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	Investigative	D07OXC	.	CTPDG010665
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	mab 224G11	"C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	Investigative	D0AD6Z	.	CTPDG008473
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	Investigative	D0BS6B	.	CTPDG008435
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	SU11274	Met kinase Inhibitor; SU-11274	9549297	Investigative	D0E1QI	.	CTPDG010666
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	Investigative	D0G3ZN	.	CTPDG008272
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	Investigative	D0I2PS	.	CTPDG008217
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	Investigative	D0M0SV	.	CTPDG008085
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	Investigative	D0N5XG	.	CTPDG010667
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	Investigative	D0N6QO	.	CTPDG008039
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	Investigative	D0NX6F	.	CTPDG008022
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	GE-137	.	91827375	Investigative	D0PS7U	.	CTPDG010668
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	Investigative	D0S0GT	.	CTPDG010669
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	CHEMBL540744	45272467	Investigative	D0S1II	.	CTPDG010670
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	Investigative	D0T1YH	.	CTPDG007865
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225	45270766	Investigative	D0U4JW	.	CTPDG010671
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	Investigative	D0W8GP	.	CTPDG007751
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	Investigative	D0Z4RX	.	CTPDG007635
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	YH013	.	.	Investigative	D0AM9O	.	CTPDG008468
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID24210504C1o	GTPL8143; BDBM50444090	44256277	Investigative	D04CUA	.	CTPDG010672
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21123062C27	GTPL8210; BDBM50334085	50942314	Investigative	D0RO9R	.	CTPDG010673
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	PMID21967808CR-16	GTPL8213; BDBM50361564	56597775	Investigative	D00EMH	.	CTPDG010674
M6ACROT05857	Hepatocyte growth factor receptor (c-Met/MET)	MET_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT05857	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05863	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05863	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05863	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05863	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05864	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05864	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05864	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05864	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT05865	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT05865	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05865	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05865	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT05866	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT05866	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05866	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05866	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05867	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05867	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05867	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	Phase 2	D0C9PZ	.	CTPDG013128
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298697	.	.	Investigative	D00JHE	.	CTPDG014625
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298744	.	.	Investigative	D01DDQ	.	CTPDG014626
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298746	.	.	Investigative	D01ZCK	.	CTPDG014627
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298745	.	.	Investigative	D07GVC	.	CTPDG014628
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298743	.	.	Investigative	D09DCJ	.	CTPDG014629
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298702	.	.	Investigative	D0B5LQ	.	CTPDG014630
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298700	.	.	Investigative	D0C2IG	.	CTPDG014631
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 175510	.	.	Investigative	D0G9BP	.	CTPDG014632
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298699	.	.	Investigative	D0L5ME	.	CTPDG014633
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298712	.	.	Investigative	D0L9KW	.	CTPDG014634
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298711	.	.	Investigative	D0SN5O	.	CTPDG014635
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	ISIS 298701	.	.	Investigative	D0X8GB	.	CTPDG014636
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Investigative	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol	5712	Investigative	D00REK	.	CTPDG014637
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 4	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	Phase 4	D0B0AX	.	CTPDG014683
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 3	IT-101	.	.	Phase 3	D06PEW	.	CTPDG001376
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 2	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	Phase 2	D06NYA	DB02342	CTPDG014684
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	PX-478	"685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	Phase 1	D06ZVO	DB06082	CTPDG005130
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	EZN-2968	.	.	Phase 1	D0NF5J	.	CTPDG004569
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Phase 1	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	Phase 1	D0Y5QD	DB05959	CTPDG004255
M6ACROT05875	Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A)	HIF1A_HUMAN	.	.	Patented	Pyrrolidine carboxamide derivative 1	PMID26882240-Compound-22	56684144	Patented	D0Q2SE	.	CTPDG014685
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Phase 3	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	Phase 3	D0U2BH	DB12116	CTPDG009944
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Phase 1/2a	BT1718	.	.	Phase 1/2a	DE2Z7V	.	CTPDG003111
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Discontinued in Phase 2	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup"	132519	Discontinued in Phase 2	D0T9HG	DB02255	CTPDG009720
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	DX-2400	"DX-2410; MMP inhibitors (fully human antibodies), Dyax"	.	Investigative	D03XBB	.	CTPDG008922
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	PMID23631440C29e	GTPL8578; BDBM50433865	46175162	Investigative	D07DRT	.	CTPDG013239
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide	CHEMBL550148; 3f17; BDBM50294120	25049753	Investigative	D09ZOA	.	CTPDG013806
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide	CHEMBL1090283; 1218922-39-4; SCHEMBL7413923	22004198	Investigative	D0NV9C	.	CTPDG013807
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide	CHEMBL83508; N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide; Hydroxamate 9; Z79; 3lk8; SCHEMBL7410575; BDBM11328; (4-Methoxyphenylsulfonylamino)acetohydroximic acid	10445302	Investigative	D0XK7G	.	CTPDG013808
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	Investigative	D0NP8A	.	CTPDG009976
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589	44478925	Investigative	D05THD	.	CTPDG009977
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935	44479701	Investigative	D07MJD	.	CTPDG009978
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896	10155934	Investigative	D0S9OL	.	CTPDG009979
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	SR-973	"CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	Investigative	D03AMR	.	CTPDG009744
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682	6914621	Investigative	D0W2UK	DB07145	CTPDG009980
M6ACROT05876	Matrix metalloproteinase-14 (MMP14)	MMP14_HUMAN	.	.	Investigative	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	Investigative	D0A4TC	DB07556	CTPDG009745
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112000	.	.	Investigative	D00LSM	.	CTPDG015409
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112022	.	.	Investigative	D00SQD	.	CTPDG015410
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112019	.	.	Investigative	D04XOE	.	CTPDG015411
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112005	.	.	Investigative	D06QZK	.	CTPDG015412
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112002	.	.	Investigative	D07FSX	.	CTPDG015413
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112023	.	.	Investigative	D07RUF	.	CTPDG015414
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111992	.	.	Investigative	D0D9OL	.	CTPDG015415
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112003	.	.	Investigative	D0GD1R	.	CTPDG015416
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111997	.	.	Investigative	D0H0YU	.	CTPDG015417
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112004	.	.	Investigative	D0H6OL	.	CTPDG015418
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112001	.	.	Investigative	D0N7OK	.	CTPDG015419
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112024	.	.	Investigative	D0QU6S	.	CTPDG015420
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112020	.	.	Investigative	D0T0XZ	.	CTPDG015421
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 111993	.	.	Investigative	D0Y4TS	.	CTPDG015422
M6ACROT05877	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)	ROA1_HUMAN	.	.	Investigative	ISIS 112021	.	.	Investigative	D0Z4RI	.	CTPDG015423
M6ACROT05888	"Alpha-(1,3)-fucosyltransferase 4 (FUT4)"	FUT4_HUMAN	.	.	Approved	99mTc-fanolesomab	LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody	.	Approved	D07WLI	.	CTPDG012881
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	PMID26666870-Compound-16	.	.	Patented	D00KXJ	.	CTPDG014988
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 1	PMID26666870-Compound-17	.	Patented	D0FL0T	.	CTPDG014989
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 2	PMID26666870-Compound-18	.	Patented	D0II7X	.	CTPDG014990
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 1	PMID26666870-Compound-19	.	Patented	D00RRB	.	CTPDG014991
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 5	PMID26666870-Compound-23	.	Patented	D01BGG	.	CTPDG014992
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 7	PMID26666870-Compound-25	.	Patented	D04IFL	.	CTPDG014993
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 8	PMID26666870-Compound-26	.	Patented	D05NRG	.	CTPDG014994
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 9	PMID26666870-Compound-27	.	Patented	D09VIE	.	CTPDG014995
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 6	PMID26666870-Compound-24	.	Patented	D0J1RB	.	CTPDG014996
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 3	PMID26666870-Compound-21	.	Patented	D0TP0S	.	CTPDG014997
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 2	PMID26666870-Compound-20	.	Patented	D0WI1G	.	CTPDG014998
M6ACROT05889	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 4	PMID26666870-Compound-22	.	Patented	D0Z6IS	.	CTPDG014999
M6ACROT05890	Cystathionine beta-synthsae (CBS)	CBS_HUMAN	.	.	Phase 1/2	OT-58	.	.	Phase 1/2	D87TMY	.	CTPDG014791
M6ACROT05890	Cystathionine beta-synthsae (CBS)	CBS_HUMAN	.	.	Investigative	aminooxyacetic acid	"(aminooxy)acetic acid; 2-(Aminooxy)acetic acid; AOAA; carboxymethoxylamine; 645-88-5; Carboxymethoxyamine; ACETIC ACID, (AMINOOXY)-; Aminooxyacetate; Aminooxy-acetic acid; (Carboxymethoxy)amine; (o-Carboxymethyl)hydroxylamine; aminoxyacetic acid; UNII-14I68GI3OQ; BRN 0878238; C2H5NO3; 14I68GI3OQ; U 7524; NQRKYASMKDDGHT-UHFFFAOYSA-N; u-7524; AOA; Aminooxyacetic acid hemihydrochloride; Carboxymethoxylamine hemihydrochloride; aminoxy-acetic acid; amino-oxyacetic acid; AOA hemihydrochloride; 2-aminooxyacetic acid"	286	Investigative	D01BTV	DB02079	CTPDG014792
M6ACROT05890	Cystathionine beta-synthsae (CBS)	CBS_HUMAN	.	.	Investigative	Heme	"protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	Investigative	D0UU1I	.	CTPDG012701
M6ACROT05891	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05891	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05891	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05892	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Dusigitumab	.	.	Phase 2	D09TQY	.	CTPDG014730
M6ACROT05892	Insulin-like growth factor 2 (IGF2)	IGF2_HUMAN	.	.	Phase 2	Xentuzumab	.	.	Phase 2	D04DNB	.	CTPDG014731
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	PMID26666870-Compound-16	.	.	Patented	D00KXJ	.	CTPDG014988
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 1	PMID26666870-Compound-17	.	Patented	D0FL0T	.	CTPDG014989
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Imidazo bicyclic iminium derivative 2	PMID26666870-Compound-18	.	Patented	D0II7X	.	CTPDG014990
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 1	PMID26666870-Compound-19	.	Patented	D00RRB	.	CTPDG014991
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 5	PMID26666870-Compound-23	.	Patented	D01BGG	.	CTPDG014992
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 7	PMID26666870-Compound-25	.	Patented	D04IFL	.	CTPDG014993
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 8	PMID26666870-Compound-26	.	Patented	D05NRG	.	CTPDG014994
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 9	PMID26666870-Compound-27	.	Patented	D09VIE	.	CTPDG014995
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 6	PMID26666870-Compound-24	.	Patented	D0J1RB	.	CTPDG014996
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 3	PMID26666870-Compound-21	.	Patented	D0TP0S	.	CTPDG014997
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 2	PMID26666870-Compound-20	.	Patented	D0WI1G	.	CTPDG014998
M6ACROT05893	Zinc finger protein GLI1 (GLI1)	GLI1_HUMAN	.	.	Patented	Isoflavone derivative 4	PMID26666870-Compound-22	.	Patented	D0Z6IS	.	CTPDG014999
M6ACROT05900	Hexokinase-2 (HK2)	HXK2_HUMAN	.	.	Phase 2	VDA-1102	.	.	Phase 2	D06QBX	.	CTPDG014520
M6ACROT05901	Solute carrier family 2 member 1 (SLC2A1)	GTR1_HUMAN	.	.	Preclinical	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	Preclinical	DCL8J5	.	CTPDG014828
M6ACROT05905	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05905	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05905	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05906	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05906	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05906	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05907	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05907	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05907	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05908	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05908	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05908	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05913	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05913	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05913	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05914	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05914	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05914	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05915	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05915	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05915	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05916	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05916	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05916	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Phase 1/2	Aderbasib	"INCB-007839; INCB-7839; Sheddase inhibitors (anticancer), Incyte; ADAM inhibitors (oral, cancer), Incyte"	16070111	Phase 1/2	D02CZF	.	CTPDG013955
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	IAI-100	"ADAM inhibitors (cancer); IAI-102; INCB-3531; INCB-3619; A disintegrin and metalloprotease inhibitors (cancer), Incyte;ADAM inhibitors (cancer), Incyte; HER-2 sheddase inhibitors (cancer), Incyte"	11625778	Investigative	D06EHW	.	CTPDG008765
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	ISIS 100748	.	.	Investigative	D02CNG	.	CTPDG015194
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	ISIS 100742	.	.	Investigative	D0J2VN	.	CTPDG015195
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	ISIS 100743	.	.	Investigative	D0JV0I	.	CTPDG015196
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	ISIS 100749	.	.	Investigative	D0Q6MK	.	CTPDG015197
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	PMID18068976C25	GTPL8568; BDBM50229655	44447430	Investigative	D0VI2A	.	CTPDG015198
M6ACROT05919	Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	ADA10_HUMAN	.	.	Investigative	ISIS 100750	.	.	Investigative	D0X7FV	.	CTPDG015199
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Avelumab	.	.	Approved	D0K7SX	.	CTPDG000301
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Durvalumab	.	.	Approved	D0LS9E	.	CTPDG012815
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	RG-7446	.	.	Approved	D0OZ4J	.	CTPDG012816
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Bavencio	.	.	Approved	D0W8HN	.	CTPDG000083
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved	Atezolizumab	.	.	Approved	D0YM2K	.	CTPDG000039
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Approved in China	Sugemalimab	.	.	Approved in China	DDZ48Y	.	CTPDG000015
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MEDI4736	.	.	Phase 3	D04RRZ	.	CTPDG001416
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	MPDL-3280A	.	.	Phase 3	D0Y5IH	.	CTPDG000981
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	CS1001	.	.	Phase 3	D3MP1S	.	CTPDG000942
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	A167	KL-A167	.	Phase 3	DI89WD	.	CTPDG000903
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 3	KN046	.	.	Phase 3	DLOQ25	.	CTPDG012817
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Pidilizumab	CT-011	.	Phase 2	D09MRL	.	CTPDG002574
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	KN035	Envafolimab	.	Phase 2	D0GF2R	.	CTPDG002356
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	CX-072	.	.	Phase 2	D0Z2BO	.	CTPDG001867
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	INCB86550	.	.	Phase 2	DKM79E	.	CTPDG001693
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	Bintrafusp alfa	.	.	Phase 2	D5J3BL	.	CTPDG001805
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 2	M7824	.	.	Phase 2	D05FPZ	.	CTPDG002813
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	BGB-A333	.	.	Phase 1/2	DC5VW9	.	CTPDG003195
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	Phase 1/2	DS6VD0	.	CTPDG003143
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1/2	NM21-1480	.	.	Phase 1/2	DUVH60	.	CTPDG003136
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3300054	.	.	Phase 1	D08HSS	.	CTPDG005054
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MSB2311	.	.	Phase 1	D0A8AU	.	CTPDG004941
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1	BMS-936559	.	Phase 1	D0KP9A	.	CTPDG004646
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FAZ053	.	.	Phase 1	D0LU1O	.	CTPDG004609
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Anti-PD-L1 CSR T cells	.	.	Phase 1	D0W7UD	.	CTPDG012818
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	BMS-986189	.	.	Phase 1	D0X1GN	.	CTPDG012819
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	Cosibelimab	CK-301/TG-1501	.	Phase 1	D17URP	.	CTPDG004200
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	.	.	Phase 1	D2Z6WF	.	CTPDG004150
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PD-L1 t-haNK	.	.	Phase 1	DH42RF	.	CTPDG003899
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	KD033	.	.	Phase 1	DJVR06	.	CTPDG003860
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	C-Met/PD-L1 CAR-T Cell	.	.	Phase 1	D03GTO	.	CTPDG010662
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	Phase 1	D09PPU	.	CTPDG004985
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	FS118	.	.	Phase 1	D0XO9F	.	CTPDG004272
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	PF-07257876	.	.	Phase 1	D1A7OP	.	CTPDG004199
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	MCLA-145	.	.	Phase 1	D2QY0Z	.	CTPDG004156
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	GEN1046	.	.	Phase 1	D3HBJ1	.	CTPDG004139
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	ALPN-202	.	.	Phase 1	D82UVG	.	CTPDG004022
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	TAK-252	SL-279252	.	Phase 1	D9SL1N	.	CTPDG003989
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	INBRX-105	.	.	Phase 1	DA1X5W	.	CTPDG003983
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	LY3415244	.	.	Phase 1	DC8HR6	.	CTPDG003954
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	A337	.	.	Phase 1	DL97UQ	.	CTPDG003833
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	IBI318	.	.	Phase 1	DX30BA	.	CTPDG003670
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example2	.	117941742	Patented	D0OK1S	.	CTPDG005729
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Patented	PMID30107136-Compound-Example1	.	117951478	Patented	D0WQ9X	.	CTPDG005575
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure7	PMID30247903Compound7	.	Investigative	D01TGF	.	CTPDG012820
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	CA-327	.	.	Investigative	D04ILU	.	CTPDG012821
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure8	PMID30247903Compound8	.	Investigative	D04QGF	.	CTPDG012822
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure5	PMID30247903Compound5	.	Investigative	D07BOF	.	CTPDG012823
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure12	PMID30247903Compound12	.	Investigative	D09BYN	.	CTPDG012824
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure9	PMID30247903Compound9	.	Investigative	D0GG6N	.	CTPDG012825
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure6	PMID30247903Compound6	.	Investigative	D0TN4F	.	CTPDG012826
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	PMID30247903-Compound-General structure10	PMID30247903Compound10	.	Investigative	D0XL3N	.	CTPDG012827
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH011	.	.	Investigative	DA91UG	.	CTPDG007607
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Investigative	YH010	.	.	Investigative	DBTI39	.	CTPDG007604
M6ACROT05923	CD274 molecule (CD274)	PD1L1_HUMAN	.	.	Phase 1	RG6084	.	.	Phase 1	DJX7K9	.	CTPDG014810
M6ACROT05926	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT05926	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Patented	PMID26161698-Compound-17	.	739323	Patented	D0FQ6V	.	CTPDG010913
M6ACROT05926	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT05926	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT05927	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Phase 1	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	Phase 1	D03DKV	.	CTPDG010909
M6ACROT05927	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Patented	PMID26161698-Compound-17	.	739323	Patented	D0FQ6V	.	CTPDG010913
M6ACROT05927	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Patented	Nitrogen mustard derivative 1	PMID26161698-Compound-55	71515463	Patented	D0LK4L	.	CTPDG013459
M6ACROT05927	Cyclin-dependent kinase 3 (CDK3)	CDK3_HUMAN	.	.	Patented	Oxazolyl methylthiothiazole derivative 1	PMID26161698-Compound-52	25195503	Patented	D0M5DX	.	CTPDG010918
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 2	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	Phase 2	D0Y1UO	DB12282	CTPDG001881
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	BI-853520	.	.	Phase 1	D00KNI	.	CTPDG005456
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	PF-562271	PF-00562271	11713159	Phase 1	D01SJT	.	CTPDG005383
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	VS-4718	PND-1186	25073775	Phase 1	D0A6VD	DB15273	CTPDG004942
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	GSK-2256098	"Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline"	46214930	Phase 1	D0B9MR	.	CTPDG004911
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	CEP-37440	"Dual ALK/FAK inhibitor (cancer), Cephalon; Dual anaplastic lymphoma kinase/focal adhesion kinase inhibitor (cancer),Cephalon"	71721648	Phase 1	D0N6NM	DB13060	CTPDG004580
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Phase 1	IN10018	.	.	Phase 1	D1EW3O	.	CTPDG014242
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Patented	"1,2,4-triazolo[1,5a]pyridine derivative 1"	PMID27774824-Compound-Figure8compoundA	.	Patented	D07XYI	.	CTPDG009392
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Investigative	PMID23414845C30	4i4f; GTPL7864; BDBM50430287; 1BR	70698427	Investigative	D0AY0F	.	CTPDG014243
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Investigative	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	Investigative	D02QAZ	.	CTPDG013329
M6ACROT05930	Protein tyrosine kinase 2 (PTK2)	FAK1_HUMAN	.	.	Investigative	BMS-536924	.	135440466	Investigative	D0M4SY	.	CTPDG010063
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 3	XEMILOFIBAN	"Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate"	60957	Discontinued in Phase 3	D07EXV	.	CTPDG014838
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 1	DMP-802	"CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid"	9812185	Discontinued in Phase 1	D0K0NP	.	CTPDG014839
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-709780	"CHEMBL32960; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid"	9885190	Terminated	D03GCN	.	CTPDG014840
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-8857	"CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid"	9933077	Terminated	D03QHI	.	CTPDG014841
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SKF-107260	"F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)"	164393	Terminated	D08CQL	.	CTPDG014842
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-738167	"CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)"	153986	Terminated	D08LIG	.	CTPDG014843
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	DMP-757	"CHEMBL65617; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid"	10031011	Terminated	D0U4ZY	.	CTPDG014844
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-5054	CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	Terminated	D0Z0XQ	.	CTPDG014845
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	Terminated	D0G9BX	.	CTPDG014846
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SB-223245	"CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid"	9823503	Terminated	D0LT1S	.	CTPDG014847
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-739758	"CHEMBL78760; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid"	9958398	Investigative	D01XUU	.	CTPDG014848
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 25237	.	.	Investigative	D02MYZ	.	CTPDG014849
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ROXIFIBAN	"UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy"	177230	Investigative	D04BHL	.	CTPDG014850
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RWJ-53419	CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	Investigative	D04XTP	.	CTPDG014851
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-750034	CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	Investigative	D05AGK	.	CTPDG014852
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-756568	CHEMBL96097; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	Investigative	D06LHH	.	CTPDG014853
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SC-54701A	"UNII-TN585Y92BI; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)"	9862322	Investigative	D08RLR	.	CTPDG014854
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-734115	"CHEMBL40502; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)"	9913833	Investigative	D0C8LA	.	CTPDG014855
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-207043	CHEMBL606910	52942958	Investigative	D0M7KS	.	CTPDG014856
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 196103	.	.	Investigative	D0Q2ZS	.	CTPDG014857
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-746233	"CHEMBL79294; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid"	10324223	Investigative	D0S8DT	.	CTPDG014858
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-767679	"CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-"	177364	Investigative	D0W5ZK	.	CTPDG014859
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfF)	CHEMBL380434	10699123	Investigative	D00YBU	.	CTPDG014860
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	Investigative	D01AXA	.	CTPDG014861
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	Investigative	D01BZH	.	CTPDG014862
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	Investigative	D01MGI	.	CTPDG014863
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603	44418280	Investigative	D01ZJF	.	CTPDG014472
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	Investigative	D03KLT	.	CTPDG014864
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	Investigative	D03YLY	.	CTPDG014865
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]2	.	91936295	Investigative	D04MCL	.	CTPDG014866
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	Investigative	D04WVG	.	CTPDG014867
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693	10416726	Investigative	D05EWB	.	CTPDG014868
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	Investigative	D05GXK	.	CTPDG014869
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2	CHEMBL414385	44388431	Investigative	D05MJG	.	CTPDG014870
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	Investigative	D05VEC	.	CTPDG014871
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	Investigative	D06JLN	.	CTPDG014872
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser	"96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-"	123811	Investigative	D06LKH	.	CTPDG014873
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	Investigative	D07QJD	.	CTPDG014874
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfMeF)	CHEMBL383747	44408450	Investigative	D07UOF	.	CTPDG014875
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077	11505585	Investigative	D08CFM	.	CTPDG014876
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	Investigative	D08DSG	.	CTPDG014877
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	Investigative	D09PLA	.	CTPDG014878
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RGDechi	.	91936353	Investigative	D0D4QZ	.	CTPDG014879
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	Investigative	D0G7QJ	.	CTPDG014473
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo(RGDfV) (control)	CHEMBL206344	44409460	Investigative	D0G8JI	.	CTPDG014880
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590	11643340	Investigative	D0H4EK	.	CTPDG014881
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISONIPECOTAMIDE	"Piperidine-4-carboxamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide"	3772	Investigative	D0H4MB	.	CTPDG014882
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309	9831456	Investigative	D0I5BY	.	CTPDG014883
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	CYCLORGDFV	"cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid"	9851104	Investigative	D0ID6U	.	CTPDG014884
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	Investigative	D0J6SP	.	CTPDG014885
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2-PTX conjugate	.	91933274	Investigative	D0K5DM	.	CTPDG014886
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]1	.	91936298	Investigative	D0L2PQ	.	CTPDG014887
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	Investigative	D0LF7W	.	CTPDG014888
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser-Pro-Lys	"Grgdspk; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-"	130667	Investigative	D0LV6B	.	CTPDG014889
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589	11636164	Investigative	D0M0BN	.	CTPDG014890
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574	10372586	Investigative	D0M6NQ	.	CTPDG014891
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]2	.	91936297	Investigative	D0N9NA	.	CTPDG014892
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	Investigative	D0O6DN	.	CTPDG014893
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	Investigative	D0O9FL	.	CTPDG014894
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]1	CHEMBL438186	44409497	Investigative	D0P4RB	.	CTPDG014895
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide"	"CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01"	558969	Investigative	D0R9AD	.	CTPDG014896
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	Investigative	D0R9GW	.	CTPDG014897
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ST-1646	CHEMBL392303	44439175	Investigative	D0R9SJ	.	CTPDG014898
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo[RGDfK(cypate)]	CHEMBL407126	44409643	Investigative	D0T1II	.	CTPDG014899
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	Investigative	D0TP8S	.	CTPDG014474
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	Investigative	D0U0VF	.	CTPDG014900
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066	44408397	Investigative	D0U2NV	.	CTPDG014901
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	Investigative	D0UE7H	.	CTPDG014902
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]2	.	91936296	Investigative	D0UO0Y	.	CTPDG014903
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056	9986643	Investigative	D0V0JC	.	CTPDG014904
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	Investigative	D0W6CJ	.	CTPDG014905
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"C[RGDf-(S,R)-alpha-Dfm-F]"	CHEMBL379911	11614485	Investigative	D0WK2F	.	CTPDG014906
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	AcDRGDS	CHEMBL241297; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	Investigative	D0X4EE	.	CTPDG014907
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]1	.	91936299	Investigative	D0Y8UD	.	CTPDG014908
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	Investigative	D0Z6WZ	.	CTPDG014909
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT05946	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 3	XEMILOFIBAN	"Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate"	60957	Discontinued in Phase 3	D07EXV	.	CTPDG014838
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 1	DMP-802	"CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid"	9812185	Discontinued in Phase 1	D0K0NP	.	CTPDG014839
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-709780	"CHEMBL32960; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid"	9885190	Terminated	D03GCN	.	CTPDG014840
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-8857	"CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid"	9933077	Terminated	D03QHI	.	CTPDG014841
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SKF-107260	"F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)"	164393	Terminated	D08CQL	.	CTPDG014842
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-738167	"CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)"	153986	Terminated	D08LIG	.	CTPDG014843
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	DMP-757	"CHEMBL65617; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid"	10031011	Terminated	D0U4ZY	.	CTPDG014844
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-5054	CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	Terminated	D0Z0XQ	.	CTPDG014845
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	Terminated	D0G9BX	.	CTPDG014846
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SB-223245	"CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid"	9823503	Terminated	D0LT1S	.	CTPDG014847
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-739758	"CHEMBL78760; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid"	9958398	Investigative	D01XUU	.	CTPDG014848
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 25237	.	.	Investigative	D02MYZ	.	CTPDG014849
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ROXIFIBAN	"UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy"	177230	Investigative	D04BHL	.	CTPDG014850
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RWJ-53419	CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	Investigative	D04XTP	.	CTPDG014851
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-750034	CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	Investigative	D05AGK	.	CTPDG014852
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-756568	CHEMBL96097; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	Investigative	D06LHH	.	CTPDG014853
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SC-54701A	"UNII-TN585Y92BI; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)"	9862322	Investigative	D08RLR	.	CTPDG014854
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-734115	"CHEMBL40502; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)"	9913833	Investigative	D0C8LA	.	CTPDG014855
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-207043	CHEMBL606910	52942958	Investigative	D0M7KS	.	CTPDG014856
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 196103	.	.	Investigative	D0Q2ZS	.	CTPDG014857
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-746233	"CHEMBL79294; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid"	10324223	Investigative	D0S8DT	.	CTPDG014858
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-767679	"CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-"	177364	Investigative	D0W5ZK	.	CTPDG014859
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfF)	CHEMBL380434	10699123	Investigative	D00YBU	.	CTPDG014860
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	Investigative	D01AXA	.	CTPDG014861
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	Investigative	D01BZH	.	CTPDG014862
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	Investigative	D01MGI	.	CTPDG014863
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603	44418280	Investigative	D01ZJF	.	CTPDG014472
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	Investigative	D03KLT	.	CTPDG014864
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	Investigative	D03YLY	.	CTPDG014865
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]2	.	91936295	Investigative	D04MCL	.	CTPDG014866
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	Investigative	D04WVG	.	CTPDG014867
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693	10416726	Investigative	D05EWB	.	CTPDG014868
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	Investigative	D05GXK	.	CTPDG014869
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2	CHEMBL414385	44388431	Investigative	D05MJG	.	CTPDG014870
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	Investigative	D05VEC	.	CTPDG014871
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	Investigative	D06JLN	.	CTPDG014872
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser	"96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-"	123811	Investigative	D06LKH	.	CTPDG014873
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	Investigative	D07QJD	.	CTPDG014874
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfMeF)	CHEMBL383747	44408450	Investigative	D07UOF	.	CTPDG014875
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077	11505585	Investigative	D08CFM	.	CTPDG014876
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	Investigative	D08DSG	.	CTPDG014877
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	Investigative	D09PLA	.	CTPDG014878
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RGDechi	.	91936353	Investigative	D0D4QZ	.	CTPDG014879
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	Investigative	D0G7QJ	.	CTPDG014473
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo(RGDfV) (control)	CHEMBL206344	44409460	Investigative	D0G8JI	.	CTPDG014880
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590	11643340	Investigative	D0H4EK	.	CTPDG014881
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISONIPECOTAMIDE	"Piperidine-4-carboxamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide"	3772	Investigative	D0H4MB	.	CTPDG014882
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309	9831456	Investigative	D0I5BY	.	CTPDG014883
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	CYCLORGDFV	"cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid"	9851104	Investigative	D0ID6U	.	CTPDG014884
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	Investigative	D0J6SP	.	CTPDG014885
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2-PTX conjugate	.	91933274	Investigative	D0K5DM	.	CTPDG014886
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]1	.	91936298	Investigative	D0L2PQ	.	CTPDG014887
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	Investigative	D0LF7W	.	CTPDG014888
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser-Pro-Lys	"Grgdspk; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-"	130667	Investigative	D0LV6B	.	CTPDG014889
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589	11636164	Investigative	D0M0BN	.	CTPDG014890
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574	10372586	Investigative	D0M6NQ	.	CTPDG014891
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]2	.	91936297	Investigative	D0N9NA	.	CTPDG014892
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	Investigative	D0O6DN	.	CTPDG014893
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	Investigative	D0O9FL	.	CTPDG014894
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]1	CHEMBL438186	44409497	Investigative	D0P4RB	.	CTPDG014895
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide"	"CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01"	558969	Investigative	D0R9AD	.	CTPDG014896
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	Investigative	D0R9GW	.	CTPDG014897
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ST-1646	CHEMBL392303	44439175	Investigative	D0R9SJ	.	CTPDG014898
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo[RGDfK(cypate)]	CHEMBL407126	44409643	Investigative	D0T1II	.	CTPDG014899
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	Investigative	D0TP8S	.	CTPDG014474
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	Investigative	D0U0VF	.	CTPDG014900
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066	44408397	Investigative	D0U2NV	.	CTPDG014901
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	Investigative	D0UE7H	.	CTPDG014902
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]2	.	91936296	Investigative	D0UO0Y	.	CTPDG014903
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056	9986643	Investigative	D0V0JC	.	CTPDG014904
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	Investigative	D0W6CJ	.	CTPDG014905
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"C[RGDf-(S,R)-alpha-Dfm-F]"	CHEMBL379911	11614485	Investigative	D0WK2F	.	CTPDG014906
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	AcDRGDS	CHEMBL241297; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	Investigative	D0X4EE	.	CTPDG014907
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]1	.	91936299	Investigative	D0Y8UD	.	CTPDG014908
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	Investigative	D0Z6WZ	.	CTPDG014909
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT05947	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 3	XEMILOFIBAN	"Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate"	60957	Discontinued in Phase 3	D07EXV	.	CTPDG014838
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 1	DMP-802	"CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid"	9812185	Discontinued in Phase 1	D0K0NP	.	CTPDG014839
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-709780	"CHEMBL32960; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid"	9885190	Terminated	D03GCN	.	CTPDG014840
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-8857	"CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid"	9933077	Terminated	D03QHI	.	CTPDG014841
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SKF-107260	"F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)"	164393	Terminated	D08CQL	.	CTPDG014842
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-738167	"CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)"	153986	Terminated	D08LIG	.	CTPDG014843
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	DMP-757	"CHEMBL65617; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid"	10031011	Terminated	D0U4ZY	.	CTPDG014844
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-5054	CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	Terminated	D0Z0XQ	.	CTPDG014845
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	Terminated	D0G9BX	.	CTPDG014846
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SB-223245	"CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid"	9823503	Terminated	D0LT1S	.	CTPDG014847
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-739758	"CHEMBL78760; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid"	9958398	Investigative	D01XUU	.	CTPDG014848
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 25237	.	.	Investigative	D02MYZ	.	CTPDG014849
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ROXIFIBAN	"UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy"	177230	Investigative	D04BHL	.	CTPDG014850
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RWJ-53419	CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	Investigative	D04XTP	.	CTPDG014851
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-750034	CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	Investigative	D05AGK	.	CTPDG014852
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-756568	CHEMBL96097; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	Investigative	D06LHH	.	CTPDG014853
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SC-54701A	"UNII-TN585Y92BI; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)"	9862322	Investigative	D08RLR	.	CTPDG014854
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-734115	"CHEMBL40502; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)"	9913833	Investigative	D0C8LA	.	CTPDG014855
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-207043	CHEMBL606910	52942958	Investigative	D0M7KS	.	CTPDG014856
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 196103	.	.	Investigative	D0Q2ZS	.	CTPDG014857
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-746233	"CHEMBL79294; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid"	10324223	Investigative	D0S8DT	.	CTPDG014858
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-767679	"CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-"	177364	Investigative	D0W5ZK	.	CTPDG014859
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfF)	CHEMBL380434	10699123	Investigative	D00YBU	.	CTPDG014860
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	Investigative	D01AXA	.	CTPDG014861
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	Investigative	D01BZH	.	CTPDG014862
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	Investigative	D01MGI	.	CTPDG014863
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603	44418280	Investigative	D01ZJF	.	CTPDG014472
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	Investigative	D03KLT	.	CTPDG014864
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	Investigative	D03YLY	.	CTPDG014865
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]2	.	91936295	Investigative	D04MCL	.	CTPDG014866
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	Investigative	D04WVG	.	CTPDG014867
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693	10416726	Investigative	D05EWB	.	CTPDG014868
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	Investigative	D05GXK	.	CTPDG014869
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2	CHEMBL414385	44388431	Investigative	D05MJG	.	CTPDG014870
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	Investigative	D05VEC	.	CTPDG014871
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	Investigative	D06JLN	.	CTPDG014872
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser	"96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-"	123811	Investigative	D06LKH	.	CTPDG014873
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	Investigative	D07QJD	.	CTPDG014874
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfMeF)	CHEMBL383747	44408450	Investigative	D07UOF	.	CTPDG014875
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077	11505585	Investigative	D08CFM	.	CTPDG014876
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	Investigative	D08DSG	.	CTPDG014877
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	Investigative	D09PLA	.	CTPDG014878
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RGDechi	.	91936353	Investigative	D0D4QZ	.	CTPDG014879
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	Investigative	D0G7QJ	.	CTPDG014473
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo(RGDfV) (control)	CHEMBL206344	44409460	Investigative	D0G8JI	.	CTPDG014880
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590	11643340	Investigative	D0H4EK	.	CTPDG014881
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISONIPECOTAMIDE	"Piperidine-4-carboxamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide"	3772	Investigative	D0H4MB	.	CTPDG014882
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309	9831456	Investigative	D0I5BY	.	CTPDG014883
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	CYCLORGDFV	"cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid"	9851104	Investigative	D0ID6U	.	CTPDG014884
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	Investigative	D0J6SP	.	CTPDG014885
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2-PTX conjugate	.	91933274	Investigative	D0K5DM	.	CTPDG014886
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]1	.	91936298	Investigative	D0L2PQ	.	CTPDG014887
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	Investigative	D0LF7W	.	CTPDG014888
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser-Pro-Lys	"Grgdspk; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-"	130667	Investigative	D0LV6B	.	CTPDG014889
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589	11636164	Investigative	D0M0BN	.	CTPDG014890
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574	10372586	Investigative	D0M6NQ	.	CTPDG014891
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]2	.	91936297	Investigative	D0N9NA	.	CTPDG014892
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	Investigative	D0O6DN	.	CTPDG014893
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	Investigative	D0O9FL	.	CTPDG014894
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]1	CHEMBL438186	44409497	Investigative	D0P4RB	.	CTPDG014895
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide"	"CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01"	558969	Investigative	D0R9AD	.	CTPDG014896
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	Investigative	D0R9GW	.	CTPDG014897
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ST-1646	CHEMBL392303	44439175	Investigative	D0R9SJ	.	CTPDG014898
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo[RGDfK(cypate)]	CHEMBL407126	44409643	Investigative	D0T1II	.	CTPDG014899
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	Investigative	D0TP8S	.	CTPDG014474
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	Investigative	D0U0VF	.	CTPDG014900
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066	44408397	Investigative	D0U2NV	.	CTPDG014901
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	Investigative	D0UE7H	.	CTPDG014902
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]2	.	91936296	Investigative	D0UO0Y	.	CTPDG014903
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056	9986643	Investigative	D0V0JC	.	CTPDG014904
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	Investigative	D0W6CJ	.	CTPDG014905
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"C[RGDf-(S,R)-alpha-Dfm-F]"	CHEMBL379911	11614485	Investigative	D0WK2F	.	CTPDG014906
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	AcDRGDS	CHEMBL241297; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	Investigative	D0X4EE	.	CTPDG014907
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]1	.	91936299	Investigative	D0Y8UD	.	CTPDG014908
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	Investigative	D0Z6WZ	.	CTPDG014909
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT05948	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 3	XEMILOFIBAN	"Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate"	60957	Discontinued in Phase 3	D07EXV	.	CTPDG014838
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Discontinued in Phase 1	DMP-802	"CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid"	9812185	Discontinued in Phase 1	D0K0NP	.	CTPDG014839
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-709780	"CHEMBL32960; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid"	9885190	Terminated	D03GCN	.	CTPDG014840
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-8857	"CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid"	9933077	Terminated	D03QHI	.	CTPDG014841
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SKF-107260	"F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)"	164393	Terminated	D08CQL	.	CTPDG014842
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	L-738167	"CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)"	153986	Terminated	D08LIG	.	CTPDG014843
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	DMP-757	"CHEMBL65617; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid"	10031011	Terminated	D0U4ZY	.	CTPDG014844
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	Ro-43-5054	CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	Terminated	D0Z0XQ	.	CTPDG014845
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	Terminated	D0G9BX	.	CTPDG014846
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Terminated	SB-223245	"CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid"	9823503	Terminated	D0LT1S	.	CTPDG014847
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-739758	"CHEMBL78760; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid"	9958398	Investigative	D01XUU	.	CTPDG014848
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 25237	.	.	Investigative	D02MYZ	.	CTPDG014849
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ROXIFIBAN	"UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy"	177230	Investigative	D04BHL	.	CTPDG014850
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RWJ-53419	CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	Investigative	D04XTP	.	CTPDG014851
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-750034	CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	Investigative	D05AGK	.	CTPDG014852
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-756568	CHEMBL96097; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	Investigative	D06LHH	.	CTPDG014853
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SC-54701A	"UNII-TN585Y92BI; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)"	9862322	Investigative	D08RLR	.	CTPDG014854
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-734115	"CHEMBL40502; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)"	9913833	Investigative	D0C8LA	.	CTPDG014855
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-207043	CHEMBL606910	52942958	Investigative	D0M7KS	.	CTPDG014856
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISIS 196103	.	.	Investigative	D0Q2ZS	.	CTPDG014857
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-746233	"CHEMBL79294; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid"	10324223	Investigative	D0S8DT	.	CTPDG014858
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	L-767679	"CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-"	177364	Investigative	D0W5ZK	.	CTPDG014859
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfF)	CHEMBL380434	10699123	Investigative	D00YBU	.	CTPDG014860
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	Investigative	D01AXA	.	CTPDG014861
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	Investigative	D01BZH	.	CTPDG014862
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	Investigative	D01MGI	.	CTPDG014863
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603	44418280	Investigative	D01ZJF	.	CTPDG014472
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	Investigative	D03KLT	.	CTPDG014864
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	Investigative	D03YLY	.	CTPDG014865
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]2	.	91936295	Investigative	D04MCL	.	CTPDG014866
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	Investigative	D04WVG	.	CTPDG014867
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693	10416726	Investigative	D05EWB	.	CTPDG014868
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	Investigative	D05GXK	.	CTPDG014869
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2	CHEMBL414385	44388431	Investigative	D05MJG	.	CTPDG014870
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	Investigative	D05VEC	.	CTPDG014871
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	Investigative	D06JLN	.	CTPDG014872
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser	"96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-"	123811	Investigative	D06LKH	.	CTPDG014873
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	Investigative	D07QJD	.	CTPDG014874
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(RGDfMeF)	CHEMBL383747	44408450	Investigative	D07UOF	.	CTPDG014875
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077	11505585	Investigative	D08CFM	.	CTPDG014876
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	Investigative	D08DSG	.	CTPDG014877
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	Investigative	D09PLA	.	CTPDG014878
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	RGDechi	.	91936353	Investigative	D0D4QZ	.	CTPDG014879
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	Investigative	D0G7QJ	.	CTPDG014473
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo(RGDfV) (control)	CHEMBL206344	44409460	Investigative	D0G8JI	.	CTPDG014880
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590	11643340	Investigative	D0H4EK	.	CTPDG014881
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ISONIPECOTAMIDE	"Piperidine-4-carboxamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide"	3772	Investigative	D0H4MB	.	CTPDG014882
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309	9831456	Investigative	D0I5BY	.	CTPDG014883
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	CYCLORGDFV	"cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid"	9851104	Investigative	D0ID6U	.	CTPDG014884
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	Investigative	D0J6SP	.	CTPDG014885
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	E[c(RGDyK)]2-PTX conjugate	.	91933274	Investigative	D0K5DM	.	CTPDG014886
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]1	.	91936298	Investigative	D0L2PQ	.	CTPDG014887
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	Investigative	D0LF7W	.	CTPDG014888
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Gly-Arg-Gly-Asp-Ser-Pro-Lys	"Grgdspk; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-"	130667	Investigative	D0LV6B	.	CTPDG014889
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589	11636164	Investigative	D0M0BN	.	CTPDG014890
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574	10372586	Investigative	D0M6NQ	.	CTPDG014891
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]2	.	91936297	Investigative	D0N9NA	.	CTPDG014892
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	Investigative	D0O6DN	.	CTPDG014893
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	Investigative	D0O9FL	.	CTPDG014894
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)2-NH2]1	CHEMBL438186	44409497	Investigative	D0P4RB	.	CTPDG014895
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide"	"CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01"	558969	Investigative	D0R9AD	.	CTPDG014896
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	Investigative	D0R9GW	.	CTPDG014897
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	ST-1646	CHEMBL392303	44439175	Investigative	D0R9SJ	.	CTPDG014898
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo[RGDfK(cypate)]	CHEMBL407126	44409643	Investigative	D0T1II	.	CTPDG014899
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	Investigative	D0TP8S	.	CTPDG014474
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	Investigative	D0U0VF	.	CTPDG014900
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066	44408397	Investigative	D0U2NV	.	CTPDG014901
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	Investigative	D0UE7H	.	CTPDG014902
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)3-NH2]2	.	91936296	Investigative	D0UO0Y	.	CTPDG014903
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056	9986643	Investigative	D0V0JC	.	CTPDG014904
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	Investigative	D0W6CJ	.	CTPDG014905
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	"C[RGDf-(S,R)-alpha-Dfm-F]"	CHEMBL379911	11614485	Investigative	D0WK2F	.	CTPDG014906
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	AcDRGDS	CHEMBL241297; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	Investigative	D0X4EE	.	CTPDG014907
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cypate-[(RGD)4-NH2]1	.	91936299	Investigative	D0Y8UD	.	CTPDG014908
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	Investigative	D0Z6WZ	.	CTPDG014909
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	SB-265123	"CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	Investigative	D0R3CY	.	CTPDG014063
M6ACROT05949	Integrin subunit beta 3 (ITGB3)	ITB3_HUMAN	.	.	Investigative	C(-GRGDfL-)	CHEMBL235999	15409414	Investigative	D0B4JU	.	CTPDG014064
M6ACROT05950	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05950	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05950	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Approved	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	Approved	D02WCI	DB04951	CTPDG012335
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	IND submitted	A435	.	.	IND submitted	D8UKA4	.	CTPDG000863
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2	Disitertide	"NAFB-001; Disitertide cream (skin disorders), Digna"	9833838	Phase 2	D0C4WC	.	CTPDG012336
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ACE-1334	.	.	Phase 1	D8NZ7T	.	CTPDG012337
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	SRK-181	.	.	Phase 1	DFZJ79	.	CTPDG003913
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ABBV-151	.	.	Phase 1	DKCI94	.	CTPDG003846
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Discontinued in Phase 2	Mannose phosphate	SCHEMBL285569; SB17274	73014169	Discontinued in Phase 2	D0U3DX	.	CTPDG012338
M6ACROT05951	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Investigative	ART-144	"Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals"	.	Investigative	D08OLR	.	CTPDG012339
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05951	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Approved	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	Approved	D02WCI	DB04951	CTPDG012335
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	IND submitted	A435	.	.	IND submitted	D8UKA4	.	CTPDG000863
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 3	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	Phase 3	D0DP3V	.	CTPDG001234
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2/3	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	Phase 2/3	D06TFI	DB11911	CTPDG001563
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 2	Disitertide	"NAFB-001; Disitertide cream (skin disorders), Digna"	9833838	Phase 2	D0C4WC	.	CTPDG012336
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ACE-1334	.	.	Phase 1	D8NZ7T	.	CTPDG012337
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	SRK-181	.	.	Phase 1	DFZJ79	.	CTPDG003913
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Phase 1	ABBV-151	.	.	Phase 1	DKCI94	.	CTPDG003846
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Discontinued in Phase 2	Mannose phosphate	SCHEMBL285569; SB17274	73014169	Discontinued in Phase 2	D0U3DX	.	CTPDG012338
M6ACROT05952	Transforming growth factor beta 1 (TGFB1)	TGFB1_HUMAN	.	.	Investigative	ART-144	"Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals"	.	Investigative	D08OLR	.	CTPDG012339
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Approved	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	Approved	D00EQL	DB12887	CTPDG012948
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 2	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	Phase 2	DNM79H	.	CTPDG001661
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	Phase 1/2	D0E6AG	DB14581	CTPDG012949
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	SHR2554	.	.	Phase 1/2	DM5X0L	.	CTPDG012950
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1/2	CPI-0209	.	.	Phase 1/2	DXL38G	.	CTPDG003128
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	GSK2816126	GSK 126; GSK-126	68210102	Phase 1	D05FIJ	.	CTPDG005212
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	Phase 1	DI1L7M	DB14799	CTPDG003886
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	Phase 1	D0LG8T	.	CTPDG004615
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Phase 1	HH2853	.	.	Phase 1	D6EU7R	.	CTPDG004066
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-33	.	121305270	Patented	D03MYI	.	CTPDG012951
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bI	.	.	Patented	D04PCW	.	CTPDG012952
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-35	.	.	Patented	D05MAR	.	CTPDG012953
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-54	.	.	Patented	D07CZI	.	CTPDG012954
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-24	.	117807842	Patented	D08MXO	.	CTPDG012955
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-27	.	76684269	Patented	D09GFF	.	CTPDG012956
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-25	.	117807842	Patented	D09PQQ	.	CTPDG012957
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-50	.	118580552	Patented	D0A0VH	.	CTPDG012958
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-47	.	118616529	Patented	D0B4TX	.	CTPDG012959
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-21	.	.	Patented	D0BL8W	.	CTPDG012960
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-41	.	118101320	Patented	D0BT6Y	.	CTPDG012961
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-53	.	121322599	Patented	D0CH4O	.	CTPDG012962
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure5aVIII	.	.	Patented	D0D1QD	.	CTPDG012963
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-38	.	78320108	Patented	D0DQ6N	.	CTPDG012964
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-51	.	118580509	Patented	D0FC9J	.	CTPDG012965
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-31	.	.	Patented	D0FI3A	.	CTPDG012966
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-42	.	118096643	Patented	D0H4HR	.	CTPDG012967
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-15	.	.	Patented	D0KR2T	.	CTPDG012968
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-52	.	118580510	Patented	D0LR5O	.	CTPDG012969
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-32	.	.	Patented	D0M1TG	.	CTPDG012970
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-23	.	117807623	Patented	D0M9BY	.	CTPDG012971
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-29	.	.	Patented	D0MH8G	.	CTPDG012972
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-30	.	.	Patented	D0MO2X	.	CTPDG012973
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-39	.	.	Patented	D0MZ8D	.	CTPDG012974
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-49	.	118572078	Patented	D0PB6T	.	CTPDG012975
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-43	.	118096796	Patented	D0PI5O	.	CTPDG012976
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-40	.	118095598	Patented	D0QH1J	.	CTPDG012977
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bIII	.	.	Patented	D0R2TQ	.	CTPDG012978
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-36	.	.	Patented	D0RD5P	.	CTPDG012979
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-28	.	91884579	Patented	D0S4OP	.	CTPDG012980
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-22	.	.	Patented	D0SQ1R	.	CTPDG012981
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-18	.	.	Patented	D0SY6P	.	CTPDG012982
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-16	.	.	Patented	D0T8QL	.	CTPDG012983
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-44	.	118096614	Patented	D0U9OH	.	CTPDG012984
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-20	.	.	Patented	D0UG5O	.	CTPDG012985
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-19	.	.	Patented	D0VF0M	.	CTPDG012986
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-37	.	78320107	Patented	D0W2KL	.	CTPDG012987
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-Figure3bII	.	.	Patented	D0W4MW	.	CTPDG012988
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-26	.	75203283	Patented	D0Z0NC	.	CTPDG012989
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-17	.	.	Patented	D0Z0QS	.	CTPDG012990
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-34	.	.	Patented	D0Z7GN	.	CTPDG012991
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID26882240-Compound-1	.	5712	Patented	D0L1TA	.	CTPDG012997
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EPZ005687	EPZ-005687; EPZ 005687	60160561	Investigative	D02BBA	.	CTPDG013001
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	EI1	KB-145943	72199293	Investigative	D02CIT	.	CTPDG013002
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	UNC1999	UNC 1999; UNC-1999	72551585	Investigative	D02YXP	.	CTPDG013003
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	Investigative	D65IMT	.	CTPDG013004
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Investigative	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	Investigative	D02TVQ	.	CTPDG013005
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-11	.	.	Patented	D0MH5C	.	CTPDG014986
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-10	.	.	Patented	D0MZ9P	.	CTPDG014987
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-14	.	90467336	Patented	D0GT7A	.	CTPDG012995
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-12	.	.	Patented	D0H8VN	.	CTPDG012996
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-13	.	86765324	Patented	D0TA4N	.	CTPDG013000
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-56	.	.	Patented	D01PZZ	.	CTPDG012992
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-46	.	102593999	Patented	D0D4UH	.	CTPDG012993
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-57	.	.	Patented	D0G1JR	.	CTPDG012994
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-55	.	.	Patented	D0M4LK	.	CTPDG012998
M6ACROT05952	Histone-lysine N-methyltransferase EZH2 (EZH2)	EZH2_HUMAN	.	.	Patented	PMID28394193-Compound-45	.	118607675	Patented	D0M8AA	.	CTPDG012999
M6ACROT05958	Interleukin-11 (IL11)	IL11_HUMAN	.	.	Phase 3	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	Phase 3	D05XKW	.	CTPDG014482
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 3	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	Phase 3	D06ETI	DB12340	CTPDG011433
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Phase 1	Briciclib	"865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	Phase 1	D0T0KT	DB12004	CTPDG004414
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510"	5281426	Investigative	D02JEZ	.	CTPDG014483
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	Investigative	D06AOY	.	CTPDG009337
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	Investigative	D00NYT	.	CTPDG009339
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	Investigative	D0C3WY	.	CTPDG009340
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	Investigative	D0EK0G	.	CTPDG009341
M6ACROT05959	G1/S-specific cyclin-D1 (CCND1)	CCND1_HUMAN	.	.	Investigative	"4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol"	.	9859248	Investigative	D0A5RM	.	CTPDG010935
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Approved	Pro-urokinase	Thrombolyse (TN)	.	Approved	D03VNX	.	CTPDG010519
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Approved	Urokinase	.	.	Approved	D0E8UO	.	CTPDG010520
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 4	PAI-1	"PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-"	3246941	Phase 4	D03ZJE	DB08324	CTPDG010521
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 3	Amediplase	"Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol"	154656	Phase 3	D0G6ZG	.	CTPDG010522
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 2	Upamostat	WX-671	9830667	Phase 2	D03KGH	.	CTPDG010523
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 2	Saruplase	"Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal"	.	Phase 2	D0G5UW	.	CTPDG010524
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Phase 1/2	HTU-PA	"Human tissue urokinase type plasminogen activator, Global Biotech"	.	Phase 1/2	D01HHJ	.	CTPDG010525
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Clinical trial	PMID18163548C4	"7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12"	449051	Clinical trial	D00EPS	.	CTPDG010526
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Clinical trial	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	Clinical trial	D0G0YZ	.	CTPDG005501
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Discontinued in Phase 2	PAI-2	"N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt"	443433	Discontinued in Phase 2	D0D3VA	.	CTPDG010527
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Discontinued in Phase 1/2	WX-UK1	"UKI-1; UNII-00LOF6890B; CHEMBL107955; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6"	9895194	Discontinued in Phase 1/2	D08INO	.	CTPDG006693
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Terminated	B-428	.	1747	Terminated	D0K1PR	.	CTPDG007303
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	UPA-targeted oncolytic Sendai virus	"BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC"	.	Investigative	D00LDI	.	CTPDG009178
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	CRA_10655	AC1O4QGF	447480	Investigative	D01LCS	DB02526	CTPDG010528
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	5-Methylsulfanyl-thiophene-2-carboxamidine	"CHEMBL28890; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine"	10313318	Investigative	D02XJW	.	CTPDG010529
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	ATN-658	"ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin"	.	Investigative	D03BWQ	.	CTPDG008984
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine"	"94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N"	180621	Investigative	D03NLL	DB07129	CTPDG010530
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	B-623	149732-37-6	9820186	Investigative	D05DNW	.	CTPDG010531
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-chloro-1-guanidino-7-isoquinolinesulphonamide	223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline	16658353	Investigative	D06CJP	.	CTPDG010532
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-Amino-5-Hydroxy-Benzimidazole	.	162636	Investigative	D09KKF	DB03729	CTPDG010533
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide	447732	Investigative	D0A8WP	DB01977	CTPDG010534
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"Thieno[2,3-B]Pyridine-2-Carboxamidine"	"amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538"	5438	Investigative	D0B1AK	DB03876	CTPDG010535
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Recombinant human pro-urokinase	Recombinant human pro-urokinase (myocardial infarction)	.	Investigative	D0D1TX	.	CTPDG010536
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	"AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea"	4286	Investigative	D0EV6B	DB03782	CTPDG010537
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-guanidino-benzyl)-carbamic acid benzyl ester	CHEMBL391969	44436702	Investigative	D0F6EZ	.	CTPDG010538
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	SCHEMBL20553177; DB07122	16758228	Investigative	D0ZM9M	DB07122	CTPDG010539
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	"4-methoxy-N'-(phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide"	695069	Investigative	D02AKP	.	CTPDG010540
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	ATF-HI-8	"urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University"	.	Investigative	D05ABK	.	CTPDG010541
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-guanidino-7-isoquinolinesulphonamide	"SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine"	16658352	Investigative	D0K4PK	.	CTPDG010542
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	CRA_8696	AC1O4QGN	447476	Investigative	D0K7YL	DB03159	CTPDG010543
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline	16658631	Investigative	D00PEJ	.	CTPDG010544
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	"BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone"	674641	Investigative	D00WFQ	.	CTPDG010545
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	4-iodobenzo[b]thiophene 2-carboxamidine	amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium	1746	Investigative	D05MJU	DB03136	CTPDG010546
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	"BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627"	674651	Investigative	D06LPR	.	CTPDG010547
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	"(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide"	6852210	Investigative	D0SP2I	.	CTPDG010548
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	"AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1"	674656	Investigative	D05ZIP	.	CTPDG010549
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Benzamidine	Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395	2332	Investigative	D07SFI	.	CTPDG010550
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	"(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole"	699665	Investigative	D08OCS	.	CTPDG010551
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	"AC1LERN1; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide"	716930	Investigative	D0IU5E	.	CTPDG010552
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	"(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone"	"AC1LDSBN; BAS 02052919; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1"	674628	Investigative	D0X1OY	.	CTPDG010553
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium	1507	Investigative	D08OLP	DB02463	CTPDG010554
M6ACROT05960	Urokinase-type plasminogen activator (PLAU)	UROK_HUMAN	.	.	Investigative	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	Investigative	D0G6XS	.	CTPDG010555
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05961	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05962	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05965	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05965	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05965	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05967	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT05967	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT05967	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Phase 4	Dichloroacetate	"2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050"	25975	Phase 4	D7I9JH	.	CTPDG000839
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 4	PMID25684022-Compound-WO2012058176 27(6)	.	Patented	D00LMA	.	CTPDG006305
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrazole derivative 61	PMID25684022-Compound-US20090111799	.	Patented	D00MLJ	.	CTPDG006303
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 37(4-6)	.	.	Patented	D00SVK	.	CTPDG006295
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 3	PMID25684022-Compound-WO2012058176 26(5)	.	Patented	D00ZXR	.	CTPDG006285
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrimidine derivative 3	PMID25684022-Compound-WO2011076327	.	Patented	D02MMG	.	CTPDG006257
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 15	PMID25684022-Compound-WO2012044157 4(58)	.	Patented	D02USE	.	CTPDG006246
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Thieno[3,2-c]pyridine-7-carboxamide derivative 2"	PMID25684022-Compound-WO2006106326c2	.	Patented	D03GFZ	.	CTPDG006232
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 9	PMID25684022-Compound-WO2012058176 32(20)	.	Patented	D03WFI	.	CTPDG006216
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 24	PMID25684022-Compound-WO2012036974 18(27)	.	Patented	D04BBA	.	CTPDG006209
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 12	PMID25684022-Compound-WO2012044157 1(1.5)	.	Patented	D04BBT	.	CTPDG006208
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 41(1.3)	.	.	Patented	D04EDM	.	CTPDG006204
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 17	PMID25684022-Compound-WO2012044157 6(360)	.	Patented	D04MHV	.	CTPDG006195
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 27	PMID25684022-Compound-WO2012036974 21(40)	.	Patented	D04QRX	.	CTPDG006188
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2008079988	.	.	Patented	D04UHW	.	CTPDG006183
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyridinone carboxamide derivative 1	PMID25684022-Compound-WO2010007116	.	Patented	D05GMT	.	CTPDG006172
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 4	PMID25684022-Compound-US20120208819 1(1.5)	.	Patented	D05OTD	.	CTPDG006164
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Thieno[3,2-c]pyridine-7-carboxamide derivative 1"	PMID25684022-Compound-WO2006106326c1	.	Patented	D06BSG	.	CTPDG006153
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 9	PMID25684022-Compound-US20130165450 18(27)	.	Patented	D06LCB	.	CTPDG006146
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2009153313	.	.	Patented	D06LLS	.	CTPDG006145
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 40(1.2)	.	.	Patented	D06LSZ	.	CTPDG006144
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 12	PMID25684022-Compound-US20130165450 21(40)	.	Patented	D06PTW	.	CTPDG006140
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2004087707	.	.	Patented	D06RGW	.	CTPDG006139
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Benzimidazole and imidazopyridine derivative 1	PMID25684022-Compound-WO2011006567	.	Patented	D06WAN	.	CTPDG006133
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 14	PMID25684022-Compound-US20130165450 24(45)	.	Patented	D06WXJ	.	CTPDG006132
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 38(5-7)	.	.	Patented	D07FMW	.	CTPDG006122
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 9	PMID25684022-Compound-US20120208819 6(360)	.	Patented	D07HOA	.	CTPDG006118
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 10	PMID25684022-Compound-US20120208819 7(402)	.	Patented	D07IQE	.	CTPDG006116
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 11	PMID25684022-Compound-US20130165450 20(38)	.	Patented	D07MSB	.	CTPDG006111
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 36(3-5)	.	.	Patented	D07XBA	.	CTPDG006096
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 45(1.5)	.	.	Patented	D07ZKE	.	CTPDG006093
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 29	PMID25684022-Compound-WO2012036974 24(45)	.	Patented	D07ZMG	.	CTPDG006092
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2008005457	.	.	Patented	D08EGT	.	CTPDG006085
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 2	PMID25684022-Compound-WO2012058176 25(3)	.	Patented	D08SNT	.	CTPDG006078
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 7	PMID25684022-Compound-US20130165450 16(16)	.	Patented	D08YPQ	.	CTPDG006071
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 11	PMID25684022-Compound-US20120208819 8(443)	.	Patented	D09BNP	.	CTPDG006067
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 39(1.1)	.	.	Patented	D09FQP	.	CTPDG006063
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 8	PMID25684022-Compound-US20120208819 5(355)	.	Patented	D0AM2D	.	CTPDG006036
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 20	PMID25684022-Compound-WO2012036974 14(14)	.	Patented	D0B2GM	.	CTPDG006030
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 36(3-5)	.	.	Patented	D0B8OB	.	CTPDG006024
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2010127754	.	.	Patented	D0C6VX	.	CTPDG006011
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Indazole derivative 1	PMID25684022-Compound-WO2003064397	.	Patented	D0CK8H	.	CTPDG006002
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic-carboxamide derivative 2	PMID25684022-Compound-WO2011044157	.	Patented	D0CQ1M	.	CTPDG005998
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 6	PMID25684022-Compound-US20120208819 3(7.6)	.	Patented	D0D0ML	.	CTPDG005991
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Imidazo quinoline derivative 1	PMID25684022-Compound-WO2008054238	.	Patented	D0D5YE	.	CTPDG005984
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 16	PMID25684022-Compound-WO2012036974 10(4)	.	Patented	D0D8PF	.	CTPDG005979
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2012135799 42(1.4)	.	.	Patented	D0DC2P	.	CTPDG005977
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Bis-indolylmaleimide derivative 1	PMID25684022-Compound-WO2005041953	.	Patented	D0DM2G	.	CTPDG005967
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 23	PMID25684022-Compound-WO2012036974 17(23)	.	Patented	D0DO6K	.	CTPDG005965
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 14	PMID25684022-Compound-WO2012044157 3(7.6)	.	Patented	D0EH9Z	.	CTPDG005947
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 18	PMID25684022-Compound-WO2012036974 12(12)	.	Patented	D0FJ4A	.	CTPDG005926
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 18	PMID25684022-Compound-WO2012044157 7(402)	.	Patented	D0FW3M	.	CTPDG005916
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 17	PMID25684022-Compound-WO2012036974 11(5)	.	Patented	D0GE6F	.	CTPDG005909
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 6	PMID25684022-Compound-WO2012058176 29(8)	.	Patented	D0GH9W	.	CTPDG005907
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 19	PMID25684022-Compound-WO2012036974 13(13)	.	Patented	D0GY8G	.	CTPDG005899
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 4	PMID25684022-Compound-US20130165450 13(13)	.	Patented	D0H6AF	.	CTPDG005888
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 1	PMID25684022-Compound-WO2012058176 24(47)	.	Patented	D0H7SO	.	CTPDG005885
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 13	PMID25684022-Compound-WO2012044157 2(2.4)	.	Patented	D0HI8X	.	CTPDG005875
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 2	PMID25684022-Compound-US20130165450 11(5)	.	Patented	D0HP8K	.	CTPDG005874
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrazolopyridines and imidazopyridine derivative 1	PMID25684022-Compound-WO2010017047	.	Patented	D0I1YQ	.	CTPDG005868
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Dibenzo [c,f]-[2,7]naphthyridine derivative 1"	PMID25684022-Compound-US20070135429	.	Patented	D0I5KI	.	CTPDG005863
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 38(5-7)	.	.	Patented	D0IO2X	.	CTPDG005850
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Benzonaphthyridine derivative 2	PMID25684022-Compound-WO2008109613	.	Patented	D0IR8B	.	CTPDG005847
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 5	PMID25684022-Compound-US20120208819 2(2.4)	.	Patented	D0J9DI	.	CTPDG005835
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 25	PMID25684022-Compound-WO2012036974 19(36)	.	Patented	D0JR0F	.	CTPDG005831
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 10	PMID25684022-Compound-US20130165450 19(36)	.	Patented	D0K8XT	.	CTPDG005814
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 22	PMID25684022-Compound-WO2012036974 16(16)	.	Patented	D0KN7T	.	CTPDG005804
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 5	PMID25684022-Compound-WO2012058176 28(7)	.	Patented	D0MG4D	.	CTPDG005776
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2008107444	.	.	Patented	D0MI3E	.	CTPDG005774
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 7	PMID25684022-Compound-WO2012058176 30(12)	.	Patented	D0MW7L	.	CTPDG005770
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2011137219 35(1-11)	.	.	Patented	D0P0WF	.	CTPDG005721
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Pyrimidinone derivative 1	PMID25684022-Compound-WO2010007114	.	Patented	D0P1VT	.	CTPDG005720
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 21	PMID25684022-Compound-WO2012036974 15(15)	.	Patented	D0P6PT	.	CTPDG005715
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 8	PMID25684022-Compound-US20130165450 17(23)	.	Patented	D0PD2I	.	CTPDG005709
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1"	PMID25684022-Compound-WO2010120854	.	Patented	D0PJ7M	.	CTPDG005708
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 1	PMID25684022-Compound-US20130165450 10(4)	.	Patented	D0Q6RC	.	CTPDG005700
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 15	PMID25684022-Compound-US20130165450 9(2)	.	Patented	D0Q8JK	.	CTPDG005698
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 28	PMID25684022-Compound-WO2012036974 23(41)	.	Patented	D0QV1E	.	CTPDG005688
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2012135799 43(1.5)	.	.	Patented	D0R0SJ	.	CTPDG005687
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 3	PMID25684022-Compound-US20130165450 12(12)	.	Patented	D0R3VG	.	CTPDG005680
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20120277229 44(1.4)	.	.	Patented	D0RE3R	.	CTPDG005668
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 16	PMID25684022-Compound-WO2012044157 5(355)	.	Patented	D0RH6G	.	CTPDG005666
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-WO2006015124	.	.	Patented	D0RP4U	.	CTPDG005663
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic-carboxamide derivative 1	PMID25684022-Compound-WO2010065384	.	Patented	D0RY6M	.	CTPDG005660
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 35(1-11)	.	.	Patented	D0SB4A	.	CTPDG005652
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 10	PMID25684022-Compound-WO2012058176 33(21)	.	Patented	D0TB2H	.	CTPDG005633
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Benzonaphthyridine derivative 1	PMID25684022-Compound-WO2008109599	.	Patented	D0U3IS	.	CTPDG005625
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 5	PMID25684022-Compound-US20130165450 14(14)	.	Patented	D0U5HB	.	CTPDG005620
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 26	PMID25684022-Compound-WO2012036974 20(38)	.	Patented	D0U7LW	.	CTPDG005616
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 7	PMID25684022-Compound-US20120208819 4(58)	.	Patented	D0W3JC	.	CTPDG005584
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heteroaryl-carboxamide derivative 8	PMID25684022-Compound-WO2012058176 31(13)	.	Patented	D0WT9J	.	CTPDG005573
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Heterocyclic derivative 19	PMID25684022-Compound-WO2012044157 8(443)	.	Patented	D0WX4H	.	CTPDG005570
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-US20130053382 37(4-6)	.	.	Patented	D0Y0RG	.	CTPDG005554
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	PMID25684022-Compound-EP20041486488	.	.	Patented	D0YD1Q	.	CTPDG005547
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 30	PMID25684022-Compound-WO2012036974 9(2)	.	Patented	D0Z3HW	.	CTPDG005534
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 6	PMID25684022-Compound-US20130165450 15(15)	.	Patented	D0Z5HL	.	CTPDG005530
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Indolinone derivative 1	PMID25684022-Compound-US200607105563	11161844	Patented	D0ZE5U	.	CTPDG005523
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	Thiazole carboxamide derivative 13	PMID25684022-Compound-US20130165450 23(41)	.	Patented	D0ZG0K	.	CTPDG005520
M6ACROT05968	PDH kinase 1 (PDK1)	PDK1_HUMAN	.	.	Patented	"Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1"	PMID25684022-Compound-WO2010019637	.	Patented	D0ZV9P	.	CTPDG005513
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT05973	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	6EP	"2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)"	74766595	Patented	D00SUC	.	CTPDG015082
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158803	CHEMBL3787438; SCHEMBL15792889	90216982	Patented	D01WHH	.	CTPDG015083
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 151"	SCHEMBL19513974; CHEMBL4060968; BDBM281211	132054530	Patented	D03POM	.	CTPDG015084
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 12"	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid	76901247	Patented	D03TKM	.	CTPDG015085
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158791	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964	77106319	Patented	D05CCY	.	CTPDG015086
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 4"	SCHEMBL15792083; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	75202257	Patented	D06TKT	.	CTPDG015087
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9611221, Example 9"	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105	71766727	Patented	D09CWB	.	CTPDG015088
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US9714230, 46"	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid	86725517	Patented	D0F3TL	.	CTPDG015089
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158794	CHEMBL3785470; SCHEMBL15792416	76282772	Patented	D0G8QR	.	CTPDG015090
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158703	CHEMBL3785832; SCHEMBL15777940	90204862	Patented	D0GH8J	.	CTPDG015091
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330656	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid	77106317	Patented	D0HT9Q	.	CTPDG015092
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	BDBM50158755	CHEMBL3786579; SCHEMBL15778210	90205053	Patented	D0K4LW	.	CTPDG015093
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 99"	"SCHEMBL16157351; BDBM320432; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid"	85469291	Patented	D0N9JZ	.	CTPDG015094
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	AKOS020330481	"3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid"	59699608	Patented	D0NG8M	.	CTPDG015095
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 5"	SCHEMBL17682496; CHEMBL4062756; BDBM281065	121279569	Patented	D0NM3B	.	CTPDG015096
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	NCGC00381656-01	"CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid"	117637389	Patented	D0PQ5P	.	CTPDG015097
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10174026, Example 2"	"SCHEMBL16149258; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	86280871	Patented	D0R2GT	.	CTPDG015098
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10022354, Example 152"	CHEMBL4059597; SCHEMBL17682668; BDBM281212	121279737	Patented	D0T8YT	.	CTPDG015099
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	"US10040779, Example 1"	SCHEMBL15792304; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid	76282043	Patented	D0VZ5E	.	CTPDG015100
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Patented	1190312-92-5	"3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid"	53412620	Patented	D0ZJ0Z	.	CTPDG015101
M6ACROT05974	Lysine-specific demethylase 5A (KDM5A)	KDM5A_HUMAN	.	.	Investigative	PBIT	"2514-30-9; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	Investigative	D0IQ7Y	.	CTPDG015102
M6ACROT05975	Insulin-like growth factor-binding protein 3 (IGFBP3)	IBP3_HUMAN	.	.	Phase 2	Salvianolic acid B	"115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0"	11629084	Phase 2	D2GV9Q	.	CTPDG014799
M6ACROT05975	Methyl-CpG-binding protein 2  (MECP2)	MECP2_HUMAN	.	.	Phase 1	AVXS-201	.	.	Phase 1	DE94CW	.	CTPDG014800
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT05976	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Phase 3	Curcumin	"458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	Phase 3	D07SDQ	DB11672	CTPDG001346
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622444	"NSC622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	Investigative	D01VNN	.	CTPDG014313
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-138419	NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	Investigative	D03PWU	.	CTPDG014314
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-319745	"61629-60-5; HB 093; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	Investigative	D06RGX	.	CTPDG014315
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-348926	"NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	Investigative	D06VVV	.	CTPDG014316
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	Investigative	D07VWC	.	CTPDG014317
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	S-tubercidinylhomocysteine	"CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	Investigative	D08TGQ	.	CTPDG014318
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-106084	CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	Investigative	D0A2ZH	.	CTPDG014319
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-154957	NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	Investigative	D0C4NA	.	CTPDG014320
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-54162	"NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	Investigative	D0FN7C	.	CTPDG014321
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-57893	MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	Investigative	D0G9NS	.	CTPDG014322
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-56071	"32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	Investigative	D0H1YK	.	CTPDG014323
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-137546	"NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	Investigative	D0I5JP	.	CTPDG014324
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-623548	"2581-36-4; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	Investigative	D0LS2U	.	CTPDG014325
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-345763	"7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	Investigative	D0MP7N	.	CTPDG014326
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	Investigative	D0W5SZ	.	CTPDG014327
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	Investigative	D09CLP	DB01752	CTPDG014328
M6ACROT05977	DNA  (cytosine-5)-methyltransferase 3B (DNMT3B)	DNM3B_HUMAN	.	.	Investigative	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	Investigative	D0J5VK	.	CTPDG014329
M6ACROT05977	Sequestosome-1 (SQSTM1)	SQSTM_HUMAN	.	.	Preclinical	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	Preclinical	D02NEZ	.	CTPDG015396
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05978	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CN	.	117968550	Patented	D02VTV	.	CTPDG014952
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CG	.	117967861	Patented	D03LZO	.	CTPDG014953
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure3CM	.	117976053	Patented	D0F8AB	.	CTPDG014954
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-Figure2aExample1	.	71521835	Patented	D01LUJ	.	CTPDG014955
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05979	Cysteine methyltransferase DNMT3A (DNMT3A)	DNM3A_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05979	Sequestosome-1 (SQSTM1)	SQSTM_HUMAN	.	.	Preclinical	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	Preclinical	D02NEZ	.	CTPDG015396
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT05980	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT05981	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT05981	Sequestosome-1 (SQSTM1)	SQSTM_HUMAN	.	.	Preclinical	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	Preclinical	D02NEZ	.	CTPDG015396
M6ACROT05995	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT05995	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT05996	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT05996	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT05997	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT05997	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT05998	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT05998	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT05999	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT05999	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT06000	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	GSK-J1	"GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240"	56963315	Investigative	D0S3DD	.	CTPDG015456
M6ACROT06000	Lysine-specific demethylase 6B  (KDM6B)	KDM6B_HUMAN	.	.	Investigative	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793"	459617	Investigative	D0X5US	.	CTPDG014984
M6ACROT06001	Histone-lysine N-methyltransferase SUV39H1  (SUV39H1)	SUV91_HUMAN	.	.	Investigative	chaetocin	"Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime"	11657687	Investigative	D04FNI	.	CTPDG015382
M6ACROT06002	Histone-lysine N-methyltransferase SUV39H1  (SUV39H1)	SUV91_HUMAN	.	.	Investigative	chaetocin	"Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime"	11657687	Investigative	D04FNI	.	CTPDG015382
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT06013	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT06014	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Human neutral insulin	.	16129672	Approved	D02EHV	.	CTPDG009918
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin Lyspro recombinant	.	.	Approved	D03VXG	.	CTPDG009919
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	"Insulin, porcine"	"Velosulin; Hog insulin; Insulin [pig]; Insulin porcine; Neutral insulin; Pig insulin; Porcine insulin; Swine insulin; A neutral, buffered solution of pork insulin; Insulin (Alopex lagopus); Insulin (Canis familiaris); Insulin (Physeter catodon); Insulin (dog); Insulin (ox); Insulin (pig); Insulin (porcine); Insulin (sperm whale); Insulin (swine); Insulin [USAN:JAN]; Insulin, neutral; Insulin,pig; Insulin (Ox), 8A-L-threonine-10A-L-isoleucine-(9CI); 8A-L-Threonine-10A-L-isoleucineinsulin (ox)"	16131098	Approved	D05ELO	.	CTPDG009920
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin recombinant	"Exubera; Endopancrine; Humilin; Dermulin; Decurvon; Musulin; Iszilin; Insulyl; Insular; Iletin; insulin-human; Dal-insulinum; Intesulin B; Insulin, dalanated; Insulina dalanatada; AERx; Insulinum dalanatum; insulin (recombinant); Imusay-131; INSULIN INJECTION; Insulini injectio neutralis; Insulina iniettabile neutra; Injectable insulini neutrale; Inyectable neutro de insulina; CHEBI:5931; CCRIS 5464; Insulinum dalanatum [INN-Latin]; HSDB 3102; Insulin, dalanated [USAN:INN]; AERx [Insulin management system]"	70678557	Approved	D06SVW	.	CTPDG009921
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Metformin arginine-hemisuccinimide	"Diap-2; Metformin arginine-hemisuccinate-hemisuccinamide; Metformin arginine-hemisuccinimide (type 2 diabetes); Diap-2 (type 2 diabetes), Arteria; Metformin arginine-hemisuccinimide (type 2 diabetes), Arteria"	.	Approved	D09PPG	.	CTPDG000485
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin-lispro	WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro	16132438	Approved	D0L6JE	.	CTPDG009922
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin-glulisine	.	16136701	Approved	D0M2XE	.	CTPDG009923
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Ryzodeq	.	.	Approved	D0Y3VQ	.	CTPDG000060
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Meglitinides	.	3033769	Approved	D07MEH	DB12518	CTPDG000562
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 3	NN5401	Insulin degludec and insulin aspart; Ryzodeg (TN)	.	Phase 3	D0U8YK	.	CTPDG009924
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2/3	Metformin glycinate	"DMMET-01; Metformin glycinate (diabetes); Type 2 diabetes therapy, Laboratorios Silanes; Metformin glycinate (diabetes), Laboratorios Silanes"	44520175	Phase 2/3	D0U3LK	.	CTPDG001530
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	MSDC-0602	"1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993"	25230266	Phase 2	D00AUX	.	CTPDG003108
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	S-707106	.	.	Phase 2	D02SXZ	.	CTPDG002957
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	NP-01	"Vanadium (buccal, nanodroplet emulsion (Aonys), type 2 diabetes/metabolic syndrome), Medesis"	.	Phase 2	D03VCJ	.	CTPDG002895
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	VVP-808	"Insulin sensitizer (type 2 diabetes), Verva Pharmaceuticals"	.	Phase 2	D07NKZ	.	CTPDG002683
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	TAK-379	"Insulin sensitizer (oral, diabetes mellitus), Takeda"	.	Phase 2	D0A6OS	.	CTPDG002543
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	EGS-21	"Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem"	6475228	Phase 2	D0D4ZW	.	CTPDG002452
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	DM-71	"Insulin sensitizer (type 2 diabetes), DiaMedica; Bethanechol + n-acetyl cysteine (type 2 diabetes), DiaMedica"	.	Phase 2	D0T5YX	.	CTPDG002014
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	Tesofensine	NS-2330	11370864	Phase 2	D0ZK7B	DB06156	CTPDG009925
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	RZ358	.	.	Phase 2	DJM3W0	.	CTPDG009926
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	AGT-182	"HIRMAb-IDUS; Iduronidase/human insulin receptor-targeting chimeric mAb fusion protein (imucopolysaccharidosis type II), ArmaGen"	.	Phase 1	D06HPP	.	CTPDG009927
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	ISF-402	"Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Pallane; Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Dia-B Tech Ltd"	.	Phase 1	D07DLA	.	CTPDG005120
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	Insulin transdermal	.	.	Phase 1	D08TGG	.	CTPDG009928
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Application submitted	NN-1218	.	.	Application submitted	D08XFJ	.	CTPDG005021
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	Insulin oral sublingual	.	.	Phase 1	D0D5EJ	.	CTPDG009930
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 2	AKP-020	"BEOV; Bis(ethylmaltolato)oxovanadium IV; Insulin enhancer (oral, type 2 diabetes), Akesis Pharmaceuticals"	.	Discontinued in Phase 2	D05LSY	.	CTPDG006616
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 2	EML-336	CRE-16336; EML-16336; ONO-5816	.	Discontinued in Phase 2	D0F1MU	.	CTPDG006528
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 2	DM-83	.	.	Discontinued in Phase 2	D0Z8UQ	.	CTPDG006397
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 1/2	KW-2450	.	56847547	Discontinued in Phase 1/2	D0M3OR	.	CTPDG009931
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Terminated	CLX-0900	CLX-0900E	.	Terminated	D02IJP	.	CTPDG009932
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Terminated	TER-16998	"TER-17411; TER-17529; TLK-16998; TLK-17411; TLK-19780; TLK-19781; Insulin receptor activators (oral, diabetes mellitus); Insulin receptor activators (oral, diabetes mellitus), ReceptorBio; Insulin receptor activators (oral, diabetes), Telik/Sanwa"	.	Terminated	D03CMR	.	CTPDG009933
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	XMetD	"Insulin receptor antagonist antibody (hypoglycemia), XOMA"	.	Investigative	D02QOL	.	CTPDG009934
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	FPT-038	"Hypoglycemic recombinant secreted protein (type 2 diabetes), Five Prime Therapeutics"	.	Investigative	D03BCE	.	CTPDG008988
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	Quick-acting insulin	"Quick-acting insulin (injectable, diabetes)"	.	Investigative	D08ZLL	.	CTPDG009935
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	XMetS	"Insulin receptor sensitizing antibody (diabetes), XOMA"	.	Investigative	D0C7QW	.	CTPDG008404
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	RHIIP	.	.	Investigative	D0I4LQ	.	CTPDG009936
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	AD10-1025	"AD10-369; AD10-371; AD10-797; AD10-798; Partial PPAR gamma agonist (oral, type 2 diabetes); Partial PPAR gamma agonist (oral, type 2 diabetes), Adamed SP; Phenyl propionic acid derivative 3 (oral, type 2 diabetes), Adamed SP; PPAR modulators (oral, hypercholesterolemia/NIDDM), Adamed"	.	Investigative	D0KC9V	.	CTPDG009937
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	NVP-TAE684	"761439-42-3; NVP-TAE 684; TAE684; TAE-684; 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; TAE684 (NVP-TAE684); TAE 684; UNII-EH1713MN4K; CHEMBL509032; EH1713MN4K; 5-Chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediamine; C30H40ClN7O3S"	16038120	Investigative	D0R2WK	.	CTPDG009938
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	DC-9703	.	.	Investigative	D0XQ0V	.	CTPDG007694
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	VVP-100X	.	.	Investigative	D0YN9H	.	CTPDG007648
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	"4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240677; BDBM50326006	43680262	Investigative	D0L7MM	.	CTPDG009939
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	"4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240676; BDBM50326004	43743432	Investigative	D0W9KO	.	CTPDG009940
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	PMID24900237C15	1022957-12-5; GTPL8220; BDBM50385590; KB-75520	25229528	Investigative	D0G4CS	.	CTPDG009941
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	L-betagamma-meATP	"UFZTZBNSLXELAL-IOSLPCCCSA-N; AMP-PCP; beta,gamma-Methylene ATP; phosphomethylphosphonic acid adenylate ester; CHEMBL133463; CHEBI:40532; 5'-O-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)adenosine; ADENOSINE 5'-[BETA,GAMMA-METHYLENE]TRIPHOSPHATE; ADENOSINE-5'-[BETA, GAMMA-METHYLENE]TRIPHOSPHATE; 3469-78-1; adenosine 5'-beta,gamma-mu-methylenetriphosphate; ({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid; AMPPCP; betagamma-methylene-adenosine 5'-triphosphate"	91532	Investigative	D0UG4S	DB03909	CTPDG009942
M6ACROT06015	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	GSK-1838705A	GSK 1838705A; GSK1838705A	25182616	Investigative	D06PJW	.	CTPDG009943
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT06015	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Human neutral insulin	.	16129672	Approved	D02EHV	.	CTPDG009918
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin Lyspro recombinant	.	.	Approved	D03VXG	.	CTPDG009919
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	"Insulin, porcine"	"Velosulin; Hog insulin; Insulin [pig]; Insulin porcine; Neutral insulin; Pig insulin; Porcine insulin; Swine insulin; A neutral, buffered solution of pork insulin; Insulin (Alopex lagopus); Insulin (Canis familiaris); Insulin (Physeter catodon); Insulin (dog); Insulin (ox); Insulin (pig); Insulin (porcine); Insulin (sperm whale); Insulin (swine); Insulin [USAN:JAN]; Insulin, neutral; Insulin,pig; Insulin (Ox), 8A-L-threonine-10A-L-isoleucine-(9CI); 8A-L-Threonine-10A-L-isoleucineinsulin (ox)"	16131098	Approved	D05ELO	.	CTPDG009920
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin recombinant	"Exubera; Endopancrine; Humilin; Dermulin; Decurvon; Musulin; Iszilin; Insulyl; Insular; Iletin; insulin-human; Dal-insulinum; Intesulin B; Insulin, dalanated; Insulina dalanatada; AERx; Insulinum dalanatum; insulin (recombinant); Imusay-131; INSULIN INJECTION; Insulini injectio neutralis; Insulina iniettabile neutra; Injectable insulini neutrale; Inyectable neutro de insulina; CHEBI:5931; CCRIS 5464; Insulinum dalanatum [INN-Latin]; HSDB 3102; Insulin, dalanated [USAN:INN]; AERx [Insulin management system]"	70678557	Approved	D06SVW	.	CTPDG009921
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Metformin arginine-hemisuccinimide	"Diap-2; Metformin arginine-hemisuccinate-hemisuccinamide; Metformin arginine-hemisuccinimide (type 2 diabetes); Diap-2 (type 2 diabetes), Arteria; Metformin arginine-hemisuccinimide (type 2 diabetes), Arteria"	.	Approved	D09PPG	.	CTPDG000485
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin-lispro	WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro	16132438	Approved	D0L6JE	.	CTPDG009922
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Insulin-glulisine	.	16136701	Approved	D0M2XE	.	CTPDG009923
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Ryzodeq	.	.	Approved	D0Y3VQ	.	CTPDG000060
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Approved	Meglitinides	.	3033769	Approved	D07MEH	DB12518	CTPDG000562
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 3	NN5401	Insulin degludec and insulin aspart; Ryzodeg (TN)	.	Phase 3	D0U8YK	.	CTPDG009924
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2/3	Metformin glycinate	"DMMET-01; Metformin glycinate (diabetes); Type 2 diabetes therapy, Laboratorios Silanes; Metformin glycinate (diabetes), Laboratorios Silanes"	44520175	Phase 2/3	D0U3LK	.	CTPDG001530
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	MSDC-0602	"1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993"	25230266	Phase 2	D00AUX	.	CTPDG003108
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	S-707106	.	.	Phase 2	D02SXZ	.	CTPDG002957
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	NP-01	"Vanadium (buccal, nanodroplet emulsion (Aonys), type 2 diabetes/metabolic syndrome), Medesis"	.	Phase 2	D03VCJ	.	CTPDG002895
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	DM-99	.	.	Phase 2	D06MOY	.	CTPDG002744
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	VVP-808	"Insulin sensitizer (type 2 diabetes), Verva Pharmaceuticals"	.	Phase 2	D07NKZ	.	CTPDG002683
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	TAK-379	"Insulin sensitizer (oral, diabetes mellitus), Takeda"	.	Phase 2	D0A6OS	.	CTPDG002543
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	EGS-21	"Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem"	6475228	Phase 2	D0D4ZW	.	CTPDG002452
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	DM-71	"Insulin sensitizer (type 2 diabetes), DiaMedica; Bethanechol + n-acetyl cysteine (type 2 diabetes), DiaMedica"	.	Phase 2	D0T5YX	.	CTPDG002014
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	Tesofensine	NS-2330	11370864	Phase 2	D0ZK7B	DB06156	CTPDG009925
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	RZ358	.	.	Phase 2	DJM3W0	.	CTPDG009926
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 2	Mitoglitazone	MSDC-0160; Mitoglitazone (TN)	10429242	Phase 2	D00SWQ	DB11721	CTPDG003065
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	AGT-182	"HIRMAb-IDUS; Iduronidase/human insulin receptor-targeting chimeric mAb fusion protein (imucopolysaccharidosis type II), ArmaGen"	.	Phase 1	D06HPP	.	CTPDG009927
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	ISF-402	"Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Pallane; Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Dia-B Tech Ltd"	.	Phase 1	D07DLA	.	CTPDG005120
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	Insulin transdermal	.	.	Phase 1	D08TGG	.	CTPDG009928
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Application submitted	NN-1218	.	.	Application submitted	D08XFJ	.	CTPDG005021
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	Insulin oral sublingual	.	.	Phase 1	D0D5EJ	.	CTPDG009930
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Phase 1	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	Phase 1	D07HPJ	.	CTPDG005106
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 2	AKP-020	"BEOV; Bis(ethylmaltolato)oxovanadium IV; Insulin enhancer (oral, type 2 diabetes), Akesis Pharmaceuticals"	.	Discontinued in Phase 2	D05LSY	.	CTPDG006616
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 2	EML-336	CRE-16336; EML-16336; ONO-5816	.	Discontinued in Phase 2	D0F1MU	.	CTPDG006528
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 2	DM-83	.	.	Discontinued in Phase 2	D0Z8UQ	.	CTPDG006397
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Discontinued in Phase 1/2	KW-2450	.	56847547	Discontinued in Phase 1/2	D0M3OR	.	CTPDG009931
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Terminated	CLX-0900	CLX-0900E	.	Terminated	D02IJP	.	CTPDG009932
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Terminated	TER-16998	"TER-17411; TER-17529; TLK-16998; TLK-17411; TLK-19780; TLK-19781; Insulin receptor activators (oral, diabetes mellitus); Insulin receptor activators (oral, diabetes mellitus), ReceptorBio; Insulin receptor activators (oral, diabetes), Telik/Sanwa"	.	Terminated	D03CMR	.	CTPDG009933
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	XMetD	"Insulin receptor antagonist antibody (hypoglycemia), XOMA"	.	Investigative	D02QOL	.	CTPDG009934
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	FPT-038	"Hypoglycemic recombinant secreted protein (type 2 diabetes), Five Prime Therapeutics"	.	Investigative	D03BCE	.	CTPDG008988
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	Quick-acting insulin	"Quick-acting insulin (injectable, diabetes)"	.	Investigative	D08ZLL	.	CTPDG009935
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	XMetS	"Insulin receptor sensitizing antibody (diabetes), XOMA"	.	Investigative	D0C7QW	.	CTPDG008404
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	RHIIP	.	.	Investigative	D0I4LQ	.	CTPDG009936
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	AD10-1025	"AD10-369; AD10-371; AD10-797; AD10-798; Partial PPAR gamma agonist (oral, type 2 diabetes); Partial PPAR gamma agonist (oral, type 2 diabetes), Adamed SP; Phenyl propionic acid derivative 3 (oral, type 2 diabetes), Adamed SP; PPAR modulators (oral, hypercholesterolemia/NIDDM), Adamed"	.	Investigative	D0KC9V	.	CTPDG009937
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	NVP-TAE684	"761439-42-3; NVP-TAE 684; TAE684; TAE-684; 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; TAE684 (NVP-TAE684); TAE 684; UNII-EH1713MN4K; CHEMBL509032; EH1713MN4K; 5-Chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediamine; C30H40ClN7O3S"	16038120	Investigative	D0R2WK	.	CTPDG009938
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	DC-9703	.	.	Investigative	D0XQ0V	.	CTPDG007694
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	VVP-100X	.	.	Investigative	D0YN9H	.	CTPDG007648
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	"4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240677; BDBM50326006	43680262	Investigative	D0L7MM	.	CTPDG009939
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	"4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol"	CHEMBL1240676; BDBM50326004	43743432	Investigative	D0W9KO	.	CTPDG009940
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	PMID24900237C15	1022957-12-5; GTPL8220; BDBM50385590; KB-75520	25229528	Investigative	D0G4CS	.	CTPDG009941
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	L-betagamma-meATP	"UFZTZBNSLXELAL-IOSLPCCCSA-N; AMP-PCP; beta,gamma-Methylene ATP; phosphomethylphosphonic acid adenylate ester; CHEMBL133463; CHEBI:40532; 5'-O-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)adenosine; ADENOSINE 5'-[BETA,GAMMA-METHYLENE]TRIPHOSPHATE; ADENOSINE-5'-[BETA, GAMMA-METHYLENE]TRIPHOSPHATE; 3469-78-1; adenosine 5'-beta,gamma-mu-methylenetriphosphate; ({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid; AMPPCP; betagamma-methylene-adenosine 5'-triphosphate"	91532	Investigative	D0UG4S	DB03909	CTPDG009942
M6ACROT06016	Insulin receptor (INSR)	INSR_HUMAN	.	.	Investigative	GSK-1838705A	GSK 1838705A; GSK1838705A	25182616	Investigative	D06PJW	.	CTPDG009943
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT06016	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT06017	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT06017	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT06017	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT06017	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	SGI110	.	137295284	Phase 3	D0Q5KZ	.	CTPDG001083
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	Guadecitabine	"UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine"	135564655	Phase 3	D0VZ4N	DB11918	CTPDG014133
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue"	9840076	Phase 3	D09NTC	.	CTPDG001300
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 3	S-110	"DNA demethylating agent (myelodysplastic syndrome), Supergen"	.	Phase 3	D0A2BO	.	CTPDG001280
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Palifosfamide	ZIO-201	100427	Phase 2	D04FDN	DB05668	CTPDG002872
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	RX-3117	"Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva"	11242315	Phase 2	D0L7WS	.	CTPDG002229
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 2	Antroquinonol	"Hocena; Fungal extract (cancer), Golden Biotechnology"	24875259	Phase 2	D0T3AW	DB12326	CTPDG002024
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Phase 1	GSK4172239	.	.	Phase 1	D5QR2M	.	CTPDG014134
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-miR-155-5p	.	.	Patented	D01CGQ	.	CTPDG014135
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example11	.	75201485	Patented	D04JIH	.	CTPDG014136
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example16	.	75201537	Patented	D05DSL	.	CTPDG014137
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example5	.	73774653	Patented	D09FMS	.	CTPDG014138
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2HPE	.	.	Patented	D0E7OA	.	CTPDG014139
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1	.	.	Patented	D0G6ON	.	CTPDG014140
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example4	.	75201432	Patented	D0K4YF	.	CTPDG014141
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-2	.	.	Patented	D0KE4E	.	CTPDG014142
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-asCEBP-1HPE	.	.	Patented	D0LK4R	.	CTPDG014143
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example8	.	75201482	Patented	D0RT6C	.	CTPDG014144
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-433	.	.	Patented	D0U5CK	.	CTPDG014145
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-Table1Example30	.	75201638	Patented	D0YK6K	.	CTPDG014146
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-424	.	.	Patented	D02WRM	.	CTPDG014147
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-427	.	.	Patented	D0HA0J	.	CTPDG014148
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-422 	.	.	Patented	D0QY0N	.	CTPDG014149
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Patented	PMID27376512-Compound-MTC-423	.	.	Patented	D0W9VZ	.	CTPDG014150
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	PMX-700	"SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox"	.	Investigative	D03DTQ	.	CTPDG014151
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	XB-05	.	.	Investigative	D0JV8Q	.	CTPDG008154
M6ACROT06018	DNA (cytosine-5)-methyltransferase 1 (DNMT1)	DNMT1_HUMAN	.	.	Investigative	CP-4200	"Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate"	.	Investigative	D0OT1S	.	CTPDG007992
M6ACROT06018	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Preclinical	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	Preclinical	DF90DS	.	CTPDG006987
M6ACROT06018	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	GNF-PF-2272	"3-Methyltoxoflavin; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	Investigative	D0P0CM	.	CTPDG014816
M6ACROT06018	Mothers against decapentaplegic homolog 3 (SMAD3)	SMAD3_HUMAN	.	.	Investigative	ELLAGIC ACID	"476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	Investigative	D0A1CM	DB08846	CTPDG010518
M6ACROT06019	Lymphocyte function-associated antigen 3 (CD58)	LFA3_HUMAN	.	.	Approved	Alefacept	Amevive (TN)	.	Approved	D09ZSO	.	CTPDG012889
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT06019	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT06020	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT06021	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT06022	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	PRI-724	.	71509318	Phase 1/2	D0Q0ZY	DB15034	CTPDG003349
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	Phase 1/2	D0DA5M	.	CTPDG012865
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Patented	Pyrrolo-pyrrolone derivative 6	PMID26924192-Compound-39	122553484	Patented	D0O9WQ	.	CTPDG014565
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	ischemin	MS120	135566302	Investigative	D00DXI	.	CTPDG014566
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	SGC-CBP30	"1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	Investigative	D03XXT	.	CTPDG014567
M6ACROT06023	CREB-binding protein (CREBBP)	CBP_HUMAN	.	.	Investigative	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	Investigative	D0J3JI	.	CTPDG014568
M6ACROT06028	Protein S100-A9 (S100A9)	S10A9_HUMAN	.	.	Phase 3	Tasquinimod	TASQ	54682876	Phase 3	D02JMU	DB05861	CTPDG014467
M6ACROT06028	Protein S100-A9 (S100A9)	S10A9_HUMAN	.	.	Phase 2	Paquinimod	"ABR-215757; ABR-25757; Project 57-57, Active Biotech"	54684617	Phase 2	D0G5SU	DB13118	CTPDG002365
M6ACROT06041	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 2	RG7155	.	.	Phase 2	D06NQH	.	CTPDG002742
M6ACROT06041	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	Emactuzumab	.	.	Phase 1	D00MJI	.	CTPDG005452
M6ACROT06041	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	PLX73086	.	.	Phase 1	D0PL8D	.	CTPDG004503
M6ACROT06041	Macrophage colony-stimulating factor 1 (CSF1)	CSF1_HUMAN	.	.	Phase 1	MSC110	Lacnotuzumab	.	Phase 1	D18QIB	.	CTPDG014468
M6ACROT06041	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06041	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06042	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	Phase 2	D01VDI	.	CTPDG014586
M6ACROT06042	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Phase 2	Resten-NG	Resten-NG (TN)	.	Phase 2	D0M4MG	.	CTPDG002208
M6ACROT06042	Myc proto-oncogene protein (MYC)	MYC_HUMAN	.	.	Investigative	TWS-119	"TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	Investigative	D0T8KR	.	CTPDG013324
M6ACROT06042	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1/2	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	Phase 1/2	DIY4C2	.	CTPDG003176
M6ACROT06042	Histone acetyltransferase p300  (P300)	EP300_HUMAN	.	.	Phase 1	FT-7051	.	.	Phase 1	DT8IL6	.	CTPDG014564
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT06043	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT06044	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Panobinostat	"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide"	6918837	Approved	D0E3SH	DB06603	CTPDG000409
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	Approved	D0E7PQ	DB02546	CTPDG010184
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Approved	Romidepsin	"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone"	5352062	Approved	D0L7LC	DB06176	CTPDG010185
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	HBI-8000	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide	12136798	Phase 1/2	D00SQN	DB06334	CTPDG000838
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	NVP-LAQ824	"Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539"	6445533	Phase 3	D0B3FV	.	CTPDG010186
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	SNDX-275	"Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate"	4261	Phase 3	D0M8FD	DB11841	CTPDG010187
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 3	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	Phase 3	D0GH3Q	DB12645	CTPDG001197
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Resminostat	864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895	11609955	Phase 2	D01UXJ	DB12392	CTPDG010188
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Sodium butyrate	"Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)"	5222465	Phase 2	D0I7IB	.	CTPDG002307
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	SB-623	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide	6918876	Phase 2	D0VE1W	.	CTPDG010189
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	MGCD-0103	"Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"	9865515	Phase 2	D00FHR	DB11830	CTPDG003093
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 2	Phenylbutyrate	"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate"	4775	Phase 2	D0B7CH	DB06819	CTPDG010190
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1/2	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	Phase 1/2	D06TKI	DB15419	CTPDG010191
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	SB-639	"CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide"	6918877	Phase 1	D07FPY	.	CTPDG005111
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	RG-2833	"RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen"	56654642	Phase 1	D0GE5B	.	CTPDG010192
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Phase 1	OBP-801	.	11178958	Phase 1	D00SSZ	DB12279	CTPDG005440
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-42	.	118366974	Patented	D0YT8O	.	CTPDG010193
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33d	.	117703486	Patented	D00ACL	.	CTPDG010194
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32u	.	.	Patented	D00GLJ	.	CTPDG010195
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33a	.	.	Patented	D00LLN	.	CTPDG010196
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32a	.	.	Patented	D00XWZ	.	CTPDG010197
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32j	.	.	Patented	D01LCZ	.	CTPDG010198
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32z	.	.	Patented	D02YDG	.	CTPDG010199
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32g	.	.	Patented	D03EUD	.	CTPDG010200
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34c	.	.	Patented	D04AMI	.	CTPDG010201
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32x	.	117703583	Patented	D04KQU	.	CTPDG010202
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33b	.	.	Patented	D04MVN	.	CTPDG010203
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32b	.	86282589	Patented	D04VQE	.	CTPDG010204
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32o	.	86282321	Patented	D06IIL	.	CTPDG010205
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33g	.	117703541	Patented	D08GBR	.	CTPDG010206
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33j	.	117703439	Patented	D08GQL	.	CTPDG010207
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33p	.	.	Patented	D08SNJ	.	CTPDG010208
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33m	.	.	Patented	D08XLK	.	CTPDG010209
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32v	.	.	Patented	D08ZJZ	.	CTPDG010210
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-24	.	.	Patented	D09PVH	.	CTPDG010211
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34b	.	.	Patented	D0BY1R	.	CTPDG010212
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33e	.	.	Patented	D0CH4M	.	CTPDG010213
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32t	.	86282179	Patented	D0CX1Y	.	CTPDG010214
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32c	.	.	Patented	D0DH7R	.	CTPDG010215
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33i	.	.	Patented	D0E5CO	.	CTPDG010216
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32r	.	86282178	Patented	D0ET4U	.	CTPDG010217
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32h	.	.	Patented	D0EU5A	.	CTPDG010218
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-65a	.	126720707	Patented	D0F3TB	.	CTPDG010219
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32y	.	.	Patented	D0HM6Y	.	CTPDG010220
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33h	.	.	Patented	D0JN0A	.	CTPDG010221
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38a	.	121304883	Patented	D0JR9L	.	CTPDG010222
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33f	.	.	Patented	D0K2UF	.	CTPDG010223
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 3	PMID28092474-Compound-11	.	Patented	D0KA3X	.	CTPDG010224
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33c	.	.	Patented	D0L3CU	.	CTPDG010225
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-39	.	124093354	Patented	D0L7HG	.	CTPDG010226
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-19	.	.	Patented	D0LV6K	.	CTPDG010227
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32e	.	.	Patented	D0M7XL	.	CTPDG010228
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32m	.	117703481	Patented	D0MQ2D	.	CTPDG010229
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32p	.	86282322	Patented	D0MR7U	.	CTPDG010230
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32d	.	86282452	Patented	D0N1RX	.	CTPDG010231
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32n	.	86282455	Patented	D0O6SJ	.	CTPDG010232
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33k	.	.	Patented	D0Q9XK	.	CTPDG010233
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32k	.	.	Patented	D0QF0Y	.	CTPDG010234
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-34a	.	.	Patented	D0QN8W	.	CTPDG010235
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Isosteric imidazolyl pyrimidine derivative 1	PMID26161698-Compound-37	44555024	Patented	D0QR1Z	.	CTPDG010236
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-22	.	71532921	Patented	D0QX3G	.	CTPDG010237
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-26	.	130361892	Patented	D0R3RJ	.	CTPDG010238
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33o	.	.	Patented	D0RD7T	.	CTPDG010239
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32f	.	.	Patented	D0S3ZB	.	CTPDG010240
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	Diaryl amine derivative 2	PMID28092474-Compound-10	.	Patented	D0S7NE	.	CTPDG010241
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-33l	.	.	Patented	D0SF8N	.	CTPDG010242
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32i	.	.	Patented	D0SK9K	.	CTPDG010243
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32q	.	86282451	Patented	D0TH3L	.	CTPDG010244
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-18	.	86302675	Patented	D0TN6E	.	CTPDG010245
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-57	.	.	Patented	D0UD9R	.	CTPDG010246
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-27	.	130227480	Patented	D0V5IQ	.	CTPDG010247
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32l	.	.	Patented	D0W1AX	.	CTPDG010248
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID28092474-Compound-32s	.	117703493	Patented	D0YC2M	.	CTPDG010249
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-38b	.	73774655	Patented	D0YD7B	.	CTPDG010250
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-28	.	.	Patented	D0Z7QI	.	CTPDG010251
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-59	.	130319551	Patented	D0C9NX	.	CTPDG010252
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-55	.	60198673	Patented	D0OU0J	.	CTPDG010253
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-73	.	124194015	Patented	D0T7OQ	.	CTPDG010254
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-13	.	71811260	Patented	D0ZG5X	.	CTPDG010255
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-11	.	118005782	Patented	D0EH2K	.	CTPDG010256
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-9	.	57381425	Patented	D0Q1QY	.	CTPDG010257
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-8	.	.	Patented	D0LN1T	.	CTPDG010258
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-61	.	.	Patented	D0JB4S	.	CTPDG010259
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-23	.	118884610	Patented	D00HXJ	.	CTPDG010260
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-44	.	72710871	Patented	D0N2DK	.	CTPDG010261
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-56	.	56965342	Patented	D0CH8Q	.	CTPDG010262
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-67	.	60201048	Patented	D0M0RE	.	CTPDG010263
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-31	.	90479372	Patented	D0DI9S	DB14979	CTPDG010264
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-21	.	86295624	Patented	D0LP1K	.	CTPDG010265
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-62	.	.	Patented	D07WAT	.	CTPDG010266
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-43	.	118515590	Patented	D0BP8I	.	CTPDG010267
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Patented	PMID29671355-Compound-25	.	126569528	Patented	D0RA0D	.	CTPDG010268
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	AN-9	"Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE"	60748	Discontinued in Phase 2	D0MP2U	DB05103	CTPDG006474
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 2	Tacedinaline	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide	2746	Discontinued in Phase 2	D0W9NH	DB12291	CTPDG006411
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Discontinued in Phase 1	Pyroxamide	"POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide"	4996	Discontinued in Phase 1	D0N3SH	DB12847	CTPDG006769
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	M-carboxycinnamic acid bishydroxamide	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide	5353484	Preclinical	D03SZR	.	CTPDG007143
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	HC-Toxin	"HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone"	107864	Preclinical	D06RQU	.	CTPDG007124
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7068	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide	9799221	Preclinical	D0DO5U	.	CTPDG007091
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Scriptaid	"CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide"	5186	Preclinical	D0J8OC	.	CTPDG007076
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	4SC-202	.	44217246	Preclinical	D0L5DZ	.	CTPDG007067
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Chlamydocin	"HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone"	124134	Preclinical	D0UC6H	.	CTPDG007043
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	SK-7041	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide	6918714	Preclinical	D0UL5X	.	CTPDG007042
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Preclinical	Depudecin	"(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9"	16219259	Preclinical	D0W8JE	.	CTPDG007035
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Terminated	Oxamflatin	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3	5353852	Terminated	D03YVR	.	CTPDG007521
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	"UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235"	11449246	Investigative	D00GBB	.	CTPDG010269
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N,8-dihydroxy-8-(naphthalen-2-yl)octanamide"	CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide	11044829	Investigative	D00LSZ	.	CTPDG010270
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	CHEMBL216292; SCHEMBL5903988	44418106	Investigative	D00PLM	.	CTPDG010271
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide	11128726	Investigative	D00RGD	.	CTPDG010272
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	NSC-746457	.	135903324	Investigative	D01EDB	.	CTPDG010273
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzenesulfonylamino-N-hydroxy-benzamide	CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid	44328873	Investigative	D02VVU	.	CTPDG010274
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide	11129854	Investigative	D03FFI	.	CTPDG010275
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-tert-butyl-N-hydroxybenzamide	"62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279"	21397854	Investigative	D03FOD	.	CTPDG010276
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	CHEMBL217083	16655084	Investigative	D03OYL	.	CTPDG010277
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N	11381650	Investigative	D03ZUZ	.	CTPDG010278
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide	11822609	Investigative	D04XPZ	.	CTPDG010279
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	CHEMBL216509; SCHEMBL5903774; BDBM50198477	10242569	Investigative	D05PYF	.	CTPDG010280
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-phenylthiophene-2-carboxamide	CHEMBL217573; SCHEMBL5903684	25002768	Investigative	D06NVX	.	CTPDG010281
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	"CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h"	25190759	Investigative	D06ONC	.	CTPDG010282
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	CHEMBL265479	44418155	Investigative	D07HUH	.	CTPDG010283
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide	10314237	Investigative	D0A6CB	.	CTPDG010284
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	CHEMBL217816; SCHEMBL5903934	44418125	Investigative	D0A7IF	.	CTPDG010285
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Gymnochrome E	.	135894458	Investigative	D0B1YM	.	CTPDG010286
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide	10891349	Investigative	D0CJ7L	.	CTPDG010287
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxybenzo[b]thiophene-2-carboxamide	"CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid"	11708207	Investigative	D0D3XC	.	CTPDG010288
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	CHEMBL426516	44418145	Investigative	D0G0OF	.	CTPDG010289
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide	11120992	Investigative	D0GJ1E	.	CTPDG010290
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide	10858374	Investigative	D0K8MF	.	CTPDG010291
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	11821974	Investigative	D0KM7H	.	CTPDG010292
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-6-oxo-6-phenylhexanamide	CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide	11031415	Investigative	D0L4ML	.	CTPDG010293
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(naphthalen-2-yl)octanamide	CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide	11833001	Investigative	D0L5WI	.	CTPDG010294
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-102550	CHEMBL217716; SCHEMBL5903759; BDBM50198218	10452725	Investigative	D0M0QJ	.	CTPDG010295
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide	10923922	Investigative	D0O7UF	.	CTPDG010296
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	CHEMBL238569; SCHEMBL1064835	9924962	Investigative	D0P1RQ	.	CTPDG010297
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-hydroxy-2,2'-bithiophene-5-carboxamide"	CHEMBL217750; SCHEMBL5903723; BDBM50198479	44418185	Investigative	D0PP3Q	.	CTPDG010298
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ADS-100380	CHEMBL216885; SCHEMBL5904027; BDBM50198221	44418141	Investigative	D0Q8QA	.	CTPDG010299
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-7-oxo-7-phenylheptanamide	CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide	10998964	Investigative	D0QX6R	.	CTPDG010300
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	CHEMBL1083440; SCHEMBL4922807	11426781	Investigative	D0T0BE	.	CTPDG010301
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	SK-683	CHEMBL116620; SCHEMBL8089576; BDBM50148757	9888071	Investigative	D0U3MB	.	CTPDG010302
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-hydroxy-9-oxo-9-phenylnonanamide	CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide	11139963	Investigative	D0Z2VP	.	CTPDG010303
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methylphenyl)octanediamide	CHEMBL1092762; BDBM50314138	46884057	Investigative	D00HFS	.	CTPDG010304
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093043; BDBM50314143	45141955	Investigative	D01AMS	.	CTPDG010305
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)quinoxaline-6-carboxamide	"benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	Investigative	D01FYB	.	CTPDG010306
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	Investigative	D01RJY	.	CTPDG010307
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093040; BDBM50314142	45141752	Investigative	D01ZMJ	.	CTPDG010308
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	Investigative	D03XXI	.	CTPDG010309
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	Investigative	D04ETX	.	CTPDG010310
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	Investigative	D04LLD	.	CTPDG010311
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1092032; BDBM50314141	45141956	Investigative	D05GRZ	.	CTPDG010312
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Phenoxy-heptanoic acid hydroxyamide	CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	Investigative	D05ZGM	.	CTPDG010313
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	Investigative	D06BKA	.	CTPDG010314
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	"CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1"	46918725	Investigative	D06FAK	.	CTPDG010315
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Desclasinose Azithromycinarylalkyl Hydroxamate	"CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10"	25151110	Investigative	D06THS	.	CTPDG010316
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093042; BDBM50314139	45141954	Investigative	D08ICY	.	CTPDG010317
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093713; BDBM50314133	45141960	Investigative	D08TIJ	.	CTPDG010318
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	CHEMBL473270	44591267	Investigative	D08XMS	.	CTPDG010319
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093357; BDBM50314144	45141957	Investigative	D0B8RC	.	CTPDG010320
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	"SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e"	25151675	Investigative	D0D7KH	.	CTPDG010321
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; SCHEMBL5724398; BDBM50232005	44454650	Investigative	D0E0TA	.	CTPDG010322
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE E	CHEMBL402363	16095101	Investigative	D0E9DD	.	CTPDG010323
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	"CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g"	25190758	Investigative	D0H3RO	.	CTPDG010324
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(3-methylphenyl)octanediamide	CHEMBL1089339; BDBM50314136	46884056	Investigative	D0H7QA	.	CTPDG010325
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Phenyl-octanoic acid hydroxyamide	CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	Investigative	D0H9DS	.	CTPDG010326
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	"CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a"	25152062	Investigative	D0I5XM	.	CTPDG010327
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	CHEMBL1093041; BDBM50314134	45141753	Investigative	D0J3CY	.	CTPDG010328
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093359; BDBM50314135	45141959	Investigative	D0L5KP	.	CTPDG010329
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	CHEMBL1091487; BDBM50314137	46884016	Investigative	D0L6YF	.	CTPDG010330
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE B	CHEMBL402727	16095112	Investigative	D0M1ZI	.	CTPDG010331
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	Investigative	D0NL6C	.	CTPDG010332
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Azithromycinarylalkylhydroxamic Acid	"CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8"	25151109	Investigative	D0P9CQ	.	CTPDG010333
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-N'-(2-methylphenyl)octanediamide	CHEMBL1076794; BDBM50314140	46884055	Investigative	D0Q2CC	.	CTPDG010334
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	nexturastat A	S7473	71462653	Investigative	D0Q5DI	.	CTPDG010335
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	AZUMAMIDE C	CHEMBL257972	16095114	Investigative	D0Q9PO	.	CTPDG010336
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide"	CHEMBL1093358; BDBM50314145	45141958	Investigative	D0SQ1F	.	CTPDG010337
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	CHEMBL511212; BDBM50258645	10383069	Investigative	D0YP4F	.	CTPDG010338
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	LARGAZOLE	CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395	24757913	Investigative	D0Z8PX	.	CTPDG010339
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	CHEMBL393260	44437872	Investigative	D00XTC	.	CTPDG010340
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	"CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide"	11427204	Investigative	D02HVH	.	CTPDG010341
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	CHEMBL390991	44437870	Investigative	D02NAF	.	CTPDG010342
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	CHEMBL394261	44437869	Investigative	D02NVY	.	CTPDG010343
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	CHEMBL391384	44437878	Investigative	D03PRG	.	CTPDG010344
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	CHEMBL393261	44437873	Investigative	D04CDZ	.	CTPDG010345
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	CHEMBL512644; SCHEMBL8226957	25032059	Investigative	D04DOL	.	CTPDG010346
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	Investigative	D04UVL	.	CTPDG010347
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	CHEMBL241555	44437879	Investigative	D0E8UH	.	CTPDG010348
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	CHEMBL428737	44437876	Investigative	D0G1EX	.	CTPDG010349
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; BDBM50232035	44454415	Investigative	D0M9LJ	.	CTPDG010350
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	CHEMBL238587	44437875	Investigative	D0N5RV	.	CTPDG010351
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; SCHEMBL1066609	44454416	Investigative	D0Q2GM	.	CTPDG010352
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	CHEMBL238596; BDBM50222727	44437883	Investigative	D0R3XO	.	CTPDG010353
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	CHEMBL393961	44437880	Investigative	D0U0EZ	.	CTPDG010354
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	CHEMBL391383	44437877	Investigative	D0X4QC	.	CTPDG010355
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-aminophenyl)-4-methoxybenzamide	"AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	Investigative	D0YO6M	.	CTPDG010356
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	CHEMBL393464	44437874	Investigative	D0Z6HR	.	CTPDG010357
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	CHEMBL238829; BDBM50222732	44437868	Investigative	D0Z6MI	.	CTPDG010358
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	Investigative	D02NWS	.	CTPDG010359
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	Investigative	D0S0WK	.	CTPDG010360
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-3050	CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222	44591988	Investigative	D01YBR	.	CTPDG010361
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	Investigative	D07YZZ	.	CTPDG010362
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2986	CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	Investigative	D0N9AK	.	CTPDG010363
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	Investigative	D00KFF	DB07553	CTPDG010364
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid phenylamide	Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	Investigative	D00SEE	.	CTPDG010365
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4	11694528	Investigative	D00ZSD	.	CTPDG010366
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	Investigative	D01MFV	.	CTPDG010367
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	Investigative	D01XWZ	.	CTPDG010368
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	Investigative	D01XXN	.	CTPDG010369
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	Investigative	D02MQM	.	CTPDG010370
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	Investigative	D02UTC	.	CTPDG010371
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	Investigative	D02WZK	.	CTPDG010372
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-4-ylamide	SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	Investigative	D04GGW	.	CTPDG010373
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	Investigative	D04HSS	.	CTPDG010374
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	Investigative	D04NSP	.	CTPDG010375
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	Investigative	D04ZDI	.	CTPDG010376
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-benzenesulfonylhexanoic acid hydroxamide	CHEMBL203207	11572583	Investigative	D05AHZ	.	CTPDG010377
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	Investigative	D05FEJ	.	CTPDG010378
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	Investigative	D05GVY	.	CTPDG010379
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	Investigative	D05LLX	.	CTPDG010380
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	Investigative	D05VFP	.	CTPDG010381
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	Investigative	D05XAN	.	CTPDG010382
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	Investigative	D06IQB	.	CTPDG010383
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	Investigative	D06VBN	.	CTPDG010384
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	Investigative	D06XNP	.	CTPDG010385
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	Investigative	D07FJU	.	CTPDG010386
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	Investigative	D09YBN	.	CTPDG010387
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	Investigative	D09ZNU	.	CTPDG010388
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	Investigative	D0A5LS	.	CTPDG010389
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	Investigative	D0AX7B	.	CTPDG010390
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	Investigative	D0B2ZJ	.	CTPDG010391
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-Mercapto-hexanoic acid phenylamide	"CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	Investigative	D0B3ZM	.	CTPDG010392
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Cyclostellettamine derivative	CHEMBL88332	23327627	Investigative	D0C0VP	.	CTPDG010393
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	Investigative	D0C2KD	.	CTPDG010394
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-Mercapto-pentanoic acid phenylamide	"N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	Investigative	D0D2KE	.	CTPDG010395
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	Octanedioic acid hydroxyamide pyridin-2-ylamide	SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	Investigative	D0E8KR	.	CTPDG010396
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	Investigative	D0F0KS	.	CTPDG010397
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; SCHEMBL4156413	24759251	Investigative	D0H1FZ	.	CTPDG010398
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	Investigative	D0KE3I	.	CTPDG010399
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	Investigative	D0QO0L	.	CTPDG010400
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	Investigative	D0R4BS	.	CTPDG010401
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	Investigative	D0R5VG	.	CTPDG010402
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	Investigative	D0RU1X	.	CTPDG010403
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	Investigative	D0S7WQ	.	CTPDG010404
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658"	11637291	Investigative	D0S9JF	.	CTPDG010405
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	ST-2987	CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	Investigative	D0T0SK	.	CTPDG007869
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	Investigative	D0T4IY	.	CTPDG010406
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	Investigative	D0V2ZO	.	CTPDG010407
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	8-Mercapto-octanoic acid phenylamide	8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	Investigative	D0XZ9Q	.	CTPDG010408
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	Investigative	D0YY9M	.	CTPDG010409
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	Investigative	D0Z3BM	.	CTPDG010410
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	Investigative	D0Z5KX	.	CTPDG010411
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	Investigative	D0Z7YS	.	CTPDG010412
M6ACROT06045	Histone deacetylase 1  (HDAC1)	HDAC1_HUMAN	.	.	Investigative	PSAMMAPLIN A	"110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	Investigative	D0N0TS	.	CTPDG010413